['[Start Loading Faiss Index]', '  > move faiss index to gpu', '  > reading index took 6.633872985839844 s', '  > the datastore shape is  (6903141, 1024)', '[Finish Loading Faiss Index Successfully ^_^]', 'S-1298\tTeeling', 'T-1298\tTeeling', 'H-1298\t-0.82470703125\tTeeling', 'D-1298\t-0.82470703125\tTeeling', 'P-1298\t-1.3887 -0.1705 -0.0352', 'S-233\t19.', 'T-233\t8 June 2001 Date of last renewal:', 'H-233\t-1.3876953125\t17 .', 'D-233\t-1.3876953125\t17.', 'P-233\t-1.5244 -1.1299 -0.0282', 'S-146\t120 mg', 'T-146\t80 mg 80 mg 120 mg 120 mg', 'H-146\t-0.73876953125\t120mg', 'D-146\t-0.73876953125\t120mg', 'P-146\t-1.4092 -0.0120 -0.0176 -0.2585', 'S-1546\t........', 'T-1546\tStructure of the EMEA', 'H-1546\t-2.166015625\t.......', 'D-1546\t-2.166015625\t.......', 'P-1546\t-2.0000 -2.1582 -0.0282', 'S-101\t12,8', 'T-101\t8.4 0.5 8.0', 'H-101\t-0.97412109375\t12.8', 'D-101\t-0.97412109375\t12.8', 'P-101\t-0.5747 -0.7354 -0.5732', 'S-747\tBauchschmerzen', 'T-747\tabdominal pain', 'H-747\t-0.64697265625\theadache', 'D-747\t-0.64697265625\theadache', 'P-747\t-0.7832 -0.0056 -0.5269 -0.1705', 'S-1882\tDosierung', 'T-1882\t16 Posology', 'H-1882\t-0.55322265625\t82 Dose', 'D-1882\t-0.55322265625\t82 Dose', 'P-1882\t-0.4207 -0.3037 -0.4521 -0.0944', 'S-1893\t-0,5', 'T-1893\t-0.5', 'H-1893\t-0.87890625\t-0.5', 'D-1893\t-0.87890625\t-0.5', 'P-1893\t-0.3213 -1.3145 -0.0634', 'S-1833\t12%', 'T-1833\t12%', 'H-1833\t-1.26953125\t12 %', 'D-1833\t-1.26953125\t12%', 'P-1833\t-2.1934 -0.0169 -0.2438', 'S-1618\tHans Wagner', 'T-1618\tHans Wagner', 'H-1618\t-1.5087890625\tManfred MOULON', 'D-1618\t-1.5087890625\tManfred MOULON', 'P-1618\t-1.4980 -1.3516 -0.4763 -0.6060 -0.0310', 'S-1611\t80 000', 'T-1611\t80 000', 'H-1611\t-1.369140625\t8 000', 'D-1611\t-1.369140625\t8 000', 'P-1611\t-2.1035 -0.3169 -0.2255', 'S-1516\t44 6', 'T-1516\t44 6', 'H-1516\t-3.119140625\t48 26 10', 'D-1516\t-3.119140625\t48 26 10', 'P-1516\t-3.1230 -1.1523 -1.0762 -1.8174', 'S-1222\t5 19', 'T-1222\t5 19', 'H-1222\t-1.5859375\t5 19', 'D-1222\t-1.5859375\t5 19', 'P-1222\t-2.1582 -0.4917 -0.4155', 'S-1018\t350 --', 'T-1018\t350 --', 'H-1018\t-1.6796875\t350 ( 535 )', 'D-1018\t-1.6796875\t350 (535)', 'P-1018\t-1.3105 -1.1826 -1.1270 -0.3691 -0.0310 -0.9019', 'S-923\t11 Monate', 'T-923\t11 months', 'H-923\t-0.67431640625\t11 months', 'D-923\t-0.67431640625\t11 months', 'P-923\t-0.9531 -0.0310 -0.3191', 'S-779\titte', 'T-779\tM ed', 'H-779\t-2.126953125\t27.0 %', 'D-779\t-2.126953125\t27.0%', 'P-779\t-3.1172 -0.7100 -0.6875 -0.3718', 'S-736\tPortugal:', 'T-736\tPortugal:', 'H-736\t-0.0352783203125\tPortugal :', 'D-736\t-0.0352783203125\tPortugal:', 'P-736\t-0.0142 -0.0270 -0.0270', 'S-665\t0,06', 'T-665\t0.06', 'H-665\t-0.33154296875\t0.06', 'D-665\t-0.33154296875\t0.06', 'P-665\t-0.3213 -0.2822 -0.0370', 'S-626\t- Depression', 'T-626\t- depression', 'H-626\t-0.9208984375\tdepression', 'D-626\t-0.9208984375\tdepression', 'P-626\t-1.3564 -0.0388', 'S-546\t46%', 'T-546\t46%', 'H-546\t-1.4794921875\t46 %', 'D-546\t-1.4794921875\t46%', 'P-546\t-2.8066 -0.0225 -0.0296', 'S-371\t0,5 g', 'T-371\t0.5 g', 'H-371\t-1.4853515625\t1.2 g', 'D-371\t-1.4853515625\t1.2 g', 'P-371\t-2.7227 -0.1042 -0.0451', 'S-287\t8.000', 'T-287\t8,000', 'H-287\t-2.166015625\t8,000', 'D-287\t-2.166015625\t8,000', 'P-287\t-2.6504 -0.6328', 'S-1459\tVersicherungen', 'T-1459\tInsurance', 'H-1459\t-1.3955078125\tPRILACTONE', 'D-1459\t-1.3955078125\tPRILACTONE', 'P-1459\t-2.6367 -0.5200 -0.3184 -0.3157 -0.3213 -0.3101 -0.0648', 'S-1648\t39', 'T-1648\t39 Other side effects which have occurred in the days or weeks after vaccination with ordinary flu vaccines include:', 'H-1648\t-2.26953125\t57', 'D-1648\t-2.26953125\t57', 'P-1648\t-2.9336 -0.5073', 'S-404\tenhance the', 'T-404\tfailure', 'H-404\t-2.630859375\ttherapy', 'D-404\t-2.630859375\ttherapy', 'P-404\t-3.1367 -0.8540', 'S-1396\tN e ue', 'T-1396\tNew', 'H-1396\t-1.6259765625\tN = 530', 'D-1396\t-1.6259765625\tN = 530', 'P-1396\t-0.9849 -1.1172 -1.6709 -0.3748 -0.1212', 'S-82\tAugenschmerzen,', 'T-82\tFlushing', 'H-82\t-1.2431640625\tEye pain ,', 'D-82\t-1.2431640625\tEye pain,', 'P-82\t-1.5684 -0.0296 -0.2776 -0.6792 -0.7114', 'S-448\tPrimäre', 'T-448\tTrial', 'H-448\t-0.796875\tPRILACTONE', 'D-448\t-0.796875\tPRILACTONE', 'P-448\t-0.8413 -0.4072 -0.3254 -0.3213 -0.3228 -0.3127 -0.0296', 'S-722\t9 b.', 'T-722\tb.', 'H-722\t-0.6083984375\t9 B .', 'D-722\t-0.6083984375\t9 B.', 'P-722\t-0.8018 -0.3135 -0.2551 -0.0275', 'S-130\t0, 0', 'T-130\t0.21 *', 'H-130\t-1.265625\t0 .', 'D-130\t-1.265625\t0.', 'P-130\t-1.4297 -0.9800 -0.0380', 'S-263\tunter 15 *', 'T-263\tbelow 15 *', 'H-263\t-0.75244140625\tless than 15 *', 'D-263\t-0.75244140625\tless than 15 *', 'P-263\t-1.5498 -0.0409 -0.0282 -0.0423 -0.3157', 'S-357\t16 / 18', 'T-357\t16 / 18', 'H-357\t-0.6455078125\t15 / 18', 'D-357\t-0.6455078125\t15 / 18', 'P-357\t-1.0967 -0.0930 -0.0810 -0.2128', 'S-363\t89,3', 'T-363\t89.3', 'H-363\t-0.7099609375\t89.3', 'D-363\t-0.7099609375\t89.3', 'P-363\t-0.3223 -0.9976 -0.1212 -0.1902', 'S-408\t9 / 69', 'T-408\t8 / 61', 'H-408\t-0.5390625\t9 / 61', 'D-408\t-0.5390625\t9 / 61', 'P-408\t-0.5747 -0.0356 -0.3223 -0.3057', 'S-500\t49 7.', 'T-500\t42 7.', 'H-500\t-0.30615234375\t46 7 .', 'D-500\t-0.30615234375\t46 7.', 'P-500\t-0.3223 -0.3145 -0.0384 -0.0285', 'S-503\t95,7', 'T-503\t95.7', 'H-503\t-1.3642578125\t97.7', 'D-503\t-1.3642578125\t97.7', 'P-503\t-0.3223 -0.9834 -1.6191 -0.2085', 'S-614\tDezember 1996', 'T-614\tAdopted by the Management Board on 4 December 1996', 'H-614\t-1.34375\tLondon , 19 December 1996', 'D-614\t-1.34375\tLondon, 19 December 1996', 'P-614\t-2.2773 -0.3127 -0.6001 -0.5439 -0.1775 -0.0282', 'S-423\tStürze', 'T-423\tInjury, poisoning and procedural complications Common: fall', 'H-423\t-1.5087890625\tFall', 'D-423\t-1.5087890625\tFall', 'P-423\t-2.0488 -0.2395', 'S-137\tMöglicherweise wird', 'T-137\tIf your liver or kidneys do not function well speak to your doctor, who may advise that you use lower insulin doses.', 'H-137\t-1.8330078125\tOpinions', 'D-137\t-1.8330078125\tOpinions', 'P-137\t-3.3594 -0.2451 -0.3635 -0.2451', 'S-1904\tZiele:', 'T-1904\tShire will conduct a Post Authorisation Safety Study (PASS) Study SPD422-401 A non- interventional, post authorisation safety study, to continuously monitor safety and pregnancy outcomes in a cohort of at-risk Essential Thrombocythaemia (ET) subjects exposed to Xagrid compared to other conventional cytoreductive treatments.', 'H-1904\t-0.75244140625\tGoals :', 'D-1904\t-0.75244140625\tGoals:', 'P-1904\t-1.6445 -0.0225 -0.0324 -0.0296', 'S-1362\tSchweden 10966', 'T-1362\tSweden 10966', 'H-1362\t-0.11761474609375\tSweden 10966', 'D-1362\t-0.11761474609375\tSweden 10966', 'P-1362\t-0.0342 -0.1998 -0.0357 -0.0113 -0.0278', 'S-1590\tVorsitzende (r)', 'T-1590\tChairperson', 'H-1590\t-2.001953125\tad hoc Working Group', 'D-1590\t-2.001953125\tad hoc Working Group', 'P-1590\t-1.9756 -0.3396 -0.0085 -0.3438 -0.2085 -0.2494 -3.3105', 'S-261\t10 Transferadapter', 'T-261\tTransfer adapter', 'H-261\t-0.83837890625\t10 Transfer adapter', 'D-261\t-0.83837890625\t10 Transfer adapter', 'P-261\t-0.9775 -0.3718 -0.2776 -0.5454 -0.0296', 'S-710\tB. an 118', 'T-710\t118 Travel', 'H-710\t-1.900390625\t136 Travel', 'D-710\t-1.900390625\t136 Travel', 'P-710\t-0.9517 -2.1953 -1.1074 -0.1127', 'S-806\t5.1 5.2', 'T-806\t5.1.', 'H-806\t-1.826171875\tSwelling', 'D-806\t-1.826171875\tSwelling', 'P-806\t-3.0625 -0.2874 -0.1803', 'S-1669\t• Kältegefühl', 'T-1669\t• feeling cold', 'H-1669\t-0.79296875\t• muscle pain', 'D-1669\t-0.79296875\t• muscle pain', 'P-1669\t-0.2335 -1.2158 -0.3030 -0.0704', 'S-174\t43,2%', 'T-174\t43.2%', 'H-174\t-0.2333984375\t43.2 %', 'D-174\t-0.2333984375\t43.2%', 'P-174\t-0.3022 -0.0255 -0.0336 -0.0320 -0.2195', 'S-246\t400 q12h', 'T-246\t400 q12h', 'H-246\t-0.397216796875\t400 q12h', 'D-246\t-0.397216796875\t400 q12h', 'P-246\t-0.4639 -0.2040 -0.3198 -0.0254 -0.0310', 'S-326\tRENAGEL', 'T-326\tRENAGEL', 'H-326\t-1.6171875\tCARTRIDGE', 'D-326\t-1.6171875\tCARTRIDGE', 'P-326\t-1.8926 -1.9990 -0.3523 -0.5581 -0.2959 -0.0535 -0.0479', 'S-341\t16 (3)', 'T-341\t16 (3)', 'H-341\t-0.7841796875\t16 ( 3 )', 'D-341\t-0.7841796875\t16 (3)', 'P-341\t-0.7100 -0.0571 -1.0322 -0.0282 -0.2324', 'S-629\t71.9%', 'T-629\t71.9%', 'H-629\t-0.55029296875\t71.9 %', 'D-629\t-0.55029296875\t71.9%', 'P-629\t-0.2311 -1.1348 -0.0218 -0.0303 -0.0275', 'S-771\t50 mg / kg', 'T-771\t50 mg / kg', 'H-771\t-0.1590576171875\t50 mg / kg', 'D-771\t-0.1590576171875\t50 mg / kg', 'P-771\t-0.0364 -0.0071 -0.0328 -0.0120 -0.3296', 'S-1215\tSUSTIVA', 'T-1215\tSUSTIVA', 'H-1215\t-0.1729736328125\tSUSTIVA', 'D-1215\t-0.1729736328125\tSUSTIVA', 'P-1215\t-0.3206 -0.0356 -0.0327 -0.0313 -0.0342', 'S-1232\t7 (7)', 'T-1232\t7 (7)', 'H-1232\t-1.337890625\t7 ( 6 )', 'D-1232\t-1.337890625\t7 (6)', 'P-1232\t-1.4170 -0.0909 -1.9414 -0.0282 -0.0366', 'S-1259\t35,1%', 'T-1259\t35.1%', 'H-1259\t-0.947265625\t35.1 %', 'D-1259\t-0.947265625\t35.1%', 'P-1259\t-0.3196 -1.6846 -0.0310 -0.0338 -0.4185', 'S-1349\tPhase III Vc', 'T-1349\tPhase III Vc', 'H-1349\t-0.69677734375\tPhase III Vc', 'D-1349\t-0.69677734375\tPhase III Vc', 'P-1349\t-1.5918 -0.1479 -0.0352 -0.0268 -0.0282', 'S-888\tDermatitits', 'T-888\tSkin and subcutaneous tissue disorders Rare: rash Very rare: dermatitis', 'H-888\t-0.88134765625\tDermatitis', 'D-888\t-0.88134765625\tDermatitis', 'P-888\t-0.9463 -0.7559 -0.0141 -0.3086', 'S-1072\tAm 3.', 'T-1072\tThe Reference Member State for this MRP was Ireland with Austria, Belgium, Denmark, Germany, Greece, Finland, Iceland, Italy, Luxembourg, Norway, Portugal, Spain, and Sweden as Concerned Member States.', 'H-1072\t-1.865234375\tA positive opinion was adopted by majority on 13 December 2007 .', 'D-1072\t-1.865234375\tA positive opinion was adopted by majority on 13 December 2007.', 'P-1072\t-1.8613 -1.2607 -0.3213 -0.3184 -0.3213 -0.2847 -0.8765 -0.3213 -1.1133 -0.9692 -0.8623 -0.1521 -0.0282', 'S-1405\t99%.', 'T-1405\tRosiglitazone Absorption Absolute bioavailability of rosiglitazone following both a 4 and an 8 mg oral dose is approximately 99%.', 'H-1405\t-1.51171875\tΑλ .', 'D-1405\t-1.51171875\tΑλ.', 'P-1405\t-2.9355 -0.3240 -0.1831 -0.0282', 'S-891\tWeiße Kappe', 'T-891\tOpen the prefilled syringe by breaking the seal of the closure and remove the white cap together with the rubber tip cap inside.', 'H-891\t-0.5966796875\tWhite', 'D-891\t-0.5966796875\tWhite', 'P-891\t-0.2859 -0.6187', 'S-1919\t100,6', 'T-1919\t100.6', 'H-1919\t-1.259765625\t100.6', 'D-1919\t-1.259765625\t100.6', 'P-1919\t-2.1680 -0.3945 -0.0465 -0.2847', 'S-877\t65 65 66', 'T-877\t65 65 66', 'H-877\t-2.701171875\t60 40 35 30', 'D-877\t-2.701171875\t60 40 35 30', 'P-877\t-2.1270 -2.2129 -0.8452 -0.7383 -1.1719', 'S-962\t1,10 ml', 'T-962\t1.10 ml', 'H-962\t-1.400390625\t1.60 ml', 'D-962\t-1.400390625\t1.60 ml', 'P-962\t-0.6543 -2.5059 -0.0282 -0.0310', 'S-1081\t57 B.', 'T-1081\t54 B.', 'H-1081\t-0.85302734375\t55 B .', 'D-1081\t-0.85302734375\t55 B.', 'P-1081\t-1.2959 -0.3359 -0.3000 -0.0282', 'S-1200\tfür 4 Wochen', 'T-1200\tfor 4 weeks', 'H-1200\t-0.084716796875\tfor 4 weeks', 'D-1200\t-0.084716796875\tfor 4 weeks', 'P-1200\t-0.0977 -0.0371 -0.0270 -0.0328', 'S-1429\t103 10.', 'T-1429\t96 10.', 'H-1429\t-0.9638671875\t98 10 .', 'D-1429\t-0.9638671875\t98 10.', 'P-1429\t-1.8232 -0.3127 -0.0493 -0.0282', 'S-1457\t5.2.', 'T-1457\t5.2.', 'H-1457\t-1.482421875\t5.2 .', 'D-1457\t-1.482421875\t5.2.', 'P-1457\t-2.0801 -1.1777 -0.1212 -0.0282', 'S-1758\t23 15.', 'T-1758\t23 15.', 'H-1758\t-0.9228515625\t22 15 .', 'D-1758\t-0.9228515625\t22 15.', 'P-1758\t-1.7412 -0.2874 -0.0634 -0.0282', 'S-1815\t370 58 59', 'T-1815\t370 58 59', 'H-1815\t-1.8642578125\tSwelling', 'D-1815\t-1.8642578125\tSwelling', 'P-1815\t-3.1328 -0.2903 -0.1803', 'S-1910\tEmadine', 'T-1910\tEmadine', 'H-1910\t-0.81005859375\tEmadine', 'D-1910\t-0.81005859375\tEmadine', 'P-1910\t-1.4102 -0.0197 -0.0578 -0.3733', 'S-816\t100 mg:', 'T-816\t100 mg:', 'H-816\t-0.18505859375\t100 mg :', 'D-816\t-0.18505859375\t100 mg:', 'P-816\t-0.3303 -0.0127 -0.0537 -0.0285', 'S-365\t• Erwachsene:', 'T-365\t• Adults:', 'H-365\t-0.421142578125\t• adults :', 'D-365\t-0.421142578125\t• adults:', 'P-365\t-0.2927 -0.6050 -0.0416 -0.0289', 'S-557\tAndreas Pott', 'T-557\tDossier assessment', 'H-557\t-0.432861328125\tOverview', 'D-557\t-0.432861328125\tOverview', 'P-557\t-0.3762 -0.3860 -0.0746', 'S-623\t- 0,2', 'T-623\t- 0 .2', 'H-623\t-1.4453125\t-0.2', 'D-623\t-1.4453125\t-0.2', 'P-623\t-2.6367 -0.1691 -0.4028 -0.1099', 'S-823\t260 10.', 'T-823\t244 10.', 'H-823\t-1.0654296875\t236 10 .', 'D-823\t-1.0654296875\t236 10.', 'P-823\t-1.6191 -0.8228 -0.2917 -0.0366 -0.0282', 'S-1304\tBereichsleiterin', 'T-1304\tHead of Sector', 'H-1304\t-1.916015625\tNew chemical substances', 'D-1304\t-1.916015625\tNew chemical substances', 'P-1304\t-0.5352 -0.3276 -0.3220 -0.1691 -3.6797', 'S-1592\t(Tage)', 'T-1592\tHaemorrhage', 'H-1592\t-0.6123046875\t( days )', 'D-1592\t-0.6123046875\t(days)', 'P-1592\t-1.0615 -0.2859 -0.0296 -0.0289', 'S-409\t(mg)', 'T-409\tValsartan (mg)', 'H-409\t-0.755859375\t( mg )', 'D-409\t-0.755859375\t(mg)', 'P-409\t-1.6543 -0.0225 -0.0296 -0.0296', 'S-714\t29.03.2001', 'T-714\t• 18.07.2000 • 29.03.2001', 'H-714\t-1.2763671875\t29 March 2001', 'D-714\t-1.2763671875\t29 March 2001', 'P-714\t-1.5508 -1.2666 -0.0817 -0.0338', 'S-1561\t(2007)', 'T-1561\tMarcelin et al (2007)', 'H-1561\t-0.422607421875\t( 2007 )', 'D-1561\t-0.422607421875\t(2007)', 'P-1561\t-0.6704 -0.2328 -0.0296 -0.0380', 'S-627\t14 / 21 B.', 'T-627\t14 / 21 B.', 'H-627\t-0.6513671875\t14 / 21 B .', 'D-627\t-0.6513671875\t14 / 21 B.', 'P-627\t-0.7881 -0.0331 -0.6904 -0.0775 -0.2917 -0.0282', 'S-1042\t1 mg) erhältlich.', 'T-1042\t1 mg).', 'H-1042\t-0.2666015625\t1 mg ) .', 'D-1042\t-0.2666015625\t1 mg).', 'P-1042\t-0.5405 -0.0113 -0.0356 -0.0842 -0.0285', 'S-1104\t19 Abbildung C:', 'T-1104\tFigure C:', 'H-1104\t-0.5478515625\t18 Figure C :', 'D-1104\t-0.5478515625\t18 Figure C:', 'P-1104\t-1.0312 -0.1818 -0.0240 -0.0289 -0.3120 -0.0282', 'S-1336\t- 0, 0 5', 'T-1336\tINH Washout', 'H-1336\t-1.09765625\tin', 'D-1336\t-1.09765625\tin', 'P-1336\t-1.3389 -0.3254', 'S-16\tBelivon Consta', 'T-16\tBelivon Consta', 'H-16\t-0.412109375\tBelivon Consta', 'D-16\t-0.412109375\tBelivon Consta', 'P-16\t-0.6626 -0.0197 -0.2891 -0.1895 -0.0169 -0.0296', 'S-34\tMicardis 20 mg', 'T-34\tMicardis 20 mg', 'H-34\t-0.075927734375\tMicardis 20 mg', 'D-34\t-0.075927734375\tMicardis 20 mg', 'P-34\t-0.0364 -0.0285 -0.0328 -0.0857 -0.0092 -0.0299', 'S-228\tVorläufig eingesetzte Mittel', 'T-228\tProvisional appropriation', 'H-228\t-1.224609375\tProvisional appropriations', 'D-228\t-1.224609375\tProvisional appropriations', 'P-228\t-3.1367 -0.0056 -0.0254 -0.3467 -0.0366 -0.0366', 'S-447\tn = 170 12%', 'T-447\tN = 170 12%', 'H-447\t-0.2222900390625\tN = 170 12 %', 'D-447\t-0.2222900390625\tN = 170 12%', 'P-447\t-0.3213 -0.0241 -0.0211 -0.2268 -0.0285 -0.0292', 'S-482\tHenlutamide', 'T-482\tHenlutamide', 'H-482\t-1.783203125\tCalcichew', 'D-482\t-1.783203125\tCalcichew', 'P-482\t-2.5156 -0.7705 -0.9214 -0.3213 -0.1550', 'S-527\tWas ist Evra?', 'T-527\tWhat is Evra?', 'H-527\t-0.09368896484375\tWhat is Evra ?', 'D-527\t-0.09368896484375\tWhat is Evra?', 'P-527\t-0.0797 -0.1030 -0.0077 -0.0157 -0.0400 -0.0285', 'S-544\tVenta-Neb', 'T-544\tVenta-Neb', 'H-544\t-1.58203125\tVenta , Neb .', 'D-544\t-1.58203125\tVenta, Neb.', 'P-544\t-2.9805 -0.0282 -1.4258 -0.0197 -0.0282 -0.5718 -0.0282', 'S-547\t12 / 02 / 2009', 'T-547\t12 / 02 / 2009', 'H-547\t-0.491943359375\t12 / 02 / 2009', 'D-547\t-0.491943359375\t12 / 02 / 2009', 'P-547\t-1.0732 -0.0507 -0.0838 -0.0317 -0.1740 -0.0282', 'S-973\tCh.-B.: ne', 'T-973\tLot dic', 'H-973\t-1.2919921875\tMonday Tuesday uc', 'D-973\t-1.2919921875\tMonday Tuesday uc', 'P-973\t-1.8584 -0.4058 -0.4382 -0.3213 -0.3691', 'S-646\tSchweres OHSS', 'T-646\tSevere OHSS', 'H-646\t-1.265625\tHeavy OHSS', 'D-646\t-1.265625\tHeavy OHSS', 'P-646\t-3.1758 -0.0732 -0.0169 -0.0282 -0.0310', 'S-713\tEspaña:', 'T-713\tEspaña:', 'H-713\t-1.1005859375\tTel .', 'D-713\t-1.1005859375\tTel.', 'P-713\t-1.2529 -0.7461 -0.1282', 'S-936\tEquibactin vet.', 'T-936\tEquibactin vet.', 'H-936\t-0.78076171875\tEquilis vet .', 'D-936\t-0.78076171875\tEquilis vet.', 'P-936\t-1.2852 -0.3662 -0.4128 -0.1550 -0.0395 -0.0296', 'S-1066\t↑ 3-7fach', 'T-1066\t↑ 3-7 fold', 'H-1066\t-1.3125\t↑ 3 @-@ 7 fold', 'D-1066\t-1.3125\t↑ 3-7 fold', 'P-1066\t-1.3838 -0.0676 -0.0338 -0.7031 -1.6162 -0.0423', 'S-1082\t1 (1,3%)', 'T-1082\t1 (1.3%)', 'H-1082\t-0.22119140625\t1 ( 1.3 % )', 'D-1082\t-0.22119140625\t1 (1.3%)', 'P-1082\t-0.1288 -0.0284 -0.1058 -0.0313 -0.0278 -0.3257', 'S-1243\t0,14 mg / ml', 'T-1243\t0.14 mg / ml', 'H-1243\t-0.07421875\t0.14 mg / ml', 'D-1243\t-0.07421875\t0.14 mg / ml', 'P-1243\t-0.0856 -0.0429 -0.0085 -0.0313 -0.0185 -0.0306', 'S-1398\tWas Aclasta enthält', 'T-1398\tWhat Aclasta contains', 'H-1398\t-0.1021728515625\tWhat Aclasta contains', 'D-1398\t-0.1021728515625\tWhat Aclasta contains', 'P-1398\t-0.0931 -0.0619 -0.0128 -0.0142 -0.0796 -0.0379', 'S-1528\t29% 35 / 120', 'T-1528\t29% 35 / 120', 'H-1528\t-1.1982421875\t29 % 35 / 120', 'D-1528\t-1.1982421875\t29% 35 / 120', 'P-1528\t-0.6187 -0.0539 -2.7598 -0.0310 -0.0197 -0.0282', 'S-1587\tFeldene Cremadol', 'T-1587\tFeldene Cremadol', 'H-1587\t-0.81494140625\tFeldene Lyons', 'D-1587\t-0.81494140625\tFeldene Lyons', 'P-1587\t-0.4255 -0.3213 -0.8818 -0.2593 -0.2537', 'S-1616\t10 (2,8)', 'T-1616\t10 (2.8)', 'H-1616\t-0.67431640625\t10 ( 2.8 )', 'D-1616\t-0.67431640625\t10 (2.8)', 'P-1616\t-0.6533 -0.0363 -0.4734 -0.7544 -0.0282 -0.0310', 'S-1672\t36 Ultratard', 'T-1672\t34 Ultratard', 'H-1672\t-1.7666015625\t36 Monotard', 'D-1672\t-1.7666015625\t36 Monotard', 'P-1672\t-1.4414 -1.8584 -0.9893 -0.3213 -0.0310', 'S-1256\tWeitere Informationen er 1.', 'T-1256\tFurther Information', 'H-1256\t-1.521484375\tFurther information he 1 .', 'D-1256\t-1.521484375\tFurther information he 1.', 'P-1256\t-1.1543 -0.0535 -3.1328 -0.0620 -0.0310 -0.0282', 'S-200\t3,2 Minuten 6,5 Minuten', 'T-200\t6.5 min', 'H-200\t-1.1435546875\t3.2 minutes 6.5 minutes', 'D-200\t-1.1435546875\t3.2 minutes 6.5 minutes', 'P-200\t-0.8628 -0.3347 -0.8677 -0.2791 -0.3621 -0.6465', 'S-1472\tKonzentrat:', 'T-1472\tConcentrate:', 'H-1472\t-0.1324462890625\tConcentrate :', 'D-1472\t-0.1324462890625\tConcentrate:', 'P-1472\t-0.2351 -0.0113 -0.0357 -0.0372 -0.0285', 'S-1364\t96 Systemorgan-', 'T-1364\t84 System Organ', 'H-1364\t-0.7333984375\t96 System Organ', 'D-1364\t-0.7333984375\t96 System Organ', 'P-1364\t-1.1055 -0.3037 -0.2720 -0.1761 -0.0690', 'S-1490\tIMPRIDA', 'T-1490\tIMPRIDA', 'H-1490\t-1.4248046875\tIMPRIDA', 'D-1490\t-1.4248046875\tIMPRIDA', 'P-1490\t-2.6055 -0.7720 -0.2593 -0.0676 -0.0366', 'S-1544\tSANDOZ', 'T-1544\tSANDOZ', 'H-1544\t-0.4501953125\tSANDOZ', 'D-1544\t-0.4501953125\tSANDOZ', 'P-1544\t-1.0654 -0.0310 -0.0254 -0.0282 -0.0331', 'S-1681\t2 (1)', 'T-1681\t15 (7)', 'H-1681\t-0.41357421875\t2 ( 1 )', 'D-1681\t-0.41357421875\t2 (1)', 'P-1681\t-0.3135 -0.0768 -0.6255 -0.0282 -0.0423', 'S-1745\t↔ 1,00 *', 'T-1745\t↔ 1.00 *', 'H-1745\t-1.62890625\tIbaflin', 'D-1745\t-1.62890625\tIbaflin', 'P-1745\t-1.8066 -0.4155 -0.3228 -0.3228 -1.4102', 'S-1748\tREVASC', 'T-1748\tREVASC', 'H-1748\t-0.56494140625\tREVASC', 'D-1748\t-0.56494140625\tREVASC', 'P-1748\t-1.0977 -0.0923 -0.2430 -0.0169 -0.0338', 'S-1755\tTeve u.', 'T-1755\tTeve u.', 'H-1755\t-0.62646484375\tTeve u .', 'D-1755\t-0.62646484375\tTeve u.', 'P-1755\t-0.9849 -0.5000 -0.0986 -0.0338 -0.0282', 'S-1762\t3 Pipetten', 'T-1762\t3 pipettes', 'H-1762\t-0.25732421875\t3 pipettes', 'D-1762\t-0.25732421875\t3 pipettes', 'P-1762\t-0.3499 -0.2495 -0.0430 -0.0042 -0.0292', 'S-1788\t183 191', 'T-1788\t183 191', 'H-1788\t-2.63671875\t159 160', 'D-1788\t-2.63671875\t159 160', 'P-1788\t-3.0801 -1.6260 -1.1777 -0.1747', 'S-1917\t74,7%', 'T-1917\t74.7%', 'H-1917\t-0.1834716796875\t74.7 %', 'D-1917\t-0.1834716796875\t74.7%', 'P-1917\t-0.2798 -0.0999 -0.0409 -0.0342 -0.0271', 'S-1990\t100 mg / g', 'T-1990\t100 mg / g', 'H-1990\t-0.1697998046875\t100 mg / g', 'D-1990\t-0.1697998046875\t100 mg / g', 'P-1990\t-0.3462 -0.0070 -0.0320 -0.0299 -0.0306', 'S-1991\t- Lactose', 'T-1991\t- Lactose', 'H-1991\t-0.82373046875\t- lactose', 'D-1991\t-0.82373046875\t- lactose', 'P-1991\t-0.7100 -1.3994 -0.0099 -0.0127 -0.0310', 'S-52\tLaboratories', 'T-52\tGlaxo Group UK', 'H-52\t-1.73828125\tLANZI', 'D-52\t-1.73828125\tLANZI', 'P-52\t-2.8438 -0.8550 -0.3494 -0.4875 -0.0310', 'S-674\tInnerer Karton', 'T-674\tInner carton text', 'H-674\t-0.46875\tbutton', 'D-674\t-0.46875\tbutton', 'P-674\t-0.4075 -0.3032', 'S-98\trascher Herzschlag', 'T-98\tblood pressure dropping heart beating fast', 'H-98\t-0.5791015625\tRapid heartbeat', 'D-98\t-0.5791015625\tRapid heartbeat', 'P-98\t-0.4902 -0.7881 -0.0211 -0.0303', 'S-1010\tTransparenz und Offenheit', 'T-1010\tTransparency and openness', 'H-1010\t-0.249755859375\tOpenness and transparency', 'D-1010\t-0.249755859375\tOpenness and transparency', 'P-1010\t-0.3223 -0.0199 -0.0206 -0.2427 -0.0901 -0.0363', 'S-1343\t≥ 1: 8', 'T-1343\t≥ 1 micrograms / ml', 'H-1343\t-0.360107421875\t≥ 1 : 8', 'D-1343\t-0.360107421875\t≥ 1: 8', 'P-1343\t-0.4036 -0.0313 -0.0292 -0.0334 -0.4485', 'S-1282\t= 5,93 Monate', 'T-1282\tMedian OS = 5.93 months', 'H-1282\t-0.53125\t= 5.93 months', 'D-1282\t-0.53125\t= 5.93 months', 'P-1282\t-1.2734 -0.0465 -0.0197 -0.0254 -0.0296', 'S-131\tLondon, 18.', 'T-131\tLondon, 18 October 2006 Doc.', 'H-131\t-1.9951171875\tLondon , 11 October 2008 Doc .', 'D-131\t-1.9951171875\tLondon, 11 October 2008 Doc.', 'P-131\t-0.0285 -0.0451 -3.2129 -1.3916 -1.9668 -0.3213 -0.3157 -0.1465 -0.0282', 'S-30\t100 SR80', 'T-30\tat least 100 SR801 at least 100 SR80 at least 100 SR80 at least 100 SR80 at least 100 SR80', 'H-30\t-2.34375\t100 shares', 'D-30\t-2.34375\t100 shares', 'P-30\t-0.5684 -3.9316 -0.0310', 'S-506\tDarüber hinaus sollte die', 'T-506\tUntil additional data become available, Zerit should be given during pregnancy only after special consideration; there is insufficient information to recommend Zerit for prevention of mother-to-child transmission of HIV.', 'H-506\t-1.8271484375\tIn addition , special attention should be paid to blood pressure monitoring during treatment .', 'D-506\t-1.8271484375\tIn addition, special attention should be paid to blood pressure monitoring during treatment.', 'P-506\t-0.7749 -0.5024 -0.3247 -2.0703 -0.3269 -0.0479 -0.0535 -0.0958 -0.0986 -0.8789 -0.2649 -0.3071 -0.3972 -0.4622 -3.0039 -0.0338', 'S-1481\tDosisunterbrechung', 'T-1481\tDose Interruption', 'H-1481\t-1.2353515625\tNo recommendation', 'D-1481\t-1.2353515625\tNo recommendation', 'P-1481\t-2.2227 -0.4382 -0.0310 -0.1465', 'S-1402\tWas ist Tarceva?', 'T-1402\tWhat is Tarceva?', 'H-1402\t-0.053985595703125\tWhat is Tarceva ?', 'D-1402\t-0.053985595703125\tWhat is Tarceva?', 'P-1402\t-0.0313 -0.0321 -0.0227 -0.0248 -0.0056 -0.0284 -0.0284', 'S-1374\tVECTIBIX', 'T-1374\tVECTIBIX', 'H-1374\t-1.23046875\tVECTIBIX', 'D-1374\t-1.23046875\tVECTIBIX', 'P-1374\t-0.8770 -2.9219 -0.0451 -0.0169 -0.0338 -0.0254 -0.0366', 'S-1335\t24,8 ± 59,7', 'T-1335\t24.8 ± 59.7', 'H-1335\t-1.2880859375\t24.8 ± 59.7', 'D-1335\t-1.2880859375\t24.8 ± 59.7', 'P-1335\t-3.6230 -0.0535 -0.1465 -0.0282 -0.0225 -0.0282 -0.2395', 'S-1163\tWas ist Abseamed?', 'T-1163\tWhat is Abseamed?', 'H-1163\t-0.1490478515625\tWhat is Abseamed ?', 'D-1163\t-0.1490478515625\tWhat is Abseamed?', 'P-1163\t-0.0619 -0.0517 -0.1553 -0.1326 -0.0190 -0.0299 -0.0285', 'S-1154\tWas ist Orfadin?', 'T-1154\tWhat is Orfadin?', 'H-1154\t-0.06341552734375\tWhat is Orfadin ?', 'D-1154\t-0.06341552734375\tWhat is Orfadin?', 'P-1154\t-0.0349 -0.0357 -0.0451 -0.0142 -0.0156 -0.0299 -0.0285', 'S-1153\t20131 Milano, Italy', 'T-1153\t20131 Milano, Italy', 'H-1153\t-0.31982421875\t20131 Milano , Italy', 'D-1153\t-0.31982421875\t20131 Milano, Italy', 'P-1153\t-0.2451 -0.0430 -0.1831 -0.0148 -0.2974 -0.0240 -0.2205', 'S-1069\tPharmacia Ltd.', 'T-1069\tPharmacia Ltd.', 'H-1069\t-0.185791015625\tPharmacia Ltd .', 'D-1069\t-0.185791015625\tPharmacia Ltd.', 'P-1069\t-0.3955 -0.0099 -0.0211 -0.0775 -0.0236 -0.0416 -0.0278', 'S-854\tMasitinib 50 mg', 'T-854\tMasitinib 50 mg', 'H-854\t-0.042022705078125\tMasitinib 50 mg', 'D-854\t-0.042022705078125\tMasitinib 50 mg', 'P-854\t-0.0206 -0.0056 -0.0035 -0.0242 -0.0400 -0.0113 -0.0299', 'S-667\tCLOMICALM', 'T-667\tCLOMICALM', 'H-667\t-1.5947265625\tCIRCUMENTS', 'D-667\t-1.5947265625\tCIRCUMENTS', 'P-667\t-0.3213 -2.9902 -0.0676 -0.1353 -1.1016 -0.3467 -0.1635', 'S-598\t94,1 100,0', 'T-598\t94.1 100.0', 'H-598\t-1.501953125\t96.5 100.0', 'D-598\t-1.501953125\t96.5 100.0', 'P-598\t-0.6973 -2.4023 -1.1611 -0.0760 -0.0310 -0.0338', 'S-76\tDickflüssiges Paraffin', 'T-76\tLiquid paraffin', 'H-76\t-0.60595703125\tLiquid paraffin', 'D-76\t-0.60595703125\tLiquid paraffin', 'P-76\t-0.9648 -0.0458 -0.0042 -0.3635 -0.0155 -0.0282 -0.5249', 'S-53\t1 Durchstechflasche +', 'T-53\t1.0 ml (1 million', 'H-53\t-0.740234375\t1 vial + 1 ampoule', 'D-53\t-0.740234375\t1 vial + 1 ampoule', 'P-53\t-0.0313 -0.0841 -0.0234 -0.0415 -1.1426 -1.2764 -0.1014 -0.0225 -0.0423', 'S-36\tScholtzstr.', 'T-36\tScholtzstr.', 'H-36\t-0.7958984375\tScholtzstr .', 'D-36\t-0.7958984375\tScholtzstr.', 'P-36\t-2.1387 -0.0113 -0.0592 -0.2720 -0.0141 -0.0338 -0.0296', 'S-1431\tSiehe Abbildung 1.', 'T-1431\tSee Figure 1.', 'H-1431\t-0.09405517578125\tSee Figure 1 .', 'D-1431\t-0.09405517578125\tSee Figure 1.', 'P-1431\t-0.0472 -0.1106 -0.0213 -0.0299 -0.0379 -0.0285', 'S-1034\t- grippeähnliche Symptome', 'T-1034\t- flu-like symptoms', 'H-1034\t-0.1448974609375\t- flu @-@ like symptoms', 'D-1034\t-0.1448974609375\t- flu-like symptoms', 'P-1034\t-0.0342 -0.2351 -0.0634 -0.0407 -0.0183 -0.0327', 'S-1067\t0 1 2 ≥ 3 1', 'T-1067\t≥ 3', 'H-1067\t-0.455322265625\t0 1 2 ≥ 3 1', 'D-1067\t-0.455322265625\t0 1 2 ≥ 3 1', 'P-1067\t-1.3027 -0.0345 -0.0373 -0.0042 -0.0275 -0.0296 -0.0282', 'S-1725\t511 70 K.', 'T-1725\t511 70 K.', 'H-1725\t-2.408203125\tNew issues to be faced in 2003 with workload implications', 'D-1725\t-2.408203125\tNew issues to be faced in 2003 with workload implications', 'P-1725\t-3.7109 -0.3240 -0.3184 -0.2676 -0.3213 -0.3467 -0.3269 -0.5718 -0.3325 -0.2986 -0.3213 -3.5566', 'S-1036\tDie entsprechenden t lä', 'T-1036\tThe corresponding incidences in patients receiving the recommended regimen of enoxaparin in the treatment of DVT were 2.3% (13 / 559), 4.6% (17 / 368), 9.7% (14 / 145)', 'H-1036\t-2.458984375\t200 D', 'D-1036\t-2.458984375\t200 D', 'P-1036\t-2.2734 -1.7178 -0.7637', 'S-788\tQuartal 2007 vorliegen muss.', 'T-788\tThis should include a proposal to assess the efficacy and safety of Yondelis in a sub-group of patients with myxoid liposarcoma and will be submitted to the EMEA by 4Q 2007.', 'H-788\t-1.6962890625\tYour doctor will have already advised you .', 'D-788\t-1.6962890625\tYour doctor will have already advised you.', 'P-788\t-2.6172 -0.4058 -0.5298 -0.7690 -0.8452 -0.3213 -0.1324 -0.6904 -0.0282', 'S-852\tWenn während der zn', 'T-852\tThese agents include desirudin, fibrinolytic agents, GP IIb / IIIa receptor antagonists, na', 'H-852\t-2.5\tDuring treatment of VTE , concomitant', 'D-852\t-2.5\tDuring treatment of VTE, concomitant', 'P-852\t-2.1250 -0.8228 -0.4338 -0.3606 -0.5835 -0.1917 -0.3662 -0.3240 -0.1465 -0.0901 -5.0898', 'S-1857\tDie Bildung von Ar', 'T-1857\tThe production of erythropoietin primarily occurs in and is regulated by the M', 'H-1857\t-2.353515625\tThe formation of ro', 'D-1857\t-2.353515625\tThe formation of ro', 'P-1857\t-2.1621 -2.0234 -0.0310 -0.5859 -1.3809', 'S-1653\t8 mg / kg +', 'T-1653\tTCZ MTX TCZ PBO TCZ PBO TCZ', 'H-1653\t-0.2467041015625\t8 mg / kg +', 'D-1653\t-0.2467041015625\t8 mg / kg +', 'P-1653\t-0.6143 -0.0056 -0.0313 -0.0134 -0.0285 -0.0296', 'S-1223\t"Probenzeit:', 'T-1223\tFill up the second sample tube (Label <<unk>> Sampling time:', 'H-1223\t-0.280517578125\tSampling time :', 'D-1223\t-0.280517578125\tSampling time:', 'P-1223\t-0.3303 -0.2771 -0.0257 -0.1313 -0.0296 -0.0282', 'S-1752\tXELOX oder', 'T-1752\tor XELOX + Avastin', 'H-1752\t-0.69482421875\tXELOX or', 'D-1752\t-0.69482421875\tXELOX or', 'P-1752\t-0.8374 -0.0197 -0.0275 -0.0240 -0.4580 -0.6694', 'S-699\t(LDPE)', 'T-699\tBottle (LDPE)', 'H-699\t-1.455078125\t55 EMEA General Report 2000', 'D-699\t-1.455078125\t55 EMEA General Report 2000', 'P-699\t-2.6914 -0.8325 -0.3213 -0.0732 -0.3213 -0.3213 -0.3381 -0.1663', 'S-1771\tge Kinder und Jugendliche:', 'T-1771\ted Children and adolescents:', 'H-1771\t-0.8388671875\ted children and adolescents :', 'D-1771\t-0.8388671875\ted children and adolescents:', 'P-1771\t-1.9883 -0.5410 -0.0296 -0.2507 -0.0155 -0.0169 -0.0493 -0.0310', 'S-837\tStudie 2301:', 'T-837\tStudy 2301:', 'H-837\t-0.3212890625\tStudy 231 :', 'D-837\t-0.3212890625\tStudy 231:', 'P-837\t-0.0826 -0.0099 -0.4407 -0.0539 -0.0306 -0.3240', 'S-407\tWie wirkt Intelence?', 'T-407\tHow does Intelence work?', 'H-407\t-0.173095703125\tHow does Intelence work ?', 'D-407\t-0.173095703125\tHow does Intelence work?', 'P-407\t-0.1273 -0.1974 -0.0863 -0.0134 -0.0722 -0.0313 -0.0285', 'S-133\t5 mg Hartkapseln', 'T-133\t5 mg hard capsules', 'H-133\t-0.21630859375\t5 mg hard capsules', 'D-133\t-0.21630859375\t5 mg hard capsules', 'P-133\t-0.4131 -0.0141 -0.1127 -0.0760 -0.0141 -0.0356 -0.0292', 'S-73\t5 kg / t *', 'T-73\t5 kg / tonne *', 'H-73\t-0.432861328125\t5 kg / tonne *', 'D-73\t-0.432861328125\t5 kg / tonne *', 'P-73\t-0.7085 -0.0211 -0.0303 -0.5620 -0.0127 -0.0275 -0.0289', 'S-1912\tEmselex 7,5 mg', 'T-1912\tEmselex 7.5 mg', 'H-1912\t-0.08111572265625\tEmselex 7.5 mg', 'D-1912\t-0.08111572265625\tEmselex 7.5 mg', 'P-1912\t-0.0371 -0.0328 -0.0106 -0.1175 -0.0106 -0.0292', 'S-946\tbis 500 mg 2-mal täglich', 'T-946\tdaily to 500 mg', 'H-946\t-1.3515625\tup to 500 mg twice daily', 'D-946\t-1.3515625\tup to 500 mg twice daily', 'P-946\t-2.9922 -0.0282 -0.4312 -0.0197 -0.2563 -0.5776 -0.0366', 'S-1172\tEinzeldosisbehältnis', 'T-1172\tSingle-dose container', 'H-1172\t-0.990234375\tSingle @-@ dose container', 'D-1172\t-0.990234375\tSingle-dose container', 'P-1172\t-0.9121 -0.2021 -0.0148 -1.1729 -0.3000', 'S-1534\tL01XX05.', 'T-1534\tL01XX05.', 'H-1534\t-0.324462890625\tL01XX05 .', 'D-1534\t-0.324462890625\tL01XX05.', 'P-1534\t-0.3074 -0.2394 -0.0271 -0.1687 -0.0331 -0.2395 -0.0282', 'S-1581\t4,23% 0,71%', 'T-1581\t4.23% 0.71%', 'H-1581\t-0.81201171875\t4.23 %', 'D-1581\t-0.81201171875\t4.23%', 'P-1581\t-0.7251 -0.2551 -0.0317 -0.8540', 'S-1828\tSelamectin 120 mg', 'T-1828\tSelamectin 120 mg', 'H-1828\t-0.0838623046875\tSelamectin 120 mg', 'D-1828\t-0.0838623046875\tSelamectin 120 mg', 'P-1828\t-0.0841 -0.0228 -0.0184 -0.0263 -0.0796 -0.0085 -0.0299', 'S-1907\tGenfarma B.V.', 'T-1907\tGenfarma B. V.', 'H-1907\t-1.64453125\t• Genfarma B. V .', 'D-1907\t-1.64453125\t• Genfarma B. V.', 'P-1907\t-1.1074 -1.0352 -2.6914 -0.0282 -0.6650 -0.1099 -0.0592 -0.0282', 'S-1956\t8 (10,0%)', 'T-1956\t8 (10.0%)', 'H-1956\t-0.302734375\t8 ( 10.0 % )', 'D-1956\t-0.302734375\t8 (10.0%)', 'P-1956\t-0.4255 -0.0306 -0.3899 -0.0380 -0.0310 -0.0282 -0.0296', 'S-284\tBeilegung von Streitfällen.', 'T-284\tContact addresses of the national competent', 'H-284\t-0.419189453125\tDispute Settlement .', 'D-284\t-0.419189453125\tDispute Settlement.', 'P-284\t-0.3091 -0.0234 -0.3188 -0.0127 -0.0197 -0.6357 -0.0282', 'S-334\tSystemische Nebenwirkungen:', 'T-334\tSystemic undesirable effects:', 'H-334\t-0.41064453125\tSystemic side effects :', 'D-334\t-0.41064453125\tSystemic side effects:', 'P-334\t-0.3364 -0.0113 -0.0176 -0.6216 -0.0557 -0.2494 -0.0282', 'S-658\tErwachsene unter Hämodialyse', 'T-658\tAdults receiving haemodialysis', 'H-658\t-0.505859375\tAdults receiving haemodialysis', 'D-658\t-0.505859375\tAdults receiving haemodialysis', 'P-658\t-0.1357 -0.5713 -0.3318 -0.2903 -0.0134 -0.0162 -0.0099 -0.0240 -0.4980', 'S-1536\tUCB Pharma Ltd.', 'T-1536\tUnited Kingdom UCB Pharma Ltd.', 'H-1536\t-0.06036376953125\tUCB Pharma Ltd .', 'D-1536\t-0.06036376953125\tUCB Pharma Ltd.', 'P-1536\t-0.0113 -0.0170 -0.0597 -0.0184 -0.0191 -0.0400 -0.0285', 'S-1038\t22.08.97 17.11.97', 'T-1038\ta) 22.08.97 b) 17.11.97', 'H-1038\t-1.6796875\t17.11.97 05.08.97', 'D-1038\t-1.6796875\t17.11.97 05.08.97', 'P-1038\t-2.8145 -0.0366 -0.0183 -1.3154 -1.0879 -0.0760 -0.0507', 'S-1711\tNespo 130 µg', 'T-1711\tNespo 130 µg Darbepoetin alfa IV / SC', 'H-1711\t-1.19140625\tNespo 130 µg', 'D-1711\t-1.19140625\tNespo 130 µg', 'P-1711\t-0.0531 -0.0357 -0.0306 -1.1973 -0.0176 -0.0197 -2.4746', 'S-491\tDyskinesien, häufiger', 'T-491\t- In clinical studies, undesirable dopaminergic effects, e. g. dyskinesia, were more common in', 'H-491\t-0.80029296875\tDyskinesia , more frequent', 'D-491\t-0.80029296875\tDyskinesia, more frequent', 'P-491\t-1.1992 -0.0134 -0.0148 -0.5845 -0.0437 -0.0423 -0.8579 -0.0310', 'S-1424\tSystemorganklass Sehr häufig', 'T-1424\t61 Table 1 shows the categorized incidence of the adverse reactions, which occurred in the clinical trials statistically significantly more frequently during treatment with Remeron than with placebo, added with adverse reactions from spontaneous reporting.', 'H-1424\t-0.63330078125\tSystem Organ Class Very common', 'D-1424\t-0.63330078125\tSystem Organ Class Very common', 'P-1424\t-0.5435 -0.4915 -0.0049 -0.3396 -0.2352 -0.1550 -0.2664', 'S-420\tAls Begleittherapie erhielten 79', 'T-420\tge Trudexa 40 mg every other week was assessed in 393 patients in two randomised, 24 week double − blind, placebo − controlled studies in patients with active ankylosing spondylitis (mean lon baseline score of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.3 in all groups) who have had an inadequate response to conventional therapy.', 'H-420\t-1.982421875\tRitonavir treatment', 'D-420\t-1.982421875\tRitonavir treatment', 'P-420\t-2.6562 -0.3228 -0.3213 -0.1437 -1.1670 -1.2002', 'S-711\t1 Fertigspritze mit 0,5 ml', 'T-711\t1 pre-filled syringe with 0.5 ml', 'H-711\t-0.352294921875\t1 pre @-@ filled syringe with 0.5 ml', 'D-711\t-0.352294921875\t1 pre-filled syringe with 0.5 ml', 'P-711\t-0.0256 -0.8359 -0.0282 -0.1655 -0.0113 -0.0063 -0.0042 -0.1465 -0.2191 -0.0113 -0.0310', 'S-578\tWie wurde Sifrol untersucht?', 'T-578\tHow has Sifrol been studied?', 'H-578\t-0.2166748046875\tHow has Sifrol been studied ?', 'D-578\t-0.2166748046875\tHow has Sifrol been studied?', 'P-578\t-0.0299 -0.2859 -0.1281 -0.0141 -0.0243 -0.0299 -0.2395 -0.0296 -0.0282', 'S-607\tKatzen älter als 8 Wochen.', 'T-607\tCats over 8 weeks of age.', 'H-607\t-0.47265625\tCats over 8 weeks of age .', 'D-607\t-0.47265625\tCats over 8 weeks of age.', 'P-607\t-0.9419 -0.0289 -0.3599 -0.0359 -0.0211 -0.2747 -0.0211 -0.0549 -0.0282', 'S-1146\tWie wurde Cystadane untersucht?', 'T-1146\tHow has Cystadane been studied?', 'H-1146\t-0.240966796875\tHow has Cystadane been studied ?', 'D-1146\t-0.240966796875\tHow has Cystadane been studied?', 'P-1146\t-0.0285 -0.2842 -0.2607 -0.0085 -0.0285 -0.0299 -0.2021 -0.0296 -0.0282', 'S-1292\tDas Trockenmittel nicht entfernen.', 'T-1292\tDo not remove the desiccant.', 'H-1292\t-0.412841796875\tDo not remove the desiccant .', 'D-1292\t-0.412841796875\tDo not remove the desiccant.', 'P-1292\t-0.7832 -0.0282 -0.0247 -0.1332 -0.1831 -0.0021 -0.0218 -0.3367 -0.0296', 'S-1400\tWarum wurde Hycamtin zugelassen?', 'T-1400\tWhy has Hycamtin been approved?', 'H-1400\t-0.2427978515625\tWhy has Hycamtin been approved ?', 'D-1400\t-0.2427978515625\tWhy has Hycamtin been approved?', 'P-1400\t-0.1910 -0.2485 -0.2585 -0.0141 -0.0113 -0.0268 -0.0993 -0.0296 -0.0282', 'S-1630\tWarum wurde Erbitux zugelassen?', 'T-1630\tWhy has Erbitux been approved?', 'H-1630\t-0.1866455078125\tWhy has Erbitux been approved ?', 'D-1630\t-0.1866455078125\tWhy has Erbitux been approved?', 'P-1630\t-0.1992 -0.2629 -0.0271 -0.0099 -0.0127 -0.0313 -0.0955 -0.0306 -0.0285', 'S-1978\tKapitel 2 Humanarzneimittel', 'T-1978\tChapter 2 Medicines for human use', 'H-1978\t-0.646484375\tChapter 2 Medicines for Human Use', 'D-1978\t-0.646484375\tChapter 2 Medicines for Human Use', 'P-1978\t-0.0085 -0.0242 -0.0320 -0.0945 -1.1992 -0.0268 -0.7285 -0.0155 -0.2874', 'S-460\tEin DSMB sollte eingerichtet werden.', 'T-460\tA DSMB should be set-up.', 'H-460\t-0.90966796875\tA DSMB should be created .', 'D-460\t-0.90966796875\tA DSMB should be created.', 'P-460\t-0.6313 -0.0176 -0.0113 -0.0486 -0.0342 -1.8818 -0.0352 -0.5059', 'S-757\tPharmakovigilanzsystem:', 'T-757\tPharmacovigilance system:', 'H-757\t-0.3740234375\tPharmacovigilance :', 'D-757\t-0.3740234375\tPharmacovigilance:', 'P-757\t-0.1366 -0.3176 -0.0225 -0.0162 -0.0049 -0.0127 -0.0211 -0.8389 -0.0275', 'S-465\tWarum wurde Reconcile zugelassen?', 'T-465\tWhy has Reconcile been approved?', 'H-465\t-0.1553955078125\tWhy has Reconcile been approved ?', 'D-465\t-0.1553955078125\tWhy has Reconcile been approved?', 'P-465\t-0.0349 -0.2712 -0.0870 -0.0169 -0.0169 -0.0285 -0.0655 -0.0313 -0.0285', 'S-986\tWARTEZEITEN', 'T-986\tWITHDRAWAL PERIODS', 'H-986\t-1.0361328125\tPRESENTATION', 'D-986\t-1.0361328125\tPRESENTATION', 'P-986\t-1.3242 -0.2803 -0.0254 -0.0324 -0.2537 -0.5283 -0.8862', 'S-1557\tWeitere Informationen über Tysabri:', 'T-1557\t2 / 3 Other information about Tysabri:', 'H-1557\t-0.1912841796875\tOther information about Tysabri :', 'D-1557\t-0.1912841796875\tOther information about Tysabri:', 'P-1557\t-0.3223 -0.0504 -0.1616 -0.0162 -0.0099 -0.0127 -0.0641 -0.0285', 'S-1620\t(1,89; 5,24)', 'T-1620\t3.57% (1.89, 5.24)', 'H-1620\t-0.451904296875\t( 1.89 , 5.24 )', 'D-1620\t-0.451904296875\t(1.89, 5.24)', 'P-1620\t-0.2179 -0.5396 -0.0345 -0.3184 -0.0760 -0.0331 -0.0282 -0.3262', 'S-157\tAlternative Injektionsstellen sind die', 'T-157\tAlternate sites are the abdomen or outer', 'H-157\t-0.39404296875\tAlternative injection sites are :', 'D-157\t-0.39404296875\tAlternative injection sites are:', 'P-157\t-0.1782 -0.3364 -0.0183 -0.0518 -0.0588 -0.2935 -0.3303', 'S-1421\t33.45% 1.91%', 'T-1421\t33.45% 1.91% 2.44% 39.80%', 'H-1421\t-0.455078125\t33.45 % 1.91 %', 'D-1421\t-0.455078125\t33.45% 1.91%', 'P-1421\t-1.4111 -0.0240 -0.0190 -0.0296 -0.0282 -0.0169 -0.0282 -0.0282', 'S-1776\tVedaprofen Equiden', 'T-1776\t7 Hydrochloric acid Propylene glycol2', 'H-1776\t-0.94677734375\tVedaprofen Sandoz', 'D-1776\t-0.94677734375\tVedaprofen Sandoz', 'P-1776\t-0.5142 -0.0313 -0.0211 -0.0342 -0.0225 -2.1895 -0.3718 -0.3213 -0.0338', 'S-1972\tWie wirkt Thymanax?', 'T-1972\tReproduction is authorised provided the source is acknowledged. control of mood.', 'H-1972\t-0.186279296875\tHow does Thymanax work ?', 'D-1972\t-0.186279296875\tHow does Thymanax work?', 'P-1972\t-0.0722 -0.4272 -0.0292 -0.0285 -0.0257 -0.0134 -0.0416 -0.0299 -0.0285', 'S-977\t16.000 ATE / mg.', 'T-977\tThe specific activity of lepirudin is approximately 16,000 ATU / mg.', 'H-977\t-0.90185546875\t16,000 ATU / mg .', 'D-977\t-0.90185546875\t16,000 ATU / mg.', 'P-977\t-2.4102 -0.3169 -0.0662 -0.2227 -0.0310 -0.0169 -0.0479 -0.0282', 'S-1377\tFebruar 2000 vom Verwaltungsrat verabschiedet.', 'T-1377\t(*) Preliminary draft budget for 2001 adopted by the Management Board 22 February 2000.', 'H-1377\t-1.6669921875\tThis work programme was adopted by the Management Board on 07 February 2000 .', 'D-1377\t-1.6669921875\tThis work programme was adopted by the Management Board on 07 February 2000.', 'P-1377\t-0.4226 -0.5566 -0.4092 -2.8438 -0.2620 -0.9160 -0.0366 -1.0908 -0.0451 -0.7046 -0.8452 -0.2367 -0.0282 -0.0395 -0.0282', 'S-554\tWeitere Informationen über Crixivan:', 'T-554\tOther information about Crixivan:', 'H-554\t-0.185302734375\tOther information about Crixivan :', 'D-554\t-0.185302734375\tOther information about Crixivan:', 'P-554\t-0.3223 -0.0581 -0.1276 -0.0218 -0.0127 -0.0106 -0.0634 -0.0285', 'S-1541\tVerschlimmerung der Wunde', 'T-1541\tWound complication', 'H-1541\t-0.92138671875\t5 Worsening of the wound', 'D-1541\t-0.92138671875\t5 Worsening of the wound', 'P-1541\t-1.6641 -0.3311 -0.0901 -0.0268 -0.1606 -0.4297 -0.1761 -0.3311', 'S-1735\tBlaue Tinte, enthält:', 'T-1735\tBlue ink containing:', 'H-1735\t-0.53564453125\tBlue ink containing :', 'D-1735\t-0.53564453125\tBlue ink containing:', 'P-1735\t-0.3962 -0.0961 -0.3142 -0.5654 -0.0345', 'S-652\tCis + 5-FU', 'T-652\t+ 5-FU', 'H-652\t-0.88330078125\tCis + 5 @-@ FU', 'D-652\t-0.88330078125\tCis + 5-FU', 'P-652\t-2.1152 -0.0606 -0.0380 -0.0423 -0.7188 -0.0535 -0.0169 -0.0310', 'S-1016\t((Innenseite 2))', 'T-1016\t((Inside 2))', 'H-1016\t-0.69140625\t( ( Inside 1 ) )', 'D-1016\t-0.69140625\t((Inside 1))', 'P-1016\t-1.1387 -0.2458 -0.3762 -0.3621 -0.0296 -0.0352 -0.0338', 'S-1792\tzentralen Verfahren erfaßt wurden.', 'T-1792\tthe centralised procedure.', 'H-1792\t-1.255859375\tCPMP activities', 'D-1792\t-1.255859375\tCPMP activities', 'P-1792\t-0.8291 -1.3740 -0.3198 -0.3706 -0.4058', 'S-143\tLorastad 1 mg / ml', 'T-143\tLorastad 1 mg / ml', 'H-143\t-0.060577392578125\tLorastad 1 mg / ml', 'D-143\t-0.060577392578125\tLorastad 1 mg / ml', 'P-143\t-0.0429 -0.0127 -0.0170 -0.0531 -0.0070 -0.0313 -0.0156 -0.0312', 'S-308\tWeitere Informationen über Mycamine:', 'T-308\tOther information about Mycamine:', 'H-308\t-0.299072265625\tOther information about Mycamine :', 'D-308\t-0.299072265625\tOther information about Mycamine:', 'P-308\t-0.6694 -0.0620 -0.1515 -0.0282 -0.0120 -0.0345 -0.0557 -0.0282', 'S-343\t10 U Reteplase', 'T-343\t10 U reteplase', 'H-343\t-1.3447265625\t10 U Reteplase', 'D-343\t-1.3447265625\t10 U Reteplase', 'P-343\t-0.6558 -0.6235 -2.6602 -0.0113 -0.0282 -0.0169 -0.0254 -0.6621', 'S-381\t(0,84; 1,49)', 'T-381\t(0.84, 1.49)', 'H-381\t-0.2685546875\t( 0.84 , 1.49 )', 'D-381\t-0.2685546875\t(0.84, 1.49)', 'P-381\t-0.3689 -0.1082 -0.0313 -0.3196 -0.0345 -0.0141 -0.0296 -0.0296', 'S-1333\tPatienten mit niedrigem Körpergewicht:', 'T-1333\td Low body weight', 'H-1333\t-0.87841796875\tLow body weight patients :', 'D-1333\t-0.87841796875\tLow body weight patients:', 'P-1333\t-1.7500 -0.1437 -0.0310 -0.5889 -0.0324 -0.0282', 'S-651\tInjektion der Dosis:', 'T-651\tInjecting the Dose:', 'H-651\t-0.72998046875\tInjecting the Dose :', 'D-651\t-0.72998046875\tInjecting the Dose:', 'P-651\t-0.3428 -0.3188 -0.0479 -0.1247 -1.2021 -0.0380 -0.4395 -0.0282', 'S-694\tNur zur intravenösen Anwendung', 'T-694\tFor intravenous use only', 'H-694\t-0.6630859375\tFor intravenous use only', 'D-694\t-0.6630859375\tFor intravenous use only', 'P-694\t-0.4607 -0.5239 -0.0232 -0.0099 -0.0211 -0.4573 -0.0240 -0.7876', 'S-1174\t5 mg Tacrolimus', 'T-1174\t5 mg tacrolimus.', 'H-1174\t-0.55712890625\t5 mg tacrolimus .', 'D-1174\t-0.55712890625\t5 mg tacrolimus.', 'P-1174\t-0.6108 -0.0113 -0.2135 -0.0310 -0.0296 -0.0063 -1.0098 -0.0282', 'S-1357\t51 (65 / 127)', 'T-1357\t51 (65 / 127)', 'H-1357\t-1.3330078125\t51 ( 66 / 127 )', 'D-1357\t-1.3330078125\t51 (66 / 127)', 'P-1357\t-1.7529 -0.0296 -2.7070 -0.0310 -0.0366 -0.0282 -0.0282 -0.0282', 'S-1660\tNalion comprimidos', 'T-1660\tNalion comprimidos', 'H-1660\t-1.5537109375\tNalion comprimidos', 'D-1660\t-1.5537109375\tNalion comprimidos', 'P-1660\t-3.5586 -0.0366 -0.0282 -1.6738 -0.0197 -0.0338 -0.0282 -0.0310', 'S-1763\tWeitere Informationen über Siklos:', 'T-1763\tOther information about Siklos:', 'H-1763\t-0.291015625\tOther information about Siklos :', 'D-1763\t-0.291015625\tOther information about Siklos:', 'P-1763\t-0.3223 -0.0560 -0.1451 -0.3811 -0.0099 -0.0113 -0.0599 -0.0282', 'S-1836\tHippotrim Vet', 'T-1836\tHippotrim Vet', 'H-1836\t-1.55859375\tHippotrim vet', 'D-1836\t-1.55859375\tHippotrim vet', 'P-1836\t-3.8320 -0.0254 -0.0282 -0.0366 -0.0254 -0.8594 -0.2001', 'S-63\tWie wurde NovoMix untersucht?', 'T-63\tHow has NovoMix been studied?', 'H-63\t-0.279296875\tHow has NovoMix been studied ?', 'D-63\t-0.279296875\tHow has NovoMix been studied?', 'P-63\t-0.3223 -0.2927 -0.0285 -0.0169 -0.0113 -0.0299 -0.2847 -0.0296 -0.0282', 'S-120\tEinnahmen aus der Veranstaltung von Seminaren', 'T-120\tRevenue from the organisation of seminars', 'H-120\t-0.267578125\tRevenue from the organisation of seminars', 'D-120\t-0.267578125\tRevenue from the organisation of seminars', 'P-120\t-0.2900 -0.0706 -0.1053 -0.1838 -0.1990 -0.0296 -0.0620 -0.0225 -0.0373', 'S-1166\t1 Dosis (0,5 ml):', 'T-1166\t1 dose (0.5 ml):', 'H-1166\t-0.342529296875\t1 dose ( 0.5 ml ) :', 'D-1166\t-0.342529296875\t1 dose (0.5 ml):', 'P-1166\t-0.2678 -0.0472 -0.6440 -0.1276 -0.0155 -0.0296 -0.0331 -0.0282', 'S-1599\t3 D-89079 Ulm Deutschland', 'T-1599\t3 D-89079 Ulm Germany', 'H-1599\t-0.330322265625\t3 D @-@ 89079 Ulm Germany', 'D-1599\t-0.330322265625\t3 D-89079 Ulm Germany', 'P-1599\t-0.9243 -0.0204 -0.0282 -0.0225 -0.0155 -0.0106 -0.0042 -0.1818 -0.0275', 'S-1350\tTerfenadin "Stada"', 'T-1350\tTerfenadin "Stada"', 'H-1350\t-0.49169921875\tTerfenadin Stada', 'D-1350\t-0.49169921875\tTerfenadin Stada', 'P-1350\t-0.3716 -0.0155 -0.1663 -0.0243 -0.5552 -0.0310 -0.4170', 'S-1140\tTel: + 39 06 33 18 21', 'T-1140\tTel: + 39 06 33 18 21', 'H-1140\t-0.09014892578125\tTel : + 39 06 33 18 21', 'D-1140\t-0.09014892578125\tTel: + 39 06 33 18 21', 'P-1140\t-0.0678 -0.0894 -0.0291 -0.0192 -0.0213 -0.0234 -0.0262 -0.0262 -0.0342', 'S-1037\t28023 Aravaca Madrid Spanien', 'T-1037\t28023 Aravaca Madrid Spain', 'H-1037\t-0.1021728515625\t28023 Aravaca Madrid Spain', 'D-1037\t-0.1021728515625\t28023 Aravaca Madrid Spain', 'P-1037\t-0.0156 -0.0256 -0.0213 -0.0070 -0.0113 -0.0263 -0.0128 -0.2335 -0.0285', 'S-791\t19 <unk> EMEA 2005 5.', 'T-791\t17 <<unk>> EMEA 2005 5.', 'H-791\t-0.5439453125\t19 EMEA 2005 5 .', 'D-791\t-0.5439453125\t19 EMEA 2005 5.', 'P-791\t-1.4189 -0.3198 -0.0070 -0.0254 -0.0282 -0.0352 -0.0310 -0.0282', 'S-734\tDies wird Ihnen Ihr Arzt erläutern.', 'T-734\tYour doctor will explain this to you.', 'H-734\t-0.7607421875\tYour doctor will explain these to you .', 'D-734\t-0.7607421875\tYour doctor will explain these to you.', 'P-734\t-0.2695 -0.0372 -0.2620 -1.0459 -0.8257 -0.3184 -0.0268 -0.0310 -0.0282', 'S-616\tWie ist Sebivo einzunehmen?', 'T-616\tHow to take Sebivo 4.', 'H-616\t-0.4306640625\tHow to take Sebivo 4 .', 'D-616\t-0.4306640625\tHow to take Sebivo 4.', 'P-616\t-0.2764 -0.0488 -0.5684 -0.0197 -0.0211 -0.0085 -0.3228 -0.3127 -0.0324', 'S-237\t(488-1.543)', 'T-237\t(488-1,543)', 'H-237\t-2.009765625\t( 191 @-@ 21 )', 'D-237\t-2.009765625\t(191-21)', 'P-237\t-0.0414 -2.4727 -2.1250 -0.0395 -1.6680 -0.0395 -0.0789', 'S-199\tSTRONGHOLD 60 mg', 'T-199\tSTRONGHOLD 60 mg', 'H-199\t-0.048065185546875\tSTRONGHOLD 60 mg', 'D-199\t-0.048065185546875\tSTRONGHOLD 60 mg', 'P-199\t-0.0227 -0.0213 -0.0142 -0.0184 -0.0170 -0.0142 -0.0299 -0.0121 -0.0298', 'S-1562\tWofür wird Iscover angewendet?', 'T-1562\tWhat is Iscover used for?', 'H-1562\t-0.270263671875\tWhat is Iscover used for ?', 'D-1562\t-0.270263671875\tWhat is Iscover used for?', 'P-1562\t-0.0759 -0.0977 -0.0532 -0.0185 -0.1252 -0.0334 -0.0292 -0.5073', 'S-1450\tActos 30 mg Tabletten.', 'T-1450\tActos 30 mg tablets.', 'H-1450\t-0.52978515625\tActos 30mg tablets .', 'D-1450\t-0.52978515625\tActos 30mg tablets.', 'P-1450\t-0.6035 -0.0155 -1.0098 -0.0225 -0.0873 -0.0380 -0.0380 -0.0296', 'S-1250\tWie wird Fuzeon angewendet?', 'T-1250\tHow is Fuzeon used?', 'H-1250\t-0.22802734375\tHow is Fuzeon used ?', 'D-1250\t-0.22802734375\tHow is Fuzeon used?', 'P-1250\t-0.3013 -0.1647 -0.0444 -0.0099 -0.0292 -0.1838 -0.0310 -0.0296', 'S-1241\tDiarrhoe, Übelkeit', 'T-1241\tdiarrhoea, nausea', 'H-1241\t-0.64453125\tDiarrhoea , nausea', 'D-1241\t-0.64453125\tDiarrhoea, nausea', 'P-1241\t-1.1914 -0.0077 -0.1803 -0.0225 -0.0409 -0.4509 -0.0070 -0.3438', 'S-1237\tDie Infusionslösung vorsichtig mischen.', 'T-1237\tMix the infusion solution gently.', 'H-1237\t-0.763671875\tGently mix .', 'D-1237\t-0.763671875\tGently mix.', 'P-1237\t-1.2617 -0.0240 -0.0613 -0.6084 -0.0493', 'S-1185\tPackung mit 2x1 Flasche.', 'T-1185\tBox of 2 x 1 bottle.', 'H-1185\t-0.9736328125\tBox of 2 x 1 bottles .', 'D-1185\t-0.9736328125\tBox of 2 x 1 bottles.', 'P-1185\t-1.0508 -0.1353 -1.5078 -0.0718 -0.0352 -0.5044 -0.0535 -0.0310', 'S-1062\tZiehen Sie die Schutzfolie ab', 'T-1062\tPull off paper tab.', 'H-1062\t-1.072265625\tPull off the protective liner', 'D-1062\t-1.072265625\tPull off the protective liner', 'P-1062\t-1.1582 -0.0085 -0.0916 -0.1958 -0.5479 -1.2021 -0.2423', 'S-210\tDrehschwindel Tinnitus', 'T-210\tVertigo Tinnitus', 'H-210\t-0.7626953125\tRapid disorders tinnitus', 'D-210\t-0.7626953125\tRapid disorders tinnitus', 'P-210\t-0.5396 -1.3682 -0.1183 -0.5537 -0.0085 -0.0141 -0.0254 -0.0296', 'S-206\tÜbelkeit (20,0%)', 'T-206\tRash, Alopecia', 'H-206\t-0.8017578125\tGastrointestinal disorders ( 20.0 % )', 'D-206\t-0.8017578125\tGastrointestinal disorders (20.0%)', 'P-206\t-2.2969 -0.0127 -0.0549 -0.0085 -0.0169 -0.3213 -0.0183 -0.0324 -0.2451 -0.0338 -0.0282 -0.0310 -0.6367', 'S-188\trz Natriumhydroxid', 'T-188\t6.2 Incompatibilities in', 'H-188\t-1.1513671875\tIngredients Sodium hydroxide', 'D-188\t-1.1513671875\tIngredients Sodium hydroxide', 'P-188\t-1.9385 -0.4128 -0.0564 -0.0254 -1.9912 -0.0113 -0.0648 -0.0197 -0.0254 -0.0366', 'S-184\tCervarix ist ein Impfstoff.', 'T-184\tCervarix is a vaccine.', 'H-184\t-0.0654296875\tCervarix is a vaccine .', 'D-184\t-0.0654296875\tCervarix is a vaccine.', 'P-184\t-0.0127 -0.0313 -0.0270 -0.0342 -0.0349 -0.0284 -0.0306 -0.0285', 'S-108\tWofür wird Zerit angewendet?', 'T-108\tWhat is Zerit used for?', 'H-108\t-0.1502685546875\tWhat is Zerit used for ?', 'D-108\t-0.1502685546875\tWhat is Zerit used for?', 'P-108\t-0.0916 -0.0842 -0.1304 -0.0444 -0.0835 -0.0327 -0.0271 -0.0292', 'S-935\t40 mg Humira jede zweite Woche', 'T-935\t40 mg Humira', 'H-935\t-0.5673828125\tevery other week', 'D-935\t-0.5673828125\tevery other week', 'P-935\t-0.8438 -0.1113 -0.0225 -0.3254', 'S-901\tPatienten mit Nierenfunktionsstörung', 'T-901\tRenal impaired patients', 'H-901\t-0.826171875\tPatients with impaired renal function', 'D-901\t-0.826171875\tPatients with impaired renal function', 'P-901\t-0.7769 -0.0225 -0.2859 -1.1719 -0.1747 -0.5605 -0.0254 -0.0395 -0.0310', 'S-859\t<unk> Phäochromozytom', 'T-859\tAbbott GmbH & Co.', 'H-859\t-0.2841796875\tPhaeochromocytoma', 'D-859\t-0.2841796875\tPhaeochromocytoma', 'P-859\t-0.2485 -0.3796 -0.0606 -0.0085 -0.0240 -0.0416 -0.0092 -0.0070 -0.0268 -0.3254', 'S-1176\t0,47 mg bis 2,5 mg).', 'T-1176\tFollowing a single', 'H-1176\t-0.6533203125\t0.47 mg to 2.5 mg ) .', 'D-1176\t-0.6533203125\t0.47 mg to 2.5 mg).', 'P-1176\t-1.5107 -0.0493 -0.3142 -0.4282 -0.0296 -0.0099 -0.0324 -0.0395 -0.0282', 'S-1820\tder Erweiterung des Anwendungsgebiets', 'T-1820\tclinical indication', 'H-1820\t-1.5810546875\tTo extend the indication .', 'D-1820\t-1.5810546875\tTo extend the indication.', 'P-1820\t-0.6206 -1.0225 -0.2690 -1.0352 -1.6572 -0.0282', 'S-1117\t1 Durchstichflasche 0 Tage', 'T-1117\t0 days', 'H-1117\t-0.96484375\t1', 'D-1117\t-0.96484375\t1', 'P-1117\t-0.3835 -1.0791', 'S-1441\tEine Änderung der Dosierung ist nicht', 'T-1441\t- Hepatic impairement without cholestasis: no dosage modification is required (see', 'H-1441\t-1.392578125\tDosage alteration is not recommended .', 'D-1441\t-1.392578125\tDosage alteration is not recommended.', 'P-1441\t-0.4568 -1.2256 -0.0240 -1.3457 -0.5044 -0.0451 -0.0366 -0.8423 -1.0371 -0.0282', 'S-755\tL 143 vom 27.06.1995', 'T-755\t1 OJ No L 290 of 05.12.95 2 OJ No L 110 of 26.04.97 3 OJ No L 272 of 25.10.96 4 OJ No L 290 of 05.12.95 5 OJ No L 143 of 27.06.95', 'H-755\t-0.2398681640625\tL 143 of 27.06.95', 'D-755\t-0.2398681640625\tL 143 of 27.06.95', 'P-755\t-0.2969 -0.0206 -0.0269 -0.0849 -0.0437 -0.0077 -0.3215 -0.0331', 'S-769\t<unk> Verwendbar Ar', 'T-769\ter Do not use Nespo after the expiry date which is stated on the carton and on the pre-filled pen label ng after EXP.', 'H-769\t-2.060546875\tAERs', 'D-769\t-2.060546875\tAERs', 'P-769\t-1.6387 -2.2676 -0.3411 -0.4902', 'S-730\t19% niedriger als bei Männern.', 'T-730\tGender The apparent clearance of paliperidone following INVEGA administration is approximately 19% lower in women than men.', 'H-730\t-1.044921875\t19 % lower than in men .', 'D-730\t-1.044921875\t19% lower than in men.', 'P-730\t-2.5156 -0.0366 -0.0549 -0.0409 -0.8369 -0.0648 -0.0620 -0.0282', 'S-1267\t13 Der Film der Tablette enthält:', 'T-1267\tThe tablet coating contains:', 'H-1267\t-0.78466796875\tThe film of the tablet contains :', 'D-1267\t-0.78466796875\tThe film of the tablet contains:', 'P-1267\t-1.3643 -0.2388 -0.0831 -0.7495 -0.0282 -0.0268 -0.0831 -0.3311 -0.0282', 'S-1132\tDies bewirkt einen Verlust der Sehkraft.', 'T-1132\tThis causes the loss of vision.', 'H-1132\t-0.93701171875\tThis causes loss of vision .', 'D-1132\t-0.93701171875\tThis causes loss of vision.', 'P-1132\t-0.8477 -1.1562 -0.7031 -0.0296 -0.2141 -0.0338 -0.0282', 'S-189\tWerfen Sie den Tupfer weg.', 'T-189\tThrow the swab away.', 'H-189\t-0.5634765625\tThrow away the swab .', 'D-189\t-0.5634765625\tThrow away the swab.', 'P-189\t-0.5532 -0.0099 -0.4009 -0.0430 -0.8726 -0.0183 -0.0366 -0.0282', 'S-1120\tFieber, Schmerzen, Gewichtsverlust', 'T-1120\tFever, pain weight loss', 'H-1120\t-0.99267578125\tFever , pain , weight loss', 'D-1120\t-0.99267578125\tFever, pain, weight loss', 'P-1120\t-2.3809 -0.0099 -0.0282 -0.3748 -0.0338 -0.3931 -0.2029 -0.0338', 'S-955\tzu • Schwäche in Armen oder Beinen.', 'T-955\tr • Numbness;', 'H-955\t-0.83984375\tris • Double vision ; • Arm or leg weakness .', 'D-955\t-0.83984375\tris • Double vision; • Arm or leg weakness.', 'P-955\t-0.8643 -0.3643 -0.4875 -0.3198 -0.3284 -0.3352 -0.5776 -0.0620 -0.0958 -0.0197 -0.2479 -0.0282', 'S-636\tHumalog Pen darf nicht angewendet werden,', 'T-636\tDo not use Humalog Pen', 'H-636\t-0.254638671875\tDo not use Humalog Pen', 'D-636\t-0.254638671875\tDo not use Humalog Pen', 'P-636\t-0.3206 -0.0320 -0.0990 -0.0722 -0.0169 -0.0183 -0.2595', 'S-313\tNasopharyngitis Überempfindlichkeit', 'T-313\tNasopharyngitis', 'H-313\t-0.513671875\tNasopharyngitis Hypersensitivity', 'D-313\t-0.513671875\tNasopharyngitis Hypersensitivity', 'P-313\t-1.6924 -0.0225 -0.0141 -0.0113 -0.0155 -0.0155 -0.3198 -0.0113 -0.0211 -0.0099 -0.0310', 'S-1124\t15 µg / ml Injektionssuspension', 'T-1124\t15 µg / ml', 'H-1124\t-0.40673828125\t15 µg / ml suspension for injection', 'D-1124\t-0.40673828125\t15 µg / ml suspension for injection', 'P-1124\t-0.5581 -0.0169 -0.0250 -0.0306 -0.0169 -0.3135 -0.2593 -0.0472 -0.0937 -0.2593', 'S-1622\t5 526000 3 083 000', 'T-1622\t5 149 000 4 29 3 000 1 658 000 6 17 000', 'H-1622\t-0.654296875\t5 526000 3 083 000', 'D-1622\t-0.654296875\t5 526000 3 083 000', 'P-1622\t-2.1211 -0.0324 -0.0197 -0.0127 -0.1761 -0.0296 -0.0113 -0.0127 -0.0282', 'S-1218\tBetrachtet man die beiden Studien ln', 'T-1218\tThe greatest reductions were seen in the studies examining Trudexa as an add-on to methotrexate: in the two studies taken together, around two thirds of the patients adding 40 mg Trudexa every 2 weeks had at lon least a 20% reduction in symptoms after 6 months, compared to a quarter of those adding placebo.', 'H-1218\t-1.8193359375\tIf you consider the two studies lon', 'D-1218\t-1.8193359375\tIf you consider the two studies lon', 'P-1218\t-2.4160 -0.1775 -0.2664 -0.7637 -0.0310 -0.5747 -1.8516 -0.2537', 'S-913\tHarndrang (1,3% vs.', 'T-913\t0.7%) Urogenital system: common: urinary urgency (1.3% vs.', 'H-913\t-0.69677734375\turine , 1.3 % vs .', 'D-913\t-0.69677734375\turine, 1.3% vs.', 'P-913\t-0.9136 -0.5938 -0.3396 -0.1958 -0.0324 -0.0887 -0.2324 -0.0296', 'S-881\t† Seroprotektionsrate:', 'T-881\t† seroprotection rate: proportion of subjects with haemagglutination', 'H-881\t-0.460693359375\tSeroprotection rate :', 'D-881\t-0.460693359375\tSeroprotection rate:', 'P-881\t-0.7490 -0.1162 -0.0042 -0.0296 -0.5073 -0.0451 -0.0296', 'S-1694\tWas VASOVIST enthält', 'T-1694\tWhat VASOVIST contains', 'H-1694\t-0.1456298828125\tWhat VASOVIST contains', 'D-1694\t-0.1456298828125\tWhat VASOVIST contains', 'P-1694\t-0.0516 -0.0429 -0.2410 -0.0262 -0.0278 -0.0218 -0.0197 -0.0708 -0.0423', 'S-1425\tEfavirenz 100 mg.', 'T-1425\tEach hard capsule contains: efavirenz 100 mg.', 'H-1425\t-0.66162109375\tEach hard capsule contains : efavirenz 100 mg .', 'D-1425\t-0.66162109375\tEach hard capsule contains: efavirenz 100 mg.', 'P-1425\t-0.4854 -0.5981 -0.3228 -0.0127 -0.0183 -0.2930 -0.5127 -0.3438 -0.0085 -0.0352 -0.0183 -0.0817 -0.2113 -0.0141 -0.5073 -0.0282', 'S-109\tWie wurde Vivanza untersucht?', 'T-109\tWhat benefit has Vivanza shown during the studies?', 'H-109\t-0.78125\tHow has Vivanza been studied ?', 'D-109\t-0.78125\tHow has Vivanza been studied?', 'P-109\t-0.3599 -0.2891 -2.0176 -0.0211 -0.0197 -0.0268 -0.0324 -0.2888 -0.0282 -0.0282', 'S-1909\tDaher ist in diesen Situationen Vorsicht geboten.', 'T-1909\tCaution should be exercised in such situations.', 'H-1909\t-1.2880859375\tTherefore , caution should be exercised in such situations .', 'D-1909\t-1.2880859375\tTherefore, caution should be exercised in such situations.', 'P-1909\t-1.8037 -0.0169 -0.8145 -0.2085 -0.8848 -0.0366 -0.3777 -0.0254 -0.0423 -1.4170 -0.3184 -0.0282 -0.0282', 'S-969\t• Leberenzymabweichungen', 'T-969\t• Liver enzyme abnormalities', 'H-969\t-0.97998046875\t• Liver enzyme abnormalities', 'D-969\t-0.97998046875\t• Liver enzyme abnormalities', 'P-969\t-0.1743 -1.5908 -0.0197 -0.5103 -0.9961 -0.0310 -0.6426 -0.1042 -0.0085 -0.0225 -0.0310', 'S-879\tDogs and cats Antiparasitic', 'T-879\t• Dogs and cats • Antiparasitic', 'H-879\t-0.352294921875\tDogs and cats • Antiparasitic', 'D-879\t-0.352294921875\tDogs and cats • Antiparasitic', 'P-879\t-0.5132 -0.0162 -0.0306 -0.0810 -0.3479 -0.2791 -0.0204 -0.0113 -0.0282 -0.0754', 'S-149\tFolgende Nebenwirkungen wurden zusätzlich beobachtet:', 'T-149\tThe following additional adverse reactions were seen:', 'H-149\t-1.02734375\tThe following adverse reactions have also been observed :', 'D-149\t-1.02734375\tThe following adverse reactions have also been observed:', 'P-149\t-0.6338 -0.0423 -1.5244 -0.0056 -0.4255 -0.0169 -0.2537 -0.9692 -0.0254 -0.6030 -0.0338 -0.0282', 'S-890\tTasigna 200 mg Hartkapseln', 'T-890\tTasigna 200 mg hard capsules', 'H-890\t-0.09527587890625\tTasigna 200 mg hard capsules', 'D-890\t-0.09527587890625\tTasigna 200 mg hard capsules', 'P-890\t-0.0328 -0.0127 -0.0085 -0.0270 -0.0099 -0.1476 -0.0671 -0.0141 -0.0306 -0.0291', 'S-542\tWarum wurde Ytracis zugelassen?', 'T-542\tWhy has Ytracis been approved?', 'H-542\t-0.1884765625\tWhy has Ytracis been approved ?', 'D-542\t-0.1884765625\tWhy has Ytracis been approved?', 'P-542\t-0.2056 -0.2588 -0.0472 -0.0264 -0.0257 -0.0271 -0.0236 -0.0775 -0.0303 -0.0282', 'S-305\t- Gehen Sie stets gleich vor.', 'T-305\t• Important tips to keep in mind', 'H-305\t-1.5986328125\t− Be consistent - use the same formula .', 'D-305\t-1.5986328125\t− Be consistent - use the same formula.', 'P-305\t-1.0693 -0.9692 -0.3340 -0.7524 -0.5156 -0.1691 -0.0366 -2.0488 -0.4453 -0.0282', 'S-1943\t- 400 Einheiten (2 x 200)', 'T-1943\t- 400 units (2x200)', 'H-1943\t-0.11700439453125\t- 400 units ( 2 x 200 )', 'D-1943\t-0.11700439453125\t- 400 units (2 x 200)', 'P-1943\t-0.1846 -0.0356 -0.0320 -0.0292 -0.0407 -0.0327 -0.0171 -0.0342 -0.0313', 'S-1817\tWie ist Xolair anzuwenden?', 'T-1817\tHow Xolair is given 4.', 'H-1817\t-0.5048828125\tHow to use Xolair 4 .', 'D-1817\t-0.5048828125\tHow to use Xolair 4.', 'P-1817\t-0.0357 -0.6670 -0.4360 -0.0275 -0.0211 -0.0211 -0.3220 -0.3198 -0.0366', 'S-378\tAzomyr 5 mg Filmtabletten', 'T-378\tAzomyr 5 mg film-coated tablets', 'H-378\t-0.258056640625\tAzomyr 5 mg film @-@ coated tablets', 'D-378\t-0.258056640625\tAzomyr 5 mg film-coated tablets', 'P-378\t-0.0163 -0.0199 -0.0141 -0.0444 -0.0099 -0.2617 -0.3198 -0.3213 -0.0282 -0.0388 -0.0416 -0.0310', 'S-1887\t1 h nach ddI + d4T', 'T-1887\t1 hr after ddI + d4T', 'H-1887\t-0.168212890625\t1 h after ddI + d4T', 'D-1887\t-0.168212890625\t1 h after ddI + d4T', 'P-1887\t-0.2073 -0.0313 -0.2551 -0.0085 -0.0271 -0.0292 -0.0271 -0.0243 -0.0285 -0.0313', 'S-1962\tPro-Roxikam 20 Mg', 'T-1962\tPro-Roxikam 20 Mg', 'H-1962\t-0.155029296875\tPro @-@ Roxikam 20 Mg', 'D-1962\t-0.155029296875\tPro-Roxikam 20 Mg', 'P-1962\t-0.0422 -0.0487 -0.0590 -0.0213 -0.0206 -0.0220 -0.0327 -0.3164 -0.0257 -0.0285', 'S-1985\tTel: + 36 - 23 446 800', 'T-1985\tTel: + 36 - 23 446 800', 'H-1985\t-0.200927734375\tTel : + 36 - 23 446 800', 'D-1985\t-0.200927734375\tTel: + 36 - 23 446 800', 'P-1985\t-0.4919 -0.0750 -0.0271 -0.0197 -0.0722 -0.0204 -0.0261 -0.0162 -0.0183 -0.0331', 'S-6\tIkterus, erhöhte Leberwerte', 'T-6\tRare: icterus, increased liver values', 'H-6\t-0.99462890625\tIcterus , increased liver function', 'D-6\t-0.99462890625\tIcterus, increased liver function', 'P-6\t-0.7686 -0.0916 -0.0472 -0.0275 -0.0388 -0.7681 -0.5708 -1.0605 -0.3438', 'S-62\tWie wirkt HBVAXPRO?', 'T-62\tHow does HBVAXPRO work?', 'H-62\t-0.2164306640625\tHow does HBVAXPRO work ?', 'D-62\t-0.2164306640625\tHow does HBVAXPRO work?', 'P-62\t-0.0685 -0.6162 -0.0070 -0.0236 -0.0299 -0.0197 -0.0127 -0.0211 -0.0542 -0.0310 -0.0282', 'S-96\tMediane Zeit seit Erstdiagnose in Monaten', 'T-96\tMedian time (range) Imatinib', 'H-96\t-0.51513671875\tMedian time from initial diagnosis in months', 'D-96\t-0.51513671875\tMedian time from initial diagnosis in months', 'P-96\t-0.0444 -0.0220 -0.3518 -1.0117 -0.2212 -0.0127 -0.1831 -0.0451 -0.0324', 'S-380\tTachykardie, Arrhythmie', 'T-380\tTachycardia, arrhythmias', 'H-380\t-0.634765625\tTachycardia , arrhythmia', 'D-380\t-0.634765625\tTachycardia, arrhythmia', 'P-380\t-1.4219 -0.0183 -0.0211 -0.0338 -0.0085 -0.0409 -0.3467 -0.0155 -0.5859 -0.0338', 'S-1041\tDieser Zeitraum kann mehrere Monate oder länger betragen.', 'T-1041\tThis period may be several months or even longer.', 'H-1041\t-1.0380859375\tThis may take several months or longer .', 'D-1041\t-1.0380859375\tThis may take several months or longer.', 'P-1041\t-0.3188 -0.9297 -1.0723 -0.3833 -0.0268 -0.0451 -1.0342 -0.0423 -0.0282', 'S-1976\tEU / 1 / 01 / 185 / XXX', 'T-1976\tEU / 1 / 01 / 185 / 069', 'H-1976\t-0.07073974609375\tEU / 1 / 01 / 185 / XXX', 'D-1976\t-0.07073974609375\tEU / 1 / 01 / 185 / XXX', 'P-1976\t-0.0227 -0.0306 -0.0575 -0.0284 -0.0364 -0.0277 -0.0127 -0.0285 -0.0085 -0.0285', 'S-1789\tPUREVAX RCP', 'T-1789\tPUREVAX RCP', 'H-1789\t-0.1597900390625\tPUREVAX RCP', 'D-1789\t-0.1597900390625\tPUREVAX RCP', 'P-1789\t-0.2832 -0.0299 -0.0285 -0.0292 -0.0278 -0.0204 -0.1342 -0.0271 -0.0225 -0.0327', 'S-1015\t• Patienten mit eingeschränkter Leberfunktion,', 'T-1015\t• patients with impairment of liver function,', 'H-1015\t-0.740234375\t• patients with hepatic impairment ,', 'D-1015\t-0.740234375\t• patients with hepatic impairment,', 'P-1015\t-0.0531 -1.1572 -0.0331 -1.0527 -0.0254 -0.0296 -0.5679 -0.0676 -0.0141 -0.0366 -0.2227 -0.0282', 'S-1295\tMai 2002 kam er zur EMEA.', 'T-1295\tHe joined the EMEA on 1 May 2002.', 'H-1295\t-0.187744140625\tHe joined the EMEA in May 2002 .', 'D-1295\t-0.187744140625\tHe joined the EMEA in May 2002.', 'P-1295\t-0.2145 -0.0641 -0.1829 -0.0479 -0.0155 -0.0278 -0.1053 -0.0472 -0.0268 -0.0310 -0.0282', 'S-1746\tPackungen mit 98 Filmtabletten:', 'T-1746\tCartons of 98 film-coated tablets:', 'H-1746\t-0.37158203125\tCartons of 98 film @-@ coated tablets :', 'D-1746\t-0.37158203125\tCartons of 98 film-coated tablets:', 'P-1746\t-0.3223 -0.2886 -0.0930 -0.0211 -0.0993 -0.3184 -0.3213 -0.0352 -0.0535 -0.0254 -0.0437 -0.0282', 'S-1687\tAtmen Sie so weit wie möglich aus.', 'T-1687\tHold the Diskus away from your mouth, breathe out as far as is comfortable.', 'H-1687\t-0.83544921875\tBreathe out as far as is comfortable .', 'D-1687\t-0.83544921875\tBreathe out as far as is comfortable.', 'P-1687\t-0.9502 -0.0296 -0.0190 -0.1726 -0.0451 -0.3049 -0.0282 -1.5557 -0.3325 -0.0564 -0.0282', 'S-1189\tWenn Sie sich hinsichtlich der Verabreichung der', 'T-1189\tIf you have questions about how to inject, please ask your doctor, nurse or pharmacist a', 'H-1189\t-2.0703125\tIf you are allergic to fluticasone or ed', 'D-1189\t-2.0703125\tIf you are allergic to fluticasone or ed', 'P-1189\t-0.8657 -0.0359 -1.3887 -1.1777 -0.0141 -0.2395 -0.9834 -1.4092 -0.3101 -0.0789 -1.0254 -1.7305 -0.3833', 'S-1372\tErkrankungen des Nerven- systems Herz- erkrankungen', 'T-1372\thaemolytic anaemia, haemolysis (see section 4.4)', 'H-1372\t-1.12890625\tNervous system disorders Cardiac disease', 'D-1372\t-1.12890625\tNervous system disorders Cardiac disease', 'P-1372\t-1.6826 -0.0564 -0.0338 -0.1254 -0.2847 -0.0225 -0.5537 -0.1099 -1.5918 -0.0338', 'S-71\t(32-2) 552 22 11', 'T-71\tCore SPC for Human plasma derived and recombinant coagulation factor VIII products Adopted June 2000', 'H-71\t-0.275390625\t( 32 @-@ 2 ) 552 22 11', 'D-71\t-0.275390625\t(32-2) 552 22 11', 'P-71\t-0.3508 -0.2008 -0.0342 -0.0313 -0.0299 -0.1674 -0.2008 -0.0289 -0.0232 -0.0296', 'S-377\t40.200 Säuglinge verabreicht.', 'T-377\t4 In a total of eleven placebo-controlled clinical trials, approximately 77800 doses of Rotarix were administered to approximately 40200 infants.', 'H-377\t-1.91796875\tIn a total of 40,200 infants were treated .', 'D-377\t-1.91796875\tIn a total of 40,200 infants were treated.', 'P-377\t-0.6294 -0.7354 -1.1064 -0.0972 -2.2422 -0.6763 -0.0197 -0.2001 -0.0197 -0.7607 -1.5947 -0.8228 -0.0282', 'S-1801\tAnwendung bei Kindern und Jugendlichen unter 18 Jahren:', 'T-1801\tUse in children and adolescents under the age of 18 years: it was agreed that <<unk>> Venlafaxine is not recommended for use in children and adolescents <<unk>>.', 'H-1801\t-0.67822265625\tUse in children and adolescents under the age of 18 years :', 'D-1801\t-0.67822265625\tUse in children and adolescents under the age of 18 years:', 'P-1801\t-0.6250 -0.2233 -0.0331 -0.0528 -0.1642 -0.0155 -0.0169 -1.0459 -0.7817 -0.0169 -0.0282 -0.0254 -0.3325 -0.0535 -0.0282', 'S-286\tWie ist Nexavar einzunehmen?', 'T-286\tHow to take Nexavar 4.', 'H-286\t-0.326416015625\tHow to take Nexavar 4 .', 'D-286\t-0.326416015625\tHow to take Nexavar 4.', 'P-286\t-0.4019 -0.0539 -0.0870 -0.0327 -0.0218 -0.0169 -0.0190 -0.3220 -0.3113 -0.0324', 'S-1652\tDie Wirksamkeit ist dosisabhängig.', 'T-1652\tEfficacy is dose dependent.', 'H-1652\t-1.1064453125\tEfficacy depends on dose .', 'D-1652\t-1.1064453125\tEfficacy depends on dose.', 'P-1652\t-1.6670 -0.1536 -0.0155 -1.6162 -0.0338 -0.2930 -0.0451 -0.0282', 'S-1679\tAbseamed darf nicht angewendet werden,', 'T-1679\tAbseamed must not be used', 'H-1679\t-0.466064453125\tDo not use Abseamed', 'D-1679\t-0.466064453125\tDo not use Abseamed', 'P-1679\t-0.3872 -0.0313 -0.1310 -0.0916 -0.0327 -0.0085 -0.8159', 'S-170\tEconor ist ein Antibiotikum.', 'T-170\tEconor is an antibiotic.', 'H-170\t-0.350341796875\tEconor is an antibiotic .', 'D-170\t-0.350341796875\tEconor is an antibiotic.', 'P-170\t-0.6694 -0.0236 -0.0342 -0.0451 -0.2410 -0.0113 -0.0197 -0.2367 -0.0282', 'S-307\tVerteilung der Neuanträge auf wissenschaftliche Beratung 2000', 'T-307\tDistribution of scientific advice requests in 2000', 'H-307\t-0.84521484375\tDistribution of new requests for scientific advice 2000', 'D-307\t-0.84521484375\tDistribution of new requests for scientific advice 2000', 'P-307\t-0.0487 -0.0127 -0.0306 -0.8037 -1.7568 -0.0324 -0.0507 -0.0380 -0.2607 -0.3296', 'S-395\tXiliarx 50 mg Tabletten', 'T-395\tXiliarx 50 mg tablets', 'H-395\t-0.12158203125\tXiliarx 50 mg tablets', 'D-395\t-0.12158203125\tXiliarx 50 mg tablets', 'P-395\t-0.0400 -0.0163 -0.0241 -0.0256 -0.1296 -0.0178 -0.0999 -0.0627 -0.0384', 'S-515\tBEITRÄGE ZU DEN', 'T-515\tCONTRIBUTIONS TO', 'H-515\t-1.88671875\tINSTRUCTIONS', 'D-515\t-1.88671875\tINSTRUCTIONS', 'P-515\t-3.1172 -0.5239 -0.2197 -0.0676 -0.0451 -0.0873 -0.0254 -2.4844', 'S-998\t26.8.2002 13.11.2002 15.11.2002', 'T-998\t• 26.8.2002 • 13.11.2002', 'H-998\t-0.67919921875\t26.8.2002 • 13.11.2002 • 15.11.2002', 'D-998\t-0.67919921875\t26.8.2002 • 13.11.2002 • 15.11.2002', 'P-998\t-2.1465 -0.0296 -0.0183 -0.4592 -0.0437 -0.0127 -0.0211 -0.1648 -0.0564 -0.0169 -0.0169 -0.0310', 'S-1253\tGlustin 15 mg Tabletten.', 'T-1253\tGlustin 15 mg tablets.', 'H-1253\t-0.27587890625\tGlustin 15 mg tablets .', 'D-1253\t-0.27587890625\tGlustin 15 mg tablets.', 'P-1253\t-0.0313 -0.0049 -0.2400 -0.5571 -0.0240 -0.0676 -0.0359 -0.0409 -0.0296', 'S-86\tWeitere Informationen über Virbagen Omega:', 'T-86\tOther information about Virbagen Omega:', 'H-86\t-0.270751953125\tOther information about Virbagen Omega :', 'D-86\t-0.270751953125\tOther information about Virbagen Omega:', 'P-86\t-0.6836 -0.0828 -0.1296 -0.0254 -0.0218 -0.0070 -0.0373 -0.0113 -0.0514 -0.0282', 'S-1294\tSOMAVERT darf nicht angewendet werden', 'T-1294\tDo not use SOMAVERT', 'H-1294\t-0.58251953125\tDo not use SOMAVERT', 'D-1294\t-0.58251953125\tDo not use SOMAVERT', 'P-1294\t-1.2393 -0.0486 -0.0881 -0.0388 -0.0120 -0.0148 -0.0225 -0.5649', 'S-480\tPRILACTONE 80 mg:', 'T-480\tPRILACTONE 80 mg:', 'H-480\t-0.06866455078125\tPRILACTONE 80 mg :', 'D-480\t-0.06866455078125\tPRILACTONE 80 mg:', 'P-480\t-0.0299 -0.0213 -0.0170 -0.0320 -0.0128 -0.0298 -0.0465 -0.0113 -0.0444 -0.0285', 'S-613\tULN = Obergrenze des Normalbereichs', 'T-613\tULN = Upper limit of normal.', 'H-613\t-0.491943359375\tULN = upper limit of normal limits', 'D-613\t-0.491943359375\tULN = upper limit of normal limits', 'P-613\t-0.1719 -0.0241 -0.0185 -0.2201 -0.1993 -0.0356 -0.2729 -0.6240 -0.2720', 'S-850\tWeitere Informationen über NeoRecormon:', 'T-850\tOther information about NeoRecormon:', 'H-850\t-0.25830078125\tOther information about NeoRecormon :', 'D-850\t-0.25830078125\tOther information about NeoRecormon:', 'P-850\t-0.6611 -0.0736 -0.1036 -0.0169 -0.0247 -0.0211 -0.0204 -0.0099 -0.0690 -0.0282', 'S-1099\tTel: + 34 93 306 42 00', 'T-1099\tTel: + 34 93 306 42 00', 'H-1099\t-0.1480712890625\tTel : + 34 93 306 42 00', 'D-1099\t-0.1480712890625\tTel: + 34 93 306 42 00', 'P-1099\t-0.0634 -0.0826 -0.0213 -0.0227 -0.0164 -0.0213 -0.0269 -0.2771 -0.0264 -0.0313', 'S-1272\t(49-30) 45 48 33 32', 'T-1272\t(49-30) 45 48 33 32', 'H-1272\t-0.187744140625\t( 49 @-@ 30 ) 45 48 33 32', 'D-1272\t-0.187744140625\t(49-30) 45 48 33 32', 'P-1272\t-0.5352 -0.0243 -0.0313 -0.0271 -0.0299 -0.0211 -0.0169 -0.0141 -0.0183 -0.0289', 'S-1307\tEntsorgung Nur zur einmaligen Anwendung.', 'T-1307\t39 Disposal For single use only.', 'H-1307\t-0.52490234375\tDisposal For single use only .', 'D-1307\t-0.52490234375\tDisposal For single use only.', 'P-1307\t-0.6704 -0.0320 -0.0225 -0.7827 -0.2296 -0.0930 -0.0324 -0.0690 -0.0296', 'S-1446\tTel: + 31 72 5 66 24 24', 'T-1446\tTel: + 31 72 5 66 24 24', 'H-1446\t-0.314453125\tTel : + 31 72 5 66 24 24', 'D-1446\t-0.314453125\tTel: + 31 72 5 66 24 24', 'P-1446\t-0.2781 -0.0879 -0.0257 -0.0257 -0.0120 -0.0313 -0.0099 -0.0299 -0.2399 -0.5122', 'S-1539\tSehr häufig • Übelkeit • Erbrechen', 'T-1539\tVery common • Vomiting • Nausea', 'H-1539\t-0.76904296875\tVery common • nausea • vomiting', 'D-1539\t-0.76904296875\tVery common • nausea • vomiting', 'P-1539\t-0.4001 -0.2318 -0.0342 -1.3076 -0.0056 -0.2494 -0.7690 -0.0056 -0.0282 -0.0310', 'S-1754\tTel. + 386 1 58 14 400', 'T-1754\tTel. + 386 1 58 14 400', 'H-1754\t-0.3017578125\tTel : + 386 1 58 14 400', 'D-1754\t-0.3017578125\tTel: + 386 1 58 14 400', 'P-1754\t-0.1467 -0.8657 -0.0261 -0.0155 -0.0261 -0.0317 -0.0148 -0.0282 -0.0162 -0.0310', 'S-265\tgélules gastro-resistantes', 'T-265\tgélules gastro-resistantes', 'H-265\t-1.52734375\tgelatin gastro @-@ resistantes', 'D-265\t-1.52734375\tgelatin gastro-resistantes', 'P-265\t-0.3835 -0.4661 -3.3926 -0.2085 -0.0310 -0.0423 -0.9609 -0.1888 -0.0338', 'S-1680\tEMEA / H / C / 588', 'T-1680\tEMEA / H / C / 588', 'H-1680\t-0.09405517578125\tEMEA / H / C / 588', 'D-1680\t-0.09405517578125\tEMEA / H / C / 588', 'P-1680\t-0.1521 -0.0099 -0.0241 -0.0372 -0.0206 -0.0285 -0.0185 -0.0299 -0.0306 -0.0141 -0.0306', 'S-1663\t28 / 01 / 2000 Verlängerung der Zulassung:', 'T-1663\t28 / 01 / 2000 Renewal date:', 'H-1663\t-0.369140625\t28 / 01 / 2000 Renewal :', 'D-1663\t-0.369140625\t28 / 01 / 2000 Renewal:', 'P-1663\t-0.2434 -0.0278 -0.0192 -0.0276 -0.0269 -0.7051 -0.0296 -0.0225 -0.3374 -0.0296', 'S-1656\tWie ist RILUTEK einzunehmen?', 'T-1656\tHow to take RILUTEK 4.', 'H-1656\t-0.3251953125\tHow to take RILUTEK 4 .', 'D-1656\t-0.3251953125\tHow to take RILUTEK 4.', 'P-1656\t-0.4390 -0.0613 -0.0944 -0.0363 -0.0106 -0.0211 -0.0141 -0.0176 -0.3223 -0.3135 -0.0402', 'S-1638\tWie ist SPRYCEL einzunehmen?', 'T-1638\tHow to take SPRYCEL 4.', 'H-1638\t-0.41748046875\tHow to take SPRYCEL 4 .', 'D-1638\t-0.41748046875\tHow to take SPRYCEL 4.', 'P-1638\t-0.7563 -0.0521 -0.0789 -0.0972 -0.0331 -0.0282 -0.0317 -0.0113 -0.3228 -0.3113 -0.0366', 'S-1488\tTel: + 421 2 57 103 777', 'T-1488\tTel: + 421 2 57 103 777', 'H-1488\t-0.16748046875\tTel : + 421 2 57 103 777', 'D-1488\t-0.16748046875\tTel: + 421 2 57 103 777', 'P-1488\t-0.4170 -0.0701 -0.0264 -0.0299 -0.0197 -0.0356 -0.0183 -0.0113 -0.0313 -0.0148 -0.0313', 'S-1302\tPiroxicam Capsules 20mg', 'T-1302\tPiroxicam Capsules 20mg', 'H-1302\t-0.2244873046875\tPiroxicam Capsules 20mg', 'D-1302\t-0.2244873046875\tPiroxicam Capsules 20mg', 'P-1302\t-0.0811 -0.0228 -0.0227 -0.0113 -0.0284 -0.2131 -0.0085 -0.0271 -0.4939 -0.0092 -0.0289', 'S-1151\tLyra 25, Kato Kifissia Griechenland', 'T-1151\tLyra 25, Kato Kifissia Greece', 'H-1151\t-0.07373046875\tLyra 25 , Kato Kifissia Greece', 'D-1151\t-0.07373046875\tLyra 25, Kato Kifissia Greece', 'P-1151\t-0.0472 -0.0163 -0.0256 -0.0284 -0.0917 -0.0269 -0.0164 -0.0092 -0.0070 -0.0134 -0.0285', 'S-1121\tManagement of adverse event reports VICH:', 'T-1121\tManagement of adverse event reports VICH:', 'H-1121\t-1.171875\tManagement of adverse event reports VICH :', 'D-1121\t-1.171875\tManagement of adverse event reports VICH:', 'P-1121\t-0.9805 -0.0359 -2.6270 -0.0056 -0.5044 -0.0395 -0.5493 -0.0676 -0.0592 -0.0423 -0.0310', 'S-930\tNutropinAq wird angewendet:', 'T-930\tNutropinAq is indicated for:', 'H-930\t-0.5966796875\tNutropinAq is used :', 'D-930\t-0.5966796875\tNutropinAq is used:', 'P-930\t-0.3916 -0.0127 -0.0141 -0.0225 -0.0250 -0.0113 -0.0493 -0.3159 -1.2061 -0.3269', 'S-893\tOptimark kann mittels Dialyse entfernt werden.', 'T-893\tOptimark can be removed using dialysis.', 'H-893\t-0.267578125\tOptimark can be removed by dialysis .', 'D-893\t-0.267578125\tOptimark can be removed by dialysis.', 'P-893\t-0.0127 -0.0170 -0.0589 -0.0306 -0.0227 -0.1831 -0.4119 -0.0092 -0.0211 -0.0373 -0.3240', 'S-875\tTel: + + 351 21 4329 500', 'T-875\tTel: + + 351 21 4329 500', 'H-875\t-0.1905517578125\tTel : + + 351 21 4329 500', 'D-875\t-0.1905517578125\tTel: + + 351 21 4329 500', 'P-875\t-0.4883 -0.0676 -0.0292 -0.0370 -0.0574 -0.0162 -0.0197 -0.0102 -0.0240 -0.0204 -0.0331', 'S-870\tEs enthält den Wirkstoff Azacitidin.', 'T-870\tIt contains the active substance azacitidine.', 'H-870\t-0.27587890625\tIt contains the active substance azacitidine .', 'D-870\t-0.27587890625\tIt contains the active substance azacitidine.', 'P-870\t-0.4028 -0.0257 -0.0539 -0.0313 -0.2427 -0.2050 -0.0402 -0.0479 -0.0514 -0.0331 -0.0282', 'S-390\t10 U 10 ml (1 U / ml)', 'T-390\t10 U 10 ml (1 U / ml)', 'H-390\t-0.177734375\t10 U 10 ml ( 1 U / ml )', 'D-390\t-0.177734375\t10 U 10 ml (1 U / ml)', 'P-390\t-0.2129 -0.0185 -0.3110 -0.0204 -0.0306 -0.0278 -0.0148 -0.0306 -0.0229 -0.0299 -0.0299', 'S-389\tEMEA / H / C / 808', 'T-389\tEMEA / H / C / 808', 'H-389\t-0.1002197265625\tEMEA / H / C / 808', 'D-389\t-0.1002197265625\tEMEA / H / C / 808', 'P-389\t-0.1632 -0.0106 -0.0242 -0.0356 -0.0213 -0.0285 -0.0192 -0.0306 -0.0327 -0.0250 -0.0313', 'S-337\tJede 1,60 ml-Pipette enthält:', 'T-337\tEach 1.60 ml pipette delivers:', 'H-337\t-0.22119140625\tEach 1.60 ml pipette delivers :', 'D-337\t-0.22119140625\tEach 1.60 ml pipette delivers:', 'P-337\t-0.0480 -0.3311 -0.0342 -0.0285 -0.0444 -0.0370 -0.0077 -0.3223 -0.0162 -0.0352 -0.0282', 'S-236\tEli Lilly Nederlands B.V.', 'T-236\tEli Lilly Nederlands B.V.', 'H-236\t-0.393310546875\tEli Lilly Nederlands B. V .', 'D-236\t-0.393310546875\tEli Lilly Nederlands B. V.', 'P-236\t-0.4036 -0.0225 -0.0063 -0.0243 -0.0518 -0.0183 -0.0127 -0.9976 -0.0493 -0.0437 -0.0282', 'S-1650\tDer Ausschlag ist gewöhnlich leicht bis mäßig.', 'T-1650\tThe rash is usually mild to moderate.', 'H-1650\t-0.88525390625\tRash is usually mild to moderate .', 'D-1650\t-0.88525390625\tRash is usually mild to moderate.', 'P-1650\t-1.9795 -0.0324 -0.0521 -0.2451 -0.4016 -0.2227 -0.0197 -0.3269 -0.0282', 'S-1131\tWofür wird INVANZ angewendet?', 'T-1131\tWhat is INVANZ used for?', 'H-1131\t-0.220458984375\tWhat is INVANZ used for ?', 'D-1131\t-0.220458984375\tWhat is INVANZ used for?', 'P-1131\t-0.1219 -0.1082 -0.0306 -0.0255 -0.0206 -0.3220 -0.1578 -0.0352 -0.0268 -0.0289', 'S-1059\tWie ist YTRACIS anzuwenden 4.', 'T-1059\tHow to use YTRACIS 4.', 'H-1059\t-0.37255859375\tHow to use YTRACIS 4 .', 'D-1059\t-0.37255859375\tHow to use YTRACIS 4.', 'P-1059\t-0.0385 -0.5674 -0.6807 -0.0395 -0.0211 -0.0169 -0.0127 -0.0458 -0.0317 -0.0296', 'S-926\tIntravenöse Anästhetika:', 'T-926\tIntravenous Anaesthetics:', 'H-926\t-0.32080078125\tIntravenous anaesthetics :', 'D-926\t-0.32080078125\tIntravenous anaesthetics:', 'P-926\t-0.3455 -0.0234 -0.0127 -0.0250 -0.0620 -0.0887 -0.6226 -0.0289 -0.0402 -0.0282', 'S-867\tWofür wird Daronrix angewendet?', 'T-867\tWhat is Daronrix used for?', 'H-867\t-0.12445068359375\tWhat is Daronrix used for ?', 'D-867\t-0.12445068359375\tWhat is Daronrix used for?', 'P-867\t-0.0916 -0.0916 -0.0472 -0.0269 -0.0213 -0.0269 -0.0991 -0.0342 -0.0271 -0.0292', 'S-1712\tWie bereite ich die Injektion vor?', 'T-1712\tHow do I prepare the injection?', 'H-1712\t-0.27392578125\tHow do I prepare my injection ?', 'D-1712\t-0.27392578125\tHow do I prepare my injection?', 'P-1712\t-0.0299 -0.0767 -0.0313 -0.0901 -0.6084 -0.0704 -0.0430 -0.0437 -0.0303', 'S-749\t- Wenn das Geschwür infiziert ist.', 'T-749\t- If your ulcer is infected.', 'H-749\t-0.5810546875\t- If your ulcer is infected .', 'D-749\t-0.5810546875\t- If your ulcer is infected.', 'P-749\t-0.2910 -0.4446 -0.3972 -0.3804 -0.0169 -0.0564 -0.0380 -0.5171 -0.0296', 'S-1733\tInjizieren Sie keine weitere Dosis.', 'T-1733\tDo not inject another dose.', 'H-1733\t-0.427978515625\tDo not inject another dose .', 'D-1733\t-0.427978515625\tDo not inject another dose.', 'P-1733\t-0.4233 -0.0285 -0.1702 -0.0155 -0.7651 -0.0218 -0.0352 -0.0310', 'S-873\t* Es müssen Durchstechflaschen verwendet werden.', 'T-873\t* Must use vial.', 'H-873\t-1.1806640625\t* Do not use vials .', 'D-873\t-1.1806640625\t* Do not use vials.', 'P-873\t-0.4058 -2.3477 -0.1353 -0.7637 -0.2959 -0.0338 -0.0930 -0.0366', 'S-1633\tstimulierende Aktivität gegenüber T-Zellen.', 'T-1633\tis activity towards T cells.', 'H-1633\t-1.2724609375\tamplitude similar to T cells .', 'D-1633\t-1.2724609375\tamplitude similar to T cells.', 'P-1633\t-0.3328 -0.3625 -1.9727 -0.0479 -1.2959 -0.0310 -0.4226 -0.2930 -0.2761 -0.0282', 'S-1371\t(abends): alle 400 mg QD mit', 'T-1371\tall administered', 'H-1371\t-1.0078125\tatazanavir 100 mg QD )', 'D-1371\t-1.0078125\tatazanavir 100 mg QD)', 'P-1371\t-0.8477 -0.3220 -0.3228 -0.3213 -0.0704 -0.6831 -0.2085 -0.3101 -0.0310 -0.3606 -0.7720', 'S-849\tDie Art der Nahrungsmittel ist dabei unwichtig.', 'T-849\tnot important.', 'H-849\t-0.52392578125\tThe type of food is not important .', 'D-849\t-0.52392578125\tThe type of food is not important.', 'P-849\t-0.0969 -0.1584 -0.0285 -0.0539 -0.2659 -1.0254 -0.1691 -0.1310 -0.0282', 'S-292\t14 28 56 112 14 28 56 112 84 84', 'T-292\t112 tablets', 'H-292\t-0.288330078125\t14 28 56 112 14 28 56 112 84 84', 'D-292\t-0.288330078125\t14 28 56 112 14 28 56 112 84 84', 'P-292\t-0.7427 -0.0254 -0.0127 -0.0099 -0.0225 -0.0204 -0.0085 -0.0063 -0.0127 -0.0106 -0.3438', 'S-1810\tkardiologischen Abteilung einer Klinik untergebracht sind.', 'T-1810\tPLEASE TELL YOUR DOCTOR IF YOU HAVE HAD ANY OF THESE CONDITIONS.', 'H-1810\t-2.85546875\tFollowing antibody induction , peak plasma concentrations of venlafaxine were observed .', 'D-1810\t-2.85546875\tFollowing antibody induction, peak plasma concentrations of venlafaxine were observed.', 'P-1810\t-3.3184 -0.5410 -1.2480 -0.3240 -0.4226 -0.3718 -2.2090 -0.8398 -0.2537 -0.0056 -1.0820 -0.0225 -0.0225 -0.9917 -2.4121 -0.6650 -0.3157 -0.1803 -0.1691 -0.6763 -2.1074 -0.5298 -0.0338', 'S-1422\t23 c Die Patienten hatten Ohrenschmerzen.', 'T-1422\tThe prevention study did not contain a placebo arm, i. e. was an uncontrolled study. b Unit dose = weight-based dosing (see section 4.2). c Patients experienced ear ache and ear pain.', 'H-1422\t-1.2451171875\tThe patients presented with earache .', 'D-1422\t-1.2451171875\tThe patients presented with earache.', 'P-1422\t-1.7402 -0.0409 -1.6963 -0.2423 -0.5103 -0.0282 -0.0479 -0.0282', 'S-1827\t<unk> Behandlung der essenziellen Hypertonie <unk>', 'T-1827\t<<unk>> Treatment of essential hypertension <<unk>>', 'H-1827\t-0.388916015625\tTreatment of essential hypertension', 'D-1827\t-0.388916015625\tTreatment of essential hypertension', 'P-1827\t-0.1128 -0.0827 -0.0255 -0.1453 -0.1233 -0.0356 -0.0070 -0.8213', 'S-1567\tDer Impfstoff enthält 5 Mikrogramm Thiomersal', 'T-1567\tIt contains 5 micrograms thiomersal', 'H-1567\t-0.31689453125\tThe vaccine contains 5 micrograms Thiomersal', 'D-1567\t-0.31689453125\tThe vaccine contains 5 micrograms Thiomersal', 'P-1567\t-0.5342 -0.2286 -0.0331 -0.0388 -0.0169 -0.0296 -0.3049 -0.0197 -0.0155 -0.0268 -0.0873', 'S-1075\tOktober 2000 Thomas Lönngren zum Direktor.', 'T-1075\tThe appointment is with effect from January 2001.', 'H-1075\t-1.2470703125\tOctober 2000 , Thomas Lönngren was appointed Director .', 'D-1075\t-1.2470703125\tOctober 2000, Thomas Lönngren was appointed Director.', 'P-1075\t-2.5762 -0.0211 -1.1270 -0.1183 -0.0366 -0.0056 -0.0254 -0.0113 -0.0225 -0.5269 -0.4170 -1.1074 -0.0507 -0.0282', 'S-194\tDopamin-Agonisten, ATC-Code:', 'T-194\tDopamine agonists; ATC code:', 'H-194\t-0.83056640625\tDopamine agonists , ATC code :', 'D-194\t-0.83056640625\tDopamine agonists, ATC code:', 'P-194\t-2.1777 -0.0085 -0.1973 -0.5298 -0.0395 -0.0225 -0.0254 -0.2395 -0.0366 -0.0282', 'S-882\t116 Wenn Sie die Tablette kauen:', 'T-882\tIf you chew the tablet:', 'H-882\t-1.3505859375\tIf you take the tablet :', 'D-882\t-1.3505859375\tIf you take the tablet:', 'P-882\t-1.3408 -0.0345 -1.6113 -1.0566 -0.0873 -0.0282 -0.5127 -0.0310', 'S-1118\t2002 fanden mehr Anhörungen vor dem COMP statt.', 'T-1118\tEMEA Annual Report 2002', 'H-1118\t-1.3212890625\tThere were more hearings at the COMP in 2002 .', 'D-1118\t-1.3212890625\tThere were more hearings at the COMP in 2002.', 'P-1118\t-2.9082 -0.1014 -0.0873 -1.1807 -0.0254 -1.1074 -0.1917 -0.2367 -0.0169 -0.2197 -0.0225 -0.0338 -0.0282', 'S-1378\tNeulasta pegfilgrastim Part A', 'T-1378\t• 177 days', 'H-1378\t-0.31396484375\tNeulasta pegfilgrastim', 'D-1378\t-0.31396484375\tNeulasta pegfilgrastim', 'P-1378\t-0.2822 -0.0349 -0.0127 -0.1428 -0.0313 -0.0271 -0.0257 -0.0229 -0.0127 -0.6577', 'S-1133\tGCP- Inspektionen GLP-', 'T-1133\tinspections', 'H-1133\t-0.52490234375\tGMP inspections GLP-', 'D-1133\t-0.52490234375\tGMP inspections GLP-', 'P-1133\t-0.0590 -0.7642 -0.2078 -0.0592 -0.0873 -0.0754 -0.6514 -0.0282 -0.0282', 'S-654\tL 248 vom 16.9.2002, S.', 'T-654\tFinancial Regulation of 25 June 2002 applicable to the general budget of the European Communities (OJ L 248, 16.09.2002, p.', 'H-654\t-1.37890625\tOJ No 248 of 16.9.2002 , p .', 'D-654\t-1.37890625\tOJ No 248 of 16.9.2002, p.', 'P-654\t-3.0430 -0.0085 -0.3748 -0.0225 -0.0282 -0.2791 -2.4766 -0.0169 -0.0169 -0.0789 -0.0225 -0.0282 -0.0282', 'S-1106\tMittel zur Chemotherapie) verabreicht wurde.', 'T-1106\t(44-20) 74 18 84 00 Fax (44-20) 74 18 84 47 E-mail: mail @ emea. europa. eu http: / / www. emea. europa. eu © EMEA 2006 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged additional treatment.', 'H-1106\t-1.8203125\tcancer chemotherapy ) .', 'D-1106\t-1.8203125\tcancer chemotherapy).', 'P-1106\t-2.3281 -2.6172 -0.0197 -0.0254 -0.4338 -0.3916 -0.0338', 'S-1969\t40% (Lacosamid 400 mg).', 'T-1969\tOverall the proportion of subjects with a 50% reduction in seizure frequency was 23%, 34%, and 40% for placebo, lacosamide 200 mg / day and lacosamide 400 mg / day.', 'H-1969\t-0.392333984375\t40 % ( lacosamide 400 mg ) .', 'D-1969\t-0.392333984375\t40% (lacosamide 400 mg).', 'P-1969\t-0.8813 -0.0282 -0.0359 -0.2008 -0.1556 -0.0247 -0.0225 -0.0388 -0.0113 -0.0310 -0.2847 -0.0282', 'S-484\tDie Dauer der kombinierten antiretroviralen', 'T-484\tcombination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone).', 'H-484\t-1.048828125\tDuration of combination antiretrovirals', 'D-484\t-1.048828125\tDuration of combination antiretrovirals', 'P-484\t-0.4521 -0.0285 -0.0313 -1.2646 -0.1071 -0.0225 -0.0141 -1.9229 -0.0282 -0.3042', 'S-1883\tEU / 1 / 00 / 140 / 001', 'T-1883\tEU / 1 / 00 / 140 / 001', 'H-1883\t-0.0787353515625\tEU / 1 / 00 / 140 / 001', 'D-1883\t-0.0787353515625\tEU / 1 / 00 / 140 / 001', 'P-1883\t-0.0285 -0.0349 -0.0349 -0.0291 -0.0284 -0.0277 -0.0171 -0.0306 -0.0386 -0.0320 -0.0299', 'S-794\tEmpreendimento Lagoas Park,', 'T-794\tEmpreendimento Lagoas Park, Edifício 7 - 3º Piso 2740-244 Porto Salvo Portugal', 'H-794\t-0.278076171875\tEmpreendimento Lagoas Park ,', 'D-794\t-0.278076171875\tEmpreendimento Lagoas Park,', 'P-794\t-0.0234 -0.0342 -0.0227 -0.0128 -0.0299 -0.0429 -0.0049 -0.0320 -0.0414 -0.0342 -0.8940', 'S-22\tEr muss 10 Sekunden lang eingedrückt gehalten wer-', 'T-22\tThen the injection button should be held down 10 seconds before withdrawing the needle from the skin.', 'H-22\t-1.345703125\tThen the syringe should be held down for 10 minutes .', 'D-22\t-1.345703125\tThen the syringe should be held down for 10 minutes.', 'P-22\t-0.3579 -0.2996 -2.4609 -0.0676 -0.0028 -0.7017 -0.0395 -0.2395 -0.3184 -0.3691 -0.1719 -0.4536 -1.0371 -0.0338', 'S-895\tLokale Reaktionen an der Injektionsstelle:', 'T-895\tAmong reactions found at the injection site, itching and hives have been also reported.', 'H-895\t-0.291748046875\tLocal reactions at the injection site :', 'D-895\t-0.291748046875\tLocal reactions at the injection site:', 'P-895\t-0.3064 -0.0662 -0.0099 -0.0430 -0.3909 -0.2346 -0.0085 -0.0359 -0.0380 -0.0282', 'S-1235\tPerikarderguss Tachykardie', 'T-1235\tUncommon Hypernatraemia Ketoacidosis', 'H-1235\t-0.20361328125\tPericardial effusion Tachycardia', 'D-1235\t-0.20361328125\tPericardial effusion Tachycardia', 'P-1235\t-0.1926 -0.0042 -0.0437 -0.1250 -0.1276 -0.0183 -0.0285 -0.3145 -0.0155 -0.0211 -0.0204 -0.0085 -0.0289', 'S-1570\t2 Dosierung bei Nierenfunktionsstörungen:', 'T-1570\tDosage in renal impairment:', 'H-1570\t-0.7880859375\t2 Dosage in renal impairment :', 'D-1570\t-0.7880859375\t2 Dosage in renal impairment:', 'P-1570\t-1.0176 -0.5044 -0.4648 -0.0254 -0.3000 -0.5693 -0.0211 -0.4988 -0.0817 -0.0113 -0.1014 -0.0479 -0.0282', 'S-1496\tDosen bis zu 300 Einheiten können gegeben werden.', 'T-1496\tDoses of up to 300 U may be given.', 'H-1496\t-0.85009765625\tDoses up to 300 units can be administered .', 'D-1496\t-0.85009765625\tDoses up to 300 units can be administered.', 'P-1496\t-0.5645 -0.0155 -0.6348 -0.0275 -0.0240 -0.4050 -0.5088 -0.0296 -1.4824 -0.0169 -0.0395 -0.0282', 'S-1465\tIreland Biogen Idec (Ireland) Ltd.', 'T-1465\t28 Ireland Biogen Idec (Ireland) Ltd.', 'H-1465\t-0.2213134765625\tIreland Biogen Idec ( Ireland ) Ltd .', 'D-1465\t-0.2213134765625\tIreland Biogen Idec (Ireland) Ltd.', 'P-1465\t-0.0227 -0.0113 -0.0120 -0.0092 -0.0227 -0.0285 -0.0198 -0.0277 -0.2402 -0.5112 -0.0282', 'S-605\tWofür sollte Evoltra angewendet werden?', 'T-605\tWhat was Evoltra expected to be used for?', 'H-605\t-0.78271484375\tWhat should Evoltra be used for ?', 'D-605\t-0.78271484375\tWhat should Evoltra be used for?', 'P-605\t-0.1219 -2.6934 -0.0690 -0.0169 -0.0113 -0.0366 -0.0732 -0.0366 -0.0282 -0.0282', 'S-1946\tDiese Zusammenfassung wurde zuletzt im April 2008 aktualisiert.', 'T-1946\tThis summary was last updated in April 2008.', 'H-1946\t-0.298583984375\tThis summary was last updated in April 2008 .', 'D-1946\t-0.298583984375\tThis summary was last updated in April 2008.', 'P-1946\t-0.4058 -0.1141 -0.0169 -0.0458 -0.0320 -0.0197 -0.0370 -0.0264 -0.0229 -0.5103 -0.0282', 'S-1942\tLiprolog Mix50 KwikPen', 'T-1942\tLiprolog Mix50 KwikPen', 'H-1942\t-0.095458984375\tLiprolog Mix50 KwikPen', 'D-1942\t-0.095458984375\tLiprolog Mix50 KwikPen', 'P-1942\t-0.0961 -0.0531 -0.0589 -0.0241 -0.0292 -0.0241 -0.0386 -0.0157 -0.0211 -0.0092 -0.0320', 'S-1934\tEMEA / H / C / 472', 'T-1934\tEMEA / H / C / 472', 'H-1934\t-0.099853515625\tEMEA / H / C / 472', 'D-1934\t-0.099853515625\tEMEA / H / C / 472', 'P-1934\t-0.1703 -0.0106 -0.0241 -0.0365 -0.0227 -0.0285 -0.0185 -0.0299 -0.0336 -0.0155 -0.0306', 'S-632\tOrale Kontrazeptiva und Östrogene:', 'T-632\t6 Oral contraceptives and oestrogens:', 'H-632\t-0.33203125\tOral contraceptives and oestrogens :', 'D-632\t-0.33203125\tOral contraceptives and oestrogens:', 'P-632\t-0.0249 -0.0071 -0.0759 -0.0156 -0.3938 -0.0306 -0.5581 -0.0141 -0.0099 -0.2791 -0.0380 -0.0282', 'S-1245\tEU / 1 / 98 / 092 / 021', 'T-1245\tEU / 1 / 98 / 092 / 021', 'H-1245\t-0.076416015625\tEU / 1 / 98 / 092 / 021', 'D-1245\t-0.076416015625\tEU / 1 / 98 / 092 / 021', 'P-1245\t-0.0357 -0.0357 -0.0313 -0.0284 -0.0184 -0.0284 -0.0298 -0.0185 -0.0299 -0.0276 -0.0255 -0.0299', 'S-1318\tREVATIO 20 mg Sildenafil', 'T-1318\tREVATIO 20 mg Sildenafil', 'H-1318\t-0.0721435546875\tREVATIO 20 mg Sildenafil', 'D-1318\t-0.0721435546875\tREVATIO 20 mg Sildenafil', 'P-1318\t-0.0414 -0.0285 -0.0170 -0.0270 -0.0248 -0.0430 -0.0099 -0.0430 -0.0171 -0.0120 -0.0213 -0.0356', 'S-1348\tEU / 1 / 97 / 031 / 020', 'T-1348\tEU / 1 / 97 / 031 / 020', 'H-1348\t-0.077392578125\tEU / 1 / 97 / 031 / 020', 'D-1348\t-0.077392578125\tEU / 1 / 97 / 031 / 020', 'P-1348\t-0.0371 -0.0371 -0.0342 -0.0291 -0.0135 -0.0291 -0.0299 -0.0213 -0.0299 -0.0269 -0.0255 -0.0299', 'S-1640\tBinocrit ist eine Injektionslösung.', 'T-1640\tBinocrit is a solution for injection.', 'H-1640\t-0.2027587890625\tBinocrit is a solution for injection .', 'D-1640\t-0.2027587890625\tBinocrit is a solution for injection.', 'P-1640\t-0.0894 -0.0241 -0.0220 -0.0298 -0.0342 -0.2661 -0.1631 -0.0715 -0.0472 -0.0760 -0.0486 -0.0282', 'S-1675\tEU / 1 / 97 / 030 / 066', 'T-1675\tEU / 1 / 97 / 030 / 066', 'H-1675\t-0.07781982421875\tEU / 1 / 97 / 030 / 066', 'D-1675\t-0.07781982421875\tEU / 1 / 97 / 030 / 066', 'P-1675\t-0.0385 -0.0385 -0.0342 -0.0299 -0.0142 -0.0284 -0.0285 -0.0299 -0.0292 -0.0278 -0.0162 -0.0299', 'S-1743\tEU / 1 / 98 / 092 / 017', 'T-1743\tEU / 1 / 98 / 092 / 017', 'H-1743\t-0.07464599609375\tEU / 1 / 98 / 092 / 017', 'D-1743\t-0.07464599609375\tEU / 1 / 98 / 092 / 017', 'P-1743\t-0.0349 -0.0357 -0.0313 -0.0284 -0.0184 -0.0284 -0.0291 -0.0162 -0.0299 -0.0262 -0.0227 -0.0299', 'S-1786\tEU / 1 / 07 / 411 / 009', 'T-1786\tEU / 1 / 07 / 411 / 009', 'H-1786\t-0.08209228515625\tEU / 1 / 07 / 411 / 009', 'D-1786\t-0.08209228515625\tEU / 1 / 07 / 411 / 009', 'P-1786\t-0.0400 -0.0371 -0.0349 -0.0299 -0.0248 -0.0285 -0.0255 -0.0241 -0.0299 -0.0320 -0.0276 -0.0299', 'S-1800\tTel.: + 48 22 699 0 699', 'T-1800\tTel.: + 48 22 699 0 699', 'H-1800\t-0.2176513671875\tTel . : + 48 22 699 0 699', 'D-1800\t-0.2176513671875\tTel.: + 48 22 699 0 699', 'P-1800\t-0.1782 -0.5239 -0.0331 -0.0282 -0.0225 -0.0247 -0.0254 -0.0183 -0.0352 -0.0240 -0.0204 -0.0324', 'S-1931\tEU / 2 / 06 / 064 / 002', 'T-1931\tEU / 2 / 06 / 064 / 002', 'H-1931\t-0.080810546875\tEU / 2 / 06 / 064 / 002', 'D-1931\t-0.080810546875\tEU / 2 / 06 / 064 / 002', 'P-1931\t-0.0328 -0.0356 -0.0386 -0.0298 -0.0234 -0.0292 -0.0313 -0.0162 -0.0299 -0.0327 -0.0292 -0.0299', 'S-1957\tEU / 1 / 05 / 331 / 008', 'T-1957\tEU / 1 / 05 / 331 / 008', 'H-1957\t-0.08050537109375\tEU / 1 / 05 / 331 / 008', 'D-1957\t-0.08050537109375\tEU / 1 / 05 / 331 / 008', 'P-1957\t-0.0349 -0.0371 -0.0364 -0.0284 -0.0227 -0.0285 -0.0285 -0.0185 -0.0299 -0.0327 -0.0299 -0.0299', 'S-125\tSIFROL kann die Milchbildung hemmen.', 'T-125\tSIFROL can reduce the production of breast milk.', 'H-125\t-0.74658203125\tSIFROL can reduce the production of breast milk .', 'D-125\t-0.74658203125\tSIFROL can reduce the production of breast milk.', 'P-125\t-0.7300 -0.0282 -0.0176 -0.0197 -0.4883 -1.0664 -0.4087 -0.2817 -0.0310 -0.3213 -0.0254 -0.0338 -0.0282', 'S-1228\tErbitux 5 mg / ml Infusionslösung', 'T-1228\tErbitux 5 mg / ml solution for infusion', 'H-1228\t-0.96142578125\tErbitux 5 mg / ml solution', 'D-1228\t-0.96142578125\tErbitux 5 mg / ml solution', 'P-1228\t-0.0199 -0.0142 -0.0113 -0.0357 -0.0063 -0.0306 -0.0135 -0.3164 -3.1445', 'S-1110\tEU / 1 / 03 / 257 / 004', 'T-1110\tr EU / 1 / 03 / 257 / 004', 'H-1110\t-0.07843017578125\tEU / 1 / 03 / 257 / 004', 'D-1110\t-0.07843017578125\tEU / 1 / 03 / 257 / 004', 'P-1110\t-0.0364 -0.0364 -0.0342 -0.0291 -0.0199 -0.0285 -0.0199 -0.0248 -0.0306 -0.0313 -0.0269 -0.0299', 'S-1896\tBayer AG Bayerwerk D-51368 Leverkusen', 'T-1896\tBayer AG Bayerwerk D-51368 Leverkusen Germany', 'H-1896\t-0.87353515625\tBayer AG Bayer AG Bayer AG D @-@ 51368 Leverkusen', 'D-1896\t-0.87353515625\tBayer AG Bayer AG Bayer AG D-51368 Leverkusen', 'P-1896\t-0.0135 -0.0306 -0.7476 -0.8550 -1.1484 -0.4509 -0.0423 -0.0282 -0.0338 -0.0338 -0.0423 -0.0451 -0.6001', 'S-990\tWie Tandemact aussieht und Inhalt der Packung:', 'T-990\tWhat Tandemact looks like and contents of the pack:', 'H-990\t-0.34619140625\tWhat Tandemact looks like and contents of the pack', 'D-990\t-0.34619140625\tWhat Tandemact looks like and contents of the pack', 'P-990\t-0.5151 -0.1082 -0.0430 -0.0127 -0.0585 -0.0296 -0.0388 -0.1620 -0.0197 -0.0345 -0.0690 -0.2072 -0.3149', 'S-1686\tKinder und Jugendliche (< 18 Jahre):', 'T-1686\tChildren and adolescents (< 18 years):', 'H-1686\t-0.2734375\tChildren and adolescents ( &lt; 18 years ) :', 'D-1686\t-0.2734375\tChildren and adolescents (< 18 years):', 'P-1686\t-0.1870 -0.0939 -0.1847 -0.0183 -0.0169 -0.0409 -0.2268 -0.0063 -0.0225 -0.0430 -0.0465 -0.0690 -0.3479 -0.0282', 'S-419\t- Agenerase - amprenavir - B', 'T-419\t- 03.01.2000 - 17.02.2000 - 43 days - 0 days', 'H-419\t-1.52734375\t- 26.02.1999 - 29.06.2000 - 174', 'D-419\t-1.52734375\t- 26.02.1999 - 29.06.2000 - 174', 'P-419\t-0.7451 -0.6270 -0.5566 -0.4565 -0.1141 -0.8145 -0.3579 -0.3157 -0.1859 -0.4592 -0.4509 -1.7021', 'S-1091\tTrübe oder verfärbte Lösungen nicht verwenden.', 'T-1091\tDo not use if particulate matter or discolouration is observed.', 'H-1091\t-0.86083984375\tDo not use if particulate matter or discolouration is observed .', 'D-1091\t-0.86083984375\tDo not use if particulate matter or discolouration is observed.', 'P-1091\t-0.0916 -0.0299 -0.0357 -0.7832 -0.3438 -0.5645 -0.2705 -0.1240 -0.0831 -1.3398 -0.0901 -0.1831 -0.1747 -0.3579 -0.0423 -0.0282', 'S-1264\tZULASSUNGSINHABER', 'T-1264\tMARKETING AUTHORISATION HOLDERS', 'H-1264\t-1.1083984375\tMARKETING AUTHORISATION', 'D-1264\t-1.1083984375\tMARKETING AUTHORISATION', 'P-1264\t-0.3223 -0.0504 -0.1807 -0.3215 -0.3213 -0.1240 -0.0514 -0.2896 -0.3198 -0.2761 -2.4141', 'S-1098\tDies kann eine Dosisanpassung notwendig machen.', 'T-1098\tThis may require an adjustment of your dose of Zonegran.', 'H-1098\t-0.88427734375\tThis may require dose adjustment .', 'D-1098\t-0.88427734375\tThis may require dose adjustment.', 'P-1098\t-0.7451 -0.4036 -0.6235 -1.1016 -0.2791 -0.0225 -0.0676 -0.0338 -0.0282', 'S-35\tBenommenheit Schlafstörungen Geschmacks- störungen', 'T-35\tConfusion and disorientation Anxiety reaction Abnormal dreams Depression Hallucinations', 'H-35\t-0.73046875\tDizziness Sleep disorders Taste disorders', 'D-35\t-0.73046875\tDizziness Sleep disorders Taste disorders', 'P-35\t-1.8613 -0.0465 -0.0240 -0.1606 -0.2974 -0.2085 -0.0169 -0.3240 -0.0620 -0.0507 -0.0169 -0.1747', 'S-251\tkapsulka dojelitowa twarda', 'T-251\tLansoTEVA 30 mg 30 mg kapsulka dojelitowa twarda', 'H-251\t-1.046875\tkapsulka dojelitowa tvarda', 'D-251\t-1.046875\tkapsulka dojelitowa tvarda', 'P-251\t-3.2695 -0.0113 -0.0197 -0.6255 -0.1747 -0.0310 -0.0113 -0.1803 -0.0282 -0.2563 -0.0113 -0.0310', 'S-1785\tKrankheitsfreies Überleben (DFS) * *', 'T-1785\tDuration of response * Disease free survival (DFS) * * Time to new treatment', 'H-1785\t-0.344970703125\tDisease @-@ free survival ( DFS ) * *', 'D-1785\t-0.344970703125\tDisease-free survival (DFS) * *', 'P-1785\t-0.0685 -0.0085 -0.0141 -0.3606 -0.2842 -0.1226 -0.6011 -0.0113 -0.0197 -0.0282 -0.0324 -0.0282 -0.0282', 'S-529\tFünf Patienten sprachen an, 3 vollständig und 2 teilweise.', 'T-529\t5 patients responded, 3 completely and 2 partially.', 'H-529\t-0.55224609375\tFive patients responded , 3 complete and 2 partial .', 'D-529\t-0.55224609375\tFive patients responded, 3 complete and 2 partial.', 'P-529\t-0.1958 -0.1768 -0.1127 -0.1726 -0.8779 -0.5947 -0.0564 -0.0296 -0.0493 -0.0324 -0.0296', 'S-240\tErkrankungen des Ohrs und des Labyrinths U', 'T-240\tEar and labyrinth disorders U', 'H-240\t-0.378662109375\tEar and labyrinth disorders U', 'D-240\t-0.378662109375\tEar and labyrinth disorders U', 'P-240\t-0.5225 -0.0099 -0.1159 -0.3542 -0.0197 -0.0359 -0.0099 -0.2128 -0.0225 -0.2634 -0.0296', 'S-690\tWelchen Nutzen hat Byetta in diesen Studien gezeigt?', 'T-690\tWhat benefit has Byetta shown during the studies?', 'H-690\t-0.330322265625\tWhat benefit has Byetta shown during the studies ?', 'D-690\t-0.330322265625\tWhat benefit has Byetta shown during the studies?', 'P-690\t-0.0560 -0.2219 -0.1567 -0.0349 -0.0077 -0.1145 -0.3213 -0.3015 -0.1198 -0.0303 -0.0282', 'S-1478\tHaltbarkeit bei handelsüblicher Verpackung 2 Jahre', 'T-1478\tShelf life as packaged for sale 2 years', 'H-1478\t-1.2421875\tShelf life at conventional packaging 2 years', 'D-1478\t-1.2421875\tShelf life at conventional packaging 2 years', 'P-1478\t-0.4358 -0.0243 -0.9966 -0.5493 -1.7021 -0.4028 -0.0254 -0.7412 -0.0395 -0.0282', 'S-1480\tItalia GE Healthcare S.r.l.', 'T-1480\tItalia GE Healthcare S. r. l.', 'H-1480\t-0.387451171875\tItalia GE Healthcare S. r. l .', 'D-1480\t-0.387451171875\tItalia GE Healthcare S. r. l.', 'P-1480\t-0.2739 -0.0276 -0.0099 -0.0127 -0.0213 -0.0199 -0.7314 -0.3228 -0.1550 -0.0310 -0.0282', 'S-1511\tOrganon (Ireland) Ltd, P.O.', 'T-1511\tOrganon (Ireland) Ltd, P. O.', 'H-1511\t-0.1649169921875\tOrganon ( Ireland ) Ltd , P. O .', 'D-1511\t-0.1649169921875\tOrganon (Ireland) Ltd, P. O.', 'P-1511\t-0.0234 -0.0256 -0.0342 -0.0242 -0.0284 -0.0099 -0.0663 -0.3213 -0.1022 -0.0313 -0.0285', 'S-1940\tWofür wird INCRELEX angewendet?', 'T-1940\tWhat is INCRELEX used for?', 'H-1940\t-0.1353759765625\tWhat is INCRELEX used for ?', 'D-1940\t-0.1353759765625\tWhat is INCRELEX used for?', 'P-1940\t-0.1181 -0.1021 -0.0327 -0.0269 -0.0171 -0.0185 -0.0213 -0.1444 -0.0342 -0.0271 -0.0285', 'S-21\t2000 <unk> 54 S. <unk> 21 x 29,7 cm', 'T-21\t2000 <<unk>> 54 pp. <<unk>> 21 x 29.7 cm', 'H-21\t-1.275390625\t2000', 'D-21\t-1.275390625\t2000', 'P-21\t-0.4417 -1.4902', 'S-32\tEU / 2 / 06 / 064 / 001', 'T-32\tEU / 2 / 06 / 064 / 001', 'H-32\t-0.08123779296875\tEU / 2 / 06 / 064 / 001', 'D-32\t-0.08123779296875\tEU / 2 / 06 / 064 / 001', 'P-32\t-0.0335 -0.0357 -0.0378 -0.0298 -0.0227 -0.0292 -0.0306 -0.0171 -0.0299 -0.0357 -0.0285 -0.0299', 'S-115\tEU / 1 / 00 / 152 / 010', 'T-115\tEU / 1 / 00 / 152 / 010', 'H-115\t-0.1925048828125\tEU / 1 / 00 / 152 / 010', 'D-115\t-0.1925048828125\tEU / 1 / 00 / 152 / 010', 'P-115\t-0.0313 -0.0357 -0.0320 -0.0284 -0.0284 -0.0284 -0.0248 -0.0299 -0.0285 -0.0458 -0.5122 -0.0296', 'S-303\tRatiopharm España S.A.', 'T-303\tRatiopharm España S. A.', 'H-303\t-0.158447265625\tRatiopharm España S. A .', 'D-303\t-0.158447265625\tRatiopharm España S. A.', 'P-303\t-0.0407 -0.0127 -0.0256 -0.0042 -0.1357 -0.0192 -0.0134 -0.0285 -0.3213 -0.0363 -0.0370 -0.0285', 'S-411\tEU / 1 / 01 / 184 / 071', 'T-411\tEU / 1 / 01 / 184 / 071', 'H-411\t-0.07763671875\tEU / 1 / 01 / 184 / 071', 'D-411\t-0.07763671875\tEU / 1 / 01 / 184 / 071', 'P-411\t-0.0328 -0.0356 -0.0371 -0.0284 -0.0270 -0.0285 -0.0199 -0.0262 -0.0285 -0.0320 -0.0192 -0.0292', 'S-31\tWelchen Nutzen hat Prialt in diesen Studien gezeigt?', 'T-31\tWhat benefit has Prialt shown during the studies?', 'H-31\t-0.35546875\tWhat benefit has Prialt shown during the studies ?', 'D-31\t-0.35546875\tWhat benefit has Prialt shown during the studies?', 'P-31\t-0.0531 -0.2233 -0.1765 -0.0961 -0.0113 -0.0947 -0.3206 -0.3022 -0.1642 -0.0289 -0.0282', 'S-560\tDiese Zusammenfassung wurde zuletzt im 11-2007 aktualisiert.', 'T-560\tThis summary was last updated in 11-2007.', 'H-560\t-0.28662109375\tThis summary was last updated in 11 @-@ 2007 .', 'D-560\t-0.28662109375\tThis summary was last updated in 11-2007.', 'P-560\t-0.0502 -0.1082 -0.0177 -0.0400 -0.0269 -0.0185 -0.2407 -0.6445 -0.0296 -0.0240 -0.0430 -0.0289', 'S-770\tSaquinavir ↔ Efavirenz ↔', 'T-770\tSaquinavir ↔ Efavirenz ↔', 'H-770\t-0.29296875\tSaquinavir ↔ Efavirenz ↔', 'D-770\t-0.29296875\tSaquinavir ↔ Efavirenz ↔', 'P-770\t-0.1537 -0.0220 -0.0285 -0.0127 -0.0021 -0.0444 -0.0155 -0.0285 -0.0113 -0.2427 -0.7192 -0.0197', 'S-906\tEU / 1 / 04 / 273 / 001', 'T-906\tEU / 1 / 04 / 273 / 001', 'H-906\t-0.1873779296875\tEU / 1 / 04 / 273 / 001', 'D-906\t-0.1873779296875\tEU / 1 / 04 / 273 / 001', 'P-906\t-0.0385 -0.0364 -0.0327 -0.0291 -0.0199 -0.0285 -0.0199 -0.0285 -0.0299 -0.0313 -0.0285 -0.5088', 'S-940\tEU / 1 / 00 / 134 / 011', 'T-940\tEU / 1 / 00 / 134 / 011', 'H-940\t-0.08270263671875\tEU / 1 / 00 / 134 / 011', 'D-940\t-0.08270263671875\tEU / 1 / 00 / 134 / 011', 'P-940\t-0.0342 -0.0357 -0.0356 -0.0291 -0.0277 -0.0285 -0.0269 -0.0262 -0.0292 -0.0356 -0.0285 -0.0299', 'S-1057\tEU / 2 / 00 / 021 / 001', 'T-1057\tEU / 2 / 00 / 021 / 001', 'H-1057\t-1.6650390625\tWithdrawal Period', 'D-1057\t-1.6650390625\tWithdrawal Period', 'P-1057\t-2.4570 -0.2676 -0.3042 -1.4570 -0.1099 -0.2847', 'S-1111\tDynastat muss vor der Anwendung aufgelöst werden.', 'T-1111\tDynastat must be reconstituted before use.', 'H-1111\t-0.4130859375\tDynastat must be dissolved before use .', 'D-1111\t-0.4130859375\tDynastat must be dissolved before use.', 'P-1111\t-0.0856 -0.0199 -0.0270 -0.5898 -0.0352 -0.1444 -0.0345 -0.0218 -0.4128 -0.3960 -0.0395 -0.0282', 'S-1126\tEU / 1 / 07 / 391 / 002', 'T-1126\tEU / 1 / 07 / 391 / 002', 'H-1126\t-0.08203125\tEU / 1 / 07 / 391 / 002', 'D-1126\t-0.08203125\tEU / 1 / 07 / 391 / 002', 'P-1126\t-0.0385 -0.0371 -0.0357 -0.0291 -0.0256 -0.0285 -0.0306 -0.0164 -0.0299 -0.0313 -0.0313 -0.0299', 'S-1134\tNicht einfrieren und vor extremer Hitze schützen.', 'T-1134\tAvoid exposure to freezing and excessive heat.', 'H-1134\t-1.0283203125\tStore below 25 ° C Do not freeze and protect from excessive heat .', 'D-1134\t-1.0283203125\tStore below 25 ° C Do not freeze and protect from excessive heat.', 'P-1134\t-1.7080 -0.3762 -0.3228 -0.1888 -0.1859 -0.3269 -0.0282 -0.1099 -1.0205 -0.0732 -0.0930 -0.5327 -0.0169 -0.2113 -0.0282', 'S-1167\tEU / 2 / 03 / 040 / 002', 'T-1167\tEU / 2 / 03 / 040 / 002', 'H-1167\t-0.0811767578125\tEU / 2 / 03 / 040 / 002', 'D-1167\t-0.0811767578125\tEU / 2 / 03 / 040 / 002', 'P-1167\t-0.0320 -0.0357 -0.0386 -0.0291 -0.0213 -0.0285 -0.0313 -0.0206 -0.0313 -0.0320 -0.0299 -0.0299', 'S-1203\tEU / 1 / 05 / 311 / 001', 'T-1203\tEU / 1 / 05 / 311 / 001', 'H-1203\t-0.190673828125\tEU / 1 / 05 / 311 / 001', 'D-1203\t-0.190673828125\tEU / 1 / 05 / 311 / 001', 'P-1203\t-0.5190 -0.0356 -0.0370 -0.0285 -0.0229 -0.0285 -0.0271 -0.0254 -0.0303 -0.0345 -0.0289 -0.0296', 'S-1224\tDiese Zusammenfassung wurde zuletzt im 04-2007 aktualisiert.', 'T-1224\tThis summary was last updated in 10-2007.', 'H-1224\t-0.29150390625\tThis summary was last updated in 04 @-@ 2007 .', 'D-1224\t-0.29150390625\tThis summary was last updated in 04-2007.', 'P-1224\t-0.0436 -0.1111 -0.0184 -0.0357 -0.0199 -0.0164 -0.1367 -0.4607 -0.0275 -0.0282 -0.3669 -0.0296', 'S-1673\tCPMP / EWP / 559 / 95', 'T-1673\tCPMP / EWP / 559 / 95', 'H-1673\t-0.107421875\tCPMP / EWP / 559 / 95', 'D-1673\t-0.107421875\tCPMP / EWP / 559 / 95', 'P-1673\t-0.1600 -0.0342 -0.0120 -0.0365 -0.0444 -0.0313 -0.0206 -0.0322 -0.0342 -0.0183 -0.0306 -0.0155 -0.0306', 'S-1719\tDosis (I.E.) 75 150 225 300', 'T-1719\tDose (IU) 75 150 225 300', 'H-1719\t-0.283447265625\tDose ( IU ) 75 150 225 300', 'D-1719\t-0.283447265625\tDose (IU) 75 150 225 300', 'P-1719\t-0.1719 -0.1328 -0.1451 -0.0327 -0.3213 -0.0289 -0.0261 -0.0155 -0.0254 -0.0211 -0.0183 -0.3206', 'S-643\tMetformin geht in Erythrozyten über.', 'T-643\tMetformin partitions into erythrocytes.', 'H-643\t-0.8115234375\tMetformin is excreted in erythrocytes .', 'D-643\t-0.8115234375\tMetformin is excreted in erythrocytes.', 'P-643\t-0.8657 -0.0070 -0.0275 -0.9033 -0.5366 -0.1691 -0.0169 -0.8354 -0.6284 -0.0254 -0.0085 -0.0225 -0.0141 -0.0310 -0.0282', 'S-685\tA EU / 1 / 01 / 184 / 032', 'T-685\ta EU / 1 / 01 / 184 / 032', 'H-685\t-0.37646484375\ted EU / 1 / 01 / 184 / 032', 'D-685\t-0.37646484375\ted EU / 1 / 01 / 184 / 032', 'P-685\t-1.3486 -0.0824 -0.0366 -0.0395 -0.0282 -0.0282 -0.0296 -0.0183 -0.0268 -0.0296 -0.0296 -0.0240 -0.0324', 'S-697\tHCV / HIV-coinfizierte Patienten:', 'T-697\tPatients co-infected with HCV / HIV:', 'H-697\t-0.60302734375\tHCV / HIV @-@ infected patients :', 'D-697\t-0.60302734375\tHCV / HIV-infected patients:', 'P-697\t-0.5581 -0.0285 -0.0190 -0.0402 -0.0120 -1.1514 -0.3889 -0.1338 -0.0409 -0.0282', 'S-839\tDie therapeutische Breite von Nespo ist sehr groß.', 'T-839\tThe therapeutic margin of Nespo is very wide.', 'H-839\t-0.34423828125\tThe therapeutic margin of Nespo is very wide .', 'D-839\t-0.34423828125\tThe therapeutic margin of Nespo is very wide.', 'P-839\t-0.2805 -0.0738 -0.0292 -0.4377 -0.0718 -0.2416 -0.0218 -0.0254 -0.0359 -0.1212 -0.2036 -0.0324 -0.0282', 'S-1238\tGelatine Titandioxid (E171)', 'T-1238\tGelatin Titanium dioxide (E171)', 'H-1238\t-0.223876953125\tGelatin Titanium dioxide ( E171 )', 'D-1238\t-0.223876953125\tGelatin Titanium dioxide (E171)', 'P-1238\t-0.0516 -0.0961 -0.3789 -0.0085 -0.0243 -0.3047 -0.0085 -0.0310 -0.0268 -0.0254 -0.0282 -0.0289 -0.0303', 'S-1300\tCPMP / BWP / 859 / 95', 'T-1300\tCPMP / BWP / 859 / 95', 'H-1300\t-0.322998046875\tCPMP / BWP / 859 / 95', 'D-1300\t-0.322998046875\tCPMP / BWP / 859 / 95', 'P-1300\t-0.4329 -0.0363 -0.0127 -0.0327 -0.0465 -0.0271 -0.0211 -0.0342 -0.7607 -0.0204 -0.0317 -0.0183 -0.0296', 'S-1519\tNorfloxacin- Ratiopharm 400 mg', 'T-1519\tNorfloxacin- Ratiopharm 400 mg', 'H-1519\t-0.07952880859375\tNorfloxacin- Ratiopharm 400 mg', 'D-1519\t-0.07952880859375\tNorfloxacin- Ratiopharm 400 mg', 'P-1519\t-0.0313 -0.0113 -0.0270 -0.0234 -0.0977 -0.0241 -0.0262 -0.0171 -0.0262 -0.0085 -0.0365 -0.0106 -0.0306', 'S-1597\tPromotion auf dem Gebiet der klinischen Pharmakologie.', 'T-1597\tDoctorate in Clinical Pharmacology.', 'H-1597\t-0.5947265625\tDoctorate in clinical pharmacology .', 'D-1597\t-0.5947265625\tDoctorate in clinical pharmacology.', 'P-1597\t-1.6035 -0.0127 -0.0859 -0.0282 -0.0648 -0.4480 -0.0240 -0.0211 -0.0493 -0.0296', 'S-1262\tWelchen Nutzen hat Opgenra in diesen Studien gezeigt?', 'T-1262\tWhat benefit has Opgenra shown during the studies?', 'H-1262\t-0.32470703125\tWhat benefit has Opgenra shown during the studies ?', 'D-1262\t-0.32470703125\tWhat benefit has Opgenra shown during the studies?', 'P-1262\t-0.0487 -0.2268 -0.1719 -0.0285 -0.0197 -0.0197 -0.0916 -0.3215 -0.3015 -0.1536 -0.0303 -0.0282', 'S-83\tBeurteilungszeit bei Typ-II- Änderungen 2001', 'T-83\tDuring 2001 di scussions were held in different forums at the', 'H-83\t-0.434326171875\tfor type II variations 2001', 'D-83\t-0.434326171875\tfor type II variations 2001', 'P-83\t-0.3223 -0.2800 -0.1584 -0.3213 -0.1022 -0.0881 -0.1240', 'S-278\tPuregon 50 IE / 0,5 ml Injektionslösung', 'T-278\tPuregon 50 IU / 0.5 ml solution for injection', 'H-278\t-0.7861328125\tPuregon 50 IE / 0.5 ml solution for injection', 'D-278\t-0.7861328125\tPuregon 50 IE / 0.5 ml solution for injection', 'P-278\t-0.0285 -0.0099 -0.0270 -0.0306 -2.6230 -0.0282 -0.1635 -0.0141 -0.2817 -0.2903 -0.0592 -0.0704 -0.0366', 'S-312\t(Rot) ALKOHOLTUPFER', 'T-312\tOne pre-filled pen of Humira One alcohol pad', 'H-312\t-1.462890625\t( red ) ALKOL CARTON', 'D-312\t-1.462890625\t(red) ALKOL CARTON', 'P-312\t-1.0400 -0.3501 -0.0310 -0.2177 -0.3184 -0.0352 -2.3945 -0.7070 -0.3127 -0.3184 -0.3101 -0.4622', 'S-379\t107 Hersteller Novartis Pharma S.A.S.', 'T-379\tManufacturer Novartis Pharma S. A. S.', 'H-379\t-0.76708984375\tManufacturer Novartis Pharma S.A.S .', 'D-379\t-0.76708984375\tManufacturer Novartis Pharma S.A.S.', 'P-379\t-2.0762 -0.0141 -0.0169 -0.3367 -0.0211 -0.0085 -0.0254 -0.0183 -0.0155 -1.1104 -0.0141 -0.0225 -0.0282 -0.0282', 'S-487\treduzierte Sehschärfe, Augenschmerzen, trockene Augen', 'T-487\tVisual acuity reduced, eye pain, eyes dry', 'H-487\t-0.6884765625\tvisual acuity reduced , eye pain , dry eyes', 'D-487\t-0.6884765625\tvisual acuity reduced, eye pain, dry eyes', 'P-487\t-2.1309 -0.0070 -0.0113 -0.0155 -0.1874 -0.0366 -0.1042 -0.0704 -0.0493 -0.0282 -0.3804 -0.0366', 'S-905\t<unk> Sie dürfen immer nur jeweils ein Pflaster tragen.', 'T-905\t<<unk>> Only one patch is to be worn at a time.', 'H-905\t-0.88427734375\tYou must only use one patch at a time .', 'D-905\t-0.88427734375\tYou must only use one patch at a time.', 'P-905\t-0.6748 -1.5596 -0.2113 -0.3733 -0.2438 -0.1409 -0.0254 -0.0958 -0.0282 -0.0282 -0.0366 -0.5073', 'S-957\tFertavid 75 IE / 0,5 ml Injektionslösung', 'T-957\tFertavid 75 IU / 0.5 ml solution for injection', 'H-957\t-0.76904296875\tFertavid 75 IE / 0.5 ml solution for injection', 'D-957\t-0.76904296875\tFertavid 75 IE / 0.5 ml solution for injection', 'P-957\t-0.0163 -0.0184 -0.0092 -0.0184 -2.6016 -0.0282 -0.1493 -0.0127 -0.2888 -0.2874 -0.0564 -0.0620 -0.0366', 'S-1236\tWas ist Fuzeon und wofür wird es angewendet?', 'T-1236\tWhat Fuzeon is and what it is used for 2.', 'H-1236\t-0.60986328125\tWhat PegIntron is and what it is used for 2 .', 'D-1236\t-0.60986328125\tWhat PegIntron is and what it is used for 2.', 'P-1236\t-0.0342 -0.3223 -0.4521 -0.5215 -0.3213 -0.1028 -0.0535 -0.0972 -0.0592 -0.2847 -0.1846 -0.0803 -0.0296 -0.3228 -0.3157 -0.0366', 'S-1565\tGlivec 50 mg Hartkapseln Imatinib', 'T-1565\tGlivec 50 mg hard capsules Imatinib', 'H-1565\t-0.181884765625\tGlivec 50 mg hard capsules Imatinib', 'D-1565\t-0.181884765625\tGlivec 50 mg hard capsules Imatinib', 'P-1565\t-0.0113 -0.0113 -0.0241 -0.0444 -0.0099 -0.2466 -0.0863 -0.0134 -0.0465 -0.2981 -0.0296 -0.0085 -0.0254 -0.0310', 'S-1022\t1 Tablette enthält 7,5 mg Olanzapin', 'T-1022\tEach tablet contains 7.5 mg olanzapine.', 'H-1022\t-0.54296875\tEach tablet contains 7.5 mg olanzapine .', 'D-1022\t-0.54296875\tEach tablet contains 7.5 mg olanzapine.', 'P-1022\t-0.7075 -0.1448 -0.0169 -0.0345 -0.2177 -0.0190 -0.1790 -0.0225 -0.0120 -0.0268 -1.0000 -0.0296', 'S-69\tN.gonorrhoeae Anaerobier', 'T-69\tSusceptibility', 'H-69\t-1.232421875\tN.gonorrhoeae', 'D-69\t-1.232421875\tN.gonorrhoeae', 'P-69\t-2.8242 -0.1127 -0.0254 -0.0169 -0.0169 -0.0648 -0.1775 -0.0085 -1.3613', 'S-276\tng Latvija Abbott Laboratories Baltics', 'T-276\tLatvija na', 'H-276\t-0.482421875\tAbbott Laboratories Baltics', 'D-276\t-0.482421875\tAbbott Laboratories Baltics', 'P-276\t-0.7300 -0.0204 -0.0282 -0.0197 -0.0218 -0.2747 -0.0225 -0.5635', 'S-1360\tel Insulin-Freisetzungs-Einheit gerät.', 'T-1360\tKeep the blue handle al', 'H-1360\t-0.97705078125\tor Insulin Release Unit .', 'D-1360\t-0.97705078125\tor Insulin Release Unit.', 'P-1360\t-2.2266 -0.4453 -0.0085 -0.0127 -0.1127 -0.0845 -0.0479 -0.0254 -0.8789 -0.0451', 'S-1984\tDie Tageshöchstdosis beträgt 8 mg.', 'T-1984\tThe maximum daily dose is 8 mg.', 'H-1984\t-0.30322265625\tThe maximum daily dose is 8 mg .', 'D-1984\t-0.30322265625\tThe maximum daily dose is 8 mg.', 'P-1984\t-0.0545 -0.5498 -0.2649 -0.0803 -0.0514 -0.0486 -0.0211 -0.0338 -0.0289', 'S-350\tDas Trocknungsmittel darf nicht geschluckt werden.', 'T-350\tDo not swallow the desiccant.', 'H-350\t-0.28662109375\tDo not swallow the desiccant .', 'D-350\t-0.28662109375\tDo not swallow the desiccant.', 'P-350\t-0.2874 -0.0299 -0.0423 -0.0169 -0.0736 -0.0768 -0.0049 -0.0211 -0.5571 -0.0303', 'S-355\t2 / 3 Welches Risiko ist mit Neupro verbunden?', 'T-355\tWhat is the risk associated with Neupro?', 'H-355\t-0.314453125\tWhat is the risk associated with Neupro ?', 'D-355\t-0.314453125\tWhat is the risk associated with Neupro?', 'P-355\t-0.5200 -0.1373 -0.0349 -0.0676 -0.1642 -0.0296 -0.1324 -0.0549 -0.0444 -0.0662', 'S-1040\tWenn Sie die Anwendung von BYETTA abbrechen:', 'T-1040\tIf you stop using BYETTA:', 'H-1040\t-0.57568359375\tIf you stop using BYETTA :', 'D-1040\t-0.57568359375\tIf you stop using BYETTA:', 'P-1040\t-0.3354 -0.0343 -0.3105 -0.4763 -0.0472 -0.0268 -0.0162 -0.0070 -1.0088 -0.0296', 'S-1705\t29 bei gesunden Probanden) und der Erkrankung.', 'T-1705\t29 for healthy volunteers) and their disease.', 'H-1705\t-1.5810546875\t29 in healthy volunteers ) and the disease .', 'D-1705\t-1.5810546875\t29 in healthy volunteers) and the disease.', 'P-1705\t-1.7314 -0.0620 -0.3228 -0.7808 -0.0310 -0.8086 -1.3154 -0.6479 -0.5664 -0.0282', 'S-1366\t1 Durchstechflasche mit 5 ml Injektionslösung', 'T-1366\t1 vial containing 5 ml solution for injection', 'H-1366\t-0.454833984375\t1 vial of 5 ml solution for injection', 'D-1366\t-0.454833984375\t1 vial of 5 ml solution for injection', 'P-1366\t-0.0313 -0.1030 -0.0342 -0.5430 -0.0486 -0.0141 -0.7109 -0.2649 -0.0662 -0.0620 -0.0395', 'S-1595\tIn klinischen Studien wurden die Patienten über 16 Wochen behandelt.', 'T-1595\tIn clinical trials patients were treated for 16 weeks.', 'H-1595\t-0.73974609375\tIn clinical trials , patients were treated for 16 weeks .', 'D-1595\t-0.73974609375\tIn clinical trials, patients were treated for 16 weeks.', 'P-1595\t-0.7983 -0.0444 -0.1233 -0.4226 -0.1106 -0.6226 -0.0437 -0.1324 -0.8975 -0.0254 -0.0366 -0.0282', 'S-1895\tBitte informieren Sie Ihren Arzt, wenn diese Nebenwirkungen auftreten.', 'T-1895\tYou should tell your doctor if this occurs.', 'H-1895\t-1.361328125\tTell your doctor if these side effects occur .', 'D-1895\t-1.361328125\tTell your doctor if these side effects occur.', 'P-1895\t-2.5312 -0.0113 -0.0324 -0.0437 -0.2410 -0.9526 -1.4121 -0.0366 -0.2085 -0.2395 -0.0310', 'S-163\tWenn Sie nur eine Insulinart anwenden 1.', 'T-163\tIf you use only one type of insulin 1.', 'H-163\t-0.796875\tIf you are using only one type of insulin 1 .', 'D-163\t-0.796875\tIf you are using only one type of insulin 1.', 'P-163\t-0.2335 -0.5591 -0.2783 -0.3403 -1.6201 -0.0310 -0.0789 -0.0282 -0.0056 -0.0113 -0.4678 -0.0282 -0.0282', 'S-534\tSie enthält keine antibakteriellen Konservierungsmittel.', 'T-534\tIt contains no antibacterial preservative.', 'H-534\t-0.58251953125\tIt does not contain any antibacterial preservatives .', 'D-534\t-0.58251953125\tIt does not contain any antibacterial preservatives.', 'P-534\t-0.1735 -0.3882 -0.0264 -0.0218 -0.2314 -0.6157 -0.3311 -0.0211 -0.0113 -0.0141 -0.0225 -0.9214 -0.0310 -0.0282', 'S-726\tKohlehydratzufuhr über den Tag zu achten ist.', 'T-726\tOverweight patients should continue their energy -restricted diet.', 'H-726\t-0.82373046875\tAdequate carbohydrate intake during the day .', 'D-726\t-0.82373046875\tAdequate carbohydrate intake during the day.', 'P-726\t-0.8564 -0.3206 -0.0042 -0.0366 -0.3064 -0.0760 -0.0268 -0.0070 -0.3564 -1.0635 -0.0366 -0.9326 -0.1917 -0.0254 -0.0760 -0.0282', 'S-570\tEine allergische Reaktion kann sich als Hautausschlag,', 'T-570\t- if you are allergic (hypersensitive) to olanzapine or any of the other ingredients of', 'H-570\t-1.369140625\tAn allergic reaction may be recognised as a rash ,', 'D-570\t-1.369140625\tAn allergic reaction may be recognised as a rash,', 'P-570\t-1.0654 -0.0148 -0.0127 -0.0359 -0.6191 -0.8579 -0.6792 -0.0310 -0.9102 -0.8906 -0.0141 -0.5493 -0.6987', 'S-1342\tNetherton-Syndrom) nicht zu empfehlen.', 'T-1342\tThe use of Protopic ointment in patients with genetic epidermal barrier defects such as Netherton <<unk>> s syndrome is not recommended due to the potential for permanently increased systemic absorption of tacrolimus.', 'H-1342\t-1.341796875\t- Netherton syndrome ) .', 'D-1342\t-1.341796875\t- Netherton syndrome).', 'P-1342\t-0.3223 -2.4766 -0.0141 -1.3682 -0.0141 -0.0366 -0.4087 -0.0310', 'S-677\tDas Dosisschema für pädiatrische', 'T-677\tSince an accurate dosing can not be achieved with this formulation, dosing according to weight bands is recommended for Epivir tablets.', 'H-677\t-1.267578125\tThe dose regimen for paediatric', 'D-677\t-1.267578125\tThe dose regimen for paediatric', 'P-677\t-0.5562 -1.9639 -0.9536 -0.0169 -0.0338 -0.2197 -0.0141 -0.0113 -0.0310 -1.2422', 'S-864\tEr wird Ihr Ansprechen und Ihren Gesundheitszustand kontrollieren.', 'T-864\tYour doctor will determine the duration of your treatment and how much ECALTA you will receive each day and will monitor your response and condition.', 'H-864\t-1.232421875\tIt will monitor your response and condition .', 'D-864\t-1.232421875\tIt will monitor your response and condition.', 'P-864\t-2.3711 -0.0380 -1.3555 -0.2227 -0.0535 -0.0423 -0.4536 -0.0423 -0.0282', 'S-1387\tNiederlande Niederlande Niederlande Polen Polen Portugal Portugal Portugal Portugal Portugal Rumänien', 'T-1387\tNetherlands Netherlands Netherlands Poland Poland Portugal Portugal Portugal Portugal Portugal Romania Romania Slovenia Slovenia Spain Spain Sweden Sweden', 'H-1387\t-0.7109375\tNetherlands The Netherlands Poland Portugal Portugal Portugal Portugal Portugal Romania', 'D-1387\t-0.7109375\tNetherlands The Netherlands Poland Portugal Portugal Portugal Portugal Portugal Romania', 'P-1387\t-1.6777 -0.3169 -0.0113 -0.0423 -0.1057 -0.1409 -0.1353 -0.1917 -0.2634 -0.0479 -0.0648', 'S-1440\tClomicalm kann mit oder ohne Futter verabreicht werden.', 'T-1440\tClomicalm may be given with or without food.', 'H-1440\t-0.51904296875\tClomicalm can be given with or without food .', 'D-1440\t-0.51904296875\tClomicalm can be given with or without food.', 'P-1440\t-0.1022 -0.0220 -0.0128 -0.6929 -0.0254 -0.6694 -0.5381 -0.0310 -0.0240 -0.1198 -0.0380 -0.0296', 'S-1361\tDer arzneilich wirksame Bestandteil ist Temoporfin.', 'T-1361\tThe active substance is temoporfin.', 'H-1361\t-0.390380859375\tThe active substance is temoporfin .', 'D-1361\t-0.390380859375\tThe active substance is temoporfin.', 'P-1361\t-0.2891 -0.3013 -0.3198 -0.1198 -0.2163 -0.0232 -0.0254 -0.1917 -0.0380 -0.0296', 'S-876\tSystemorganklassen Infektionen und parasitäre Erkrankungen Immunsystem', 'T-876\tCutaneous hypersensitivity reactions', 'H-876\t-0.93603515625\tSystem Organ Class Infections and Infestations', 'D-876\t-0.93603515625\tSystem Organ Class Infections and Infestations', 'P-876\t-0.9326 -0.4805 -0.0113 -0.5845 -0.0240 -0.0169 -0.0507 -1.0664 -0.3042 -0.0873 -0.3889', 'S-900\tDie klinische Relevanz dieser Reduktion ist jedoch unbekannt.', 'T-900\tHowever the clinical significance of this reduction is unknown.', 'H-900\t-0.568359375\tHowever , the clinical relevance of this reduction is unknown .', 'D-900\t-0.568359375\tHowever, the clinical relevance of this reduction is unknown.', 'P-900\t-1.1416 -0.1423 -0.0514 -0.0148 -0.0465 -0.0240 -0.0317 -0.0662 -0.5747 -0.2001 -0.2959 -0.0296 -0.0282', 'S-921\tPulver in Durchstechflasche der Glasart Typ I.', 'T-921\tPowder in Type I glass vial.', 'H-921\t-0.7939453125\tPowder in a vial ( Type I glass ) .', 'D-921\t-0.7939453125\tPowder in a vial (Type I glass).', 'P-921\t-0.6084 -0.0155 -0.3472 -0.0557 -0.7339 -0.0395 -0.0240 -0.3198 -1.0566 -0.0479 -0.2930 -0.0366 -0.2593 -0.0282', 'S-1816\tPackung mit 1 Durchstechflasche zur einmaligen Anwendung.', 'T-1816\tPack containing 1 single-use vial.', 'H-1816\t-0.63525390625\tPack of 1 vial ( s ) for single use .', 'D-1816\t-0.63525390625\tPack of 1 vial (s) for single use.', 'P-1816\t-0.6558 -0.0472 -0.1127 -0.1472 -0.5532 -0.0268 -0.5605 -0.3833 -0.0282 -0.0662 -0.2227 -0.2141 -0.0451 -0.0310', 'S-1859\tKAPITEL 2 4 <unk> INSGESAMT', 'T-1859\tCHAPTER 2 4 <<unk>> TOTAL', 'H-1859\t-0.5380859375\tCHAPTER 2 4 - TOTAL', 'D-1859\t-0.5380859375\tCHAPTER 2 4 - TOTAL', 'P-1859\t-0.2137 -0.0171 -0.0285 -0.0028 -0.0276 -0.2120 -1.5254 -0.1859 -0.0056 -0.0169 -0.0324', 'S-1981\tNach der Zubereitung darf es nicht gekühlt werden.', 'T-1981\tDo not refrigerate after formulation.', 'H-1981\t-1.2021484375\tAfter reconstitution , it must not be cooled .', 'D-1981\t-1.2021484375\tAfter reconstitution, it must not be cooled.', 'P-1981\t-1.9697 -0.3228 -0.3228 -0.5015 -0.6479 -0.4368 -0.0366 -0.0310 -0.5015 -0.0282 -0.5103 -0.0282', 'S-177\tlas 6 Falcon Way Shire Park Welwyn Garden City', 'T-177\ts ori Roche Registration Limited 6 Falcon Way', 'H-177\t-0.58251953125\t6 Falcon Way Shire Park rod', 'D-177\t-0.58251953125\t6 Falcon Way Shire Park rod', 'P-177\t-0.1766 -0.0178 -0.0085 -0.0141 -0.2466 -0.0127 -0.0141 -1.3643 -0.3228', 'S-183\tIhr Arzt sollte dies mit Ihnen zu gegebener Zeit besprechen.', 'T-183\tYour doctor should discuss this with you at that time.', 'H-183\t-0.607421875\tYour doctor should discuss this with you in due time .', 'D-183\t-0.607421875\tYour doctor should discuss this with you in due time.', 'P-183\t-0.3762 -0.0458 -0.0395 -0.3542 -0.3516 -0.0423 -0.0268 -0.4712 -0.0507 -0.8818 -0.0296 -0.0282', 'S-217\tKlinische Überwachung und die Überwachung der biologischen Funktionen ist erforderlich.', 'T-217\tClinical and biological monitoring is required.', 'H-217\t-0.98681640625\tClinical and biological monitoring is required .', 'D-217\t-0.98681640625\tClinical and biological monitoring is required.', 'P-217\t-0.5991 -0.0169 -1.5117 -0.0845 -0.3169 -0.3184 -0.0972 -0.9160 -0.0395 -0.0282', 'S-1927\t- wenn Sie schwanger sind oder glauben schwanger zu sein.', 'T-1927\t- if you are pregnant or think you may be pregnant', 'H-1927\t-0.75\t- if you are pregnant or think you may be pregnant .', 'D-1927\t-0.75\t- if you are pregnant or think you may be pregnant.', 'P-1927\t-0.4226 -0.7905 -0.0359 -0.0486 -0.0240 -0.0571 -0.7261 -0.0760 -0.9863 -0.0395 -0.0479 -0.2113 -0.0310', 'S-106\tEs enthält den Wirkstoff Porfimer- Natrium.', 'T-106\tIt contains the active substance porfimer sodium.', 'H-106\t-0.337890625\tIt contains the active substance porfimer sodium .', 'D-106\t-0.337890625\tIt contains the active substance porfimer sodium.', 'P-106\t-0.2791 -0.0278 -0.0516 -0.0227 -0.4656 -0.3086 -0.2402 -0.0063 -0.0746 -0.0268 -0.0085 -0.0324 -0.0296', 'S-367\tNicht anwenden bei trächtigen oder laktierenden Stuten.', 'T-367\tDo not use in pregnant or lactating mares.', 'H-367\t-0.35107421875\tDo not use in pregnant or lactating mares .', 'D-367\t-0.35107421875\tDo not use in pregnant or lactating mares.', 'P-367\t-0.3525 -0.0285 -0.1022 -0.1624 -0.0106 -0.1603 -0.0310 -0.0148 -0.0254 -0.6479 -0.0296 -0.0409 -0.0296', 'S-495\tWelchen Nutzen hat Cyanokit in diesen Studien gezeigt?', 'T-495\tWhat benefit has Cyanokit shown during the studies?', 'H-495\t-0.44580078125\tWhat benefit has Cyanokit shown during the studies ?', 'D-495\t-0.44580078125\tWhat benefit has Cyanokit shown during the studies?', 'P-495\t-0.0531 -0.2561 -0.1616 -0.3188 -0.0366 -0.0627 -0.2563 -0.1007 -0.3191 -0.2974 -0.1564 -0.0310 -0.0282', 'S-611\t(17,9) (21,0) (13,6)', 'T-611\t(17.9) (21.0) (13.6)', 'H-611\t-1.7607421875\t( 17.1 )', 'D-611\t-1.7607421875\t(17.1)', 'P-611\t-0.1664 -1.4766 -1.8818 -0.0282 -1.0732', 'S-934\t558 Dompé Biotec S.p.A.', 'T-934\tau Dompé Biotec S.p.A.', 'H-934\t-0.56591796875\tDompé Biotec S. p . A .', 'D-934\t-0.56591796875\tDompé Biotec S. p. A.', 'P-934\t-1.0635 -0.0718 -0.0416 -0.0416 -0.0211 -0.0056 -0.4438 -0.3228 -0.0465 -0.3042 -0.0578 -0.0930', 'S-1177\tWelchen Nutzen hat Mimpara in diesen Studien gezeigt?', 'T-1177\tWhat benefit has Mimpara shown during the studies?', 'H-1177\t-0.350830078125\tWhat benefit has Mimpara shown during the studies ?', 'D-1177\t-0.350830078125\tWhat benefit has Mimpara shown during the studies?', 'P-1177\t-0.0553 -0.2467 -0.1696 -0.1592 -0.0134 -0.0211 -0.0285 -0.1014 -0.3206 -0.3000 -0.1606 -0.0296 -0.0282', 'S-1550\tKontrastmittel für die Magnetresonanztomographie', 'T-1550\tContrast medium for magnetic resonance imaging', 'H-1550\t-0.71484375\tContrast medium for magnetic resonance imaging', 'D-1550\t-0.71484375\tContrast medium for magnetic resonance imaging', 'P-1550\t-2.5137 -0.0169 -0.0887 -0.2551 -0.0282 -0.1888 -0.0282 -0.0113 -0.0197 -0.0254 -0.1014 -0.0197 -0.0338', 'S-1614\tCircovac ist ein Impfstoff zur Anwendung bei Schweinen.', 'T-1614\tCircovac is a vaccine for use in pigs.', 'H-1614\t-0.1904296875\tCircovac is a vaccine for use in pigs .', 'D-1614\t-0.1904296875\tCircovac is a vaccine for use in pigs.', 'P-1614\t-0.0811 -0.0220 -0.0056 -0.0386 -0.0415 -0.0574 -0.1790 -0.0430 -0.0708 -0.2634 -0.0254 -0.0310 -0.0282', 'S-258\tBesondere Vorsicht bei der Anwendung von Ventavis ist erforderlich,', 'T-258\tTake special care with Ventavis:', 'H-258\t-0.625\tTake special care with Ventavis', 'D-258\t-0.625\tTake special care with Ventavis', 'P-258\t-0.3135 -0.2268 -0.0299 -0.3062 -0.4536 -0.0183 -0.0282 -0.7988', 'S-267\tRifen 2,4 g Pulver zum Eingeben für Rinder', 'T-267\tRifen 2.4 g oral powder', 'H-267\t-0.740234375\tRifen 2.4 g Oral Powder for Horses', 'D-267\t-0.740234375\tRifen 2.4 g Oral Powder for Horses', 'P-267\t-0.4368 -0.1233 -0.1547 -0.3787 -0.0296 -0.4353 -0.4353 -0.3142 -0.0141 -0.0282 -0.0648 -0.6621 -0.4368 -0.0930', 'S-472\t32,7% 44,5% 58,2% 62%', 'T-472\t62%', 'H-472\t-0.3232421875\t32.7 % 44.5 % 58.2 % 62 %', 'D-472\t-0.3232421875\t32.7% 44.5% 58.2% 62%', 'P-472\t-0.6357 -0.3167 -0.0282 -0.0296 -0.3706 -0.0303 -0.0240 -0.0261 -0.0310 -0.0211 -0.0296 -0.0240 -0.0197 -0.0268 -0.0282', 'S-102\tCPMP / 3086 / 03-REV.1', 'T-102\tCPMP / 3086 / 03-REV.1 1.', 'H-102\t-0.09173583984375\tCPMP / 3086 / 03 @-@ REV.1', 'D-102\t-0.09173583984375\tCPMP / 3086 / 03-REV.1', 'P-102\t-0.0886 -0.0270 -0.0121 -0.0299 -0.0523 -0.0285 -0.0320 -0.0262 -0.0285 -0.0349 -0.0262 -0.0113 -0.0299', 'S-8\tRevlimid 15 mg Hartkapseln Lenalidomid', 'T-8\tRevlimid 15 mg hard capsules lenalidomide', 'H-8\t-0.216064453125\tRevlimid 15 mg hard capsules lenalidomide', 'D-8\t-0.216064453125\tRevlimid 15 mg hard capsules lenalidomide', 'P-8\t-0.0113 -0.0170 -0.0227 -0.3843 -0.0113 -0.2169 -0.0895 -0.0134 -0.0373 -0.1980 -0.0162 -0.0148 -0.0063 -0.0289 -0.0296', 'S-872\t- wenn Sie einen Tumor der Nebenniere haben,', 'T-872\t- if you have a tumour of the adrenal gland', 'H-872\t-0.47119140625\t- if you have a tumour of the adrenal gland ,', 'D-872\t-0.47119140625\t- if you have a tumour of the adrenal gland,', 'P-872\t-0.3101 -0.2268 -0.0370 -0.1926 -0.1592 -0.0099 -0.4199 -0.0620 -0.0578 -0.0437 -0.0113 -0.0282 -0.3352 -0.0099 -0.5537 -0.0296', 'S-846\tAlle schweren Nebenwirkungen wurden als nicht therapiebedingt bewertet.', 'T-846\tAll of the SAEs were assessed as unrelated to treatment.', 'H-846\t-1.56640625\tAll severe adverse reactions have been assessed as not related to therapy .', 'D-846\t-1.56640625\tAll severe adverse reactions have been assessed as not related to therapy.', 'P-846\t-0.1655 -0.9707 -0.5923 -0.0099 -1.0322 -0.0127 -1.2764 -0.0366 -1.3809 -0.0141 -0.3352 -1.6230 -0.7324 -0.0282 -0.3042 -0.0338 -0.0282', 'S-965\t- eine Verbesserung der Insulinempfindlichkeit (z.', 'T-965\t- unaccustomed, increased or prolonged physical activity,', 'H-965\t-0.62890625\t- improved insulin sensitivity ( e. g .', 'D-965\t-0.62890625\t- improved insulin sensitivity (e. g.', 'P-965\t-0.0516 -0.3284 -0.0356 -0.0134 -0.0271 -0.0197 -0.2434 -1.0010 -0.0521 -0.9639 -0.0296 -0.0282', 'S-1288\tTenofovir wird hauptsächlich renal eliminiert.', 'T-1288\tTenofovir is principally eliminated via the kidney.', 'H-1288\t-0.58203125\tTenofovir is mainly renally eliminated .', 'D-1288\t-0.58203125\tTenofovir is mainly renally eliminated.', 'P-1288\t-0.0285 -0.0256 -0.0170 -0.0127 -0.0228 -0.0458 -1.1914 -0.5938 -0.1719 -0.3296 -0.0127 -0.2339 -0.0282', 'S-1394\t- nichtsteroidale Antirheumatika', 'T-1394\t- Non-steroidal anti-inflammatory medicines', 'H-1394\t-0.94970703125\t- nonsteroidal anti @-@ inflammatory drugs', 'D-1394\t-0.94970703125\t- nonsteroidal anti-inflammatory drugs', 'P-1394\t-0.0328 -2.5098 -0.0141 -0.0352 -0.0169 -0.0113 -0.4846 -0.0395 -0.1803 -0.0225 -0.0141 -0.1071 -1.1211 -0.0366', 'S-1479\tRitonavir 500 mg zweimal täglich, 3 Gaben', 'T-1479\tOther Protease Inhibitor (PIs) Ritonavir', 'H-1479\t-0.295166015625\tRitonavir 500 mg twice daily', 'D-1479\t-0.295166015625\tRitonavir 500 mg twice daily', 'P-1479\t-0.0142 -0.0270 -0.0141 -0.0199 -0.0342 -0.0241 -0.0842 -0.0961 -0.7891', 'S-430\t125 mg Lactose-Monohydrat.', 'T-430\tEach tablet contains approximately 125 mg lactose monohydrate.', 'H-430\t-0.2210693359375\t125 mg of lactose monohydrate .', 'D-430\t-0.2210693359375\t125 mg of lactose monohydrate.', 'P-430\t-0.2104 -0.0157 -0.2374 -0.0486 -0.0085 -0.0113 -0.0211 -0.0127 -0.0257 -0.0155 -0.0257 -0.3691 -0.0282', 'S-1089\t3640 AE Mijdrecht, The Netherlands,', 'T-1089\tBox 217, 3640 AE Mijdrecht, The Netherlands,', 'H-1089\t-0.70166015625\t3640 AE Mijdrecht , The Netherlands ,', 'D-1089\t-0.70166015625\t3640 AE Mijdrecht, The Netherlands,', 'P-1089\t-1.4043 -0.0232 -0.0627 -0.0549 -0.0366 -0.0268 -0.0183 -0.0070 -0.0310 -0.0395 -0.0113 -0.0760 -1.4766', 'S-1482\tWirksamkeitsendpunkt progressionsfreies Überleben', 'T-1482\t(95% CI) p-value c Progression-free survival', 'H-1482\t-1.1259765625\tEfficacy Endpoint PFS', 'D-1482\t-1.1259765625\tEfficacy Endpoint PFS', 'P-1482\t-0.0285 -0.5063 -0.0120 -1.6514 -0.0254 -1.6367 -0.0254 -0.0056 -0.3184', 'S-1774\tEMEA / CVMP / 816 / 00', 'T-1774\tEMEA / CPMP / BWP / 2571 / 00', 'H-1774\t-1.5380859375\tchronic thromboembolism', 'D-1774\t-1.5380859375\tchronic thromboembolism', 'P-1774\t-1.8232 -0.3228 -0.0549 -0.5918 -0.0662 -2.0098 -0.0113 -0.4763', 'S-1798\tHDPE-Flaschen mit einem kindersicheren Verschluss.', 'T-1798\tHDPE bottles with a child resistant / tamper evident closure.', 'H-1798\t-0.935546875\tHDPE bottles with a child resistant closure .', 'D-1798\t-0.935546875\tHDPE bottles with a child resistant closure.', 'P-1798\t-0.0945 -0.0099 -0.5088 -0.1719 -1.1064 -0.6621 -0.8989 -0.0113 -0.4028 -0.0451 -0.0310', 'S-1325\tMai 2008 wurde die Uhr erneut angehalten und am 6.', 'T-1325\tThe Marketing Authorisation Holders and Applicant submitted written responses and the clock was re- started on 14 March 2008.', 'H-1325\t-1.7314453125\tThe marketing authorisation was renewed on 21 May 2008 .', 'D-1325\t-1.7314453125\tThe marketing authorisation was renewed on 21 May 2008.', 'P-1325\t-0.7510 -2.9531 -0.3213 -0.2283 -0.3916 -0.3101 -0.1747 -1.8145 -0.4790 -0.0676 -0.1747 -0.0282', 'S-1728\tNoël Wathion Isabelle Moulon', 'T-1728\tNoël WATHION Isabelle MOULON John PURVES Marisa PAPALUCA AMATI Patrick LE COURTOIS Anthony HUMPHREYS', 'H-1728\t-1.021484375\tNoël Wathion Isabelle Moulon', 'D-1728\t-1.021484375\tNoël Wathion Isabelle Moulon', 'P-1728\t-0.8550 -0.0676 -0.0183 -0.1606 -0.7144 -0.0240 -0.0254 -2.1816 -0.0169 -0.6284 -0.0085 -0.0282 -0.0310', 'S-26\t37,1%; p = 0,0015).', 'T-26\tTreatment with Tracleer was associated with a significant reduction in the rate of clinical worsening compared with placebo at 28 weeks (10.7% vs 37.1%, respectively; p = 0.0015).', 'H-26\t-0.358154296875\t37.1 % ; p = 0.0015 ) .', 'D-26\t-0.358154296875\t37.1%; p = 0.0015).', 'P-26\t-0.5430 -0.1420 -0.0299 -0.0285 -0.0345 -0.6538 -0.0254 -0.0352 -0.0592 -0.0268 -0.0296 -0.0338 -0.0282', 'S-1667\t1,8fach im Vergleich zum Wildtyp-Virus.', 'T-1667\tIsolates retained susceptibility to tipranavir with a median increase of IC50 in baseline and rebound isolates of 1.9- and 1.8 <<unk>> fold, respectively, compared to wild type virus.', 'H-1667\t-0.9736328125\tPlease refer to the Aptivus Summary of Product', 'D-1667\t-0.9736328125\tPlease refer to the Aptivus Summary of Product', 'P-1667\t-0.3489 -1.0605 -0.0444 -0.1986 -0.3452 -0.3228 -0.3157 -0.3228 -0.2537 -0.3042 -0.3213 -0.4846', 'S-576\tDie rekonstituierte Lösung ist schwebstofffrei und klar.', 'T-576\tThe reconstituted solution is without particles and clear.', 'H-576\t-1.1630859375\tThe reconstituted solution is free of particulate matter and clear .', 'D-576\t-1.1630859375\tThe reconstituted solution is free of particulate matter and clear.', 'P-576\t-0.2678 -0.1273 -0.0099 -0.0211 -0.4080 -0.5186 -1.7021 -0.8677 -0.7466 -1.0342 -0.0056 -0.0423 -0.0930 -0.0338 -0.0282', 'S-336\tProfender 50 mg / 10 mg Tabletten für mittelgroße Hunde', 'T-336\tProfender 50 mg / 10 mg tablets for medium dogs', 'H-336\t-0.54541015625\tProfender 50 mg / 10 mg tablets for medium dogs', 'D-336\t-0.54541015625\tProfender 50 mg / 10 mg tablets for medium dogs', 'P-336\t-0.0886 -0.0199 -0.0531 -0.0106 -0.0335 -0.0342 -0.0171 -0.0931 -0.1429 -0.0342 -1.1689 -0.8057 -0.0380', 'S-1642\tTabletten 40 mg, 80 mg 10 Packungsgrößen', 'T-1642\tTablets 40 mg, 80 mg 10 presentations', 'H-1642\t-0.470947265625\tTablets 40 mg , 80 mg 10 presentations', 'D-1642\t-0.470947265625\tTablets 40 mg, 80 mg 10 presentations', 'P-1642\t-0.3826 -0.0560 -0.0782 -0.0141 -0.0486 -0.0334 -0.0141 -0.6509 -0.3228 -0.2859 -0.0676 -0.1367', 'S-731\tWas Lansoprazol-ratiopharm 15 mg enthält:', 'T-731\tWhat Lansoprazol-ratiopharm contains', 'H-731\t-0.4306640625\tWhat Lansoprazol @-@ ratiopharm contains', 'D-731\t-0.4306640625\tWhat Lansoprazol-ratiopharm contains', 'P-731\t-0.0849 -0.1227 -0.0035 -0.3208 -0.1965 -0.0240 -0.0423 -0.0085 -0.0232 -0.0070 -0.7363 -0.3438', 'S-277\tEs ist keine altersbedingte Dosisanpassung erforderlich.', 'T-277\tNo dose adjustment is necessary in the elderly.', 'H-277\t-0.9296875\tNo dosage adjustment is necessary in relation to age .', 'D-277\t-0.9296875\tNo dosage adjustment is necessary in relation to age.', 'P-277\t-0.9448 -1.0752 -0.0479 -0.0282 -0.0930 -0.0113 -0.0437 -0.5029 -0.5239 -1.0566 -0.2423 -0.0310 -0.0535 -0.0366 -0.0282', 'S-119\t37 • SONSTIGE BEDINGUNGEN', 'T-119\t35 • OTHER CONDITIONS', 'H-119\t-0.5185546875\t37 • OTHER CONDITIONS', 'D-119\t-0.5185546875\t37 • OTHER CONDITIONS', 'P-119\t-1.3350 -0.0240 -0.3755 -0.0099 -0.0451 -0.1212 -0.0240 -0.0141 -0.0155 -0.0099 -0.0197 -0.3086', 'S-1933\tDie übrigen 76% blieben durchgehend antikörper-negativ.', 'T-1933\tThe remaining 76% remained antibody negative throughout.', 'H-1933\t-1.1103515625\tThe remaining 76 % remained anti @-@ body negative throughout .', 'D-1933\t-1.1103515625\tThe remaining 76% remained anti-body negative throughout.', 'P-1933\t-0.6816 -0.6245 -0.0183 -0.0388 -0.4868 -1.0693 -0.0282 -0.0535 -0.1381 -1.7217 -0.0423 -0.0282', 'S-1427\tDeshalb werden keine Informationen zur Anwendung bei Schwangerschaft und Stillzeit angegeben.', 'T-1427\tTherefore, this information is not applicable.', 'H-1427\t-1.5400390625\tTherefore , no information regarding exposed pregnancies and lactation are given .', 'D-1427\t-1.5400390625\tTherefore, no information regarding exposed pregnancies and lactation are given.', 'P-1427\t-1.0635 -0.0183 -0.4678 -1.3311 -0.0409 -0.7974 -0.8818 -0.3184 -0.0620 -0.0141 -0.7188 -0.1578 -0.0113 -0.0507 -1.0986 -1.3867 -0.2761 -0.0282', 'S-567\tTasmar kann zusammen mit oder auch ohne Nahrungsmittel eingenommen werden.', 'T-567\tTasmar can be taken with or without food.', 'H-567\t-0.4306640625\tTasmar can be taken with or without food .', 'D-567\t-0.4306640625\tTasmar can be taken with or without food.', 'P-567\t-0.0834 -0.0220 -0.5171 -0.0285 -0.7686 -0.1388 -0.0521 -0.0296 -0.1000 -0.0451 -0.0310', 'S-319\tEasotic, Ohrentropfen, Suspension für Hunde', 'T-319\tEasotic, ear drops suspension, for dogs', 'H-319\t-0.229248046875\tEasotic , ear drops suspension for dogs', 'D-319\t-0.229248046875\tEasotic, ear drops suspension for dogs', 'P-319\t-0.0313 -0.0184 -0.0120 -0.0414 -0.1902 -0.0516 -0.4453 -0.0578 -0.0225 -0.0423', 'S-568\tBei Einnahme von Stalevo zusammen mit Nahrungsmitteln und Getränken', 'T-568\tTaking Stalevo with food and drink', 'H-568\t-0.44091796875\tTaking Stalevo with food and drink', 'D-568\t-0.44091796875\tTaking Stalevo with food and drink', 'P-568\t-0.6816 -0.1603 -0.0127 -0.0225 -0.2458 -0.0810 -0.0402 -0.2551 -0.1493', 'S-1678\tsich um nicht verschreibungspflichtige Arzneimittel handelt.', 'T-1678\twithout a prescription,', 'H-1678\t-1.2568359375\tor medicines obtained without a prescription .', 'D-1678\t-1.2568359375\tor medicines obtained without a prescription.', 'P-1678\t-1.4551 -0.3340 -0.8184 -1.5312 -0.2705 -0.1775 -0.0225 -0.0564 -0.0310', 'S-1710\t5 mg Drotrecogin alfa (aktiviert).', 'T-1710\tEach vial contains 5 mg of Drotrecogin alfa (activated).', 'H-1710\t-0.25390625\t5 mg of drotrecogin alfa ( activated ) .', 'D-1710\t-0.25390625\t5 mg of drotrecogin alfa (activated).', 'P-1710\t-0.2576 -0.0127 -0.2534 -0.4231 -0.0838 -0.0028 -0.0077 -0.0373 -0.0127 -0.0366 -0.0247 -0.0296 -0.0296 -0.0500 -0.0282', 'S-362\tBesserung der manischen Symptome über einen Zeitraum von 3 Wochen.', 'T-362\tIn patients with a manic or mixed episode of bipolar disorder, olanzapine demonstrated superior efficacy to placebo and valproate semisodium (divalproex) in reduction of manic symptoms over 3 weeks.', 'H-362\t-1.333984375\tRelief of manic symptoms for 3 weeks .', 'D-362\t-1.333984375\tRelief of manic symptoms for 3 weeks.', 'P-362\t-3.2441 -0.0789 -0.0507 -0.3352 -0.0169 -0.0225 -1.5664 -0.1945 -0.0282 -0.0564 -0.0310', 'S-1404\tOktober 2007 von der Europäischen Kommission in eine Entscheidung umgewandelt.', 'T-1404\tThe final opinion was converted into a Decision by the European Commission on 1 October 2007.', 'H-1404\t-0.66943359375\tThe final opinion was converted into a Decision by the European Commission on 17 October 2007 .', 'D-1404\t-0.66943359375\tThe final opinion was converted into a Decision by the European Commission on 17 October 2007.', 'P-1404\t-0.5132 -0.6929 -0.3213 -0.1479 -0.2917 -0.1592 -0.0395 -0.2888 -0.0211 -0.0240 -0.1493 -0.0324 -0.0437 -0.0254 -0.1296 -0.7017 -0.3635 -0.0310 -0.0338 -0.0282', 'S-639\t738 33,74 616 0,55 447 0,40', 'T-639\t37,738 33.74 616 0.55 447 0.40 1,280 1.14', 'H-639\t-1.0400390625\t738 33.74 616 0.55 447 0.40', 'D-639\t-1.0400390625\t738 33.74 616 0.55 447 0.40', 'P-639\t-1.0312 -0.3105 -0.5952 -0.3113 -0.0141 -0.0225 -0.0240 -0.1240 -0.0197 -0.0211 -0.0183 -0.0789 -0.0225 -2.4727', 'S-1682\tWofür wird Rasilez HCT angewendet?', 'T-1682\tWhat is Rasilez HCT used for?', 'H-1682\t-0.1187744140625\tWhat is Rasilez HCT used for ?', 'D-1682\t-0.1187744140625\tWhat is Rasilez HCT used for?', 'P-1682\t-0.1022 -0.0700 -0.0781 -0.0213 -0.0185 -0.0213 -0.0269 -0.0262 -0.0229 -0.0768 -0.0320 -0.0278 -0.0292', 'S-988\tZonegran 25 mg Hartkapseln Zonisamid', 'T-988\tZonegran 25 mg hard capsules zonisamide', 'H-988\t-0.177490234375\tZonegran 25 mg hard capsules zonisamide', 'D-988\t-0.177490234375\tZonegran 25 mg hard capsules zonisamide', 'P-988\t-0.1483 -0.0156 -0.0156 -0.0255 -0.0423 -0.0127 -0.2205 -0.0976 -0.0113 -0.0430 -0.1638 -0.0437 -0.0218 -0.0134 -0.0324 -0.0296', 'S-1799\tDie folgenden Nebenwirkungen können nach Anwendung von Silgard beobachtet werden:', 'T-1799\tThe following side effects can be seen after the use of Silgard:', 'H-1799\t-0.947265625\tThe following side effects can be seen after the use of Silgard :', 'D-1799\t-0.947265625\tThe following side effects can be seen after the use of Silgard:', 'P-1799\t-0.0634 -0.0451 -0.4883 -0.3142 -0.5176 -0.0310 -0.4087 -0.3564 -1.7090 -0.7554 -0.0282 -0.0197 -0.0085 -0.0366 -0.0282', 'S-1197\tIhr Arzt wird Ihre Behandlung mit Herceptin genau überwachen.', 'T-1197\tYour doctor will closely supervise your therapy with Herceptin.', 'H-1197\t-0.66552734375\tYour doctor will carefully monitor your treatment with Herceptin .', 'D-1197\t-0.66552734375\tYour doctor will carefully monitor your treatment with Herceptin.', 'P-1197\t-0.0256 -0.0342 -0.4463 -1.6973 -0.2240 -0.4016 -0.1381 -0.0338 -0.0225 -0.0056 -0.0113 -0.0338 -0.0282', 'S-1096\tJede Lösung enthält 10 mg / ml Rituximab.', 'T-1096\tEach solution contains 10 mg / ml of Rituximab.', 'H-1096\t-0.232421875\tEach solution contains 10 mg / ml rituximab .', 'D-1096\t-0.232421875\tEach solution contains 10 mg / ml rituximab.', 'P-1096\t-0.0444 -0.0400 -0.0444 -0.1074 -0.0099 -0.0313 -0.0386 -0.6895 -0.0035 -0.0204 -0.0190 -0.0218 -0.0345 -0.0282', 'S-911\tPatienten sprechen unterschiedlich auf die Behandlung mit Epivir an.', 'T-911\tResponse to treatment with Epivir varies between patients.', 'H-911\t-0.78466796875\tResponse to treatment with Epivir varies between patients .', 'D-911\t-0.78466796875\tResponse to treatment with Epivir varies between patients.', 'P-911\t-0.4104 -0.2201 -0.1881 -2.3203 -0.0423 -0.1803 -0.0141 -0.0169 -0.0225 -0.0789 -0.0310 -0.3381 -0.0564 -0.0366 -0.0282', 'S-1853\tHeiligenstädterstraße 52 / 2 / 8 1190 Wien Österreich', 'T-1853\tHeiligenstädterstraße 52 / 2 / 8 1190 Wien Austria', 'H-1853\t-0.293212890625\tHeiligenstädterstraße 52 / 2 / 8 1190 Wien Austria', 'D-1853\t-0.293212890625\tHeiligenstädterstraße 52 / 2 / 8 1190 Wien Austria', 'P-1853\t-0.0220 -0.1719 -0.0185 -0.3411 -0.0141 -0.0292 -0.0271 -0.0299 -0.0243 -0.2842 -0.0085 -0.3064 -0.1219 -0.0296', 'S-1784\tIntravenöse Infusion nach Auflösung und Verdünnung.', 'T-1784\tIntravenous infusion after reconstitution and dilution.', 'H-1784\t-0.4423828125\tIntravenous infusion after reconstitution and dilution .', 'D-1784\t-0.4423828125\tIntravenous infusion after reconstitution and dilution.', 'P-1784\t-0.0545 -0.0199 -0.0099 -0.0263 -0.7007 -0.0169 -0.4600 -0.3220 -0.3213 -0.0493 -0.0746 -0.0099 -0.0620 -0.0282', 'S-1452\t31.05.2000 31.07.2000 27.10.2000 89 days', 'T-1452\t- 16.07.1999 - 13.10.1999 - 86 days -0', 'H-1452\t-1.58203125\t• 31.05.2000 31.07.2000', 'D-1452\t-1.58203125\t• 31.05.2000 31.07.2000', 'P-1452\t-1.7559 -2.1621 -0.0085 -0.0141 -0.0169 -1.1973 -0.0085 -0.0169 -0.0169 -1.1045', 'S-1195\t19,0%); Fieber (G3 / 4:', 'T-1195\t19.0%); Fever (G3 / 4:', 'H-1195\t-0.247802734375\t19.0 % ) ; Fever ( G3 / 4 :', 'D-1195\t-0.247802734375\t19.0%); Fever (G3 / 4:', 'P-1195\t-0.4075 -0.0299 -0.0292 -0.0299 -0.0402 -0.4185 -0.0155 -0.0310 -0.0282 -0.0303 -0.0296 -0.0268 -0.0620 -0.0289', 'S-1102\tSpritze und Filter mit der Kanüle verbinden.', 'T-1102\tAttach the syringe and filter to the cannula.', 'H-1102\t-0.5947265625\tAttach the syringe and the filter to the needle .', 'D-1102\t-0.5947265625\tAttach the syringe and the filter to the needle.', 'P-1102\t-1.1611 -0.0056 -0.4551 -0.0324 -0.0042 -0.0028 -0.0310 -0.8467 -0.0845 -0.0521 -0.0338 -0.2240 -0.0225 -0.0366 -0.0282', 'S-1071\tJede Faltschachtel enthält eine Flasche mit 30 Kapseln.', 'T-1071\tEach carton contains 1 bottle of 30 hard capsules.', 'H-1071\t-0.496337890625\tEach carton contains 1 bottle of 30 capsules .', 'D-1071\t-0.496337890625\tEach carton contains 1 bottle of 30 capsules.', 'P-1071\t-0.1934 -0.2754 -0.0127 -0.0669 -0.8833 -0.1169 -0.1254 -0.0324 -0.4958 -0.0183 -0.0240 -0.0380 -0.0296', 'S-1003\tChiesi Farmaceutici S.p.A.', 'T-1003\tChiesi Farmaceutici S. p. A.', 'H-1003\t-0.294677734375\tChiesi Farmaceutici S. p . A .', 'D-1003\t-0.294677734375\tChiesi Farmaceutici S. p. A.', 'P-1003\t-0.0472 -0.0213 -0.0270 -0.0291 -0.0156 -0.0085 -0.0106 -0.0249 -0.4805 -0.3223 -0.0423 -0.3101 -0.0676 -0.0282', 'S-647\t1 Dosis Silgard enthält 0,5 ml Injektionssuspension.', 'T-647\t1 dose of Silgard suspension for injection contains 0.5 ml.', 'H-647\t-0.685546875\t1 dose of Silgard suspension for injection contains 0.5 ml .', 'D-647\t-0.685546875\t1 dose of Silgard suspension for injection contains 0.5 ml.', 'P-647\t-0.6357 -0.0437 -0.4294 -0.1606 -0.0056 -0.9199 -0.3494 -0.2227 -0.1324 -0.2255 -0.1099 -0.0197 -0.0564 -0.0282', 'S-392\tWeitere Informationen über Purevax RCP FeLV:', 'T-392\tOther information about Purevax RCP FeLV:', 'H-392\t-0.1639404296875\tOther information about Purevax RCP FeLV :', 'D-392\t-0.1639404296875\tOther information about Purevax RCP FeLV:', 'P-392\t-0.3213 -0.0657 -0.1229 -0.0292 -0.0299 -0.0092 -0.0299 -0.0271 -0.0211 -0.0169 -0.0285 -0.0271 -0.0416 -0.0282', 'S-1858\tZu Calcitonin wurden keine Studien an Schwangeren durchgeführt.', 'T-1858\tCalcitonin has not been studied in pregnant women.', 'H-1858\t-1.1533203125\tNo studies have been carried out in pregnant women on calcitonin .', 'D-1858\t-1.1533203125\tNo studies have been carried out in pregnant women on calcitonin.', 'P-1858\t-0.9961 -0.0324 -0.8989 -0.0268 -1.7090 -0.0282 -0.5469 -0.0169 -0.0366 -1.6367 -0.0282 -0.0169 -0.0225 -0.0282 -0.0338 -0.0282', 'S-45\tSie werden nur Temodal einmal täglich für die ersten 5 Tage erhalten.', 'T-45\tYou will receive Temodal alone once daily for the first 5 days.', 'H-45\t-0.8876953125\tYou will only be given Temodal once a day for the first 5 days .', 'D-45\t-0.8876953125\tYou will only be given Temodal once a day for the first 5 days.', 'P-45\t-0.5884 -0.0423 -1.2598 -0.9341 -0.1451 -0.1663 -0.0254 -0.0366 -0.5581 -0.8174 -0.0282 -0.2057 -0.0395 -0.0338 -0.0479 -0.0310 -0.0423 -0.0282', 'S-1319\tA1 A2 A3 A4 A5 A6 A7 A8', 'T-1319\tA2', 'H-1319\t-0.71826171875\t1 A2 A3 A4 A5 A6 A7 A8', 'D-1319\t-0.71826171875\t1 A2 A3 A4 A5 A6 A7 A8', 'P-1319\t-1.6494 -0.3086 -0.0409 -0.3889 -0.0254 -0.0296 -0.7891 -0.0282 -0.0282 -0.0282 -0.0254 -0.0282 -0.0282 -0.0254 -0.2227', 'S-1275\tVe r a b s c h ie d e t im Januar 1998', 'T-1275\tAdopted in January 1998', 'H-1275\t-0.5869140625\tAdopted in January 1998', 'D-1275\t-0.5869140625\tAdopted in January 1998', 'P-1275\t-0.3489 -0.3179 -0.2244 -0.4705 -0.0352 -0.3232', 'S-943\tDie Kanüle ist mit einem Dreiwegehahn zu verbinden.', 'T-943\tway stopcock to the cannula.', 'H-943\t-0.8671875\tThe needle should be attached to a three @-@ way stopcock .', 'D-943\t-0.8671875\tThe needle should be attached to a three-way stopcock.', 'P-943\t-0.5737 -0.4265 -0.0218 -0.7559 -0.0310 -0.4763 -1.2480 -0.2874 -0.1071 -0.0789 -0.0254 -0.2986 -0.0085 -0.0366 -0.0282', 'S-234\tErwachsene und Jugendliche über 12 Jahre 10 mg einmal täglich als 1 Tablette', 'T-234\t10 mg once daily as 1 tablet.', 'H-234\t-0.98974609375\tAdults and adolescents over 12 years : 10 mg once a day as 1 tablet', 'D-234\t-0.98974609375\tAdults and adolescents over 12 years: 10 mg once a day as 1 tablet', 'P-234\t-0.3064 -0.0134 -0.0430 -0.2335 -0.0127 -0.0141 -0.7622 -0.2311 -0.0366 -1.9033 -0.0873 -0.0310 -0.0845 -0.4001 -0.0310 -0.6338 -1.0254 -0.0507 -0.0225 -0.0507', 'S-405\tÜber Blasenbildung und Schwellungen wurde in seltenen Fällen berichtet.', 'T-405\tBlisters and swelling were reported rarely.', 'H-405\t-1.3349609375\tBlister formation and swelling were reported rarely .', 'D-405\t-1.3349609375\tBlister formation and swelling were reported rarely.', 'P-405\t-2.5918 -0.6763 -0.4368 -0.0310 -0.0197 -0.0225 -0.6001 -0.1663 -1.0146 -0.0395 -0.0282', 'S-1213\tDie Kapseln können mit oder ohne eine Mahlzeit eingenommen werden.', 'T-1213\tThey can be taken with or without food.', 'H-1213\t-0.26220703125\tThe capsules can be taken with or without food .', 'D-1213\t-0.26220703125\tThe capsules can be taken with or without food.', 'P-1213\t-0.2561 -0.0356 -0.0155 -0.0255 -0.3428 -0.0257 -0.0356 -0.0430 -0.0303 -0.0289 -0.3191 -0.0345 -0.0296', 'S-1600\tWenn Sie eine größere Menge von Viread eingenommen haben, als Sie sollten', 'T-1600\tIf you take more Viread than you should', 'H-1600\t-0.498291015625\tIf you take more Viread than you should', 'D-1600\t-0.498291015625\tIf you take more Viread than you should', 'P-1600\t-0.6533 -0.0342 -0.3198 -0.3049 -0.1670 -0.0155 -0.0564 -0.0352 -0.0423 -0.3550', 'S-1977\tBei Anwendung von Myocet zusammen mit Nahrungsmitteln und Getränken:', 'T-1977\tUsing Myocet with food and drink.', 'H-1977\t-0.53125\tUsing Myocet with food and drink :', 'D-1977\t-0.53125\tUsing Myocet with food and drink:', 'P-1977\t-1.0195 -0.0542 -0.0141 -0.0268 -0.0211 -0.2402 -0.1444 -0.0465 -0.2649 -0.3718 -0.0352', 'S-328\t89 4.4 Besondere Warnhinweise und Vorsichtsmaßnahmen für die Anwendung', 'T-328\t75 4.4 Special warnings and precautions for use', 'H-328\t-0.419921875\t85 4.4 Special warnings and precautions for use', 'D-328\t-0.419921875\t85 4.4 Special warnings and precautions for use', 'P-328\t-1.0225 -0.1790 -0.0296 -0.0838 -0.1014 -0.0303 -0.0254 -0.0070 -0.0549 -0.0704 -0.2141 -0.0451', 'S-1401\tDURCHSTECHFLASCHE ZU 3,5 ML', 'T-1401\tVIAL 3.5 ML PRESENTATION', 'H-1401\t-1.111328125\tBOTTLE OF 3.5 ML', 'D-1401\t-1.111328125\tBOTTLE OF 3.5 ML', 'P-1401\t-3.0488 -0.0564 -0.0310 -0.0366 -0.2874 -0.0310 -0.4395 -0.4226 -0.0169 -0.0564', 'S-155\tDrücken Sie den Dosierkopf so weit wie möglich herunter.', 'T-155\tPress the nozzle down as far as it will go.', 'H-155\t-0.84619140625\tPush the nozzle down as far as it will go .', 'D-155\t-0.84619140625\tPush the nozzle down as far as it will go.', 'P-155\t-1.1279 -0.0127 -0.2402 -0.3228 -0.0099 -0.4297 -0.0423 -0.1958 -0.0268 -1.1592 -0.3213 -0.1719 -0.0338 -0.0282', 'S-250\t643 GEBRAUCHSINFORMATION:', 'T-250\t617 PACKAGE LEAFLET:', 'H-250\t-0.75\t643 PACKAGE LEAFLET :', 'D-250\t-0.75\t643 PACKAGE LEAFLET:', 'P-250\t-0.6724 -0.5654 -0.3220 -0.3213 -0.0338 -0.0085 -0.1564 -0.3228 -0.3198 -0.3213 -0.2959 -0.1296 -0.0282', 'S-1874\tIhr Arzt wird möglicherweise zusätzliche Kontrollen Ihrer Blutwerte während der Behandlung anordnen.', 'T-1874\tYour physician may order additional blood tests during your treatment.', 'H-1874\t-0.55419921875\tYour doctor may order additional blood tests during treatment .', 'D-1874\t-0.55419921875\tYour doctor may order additional blood tests during treatment.', 'P-1874\t-0.2104 -0.0285 -0.0842 -0.3896 -0.1099 -0.2847 -0.0887 -0.0514 -1.0293 -0.0310 -0.0282', 'S-1916\t{Monat / Jahr} Innerhalb von 3 Stunden nach Verdünnung anwenden', 'T-1916\t{mon / year} Use within 3 hours after dilution', 'H-1916\t-0.8603515625\tEXP Use within 3 hours after dilution', 'D-1916\t-0.8603515625\tEXP Use within 3 hours after dilution', 'P-1916\t-0.4131 -0.3215 -0.7446 -0.1042 -0.0676 -0.0352 -0.8271 -0.1859 -0.0085 -0.7158', 'S-388\tDynastat ist in Packungen mit 10 Durchstechflaschen erhältlich.', 'T-388\tDynastat is available in packs containing 10 vials.', 'H-388\t-0.2481689453125\tDynastat is available in packs of 10 vials .', 'D-388\t-0.2481689453125\tDynastat is available in packs of 10 vials.', 'P-388\t-0.0071 -0.0177 -0.0270 -0.0458 -0.5708 -0.0285 -0.1592 -0.0134 -0.0444 -0.0331 -0.1768 -0.0183 -0.0373 -0.0296', 'S-497\tWie wird Omnitrope 3,3 mg / ml injiziert?', 'T-497\tHow to inject Omnitrope 3.3 mg / ml', 'H-497\t-0.315673828125\tHow to inject Omnitrope 3.3 mg / ml', 'D-497\t-0.315673828125\tHow to inject Omnitrope 3.3 mg / ml', 'P-497\t-0.1703 -0.6870 -0.0698 -0.0218 -0.0289 -0.0359 -0.0148 -0.0232 -0.1050 -0.0732 -0.0099 -0.0296 -0.0211 -0.2479', 'S-540\tIhr Arzt wird Ihnen die für Sie am besten geeignete Stärke verschreiben.', 'T-540\tYour doctor will have prescribed the strength most suitable for you.', 'H-540\t-0.83544921875\tYour doctor will prescribe the strength that is best for you .', 'D-540\t-0.83544921875\tYour doctor will prescribe the strength that is best for you.', 'P-540\t-0.0385 -0.0414 -0.0371 -0.0487 -0.0198 -1.3428 -0.4465 -1.2344 -0.1465 -0.4648 -0.1550 -0.0310 -0.0338 -0.0282', 'S-737\tGlivec war wirksamer als die Vergleichsmedikamente.', 'T-737\tGlivec was more effective than the comparator medicines.', 'H-737\t-0.424072265625\tGlivec was more effective than the comparator medicines .', 'D-737\t-0.424072265625\tGlivec was more effective than the comparator medicines.', 'P-737\t-0.0099 -0.0120 -0.0256 -0.0502 -0.0451 -0.0752 -0.0306 -0.3223 -0.2074 -0.6729 -0.1945 -0.3621 -0.0296 -0.0282', 'S-1311\tArthralgie * Rückenschmerzen * Schmerzen in den Extremitäten', 'T-1311\tarthralgia * back pain * pain in extremity', 'H-1311\t-0.88818359375\tArthralgia * Back pain * Pain in extremity', 'D-1311\t-0.88818359375\tArthralgia * Back pain * Pain in extremity', 'P-1311\t-0.9370 -0.0247 -0.0232 -0.0564 -0.0395 -0.7314 -0.2537 -0.0338 -0.1818 -0.0056 -0.0380 -0.2676 -0.5186 -1.2168', 'S-1918\t* Die Dosis kann bei Bedarf auf 400 mg / Tag erhöht werden.', 'T-1918\t* Dose may be increased to 400 mg / day as needed', 'H-1918\t-1.30078125\t* The dose may be increased up to 400 mg / day .', 'D-1918\t-1.30078125\t* The dose may be increased up to 400 mg / day.', 'P-1918\t-0.6904 -0.6875 -0.5552 -0.4932 -0.5493 -0.0620 -0.7271 -0.0310 -0.0704 -0.0141 -0.4819 -0.0338 -1.9102 -0.0282', 'S-1971\tJede Durchstechflasche enthält 10 mg Basiliximab *.', 'T-1971\tEach vial contains 10 mg basiliximab *.', 'H-1971\t-0.261474609375\tEach vial contains 10 mg of basiliximab * .', 'D-1971\t-0.261474609375\tEach vial contains 10 mg of basiliximab *.', 'P-1971\t-0.0328 -0.0277 -0.0156 -0.0604 -0.0945 -0.0155 -0.8613 -0.0169 -0.0268 -0.0268 -0.0155 -0.0218 -0.0465 -0.0373 -0.0282', 'S-164\tDie Mehrzahl der Ereignisse waren asymptomatische distale TVT.', 'T-164\tThe majority of events were asymptomatic distal DVT.', 'H-164\t-0.484375\tThe majority of events were asymptomatic distal DVT .', 'D-164\t-0.484375\tThe majority of events were asymptomatic distal DVT.', 'P-164\t-0.2360 -0.0444 -0.0313 -0.6069 -0.6650 -0.1761 -0.0127 -0.0070 -0.0169 -0.2494 -0.0183 -0.2466 -0.0775 -0.0423 -0.0282', 'S-375\tEs gibt keine Hinweise, die eine neuerliche Sicherheitsprüfung erforderlich machen.', 'T-375\tThere is no indication that necessitates a new safety assessment.', 'H-375\t-1.748046875\tThere is no evidence to suggest a re- examination is required .', 'D-375\t-1.748046875\tThere is no evidence to suggest a re- examination is required.', 'P-375\t-0.6025 -0.8530 -0.0465 -0.2874 -0.9160 -0.5410 -2.0410 -0.8228 -0.3325 -0.3157 -0.2311 -0.9863 -0.0395 -0.5073', 'S-486\tEs ist als runde, weiße Tabletten (20 mg) erhältlich.', 'T-486\tIt is available as round, white tablets (20 mg).', 'H-486\t-0.425048828125\tIt is available as round , white tablets ( 20 mg ) .', 'D-486\t-0.425048828125\tIt is available as round, white tablets (20 mg).', 'P-486\t-0.0612 -0.0400 -0.0400 -0.1382 -0.8286 -0.1747 -0.0331 -0.5615 -0.0268 -0.0324 -0.0972 -0.0225 -0.0366 -0.0366 -0.0296', 'S-1351\t- Magenschmerzen, Durchfall, Übelkeit, Erbrechen', 'T-1351\t- stomach pain, diarrhoea, feeling sick (nausea), vomiting', 'H-1351\t-0.40869140625\t- stomach ache , diarrhoea , nausea , vomiting', 'D-1351\t-0.40869140625\t- stomach ache, diarrhoea, nausea, vomiting', 'P-1351\t-0.0385 -0.4351 -0.8003 -0.0282 -0.0247 -0.0085 -0.1993 -0.0099 -0.0296 -0.4185 -0.0056 -0.0409 -0.0310 -0.0070 -0.0282 -0.0521', 'S-5\tNikotinsäurederivate, Colestipol),', 'T-5\t{PRODUCT NAME} belongs to a group of medicines known as statins, which are lipid (fat) regulating medicines.', 'H-5\t-0.791015625\tnicotinic acid derivatives , colestipol ) ,', 'D-5\t-0.791015625\tnicotinic acid derivatives, colestipol),', 'P-5\t-2.6055 -0.1958 -0.0930 -0.0169 -0.0197 -0.2423 -0.0197 -0.0310 -0.0507 -0.1859 -0.0169 -0.0366 -0.0366 -0.4368 -0.0282', 'S-345\t9 von Ihnen erzielten eine CHR und ein Patient eine PHR.', 'T-345\tIn eleven patients PDGFR gene rearrangements was detected, 9 of them achieved a CHR and 1 PHR.', 'H-345\t-1.107421875\tNine of them achieved a CHR and one patient a PHR .', 'D-345\t-1.107421875\tNine of them achieved a CHR and one patient a PHR.', 'P-345\t-0.8066 -0.6631 -0.6299 -0.8564 -0.3411 -0.1353 -0.0254 -0.4312 -0.3467 -0.1127 -1.1494 -0.0338 -0.0282 -0.0338 -0.0282', 'S-1540\tPuregon enthält den Wirkstoff Follitropin beta.', 'T-1540\tPuregon contains the active substance follitropin beta.', 'H-1540\t-0.20166015625\tPuregon contains the active substance follitropin beta .', 'D-1540\t-0.20166015625\tPuregon contains the active substance follitropin beta.', 'P-1540\t-0.1437 -0.0106 -0.0589 -0.0327 -0.0437 -0.0241 -0.2605 -0.1282 -0.0211 -0.0359 -0.1584 -0.0162 -0.0282 -0.0338 -0.0282', 'S-1494\tInsulatard ist ein lang wirkendes Insulin.', 'T-1494\tInsulatard is a long-acting insulin.', 'H-1494\t-0.2032470703125\tInsulatard is a long @-@ acting insulin .', 'D-1494\t-0.2032470703125\tInsulatard is a long-acting insulin.', 'P-1494\t-0.0502 -0.0070 -0.0487 -0.0811 -0.0356 -0.0486 -0.0708 -0.2131 -0.0056 -0.0183 -0.3030 -0.0366 -0.0282', 'S-230\tJede Durchstechflasche enthält 400 Einheiten Imiglucerase.', 'T-230\tEach vial contains 400 units of imiglucerase.', 'H-230\t-0.1348876953125\tEach vial contains 400 units of imiglucerase .', 'D-230\t-0.1348876953125\tEach vial contains 400 units of imiglucerase.', 'P-230\t-0.0313 -0.0378 -0.0142 -0.0502 -0.0306 -0.0486 -0.0516 -0.2668 -0.0204 -0.0155 -0.0099 -0.0155 -0.0356 -0.0292', 'S-498\tHepatomegalie, Hyperbilirubinämie', 'T-498\tHepatomegaly, hyperbilirubinemia', 'H-498\t-0.56103515625\tHepatomegaly , hyperbilirubinaemia', 'D-498\t-0.56103515625\tHepatomegaly, hyperbilirubinaemia', 'P-498\t-0.6724 -0.0155 -0.0197 -0.0106 -0.0151 -0.0240 -0.0416 -0.5444 -0.0134 -0.0134 -0.0373 -1.0527 -0.0395 -0.0254 -0.3240', 'S-541\tEthanol kann die Effekte anderer Arzneimittel verändern oder erhöhen.', 'T-541\tIt may modify or increase the effects of other medicines.', 'H-541\t-0.64892578125\tEthanol may alter or increase the effects of other medicines .', 'D-541\t-0.64892578125\tEthanol may alter or increase the effects of other medicines.', 'P-541\t-0.1992 -0.0085 -0.0106 -0.6714 -1.1621 -0.0409 -0.1536 -0.3071 -0.4199 -0.0310 -0.0366 -0.1268 -0.0676 -0.0338 -0.0282', 'S-645\tEine Durchstechflasche enthält 150 mg Omalizumab.', 'T-645\tOne vial contains 150 mg of omalizumab.', 'H-645\t-0.5078125\tEach vial contains 150 mg of omalizumab .', 'D-645\t-0.5078125\tEach vial contains 150 mg of omalizumab.', 'P-645\t-1.9023 -0.0592 -0.0155 -0.0535 -0.0521 -0.0254 -0.2100 -0.0240 -0.0268 -0.0056 -0.0183 -0.0197 -0.0338 -0.0282', 'S-761\tPatienten und Pflegepersonen sind hierüber entspechend aufzuklären.', 'T-761\tPatients and caregivers should be instructed accordingly.', 'H-761\t-0.67822265625\tPatients and caregivers should be informed accordingly .', 'D-761\t-0.67822265625\tPatients and caregivers should be informed accordingly.', 'P-761\t-0.5532 -0.0183 -0.0313 -0.1120 -0.1567 -0.0183 -0.2754 -0.0444 -1.5127 -0.3494 -0.0197 -0.0395 -0.0282', 'S-826\tLHRH-Antagonist, ATC-Code:', 'T-826\tLHRH-Antagonist, ATC code:', 'H-826\t-0.4306640625\tLHRH antagonist , ATC code :', 'D-826\t-0.4306640625\tLHRH antagonist, ATC code:', 'P-826\t-0.5508 -0.0085 -0.0176 -0.7437 -0.0085 -0.0247 -0.0395 -0.0225 -0.0240 -0.4128 -0.0324 -0.0282', 'S-956\tZusammenfassung der Pro- dukteigenschaften, 4.2)', 'T-956\tSummary of Product Characteristics, 4.2)', 'H-956\t-0.9736328125\tSummary of product characteristics , 4.2 )', 'D-956\t-0.9736328125\tSummary of product characteristics, 4.2)', 'P-956\t-0.5693 -0.0190 -0.0313 -1.9053 -1.1328 -0.0282 -0.0479 -0.0225 -0.0282 -0.2847 -0.0338', 'S-1355\t25 Folgemaßnahmen des Inhabers der Genehmigung für das Inverkehrbringen', 'T-1355\t22 Follow-up measures of the Marketing Authorisation Holder', 'H-1355\t-0.56640625\t25 Follow @-@ up measures of the Marketing Authorisation Holder', 'D-1355\t-0.56640625\t25 Follow-up measures of the Marketing Authorisation Holder', 'P-1355\t-0.8813 -0.0789 -0.1952 -0.0310 -0.2529 -0.2698 -0.0958 -0.6719 -0.0183 -0.0916 -0.0451 -0.0732 -0.0197 -0.0352', 'S-161\t1 / 2 EU / 1 / 04 / 285 / 019', 'T-161\t1 / 2 EU / 1 / 04 / 285 / 019', 'H-161\t-0.29248046875\tEU / 1 / 04 / 285 / 019', 'D-161\t-0.29248046875\tEU / 1 / 04 / 285 / 019', 'P-161\t-0.5757 -0.1420 -0.0416 -0.0310 -0.0218 -0.0289 -0.0303 -0.0254 -0.0289 -0.0416 -0.2487 -0.0831', 'S-317\tDas Verfallsdatum auf dem Deckel des Trägers prüfen.', 'T-317\tCheck the expiry date on the lid of the tray.', 'H-317\t-0.64404296875\tCheck the expiry date on the cap of the tray .', 'D-317\t-0.64404296875\tCheck the expiry date on the cap of the tray.', 'P-317\t-0.0634 -0.0930 -0.2113 -0.1219 -0.0313 -0.4004 -0.0345 -0.7783 -0.4058 -0.0451 -0.8579 -0.0197 -0.0479 -0.0282', 'S-1045\tEU / 2 / 97 / 003 / 017 Dicural', 'T-1045\tEU / 2 / 97 / 003 / 017 Dicural', 'H-1045\t-0.2890625\tEU / 2 / 97 / 003 / 017 Dicural', 'D-1045\t-0.2890625\tEU / 2 / 97 / 003 / 017 Dicural', 'P-1045\t-0.1807 -0.0414 -0.0414 -0.0306 -0.0155 -0.0292 -0.0342 -0.0306 -0.0285 -0.4963 -0.0261 -0.1113 -0.0113 -0.0542 -0.3367', 'S-1531\tWichtige Informationen über bestimmte sonstige Bestandteile von EMADINE', 'T-1531\tImportant information about some of the ingredients of EM ADINE', 'H-1531\t-0.638671875\tImportant information about some of the ingredients of EMADINE', 'D-1531\t-0.638671875\tImportant information about some of the ingredients of EMADINE', 'P-1531\t-0.2169 -0.0141 -0.0241 -0.0872 -0.1648 -0.3093 -0.2910 -0.1028 -0.3198 -0.2761 -1.0498 -0.0127 -0.0197 -0.0282 -0.3269', 'S-729\tVor der Behandlung übermäßigen Haarwuchs an der Behandlungsstelle entfernen.', 'T-729\tExcess hair around the treatment area should be cut.', 'H-729\t-1.263671875\tRemove the growth at the application site before treatment .', 'D-729\t-1.263671875\tRemove the growth at the application site before treatment.', 'P-729\t-2.0312 -0.0127 -0.0268 -0.5103 -0.3972 -1.1924 -0.0451 -0.5469 -0.1155 -0.7212 -0.2169 -0.0451 -0.0282', 'S-1871\tPotenzielle Beeinflussung anderer Arzneimittel durch Zonegran', 'T-1871\t4 Potential for Zonegran to affect other medicinal products', 'H-1871\t-0.775390625\tPotential for other medicinal products to be affected by Zonegran', 'D-1871\t-0.775390625\tPotential for other medicinal products to be affected by Zonegran', 'P-1871\t-0.4529 -0.0155 -1.3340 -1.0830 -0.2141 -0.2451 -0.0282 -0.0564 -0.0395 -0.4028 -0.0366 -0.0986 -0.0085 -0.0141 -0.0254 -0.0395', 'S-1989\tWelches Risiko ist mit Thalidomide Celgene verbunden?', 'T-1989\tWhat is the risk associated with Thalidomide Celgene?', 'H-1989\t-0.1590576171875\tWhat is the risk associated with Thalidomide Celgene ?', 'D-1989\t-0.1590576171875\tWhat is the risk associated with Thalidomide Celgene?', 'P-1989\t-0.0502 -0.1082 -0.0378 -0.0553 -0.1233 -0.0299 -0.2360 -0.0120 -0.0176 -0.0127 -0.0377 -0.0183 -0.0070 -0.0331 -0.0289', 'S-1992\t9,9 (123 / 1,242) 7,7; 12,1', 'T-1992\t9.9 (123 / 1,242) 7.7, 12.1', 'H-1992\t-0.1644287109375\t9.9 ( 123 / 1,242 ) 7.7 , 12.1', 'D-1992\t-0.1644287109375\t9.9 (123 / 1,242) 7.7, 12.1', 'P-1992\t-0.0856 -0.0285 -0.0334 -0.0099 -0.0299 -0.0803 -0.0227 -0.0255 -0.0299 -0.0320 -0.0211 -0.3206 -0.0497 -0.0310 -0.0345', 'S-288\t1 Durchstechflasche + 1 Fertigspritze + 1 Nadel', 'T-288\t1 vial + 1 pre-filled syringe + 1 needle', 'H-288\t-0.97412109375\t1 vial + 1 syringe + 1 needle', 'D-288\t-0.97412109375\t1 vial + 1 syringe + 1 needle', 'P-288\t-0.0299 -0.0953 -0.0299 -0.0342 -0.0269 -3.9004 -0.0113 -0.0056 -0.0282 -0.0310 -0.0254 -0.0197 -0.3015', 'S-320\tWie wirkt Nobilis Influenza H5N6?', 'T-320\tHow does Nobilis Influenza H5N6 work?', 'H-320\t-0.1221923828125\tHow does Nobilis Influenza H5N6 work ?', 'D-320\t-0.1221923828125\tHow does Nobilis Influenza H5N6 work?', 'P-320\t-0.0649 -0.0385 -0.0604 -0.0070 -0.0285 -0.1926 -0.0085 -0.0085 -0.0271 -0.0225 -0.0236 -0.0243 -0.0292 -0.0486 -0.0320 -0.0285', 'S-703\tBei älteren Patienten wurden keine pharmakokinetischen Studien durchgeführt.', 'T-703\tPharmacokinetic studies have not been performed in the elderly.', 'H-703\t-1.03515625\tPharmacokinetics studies have not been conducted in elderly patients .', 'D-703\t-1.03515625\tPharmacokinetics studies have not been conducted in elderly patients.', 'P-703\t-0.8750 -0.0155 -0.0564 -0.0113 -0.0099 -1.4355 -0.1663 -0.7495 -0.0423 -0.0282 -0.8594 -0.0986 -1.0283 -0.0310 -0.0310 -0.0282', 'S-743\tAPTIVUS ist in Flaschen mit 120 Kapseln erhältlich.', 'T-743\tAPTIVUS is supplied in bottles containing 120 capsules.', 'H-743\t-0.75927734375\tAPTIVUS is available in bottles of 120 capsules .', 'D-743\t-0.75927734375\tAPTIVUS is available in bottles of 120 capsules.', 'P-743\t-0.1895 -0.0278 -0.0134 -0.0162 -0.2910 -1.1553 -0.0310 -0.6821 -0.8032 -0.0225 -0.5156 -0.0197 -0.0225 -0.0366 -0.0282', 'S-907\tEs liegen keine Daten zur breiten Anwendung von Pandemrix vor.', 'T-907\tNo post-marketing surveillance data are available following Pandemrix administration.', 'H-907\t-0.81005859375\tThere are no data on the large use of Pandemrix .', 'D-907\t-0.81005859375\tThere are no data on the large use of Pandemrix.', 'P-907\t-0.7524 -0.2563 -0.0366 -0.0803 -0.7876 -0.6919 -0.9116 -0.3889 -0.0310 -0.0310 -0.0085 -0.0225 -0.0282 -0.0592 -0.0282', 'S-1061\tBetaferon Interferon beta -1b Part A', 'T-1061\tBet aferon Interferon beta -1b Part A', 'H-1061\t-0.330322265625\tBetaferon Interferon beta -1b', 'D-1061\t-0.330322265625\tBetaferon Interferon beta -1b', 'P-1061\t-0.2627 -0.0199 -0.0157 -0.1296 -0.1694 -0.0127 -0.0285 -0.2688 -0.0268 -0.0303 -0.0240 -0.0225 -0.5278', 'S-1418\tArthrose Die empfohlene Dosis beträgt 60 mg einmal täglich.', 'T-1418\tOsteoarthritis The recommended dose is 60 mg once daily.', 'H-1418\t-0.375\tOsteoarthritis The recommended dose is 60 mg once daily .', 'D-1418\t-0.375\tOsteoarthritis The recommended dose is 60 mg once daily.', 'P-1418\t-0.7109 -0.0099 -0.0299 -0.0155 -0.0056 -0.0225 -0.1148 -0.0254 -0.0627 -0.0373 -0.0684 -0.0268 -0.0458 -0.7432 -0.0324 -0.0282', 'S-481\tV09IX Zur Durchführung szintigraphischer Bildebung', 'T-481\tV09IX Imaging of carcinoma of colon or rectum', 'H-481\t-1.21484375\tV09IX Conduct scintigraphic imaging', 'D-481\t-1.21484375\tV09IX Conduct scintigraphic imaging', 'P-481\t-0.3762 -0.0113 -0.0285 -0.0236 -3.1055 -0.0254 -0.2620 -0.2367 -0.1691 -0.0704 -1.2822 -0.0141 -0.0535', 'S-1455\tWas ist Twinrix Erwachsene und wofür wird es angewendet?', 'T-1455\tWhat Twinrix Adult is and what it is used for 2.', 'H-1455\t-0.4130859375\tWhat Twinrix Adult is and what it is used for 2 .', 'D-1455\t-0.4130859375\tWhat Twinrix Adult is and what it is used for 2.', 'P-1455\t-0.0306 -0.3223 -0.0148 -0.0204 -0.0292 -0.1990 -0.1973 -0.0775 -0.0740 -0.0648 -0.3071 -0.1254 -0.0831 -0.0296 -0.3228 -0.3169 -0.0465', 'S-575\tINTANZA kann zeitgleich mit anderen Impfstoffen in unterschiedliche', 'T-575\tINTANZA can be given at the same time as other vaccines by using separate', 'H-575\t-0.73681640625\tINTANZA', 'D-575\t-0.73681640625\tINTANZA', 'P-575\t-1.0576 -0.0282 -0.0331 -0.0211 -0.0268 -0.9912', 'S-259\tSpätkomplikationen bei Erwachsenen und Kindern im Alter über 12 Jahren.', 'T-259\tadults and children above 12 years of age.', 'H-259\t-0.5986328125\tcomplications in adults and children over 12 years of age .', 'D-259\t-0.5986328125\tcomplications in adults and children over 12 years of age.', 'P-259\t-1.0723 -0.0310 -0.1176 -0.0366 -0.0359 -0.0423 -0.7427 -0.1859 -0.0409 -0.3691 -0.0296 -0.0535 -0.0310', 'S-221\tzu 73, rue de Stalle B-1180 Bruxelles Belgien', 'T-221\ts B-1180 Bruxelles', 'H-221\t-0.447265625\tge 73 , rue de Stalle B @-@ 1180 Bruxelles Belgium', 'D-221\t-0.447265625\tge 73, rue de Stalle B-1180 Bruxelles Belgium', 'P-221\t-1.5918 -0.0352 -0.0352 -0.0141 -0.0254 -0.0211 -0.0268 -0.0197 -0.5088 -0.0282 -0.0225 -0.0099 -0.0338 -0.0197 -0.0070 -0.0211 -0.0282', 'S-1428\tStephen Fairchild, Leiter des Bereichs Inspektionen, geboren am 19.', 'T-1428\t19 June 1943, n.', 'H-1428\t-1.138671875\tKarel de Neef Stephen Fairchild , Head of Sector for inspections , b .', 'D-1428\t-1.138671875\tKarel de Neef Stephen Fairchild, Head of Sector for inspections, b.', 'P-1428\t-0.9297 -0.3184 -0.3411 -0.3213 -0.3213 -1.4932 -0.5439 -0.0254 -0.0395 -0.2847 -0.0338 -0.3916 -0.1493 -0.3606 -0.5605 -0.1973 -0.1296 -0.3213 -0.0789 -0.0338', 'S-46\tIhre erste Injektion von Avonex kann Ihnen von Ihrem Arzt verabreicht', 'T-46\tIt may make you', 'H-46\t-0.51220703125\tYour first injection of Avonex can be given to you by your doctor', 'D-46\t-0.51220703125\tYour first injection of Avonex can be given to you by your doctor', 'P-46\t-0.2252 -0.0812 -0.0444 -0.0134 -0.0306 -0.0285 -0.0085 -0.0155 -0.5601 -0.0472 -0.6108 -0.6157 -0.0268 -0.0310 -0.0366 -0.0395 -0.3889', 'S-869\tPlastikflasche aus 980 ml Polyethylen von hoher Dichte', 'T-869\t980 ml', 'H-869\t-1.6748046875\t479 soft capsules', 'D-869\t-1.6748046875\t479 soft capsules', 'P-869\t-0.4734 -2.1016 -1.2295 -0.3550 -0.0789 -0.1437 -1.0029', 'S-474\tDaten zu anderen CYP3A4-Induktoren, wie z.', 'T-474\tA subsequent significantly reduced effect of bosentan is expected when it is co-administered with rifampicin.', 'H-474\t-1.763671875\tData about other CYP3A4 inducers , such as phenytoin , carbamazepine or St .', 'D-474\t-1.763671875\tData about other CYP3A4 inducers, such as phenytoin, carbamazepine or St.', 'P-474\t-0.3750 -0.9648 -0.2352 -0.3777 -0.0225 -0.0268 -0.0268 -0.0141 -0.0859 -0.0070 -0.3127 -1.0225 -0.9751 -0.0282 -1.0879 -0.3718 -0.3269 -0.3213 -0.3157 -0.7495 -0.3269 -0.3213 -0.3101 -0.1973 -2.3945 -1.3584 -0.4509 -0.0225', 'S-386\tHäufige Nebenwirkungen Diese können bis zu 1 von 10 Patienten betreffen:', 'T-386\tCommon side effects These may affect up to 1 in 10 people: • aggression or irritability • rapid, uncontrollable eye movements (nystagmus) • shaking or tremors • difficulty in sleeping • diarrhoea • dry mouth • feeling tired • pain in your back or joints, or elsewhere.', 'H-386\t-0.76416015625\tCommon side effects These may affect up to 1 in 10 people :', 'D-386\t-0.76416015625\tCommon side effects These may affect up to 1 in 10 people:', 'P-386\t-0.0781 -0.0249 -0.1521 -0.0451 -0.2595 -0.2595 -0.0648 -0.0606 -0.0282 -0.2578 -0.3840 -0.0338 -0.8989 -0.3127 -1.0205', 'S-80\tSuspension zum Einnehmen: < Firmenspezifisch >.', 'T-80\tTablet, soluble tablet, effervescent tablet or coated tablet: < Company-specific > Granules or powder for oral suspension: < Company-specific > Capsule, hard capsule: < Company-specific > Oral suspension: < Company-specific >', 'H-80\t-0.5048828125\tOral suspension : &lt; Company @-@ specific &gt; .', 'D-80\t-0.5048828125\tOral suspension: < Company-specific >.', 'P-80\t-0.9419 -0.2578 -0.2881 -0.0395 -0.0099 -0.0155 -0.0225 -0.3113 -0.2240 -0.1775 -0.0070 -0.0296 -0.0282', 'S-1283\tWenn Sie vermuten, allergisch auf EXUBERA zu sein,', 'T-1283\tSee the information at the end of section 4 <<unk>> Possible side effects <<unk>> of this leaflet for further advice. • If you are allergic to insulin, the active ingredient contained in EXUBERA or any of the other ingredients of EXUBERA.', 'H-1283\t-1.0009765625\tIf you think you may be allergic to EXUBERA ,', 'D-1283\t-1.0009765625\tIf you think you may be allergic to EXUBERA,', 'P-1283\t-0.5972 -0.0327 -0.4819 -0.0620 -1.0576 -0.0324 -0.0169 -0.0113 -0.0310 -0.0197 -0.0254 -0.0211 -0.0296 -0.3748 -2.2891', 'S-229\tDeshalb sollte Nateglinid nicht bei stillenden Frauen angewendet werden.', 'T-229\tAlthough it is not known whether nateglinide is excreted in human milk, the potential for hypoglycaemia in breast-fed infants may exist and therefore nateglinide should not be used in lactating women.', 'H-229\t-0.8134765625\tTherefore , nateglinide should not be used in women who are breast @-@ feeding .', 'D-229\t-0.8134765625\tTherefore, nateglinide should not be used in women who are breast-feeding.', 'P-229\t-0.7666 -0.0176 -0.3284 -0.1500 -0.0204 -0.0557 -0.1859 -0.0352 -0.0310 -0.0282 -0.4185 -0.7808 -0.8511 -0.1917 -0.2507 -0.5806 -0.1240 -0.0338 -0.0338 -0.0282', 'S-1621\t54 mg Fenofibrat und 850 mg Metformin.', 'T-1621\tThe tablets contain 80 mg fenofibrate and 500 mg metformin, 80 mg fenofibrate and 850 mg metformin, or 54 mg fenofibrate and 850 mg metformin.', 'H-1621\t-0.30615234375\t54 mg fenofibrate and 850 mg metformin .', 'D-1621\t-0.30615234375\t54 mg fenofibrate and 850 mg metformin.', 'P-1621\t-1.1289 -0.0254 -0.1050 -0.0416 -0.0183 -0.0155 -0.0247 -0.0388 -0.0268 -0.0282 -0.0169 -0.0197 -0.0099 -0.0282 -0.0592 -0.0296', 'S-231\tAllerdings wurden in den abgeschlossenen klinischen Studien keine derartigen Reaktionen genannt.', 'T-231\tAs with all other contrast media of the same class, late reactions may occur (after hours or days) in rare cases; however, none were reported in the completed clinical trials.', 'H-231\t-1.38671875\tHowever , no such reactions were reported in completed clinical trials .', 'D-231\t-1.38671875\tHowever, no such reactions were reported in completed clinical trials.', 'P-231\t-1.0762 -0.0465 -1.0693 -0.1493 -0.2113 -0.0099 -0.5845 -1.0732 -0.5947 -0.9551 -0.0282 -0.9019 -0.0282 -0.0282', 'S-269\tVorhofflimmern, erhöhte Herzfre- quenz, Palpitationen', 'T-269\tatrial fibrillation, heart rate increased, palpitations a', 'H-269\t-0.53515625\tAtrial fibrillation , increased heart rate , palpitations', 'D-269\t-0.53515625\tAtrial fibrillation, increased heart rate, palpitations', 'P-269\t-1.2959 -0.0035 -0.0528 -0.0169 -0.0113 -0.0155 -0.0303 -0.3586 -0.2197 -0.0423 -0.0352 -0.0211 -0.0127 -0.2761 -0.3254', 'S-524\t- Überempfindlichkeit gegen die Wirkstoffe oder einen der sonstigen Bestandteile', 'T-524\t- Hypersensitivity to the active substances or to any of the excipients', 'H-524\t-0.5693359375\t- Hypersensitivity to the active substances or to any of the excipients', 'D-524\t-0.5693359375\t- Hypersensitivity to the active substances or to any of the excipients', 'P-524\t-0.0429 -0.7007 -0.0310 -0.0268 -0.0148 -0.0620 -0.1373 -0.0373 -0.2571 -0.0204 -0.0402 -0.2888 -0.1057 -0.0901 -0.0437 -0.3228 -0.2169 -0.0197 -0.1423 -0.8369', 'S-1726\t1 Tropfen Lösung entsprechend 0,5 mg Memantinhydrochlorid.', 'T-1726\tOne drop of solution is equivalent to 0.5 mg memantine hydrochloride.', 'H-1726\t-0.548828125\tOne drop of solution equivalent to 0,5 mg memantine hydrochloride .', 'D-1726\t-0.548828125\tOne drop of solution equivalent to 0,5 mg memantine hydrochloride.', 'P-1726\t-0.8579 -0.0331 -0.2981 -0.0373 -0.4248 -0.0324 -0.7427 -0.0141 -0.1254 -0.0141 -0.0268 -0.0183 -0.0254 -0.0254 -0.0169 -0.0211 -0.3662 -0.0282', 'S-1772\tPharmazeutischer Unternehmer Teva Generics GmbH Kandelstr.', 'T-1772\tMarketing Authorisation Holder Teva Generics GmbH Kandelstr.', 'H-1772\t-0.495849609375\tMarketing Authorisation Holder Teva Generics GmbH Kandelstr .', 'D-1772\t-0.495849609375\tMarketing Authorisation Holder Teva Generics GmbH Kandelstr.', 'P-1772\t-0.3223 -0.3223 -0.3079 -0.3127 -0.3228 -0.1818 -0.1127 -0.0169 -0.0141 -0.0183 -0.4888 -0.2382 -0.0282 -0.0197 -0.0338 -0.0127 -0.0282 -0.0282', 'S-1085\tSTOCRIN 600 mg Filmtabletten Efavirenz', 'T-1085\tSTOCRIN 600 mg film-coated tablets efavirenz', 'H-1085\t-0.316650390625\tSTOCRIN 600 mg film @-@ coated tablets efavirenz', 'D-1085\t-0.316650390625\tSTOCRIN 600 mg film-coated tablets efavirenz', 'P-1085\t-0.0256 -0.0242 -0.0156 -0.0472 -0.0213 -0.0156 -0.2739 -0.3198 -0.3213 -0.0275 -0.2141 -0.0564 -0.2563 -0.0085 -0.0254 -0.0183 -0.0916 -0.0310', 'S-1635\tDie Änderungsanträge werden innerhalb der gesetzlich vorgegebenen Frist bearbeitet.', 'T-1635\tApplications for variations will be processed within the legislative time frame.', 'H-1635\t-1.748046875\tThe amendments will be treated within the specified time', 'D-1635\t-1.748046875\tThe amendments will be treated within the specified time', 'P-1635\t-0.7817 -1.9180 -0.0380 -0.5649 -0.0338 -0.8906 -0.0676 -0.0507 -2.0742 -0.0169 -0.4226 -0.9072', 'S-324\tEs ist als blaugrüne, kapselförmige Tabletten erhältlich.', 'T-324\tIt is available as blue-green, capsule-shaped tablets.', 'H-324\t-0.42724609375\tIt is available as blue @-@ green capsule @-@ shaped tablets .', 'D-324\t-0.42724609375\tIt is available as blue-green capsule-shaped tablets.', 'P-324\t-0.0494 -0.0407 -0.0407 -0.1022 -0.1805 -0.1310 -0.0243 -0.8525 -0.0085 -0.2085 -0.1212 -0.1028 -0.0254 -0.3086 -0.0310 -0.0282', 'S-1419\t- Erfahrungen bei Patienten mit Silver-Russell-Syndrom sind begrenzt.', 'T-1419\t- Experience in patients with Silver-Russell syndrome is limited.', 'H-1419\t-0.33984375\t- Experience in patients with Silver @-@ Russell syndrome is limited .', 'D-1419\t-0.33984375\t- Experience in patients with Silver-Russell syndrome is limited.', 'P-1419\t-0.3267 -0.2115 -0.0056 -0.0835 -0.1926 -0.1205 -0.0430 -0.0211 -0.2607 -0.0099 -0.3311 -0.0197 -0.0479 -0.0437 -0.0479 -0.0282', 'S-1346\t- wenn bei Ihnen eine Erkrankung Ihres Immunsystems diagnostiziert ist.', 'T-1346\t- If you have been diagnosed as having a disorder of your immune system.', 'H-1346\t-1.5\t- if you have Wegener &quot; s granulomatosis .', 'D-1346\t-1.5\t- if you have Wegener "s granulomatosis.', 'P-1346\t-0.6733 -0.6426 -0.5747 -0.7031 -1.2070 -0.3213 -0.3213 -0.2563 -0.3269 -0.2593 -0.2874 -0.2761 -0.2197 -0.0620 -1.7578 -0.0282', 'S-1297\tImmunglobuline sind normaler Bestandteil des menschlichen Körpers.', 'T-1297\tImmunoglobulins are a normal constituent of the human body.', 'H-1297\t-0.355712890625\tImmunoglobulins are a normal constituent of the human body .', 'D-1297\t-0.355712890625\tImmunoglobulins are a normal constituent of the human body.', 'P-1297\t-0.1389 -0.1647 -0.0148 -0.0213 -0.0322 -0.0342 -0.5264 -0.0648 -0.4121 -0.0402 -0.0704 -0.2395 -0.0268 -0.0324 -0.0310 -0.0282', 'S-982\t70,6 (12 / 17) 42,1; 99,1', 'T-982\t70.6 (12 / 17) 42.1, 99.1', 'H-982\t-0.343017578125\t70.6 ( 12 / 17 ) 42.1 , 99.1', 'D-982\t-0.343017578125\t70.6 (12 / 17) 42.1, 99.1', 'P-982\t-0.5542 -0.1265 -0.0356 -0.0292 -0.0268 -0.0289 -0.2303 -0.0296 -0.2671 -0.0211 -0.0268 -0.3206 -0.0296 -0.0240 -0.0282 -0.0324', 'S-621\tDocetaxel Winthrop ist ein Arzneimittel gegen Krebs.', 'T-621\tDocetaxel Winthrop is an anticancer medicine.', 'H-621\t-0.243408203125\tDocetaxel Winthrop is an anticancer medicine .', 'D-621\t-0.243408203125\tDocetaxel Winthrop is an anticancer medicine.', 'P-621\t-0.5024 -0.0243 -0.0162 -0.0085 -0.0197 -0.0465 -0.0035 -0.0236 -0.0342 -0.2159 -0.2395 -0.0063 -0.0049 -0.0796 -0.0310 -0.0282', 'S-28\tPiroxicam ist in der Europäischen Union nach einzelstaatlichen Verfahren zugelassen.', 'T-28\tPiroxicam is authorised in the European Union following national marketing procedures.', 'H-28\t-0.3291015625\tPiroxicam is authorised in the European Union via national procedures .', 'D-28\t-0.3291015625\tPiroxicam is authorised in the European Union via national procedures.', 'P-28\t-0.2822 -0.0213 -0.0213 -0.0141 -0.0269 -0.2617 -0.2352 -0.0247 -0.0881 -0.0345 -0.2120 -0.0268 -0.3206 -0.0451 -0.1282 -0.0310 -0.0282', 'S-595\tEptacog alfa wirkt auf die gleiche Weise wie Faktor VII.', 'T-595\tEptacog alfa works in the same way as factor VII.', 'H-595\t-0.70068359375\tEptacog alfa acts in the same way as factor VII .', 'D-595\t-0.70068359375\tEptacog alfa acts in the same way as factor VII.', 'P-595\t-1.1514 -0.0049 -0.0254 -0.0197 -0.0296 -0.0106 -0.9370 -0.1099 -0.7690 -0.0254 -0.0507 -0.2367 -0.3523 -0.0282 -0.0197 -0.0366 -0.0282', 'S-752\tSumneytown Pike West POINT, Pennsylvania 19486 USA', 'T-752\tSumneytown Pike West POINT, Pennsylvania 19486 USA', 'H-752\t-0.0845947265625\tSumneytown Pike West POINT , Pennsylvania 19486 USA', 'D-752\t-0.0845947265625\tSumneytown Pike West POINT, Pennsylvania 19486 USA', 'P-752\t-0.0127 -0.0142 -0.0256 -0.0184 -0.0141 -0.0213 -0.0241 -0.0977 -0.0213 -0.0241 -0.0285 -0.0262 -0.0456 -0.0211 -0.0176 -0.0211 -0.0292', 'S-894\t79% (143 / 182) 86% (85 / 99)', 'T-894\t79% (143 / 182) 86% (85 / 99)', 'H-894\t-0.166748046875\t79 % ( 143 / 182 ) 86 % ( 85 / 99 )', 'D-894\t-0.166748046875\t79% (143 / 182) 86% (85 / 99)', 'P-894\t-0.2113 -0.0299 -0.0285 -0.0262 -0.0299 -0.0292 -0.0241 -0.0271 -0.0292 -0.0141 -0.0264 -0.0271 -0.0113 -0.0299 -0.0155 -0.0285 -0.3245', 'S-1142\tVia Virgilio Maroso, 50 I-00142', 'T-1142\tVia Virgilio Maroso, 50 I-00142', 'H-1142\t-1.859375\tI @-@ 00142', 'D-1142\t-1.859375\tI-00142', 'P-1142\t-2.8008 -0.0606 -0.0240 -0.8086 -0.0592 -1.6963', 'S-1180\t100 mg Lopinavir und 25 mg Ritonavir; gelb:', 'T-1180\t100 mg lopinavir and 25 mg ritonavir; yellow:', 'H-1180\t-0.2783203125\t100 mg lopinavir and 25 mg ritonavir ; yellow :', 'D-1180\t-0.2783203125\t100 mg lopinavir and 25 mg ritonavir; yellow:', 'P-1180\t-0.5122 -0.0225 -0.2825 -0.3057 -0.0275 -0.0141 -0.0409 -0.0275 -0.0155 -0.0282 -0.0268 -0.0141 -0.0169 -0.0796 -0.0373 -0.0437 -0.0282', 'S-1233\tTel: + 34 91 321 06 00 crixivan @ msd.es', 'T-1233\tTel: + 34 91 321 06 00 crixivan @ msd. es', 'H-1233\t-0.68701171875\tTel : + 34 91 321 06 00 crixivan @ msd. es', 'D-1233\t-0.68701171875\tTel: + 34 91 321 06 00 crixivan @ msd. es', 'P-1233\t-0.0977 -0.0444 -0.0227 -0.0226 -0.0171 -0.0255 -0.0206 -0.0185 -0.0192 -2.4102 -0.0197 -0.0113 -0.0211 -0.0113 -0.9424 -0.0225 -0.0338', "S-1277\tRue de l 'Institut 89 B-1330 Rixensart Belgien", 'T-1277\tRue de l <<unk>> Institut 89 B-1330 Rixensart Belgium', 'H-1277\t-0.315673828125\tRue de l &quot; Institut 89 B @-@ 1330 Rixensart Belgium', 'D-1277\t-0.315673828125\tRue de l "Institut 89 B-1330 Rixensart Belgium', 'P-1277\t-0.4756 -0.0113 -0.0211 -0.0183 -0.9419 -0.0296 -0.0113 -0.0197 -0.0282 -0.0169 -0.0268 -0.0211 -0.0197 -0.0127 -0.0183 -0.0254 -0.0296', 'S-1356\t20 H-1034 Budapest Tel.: + 36 1 430 2890', 'T-1356\t20 H-1034 Budapest Tel.: + 36 1 430 2890', 'H-1356\t-0.312255859375\t20 H @-@ 1034 Budapest Tel . : + 36 1 430 2890', 'D-1356\t-0.312255859375\t20 H-1034 Budapest Tel.: + 36 1 430 2890', 'P-1356\t-0.8501 -0.0218 -0.0303 -0.0225 -0.0197 -0.0169 -0.1782 -0.3296 -0.0310 -0.0225 -0.0197 -0.0282 -0.0254 -0.0240 -0.0197 -0.0197 -0.0493', 'S-1406\t- bestimmen, wie viel Insuman Comb 25 Sie pro Tag benötigen,', 'T-1406\t- determine how much Insuman Comb 25 per day you will need,', 'H-1406\t-0.25341796875\t- determine how much Insuman Comb 25 per day you will need ,', 'D-1406\t-0.25341796875\t- determine how much Insuman Comb 25 per day you will need,', 'P-1406\t-0.0444 -0.1250 -0.0634 -0.0826 -0.0460 -0.0176 -0.0299 -0.0299 -0.0257 -0.0306 -0.3213 -0.0331 -0.0500 -0.2859 -0.0542 -0.1176 -0.0296', 'S-1416\t121 / 200 (61%) 114 / 200 (57%)', 'T-1416\t121 / 200 (61%) 114 / 200 (57%)', 'H-1416\t-0.414794921875\t121 / 200 ( 61 % ) 114 / 200 ( 57 % )', 'D-1416\t-0.414794921875\t121 / 200 (61%) 114 / 200 (57%)', 'P-1416\t-1.7705 -0.0282 -0.0324 -0.0197 -0.0282 -0.0183 -0.0310 -0.0296 -0.1226 -0.0197 -0.0296 -0.0169 -0.0268 -0.0113 -0.0282 -0.0282 -0.0296', 'S-1602\t112 mäßige Zunahme der Olanzapin-Clearance.', 'T-1602\tOnly slight to moderate increase in olanzapine clearance has been observed.', 'H-1602\t-0.4375\t112 Moderate increase in olanzapine clearance .', 'D-1602\t-0.4375\t112 Moderate increase in olanzapine clearance.', 'P-1602\t-0.6152 -0.6553 -0.0247 -0.4517 -0.0831 -0.0141 -0.0183 -0.0085 -0.0240 -0.0197 -0.0296 -0.0648 -0.0296', 'S-1637\t8 mg Rosiglitazon und 4 mg Glimepirid).', 'T-1637\t8 mg rosiglitazone and 4 mg glimepiride).', 'H-1637\t-0.447021484375\t8 mg rosiglitazone and 4 mg glimepiride ) .', 'D-1637\t-0.447021484375\t8 mg rosiglitazone and 4 mg glimepiride).', 'P-1637\t-1.6846 -0.0183 -0.4099 -0.0085 -0.0225 -0.0183 -0.0324 -0.0409 -0.0296 -0.0127 -0.0113 -0.0155 -0.0113 -0.0254 -0.0352 -0.0423 -0.0282', 'S-1683\tDer Zulassungsinhaber muss alle 12 Monate einen PSUR einreichen.', 'T-1683\tThe marketing authorisation holder should submit 12-monthly PSURs.', 'H-1683\t-1.0712890625\tThe Marketing Authorisation Holder will have to submit PSURs every 12 months .', 'D-1683\t-1.0712890625\tThe Marketing Authorisation Holder will have to submit PSURs every 12 months.', 'P-1683\t-0.2427 -1.2021 -0.0282 -0.0930 -0.0873 -0.0535 -0.0197 -1.6611 -0.3523 -0.0310 -0.2057 -0.0113 -1.3076 -0.6567 -0.2085 -0.0225 -0.3550 -0.0282 -0.0282 -0.0338 -0.0282', 'S-1730\tJede Flasche ist etwa zur Hälfte gefüllt, und enthält drei Milliliter Lösung.', 'T-1730\tEach bottle is about half full and contains 3 millilitres of solution.', 'H-1730\t-0.5224609375\tEach bottle is approximately half full and contains 3 millilitres of solution .', 'D-1730\t-0.5224609375\tEach bottle is approximately half full and contains 3 millilitres of solution.', 'P-1730\t-0.0364 -0.0313 -0.0393 -0.2917 -0.1014 -0.2145 -0.6816 -0.0451 -0.2888 -0.1606 -0.0197 -0.7578 -0.0240 -0.0718 -0.0338 -0.0324 -0.0282', 'S-1928\t22 / 116 (19%) 9 / 116 (8%)', 'T-1928\t22 / 116 (19%) 9 / 116 (8%)', 'H-1928\t-0.50244140625\t22 / 116 ( 19 % ) 9 / 116 ( 8 % )', 'D-1928\t-0.50244140625\t22 / 116 (19%) 9 / 116 (8%)', 'P-1928\t-0.8940 -0.0331 -0.0268 -0.0211 -0.0261 -0.0331 -0.0310 -0.0289 -1.1465 -0.0282 -0.0240 -0.0211 -0.0268 -0.0268 -0.0296 -0.0282 -0.3240', 'S-393\tEU / 2 / 05 / 055 / 002 Equilis Te', 'T-393\tEU / 2 / 05 / 055 / 002 Equilis Te', 'H-393\t-0.28271484375\tEU / 2 / 05 / 055 / 002 Equilis Te', 'D-393\t-0.28271484375\tEU / 2 / 05 / 055 / 002 Equilis Te', 'P-393\t-0.6196 -0.0342 -0.0402 -0.0282 -0.0232 -0.0282 -0.0282 -0.0183 -0.0289 -0.0345 -0.0331 -0.1472 -0.0106 -0.0254 -0.3938 -0.0225 -0.0324', 'S-443\tDeutschland Eisai GmbH Tel: + 49 (0) 69 66 58 50', 'T-443\t42 Deutschland Eisai GmbH Tel: + 49 (0) 69 66 58 50', 'H-443\t-0.180908203125\tDeutschland Eisai GmbH Tel : + 49 ( 0 ) 69 66 58 50', 'D-443\t-0.180908203125\tDeutschland Eisai GmbH Tel: + 49 (0) 69 66 58 50', 'P-443\t-0.5093 -0.0141 -0.0162 -0.0271 -0.0243 -0.1191 -0.0472 -0.0303 -0.0176 -0.0310 -0.0247 -0.0282 -0.0148 -0.0113 -0.0176 -0.0218 -0.0352', 'S-727\tTrocoxil 95 mg Kautabletten für Hunde Mavacoxib', 'T-727\tTrocoxil 95 mg chewable tablets for dogs Mavacoxib', 'H-727\t-0.397216796875\tTrocoxil 75 mg chewable tablets for dogs Mavacoxib', 'D-727\t-0.397216796875\tTrocoxil 75 mg chewable tablets for dogs Mavacoxib', 'P-727\t-0.0939 -0.0241 -0.0227 -0.0106 -1.3135 -0.0183 -0.2817 -0.0648 -0.0366 -0.1324 -0.0338 -0.0521 -0.0211 -0.0648 -0.0155 -0.0085 -0.0225 -0.0324', 'S-840\tBei Überdosierung kann eine Verschlimmerung der Nebenwirkungen erwartet werden.', 'T-840\tIn cases of overdose, exacerbation of adverse events may be expected.', 'H-840\t-1.4892578125\tIn case of overdose , the side effects may worsen .', 'D-840\t-1.4892578125\tIn case of overdose, the side effects may worsen.', 'P-840\t-1.1494 -1.0000 -0.0310 -0.2888 -0.1071 -0.3789 -1.4258 -0.3411 -0.0423 -0.5552 -1.8594 -0.0113 -0.0338 -0.0282', 'S-1510\tManchmal wird das Virus nach vielen Jahren wieder aktiv und verursacht Gürtelrose.', 'T-1510\tSometimes, after many years, the virus becomes active again and causes shingles.', 'H-1510\t-1.5146484375\tSometimes , the virus is activated after many years and causes shingles .', 'D-1510\t-1.5146484375\tSometimes, the virus is activated after many years and causes shingles.', 'P-1510\t-0.5972 -0.5581 -0.9326 -0.0141 -2.3340 -1.1104 -0.0254 -0.9438 -0.5859 -0.0282 -0.2874 -0.1465 -0.6426 -0.0056 -0.0169 -0.0338 -0.0282', 'S-318\tKombination mit Interferon beta oder Glatirameracetat.', 'T-318\tCombination with beta-interferons or glatiramer acetate.', 'H-318\t-0.41845703125\tCombination with interferon beta or glatiramer acetate .', 'D-318\t-0.41845703125\tCombination with interferon beta or glatiramer acetate.', 'P-318\t-1.5508 -0.0606 -0.0352 -0.0831 -0.0113 -0.0296 -0.0127 -0.0282 -0.0338 -0.0324 -0.0662 -0.0352 -0.0141 -0.0225 -0.0211 -0.0240 -0.2803 -0.0282', 'S-805\tsilikonfreien Minispike aus der Durchstechflasche entnommen werden.', 'T-805\tneedle or attached to a sterile non-siliconised mini-spike.', 'H-805\t-1.3232421875\tsilicone @-@ free Mini @-@ Spike from the vial .', 'D-805\t-1.3232421875\tsilicone-free Mini-Spike from the vial.', 'P-805\t-2.8848 -0.0225 -0.0225 -0.3269 -0.0225 -0.5269 -0.5522 -0.0423 -0.0225 -1.7754 -0.1014 -0.3042 -0.0225 -0.0620 -0.0282', 'S-1880\t20 mg) und als Pulver zur Herstellung einer Injektionslösung erhältlich.', 'T-1880\t20 mg) and as a powder to be made up into a solution for injection.', 'H-1880\t-0.485595703125\t20 mg ) and as a powder for solution for injection .', 'D-1880\t-0.485595703125\t20 mg) and as a powder for solution for injection.', 'P-1880\t-0.0604 -0.0135 -0.0364 -0.0796 -0.1451 -0.1765 -0.0218 -1.0020 -0.3228 -0.3113 -0.0620 -0.0507 -0.0549 -0.0296', 'S-1915\tInformieren Sie Ihren Arzt, wenn eine dieser Nebenwirkungen bei Ihnen auftritt.', 'T-1915\tIf you should experience one of these side effects, you are advised to contact your doctor.', 'H-1915\t-0.85791015625\tTell your doctor if you experience any of these side effects .', 'D-1915\t-0.85791015625\tTell your doctor if you experience any of these side effects.', 'P-1915\t-1.1309 -0.0148 -0.0310 -0.0338 -0.0514 -0.7554 -0.9297 -0.0395 -0.0338 -0.0366 -1.0283 -0.0310 -0.0338 -0.0282', 'S-272\ta) Dicural b) Difloxacin c) Teil B', 'T-272\t(a) Dicural (b) Difloxacin (c) Part B', 'H-272\t-0.378173828125\ta ) Dicural b ) Difloxacin c ) Part B', 'D-272\t-0.378173828125\ta) Dicural b) Difloxacin c) Part B', 'P-272\t-0.0502 -0.0299 -0.6851 -0.0113 -0.0824 -0.0416 -0.0289 -0.8979 -0.0127 -0.0225 -0.0183 -0.0268 -0.0310 -0.0282 -0.0535 -0.0211 -0.0296', 'S-1322\tApidra 100 Einheiten / ml, Injektionslösung in einer Patrone', 'T-1322\tApidra 100 Units / ml, solution for injection in a cartridge.', 'H-1322\t-0.5927734375\tApidra 100 Units / ml , solution for injection in a cartridge', 'D-1322\t-0.5927734375\tApidra 100 Units / ml, solution for injection in a cartridge', 'P-1322\t-0.4075 -0.0176 -0.0063 -0.1913 -0.2311 -0.0218 -0.0296 -0.0211 -0.0528 -0.2747 -0.2817 -0.0592 -0.0296 -0.0817 -0.9878 -0.1155 -0.0141 -0.0169 -0.6284', 'S-1088\tmikrobiologischen Erwägungen unmittelbar nach Zubereitung angewendet werden.', 'T-1088\tFrom a microbiological point of view, however, the diluted product should be used immediately.', 'H-1088\t-1.01953125\tmicrobiological considerations should be used immediately after preparation .', 'D-1088\t-1.01953125\tmicrobiological considerations should be used immediately after preparation.', 'P-1088\t-1.6016 -0.0225 -0.2184 -0.2944 -0.0240 -0.4297 -0.0395 -0.7173 -0.0732 -0.4734 -0.7832 -0.0451 -0.0282', 'S-1824\t63 Schlafes, oder Lungen- oder Atemwegsinfektionen.', 'T-1824\tPatients with PWS and one or more of these risk factors may be at greater risk.', 'H-1824\t-1.3916015625\t63 falling asleep , or lung or respiratory tract infections .', 'D-1824\t-1.3916015625\t63 falling asleep, or lung or respiratory tract infections.', 'P-1824\t-2.0098 -0.9609 -0.0338 -0.0085 -0.3127 -0.0395 -1.9756 -0.0395 -0.2507 -0.0085 -0.0113 -1.2822 -0.0113 -0.4170 -0.0113 -0.2197 -0.0282', 'S-803\tJede Fertigspritze mit 1 ml Lösung enthält 150 mg Omalizumab', 'T-803\tEach pre-filled syringe of 1 ml solution contains 150 mg of omalizumab.', 'H-803\t-0.5791015625\tEach pre @-@ filled syringe of 1 ml solution contains 150 mg omalizumab', 'D-803\t-0.5791015625\tEach pre-filled syringe of 1 ml solution contains 150 mg omalizumab', 'P-803\t-0.0444 -0.8926 -0.0282 -0.1726 -0.0127 -0.0085 -0.0042 -0.6035 -0.0451 -0.0183 -0.1493 -0.0310 -0.0338 -0.0141 -0.7793 -0.0254 -0.0042 -0.0183 -0.0225 -0.5859', 'S-1738\t13 zurück und waren nicht mit histopathologischen Auffälligkeiten verbunden.', 'T-1738\tThey were reversible despite continued treatment and were not associated with histopathological abnormalities.', 'H-1738\t-1.359375\t13 and not associated with histopathological abnormalities .', 'D-1738\t-1.359375\t13 and not associated with histopathological abnormalities.', 'P-1738\t-1.8643 -1.3086 -1.6484 -0.6650 -0.0282 -0.1240 -0.0225 -0.0141 -0.5352 -0.3381 -0.2649 -0.0056 -0.0225 -0.0338 -0.0282', 'S-1761\tDie Anfangsdosis beträgt 60 mg täglich (zwei Tabletten).', 'T-1761\tStarting dose is 60 mg daily (two tablets), increasing to 120 mg (four tablets) daily if required.', 'H-1761\t-0.44384765625\tThe starting dose is 60 mg daily ( two tablets ) .', 'D-1761\t-0.44384765625\tThe starting dose is 60 mg daily (two tablets).', 'P-1761\t-0.9194 -0.6147 -0.0845 -0.0451 -0.0746 -0.0521 -0.0930 -0.0324 -0.0817 -0.0521 -0.0225 -0.0310 -0.0310 -0.0282', 'S-689\ta) Solution for inje ction b) Multi dose c) 2', 'T-689\ta) Solution for injection b) Multidose c) 2', 'H-689\t-1.533203125\tSolution for injection 6', 'D-689\t-1.533203125\tSolution for injection 6', 'P-689\t-1.5693 -0.0282 -0.0437 -0.0916 -0.3228 -0.3284 -2.5410', 'S-40\tOPTRUMA hat keine stimulierende Wirkung auf die Brustdrüse.', 'T-40\tOPTRUMA does not stimulate breast tissue.', 'H-40\t-0.625\tOPTRUMA does not stimulate breast tissue .', 'D-40\t-0.625\tOPTRUMA does not stimulate breast tissue.', 'P-40\t-0.4160 -0.0183 -0.0250 -0.0106 -1.1562 -0.0310 -0.3127 -0.0268 -0.3340 -0.3564 -0.0592 -0.0310', 'S-238\tKlinische Studien über zwei Jahre haben die Aufrechterhaltung dieser Wirkung belegt.', 'T-238\tTwo-year clinical studies have shown maintenance of this effect.', 'H-238\t-1.7119140625\tClinical studies up to two years have demonstrated that this effect is maintained .', 'D-238\t-1.7119140625\tClinical studies up to two years have demonstrated that this effect is maintained.', 'P-238\t-0.4321 -0.0211 -0.4893 -2.5430 -0.0395 -0.0564 -0.0254 -0.7720 -0.8818 -0.2903 -1.6680 -0.0395 -0.6313 -1.0820 -0.0338 -0.0282', 'S-698\tWenn diese Reaktionen andauern oder sich verschlimmern, informieren Sie Ihren Arzt.', 'T-698\tIf these events continue or become severe, tell your doctor.', 'H-698\t-1.0517578125\tIf these events continue or worsen , tell your doctor .', 'D-698\t-1.0517578125\tIf these events continue or worsen, tell your doctor.', 'P-698\t-0.8530 -0.1775 -0.6504 -0.5200 -0.1395 -1.4580 -0.0085 -0.0451 -0.2537 -0.0310 -0.6934 -0.0423 -0.0282', 'S-815\tDies führt möglicherweise zu einer Leberschädigung und neurologischen Störungen.', 'T-815\tThis potentially leads to liver damage and neurological disorders.', 'H-815\t-0.99755859375\tThis may lead to liver damage and neurological disorders .', 'D-815\t-0.99755859375\tThis may lead to liver damage and neurological disorders.', 'P-815\t-0.4822 -0.9639 -0.7593 -0.0310 -0.9595 -0.4648 -0.0366 -0.0169 -0.0338 -0.8198 -0.0197 -0.0310 -0.0282', 'S-860\t41 Die folgenden Informationen sind nur für Ärzte bzw. medizinisches Fachpersonal bestimmt:', 'T-860\t37 The following information is intended for medical or healthcare professionals only', 'H-860\t-0.7255859375\t41 The following information is intended for medical or healthcare professionals only :', 'D-860\t-0.7255859375\t41 The following information is intended for medical or healthcare professionals only:', 'P-860\t-1.4053 -0.0542 -0.0310 -0.0423 -0.0521 -0.1635 -0.1437 -0.1986 -0.3184 -0.4932 -0.0225 -0.0648 -0.5156 -0.0282', 'S-1019\tng EU / 1 / 03 / 257 / 001 t lä', 'T-1019\tris EU / 1 / 03 / 257 / 001', 'H-1019\t-0.5693359375\tl EU / 1 / 03 / 257 / 001', 'D-1019\t-0.5693359375\tl EU / 1 / 03 / 257 / 001', 'P-1019\t-0.3716 -0.3064 -0.0384 -0.0296 -0.0296 -0.0197 -0.0296 -0.0204 -0.0254 -0.0296 -0.0261 -0.0303 -1.6953', 'S-1252\tDas schmerzt weniger, als wenn Sie die Nadel langsam einführen.', 'T-1252\tThis hurts less than pushing the needle in slowly.', 'H-1252\t-1.3359375\tThis means less pain than carefully inserting the needle .', 'D-1252\t-1.3359375\tThis means less pain than carefully inserting the needle.', 'P-1252\t-0.4226 -1.9834 -0.4592 -0.0254 -0.5918 -2.3281 -0.2930 -0.0113 -0.0282 -0.2311 -0.0225 -0.0282 -0.0564 -0.0282', 'S-128\tDie maximalen Plasmakonzentrationen waren bei älteren Patienten nicht erhöht.', 'T-128\tPeak plasma levels were not increased in the elderly.', 'H-128\t-0.88818359375\tMaximum plasma concentrations were not increased in elderly patients .', 'D-128\t-0.88818359375\tMaximum plasma concentrations were not increased in elderly patients.', 'P-128\t-2.2168 -0.0310 -0.4087 -0.0113 -0.0183 -0.3228 -0.0085 -0.0225 -0.2141 -0.0338 -0.0676 -0.0423 -1.1973 -0.0338 -0.0310 -0.0282', 'S-147\tDie Bioverfügbarkeit von Rufinamid ist dosisabhängig.', 'T-147\tThe bioavailability of rufinamide is dependent on dose.', 'H-147\t-0.48193359375\tThe bioavailability of rufinamide is dose @-@ dependent .', 'D-147\t-0.48193359375\tThe bioavailability of rufinamide is dose-dependent.', 'P-147\t-0.1952 -0.2113 -0.0342 -0.0285 -0.0620 -0.0342 -0.0236 -0.0204 -0.3853 -0.0352 -0.9370 -0.3228 -0.0296 -0.0282', 'S-235\tDen vollständigen Wortlaut des EPAR für Gliolan finden Sie hier.', 'T-235\tThe full EPAR for Gliolan can be found here.', 'H-235\t-0.3779296875\tThe full EPAR for Gliolan can be found here .', 'D-235\t-0.3779296875\tThe full EPAR for Gliolan can be found here.', 'P-235\t-0.1830 -0.0386 -0.2800 -0.0155 -0.1106 -0.1162 -0.0204 -0.0338 -0.8589 -0.0268 -0.0521 -0.0282 -0.0479 -0.0296', 'S-493\t27 Häufige Nebenwirkungen (Bei 1 bis 10 von 100 Anwendern)', 'T-493\tCommon side effects (affects 1 to 10 users in 100)', 'H-493\t-0.869140625\t24 Common side effects ( affects 1 to 10 users in 100 )', 'D-493\t-0.869140625\t24 Common side effects (affects 1 to 10 users in 100)', 'P-493\t-1.5107 -0.3621 -0.0240 -0.2113 -0.0268 -0.0310 -0.3564 -0.0634 -0.0620 -0.0338 -0.2944 -0.2847 -0.3606 -0.4705 -0.3213', 'S-545\tDazu gehören auch Ausgaben für Helpdesk-Dienstleistungen für die Tätigkeit der Agentur.', 'T-545\tIt also includes helpdesk services for the operation of the Agency.', 'H-545\t-0.7060546875\tIt also includes helpdesk services for the operation of the Agency .', 'D-545\t-0.7060546875\tIt also includes helpdesk services for the operation of the Agency.', 'P-545\t-0.5435 -0.1521 -0.1272 -0.3340 -0.0127 -0.2303 -0.2247 -0.0592 -1.0322 -0.0282 -0.0338 -0.6001 -0.0338 -0.0282', 'S-776\t• Gleichzeitige Verabreichung mit Immunoglobulin (IG)', 'T-776\t• Co-administration with immunoglobulin (IG)', 'H-776\t-0.281982421875\t• Co @-@ administration with immunoglobulin ( IG )', 'D-776\t-0.281982421875\t• Co-administration with immunoglobulin (IG)', 'P-776\t-0.0864 -0.6025 -0.0299 -0.0486 -0.0472 -0.3643 -0.0232 -0.0141 -0.0197 -0.0303 -0.0310 -0.0056 -0.0289 -0.0423', 'S-1074\t28 Die übliche Dosierung beträgt 2-4 mg pro kg Körpergewicht.', 'T-1074\tThe usual dose is 2-4 mg per kg body weight.', 'H-1074\t-0.748046875\tThe usual dose is 2 @-@ 4 mg per kg body weight .', 'D-1074\t-0.748046875\tThe usual dose is 2-4 mg per kg body weight.', 'P-1074\t-1.3213 -0.1176 -0.2402 -0.0578 -0.0479 -0.3931 -0.3101 -0.0183 -0.0775 -0.4170 -0.5581 -0.0254 -0.0338 -0.0282', 'S-91\tEs gibt Berichte über Durchbruchblutungen und unbeabsichtigte Schwangerschaften.', 'T-91\tBreakthrough bleeding and unintended pregnancies have been reported.', 'H-91\t-0.7314453125\tThere have been reports of breakthrough bleeding and unintended pregnancies .', 'D-91\t-0.7314453125\tThere have been reports of breakthrough bleeding and unintended pregnancies.', 'P-91\t-0.5991 -0.5063 -0.0289 -0.0388 -0.0296 -0.6489 -0.1859 -0.3972 -0.0352 -0.4749 -0.0873 -0.7324 -0.0169 -0.0197 -0.0310 -0.0282', 'S-1469\tWIE IST REBIF ANZUWENDEN?', 'T-1469\tHOW TO USE REBIF', 'H-1469\t-0.317626953125\tHOW TO USE REBIF', 'D-1469\t-0.317626953125\tHOW TO USE REBIF', 'P-1469\t-0.0299 -0.0113 -0.6895 -0.0796 -0.0134 -0.0388 -0.0268 -0.0282 -0.0282 -0.3184', 'S-1122\tDies betrifft alle Arzneimittel, auch nicht verschreibungspflichtige.', 'T-1122\tThis includes any other medicines including medicines obtained without a prescription.', 'H-1122\t-1.005859375\tThis applies to all medicines , even medicines obtained without a prescription .', 'D-1122\t-1.005859375\tThis applies to all medicines, even medicines obtained without a prescription.', 'P-1122\t-0.4473 -1.1689 -0.0310 -0.0324 -0.0606 -0.1240 -0.5366 -0.9917 -0.7974 -0.1212 -0.5127 -0.2537 -0.1606 -0.0113 -0.0310 -0.0282', 'S-1141\t21 Erkrankungen der Haut und des Unterhautzellgewebes Häufig:', 'T-1141\tSkin and subcutaneous tissue disorders Common:', 'H-1141\t-0.79736328125\tSkin and subcutaneous tissue disorders Common :', 'D-1141\t-0.79736328125\tSkin and subcutaneous tissue disorders Common:', 'P-1141\t-2.8359 -0.0197 -0.0409 -0.0451 -0.0225 -0.0113 -0.0225 -0.0310 -0.0760 -0.2029 -0.0225 -0.6284 -0.0254 -0.0338 -0.0310', 'S-1509\tBei den verschiedenen Isolaten waren die Positionen dieser Mutationen uneinheitlich.', 'T-1509\tThe position of these mutations was not consistent between different isolates.', 'H-1509\t-1.466796875\tThe positions of these mutations were inconsistent between isolates .', 'D-1509\t-1.466796875\tThe positions of these mutations were inconsistent between isolates.', 'P-1509\t-1.0752 -1.7246 -0.0352 -0.0803 -0.0169 -0.0282 -0.3296 -1.1270 -0.3777 -1.8203 -0.4395 -0.0282 -0.0338 -0.0282', 'S-1671\tWenn Sie die Anwendung von Epoetin alfa HEXAL vergessen haben', 'T-1671\tIf you forget to use Epoetin alfa HEXAL', 'H-1671\t-0.376220703125\tIf you forget to use Epoetin alfa HEXAL', 'D-1671\t-0.376220703125\tIf you forget to use Epoetin alfa HEXAL', 'P-1671\t-0.1197 -0.0298 -0.2866 -0.1282 -0.6045 -0.2487 -0.0169 -0.0070 -0.0310 -0.0380 -0.0085 -0.0197 -0.0254 -0.0268 -0.3198', 'S-1697\tNehmen Sie Pritor immer genau nach Anweisung des Arztes ein.', 'T-1697\tAlways take Pritor exactly as your doctor has told you.', 'H-1697\t-0.386474609375\tAlways take Pritor exactly as your doctor has told you .', 'D-1697\t-0.386474609375\tAlways take Pritor exactly as your doctor has told you.', 'P-1697\t-0.0685 -0.0149 -0.3984 -0.0588 -0.0077 -0.0278 -0.1930 -0.0859 -0.3142 -0.0204 -0.2698 -0.3042 -0.0254 -0.1437 -0.0282', 'S-1884\tStabilität der rekonstituierten Suspension im Infusionsbeutel:', 'T-1884\tStability of the reconstituted suspension in the infusion bag:', 'H-1884\t-0.38720703125\tStability of the reconstituted suspension in the infusion bag :', 'D-1884\t-0.38720703125\tStability of the reconstituted suspension in the infusion bag:', 'P-1884\t-0.0939 -0.0270 -0.1382 -0.4819 -0.1726 -0.0070 -0.0204 -0.0634 -0.0514 -0.0873 -0.1556 -0.3411 -0.2563 -0.0409 -0.0282', 'S-1980\tEine Durchstechflasche mit 5 ml enthält 5 mg Galsulfase.', 'T-1980\tOne vial of 5 ml contains 5 mg galsulfase.', 'H-1980\t-0.54345703125\tOne vial of 5 ml contains 5 mg of galsulfase .', 'D-1980\t-0.54345703125\tOne vial of 5 ml contains 5 mg of galsulfase.', 'P-1980\t-0.5142 -0.1592 -0.0211 -0.1663 -0.0303 -0.0247 -0.0282 -0.0373 -0.0183 -1.4092 -0.0873 -0.0197 -0.2578 -0.0282 -0.0366 -0.0296', 'S-110\tDie Bedingungen der Genehmigung für das Inverkehrbringen sind in Anhang IV aufgeführt.', 'T-110\tThe conditions to the Marketing Authorisation as listed in Annex IV.', 'H-110\t-0.58447265625\tThe conditions of the Marketing Authorisation are set out in Annex IV .', 'D-110\t-0.58447265625\tThe conditions of the Marketing Authorisation are set out in Annex IV.', 'P-110\t-0.7905 -0.0916 -0.4648 -0.1803 -0.6270 -0.0409 -0.1000 -0.2747 -0.0549 -0.3508 -0.0366 -0.0310 -0.0366 -0.0254 -0.0225 -0.0451 -0.0282', 'S-462\tLitvinovska 609 / 3 190 21 Praha 9 Tschechische Republik', 'T-462\tLitvinovska 609 / 3 190 21 Praha 9 Czech Republic', 'H-462\t-0.61767578125\tLithuania 609 / 3 190 21 Praha 9 Czech Republic', 'D-462\t-0.61767578125\tLithuania 609 / 3 190 21 Praha 9 Czech Republic', 'P-462\t-1.9961 -0.1268 -0.1409 -0.0324 -0.0268 -0.0296 -0.0366 -0.0197 -0.0211 -0.1733 -0.0338 -0.0409 -0.0211 -0.4058 -0.0310', 'S-880\tEU / 1 / 01 / 192 / 001-005 itte', 'T-880\tr EU / 1 / 01 / 192 / 001-005', 'H-880\t-0.325927734375\tEU / 1 / 01 / 192 / 001 @-@ 005', 'D-880\t-0.325927734375\tEU / 1 / 01 / 192 / 001-005', 'P-880\t-0.2195 -0.0701 -0.0627 -0.0292 -0.0285 -0.0278 -0.0183 -0.0292 -0.0285 -0.0257 -0.0285 -0.0342 -0.0183 -0.0257 -1.0088', 'S-991\tVenlafaxin wird in der Leber extensiv metabolisiert.', 'T-991\tVenlafaxine undergoes extensive hepatic metabolism.', 'H-991\t-0.393798828125\tVenlafaxine is extensively metabolised in the liver .', 'D-991\t-0.393798828125\tVenlafaxine is extensively metabolised in the liver.', 'P-991\t-0.0285 -0.0142 -0.0199 -0.0242 -0.0386 -0.0444 -0.1727 -0.0148 -0.0197 -0.0134 -0.7388 -0.8403 -0.0352 -0.0127 -0.0324 -0.0282', 'S-1328\tNobilis Influenza H7N1 ist ein Impfstoff.', 'T-1328\tNobilis Influenza H7N1 is a vaccine.', 'H-1328\t-0.1297607421875\tNobilis Influenza H7N1 is a vaccine .', 'D-1328\t-0.1297607421875\tNobilis Influenza H7N1 is a vaccine.', 'P-1328\t-0.0841 -0.0042 -0.0285 -0.2251 -0.0070 -0.0070 -0.0271 -0.0313 -0.0229 -0.0236 -0.0285 -0.0342 -0.0402 -0.0553 -0.0370 -0.0285', 'S-1527\tDie Verbindung mit Plasmaproteinen liegt bei 90-92%.', 'T-1527\tBinding to plasmatic proteins is about 90-92%.', 'H-1527\t-0.728515625\tPlasma protein binding is 90 @-@ 92 % .', 'D-1527\t-0.728515625\tPlasma protein binding is 90-92%.', 'P-1527\t-0.8262 -0.0106 -0.0169 -0.1338 -0.3135 -0.1444 -0.1803 -1.2598 -0.3833 -0.0141 -0.0366 -0.0479 -0.0282', 'S-1982\tWIE IST KOGENATE Bayer 250 I.E.', 'T-1982\tHOW TO USE KOGENATE Bayer 250 IU', 'H-1982\t-1.294921875\tHOW TO USE IT', 'D-1982\t-1.294921875\tHOW TO USE IT', 'P-1982\t-0.1068 -0.0085 -0.2856 -0.3152 -0.0088 -3.1172 -0.3213', 'S-100\tTél / Tel: + 32 (0) 2 735 45 34', 'T-100\tTél / Tel: + 32 (0) 2 735 45 34', 'H-100\t-0.166015625\tTél / Tel : + 32 ( 0 ) 2 735 45 34', 'D-100\t-0.166015625\tTél / Tel: + 32 (0) 2 735 45 34', 'P-100\t-0.2510 -0.0576 -0.0220 -0.0664 -0.1553 -0.0458 -0.0250 -0.0183 -0.0532 -0.0268 -0.0289 -0.0345 -0.0268 -0.0225 -0.0204 -0.0232 -0.0310', 'S-915\t79 RADIOLOGISCHE PROGRESSION:', 'T-915\t71 RADIOGRAPHIC PROGRESSION:', 'H-915\t-0.481201171875\t79 RADIOGRAPHIC PROGRESSION :', 'D-915\t-0.481201171875\t79 RADIOGRAPHIC PROGRESSION:', 'P-915\t-1.0215 -0.0500 -0.0120 -0.3228 -0.2803 -0.3184 -0.2352 -0.0395 -0.0268 -0.0197 -0.0240 -0.0197 -0.0113 -0.0437 -0.0859 -0.0282', 'S-1443\tNeoclarityn 0,5 mg / ml Sirup Desloratadin', 'T-1443\tNeoclarityn 0.5 mg / ml syrup desloratadine', 'H-1443\t-0.2049560546875\tNeoclarityn 0.5 mg / ml syrup desloratadine', 'D-1443\t-0.2049560546875\tNeoclarityn 0.5 mg / ml syrup desloratadine', 'P-1443\t-0.0306 -0.0306 -0.0127 -0.0327 -0.0170 -0.0270 -0.2551 -0.0063 -0.0327 -0.0127 -0.2744 -0.0141 -0.2388 -0.0042 -0.0240 -0.0641 -0.0521 -0.0317', 'S-1208\tVia Complutense 140 28805 Alcala de Henares Spanien', 'T-1208\tVia Compultense 140 28805 Alcala de Henares Spain', 'H-1208\t-0.1168212890625\tVia Complutense 140 28805 Alcala de Henares Spain', 'D-1208\t-0.1168212890625\tVia Complutense 140 28805 Alcala de Henares Spain', 'P-1208\t-0.0199 -0.0263 -0.0206 -0.0177 -0.0191 -0.0028 -0.0099 -0.0170 -0.0227 -0.0213 -0.0228 -0.0171 -0.0269 -0.0255 -0.0099 -0.0120 -0.3418 -0.0285', 'S-1182\tEinige dieser Reaktionen können schwerwiegend und möglicherweise letal sein (siehe 4.4).', 'T-1182\tSome of these reactions can be serious and potentially fatal (see 4.4).', 'H-1182\t-0.66748046875\tSome of these reactions can be serious and potentially fatal ( see 4.4 ) .', 'D-1182\t-0.66748046875\tSome of these reactions can be serious and potentially fatal (see 4.4).', 'P-1182\t-0.0371 -0.0385 -0.0444 -0.3889 -0.0127 -1.2256 -0.0268 -0.2494 -0.0479 -0.2339 -0.2563 -0.0324 -0.0310 -1.0381 -0.0282 -0.0310 -0.0310 -0.0282', 'S-1028\tPresent ation a) Form b) Dose c) Number of Presentations', 'T-1028\tPresent ation a) Form b) Dose c) Number of Presentations', 'H-1028\t-0.93994140625\tPresent a ) Form b ) Notice c ) Number of Presentations', 'D-1028\t-0.93994140625\tPresent a) Form b) Notice c) Number of Presentations', 'P-1028\t-0.0849 -0.5142 -0.3398 -0.0303 -0.0303 -0.0282 -0.0275 -2.3086 -0.8960 -0.0282 -0.0282 -0.3071 -0.0310 -0.4226 -0.0113 -0.0225 -0.0310', 'S-1021\tCorporation Eesti Pirita tee 20 10127 Tallinn Estland', 'T-1021\tCorporation Eesti Pirita tee 20 10127 Tallinn Estonia', 'H-1021\t-0.2685546875\tCorporation Eesti Pirita tee 20 10127 Tallinn Estonia', 'D-1021\t-0.2685546875\tCorporation Eesti Pirita tee 20 10127 Tallinn Estonia', 'P-1021\t-1.1055 -0.0345 -0.0148 -0.0247 -0.0155 -0.0085 -0.0268 -0.0204 -0.0268 -0.0240 -0.0204 -0.0254 -0.0282 -0.0141 -0.0070 -0.0817 -0.0155 -0.0282', 'S-273\t1,25 mg Tabletten 2,5 mg Tabletten N 2,5 mg Tabletten', 'T-273\t1,25 mg Tabletten 2,5 mg Tabletten N 2,5 mg Tabletten', 'H-273\t-0.74462890625\t1,25 mg tablets 2.5 mg tablets N 2.5 mg tablets', 'D-273\t-0.74462890625\t1,25 mg tablets 2.5 mg tablets N 2.5 mg tablets', 'P-273\t-0.8403 -0.0514 -0.0296 -0.1500 -0.0676 -1.6201 -0.0183 -0.0479 -0.0395 -0.5029 -0.3042 -0.0169 -0.0254 -0.0338 -0.0338', 'S-252\tAvda Barcelona 69 Sant Joan Despi ES-08970 Barcelona, Spanien', 'T-252\tAvda Barcelona 69 Sant Joan Despi ES-08970 Barcelona, Spain', 'H-252\t-0.07989501953125\tAvda Barcelona 69 Sant Joan Despi ES @-@ 08970 Barcelona , Spain', 'D-252\t-0.07989501953125\tAvda Barcelona 69 Sant Joan Despi ES-08970 Barcelona, Spain', 'P-252\t-0.1343 -0.0177 -0.0170 -0.0142 -0.0255 -0.0227 -0.0070 -0.0042 -0.0262 -0.0127 -0.0285 -0.0113 -0.0220 -0.0190 -0.0134 -0.0299 -0.0183 -0.0285', 'S-211\tNovartis Norge AS Postboks 237 Økern 0510 Oslo Norwegen', 'T-211\tNovartis Norge AS Postboks 237 Økern 0510 Oslo Norway', 'H-211\t-0.09661865234375\tNovartis Norge AS Postboks 237 Økern 0510 Oslo Norway', 'D-211\t-0.09661865234375\tNovartis Norge AS Postboks 237 Økern 0510 Oslo Norway', 'P-211\t-0.0113 -0.0099 -0.0263 -0.0156 -0.0227 -0.0099 -0.0213 -0.0256 -0.0184 -0.0235 -0.0148 -0.0113 -0.0007 -0.0070 -0.0241 -0.0063 -0.2688 -0.0292', 'S-1702\tKnochenmark-aplasie Disseminierte intravasale Koagulation', 'T-1702\tAplasia bone marrow Disseminated intravascular coagulation', 'H-1702\t-0.7509765625\tBone marrow aplasia Disseminated intravascular coagulation', 'D-1702\t-0.7509765625\tBone marrow aplasia Disseminated intravascular coagulation', 'P-1702\t-1.1582 -0.0197 -0.0859 -0.0092 -0.0240 -0.0141 -0.0254 -2.7129 -0.0028 -0.0254 -0.0310 -0.0113 -0.0225 -0.0225 -0.0225 -0.0197 -0.0169 -0.0310', 'S-1598\t2,5 ml (1,25 mg) Azomyr Lösung zum Einnehmen einmal täglich.', 'T-1598\t2.5 ml (1.25 mg) Azomyr oral solution once a day.', 'H-1598\t-0.280029296875\t2.5 ml ( 1.25 mg ) Azomyr oral solution once a day .', 'D-1598\t-0.280029296875\t2.5 ml (1.25 mg) Azomyr oral solution once a day.', 'P-1598\t-0.1219 -0.0371 -0.0313 -0.0530 -0.0372 -0.0262 -0.0299 -0.2434 -0.0183 -0.0451 -0.3223 -0.0951 -0.2197 -0.1459 -0.0275 -0.0479 -0.0310', 'S-1162\tOffene Atemwege und eine unterstützende oder kontrollierte Beatmung müssen sichergestellt werden.', 'T-1162\tA patent airway and assisted or controlled ventilation must be assured.', 'H-1162\t-0.99267578125\tEstablish a clear airway and supportive or controlled ventilation .', 'D-1162\t-0.99267578125\tEstablish a clear airway and supportive or controlled ventilation.', 'P-1162\t-0.8052 -0.3269 -0.0035 -0.5239 -1.4795 -0.2423 -0.0282 -0.0901 -1.4141 -0.0451 -0.0423 -0.0732 -0.0056 -0.0338 -0.0958 -0.0282', 'S-1054\tEU-Nummer EU / 1 / 05 / 315 / 001 / 001', 'T-1054\tEU number EU / 1 / 05 / 315 / 001 / 001', 'H-1054\t-0.333984375\tEU Number EU / 1 / 05 / 315 / 001 / 001', 'D-1054\t-0.333984375\tEU Number EU / 1 / 05 / 315 / 001 / 001', 'P-1054\t-0.3606 -1.0264 -0.0655 -0.0310 -0.0296 -0.0282 -0.0169 -0.0296 -0.0254 -0.0211 -0.0296 -0.0240 -0.0282 -0.0282 -0.0254 -0.0282 -0.0310', 'S-1051\tEs gibt keine Erfahrungen mit der Anwendung von EXUBERA bei schwangeren Frauen.', 'T-1051\tThere is no experience on the use of EXUBERA in pregnant women.', 'H-1051\t-0.673828125\tThere is limited experience with EXUBERA in pregnant women .', 'D-1051\t-0.673828125\tThere is limited experience with EXUBERA in pregnant women.', 'P-1051\t-0.1060 -0.0917 -1.6543 -0.0775 -0.6704 -0.3142 -0.0225 -0.0141 -0.0282 -0.1691 -0.0395 -0.0310 -0.0366 -0.0282', 'S-1031\tBei Erwachsenen erwiesen sich zwei Impfstoffdosen als genauso wirksam wie drei Dosen.', 'T-1031\tIn adults, two vaccine doses were shown to be as effective as three.', 'H-1031\t-0.6240234375\tIn adults , two vaccine doses were as effective as three doses .', 'D-1031\t-0.6240234375\tIn adults, two vaccine doses were as effective as three doses.', 'P-1031\t-0.5791 -0.0243 -0.0493 -0.0416 -0.4434 -0.0296 -0.0183 -0.4121 -0.9341 -0.0296 -0.0324 -0.5566 -0.0676 -0.0141 -0.0338 -0.0282', 'S-836\tThrombozytopenie, Neutropenie, Anämie', 'T-836\tthrombocytopenia, neutropenia, anaemia', 'H-836\t-0.4794921875\tthrombocytopenia , neutropenia , anaemia', 'D-836\t-0.4794921875\tthrombocytopenia, neutropenia, anaemia', 'P-836\t-1.6348 -0.0141 -0.0113 -0.0113 -0.0211 -0.0099 -0.0296 -0.0352 -0.4565 -0.0183 -0.0127 -0.0395 -0.0254 -0.2395 -0.0056 -0.0254 -0.0352', 'S-558\tEU / 1 / 02 / 212 / 018 50 Filmtabletten:', 'T-558\tEU / I / 02 / 212 / 018 50 tabs:', 'H-558\t-0.31689453125\tEU / I / 02 / 212 / 018 50 tabs :', 'D-558\t-0.31689453125\tEU / I / 02 / 212 / 018 50 tabs:', 'P-558\t-0.0767 -0.0357 -0.3223 -0.0320 -0.0278 -0.0299 -0.0349 -0.0236 -0.0313 -0.0402 -0.0243 -0.1532 -0.2832 -0.3198 -0.2064 -0.0310', 'S-1386\tDieser Effekt kann bei einer Dosis von 25 mg noch ausgeprägter sein.', 'T-1386\tThe effect may also be more pronounced at a 25 mg dose.', 'H-1386\t-1.451171875\tThis effect may be more pronounced with the dose of 25 mg .', 'D-1386\t-1.451171875\tThis effect may be more pronounced with the dose of 25 mg.', 'P-1386\t-1.0156 -0.0634 -0.5088 -0.2352 -0.9805 -0.8511 -0.0141 -1.1162 -1.2119 -0.6704 -0.0395 -0.0789 -0.0395 -0.5127 -0.0282', 'S-466\tImpfstoff zu der Natriumhydrogencarbonat-Lösung hinzufügen.', 'T-466\tAdd the vaccine to the sodium hydrogen carbonate solution.', 'H-466\t-0.48828125\tAdd the vaccine to the sodium hydrogen carbonate solution .', 'D-466\t-0.48828125\tAdd the vaccine to the sodium hydrogen carbonate solution.', 'P-466\t-0.2576 -1.3242 -0.0662 -0.1775 -0.0606 -0.0972 -0.0141 -0.1635 -0.0352 -0.0254 -0.0113 -0.0225 -0.1550 -0.0409 -0.0282', 'S-1873\tDie optimale Dosis beträgt für die Mehrzahl der Patienten 1 mg einmal täglich.', 'T-1873\tThe optimum dose is 1 mg once daily for most patients.', 'H-1873\t-0.5634765625\tThe optimum dose is 1 mg once daily for most patients .', 'D-1873\t-0.5634765625\tThe optimum dose is 1 mg once daily for most patients.', 'P-1873\t-0.0961 -0.5972 -0.0236 -0.1039 -0.2634 -0.4163 -0.0197 -0.0676 -0.4270 -0.0930 -0.5269 -0.0493 -0.0324 -0.0296', 'S-364\tWenn Sie die Einnahme von Glustin 45 mg Tabletten vergessen haben:', 'T-364\tIf you forget to take Glustin 45 mg tablets:', 'H-364\t-0.3955078125\tIf you forget to take Glustin 45 mg tablets :', 'D-364\t-0.3955078125\tIf you forget to take Glustin 45 mg tablets:', 'P-364\t-0.2986 -0.0313 -0.5884 -0.0641 -0.0218 -0.2522 -0.0077 -0.2360 -0.2141 -0.0296 -0.0775 -0.0338 -0.0423 -0.0296', 'S-499\tWenn Sie eine größere Menge von Zonegran eingenommen haben, als sie sollten', 'T-499\tIf you take more Zonegran than you should', 'H-499\t-0.44873046875\tIf you take more Zonegran than you should', 'D-499\t-0.44873046875\tIf you take more Zonegran than you should', 'P-499\t-0.5571 -0.0313 -0.3174 -0.2866 -0.1648 -0.0106 -0.0190 -0.0247 -0.0535 -0.0606 -0.0493 -0.4185', 'S-1718\tWIE IST INVEGA EINZUNEHMEN?', 'T-1718\tHOW TO TAKE INVEGA', 'H-1718\t-0.26806640625\tHOW TO TAKE INVEGA', 'D-1718\t-0.26806640625\tHOW TO TAKE INVEGA', 'P-1718\t-0.0313 -0.0127 -0.2942 -0.3203 -0.0546 -0.0109 -0.0254 -0.0282 -0.0240 -0.0141 -0.3142', 'S-1055\tWIE IST KIVEXA EINZUNEHMEN?', 'T-1055\tHOW TO TAKE KIVEXA', 'H-1055\t-0.28662109375\tHOW TO TAKE KIVEXA', 'D-1055\t-0.28662109375\tHOW TO TAKE KIVEXA', 'P-1055\t-0.0385 -0.0113 -0.2791 -0.3149 -0.0560 -0.0113 -0.1159 -0.0155 -0.0261 -0.0261 -0.3135', 'S-827\tWIE IST EVOLTRA ANZUWENDEN?', 'T-827\tHOW TO USE EVOLTRA', 'H-827\t-0.25634765625\tHOW TO USE EVOLTRA', 'D-827\t-0.25634765625\tHOW TO USE EVOLTRA', 'P-827\t-0.0400 -0.0113 -0.4502 -0.0676 -0.0127 -0.0828 -0.0257 -0.0155 -0.0310 -0.0247 -0.3191', 'S-705\tEin Behandlungseffekt wurde bereits nach Einnahme der ersten Dosis erzielt.', 'T-705\tA treatment effect was achieved after the first dose.', 'H-705\t-1.5380859375\tTreatment effect was obtained as early as after the first dose .', 'D-705\t-1.5380859375\tTreatment effect was obtained as early as after the first dose.', 'P-705\t-2.0371 -0.0254 -0.0282 -0.4016 -0.3113 -1.1777 -1.6709 -0.2311 -0.0282 -0.0845 -0.8677 -0.0901 -0.0451 -0.7832 -0.0282', 'S-528\tWIE IST NOVORAPID ANZUWENDEN?', 'T-528\tHOW TO USE NOVORAPID', 'H-528\t-0.38671875\tHOW TO USE NOVORAPID', 'D-528\t-0.38671875\tHOW TO USE NOVORAPID', 'P-528\t-0.0270 -0.0113 -0.6216 -0.5508 -0.0127 -0.0183 -0.0289 -0.0155 -0.0085 -0.0169 -0.3184', 'S-759\twieder zeitgerecht veröffentlicht und wurden auch über die Internet- Homepage der Agentur zugänglich gemacht.', 'T-759\tInternet web site.', 'H-759\t-2.248046875\tEuropean Community ( Directorate @-@ General for Enlargement and the IDA programme ) .', 'D-759\t-2.248046875\tEuropean Community (Directorate-General for Enlargement and the IDA programme).', 'P-759\t-2.0059 -0.5762 -0.3423 -3.6133 -0.0732 -0.0225 -0.2593 -0.0451 -0.4678 -1.3643 -0.2479 -0.1014 -1.3525 -0.9185 -0.4001 -0.5747 -0.3381 -0.1014 -0.7212 -0.0338', 'S-1242\tFollitropin alfa, entsprechend 33 Mikrogramm in 0,75 ml.', 'T-1242\tOne cartridge delivers 450 IU follitropin alfa, equivalent to 33 micrograms, per 0.75 ml.', 'H-1242\t-0.84326171875\tFollitropin alfa equivalent 33 micrograms in 0.75 ml .', 'D-1242\t-0.84326171875\tFollitropin alfa equivalent 33 micrograms in 0.75 ml.', 'P-1242\t-1.6484 -0.0254 -0.0451 -0.1409 -0.0254 -0.0211 -0.7959 -0.7017 -0.0310 -0.0789 -0.3157 -0.4902 -0.0282 -0.0282 -0.0451 -0.0310', 'S-1032\tDaten aus verschiedenen Studien belegen, dass insgesamt 95,5% bzw.', 'T-1032\tau studies show that, overall, 95.5% and 99.9% of subjects had anti-diphtheria and anti-tetanus titres ≥ 0.1 IU / ml one month after completion of the primary vaccination course.', 'H-1032\t-2.505859375\tData from several studies show that a total of 95.5 and 6.5 % of the 1164 patients respectively achieved a major cytogenetic response .', 'D-1032\t-2.505859375\tData from several studies show that a total of 95.5 and 6.5% of the 1164 patients respectively achieved a major cytogenetic response.', 'P-1032\t-1.0859 -0.0613 -1.2109 -0.1986 -0.9258 -0.0479 -1.8516 -0.0310 -0.0338 -0.0254 -0.0451 -1.6172 -1.5156 -0.1014 -1.5332 -0.8735 -0.5186 -0.3718 -0.4734 -0.3494 -0.9019 -0.9019 -0.2817 -0.3269 -0.3269 -0.3157 -0.3157 -0.3269 -2.6934 -0.0225', 'S-1781\t39 ANGABEN AUF DEM BEHÄLTNIS', 'T-1781\t37 PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING BOTTLE LABEL FOR ORAL SOLUTION', 'H-1781\t-1.0322265625\t36 PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING', 'D-1781\t-1.0322265625\t36 PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING', 'P-1781\t-1.5371 -0.3228 -0.2734 -0.1014 -0.3015 -0.2169 -0.2451 -0.3071 -0.3213 -0.2959 -0.1831 -0.2930 -0.2903 -0.0817 -0.8086 -0.2705 -0.0056 -0.0056 -0.1917 -0.3213 -0.3157 -0.0676 -0.0056 -0.3157 -0.0395', 'S-14\tVia Crosa, 86 28065 Cerano (NO) Italien', 'T-14\tTakeda Italia Farmaceutici S. p. A Via Crosa, 86 28065 Cerano (NO) Italy', 'H-14\t-0.145263671875\tVia Crosa , 86 28065 Cerano ( NO ) Italy', 'D-14\t-0.145263671875\tVia Crosa, 86 28065 Cerano (NO) Italy', 'P-14\t-0.3013 -0.0269 -0.0185 -0.0276 -0.0271 -0.0113 -0.0183 -0.0257 -0.0162 -0.0169 -0.0141 -0.0285 -0.0225 -0.1663 -0.0282 -0.0190 -0.0268', 'S-1898\t8 / 11 (72,7%) 8 / 15 (53,3%)', 'T-1898\t6 / 8 2 / 3', 'H-1898\t-1.0048828125\t8 / 11 ( 72.7 % )', 'D-1898\t-1.0048828125\t8 / 11 (72.7%)', 'P-1898\t-0.2729 -0.0306 -0.0306 -0.0278 -0.0271 -0.0250 -0.0257 -0.0292 -0.0299 -3.5000', 'S-1227\tAchten Sie sorgfältig auf die Anzeichen des erniedrigten Blutzuckers, insbesondere', 'T-1227\tWatch carefully for signs of low blood sugar, especially', 'H-1227\t-1.6015625\tNever drive or use machinery if you feel a hypo coming Me', 'D-1227\t-1.6015625\tNever drive or use machinery if you feel a hypo coming Me', 'P-1227\t-3.0117 -0.4143 -0.3325 -0.3494 -0.3691 -0.0395 -0.0310 -0.3467 -0.1775 -0.7158 -0.4114 -0.3213 -0.3157 -0.2761 -0.3213 -1.0654 -0.2705', 'S-1358\tRippengegend, Entzündung, die Bauchschmerzen oder Durchfall hervorruft', 'T-1358\tcauses abdominal pain or diarrhoea', 'H-1358\t-0.9052734375\tChest , inflammation causing abdominal pain or diarrhoea', 'D-1358\t-0.9052734375\tChest, inflammation causing abdominal pain or diarrhoea', 'P-1358\t-2.5234 -0.3169 -0.4902 -0.3269 -0.0141 -0.0282 -0.7637 -0.0732 -0.0056 -0.0169 -0.0310 -0.0479 -0.0282 -0.0085 -0.2197 -0.0113 -0.0507', 'S-1451\tIn Studien an trächtigen Tieren haben Interferone manchmal Fehlgeburten verursacht.', 'T-1451\tIn studies in pregnant animal, interferons have sometimes caused miscarriage.', 'H-1451\t-0.401611328125\tIn studies in pregnant animals , interferons have sometimes caused miscarriage .', 'D-1451\t-0.401611328125\tIn studies in pregnant animals, interferons have sometimes caused miscarriage.', 'P-1451\t-0.0722 -0.0516 -0.5171 -0.0243 -0.0927 -0.0641 -0.0359 -0.0134 -0.0331 -0.1521 -0.0909 -0.2106 -0.1324 -0.0155 -0.0099 -0.6987 -0.0324 -0.0282', 'S-1701\tIndustriepark 30 B-2220 Heist-op-den-Berg Belgien.', 'T-1701\tIndustriepark 30 B-2220 Heist-op-den-Berg Belgium.', 'H-1701\t-0.415283203125\tIndustriepark 30 B @-@ 2220 Heist @-@ op @-@ den @-@ Berg Belgium .', 'D-1701\t-0.415283203125\tIndustriepark 30 B-2220 Heist-op-den-Berg Belgium.', 'P-1701\t-1.0947 -0.0197 -0.0423 -0.5112 -0.0296 -0.0197 -0.0254 -0.0155 -0.0169 -0.0338 -0.0211 -0.0268 -0.0099 -0.0282 -0.0056 -0.0380 -0.3833 -0.0296', 'S-1751\t- diabetischer Ketoazidose oder diabetischem Präkoma', 'T-1751\t- diabetic ketoacidosis or diabetic pre-coma', 'H-1751\t-0.3515625\t- diabetic ketoacidosis or diabetic pre @-@ coma', 'D-1751\t-0.3515625\t- diabetic ketoacidosis or diabetic pre-coma', 'P-1751\t-0.0916 -0.9150 -0.0070 -0.0254 -0.0225 -0.0345 -0.0035 -0.0085 -0.0197 -0.0345 -0.0345 -0.0113 -0.0225 -0.3022 -0.0352 -0.0338 -0.0310 -0.3579', 'S-68\tSucralose Butylhydroxyanisol Macrogol 400', 'T-68\tSucralose Butylated hydroxyanisole Macrogol 400', 'H-68\t-0.425537109375\tSucralose Butylhydroxyanisole Macrogol 400', 'D-68\t-0.425537109375\tSucralose Butylhydroxyanisole Macrogol 400', 'P-68\t-0.2927 -0.0127 -0.0227 -0.0127 -0.4001 -0.4297 -0.0085 -0.0247 -0.0240 -0.0331 -0.0162 -0.2937 -0.7227 -0.0197 -0.0211 -0.0197 -0.0254 -0.0296', 'S-716\tDie Ausscheidung von Dibotermin alfa wurde am Tier nicht untersucht.', 'T-716\tThe excretion of dibotermin alfa has not been studied in animals.', 'H-716\t-0.58984375\tExcretion of dibotermin alfa has not been studied in animals .', 'D-716\t-0.58984375\tExcretion of dibotermin alfa has not been studied in animals.', 'P-716\t-1.4004 -0.0099 -0.0324 -0.0423 -0.2776 -0.2690 -0.0225 -0.2944 -0.0296 -0.0127 -0.2352 -0.0366 -0.0268 -0.2776 -0.1353 -0.1775 -0.0338 -0.0282', 'S-471\tZonegran 100 mg Hartkapseln enthalten 100 mg Zonisamid.', 'T-471\tZonegran 100 mg hard capsules contain 100 mg zonisamide.', 'H-471\t-0.390869140625\tZonegran 100 mg hard capsules contain 100 mg zonisamide .', 'D-471\t-0.390869140625\tZonegran 100 mg hard capsules contain 100 mg zonisamide.', 'P-471\t-0.0886 -0.0141 -0.0163 -0.0255 -0.0393 -0.0241 -0.1383 -0.0856 -0.0134 -0.0285 -0.0648 -0.0204 -0.0141 -1.1084 -0.0704 -0.0169 -0.0127 -0.0310 -0.5171 -0.0296', 'S-1577\tKinder Zerene ist für Kinder kontraindiziert (siehe Abschnitt 4.3).', 'T-1577\tPaediatric patients Zerene is contraindicated in children (see section 4.3).', 'H-1577\t-0.705078125\tLansoprazole is contraindicated in children ( see section 4.3 ) .', 'D-1577\t-0.705078125\tLansoprazole is contraindicated in children (see section 4.3).', 'P-1577\t-1.3350 -0.3220 -0.9243 -0.2395 -0.1437 -0.0113 -0.0085 -0.2986 -0.1888 -0.0366 -0.0479 -0.1353 -0.0366 -0.0366 -0.0366 -0.0310 -0.0282', 'S-1894\tKlinische Erfolgsraten bei Oropharyngealer Candidose Endpunkt', 'T-1894\tClinical success rates in Oropharyngeal Candidiasis Endpoint', 'H-1894\t-1.123046875\tClinical success in Oropharyngeal Candididiasis Outcome Events', 'D-1894\t-1.123046875\tClinical success in Oropharyngeal Candididiasis Outcome Events', 'P-1894\t-0.6206 -0.0169 -0.1282 -1.2051 -0.9424 -0.0254 -0.0141 -0.0197 -0.0113 -0.0254 -0.0338 -0.7383 -0.1578 -0.1691 -0.6987 -0.2537 -0.0254 -0.9102 -0.1465 -0.6255 -0.2085', 'S-94\t59,4 (326 / 549) 54,0; 64,8', 'T-94\t38.6 (549 / 1,423) 59.4 (326 / 549) 54.0,64.8', 'H-94\t-0.282470703125\t59.4 ( 326 / 549 ) 54.0 , 64.8', 'D-94\t-0.282470703125\t59.4 (326 / 549) 54.0, 64.8', 'P-94\t-0.3049 -0.4170 -0.0395 -0.0331 -0.0268 -0.0204 -0.0282 -0.0225 -0.0134 -0.0296 -0.1993 -0.0169 -0.0240 -0.3206 -0.0268 -0.0183 -0.0268 -0.0324', 'S-657\tFür Patienten > 120 kg, 80 μg / 0,5 ml Durchstechflaschen benutzen', 'T-657\tMinimum delivery for pen is 0.3 ml. * * For patients > 120 kg, use 80 μg / 0.5 ml vial', 'H-657\t-0.98291015625\tFor patients &gt; 120 kg , 80 μg / 0.5 ml vials .', 'D-657\t-0.98291015625\tFor patients > 120 kg, 80 μg / 0.5 ml vials.', 'P-657\t-0.8228 -0.2318 -0.0690 -0.4263 -0.0282 -0.0690 -0.3804 -1.1543 -0.0282 -0.0338 -0.4226 -0.0197 -0.1521 -0.4790 -0.8286 -0.0423', 'S-260\tZinkchlorid, m-Cresol, Glycerol,', 'T-260\t- The other ingredients of Optisulin are: zinc chloride, m-cresol, glycerol, sodium hydroxide,', 'H-260\t-0.7041015625\tZinc chloride , m @-@ cresol , glycerol ,', 'D-260\t-0.7041015625\tZinc chloride, m-cresol, glycerol,', 'P-260\t-2.7500 -0.0240 -0.0564 -0.0197 -0.0211 -0.0225 -0.0310 -0.0451 -0.0282 -0.0423 -0.0169 -0.0225 -0.0310 -0.0310 -0.0141 -0.0141 -0.0141 -0.0479 -0.8877', 'S-215\tActivelle 0,5 mg / 0,1 mg compresse film- rivestite', 'T-215\tActivelle 0,5 mg / 0,1 Estradiol (as hemihydrate) 0.5 mg Film-coated tablets Oral use mg compresse film- + Norethisterone acetate 0.1 mg rivestite', 'H-215\t-0.7275390625\tActivelle 0.5 mg / 0.1 mg compresse film rivestite', 'D-215\t-0.7275390625\tActivelle 0.5 mg / 0.1 mg compresse film rivestite', 'P-215\t-0.0349 -0.0106 -0.0127 -1.1504 -0.0085 -0.0303 -0.0225 -0.0472 -0.0197 -0.5112 -0.0366 -0.0873 -1.3359 -0.5635 -0.0592 -0.0225 -0.0310', 'S-696\t0,07 - 0,18 µM (42 - 108 ng / ml).', 'T-696\tTipranavir inhibits the replication of laboratory strains of HIV-1 and clinical isolates in acute models of T-cell infection, with 50% and 90% effective concentrations (EC50 and EC90) ranging from 0.03 to 0.07 µM (18-42 ng / ml) and 0.07 to 0.18 µM (42-108 ng / ml), respectively.', 'H-696\t-0.62109375\t0.07 @-@ 0.18 µM ( 42 @-@ 108 ng / ml ) .', 'D-696\t-0.62109375\t0.07-0.18 µM (42-108 ng / ml).', 'P-696\t-0.7148 -0.2998 -0.6113 -0.0240 -0.0380 -0.0211 -0.0268 -0.0296 -0.0211 -0.6987 -0.6030 -0.0141 -0.0225 -0.0310 -0.0225 -0.0310 -0.2817 -0.0282', 'S-1766\t1 A Pharma GmbH Keltenring 1 + 3 82041 Oberhaching Germany', 'T-1766\t1 A Pharma GmbH Keltenring 1 + 3 82041 Oberhaching Germany', 'H-1766\t-1.06640625\t1 A Pharma GmbH Keltenring 1 + 3 82041 Oberhaching Germany', 'D-1766\t-1.06640625\t1 A Pharma GmbH Keltenring 1 + 3 82041 Oberhaching Germany', 'P-1766\t-2.1074 -0.3564 -0.0254 -0.0127 -0.0310 -3.3613 -0.0282 -0.0225 -0.0338 -0.0338 -0.0282 -0.0282 -0.0282 -0.0225 -0.0169 -0.0225 -0.0225 -0.0282 -0.0282', 'S-517\tIn klinischen Studien wurde PROCOMVAX im Allgemeinen gut vertragen.', 'T-517\tPROCOMVAX has been generally well tolerated in clinical trials.', 'H-517\t-0.59228515625\tIn clinical studies , PROCOMVAX was generally well tolerated .', 'D-517\t-0.59228515625\tIn clinical studies, PROCOMVAX was generally well tolerated.', 'P-517\t-0.8423 -0.0486 -0.6699 -0.2620 -0.1141 -0.0183 -0.0211 -0.0268 -0.0268 -0.0282 -0.0183 -1.0479 -0.0704 -0.0564 -0.0197 -0.0254 -0.0310 -0.0282', 'S-556\tDie Auflage soll mindestens einmal täglich gewechselt werden, um die Wunde feucht zu halten.', 'T-556\tThe dressing should be changed at least once a day to keep the wound moist.', 'H-556\t-1.13671875\tThe bandage should be changed at least once daily to protect from moisture .', 'D-556\t-1.13671875\tThe bandage should be changed at least once daily to protect from moisture.', 'P-556\t-1.1113 -2.0664 -0.0338 -0.1042 -0.0310 -0.6030 -0.2227 -0.0254 -0.0338 -0.8594 -0.3157 -0.3213 -0.3184 -0.2197 -0.0395 -0.0338 -0.0732 -0.0282', 'S-1095\t- Wenn Ihnen übel ist oder Sie Diarrhöe (Durchfall) haben,', 'T-1095\t- If you feel sick or have diarrhoea (loose bowels);', 'H-1095\t-1.607421875\t- If you feel unwell or have diarrhoea ,', 'D-1095\t-1.607421875\t- If you feel unwell or have diarrhoea,', 'P-1095\t-0.0759 -0.7300 -0.8032 -1.4170 -0.7324 -0.5156 -0.0479 -0.9722 -0.0338 -0.0056 -0.2029 -0.0169 -0.6001 -1.6797', 'S-1148\t48 Die Sicherheitshülse schiebt sich über die Nadel und rastet ein.', 'T-1148\tThe needle safety cover will move down over the needle and lock into place.', 'H-1148\t-1.181640625\tThe needle safety cover will move down over the needle and lock into place .', 'D-1148\t-1.181640625\tThe needle safety cover will move down over the needle and lock into place.', 'P-1148\t-2.4199 -0.7495 -0.0282 -0.3325 -0.5352 -0.4932 -0.3381 -0.6455 -0.2791 -0.0451 -0.0676 -0.0282 -0.0620 -0.2930 -0.2423 -0.0732 -0.0338 -0.0282', 'S-1868\tDies könnte auf eine Induktion des Bupropion-Abbaus zurückzuführen sein.', 'T-1868\tThis effect may be due to induction of bupropion metabolism.', 'H-1868\t-0.87841796875\tThis could be due to induction of bupropion metabolism .', 'D-1868\t-0.87841796875\tThis could be due to induction of bupropion metabolism.', 'P-1868\t-0.8672 -1.1123 -0.0423 -0.8916 -0.0282 -0.3240 -0.0225 -0.0310 -0.1099 -0.0225 -0.0141 -0.0366 -1.1416 -0.0197 -0.0817 -0.0338 -0.0282', 'S-23\tEMEND kann Auswirkungen auf andere Arzneimittel sowohl während als auch nach der Behandlung haben.', 'T-23\tEMEND can affect other medicines both during and after treatment with EMEND.', 'H-23\t-0.6669921875\tEMEND can affect other medicines both during and after treatment .', 'D-23\t-0.6669921875\tEMEND can affect other medicines both during and after treatment.', 'P-23\t-0.0199 -0.0270 -0.0163 -0.9624 -0.4607 -0.0352 -0.0549 -0.5269 -0.4565 -0.0380 -0.1859 -0.1945 -0.3467 -0.0338 -0.0282', 'S-129\tDie Ausscheidung von Filgrastim in die Milch wurde nicht an Tieren untersucht.', 'T-129\tThe excretion of filgrastim in milk has not been studied in animals.', 'H-129\t-0.421630859375\tThe excretion of filgrastim in milk has not been studied in animals .', 'D-129\t-0.421630859375\tThe excretion of filgrastim in milk has not been studied in animals.', 'P-129\t-0.8657 -0.2430 -0.0056 -0.0373 -0.0310 -0.0247 -0.0289 -0.0881 -0.0282 -0.2522 -0.0930 -0.2255 -0.0324 -0.0268 -0.2352 -0.1353 -0.0549 -0.0310 -0.0282', 'S-853\t4.10 Überdosierung (Symptome, Notfallmaßnahmen, Gegenmittel), falls erforderlich ke', 'T-853\t4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary tin', 'H-853\t-0.6923828125\t4.10 Overdose ( symptoms , emergency procedures , antidotes ) , if necessary', 'D-853\t-0.6923828125\t4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary', 'P-853\t-1.0811 -0.2727 -0.0859 -0.1578 -0.0352 -0.3086 -0.0296 -0.0437 -0.3184 -0.0352 -0.0873 -0.0240 -0.1409 -0.0352 -0.2466 -0.1042 -0.0873 -0.8286', 'S-1202\tDie Gabe von Janumet in Kombination mit Insulin wurde nicht ausreichend untersucht.', 'T-1202\tThe use of Janumet in combination with insulin has not been adequately studied.', 'H-1202\t-0.388916015625\tThe use of Janumet in combination with insulin has not been adequately studied .', 'D-1202\t-0.388916015625\tThe use of Janumet in combination with insulin has not been adequately studied.', 'P-1202\t-0.2544 -0.5239 -0.0282 -0.0204 -0.0169 -0.0225 -0.0542 -0.0225 -0.0289 -0.0169 -0.0099 -0.2128 -0.0472 -0.0402 -0.6211 -0.0183 -0.2776 -0.0310 -0.0282', 'S-1287\tBei Hühnern und Truthühnern wurden keine Nebenwirkungen durch Dicural festgestellt.', 'T-1287\tIn chickens and turkeys, no side effects from Dicural are known.', 'H-1287\t-1.1875\tThere were no adverse events in chickens and turkeys due to Dicural .', 'D-1287\t-1.1875\tThere were no adverse events in chickens and turkeys due to Dicural.', 'P-1287\t-1.8779 -0.3381 -0.0352 -0.2507 -0.0056 -0.8174 -1.3359 -0.3296 -0.0085 -0.0225 -0.1353 -0.0225 -0.0113 -1.5332 -0.0282 -0.2817 -0.0169 -0.0451 -0.0451 -0.0282', 'S-1320\tIm Falle einer Überdosierung ist der Patient zu beobachten und angemessen supportiv zu versorgen.', 'T-1320\tIn the event of overdose, the patient should be observed and appropriate supportive treatment given.', 'H-1320\t-1.5078125\tIn the event of an overdose , the patient should be monitored and treated appropriately .', 'D-1320\t-1.5078125\tIn the event of an overdose, the patient should be monitored and treated appropriately.', 'P-1320\t-0.8501 -0.9448 -0.1395 -0.0296 -1.1582 -0.0225 -0.0169 -0.7046 -0.1917 -0.0197 -1.0312 -0.0338 -1.0283 -0.0225 -0.5581 -1.7246 -0.4678 -0.0225 -0.1014 -0.0282', 'S-1392\t5 x 3 ml Humalog Mix50 Patronen für einen 3 ml Pen.', 'T-1392\t5 x 3 ml Humalog Mix50 cartridges for a 3 ml pen.', 'H-1392\t-0.188232421875\t5 x 3 ml Humalog Mix50 cartridges for a 3 ml pen .', 'D-1392\t-0.188232421875\t5 x 3 ml Humalog Mix50 cartridges for a 3 ml pen.', 'P-1392\t-0.3625 -0.0183 -0.0518 -0.0148 -0.0546 -0.0106 -0.0648 -0.0409 -0.0257 -0.0824 -0.0070 -0.0247 -0.0338 -0.0944 -0.0578 -0.0169 -0.0521 -0.0592 -0.0296', 'S-1521\tVeränderungen des Kalziumstoffwechsels wurden in klinischen Studien am Menschen nicht untersucht.', 'T-1521\tAlterations in calcium metabolism have not been examined in human clinical studies.', 'H-1521\t-0.78173828125\tChanges in calcium metabolism have not been studied in human clinical trials .', 'D-1521\t-0.78173828125\tChanges in calcium metabolism have not been studied in human clinical trials.', 'P-1521\t-0.8735 -0.0183 -0.0254 -0.2021 -0.5542 -0.0141 -0.0211 -0.0282 -0.0113 -0.0240 -0.7720 -0.0338 -0.0240 -0.7114 -0.0366 -0.4592 -0.0395 -0.8115 -0.0310 -0.0282', 'S-49\t- Der dosislimitierende Parasit war nicht angegeben bzw. ausgewählt worden.', 'T-49\t- The dose-limiting parasite had not been specified or selected.', 'H-49\t-1.3115234375\t- The dose @-@ limiting parasite had not been presented or selected .', 'D-49\t-1.3115234375\t- The dose-limiting parasite had not been presented or selected.', 'P-49\t-0.3169 -1.9512 -0.0296 -0.8413 -0.0592 -0.0254 -0.0225 -0.0085 -0.1268 -0.5581 -0.0366 -0.0338 -1.6738 -0.4875 -0.9297 -0.0507 -0.0282', 'S-4\tWelche Risiken sind mit Poulvac FluFend H5N3 RG verbunden?', 'T-4\tWhat is the risk associated with Poulvac FluFend H5N3 RG?', 'H-4\t-0.1619873046875\tWhat is the risk associated with Poulvac FluFend H5N3 RG ?', 'D-4\t-0.1619873046875\tWhat is the risk associated with Poulvac FluFend H5N3 RG?', 'P-4\t-0.0590 -0.3062 -0.0391 -0.0729 -0.1134 -0.0320 -0.0581 -0.0127 -0.0042 -0.0113 -0.0285 -0.0261 -0.0296 -0.0240 -0.0254 -0.0282 -0.0268 -0.0169 -0.0345 -0.0289', 'S-483\t- wenn Sie eine Lebererkrankung oder erhöhte Blutspiegel einiger Leberenzyme', 'T-483\t- if you have any liver disease or increased blood levels of some enzymes of the liver', 'H-483\t-0.892578125\t- if you have liver disease or increased blood levels of some liver enzymes', 'D-483\t-0.892578125\t- if you have liver disease or increased blood levels of some liver enzymes', 'P-483\t-0.3311 -0.7134 -0.0268 -0.3220 -0.7188 -0.0268 -0.0366 -0.5327 -0.2169 -0.5269 -0.0395 -0.4875 -0.0225 -0.0113 -0.0197 -0.0254 -0.8286', 'S-579\tKörperoberfläche * (m ²) 0,25 0,50 1,00 1,25 1,50', 'T-579\tBody Surface area * (m ²) 0.25 0.50 1.00 1.25 1.50', 'H-579\t-0.62744140625\tBody surface area * ( m2 ) 0.25 0.50 1.00 1.25 1.50', 'D-579\t-0.62744140625\tBody surface area * (m2) 0.25 0.50 1.00 1.25 1.50', 'P-579\t-0.1624 -0.0916 -0.4731 -0.0268 -0.0261 -0.7417 -0.0296 -0.3157 -0.0282 -0.2676 -0.0240 -0.6284 -0.0240 -0.5059 -0.0282 -0.1240 -0.0282 -0.0282', 'S-1150\tStillzeit Während Sie Panretin anwenden, dürfen Sie Ihr Baby nicht stillen.', 'T-1150\tBreast-feeding Do not breast-feed your baby while you are using Panretin.', 'H-1150\t-0.98193359375\tBreast @-@ feeding Do not breast @-@ feed your baby while using Panretin .', 'D-1150\t-0.98193359375\tBreast-feeding Do not breast-feed your baby while using Panretin.', 'P-1150\t-0.0841 -0.3135 -0.1941 -0.0141 -1.5840 -0.0282 -0.5127 -0.0676 -0.0127 -0.8945 -0.0338 -0.5103 -1.0000 -0.1888 -0.0225 -0.0113 -0.0592 -0.0310', 'S-1504\tSonstiger Bestandteil: enthält ebenfalls 20 mg Aspartam (E951).', 'T-1504\tExcipient: also contains 20 mg of aspartame (E951).', 'H-1504\t-0.90234375\tExcipient Contains 20 mg aspartame ( E951 ) .', 'D-1504\t-0.90234375\tExcipient Contains 20 mg aspartame (E951).', 'P-1504\t-2.8008 -0.3213 -0.0197 -0.0282 -0.5918 -0.1465 -0.5269 -0.0225 -0.1353 -0.0028 -0.0225 -0.0592 -0.0479 -0.0282 -0.0169 -0.0310 -0.2791 -0.0310', 'S-1212\tDexamethason wurde 30 Minuten vor Beginn der Chemotherapie an Tag 1 gegeben.', 'T-1212\tDexamethasone was administered 30 minutes prior to chemotherapy treatment on Day 1.', 'H-1212\t-0.73388671875\tDexamethasone was administered 30 minutes prior to chemotherapy treatment on Day 1 .', 'D-1212\t-0.73388671875\tDexamethasone was administered 30 minutes prior to chemotherapy treatment on Day 1.', 'P-1212\t-0.1632 -0.0085 -0.0114 -0.0276 -0.0141 -0.1420 -0.6646 -0.0190 -0.0578 -0.0247 -0.9565 -0.0282 -0.3101 -0.0141 -0.0197 -0.6128 -0.6338 -0.7607 -0.0338 -0.0310 -0.0282', 'S-1206\tTorrex Chiesi Pharma Gmbh Gonzagagasse 16 / 16', 'T-1206\tTorrex Chiesi Pharma Gmbh Gonzagagasse 16 / 16 1010 Vienna Austria', 'H-1206\t-0.468505859375\tTorrex Chiesi Pharma Gmbh Gonagagasse 16 / 16', 'D-1206\t-0.468505859375\tTorrex Chiesi Pharma Gmbh Gonagagasse 16 / 16', 'P-1206\t-0.0700 -0.0306 -0.0263 -0.0142 -0.0213 -0.0256 -0.0171 -0.0185 -0.2427 -0.0155 -0.0243 -1.6934 -0.0916 -0.0845 -0.2227 -0.0423 -0.0310 -0.0366 -0.0324', 'S-1230\tSie ist zu verwerfen, wenn sie Partikel enthält oder verfärbt ist.', 'T-1230\tThe product should be discarded before use if it contains particulate matter or is discoloured.', 'H-1230\t-0.83349609375\tDiscard the product before use if it contains particles or is discoloured .', 'D-1230\t-0.83349609375\tDiscard the product before use if it contains particles or is discoloured.', 'P-1230\t-0.3716 -0.2778 -0.3015 -0.3232 -0.8926 -0.2676 -0.1226 -0.4832 -0.0901 -0.0676 -1.0088 -0.0423 -0.1859 -0.0564 -0.0197 -0.1437 -0.0366 -0.0282', 'S-1556\tNehmen Sie Efexor jeden Tag etwa zur gleichen Zeit morgens und abends ein.', 'T-1556\tTake Efexor at approximately the same time each day, in the morning and in the evening.', 'H-1556\t-1.0302734375\tTake Efexor at about the same time each day , morning and evening .', 'D-1556\t-1.0302734375\tTake Efexor at about the same time each day, morning and evening.', 'P-1556\t-0.5874 -0.2255 -0.0282 -0.0155 -0.0275 -0.2922 -1.4570 -0.0338 -0.0254 -0.1917 -0.9678 -0.1268 -0.8115 -0.8511 -0.0366 -0.0930 -0.0338 -0.0282', 'S-1769\tHumira ist auch als Fertigspritze oder als vorgefüllter Pen erhältlich.', 'T-1769\tHumira is also available as a pre-filled syringe or a pre-filled pen.', 'H-1769\t-0.3193359375\tHumira is also available as a pre @-@ filled syringe or a pre @-@ filled pen .', 'D-1769\t-0.3193359375\tHumira is also available as a pre-filled syringe or a pre-filled pen.', 'P-1769\t-0.0678 -0.0241 -0.0156 -0.0415 -0.0386 -0.0285 -0.5981 -0.1564 -0.1345 -0.0282 -0.0240 -0.2233 -0.0085 -0.0028 -0.0578 -0.3042 -0.1479 -0.0282 -0.0169 -0.0296 -0.0352 -0.0282', 'S-1861\tFür die Chargenfreigabe verantwortlicher Hersteller Pfizer Italia s.r.l.', 'T-1861\tManufacturing Authorisation Holder Responsible for Batch Release Pfizer Italia s. r. l.', 'H-1861\t-0.7021484375\tManufacturer responsible for batch release Responsible for batch release Pfizer Italia s.r.l .', 'D-1861\t-0.7021484375\tManufacturer responsible for batch release Responsible for batch release Pfizer Italia s.r.l.', 'P-1861\t-0.1766 -0.0141 -0.6367 -0.0507 -1.1543 -0.0296 -0.0634 -0.0268 -0.1986 -0.8130 -0.0310 -0.0704 -0.2847 -0.0395 -0.1775 -0.0648 -0.0141 -0.0113 -0.0282 -0.8286 -0.0197 -0.0254 -0.0254 -0.0310 -0.0282', 'S-789\tNehmen Sie einmal täglich eine Tablette ein, jeweils etwa zur gleichen Tageszeit.', 'T-789\tTake one tablet once a day, at about the same time each day Take the tablet with a glass of water.', 'H-789\t-0.59033203125\tTake one tablet once a day , at about the same time each day .', 'D-789\t-0.59033203125\tTake one tablet once a day, at about the same time each day.', 'P-789\t-0.2500 -0.8750 -0.0599 -0.0225 -0.1240 -0.5947 -0.0296 -0.1874 -0.1803 -0.4241 -0.0296 -0.0268 -0.0324 -0.3030 -0.0310 -0.0338 -0.0282', 'S-1493\tNephrotoxizitätsrisiko von NSAR bei dehydrierten Patienten erhöhen.', 'T-1493\t- anticoagulants: ibuprofen may increase the effect of anticoagulants and enhance the risk of', 'H-1493\t-1.04296875\trisk of nephrotoxicity of NSAIDs in dehydrated patients .', 'D-1493\t-1.04296875\trisk of nephrotoxicity of NSAIDs in dehydrated patients.', 'P-1493\t-2.3516 -0.5225 -0.1014 -0.0395 -0.0113 -0.0056 -0.0282 -0.0141 -0.0254 -1.0938 -0.0113 -0.0085 -0.0423 -0.0592 -0.6226 -0.0169 -0.0254 -0.3240 -0.9639 -0.0282', 'S-1819\tVigabatrin darf während der Schwangerschaft nur wenn unbedingt notwendig eingenommen werden.', 'T-1819\tVigabatrin should only be used during pregnancy if clearly necessary.', 'H-1819\t-0.7626953125\tVigabatrin should be used during pregnancy only if clearly necessary .', 'D-1819\t-0.7626953125\tVigabatrin should be used during pregnancy only if clearly necessary.', 'P-1819\t-0.3118 -0.0162 -0.0285 -0.0243 -0.0292 -0.7476 -0.2247 -0.3452 -0.5635 -0.0268 -0.0324 -0.1324 -1.1553 -0.3296 -0.0310 -0.0282', 'S-1268\tWIE IST TAMIFLU EINZUNEHMEN?', 'T-1268\tHOW TO TAKE TAMIFLU', 'H-1268\t-1.048828125\tHOW TO TAMIFLU', 'D-1268\t-1.048828125\tHOW TO TAMIFLU', 'P-1268\t-0.0378 -0.0106 -0.2703 -0.3047 -2.8770 -0.0423 -0.0282 -0.0282 -0.3213', 'S-1846\tWIE IST TESAVEL EINZUNEHMEN?', 'T-1846\tHOW TO TAKE TESAVEL', 'H-1846\t-1.3251953125\tHOW TO TESAVEL', 'D-1846\t-1.3251953125\tHOW TO TESAVEL', 'P-1846\t-0.0480 -0.0099 -0.2764 -0.3032 -3.9316 -0.0254 -0.0225 -0.0141 -0.3213', 'S-401\t- Informieren Sie Ihren Arzt, wenn sich bei Ihnen ein Hautausschlag entwickelt.', 'T-401\t- Tell your doctor if you develop a rash.', 'H-401\t-0.681640625\t- Tell your doctor if you develop a rash .', 'D-401\t-0.681640625\t- Tell your doctor if you develop a rash.', 'P-401\t-0.7100 -0.2205 -0.0176 -0.0352 -0.0366 -0.0535 -0.1691 -0.4846 -0.2043 -0.9932 -0.0141 -0.2057 -0.0310', 'S-1545\tÄndern Sie nicht Ihre Dosis, ohne dass Ihr Arzt es Ihnen vorgeschrieben hat.', 'T-1545\tDo not change your dose unless your doctor has told you to.', 'H-1545\t-0.8173828125\tDo not change your dose without the advice of your doctor .', 'D-1545\t-0.8173828125\tDo not change your dose without the advice of your doctor.', 'P-1545\t-0.7427 -0.0261 -0.0373 -0.7383 -0.0268 -0.7622 -0.6001 -0.3157 -0.0507 -0.0310 -0.4087 -0.0338 -0.0338', 'S-1826\tDaher sind Patienten, die sich einer Operation unterziehen müssen, sorgfältig zu untersuchen.', 'T-1826\tTherefore, patients undergoing surgery should be carefully evaluated.', 'H-1826\t-1.0634765625\tTherefore , patients undergoing surgery should be evaluated carefully .', 'D-1826\t-1.0634765625\tTherefore, patients undergoing surgery should be evaluated carefully.', 'P-1826\t-0.7334 -0.0183 -0.4812 -0.6934 -0.7622 -0.0225 -0.4087 -0.6875 -0.0395 -0.9185 -0.0225 -0.1099 -0.2563 -0.0282', 'S-548\tIn manchen Fällen kann die Herbeiführung eines positiven Atemwegsdrucks erforderlich sein.', 'T-548\tInstitution of positive-airway pressure may be necessary in some cases.', 'H-548\t-1.3427734375\tIn some cases hypertension may be necessary .', 'D-548\t-1.3427734375\tIn some cases hypertension may be necessary.', 'P-548\t-0.8003 -0.0458 -0.2106 -1.6738 -1.1416 -0.3269 -0.0760 -0.9438 -0.0958 -0.0310', 'S-684\tDer Inhaber der Genehmigung für das Inverkehrbringen ist Beaufour Ipsen Pharma.', 'T-684\tThe marketing authorisation holder is Beaufour Ipsen Pharma.', 'H-684\t-0.429443359375\tThe marketing authorisation holder is Beaufour Ipsen Pharma .', 'D-684\t-0.429443359375\tThe marketing authorisation holder is Beaufour Ipsen Pharma.', 'P-684\t-0.3328 -0.3196 -0.0768 -0.0268 -0.0782 -0.0380 -0.6592 -0.0028 -0.0254 -0.0056 -0.0197 -0.0197 -0.0127 -0.5342 -0.0282', 'S-1389\tLamictal 50 mg, 50 mg comprime dispersible ou a croquer', 'T-1389\t50 mg, comprimé dispersible ou à 50 mg', 'H-1389\t-0.89794921875\tLamictal 50 mg , 50 mg comprime dispersible or à croquet', 'D-1389\t-0.89794921875\tLamictal 50 mg, 50 mg comprime dispersible or à croquet', 'P-1389\t-1.4805 -0.0183 -0.0113 -0.0254 -0.0352 -0.0113 -0.0324 -0.0296 -0.0155 -0.0296 -0.3381 -0.2649 -0.0197 -0.0141 -0.8018 -0.5859 -1.1865 -0.3213 -0.0338', 'S-1768\tIn den meisten Fällen sind diese Nebenwirkungen von gering- bis mittelgradiger Schwere.', 'T-1768\tThe majority of these reactions are mild to moderate in severity.', 'H-1768\t-1.4306640625\tIn most cases , these side effects are mild to moderate .', 'D-1768\t-1.4306640625\tIn most cases, these side effects are mild to moderate.', 'P-1768\t-0.7158 -0.3057 -0.6904 -0.3960 -0.4170 -1.4199 -0.3352 -0.0676 -0.5269 -0.3718 -0.1127 -1.2793 -0.0282', 'S-924\tFirazyr wird immer von Ihrem Arzt oder einer Krankenschwester injiziert.', 'T-924\tFirazyr will always be injected by your doctor or nurse.', 'H-924\t-0.47509765625\tFirazyr is always injected by your doctor or nurse .', 'D-924\t-0.47509765625\tFirazyr is always injected by your doctor or nurse.', 'P-924\t-0.0553 -0.0206 -0.0113 -0.0299 -0.5225 -0.0944 -0.1289 -0.0232 -0.3508 -0.4395 -0.4028 -0.0268 -0.2423 -0.0352 -0.0296', 'S-1274\tDie Überlebensrate von 41% war in hohem Maße von der klinischen Situation abhängig.', 'T-1274\tThe survival rate of 41% depended very much on the clinical situation.', 'H-1274\t-1.0126953125\tThe survival rate of 41 % was highly dependent on clinical situation .', 'D-1274\t-1.0126953125\tThe survival rate of 41% was highly dependent on clinical situation.', 'P-1274\t-0.7148 -0.3118 -0.2318 -0.0472 -0.1768 -0.0352 -0.0817 -1.9062 -0.3718 -0.0479 -0.2057 -0.7383 -0.0338 -0.0282', 'S-1353\tJede Filmtablette enthält 7,5 mg Olanzapin Sonstiger Bestandteil:', 'T-1353\tEach film-coated tablet contains 7.5 mg olanzapine.', 'H-1353\t-0.279052734375\tEach film @-@ coated tablet contains 7.5 mg olanzapine .', 'D-1353\t-0.279052734375\tEach film-coated tablet contains 7.5 mg olanzapine.', 'P-1353\t-0.0357 -0.1022 -0.3198 -0.3223 -0.0218 -0.0366 -0.0232 -0.0338 -0.1155 -0.0141 -0.1902 -0.0225 -0.0120 -0.0218 -0.1515 -0.0507', 'S-1445\tWichtige Information zu einigen der in Aldara Creme enthaltenen Bestandteile:', 'T-1445\tImportant information about some of the ingredients of Aldara cream:', 'H-1445\t-0.256591796875\tImportant information about some of the ingredients in Aldara cream :', 'D-1445\t-0.256591796875\tImportant information about some of the ingredients in Aldara cream:', 'P-1445\t-0.0560 -0.0170 -0.0270 -0.0759 -0.1854 -0.0574 -0.0430 -0.0377 -0.0606 -0.4573 -0.0627 -0.0183 -0.0282 -0.1465 -0.0528 -0.0282', 'S-455\tWIE IST XERISTAR EINZUNEHMEN?', 'T-455\tHOW TO TAKE XERISTAR', 'H-455\t-0.373779296875\tHOW TO TAKE XERISTAR', 'D-455\t-0.373779296875\tHOW TO TAKE XERISTAR', 'P-455\t-0.0328 -0.0092 -0.2822 -0.3179 -0.0736 -0.0113 -0.1803 -0.0324 -0.0113 -0.1895 -0.2014 -0.3176', 'S-232\tDas Vorhandensein dieser Schlieren beeinträchtigt die Qualität von Rapamune nicht.', 'T-232\tThe presence of this haze does not affect the quality of Rapamune.', 'H-232\t-0.546875\tThe presence of these striae does not affect the quality of Rapamune .', 'D-232\t-0.546875\tThe presence of these striae does not affect the quality of Rapamune.', 'P-232\t-0.1158 -0.2585 -0.0299 -0.6846 -0.5566 -0.1831 -0.7046 -0.0296 -0.1902 -0.0676 -0.0197 -0.0310 -0.0197 -0.0254 -0.0085 -0.0395 -0.0282', 'S-316\tWenn Sie glauben, dass Sie eine Dosis vergessen haben, informieren Sie sofort Ihren Arzt.', 'T-316\tIf you think that you have missed a dose, tell your doctor straight away.', 'H-316\t-0.7314453125\tIf you think you forgot a dose , tell your doctor immediately .', 'D-316\t-0.7314453125\tIf you think you forgot a dose, tell your doctor immediately.', 'P-316\t-0.6626 -0.0271 -0.3508 -0.0254 -0.3909 -0.1268 -0.1564 -0.0197 -0.0465 -1.5078 -0.0254 -0.0366 -0.2791 -0.0282 -0.0310', 'S-402\tDie übliche Dosis von Kinzalkomb ist eine Tablette täglich.', 'T-402\tThe usual dose of Kinzalkomb is one tablet a day.', 'H-402\t-0.1865234375\tThe usual dose of Kinzalkomb is one tablet a day .', 'D-402\t-0.1865234375\tThe usual dose of Kinzalkomb is one tablet a day.', 'P-402\t-0.0436 -0.0634 -0.0241 -0.0349 -0.0560 -0.0157 -0.0185 -0.2368 -0.0250 -0.0313 -0.0634 -0.0620 -0.0211 -0.2402 -0.0268 -0.0296 -0.0282', 'S-446\tArava kann gelegentlich zu Problemen mit Ihrem Blut, Ihrer Leber oder Lunge führen.', 'T-446\tArava can occasionally cause some problems with your blood, liver or lungs.', 'H-446\t-0.6201171875\tArava may sometimes cause problems with your blood , liver or lungs .', 'D-446\t-0.6201171875\tArava may sometimes cause problems with your blood, liver or lungs.', 'P-446\t-0.0242 -0.0156 -0.5317 -0.7920 -0.4233 -0.1592 -0.2944 -0.3972 -0.0296 -0.0296 -0.0240 -0.0887 -0.3945 -0.0085 -0.0310 -0.0282', 'S-608\tAlopezie, Erythem, nächtliche Schweißausbrüche Hautausschlag', 'T-608\tAlopecia, erythema, night sweats Skin rash', 'H-608\t-0.501953125\tAlopecia , erythema , night sweats Rash', 'D-608\t-0.501953125\tAlopecia, erythema, night sweats Rash', 'P-608\t-0.8052 -0.0127 -0.0099 -0.0113 -0.0303 -0.6270 -0.0338 -0.0085 -0.0296 -0.1775 -0.0127 -0.1395 -0.5933 -0.0240 -0.0338', 'S-618\tDosierung Die empfohlene Dosis beträgt 0,5 ml - 3,0 ml pro Patient.', 'T-618\tDosage The recommended dose is 0.5 ml - 3.0 ml per patient.', 'H-618\t-0.51904296875\tDosage The recommended dose is 0.5 ml - 3.0 ml per patient .', 'D-618\t-0.51904296875\tDosage The recommended dose is 0.5 ml - 3.0 ml per patient.', 'P-618\t-0.7427 -0.4185 -0.0282 -0.1254 -0.0240 -0.1437 -0.0479 -0.1747 -0.6367 -0.2690 -0.0535 -0.0282 -0.0155 -0.0423 -0.0211 -0.0395 -0.0296', 'S-715\tVerdickung des Endometriums Vulvovaginale Mykosen', 'T-715\tBetween 3 and 7 (best estimate = 5) for 10 years <<unk>> use.', 'H-715\t-0.83837890625\tThickening of the endometrium Vaginal mycoses', 'D-715\t-0.83837890625\tThickening of the endometrium Vaginal mycoses', 'P-715\t-2.1270 -0.0070 -0.0169 -0.0310 -0.3325 -0.0099 -0.0113 -0.0535 -0.0296 -1.0059 -0.4058 -0.0620 -0.1353 -0.1268 -0.0395 -0.0310', 'S-796\tNur anwenden nach entsprechender Nutzen-Risiko-Bewertung durch den behandelnden Tierarzt.', 'T-796\tUse only according to the risk / benefit assessment by the responsible veterinarian.', 'H-796\t-0.9296875\tUse only after benefit @-@ risk assessment by the responsible veterinarian .', 'D-796\t-0.9296875\tUse only after benefit-risk assessment by the responsible veterinarian.', 'P-796\t-0.3108 -0.0502 -0.9932 -1.0684 -1.0859 -0.0254 -0.1042 -0.2227 -0.0620 -0.6255 -0.0366 -0.0451 -0.0113 -0.0479 -0.0310', 'S-1201\tEs leitet sich von einer Substanz ab, die von bestimmten Pilzarten produziert wird.', 'T-1201\tIt is derived from a compound produced by certain types of fungus.', 'H-1201\t-1.1689453125\tIt results from a substance produced by some types of fungi .', 'D-1201\t-1.1689453125\tIt results from a substance produced by some types of fungi.', 'P-1201\t-1.1992 -1.4873 -0.3127 -0.0620 -0.0338 -0.5581 -0.0310 -1.6738 -0.2903 -0.0282 -0.0760 -0.0085 -0.1042 -0.0395 -0.0282', 'S-1430\tEs wurden keine Fälle von Überdosierung mit Macugen in klinischen Studien berichtet.', 'T-1430\tOverdosage with Macugen has not been reported in clinical trials.', 'H-1430\t-0.8173828125\tNo cases of overdose have been reported with Macugen in clinical trials .', 'D-1430\t-0.8173828125\tNo cases of overdose have been reported with Macugen in clinical trials.', 'P-1430\t-0.1576 -0.9561 -0.0352 -0.1226 -0.1028 -0.8262 -0.0254 -0.0127 -0.6084 -0.0606 -0.0197 -0.0141 -0.2507 -0.4932 -0.7241 -0.0338 -0.0282', 'S-1787\t• Nehmen Sie CIALIS immer genau nach Anweisung des Arztes ein.', 'T-1787\t• Always take CIALIS exactly as your doctor has told you.', 'H-1787\t-0.3369140625\t• Always take CIALIS exactly as your doctor has told you .', 'D-1787\t-0.3369140625\t• Always take CIALIS exactly as your doctor has told you.', 'P-1787\t-0.0797 -0.0685 -0.0135 -0.0619 -0.0931 -0.0285 -0.0197 -0.0134 -0.2544 -0.0979 -0.3105 -0.0303 -0.2683 -0.3071 -0.0268 -0.1409 -0.0296', 'S-1924\tInvega ist ein Arzneimittel, das den Wirkstoff Paliperidon enthält.', 'T-1924\tInvega is a medicine that contains the active substance paliperidone.', 'H-1924\t-0.414794921875\tInvega is a medicine that contains the active substance paliperidone .', 'D-1924\t-0.414794921875\tInvega is a medicine that contains the active substance paliperidone.', 'P-1924\t-0.0414 -0.0149 -0.0277 -0.0342 -0.0458 -0.1022 -0.7349 -0.0359 -0.1423 -0.0225 -0.2607 -0.7271 -0.0113 -0.0085 -0.0028 -0.0310 -0.0282', 'S-1994\tDie Reaktionsdauer ist bei Patienten, die eine HSCT erhielten, nicht eindeutig.', 'T-1994\tResponse durations are confounded in patients who received a HSCT.', 'H-1994\t-0.9765625\tThe duration of response is unclear in patients receiving HSCT .', 'D-1994\t-0.9765625\tThe duration of response is unclear in patients receiving HSCT.', 'P-1994\t-0.7603 -0.4346 -0.0282 -0.0395 -0.7158 -0.6382 -0.7930 -0.3296 -0.0648 -0.9043 -0.1212 -0.0310 -0.0225 -0.0451 -0.0282', 'S-339\tist aber wahrscheinlich klinisch nicht relevant, da die Probandenzahl sehr klein war.', 'T-339\t2, 4, 6', 'H-339\t-1.9755859375\tis likely not clinically relevant since the number of subjects was very small .', 'D-339\t-1.9755859375\tis likely not clinically relevant since the number of subjects was very small.', 'P-339\t-3.2969 -1.3496 -0.4846 -0.0141 -0.0282 -0.7437 -1.6455 -0.6704 -0.4846 -0.0282 -1.0029 -0.2085 -0.0789 -0.3269 -0.0338 -0.0282', 'S-833\tWIE IST COMTAN AUFZUBEWAHREN?', 'T-833\tHOW TO STORE COMTAN', 'H-833\t-0.356201171875\tHOW TO STORE COMTAN', 'D-833\t-0.356201171875\tHOW TO STORE COMTAN', 'P-833\t-0.0531 -0.0099 -0.2739 -0.3145 -0.3118 -0.0620 -0.0331 -0.0324 -0.0141 -0.3127', 'S-1007\tPulver zur Herstellung einer Suspension zum Einnehmen und zubereitete Suspension:', 'T-1007\tPowder for oral suspension and reconstituted suspension:', 'H-1007\t-1.0556640625\tPowder for oral suspension .', 'D-1007\t-1.0556640625\tPowder for oral suspension.', 'P-1007\t-0.6655 -0.0155 -0.1099 -0.1437 -0.3220 -0.2522 -1.8438 -0.3213', 'S-1486\tDer Schweregrad der unerwünschten Wirkungen war im Allgemeinen geringfügig bis mäßig.', 'T-1486\tAdverse reactions were usually mild to moderate in severity.', 'H-1486\t-0.76708984375\tAdverse reactions were generally mild to moderate in severity .', 'D-1486\t-0.76708984375\tAdverse reactions were generally mild to moderate in severity.', 'P-1486\t-1.1309 -0.0113 -0.6587 -0.0099 -0.1465 -0.3789 -0.3662 -0.0620 -0.0240 -0.0704 -0.5933 -0.0254 -0.2311 -0.0282', 'S-479\tSchrauben Sie die Injektionsnadel auf das Luer-Verbindungsstück.', 'T-479\tTwist to lock the needle to the Luer connector.', 'H-479\t-1.0517578125\tConnect the injection needle to the syringe Luer connector .', 'D-479\t-1.0517578125\tConnect the injection needle to the syringe Luer connector.', 'P-479\t-1.6865 -0.0535 -0.0169 -0.1691 -1.1084 -0.0197 -0.0338 -0.0225 -0.3157 -0.0366 -0.5664 -0.0169 0.0000 -0.7383 -0.0254 -1.2539 -0.0225 -0.0395 -0.0282', 'S-562\t6 von 103 Patienten (6%) erlitten eine venookklusive Erkrankung der Leber.', 'T-562\tSix of 103 patients (6%) experienced HVOD.', 'H-562\t-1.689453125\tSix of the 103 patients ( 6 % ) experienced VOD .', 'D-562\t-1.689453125\tSix of the 103 patients (6%) experienced VOD.', 'P-562\t-2.6562 -1.2471 -0.7637 -0.6143 -0.3184 -0.0366 -0.0338 -0.0366 -0.0282 -1.1748 -0.6084 -0.6030 -0.2085 -0.2197 -0.0282', 'S-1014\tKosten für die Organisation von Ausbildungspraktika für Hochschulabsolventen bei der Agentur', 'T-1014\tCost of organising graduate traineeships with the Agency', 'H-1014\t-1.6904296875\tExpenditure incurred in practical administrative training for young graduates with the Agency', 'D-1014\t-1.6904296875\tExpenditure incurred in practical administrative training for young graduates with the Agency', 'P-1014\t-2.0156 -0.0056 -0.0901 -0.0620 -2.1660 -0.0225 -0.3438 -0.3718 -0.4058 -0.1099 -0.1071 -0.4199 -0.0732 -0.0169 -2.7559 -0.0395 -0.5352 -0.0395', 'S-1890\tHierzu wird das eingefrorene Pulver mit dem Lösungsmittel gemischt.', 'T-1890\tImmediately before administration, the doctor or nurse will need to make up the suspension for injection by dissolving the frozen powder with the solvent.', 'H-1890\t-1.1064453125\tFor this purpose , the fresh powder is mixed with the solvent .', 'D-1890\t-1.1064453125\tFor this purpose, the fresh powder is mixed with the solvent.', 'P-1890\t-1.7783 -0.0479 -0.1733 -0.3367 -0.0437 -1.1650 -0.2311 -0.0845 -0.0479 -1.2373 -0.3523 -0.0338 -0.0225 -0.0338 -0.0282', 'S-775\tReconcile wurde in vier verschiedenen Studien an Haushunden über bis zu 8 Wochen untersucht.', 'T-775\tIn both of those studies the effectiveness of Reconcile was compared with that of placebo (a dummy treatment) for up to 8 weeks.', 'H-775\t-0.7919921875\tReconcile has been studied in four different studies involving dogs for up to 8 weeks .', 'D-775\t-0.7919921875\tReconcile has been studied in four different studies involving dogs for up to 8 weeks.', 'P-775\t-0.0487 -0.0127 -0.0184 -0.5469 -0.0327 -0.2021 -0.0542 -0.0373 -0.4050 -0.0423 -1.4189 -0.2720 -0.8086 -0.0451 -0.0282 -0.0901 -0.0225 -0.5186 -0.0282', 'S-1116\tVon 1984 bis 1994 war sie Medizinische Leiterin der Abteilung Arzneimittel beim italienischen Gesundheitsministerium.', 'T-1116\tFrom 1984 to 1994, as medical director of the Pharmaceutical Department of the Italian Ministry of Health, she was an Italian member of the former Committee for Proprietary Medicinal Products.', 'H-1116\t-0.9453125\tFrom 1984 to 1994 , as medical director of the Pharmaceutical Department of the Italian Ministry of Health .', 'D-1116\t-0.9453125\tFrom 1984 to 1994, as medical director of the Pharmaceutical Department of the Italian Ministry of Health.', 'P-1116\t-1.1133 -0.0204 -0.0641 -0.0127 -0.6240 -0.5044 -0.3015 -0.0732 -0.1338 -0.0690 -0.8877 -0.1099 -0.0113 -0.3972 -0.6143 -0.2339 -0.3352 -0.0366 -0.0986 -0.0817 -0.0338 -0.0366 -0.5410 -0.0282', 'S-1321\tCalciumantagonisten) kann das Kardiotoxizitätsrisiko erhöhen.', 'T-1321\tConcomitant therapy with other liposomal or lipid-complexed substances or intravenous fat emulsions could change the pharmacokinetic profile of Myocet.', 'H-1321\t-1.138671875\tcalcium channel blockers ) may increase the risk of cardiotoxicity .', 'D-1321\t-1.138671875\tcalcium channel blockers) may increase the risk of cardiotoxicity.', 'P-1321\t-2.8906 -0.0197 -0.0254 -0.9917 -0.5381 -0.0254 -0.0366 -0.1775 -0.5215 -0.5156 -0.0507 -0.0338 -0.1409 -0.5693 -0.0225 -0.0225 -0.0225 -0.0338 -0.0282', 'S-1560\tDie EMEA empfing 2002 eine Reihe von Besuchern aus Nicht-EU-Staaten.', 'T-1560\tThe ICH meetings in 2002 in particular led to the finalisation of the electronic format for the common technical document, first discussions on standards for gene therapy and further guidance on risk management and pharmacovigilance.', 'H-1560\t-1.2353515625\tThe EMEA received a number of visitors from a number of non @-@ EU countries in 2002 .', 'D-1560\t-1.2353515625\tThe EMEA received a number of visitors from a number of non-EU countries in 2002.', 'P-1560\t-1.3945 -0.4087 -0.0183 -0.0254 -1.6807 -0.1606 -0.1691 -0.0282 -1.2676 -0.1578 -0.5664 -0.2029 -0.0282 -0.1859 -0.0507 -0.0507 -0.0564 -1.1436 -0.0225 -0.0282 -0.0282', 'S-963\tEur.) Citronensäure Stearinsäure (Ph.', 'T-963\tBlue, immediate-release layer: maize starch microcrystalline cellulose edetate disodium citric acid stearic acid colorant (Indigo Carmine E132 Aluminum lake).', 'H-963\t-0.919921875\tMannitol Citric acid Stearic acid ( Ph .', 'D-963\t-0.919921875\tMannitol Citric acid Stearic acid (Ph.', 'P-963\t-1.4102 -0.6099 -0.3086 -1.2783 -0.0085 -0.4902 -0.1183 -0.0113 -0.0225 -0.0479 -0.0338 -0.2423 -0.0254 -0.0338 -0.0310', 'S-148\tInfusion mit Bivalirudin bis unmittelbar eine Stunde vor dem Eingriff fortgesetzt werden.', 'T-148\t2 For patients who proceed to CABG surgery on pump, the IV infusion of bivalirudin should be continued until 1 hour prior to surgery after which the infusion should be discontinued and the patient treated with unfractionated heparin.', 'H-148\t-1.306640625\tInfusion with bivalirudin should be continued up to one hour before surgery .', 'D-148\t-1.306640625\tInfusion with bivalirudin should be continued up to one hour before surgery.', 'P-148\t-2.4082 -0.1409 -0.0662 -0.1000 -0.0099 -0.0169 -0.0282 -0.2451 -0.5552 -0.6567 -0.1973 -0.6821 -0.0732 -0.7944 -0.0225 -0.7383 -0.8286 -0.0564 -0.0282', 'S-1723\tIbuprofen, Naproxen oder Etoricoxib) behandelt werden.', 'T-1723\tIt is particularly important to tell your doctor if you are being treated with clopidogrel (an anti-platelet agent), warfarin (an anti-coagulant), or <<unk>> non steroidal anti inflammatory drugs <<unk>> for pain and fever (such as ibuprofen, naproxen, etoricoxib).', 'H-1723\t-0.65771484375\tibuprofen , naproxen or etoricoxib ) .', 'D-1723\t-0.65771484375\tibuprofen, naproxen or etoricoxib).', 'P-1723\t-2.7891 -0.0183 -0.0183 -0.0056 -0.0324 -0.0324 -0.0197 -0.0225 -0.0056 -0.1042 -0.0310 -0.0732 -0.0197 -0.0085 -0.0225 -0.0338 -0.4622 -0.0282', 'S-754\tJuli 2006 legte der Inhaber der Genehmigung für das Inverkehrbringen schriftliche Erklärungen vor.', 'T-754\tDuring their September 2006 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit / risk ratio is favourable for Glucomed and associated names for the relief of symptoms in mild to moderate osteoarthritis of the knee, that there was no objection for the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State', 'H-754\t-0.98974609375\tThe Marketing Authorisation Holder provided written explanations on 23 July 2006 .', 'D-754\t-0.98974609375\tThe Marketing Authorisation Holder provided written explanations on 23 July 2006.', 'P-754\t-1.0996 -0.6924 -0.0225 -0.0718 -0.0310 -0.2551 -0.0225 -0.3000 -0.0409 -0.3142 -0.0254 -0.2156 -1.8965 -0.3352 -0.0282 -0.0395 -0.0282', 'S-949\tAls der Antrag vom Unternehmen zurückgezogen wurde, war in dem Antragsverfahren Tag 113 erreicht.', 'T-949\tThe application was at day 113 when the company withdrew.', 'H-949\t-0.55224609375\tThe application was at day 113 when the company withdrew .', 'D-949\t-0.55224609375\tThe application was at day 113 when the company withdrew.', 'P-949\t-0.8198 -0.2649 -0.2240 -0.3213 -0.2974 -0.0296 -0.0254 -0.1437 -0.0916 -0.0789 -0.0437 -0.0169 -0.3057 -0.0282', 'S-383\t2 VIRAMUNE 200 mg Tabletten können mit oder ohne Nahrung eingenommen werden.', 'T-383\tVIRAMUNE may be taken with or without food.', 'H-383\t-0.6611328125\t2 VIRAMUNE 200 mg tablets can be taken with or without food .', 'D-383\t-0.6611328125\t2 VIRAMUNE 200 mg tablets can be taken with or without food.', 'P-383\t-0.5674 -2.6367 -0.0141 -0.0169 -0.0197 -0.0282 -0.0648 -0.0282 -0.0676 -0.0338 -0.1042 -0.0254 -0.0282 -0.0423 -0.0338 -0.0282 -0.0564 -0.0423 -0.0310', 'S-104\tBei Einnahme von Lansoprazol AbZ 30 mg zusammen mit Nahrungsmitteln und Getränken', 'T-104\tTaking Lansoprazol AbZ with food and drink:', 'H-104\t-0.77783203125\tTaking Lansoprazol AbZ 30 mg with food and drink', 'D-104\t-0.77783203125\tTaking Lansoprazol AbZ 30 mg with food and drink', 'P-104\t-0.5049 -0.1846 -0.0028 -0.3213 -0.2113 -0.0240 -0.0155 -0.0113 -1.3584 -0.0211 -0.5200 -0.0873 -0.0479 -0.2563 -0.3804', 'S-666\tWas ist Liprolog Mix25 KwikPen und wofür wird es angewendet?', 'T-666\tWhat Liprolog Mix25 KwikPen is and what it is used for 2.', 'H-666\t-0.3310546875\tWhat Liprolog Mix25 KwikPen is and what it is used for 2 .', 'D-666\t-0.3310546875\tWhat Liprolog Mix25 KwikPen is and what it is used for 2.', 'P-666\t-0.0292 -0.3223 -0.0292 -0.0271 -0.0162 -0.0285 -0.0271 -0.1068 -0.0141 -0.0211 -0.0077 -0.0444 -0.0778 -0.0578 -0.3071 -0.1571 -0.0704 -0.0296 -0.3228 -0.3184 -0.0423', 'S-1744\tLietuva Pfizer Luxembourg SARL filialas Lietuvoje.', 'T-1744\tLietuva Pfizer Luxembourg SARL filialas Lietuvoje.', 'H-1744\t-0.39208984375\tLietuva Pfizer Luxembourg SARL filialas Lietuvoje', 'D-1744\t-0.39208984375\tLietuva Pfizer Luxembourg SARL filialas Lietuvoje', 'P-1744\t-0.0458 -0.0142 -0.0213 -0.0042 -0.0213 -0.0256 -0.0142 -0.0457 -0.0206 -0.0206 -0.0620 -0.0255 -0.0292 -0.0227 -0.0056 -0.0120 -0.0169 -0.0155 -1.8711', 'S-786\tInovelon war bei Mäusen, Ratten oder Kaninchen nicht teratogen.', 'T-786\tInovelon was not teratogenic in mice, rats or rabbits.', 'H-786\t-0.2060546875\tInovelon was not teratogenic in mice , rats or rabbits .', 'D-786\t-0.2060546875\tInovelon was not teratogenic in mice, rats or rabbits.', 'P-786\t-0.5142 -0.0085 -0.0930 -0.0525 -0.0458 -0.0088 -0.0218 -0.0810 -0.0197 -0.0232 -0.0437 -0.0359 -0.0155 -0.0296 -0.0254 -0.1536 -0.0155 -0.0085 -0.0254 -0.0303 -0.0282', 'S-1961\tEs ergab sich kein Hinweis auf Veränderungen der Pharmakokinetik von Micafungin.', 'T-1961\tIn these studies, no evidence of altered pharmacokinetics of micafungin was observed.', 'H-1961\t-0.7607421875\tThere was no evidence of a change in the pharmacokinetics of micafungin .', 'D-1961\t-0.7607421875\tThere was no evidence of a change in the pharmacokinetics of micafungin.', 'P-1961\t-1.3486 -0.3467 -0.0324 -0.3691 -0.4185 -0.6353 -0.0958 -0.2423 -0.3184 -0.0282 -0.0113 -0.0169 -0.0310 -0.0338 -0.2141 -0.3213 -0.0169 -0.0479 -0.0338 -0.0282', 'S-156\tTeilen Sie Ihrem Arzt mit, wenn Sie schwanger sind, eine Schwangerschaft vermuten oder planen.', 'T-156\tTell your doctor if you are pregnant, think you may be pregnant, or are planning to become pregnant.', 'H-156\t-0.935546875\tTell your doctor if you are pregnant , think you are pregnant or planning to become pregnant .', 'D-156\t-0.935546875\tTell your doctor if you are pregnant, think you are pregnant or planning to become pregnant.', 'P-156\t-1.1914 -0.0113 -0.0345 -0.0310 -0.0486 -0.0289 -0.0564 -0.4607 -0.0507 -0.3621 -0.3086 -0.7300 -0.0507 -0.5635 -1.2344 -0.1324 -0.2593 -0.0197 -0.0423 -0.0282', 'S-1535\t3 Die Anzahl der von der Krankheit betroffenen Patienten wird geschätzt für die Zwecke der Ausweisung.', 'T-1535\t3 The number of patients affected by the condition is estimated and assessed for the purpose of the designation.', 'H-1535\t-1.28125\t3 The number of patients affected by the disease is estimated for authorisation .', 'D-1535\t-1.28125\t3 The number of patients affected by the disease is estimated for authorisation.', 'P-1535\t-1.4951 -0.6719 -0.0395 -0.0268 -0.0732 -0.1169 -0.0338 -0.8818 -0.2451 -0.4763 -0.0395 -0.2029 -1.6035 -0.5918 -0.2367 -0.0282', 'S-1731\tPedea soll als Kurzinfusion über 15 Minuten am besten unverdünnt gegeben werden.', 'T-1731\tPedea should be administered as a short infusion over 15 minutes, preferably undiluted.', 'H-1731\t-0.83837890625\tPedea should be administered as a short infusion over 15 minutes , preferably undiluted .', 'D-1731\t-0.83837890625\tPedea should be administered as a short infusion over 15 minutes, preferably undiluted.', 'P-1731\t-0.6035 -0.0264 -0.0285 -0.1398 -0.0881 -0.7017 -0.0197 -2.1602 -0.1409 -0.0648 -0.0930 -0.0141 -0.2791 -0.0535 -0.0282 -0.2197 -0.2507 -0.2113 -0.2930 -0.0141 -0.0141 -0.0310 -0.0282', 'S-810\tInfolge dieser Bindung werden einige östrogene Wege aktiviert, andere hingegen blockiert.', 'T-810\tThis binding results in the activation of some estrogenic pathways and a blockade of others.', 'H-810\t-0.91943359375\tAs a result of this binding , some oestrogenic pathways are activated , while others are blocked .', 'D-810\t-0.91943359375\tAs a result of this binding, some oestrogenic pathways are activated, while others are blocked.', 'P-810\t-1.1475 -0.0296 -0.3176 -0.1113 -0.1183 -0.1917 -0.0211 -0.1747 -0.0578 -0.8564 -0.0113 -0.0141 -0.2113 -0.2593 -0.0479 -0.3042 -0.2001 -0.0254 -0.0282 -0.1465 -1.1104 -0.1381 -0.2593 -0.6479 -0.0338 -0.0282', 'S-979\tIhr Kind das Risiko besteht, an Windpocken zu erkranken, informieren Sie Ihren Arzt.', 'T-979\tTell your doctor if you or the child are exposed to chickenpox when using Enbrel.', 'H-979\t-0.91943359375\tIf your child is exposed to chickenpox , tell your doctor .', 'D-979\t-0.91943359375\tIf your child is exposed to chickenpox, tell your doctor.', 'P-979\t-1.6865 -0.4521 -0.0409 -0.4705 -0.4465 -0.0310 -0.2903 -0.0056 -0.0141 -0.0169 -0.0197 -0.6284 -0.8032 -0.0366 -0.0310 -0.0310 -0.0282', 'S-1399\tIn diesen Fällen ist der Impfstoff mindestens sechs Monate nach der letzten Gabe des ersten Ar', 'T-1399\tQuintanrix can be given to children who received a hepatitis B vaccine at birth. i dic', 'H-1399\t-2.00390625\tIn these cases , the vaccine should be given for at least six months after the last dose of the first 150 mg dose .', 'D-1399\t-2.00390625\tIn these cases, the vaccine should be given for at least six months after the last dose of the first 150 mg dose.', 'P-1399\t-0.7832 -1.0703 -0.1874 -0.1310 -0.2339 -0.0240 -1.6973 -0.2283 -0.3240 -1.6367 -0.0676 -0.0169 -0.0395 -0.0282 -0.2986 -0.3157 -0.3662 -1.1719 -0.2197 -0.1071 -0.2986 -0.9805 -0.6821 -1.5781 -1.6113 -0.0451', 'S-1296\tDie Packungen sind mit der Aufschrift <unk> Woche 1 (2, 3 bzw.', 'T-1296\t34 tablets each, for the first 2 to 4 weeks of therapy depending on the patient <<unk>> s response and tolerability.', 'H-1296\t-2.001953125\tPacks are printed with &quot; Week 1 &quot; on the body .', 'D-1296\t-2.001953125\tPacks are printed with "Week 1" on the body.', 'P-1296\t-1.5244 -0.6396 -0.2563 -1.1299 -0.5776 -0.7920 -0.7495 -0.0479 -0.1945 -0.7383 -1.5947 -1.2910 -0.1917 -0.0282', 'S-1170\tDie Patronen sind in einem Fertigpen namens <unk> KwikPen <unk> montiert.', 'T-1170\tThe 3 ml cartridges are sealed in a disposable pen injector, called the <<unk>> KwikPen <<unk>>.', 'H-1170\t-0.95263671875\tThe 3 ml cartridges are sealed in a disposable pen , called the KwikPen .', 'D-1170\t-0.95263671875\tThe 3 ml cartridges are sealed in a disposable pen, called the KwikPen.', 'P-1170\t-0.7686 -0.7305 -0.3254 -0.0831 -0.0014 -0.0183 -0.0521 -0.4888 -0.3677 -0.0395 -0.3875 -0.0282 -0.0366 -1.6543 -0.0648 -0.7241 -0.1747 -0.0169 -0.0225 -0.0113 -0.0620 -0.0282', 'S-733\tPatienten, die eine kochsalzarme Diät einhalten müssen, sollten dies berücksichtigen.', 'T-733\tDUKORAL contains approximately 1.1 g sodium per dose, which should be taken into consideration by patients on a controlled sodium diet.', 'H-733\t-0.86572265625\tPatients on a controlled sodium diet should take this into account .', 'D-733\t-0.86572265625\tPatients on a controlled sodium diet should take this into account.', 'P-733\t-0.2467 -0.0192 -0.3005 -0.1000 -0.5327 -0.6958 -0.0169 -0.0606 -0.0521 -1.2100 -0.4988 -0.0197 -0.5806 -0.0338 -0.0282', 'S-780\tAlter der Mutter, Eigenschaften der Spermien) und Mehrlingsschwangerschaften zurückzuführen ist.', 'T-780\tThis is thought to be due to differences in parental characteristics (e. g. maternal age, sperm characteristics) and multiple pregnancies.', 'H-780\t-0.953125\tThis is due to differences in parental characteristics ( e. g . , maternal age , sperm characteristics ) and multiple gestations .', 'D-780\t-0.953125\tThis is due to differences in parental characteristics (e. g., maternal age, sperm characteristics) and multiple gestations.', 'P-780\t-0.4255 -0.3699 -0.7617 -0.0352 -0.3340 -0.0409 -0.3254 -0.1099 -0.3042 -0.0254 -0.1930 -0.4565 -0.2734 -1.1465 -0.0310 -0.1324 -0.4763 -0.0113 -0.0282 -0.0197 -0.0423 -0.0817 -0.0282 -0.1240 -0.0282 -0.0338 -0.0395 -0.0676 -1.2227 -0.4001 -0.0282 -0.0282', 'S-352\tSechster allgemeiner Tätigkeitsbericht der Europäischen Agentur für die Beurteilung von Arzneimitteln <unk> 2000', 'T-352\tNote for guidance on the Clinical investigation of human anti-D immunoglobulin for intravenous and / or intramuscular use Adopted June 2000', 'H-352\t-1.052734375\tSixth General Report on the activities of the European Agency for the Evaluation of Medicinal Products', 'D-352\t-1.052734375\tSixth General Report on the activities of the European Agency for the Evaluation of Medicinal Products', 'P-352\t-0.0939 -0.0234 -0.2434 -0.3445 -0.2859 -0.1846 -2.4688 -0.0310 -0.0338 -0.0282 -0.1973 -0.0310 -0.0338 -0.0254 -0.0225 -0.0282 -0.0085 -0.0254 -0.0113 -0.0225 -2.3945', 'S-1255\tNur 12 der 492 Patienten mit Langzeitansprechen erlitten während dieser Studie einen Rückfall. ich', "T-1255\t462 patients completed at least 5 years of long-term follow-up and only 12 sustained responders' out of 492 relapsed during this study. no", 'H-1255\t-0.818359375\t462 patients completed at least 5 years of long @-@ term follow @-@ up and only 12 sustained responders &apos; out of 492 relapsed during this study .', "D-1255\t-0.818359375\t462 patients completed at least 5 years of long-term follow-up and only 12 sustained responders' out of 492 relapsed during this study.", 'P-1255\t-0.4617 -0.3223 -0.1676 -0.3303 -0.3240 -0.0901 -0.4480 -0.2803 -0.1240 -0.3325 -0.0606 -0.0507 -0.3042 -0.2029 -0.0395 -0.3157 -0.1775 -0.0366 -0.3269 -0.3240 -0.1437 -0.4678 -0.3213 -0.0395 -0.0535 -0.0169 -0.1945 -0.0169 -0.3101 -0.1635 -0.1803 -0.0732 -0.0507 -0.0395', 'S-1380\t<unk> Die empfohlene Anfangsdosis für Diovan beträgt 40 mg zweimal täglich.', 'T-1380\tTherefore the MAH should address the lack of (additional) clinical benefit and increased adverse events In conclusion; the CHMP adopts the revised text: <<unk>> The recommended starting dose of Diovan is 40 mg twice daily.', 'H-1380\t-0.798828125\tThe recommended starting dose for Diovan is 40 mg twice daily .', 'D-1380\t-0.798828125\tThe recommended starting dose for Diovan is 40 mg twice daily.', 'P-1380\t-0.3311 -0.0313 -0.2360 -0.0349 -0.6543 -1.4258 -0.0197 -0.0056 -0.0296 -0.2466 -0.0338 -0.0535 -0.7070 -0.2169 -0.0282', 'S-193\t4-Aminochinoline können die Wirkung von Xeomin abschwächen.', 'T-193\t4-Aminochinolines may reduce the effect of Xeomin.', 'H-193\t-1.0537109375\t4 @-@ Aminochinolines may attenuate the effect of Xeomin .', 'D-193\t-1.0537109375\t4-Aminochinolines may attenuate the effect of Xeomin.', 'P-193\t-1.2100 -0.0282 -1.1006 -0.0169 -0.3889 -0.0268 -0.0817 -0.1000 -0.7212 -1.6797 -0.0141 -0.0310 -0.0704 -0.6284 -0.0338 -0.2311 -0.0282 -0.0169 -0.0676 -0.0451 -0.0282', 'S-1529\t2 / 3 Thymanax darf nicht bei älteren Patienten mit Demenz angewendet werden.', 'T-1529\tThymanax should not be used in elderly patients with dementia.', 'H-1529\t-0.91357421875\t2 / 3 Thymanax should not be used in elderly patients with dementia .', 'D-1529\t-0.91357421875\t2 / 3 Thymanax should not be used in elderly patients with dementia.', 'P-1529\t-2.8184 -0.0296 -0.0352 -0.7749 -0.0254 -0.0254 -0.0113 -0.8906 -0.0338 -0.0310 -0.0620 -0.0873 -0.1521 -0.0592 -0.0479 -0.0169 -0.0479 -0.0282', 'S-1629\tDie Gabe von Volumenersatzmitteln und Vasopressoren wird empfohlen.', 'T-1629\tVolume expanders and vasopressors are recommended.', 'H-1629\t-1.091796875\tAdministration of fluids and vasopressor is recommended .', 'D-1629\t-1.091796875\tAdministration of fluids and vasopressor is recommended.', 'P-1629\t-1.5361 -0.0296 -0.4917 -1.6172 -0.9243 -0.0817 -0.0225 -0.0254 -0.0169 -0.0535 -0.3127 -0.3296 -0.0395 -0.0338 -0.0282', 'S-952\tTragen Sie stets einen Ersatzpen bei sich, falls der andere verloren geht oder beschädigt wird.', 'T-952\tAlways carry an extra Pen in case yours is lost or damaged.', 'H-952\t-0.8525390625\tAlways carry a spare pen in case you lose your pen or it gets damaged .', 'D-952\t-0.8525390625\tAlways carry a spare pen in case you lose your pen or it gets damaged.', 'P-952\t-0.1022 -0.0121 -0.0679 -0.0604 -0.1068 -0.1443 -0.5718 -0.0472 -1.4375 -0.1437 -0.3184 -1.2031 -0.0535 -0.3467 -0.1240 -0.0197 -0.0423 -0.0282', 'S-1281\tDie Anwendung von Lucentis über einen Zeitraum von mehr als 24 Monaten wurde nicht untersucht.', 'T-1281\tThe use of Lucentis beyond 24 months has not been studied.', 'H-1281\t-0.71435546875\tThe use of Lucentis for more than 24 months has not been studied .', 'D-1281\t-0.71435546875\tThe use of Lucentis for more than 24 months has not been studied.', 'P-1281\t-0.6646 -0.0680 -0.0282 -0.0296 -0.0289 -0.0056 -0.0261 -1.1924 -0.8818 -0.0310 -0.0366 -0.0338 -0.6313 -0.0338 -0.0282 -0.2649 -0.0338 -0.0282', 'S-132\t-1,69 -0,37 -1,32 (-1,58; -1,05) d', 'T-132\t-1.69 -0.37 1.32 (1.58; 1.05) d', 'H-132\t-0.28466796875\t-1.69 -0.37 -1.32 ( -1.58 ; -1.05 ) d', 'D-132\t-0.28466796875\t-1.69 -0.37 -1.32 (-1.58; -1.05) d', 'P-132\t-0.0199 -0.5898 -0.4248 -0.0197 -0.0345 -0.0155 -0.0211 -0.0254 -0.0197 -0.0268 -0.0240 -0.0232 -0.0127 -0.0254 -0.0169 -0.0225 -0.0176 -0.0282 -0.0282 -0.3220', 'S-1188\t24 Augenerkrankungen: vorübergehendes verschwommenes Sehen, Xanthopsie', 'T-1188\tEye disorders: transient blurred vision, xanthopsia', 'H-1188\t-0.8134765625\t24 Eye disorders : transient blurred vision , xanthopsia', 'D-1188\t-0.8134765625\t24 Eye disorders: transient blurred vision, xanthopsia', 'P-1188\t-1.2363 -0.3049 -0.2690 -0.5874 -0.0197 -0.2620 -0.8652 -0.0141 -0.0395 -0.5889 -0.1691 -0.0225 -0.0395 -0.0282 -0.0141 -0.0197 -0.0901 -0.0395', 'S-241\tBitte ändern Sie diese Dosierung nicht, ohne vorher mit Ihrem Arzt oder Apotheker zu sprechen.', 'T-241\tPlease do not change the dosage without consulting the doctor or pharmacist.', 'H-241\t-0.94482421875\tPlease do not change the dosage without talking to your doctor or pharmacist .', 'D-241\t-0.94482421875\tPlease do not change the dosage without talking to your doctor or pharmacist.', 'P-241\t-0.4685 -0.0532 -0.0271 -0.0676 -0.6768 -0.6338 -0.0169 -0.0268 -0.1338 -1.4629 -0.0930 -0.0366 -0.0479 -0.2817 -0.4790 -0.0197 -0.7944 -0.0310', 'S-296\tEs gibt keinen geschlechtspezifischen Einfluss auf die Kinetik von Imatinib.', 'T-296\tThere is no effect of gender on the kinetics of imatinib.', 'H-296\t-0.76904296875\tThere is no effect of gender on the kinetics of imatinib .', 'D-296\t-0.76904296875\tThere is no effect of gender on the kinetics of imatinib.', 'P-296\t-0.2534 -0.0414 -0.0327 -1.8486 -0.1930 -0.1240 -0.0409 -1.3721 -0.0254 -0.0169 -0.2339 -0.0310 -0.0310 -0.0225 -0.0085 -0.0225 -0.0338 -0.0282', 'S-126\tSUSTIVA kann die Menge an Posaconazol in Ihrem Blut verringern.', 'T-126\tSUSTIVA may reduce the amount of posaconazole in your blood.', 'H-126\t-0.279296875\tSUSTIVA can reduce the amount of posaconazole in your blood .', 'D-126\t-0.279296875\tSUSTIVA can reduce the amount of posaconazole in your blood.', 'P-126\t-0.0163 -0.0191 -0.0249 -0.0256 -0.6714 -0.5073 -0.0345 -0.0380 -0.0282 -0.0282 -0.0240 -0.0225 -0.0099 -0.0127 -0.0338 -0.0324 -0.0352 -0.0409 -0.0296', 'S-1375\tNach dem ersten Öffnen der Flasche ist das Arzneimittel innerhalb von 30 Tagen zu verbrauchen.', 'T-1375\tOnce the bottle is opened, the product must be used within 30 days', 'H-1375\t-1.0576171875\tAfter the first opening of the bottle , the product should be used within 30 days .', 'D-1375\t-1.0576171875\tAfter the first opening of the bottle, the product should be used within 30 days.', 'P-1375\t-1.0889 -1.5439 -0.0873 -0.0704 -0.0676 -0.0409 -0.0366 -0.6426 -0.2255 -0.8706 -0.8594 -0.0310 -0.2563 -0.0395 -0.0395 -0.0225 -0.0395 -0.0282', 'S-220\tWenn eine Kaloriensubstitution erforderlich ist, wird ein proteinfreies Produkt empfohlen.', 'T-220\tIf caloric supplementation is indicated, a protein-free product is recommended.', 'H-220\t-1.3583984375\tIf calorie supplementation is necessary , a protein @-@ free product is recommended .', 'D-220\t-1.3583984375\tIf calorie supplementation is necessary, a protein-free product is recommended.', 'P-220\t-1.1943 -1.0254 -0.0479 -1.5029 -0.0760 -0.0254 -0.0310 -1.4707 -0.4199 -1.2168 -0.0169 -0.4734 -0.0225 -0.0338 -0.0395 -0.0338 -0.0338 -0.0282', 'S-594\tWie alle Arzneimittel kann Ziagen Nebenwirkungen haben, die aber nicht bei jedem auftreten müssen.', 'T-594\tLike all medicines, Ziagen can cause side effects, although not everybody gets them.', 'H-594\t-0.56396484375\tLike all medicines , Ziagen can cause side effects , although not everybody gets them .', 'D-594\t-0.56396484375\tLike all medicines, Ziagen can cause side effects, although not everybody gets them.', 'P-594\t-0.9272 -0.0662 -0.1071 -0.0698 -0.0373 -0.2050 -0.0176 -0.0746 -0.2607 -0.0282 -0.0521 -0.1620 -0.2974 -0.1071 -0.3113 -0.3169 -0.2001 -0.0310 -0.0282', 'S-656\tFlebogammadif hat eine Halbwertszeit von etwa 30 <unk> 32 Tagen.', 'T-656\tFlebogammadif has a half-life of about 30-32 days.', 'H-656\t-0.26025390625\tFlebogammadif has a half @-@ life of about 30 to 32 days .', 'D-656\t-0.26025390625\tFlebogammadif has a half-life of about 30 to 32 days.', 'P-656\t-0.1320 -0.0277 -0.0575 -0.0185 -0.0155 -0.0199 -0.0313 -0.0320 -0.0329 -0.0680 -0.0285 -0.0313 -0.5415 -0.0275 -0.3542 -0.0183 -0.0254 -0.0324 -0.0282', 'S-948\tFür weitere Informationen hierzu lesen Sie bitte Abschnitt 4 <unk> Welche Nebenwirkungen sind möglich? <unk>.', 'T-948\tFor more information on these, please read section 4 (Possible Side Effects).', 'H-948\t-1.486328125\tRead section 5 - Possible side effects .', 'D-948\t-1.486328125\tRead section 5 - Possible side effects.', 'P-948\t-1.4766 -0.3494 -1.0215 -0.8071 -0.4312 -0.0113 -0.4143 -0.0592 -0.8369 -0.5103', 'S-1144\t1 ml Lösung zum Einnehmen enthält 1 mg Cetirizindihydrochlorid', 'T-1144\t1 ml solution contain 1 mg of cetirizine dihydrochloride', 'H-1144\t-0.6494140625\t1 ml oral solution contains 1 mg cetirizine dihydrochloride', 'D-1144\t-0.6494140625\t1 ml oral solution contains 1 mg cetirizine dihydrochloride', 'P-1144\t-0.9180 -0.0197 -0.9307 -0.0634 -0.0620 -0.1635 -0.0155 -0.5903 -0.0282 -0.0225 -0.0775 -0.0873 -0.1606 -0.0704 -0.0282 -0.0254 -0.0141 -0.0225 -0.5015', 'S-1764\tKinzalkomb enthält Milchzucker (Lactose) und Sorbitol.', 'T-1764\tKinzalkomb contains milk sugar (lactose) and sorbitol.', 'H-1764\t-0.2001953125\tKinzalkomb contains milk sugar ( lactose ) and sorbitol .', 'D-1764\t-0.2001953125\tKinzalkomb contains milk sugar (lactose) and sorbitol.', 'P-1764\t-0.0901 -0.0199 -0.0206 -0.1853 -0.0269 -0.0312 -0.3789 -0.0331 -0.0296 -0.1838 -0.0063 -0.0127 -0.0296 -0.0310 -0.0134 -0.0063 -0.0099 -0.0345 -0.0282', 'S-1944\tRosiglitazon ist angezeigt zur Behandlung des Typ-2-Diabetes mellitus:', 'T-1944\tRosiglitazone is indicated in the treatment of type 2 diabetes mellitus:', 'H-1944\t-0.51123046875\tRosiglitazone is indicated for the treatment of type 2 diabetes mellitus :', 'D-1944\t-0.51123046875\tRosiglitazone is indicated for the treatment of type 2 diabetes mellitus:', 'P-1944\t-0.9102 -0.0113 -0.0211 -0.0169 -0.0402 -0.0402 -0.0423 -0.4846 -0.7666 -0.0254 -0.0282 -0.2283 -0.0338 -0.0197 -0.2156 -0.0211 -0.0056 -0.0535 -0.0282', 'S-268\tZur Aufrechterhaltung des Impfschutzes sollten alle 6 Wochen Wiederholungsimpfungen erfolgen.', 'T-268\tFor long-lasting immunity, chickens should be revaccinated every 6 weeks.', 'H-268\t-1.3330078125\tRevaccination should be administered every 6 weeks to maintain protection .', 'D-268\t-1.3330078125\tRevaccination should be administered every 6 weeks to maintain protection.', 'P-268\t-0.4639 -0.3223 -0.6592 -0.6240 -0.0451 -2.6465 -0.0169 -0.0704 -0.0704 -0.0225 -0.3381 -0.6201 -0.6650 -0.1747 -0.0282', 'S-1636\tÜber vorübergehenden Blutdruckabfall, ohne Notwendigkeit klinischer Behandlung, wurde fallweise berichtet.', 'T-1636\tTransient decreases in blood pressure, not requiring clinical treatment, have been reported occasionally.', 'H-1636\t-1.21484375\tTransient decreases in blood pressure , without the need for clinical treatment , have been reported occasionally .', 'D-1636\t-1.21484375\tTransient decreases in blood pressure, without the need for clinical treatment, have been reported occasionally.', 'P-1636\t-0.6055 -0.0243 -0.0532 -1.2070 -0.1564 -0.1945 -0.0282 -0.0155 -1.0508 -0.9468 -0.2395 -0.0479 -0.0535 -0.0648 -1.5557 -0.2986 -0.7554 -0.0282 -0.0395 -0.3325 -0.0338 -0.0282', 'S-843\tNovoMix 70 Penfill 100 E / ml, Injektionssuspension in einer Patrone.', 'T-843\tNovoMix 70 Penfill 100 U / ml, suspension for injection in a cartridge.', 'H-843\t-0.3291015625\tNovoMix 70 Penfill 100 U / ml , suspension for injection in a cartridge .', 'D-843\t-0.3291015625\tNovoMix 70 Penfill 100 U / ml, suspension for injection in a cartridge.', 'P-843\t-0.0342 -0.0163 -0.0078 -0.0306 -0.0270 -0.0142 -0.0357 -0.3206 -0.0299 -0.0148 -0.0560 -0.3018 -0.3064 -0.0606 -0.1487 -0.0831 -0.2903 -0.2014 -0.0155 -0.0155 -0.0634 -0.0296', 'S-728\tEviana филмирани таблетки', 'T-728\tEviana филмирани таблетки', 'H-728\t-1.1650390625\tEviana chorio- gonadotropin alfa', 'D-728\t-1.1650390625\tEviana chorio- gonadotropin alfa', 'P-728\t-0.2805 -0.0171 -0.0407 -1.1709 -0.3240 -0.3213 -0.3228 -0.3904 -0.3198 -0.3213 -0.2986 -0.2791 -0.3015 -0.7300 -0.3777 -0.6538', 'S-763\tNycomed Pharma AS Drammernsveien 852 NO-1372 Asker Norwegen', 'T-763\tNycomed Pharma AS Drammernsveien 852 NO-1372 Asker Norway', 'H-763\t-0.250244140625\tNycomed Pharma AS Drammennsveien 852 NO @-@ 1372 Asker Norway', 'D-763\t-0.250244140625\tNycomed Pharma AS Drammennsveien 852 NO-1372 Asker Norway', 'P-763\t-0.0071 -0.0007 -0.0227 -0.0142 -0.0149 -0.0249 -0.3225 -0.2800 -0.0077 -0.0359 -0.0042 -0.0240 -0.0211 -0.0296 -0.0261 -0.0275 -0.0197 -0.0169 -0.0134 -0.0289 -0.6274 -0.0296', 'S-808\tLaboratoire Qualimed 34, rue Saint-Romain 69008 Lyon Frankreich', 'T-808\tLaboratoire Qualimed 34, rue Saint-Romain 69008 Lyon France', 'H-808\t-0.09600830078125\tLaboratoire Qualimed 34 , rue Saint @-@ Romain 69008 Lyon France', 'D-808\t-0.09600830078125\tLaboratoire Qualimed 34, rue Saint-Romain 69008 Lyon France', 'P-808\t-0.0142 -0.0256 -0.0242 -0.0242 -0.0149 -0.0415 -0.0014 -0.0170 -0.0284 -0.0141 -0.0241 -0.0113 -0.0292 -0.0127 -0.0099 -0.0070 -0.0185 -0.0248 -0.0092 -0.2164 -0.0278', 'S-861\t- Während der Einnahme von Advagraf sollten Sie wegen des möglichen Risikos bösartiger', 'T-861\t- Limit your exposure to sunlight and UV light whilst taking Advagraf by wearing appropriate', 'H-861\t-2.36328125\t- Having taken Advagraf Do not take Advagraf before you take any other medicines', 'D-861\t-2.36328125\t- Having taken Advagraf Do not take Advagraf before you take any other medicines', 'P-861\t-0.0604 -1.2324 -2.6738 -0.4114 -0.0056 -0.0085 -1.0225 -0.1183 -0.8340 -1.2451 -0.0113 -0.0113 -1.2227 -0.6538 -0.3269 -0.7158 -0.9805 -0.5239 -0.1127 -2.0859', 'S-1009\tBoehringer Ingelheim France 12, rue André Huet 51100 Reims Frankreich', 'T-1009\tBoehringer Ingelheim France 12, rue André Huet 51100 Reims France', 'H-1009\t-0.1114501953125\tBoehringer Ingelheim France 12 , rue André Huet 51100 Reims France', 'D-1009\t-0.1114501953125\tBoehringer Ingelheim France 12, rue André Huet 51100 Reims France', 'P-1009\t-0.0213 -0.0042 -0.0099 -0.0241 -0.0142 -0.0070 -0.0163 -0.0270 -0.0284 -0.0170 -0.0256 -0.0171 -0.2900 -0.0218 -0.0278 -0.0285 -0.0225 -0.0218 -0.0197 -0.0197 -0.0285', 'S-1849\tDemonstration of efficacy for veterinary medicinal products containing antimicrobial subsatnces', 'T-1849\tDemonstration of efficacy for veterinary medicinal products containing antimicrobial subsatnces', 'H-1849\t-0.57080078125\tDemonstration of efficacy for veterinary medicinal products containing antimicrobial substrates', 'D-1849\t-0.57080078125\tDemonstration of efficacy for veterinary medicinal products containing antimicrobial substrates', 'P-1849\t-2.5762 -0.0296 -0.1353 -0.0127 -0.0197 -0.0324 -0.0099 -0.0113 -0.0268 -0.0127 -0.0254 -0.0704 -0.0141 -0.0113 -0.0169 -0.0254 -0.0225 -0.3213 -0.0366 -0.0338', 'S-1995\tDie Verlängerung des QT-Intervalls kann Patienten dem Risiko für einen tödlichen Ausgang aussetzen.', 'T-1995\tProlongation of the QT interval may expose patients to the risk of fatal outcome.', 'H-1995\t-0.64892578125\tQT interval prolongation may expose patients to a potential fatal outcome .', 'D-1995\t-0.64892578125\tQT interval prolongation may expose patients to a potential fatal outcome.', 'P-1995\t-0.5215 -0.0313 -0.2673 -0.0380 -0.2339 -0.1599 -0.0451 -0.5234 -0.2043 -0.0056 -0.1691 -0.0324 -0.5591 -0.5708 -0.2339 -0.0169 -0.0338 -0.0282', 'S-50\tAxura 10 mg Filmtabletten enthalten Lactose-Monohydrat.', 'T-50\tAxura 10 mg film-coated tablets contain lactose monohydrate.', 'H-50\t-0.580078125\tAxura 10 mg film tablets contain lactose monohydrate .', 'D-50\t-0.580078125\tAxura 10 mg film tablets contain lactose monohydrate.', 'P-50\t-0.0429 -0.0234 -0.0085 -0.1022 -0.0134 -0.1344 -2.5723 -0.0338 -0.0395 -0.0479 -0.0113 -0.0141 -0.0254 -0.0141 -0.0254 -0.0254 -0.0282 -0.2029 -0.0310', 'S-190\tzu Wenn Sie weitere Fragen zur Anwendung des Arzneimittels haben, fragen Sie Ihren Arzt oder Apotheker.', 'T-190\t72 If you have any further questions about how to use this product, ask your doctor or pharmacist.', 'H-190\t-0.849609375\tho If you have any further questions on the use of this medicine , ask your doctor or pharmacist .', 'D-190\t-0.849609375\tho If you have any further questions on the use of this medicine, ask your doctor or pharmacist.', 'P-190\t-0.3354 -1.2637 -0.0268 -0.2522 -0.1747 -0.3987 -0.0338 -0.2859 -0.1254 -0.0901 -0.0310 -0.2649 -1.0879 -0.2479 -0.3579 -0.0366 -0.0732 -0.0338 -0.0366 -0.0197 -0.2197 -0.0310', 'S-475\tPostbus 100 NL-7255 ZK Hengelo (Gld), Niederlande', 'T-475\tPostbus 100 NL-7255 ZK Hengelo (Gld), Netherlands', 'H-475\t-0.1387939453125\tPostbus 100 NL @-@ 7255 ZK Hengelo ( Gld ) , Netherlands', 'D-475\t-0.1387939453125\tPostbus 100 NL-7255 ZK Hengelo (Gld), Netherlands', 'P-475\t-0.0487 -0.0170 -0.0342 -0.0284 -0.0234 -0.0298 -0.0269 -0.0220 -0.0269 -0.0269 -0.0185 -0.0113 -0.0113 -0.0269 -0.0298 -0.0278 -0.0035 -0.0285 -0.2512 -0.1381 -0.0310', 'S-244\tIhr Arzt wird während der Behandlung mit Dynepo Ihren Eisen-Spiegel im Blut messen und Ihnen', 'T-244\tYour doctor will measure your blood iron level during treatment with Dynepo and may give you iron supplements.', 'H-244\t-1.30859375\tYour doctor will measure the amount of iron in your blood during treatment with Dynepo .', 'D-244\t-1.30859375\tYour doctor will measure the amount of iron in your blood during treatment with Dynepo.', 'P-244\t-0.5728 -0.0500 -0.4233 -0.4670 -1.6318 -0.5747 -0.1803 -0.0423 -0.0592 -0.2649 -0.0282 -0.9438 -0.4143 -0.0901 -0.0338 -0.0169 -0.0225 -1.7920 -0.0507', 'S-537\tBei nicht optimaler Heparinisierung ist ein Verschluss des Dialyse-Systems möglich.', 'T-537\tOcclusion of the dialysis system is possible if heparinisation is not optimum.', 'H-537\t-0.84375\tClosure of the dialysis system is possible in case of inadequate heparinisation .', 'D-537\t-0.84375\tClosure of the dialysis system is possible in case of inadequate heparinisation.', 'P-537\t-0.3899 -0.1941 -0.0271 -0.2878 -0.0486 -0.8657 -0.0085 -0.0282 -0.1212 -0.4438 -0.1917 -1.0225 -0.6143 -0.0592 -0.2903 -0.2930 -0.0282 -0.0197 -0.3184 -0.0789 -0.0338 -0.0282', 'S-533\tDer Behandlungserfolg kann beeinflusst werden, wenn Diovan zusammen mit bestimmten anderen Arzneimitteln verwendet wird.', 'T-533\t51 The effect of the treatment can be influenced if Diovan is taken together with certain other medicines.', 'H-533\t-1.16015625\tTreatment success may be affected when Diovan is used in combination with certain other medicines .', 'D-533\t-1.16015625\tTreatment success may be affected when Diovan is used in combination with certain other medicines.', 'P-533\t-1.0127 -0.0197 -0.0268 -0.1296 -0.4641 -0.0352 -0.7808 -0.8735 -1.3867 -0.0225 -0.0056 -0.4170 -0.3042 -0.9072 -0.2029 -0.0282 -0.2423 -0.3101 -0.0845 -0.0958 -0.0338 -0.0282', 'S-1949\tWeniger als 10% des verabreichten Fentanyls wird unverändert über die Nieren ausgeschieden.', 'T-1949\tLess than 10% of administered fentanyl is excreted unchanged by the kidney.', 'H-1949\t-0.52294921875\tLess than 10 % of the administered fentanyl is excreted unchanged by the kidneys .', 'D-1949\t-0.52294921875\tLess than 10% of the administered fentanyl is excreted unchanged by the kidneys.', 'P-1949\t-0.2551 -0.0141 -0.0292 -0.0276 -0.0684 -0.0299 -0.2201 -0.3542 -0.0211 -0.0240 -0.0148 -0.0099 -0.0275 -0.0514 -0.4360 -0.0056 -0.0211 -0.3662 -0.1071 -0.9707 -0.0366 -0.0197 -0.5156 -0.0085 -0.0310 -0.0282', 'S-1514\tMessen Sie diese Dosis ab und verabreichen Sie diese Dosis am Dosis am Morgen Abend', 'T-1514\tRebetol oral solution Usual Dosage in Children If the patient weighs Measure and give this dose', 'H-1514\t-1.6748046875\tThis dose should be measured and given in the morning and evening .', 'D-1514\t-1.6748046875\tThis dose should be measured and given in the morning and evening.', 'P-1514\t-0.6792 -0.0648 -0.1663 -0.0310 -0.5933 -0.5508 -1.3242 -1.0146 -0.1859 -0.0310 -1.6094 -0.5859 -1.2910 -0.0338', 'S-1759\tInterferon alfa-2b (Erwachsene und Kinder) auf die Hälfte reduzieren, wenn:', 'T-1759\t(adult) or interferon alfa- 2b dose (adult and paediatric) to one-half dose, if:', 'H-1759\t-0.890625\tReduce interferon alfa @-@ 2b ( adults and children ) to half dose if :', 'D-1759\t-0.890625\tReduce interferon alfa-2b (adults and children) to half dose if:', 'P-1759\t-0.9976 -0.0204 -0.5488 -0.0141 -0.0254 -0.0310 -0.0141 -0.0282 -0.0254 -0.0225 -0.0423 -0.0395 -0.0338 -0.0268 -0.0296 -0.6494 -1.1904 -0.3296 -1.1182 -0.3127 -0.0310', 'S-753\tBolus in Dosierungen von 1 bis 16 mg / kg eine lineare Kinetik.', 'T-753\tSugammadex exhibits linear kinetics in the dosage range of 1 to 16 mg / kg when administered as an IV bolus dose.', 'H-753\t-1.9482421875\t20 mg / kg by bolus is linear kinetics .', 'D-753\t-1.9482421875\t20 mg / kg by bolus is linear kinetics.', 'P-753\t-0.7808 -1.1641 -0.6509 -0.0268 -0.5845 -0.3860 -0.0338 -2.6289 -2.6934 -0.0225 -0.3101 -0.0113 -0.0395 -0.5239 -0.0338', 'S-1330\t2 x (5 x 3 ml) Liprolog Patronen für einen 3 ml Pen.', 'T-1330\t5 x 3 ml Liprolog cartridges for a 3 ml pen 2 x (5 x 3 ml) Liprolog cartridges for a 3 ml pen', 'H-1330\t-0.3046875\t2 x ( 5 x 3 ml ) Liprolog cartridges for a 3 ml pen .', 'D-1330\t-0.3046875\t2 x (5 x 3 ml) Liprolog cartridges for a 3 ml pen.', 'P-1330\t-0.6836 -0.0299 -0.2458 -0.0388 -0.0289 -0.0479 -0.0310 -0.0289 -0.1191 -0.0303 -0.0676 -0.0965 -0.0070 -0.0211 -0.0324 -0.1183 -0.0648 -0.0183 -0.0732 -0.0803 -0.0296', 'S-1068\tAbschluss in Veterinärmedizin an der Fakultät für Veterinärwissenschaften der Universität Liverpool.', 'T-1068\tGraduated in veterinary medicine from the Faculty of Veterinary Science at Liverpool University and is a Member of the Royal College of Veterinary Surgeons of the United Kingdom.', 'H-1068\t-0.970703125\tRoyal College of Veterinary Surgeons of the Faculty of Veterinary', 'D-1068\t-0.970703125\tRoyal College of Veterinary Surgeons of the Faculty of Veterinary', 'P-1068\t-1.7119 -0.4099 -0.0380 -0.0366 -0.0113 -0.3254 -0.0127 -0.0169 -0.3213 -0.2747 -0.3550 -0.0113 -0.0254 -0.0310 -0.0169 -0.0085 -1.7051', 'S-725\t3,0 ml der Lösung entnehmen, ohne die Durchstechflasche auf den Kopf zu drehen.', 'T-725\tWithdraw 3.0 ml of the solution without turning the vial upside down.', 'H-725\t-0.74755859375\tWithdraw 3.0 ml of the solution without turning the vial upside down .', 'D-725\t-0.74755859375\tWithdraw 3.0 ml of the solution without turning the vial upside down.', 'P-725\t-0.3699 -0.1560 -0.9160 -0.0338 -0.0183 -0.0578 -1.4414 -0.2395 -0.1296 -0.1240 -0.0338 -0.0564 -0.0197 -0.1409 -0.0225 -0.2507 -0.1945 -0.0310', 'S-1862\tALIMTA 500 mg Pulver zur Herstellung eines Konzentrates zur Herstellung einer Infusionslösung', 'T-1862\tALIMTA 500 mg powder for concentrate for solution for infusion', 'H-1862\t-0.42822265625\tALIMTA 500 mg powder for concentrate for solution for infusion', 'D-1862\t-0.42822265625\tALIMTA 500 mg powder for concentrate for solution for infusion', 'P-1862\t-0.0371 -0.0156 -0.0085 -0.0285 -0.0121 -0.0589 -0.1389 -0.3213 -0.3013 -0.3191 -0.3184 -0.0930 -0.0197 -0.4143', 'S-523\tIn kontrollierten klinischen Studien wurden die Patienten über einen Zeitraum von 12 Wochen nach der Behandlung beobachtet.', 'T-523\tIn controlled clinical trials patients were followed for 12 weeks after single treatment.', 'H-523\t-0.9560546875\tIn controlled clinical trials , patients were followed for 12 weeks after treatment .', 'D-523\t-0.9560546875\tIn controlled clinical trials, patients were followed for 12 weeks after treatment.', 'P-523\t-0.7856 -0.0416 -0.0282 -0.1134 -0.3811 -0.0775 -0.1508 -0.8130 -0.9624 -0.1493 -0.0254 -1.1807 -0.0817 -0.0338 -0.0282', 'S-961\tWenn der Vorfall vorüber ist, kann die Behandlung mit INCRELEX wieder aufgenommen werden.', 'T-961\tINCRELEX may be started again after the episode is over.', 'H-961\t-1.2314453125\tTreatment with INCRELEX can be resumed once the accident is resolved .', 'D-961\t-1.2314453125\tTreatment with INCRELEX can be resumed once the accident is resolved.', 'P-961\t-2.2461 -0.0225 -0.0268 -0.0887 -0.0366 -0.0282 -0.0169 -0.0197 -0.0197 -0.5835 -0.3184 -0.0789 -0.3606 -0.0254 -1.6484 -0.2001 -0.6426 -0.7832 -0.4453 -0.0338 -0.0282', 'S-216\tDie Pipetten müssen in der intakten Folienverpackung aufbewahrt werden.', 'T-216\tStored pipettes must be kept in the intact foil package.', 'H-216\t-0.640625\tThe pipettes must be stored in its intact sachet .', 'D-216\t-0.640625\tThe pipettes must be stored in its intact sachet.', 'P-216\t-0.9370 -0.0923 -0.0458 -0.0035 -0.4727 -0.0338 -0.1508 -0.0282 -0.0395 -0.5327 -0.0676 -0.0056 -0.8145 -0.0873 -0.0423 -0.0282', 'S-311\tAuch Metformin hatte keinen Einfluss auf die Pharmakokinetik von Vareniclin.', 'T-311\tMetformin had no effect on varenicline pharmacokinetics.', 'H-311\t-0.68212890625\tMetformin did not affect the pharmacokinetics of varenicline .', 'D-311\t-0.68212890625\tMetformin did not affect the pharmacokinetics of varenicline.', 'P-311\t-0.7666 -0.0085 -0.0282 -1.5811 -0.0395 -0.8789 -0.0817 -0.0254 -0.0113 -0.0169 -0.0282 -0.0310 -0.0282 -0.0254 -0.0169 -0.0592 -0.2085 -0.0282', 'S-738\tDer Inhaber der Genehmigung für das Inverkehrbringen ist Eli Lilly Nederland B.V.', 'T-738\tThe marketing authorisation holder is Eli Lilly Nederland BV.', 'H-738\t-0.2120361328125\tThe marketing authorisation holder is Eli Lilly Nederland B. V .', 'D-738\t-0.2120361328125\tThe marketing authorisation holder is Eli Lilly Nederland B. V.', 'P-738\t-0.0722 -0.3188 -0.0430 -0.0285 -0.0870 -0.0377 -0.0264 -0.0257 -0.0056 -0.0243 -0.0225 -0.0169 -0.0204 -0.3213 -0.0373 -0.0444 -0.0282', 'S-60\t- Appetitlosigkeit, Erbrechen, Bauchschmerzen und -krämpfe, Durchfall.', 'T-60\tA reduction in your white blood cell count can make you more prone to infection.', 'H-60\t-0.52001953125\t- lack of appetite , vomiting , abdominal pain and cramps , diarrhoea .', 'D-60\t-0.52001953125\t- lack of appetite, vomiting, abdominal pain and cramps, diarrhoea.', 'P-60\t-0.0619 -1.3877 -0.0282 -0.0127 -0.0183 -0.0296 -0.2479 -0.0070 -0.0282 -0.0310 -0.2522 -0.0085 -0.0183 -0.3367 -0.0423 -0.0535 -0.0451 -0.0366 -0.0310 -0.0070 -0.2184 -0.0113 -0.5581 -0.0282', 'S-136\tEine Ampulle mit Lösungsmittel enthält 0,7 ml Wasser für Injektionszwecke.', 'T-136\tOne ampoule of solvent contains 0.7 ml of water for injections.', 'H-136\t-0.6298828125\tOne ampoule solvent contains 0.7 ml of water for injections .', 'D-136\t-0.6298828125\tOne ampoule solvent contains 0.7 ml of water for injections.', 'P-136\t-0.3213 -0.3428 -0.0127 -0.0197 -1.2725 -0.0211 -0.0972 -0.0775 -0.0366 -0.0197 -0.6748 -0.0451 -0.0648 -0.0479 -0.3127 -0.0507 -0.0282', 'S-327\tDer primäre, aktive Metabolit macht 23 bis 37% der Gesamtexposition aus.', 'T-327\tThe primary active metabolite comprises 23 to 37% of the total exposure.', 'H-327\t-0.4931640625\tThe primary active metabolite accounts for 23 to 37 % of total exposure .', 'D-327\t-0.4931640625\tThe primary active metabolite accounts for 23 to 37% of total exposure.', 'P-327\t-0.4871 -0.0292 -0.2859 -0.0310 -0.0169 -0.0169 -0.2036 -0.0268 -0.4509 -0.4368 -0.0169 -0.0507 -0.0282 -0.5127 -0.0380 -0.0395 -0.0282', 'S-1214\t200 Zubereitungen zur Mehrfachanwendung dürfen nur von ein und demselben Patienten verwendet werden.', 'T-1214\tMultidose presentations must be for individual patient use only.', 'H-1214\t-1.7939453125\t200 repe preparations are for use by one patient only .', 'D-1214\t-1.7939453125\t200 repe preparations are for use by one patient only.', 'P-1214\t-0.8374 -1.7129 -1.0000 -0.3071 -0.0282 -1.5947 -0.3184 -0.4678 -0.1859 -1.4033 -0.7158 -0.0958 -0.0451 -0.0282', 'S-1187\tDas Risiko für unerwünschte hepatische Ereignisse ist in den ersten 6 Wochen der Behandlung am größten.', 'T-1187\tThe risk of hepatic events is greatest in the first 6 weeks of therapy.', 'H-1187\t-0.88623046875\tThe risk of hepatic adverse events is greatest in the first 6 weeks of treatment .', 'D-1187\t-0.88623046875\tThe risk of hepatic adverse events is greatest in the first 6 weeks of treatment.', 'P-1187\t-0.0649 -0.3625 -0.0961 -1.6650 -0.0056 -0.0197 -0.9019 -0.0197 -0.0113 -0.0930 -0.3945 -0.7832 -0.0310 -0.0338 -0.0930 -0.0254 -0.0395 -0.6426 -0.0338 -0.0282', 'S-941\tDiese Symptome können entweder für serotonerge Effekte oder für Expositions-Symptome sprechen.', 'T-941\t29 These symptoms may be due to either serotonergic effects or exposure symptoms.', 'H-941\t-0.57470703125\tThese symptoms may be due to either serotonergic effects or exposure symptoms .', 'D-941\t-0.57470703125\tThese symptoms may be due to either serotonergic effects or exposure symptoms.', 'P-941\t-0.7251 -0.3169 -0.4390 -0.3113 -0.3127 -0.1183 -0.1493 -0.1141 -0.0211 -0.0183 -0.1705 -0.0042 -0.0479 -0.2268 -0.0901 -0.1296 -0.0310 -0.0282', 'S-1079\tINFORMATION IN BRAILLE-SCHRIFT eim zn Ar', 'T-1079\tINFORMATION IN BRAILLE lP na ici ed M', 'H-1079\t-0.72607421875\tINFORMATION IN BRAILLE i dic Me', 'D-1079\t-0.72607421875\tINFORMATION IN BRAILLE i dic Me', 'P-1079\t-0.1886 -0.0269 -0.0127 -0.0299 -0.0171 -0.0092 -0.0451 -0.1037 -0.0574 -0.0197 -0.1321 -1.5332 -0.6934 -0.6060 -0.2141', 'S-1310\tKommission a) An die Kommission geschickt am b) Datum der Verordnung c) OJ Nr.', 'T-1310\tCommission a) Sent to Commission b) Date of regulation c) Official Journal', 'H-1310\t-0.73681640625\tCommission a ) zoledronic', 'D-1310\t-0.73681640625\tCommission a) zoledronic', 'P-1310\t-0.0953 -0.5737 -0.0313 -0.4321 -0.4170 -0.3184 -0.3411 -0.3579', 'S-1385\ta) die Verabreichung des Produktes an Tiere in die Umsetzung staatlicher Programme zur Ar', 'T-1385\ta) the administration of the product to animals will interfere with the implementation of national M', 'H-1385\t-1.552734375\ta ) the administration of the product to animals in the implementation of national measures for', 'D-1385\t-1.552734375\ta) the administration of the product to animals in the implementation of national measures for', 'P-1385\t-0.4734 -0.0327 -0.3716 -0.3445 -0.0331 -0.1930 -0.0423 -0.3804 -0.0451 -1.1973 -0.0817 -0.0845 -0.0310 -0.4087 -1.6064 -1.9277 -1.2451', 'S-756\tDie Patienten sind nach 2 bis 4 Wochen hinsichtlich ihres Ansprechens auf Montelukast zu untersuchen.', 'T-756\tPatients should be evaluated after 2 to 4 weeks for response to montelukast.', 'H-756\t-0.740234375\tTreatment should be discontinued if a lack of response is observed .', 'D-756\t-0.740234375\tTreatment should be discontinued if a lack of response is observed.', 'P-756\t-0.4980 -0.0409 -0.0782 -0.3691 -0.1085 -0.3748 -0.0437 -0.3972 -0.3142 -0.3564 -0.0324 -0.3367 -0.3101 -0.3127 -0.2620 -0.0732', 'S-1497\tDie Lösung zum Einnehmen enthält 20 mg / ml Abacavir (als Sulfat).', 'T-1497\tOral solution containing 20 mg / ml of abacavir (as sulfate).', 'H-1497\t-0.58349609375\tThe oral solution contains 20 mg / ml of abacavir ( as sulphate ) .', 'D-1497\t-0.58349609375\tThe oral solution contains 20 mg / ml of abacavir (as sulphate).', 'P-1497\t-0.9087 -0.4185 -0.1022 -0.0472 -0.1818 -0.0113 -0.0310 -0.0310 -0.7539 -0.0746 -0.0211 -0.0310 -0.0183 -0.0465 -0.1296 -0.0592 -0.1888 -0.0225 -0.0338 -0.4875 -0.0282', 'S-1959\tDer Wirkstoff in Renagel, Sevelamer, ist ein Phosphatbinder.', 'T-1959\tThe effects of Renagel were first tested in experimental models before being studied in humans.', 'H-1959\t-0.51611328125\tThe active substance in Renagel , sevelamer , is a phosphate binder .', 'D-1959\t-0.51611328125\tThe active substance in Renagel, sevelamer, is a phosphate binder.', 'P-1959\t-1.7314 -0.3113 -0.2676 -0.0451 -0.0296 -0.0352 -0.0085 -0.0352 -0.4270 -0.0197 -0.0254 -0.0366 -0.0282 -0.0310 -0.0254 -0.0197 -0.0254 -0.0197 -0.0282 -0.0282 -0.0282', 'S-176\tStrada Statale 156 KM 50 04010 Borgo San Michele Latina Italien', 'T-176\tStrada Statale 156 KM 50 04010 Borgo San Michele Latina Italy', 'H-176\t-0.061370849609375\tStrada Statale 156 KM 50 04010 Borgo San Michele Latina Italy', 'D-176\t-0.061370849609375\tStrada Statale 156 KM 50 04010 Borgo San Michele Latina Italy', 'P-176\t-0.0092 -0.0156 -0.0099 -0.0191 -0.0227 -0.0277 -0.0234 -0.0184 -0.0270 -0.0255 -0.0178 -0.0269 -0.0127 -0.0206 -0.0141 -0.0077 -0.0063 -0.0106 -0.0185 -0.0192 -0.0284', 'S-522\tEs ist nicht bekannt, ob Cinacalcet beim Menschen in die Muttermilch übertritt.', 'T-522\tIt is not known whether cinacalcet is excreted in human milk.', 'H-522\t-0.5927734375\tIt is not known whether cinacalcet is excreted in human milk .', 'D-522\t-0.5927734375\tIt is not known whether cinacalcet is excreted in human milk.', 'P-522\t-0.0553 -0.0357 -0.3745 -0.0327 -0.1360 -0.2747 -0.0268 -0.0240 -0.0359 -0.0211 -0.4226 -0.4839 -0.1451 -0.0324 -0.2593 -0.1324 -0.9146 -0.0338 -0.0282', 'S-1271\tDer Blutdruck wurde in <unk> Millimeter von Quecksilber <unk> (mmHg) gemessen.', 'T-1271\tThe blood pressure was measured in <<unk>> millimetres of mercury <<unk>> (mmHg).', 'H-1271\t-0.433349609375\tBlood pressure was measured in &apos; millimetres of mercury &quot; ( mmHg ) .', 'D-1271\t-0.433349609375\tBlood pressure was measured in \'millimetres of mercury "(mmHg).', 'P-1271\t-0.2244 -0.0155 -0.0155 -0.1799 -0.1265 -0.0363 -0.5093 -0.0056 -0.1176 -0.2556 -0.0254 -0.0099 -0.0254 -0.9243 -0.0662 -0.0113 -0.0225 -0.0254 -0.0296 -0.0380 -0.0282', 'S-857\tEine Nieren- oder Leberfunktionsstörung kann den Insulinbedarf des Patienten verringern.', 'T-857\tRenal or hepatic impairment may reduce the patient <<unk>> s insulin requirements.', 'H-857\t-1.05078125\tRenal or hepatic impairment may reduce the patient &quot; s insulin requirements .', 'D-857\t-1.05078125\tRenal or hepatic impairment may reduce the patient "s insulin requirements.', 'P-857\t-1.4678 -0.0324 -0.0634 -0.3042 -0.0451 -0.0254 -0.6045 -0.1085 -0.0099 -0.0465 -0.6084 -0.3157 -0.1099 -0.4988 -1.2344 -0.0310 -0.1521 -0.0169 -0.7944 -0.0282 -0.0282', 'S-820\tAufgrund der fehlenden Humandaten sollte TESAVEL in der Schwangerschaft nicht eingenommen werden.', 'T-820\tDue to lack of human data, TESAVEL should not be used during pregnancy.', 'H-820\t-0.5361328125\tDue to lack of human data , TESAVEL should not be used during pregnancy .', 'D-820\t-0.5361328125\tDue to lack of human data, TESAVEL should not be used during pregnancy.', 'P-820\t-1.0898 -0.0141 -0.0282 -0.5151 -0.0282 -0.0662 -0.0507 -0.2156 -0.0507 -0.0211 -0.0282 -0.0211 -0.0127 -0.0380 -0.0352 -0.0268 -0.8862 -0.1212 -0.0225 -0.0310 -0.0282', 'S-807\tAdvocate wird Katzen und Hunden aus Fertigpipetten zum Auftropfen verabreicht.', 'T-807\tAdvocate is applied to cats and dogs from pre-filled spot-on pipettes.', 'H-807\t-1.228515625\tAdvocate is given to cats and dogs from prefilled pipettes .', 'D-807\t-1.228515625\tAdvocate is given to cats and dogs from prefilled pipettes.', 'P-807\t-0.1405 -0.0063 -0.0284 -0.0590 -0.8184 -0.2169 -0.0718 -0.0303 -0.0225 -1.1055 -1.9834 -0.4763 -0.1071 -0.0282 -0.0113 -1.5889 -0.0282', 'S-746\tΚύπρος Lifepharma (Z.A.M.) Ltd Aγ.', 'T-746\tΚύπρος Lifepharma (Z. A. M.) Ltd Aγ.', 'H-746\t-0.6025390625\tБαπρος Lifepharma ( Z.A.M. ) Ltd Aγ .', 'D-746\t-0.6025390625\tБαπρος Lifepharma (Z.A.M.) Ltd Aγ.', 'P-746\t-2.0664 -0.3101 -0.5396 -0.0197 -0.0423 -0.0535 -0.0366 -0.0169 -0.0423 -0.0338 -0.0113 -0.0282 -0.0225 -0.0338 -0.0113 -0.0254 -0.0310 -0.0113 -0.1859 -0.2479 -0.0507 -0.0282', 'S-95\t42 / 129 Metacam 5 mg / ml Injektionslösung für Rinder und Schweine', 'T-95\t41 / 125 Metacam 5 mg / ml solution for injection for cattle and pigs', 'H-95\t-0.5673828125\t42 / 125 Metacam 5 mg / ml solution for injection for cattle and pigs', 'D-95\t-0.5673828125\t42 / 125 Metacam 5 mg / ml solution for injection for cattle and pigs', 'P-95\t-1.6328 -0.0296 -0.3228 -0.0183 -0.0211 -0.0240 -0.0451 -0.0070 -0.0310 -0.0155 -0.3157 -0.0535 -0.3157 -0.0760 -0.3042 -0.1155 -0.0141 -0.0395 -0.0760 -0.0310 -0.0366', 'S-1889\tDie am häufigsten berichteten Nebenwirkungen in diesen Patientengruppen waren Übelkeit und Erbrechen.', 'T-1889\tThe most frequent ADRs in these patient populations were nausea and vomiting.', 'H-1889\t-0.8486328125\tThe most commonly reported adverse reactions in these patient populations were nausea and vomiting .', 'D-1889\t-0.8486328125\tThe most commonly reported adverse reactions in these patient populations were nausea and vomiting.', 'P-1889\t-0.2163 -0.0248 -0.9009 -0.0176 -1.0312 -0.0056 -0.5254 -0.0127 -0.3396 -0.5806 -0.1324 -0.7100 -0.0141 -0.4648 -0.0113 -0.0056 -0.3213 -0.0225 -0.0056 -0.0254 -0.0282 -0.0282', 'S-1105\tHäufigkeit der Nebenwirkungen von Metformin aus Daten von klinischen Studien und nach Markteinführung', 'T-1105\tThe frequency of metformin adverse reactions identified from clinical trial and postmarketing data', 'H-1105\t-1.5341796875\tFrequency of adverse drug reactions for metformin in clinical trial and post- marketing data', 'D-1105\t-1.5341796875\tFrequency of adverse drug reactions for metformin in clinical trial and post- marketing data', 'P-1105\t-1.2236 -0.0148 -0.0197 -0.0331 -0.4106 -0.0042 -1.6865 -0.2227 -0.0028 -1.3135 -0.0225 -0.0085 -0.0282 -2.0156 -0.0958 -0.4001 -0.5972 -0.3381 -0.9863 -0.3042 -0.0395 -0.0338', 'S-838\tSie sollten AMMONAPS verteilt auf gleiche Einzeldosen mit jeder Mahlzeit einnehmen.', 'T-838\tYou should take AMMONAPS by mouth in equally divided doses with each meal.', 'H-838\t-0.740234375\tYou should take AMMONAPS in equally divided doses with each meal .', 'D-838\t-0.740234375\tYou should take AMMONAPS in equally divided doses with each meal.', 'P-838\t-0.1312 -0.0327 -0.0678 -0.0916 -0.0285 -0.0250 -0.0327 -0.0169 -0.6484 -0.3860 -0.3228 -0.2537 -0.0169 -1.8848 -0.1578 -0.0338 -0.0366 -0.0282', 'S-1825\tDas QT-Intervall wurde nach der Fridericia-Formel frequenzkorrigiert.', "T-1825\tQT interval was corrected for heart rate by Fridericia's method.", 'H-1825\t-1.0556640625\tThe QT interval was regulated using the Fridericia formula .', 'D-1825\t-1.0556640625\tThe QT interval was regulated using the Fridericia formula.', 'P-1825\t-0.4456 -0.3167 -0.3508 -0.1373 -0.0134 -0.5835 -1.8438 -0.0254 -1.0625 -0.0423 -0.4170 -0.0197 -0.0085 -0.0282 -0.4114 -0.0423 -0.0282', 'S-1709\t30 überzogene Tabletten 30 x 2 mg oder 100 überzogene Tabletten 100 x 2 mg', 'T-1709\t30 coated tablets 30 x 2 mg 100 coated tablets 100 x 2 mg', 'H-1709\t-0.436767578125\t30 coated tablets 30 x 2 mg 100 coated tablets 100 x 2 mg', 'D-1709\t-0.436767578125\t30 coated tablets 30 x 2 mg 100 coated tablets 100 x 2 mg', 'P-1709\t-0.0502 -0.2418 -0.0199 -0.0444 -0.3882 -0.1268 -0.0282 -0.0557 -0.0211 -0.8423 -0.3228 -0.0169 -0.0211 -0.0268 -0.1000 -0.0282 -0.0310 -0.0183 -0.1719', 'S-61\tIntrinsa 300 Mikrogramm wird zur Anwendung bei Frauen in der natürlichen Menopause nicht empfohlen.', 'T-61\tIntrinsa 300 micrograms is not recommended in naturally menopausal women.', 'H-61\t-0.6923828125\tIntrinsa 300 micrograms is not recommended in naturally menopausal women .', 'D-61\t-0.6923828125\tIntrinsa 300 micrograms is not recommended in naturally menopausal women.', 'P-61\t-0.3152 -0.0162 -0.0155 -0.0313 -0.0313 -0.0877 -0.1515 -0.0662 -0.0331 -0.0275 -2.7578 -0.3296 -0.0479 -0.0169 -0.0056 -0.0254 -0.0282 -0.0366 -0.0282', 'S-1948\tOvitrelle 250 Mikrogramm Pulver und Lösungsmittel zur Herstellung einer Injektionslösung.', 'T-1948\tOvitrelle 250 micrograms powder and solvent for solution for injection.', 'H-1948\t-0.4541015625\tOvitrelle 250 micrograms powder and solvent for solution for injection .', 'D-1948\t-0.4541015625\tOvitrelle 250 micrograms powder and solvent for solution for injection.', 'P-1948\t-0.1703 -0.0085 -0.0213 -0.0070 -0.0313 -0.0916 -0.1990 -0.7627 -0.0331 -0.0261 -0.0395 -0.1268 -0.3228 -0.3113 -0.0620 -0.0366 -0.2930 -0.0296', 'S-158\tDas Sicherheitsprofil änderte sich auch in dieser Altersgruppe nicht mit der längeren Dauer der Behandlung.', 'T-158\tWith prolonged treatment, the safety profile did not change in these patients either.', 'H-158\t-1.20703125\tThe safety profile did not change with prolonged treatment .', 'D-158\t-1.20703125\tThe safety profile did not change with prolonged treatment.', 'P-158\t-0.1074 -0.0349 -0.0170 -0.4395 -0.0271 -0.1130 -0.9292 -1.7471 -0.0141 -0.0197 -0.2874 -1.8369 -0.0479', 'S-1717\tas Jede 1,0 ml Durchstechflasche enthält 40 Mikrogramm Darbepoetin alfa.', 'T-1717\tEach 1 ml vial 40 micrograms darbepoetin alfa.', 'H-1717\t-0.60546875\tEach 1 ml vial 60 micrograms darbepoetin alfa .', 'D-1717\t-0.60546875\tEach 1 ml vial 60 micrograms darbepoetin alfa.', 'P-1717\t-0.1451 -0.3188 -0.0634 -0.0176 -0.0155 -1.8584 -0.1620 -0.0564 -0.2874 -0.0338 -0.0310 -0.0366 -0.0395 -0.0479 -0.0169 -0.1521 -0.0310', 'S-72\tFabrazyme 35 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung.', 'T-72\tFabrazyme 35 mg, powder for concentrate for solution for infusion.', 'H-72\t-0.339111328125\tFabrazyme 35 mg powder for concentrate for solution for infusion .', 'D-72\t-0.339111328125\tFabrazyme 35 mg powder for concentrate for solution for infusion.', 'P-72\t-0.0127 -0.0199 -0.0085 -0.0191 -0.0797 -0.0113 -0.0627 -0.0590 -0.2620 -0.2036 -0.3228 -0.3071 -0.1042 -0.0409 -0.2451 -0.0310', 'S-1841\tDurchstechflasche in der Originalverpackung aufbewahren, um den Inhalt vor Licht zu schützen.', 'T-1841\tKeep the vial in the original package in order to protect from light.', 'H-1841\t-0.52490234375\tKeep the vial in the outer carton in order to protect from light .', 'D-1841\t-0.52490234375\tKeep the vial in the outer carton in order to protect from light.', 'P-1841\t-0.2585 -0.1648 -0.1768 -0.0444 -0.0722 -0.2173 -0.3228 -0.0303 -0.3220 -0.0535 -0.6455 -0.0930 -0.0282 -0.0803 -0.3157 -0.0592 -0.0578 -0.0310', 'S-1834\t(2,5 mg / Tag) nicht erforderlich; die Tageshöchstdosis beträgt 5 mg.', 'T-1834\t(2.5 mg / day); the maximal daily dose is 5 mg;', 'H-1834\t-0.58203125\tthe maximal daily dose is 5 mg ;', 'D-1834\t-0.58203125\tthe maximal daily dose is 5 mg;', 'P-1834\t-0.4036 -0.3284 -0.1543 -0.0993 -0.1705 -0.3459 -0.0211 -0.3284 -0.3228', 'S-1403\t- Simvastatin (wird angewendet, um den Cholesterinspiegel zu senken),', 'T-1403\t- simvastatin (used to lower cholesterol),', 'H-1403\t-0.59716796875\t- simvastatin ( used to lower cholesterol levels ) ,', 'D-1403\t-0.59716796875\t- simvastatin (used to lower cholesterol levels),', 'P-1403\t-0.2551 -0.8550 -0.0268 -0.0070 -0.0099 -0.0099 -0.0331 -0.1472 -0.0458 -0.6572 -0.3042 -0.0127 -0.0127 -0.7510 -0.0310 -0.0817 -0.0282', 'S-301\tKommt es während der Therapie zu einer Superinfektion, so sollten geeignete Maßnahmen getroffen werden.', 'T-301\tIf superinfection occurs during therapy, appropriate measures should be taken.', 'H-301\t-0.45361328125\tIf a superinfection occurs during therapy , appropriate measures should be taken .', 'D-301\t-0.45361328125\tIf a superinfection occurs during therapy, appropriate measures should be taken.', 'P-301\t-0.3005 -0.2419 -0.0930 -0.0204 -0.2952 -0.0232 -0.0275 -0.5283 -0.0437 -0.3833 -0.2649 -0.0409 -0.0282 -0.0366 -0.0366 -0.0296', 'S-978\tWIE IST FOSAVANCE EINZUNEHMEN? halten.', 'T-978\tHOW TO TAKE FOSAVANCE.', 'H-978\t-0.411376953125\tHOW TO TAKE FOSAVANCE .', 'D-978\t-0.411376953125\tHOW TO TAKE FOSAVANCE.', 'P-978\t-0.0458 -0.0099 -0.2610 -0.3145 -0.0588 -0.0127 -0.1743 -0.0190 -0.0225 -0.0268 -0.0169 -0.0099 -0.9990 -0.0338', 'S-724\tBei männlichen und weiblichen Nagetieren führt DMA zu einer verminderten Fertilität.', 'T-724\tDMA decreases fertility in male and female rodents.', 'H-724\t-1.0888671875\tIn male and female rodents , DMA results in decreased fertility .', 'D-724\t-1.0888671875\tIn male and female rodents, DMA results in decreased fertility.', 'P-724\t-1.9580 -0.3635 -0.0338 -0.0155 -0.0493 -0.0141 -0.6592 -0.1663 -0.0141 -1.2793 -0.0310 -1.2314 -0.0282 -0.0282 -0.0225 -0.0395 -0.0282', 'S-1107\tKopfschmerzen, Verwirrtheitszustände, senso-motorische Störungen - wie', 'T-1107\tHypertensive crisis with encephalopathy-like symptoms (e. g. headaches and confused state, sensorimotor disorders - such as speech disturbance or impaired gait - up to tonoclonic seizures) may also occur in individual patients with otherwise normal or low blood pressure (see section 4.4).', 'H-1107\t-1.5986328125\tHeadache , confusional state , sensory @-@ motor disorders such as', 'D-1107\t-1.5986328125\tHeadache, confusional state, sensory-motor disorders such as', 'P-1107\t-1.8242 -0.0113 -0.0113 -0.2141 -0.0296 -0.7808 -0.2649 -0.3213 -0.3523 -0.0451 -0.2705 -0.0310 -1.3359 -0.0310 -1.5381 -0.0225 -1.0254 -0.0395 -1.2061', 'S-451\tEs ist noch nicht bekannt, ob eine Auffrischimpfung erforderlich ist (siehe Abschnitt 5.1).', 'T-451\tThe need for a booster dose has not been established (see section 5.1).', 'H-451\t-0.79443359375\tIt is not yet known whether a booster dose is required ( see section 5.1 ) .', 'D-451\t-0.79443359375\tIt is not yet known whether a booster dose is required (see section 5.1).', 'P-451\t-0.6602 -0.0349 -0.0539 -0.7163 -0.0282 -0.1099 -0.2227 -0.2240 -0.0197 -0.3198 -0.5215 -1.4902 -0.0395 -0.0423 -0.1635 -0.0254 -0.0282 -0.0366 -0.0310 -0.0282', 'S-248\tDie Therapie mit < Cozaar Comp > muss abgebrochen und der Patient streng überwacht werden.', 'T-248\tTherapy with Cozaar Comp should be discontinued and the patient observed closely.', 'H-248\t-1.31640625\tTreatment with Cozaar Comp should be discontinued and the patient monitored closely .', 'D-248\t-1.31640625\tTreatment with Cozaar Comp should be discontinued and the patient monitored closely.', 'P-248\t-1.8213 -0.0225 -0.0296 -0.0578 -0.6143 -0.0169 -0.0197 -0.1282 -0.0197 -0.7383 -0.0535 -0.8848 -0.0056 -0.8594 -0.7241 -0.0169 -1.6738 -0.0282 -0.1917 -0.2479 -0.0282', 'S-212\tDie Informationsbroschüren für männliche Partner von Frauen im gebärfähigen Alter müssen die folgenden Informationen enthalten:', 'T-212\tThe information for male partners of women with child-bearing potential should include the following information:', 'H-212\t-1.291015625\t31 Booklet for male partners of women with child @-@ bearing potential should contain the following information :', 'D-212\t-1.291015625\t31 Booklet for male partners of women with child-bearing potential should contain the following information:', 'P-212\t-0.6963 -1.7207 -0.0535 -0.5820 -0.1268 -0.1296 -0.0310 -0.1014 -0.0958 -0.8311 -0.6113 -0.2620 -0.0169 -0.3213 -0.7554 -1.0654 -0.1578 -0.0338 -0.3662 -0.0395 -0.0282', 'S-173\tDukoral ist ein Impfstoff, der als Suspension in einer Durchstechflasche erhältlich ist.', 'T-173\tDukoral is a vaccine, which is available as a suspension in a vial.', 'H-173\t-0.38037109375\tDukoral is a vaccine , which is available in a vial .', 'D-173\t-0.38037109375\tDukoral is a vaccine, which is available in a vial.', 'P-173\t-0.0242 -0.0085 -0.0285 -0.0429 -0.0400 -0.0700 -0.2910 -0.1219 -0.1205 -0.0585 -0.2120 -0.5332 -0.1437 -0.0099 -0.2720 -0.0310', 'S-1809\tOptimark sollte nur von Ärzten angewendet werden, die Erfahrung in der klinischen MRT-Praxis besitzen.', 'T-1809\tOptimark should only be administered by physicians experienced in clinical MRI practice.', 'H-1809\t-0.98388671875\tOptimark should only be used by physicians who have experience in the clinical MRI practice .', 'D-1809\t-0.98388671875\tOptimark should only be used by physicians who have experience in the clinical MRI practice.', 'P-1809\t-0.0191 -0.0141 -0.0371 -0.5620 -0.0285 -0.7437 -0.0338 -1.2324 -0.0155 -1.3936 -0.3381 -0.0901 -0.0845 -0.6001 -0.5073 -0.0535 -0.0338 -0.0901 -0.0338 -0.0282', 'S-1073\t16 Fälle wurde als mögliche oder wahrscheinliche Fälle eines erworbenen Nierenversagens eingestuft.', 'T-1073\tSixteen cases were identified as possible or probable cases of acquired renal failure.', 'H-1073\t-1.353515625\tSixteen cases have been assessed as a possible or probable case of acquired renal failure .', 'D-1073\t-1.353515625\tSixteen cases have been assessed as a possible or probable case of acquired renal failure.', 'P-1073\t-2.5156 -0.0155 -0.4438 -1.5615 -0.0225 -0.5835 -0.0169 -0.0282 -1.1582 -0.2649 -0.0395 -0.0845 -0.0225 -0.0507 -0.0338 -1.2119 -0.2593 -0.0225 -0.0169 -0.0282 -0.0282', 'S-209\tIntronA wird nach einer Operation zur Vorbeugung gegen das Wiederauftreten des Melanoms angewendet.', 'T-209\tIntronA is used after surgery in patients whose melanoma could come back.', 'H-209\t-0.89306640625\tIntronA is used to prevent recurrence of melanoma after an operation .', 'D-209\t-0.89306640625\tIntronA is used to prevent recurrence of melanoma after an operation.', 'P-209\t-0.2137 -0.0171 -0.0255 -0.0444 -0.4263 -1.3330 -0.0437 -0.6792 -0.0113 -0.0352 -0.0183 -0.0409 -0.2141 -0.0197 -0.0085 -1.2627 -0.9019 -0.0338 -0.0338 -0.0282', 'S-1303\tDepressive Patienten zeigen eine Reihe von Symptomen, die mit der Grunderkrankung im Zusammenhang stehen.', 'T-1303\tDepressed patients display a number of symptoms that are associated with the illness itself.', 'H-1303\t-1.3056640625\tDespite this , in special cases your doctor may prescribe Remeron for you .', 'D-1303\t-1.3056640625\tDespite this, in special cases your doctor may prescribe Remeron for you.', 'P-1303\t-0.6133 -0.2673 -0.1036 -0.3220 -0.3284 -0.2072 -0.3228 -0.3198 -0.3311 -0.5552 -0.0197 -0.4819 -0.3325 -0.3213 -0.3269 -0.3042 -2.1914 -0.0451', 'S-452\tHalten Sie sich an diese Empfehlung, es sei denn, Ihr Arzt verordnet Ihnen eine andere Dosierung.', 'T-452\tUse this much unless your doctor tells you something differently.', 'H-452\t-0.66650390625\tUse this much unless your doctor tells you to do something different .', 'D-452\t-0.66650390625\tUse this much unless your doctor tells you to do something different.', 'P-452\t-0.3418 -0.1097 -0.3220 -0.3015 -0.0521 -0.0338 -0.8721 -0.0268 -0.2085 -0.2888 -0.3508 -0.2311 -0.0564 -0.0507', 'S-559\tRebif ist als Injektionslösung in einer Fertigspritze mit feststehender Nadel erhältlich.', 'T-559\tRebif is available as a solution for injection in a pre-filled syringe with a fixed needle for self- administration.', 'H-559\t-0.61669921875\tRebif is a solution for injection in a pre @-@ filled syringe with a fixed needle for self @-@ administration .', 'D-559\t-0.61669921875\tRebif is a solution for injection in a pre-filled syringe with a fixed needle for self-administration.', 'P-559\t-0.0242 -0.0242 -0.0414 -1.0146 -0.4043 -0.1635 -0.0690 -0.0760 -0.3352 -0.0620 -0.1945 -0.0268 -0.2128 -0.0211 -0.0099 -0.0028 -0.0592 -0.2423 -0.0338 -0.0310 -0.0197 -0.5747 -0.3352 -0.1071 -0.3042 -0.0366 -0.0282', 'S-1063\tVor der Verabreichung von Beromun wird zunächst das betroffene Gliedmaß isoliert:', 'T-1063\tBefore Beromun is given, the limb is first isolated: while the patient is under general anaesthetic, a tight band is placed around the top of the limb to isolate its blood supply and prevent the medicine reaching the rest of the body.', 'H-1063\t-1.251953125\tBefore administration of Beromun , the affected limb is isolated :', 'D-1063\t-1.251953125\tBefore administration of Beromun, the affected limb is isolated:', 'P-1063\t-0.5654 -1.1074 -0.0507 -0.0282 -0.0169 -0.0197 -0.3916 -0.7959 -0.0676 -0.6987 -0.0113 -0.1578 -2.0059 -0.1127 -0.3269', 'S-1739\tRifabutin / Efavirenz (300 q.d. / 600 q.d.)', 'T-1739\tRifabutin / Efavirenz (300 q. d. / 600 q. d.) Rifabutin / Emtricitabine Rifabutin / Tenofovir disoproxil fumarate', 'H-1739\t-0.273193359375\tRifabutin / Efavirenz ( 300 q. d . / 600 q. d . )', 'D-1739\t-0.273193359375\tRifabutin / Efavirenz (300 q. d. / 600 q. d.)', 'P-1739\t-0.1775 -0.0099 -0.0171 -0.0327 -0.0414 -0.0701 -0.0141 -0.0285 -0.0070 -0.0370 -0.0299 -0.0306 -0.0887 -0.3213 -0.2783 -0.1556 -0.0289 -0.0169 -0.0303 -0.2974 -0.0338 -0.0296 -0.0310 -0.0310', 'S-1169\t402 ANGABEN AUF DER ÄUSSEREN UMHÜLLUNG', 'T-1169\t342 PARTICULARS TO APPEAR ON THE OUTER PACKAGING UNBLISTERED PRE-FILLED SYRINGE CARTON', 'H-1169\t-1.111328125\t402 PARTICULARS TO APPEAR ON THE OUTER PACKAGING', 'D-1169\t-1.111328125\t402 PARTICULARS TO APPEAR ON THE OUTER PACKAGING', 'P-1169\t-2.5215 -0.0183 -0.3228 -0.2620 -0.0366 -0.2930 -0.2255 -0.2113 -0.3184 -0.3213 -0.2847 -0.2001 -0.3015 -0.3042 -0.0817 -0.0901 -0.1071 -0.0338 -0.2141 -0.3213 -0.3157 -0.0789 -0.0113 -0.1635 -0.6313', 'S-1851\t19% erhöht, wenn Ketoconazol gleichzeitig mit Amprenavir allein verabreicht wurde.', 'T-1851\tKetoconazole / Itraconazole: the AUC and Cmax of ketoconazole were increased by 44% and 19%, respectively when given with amprenavir alone.', 'H-1851\t-1.2578125\tKetoconazole / Itraconazole : the AUC and Cmax of ketoconazole were increased by 44 % and 19 % respectively .', 'D-1851\t-1.2578125\tKetoconazole / Itraconazole: the AUC and Cmax of ketoconazole were increased by 44% and 19% respectively.', 'P-1851\t-0.3213 -0.0248 -0.0271 -0.0099 -0.0077 -0.3303 -0.3472 -0.3247 -0.3030 -0.0718 -0.0028 -0.3284 -0.3184 -0.3550 -0.3157 -0.3550 -0.3240 -0.4143 -0.3213 -0.4001 -0.0366 -0.0338 -0.0141 -0.0056 -0.2817 -0.1240 -0.1691 -0.5859 -0.0451 -0.4846 -0.2649 -0.0338 -0.2367 -3.3750 -0.0282', 'S-1113\t442 dieser Patienten erhielten eine Dosis von 2x täglich 400 / 100 mg (3 Kapseln).', 'T-1113\tThe safety of Kaletra has been investigated in 612 patients in Phase II / III clinical trials, of which 442 have received a dose of 400 / 100 mg (3 capsules) twice daily.', 'H-1113\t-0.9208984375\t442 of these patients received a dose of 400 / 100 mg ( 3 capsules ) twice daily .', 'D-1113\t-0.9208984375\t442 of these patients received a dose of 400 / 100 mg (3 capsules) twice daily.', 'P-1113\t-2.6523 -0.0155 -0.2156 -0.0648 -0.0225 -0.3916 -0.4114 -0.9526 -0.0310 -0.0423 -0.0310 -0.0479 -0.0169 -0.1071 -0.0423 -0.0338 -0.0169 -0.0225 -0.0338 -0.0592 -0.4087 -0.3945 -0.0282', 'S-361\tDiese Dosis kann jedoch auf zwei Sprühstöße erhöht werden, wenn die Symptome nicht unter Kontrolle sind.', 'T-361\tAVAMYS should only be used for as long as the patient is exposed to the allergen, such as pollen, house dust mites or other animals.', 'H-361\t-1.1728515625\tHowever , this dose may be increased to two sprays if symptoms are not controlled .', 'D-361\t-1.1728515625\tHowever, this dose may be increased to two sprays if symptoms are not controlled.', 'P-361\t-1.4697 -0.6831 -0.5708 -0.4155 -0.8818 -0.0366 -0.3662 -0.0564 -0.0507 -0.1973 -0.0225 -0.0789 -0.9019 -0.0395 -0.1409 -0.2930 -0.4114 -0.0282', 'S-1974\ts las Nicht verwendetes Arzneimittel oder Abfallmaterial sind entsprechend den nationalen Anforderungen zu entsorgen.', 'T-1974\t42 Any unused product or waste material should be disposed of in accordance with local requirements.', 'H-1974\t-0.67333984375\tAny unused product or waste material should be disposed of in accordance with local requirements .', 'D-1974\t-0.67333984375\tAny unused product or waste material should be disposed of in accordance with local requirements.', 'P-1974\t-0.8032 -0.1141 -0.0296 -1.1113 -0.0564 -0.0352 -0.3325 -0.2874 -0.0296 -0.0775 -0.0113 -0.0338 -0.1917 -0.0760 -0.0225 -0.0310 -0.3213 -0.4312 -0.0395 -0.0282', 'S-356\tUnter Langzeittherapie lag die Infektionsrate bei 1,8 pro 100 Patientenjahren (siehe Abschnitt 4.4).', 'T-356\tOver long term treatment, the incidence of serious infection was 1.8 per 100 patient years (see section 4.).', 'H-356\t-1.6005859375\tPlacement rates were 1.8 per 100 patient years during long @-@ term treatment ( see section 4.4 ) .', 'D-356\t-1.6005859375\tPlacement rates were 1.8 per 100 patient years during long-term treatment (see section 4.4).', 'P-356\t-2.1250 -0.5972 -1.5107 -1.3105 -0.0958 -0.0169 -0.2563 -0.0282 -0.1071 -0.6143 -2.0117 -0.3550 -0.5352 -0.0282 -0.4622 -0.0451 -0.0395 -0.2141 -0.0225 -0.0282 -0.0395 -0.0338 -0.0282', 'S-1835\tHistologisch glichen diese Veränderungen denen bei Albino-Ratten nach übermäßiger Lichtexposition.', 'T-1835\tThe histologic appearance of these changes was similar to that found in albino rats following excessive exposure to light.', 'H-1835\t-0.96435546875\tHistologically , these changes were similar to that of albino rats following excessive exposure to light .', 'D-1835\t-0.96435546875\tHistologically, these changes were similar to that of albino rats following excessive exposure to light.', 'P-1835\t-0.9502 -0.0409 -0.0254 -0.4839 -0.0775 -0.0395 -0.4338 -0.0395 -0.0324 -0.6455 -2.0723 -0.0310 -0.0141 -0.0366 -0.2085 -0.3945 -0.0732 -0.2959 -0.1521 -0.0564 -0.0282 -0.0282', 'S-1605\tMIRCERA 60 Mikrogramm / 0,3 ml Injektionslösung in einer Fertigspritze', 'T-1605\tMIRCERA 60 micrograms / 0.3 ml solution for injection in pre-filled syringe.', 'H-1605\t-0.38671875\tMIRCERA 60 micrograms / 0.3 ml solution for injection in pre @-@ filled syringe', 'D-1605\t-0.38671875\tMIRCERA 60 micrograms / 0.3 ml solution for injection in pre-filled syringe', 'P-1605\t-0.0538 -0.0141 -0.0284 -0.0177 -0.0270 -0.0298 -0.1058 -0.1265 -0.0320 -0.0976 -0.0342 -0.0197 -0.2866 -0.3101 -0.1028 -0.0430 -0.0669 -0.3184 -0.0268 -0.1691 -0.0211 -0.0366 -0.0028 -0.6328', 'S-1487\tIm Urin finden sich weniger als 2% einer am Auge gegebenen Dosis als freie Säure.', 'T-1487\tLess than 2% of an ocular dose of travoprost was recovered in urine as free acid.', 'H-1487\t-1.18359375\tLess than 2 % of an administered dose in the eye is recovered in the urine as free acid .', 'D-1487\t-1.18359375\tLess than 2% of an administered dose in the eye is recovered in the urine as free acid.', 'P-1487\t-0.6592 -0.0127 -0.0313 -0.0373 -0.0388 -0.0310 -1.7764 -0.5044 -0.0197 -0.2593 -0.7974 -0.0366 -0.1240 -0.6821 -0.6621 -0.4536 -0.7495 -0.0169 -0.0169 -0.1465 -0.8057 -0.0451 -0.0338 -0.0282', 'S-1891\tJede Filmtablette enthält 300 mg Irbesartan (als Hydrochlorid).', 'T-1891\tEach film-coated tablet contains 300 mg irbesartan (as hydrochloride).', 'H-1891\t-0.427978515625\tEach film @-@ coated tablet contains 300 mg irbesartan ( as hydrochloride ) .', 'D-1891\t-0.427978515625\tEach film-coated tablet contains 300 mg irbesartan (as hydrochloride).', 'P-1891\t-0.0590 -0.0841 -0.3198 -0.3220 -0.0282 -0.0388 -0.0240 -0.0416 -0.0620 -0.0204 -1.2207 -0.0380 -0.0070 -0.0451 -0.0352 -0.1198 -0.0507 -0.0268 -0.0268 -0.0169 -0.0211 -0.0310 -0.2128 -0.0282', 'S-1559\tWenn Sie eine Diabetesdiät befolgen, sollten Sie diese unter Tandemact fortführen.', 'T-1559\tIf you are following a special diet for diabetes, you should continue with this while you are taking Tandemact.', 'H-1559\t-0.5205078125\tIf you are following a diabetic diet , you should continue with Tandemact .', 'D-1559\t-0.5205078125\tIf you are following a diabetic diet, you should continue with Tandemact.', 'P-1559\t-0.1998 -0.0285 -0.2485 -0.1515 -0.0384 -0.2913 -0.0613 -0.0331 -0.0225 -0.0760 -0.8413 -0.0380 -0.0690 -0.6763 -0.1550 -0.0366 -0.0085 -0.0423 -0.0282', 'S-640\tDiltiazem / Efavirenz (240 q.d. / 600 q.d.)', 'T-640\tDiltiazem / Efavirenz (240 q. d. / 600 q. d.)', 'H-640\t-0.3251953125\tDiltiazem / Efavirenz ( 240 q. d . / 600 q. d . )', 'D-640\t-0.3251953125\tDiltiazem / Efavirenz (240 q. d. / 600 q. d.)', 'P-640\t-0.5327 -0.0225 -0.0127 -0.0183 -0.0430 -0.0856 -0.0137 -0.0240 -0.0099 -0.0972 -0.0303 -0.0247 -0.0352 -0.3228 -0.2859 -0.1381 -0.0296 -0.0169 -0.0183 -0.3042 -0.0310 -0.0296 -0.0310 -0.0310', 'S-513\tFrankenschmidt A., Naber K.G., Bischoff W., Kullmann K.', 'T-513\t1. Frankenschmidt A., Naber K. G., Bischoff W., Kullmann K.', 'H-513\t-2.029296875\tRichard Woodward , Hedrich Ā , Toivonen K .', 'D-513\t-2.029296875\tRichard Woodward, Hedrich Ā, Toivonen K.', 'P-513\t-0.5674 -1.5488 -0.1691 -0.7158 -0.6084 -0.3718 -1.0449 -0.3916 -1.9980 -1.0654 -0.2479 -0.2649 -1.2061 -0.0620 -0.0395', 'S-958\tEine gemeinsame Anwendung von Nifedipin und Rifampicin ist daher kontraindiziert.', 'T-958\tCo-administration of nifedipine with rifampicin is therefore contra-indicated.', 'H-958\t-0.5693359375\tCo @-@ administration of nifedipine and rifampicin is therefore contraindicated .', 'D-958\t-0.5693359375\tCo-administration of nifedipine and rifampicin is therefore contraindicated.', 'P-958\t-2.0215 -0.0282 -0.2847 -0.0409 -0.1310 -0.0225 -0.0169 -0.0507 -0.0225 -0.0564 -0.0183 -0.0169 -0.0268 -0.0183 -0.0845 -0.0507 -0.5073 -0.0732 -0.0056 -0.0310 -0.0282', 'S-354\tmcg / m2 intramuskulär 125 mcg / m2 intramuskulär', 'T-354\t300 mcg / m2 125 mcg / m2 intramuscularly intramuscularly', 'H-354\t-0.427978515625\tmcg / m2 intramuscularly 125 mcg / m2 intramuscularly', 'D-354\t-0.427978515625\tmcg / m2 intramuscularly 125 mcg / m2 intramuscularly', 'P-354\t-0.0299 -0.0249 -0.0256 -0.0278 -0.0135 -0.0298 -0.0213 -0.0141 -0.8784 -0.0620 -0.0113 -0.0204 -0.0240 -0.0240 -0.0282 -0.0056 -0.0204 -0.0169 -0.0070 -1.1016 -0.0169 -0.3296', 'S-1676\t20 ml (10 Dosen) 50 ml (25 Dosen) 100 ml (50 Dosen)', 'T-1676\t20 ml (10 doses) 50 ml (25 doses) 100 ml (50 doses)', 'H-1676\t-0.70751953125\t20 ml ( 10 doses ) 50 ml ( 25 doses )', 'D-1676\t-0.70751953125\t20 ml (10 doses) 50 ml (25 doses)', 'P-1676\t-0.0444 -0.0184 -0.0284 -0.0270 -0.2761 -0.0264 -0.0278 -0.0250 -0.0127 -0.0278 -0.0204 -0.0183 -0.0211 -0.0285 -2.9902', 'S-1569\tDyspnoe, Diplopie, Fieber, Ptosis, Stimmveränderungen.', 'T-1569\tDyspnoea, diplopia, fever, ptosis, voice alteration.', 'H-1569\t-0.66162109375\tDyspnoea , diplopia , fever , ptosis , voice alteration .', 'D-1569\t-0.66162109375\tDyspnoea, diplopia, fever, ptosis, voice alteration.', 'P-1569\t-0.8657 -0.0225 -0.4727 -0.0359 -0.0296 -0.2148 -0.0169 -0.0338 -0.0169 -0.0296 -0.4453 -0.0183 -0.0310 -0.0197 -0.0197 -0.0155 -0.0395 -0.2747 -0.6240 -0.7324 -0.2395 -0.0282', 'S-751\tEine Hämodialyse ist nicht sinnvoll, da Nifedipin nicht dialysiert werden kann.', 'T-751\tHaemodialysis is not useful, since nifedipine cannot be dialysed.', 'H-751\t-1.0576171875\tHemodialysis is inappropriate , as nifedipine cannot be dialysed .', 'D-751\t-1.0576171875\tHemodialysis is inappropriate, as nifedipine cannot be dialysed.', 'P-751\t-0.7314 -0.0049 -0.0141 -0.0120 -0.0183 -0.0698 -0.3198 -1.5498 -0.5015 -0.3972 -0.0197 -0.0141 -0.0592 -0.0225 -0.6934 -0.0310 -1.2510 -0.0254 -0.7749 -0.0338 -0.0282', 'S-587\tRatiopharm Gmbh Graf-Arco Strasse 3 D-89070 Ulm Deutschland', 'T-587\tRatiopharm Gmbh Graf-Arco Strasse 3 D-89070 Ulm Germany', 'H-587\t-0.0640869140625\tRatiopharm Gmbh Graf @-@ Arco Strasse 3 D @-@ 89070 Ulm Germany', 'D-587\t-0.0640869140625\tRatiopharm Gmbh Graf-Arco Strasse 3 D-89070 Ulm Germany', 'P-587\t-0.0220 -0.0127 -0.0242 -0.0028 -0.0386 -0.0092 -0.0227 -0.0042 -0.0277 -0.0227 -0.0178 -0.0113 -0.0092 -0.0269 -0.0178 -0.0292 -0.0241 -0.0141 -0.0171 -0.0056 -0.0211 -0.0285', 'S-64\tEs gibt keine Daten zur Anwendung von Rotarix zur postexpositionellen Prophylaxe.', 'T-64\tNo data are available on the use of Rotarix for post-exposure prophylaxis.', 'H-64\t-0.62158203125\tThere are no data from the use of Rotarix for post @-@ exposure prophylaxis .', 'D-64\t-0.62158203125\tThere are no data from the use of Rotarix for post-exposure prophylaxis.', 'P-64\t-0.9546 -0.2255 -0.0303 -0.0620 -1.3682 -0.1888 -0.0817 -0.0282 -0.0141 -0.0169 -0.0254 -0.3916 -0.1381 -0.0366 -0.0366 -0.2311 -0.0169 -0.0282 -0.0169 -0.0197 -0.0338 -0.0282', 'S-1742\tBis zum Vorliegen zusätzlicher klinischer Daten sollte die empfohlene Behandlungszeit von 24 Monaten nicht überschritten werden.', 'T-1742\tUntil further clinical data becomes available the recommended treatment time of 24 months should not be exceeded.', 'H-1742\t-0.400146484375\tUntil further clinical data become available , the recommended treatment time of 24 months should not be exceeded .', 'D-1742\t-0.400146484375\tUntil further clinical data become available, the recommended treatment time of 24 months should not be exceeded.', 'P-1742\t-0.1982 -0.2856 -0.0327 -0.0384 -0.3311 -0.0169 -0.1945 -0.0859 -0.0183 -0.1226 -0.3987 -0.0423 -0.0254 -0.4917 -0.0493 -0.0395 -0.0296 -0.0113 -0.0141 -0.0324 -0.0282', 'S-344\t- sichergestellt ist, dass der Patient über die Infusionsdauer sorgfältig auf etwaige Symptome überwacht', 'T-344\tIn', 'H-344\t-1.47265625\t- to ensure that the patient is carefully monitored for any symptoms throughout the infusion period', 'D-344\t-1.47265625\t- to ensure that the patient is carefully monitored for any symptoms throughout the infusion period', 'P-344\t-0.1561 -2.0352 -0.4902 -0.9214 -0.4734 -0.0197 -1.3643 -0.4058 -0.0507 -0.0169 -0.0732 -0.1127 -0.1240 -0.5581 -0.0395 -0.2986 -0.0282 -0.6030 -0.8398', 'S-686\teinbezogenen Ponys nicht angegeben, weshalb die Adäquatheit der Infektionen nicht dokumentiert werden kann.', 'T-686\twas not stated therefore the adequacy of the infections cannot be documented.', 'H-686\t-3.404296875\tThe CHMP would not only provide cumulative reviews of the efficacy of KIOVIG .', 'D-686\t-3.404296875\tThe CHMP would not only provide cumulative reviews of the efficacy of KIOVIG.', 'P-686\t-1.3037 -2.3672 -0.3213 -2.7637 -0.0338 -1.3242 -2.3789 -1.4873 -0.0113 -0.0225 -0.3606 -0.5298 -1.0820 -1.3867 -0.0225 -0.0225 -0.5747 -2.3789 -0.6875 -0.3269 -0.3269 -2.5586 -0.0564', 'S-178\t- Pflanzliche Heilmittel wie Johanniskraut (Hypericum perforatum) oder andere', 'T-178\tJohn <<unk>> s wort (Hypericum perforatum) or any', 'H-178\t-0.583984375\tJohn &apos;s Wort ( Hypericum perforatum ) or any', "D-178\t-0.583984375\tJohn's Wort (Hypericum perforatum) or any", 'P-178\t-0.3552 -1.0000 -0.5806 -0.0395 -0.0803 -0.0225 -0.0211 -0.0240 -0.0296 -0.0183 -0.0197 -0.0197 -0.0296 -0.0592 -0.4438 -0.3396', 'S-577\tWIE IST HBVAXPRO 10 Mikrogramm / ml ANZUWENDEN?', 'T-577\tHOW TO USE HBVAXPRO 10 micrograms / ml', 'H-577\t-0.31396484375\tHOW TO USE HBVAXPRO 10 micrograms / ml', 'D-577\t-0.31396484375\tHOW TO USE HBVAXPRO 10 micrograms / ml', 'P-577\t-0.0199 -0.0127 -0.1389 -0.0546 -0.0127 -0.0269 -0.0269 -0.0269 -0.0185 -0.0120 -0.0204 -0.2434 -0.0588 -0.0627 -0.0324 -0.0388 -0.9121', 'S-1103\tErgebnisse zur Wirksamkeit (solide Tumoren außer Mammakarzinom und Prostatakarzinom)', 'T-1103\tEfficacy results (solid tumours other than breast or prostate cancer)', 'H-1103\t-0.7314453125\tEfficacy results ( solid tumours except breast cancer and prostate cancer )', 'D-1103\t-0.7314453125\tEfficacy results (solid tumours except breast cancer and prostate cancer)', 'P-1103\t-0.0872 -0.0983 -0.0113 -0.4023 -0.0320 -0.0271 -0.0197 -0.2205 -1.7559 -0.1479 -0.9961 -0.0366 -0.0225 -0.0141 -0.0704 -0.0282 -0.0338', 'S-1269\tDie Durchstechflaschen enthalten 20 ml steriles Konzentrat und sind in einer Schachtel verpackt.', 'T-1269\tThe vials contain 20 ml sterile concentrate and are packaged in a box.', 'H-1269\t-0.58837890625\tThe vials contain 20 ml sterile concentrate and are packaged in a box .', 'D-1269\t-0.58837890625\tThe vials contain 20 ml sterile concentrate and are packaged in a box.', 'P-1269\t-0.0797 -0.0531 -0.0299 -0.0634 -0.0386 -0.5488 -0.6514 -0.0169 -0.0155 -0.6748 -0.0803 -0.5000 -0.0225 -0.0310 -0.0775 -0.3845 -0.0338 -0.0310', 'S-1444\tFalls Sie vermuten, dass jemand versehentlich Rapinyl eingenommen hat, rufen Sie sofort den Notarzt.', 'T-1444\tIf you think someone has taken Rapinyl by accident seek emergency medical help immediately.', 'H-1444\t-1.259765625\tIf you suspect someone has accidentally taken Rapinyl , call for emergency help immediately .', 'D-1444\t-1.259765625\tIf you suspect someone has accidentally taken Rapinyl, call for emergency help immediately.', 'P-1444\t-0.3945 -0.0327 -0.9043 -0.5239 -0.7705 -0.2043 -0.0240 -0.1071 -0.0535 -0.0254 -0.0141 -0.2283 -1.4902 -0.7554 -0.3777 -0.7891 -0.6143 -0.0338 -0.0282', 'S-239\tJede neue Injektion sollte mindestens im Abstand von 3 cm von der letzten Injektionsstelle verabreicht werden.', 'T-239\tEach new injection should be given at least 3 cm from the last injection site.', 'H-239\t-0.427978515625\tEach new injection should be given at least 3 cm from the last injection site .', 'D-239\t-0.427978515625\tEach new injection should be given at least 3 cm from the last injection site.', 'P-239\t-0.3762 -0.0828 -0.0402 -0.3970 -0.0416 -0.0388 -0.2903 -0.0930 -0.1536 -0.1536 -0.0493 -0.2113 -0.1479 -0.1028 -0.2072 -0.0085 -0.0465 -0.0352 -0.0296', 'S-996\tTierexperimentelle Studien haben eine minimale Entwicklungstoxizität gezeigt (siehe Abschnitt 5.3).', 'T-996\tAnimal studies have revealed minimal developmental toxicity (see section 5.3).', 'H-996\t-0.484375\tStudies in animals have shown minimal developmental toxicity ( see section 5.3 ) .', 'D-996\t-0.484375\tStudies in animals have shown minimal developmental toxicity (see section 5.3).', 'P-996\t-0.7603 -0.2395 -0.2739 -0.0634 -0.1007 -0.5415 -0.0352 -0.0169 -0.0155 -0.0127 -0.0197 -0.0352 -0.0423 -0.5312 -0.0268 -0.0268 -0.0338 -0.0296 -0.0282', 'S-1447\tCeplene ist in Packungsgrößen von 14 Durchstechflaschen zum einmaligen Gebrauch erhältlich.', 'T-1447\tCeplene is available in pack sizes of 14 single-use vials.', 'H-1447\t-0.7275390625\tCeplene is available in packs of 14 single @-@ use vials .', 'D-1447\t-0.7275390625\tCeplene is available in packs of 14 single-use vials.', 'P-1447\t-0.5342 -0.0183 -0.0236 -0.0148 -0.0532 -0.0384 -0.0342 -1.0752 -0.0634 -0.4805 -0.0296 -0.5845 -0.8311 -0.0085 -0.2395 -0.0254 -0.0366 -0.0310', 'S-525\tInfektion, orale Moniliasis, Herpes zoster, Harnwegs- infektion', 'T-525\tInfection, oral moniliasis, herpes zoster, urinary tract infection', 'H-525\t-0.38037109375\tInfection , oral moniliasis , herpes zoster , urinary tract infection', 'D-525\t-0.38037109375\tInfection, oral moniliasis, herpes zoster, urinary tract infection', 'P-525\t-0.5073 -0.2903 -0.0310 -0.8086 -0.0451 -0.0127 -0.0183 -0.0240 -0.0296 -0.3352 -0.0099 -0.0056 -0.0254 -0.0296 -0.0127 -0.0085 -0.0296 -0.0169 -0.0225 -0.0324', 'S-1168\tInjektionsnadeln von anderen Ländern passen unter Umständen nicht auf Ihren NutropinAq Pen.', 'T-1168\tNeedles from other countries may not fit on your NutropinAq Pen.', 'H-1168\t-1.04296875\tInjection needles produced in other countries may not be compatible with your NutropinAq Pen .', 'D-1168\t-1.04296875\tInjection needles produced in other countries may not be compatible with your NutropinAq Pen.', 'P-1168\t-1.2227 -0.0268 -0.0690 -0.0240 -0.6025 -1.1895 -0.3916 -0.0282 -0.3833 -0.0338 -1.4092 -0.8423 -0.0056 -0.0225 -0.5073 -0.1353 -0.0225 -0.0169 -0.0169 -0.0225 -0.0282 -0.0169 -0.1127 -0.0395 -0.0282', 'S-1220\tAranesp 30 µg Injektionszubereitung Darbepoetin alfa IV / SC', 'T-1220\tAranesp 30 µg injection Darbepoetin alfa IV / SC', 'H-1220\t-0.173095703125\tAranesp 30 µg injection Darbepoetin alfa IV / SC', 'D-1220\t-0.173095703125\tAranesp 30 µg injection Darbepoetin alfa IV / SC', 'P-1220\t-0.0342 -0.0141 -0.0234 -0.0213 -0.0335 -0.0099 -0.0227 -0.2676 -0.0243 -0.3223 -0.0268 -0.0268 -0.0183 -0.0296 -0.0402 -0.0099 -0.0176 -0.0296 -0.0134 -0.0592', 'S-1370\tDieses kann zu falsch positiven HIV-Testergebnissen beim anti-HIV-ELISA-Test führen.', 'T-1370\tThis may result in a false positive HIV test with the anti-HIV ELISA test.', 'H-1370\t-1.5107421875\tThis may lead to misleading HIV test results from the anti @-@ HIV @-@ ELISA assay .', 'D-1370\t-1.5107421875\tThis may lead to misleading HIV test results from the anti-HIV-ELISA assay.', 'P-1370\t-0.7041 -0.6646 -1.5723 -0.0310 -1.6709 -0.2986 -0.1155 -0.1775 -0.0254 -1.3154 -0.9526 -0.0620 -0.0395 -0.0225 -0.8735 -0.0169 -0.0282 -0.0169 -0.9751 -0.0225 -0.0338 -0.0282', 'S-369\tDie Auswirkung dieser Antikörper auf die Sicherheit und Wirksamkeit des Arzneimittels ist noch nicht vollständig bekannt.', 'T-369\tThe effect of these on the safety and effectiveness of the medicine is not fully known.', 'H-369\t-0.91357421875\tThe effect of these antibodies on the safety and efficacy of the product is unknown .', 'D-369\t-0.91357421875\tThe effect of these antibodies on the safety and efficacy of the product is unknown.', 'P-369\t-0.0451 -0.3835 -0.0327 -0.2156 -0.0225 -0.0127 -0.0310 -0.5063 -0.0430 -0.0289 -0.3691 -0.0085 -0.0169 -0.0282 -0.0507 -1.4170 -0.0366 -2.1387 -0.0986 -0.0282', 'S-1756\tPatienten und Pflegekräfte müssen vorsichtig sein, bis sie mit den potenziellen Wirkungen dieses Arzneimittels vertraut sind.', 'T-1756\tPatients and carers should exercise caution until they are familiar with the potential effects of this medicinal product.', 'H-1756\t-0.6337890625\tPatients and caregivers must be careful until they are familiar with the potential effects of this medicinal product .', 'D-1756\t-0.6337890625\tPatients and caregivers must be careful until they are familiar with the potential effects of this medicinal product.', 'P-1756\t-0.0234 -0.0177 -0.0292 -0.4863 -0.4485 -0.0169 -0.4417 -0.4607 -0.8511 -0.0803 -0.0409 -0.1521 -0.1465 -0.0282 -0.0451 -0.0873 -0.1268 -0.0366 -0.0592 -0.5581 -0.0507 -0.0225 -0.0310 -0.0282', 'S-1773\tEU / 1 / 97 / 030 / 048 EU / 1 / 97 / 030 / 049', 'T-1773\tEU / 1 / 97 / 030 / 048 EU / 1 / 97 / 030 / 049', 'H-1773\t-0.1358642578125\tEU / 1 / 97 / 030 / 048 EU / 1 / 97 / 030 / 049', 'D-1773\t-0.1358642578125\tEU / 1 / 97 / 030 / 048 EU / 1 / 97 / 030 / 049', 'P-1773\t-0.0357 -0.0327 -0.0284 -0.0299 -0.0135 -0.0284 -0.0285 -0.0255 -0.0285 -0.0285 -0.3132 -0.0292 -0.0306 -0.0271 -0.0299 -0.0106 -0.0282 -0.0225 -0.0254 -0.0282 -0.0218 -0.0155 -0.0296', 'S-1869\tLinearität Amlodipin und Valsartan zeigen eine lineare Pharmakokinetik.', 'T-1869\tLinearity Amlodipine and valsartan exhibit linear pharmacokinetics.', 'H-1869\t-0.30615234375\tLinearity amlodipine and valsartan exhibit linear pharmacokinetics .', 'D-1869\t-0.30615234375\tLinearity amlodipine and valsartan exhibit linear pharmacokinetics.', 'P-1869\t-0.2056 -0.0120 -0.0134 -0.4636 -0.0211 -0.0197 -0.0444 -0.0204 -0.0310 -0.0232 -0.0218 -0.0127 -0.0352 -0.5903 -0.0183 -0.1663 -0.0197 -0.1564 -0.0113 -0.0113 -0.0380 -0.0437 -0.0296', 'S-597\tPREZISTA sollte bei Patienten mit bekannter Sulfonamidallergie mit Vorsicht angewendet werden.', 'T-597\tPREZISTA should be used with caution in patients with a known sulphonamide allergy.', 'H-597\t-0.409912109375\tPREZISTA should be used with caution in patients with a known sulphonamide allergy .', 'D-597\t-0.409912109375\tPREZISTA should be used with caution in patients with a known sulphonamide allergy.', 'P-597\t-0.0277 -0.0961 -0.0142 -0.0070 -0.0414 -0.0357 -0.3276 -0.1296 -0.0807 -0.0859 -0.0331 -0.3276 -0.2810 -0.5044 -0.2395 -0.2649 -0.1099 -0.0268 -0.0183 -0.0155 -0.0070 -0.0240 -0.0324 -0.0296', 'S-829\tLamictal 50 mg Tabletten zur Herstellung einer Suspension zum Einnehmen bzw.', 'T-829\tLamictal 50 mg dispersible / chewable tablets are square with rounded corners.', 'H-829\t-0.94677734375\tLamictal 50 mg dispersible / chewable tablets are round .', 'D-829\t-0.94677734375\tLamictal 50 mg dispersible / chewable tablets are round.', 'P-829\t-0.1451 -0.0184 -0.0114 -0.0248 -0.2576 -0.0120 -0.3228 -0.3176 -0.3206 -0.3213 -0.3228 -0.1986 -0.0775 -0.1493 -0.0493 -0.3213 -2.3086 -0.3240 -0.0366', 'S-1936\tSymptome des Nervensystems treten meist bei Behandlungsbeginn auf, klingen aber im Allgemeinen innerhalb der ersten Wochen wieder ab.', 'T-1936\tThe nervous system symptoms tend to occur when treatment is first started, but generally decrease in the first few weeks.', 'H-1936\t-1.5966796875\tSymptoms of the nervous system usually occur at the beginning of treatment , but in general they subside within the first few weeks .', 'D-1936\t-1.5966796875\tSymptoms of the nervous system usually occur at the beginning of treatment, but in general they subside within the first few weeks.', 'P-1936\t-0.5684 -0.0070 -0.0306 -0.0391 -0.0218 -0.0225 -1.7275 -1.6904 -0.3325 -0.0479 -0.4705 -0.0310 -0.3015 -1.1895 -0.2817 -1.2451 -0.0282 -0.8564 -0.9526 -0.0056 -0.0789 -0.3269 -0.0282 -0.7271 -0.0225 -0.4734 -0.0282', 'S-1083\tJede Olanzapin Teva 20 mg Filmtablette enthält 20 mg des Wirkstoffs.', 'T-1083\tEach Olanzapine Teva 20 mg film -coated tablet contains 20 mg of the active substance.', 'H-1083\t-0.306640625\tEach Olanzapine Teva 20 mg film @-@ coated tablet contains 20 mg of the active substance .', 'D-1083\t-0.306640625\tEach Olanzapine Teva 20 mg film-coated tablet contains 20 mg of the active substance.', 'P-1083\t-0.0371 -0.2891 -0.0185 -0.0218 -0.0148 -0.0257 -0.0458 -0.0169 -0.0993 -0.0169 -0.1881 -0.3206 -0.3228 -0.0395 -0.0493 -0.0240 -0.0324 -0.0465 -0.0169 -0.0352 -0.0620 -0.0465 -0.2847 -0.0324 -0.0282', 'S-1145\tEine Impfdosis zu 2 ml wird tief intramuskulär entsprechend dem folgenden Impfplan verabreicht:', 'T-1145\tAdminister one 2 ml dose by deep intramuscular injection in accordance with the following vaccination scheme:', 'H-1145\t-1.5966796875\tEach vial contains 2 ml of vaccine deep intramuscularly according to the following schedule :', 'D-1145\t-1.5966796875\tEach vial contains 2 ml of vaccine deep intramuscularly according to the following schedule:', 'P-1145\t-1.2158 -1.7598 -0.2311 -1.4873 -0.8003 -0.0817 -0.4819 -0.3213 -0.8452 -0.3213 -0.0282 -0.0113 -0.2593 -0.0395 -1.0205 -0.0338 -0.0395 -0.0338 -0.8286 -0.0507 -0.0282', 'S-1938\t- Sie innerhalb eines relativ kurzen Zeitraums eine fortschreitende Appetitlosigkeit, Asthenie', 'T-1938\t- experience progressive anorexia, asthenia (weakness, exhaustion) and weight decrease within a', 'H-1938\t-1.068359375\t- you experience progressive anorexia , asthenia within a relatively short period of time', 'D-1938\t-1.068359375\t- you experience progressive anorexia, asthenia within a relatively short period of time', 'P-1938\t-0.2104 -1.2715 -0.2986 -0.3015 -0.7563 -0.0409 -0.0225 -0.0141 -0.0395 -0.2649 -0.0169 -0.0225 -0.0169 -1.2422 -0.0338 -0.2169 -0.0760 -0.5073 -0.1042 -0.0282 -1.1523', 'S-1903\t- Wenn Sie gegenüber Imiquimod (dem Wirkstoff) oder einem der sonstigen Bestandteile der', 'T-1903\t- If you are allergic to imiquimod (the active ingredient) or any of the ingredients of the cream.', 'H-1903\t-1.083984375\t- If you are hypersensitive to imiquimod ( the active substance ) or any of the other ingredients of', 'D-1903\t-1.083984375\t- If you are hypersensitive to imiquimod (the active substance) or any of the other ingredients of', 'P-1903\t-0.0841 -0.5664 -0.0655 -0.2998 -0.9453 -0.0324 -0.6455 -0.3960 -0.0254 -0.0282 -0.0141 -0.0169 -0.0620 -0.5298 -0.0282 -0.2761 -0.0310 -0.2255 -0.5747 -0.1296 -0.0479 -0.1268 -0.2113 -0.2874 -1.8291', 'S-1239\tIn einer klinischen Studie an Patienten wurden steigende Dosierungen von bis zu 720 mg Starlix pro', 'T-1239\tIn a clinical study in patients, Starlix was administered in increasing doses up to 720 mg a day for 7 days and was well tolerated.', 'H-1239\t-1.673828125\tIn a clinical study in patients , Tractocile produced increasing doses of up to 720 mg Starlix per kilogram of body', 'D-1239\t-1.673828125\tIn a clinical study in patients, Tractocile produced increasing doses of up to 720 mg Starlix per kilogram of body', 'P-1239\t-0.1790 -0.2427 -0.0250 -0.4480 -0.3826 -0.0296 -0.1952 -0.3494 -2.1895 -0.3213 -0.3184 -0.3213 -1.9580 -0.8735 -0.0225 -0.6030 -0.6538 -1.1211 -0.0282 -0.0338 -0.0901 -0.0225 -0.3042 -0.0225 -0.0282 -0.5186 -0.6875 -0.1127 -0.0113 -0.7100 -0.3381 -0.2479', 'S-1685\tEU / 1 / 97 / 030 / 046 EU / 1 / 97 / 030 / 047', 'T-1685\tEU / 1 / 97 / 030 / 046 EU / 1 / 97 / 030 / 047', 'H-1685\t-0.1593017578125\tEU / 1 / 97 / 030 / 046 EU / 1 / 97 / 030 / 047', 'D-1685\t-0.1593017578125\tEU / 1 / 97 / 030 / 046 EU / 1 / 97 / 030 / 047', 'P-1685\t-0.0357 -0.0327 -0.0277 -0.0299 -0.0135 -0.0284 -0.0285 -0.0255 -0.0285 -0.0262 -0.4727 -0.0289 -0.0303 -0.0268 -0.0296 -0.0106 -0.0282 -0.0225 -0.0254 -0.0282 -0.0211 -0.0148 -0.0296', 'S-1947\tDie Ergebnisse für die auf diese Weise gemessene Wirksamkeit von Eqvalan lagen ebenfalls unter 90%.', 'T-1947\tThe results for efficacy of Eqvalan measured this way were also below 90%.', 'H-1947\t-1.3212890625\tThe results for the effectiveness of Eqvalan measured in this way were also below 90 % .', 'D-1947\t-1.3212890625\tThe results for the effectiveness of Eqvalan measured in this way were also below 90%.', 'P-1947\t-0.1437 -0.8530 -1.1387 -0.5762 -0.2296 -0.0225 -0.0451 -0.1014 -0.0113 -0.0169 -0.0310 -2.1914 -0.1042 -0.0338 -0.1240 -0.7383 -1.0479 -0.9131 -0.0282 -0.0338 -0.0282 -0.0282', 'S-507\tTysabri wird zur Behandlung von Erwachsenen mit multipler Sklerose (MS) angewendet.', 'T-507\tTysabri is used to treat adults with multiple sclerosis (MS).', 'H-507\t-0.326416015625\tTysabri is used to treat adults with multiple sclerosis ( MS ) .', 'D-507\t-0.326416015625\tTysabri is used to treat adults with multiple sclerosis (MS).', 'P-507\t-0.0170 -0.0071 -0.0099 -0.0414 -0.0531 -0.1561 -0.0127 -0.2981 -0.5430 -0.5620 -0.0197 -0.0099 -0.0268 -0.0183 -0.0338 -0.0113 -0.0282 -0.0338 -0.0282', 'S-828\tDie Ausscheidung von Ranolazin in die Muttermilch ist nicht am Tiermodell untersucht worden.', 'T-828\tThe excretion of ranolazine in milk has not been studied in animals.', 'H-828\t-0.68359375\tThe excretion of ranolazine in milk has not been studied in animals .', 'D-828\t-0.68359375\tThe excretion of ranolazine in milk has not been studied in animals.', 'P-828\t-1.0811 -0.4121 -0.0099 -0.0338 -0.0296 -0.1057 -0.0268 -0.0423 -0.0493 -0.2451 -0.3157 -0.0958 -0.0324 -0.0296 -0.2227 -0.1676 -1.0400 -0.0338 -0.0282', 'S-1326\tDer InnoLet darf nicht in medizinischen Alkohol gelegt, gewaschen oder mit einem Schmiermittel behandelt werden.', 'T-1326\tDo not soak it in surgical spirit or wash or lubricate it.', 'H-1326\t-1.0458984375\tInnoLet should not be immersed in surgical spirit , rinsed or treated with an antiseptic .', 'D-1326\t-1.0458984375\tInnoLet should not be immersed in surgical spirit, rinsed or treated with an antiseptic.', 'P-1326\t-0.2451 -0.0255 -0.0576 -0.5918 -0.0373 -0.0303 -2.2637 -0.0225 -0.0423 -0.3523 -0.0592 -0.0282 -0.3550 -0.0535 -0.8228 -0.0282 -0.0760 -0.5469 -0.0366 -0.9243 -0.3718 -0.2537 -0.0225 -0.0056 -0.1071 -0.0282', 'S-65\t6 Fruchtbarkeit Busulfan und DMA können die Fruchtbarkeit bei Männern und Frauen beeinträchtigen.', 'T-65\tFertility Busulfan and DMA can impair fertility in man or woman.', 'H-65\t-1.09765625\t6 Fertility : busulfan and DMA may impair fertility in men and women .', 'D-65\t-1.09765625\t6 Fertility: busulfan and DMA may impair fertility in men and women.', 'P-65\t-2.5703 -0.0564 -0.0113 -0.0211 -1.4062 -0.5835 -0.0338 -0.0197 -0.0395 -0.0338 -0.0141 -0.2423 -0.6958 -0.0254 -0.0507 -0.0225 -0.0564 -0.9639 -0.0395 -0.0282 -0.0676 -0.0282', 'S-300\tDie Behandlung mit Avonex muss von einem Arzt eingeleitet werden, der Erfahrung in der Behandlung von MS hat.', 'T-300\tAvonex treatment should be started by a doctor who has experience in the management of MS.', 'H-300\t-0.7431640625\tTreatment with Avonex must be initiated by a doctor who has experience in the treatment of MS .', 'D-300\t-0.7431640625\tTreatment with Avonex must be initiated by a doctor who has experience in the treatment of MS.', 'P-300\t-1.5488 -0.0183 -0.0254 -0.0409 -0.0268 -0.0099 -0.0169 -0.9736 -0.0380 -0.6382 -0.0282 -0.0338 -0.0395 -0.1465 -0.3860 -0.1042 -0.0676 -0.0760 -0.1521 -0.5127 -0.0310 -0.0254 -0.0338 -0.0282', 'S-834\tWiederholen Sie die Schritte 4. bis 8. in der gleichen Weise bis Sie die gesamte Dosis eingenommen haben.', 'T-834\tRepeat steps 4 to 8 in the same way until you have taken the whole dose.', 'H-834\t-0.9228515625\tRepeat steps 4 to 8 in the same way until you take the full dose .', 'D-834\t-0.9228515625\tRepeat steps 4 to 8 in the same way until you take the full dose.', 'P-834\t-0.2235 -0.0092 -0.0269 -0.1257 -0.2402 -0.6201 -0.0296 -0.0901 -0.1676 -0.0211 -0.7383 -0.0507 -0.0310 -1.4863 -0.0479 -1.3750 -0.0564 -0.0310 -0.0282', 'S-897\tWenden Sie Exelon transdermale Pflaster immer genau nach Anweisung des Arztes an.', 'T-897\tAlways use Exelon transdermal patches exactly as your doctor has told you.', 'H-897\t-0.50341796875\tAlways use Exelon transdermal patches exactly as your doctor has told you .', 'D-897\t-0.50341796875\tAlways use Exelon transdermal patches exactly as your doctor has told you.', 'P-897\t-0.2688 -0.0155 -0.1926 -0.2169 -0.0190 -0.0268 -0.1261 -0.0141 -0.0169 -0.0113 -0.0225 -0.2458 -0.0796 -0.3164 -0.0507 -0.6650 -0.5566 -0.0310 -0.1338 -0.0282', 'S-1217\tEliminierung Die Clearance von Bevacizumab betrug 0,231 Liter / Tag.', 'T-1217\tElimination Bevacizumab clearance was 0.231 l / day.', 'H-1217\t-0.59326171875\tElimination Total clearance of bevacizumab was 0.231 litres / day .', 'D-1217\t-0.59326171875\tElimination Total clearance of bevacizumab was 0.231 litres / day.', 'P-1217\t-0.4727 -0.0056 -0.0306 -1.3975 -0.6211 -0.0324 -0.1042 -0.0282 -0.0183 -0.0070 -0.0056 -0.0183 -0.0211 -0.0380 -0.0760 -0.0254 -0.0254 -0.3691 -0.4734 -0.0254 -0.0732 -0.0423 -0.0535 -0.0282', 'S-1856\tMit ATryn behandelte Patienten sollten auf potentielle klinisch-immunologische Reaktionen überwacht werden.', 'T-1856\tPatients treated with ATryn should be monitored for possible clinical immunological reactions.', 'H-1856\t-0.489990234375\tPatients treated with ATryn should be monitored for possible clinical immunological reactions .', 'D-1856\t-0.489990234375\tPatients treated with ATryn should be monitored for possible clinical immunological reactions.', 'P-1856\t-0.2400 -0.0199 -0.4148 -0.0342 -0.0461 -0.0162 -0.0099 -0.1958 -0.0303 -0.0451 -0.0204 -0.0338 -0.9233 -0.0380 -0.3523 -0.2537 -0.2043 -0.0155 -0.0338 -0.0282', 'S-1965\tRivastigmin sollte zweimal täglich, mit dem Frühstück und dem Abendessen, eingenommen werden.', 'T-1965\tRivastigmine should be administered twice a day, with morning and evening meals.', 'H-1965\t-0.658203125\tRivastigmine should be given twice a day , with morning and evening meals .', 'D-1965\t-0.658203125\tRivastigmine should be given twice a day, with morning and evening meals.', 'P-1965\t-0.2327 -0.0171 -0.0120 -0.0171 -0.0530 -0.0402 -0.0299 -1.6016 -0.0338 -0.4917 -0.0282 -0.3762 -0.0986 -0.3213 -0.2676 -0.0986 -0.0676 -0.0366 -0.0282', 'S-1615\tDie peripheren Blutwerte können weiter absinken, nachdem die Behandlung mit Gemcitabin beendet wurde.', 'T-1615\tPeripheral blood counts may continue to deteriorate after gemcitabine administration has been stopped.', 'H-1615\t-1.9921875\tPeripheral haematologic tests may decrease after co @-@ administration with gemcitabine has been stopped .', 'D-1615\t-1.9921875\tPeripheral haematologic tests may decrease after co-administration with gemcitabine has been stopped.', 'P-1615\t-0.7749 -0.0049 -0.0261 -2.2344 -0.1381 -0.0676 -0.8003 -0.0225 -0.4565 -0.2001 -2.3184 -0.0169 -1.1436 -1.7754 -0.0282 -0.2874 -0.9297 -0.0056 -0.0113 -0.0225 -0.0225 -0.9409 -0.8340 -0.9355 -0.0338 -0.0338', 'S-1698\tEs wird empfohlen, die Patienten vor Beginn der Therapie mit Etoricoxib zu rehydrieren.', 'T-1698\tIt is advisable to rehydrate patients prior to starting therapy with etoricoxib.', 'H-1698\t-0.64453125\tIt is recommended to rehydrate patients prior to initiating treatment with etoricoxib .', 'D-1698\t-0.64453125\tIt is recommended to rehydrate patients prior to initiating treatment with etoricoxib.', 'P-1698\t-0.3347 -0.0299 -0.0472 -0.1007 -0.0504 -0.0141 -0.0257 -0.1427 -0.5190 -0.0275 -0.7188 -0.7397 -0.8789 -0.0395 -0.1465 -0.0817 -0.0141 -0.0085 -0.0225 -0.0338 -0.0282', 'S-1829\tEs liegen keine klinischen Erfahrungen über die Auswirkungen einer akuten Überdosierung mit Degarelix vor.', 'T-1829\tThere is no clinical experience with the effects of an acute overdose with degarelix.', 'H-1829\t-0.62890625\tThere is no clinical experience with the effects of acute overdose with degarelix .', 'D-1829\t-0.62890625\tThere is no clinical experience with the effects of acute overdose with degarelix.', 'P-1829\t-0.6011 -0.1483 -0.0402 -0.0542 -0.1578 -0.2791 -0.5889 -0.0620 -0.0324 -0.3579 -0.0127 -0.1183 -0.6187 -0.1409 -0.4648 -0.0113 -0.0197 -0.0169 -0.0395 -0.0282', 'S-473\tFalls eine Schwangerschaft während der Einnahme von Activelle eintritt, sollte die Behandlung sofort abgebrochen werden.', 'T-473\tIf pregnancy occurs during medication with Activelle, treatment should be withdrawn immediately.', 'H-473\t-1.2265625\tIf pregnancy occurs while taking Activelle , treatment should be stopped immediately .', 'D-473\t-1.2265625\tIf pregnancy occurs while taking Activelle, treatment should be stopped immediately.', 'P-473\t-0.4199 -1.2090 -0.1479 -0.0155 -1.1611 -0.8706 -0.2563 -0.0113 -0.0141 -0.0507 -1.0283 -0.0338 -0.0395 -1.2451 -0.1521 -0.0282 -0.0282', 'S-55\tFür Patienten mit beeinträchtigter Nierenfunktion sind die folgenden Dosisanpassungen zu erwägen:', 'T-55\tFor patients with renal impairment the following dosage adjustments should be considered:', 'H-55\t-0.56787109375\tThe following dose adjustments should be considered for patients with renal impairment :', 'D-55\t-0.56787109375\tThe following dose adjustments should be considered for patients with renal impairment:', 'P-55\t-0.7437 -0.0514 -0.1050 -0.0542 -0.0183 -0.0289 -0.2113 -0.0296 -0.0486 -0.3530 -0.1930 -0.0352 -1.1934 -0.0225 -0.1155 -0.1183 -0.0141 -0.0254 -0.0366 -0.0282', 'S-167\tDer Einfluss unterschiedlicher Injektionsstellen auf die Resorption von NovoMix 30 wurde nicht untersucht.', 'T-167\tThe influence of different injection sites on the absorption of NovoMix 30 has not been investigated.', 'H-167\t-0.357666015625\tThe influence of different injection sites on the absorption of NovoMix 30 has not been investigated .', 'D-167\t-0.357666015625\tThe influence of different injection sites on the absorption of NovoMix 30 has not been investigated.', 'P-167\t-0.0834 -0.5376 -0.0327 -0.0838 -0.0331 -0.0155 -0.0521 -0.0338 -0.0838 -0.1683 -0.0162 -0.0331 -0.0240 -0.0155 -0.0099 -0.0282 -0.2367 -0.0324 -0.0324 -0.6733 -0.0310 -0.0282', 'S-426\tSubkutane Anwendung Nur zum Gebrauch mit einem Pen-Injektor, genannt Puregon Pen.', 'T-426\tSubcutaneous use For use only with a pen injector called Puregon Pen.', 'H-426\t-0.44970703125\tSubcutaneous use For use only with a pen injector called Puregon Pen .', 'D-426\t-0.44970703125\tSubcutaneous use For use only with a pen injector called Puregon Pen.', 'P-426\t-0.1632 -0.0114 -0.0141 -0.0285 -0.0299 -0.2056 -0.2441 -0.0275 -0.7637 -0.1986 -0.1508 -0.0310 -0.1635 -0.0141 -0.0268 -0.3340 -0.1268 -0.0099 -0.0282 -0.0268 -0.2438 -0.0310', 'S-1219\tHumira 40 mg Injektionslösung im vorgefüllten Pen zum einmaligen Gebrauch durch den Patienten:', 'T-1219\tHumira 40 mg solution for injection in single-use pre-filled pen for patient use.', 'H-1219\t-0.7109375\tHumira 40 mg solution for injection in pre @-@ filled pen for single use :', 'D-1219\t-0.7109375\tHumira 40 mg solution for injection in pre-filled pen for single use:', 'P-1219\t-0.0371 -0.0270 -0.0156 -0.0633 -0.0142 -0.2842 -0.2920 -0.2585 -0.0324 -0.1022 -1.3516 -0.0380 -0.0113 -0.5493 -0.0817 -0.2227 -0.2113 -0.5381 -0.0310', 'S-1512\tFalls der Tumor fortschreitet, ist ein Behandlungserfolg unwahrscheinlich, und die Behandlung sollte überdacht werden.', 'T-1512\tIn case of tumour progression, treatment is unlikely to be successful and the treatment should be reviewed.', 'H-1512\t-1.18359375\tIf the tumour progresses , treatment success is unlikely and treatment should be reconsidered .', 'D-1512\t-1.18359375\tIf the tumour progresses, treatment success is unlikely and treatment should be reconsidered.', 'P-1512\t-0.8149 -0.0873 -0.0282 -0.1050 -0.8101 -0.0254 -0.0620 -1.0479 -1.5664 -0.3042 -0.0282 -0.1353 -0.7666 -0.0620 -0.0282 -0.5693 -0.4282 -0.0282 -0.0282', 'S-1580\tDas mittlere Alter der Patienten lag bei 67 Jahren und annähernd 60% waren mindestens 65 Jahre alt.', 'T-1580\tThe mean age of the patients was 67 years, and approximately 60% were at least 65 years old.', 'H-1580\t-0.720703125\tThe mean age of the patients was 67 years , and approximately 60 % were at least 65 years old .', 'D-1580\t-0.720703125\tThe mean age of the patients was 67 years, and approximately 60% were at least 65 years old.', 'P-1580\t-0.1926 -0.2942 -0.0486 -0.0416 -1.1250 -0.1254 -0.0409 -0.0169 -0.0887 -0.9282 -0.0958 -0.3438 -0.0282 -0.0310 -0.0676 -0.1606 -0.0141 -0.0197 -0.0423 -0.8398 -0.0310 -0.0282', 'S-438\t- Die OPTISON Durchstechflasche muss umgedreht und etwa 3 Minuten lang vorsichtig hin und her', 'T-438\t- The OPTISON vial must be inverted and gently rotated for approximately three minutes to', 'H-438\t-1.39453125\t- The OPTISON vial should be inverted and gently inverted for approximately 3 minutes .', 'D-438\t-1.39453125\t- The OPTISON vial should be inverted and gently inverted for approximately 3 minutes.', 'P-438\t-0.0385 -0.4114 -0.0211 -0.0299 -0.0176 -0.0155 -0.0546 -0.0243 -1.7480 -0.3042 -1.3750 -0.0141 -0.0479 -0.0507 -0.6455 -0.6934 -0.0845 -0.0338 -0.4143 -0.8848 -0.3042 -0.7100 -1.4258 -0.0338', 'S-638\tDer Wirkstoff in Tekturna, Aliskiren, ist ein Renin-Inhibitor.', 'T-638\tThe active substance in Tekturna, aliskiren, is a renin inhibitor.', 'H-638\t-0.28662109375\tThe active substance in Tekturna , aliskiren , is a renin inhibitor .', 'D-638\t-0.28662109375\tThe active substance in Tekturna, aliskiren, is a renin inhibitor.', 'P-638\t-0.1895 -0.1357 -0.2115 -0.0518 -0.1082 -0.0127 -0.0070 -0.0310 -0.3240 -0.3198 -0.1670 -0.0240 -0.0465 -0.0296 -0.0324 -0.0197 -0.0352 -0.0211 -0.0141 -0.0141 -0.0268 -0.0310 -0.0282', 'S-740\tBei pädiatrischen Patienten wurde die Wirksamkeit und Verträglichkeit von SUTENT nicht untersucht.', 'T-740\tThe safety and efficacy of SUTENT in paediatric patients have not been established.', 'H-740\t-0.892578125\tThe efficacy and safety of SUTENT in paediatric patients have not been studied .', 'D-740\t-0.892578125\tThe efficacy and safety of SUTENT in paediatric patients have not been studied.', 'P-740\t-1.6035 -0.5591 -0.0085 -0.0211 -0.0380 -0.3213 -0.0423 -0.0141 -0.0240 -0.0225 -0.0225 -1.2002 -0.2479 -0.0141 -0.0113 -0.0310 -0.0338 -0.2761 -0.0310 -0.0282 -0.8003 -0.4763 -0.0282', 'S-1183\tAus mikrobiologischer Sicht sollte die rekonstituierte Lösung verdünnt und sofort verwendet werden.', 'T-1183\tFrom a microbiological point of view, the reconstituted solution should be diluted and used immediately.', 'H-1183\t-0.212158203125\tFrom a microbiological point of view , the reconstituted solution should be diluted and used immediately .', 'D-1183\t-0.212158203125\tFrom a microbiological point of view, the reconstituted solution should be diluted and used immediately.', 'P-1183\t-0.2268 -0.1152 -0.0171 -0.0227 -0.0271 -0.1328 -0.0271 -0.0155 -0.0976 -0.1831 -0.1310 -0.0085 -0.0225 -0.0247 -0.0416 -0.0310 -0.0254 -0.0169 -0.0366 -0.1022 -0.0289 -0.0296 -0.0282', 'S-1278\tI. de Pocé 29 route des Industries F-37530 Pocé sur Cisse Frankreich', 'T-1278\tI. de Pocé 29 route des Industries F-37530 Pocé sur Cisse France', 'H-1278\t-0.32421875\tI. de Pocé 29 route des Industries F @-@ 37530 Pocé sur Cisse France', 'D-1278\t-0.32421875\tI. de Pocé 29 route des Industries F-37530 Pocé sur Cisse France', 'P-1278\t-0.0407 -0.0270 -0.0213 -1.1104 -0.0183 -0.0176 -0.5938 -0.0155 -0.0056 -0.0240 -0.0169 -0.0282 -0.0113 -0.0254 -0.0240 -0.0183 -0.0225 -0.0197 -0.0070 -0.0296 -0.0042 -0.0183 -0.0282', 'S-1339\tFür Dokumente mit mehr als 30 Seiten wird jedoch gemäß den Grundsätzen der Kommission eine angemessene Gebühr erhoben.', 'T-1339\tHowever, a reasonable charge is requested for 6 documents of 30 pages or more in accordance with Commission policy.', 'H-1339\t-1.8232421875\tHowever , a sufficient fee is payable for documents of more than 30 pages in accordance with the Commission &apos;s policy .', "D-1339\t-1.8232421875\tHowever, a sufficient fee is payable for documents of more than 30 pages in accordance with the Commission's policy.", 'P-1339\t-0.6133 -0.0416 -2.2930 -0.9297 -1.1494 -0.5552 -0.3352 -0.0282 -0.5410 -0.0338 -0.8228 -0.2874 -0.0282 -0.0338 -0.0789 -1.5889 -0.7383 -0.0225 -0.0282 -0.6479 -0.8228 -0.2367 -0.6538 -0.0338 -0.0338', 'S-1397\tEU / 1 / 06 / 368 / 001 EU / 1 / 06 / 368 / 002', 'T-1397\tEU / 1 / 06 / 368 / 001 EU / 1 / 06 / 368 / 002', 'H-1397\t-0.09442138671875\tEU / 1 / 06 / 368 / 001 EU / 1 / 06 / 368 / 002', 'D-1397\t-0.09442138671875\tEU / 1 / 06 / 368 / 001 EU / 1 / 06 / 368 / 002', 'P-1397\t-0.0349 -0.0321 -0.0270 -0.0299 -0.0227 -0.0284 -0.0270 -0.0099 -0.0299 -0.0285 -0.0313 -0.0299 -0.0306 -0.0271 -0.0299 -0.0197 -0.0292 -0.0278 -0.0106 -0.0292 -0.0250 -0.0285 -0.0299', 'S-463\tEMEA / V / C / 0106 EMEA / CVMP / 343692 / 2006', 'T-463\tEMEA / V / C / 0106 EMEA / CVMP / 254129 / 2006', 'H-463\t-0.172607421875\tEMEA / V / C / 0106 EMEA / CVMP / 343692 / 2006', 'D-463\t-0.172607421875\tEMEA / V / C / 0106 EMEA / CVMP / 343692 / 2006', 'P-463\t-0.0313 -0.0142 -0.0235 -0.0313 -0.0298 -0.0291 -0.0184 -0.0306 -0.0299 -0.2153 -0.4297 -0.0127 -0.0225 -0.0296 -0.0268 -0.0225 -0.0106 -0.0289 -0.0155 -0.0141 -0.0134 -0.0303 -0.0218 -0.0296', 'S-1115\t- wenn Sie überempfindlich (allergisch) gegen Bevacizumab oder einen der sonstigen', 'T-1115\t- you are allergic (hypersensitive) to bevacizumab or to any of the other ingredients of Avastin.', 'H-1115\t-0.638671875\t- if you are allergic ( hypersensitive ) to bevacizumab or any of the other', 'D-1115\t-0.638671875\t- if you are allergic (hypersensitive) to bevacizumab or any of the other', 'P-1115\t-0.2791 -0.5283 -0.0296 -0.0451 -0.3184 -0.0183 -0.1790 -0.2029 -0.0127 -0.0324 -0.0338 -0.1057 -0.0211 -0.0070 -0.0056 -0.0169 -0.0240 -0.0409 -0.1183 -0.0676 -0.0493 -0.1085 -1.9453', 'S-349\tJede Filmtablette enthält 20 mg Memantinhydrochlorid, entsprechend 16,62 mg Memantin.', 'T-349\tEach film-coated tablet contains 20 mg of memantine hydrochloride equivalent to 16.62 mg memantine.', 'H-349\t-0.294921875\tEach film @-@ coated tablet contains 20 mg of memantine hydrochloride equivalent to 16.62 mg memantine .', 'D-349\t-0.294921875\tEach film-coated tablet contains 20 mg of memantine hydrochloride equivalent to 16.62 mg memantine.', 'P-349\t-0.0465 -0.0685 -0.3203 -0.3213 -0.0514 -0.0472 -0.0240 -0.0409 -0.0676 -0.0197 -0.1902 -0.0162 -0.0120 -0.0240 -0.0190 -0.0282 -0.0240 -0.0162 -0.0211 -0.3157 -0.0310 -0.0916 -0.0183 -0.0113 -0.2803 -0.0169 -0.0338 -0.0380 -0.0282', 'S-1258\tEntsprechend scheint die Kinetik von Gadoversetamid in diesem Dosisbereich linear zu sein.', 'T-1258\tTherefore, within this dose range, the kinetics of gadoversetamide appear to be linear.', 'H-1258\t-0.7529296875\tAccordingly , the kinetics of gadoversetamide appear to be linear in this dose range .', 'D-1258\t-0.7529296875\tAccordingly, the kinetics of gadoversetamide appear to be linear in this dose range.', 'P-1258\t-1.4189 -0.0063 -0.0190 -0.2423 -0.2903 -0.0578 -0.0056 -0.0268 -0.0338 -0.0127 -0.0268 -0.0197 -0.0225 -0.0141 -0.0113 -0.0296 -1.1641 -0.0873 -0.0282 -0.0169 -0.0197 -0.7944 -0.2227 -0.5835 -0.2311 -0.0282 -0.0282', 'S-1092\t- Eine Folgepackung mit 2 durchsichtigen Blisterpackungen mit 28 CHAMPIX 0,5 mg', 'T-1092\t- A follow-on (maintenance) pack containing 2 clear blisters of 28 x CHAMPIX 0.5 mg film-', 'H-1092\t-0.65625\t- A follow @-@ on ( maintenance ) pack containing 2 clear blisters of 28 x CHAMPIX 0.5 mg film-', 'D-1092\t-0.65625\t- A follow-on (maintenance) pack containing 2 clear blisters of 28 x CHAMPIX 0.5 mg film-', 'P-1092\t-0.0400 -0.1942 -0.0567 -0.0842 -0.6099 -0.3228 -0.3228 -0.0690 -0.1550 -0.3101 -0.0760 -0.2057 -0.0592 -0.2859 -0.1986 -0.0282 -0.3213 -0.3945 -0.0254 -0.0141 -0.0254 -0.0197 -0.1831 -0.0169 -0.3213 -0.2903 -0.1099', 'S-1053\t- für weniger als einen Tag (bis zu 24 Stunden): das Pflaster muss an derselben Stelle wieder', 'T-1053\t- for less than one day (up to 24 hours): it should be re-applied to the same place or replaced with', 'H-1053\t-0.9462890625\t- for less than one day ( up to 24 hours ) : the patch must be replaced in the same place', 'D-1053\t-0.9462890625\t- for less than one day (up to 24 hours): the patch must be replaced in the same place', 'P-1053\t-0.2080 -0.3669 -0.0299 -0.0370 -0.2571 -0.0282 -0.0310 -0.0500 -0.0289 -0.0310 -0.0296 -0.0303 -0.0458 -0.3494 -0.5537 -0.0380 -0.7227 -0.2367 -1.0176 -0.4592 -0.0451 -0.0366 -0.9526 -0.7832', 'S-410\tIhr Arzt wird entscheiden, ob Sie mit Xarelto behandelt werden und ob Sie genauer überwacht werden müssen.', 'T-410\tYour doctor will decide, if you should be treated with Xarelto and if you should be kept under closer observation.', 'H-410\t-0.884765625\tYour doctor will decide if you should be treated with Xarelto and whether you should be monitored more closely .', 'D-410\t-0.884765625\tYour doctor will decide if you should be treated with Xarelto and whether you should be monitored more closely.', 'P-410\t-0.4001 -0.0574 -0.2856 -0.0592 -0.2318 -0.0528 -1.2178 -0.1155 -0.0352 -0.0395 -0.0197 -0.0268 -0.0183 -0.0282 -0.7314 -1.3301 -0.5972 -0.4001 -0.0592 -0.0873 -0.0225 -0.1917 -0.0338 -0.0338 -0.0282', 'S-376\tFalls sie wegen der Veränderungen Ihrer Atmung beunruhigt sind, sollten Sie umgehend Ihren Arzt kontaktieren.', 'T-376\tIf you are concerned about changes in your breathing pattern when using TRAVATAN advise your doctor as soon as possible.', 'H-376\t-0.99658203125\tIf you are concerned about changes in your breathing , you should contact your doctor immediately .', 'D-376\t-0.99658203125\tIf you are concerned about changes in your breathing, you should contact your doctor immediately.', 'P-376\t-0.8770 -0.0416 -0.0690 -1.3711 -0.2551 -0.1663 -0.0606 -0.2085 -0.0592 -0.5522 -0.8594 -0.0423 -0.5718 -0.0338 -0.0620 -0.3579 -0.0310 -0.0282', 'S-1471\tHören Sie jedoch nicht auf ZYPREXA einzunehmen, es sei denn Ihr Arzt sagt es Ihnen.', 'T-1471\tConsult your doctor if your symptoms return but do not stop taking ZYPREXA unless your doctor tells you to.', 'H-1471\t-0.748046875\tHowever , do not stop taking ZYPREXA unless your doctor tells you to .', 'D-1471\t-0.748046875\tHowever, do not stop taking ZYPREXA unless your doctor tells you to.', 'P-1471\t-2.9609 -0.0310 -0.0986 -0.0282 -0.0564 -0.0225 -0.0732 -0.0282 -0.0085 -0.0169 -0.0282 -0.0338 -0.0535 -0.0310 -0.0507 -0.0254 -0.2593 -0.0648 -0.5073', 'S-795\tNote for guidance on maximum shelf-life for sterile products for human use after first opening or following reconstitution', 'T-795\tNote for guidance on maximum shelf-life for sterile products for human use after f irst opening or following reconstitution', 'H-795\t-0.1917724609375\tNote for guidance on maximum shelf @-@ life for sterile products for human use after first opening or following reconstitution', 'D-795\t-0.1917724609375\tNote for guidance on maximum shelf-life for sterile products for human use after first opening or following reconstitution', 'P-795\t-0.2169 -0.0842 -0.0192 -0.0327 -0.0298 -0.0451 -0.0141 -0.0451 -0.0229 -0.0327 -0.0127 -0.0155 -0.0518 -0.0299 -0.0264 -0.0320 -0.0821 -0.1642 -0.0190 -0.1360 -0.0768 -0.0528 -0.0155 -0.0331', 'S-255\tAranesp <unk> vorgefüllter Injektor (SureClick) - Packungsbeilage beachten', 'T-255\tAranesp SureClick Pre-filled pen - Read package leaflet before use ENGLISH', 'H-255\t-0.99609375\tAranesp Pre @-@ filled pen - Read package leaflet before use', 'D-255\t-0.99609375\tAranesp Pre-filled pen - Read package leaflet before use', 'P-255\t-0.0414 -0.0120 -0.0220 -0.0213 -1.1387 -0.0099 -0.2240 -0.1761 -0.4734 -0.5103 -0.3467 -0.7212 -0.1014 -0.0113 -0.0535 -0.3213 -0.2761 -1.1807', 'S-1818\t≥ 1,48 GBq, entsprechend 0,44 ml bis 0,89 ml Yttrium-90-Lösung', 'T-1818\t≥ 1.48 GBq corresponding to 0.44 ml to 0.89 ml of yttrium-90 solution', 'H-1818\t-0.80810546875\t≥ 1.48 GBq equivalent to 0.44 ml to 0.89 ml of the yttrium @-@ 90 solution', 'D-1818\t-0.80810546875\t≥ 1.48 GBq equivalent to 0.44 ml to 0.89 ml of the yttrium-90 solution', 'P-1818\t-0.8452 -0.0592 -0.0176 -0.0261 -0.0310 -0.0106 -0.9600 -0.0549 -0.0380 -0.0296 -0.7368 -0.0493 -0.0197 -0.0099 -0.0197 -0.4395 -1.4199 -0.5693 -0.0085 -0.0225 -0.0225 -0.0901 -0.0225 -0.0366 -0.0338', 'S-1049\tRISPERDAL sollte, beginnend mit 2 mg Risperidon, einmal täglich verabreicht werden.', 'T-1049\tRISPERDAL should be administered on a once daily schedule, starting with 2 mg risperidone.', 'H-1049\t-0.84619140625\tRISPERDAL should be given once daily starting at 2 mg of risperidone .', 'D-1049\t-0.84619140625\tRISPERDAL should be given once daily starting at 2 mg of risperidone.', 'P-1049\t-0.0472 -0.0134 -0.0170 -0.0177 -0.0206 -0.0342 -0.0372 -0.3955 -0.6851 -0.6958 -1.0146 -0.6313 -0.1014 -0.0254 -1.3916 -0.0310 -0.0225 -0.0085 -0.0028 -0.0366 -0.0282', 'S-831\tNebennierenrindeninsuffizienz Hyperthyreose, Hypothyreose', 'T-831\tAdrenal insufficiency Hyperthyroidism, hypothyroidism', 'H-831\t-0.4453125\tadrenal insufficiency Hyperthyroidism , hypothyroidism', 'D-831\t-0.4453125\tadrenal insufficiency Hyperthyroidism, hypothyroidism', 'P-831\t-0.9932 -0.2255 -0.2233 -0.3826 -0.0155 -0.0085 -0.0183 -0.3452 -0.0183 -0.0254 -0.0254 -0.0183 -0.0225 -0.0056 -0.0310 -0.0409 -0.4607 -0.0240 -0.0324 -0.0113 -0.0085 -0.0028 -0.0282 -0.0310', 'S-821\tHautpflegemittel dürfen innerhalb von 2 Stunden vor bzw. nach Applikation von Protopy Salbe nicht m', 'T-821\tEmollients should not be applied to the same area within 2 hours of applying Protopy ointment.', 'H-821\t-0.79833984375\tEmollients should not be applied within 2 hours of applying Protopy ointment .', 'D-821\t-0.79833984375\tEmollients should not be applied within 2 hours of applying Protopy ointment.', 'P-821\t-0.3311 -0.1663 -0.0028 -0.1060 -0.4124 -0.0416 -0.0402 -1.0811 -0.4663 -0.2974 -0.0310 -0.6455 -0.2903 -0.0564 -0.0197 -0.0310 -0.3777 -0.0028 -0.0197 -0.4648 -0.0760', 'S-817\t- Klinisch relevante Elektrolytstörungen, die sich im Laufe der Behandlung mit TRITAZIDE', 'T-817\t- Clinically relevant electrolyte disturbances which may worsen following treatment with TRITAZIDE', 'H-817\t-1.2607421875\t- Clinically significant electrolyte disturbances occurring during treatment with TRITAZIDE', 'D-817\t-1.2607421875\t- Clinically significant electrolyte disturbances occurring during treatment with TRITAZIDE', 'P-817\t-0.9766 -0.2169 -0.0254 -1.3340 -0.3916 -0.0141 -0.0169 -0.0564 -0.8906 -0.2255 -0.0225 -2.0801 -0.0225 -0.5747 -0.6255 -0.3494 -0.0676 -0.0225 -0.0676 -0.1691 -0.0282 -0.0282 -0.0676', 'S-74\tPolysorbat 20 Natriumchlorid Natriumhydroxid Wasser für Injektionszwecke', 'T-74\tPolysorbate 20 Sodium chloride Sodium hydroxide Water for injections', 'H-74\t-0.298095703125\tPolysorbate 20 Sodium chloride Sodium hydroxide Water for injections', 'D-74\t-0.298095703125\tPolysorbate 20 Sodium chloride Sodium hydroxide Water for injections', 'P-74\t-0.7563 -0.0127 -0.0204 -0.0247 -0.0254 -0.0296 -0.0085 -0.0634 -0.0197 -0.0162 -0.0254 -0.2747 -0.0085 -0.0099 -0.0056 -0.0211 -0.1050 -0.0521 -0.0324 -0.3101 -0.0310', 'S-172\tEnthält auch Aspartam (E951) und Saccharose (Packungsbeilage beachten).', 'T-172\tAlso contains aspartame (E951) and sucrose (see leaflet for further information).', 'H-172\t-0.47412109375\tAlso contains aspartame ( E951 ) and sucrose ( see package leaflet ) .', 'D-172\t-0.47412109375\tAlso contains aspartame (E951) and sucrose (see package leaflet).', 'P-172\t-0.5591 -0.0444 -0.0416 -0.0028 -0.0204 -0.0320 -0.0402 -0.0261 -0.0148 -0.0303 -0.0359 -0.0211 -0.0042 -0.0155 -0.3643 -0.1451 -1.0850 -0.1663 -0.0141 -0.0240 -0.0380 -0.3550 -0.0310', 'S-19\tAndere, weniger häufige Nebenwirkungen sind Schmerzen im Brustkorb, niedriger Blutdruck und Kurzatmigkeit.', 'T-19\tFor the full list of all side effects reported with Rapilysin, please see the Package Leaflet.', 'H-19\t-0.5556640625\tOther less common side effects are chest pain , low blood pressure and shortness of breath .', 'D-19\t-0.5556640625\tOther less common side effects are chest pain, low blood pressure and shortness of breath.', 'P-19\t-0.1664 -0.2610 -0.4097 -0.3875 -0.0578 -0.9043 -0.3423 -0.0479 -0.0296 -0.0409 -0.0211 -0.0155 -0.4297 -0.0225 -0.0169 -0.0282 -0.0141 -0.0282 -0.0282', 'S-1414\tDas Risiko scheint bei Personen über 60 Jahren höher zu sein, es wurde jedoch auch über Fälle bei jüngeren Personen berichtet.', 'T-1414\tThe risk appears to be higher in those aged over 60 years, although cases have been also reported in younger persons.', 'H-1414\t-1.177734375\tThe risk appears to be higher in people above 60 years of age , but cases have also been reported in younger subjects .', 'D-1414\t-1.177734375\tThe risk appears to be higher in people above 60 years of age, but cases have also been reported in younger subjects.', 'P-1414\t-0.6523 -0.0271 -0.4927 -0.0388 -0.0247 -0.4734 -0.1042 -0.6553 -0.9551 -0.4875 -0.1663 -0.5718 -0.0225 -0.6821 -0.5522 -0.4001 -0.0901 -0.3777 -0.0282 -0.0169 -0.0732 -0.2479 -0.9297 -0.0282 -0.0282', 'S-916\tmedac Gesellschaft für klinische Spezialpräparate mbH Fehlandtstraße 3 D-20354 Hamburg Deutschland', 'T-916\tmedac Gesellschaft für klinische Spezialpräparate mbH Fehlandtstraße 3 D-20354 Hamburg Germany', 'H-916\t-0.1846923828125\tmedac Gesellschaft für klinische Spezialpräparate mbH Fehlandtstraße 3 D @-@ 20354 Hamburg Germany', 'D-916\t-0.1846923828125\tmedac Gesellschaft für klinische Spezialpräparate mbH Fehlandtstraße 3 D-20354 Hamburg Germany', 'P-916\t-0.0099 -0.0284 -0.2527 -0.0313 -0.0414 -0.1007 -0.0028 -0.1610 -0.0916 -0.0099 -0.0035 -0.0127 -0.0099 -0.0225 -0.0416 -0.0275 -0.2346 -0.0282 -0.0183 -0.0268 -0.0141 -0.0134 -0.0310 -0.0296', 'S-814\tNach oraler Anwendung werden die maximalen Telmisartan- Konzentrationen nach 0,5-1,5 h erreicht.', 'T-814\tFollowing oral administration peak concentrations of telmisartan are reached in 0.5 <<unk>> 1.5 h after dosing.', 'H-814\t-1.4609375\tAfter oral administration , maximum telmisartan concentrations are reached after 0.5 @-@ 1.5 h ..', 'D-814\t-1.4609375\tAfter oral administration, maximum telmisartan concentrations are reached after 0.5-1.5 h..', 'P-814\t-0.8770 -0.0232 -0.3176 -1.0508 -0.6846 -1.6426 -0.0197 -0.0197 -0.0366 -0.5664 -0.0085 -0.0169 -0.4282 -1.2734 -0.1859 -0.0732 -0.8228 -0.0282 -0.1240 -0.8511 -0.0282', 'S-809\tDeutschland JANSSEN-CILAG GmbH Tel: + 49 2137-955-955', 'T-809\tDeutschland JANSSEN-CILAG GmbH Tel: + 49 2137-955-955', 'H-809\t-0.39794921875\tDeutschland JANSSEN @-@ CILAG GmbH Tel : + 49 2137 @-@ 955 @-@ 955', 'D-809\t-0.39794921875\tDeutschland JANSSEN-CILAG GmbH Tel: + 49 2137-955-955', 'P-809\t-1.3857 -0.0366 -0.0232 -0.0127 -0.0183 -0.0296 -0.0254 -0.0141 -0.0141 -0.0592 -0.6987 -0.0535 -0.0296 -0.0155 -0.0310 -0.0197 -0.0268 -0.0380 -0.0240 -0.0197 -0.0296 -0.0240 -0.0183 -0.0324', 'S-196\tWährend der Behandlung mit Cefuroximaxetil kann der Coombs-Test falsch positiv ausfallen.', 'T-196\tThe use of cefuroxime axetil may be accompanied by a false positive Coombs test.', 'H-196\t-1.1591796875\tDuring the treatment with cefuroxime axetil the use of the Coombs test may be false @-@ positive .', 'D-196\t-1.1591796875\tDuring the treatment with cefuroxime axetil the use of the Coombs test may be false-positive.', 'P-196\t-0.7261 -1.1602 -0.0760 -0.0409 -0.3860 -0.0662 -0.0211 -0.2339 -0.0549 -0.0183 -0.0732 -0.0366 -0.9551 -0.4763 -0.0310 -0.8623 -0.0479 -0.0169 -0.6680 -0.2085 -0.6426 -0.9580 -0.1803 -0.3606 -0.0113 -0.0338 -0.0282', 'S-1872\tWie alle Arzneimittel kann Neoclarityn Nebenwirkungen haben, die aber nicht bei jedem auftreten müssen.', 'T-1872\tLike all medicines, Neoclarityn can cause side effects, although not everybody gets them.', 'H-1872\t-0.576171875\tLike all medicines , Neoclarityn can cause side effects , although not everybody gets them .', 'D-1872\t-0.576171875\tLike all medicines, Neoclarityn can cause side effects, although not everybody gets them.', 'P-1872\t-0.1090 -0.0626 -0.1204 -0.0694 -0.1328 -0.1736 -0.0320 -0.0141 -0.0292 -0.0176 -0.0303 -0.1289 -0.9565 -0.0521 -0.0451 -0.4409 -0.2859 -0.1493 -0.3169 -0.3213 -0.2311 -0.0338 -0.0282', 'S-993\tEs ist Sorge zu tragen, dass eine Verbreitung des Impfvirus von Impflingen auf Fasane vermieden wird.', 'T-993\tCare should be taken to avoid spread of the vaccine virus from vaccinated chickens to pheasants.', 'H-993\t-0.7451171875\tCare should be taken to avoid spread of the vaccine virus from vaccinees to pheasants .', 'D-993\t-0.7451171875\tCare should be taken to avoid spread of the vaccine virus from vaccinees to pheasants.', 'P-993\t-0.3809 -0.5225 -0.0331 -0.0141 -0.0690 -0.6870 -0.5059 -0.0366 -0.9692 -0.3606 -0.2255 -0.0620 -0.1268 -0.3157 -0.1296 -0.0366 -0.0056 -0.0141 -0.0789 -0.0310 -0.0282', 'S-186\tHäufige Nebenwirkungen sind in weniger als 1 von 10, aber in mehr als 1 von 100 Fällen zu beobachten.', 'T-186\tCommon side effects are experienced in less than 1 in 10 patients but in at least 1 per 100 patients.', 'H-186\t-1.1064453125\tCommon side effects are experienced in less than 1 in 10 patients but more than 1 in 100 patients .', 'D-186\t-1.1064453125\tCommon side effects are experienced in less than 1 in 10 patients but more than 1 in 100 patients.', 'P-186\t-0.5518 -0.0264 -0.1317 -0.3508 -0.2487 -0.4685 -0.0352 -0.0887 -0.0282 -0.5112 -1.4414 -0.0395 -0.3411 -0.4958 -1.4346 -0.0282 -0.0395 -0.4958 -0.0225 -0.2311 -0.0338 -0.0282', 'S-1720\tKIOVIG ist zur intravenösen Verabreichung (Infusion in eine Vene) bestimmt.', 'T-1720\tKIOVIG is intended for intravenous administration (infusion into a vein).', 'H-1720\t-0.365234375\tKIOVIG is intended for intravenous administration ( infusion into a vein ) .', 'D-1720\t-0.365234375\tKIOVIG is intended for intravenous administration (infusion into a vein).', 'P-1720\t-0.0444 -0.0142 -0.0285 -0.0085 -0.0437 -1.1299 -0.0465 -0.0916 -0.0282 -0.0099 -0.0254 -0.4861 -0.0324 -0.0648 -0.0296 -0.0718 -0.0535 -0.0240 -0.0085 -0.0296 -0.0338 -0.0282', 'S-0\tÄußerlich kann Levemir InnoLet durch Abwischen mit einem medizinischen Tupfer gereinigt werden.', 'T-0\tYou can clean your Levemir InnoLet by wiping it with a medicinal swab.', 'H-0\t-0.412353515625\tYou can clean the exterior of Levemir InnoLet by wiping it with a medicinal swab .', 'D-0\t-0.412353515625\tYou can clean the exterior of Levemir InnoLet by wiping it with a medicinal swab.', 'P-0\t-0.3196 -0.0428 -0.1342 -0.8970 -0.2169 -0.0113 -0.1057 -0.0592 -0.0155 -0.0085 -0.0240 -0.0254 -0.0564 -0.1226 -0.0296 -0.0169 -0.1635 -0.1071 -0.0409 -0.3086 -0.0141 -0.0437 -0.0197 -0.0338 -0.0282', 'S-1885\tGrapefruit kann die Tasigna- Konzentration im Blut steigern, möglicherweise bis auf eine gefährliche Höhe.', 'T-1885\tIt may increase the amount of Tasigna in the blood, possibly to a harmful level.', 'H-1885\t-1.0244140625\tGrapefruit may increase the concentration of Tasigna in the blood , possibly up to a dangerous level .', 'D-1885\t-1.0244140625\tGrapefruit may increase the concentration of Tasigna in the blood, possibly up to a dangerous level.', 'P-1885\t-0.0170 -0.0142 -0.0142 -0.0156 -0.0249 -0.2773 -0.2335 -1.5107 -1.2314 -0.0366 -0.2734 -0.0225 -0.0395 -0.0366 -0.2563 -0.0338 -0.6538 -0.5410 -0.7749 -0.0282 -0.8174 -0.0901 -0.0620 -0.0338 -0.0282', 'S-1722\tBitte informieren Sie den die Impfung vornehmenden Arzt vor einer Impfung über Ihre Behandlung mit Privigen.', 'T-1722\tPlease tell your vaccinating doctor prior to a vaccination about your treatment with Privigen.', 'H-1722\t-1.306640625\tBefore receiving a vaccination tell your doctor about your treatment with Privigen .', 'D-1722\t-1.306640625\tBefore receiving a vaccination tell your doctor about your treatment with Privigen.', 'P-1722\t-1.9766 -0.6509 -0.6128 -0.5835 -0.0282 -0.7578 -1.0508 -0.0845 -0.6396 -0.0620 -0.0845 -0.0451 -0.1521 -0.0056 -0.3213 -0.0620 -0.0338', 'S-1607\tNach Therapieabbruch ist keine weitere Erhöhung des Gehaltes an braunem Irispigment beobachtet worden.', 'T-1607\tAfter discontinuation of therapy, no further increase in brown iris pigment has been observed.', 'H-1607\t-1.75390625\tNo further increases in the concentration of brown iris pigment were observed after discontinuation of treatment .', 'D-1607\t-1.75390625\tNo further increases in the concentration of brown iris pigment were observed after discontinuation of treatment.', 'P-1607\t-0.7490 -0.4558 -0.6367 -0.4241 -1.9893 -2.0859 -0.0282 -0.0169 -0.3438 -0.0676 -0.0113 -0.7720 -0.6255 -0.6084 -0.3889 -0.9355 -0.0451 -0.0282 -0.0395 -0.8960 -0.0282 -0.0282', 'S-581\tund geforderte Unterlagen beim zentralen Verfahren (EMEA / NTA / 001 / 96) • Schiedsverfahren im', 'T-581\tthe Centralised Procedure (EMEA / NTA / 001 / 96)', 'H-581\t-1.435546875\tand documents requested in the centralised procedure ( EMEA / NTA / 001 / 96 )', 'D-581\t-1.435546875\tand documents requested in the centralised procedure (EMEA / NTA / 001 / 96)', 'P-581\t-3.1328 -0.7412 -1.4873 -0.6621 -0.2197 -0.3325 -0.0113 -0.0789 -0.9468 -0.0338 -0.0282 -0.0169 -0.0225 -0.0282 -0.0225 -0.0113 -0.0282 -0.0225 -0.0282 -0.0282 -0.0169 -0.0282 -1.4932', 'S-781\tDezember 1998 erteilte die Europäische Kommission eine Genehmigung für das Inverkehrbringen von Pritor in der gesamten Europäischen Union.', 'T-781\tThe European Commission granted a marketing authorisation valid throughout the European Union for Pritor on 11 December 1998.', 'H-781\t-0.5791015625\tThe European Commission granted a marketing authorisation valid throughout the European Union for Pritor on 4 December 1998 .', 'D-781\t-0.5791015625\tThe European Commission granted a marketing authorisation valid throughout the European Union for Pritor on 4 December 1998.', 'P-781\t-0.2927 -0.0750 -0.0250 -0.2568 -0.2739 -0.0359 -0.0718 -0.0197 -0.3228 -0.0373 -0.2177 -0.0352 -0.0986 -0.0352 -0.1917 -0.0732 -0.0070 -0.0352 -0.2832 -1.3398 -0.0817 -0.0254 -0.0338 -0.0282', 'S-1906\tAußerdem wurde Agenerase bei 268 HIV-infizierten Kindern im Alter zwischen sechs Monaten und 18 Jahren untersucht.', 'T-1906\tAgenerase has also been studied in 268 HIV-infected children aged between six months and 18 years.', 'H-1906\t-0.748046875\tAgenerase has also been studied in 268 HIV @-@ infected children aged between six months and 18 years .', 'D-1906\t-0.748046875\tAgenerase has also been studied in 268 HIV-infected children aged between six months and 18 years.', 'P-1906\t-0.3411 -0.0356 -0.0155 -0.5464 -0.3198 -0.0261 -0.1698 -0.0690 -0.0197 -0.0211 -0.1917 -0.7173 -0.0578 -0.1564 -0.3367 -1.6201 -0.0423 -0.0254 -0.0338 -0.0225 -0.0338 -0.0817 -0.0282', 'S-1860\tDie Behandlung mit Wilzin sollte von einem Arzt eingeleitet werden, der Erfahrung in der Behandlung des Morbus Wilson hat.', 'T-1860\tWilzin treatment should be started by a doctor who has experience in the treatment of Wilson <<unk>> s disease.', 'H-1860\t-0.70947265625\tWilzin treatment should be started by a doctor who has experience in the treatment of Wilson &quot; s disease .', 'D-1860\t-0.70947265625\tWilzin treatment should be started by a doctor who has experience in the treatment of Wilson "s disease.', 'P-1860\t-0.3865 -0.0532 -0.0458 -0.2352 -0.0444 -0.0380 -0.6396 -0.0352 -0.0380 -0.8862 -0.2255 -0.0803 -0.0606 -0.1071 -0.2776 -0.3240 -0.0310 -0.0141 -0.5410 -0.0225 -0.0535 -0.4875 -0.0282', 'S-1388\t185 MBq / 2,5 ml um 12.00 Uhr MEZ am TT / MM / JJJJ', 'T-1388\t185 MBq / 2.5 ml at 1200 CET on DD / MM / YYYY', 'H-1388\t-0.336669921875\t185 MBq / 2.5 ml at 1200 CET on DD / MM / YYYY', 'D-1388\t-0.336669921875\t185 MBq / 2.5 ml at 1200 CET on DD / MM / YYYY', 'P-1388\t-0.0444 -0.1459 -0.0327 -0.0141 -0.0299 -0.3411 -0.0225 -0.0567 -0.5977 -0.1761 -0.0169 -0.1296 -0.1761 -0.0944 -0.0282 -0.0366 -0.0211 -0.0268 -0.0282 -0.0268 -0.0366 -0.0958 -0.0310', 'S-1382\tWenn Sie Pradaxa Kapseln aus der Blisterpackung entnehmen, beachten Sie bitte folgende Anweisungen:', 'T-1382\tWhen taking Pradaxa capsules out of the blister pack, please observe the following instructions', 'H-1382\t-0.5869140625\tWhen taking Pradaxa capsules out of the blister pack , please observe the following instructions :', 'D-1382\t-0.5869140625\tWhen taking Pradaxa capsules out of the blister pack, please observe the following instructions:', 'P-1382\t-0.4656 -0.2360 -0.0416 -0.0190 -0.0211 -0.0296 -0.0388 -0.0169 -0.0232 -0.5112 -0.0310 -0.1141 -0.0183 -0.0183 -0.3284 -0.1803 -0.2859 -0.7651 -0.0141 -0.0366 -0.2563 -0.0451 -0.4282 -0.0282', 'S-1184\tAus dem Apothekenetikett können sie ersehen, welche Menge dieses Arzneimittels Sie wie oft einnehmen sollen.', 'T-1184\tThe dispensing label will tell you much of this medicine you should take and how often you should take.', 'H-1184\t-1.240234375\tThe dispensing label will tell you how much medicine to take and how often .', 'D-1184\t-1.240234375\tThe dispensing label will tell you how much medicine to take and how often.', 'P-1184\t-0.8906 -0.3228 -0.0155 -0.3269 -0.0901 -0.8213 -0.8496 -0.0395 -0.7158 -0.1606 -0.6875 -0.7749 -0.1268 -0.1465 -0.0338 -0.0564 -0.9355 -0.0282', 'S-812\tHarmire Road, Barnard Castle, County Durham DL12 8DT, Vereinigtes Königreich.', 'T-812\tHarmire Road, Barnard Castle, County Durham DL12 8DT, United Kingdom.', 'H-812\t-0.1949462890625\tHarmire Road , Barnard Castle , County Durham DL12 8DT , United Kingdom .', 'D-812\t-0.1949462890625\tHarmire Road, Barnard Castle, County Durham DL12 8DT, United Kingdom.', 'P-812\t-0.0220 -0.0163 -0.0213 -0.0199 -0.3330 -0.0197 -0.0229 -0.0197 -0.0176 -0.0285 -0.0271 -0.0106 -0.0127 -0.0141 -0.0264 -0.0243 -0.0250 -0.0229 -0.0993 -0.4226 -0.0141 -0.0310 -0.0282', 'S-222\tDer Zeitpunkt für die Bereitstellung der wissenschaftlichen Gutachten und Anhänge in weiteren Sprachen wird mit der Kommission abzuklären sein.', 'T-222\tThe timing of additional language versions of scientific opinions and annexes will have to be checked with the Commission.', 'H-222\t-1.568359375\tTimepoints for the provision of scientific opinions and its annexes in other languages should be agreed with the Commission .', 'D-222\t-1.568359375\tTimepoints for the provision of scientific opinions and its annexes in other languages should be agreed with the Commission.', 'P-222\t-1.8516 -0.6411 -0.3228 -0.1042 -1.2168 -0.8906 -0.0366 -0.6396 -0.4058 -0.0338 -0.9019 -0.0958 -0.0056 -0.0225 -0.4395 -0.8115 -0.0225 -0.9863 -0.0338 -0.3606 -0.8789 -0.0282 -0.0282 -0.0338 -0.0282', 'S-1477\t32 / 33 Italia Pfizer Italia S.r.l., Telefono: + 39 06 3318 2933', 'T-1477\tItalia Pfizer Italia S. r. l., Telefono: + 39 06 3318 2933', 'H-1477\t-0.494140625\t32 / 33 Italia Pfizer Italia S.r.l. , Telefono : + 39 06 3318 2933', 'D-1477\t-0.494140625\t32 / 33 Italia Pfizer Italia S.r.l., Telefono: + 39 06 3318 2933', 'P-1477\t-1.1709 -0.0289 -0.4685 -0.0507 -0.0268 -0.0042 -0.0169 -0.0099 -0.0268 -0.9917 -0.0225 -0.0240 -0.0141 -0.0324 -0.2761 -0.0282 -0.0338 -0.0338 -0.0197 -0.0169 -0.0169 -0.0254 -0.0197 -0.0197 -0.0310', 'S-1205\tEs wirkt, indem es das Wachstum dieser anormalen weißen Blutkörperchen behindert und sie schließlich abtötet.', 'T-1205\tIt works by hindering the growth of these abnormal white blood cells, and eventually kills them.', 'H-1205\t-0.89306640625\tIt works by inhibiting the growth of these abnormal white blood cells and eventually killing them .', 'D-1205\t-0.89306640625\tIt works by inhibiting the growth of these abnormal white blood cells and eventually killing them.', 'P-1205\t-0.3445 -0.4226 -0.0282 -1.4219 -0.0099 -0.0183 -0.1395 -0.1818 -0.2944 -0.0493 -0.1493 -0.0141 -0.0197 -0.2423 -0.3352 -0.2620 -1.2793 -0.1973 -0.0254 -0.0845 -0.0282', 'S-1796\tBasiliximab ist während der Schwangerschaft und Stillzeit kontraindiziert (siehe Abschnitt 4.3).', 'T-1796\tSimulect is contraindicated in pregnancy and lactation (see section 4.3).', 'H-1796\t-0.2958984375\tBasiliximab is contraindicated during pregnancy and lactation ( see section 4.3 ) .', 'D-1796\t-0.2958984375\tBasiliximab is contraindicated during pregnancy and lactation (see section 4.3).', 'P-1796\t-0.0371 -0.0234 -0.0156 -0.0184 -0.0199 -0.0386 -0.0128 -0.0035 -0.4705 -0.0292 -0.0327 -0.8071 -0.0099 -0.0225 -0.0338 -0.0395 -0.1282 -0.0240 -0.0282 -0.0352 -0.0310 -0.0296', 'S-510\tDie Überwachung der Cholesterinwerte und eine nachfolgende Dosisanpassung sollten in Betracht gezogen werden.', 'T-510\tMonitoring of cholesterol levels and subsequent dosage adjustment should be considered.', 'H-510\t-0.6455078125\tCholesterol monitoring and dose adjustment should be considered .', 'D-510\t-0.6455078125\tCholesterol monitoring and dose adjustment should be considered.', 'P-510\t-0.4407 -0.0370 -0.0120 -0.0155 -0.0863 -0.3398 -0.5093 -0.4333 -0.0169 -0.5239 -0.3352 -0.0423 -0.0930 -0.3635 -0.0282', 'S-223\tEs wurde gezeigt, dass Cinacalcet bei Kaninchen die Plazentaschranke überschreitet.', 'T-223\tCinacalcet has been shown to cross the placental barrier in rabbits.', 'H-223\t-0.446533203125\tCinacalcet has been shown to cross the placental barrier in rabbits .', 'D-223\t-0.446533203125\tCinacalcet has been shown to cross the placental barrier in rabbits.', 'P-223\t-0.2351 -0.0213 -0.0285 -0.0313 -0.0185 -0.3435 -0.0306 -0.2378 -0.0373 -0.1487 -0.0373 -0.0176 -0.0092 -1.0176 -0.0310 -0.0535 -0.3804 -0.0099 -0.0254 -0.0310 -0.0296', 'S-1665\tDie NNT in dieser Studie betrug 28 (95% Konfidenzintervall 24 <unk> 50).', 'T-1665\tThe NNT in this study was 28 (95% CI 24 <<unk>> 50).', 'H-1665\t-0.4951171875\tThe NNT in this study was 28 ( 95 % confidence interval 24 @-@ 50 ) .', 'D-1665\t-0.4951171875\tThe NNT in this study was 28 (95% confidence interval 24-50).', 'P-1665\t-0.1212 -0.0671 -0.0292 -0.0241 -0.1282 -0.0430 -0.0370 -0.0342 -0.0243 -0.0370 -0.0204 -0.0370 -1.0303 -0.0592 -0.0127 -0.0704 -0.5972 -0.0240 -0.0282 -0.6240 -0.0282', 'S-271\tDas Verteilungsvolumen war leicht verringert, daher verlängerte sich die Halbwertszeit nur um 14%.', 'T-271\tVolume of distribution was slightly decreased and thus half-life only increased by 14%.', 'H-271\t-1.1162109375\tThe volume of distribution was slightly reduced , so the half @-@ life was prolonged by 13 % .', 'D-271\t-1.1162109375\tThe volume of distribution was slightly reduced, so the half-life was prolonged by 13%.', 'P-271\t-0.2120 -0.4243 -0.0768 -0.1750 -0.0500 -0.2754 -0.3347 -0.7002 -0.6792 -0.9663 -0.2930 -0.0648 -0.0395 -0.1859 -0.9946 -0.0085 -0.0197 -0.0930 -1.3721 -0.0338 -0.1071 -0.0282', 'S-1065\tBesondere Vorsicht bei der Einnahme von Revlimid ist erforderlich Bitte sprechen Sie in den folgenden Situationen mit Ihrem Arzt:', 'T-1065\t82 Take special care with Revlimid Please talk to your doctor in the following situations:', 'H-1065\t-1.546875\tTake special care with Revlimid Check with your doctor if you have any of the following :', 'D-1065\t-1.546875\tTake special care with Revlimid Check with your doctor if you have any of the following:', 'P-1065\t-1.0732 -0.2634 -0.0782 -0.3191 -0.2466 -0.0127 -0.0324 -2.2207 -0.0366 -0.0338 -0.0592 -0.9526 -0.7749 -1.0703 -0.3833 -0.6201 -0.0395 -0.0225 -1.0703 -0.0282', 'S-1657\t• Halten Sie für den Fall eines Verlustes oder einer Beschädigung des Pens immer einen zweiten Pen verfügbar.', 'T-1657\t• Always carry an extra pen in case yours is lost or damaged.', 'H-1657\t-0.67236328125\t• Always have a second pen in case your pen is lost or damaged .', 'D-1657\t-0.67236328125\t• Always have a second pen in case your pen is lost or damaged.', 'P-1657\t-0.4058 -0.0901 -0.0155 -1.2275 -0.0437 -0.1888 -0.1578 -0.4043 -0.1000 -0.3142 -0.0676 -0.4226 -0.0930 -0.0338 -0.0282 -0.0535 -0.0338', 'S-1522\tIn klinischen Studien wurde die Behandlung mit Glivec bis zum Auftreten einer Progression der Erkrankung fortgeführt.', 'T-1522\tIn clinical trials, treatment with Glivec was continued until disease progression.', 'H-1522\t-0.6279296875\tIn clinical trials , treatment with Glivec was continued until disease progression .', 'D-1522\t-0.6279296875\tIn clinical trials, treatment with Glivec was continued until disease progression.', 'P-1522\t-0.3569 -0.0291 -0.7251 -0.1733 -0.1543 -0.3086 -0.0324 -0.0127 -0.0254 -0.2283 -0.6084 -0.1930 -0.2352 -0.0225 -0.0225 -0.2817 -0.0282', 'S-123\tUm den optimalen Behandlungseffekt zu erzielen, ist es wichtig, die oben genannten Empfehlungen einzuhalten.', 'T-123\t2 It is important to follow the above recommendations to achieve the optimal treatment effect.', 'H-123\t-1.572265625\tTo achieve the optimum treatment effect , it is important to adhere to the recommendations listed above .', 'D-123\t-1.572265625\tTo achieve the optimum treatment effect, it is important to adhere to the recommendations listed above.', 'P-123\t-1.1240 -1.4414 -0.4155 -1.2480 -0.0254 -1.3496 -0.0648 -0.2311 -0.2930 -0.0282 -0.0451 -0.4226 -1.3809 -0.0113 -0.0282 -0.0338 -0.5972 -0.9409 -0.0338 -0.0282 -0.0282', 'S-87\t50 mg losartan potassium - Filmtablette 12,5 mg hydrochlorothiazide', 'T-87\tFilm-coated tablet', 'H-87\t-0.7705078125\tCOZAAR PLUS 50 mg losartan potassium 12,5 mg hydrochlorothiazide', 'D-87\t-0.7705078125\tCOZAAR PLUS 50 mg losartan potassium 12,5 mg hydrochlorothiazide', 'P-87\t-0.5674 -0.4351 -0.3206 -0.3228 -0.6807 -0.2072 -0.5835 -0.8960 -0.0732 -0.0113 -0.0254 -0.0141 -0.0113 -0.0225 -1.0146 -0.0282 -0.0141 -0.0197 -0.0282 -0.0085 -0.0282 -0.0141 -0.0169 -0.0113 -0.0479 -0.0395', 'S-107\t- Es wurde nicht nachgewiesen, dass CYSTAGON eine Anhäufung von Cystinkristallen im Auge', 'T-107\tWhere', 'H-107\t-1.5107421875\t- it has not been demonstrated that CYSTAGON is an accumulation of cystine crystals in eyes', 'D-107\t-1.5107421875\t- it has not been demonstrated that CYSTAGON is an accumulation of cystine crystals in eyes', 'P-107\t-0.0320 -2.0801 -0.3269 -0.0324 -0.0268 -0.9272 -0.0507 -0.0676 -0.0254 -0.0197 -0.0113 -0.0535 -1.1611 -2.7812 -0.0395 -0.0169 -0.0338 -0.1803 -0.2029 -0.0169 -0.0056 -0.0225 -0.1409 -0.9692 -1.1943', 'S-1877\tVon der Verwendung von EXUBERA bei Patienten, die eine Dosisanpassung in kleineren Schritten ei', 'T-1877\tDose adjustment may be required based on the meal size and nutrient composition, time of day (higher insulin requirements in the morning), pre-meal blood glucose concentration, recent or al', 'H-1877\t-1.7705078125\tThe use of EXUBERA in patients requiring dose adjustment in small increments', 'D-1877\t-1.7705078125\tThe use of EXUBERA in patients requiring dose adjustment in small increments', 'P-1877\t-3.2969 -0.2227 -0.0310 -0.1945 -0.0225 -0.0141 -0.0282 -0.0845 -0.0282 -0.6479 -0.2620 -1.0059 -0.0225 -0.2649 -0.0507 -0.3438 -0.3889 -0.0282 -3.4258', 'S-748\tAlle Patienten erhielten Alglucosidase alfa in einer Dosierung von 20 mg / kg Körpergewicht.', 'T-748\tThe pharmacokinetics of Myozyme were also evaluated in a separate trial in 21 patients with infantile- onset Pompe disease (all aged between 6 months and 3.5 years at treatment-onset) who received doses of 20 mg / kg of alglucosidase alfa.', 'H-748\t-0.76708984375\tAll patients received alglucosidase alfa at a dose of 20 mg / kg body weight .', 'D-748\t-0.76708984375\tAll patients received alglucosidase alfa at a dose of 20 mg / kg body weight.', 'P-748\t-0.4805 -0.0458 -0.5503 -0.9214 -0.0901 -0.0324 -0.0775 -0.0254 -0.0155 -0.0423 -0.0127 -1.5273 -0.2986 -0.1493 -0.0310 -0.0676 -0.4565 -0.0366 -0.0169 -0.0789 -0.0169 -0.0338 -0.0282', 'S-574\tDurch die Anwendung von Arixtra nach einer Operation wird das Risiko der Bildung eines Blutgerinnsels stark vermindert.', 'T-574\tBy using Arixtra after surgery, the risk of a blood clot forming is greatly reduced.', 'H-574\t-1.3427734375\tThe use of Arixtra after an operation greatly reduces the risk of a blood clot forming .', 'D-574\t-1.3427734375\tThe use of Arixtra after an operation greatly reduces the risk of a blood clot forming.', 'P-574\t-1.6348 -1.8115 -0.0282 -0.0282 -0.0254 -0.0085 -0.7690 -0.9072 -0.0282 -0.6650 -0.0564 -0.0225 -0.0338 -0.0225 -0.0338 -1.8486 -0.1691 -0.0282 -0.0113 -0.3833 -0.0338 -0.0282', 'S-659\tlas Bakterien oder Viren ausgesetzt, ist das Immunsystem schneller in der Lage, entsprechende Antikörper zu produzieren.', 'T-659\ted to stimulate a better immune response.', 'H-659\t-0.88330078125\tWhen it is exposed to bacteria or viruses , the immune system will be able to produce antibodies more quickly .', 'D-659\t-0.88330078125\tWhen it is exposed to bacteria or viruses, the immune system will be able to produce antibodies more quickly.', 'P-659\t-0.4844 -0.4414 -0.2008 -0.0331 -0.0282 -0.5366 -0.0352 -0.1578 -0.0197 -0.0423 -0.8594 -0.3169 -0.0225 -0.8003 -0.1578 -0.1240 -0.0338 -0.6567 -0.3972 -0.0169 -0.4509 -0.0620 -0.0395 -0.0282', 'S-416\tReinigen Sie zunächst die Hautflächen, auf denen Sie dieses Arzneimittel anwenden werden, und trocknen Sie sie ab.', 'T-416\tClean and dry the areas of the skin where you will be using it.', 'H-416\t-2.07421875\tClean the areas of skin where you are going to use this product and dry them .', 'D-416\t-2.07421875\tClean the areas of skin where you are going to use this product and dry them.', 'P-416\t-2.1934 -0.0662 -0.7158 -0.8286 -0.0423 -0.6313 -0.6846 -0.1042 -0.7354 -1.3584 -0.0282 -0.3269 -0.6030 -0.6538 -0.9580 -1.2734 -0.5859 -0.3157 -0.0338', 'S-980\tBitte lesen Sie die folgende Bedienungsanleitung vor der Benutzung von Protaphane InnoLet sorgfältig durch.', 'T-980\tPlease read the following instructions carefully before using your Protaphane InnoLet.', 'H-980\t-0.393310546875\tPlease read the following instructions carefully before using Protaphane InnoLet .', 'D-980\t-0.393310546875\tPlease read the following instructions carefully before using Protaphane InnoLet.', 'P-980\t-0.2467 -0.0590 -0.0754 -0.0532 -0.2771 -0.0986 -0.0423 -0.0732 -0.9370 -0.0070 -0.0085 -0.0254 -0.0240 -0.0704 -0.0437 -0.0352', 'S-1305\t<unk> Overall Success <unk> definiert sich über folgende primären Wirksamkeits- und Sicherheitserwägungen:', 'T-1305\tOverall success consists of the following primary efficacy and safety considerations:', 'H-1305\t-1.720703125\tReproduction is based on the following primary efficacy and safety issues :', 'D-1305\t-1.720703125\tReproduction is based on the following primary efficacy and safety issues:', 'P-1305\t-1.2598 -0.3938 -0.2803 -1.9092 -0.0592 -0.0704 -0.0395 -1.2734 -1.0205 -0.0113 -0.0225 -0.0338 -0.0225 -2.3945 -0.2593 -0.0282', 'S-1453\tBerühren Sie die gereinigten Zitzenspitzen vor der Instillation des Tierarzneimittels nicht mehr.', 'T-1453\tDo not touch cleaned teat ends before administering the infusion substance.', 'H-1453\t-0.86083984375\tDo not touch the cleaned teat end again before infusion of the veterinary medicinal product .', 'D-1453\t-0.86083984375\tDo not touch the cleaned teat end again before infusion of the veterinary medicinal product.', 'P-1453\t-0.3853 -0.0285 -0.0525 -0.2275 -0.3445 -0.0310 -0.2500 -0.0676 -0.3445 -0.5239 -0.3396 -0.3325 -0.3213 -0.3042 -0.0817 -0.8511 -0.0338 -0.3015 -0.1324 -0.0366 -0.4819 -0.0282', 'S-1960\tFür die Anfangsbehandlung sind Spezialpackungen mit der korrekten Anzahl an Spritzen oder Patronen erhältlich.', 'T-1960\tThe patients can inject Rebif themselves if they have been trained appropriately.', 'H-1960\t-0.818359375\tA special pack with the correct number of syringes or cartridges is available for initiation of therapy .', 'D-1960\t-0.818359375\tA special pack with the correct number of syringes or cartridges is available for initiation of therapy.', 'P-1960\t-1.4404 -0.1642 -0.2551 -0.1846 -0.1493 -0.1945 -0.0930 -0.0296 -0.0282 -0.0085 -0.0282 -0.3000 -0.4155 -0.0056 -0.0169 -0.0620 -0.0395 -0.0479 -0.5215 -0.3467 -0.3269 -0.7861 -0.0366 -0.0282', 'S-47\tJede Durchstechflasche enthält 75 oder 150 mg des arzneilich wirksamen Bestandteils Omalizumab.', 'T-47\tEach vial contains 75 or 150 mg of the active substance omalizumab.', 'H-47\t-0.388916015625\tEach vial contains 75 or 150 mg of the active substance of omalizumab .', 'D-47\t-0.388916015625\tEach vial contains 75 or 150 mg of the active substance of omalizumab.', 'P-47\t-0.0270 -0.0414 -0.0113 -0.0560 -0.1814 -0.0449 -0.0299 -0.0278 -0.0356 -0.0856 -0.2986 -0.3184 -1.0254 -0.0155 -0.0352 -0.0056 -0.0169 -0.0211 -0.0395 -0.0296', 'S-974\tWenn Sie eine Anwendung von AZARGA vergessen haben, setzen Sie die Behandlung mit der nächsten planmäßigen Anwendung fort.', 'T-974\tIf you forget to use AZARGA, continue with the next dose as planned.', 'H-974\t-0.54296875\tIf you forget to use AZARGA , continue with the next dose as planned .', 'D-974\t-0.54296875\tIf you forget to use AZARGA, continue with the next dose as planned.', 'P-974\t-0.0759 -0.0320 -0.2620 -0.1670 -0.1687 -0.0525 -0.0254 -0.0183 -0.0085 -0.0867 -0.5645 -0.3396 -0.1381 -0.0760 -0.5933 -0.2607 -0.2367 -0.0395 -0.0338', 'S-25\tSie dürfen Kentera nach dem auf dem Beutel und dem Karton angegebenen Verfallsdatum nicht mehr verwenden.', 'T-25\tDo not use Kentera after the date shown on the sachet and the carton.', 'H-25\t-0.5732421875\tDo not use Kentera after the expiry date which is stated on the sachet and carton .', 'D-25\t-0.5732421875\tDo not use Kentera after the expiry date which is stated on the sachet and carton.', 'P-25\t-0.5200 -0.0299 -0.0409 -0.2001 -0.0099 -0.0275 -0.1085 -0.0718 -0.0592 -0.1240 -0.0338 -0.6016 -0.1268 -0.2563 -0.0324 -0.0578 -0.5537 -0.0254 -0.0423 -0.3523 -0.1240 -0.3325 -0.0310', 'S-1344\tNovember 2007 gingen die Antworten der Inhaber der Genehmigung für das Inverkehrbringen auf die Fragen ein, und das Verfahren lief weiter.', 'T-1344\tOn 16 November 2007 responses to the questions were received from MAH and the clock restarted.', 'H-1344\t-1.3916015625\tOn 30 November 2007 responses to the List of Questions were received by the Marketing Authorisation Holders and the clock was re @-@ started .', 'D-1344\t-1.3916015625\tOn 30 November 2007 responses to the List of Questions were received by the Marketing Authorisation Holders and the clock was re-started.', 'P-1344\t-0.4863 -1.5684 -0.0817 -0.0254 -0.4663 -0.2410 -0.2791 -0.8369 -0.9043 -0.2537 -0.0254 -0.2649 -0.0789 -0.7554 -0.6704 -0.3157 -0.0169 -0.0395 -0.0564 -0.2705 -0.0395 -0.6763 -0.0901 -0.3662 -1.1670 -0.3269 -0.0282 -0.3101 -0.0395 -0.0282', 'S-306\tFalls gastrointestinale Nebenwirkungen auftreten, ist die Behandlung bis zum Abklingen der Symptome zeitweise zu unterbrechen.', 'T-306\tTreatment should be temporarily interrupted if gastrointestinal adverse reactions are observed until these adverse reactions resolve.', 'H-306\t-1.5498046875\tIf gastrointestinal adverse reactions occur , treatment must be temporarily discontinued until symptoms abate .', 'D-306\t-1.5498046875\tIf gastrointestinal adverse reactions occur, treatment must be temporarily discontinued until symptoms abate.', 'P-306\t-0.4678 -0.9165 -0.0303 -0.0049 -0.0113 -0.0176 -0.4128 -0.0197 -1.5371 -0.0282 -0.0760 -0.3213 -0.9805 -1.1162 -0.0564 -0.4395 -0.7324 -0.0169 -0.0507 -0.7158 -2.4238 -0.0056 -0.0282 -0.0282', 'S-1139\t50-80% der angewendeten Dosis werden als Glucuronid mit dem Urin ausgeschieden.', 'T-1139\tThe 5 <<unk>> -glucuronide of zidovudine is the major metabolite in both plasma and urine, accounting for approximately 50 <<unk>> 80% of the administered dose eliminated by renal excretion.', 'H-1139\t-1.13671875\t50 @-@ 80 % of the administered dose is excreted in the urine as glucuronide .', 'D-1139\t-1.13671875\t50-80% of the administered dose is excreted in the urine as glucuronide.', 'P-1139\t-2.5547 -0.0803 -0.0225 -0.0310 -0.0296 -0.0465 -1.4961 -0.0225 -0.1099 -0.4622 -0.0732 -0.0085 -0.0282 -0.8057 -0.6875 -0.0169 -0.0169 -0.1521 -0.4846 -0.0225 -0.0169 -0.0225 -0.4338 -0.0282', 'S-485\tSie sollten dann Ihr Blut untersuchen lassen, um sicherzugehen, dass Arava ausreichend aus dem Körper ausgeschieden wurde.', 'T-485\tTo minimise any possible risk, men wishing to father a child should contact their doctor who may advise you to stop taking Arava and take certain medicines to speed up the removal of 66 Arava from your body.', 'H-485\t-1.37890625\tYou should then have your blood monitored to make sure Arava has been sufficiently removed from your body .', 'D-485\t-1.37890625\tYou should then have your blood monitored to make sure Arava has been sufficiently removed from your body.', 'P-485\t-0.7617 -0.2839 -1.7852 -0.5537 -0.2507 -0.0197 -0.3325 -0.0338 -0.2620 -1.7529 -0.0282 -0.3945 -0.0169 -0.2141 -0.0732 -0.3438 -0.0113 -0.0169 -0.7046 -0.3945 -0.9639 -0.0282 -0.0338 -0.0282', 'S-1572\tSeptember 2007 mit der Annahme einer Fragenliste des CHMP an die Inhaber der Genehmigung für das Inverkehrbringen eingeleitet.', 'T-1572\tThe referral procedure was initiated on 20 September 2007 with the adoption of a CHMP list of questions that were to be addressed by the marketing authorisation holders (MAHs).', 'H-1572\t-0.796875\tThe Referral procedure was initiated on 8 September 2007 with the adoption of a CHMP List of Questions to be addressed by the MAHs .', 'D-1572\t-0.796875\tThe Referral procedure was initiated on 8 September 2007 with the adoption of a CHMP List of Questions to be addressed by the MAHs.', 'P-1572\t-0.3411 -0.3311 -0.0342 -0.3181 -0.2382 -0.1874 -0.0296 -0.2029 -0.8623 -0.0930 -0.0296 -0.0986 -0.0395 -0.1000 -0.0141 -0.0760 -0.0817 -0.2367 -0.0113 -0.3325 -0.0395 -0.0507 -0.0310 -0.1803 -0.3691 -0.1859 -0.5015 -0.0901 -0.3777 -0.3945 -0.3213 -0.2649 -0.0282', 'S-1155\tB. bei hoher Pertussisinzidenz, kann der potenzielle Nutzen der Impfung gegenüber möglichen Risiken überwiegen.', 'T-1155\t3 The vaccine will not prevent infection caused by other pathogens known to infect the liver such as hepatitis A, hepatitis C and hepatitis E virus.', 'H-1155\t-1.54296875\tIf the incidence of pertussis is high , the potential benefits outweigh possible risks .', 'D-1155\t-1.54296875\tIf the incidence of pertussis is high, the potential benefits outweigh possible risks.', 'P-1155\t-2.6680 -1.9756 -0.8003 -0.0169 -0.0479 -0.2057 -0.0056 -0.0451 -0.0225 -0.2705 -0.2874 -0.0507 -1.0479 -0.0451 -0.5186 -0.5469 -0.0113 -0.8789 -0.0395 -0.0732 -0.0282', 'S-322\t- Erarbeitung von neuen CPMP-Sicherheitsleitlinien, Informationsblättern und Diskussionspapieren:', 'T-322\tSupport to the Herbal Medicinal Products Working Party will continue in 2001-2002, with the working party expected to meet 3 times a year in 2001 and 2002.', 'H-322\t-1.2451171875\tDirective 90 / 677 / EEC', 'D-322\t-1.2451171875\tDirective 90 / 677 / EEC', 'P-322\t-2.1738 -0.1775 -0.3254 -0.1493 -0.5493 -0.4678 -0.1747 -0.4087 -0.1127 -0.4170', 'S-1736\tÜberschreiten Sie nicht die vom Arzt verordnete Dosis, die auch in dieser Packungsbeilage genannt wird.', 'T-1736\tIf you take more VIRAMUNE than you should Do not exceed the dose prescribed by your doctor and described in this leaflet.', 'H-1736\t-0.486328125\tDo not exceed the dose prescribed by your doctor and described in this leaflet .', 'D-1736\t-0.486328125\tDo not exceed the dose prescribed by your doctor and described in this leaflet.', 'P-1736\t-0.1703 -0.0292 -0.0199 -0.0199 -0.0678 -0.2981 -0.1895 -0.0169 -0.0303 -0.1719 -0.0402 -0.3572 -0.3149 -0.0564 -0.1310 -0.2803 -0.0169 -0.0169 -0.2001 -0.5088', 'S-1649\tArt der Anwendung Lansoprazol-CT 15 mg werden als Ganzes mit ausreichend Flüssigkeit (z.', 'T-1649\tLansoprazol-CT capsules are swallowed whole with sufficient liquid (e. g. a glass of water).', 'H-1649\t-1.1787109375\tLansoprazol @-@ CT is swallowed whole with sufficient liquid ( e. g .', 'D-1649\t-1.1787109375\tLansoprazol-CT is swallowed whole with sufficient liquid (e. g.', 'P-1649\t-0.4521 -0.0028 -0.3206 -0.2072 -0.0218 -0.1113 -0.0296 -0.0127 -1.0410 -2.2578 -0.0141 -0.0169 -0.2817 -0.1635 -0.1831 -0.3833 -0.0676 -0.9019 -0.0451 -0.9580 -0.0282 -0.0282', 'S-1058\t18 Die Inzidenz einiger Nebenwirkungen war bei Kindern höher als bei Erwachsenen (siehe Ab- schnitt 4.8).', 'T-1058\tThe incidence of some adverse reactions was higher in paediatric patients than in adult patients (see section 4.8).', 'H-1058\t-1.0673828125\tIn children , the incidence of some side effects was higher than in adults ( see section 4.8 ) .', 'D-1058\t-1.0673828125\tIn children, the incidence of some side effects was higher than in adults (see section 4.8).', 'P-1058\t-1.5381 -0.7764 -0.5537 -0.3411 -0.1353 -0.0225 -0.0338 -0.3438 -1.7158 -0.3269 -0.4058 -0.0507 -0.0338 -0.2537 -0.0225 -0.0338 -0.0395 -0.2311 -0.0225 -0.0282 -0.0338 -0.0338 -0.0282', 'S-1476\tDie Flasche mit der Spritze nun wieder umdrehen und die Dosierspritze durch Drehen abnehmen.', 'T-1476\tTurn the bottle right way up and with a twisting movement separate the dosing syringe from the bottle.', 'H-1476\t-1.6513671875\tTurn the bottle @-@ syringe the correct way up and remove the syringe by turning it off .', 'D-1476\t-1.6513671875\tTurn the bottle-syringe the correct way up and remove the syringe by turning it off.', 'P-1476\t-0.7461 -0.0240 -0.2986 -0.7388 -1.7705 -0.1635 -0.0056 -0.0085 -1.5977 -0.5015 -0.0282 -0.3606 -0.2423 -0.8286 -0.0451 -0.9917 -0.0056 -0.0056 -0.4565 -0.2817 -1.1494 -0.7720 -0.0620 -0.0282', 'S-1308\tHCA akkumuliert so in der Haut des Hundes, was eine lokale Wirksamkeit bei niedriger Dosierung ermöglicht.', 'T-1308\tHCA thus accumulates in the dog <<unk>> s skin allowing local efficacy at low dosage.', 'H-1308\t-1.4140625\tHCA accumulates in the dog &quot; s skin , thereby allowing a local efficacy at a low dose .', 'D-1308\t-1.4140625\tHCA accumulates in the dog "s skin, thereby allowing a local efficacy at a low dose.', 'P-1308\t-0.6445 -0.0106 -0.8413 -0.4282 -0.0240 -0.2240 -0.3423 -0.5342 -0.3213 -0.0225 -0.0225 -0.0986 -2.0098 -0.0141 -0.4368 -1.0986 -0.1917 -1.2002 -0.0113 -0.0169 -0.1296 -1.0254 -0.0676 -0.2141 -0.0282 -0.0282', 'S-1870\tDie Behandlung mit LITAK muss von einem qualifizierten Arzt mit Erfahrungen in der Krebschemotherapie eingeleitet werden.', 'T-1870\tTherapy with LITAK should be initiated by a qualified physician with experience in cancer chemotherapy.', 'H-1870\t-0.92431640625\tLITAK treatment should be initiated by a qualified doctor who has experience in anti @-@ cancer chemotherapy .', 'D-1870\t-0.92431640625\tLITAK treatment should be initiated by a qualified doctor who has experience in anti-cancer chemotherapy.', 'P-1870\t-0.5693 -0.0229 -0.0141 -0.2311 -0.2986 -0.0352 -0.6265 -0.0282 -0.0338 -0.0380 -0.5479 -0.3071 -1.5244 -0.0845 -0.1183 -0.0817 -1.4570 -0.0338 -0.0395 -0.0395 -0.0113 -0.0169 -0.0338 -0.0282', 'S-59\t2 BG-София 1407 Тел.: + 359 2 806 301', 'T-59\t2 BG-София 1407 Тел.: + 359 2 806 301', 'H-59\t-0.45751953125\t2 BG @-@ София 1407 Тел . : + 359 2 806 301', 'D-59\t-0.45751953125\t2 BG-София 1407 Тел.: + 359 2 806 301', 'P-59\t-0.1942 -0.2340 -0.0271 -0.1096 -0.3228 -0.1965 -0.3213 -0.1782 -0.3213 -0.0380 -0.0169 -0.3228 -0.2240 -0.3127 -0.0887 -0.0310 -0.0282 -0.0225 -0.0169 -0.0338 -0.0254 -0.0169 -0.0169 -0.0254 -0.0310', 'S-294\tVolumen- und / oder Natriummangel sind vor Verabreichung von Kinzalmono auszugleichen.', 'T-294\tVolume and / or sodium depletion should be corrected prior to administration of Kinzalmono.', 'H-294\t-0.481201171875\tVolume and / or sodium depletion should be corrected before the administration of Kinzalmono .', 'D-294\t-0.481201171875\tVolume and / or sodium depletion should be corrected before the administration of Kinzalmono.', 'P-294\t-0.0619 -0.0298 -0.0472 -0.0349 -0.0256 -0.0213 -0.0070 -0.4092 -0.3398 -0.0662 -0.3340 -0.0289 -0.3000 -0.0268 -0.9243 -0.2903 -0.0901 -0.0310 -0.1042 -0.0197 -0.0169 -0.0141 -0.0282 -0.0395 -0.0282', 'S-314\tLaboratório Medinfar - Produtos Farmacêuticos, S.A.', 'T-314\tLaboratório Medinfar - Produtos Farmacêuticos, S. A.', 'H-314\t-1.0751953125\tMedinfar Laboratoire - Produtos Farmacêuticos , S. A .', 'D-314\t-1.0751953125\tMedinfar Laboratoire - Produtos Farmacêuticos, S. A.', 'P-314\t-4.3750 -0.0141 -0.0169 -0.1268 -0.2423 -0.0507 -1.2881 -0.0225 -0.0395 -0.0901 -0.0225 -0.0169 -0.0225 -0.0169 -0.0169 -0.0056 -0.0225 -0.0225 -0.0056 -0.0282 -0.6987 -0.0282 -0.0338 -0.0282', 'S-321\tEs gibt Packungen mit 1, 3, 4, 5, 6, 8, 9 und 10 Patronen.', 'T-321\tPacks of 1, 3, 4, 5, 6, 8, 9 and 10 cartridges are available.', 'H-321\t-0.2327880859375\tPacks of 1 , 3 , 4 , 5 , 6 , 8 , 9 and 10 cartridges are available .', 'D-321\t-0.2327880859375\tPacks of 1, 3, 4, 5, 6, 8, 9 and 10 cartridges are available.', 'P-321\t-0.1974 -0.0255 -0.0796 -0.0365 -0.0284 -0.0285 -0.0292 -0.0278 -0.0292 -0.0271 -0.0285 -0.0271 -0.0292 -0.0250 -0.0292 -0.0243 -0.5981 -0.0254 -0.0740 -0.0085 -0.0211 -0.0782 -0.0549 -0.0437 -0.0296', 'S-418\t- Bei gleichzeitiger Einnahme von [Phantasiebezeichnung] Tabletten und Aktivkohle wird die', 'T-418\t- Taking oral medicinal charcoal at the same time as [Invented name] tablets reduces the action of', 'H-418\t-1.6162109375\tIf you are taking &#91; Invented name &#93; tablets and activated charcoal talk to your doctor .', 'D-418\t-1.6162109375\tIf you are taking [Invented name] tablets and activated charcoal talk to your doctor.', 'P-418\t-1.3857 -1.3584 -0.4480 -0.4028 -1.1523 -0.3213 -0.0873 -0.3101 -0.0423 -0.0845 -0.0197 -0.0535 -0.0817 -0.0225 -0.2141 -0.0225 -0.5127 -0.2649 -1.1719 -0.3101 -2.0234 -0.0338', 'S-1047\tIndinavir Cmin: ↑ 49% (Im Vergleich zu Indinavir 800 mg TID allein)', 'T-1047\tIndinavir Cmin: ↑ 49% (Relative to Indinavir 800 mg TID alone)', 'H-1047\t-0.217529296875\tIndinavir Cmin : ↑ 49 % ( Relative to Indinavir 800 mg TID alone )', 'D-1047\t-0.217529296875\tIndinavir Cmin: ↑ 49% (Relative to Indinavir 800 mg TID alone)', 'P-1047\t-0.3030 -0.0127 -0.0113 -0.0185 -0.0384 -0.0127 -0.0356 -0.0760 -0.0190 -0.0271 -0.0342 -0.3223 -0.1515 -0.0352 -0.0993 -0.0120 -0.0092 -0.0190 -0.0662 -0.0162 -0.0289 -0.0134 -0.0740 -0.0296 -0.0352', 'S-1359\tFLASCHENETIKETT MIT 60 FILMTABLETTEN (150 mg)', 'T-1359\tBOTTLE LABEL X 60 FILM-COATED TABLETS (150 mg)', 'H-1359\t-0.833984375\tBOTTLE LABEL OF 60 FILM @-@ COATED TABLETS ( 150 mg )', 'D-1359\t-0.833984375\tBOTTLE LABEL OF 60 FILM-COATED TABLETS (150 mg)', 'P-1359\t-0.0429 -0.0626 -0.0156 -0.0357 -0.2998 -0.1825 -0.0532 -0.8086 -0.0141 -1.8691 -0.1268 -0.0760 -0.0254 -0.3184 -0.3213 -0.3213 -0.3184 -0.3691 -0.0056 -0.0169 -0.3127 -0.0366 -0.1719 -0.0225 -0.0282 -0.0338', 'S-918\tHautreaktionen, wie Rötungen, Schwellungen und / oder Schmerzen am Ort der Infusion, können auftreten.', 'T-918\tSkin reactions such as redness, swelling and / or pain at the infusion site may occur.', 'H-918\t-0.83203125\tSkin reactions such as redness , swelling and / or pain at the infusion site may occur .', 'D-918\t-0.83203125\tSkin reactions such as redness, swelling and / or pain at the infusion site may occur.', 'P-918\t-1.6748 -0.0225 -0.0437 -0.0169 -0.7832 -0.0296 -0.0775 -0.0155 -0.0324 -0.0211 -0.0296 -0.5073 -0.0338 -0.0254 -0.2001 -0.2113 -0.0338 -0.8398 -0.0169 -0.0676 -0.7974 -0.0535 -0.0366 -0.0282', 'S-1518\tBei Patienten mit generalisierter Erythrodermie ist die Unbedenklichkeit von Protopic nicht nachgewiesen.', 'T-1518\tThe safety of Protopic ointment has not been established in patients with generalised erythroderma.', 'H-1518\t-1.0078125\tThe safety of Protopic has not been established in patients with generalised erythroderma .', 'D-1518\t-1.0078125\tThe safety of Protopic has not been established in patients with generalised erythroderma.', 'P-1518\t-2.4785 -0.0592 -0.0493 -0.3860 -0.0169 -0.0197 -1.3496 -0.0310 -0.0338 -0.2930 -0.0901 -0.0197 -0.0423 -0.2507 -0.2395 -0.5747 -0.0225 -0.0056 -0.0169 -0.3945 -0.0338 -0.0282', 'S-1855\t- Ältere Patienten: es sind zwischen älteren (≥ 65 Jahre) oder sehr alten Patienten (≥ 75 Jahre) und', 'T-1855\t- Elderly: no pharmacokinetic differences (AUC and Cmax) have been observed between elderly (≥', 'H-1855\t-1.4599609375\t- Elderly ( ≥ 65 years ) or elderly ( ≥ 75 years )', 'D-1855\t-1.4599609375\t- Elderly (≥ 65 years) or elderly (≥ 75 years)', 'P-1855\t-0.4390 -0.9805 -0.0141 -1.2363 -0.4917 -0.0366 -0.0648 -0.0564 -0.3916 -0.9043 -0.4170 -0.0169 -0.0169 -0.0366 -0.0282 -2.5723', 'S-1412\tDarüber hinaus kann Ihr Arzt abnormale Veränderungen in Ihren Blutwerten wie erhöhte Kreatinkinase (häufig) feststellen.', 'T-1412\tIn addition your doctor may identify abnormal changes in your blood components such as creatine kinase increased (common).', 'H-1412\t-1.04296875\tIn addition , your doctor may identify abnormal changes in your blood tests such as increased creatine kinase ( common ) .', 'D-1412\t-1.04296875\tIn addition, your doctor may identify abnormal changes in your blood tests such as increased creatine kinase (common).', 'P-1412\t-0.5352 -0.0183 -0.6074 -0.0282 -0.0254 -0.0380 -0.3423 -0.2438 -0.2747 -0.0395 -0.4016 -0.1930 -0.0211 -1.3398 -0.7212 -0.0310 -1.6318 -0.2479 -0.0225 -0.0225 -0.0113 -0.0169 -0.0282 -0.3157 -0.0282 -0.3213 -0.0282', 'S-1732\t25 mg, 100 mg oder 150 mg Erlotinib (als Erlotinibhydrochlorid).', 'T-1732\tor 150 mg of erlotinib (as erlotinib hydrochloride) depending on the strength.', 'H-1732\t-0.38427734375\t25 mg , 100 mg or 150 mg of erlotinib ( as erlotinib hydrochloride ) .', 'D-1732\t-0.38427734375\t25 mg, 100 mg or 150 mg of erlotinib (as erlotinib hydrochloride).', 'P-1732\t-0.8052 -0.3269 -0.0345 -0.0197 -0.0134 -0.0634 -0.0183 -0.0155 -0.9575 -0.0113 -0.0099 -0.0085 -0.0282 -0.0352 -0.1127 -0.0155 -0.0113 -0.0141 -0.0352 -0.0282 -0.0240 -0.0268 -0.0183 -0.0240 -0.0296 -0.0620 -0.0282', 'S-1741\tBei klinisch bedeutsamen Veränderungen ist eine Anpassung der immunsuppressiven Medikation zu erwägen.', 'T-1741\tIf clinically relevant changes are seen, adjustments of the immunosuppressive regimen should be considered.', 'H-1741\t-1.61328125\tDuring the initial post @-@ transplant period , monitoring of the following parameters should be undertaken .', 'D-1741\t-1.61328125\tDuring the initial post-transplant period, monitoring of the following parameters should be undertaken.', 'P-1741\t-1.7598 -0.3411 -0.3228 -0.3467 -0.0930 -0.3523 -0.2734 -0.2817 -0.1945 -0.7578 -0.2255 -0.5215 -0.9551 -0.4114 -0.0789 -0.0225 -0.3606 -0.0451 -0.6821 -0.0282 -2.2266 -0.0282', 'S-159\tMetacam sollte nicht zusammen mit anderen NSAIDs oder Glukokortikoiden verabreicht werden.', 'T-159\tMetacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids.', 'H-159\t-0.5673828125\tMetacam must not be administered in conjunction with other NSAIDs or glucocorticoids .', 'D-159\t-0.5673828125\tMetacam must not be administered in conjunction with other NSAIDs or glucocorticoids.', 'P-159\t-0.0349 -0.0198 -0.0241 -1.0596 -0.0282 -0.0282 -0.1782 -0.0197 -0.2556 -0.2184 -0.0113 -0.0296 -0.1085 -0.1803 -0.0085 -0.0268 -0.0338 -0.0141 -0.0296 -0.0183 -0.0240 -0.0211 -1.4824 -0.0310 -0.0282', 'S-1347\tWichtige Informationen über bestimmte sonstige Bestandteile von Xagrid Laktose ist ein Bestandteil in Xagrid.', 'T-1347\tImportant information about some of the ingredients of Xagrid Lactose is an ingredient in Xagrid.', 'H-1347\t-0.533203125\tImportant information about some of the ingredients of Xagrid lactose is part of Xagrid .', 'D-1347\t-0.533203125\tImportant information about some of the ingredients of Xagrid lactose is part of Xagrid.', 'P-1347\t-0.4590 -0.0148 -0.0257 -0.0560 -0.1219 -0.3088 -0.3086 -0.0514 -0.3149 -0.0648 -0.1493 -0.0211 -0.0056 -0.3635 -0.0169 -0.0183 -0.0423 -1.0576 -0.0338 -0.0507 -0.0197 -0.0056 -0.0479 -0.0310', 'S-1576\t- Für die Behandlung des metastasierten Magenkarzinoms wird Docetaxel Winthrop in', 'T-1576\t- For the treatment of metastatic gastric cancer, Docetaxel Winthrop is administered in combination', 'H-1576\t-0.5263671875\t- For the treatment of metastatic gastric cancer , Docetaxel Winthrop is administered in', 'D-1576\t-0.5263671875\t- For the treatment of metastatic gastric cancer, Docetaxel Winthrop is administered in', 'P-1576\t-0.0385 -0.1327 -0.0977 -0.0269 -0.0292 -0.0356 -0.0243 -0.0155 -0.0796 -0.0070 -0.0197 -0.1687 -0.1310 -0.1937 -0.0240 -0.0162 -0.0063 -0.0190 -0.0254 -0.0035 -0.0197 -1.3398 -0.3157 -0.0169 -0.5605 -0.3691', 'S-1970\tSekundäre Zielkriterien umfassten die Zeit bis zur Progression (TTP) sowie die Ansprechdauer.', 'T-1970\tSecondary efficacy endpoints included time to disease progression (TTP) and duration of response (DR).', 'H-1970\t-0.64990234375\tSecondary endpoints included time to progression ( TTP ) and duration of response .', 'D-1970\t-0.64990234375\tSecondary endpoints included time to progression (TTP) and duration of response.', 'P-1970\t-0.8940 -0.0127 -0.3733 -0.1289 -0.5000 -0.5605 -0.1353 -0.0972 -0.0254 -0.0451 -0.0127 -0.0197 -0.0296 -0.3157 -0.4932 -0.0282 -0.0338 -0.1521 -0.0366 -0.0282', 'S-1929\tDie Häufigkeit der Einreichung der PSURs wird bei der jährlichen Neubewertung des Produktes festgelegt.', 'T-1929\tThe frequency of submissions of PSUR reports will be assessed at the annual reassessment of the product.', 'H-1929\t-1.4248046875\tThe frequency of submission of 6 @-@ month PSURs is determined in the annual reassessment of the product .', 'D-1929\t-1.4248046875\tThe frequency of submission of 6-month PSURs is determined in the annual reassessment of the product.', 'P-1929\t-0.2822 -0.3101 -0.0176 -0.0356 -1.0342 -0.0634 -0.0564 -1.0127 -1.0654 -0.4424 -0.1155 -0.3352 -0.0113 -0.0254 -0.4001 -0.3718 -1.9102 -0.4338 -0.5239 -0.4170 -0.9751 -0.0620 -0.0564 -0.0395 -0.0338 -0.0282', 'S-1634\tHypokalzämien (siehe Abschnitt 4.4), verringerte Testosteronwerte (siehe Abschnitt 4.4)', 'T-1634\t6 Investigations Common: hypocalcaemia (see section 4.4), reduced testosterone levels (see section 4.4)', 'H-1634\t-0.849609375\tHypocalcaemia ( see section 4.4 ) , reduced testosterone ( see section 4.4 )', 'D-1634\t-0.849609375\tHypocalcaemia (see section 4.4), reduced testosterone (see section 4.4)', 'P-1634\t-0.9663 -0.0113 -0.0416 -0.7080 -0.1578 -0.0592 -0.0338 -0.0521 -0.1917 -0.0240 -0.0282 -0.0310 -0.9917 -0.7017 -0.0620 -0.0056 -0.0113 -0.0254 -1.2656 -0.0225 -0.0338 -0.0225 -0.0282 -0.0282 -0.3579', 'S-530\tge 10, rue d <unk> Arcueil BP 90233 F-94528 Rungis Cedex', 'T-530\tau BP 90233 F-94528 Rungis Cedex Tél: + 33 (0) 1 45 60 25 00', 'H-530\t-1.328125\t30 Abbott France 10 , rue d &apos;Arcueil BP 90233 F @-@ 94528', "D-530\t-1.328125\t30 Abbott France 10, rue d'Arcueil BP 90233 F-94528", 'P-530\t-0.6724 -1.2061 -0.3594 -0.3198 -0.0380 -0.0268 -0.0254 -0.0268 -0.0366 -0.0352 -0.0479 -0.0014 -0.0704 -0.0282 -0.0225 -0.0169 -0.1409 -0.0282 -0.0310 -0.0169 -0.0225 -5.3125', 'S-122\tIm Januar 1998 erfolgte die Ernennung der CPMP-Mitglieder für den zweiten Dreijahreszeitraum (1998-2000).', 'T-122\tIn January 1998 nominations for CPMP members were made for the second three-year term of the CPMP (1998-2000).', 'H-122\t-1.4052734375\tIn January 1998 CPMP members were nominated for the second three @-@ year mandate ( 1998 @-@ 2000 ) .', 'D-122\t-1.4052734375\tIn January 1998 CPMP members were nominated for the second three-year mandate (1998-2000).', 'P-122\t-2.1719 -0.0225 -0.0211 -1.5811 -0.0310 -0.0169 -0.4592 -0.0479 -1.2852 -0.3718 -0.7666 -0.0282 -0.1691 -0.0620 -0.0338 -1.2227 -0.0507 -0.1409 -0.6255 -0.0225 -0.0282 -0.0338 -0.0282', 'S-41\tDie Emselex-Tabletten werden einmal täglich mit etwas Wasser eingenommen, jeden Tag ungefähr zur selben Uhrzeit.', 'T-41\tWhen and how to take Emselex Take Emselex tablets once a day with water, at about the same time each day.', 'H-41\t-0.671875\tEmselex tablets are taken with some water once a day , at about the same time each day .', 'D-41\t-0.671875\tEmselex tablets are taken with some water once a day, at about the same time each day.', 'P-41\t-0.0502 -0.0156 -0.0113 -0.1082 -0.0213 -0.2288 -0.4128 -1.1611 -0.9834 -0.0310 -0.0592 -0.0676 -0.0282 -0.2197 -0.2197 -0.3833 -0.0282 -0.0282 -0.0423 -0.2141 -0.0282 -0.0338 -0.0310', 'S-1020\tMerck Sharp und Dohme, B.V., Waarderweg 39, 2031 BN Haarlem, Niederlande', 'T-1020\tMerck Sharp and Dohme, B. V., Waarderweg, 39, 2031 BN Haarlem, The Netherlands', 'H-1020\t-0.326416015625\tMerck Sharp and Dohme , B.V. , Waarderweg 39 , 2031 BN Haarlem , The Netherlands', 'D-1020\t-0.326416015625\tMerck Sharp and Dohme, B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands', 'P-1020\t-0.0277 -0.0241 -0.0256 -0.0242 -0.0516 -0.0135 -0.0228 -0.0313 -0.4395 -0.0141 -0.0292 -0.0155 -0.0218 -0.0225 -0.0042 -0.4958 -0.0282 -0.0218 -0.0176 -0.0282 -0.0169 -0.0077 -0.0063 -0.4480 -0.1635 -0.0240 -0.3311', 'S-800\tInsuman Rapid gibt es in Fertigpens, OptiSet, mit 3 ml Lösung (300 I.E.).', 'T-800\tInsuman Rapid is supplied in pre-filled pens, OptiSet, containing 3 ml solution (300 IU).', 'H-800\t-0.34619140625\tInsuman Rapid is supplied in pre @-@ filled pens , OptiSet , containing 3 ml solution ( 300 IU ) .', 'D-800\t-0.34619140625\tInsuman Rapid is supplied in pre-filled pens, OptiSet, containing 3 ml solution (300 IU).', 'P-800\t-0.0313 -0.0177 -0.0284 -0.0106 -0.1068 -0.3196 -0.0218 -0.0634 -0.3071 -0.0380 -0.2458 -0.0542 -0.0176 -0.1071 -0.0190 -0.0240 -0.0444 -0.3169 -0.1423 -0.0183 -0.1155 -0.0352 -0.0225 -0.0451 -0.2974 -0.0465 -0.0324 -0.0282', 'S-1013\tSie wird durch einen Pumpstoß aus der zusammen mit der Flasche gelieferten Pumpe direkt ins Ohr gegeben.', 'T-1013\tThe dose is 1 ml, which is given directly into the ear by one activation of the pump supplied with the bottle.', 'H-1013\t-1.353515625\tIt is given directly into the ear by pumping from the pump provided with the bottle .', 'D-1013\t-1.353515625\tIt is given directly into the ear by pumping from the pump provided with the bottle.', 'P-1013\t-0.4656 -0.3643 -1.0850 -0.9766 -0.5635 -0.2705 -0.0282 -0.1127 -0.6650 -0.0197 -1.9414 -0.0451 -0.3269 -0.5581 -0.1183 -0.0338 -0.2874 -0.0338 -0.0282', 'S-417\tDie Inzidenz für Somnolenz ist bei Tagesdosen über 1,5 mg erhöht (siehe Abschnitt 4.2).', 'T-417\tThe incidence of somnolence is increased at doses higher than 1.5 mg / day (see section 4.2).', 'H-417\t-0.53759765625\tThe incidence of somnolence is increased at daily doses above 1.5 mg ( see section 4.2 ) .', 'D-417\t-0.53759765625\tThe incidence of somnolence is increased at daily doses above 1.5 mg (see section 4.2).', 'P-417\t-0.5273 -0.0176 -0.0169 -0.0581 -0.0299 -0.0349 -0.0113 -0.0472 -0.3430 -0.0796 -0.3938 -0.8779 -0.0268 -0.0338 -0.7593 -0.0732 -0.0141 -0.0395 -0.0479 -0.1353 -0.0225 -0.0282 -0.0338 -0.0310 -0.0282', 'S-1757\tDie Pharmakokinetik von Efavirenz wurde bei Patienten mit Nierenfunktionsstörung nicht untersucht.', 'T-1757\tThe pharmacokinetics of efavirenz have not been studied in patients with renal impairment.', 'H-1757\t-0.3505859375\tThe pharmacokinetics of efavirenz have not been studied in patients with renal impairment .', 'D-1757\t-0.3505859375\tThe pharmacokinetics of efavirenz have not been studied in patients with renal impairment.', 'P-1757\t-0.2671 -0.0313 -0.0077 -0.0171 -0.0327 -0.0305 -0.1420 -0.0070 -0.0243 -0.0141 -0.0518 -0.2402 -0.0310 -0.0268 -0.8120 -0.0451 -0.0521 -0.0338 -0.1240 -0.0183 -0.3157 -0.0549 -0.0113 -0.0268 -0.0310 -0.0282', 'S-1714\tWenn ein Pflaster sich abzulösen beginnt, können Sie es möglicherweise durch festes Andrücken wie - der ankleben.', 'T-1714\tIf a patch does begin to come off, you may be able to make it stick again by pressing on it firmly.', 'H-1714\t-2.650390625\tIf a patch begins to fall off , you can stick it to your skin by pushing it firmly as far as it will go .', 'D-1714\t-2.650390625\tIf a patch begins to fall off, you can stick it to your skin by pushing it firmly as far as it will go.', 'P-1714\t-1.2568 -0.5635 -0.3718 -0.0282 -0.8989 -0.1663 -1.7754 -0.1775 -0.0732 -0.4255 -0.8398 -0.4734 -0.4453 -2.2598 -0.6367 -0.3269 -0.4453 -0.4565 -1.6230 -1.2402 -1.7021 -1.6230 -0.0451 -0.4058 -1.0820 -0.1465 -0.0451 -0.0338', 'S-58\tPortugal Tecnifar- Indústria Técnica Farmacêutica, S.A.', 'T-58\tPortugal Tecnifar- Indústria Técnica Farmacêutica, S. A.', 'H-58\t-0.1976318359375\tPortugal Tecnifar- Indústria Técnica Farmacêutica , S. A .', 'D-58\t-0.1976318359375\tPortugal Tecnifar- Indústria Técnica Farmacêutica, S. A.', 'P-58\t-0.0487 -0.0811 -0.0227 -0.0142 -0.0378 -0.0292 -0.1351 -0.0197 -0.0085 -0.0127 -0.0271 -0.0930 -0.0662 -0.0257 -0.0148 -0.0155 -0.0183 -0.0176 -0.0035 -0.0236 -0.0028 -0.0310 -0.5415 -0.0359 -0.0416 -0.0282', 'S-142\tDies gilt insbesondere für die nachstehend aufgeführten Arzneimittel, wenn diese gleichzeitig mit Kinzalmono eingenommen werden:', 'T-142\tThis applies especially to the medicines listed below taken at the same time with Kinzalmono:', 'H-142\t-0.53271484375\tThis applies especially to the medicines listed below taken at the same time with Kinzalmono :', 'D-142\t-0.53271484375\tThis applies especially to the medicines listed below taken at the same time with Kinzalmono:', 'P-142\t-0.2822 -0.3833 -0.3008 -0.0606 -0.1373 -0.1790 -0.1711 -0.0704 -0.0324 -0.3228 -0.2466 -0.0338 -0.0380 -0.0197 -0.5762 -0.0958 -0.0169 -0.0169 -0.0141 -0.0282 -0.0564 -0.3213', 'S-1373\tDiese umfassen Ketoconazol, Fluconazol, Itraconazol und Voriconazol.', 'T-1373\tThese include ketoconazole, fluconazole, itraconazole and voriconazole.', 'H-1373\t-0.444091796875\tThese include ketoconazole , fluconazole , itraconazole and voriconazole .', 'D-1373\t-0.444091796875\tThese include ketoconazole, fluconazole, itraconazole and voriconazole.', 'P-1373\t-1.3818 -0.0542 -0.0225 -0.0282 -0.0310 -0.0113 -0.0085 -0.2479 -0.0085 -0.0282 -0.0113 -0.0085 -0.0296 -0.0056 -0.0211 -0.0310 -0.0113 -0.0085 -0.7876 -0.0085 -0.0085 -0.0099 -0.0099 -0.2620 -0.0282', 'S-1143\tAlle parenteralen Lösungen sind vor Verabreichung visuell auf Schwebeteilchen und Verfärbungen zu untersuchen.', 'T-1143\tAll parenteral solutions should be inspected visually for particulate matter and discoloration prior to administration.', 'H-1143\t-0.73046875\tParenteral solutions should be inspected visually for particulate matter and discolouration prior to administration .', 'D-1143\t-0.73046875\tParenteral solutions should be inspected visually for particulate matter and discolouration prior to administration.', 'P-1143\t-0.9150 -0.0232 -0.0289 -0.0993 -0.2620 -0.0409 -0.7383 -0.0268 -0.1028 -0.0211 -0.0690 -0.2240 -0.6211 -0.0282 -0.0366 -0.0620 -0.6313 -0.0366 -0.0732 -0.6567 -0.0338 -0.1183 -0.0395 -0.0282', 'S-1790\tEs ist wichtig, dass Sie sofort mit Ihrem Arzt sprechen, wenn Sie vermuten schwanger zu sein oder eine Schwangerschaft planen.', 'T-1790\tIt is important to talk to your doctor immediately if you think you may be pregnant or are planning to become pregnant.', 'H-1790\t-0.849609375\tIt is important that you speak to your doctor immediately if you think you may be pregnant or are planning to become pregnant .', 'D-1790\t-0.849609375\tIt is important that you speak to your doctor immediately if you think you may be pregnant or are planning to become pregnant.', 'P-1790\t-0.3945 -0.0444 -0.0525 -0.1437 -0.0292 -0.7158 -0.1429 -0.3423 -0.0549 -0.1409 -0.0465 -0.0282 -0.5254 -0.5845 -0.7861 -0.0366 -0.0197 -0.0451 -1.1807 -0.0310 -0.2057 -0.2311 -0.0169 -0.0338 -0.0282', 'S-661\tInformieren Sie Ihren Arzt, wenn Sie schwanger sind oder glauben, schwanger zu sein oder eine Schwangerschaft planen.', 'T-661\tIf you are pregnant, or think you might be pregnant, or are planning to get pregnant, tell your doctor.', 'H-661\t-0.8974609375\tTell your doctor if you are or think you are pregnant or planning to become pregnant .', 'D-661\t-0.8974609375\tTell your doctor if you are or think you are pregnant or planning to become pregnant.', 'P-661\t-0.9375 -0.0120 -0.0324 -0.0331 -0.0402 -0.0268 -0.0514 -0.9097 -0.3157 -0.0437 -1.0635 -0.0197 -0.0395 -1.1240 -0.2563 -0.2537 -0.0254 -0.0338 -0.0310', 'S-66\tOnsior Tabletten für Katzen sind in Faltschachteln mit 1, 2 oder 10 Blistern verfügbar.', 'T-66\tOnsior tablets for cats are available in cardboard boxes containing 1, 2 or 10 blisters.', 'H-66\t-0.54931640625\tOnsior tablets for cats are available in cartons containing 1 , 2 or 10 blisters .', 'D-66\t-0.54931640625\tOnsior tablets for cats are available in cartons containing 1, 2 or 10 blisters.', 'P-66\t-0.0184 -0.0220 -0.0256 -0.1710 -0.0269 -0.0451 -0.0157 -0.0444 -0.4185 -0.0303 -0.3289 -0.6440 -1.0020 -0.0366 -0.0310 -0.0282 -0.4395 -0.0254 -0.0395 -0.0479 -0.0395 -0.0310', 'S-886\tDer durchschnittliche Insulinbedarf liegt jedoch oft bei 0,5 bis 1,0 I.E. pro kg Körpergewicht pro Tag.', 'T-886\tHowever, the average insulin requirement is often 0.5 to 1.0 IU per kg body weight per day.', 'H-886\t-0.916015625\tHowever , insulin requirements are often between 0.5 and 1.0 IU per kg bodyweight per day .', 'D-886\t-0.916015625\tHowever, insulin requirements are often between 0.5 and 1.0 IU per kg bodyweight per day.', 'P-886\t-0.8516 -0.0437 -0.7812 -0.0113 -0.2761 -0.1606 -0.8115 -0.2649 -0.0338 -0.0817 -0.0592 -0.0254 -0.0395 -0.2734 -0.0704 -0.1099 -0.9893 -0.0197 -0.8564 -0.0282 -0.0338 -0.0282', 'S-612\tSolche Nebenwirkungen wurden bei wiederholter und langfristiger Verabreichung von Typ I Interferon bei Menschen beschrieben.', 'T-612\tSuch side effects have been described after multiple and long-term administration of type I interferon in man.', 'H-612\t-1.6484375\tThese undesirable effects have been reported with repeated long @-@ term use of type I interferon in humans .', 'D-612\t-1.6484375\tThese undesirable effects have been reported with repeated long-term use of type I interferon in humans.', 'P-612\t-1.8301 -1.6416 -0.2959 -0.0564 -0.2311 -0.1014 -0.0282 -0.2479 -1.0732 -0.3381 -2.1133 -0.2649 -0.0282 -1.8145 -0.0338 -0.1071 -0.0564 -0.0338 -0.0169 -0.0282 -0.0451 -0.6538 -0.0282 -0.0282', 'S-1812\tKinder und Jugendliche sollten die Fosamprenavir Suspension zum Einnehmen mit einer Mahlzeit einnehmen.', 'T-1812\tIn children and adolescents the fosamprenavir oral suspension should be taken with food.', 'H-1812\t-0.4677734375\tChildren and adolescents should take fosamprenavir oral suspension with food .', 'D-1812\t-0.4677734375\tChildren and adolescents should take fosamprenavir oral suspension with food.', 'P-1812\t-0.2235 -0.0313 -0.0699 -0.0148 -0.0171 -0.0357 -0.0669 -0.9370 -0.0155 -0.0085 -0.0035 -0.0712 -0.0141 -0.5479 -0.1945 -0.0887 -0.3184 -0.0493 -0.0296', 'S-442\tEs wurden fünf Hauptstudien mit fast 5 200 Patienten durchgeführt, die zumeist leichten bis mittelschweren Bluthochdruck hatten.', 'T-442\tFive main studies involving nearly 5,200 patients, mostly with mild to moderate hypertension, were carried out.', 'H-442\t-1.0595703125\tThere were five main studies involving almost 5,200 patients , most of whom had mild to moderate hypertension .', 'D-442\t-1.0595703125\tThere were five main studies involving almost 5,200 patients, most of whom had mild to moderate hypertension.', 'P-442\t-0.6748 -0.1895 -0.0359 -0.1148 -0.0768 -0.3733 -0.3987 -1.4326 -0.0197 -0.0338 -0.0620 -1.4795 -0.2705 -0.0704 -0.5493 -0.0338 -0.2141 -0.3101 -0.3325 -0.0338 -0.0338 -0.0282', 'S-437\tActraphane 10 NovoLet wurde für die Verwendung mit NovoFine Injektionsnadeln entwickelt.', 'T-437\tActraphane 10 NovoLet is designed to be used with NovoFine needles.', 'H-437\t-0.2274169921875\tActraphane 10 NovoLet is designed to be used with NovoFine needles .', 'D-437\t-0.2274169921875\tActraphane 10 NovoLet is designed to be used with NovoFine needles.', 'P-437\t-0.0487 -0.0191 -0.0106 -0.0092 -0.0285 -0.0313 -0.0220 -0.0510 -0.2444 -0.1528 -0.2444 -0.0684 -0.0486 -0.0549 -0.1028 -0.0268 -0.0282 -0.0211 -0.1261 -0.0395 -0.0444 -0.0296', 'S-279\tBei allen Patienten mit PWS muss vor und unter der Wachstumshormontherapie eine effektive Gewichtskontrolle erfolgen.', 'T-279\tAll patients with PWS should have effective weight control before and during treatment with somatropin.', 'H-279\t-1.14453125\tEffective weight control must be performed in all patients with PWS before and during growth hormone therapy .', 'D-279\t-1.14453125\tEffective weight control must be performed in all patients with PWS before and during growth hormone therapy.', 'P-279\t-1.3066 -0.0211 -0.0240 -0.1064 -0.9722 -0.2494 -1.0986 -0.8340 -0.0310 -0.0676 -0.0423 -0.4058 -0.0451 -0.0225 -0.9385 -0.2874 -0.1859 -0.4846 -0.0225 -0.0113 -0.2930 -0.0338 -0.0282', 'S-663\tMan geht davon aus, dass das E2 Glykoprotein mit allen Feldstämmen kreuzreagiert. itte', 'T-663\tThe vaccine od', 'H-663\t-0.67041015625\tThe E2 glycoprotein is thought to cross @-@ react with all field strains .', 'D-663\t-0.67041015625\tThe E2 glycoprotein is thought to cross-react with all field strains.', 'P-663\t-1.2568 -0.0873 -0.0310 -0.0718 -0.0113 -0.0197 -0.0141 -0.0225 -0.0338 -1.2129 -0.0282 -0.4875 -0.2423 -0.1212 -0.0338 -0.0592 -0.2959 -0.0507 -0.0141 -0.0423 -0.0282', 'S-704\tBitte melden Sie sich bei Ihrem Arzt oder Apotheker, wenn Sie glauben, dass Sie nicht die vollständige Dosis erhalten haben.', 'T-704\tCall your health care provider if you think you have not received the full dose.', 'H-704\t-0.8134765625\tPlease contact your doctor or pharmacist if you think you may not have received the full dose .', 'D-704\t-0.8134765625\tPlease contact your doctor or pharmacist if you think you may not have received the full dose.', 'P-704\t-0.4814 -1.1875 -0.0254 -0.0451 -0.0240 -0.0324 -0.0211 -0.0197 -0.0282 -0.2255 -0.7451 -0.3818 -0.9976 -0.0338 -0.0704 -0.3325 -0.0930 -0.0986 -0.0310 -0.0366', 'S-17\tWAS IST TAMIFLU UND WOFÜR WIRD ES ANGEWENDET?', 'T-17\tWHAT TAMIFLU IS AND WHAT IT IS USED FOR', 'H-17\t-0.371337890625\tWHAT TAMIFLU IS AND WHAT IT IS USED FOR', 'D-17\t-0.371337890625\tWHAT TAMIFLU IS AND WHAT IT IS USED FOR', 'P-17\t-0.0256 -0.0177 -0.3206 -0.0257 -0.0299 -0.0271 -0.0211 -0.0961 -0.1898 -0.0472 -0.1853 -0.3086 -0.0592 -0.2227 -0.0310 -0.1691 -0.0113 -0.3157', 'S-1604\tWAS IST GARDASIL UND WOFÜR WIRD ES ANGEWENDET?', 'T-1604\tWHAT GARDASIL IS AND WHAT IT IS USED FOR', 'H-1604\t-0.6162109375\tWHAT ARE GARDASIL AND WHAT IT IS USED FOR', 'D-1604\t-0.6162109375\tWHAT ARE GARDASIL AND WHAT IT IS USED FOR', 'P-1604\t-0.0249 -0.0184 -1.8555 -0.0592 -0.0901 -0.0380 -0.0535 -0.0211 -0.0141 -0.0380 -0.0507 -0.1973 -0.3157 -0.0690 -0.2113 -0.0366 -0.1803 -0.0113 -0.3213', 'S-589\tEs wurden bei Verabreichung der doppelten Dosis keine anderen Nebenwirkungen beobachtet als nach Verabreichung einer einfachen Dosis.', 'T-589\tNo other undesirable effects observed at double dose when compared with one dose of vaccine.', 'H-589\t-1.5556640625\tNo adverse reactions have been observed when the product is administered in a double dose .', 'D-589\t-1.5556640625\tNo adverse reactions have been observed when the product is administered in a double dose.', 'P-589\t-0.5024 -0.3669 -0.0042 -0.2311 -0.0141 -1.4375 -0.0324 -0.3677 -2.3418 -0.3550 -0.5410 -0.3550 -0.3269 -0.0169 -0.3662 -0.2705 -0.1014 -0.0338 -1.6396 -0.0789', 'S-169\tKlinisch beachtenswerte Wechselwirkungen mit anderen Arzneimitteln wurden bisher bei einer GONAL-f-Therapie nicht beobachtet.', 'T-169\tNo other clinically significant drug interaction has been reported during GONAL-f therapy.', 'H-169\t-1.001953125\tTo date no clinically meaningful interactions with other medicinal products have been observed with GONAL @-@ f therapy .', 'D-169\t-1.001953125\tTo date no clinically meaningful interactions with other medicinal products have been observed with GONAL-f therapy.', 'P-169\t-0.5444 -0.0197 -2.1836 -0.0901 -0.0225 -0.8311 -0.0310 -0.2847 -0.5635 -0.0507 -0.2169 -0.3101 -0.0704 -0.2761 -0.0310 -0.3804 -0.4734 -0.1183 -0.0169 -0.0169 -0.0395 -0.0338 -0.2479 -0.0282 -0.0282', 'S-620\tÜber ein Absterben von Haut und Gewebe (Nekrosen) im Injektionsbereich wurde seltener berichtet.', 'T-620\tDead skin and tissue around the injection site (necrosis) are reported less frequently.', 'H-620\t-1.4189453125\tReversing of the skin and tissue ( necrosis ) in the injection area has been reported less commonly .', 'D-620\t-1.4189453125\tReversing of the skin and tissue (necrosis) in the injection area has been reported less commonly.', 'P-620\t-0.6904 -1.5488 -0.2522 -0.1663 -0.7944 -0.1042 -0.0366 -0.8765 -0.2113 -0.0479 -0.0056 -0.0197 -0.0310 -0.9497 -0.3240 -0.2255 -0.0169 -0.2197 -0.7437 -0.2817 -0.3777 -0.8960 -0.9072 -0.0338 -0.0282', 'S-1128\tBeha ndlung der symptomatischen, chemotherapieinduzierten Anämie bei Tumorpatienten el', 'T-1128\tis Treatment of symptomatic chemotherapy induced anaemia in cancer patients', 'H-1128\t-1.3603515625\tTreatment of symptomatic chemotherapy induced anaemia in cancer patients have been shown to be effective and safe .', 'D-1128\t-1.3603515625\tTreatment of symptomatic chemotherapy induced anaemia in cancer patients have been shown to be effective and safe.', 'P-1128\t-0.1212 -0.0270 -0.0234 -0.0328 -0.0546 -0.0171 -0.0148 -0.1584 -0.0106 -0.0211 -0.6001 -0.0127 -0.0225 -0.2036 -0.0042 -0.0247 -0.0388 -0.5732 -0.0211 -0.4155 -0.7944 -1.2930 -0.1071 -1.8037 -0.4001 -1.7695 -0.3606 -1.2959 -0.0338', 'S-1902\tWenn Humira abgesetzt wurde, kann es erneut verabreicht werden, wenn die Zeichen und Symptome der Erkrankung wieder auftreten.', 'T-1902\tAlternatively, if a patient has stopped Humira and signs and symptoms of disease recur, Humira may be re-administered.', 'H-1902\t-1.439453125\tIf Humira is discontinued , it can be re @-@ administered if signs and symptoms re @-@ emerge .', 'D-1902\t-1.439453125\tIf Humira is discontinued, it can be re-administered if signs and symptoms re-emerge.', 'P-1902\t-1.0674 -0.0789 -0.0289 -0.0169 -0.7197 -1.1426 -0.0028 -0.0592 -0.2649 -0.6479 -0.0395 -0.9805 -0.0282 -0.1155 -0.0197 -1.7354 -1.1670 -0.0338 -0.0169 -1.1777 -0.0282 -0.1747 -0.1127 -0.0282', 'S-179\tDa in der Regel mit zunehmendem Alter die Nierenfunktion abnimmt, können ältere Patienten eine reduzierte Elimination', 'T-179\tAs renal function generally decreases with age, elderly patients may show reduced elimination and increased exposure of fondaparinux (see section 5.2).', 'H-179\t-1.5087890625\tAs renal function is generally decreased with increasing age , elderly patients may have reduced elimination .', 'D-179\t-1.5087890625\tAs renal function is generally decreased with increasing age, elderly patients may have reduced elimination.', 'P-179\t-0.5444 -0.2783 -0.0197 -0.0225 -0.3699 -0.2021 -0.2057 -0.8369 -0.0718 -1.2295 -0.0282 -0.1747 -0.3916 -0.0225 -0.4932 -1.2344 -2.0000 -0.2423 -0.0282 -0.9468 -0.0282', 'S-1417\tNach subkutaner Verabreichung von Omnitrope ergibt sich jedoch eine Halbwertszeit von 3 Stunden.', 'T-1417\tHowever, after subcutaneous administration of Omnitrope 3.3 mg / ml solution for injection, a half-life of 3 hours is achieved.', 'H-1417\t-0.374755859375\tHowever , after subcutaneous administration of Omnitrope , a half @-@ life of 3 hours is achieved .', 'D-1417\t-0.374755859375\tHowever, after subcutaneous administration of Omnitrope, a half-life of 3 hours is achieved.', 'P-1417\t-0.2544 -0.0611 -0.2104 -0.0627 -0.0127 -0.0099 -0.0271 -0.0285 -0.0828 -0.0416 -0.0282 -0.0345 -0.0169 -0.0240 -0.5327 -0.1790 -0.0479 -0.0986 -0.0324 -0.0423 -0.0549 -0.3635 -0.1635 -0.1803 -0.0296 -0.0282', 'S-385\tAbhängig von dem Ansprechen auf die Behandlung, von Alter und Körpergewicht können im Laufe der Zeit Anpassungen notwendig sein.', 'T-385\tThe doctor calculates individually the dose for each patient depending on the condition, and this may need to be adjusted over time, depending on response, age and body weight.', 'H-385\t-1.6923828125\tThe solvent supplied with Valtropin contains metacresol ; patients who are allergic to metacresol should prepare the solution using water for injections .', 'D-385\t-1.6923828125\tThe solvent supplied with Valtropin contains metacresol; patients who are allergic to metacresol should prepare the solution using water for injections.', 'P-385\t-0.3716 -0.3469 -0.3135 -0.3232 -0.3691 -0.3015 -0.3550 -0.3889 -0.3213 -0.3269 -0.6792 -0.3240 -0.3213 -0.3213 -0.4255 -0.3213 -0.4226 -0.6143 -0.3662 -0.0282 -2.6152 -0.3269 -0.1409 -0.1183 -0.5469 -0.4001 -0.5581 -0.3157 -0.3157 -0.3269 -0.3157 -0.3269 -0.3157 -0.3494 -0.2817 -0.0338', 'S-896\tLeukozytopenie 96%, Thrombozytopenie 94% und Anämie 88%.', 'T-896\tTherefore all patients experienced profound cytopenia: leukopenia 96%, thrombocytopenia 94%, and anemia 88%.', 'H-896\t-0.81591796875\tLeukopenia 96 % , thrombocytopenia 94 % and anaemia 88 % .', 'D-896\t-0.81591796875\tLeukopenia 96%, thrombocytopenia 94% and anaemia 88%.', 'P-896\t-1.7783 -1.5918 -0.1240 -0.0085 -0.0225 -0.0254 -0.4170 -0.2705 -0.0225 -0.0141 -0.0085 -0.0225 -0.0113 -0.0085 -0.0225 -0.5493 -0.0282 -0.2451 -0.0056 -0.0254 -0.0141 -0.0254 -0.2227 -0.0282', 'S-1727\tEs liegen keine Hinweise auf eine mitochondriale Toxizität in vitro oder in vivo vor.', 'T-1727\tBoth emtricitabine triphosphate and tenofovir diphosphate are weak inhibitors of mammalian DNA polymerases and there was no evidence of toxicity to mitochondria in vitro and in vivo.', 'H-1727\t-0.41455078125\tThere is no evidence of toxicity to mitochondria in vitro or in vivo .', 'D-1727\t-0.41455078125\tThere is no evidence of toxicity to mitochondria in vitro or in vivo.', 'P-1727\t-0.2620 -0.7007 -0.0317 -0.0690 -0.5088 -0.3325 -0.0225 -0.0225 -0.1945 -0.0746 -0.0113 -0.0197 -0.0240 -0.0127 -0.1917 -0.0775 -0.0395 -0.0155 -0.0380 -0.0423 -0.0225 -0.0099 -0.0366 -0.0296', 'S-668\tKinzalkomb Kinzalkomb Kinzalkomb Kinzalkomb Kinzalkomb', 'T-668\tKinzalkomb Kinzalkomb Kinzalkomb Kinzalkomb Kinzalkomb Kinzalkomb Kinzalkomb Kinzalkomb Kinzalkomb Kinzalkomb Kinzalkomb Kinzalkomb Kinzalkomb Kinzalkomb Kinzalkomb', 'H-668\t-0.3994140625\tKinzalkomb Kinzalkomb Kinzalkomb Kinzalkomb', 'D-668\t-0.3994140625\tKinzalkomb Kinzalkomb Kinzalkomb Kinzalkomb', 'P-668\t-0.5000 -0.0183 -0.0225 -0.0870 -0.0292 -0.0120 -0.0190 -0.0218 -0.0676 -0.0240 -0.0085 -0.0197 -0.0218 -0.0634 -0.0225 -0.2896 -0.0204 -0.0225 -0.0592 -0.0232 -1.1299', 'S-1830\t1.148,5 ng • Std / ml mit bzw. ohne Standardmahlzeit mit hohem Fettgehalt).', 'T-1830\tThe co-administration of applesauce or a high-fat standard meal with the granule formulation did not have a clinically meaningful effect on the pharmacokinetics of montelukast as determined by AUC (1225.7 vs 1223.1 ng. hr / mL with and without applesauce, respectively, and 1191.8 vs 1148.5 ng. hr / mL with and without a high-fat standard meal, respectively).', 'H-1830\t-1.42578125\t1.148.5 ng • hr / ml with or without a high fat meal ) .', 'D-1830\t-1.42578125\t1.148.5 ng • hr / ml with or without a high fat meal).', 'P-1830\t-2.9219 -0.0254 -0.1324 -0.5073 -0.0169 -0.0225 -0.0732 -0.5605 -0.0282 -0.0366 -0.3101 -0.0564 -0.0254 -0.3916 -2.0488 -1.0596 -0.2705 -0.0338 -0.0564 -0.0282', 'S-1803\tBei Patienten mit einer Kreatinin-Clearance von ≥ 50 ml / min ist keine Dosisanpassung erforderlich.', 'T-1803\tNo dose adjustment is necessary for patients with creatinine clearance ≥ 50 ml / min.', 'H-1803\t-0.646484375\tNo dosage adjustment is necessary for patients with creatinine clearance of ≥ 50 ml / min .', 'D-1803\t-0.646484375\tNo dosage adjustment is necessary for patients with creatinine clearance of ≥ 50 ml / min.', 'P-1803\t-0.8135 -0.8247 -0.0423 -0.0240 -0.0395 -0.0141 -0.2676 -0.0479 -0.2128 -1.2188 -0.0338 -0.0507 -0.2367 -0.0169 -0.0310 -0.0282 -0.0282 -0.0338 -0.3494 -0.0789 -0.0282 -0.0282 -0.0282 -0.0225 -0.0395 -0.0282', 'S-723\tSchilddrüsenüberfunktion, die zu gesteigertem Appetit, Gewichtsabnahme oder Schwitzen führen kann', 'T-723\twhich can cause increased appetite, weight loss or sweating', 'H-723\t-0.83837890625\tOveractive thyroid gland which can cause increased appetite , weight loss or sweating', 'D-723\t-0.83837890625\tOveractive thyroid gland which can cause increased appetite, weight loss or sweating', 'P-723\t-1.0605 -0.4487 -0.0155 -0.0197 -0.0141 -0.0197 -0.3296 -0.0070 -0.2522 -0.8677 -0.2930 -0.0732 -0.0310 -0.0169 -0.0282 -0.0254 -0.3550 -0.8989 -0.0451 -0.0338 -0.3718', 'S-1433\t47 Ritonavir hemmt den CYP3A-vermittelten Metabolismus von Ketoconazol.', 'T-1433\tSulfamethoxazole / Trimethoprim2', 'H-1433\t-0.642578125\t47 Ritonavir inhibits ketoconazole metabolism mediated by CYP3A .', 'D-1433\t-0.642578125\t47 Ritonavir inhibits ketoconazole metabolism mediated by CYP3A.', 'P-1433\t-1.1240 -0.4319 -0.0254 -0.0211 -0.0211 -0.5298 -0.0155 -0.0141 -1.2920 -0.0310 -0.0338 -0.0085 -0.0056 -0.4199 -0.0056 -0.0254 -0.2479 -0.0310 -0.0366 -0.0395 -0.0254 -0.0254 -0.0225 -0.0282 -0.0479 -0.0310', 'S-1588\tWenn Sie eine größere Menge von Orgalutran angewendet haben, als Sie sollten Setzen Sie sich mit Ihrem Arzt in Verbindung.', 'T-1588\tIf you use more Orgalutran than you should Contact your doctor.', 'H-1588\t-0.861328125\tIf you use more Orgalutran than you should , contact your doctor .', 'D-1588\t-0.861328125\tIf you use more Orgalutran than you should, contact your doctor.', 'P-1588\t-0.2451 -0.0285 -0.3215 -0.2986 -1.3613 -0.0085 -0.0282 -0.0127 -0.0620 -0.0395 -0.0479 -1.8291 -0.1663 -0.0395 -0.0704 -0.1042 -0.0507', 'S-899\tFLASCHENETIKETT FÜR DIE LÖSUNG ZUM EINNEHMEN', 'T-899\tBOTTLE LABEL FOR ORAL SOLUTION', 'H-899\t-0.5224609375\tBOTTLE LABEL FOR ORAL SOLUTION', 'D-899\t-0.5224609375\tBOTTLE LABEL FOR ORAL SOLUTION', 'P-899\t-0.3022 -0.0676 -0.0127 -0.0409 -0.2720 -0.1268 -0.0965 -0.0430 -0.0204 -0.3247 -0.3220 -0.7061 -0.0240 -0.1536 -0.0070 -0.0282 -0.3127', 'S-114\tDie Penetration von Amprenavir in die zerebrospinale Flüssigkeit ist beim Menschen vernachlässigbar.', 'T-114\tCSF penetration of amprenavir is negligible in humans.', 'H-114\t-0.904296875\tThe penetration of amprenavir into cerebrospinal fluid is negligible in humans .', 'D-114\t-0.904296875\tThe penetration of amprenavir into cerebrospinal fluid is negligible in humans.', 'P-114\t-2.0352 -0.0254 -0.0183 -0.0380 -0.0225 -0.0099 -0.1367 -0.0211 -0.2930 -2.5918 -0.0141 -0.0366 -0.0028 -0.0085 -0.0113 -0.0395 -0.3945 -0.2029 -0.0056 -0.0113 -0.0169 -0.0451 -0.2029 -0.0282 -0.0282', 'S-565\tWenn Sie an einer Sepsis genannten schwerwiegenden Blutinfektion erkrankt sind oder bei Ihnen das Risiko einer Sepsis besteht.', 'T-565\tIf you have or are at risk of developing a serious blood infection called sepsis.', 'H-565\t-0.6923828125\tIf you have , or are at risk of developing , a serious blood infection called sepsis .', 'D-565\t-0.6923828125\tIf you have, or are at risk of developing, a serious blood infection called sepsis.', 'P-565\t-0.3872 -0.0313 -0.3030 -0.6284 -0.0796 -0.1866 -0.1367 -0.0324 -0.3706 -0.3184 -1.0000 -0.0930 -0.2085 -0.0395 -0.0254 -0.1183 -0.0197 -0.0169 -0.0197 -0.2593 -0.0282', 'S-358\tSollte dies eintreten, beenden Sie die Einnahme von Ciprofloxacin Bayer und wenden sich unverzüglich an Ihren Arzt.', 'T-358\tIf this happens, stop taking Ciprofloxacin Bayer and contact your doctor immediately.', 'H-358\t-0.6611328125\tIf this happens , stop taking Ciprofloxacin Bayer and contact your doctor immediately .', 'D-358\t-0.6611328125\tIf this happens, stop taking Ciprofloxacin Bayer and contact your doctor immediately.', 'P-358\t-0.5063 -0.0613 -0.5513 -0.0571 -0.1437 -0.0373 -0.2367 -0.0042 -0.0183 -0.0254 -0.0211 -0.0268 -0.0211 -0.0409 -1.8135 -0.0310 -0.0423 -0.2903 -0.0310 -0.0310', 'S-1093\t100 x 1 Hartkapsel in perforierte nPVC / Aluminium-Blistern zur Abgabe von Einzeldosen.', 'T-1093\t100 x 1 hard capsules in PVC / Aluminium perforated unit dose blisters.', 'H-1093\t-0.93115234375\t100 x 1 hard capsule in aluminium / PVC perforated unit dose blisters .', 'D-1093\t-0.93115234375\t100 x 1 hard capsule in aluminium / PVC perforated unit dose blisters.', 'P-1093\t-0.1854 -0.0342 -0.0299 -0.4973 -0.2917 -0.0070 -0.0310 -0.0690 -1.3809 -0.0760 -0.9282 -0.3071 -0.0423 -0.2563 -0.0197 -0.0310 -0.3213 -0.3213 -0.2227 -0.6821 -0.1831 -0.0338', 'S-1500\t61 Die Pen-Kappe muss nach jeder Injektion wieder auf den Pen gesetzt werden, um den Inhalt vor Licht zu schützen.', 'T-1500\tThe pen cap must be put back on the pen after each injection in order to protect from light.', 'H-1500\t-1.38671875\t61 The pen cap must be replaced on the pen after each injection to protect from light .', 'D-1500\t-1.38671875\t61 The pen cap must be replaced on the pen after each injection to protect from light.', 'P-1500\t-1.7783 -1.8936 -0.0620 -0.0507 -1.2793 -0.0395 -0.4734 -1.1973 -0.2197 -0.0282 -0.3325 -0.0901 -0.0338 -0.0113 -0.3438 -0.0564 -0.3213 -0.0507 -0.0676 -0.0395', 'S-504\tBestimmen Sie die Dosis und die Anzahl der benötigten ORENCIA-Durchstechflaschen (siehe Abschnitt 4.2).', 'T-504\tDetermine the dose and the number of ORENCIA vials needed (see section 4.2).', 'H-504\t-0.66943359375\tDetermine the dose and the number of Required ORENCIA vials ( see section 4.2 ) .', 'D-504\t-0.66943359375\tDetermine the dose and the number of Required ORENCIA vials (see section 4.2).', 'P-504\t-0.3240 -0.0171 -0.0042 -0.0481 -0.0627 -0.0409 -0.8623 -0.0402 -0.0282 -2.2324 -0.1099 -0.0225 -0.0789 -0.0225 -0.0141 -0.2676 -0.0282 -0.0366 -0.0535 -0.1691 -0.0282 -0.0310 -0.0310 -0.0338 -0.0310', 'S-346\tw.19 w.28 w.37 w.46 w.55 w.64 w.73 16 400 IE / kg IL-2 und danach 0,5 ml', 'T-346\tw.1 w.2 w.3 w.4 w.55 w.6 w.7 IL-2 16 400 IU / kg followed by 0.5 ml', 'H-346\t-0.708984375\tw.19 w.28 w.37 w.46 w.55 w.64 w.73 16 400 IU / kg IL @-@ 2 and thereafter 0.5 ml', 'D-346\t-0.708984375\tw.19 w.28 w.37 w.46 w.55 w.64 w.73 16 400 IU / kg IL-2 and thereafter 0.5 ml', 'P-346\t-2.2578 -0.0225 -0.0141 -0.0183 -0.0155 -0.0169 -0.0197 -0.0127 -0.0183 -0.0211 -0.0141 -0.0141 -0.0155 -0.0155 -0.5015 -0.0141 -0.3071 -0.0085 -0.0282 -0.0169 -0.0197 -0.0282 -0.0282 -0.0395 -0.9468 -0.0169 -0.0254 -0.9551 -0.0141 -0.0310', 'S-444\tHypertonie, Hyperlipidämie) müssen im Rahmen der üblichen Therapiestandards überwacht und behandelt werden.', 'T-444\t5 Cardiovascular risk RA patients have an increased risk for cardiovascular disorders and should have risk factors (e. g. hypertension, hyperlipidaemia) managed as part of usual standard of care.', 'H-444\t-1.318359375\tPatients with significant risk factors for cardiovascular events ( e. g. hypertension , hyperlipidaemia ) should be monitored and treated according to standard care .', 'D-444\t-1.318359375\tPatients with significant risk factors for cardiovascular events (e. g. hypertension, hyperlipidaemia) should be monitored and treated according to standard care.', 'P-444\t-1.3135 -0.0240 -0.2233 -1.1562 -0.3650 -0.5835 -0.2227 -0.4705 -0.2169 -0.0113 -0.0085 -0.3550 -0.2141 -0.8540 -0.1691 -0.0620 -0.0789 -0.3042 -0.0901 -0.0282 -0.6313 -0.6313 -0.0676 -0.0676 -0.0225 -0.0338 -0.3101 -0.0507 -0.5522 -0.0169 -0.0338 -0.0225 -0.8735 -0.0282 -0.2593 -1.2119 -0.0901 -0.0338', 'S-552\tWoche 195 Zellen / mm3 und 207 Zellen / mm3 in der Nelfinavir- bzw.', 'T-552\tThe mean increase from baseline in CD4 + cell count at week 48 was 195 cells / mm3 and 207 cells / mm3 in the nelfinavir and lopinavir / ritonavir groups', 'H-552\t-1.1162109375\tWeek 195 cells / mm3 and 207 cells / mm3 in the nelfinavir vs .', 'D-552\t-1.1162109375\tWeek 195 cells / mm3 and 207 cells / mm3 in the nelfinavir vs.', 'P-552\t-2.8770 -0.0225 -0.0282 -0.0310 -0.0310 -0.0113 -0.0282 -0.0451 -0.0225 -0.0254 -0.0141 -0.0282 -0.0085 -0.0282 -0.2141 -0.6084 -0.2085 -0.0338 -0.0395 -0.1973 -0.2367 -1.2002 -1.5498 -0.0282', 'S-914\tJede Ampulle enthält 100 internationale Einheiten (IE) des Wirkstoffs Lachs-Calcitonin. t lä', 'T-914\tEach ampoule contains 100 IU (International Units) of the active substance salmon calcitonin. ol What is Forcaltonin used for?', 'H-914\t-0.52587890625\tEach ampoule contains 100 international units ( IU ) of the active substance salmon calcitonin .', 'D-914\t-0.52587890625\tEach ampoule contains 100 international units (IU) of the active substance salmon calcitonin.', 'P-914\t-0.0545 -0.2969 -0.0099 -0.0183 -0.0493 -0.0349 -0.3435 -0.0148 -0.0578 -0.1895 -0.0106 -0.0289 -0.0324 -0.5537 -0.0423 -0.8101 -0.0760 -0.0070 -0.1648 -0.0099 -0.0197 -0.5762 -0.0507 -0.0873', 'S-848\tSie ist als Einheitspackung mit einer Flasche oder Bündelpackung mit 5 Packungen zu je einer Flasche erhältlich.', 'T-848\tIt is supplied in packs containing one bottle as unit pack or in multi-packs comprising 5 packs, each containing 1 bottle.', 'H-848\t-1.091796875\tIt is available in packs containing one bottle or multipacks comprising 5 packs , each containing 1 bottle .', 'D-848\t-1.091796875\tIt is available in packs containing one bottle or multipacks comprising 5 packs, each containing 1 bottle.', 'P-848\t-0.0991 -0.0502 -0.5112 -0.6240 -0.7544 -0.0127 -0.3127 -0.3228 -0.1282 -0.6509 -1.1689 -0.1747 -0.0113 -0.3213 -0.0169 -0.0986 -0.2057 -0.0225 -0.3071 -0.1409 -0.2593 -0.9580 -0.0395 -0.3157 -0.0282', 'S-700\tInfektionen (einschließlich Herpes simplex, orale Candidose, Pharyngitis, Rhinitis)', 'T-700\tVery common: infection (including herpes simplex, oral candidiasis, pharyngitis, rhinitis)', 'H-700\t-0.5888671875\tInfections ( including herpes simplex , oral candidiasis , pharyngitis , rhinitis )', 'D-700\t-0.5888671875\tInfections (including herpes simplex, oral candidiasis, pharyngitis, rhinitis)', 'P-700\t-0.7476 -0.0317 -0.0331 -0.0204 -0.2917 -0.0099 -0.0092 -0.0261 -0.0218 -0.0296 -0.2430 -0.4749 -0.0732 -0.3621 -1.4385 -0.0254 -0.0310 -0.0366 -0.0225 -0.0141 -0.0169 -0.0141 -0.0310 -0.0310 -0.0141 -0.0254 -0.0113 -0.0310 -0.3240', 'S-653\tEMEND wurde oral 1 Stunde vor Beginn der Chemotherapie an Tag 1 sowie an den Tagen 2 und 3 morgens gegeben.', 'T-653\tEMEND was administered orally 1 hour prior to chemotherapy treatment on Day 1 and in the morning on Days 2 and 3.', 'H-653\t-0.7314453125\tEMEND was administered orally 1 hour prior to chemotherapy treatment on Day 1 and in the morning on Days 2 and 3 .', 'D-653\t-0.7314453125\tEMEND was administered orally 1 hour prior to chemotherapy treatment on Day 1 and in the morning on Days 2 and 3.', 'P-653\t-0.0277 -0.0291 -0.0170 -0.2103 -0.9004 -0.0197 -0.0197 -0.0155 -0.3662 -0.0338 -0.8931 -0.0296 -0.4861 -0.0113 -0.0197 -0.4734 -0.4395 -0.2649 -0.0310 -0.4819 -0.3662 -0.0930 -0.1353 -0.0507 -0.0564 -0.0310 -0.0338 -0.0310 -0.0338 -0.0282', 'S-1651\tWelche Rolle dieser Mechanismus für die therapeutischen Wirkungen von < RENITEC > spielt, ist noch unklar.', 'T-1651\tHowever, the role that this plays in the therapeutic effects of < Renitec > remains to be elucidated.', 'H-1651\t-1.076171875\tThe role of this mechanism in the therapeutic effects of &lt; Renitec &gt; is still unclear .', 'D-1651\t-1.076171875\tThe role of this mechanism in the therapeutic effects of < Renitec > is still unclear.', 'P-1651\t-0.7524 -2.0605 -0.1169 -0.2141 -0.0282 -0.0197 -1.2373 -0.0986 -0.0197 -0.0225 -0.5156 -0.0310 -0.1212 -0.0085 -0.0225 -0.3213 -0.0423 -0.0113 -0.0141 -0.0817 -0.8032 -0.6479 -0.0282 -0.0282', 'S-476\tWegen des Auftretens möglicher Nebenwirkungen beim gestillten Säugling sollte vor Beginn der Behandlung abgestillt werden.', 'T-476\tBecause of the potential for adverse reactions in nursing infants, nursing should be discontinued prior to initiation of treatment.', 'H-476\t-1.01953125\tBecause of the potential for adverse reactions in nursing infants , nursing should be discontinued at the start of treatment .', 'D-476\t-1.01953125\tBecause of the potential for adverse reactions in nursing infants, nursing should be discontinued at the start of treatment.', 'P-476\t-0.5552 -0.0437 -0.1733 -0.3691 -0.5381 -0.3071 -0.0113 -0.2367 -0.0451 -0.1521 -0.6060 -0.0592 -0.0845 -0.0169 -0.0845 -0.7129 -0.0225 -0.3157 -0.0592 -0.3889 -0.0085 -1.8818 -0.1465 -0.2705 -0.0282 -0.3494 -0.0338 -0.0282', 'S-681\tWenn Sie unsicher sein sollten, ob Ihre Arzneimittel diese Wirkstoffe enthalten, sprechen Sie bitte mit Ihrem Arzt oder Apotheker.', 'T-681\tIf you are uncertain if your medicines contain these substances, you should check with your doctor or pharmacist.', 'H-681\t-1.13671875\tIf you are unsure , ask your doctor or pharmacist if your medicines contain these active substances .', 'D-681\t-1.13671875\tIf you are unsure, ask your doctor or pharmacist if your medicines contain these active substances.', 'P-681\t-0.2268 -0.0313 -0.0662 -1.3643 -0.0113 -1.0654 -0.6680 -0.0535 -0.0620 -0.2395 -0.0451 -0.0225 -0.3945 -0.5015 -0.7437 -0.0479 -0.0423 -0.2423 -1.3018 -0.2423 -0.0169 -0.0395 -0.0338', 'S-709\t31 Eine Topotecan-induzierte Neutropenie kann zu einer neutropenischen Kolitis führen.', 'T-709\tTopotecan-induced neutropenia can cause neutropenic colitis.', 'H-709\t-0.70849609375\t31 Topotecan @-@ induced neutropenia may lead to neutropenic colitis .', 'D-709\t-0.70849609375\t31 Topotecan-induced neutropenia may lead to neutropenic colitis.', 'P-709\t-2.4258 -0.0197 -0.0282 -0.0338 -0.0254 -0.5552 -0.2339 -0.0197 -0.0225 -0.0113 -0.0197 -0.0225 -0.2283 -0.6284 -0.0310 -0.2676 -0.0169 -0.0282 -0.0254 -0.0169 -0.0225 -0.0225 -0.0366 -0.0282', 'S-1491\tNach derzeitiger Datenlage empfiehlt sich eine kontinuierliche Behandlung mit Preotact bis zu 24 Monate (siehe Abschnitt 4.4).', 'T-1491\tData support continuous treatment with Preotact for up to 24 months (see section 4.4).', 'H-1491\t-1.423828125\tBased on information available to date regular treatment with Preotact is recommended for up to 24 months ( see section 4.4 ) .', 'D-1491\t-1.423828125\tBased on information available to date regular treatment with Preotact is recommended for up to 24 months (see section 4.4).', 'P-1491\t-2.3281 -0.0324 -1.4092 -0.1945 -0.4255 -0.1831 -1.2822 -1.1719 -0.0451 -0.0225 -0.0169 -0.0169 -1.7637 -0.0451 -0.5410 -0.0676 -0.0282 -0.0225 -0.0338 -0.0395 -0.0395 -0.4282 -0.0225 -0.0282 -0.0338 -0.0338 -0.0282', 'S-526\tOctreotid / Lanreotid kann den Insulinbedarf sowohl senken als auch erhöhen. zn', 'T-526\tOctreotide / laneotide may both decrease and increase insulin requirement. t', 'H-526\t-0.62646484375\tOctreotide / lanreotide may both decrease and increase insulin activity .', 'D-526\t-0.62646484375\tOctreotide / lanreotide may both decrease and increase insulin activity.', 'P-526\t-0.0199 -0.0242 -0.0292 -0.0077 -0.0306 -0.0135 -0.0444 -0.0227 -0.0070 -0.4241 -0.2374 -0.4917 -0.0232 -0.0472 -0.1691 -0.2268 -0.0113 -1.5312 -0.3184 -0.0986', 'S-1555\tDie vollständige Auflistung der im Zusammenhang mit Sustiva berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen.', 'T-1555\tFor a more complete list of side effects reported with Sustiva, see the Package Leaflet.', 'H-1555\t-0.6240234375\tFor the full list of all side effects reported with Sustiva , see the Package Leaflet .', 'D-1555\t-0.6240234375\tFor the full list of all side effects reported with Sustiva, see the Package Leaflet.', 'P-1555\t-0.2368 -0.2034 -0.0976 -0.0901 -0.0292 -0.3213 -0.2683 -0.0479 -0.2720 -0.2720 -1.1201 -0.0085 -0.0169 -0.0845 -0.1578 -0.0958 -0.3213 -0.0395 -0.3184 -0.0028 -0.0225 -0.0366 -0.0310', 'S-1724\tGenerell muss Kinzalkomb vor Beginn einer Schwangerschaft durch geeignete blutdrucksenkende Arzneimittel ersetzt werden.', 'T-1724\tAppropriate antihypertensive drug must usually replace Kinzalkomb before starting a pregnancy.', 'H-1724\t-0.49951171875\tAppropriate antihypertensive drug must usually replace Kinzalkomb before starting a pregnancy .', 'D-1724\t-0.49951171875\tAppropriate antihypertensive drug must usually replace Kinzalkomb before starting a pregnancy.', 'P-1724\t-0.3372 -0.0298 -0.0099 -0.0243 -0.2969 -0.0486 -0.0141 -0.0169 -0.3508 -0.3184 -0.3169 -0.3169 -0.2776 -0.0254 -0.0225 -0.1395 -0.0268 -0.1381 -0.3157 -0.1747 -0.0141 -0.0338 -0.0282', 'S-1753\tDiese Mutation wurde bei 90% der mit Efavirenz behandelten Patienten mit virologischem Versagen beobachtet.', 'T-1753\tThis mutation was observed in 90% of patients receiving efavirenz with virological failure.', 'H-1753\t-0.96240234375\tThis mutation was observed in 90 % of patients receiving efavirenz .', 'D-1753\t-0.96240234375\tThis mutation was observed in 90% of patients receiving efavirenz.', 'P-1753\t-0.3328 -1.2656 -0.0296 -0.2664 -0.5352 -0.0324 -0.0916 -0.0352 -0.2156 -0.1296 -0.9385 -0.6367 -0.0085 -0.0282 -0.0282 -0.0676 -0.7808 -0.0310', 'S-1939\tDie vollständige Auflistung aller im Zusammenhang mit Preotact berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen.', 'T-1939\tFor the full list of all side effects reported with Preotact, see the Package Leaflet.', 'H-1939\t-0.450439453125\tFor the full list of all side effects reported with Preotact , see the Package Leaflet .', 'D-1939\t-0.450439453125\tFor the full list of all side effects reported with Preotact, see the Package Leaflet.', 'P-1939\t-0.2720 -0.2024 -0.1736 -0.1324 -0.0303 -0.0901 -0.2620 -0.0416 -0.2803 -0.2761 -0.0254 -0.0197 -0.0211 -0.0873 -0.1874 -0.0831 -0.3198 -0.0409 -0.3184 -0.0028 -0.0240 -0.0338 -0.0310', 'S-1993\tProphylaxe postoperativer Infektionen des Bauchraums nach elektiven kolorektalen Eingriffen bei Erwachsenen:', 'T-1993\tProphylaxis of surgical site infection following elective colorectal surgery in adults:', 'H-1993\t-0.7236328125\tPrevention of surgical site infection following elective colorectal surgery in adults :', 'D-1993\t-0.7236328125\tPrevention of surgical site infection following elective colorectal surgery in adults:', 'P-1993\t-1.0713 -0.0514 -0.0331 -0.4275 -0.0113 -0.0254 -0.3269 -1.1611 -0.2986 -0.1127 -0.0451 -0.0310 -0.0535 -0.0113 -0.0141 -0.1831 -0.0620 -0.0423 -0.3748 -0.0282', 'S-1999\tDie vollständige Auflistung der im Zusammenhang mit OptiMARK berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen.', 'T-1999\tFor the full list of all side effects reported with OptiMARK, see the Package Leaflet.', 'H-1999\t-0.4462890625\tFor the full list of all side effects reported with OptiMARK , see the Package Leaflet .', 'D-1999\t-0.4462890625\tFor the full list of all side effects reported with OptiMARK, see the Package Leaflet.', 'P-1999\t-0.2561 -0.2131 -0.1250 -0.1120 -0.0292 -0.3987 -0.2494 -0.0416 -0.0585 -0.2690 -0.0099 -0.0296 -0.0225 -0.0746 -0.1818 -0.0873 -0.3213 -0.0380 -0.3184 -0.0042 -0.0197 -0.0366 -0.0310', 'S-1286\t37 Paxene enthält Macrogolglycerolricinoleat, das eine allergische Reaktion auslösen kann.', 'T-1286\tPaxene contains polyoxyl castor oil, which can cause an allergic reaction.', 'H-1286\t-1.15625\t37 Paxene contains macrogolglycerol ricinoleate , which may cause an allergic reaction .', 'D-1286\t-1.15625\t37 Paxene contains macrogolglycerol ricinoleate, which may cause an allergic reaction.', 'P-1286\t-2.4238 -0.2747 -0.0197 -0.0606 -0.0409 -1.4375 -0.0282 -0.0366 -0.0282 -0.0113 -0.0113 -0.3101 -0.0395 -0.0085 -0.2930 -0.0113 -1.0059 -0.0395 -0.7383 -0.2311 -0.9751 -0.0169 -0.0169 -0.0395 -0.0395 -0.0282', 'S-995\tDie folgenden Angaben entsprechen den pharmakokinetischen Eigenschaften der einzelnen in AVANDAMET enthaltenen Wirkstoffe:', 'T-995\tThe following statements reflect the pharmacokinetic properties of the individual active substances of AVANDAMET.', 'H-995\t-0.493896484375\tThe following statements reflect the pharmacokinetic properties of the individual active substances of AVANDAMET :', 'D-995\t-0.493896484375\tThe following statements reflect the pharmacokinetic properties of the individual active substances of AVANDAMET:', 'P-995\t-0.0393 -0.0327 -0.3042 -0.3093 -0.0388 -0.0183 -0.0148 -0.0085 -0.0331 -0.0690 -0.0310 -0.3164 -0.2078 -0.1212 -0.2255 -0.0183 -0.7437 -0.0479 -0.0254 -0.0056 -0.0197 -0.0113 -0.6553 -0.0282', 'S-1135\tBei diesen Patienten wird Erbitux in Kombination mit einer Bestrahlung oder in Kombination mit anderen Krebsmedikamenten angewendet.', 'T-1135\tIn these patients, Erbitux is used in combination with radiation therapy or with other anticancer medicines.', 'H-1135\t-0.58984375\tIn these patients , Erbitux is used in combination with radiation therapy or in combination with other anticancer medicines .', 'D-1135\t-0.58984375\tIn these patients, Erbitux is used in combination with radiation therapy or in combination with other anticancer medicines.', 'P-1135\t-0.2073 -0.2764 -0.0257 -0.2057 -0.0240 -0.0085 -0.0099 -0.0486 -0.0873 -0.0500 -0.0218 -0.0289 -0.5542 -1.1543 -0.0535 -0.1465 -0.0254 -0.0310 -0.0310 -0.4958 -0.0056 -0.0113 -0.1663 -0.4395 -0.0310 -0.0282', 'S-1975\tInsulin, das in den Vorratsbehälter der Pumpe umgefüllt ist, kann 2 Wochen lang verwendet werden.', 'T-1975\tInsulin that has been filled into the pump reservoir may be used for two weeks thereafter.', 'H-1975\t-1.150390625\tInsulin filled into the pump reservoir can be used for 2 weeks .', 'D-1975\t-1.150390625\tInsulin filled into the pump reservoir can be used for 2 weeks.', 'P-1975\t-0.2910 -0.0077 -0.0127 -0.4685 -0.9531 -0.0493 -0.2803 -1.3105 -0.0113 -0.0141 -1.3271 -0.0395 -0.7920 -0.2537 -0.5918 -0.0282 -0.0507 -0.0338', 'S-112\tAbhängig von den Ergebnissen dieser Untersuchungen müssen Sie möglicherweise auf Anweisung Ihres Arztes die Dosierung von Sebivo ändern.', 'T-112\tDepending on the results of these tests your doctor may advise you to change how often you take Sebivo.', 'H-112\t-1.259765625\tDepending on the results of these tests , you may need to change the dosage of Sebivo on the advice of your doctor .', 'D-112\t-1.259765625\tDepending on the results of these tests, you may need to change the dosage of Sebivo on the advice of your doctor.', 'P-112\t-0.4011 -0.0120 -0.6689 -0.0606 -0.1459 -0.0352 -0.0930 -0.3164 -0.4846 -0.7524 -0.2085 -0.5044 -0.0310 -0.5605 -0.6172 -1.5781 -0.0225 -0.0282 -0.0338 -0.0225 -0.0225 -0.0113 -2.4062 -0.1973 -0.2986 -0.0282 -0.0338 -0.0676 -0.0282 -0.0282', 'S-1654\tMenschen mit bekannter Überempfindlichkeit gegenüber Makrolidantibiotika sollten den Kontakt mit dem Tierarzneimittel vermeiden.', 'T-1654\tPeople with known hypersensitivity to the macrolide class should avoid contact with the veterinary medicinal product.', 'H-1654\t-0.44091796875\tPeople with known hypersensitivity to macrolide antibiotics should avoid contact with the veterinary medicinal product .', 'D-1654\t-0.44091796875\tPeople with known hypersensitivity to macrolide antibiotics should avoid contact with the veterinary medicinal product.', 'P-1654\t-0.2476 -0.0516 -0.6348 -0.0388 -0.0085 -0.0141 -0.0345 -0.1797 -0.0296 -0.0211 -0.8359 -0.0254 -0.0141 -0.0183 -0.0296 -0.0296 -0.0395 -0.0310 -0.3367 -0.0366 -0.0352 -0.2720 -0.0676 -0.0225 -0.0310 -0.0282', 'S-1794\tDer Impfstoff enthält keinerlei Inhaltsstoffe, die für Menschen bedenklich sind, die die geimpften Vögel verzehren.', 'T-1794\tZero days The vaccine does not contain any ingredients that are likely to pose a risk for consumers of vaccinated birds.', 'H-1794\t-0.68603515625\tThe vaccine does not contain any ingredients that are likely to pose a risk to consumers of vaccinated birds .', 'D-1794\t-0.68603515625\tThe vaccine does not contain any ingredients that are likely to pose a risk to consumers of vaccinated birds.', 'P-1794\t-0.4580 -0.0472 -0.1521 -0.0257 -0.0197 -0.0504 -0.1022 -0.2712 -0.1888 -0.3120 -0.0324 -0.3000 -0.1381 -0.2423 -0.9453 -0.4143 -0.1296 -0.4395 -0.0169 -0.0395 -0.0310 -0.0282', 'S-959\tEine Überprüfung der veröffentlichten Daten ergibt, dass die verschiedenen Gelbfieber-Impfstoffe subkutan verabreicht werden sollten.', 'T-959\tFollowing a review of published data the recommended route of administration of different yellow fever vaccines is subcutaneous.', 'H-959\t-0.82373046875\tReview of the published data shows that the various yellow fever vaccines should be administered subcutaneously .', 'D-959\t-0.82373046875\tReview of the published data shows that the various yellow fever vaccines should be administered subcutaneously.', 'P-959\t-0.6929 -0.0342 -0.8423 -0.1663 -0.0254 -1.1211 -0.0423 -0.5947 -0.6396 -0.3691 -0.0254 -0.0141 -0.0169 -0.0225 -0.0423 -0.0282 -0.7637 -0.0197 -0.0789 -0.0085 -0.0085 -0.0282 -0.0366 -0.0310 -0.0282', 'S-1442\tVIRAMUNE sollte nur von einem Arzt gegeben werden, der Erfahrung in der Behandlung von HIV- Infektionen hat.', 'T-1442\tTreatment with VIRAMUNE should be given by a doctor who has experience in the treatment of HIV infection.', 'H-1442\t-0.63330078125\tVIRAMUNE should only be given by a doctor who has experience in the treatment of HIV infection .', 'D-1442\t-0.63330078125\tVIRAMUNE should only be given by a doctor who has experience in the treatment of HIV infection.', 'P-1442\t-0.1296 -0.0177 -0.0149 -0.0269 -0.0269 -0.0414 -1.1895 -0.0282 -0.8271 -0.0395 -0.2367 -0.1198 -0.1930 -0.0986 -0.0732 -0.0704 -0.1973 -0.4988 -0.0310 -0.0338 -0.2001 -0.0338 -0.0282', 'S-1879\tEine Anämie (Hämoglobin < 8,0 g / dl) trat bei 69% der Patienten auf.', 'T-1879\tAnaemia (haemoglobin < 8.0 g / dl) occurred in 69% of patients.', 'H-1879\t-0.330322265625\tAnaemia ( haemoglobin &lt; 8.0 g / dl ) occurred in 69 % of patients .', 'D-1879\t-0.330322265625\tAnaemia (haemoglobin < 8.0 g / dl) occurred in 69% of patients.', 'P-1879\t-0.1600 -0.0663 -0.0085 -0.0276 -0.0437 -0.6260 -0.0085 -0.0113 -0.0268 -0.0063 -0.0120 -0.0204 -0.0704 -0.0296 -0.0345 -0.0296 -0.1000 -0.0282 -0.1345 -0.0296 -0.0127 -0.0324 -0.2494 -0.5029 -0.0324 -0.0282', 'S-1845\tWenn die Wehen wiederkehren, kann die Behandlung mit Tractocile bis zu drei Mal während der Schwangerschaft wiederholt werden.', 'T-1845\tIf contractions come back, treatment with Tractocile can be repeated up to three more times during the pregnancy.', 'H-1845\t-0.73681640625\tIf contractions recur , treatment with Tractocile can be repeated up to three times during pregnancy .', 'D-1845\t-0.73681640625\tIf contractions recur, treatment with Tractocile can be repeated up to three times during pregnancy.', 'P-1845\t-0.9355 -0.4861 -0.0099 -0.9722 -0.0070 -0.1818 -0.7832 -0.0451 -0.0479 -0.0254 -0.0254 -0.0254 -0.0197 -0.5806 -0.0282 -0.0197 -0.5127 -0.0282 -0.0338 -0.0254 -0.0535 -0.0535 -0.0310 -0.0282', 'S-57\tEbenso könnte auch Indinavir die Pharmakokinetik anderer Stoffe beeinflussen, die über diesen Weg metabolisiert werden.', 'T-57\tSimilarly, indinavir might also modify the pharmacokinetics of other substances that share this metabolic pathway.', 'H-57\t-1.158203125\tLikewise , indinavir might also modify the pharmacokinetics of other substances metabolised by this pathway .', 'D-57\t-1.158203125\tLikewise, indinavir might also modify the pharmacokinetics of other substances metabolised by this pathway.', 'P-57\t-2.1113 -0.0113 -0.0127 -0.0803 -0.0409 -0.0155 -0.0155 -0.0197 -1.5752 -0.9214 -0.3213 -0.0225 -0.0535 -0.0366 -0.0169 -0.0169 -0.0254 -0.0310 -0.0479 -0.4958 -0.0169 -0.7666 -0.0225 -0.4622 -1.1045 -0.1183 -0.4734 -0.0225 -0.0282 -0.0282', 'S-1090\tDiese Effekte sind allerdings unter der Inhalationsbehandlung viel weniger wahrscheinlich als unter der oralen Gabe von Kortikoiden.', 'T-1090\tSituations, which could potentially trigger acute adrenal crisis include trauma, surgery, infection or any rapid reduction in dosage.', 'H-1090\t-1.28125\t1x28 , 1x60 , 2x60 , Double foil 3x60 , 10x60 doses 28 or 60 dose', 'D-1090\t-1.28125\t1x28, 1x60, 2x60, Double foil 3x60, 10x60 doses 28 or 60 dose', 'P-1090\t-0.6807 -0.3889 -0.3228 -0.2720 -0.3284 -0.0606 -0.3325 -0.2296 -0.6060 -0.0338 -0.3071 -0.2563 -1.0342 -0.3213 -0.3127 -0.3240 -0.0225 -0.3101 -0.4395 -0.3269 -0.0958 -0.3101 -0.5747 -0.1240 -0.3381 -0.3269 -0.3213 -0.3438 -0.3213', 'S-1625\t33 Humalog Mix25 Patronen sind nicht zum Mischen mit anderen Insulinen in der Patrone ausgelegt.', 'T-1625\t30 Humalog Mix25 cartridges are not designed to allow any other insulin to be mixed in the cartridge.', 'H-1625\t-0.71240234375\t33 Humalog Mix25 cartridges are not designed to allow any other insulin to be mixed in the cartridge .', 'D-1625\t-0.71240234375\t33 Humalog Mix25 cartridges are not designed to allow any other insulin to be mixed in the cartridge.', 'P-1625\t-2.7578 -0.0169 -0.0099 -0.0423 -0.0338 -0.0268 -0.0930 -0.0056 -0.0169 -0.0395 -0.0423 -0.0760 -0.1691 -0.3213 -0.3213 -0.2705 -0.0423 -0.0592 -0.2930 -0.1268 -0.0648 -0.2001 -0.0901 -0.0338 -0.0141 -0.0169 -0.0451 -0.0282', 'S-1240\t6 D-63128 Dietzenbach Németország Tel: + 49 6074 812160', 'T-1240\t6 D-63128 Dietzenbach Németország Tel: + 49 6074 812160', 'H-1240\t-0.1619873046875\t6 D @-@ 63128 Dietzenbach Németország Tel : + 49 6074 812160', 'D-1240\t-0.1619873046875\t6 D-63128 Dietzenbach Németország Tel: + 49 6074 812160', 'P-1240\t-0.0604 -0.1097 -0.0292 -0.0356 -0.0278 -0.0234 -0.0269 -0.2808 -0.0176 -0.0500 -0.0099 -0.1007 -0.0183 -0.0197 -0.0282 -0.0056 -0.0127 -0.0225 -0.1057 -0.0606 -0.0218 -0.0155 -0.0113 -0.0099 -0.0247 -0.0197 -0.0099 -0.0373', 'S-648\tSverige Les Laboratoires Servier / Frankrike Tel: + 33 (0) 1 55 72 60 00', 'T-648\tSverige Les Laboratoires Servier / Frankrike Tel: + 33 (0) 1 55 72 60 00', 'H-648\t-0.1119384765625\tSverige Les Laboratoires Servier / Frankrike Tel : + 33 ( 0 ) 1 55 72 60 00', 'D-648\t-0.1119384765625\tSverige Les Laboratoires Servier / Frankrike Tel: + 33 (0) 1 55 72 60 00', 'P-648\t-0.0886 -0.0134 -0.0042 -0.0213 -0.0128 -0.0199 -0.0213 -0.0255 -0.0070 -0.0199 -0.0134 -0.0313 -0.0872 -0.0070 -0.0204 -0.1068 -0.0444 -0.0257 -0.0229 -0.0402 -0.0243 -0.0285 -0.0285 -0.0159 -0.0113 -0.0240 -0.0268 -0.0338', 'S-604\t0,60 (0,49 bis 0,73) 0,56 (0,40 bis 0,78) 0,75 (0,61 bis 0,91)', 'T-604\t0.60 (0.49 to 0.73) 0.56 (0.40 to 0.78) 0.75 (0.61 to 0.91)', 'H-604\t-0.544921875\t0.60 ( 0.49 to 0.73 ) 0.56 ( 0.40 to 0.78 ) 0.75 ( 0.61 to 0.91 )', 'D-604\t-0.544921875\t0.60 (0.49 to 0.73) 0.56 (0.40 to 0.78) 0.75 (0.61 to 0.91)', 'P-604\t-2.5156 -0.0310 -0.0282 -0.0423 -0.0225 -0.6523 -0.0254 -0.0169 -0.0282 -0.0366 -0.0141 -0.0254 -0.0282 -0.0225 -0.0282 -0.0254 -0.2113 -0.0282 -0.0254 -0.0169 -0.0254 -0.0338 -0.0169 -0.0282 -0.0254 -0.0113 -0.0282 -0.0310', 'S-549\tPlanta de Producción Ronda de Santa Maria 158 E-08210 Barberà del Vallès, Barcelona Spanien', 'T-549\tPlanta de Producción Ronda de Santa Maria 158 E-08210 Barberà del Vallès, Barcelona Spain', 'H-549\t-0.57958984375\tPlanta de Producción Ronda de Santa Maria 158 E @-@ 08210 Barberà del Vallès , Barcelona Spain', 'D-549\t-0.57958984375\tPlanta de Producción Ronda de Santa Maria 158 E-08210 Barberà del Vallès, Barcelona Spain', 'P-549\t-2.6562 -0.0169 -0.0296 -0.0620 -0.0113 -0.0211 -0.0127 -0.0197 -0.0254 -0.0099 -0.0310 -0.0254 -0.0282 -0.2847 -0.0282 -0.0141 -0.2423 -0.3945 -0.0451 -0.0704 -0.0254 -0.0760 -0.0310 -0.0197 -0.0310 -0.0141 -0.0225 -0.0310', 'S-396\tTeva Pharmaceutical Works Private Limited Company Pallagi út 13 Debrecen H-4042 Ungarn', 'T-396\tTeva Pharmaceutical Works Private Limited Company Pallagi út 13 Debrecen H-4042 Hungary', 'H-396\t-0.10064697265625\tTeva Pharmaceutical Works Private Limited Company Pallagi út 13 Debrecen H @-@ 4042 Hungary', 'D-396\t-0.10064697265625\tTeva Pharmaceutical Works Private Limited Company Pallagi út 13 Debrecen H-4042 Hungary', 'P-396\t-0.2137 -0.0141 -0.0255 -0.0070 -0.0227 -0.0148 -0.0213 -0.0185 -0.0257 -0.0211 -0.0092 -0.0176 -0.0257 -0.0141 -0.0176 -0.0250 -0.0099 -0.0250 -0.0211 -0.0134 -0.0141 -0.0183 -0.0190 -0.0285 -0.0190 -0.0211 -0.0306 -0.0292', 'S-1341\tVor Beginn der Therapie mit Suboxone muss die Methadon-Dosis auf maximal 30 mg / Tag reduziert werden.', 'T-1341\tBefore beginning Suboxone therapy, the dose of methadone must be reduced to a maximum of 30 mg / day.', 'H-1341\t-1.2197265625\tBefore initiation of treatment with Suboxone , the dose of methadone should be reduced to a maximum of 30 mg / day .', 'D-1341\t-1.2197265625\tBefore initiation of treatment with Suboxone, the dose of methadone should be reduced to a maximum of 30 mg / day.', 'P-1341\t-1.5947 -0.8652 -1.0283 -0.0338 -0.8564 -0.0507 -0.0479 -0.0141 -0.0225 -0.0282 -1.0654 -0.0704 -0.7354 -0.0451 -0.0225 -0.0169 -0.0282 -0.8511 -0.0451 -0.3662 -0.3157 -0.1465 -0.1635 -0.0395 -0.0507 -0.0113 -0.7778 -0.0338 -0.0338 -0.0282', 'S-695\tWenn Sie entscheiden, die Behandlung an einem Montag zu beginnen, müssen Sie das Pflaster immer an einem Donnerstag und einem Montag wechseln.', 'T-695\tIf you decide to start treatment on a Monday, then you have to change your patch always on a Thursday and a Monday.', 'H-695\t-1.6796875\tIf you decide to start treatment on a Monday , you must change your patch on a Thursday and Monday .', 'D-695\t-1.6796875\tIf you decide to start treatment on a Monday, you must change your patch on a Thursday and Monday.', 'P-695\t-0.2551 -0.0299 -0.6973 -0.0352 -0.5361 -1.2021 -0.4143 -0.9526 -0.1268 -0.4932 -0.2986 -0.4312 -0.8906 -0.8174 -0.0395 -0.0620 -0.1917 -0.9131 -0.8398 -0.0620 -0.6084 -1.0938 -0.0338', 'S-622\t24 Die übliche Dosis beträgt 1 bis 2 g Ceftriaxon, einmal täglich (alle 24 Stunden) verabreicht.', 'T-622\tThe usual dose is 1 to 2 g of ceftriaxone, administered once a day (every 24 hours).', 'H-622\t-0.86083984375\t22 The usual dose is 1 to 2 g of ceftriaxone , administered once a day ( every 24 hours ) .', 'D-622\t-0.86083984375\t22 The usual dose is 1 to 2 g of ceftriaxone, administered once a day (every 24 hours).', 'P-622\t-1.7217 -0.0732 -0.0831 -0.0732 -0.0648 -0.7705 -0.1014 -0.0592 -0.2283 -0.6396 -0.0620 -0.0141 -0.0197 -0.0113 -0.0169 -0.4199 -0.3042 -0.0197 -0.2734 -0.6313 -0.0254 -0.4282 -0.1635 -0.0338 -0.0282 -0.0282 -0.0338 -0.0282', 'S-735\tAlle diese Studien basierten auf denselben Patientenkollektiven mit unterschiedlichem Umfang und können daher nicht als unabhängig betrachtet werden.', 'T-735\tAll of these studies used the same population of patients to varying degrees and as such cannot be considered as independent.', 'H-735\t-2.474609375\tAll of these studies were based on the same patient populations , with different degrees of magnitude and are not therefore considered to be independent .', 'D-735\t-2.474609375\tAll of these studies were based on the same patient populations, with different degrees of magnitude and are not therefore considered to be independent.', 'P-735\t-0.3152 -0.3916 -0.6055 -0.3755 -1.0508 -0.0718 -0.0324 -0.0366 -0.0225 -0.2395 -0.3438 -0.0141 -2.1367 -0.5127 -1.2002 -1.2227 -0.0451 -2.7324 -0.0169 -0.0225 -0.7046 -1.6455 -0.6201 -1.8818 -1.0938 -1.5557 -0.0338 -0.0338 -0.0451 -0.0338', 'S-1315\tDas Risiko kann für Patienten mit einer kurz zurückliegenden Vorgeschichte von pulmonalen Infiltraten oder Pneumonie höher sein.', 'T-1315\tPatients with a recent history of pulmonary infiltrates or pneumonia may be at higher risk.', 'H-1315\t-0.841796875\tThe risk may be higher in patients with a recent history of pulmonary infiltrates or pneumonia .', 'D-1315\t-0.841796875\tThe risk may be higher in patients with a recent history of pulmonary infiltrates or pneumonia.', 'P-1315\t-2.1191 -0.0225 -0.3691 -0.0282 -0.3889 -0.2283 -0.0648 -0.0479 -0.6987 -0.5186 -0.2113 -0.0282 -0.2141 -0.0225 -0.0254 -0.0395 -0.0056 -0.2734 -0.1747 -0.0395 -0.0366 -0.0141 -0.0169 -0.2959 -0.0338 -0.0282', 'S-1006\tIntronA ist als Pulver in den Stärken 30 Millionen I.E. / ml für den Gebrauch als Einzeldosis erhältlich.', 'T-1006\tIntronA is supplied as a powder at strengths of 30 million IU / ml for single-dose use.', 'H-1006\t-0.385986328125\tIntronA is supplied as a powder at strengths of 30 million IU / ml for single @-@ dose use .', 'D-1006\t-0.385986328125\tIntronA is supplied as a powder at strengths of 30 million IU / ml for single-dose use.', 'P-1006\t-0.0357 -0.0156 -0.0256 -0.0472 -0.3198 -0.0243 -0.1736 -0.0694 -0.1159 -0.3164 -0.3149 -0.0240 -0.0564 -0.3127 -0.0549 -0.0479 -0.1353 -0.0338 -0.0197 -0.0916 -0.1592 -0.1945 -0.0211 -0.0549 -0.0324 -0.0296', 'S-1558\tNehmen Sie Wilzin immer auf leeren Magen mindestens eine Stunde vor oder 2-3 Stunden nach den Mahlzeiten ein.', 'T-1558\tAlways take Wilzin on an empty stomach, at least one hour before or 2-3 hours after meals.', 'H-1558\t-0.298095703125\tAlways take Wilzin on an empty stomach , at least one hour before or 2 @-@ 3 hours after meals .', 'D-1558\t-0.298095703125\tAlways take Wilzin on an empty stomach, at least one hour before or 2-3 hours after meals.', 'P-1558\t-0.0575 -0.0184 -0.0472 -0.0723 -0.0407 -0.0306 -0.0320 -0.0342 -0.0070 -0.0134 -0.6523 -0.0402 -0.0190 -0.6284 -0.0197 -0.0282 -0.0634 -0.0437 -0.0395 -0.0282 -0.0211 -0.0310 -0.0282 -0.0310 -0.0296', 'S-688\t1A, Clă direa C1, Etaj 3 Sector 1, Bucureş ti, România', 'T-688\t1A, Clă direa C1, Etaj 3 Sector 1, Bucureş ti Romania', 'H-688\t-0.5205078125\t1A , Clă direa C1 , Etaj 3 Sector 1 , Bucureş ti , România', 'D-688\t-0.5205078125\t1A, Clă direa C1, Etaj 3 Sector 1, Bucureş ti, România', 'P-688\t-0.1521 -0.0327 -0.0379 -1.7725 -0.0141 -0.0113 -0.0282 -0.0338 -0.0282 -0.5171 -0.0775 -0.0183 -0.0155 -0.0352 -0.0225 -0.0155 -0.0268 -0.0296 -0.0732 -0.0395 -0.0760 -0.1240 -0.0113 -0.0338 -0.3804 -0.0282 -0.0113 -0.1973', 'S-675\tDuoTrav wird zur Senkung des Augeninnendrucks (der auf der Augeninnenwand lastende Druck) eingesetzt.', 'T-675\tDuoTrav is used to reduce intraocular pressure (IOP, the pressure inside the eye).', 'H-675\t-0.599609375\tDuoTrav is used to reduce intraocular pressure ( pressure inside the eye ) .', 'D-675\t-0.599609375\tDuoTrav is used to reduce intraocular pressure (pressure inside the eye).', 'P-675\t-0.3745 -0.0229 -0.0197 -0.0211 -0.0507 -0.5508 -0.0958 -0.1859 -0.9468 -0.4128 -0.0155 -0.0268 -0.0324 -0.0352 -0.2296 -0.3213 -0.0451 -0.0986 -0.1747 -0.0366 -0.0282', 'S-514\tWenn eine gleichzeitige Behandlung mit Vitamin K Antagonisten erforderlich ist, müssen die Angaben in Abschnitt 4.5 beachtet werden.', 'T-514\ttherapy with vitamin K antagonist should be administered in accordance with the information of Section 4.5.', 'H-514\t-0.89111328125\tWhen required , concomitant therapy with vitamin K antagonists should be administered in accordance with the information of Section 4.5 .', 'D-514\t-0.89111328125\tWhen required, concomitant therapy with vitamin K antagonists should be administered in accordance with the information of Section 4.5.', 'P-514\t-0.5273 -0.3435 -0.2352 -0.2981 -0.2556 -0.0113 -0.0324 -0.4072 -0.0479 -0.0564 -0.0183 -0.0282 -0.2537 -0.0127 -0.2607 -1.5762 -0.1635 -0.3438 -0.0169 -0.2001 -0.1353 -0.0254 -0.0338 -0.2847 -0.2593 -0.6650 -0.4902 -0.0169 -0.0225 -0.0282 -0.0507 -0.0282', 'S-511\tInsulin Human Winthrop Comb 50 ist eine Flüssigkeit (Suspension) zum Spritzen unter die Haut.', 'T-511\tInsulin Human Winthrop Comb 50 is a fluid (suspension) for injection under the skin.', 'H-511\t-0.1922607421875\tInsulin Human Winthrop Comb 50 is a fluid ( suspension ) for injection under the skin .', 'D-511\t-0.1922607421875\tInsulin Human Winthrop Comb 50 is a fluid (suspension) for injection under the skin.', 'P-511\t-0.0320 -0.0056 -0.0113 -0.0538 -0.0113 -0.0035 -0.0206 -0.0379 -0.0227 -0.0407 -0.0356 -0.0400 -0.2830 -0.0183 -0.0423 -0.0250 -0.0299 -0.1698 -0.0416 -0.1571 -0.1155 -0.0493 -0.0176 -0.0331 -0.0289', 'S-431\tIn-vivo-Studien ergaben keinen Hinweis auf eine Abspaltung der Furoatgruppe unter Bildung von Fluticason.', 'T-431\tIn vivo studies have revealed no evidence of cleavage of the furoate moiety to form fluticasone.', 'H-431\t-1.8330078125\tIn vivo studies have not produced any evidence of N @-@ dealkylation of fluticasone .', 'D-431\t-1.8330078125\tIn vivo studies have not produced any evidence of N-dealkylation of fluticasone.', 'P-431\t-0.1655 -0.1328 -0.0113 -0.0407 -1.9160 -0.2043 -1.1016 -0.1353 -0.7637 -0.5469 -1.4004 -0.1635 -1.1494 -0.3213 -0.3213 -0.3101 -0.4001 -0.2874 -0.0225 -0.0225 -0.0169 -2.5586 -0.0338', 'S-360\tDaher ist eine sexuelle Stimulation nötig, damit Sildenafil den beabsichtigten günstigen pharmakologischen Effekt entwickeln kann.', 'T-360\tTherefore sexual stimulation is required in order for sildenafil to produce its intended beneficial pharmacological effects.', 'H-360\t-0.85302734375\tSexual stimulation is therefore required for sildenafil to produce its beneficial pharmacological effects .', 'D-360\t-0.85302734375\tSexual stimulation is therefore required for sildenafil to produce its beneficial pharmacological effects.', 'P-360\t-0.2627 -0.0185 -0.0085 -0.0199 -0.0414 -0.5571 -1.0137 -1.1895 -0.2507 -0.0169 -0.0113 -0.0197 -0.0310 -0.3157 -0.3860 -0.3662 -0.0141 -0.0395 -0.2113 -0.5327 -0.1183 -0.0282', 'S-1623\tIn klinischen Studien trat bei jedem fünften Patienten eine Hypoglykämie auf, die eine Unterstützung bei der Behandlung erforderte.', 'T-1623\tTaking too much or too little Monotard may cause respectively hypo or hyperglycaemia.', 'H-1623\t-1.3212890625\tIn clinical trials , 1 in 5 patients experienced hypoglycaemia requiring treatment support .', 'D-1623\t-1.3212890625\tIn clinical trials, 1 in 5 patients experienced hypoglycaemia requiring treatment support.', 'P-1623\t-0.5630 -0.0257 -0.6567 -0.3904 -1.1865 -0.4946 -0.0366 -0.3833 -1.5752 -0.0197 -0.0197 -0.0141 -0.2986 -0.0592 -0.0282 -0.8369 -0.2761 -1.0430 -0.0338 -0.0282', 'S-1329\tDer vorgefüllte PegIntron-Injektor darf nur von einer Person und nicht von mehreren Personen gemeinsam verwendet werden.', 'T-1329\tThe PegIntron pre-filled pen should be used by one person only and must not be shared.', 'H-1329\t-0.72119140625\tThe PegIntron pre @-@ filled pen should be used by one person only and must not be shared .', 'D-1329\t-0.72119140625\tThe PegIntron pre-filled pen should be used by one person only and must not be shared.', 'P-1329\t-0.3013 -0.3171 -0.0243 -0.0250 -0.0141 -0.0243 -0.2976 -0.0268 -0.0366 -0.3220 -0.3042 -0.5591 -0.2776 -0.1268 -0.4592 -0.0366 -0.1663 -0.3157 -0.5239 -0.0310 -0.0310 -0.2113 -0.3916 -0.0310', 'S-1848\tHBVAXPRO recombinant Hepatitis B virus small surface antigen (HbsAg) Part A', 'T-1848\tHBVAXPRO recombinant Hepatitis B virus small surface', 'H-1848\t-0.484375\tHBVAXPRO recombinant hepatitis B', 'D-1848\t-0.484375\tHBVAXPRO recombinant hepatitis B', 'P-1848\t-0.0071 -0.0227 -0.0277 -0.0184 -0.0113 -0.0227 -0.0931 -0.0185 -0.0127 -0.0220 -0.1206 -0.0099 -0.0127 -0.0197 -2.0410', 'S-295\t- Patienten, die Zevalin als Monotherapie erhalten, mit Thrombozytenzahlen < 100.000 / mm3', 'T-295\t- patients receiving Zevalin as monotherapy with platelet counts < 100,000 / mm3 and patients', 'H-295\t-0.5146484375\t- Patients receiving Zevalin monotherapy with platelet counts &lt; 100,000 / mm3', 'D-295\t-0.5146484375\t- Patients receiving Zevalin monotherapy with platelet counts < 100,000 / mm3', 'P-295\t-0.2485 -0.5947 -0.0218 -0.4973 -0.0901 -0.0070 -0.0211 -0.0296 -1.1240 -0.0366 -0.0225 -0.1381 -0.1155 -0.0141 -0.0338 -0.0648 -0.0873 -0.0141 -0.0225 -0.1691 -0.0310 -0.0141 -0.0282 -0.0366', 'S-153\tÜberprüfen Sie anhand des Etiketts, ob Actraphane 10 NovoLet den richtigen Insulintyp enthält.', 'T-153\tCheck the label to make sure that your Actraphane 10 NovoLet contains the correct type of insulin.', 'H-153\t-0.317138671875\tCheck the label to make sure that your Actraphane 10 NovoLet contains the correct type of insulin .', 'D-153\t-0.317138671875\tCheck the label to make sure that your Actraphane 10 NovoLet contains the correct type of insulin.', 'P-153\t-0.1537 -0.1886 -0.0127 -0.1036 -0.4585 -0.0211 -0.1360 -0.3206 -0.0521 -0.0169 -0.0099 -0.0099 -0.0310 -0.0183 -0.0169 -0.0380 -0.0437 -0.0310 -0.1705 -0.2339 -0.0282 -0.0099 -0.0197 -0.0338 -0.0296', 'S-139\tIm Fall einer Überdosierung ist sofort eine symptomatische und supportive Therapie einzuleiten und so lange wie erforderlich fortzuführen.', 'T-139\tIn the event of overdose, start symptomatic and supportive treatment immediately and maintain it for as long as necessary.', 'H-139\t-0.96240234375\tIn the event of an overdose , start symptomatic and supportive treatment immediately and maintain it for as long as necessary .', 'D-139\t-0.96240234375\tIn the event of an overdose, start symptomatic and supportive treatment immediately and maintain it for as long as necessary.', 'P-139\t-0.2703 -0.5518 -0.1592 -0.0289 -1.1768 -0.0197 -0.0183 -0.1254 -1.3867 -0.1831 -0.0141 -0.0169 -0.0395 -0.0113 -0.7437 -0.4087 -0.5239 -0.3635 -0.1240 -0.1691 -0.0282 -0.0282 -0.0282 -0.3213 -0.0282 -0.0282', 'S-1770\tBei zweimaliger Gabe pro Tag wird nach 2 <unk> 3 Dosisgaben ein stabiler Zustand der Serumkonzentration erreicht.', 'T-1770\tWhen administered twice daily, steady state serum concentrations are reached after 2-3 dose administrations.', 'H-1770\t-1.3212890625\tIf administered twice daily , steady serum concentrations are reached after 2 to 3 dose administrations .', 'D-1770\t-1.3212890625\tIf administered twice daily, steady serum concentrations are reached after 2 to 3 dose administrations.', 'P-1770\t-0.4114 -0.3049 -0.0169 -0.1388 -0.6592 -0.0521 -0.5718 -0.2563 -0.0282 -1.1328 -0.0169 -0.0169 -0.4846 -1.1641 -0.6226 -0.3833 -1.5049 -0.0282 -0.3945 -0.2930 -0.1240 -0.0338 -0.0282', 'S-1475\tResorption Die Resorption von Rivastigmin aus den Exelon transdermalen Pflastern verläuft langsam.', 'T-1475\tAbsorption Absorption of rivastigmine from Exelon transdermal patches is slow.', 'H-1475\t-0.2210693359375\tAbsorption Absorption of rivastigmine from Exelon transdermal patches is slow .', 'D-1475\t-0.2210693359375\tAbsorption Absorption of rivastigmine from Exelon transdermal patches is slow.', 'P-1475\t-0.3013 -0.0063 -0.0269 -0.3213 -0.0049 -0.0190 -0.0528 -0.0169 -0.0085 -0.0197 -0.0388 -0.0521 -0.2036 -0.0183 -0.0254 -0.0451 -0.0113 -0.0092 -0.0240 -0.0183 -0.1148 -0.0740 -0.0472 -0.0282', 'S-1097\tInsgesamt wurden 1.323 Patienten (879 in der mit Wirkstoff behandelten Gruppe und 444 in der Kontrollgruppe) eingeschlossen.', 'T-1097\tA total of 1,323 patients (879 active and 444 control) were enrolled in these studies.', 'H-1097\t-1.00390625\tA total of 1,323 patients ( 879 in the active @-@ controlled group and 444 in the control group ) were included .', 'D-1097\t-1.00390625\tA total of 1,323 patients (879 in the active-controlled group and 444 in the control group) were included.', 'P-1097\t-0.6196 -0.0218 -0.0278 -0.9536 -0.0268 -0.0211 -0.0310 -0.5015 -0.0296 -0.0113 -0.4678 -0.0395 -1.3008 -0.9385 -0.3213 -0.0704 -0.0535 -0.0282 -0.0197 -0.0282 -0.0310 -0.3972 -0.0282 -0.0282 -0.0451 -1.1162 -0.2255 -0.0282', 'S-1048\tDie Dosis sollte einmal wöchentlich 0,8 mg / kg Körpergewicht (bis zu einer Maximaldosis von 50 mg) betragen.', 'T-1048\tThe dose should be 0.8 mg / kg (up to a maximum of 50 mg per dose) once weekly.', 'H-1048\t-0.52392578125\tThe dose should be 0.8 mg / kg body weight once a week ( up to a maximum of 50 mg ) .', 'D-1048\t-0.52392578125\tThe dose should be 0.8 mg / kg body weight once a week (up to a maximum of 50 mg).', 'P-1048\t-0.3518 -0.2520 -0.0532 -0.0504 -0.0958 -0.0500 -0.0113 -0.0521 -0.0155 -0.4670 -0.0176 -0.1528 -0.3804 -0.0240 -0.0352 -0.0578 -0.0282 -0.3113 -0.0225 -1.0371 -0.0366 -0.0113 -0.0366 -0.0338 -0.0282', 'S-70\tDie Spezifitätsschätzwerte lagen alle über 90% mit entsprechenden unteren Konfidenzgrenzen im Bereich von 85% bis 90%.', 'T-70\tThe specificity estimates were all above 90% with corresponding lower confidence limits ranging from 85% to 90%.', 'H-70\t-1.4697265625\tThe specificity estimates have all been maintained above 90 % with the corresponding lower confidence limits ranging from 85 % to 90 % .', 'D-70\t-1.4697265625\tThe specificity estimates have all been maintained above 90% with the corresponding lower confidence limits ranging from 85% to 90%.', 'P-70\t-2.8535 -0.0521 -0.0169 -0.2423 -1.7158 -0.7129 -0.0732 -0.8765 -0.1691 -0.0395 -0.0338 -0.6538 -1.4092 -0.4790 -0.0225 -0.0507 -0.0564 -0.3550 -0.2367 -0.0789 -0.0169 -0.3269 -0.0395 -0.0169 -0.0282 -0.0282 -0.0282', 'S-1354\tIst die Verträglichkeit bei einem Patienten gesichert, kann die Infusionsrate bei den nachfolgenden Infusionen allmählich erhöht werden.', 'T-1354\tAfter patient tolerance is established, the infusion rate may be increased gradually with subsequent infusions.', 'H-1354\t-1.90625\tIf safety and efficacy have been established in one patient , the infusion rate may gradually be increased during subsequent infusions .', 'D-1354\t-1.90625\tIf safety and efficacy have been established in one patient, the infusion rate may gradually be increased during subsequent infusions.', 'P-1354\t-0.6948 -0.9648 -1.7275 -1.0342 -0.0085 -0.0113 -0.8423 -0.0338 -0.4058 -0.7129 -0.5859 -0.0395 -0.3718 -0.1747 -0.6084 -0.0169 -0.3777 -1.2402 -0.9526 -0.1240 -0.0507 -2.2871 -0.3945 -0.3042 -0.0225 -0.0225 -0.0338 -0.0338', 'S-536\tBitte seien Sie vorsichtig und verwechseln Ihr Seretide Inhalationsgerät nicht mit dem Inhalationsgerät für die Akutbehandlung.', 'T-536\tBe careful not to confuse your Seretide inhaler with your <<unk>> rescue <<unk>> inhaler.', 'H-536\t-0.60107421875\tBe careful not to confuse your Seretide inhaler with your &apos; rescue &quot; inhaler .', 'D-536\t-0.60107421875\tBe careful not to confuse your Seretide inhaler with your \'rescue "inhaler.', 'P-536\t-0.4187 -0.2279 -0.2507 -0.0254 -0.1198 -0.0197 -0.1205 -0.3064 -0.0324 -0.0634 -0.0592 -0.2803 -0.1155 -0.3030 -0.3650 -0.3213 -0.3240 -0.0338 -0.2339 -0.0845 -0.0310', 'S-12\tProfender Tabletten sind mit Fleisch-Geschmackstoffen versetzt und werden normalerweise von Hunden ohne zusätzliches Futter gut akzeptiert.', 'T-12\tProfender tablets are meat flavoured and usually dogs will accept them without any food.', 'H-12\t-1.1611328125\tProfender tablets are reconstituted with meats flavours and are usually well accepted by dogs without additional food .', 'D-12\t-1.1611328125\tProfender tablets are reconstituted with meats flavours and are usually well accepted by dogs without additional food.', 'P-12\t-0.2467 -0.0560 -0.0357 -0.0229 -0.0416 -0.9209 -0.1085 -0.0176 -0.0338 -0.8735 -0.2367 -0.3254 -0.4028 -0.2057 -0.2227 -0.6958 -1.2627 -0.1183 -0.1014 -0.0395 -0.0225 -0.1747 -1.6455 -0.3269 -0.0338 -0.0282', 'S-382\teingereichten Anträge zu erleichtern, wurden Standardarbeitsanweisungen zur Verbesserung der Bearbeitungsverfahren anhand der bisherigen Erfahrungen erarbeitet.', 'T-382\tprocessing of applications submitted the EMEA, standard operational procedures have been developed to', 'H-382\t-1.310546875\tThe first guideline covers pre @-@ authorisation 2 4 EMEA Annual Report 2001', 'D-382\t-1.310546875\tThe first guideline covers pre-authorisation 2 4 EMEA Annual Report 2001', 'P-382\t-1.2549 -1.5557 -0.6001 -0.0789 -0.0282 -0.3325 -0.6479 -0.0310 -0.3411 -0.1831 -0.4114 -0.3411 -0.3269 -0.3213 -0.0395 -0.3269 -0.0169 -0.2874 -0.3494 -0.4338', 'S-1483\tWie bei anderen Impfstoffen sollte die Entnahme der erforderlichen Impfstoffmenge unter strengen aseptischen Verhältnissen und, zur itte', 'T-1483\tAs with other vaccines, a dose of vaccine should be withdrawn under', 'H-1483\t-1.2529296875\tAs with other vaccines , a dose of the vaccine should be withdrawn under strict pregnancy prevention measures .', 'D-1483\t-1.2529296875\tAs with other vaccines, a dose of the vaccine should be withdrawn under strict pregnancy prevention measures.', 'P-1483\t-0.0856 -0.0568 -0.0679 -0.0206 -0.0185 -0.6284 -1.5908 -0.4028 -0.0873 -0.8906 -0.1803 -0.6113 -0.0366 -0.2959 -0.0310 -0.2085 -0.1521 -0.7046 -0.3213 -0.0620 -0.3889 -1.3525 -0.0282', 'S-1160\tMöglicherweise muss nach Beginn der Behandlung mit Somatropin die Insulintherapie neu eingestellt bzw. mit einer Insulintherapie begonnen werden.', 'T-1160\tto be adjusted or started after somatropin therapy is initiated.', 'H-1160\t-1.447265625\tInsulin therapy may require adjustment or initiation of insulin therapy after treatment with somatropin .', 'D-1160\t-1.447265625\tInsulin therapy may require adjustment or initiation of insulin therapy after treatment with somatropin.', 'P-1160\t-1.9639 -0.0099 -0.0127 -0.0338 -0.0845 -1.7559 -0.3325 -0.1099 -0.0507 -0.9551 -1.7080 -0.0395 -0.0338 -0.0225 -0.0169 -0.0338 -1.4141 -0.8003 -0.0451 -0.1521 -0.0225 -0.0169 -0.0338 -0.3101 -0.0282', 'S-1024\tEinzeldosen von bis zu 1.200 mg sind von gesunden Probanden ohne unerwünschte symptomatische Wirkungen eingenommen worden.', 'T-1024\tAt high doses that lead to', 'H-1024\t-0.81298828125\tSingle doses up to 1,200 mg have been taken by healthy subjects without adverse symptomatic effects .', 'D-1024\t-0.81298828125\tSingle doses up to 1,200 mg have been taken by healthy subjects without adverse symptomatic effects.', 'P-1024\t-0.5811 -0.0299 -0.0190 -1.0020 -0.0282 -0.8789 -0.0338 -0.0183 -0.1803 -0.0268 -0.0986 -0.0592 -0.0282 -0.4114 -0.7974 -0.7554 -0.0254 -0.2197 -0.0310 -0.0169 -0.0338 -0.0310 -0.0282', 'S-436\tANGABEN IN BLINDENSCHRIFT än Dynepo 8000 tl ch ni el itt m ei zn Ar', 'T-436\tDynepo 8000', 'H-436\t-0.92578125\tDynepo 6000', 'D-436\t-0.92578125\tDynepo 6000', 'P-436\t-0.3223 -0.0220 -0.0185 -1.7441 -0.3228', 'S-1524\tDiese Stärken sind als Blisterpackungen mit 28, 56, 112, 3 x 112 oder 360 Filmtabletten erhältlich.', 'T-1524\tThese strengths are supplied in blister packs containing 28, 56, 112, 3x112 or 360 film-coated tablets.', 'H-1524\t-0.64794921875\tThey are available in blister packs containing 28 , 56 , 112 , 3 x 112 or 360 film @-@ coated tablets .', 'D-1524\t-0.64794921875\tThey are available in blister packs containing 28, 56, 112, 3 x 112 or 360 film-coated tablets.', 'P-1524\t-0.4358 -0.3264 -0.0472 -0.1353 -0.0380 -1.0898 -0.0916 -0.0127 -0.3157 -0.0437 -0.0310 -0.0141 -0.0296 -0.0113 -0.0296 -0.4226 -0.0395 -0.0141 -0.4902 -0.0085 -0.3804 -0.3213 -0.3213 -0.0169 -0.0310 -0.0254 -0.0338 -0.0282', 'S-967\tDabei handelt es sich zu einem Großteil um Sachverständige für die Beurteilung von Humanarzneimitteln (siehe Abschnitt 5.3).', 'T-967\tThe workload arising from these priorities can be seen in the increase in meeting days forecast for 2002 and also in the significant rise in the number of reimbursed delegates expected in 2002, a significant number of which are experts for the evaluation of medicines for human use (see Section 5.3).', 'H-967\t-1.0556640625\tMost of these experts are experts in the assessment of medicines for human use ( see section 5.3 ) .', 'D-967\t-1.0556640625\tMost of these experts are experts in the assessment of medicines for human use (see section 5.3).', 'P-967\t-0.9707 -0.6890 -0.2057 -0.8174 -0.8228 -0.1324 -0.9805 -0.2423 -0.8789 -0.0310 -0.0338 -0.6201 -0.0395 -0.0169 -0.0225 -0.0338 -0.0395 -0.1803 -0.0282 -0.0282 -0.0507 -0.0338 -0.0282', 'S-793\tEntsprechend sollte vor der Behandlung mit Onsior eine behandlungsfreie Periode mit solchenSubstanzen von mindestens 24 Stunden eingehalten werden.', 'T-793\tPre-treatment with other anti- inflammatory medicines may result in additional or increased adverse effects and accordingly a treatment-free period with such substances should be observed for at least 24 hours before the commencement of treatment with Onsior.', 'H-793\t-1.0732421875\tPre @-@ treatment with Onsior a treatment @-@ free period with such substances should be observed for at least 24 hours .', 'D-793\t-1.0732421875\tPre-treatment with Onsior a treatment-free period with such substances should be observed for at least 24 hours.', 'P-793\t-0.3384 -0.2568 -0.0581 -0.0402 -0.0602 -1.1611 -0.0225 -0.0254 -2.0215 -0.1268 -0.0760 -0.0310 -0.0507 -0.3269 -0.1155 -0.8115 -0.0169 -0.4058 -0.1691 -0.4001 -0.2593 -0.1296 -0.0282 -0.0225 -0.0282 -0.7383 -0.0282', 'S-368\tIn diesem Fall soll die Dosierung durch Verlängerung des Zeitintervalls zwischen den Dosen angepasst werden, wie in Tabelle 1 beschrieben.', 'T-368\tIf use of the oral solution is not possible, Sebivo film-coated tablets could be used as an alternative and dosing should be adjusted by increasing the time interval between doses, as detailed in Table 1.', 'H-368\t-1.0869140625\tIn this case , the dose should be adjusted by extending the interval between doses as described in Table 1 .', 'D-368\t-1.0869140625\tIn this case, the dose should be adjusted by extending the interval between doses as described in Table 1.', 'P-368\t-0.8179 -0.4028 -0.0310 -0.3657 -0.2944 -1.1426 -0.1071 -0.0282 -0.4846 -0.2141 -0.9019 -0.0282 -0.1803 -0.8398 -0.0225 -0.0901 -0.0789 -0.0169 -0.3889 -0.8398 -0.0338 -0.1014 -0.0282 -0.0338 -0.0282', 'S-1608\tMaisstärke, Povidon (E 1201), Crospovidon (E 1202), Talkum', 'T-1608\t- The other ingredients are: maize starch, povidone (E1201), crospovidone (E1202), talc (E553b),', 'H-1608\t-0.490966796875\tMaize starch , Povidone ( E1201 ) , Crospovidone ( E1202 ) , Talc', 'D-1608\t-0.490966796875\tMaize starch, Povidone (E1201), Crospovidone (E1202), Talc', 'P-1608\t-1.1523 -0.0113 -0.1620 -0.0155 -0.0289 -0.8701 -0.0225 -0.0676 -0.0296 -0.3184 -0.0225 -0.0183 -0.0296 -0.0296 -0.0282 -0.1945 -0.0254 -0.0282 -0.0282 -0.0282 -0.1240 -0.0225 -0.0169 -0.0254 -0.0282 -0.0282 -0.0366 -0.1099 -0.2001', 'S-1000\tEin neu auftretendes nephrotisches Syndrom wurde bei 2% der Patienten festgestellt (siehe Abschnitt 4.8).', 'T-1000\tNew onset nephrosis (nephrotic syndrome) was also reported in 2% of the patients in the study (see section 4.8).', 'H-1000\t-0.89111328125\tNot recommended combinations : new onset nephrotic syndrome was observed in 2 % of patients ( see section 4.8 ) .', 'D-1000\t-0.89111328125\tNot recommended combinations: new onset nephrotic syndrome was observed in 2% of patients (see section 4.8).', 'P-1000\t-0.6523 -0.4663 -0.4170 -0.2197 -0.0240 -0.3789 -0.3662 -0.6934 -0.0479 -0.1183 -0.0056 -0.0197 -0.0225 -0.0423 -0.0225 -0.1014 -1.5840 -0.0395 -0.0507 -0.0310 -0.4255 -0.7354 -0.0395 -0.0451 -0.1521 -0.0225 -0.0282 -0.0395 -0.0395 -0.0282', 'S-1207\tmit 1 x 30 ml (1 ml Schritte) vorgefülltem Injektor (Ibaflin 7,5% zur oralen', 'T-1207\t- carton box with 1 x 30 ml (1 ml steps) pre-filled syringe (Ibaflin 7.5% Oral Gel)', 'H-1207\t-0.64990234375\t- carton box with 1 x 30 ml ( 1 ml steps ) pre @-@ filled syringe ( Ibaflin 7.5 % Oral Gel )', 'D-1207\t-0.64990234375\t- carton box with 1 x 30 ml (1 ml steps) pre-filled syringe (Ibaflin 7.5% Oral Gel)', 'P-1207\t-0.3542 -0.3755 -0.3169 -0.3535 -0.1676 -0.0493 -0.0451 -0.0380 -0.0225 -0.0648 -0.1099 -0.0240 -0.0493 -0.0310 -0.1564 -0.0352 -0.0268 -0.4509 -0.8960 -0.0056 -0.0958 -0.1550 -0.0338 -0.0225 -0.0760 -0.1099 -0.0282 -0.3213 -0.0085 -0.3240 -0.1803 -0.2423 -0.1240', 'S-478\tTests der Schilddrüsenfunktion sind zu Beginn und bei abnormen Werten alle 6 - 12 Monate nach Therapiebeginn zu empfehlen.', 'T-478\tThyroid function testing is recommended at baseline and if abnormal, every 6-12 months following initiation of therapy.', 'H-478\t-1.6650390625\tTesting of thyroid function is recommended every 6 @-@ 12 months after initiation of therapy if abnormal values occur .', 'D-478\t-1.6650390625\tTesting of thyroid function is recommended every 6-12 months after initiation of therapy if abnormal values occur.', 'P-478\t-0.7627 -0.0402 -0.0768 -0.2430 -0.0218 -0.0113 -0.0197 -0.0211 -0.0824 -0.0486 -0.6924 -0.0423 -0.2100 -0.0240 -0.0282 -0.7158 -1.8994 -0.3550 -0.0817 -0.8960 -1.3408 -2.0625 -0.4902 -1.2061 -0.5859 -0.0338 -0.0338', 'S-353\tZwischenberichte zum Fortgang der Studie und zur Rekrutierung werden zusammen mit den jährlichen Bewertungsberichten / PSURs zur Verfügung gestellt.', 'T-353\tProgress and recruitment updates will be provided alongside the Annual Re-assessment / PSURs.', 'H-353\t-1.5078125\tSO2 004.2 All clinical trial patients are currently receiving the product manufactured by the commercial process .', 'D-353\t-1.5078125\tSO2 004.2 All clinical trial patients are currently receiving the product manufactured by the commercial process.', 'P-353\t-2.9258 -0.3213 -0.3325 -0.4875 -0.3213 -0.3240 -0.3240 -0.3071 -0.3352 -0.3748 -0.3945 -0.3550 -0.2930 -0.3213 -0.3213 -0.2930 -0.2930 -0.2705 -0.3438 -0.3213 -0.2705 -0.1014', 'S-1077\tBei allen mit Retacrit behandelten Patienten ist während des gesamten Behandlungszeitraums eine adäquate Eisensubstitution (z.B.', 'T-1077\t5 All patients being treated with Retacrit should receive adequate iron supplementation (e. g.', 'H-1077\t-0.8603515625\tAll patients being treated with Retacrit should receive adequate iron supplementation ( e. g .', 'D-1077\t-0.8603515625\tAll patients being treated with Retacrit should receive adequate iron supplementation (e. g.', 'P-1077\t-0.3030 -0.0444 -0.7085 -0.0183 -0.0331 -0.3748 -0.0338 -0.1296 -0.2974 -0.3030 -0.2296 -0.0831 -0.4395 -0.1155 -0.0197 -0.2227 -0.6226 -0.0423 -0.9775 -0.0282 -0.3184', 'S-1914\tDies trägt dazu bei, den Blutzucker nach den Mahlzeiten zu regeln, und dient der Einstellung von Patienten mit Typ 2- Diabetes.', 'T-1914\tThis helps to keep the blood glucose controlled after meals and is used to control type 2 diabetes.', 'H-1914\t-1.421875\tThe second , which did not compare Renagel with any', 'D-1914\t-1.421875\tThe second, which did not compare Renagel with any', 'P-1914\t-2.0527 -0.9961 -0.3550 -0.3240 -0.4424 -0.0901 -0.3718 -0.3411 -0.3550 -0.3213 -0.3127 -0.3438 -0.3213', 'S-1498\tBei der Untersuchung von Patienten mit Herzinsuffizienz sollte immer eine Beurteilung der Nierenfunktion durchgeführt werden (siehe Abschnitt 4.2).', 'T-1498\tEvaluation of patients with heart failure should always include assessment of renal function (see section 4.2).', 'H-1498\t-0.818359375\tEvaluation of post @-@ marketing patients should always include assessment of renal function ( see section 4.2 ) .', 'D-1498\t-0.818359375\tEvaluation of post-marketing patients should always include assessment of renal function (see section 4.2).', 'P-1498\t-0.3303 -0.1097 -0.0313 -1.2852 -0.2649 -0.3987 -0.6455 -0.5918 -0.0564 -0.3945 -0.3101 -0.0338 -0.2057 -0.0225 -0.0254 -0.2791 -0.0479 -0.1747 -0.0254 -0.0282 -0.0395 -0.0395 -0.0310', 'S-1029\tEs stehen begrenzte pharmakokinetische Daten für hypertensive Kinder im Alter von über einem Monat zur Verfügung (siehe 5.2:', 'T-1029\tLimited pharmacokinetic data are available in hypertensive children above one month of age (see 5.2:', 'H-1029\t-0.87841796875\tLimited pharmacokinetic data are available for hypertensive children over one month of age ( see 5.2 :', 'D-1029\t-0.87841796875\tLimited pharmacokinetic data are available for hypertensive children over one month of age (see 5.2:', 'P-1029\t-0.9595 -0.0275 -0.0085 -0.0085 -0.0345 -0.0254 -0.9707 -0.0352 -1.0273 -0.0254 -0.0225 -0.0254 -0.5776 -0.8818 -0.4338 -0.0395 -0.1099 -0.0254 -0.0338 -0.0310 -0.3833 -0.0282 -0.1691 -0.0282', 'S-1251\tEtwa die Hälfte der Studienpopulation wies in der Anamnese mindestens zwei der kardiovaskulären Einschlusskriterien auf.', 'T-1251\tApproximately half of the study population had at least two of the cardiovascular history entry criteria.', 'H-1251\t-0.93603515625\tAbout half of the study population had at least two of the cardiovascular inclusion criteria in patients &quot; histories .', 'D-1251\t-0.93603515625\tAbout half of the study population had at least two of the cardiovascular inclusion criteria in patients "histories.', 'P-1251\t-1.5117 -0.0366 -0.0676 -0.0324 -0.4312 -0.0352 -0.3904 -0.3042 -0.0197 -0.0338 -0.1465 -0.4114 -0.5522 -0.0141 -0.0169 -0.0113 -0.0958 -0.0310 -0.0423 -0.5298 -0.4932 -0.9355 -0.3606 -0.0451 -0.0338 -0.0282', 'S-1334\tAdvexin hätte die Krankheit heilen oder deren Fortschreiten verlangsamen sollen, indem die normale Schutzfunktion der Zellen wiederhergestellt wird.', 'T-1334\tAdvexin was expected to cure or slow down the disease by restoring the normal protective function of the cells.', 'H-1334\t-1.421875\tAdvexin was expected to cure the disease or slow the progression of the disease by re @-@ setting the cells &quot; normal protection .', 'D-1334\t-1.421875\tAdvexin was expected to cure the disease or slow the progression of the disease by re-setting the cells "normal protection.', 'P-1334\t-0.0953 -0.0213 -0.0291 -0.4358 -0.5562 -0.0282 -0.0669 -1.6807 -0.2903 -0.3213 -0.5269 -0.9185 -0.9468 -0.0282 -0.2986 -0.1296 -0.2197 -0.0564 -0.6987 -0.0282 -0.3213 -0.7666 -0.3157 -0.3438 -0.2649 -0.8735 -0.2085 -0.0282', 'S-373\tDarifenacin-Hydrobromid ist eine Substanz, welche die Aktivität einer überaktiven Harnblase verringert.', 'T-373\tDarifenacin hydrobromide is a substance which reduces the activity of an overactive bladder.', 'H-373\t-0.81005859375\tDarifenacin hydrobromide is a substance which reduces the activity of an overactive bladder .', 'D-373\t-0.81005859375\tDarifenacin hydrobromide is a substance which reduces the activity of an overactive bladder.', 'P-373\t-0.7041 -0.0113 -0.0028 -0.0215 -0.0261 -0.0542 -0.0127 -0.0141 -0.0218 -0.0345 -0.2296 -0.8623 -0.8862 -1.4072 -0.0225 -0.0366 -0.1973 -0.0310 -0.5552 -0.0310 -0.0197 -0.3325 -0.0085 -0.0338 -0.0310', 'S-1613\tStratifizierte Analysen nach dem Alter bei Kindern und Jugendlichen ergaben keinen Unterschied in den Effektgrößen zwischen diesen beiden Gruppen.', 'T-1613\tStratified analysis by age on children and adolescents indicated no difference in effect sizes between these two groups.', 'H-1613\t-1.2744140625\tStratified analyses based on age in children and adolescents revealed no difference in effect sizes between these two groups .', 'D-1613\t-1.2744140625\tStratified analyses based on age in children and adolescents revealed no difference in effect sizes between these two groups.', 'P-1613\t-2.4961 -0.0225 -0.0423 -0.1874 -0.0225 -0.8213 -0.0310 -0.0845 -0.3240 -0.0479 -0.0254 -0.0507 -0.0254 -0.0141 -2.0938 -0.0282 -0.0564 -0.2537 -0.9639 -0.1409 -0.0169 -0.0507 -1.2002 -0.0338 -0.1183 -0.0282 -0.0282', 'S-227\tDer behandelnde Tierarzt sollte bedenken, dass die allergischen Symptome nach Beendigung der symptomatischen Therapie wieder aufflammen können.', 'T-227\tVeterinarians should be aware that reappearance of the allergic symptoms may occur when symptomatic therapy is discontinued.', 'H-227\t-1.8037109375\tThe responsible veterinarian should take into account that allergic symptoms may start up after discontinuation of symptomatic therapy .', 'D-227\t-1.8037109375\tThe responsible veterinarian should take into account that allergic symptoms may start up after discontinuation of symptomatic therapy.', 'P-227\t-1.9385 -1.0371 -0.0395 -0.0507 -0.0141 -0.0366 -1.7861 -0.1465 -0.1409 -0.0930 -0.7637 -0.0169 -0.2311 -0.4395 -1.4424 -0.2986 -1.5107 -1.1611 -0.1071 -0.0282 -0.0282 -1.1104 -0.0113 -0.0225 -0.5073 -0.0338 -0.0338', 'S-1542\tTabelle 5 zeigt ausgewählte virologische, biochemische und serologische Verlaufsparameter und Tabelle 6 das histologische Ansprechen.', 'T-1542\tSelected virological, biochemical and serological outcome measures are shown in Table 5 and histological response in Table 6.', 'H-1542\t-0.9248046875\tTable 5 shows selected virological , biochemical and serological parameters and Table 6 shows histological response .', 'D-1542\t-0.9248046875\tTable 5 shows selected virological, biochemical and serological parameters and Table 6 shows histological response.', 'P-1542\t-0.7495 -0.0338 -0.7046 -0.1493 -0.1945 -0.0211 -0.3904 -0.0296 -0.0197 -0.0141 -0.5088 -0.0183 -0.1479 -0.6763 -0.0197 -0.0197 -0.0986 -0.5156 -0.0282 -0.8789 -0.5015 -0.2085 -0.3777 -0.0451 -0.0282', 'S-1632\tWAS IST LIPROLOG BASAL UND WOFÜR WIRD ES ANGEWENDET?', 'T-1632\tWHAT LIPROLOG Basal IS AND WHAT IT IS USED FOR', 'H-1632\t-0.52294921875\tWHAT LIPROLOG BASAL IS AND WHAT IT IS USED FOR', 'D-1632\t-0.52294921875\tWHAT LIPROLOG BASAL IS AND WHAT IT IS USED FOR', 'P-1632\t-0.0270 -0.0163 -0.3206 -0.0148 -0.0257 -0.0183 -0.0613 -0.9404 -0.0113 -0.1353 -0.1028 -0.2734 -0.0479 -0.1521 -0.3169 -0.0592 -0.1874 -0.0296 -0.1761 -0.0141 -0.3184', 'S-27\tDementsprechend wird eine Kontrolle der Nierenfunktion in regelmäßigen Abständen bei Patientinnen mit chronischer Niereninsuffizienz empfohlen.', 'T-27\tIn accordance with good medical practice, periodic assessment of renal function is recommended in patients with chronic renal impairment.', 'H-27\t-1.0986328125\tMonitoring of renal function on a regular basis is therefore recommended in chronic renal failure patients .', 'D-27\t-1.0986328125\tMonitoring of renal function on a regular basis is therefore recommended in chronic renal failure patients.', 'P-27\t-2.4316 -0.0127 -0.0225 -0.3086 -0.2029 -0.0254 -0.0197 -0.5352 -0.0338 -0.0395 -0.0254 -0.0901 -0.8765 -0.0338 -0.6592 -0.7412 -0.1240 -0.0169 -0.7324 -0.0338 -0.0282 -0.0282', 'S-315\ts • Informieren Sie Ihren Arzt, wenn Sie Träger des Hepatitis B-Virus (HBV) sind, wenn Sie eine', 'T-315\t• Advise your doctor if you have a history of recurrent infections or other conditions that increase the risk of infections.', 'H-315\t-1.0703125\td • Tell your doctor if you are a carrier of the hepatitis B virus ( HBV ) , if you suffer from liver', 'D-315\t-1.0703125\td • Tell your doctor if you are a carrier of the hepatitis B virus (HBV), if you suffer from liver', 'P-315\t-1.0527 -0.3352 -0.4001 -0.0127 -0.0493 -0.0578 -0.0366 -0.0268 -0.5029 -0.0690 -0.0535 -0.0282 -0.1268 -0.0718 -0.0056 -0.0127 -0.0197 -0.0141 -0.0296 -0.0113 -0.0225 -0.0282 -0.6704 -0.5835 -0.0282 -1.0088 -0.4763 -0.7129 -1.6289', 'S-742\tNelarabin wird nur in geringem Ausmaß (5 bis 10% der verwendeten Dosis) über die Nieren ausgeschieden.', 'T-742\tNelarabine is excreted by the kidney to a small extent (5 to 10% of the administered dose).', 'H-742\t-1.205078125\tNelarabine is excreted by the kidney only to a small extent ( 5 to 10 % of the administered dose ) .', 'D-742\t-1.205078125\tNelarabine is excreted by the kidney only to a small extent (5 to 10% of the administered dose).', 'P-742\t-0.3196 -0.0164 -0.0085 -0.0250 -0.0567 -0.8550 -0.0070 -0.0183 -2.2793 -0.0423 -0.0254 -0.8369 -0.7070 -0.2227 -0.0789 -0.7158 -0.0845 -0.0338 -0.2930 -0.6650 -0.0282 -0.0338 -0.0338 -0.1296 -1.5781 -0.0225 -0.0620 -0.0282 -0.0338 -0.0282', 'S-302\tEU / 1 / 00 / 135 / 001 (2,5 ml) EU / 1 / 00 / 135 / 002 (5.0 ml)', 'T-302\tEU / 1 / 00 / 135 / 001 (2.5 ml) EU / 1 / 00 / 135 / 002 (5.0 ml)', 'H-302\t-0.11871337890625\tEU / 1 / 00 / 135 / 001 ( 2.5 ml ) EU / 1 / 00 / 135 / 002 ( 5.0 ml )', 'D-302\t-0.11871337890625\tEU / 1 / 00 / 135 / 001 (2.5 ml) EU / 1 / 00 / 135 / 002 (5.0 ml)', 'P-302\t-0.0299 -0.0306 -0.0270 -0.0291 -0.0284 -0.0284 -0.0128 -0.0292 -0.0262 -0.0292 -0.0299 -0.1383 -0.0327 -0.0299 -0.0250 -0.0299 -0.0264 -0.0285 -0.0285 -0.0285 -0.0113 -0.0285 -0.0240 -0.0268 -0.0275 -0.0282 -0.0310 -0.0085 -0.0296 -0.0296', 'S-387\tLatvija Servier International Pā rstā vniecī ba Latvijā Tel: + 371 7502039', 'T-387\tLatvija Servier International Pā rstā vniecī ba Latvijā Tel: + 371 7502039', 'H-387\t-0.1861572265625\tLatvija Servier International Pā rstā vniecī ba Latvijā Tel : + 371 7502039', 'D-387\t-0.1861572265625\tLatvija Servier International Pā rstā vniecī ba Latvijā Tel: + 371 7502039', 'P-387\t-0.3135 -0.0400 -0.0157 -0.0176 -0.0356 -0.0243 -0.2402 -0.1740 -0.0366 -0.0197 -0.0197 -0.0430 -0.0176 -0.0218 -0.0056 -0.0085 -0.0155 -0.0155 -0.0373 -0.0070 -0.0838 -0.0493 -0.0218 -0.0254 -0.0099 -0.0275 -0.0225 -0.0218 -0.0169 -0.0444', 'S-1968\tJede Packung Convenia enthält zwei Durchstechflaschen, eine mit dem Pulver, und die andere mit dem Verdünnungsmittel.', 'T-1968\tThere are two vials in each pack of Convenia, one vial containing a powder, and one vial containing the diluent.', 'H-1968\t-0.78271484375\tEach pack of Convenia contains two vials , one of powder and the other of diluent .', 'D-1968\t-0.78271484375\tEach pack of Convenia contains two vials, one of powder and the other of diluent.', 'P-1968\t-0.2874 -0.3706 -0.0796 -0.1937 -0.0127 -0.0268 -0.2776 -0.0345 -0.3079 -0.3340 -0.0944 -0.0310 -0.9312 -0.2986 -0.0845 -0.4902 -0.0254 -0.7354 -0.2197 -0.1324 -0.0958 -0.0395 -0.0310', 'S-187\tInsgesamt gingen bei der EMEA 14 Anträge ein, darunter 4 Vollanträge und 10 Anträge auf Erweiterung auf andere Tierarten bzw.', 'T-187\tA total of 14 applications were received, including four full applications and 10 applications for extensions to other species 45 or modification to existing MRLs.', 'H-187\t-1.7939453125\tA total of 14 applications were made to the EMEA , including 4 applications for the establishment of MRLs and 10 for modification to new species or strengths .', 'D-187\t-1.7939453125\tA total of 14 applications were made to the EMEA, including 4 applications for the establishment of MRLs and 10 for modification to new species or strengths.', 'P-187\t-0.7578 -0.0211 -0.0282 -0.0331 -0.1670 -0.4099 -1.3076 -0.1550 -0.1183 -0.0310 -0.0169 -0.0254 -0.2734 -0.1127 -0.4846 -1.3721 -0.4902 -0.7495 -0.6143 -0.0620 -0.4846 -0.3777 -0.0676 -0.0845 -0.0395 -0.4226 -1.2119 -0.4058 -0.7607 -0.3325 -0.0789 -0.4846 -1.5781 -0.0113 -1.8037 -0.0225', 'S-680\t- Die sonstigen Bestandteile sind Sucrose (Saccharose), Natriumchlorid, Natriumcitrat,', 'T-680\t- The other ingredients are sucrose, sodium chloride, sodium citrate, citric acid, hydrochloric acid', 'H-680\t-0.51611328125\t- The other ingredients are sucrose , sodium chloride , sodium citrate ,', 'D-680\t-0.51611328125\t- The other ingredients are sucrose, sodium chloride, sodium citrate,', 'P-680\t-0.2203 -0.1639 -0.0546 -0.1606 -0.0613 -0.0740 -0.0077 -0.0085 -0.4270 -0.0451 -0.0085 -0.0359 -0.0183 -0.0183 -0.0240 -0.0359 -0.0845 -0.0085 -0.1803 -0.0141 -0.0564 -1.5889', 'S-1695\tWeitere Arbeitsgebiete sind die Handhabung der Sprachenvielfalt und diesbezügliche Programme, darunter die Standardisierung der Terminologie.', 'T-1695\tIssues relating to the management of multiple languages are being addressed and work on programs dealing with these issues, including standardisation of terminology, is ongoing.', 'H-1695\t-1.7958984375\t• Increase of number of video conferences to approximately 40 in 2003', 'D-1695\t-1.7958984375\t• Increase of number of video conferences to approximately 40 in 2003', 'P-1695\t-1.9727 -0.5103 -0.6509 -0.6567 -0.6172 -1.9219 -0.0620 -0.6030 -0.3213 -0.0901 -0.2479 -0.3606 -0.3213 -0.3833 -0.3213 -0.3269 -0.4678', 'S-1448\tWenn wir feststellen, daß das System von Anfang an erfolgreich war - und ich freue mich sagen zu können, daß dies in weiten Kreisen so gesehen wird', 'T-1448\tIf the new system has started well, and I am glad to say that is a widely held view, the credit should be shared by all those who have made a substantive contribution.', 'H-1448\t-2.06640625\tIf you have seen that the system proved successful from the beginning - and I am happy to say that this is widely accepted .', 'D-1448\t-2.06640625\tIf you have seen that the system proved successful from the beginning - and I am happy to say that this is widely accepted.', 'P-1448\t-0.7510 -0.7666 -1.1211 -0.8916 -0.1888 -1.2090 -0.1859 -1.6260 -0.7271 -0.1014 -0.0451 -0.8735 -1.3867 -0.0395 -0.0564 -0.1183 -0.2197 -0.0282 -0.0282 -0.1183 -0.8398 -0.0564 -1.4824 -0.3606 -1.3408 -0.0338', 'S-162\t27 bekannt ist, ist bei rund 1 von 100 Personen aufgetreten, die im Rahmen von klinischen Studien Ferriprox eingenommen haben.', 'T-162\tThis condition, known as severe neutropenia or agranulocytosis, has occurred in about 1 out of 100 people who have taken Ferriprox in clinical studies.', 'H-162\t-1.283203125\t24 , occurs in about 1 in 100 people who have taken Ferriprox in clinical studies .', 'D-162\t-1.283203125\t24, occurs in about 1 in 100 people who have taken Ferriprox in clinical studies.', 'P-162\t-1.7812 -0.3635 -0.6665 -0.2184 -0.0366 -1.0254 -0.0366 -0.7129 -0.5581 -0.0535 -0.7749 -0.4958 -0.1635 -0.0282 -0.0225 -0.0225 -0.0282 -0.2141 -0.0507 -0.8848 -0.0338 -0.0282', 'S-213\tDie Arbeitslast bei der Bearbeitung von Produktmängeln dürfte sich erhöhen, da von einer Erhöhung der Anzahl zugelassener Arzneimittel ausgegangen wird.', 'T-213\tQuality of Medicines (EDQM) will come into operation from the beginning of 2003', 'H-213\t-1.6796875\tThe workload for the processing of defective products is expected to increase due to the anticipated increase in the number of authorised products .', 'D-213\t-1.6796875\tThe workload for the processing of defective products is expected to increase due to the anticipated increase in the number of authorised products.', 'P-213\t-1.5947 -0.3987 -0.0240 -0.7031 -0.7197 -0.9409 -0.0282 -0.4424 -0.6763 -0.0676 -0.3777 -0.4790 -0.0282 -0.8115 -1.3584 -0.0282 -0.3606 -1.6006 -0.2817 -0.3157 -0.1014 -0.0338 -0.0282 -0.2649 -0.0338 -0.6201 -0.0451 -0.0338', 'S-1666\tDrücken Sie den vorgefüllten Injektor auf die Haut, um die Sicherheitshülse zu entriegeln. ge än tl', 'T-1666\tPress the pre-filled pen onto the sk in to unlock the safety guard.', 'H-1666\t-0.66162109375\tPress the pre @-@ filled pen onto the skin to unlock the safety guard .', 'D-1666\t-0.66162109375\tPress the pre-filled pen onto the skin to unlock the safety guard.', 'P-1666\t-1.0176 -0.1268 -0.3762 -0.0282 -0.0169 -0.3228 -0.2563 -0.2747 -0.0310 -0.1282 -0.0592 -0.0564 -0.0395 -0.1691 -0.5581 -0.1296 -0.0310', 'S-77\t11 anhaltendes Schreien über ≥ 3 Stunden innerhalb von 48 Stunden, Krämpfe mit oder ohne Fieber innerhalb von 3 Tagen.', 'T-77\tConvulsions with or without fever, occurring within 3 days.', 'H-77\t-1.2998046875\t11 prolonged crying ≥ 3 hours within 48 hours , convulsions with or without fever within 3 days .', 'D-77\t-1.2998046875\t11 prolonged crying ≥ 3 hours within 48 hours, convulsions with or without fever within 3 days.', 'P-77\t-2.0918 -1.1592 -0.0141 -0.0197 -0.2479 -1.2764 -0.0395 -0.0310 -0.6904 -0.0225 -0.0282 -0.3579 -0.9751 -0.0113 -0.0225 -0.9131 -0.0338 -0.0225 -0.2141 -0.0169 -0.4622 -0.0338 -0.0282 -0.2255 -0.0282', 'S-290\tAtazanavir kann mit PREZISTA bei gleichzeitiger Anwendung von 100 mg Ritonavir angewendet werden.', 'T-290\tAtazanavir can be used with PREZISTA co-administered with 100 mg ritonavir.', 'H-290\t-0.62158203125\tAtazanavir can be used with PREZISTA co @-@ administered with 100 mg ritonavir .', 'D-290\t-0.62158203125\tAtazanavir can be used with PREZISTA co-administered with 100 mg ritonavir.', 'P-290\t-0.9531 -0.0211 -0.0218 -0.0169 -0.0085 -0.0211 -0.7412 -0.0282 -0.6455 -0.0704 -0.0282 -0.0282 -0.0127 -0.0085 -0.6465 -0.0282 -0.2001 -0.0507 -0.0395 -0.1324 -0.0113 -0.6426 -0.0282 -0.0113 -0.0225 -0.0423 -0.0310', 'S-1454\tPegIntron wird einmal wöchentlich als Spritze unter die Haut (subkutane Injektion) verabreicht.', 'T-1454\tPegIntron is given once a week as a subcutaneous injection (under the skin).', 'H-1454\t-0.439453125\tPegIntron is given once a week as an injection under the skin ( subcutaneous injection ) .', 'D-1454\t-0.439453125\tPegIntron is given once a week as an injection under the skin (subcutaneous injection).', 'P-1454\t-0.2942 -0.0451 -0.0269 -0.0106 -0.0250 -0.0437 -0.2292 -0.3706 -0.3987 -0.0282 -0.5225 -0.1212 -0.0578 -0.0211 -0.0916 -0.0324 -0.0183 -0.0324 -0.6650 -0.0113 -0.0113 -0.0254 -0.0310 -0.0282 -0.0169 -0.0282 -0.0310 -0.0282', 'S-454\tDuoTrav enthält Benzalkoniumchlorid, das bekanntermaßen weiche Kontaktlinsen verfärbt.', 'T-454\tDuoTrav contains benzalkonium chloride which is known to discolour soft contact lenses.', 'H-454\t-0.2427978515625\tDuoTrav contains benzalkonium chloride , which is known to discolour soft contact lenses .', 'D-454\t-0.2427978515625\tDuoTrav contains benzalkonium chloride, which is known to discolour soft contact lenses.', 'P-454\t-0.0184 -0.0241 -0.0170 -0.0242 -0.0342 -0.0142 -0.1174 -0.0590 -0.2367 -0.0049 -0.0306 -0.0176 -0.0141 -0.0229 -0.2318 -0.0704 -0.0909 -0.0993 -0.0345 -0.1401 -0.0887 -0.2275 -0.0521 -0.0240 -0.0225 -0.0169 -0.0310 -0.0282', 'S-580\tDie Behandlung mit Ovitrelle sollte von einem Arzt ausgeführt werden, der in der Behandlung von Fruchtbarkeitsstörungen erfahren ist.', 'T-580\tTreatment with Ovitrelle should be carried out by a doctor who has experience in the treatment of fertility problems.', 'H-580\t-0.408935546875\tTreatment with Ovitrelle should be carried out by a doctor experienced in the treatment of fertility problems .', 'D-580\t-0.408935546875\tTreatment with Ovitrelle should be carried out by a doctor experienced in the treatment of fertility problems.', 'P-580\t-0.2952 -0.0178 -0.0255 -0.0458 -0.1022 -0.0099 -0.0292 -0.0106 -0.0500 -0.0306 -0.2152 -0.0254 -0.0310 -0.0437 -0.0746 -1.2139 -0.0338 -0.1578 -0.0338 -0.0296 -0.0746 -0.0197 -0.1917 -0.0310 -0.0296', 'S-116\tEs wurden keine Studien zu den Auswirkungen von ADENURIC auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen durchgeführt.', 'T-116\tDriving and using machines No studies on the effects of ADENURIC on the ability to drive and use machines have been performed.', 'H-116\t-0.6328125\tNo studies on the effects of ADENURIC on the ability to drive and use machines have been performed .', 'D-116\t-0.6328125\tNo studies on the effects of ADENURIC on the ability to drive and use machines have been performed.', 'P-116\t-0.2859 -0.0306 -0.6904 -0.0648 -0.1247 -0.4888 -0.0240 -0.0197 -0.0169 -0.0127 -0.0507 -0.2776 -0.2664 -0.0690 -0.2100 -0.4846 -0.3101 -0.2197 -0.1353 -0.0282 -0.2761 -0.0366 -0.0282', 'S-1149\tJedes Pflaster enthä lt 8,4 mg Testosteron und setzt über 24 Stunden 300 Mikrogramm Testosteron frei.', 'T-1149\tEach patch contains 8.4 mg of testosterone, releasing 300 micrograms of testosterone over 24 hours.', 'H-1149\t-0.4853515625\tEach patch contains 8.4 mg of testosterone and provides 300 micrograms of testosterone per 24 hours .', 'D-1149\t-0.4853515625\tEach patch contains 8.4 mg of testosterone and provides 300 micrograms of testosterone per 24 hours.', 'P-1149\t-0.0385 -0.0142 -0.0256 -0.0298 -0.0270 -0.0767 -0.0334 -1.0039 -0.0225 -0.0099 -0.0141 -0.0254 -0.1655 -0.5171 -0.0634 -0.0282 -0.0409 -0.1042 -0.0211 -0.0099 -0.0113 -0.0268 -0.8833 -0.2001 -0.0423 -0.0423 -0.0282', 'S-1290\tWichtige Informationen über bestimmte sonstige Bestandteile von INTELENCE INTELENCE Tabletten enthalten Lactose.', 'T-1290\tImportant information about some of the ingredients of INTELENCE INTELENCE tablets contain lactose.', 'H-1290\t-0.349853515625\tImportant information about some of the ingredients of INTELENCE INTELENCE tablets contain lactose .', 'D-1290\t-0.349853515625\tImportant information about some of the ingredients of INTELENCE INTELENCE tablets contain lactose.', 'P-1290\t-0.2576 -0.0127 -0.0241 -0.0870 -0.1775 -0.5518 -0.2959 -0.0359 -0.2847 -0.1240 -0.0662 -0.0268 -0.0183 -0.0225 -0.0099 -0.0648 -0.0268 -0.0169 -0.0225 -0.0099 -0.1226 -0.0240 -0.1818 -0.0197 -0.0099 -0.0155 -0.0437 -0.0296', 'S-1508\tGelb, länglich, mit Bruchkerbe und Prägung des Codes <unk> ucb <unk> und <unk> 500 <unk> auf einer Seite.', 'T-1508\tYellow, oblong, scored and debossed with the code <<unk>> ucb <<unk>> and <<unk>> 500 <<unk>> on one side.', 'H-1508\t-1.2626953125\tYellow , oblong , scored and debossed with the code &quot; UCB &quot; and &quot; 500 &quot; on one side .', 'D-1508\t-1.2626953125\tYellow, oblong, scored and debossed with the code "UCB" and "500" on one side.', 'P-1508\t-1.7686 -0.0099 -0.0535 -0.2690 -0.0099 -0.0676 -0.3228 -0.3030 -0.3411 -0.3213 -0.1071 -0.2227 -0.2930 -0.2959 -0.7607 -1.9102 -0.2367 -0.1183 -0.0395 -0.2874 -0.3157 -0.7495 -0.0451 -0.0564 -0.1521 -0.0395 -0.0282', 'S-1566\tBei gleichzeitiger Anwendung mit Hydrochlorthiazid ist für Febuxostat keine Dosisanpassung erforderlich.', 'T-1566\tNo dose adjustment is necessary for febuxostat when administered with hydrochlorothiazide.', 'H-1566\t-0.68603515625\tNo dose adjustment is necessary for febuxostat when co @-@ administered with hydrochlorothiazide .', 'D-1566\t-0.68603515625\tNo dose adjustment is necessary for febuxostat when co-administered with hydrochlorothiazide.', 'P-1566\t-0.4463 -0.8608 -0.0514 -0.0183 -0.0359 -0.0676 -0.6665 -0.0958 -0.2705 -0.1719 -0.0225 -0.0169 -0.0085 -0.0310 -0.2283 -1.5049 -0.0282 -0.2874 -0.0310 -0.0338 -0.0254 -0.0225 -0.0789 -0.1465 -0.0113 -0.0282 -0.0028 -0.0225 -0.0366 -0.0282', 'S-203\tÍsland SANOFI PASTEUR MSD Sími: + 32.2.726.95.84', 'T-203\tÍsland SANOFI PASTEUR MSD Sími: + 32.2.726.95.84', 'H-203\t-0.2327880859375\tÍsland SANOFI PASTEUR MSD Sími : + 32.2.726.95.84', 'D-203\t-0.2327880859375\tÍsland SANOFI PASTEUR MSD Sími: + 32.2.726.95.84', 'P-203\t-0.6118 -0.0250 -0.0356 -0.1074 -0.0155 -0.0261 -0.0268 -0.0268 -0.0437 -0.0345 -0.0141 -0.0183 -0.0514 -0.0275 -0.0155 -0.3359 -0.0437 -0.0070 -0.0296 -0.0282 -0.0395 -0.0197 -0.0225 -0.0338 -0.0324 -0.0211 -0.0211 -0.0099 -0.0310', 'S-253\tМилко Бичев "№ 7, ет .3 BG-София 1504', 'T-253\tМилко Бичев "№ 7, ет .3 BG-София 1504', 'H-253\t-1.05859375\tБилко Бичев &quot; № 7 , ет.3 BG @-@ София 1504', 'D-253\t-1.05859375\tБилко Бичев "№ 7, ет.3 BG-София 1504', 'P-253\t-1.8818 -0.9497 -0.0732 -0.3071 -0.3157 -0.3157 -0.1691 -0.3325 -0.1973 -0.3213 -0.0423 -0.0085 -0.0282 -0.0338 -0.3127 -1.2031 -0.1465 -0.0282 -0.0620 -0.0169 -0.0338 -0.0113 -0.2423 -0.3213 -0.2311 -0.3213 -0.0282 -0.0169 -0.0338', 'S-439\t- Ängstlichkeit; Depressionen; Ohrensausen; Verwirrtheit; Benommenheit; Unruhe; Zittern;', 'T-439\t- Anxiety, depression, tingling, confusion, dizziness, agitation, trembling, hallucinations and', 'H-439\t-0.9912109375\t- anxiety ; depression ; ringing in the ears ; confusion ; dizziness ; restlessness ;', 'D-439\t-0.9912109375\t- anxiety; depression; ringing in the ears; confusion; dizziness; restlessness;', 'P-439\t-0.0465 -0.6216 -0.6279 -0.0373 -0.4883 -0.1761 -0.0310 -0.2324 -0.3594 -0.0240 -0.0310 -0.0479 -0.0268 -0.9355 -0.0451 -0.0282 -0.0282 -0.7720 -0.0056 -0.0254 -0.4958 -1.2480', 'S-470\tDie verwendeten Spritzen sollten klein genug sein, um das Aufziehen der verordneten Dosis mit angemessener Genauigkeit zu ermöglichen.', 'T-470\tThe syringes should be of small enough volume that the prescribed dose can be withdrawn from the vial with reasonable accuracy.', 'H-470\t-1.1865234375\tThe syringes used should be small enough to ensure proper measurement of the prescribed dose .', 'D-470\t-1.1865234375\tThe syringes used should be small enough to ensure proper measurement of the prescribed dose.', 'P-470\t-0.6724 -0.2229 -0.0169 -0.0268 -0.8701 -0.0493 -0.0282 -0.1874 -0.0324 -1.1289 -0.7944 -1.6094 -0.6904 -0.0282 -0.0451 -0.0958 -0.0958 -0.3945 -0.0169 -0.1859 -0.3606 -0.0282', 'S-662\tWie bei anderen Arzneimitteln, die als subkutane Injektion gegeben werden, sollte die Injektionsstelle regelmäßig gewechselt werden.', 'T-662\tAs with other medicinal products administered by subcutaneous injection, the injection site should vary periodically.', 'H-662\t-1.052734375\tAs with other drugs taken as a subcutaneous injection , the site of injection should be changed regularly .', 'D-662\t-1.052734375\tAs with other drugs taken as a subcutaneous injection, the site of injection should be changed regularly.', 'P-662\t-0.3135 -0.3071 -0.0613 -0.9639 -1.5361 -0.8511 -0.1775 -0.0620 -0.0141 -0.0113 -0.0282 -0.0282 -0.0338 -0.0141 -0.3777 -0.0564 -1.0762 -0.3325 -0.1183 -0.0169 -0.0395 -0.0338 -0.7891 -0.1353 -0.0338 -0.0282', 'S-1017\tDie zusätzliche Gabe eines Diuretikums wie Hydrochlorothiazid senkt den Blutdruck bei diesen Patienten noch stärker.', 'T-1017\tThe addition of a diuretic such as hydrochlorothiazide will decrease blood pressure even further in these patients.', 'H-1017\t-0.77294921875\tAdding a diuretic such as hydrochlorothiazide reduces blood pressure to a greater degree in these patients .', 'D-1017\t-0.77294921875\tAdding a diuretic such as hydrochlorothiazide reduces blood pressure to a greater degree in these patients.', 'P-1017\t-0.6919 -0.6455 -0.4521 -0.0310 -0.0099 -0.0197 -0.2014 -0.0282 -0.0211 -0.0254 -0.0113 -0.0268 -0.0113 -0.0225 -0.0042 -0.0169 -0.9033 -0.0254 -0.3411 -0.0197 -0.8931 -0.2761 -0.1747 -0.5859 -0.0760 -0.2339 -0.0225 -0.0282 -0.0282', 'S-1716\tWährend einer gleichzeitigen Gabe besteht außerdem die Möglichkeit von pharmakodynamischen Wechselwirkungen wegen additiver renaler Wirkungen.', 'T-1716\tIn addition, there is a potential for a pharmacodynamic interaction to occur during co- administration due to additive renal effects.', 'H-1716\t-1.720703125\tDuring concomitant administration , there is also the potential of pharmacodynamic interactions due to additive renal effects .', 'D-1716\t-1.720703125\tDuring concomitant administration, there is also the potential of pharmacodynamic interactions due to additive renal effects.', 'P-1716\t-2.8594 -1.5127 -0.2791 -0.0169 -0.0282 -0.2593 -0.9385 -1.2910 -0.0451 -0.7324 -1.0205 -0.9409 -0.4226 -0.1465 -0.0395 -0.0169 -0.2537 -0.2479 -0.4453 -0.0282 -0.7046 -0.0225 -0.0113 -0.0338 -0.0676 -0.0338 -0.0338', 'S-38\tInsgesamt 810 Patienten (403 R-FC, 407 FC) wurden in Bezug auf Wirksamkeit ausgewertet (Tabelle 6).', 'T-38\tA total of 810 patients (403 R-FC, 407 FC) were analyzed for efficacy (Table 6).', 'H-38\t-0.57080078125\tA total of 810 patients ( 403 R @-@ FC , 407 FC ) were evaluated for efficacy ( Table 6 ) .', 'D-38\t-0.57080078125\tA total of 810 patients (403 R-FC, 407 FC) were evaluated for efficacy (Table 6).', 'P-38\t-0.9219 -0.0211 -0.0282 -0.0296 -0.0261 -0.2649 -0.0380 -0.0275 -0.0197 -0.0416 -0.0310 -0.0634 -0.0409 -0.0282 -0.0169 -0.0225 -0.0296 -1.0254 -0.0521 -0.0254 -0.9624 -0.1888 -0.0113 -0.0197 -0.2705 -0.0648 -0.0338 -0.0282 -0.0310 -0.0282', 'S-1210\tEs wurden schwere Fälle von allergischer Vaskulitis, häufig mit Purpura (blaue und rote Flecken) an den', 'T-1210\tIsotretinoin should be discontinued if hypertriglyceridaemia cannot be controlled at an acceptable level or if symptoms of', 'H-1210\t-1.345703125\tSerious cases of allergic vasculitis have occurred , often with purpura ( bruising and red spots ) on the eyelids', 'D-1210\t-1.345703125\tSerious cases of allergic vasculitis have occurred, often with purpura (bruising and red spots) on the eyelids', 'P-1210\t-1.2461 -0.0310 -0.0444 -0.0409 -0.0303 -0.0169 -0.0310 -0.0176 -0.0099 -0.0197 -0.0282 -1.8818 -0.3101 -0.7188 -0.4143 -0.0620 -1.3584 -0.2197 -0.0338 -0.0451 -0.1635 -0.2367 -0.0395 -0.0395 -0.6821 -0.0282 -0.4846 -0.1071 -0.7778 -0.1465 -0.0169 -1.4824', 'S-351\tWährend der Behandlung mit Jalra ist die Leberfunktion im ersten Jahr alle drei Monate und danach in regelmäßigen Abständen zu überprüfen.', 'T-351\tLiver function should be monitored during treatment with Jalra at three-month intervals during the first year and periodically thereafter.', 'H-351\t-0.5888671875\tLiver function should be monitored during treatment with Jalra at three @-@ month intervals during the first year and periodically thereafter .', 'D-351\t-0.5888671875\tLiver function should be monitored during treatment with Jalra at three-month intervals during the first year and periodically thereafter.', 'P-351\t-0.3635 -0.0127 -0.0243 -0.3301 -0.0310 -0.3064 -0.0240 -0.3789 -0.6201 -0.0380 -0.0352 -0.0240 -0.0169 -0.2986 -0.4580 -0.2169 -0.1635 -0.0113 -0.0113 -0.4622 -0.0395 -0.0254 -0.0310 -0.1268 -0.3015 -0.0366 -0.0282 -0.1945 -0.0197 -0.0225 -0.0310 -0.0282', 'S-744\tActos 15 mg Tabletten werden zur Behandlung von Diabetes mellitus vom Typ 2 (nicht insulinpflichtig) angewendet.', 'T-744\tActos 15mg tablets are an anti-diabetic medicine used to treat type 2 (non-insulin dependent) diabetes mellitus.', 'H-744\t-0.546875\tActos 15 mg tablets are an anti @-@ diabetic medicine used to treat type 2 ( non @-@ insulin dependent ) diabetes mellitus .', 'D-744\t-0.546875\tActos 15 mg tablets are an anti-diabetic medicine used to treat type 2 (non-insulin dependent) diabetes mellitus.', 'P-744\t-0.2720 -0.0234 -0.7705 -0.0148 -0.0740 -0.0359 -0.0557 -0.3228 -0.3086 -0.0310 -0.3030 -0.0099 -0.0197 -0.3086 -0.2847 -0.2676 -0.0169 -0.0592 -0.0366 -0.3184 -0.1917 -0.0451 -0.0479 -0.0085 -0.3042 -0.0254 -0.0366 -0.0845 -0.0254 -0.0056 -0.0395 -0.0282', 'S-1345\tArzneimittelexanthem, toxisches Exanthem (Überempfindlichkeitsreaktion), Hautauschlag, Ekzem', 'T-1345\tHyperhidrosis, pruritus Erythema, angioedema, urticaria Drug eruption, toxic skin eruption, rash, eczema', 'H-1345\t-0.796875\tdrug eruption , toxic skin eruption , eczema', 'D-1345\t-0.796875\tdrug eruption, toxic skin eruption, eczema', 'P-1345\t-0.3933 -0.4026 -0.0430 -0.0373 -0.0176 -0.3213 -0.1528 -0.5088 -0.8789 -0.0451 -0.0085 -0.0085 -0.8960', 'S-1260\tEs besitzt praktisch keine anticholinerge Wirkung und hat in therapeutischen Dosen nahezu keinen Einfluss auf das kardiovaskuläre System.', 'T-1260\tInsulin and / or oral hypoglycaemic dosage may need to be adjusted and close monitoring is recommended.', 'H-1260\t-0.84814453125\tIt has virtually no anticholinergic effects and has virtually no effect on the cardiovascular system at therapeutic doses .', 'D-1260\t-0.84814453125\tIt has virtually no anticholinergic effects and has virtually no effect on the cardiovascular system at therapeutic doses.', 'P-1260\t-0.0894 -0.2593 -0.2578 -0.0384 -0.6821 -0.0127 -0.0232 -0.0254 -0.0063 -1.4521 -0.4382 -0.5581 -0.2423 -0.0395 -0.3550 -0.0423 -0.3438 -0.1014 -0.0141 -0.0169 -0.0141 -0.0225 -0.8765 -0.2649 -0.0225 -0.1183 -0.0225 -0.0282 -0.0282', 'S-797\t290 Ausflockungen in der Flüssigkeit oder an Glaswand oder <unk> boden, so darf Insuman Comb 50 nicht verwendet werden.', 'T-797\tInsuman Comb 50 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.', 'H-797\t-1.234375\tInsuman Comb 50 must not be used if this cannot be achieved , i. e. if the suspension remains clear .', 'D-797\t-1.234375\tInsuman Comb 50 must not be used if this cannot be achieved, i. e. if the suspension remains clear.', 'P-797\t-0.2302 -0.0157 -0.0285 -0.0451 -0.0241 -0.0488 -0.2395 -0.0465 -0.0363 -0.0652 -0.3101 -0.4641 -0.3228 -0.0592 -0.3213 -0.3184 -0.3240 -0.4143 -0.1212 -0.0310 -0.2537 -0.3101 -0.3213 -0.3184 -0.3213 -3.8965 -0.0282', 'S-822\tPatienten mit Herzinsuffizienz, die mit einem ACE-Hemmer stabil eingestellt sind, sollten nicht auf Losartan umgestellt werden.', 'T-822\t25 • Treatment of chronic heart failure (in patients ≥ 60 years), when treatment with ACE inhibitors is not considered suitable due to incompatibility, especially cough, or contraindication.', 'H-822\t-0.478271484375\tPatients with heart failure who have been stabilised with an ACE inhibitor should not be switched to losartan .', 'D-822\t-0.478271484375\tPatients with heart failure who have been stabilised with an ACE inhibitor should not be switched to losartan.', 'P-822\t-0.0414 -0.0198 -0.0560 -0.2277 -0.0227 -0.0923 -0.5396 -0.2791 -0.2795 -0.2466 -0.0690 -0.1578 -0.0240 -0.0211 -0.6694 -0.0099 -0.0240 -0.0240 -0.0352 -0.0310 -0.1761 -0.1775 -0.0564 -0.1550 -0.0085 -0.0254 -0.0338 -0.0282', 'S-1950\tWird die Kombination dennoch als notwendig erachtet, sollten die Serumlithiumwerte sorgfältig überwacht werden (siehe Abschnitt 4.4).', 'T-1950\tUse of Zestril with lithium is not recommended, but if the combination proves necessary, careful monitoring of serum lithium levels should be performed (see section 4.4).', 'H-1950\t-0.7890625\tIf the combination is nevertheless considered necessary , serum lithium levels should be carefully monitored ( see section 4.4 ) .', 'D-1950\t-0.7890625\tIf the combination is nevertheless considered necessary, serum lithium levels should be carefully monitored (see section 4.4).', 'P-1950\t-0.4744 -0.1610 -0.0810 -0.1825 -0.5225 -0.0169 -1.3535 -0.0479 -0.0437 -0.2974 -0.0366 -0.0282 -0.0085 -0.0197 -0.8818 -0.0338 -0.0395 -0.9160 -0.2563 -0.0197 -0.0338 -0.0395 -0.1775 -0.0254 -0.0282 -0.0423 -0.0310 -0.0282', 'S-1596\t7 µg / ml bei Patienten mit Morbus Crohn, die eine Erhaltungsdosis von 40 mg Humira alle zwei Wochen erhielten.', 'T-1596\tMean steady-state trough levels of approximately 7 µg / ml were observed in Crohn <<unk>> s disease patients who received a maintenance dose of 40 mg Humira every other week.', 'H-1596\t-0.80078125\tMean steady @-@ state trough levels of approximately 7 µg / ml were observed in Crohn &quot; s disease patients who received a maintenance dose of 40 mg Humira every two weeks .', 'D-1596\t-0.80078125\tMean steady-state trough levels of approximately 7 µg / ml were observed in Crohn "s disease patients who received a maintenance dose of 40 mg Humira every two weeks.', 'P-1596\t-0.3508 -0.3188 -0.3301 -0.3169 -0.2374 -0.3254 -0.2747 -0.0409 -0.3254 -0.1578 -0.5425 -0.4734 -0.0845 -0.0225 -0.0310 -0.0338 -0.3325 -0.2029 -0.0732 -0.3296 -0.0028 -0.5664 -0.0197 -0.0732 -0.0141 -0.5044 -0.1521 -0.0958 -0.0225 -0.0564 -0.0338 -0.0395 -0.0169 -0.4509 -0.0282 -0.0169 -0.0225 -0.4282 -0.0225 -0.0338 -0.0282', 'S-975\t- Staphylococcus spp. ≤ 1 µg / ml für empfindlich, > 1 µg / ml für resistent;', 'T-975\t- Staphylococcus spp. ≤ 1 µg / ml for susceptible, > 1 µg / ml for resistant;', 'H-975\t-0.31103515625\t- Staphylococcus spp. ≤ 1 µg / ml for susceptible , &gt; 1 µg / ml for resistant ;', 'D-975\t-0.31103515625\t- Staphylococcus spp. ≤ 1 µg / ml for susceptible, > 1 µg / ml for resistant;', 'P-975\t-0.0429 -0.0270 -0.0199 -0.0184 -0.0249 -0.0213 -0.0070 -0.0241 -0.0199 -0.8955 -0.1642 -0.3860 -0.0225 -0.0240 -0.0296 -0.0240 -0.0409 -0.3184 -0.0704 -0.0099 -0.0211 -0.0240 -0.0535 -0.0141 -0.0338 -0.0099 -0.0225 -0.0296 -0.0141 -0.0254 -0.0310 -0.0197 -0.0620 -0.0282', 'S-325\tColfosceriltetradecanoat, (3-sn-Phosphatidyl) cholin aus Eigelb,', 'T-325\t- The other ingredients are dimyristoyl phosphatidylcholine, egg phosphatidylglycerol, ascorbyl', 'H-325\t-1.919921875\tCholfosceriltetradecanoate , Egg phosphatidylglycerol , ( 3 @-@ sn @-@ phosphatidylglycerol ) ,', 'D-325\t-1.919921875\tCholfosceriltetradecanoate, Egg phosphatidylglycerol, (3-sn-phosphatidylglycerol),', 'P-325\t-2.2812 -0.0493 -0.6084 -0.0141 -0.0254 -0.0732 -0.0282 -2.5605 -0.0113 -0.0338 -0.0338 -0.0901 -1.5557 -0.0225 -0.3269 -0.0225 -0.0225 -0.0169 -0.2874 -0.5410 -0.2874 -0.3157 -0.0395 -0.3606 -1.0479 -0.5186 -0.0282 -0.0564 -0.0282 -0.2761 -0.0564 -0.0113 -0.0113 -0.0113 -0.1240 -1.5664 -0.0564 -0.1917 -0.0789 -1.4990 -1.0596 -1.8486', 'S-1864\tNebenwirkungen bei Patienten, die Xiliarx 100 mg täglich als Monotherapie in Doppelblind-Studien erhielten (N = 1.855)', 'T-1864\tAdverse reactions reported in patients who received Xiliarx 100 mg daily as monotherapy in double-blind studies (N = 1,855)', 'H-1864\t-0.369140625\tAdverse reactions reported in patients who received Xiliarx 100 mg daily as monotherapy in double @-@ blind studies ( N = 1,855 )', 'D-1864\t-0.369140625\tAdverse reactions reported in patients who received Xiliarx 100 mg daily as monotherapy in double-blind studies (N = 1,855)', 'P-1864\t-0.2703 -0.0056 -0.2400 -0.0028 -0.3223 -0.0676 -0.0718 -0.2268 -0.0240 -0.0458 -0.0155 -0.0240 -0.0331 -0.0486 -0.0141 -0.0444 -0.1719 -0.2339 -0.0324 -0.0127 -0.0338 -0.0366 -0.0578 -0.0211 -0.0901 -0.0338 -0.0211 -0.0282 -0.6719 -0.0225 -0.0197 -0.0282 -0.0366', 'S-1426\tIhr Arzt wird Ihren Gesundheitszustand während der Einnahme von Epivir regelmäßig auf Anzeichen einer sich entwickelnden Laktatazidose hin kontrollieren.', 'T-1426\tWhile you are being treated with Epivir, your doctor will monitor you closely for any signs that you may be developing lactic acidosis.', 'H-1426\t-0.73388671875\tWhile you are being treated with Epivir , your doctor will monitor you closely for any signs that you may be developing lactic acidosis .', 'D-1426\t-0.73388671875\tWhile you are being treated with Epivir, your doctor will monitor you closely for any signs that you may be developing lactic acidosis.', 'P-1426\t-0.6836 -0.5986 -0.1120 -0.5093 -0.2283 -0.2747 -0.0592 -0.0141 -0.0197 -0.0225 -0.1846 -0.0423 -0.0324 -0.0423 -0.4480 -0.2761 -0.3381 -0.0564 -0.2959 -0.0704 -0.3042 -0.2339 -0.1917 -0.2705 -0.0817 -0.0197 -0.3127 -0.0535 -0.0169 -0.0169 -0.0338 -0.0282', 'S-1866\tBrustschmerz, vasovagale Reaktionen und Überempfindlichkeitsreaktionen, die vereinzelt einen schweren Verlauf nehmen können, wurden berichtet.', 'T-1866\tChest pain, vasovagal reactions and hypersensitivity reactions, which on rare occasions can be severe, have been reported.', 'H-1866\t-0.72216796875\tChest pain , vasovagal reactions and hypersensitivity reactions , which on rare occasions can be severe , have been reported .', 'D-1866\t-0.72216796875\tChest pain, vasovagal reactions and hypersensitivity reactions, which on rare occasions can be severe, have been reported.', 'P-1866\t-0.5610 -0.0190 -0.0285 -0.0292 -0.1370 -0.0197 -0.0528 -0.0240 -0.0444 -0.8228 -0.0211 -0.6157 -0.1226 -0.0254 -0.2917 -0.0817 -0.0225 -0.1268 -0.1042 -0.3240 -0.3184 -0.0141 -1.0762 -0.2705 -0.1945 -0.0535 -0.1437 -0.0395 -0.0254 -0.0310 -0.0282', 'S-1449\tPatienten müssen täglich orale Gaben von Folsäure oder Multivi- tamine mit Folsäure (350 bis 1000 Mikrogramm) erhalten.', 'T-1449\tPatients must take oral folic acid or a multivitamin containing folic acid (350 to 1000 micrograms) on a daily basis.', 'H-1449\t-1.2841796875\tPatients must receive oral doses of folic acid or a multivalent containing folic acid ( 350 to 1000 micrograms ) per day .', 'D-1449\t-1.2841796875\tPatients must receive oral doses of folic acid or a multivalent containing folic acid (350 to 1000 micrograms) per day.', 'P-1449\t-0.1862 -0.0220 -0.6929 -0.2739 -0.7031 -1.0000 -0.7593 -0.3889 -0.5127 -0.0282 -0.0169 -0.0676 -0.9409 -0.1042 -0.4678 -0.5747 -0.3157 -1.2568 -0.1127 -0.0282 -0.0113 -0.0564 -0.0564 -0.0845 -0.0620 -0.0282 -0.0789 -0.0338 -1.3184 -0.0282 -0.0338 -0.0282', 'S-219\tIreland Wyeth Pharmaceuticals Tel: + 353 1 449 35 00 Fax: + 353 1 449 3522', 'T-219\tIreland Wyeth Pharmaceuticals Tel: + 353 1 449 3500 Fax: + 353 1 449 3522', 'H-219\t-0.1002197265625\tIreland Wyeth Pharmaceuticals Tel : + 353 1 449 35 00 Fax : + 353 1 449 3522', 'D-219\t-0.1002197265625\tIreland Wyeth Pharmaceuticals Tel: + 353 1 449 35 00 Fax: + 353 1 449 3522', 'P-219\t-0.0767 -0.0256 -0.0170 -0.0241 -0.0255 -0.0092 -0.0206 -0.0141 -0.0178 -0.0227 -0.0655 -0.0327 -0.0278 -0.0306 -0.0162 -0.0285 -0.0229 -0.0141 -0.0211 -0.0243 -0.0197 -0.0278 -0.0197 -0.0271 -0.0169 -0.0243 -0.0190 -0.0120 -0.0254 -0.0247 -0.0331', 'S-902\tDa viele Bakterienstämme an einer Otitis externa beteiligt sein können, können die Resistenzmechanismen variieren.', 'T-902\tSince many bacterial strains may be involved in otitis externa in dogs, the mechanisms of resistance can vary.', 'H-902\t-0.81005859375\tAs many strains of bacteria may be involved in otitis externa , resistance mechanisms may vary .', 'D-902\t-0.81005859375\tAs many strains of bacteria may be involved in otitis externa, resistance mechanisms may vary.', 'P-902\t-1.2549 -0.0409 -0.6938 -0.0127 -0.0380 -0.1282 -0.1930 -0.6201 -0.3381 -0.0338 -0.0873 -0.0254 -0.0141 -0.0282 -0.0141 -0.0254 -0.2197 -0.9526 -0.1071 -0.0225 -0.4565 -0.0395 -0.0141 -0.2001 -0.0282', 'S-374\tWie bei anderen Impfstoffen auch sind nach Impfung mit M-M-RVAXPRO möglicherweise nicht alle geimpften Personen geschützt.', 'T-374\tAs for any vaccine, vaccination with M-M-RVAXPRO may not result in protection in all vaccinees.', 'H-374\t-0.6416015625\tAs with other vaccines , M @-@ M @-@ RVAXPRO may not completely protect all persons who are vaccinated .', 'D-374\t-0.6416015625\tAs with other vaccines, M-M-RVAXPRO may not completely protect all persons who are vaccinated.', 'P-374\t-0.1112 -0.3347 -0.0768 -0.0197 -0.0306 -0.0909 -0.3955 -0.0268 -0.0225 -0.0310 -0.0331 -0.0275 -0.0254 -0.0197 -0.0127 -0.0240 -0.1345 -0.0345 -0.9624 -0.0268 -0.1367 -1.1455 -0.3411 -0.5239 -0.0620 -0.0197 -0.0423 -0.0282', 'S-1582\tUnverträglichkeit gegenüber Alkohol (Rötung der Gesichtshaut oder Hautreizungen nach dem Genuss alkoholischer Getränke) war häufig.', 'T-1582\tAlcohol intolerance (facial flushing or skin irritation after consumption of an alcoholic beverage) was common.', 'H-1582\t-0.87060546875\tAlcohol intolerance ( facial flushing or skin irritation after consumption of an alcoholic beverage ) was common .', 'D-1582\t-0.87060546875\tAlcohol intolerance (facial flushing or skin irritation after consumption of an alcoholic beverage) was common.', 'P-1582\t-0.6143 -0.0113 -0.0271 -0.0662 -0.0081 -0.0247 -0.0402 -0.5186 -0.3494 -0.0620 -0.1536 -0.1818 -0.6567 -0.2563 -0.4001 -1.2002 -0.0338 -0.4536 -0.0197 -0.0113 -0.0254 -0.1803 -0.0113 -0.0310 -0.9185 -0.1127 -0.0338 -0.0282', 'S-1484\tNeoclarityn Lyophilisat zum Einnehmen ist ein antiallergisches Arzneimittel, welches Sie nicht schläfrig macht.', 'T-1484\tNeoclarityn oral lyophilisate is an antiallergy medicine that does not make you drowsy.', 'H-1484\t-0.32470703125\tNeoclarityn oral lyophilisate is an antiallergy medicine that does not make you drowsy .', 'D-1484\t-0.32470703125\tNeoclarityn oral lyophilisate is an antiallergy medicine that does not make you drowsy.', 'P-1484\t-0.1282 -0.0320 -0.0142 -0.0313 -0.0162 -0.0299 -0.3223 -0.1191 -0.0127 -0.2874 -0.0268 -0.0465 -0.0402 -0.1761 -0.2937 -0.0127 -0.0352 -0.1099 -0.2128 -0.1000 -0.0282 -0.0831 -0.0310 -0.1155 -0.0155 -0.0141 -0.0338 -0.0296', 'S-1086\tDie Tabellen 2 und 3 dürfen nicht für die Umstellung von transdermalem Fentanyl auf eine Morphin- Therapie verwendet werden.', 'T-1086\tTables 2 and 3 should not be used to switch from transdermal fentanyl to a morphine treatment.', 'H-1086\t-0.8828125\tThe tables 2 and 3 must not be used for conversion from transdermal fentanyl to morphine therapy .', 'D-1086\t-0.8828125\tThe tables 2 and 3 must not be used for conversion from transdermal fentanyl to morphine therapy.', 'P-1086\t-0.7734 -0.5366 -0.0373 -0.0317 -0.0282 -0.8003 -0.0324 -0.0310 -0.0338 -0.6226 -1.5303 -0.0197 -0.4592 -0.4678 -0.0141 -0.0197 -0.0197 -0.0141 -0.0113 -0.0225 -0.0535 -0.0310 -0.0282 -0.0197 -0.6792 -0.0338 -0.0282', 'S-628\tTasmar sollte daher nur dann während der Schwangerschaft verwendet werden, wenn der zu erwartende Nutzen das potentielle Risiko für den Feten rechtfertigt.', 'T-628\tTherefore, Tasmar should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.', 'H-628\t-0.66162109375\tTasmar should not be used during pregnancy unless the potential benefit justifies the potential risk to the foetus .', 'D-628\t-0.66162109375\tTasmar should not be used during pregnancy unless the potential benefit justifies the potential risk to the foetus.', 'P-628\t-0.5000 -0.0257 -0.2822 -0.8687 -0.1057 -0.0465 -0.1141 -0.0310 -0.0986 -0.0916 -1.1553 -0.1550 -0.0732 -0.0225 -0.0704 -0.0817 -0.0338 -0.0817 -0.0395 -0.4648 -0.0056 -0.0282 -0.0395 -0.0366', 'S-538\tNach Absetzen der Behandlung mit Galvus und Normalisierung der Leberfunktionswerte darf die Behandlung mit Galvus nicht wieder begonnen werden.', 'T-538\tFollowing withdrawal of treatment with Galvus and LFT normalisation, treatment with Galvus should not be reinitiated.', 'H-538\t-0.6494140625\tFollowing withdrawal of treatment with Galvus and LFT normalisation , treatment with Galvus should not be re @-@ initiated .', 'D-538\t-0.6494140625\tFollowing withdrawal of treatment with Galvus and LFT normalisation, treatment with Galvus should not be re-initiated.', 'P-538\t-0.5171 -0.8359 -0.1317 -0.2156 -0.0395 -0.3240 -0.0127 -0.0324 -0.0423 -0.3284 -0.3325 -0.3071 -0.0225 -0.1014 -0.1183 -0.0451 -0.0113 -0.0169 -0.0310 -0.2705 -0.0395 -0.0507 -0.4705 -0.0310 -0.3804 -0.0254 -0.0338 -0.0282', 'S-214\tFolgen Sie bitte sorgfältig allen Anweisungen Ihres Arztes, auch wenn sie von den allgemeinen Informationen in dieser Packungsbeilage abweichen.', 'T-214\tFollow all your doctor <<unk>> s instructions carefully, even if they differ from the general information contained in this leaflet.', 'H-214\t-1.3837890625\tPlease carefully follow all of your doctor &apos;s instructions , even if they differ from the general information given in this leaflet .', "D-214\t-1.3837890625\tPlease carefully follow all of your doctor's instructions, even if they differ from the general information given in this leaflet.", 'P-214\t-1.6777 -0.8242 -0.0169 -0.5239 -1.9053 -0.1945 -0.0592 -0.7158 -0.3662 -0.5747 -0.0451 -0.0564 -0.0564 -0.2761 -0.0169 -0.0282 -0.0451 -0.0564 -0.0395 -1.4824 -0.0451 -0.2705 -0.2817 -0.0113 -0.0169 -0.3889 -0.0282', 'S-1216\tIn dieser Untergruppe gab es eine 56% ige (463 / 823) anhaltende virologische Ansprechrate (SVR).', 'T-1216\tIn this subgroup, there was a 56% (463 / 823) sustained virological response rate.', 'H-1216\t-0.52490234375\tIn this subgroup , there was a 56 % ( 463 / 823 ) sustained virological response rate ( SVR ) .', 'D-1216\t-0.52490234375\tIn this subgroup, there was a 56% (463 / 823) sustained virological response rate (SVR).', 'P-1216\t-0.2561 -0.0414 -0.0553 -0.0537 -0.2219 -0.2500 -0.0338 -0.3635 -0.0127 -0.0373 -0.3071 -0.0169 -0.0254 -0.0338 -0.0225 -0.0197 -0.0296 -0.0775 -0.4973 -0.0197 -0.5239 -0.0113 -0.8931 -0.0310 -0.0169 -0.0169 -0.0282 -0.0338 -0.0282', 'S-591\tDie Flasche mit dem Lösungsmittel umdrehen und den Gummistöpsel der Pulverflasche mit der Transfernadel durchstechen.', 'T-591\tInvert the solvent vial and pierce the stopper of the vial containing the powder.', 'H-591\t-1.3232421875\tInvert the bottle with solvent and pierce the rubber stopper of the powder vial with the transfer needle .', 'D-591\t-1.3232421875\tInvert the bottle with solvent and pierce the rubber stopper of the powder vial with the transfer needle.', 'P-591\t-1.7256 -0.0310 -0.3030 -0.8423 -0.6875 -0.8989 -0.0197 -0.3972 -0.9609 -0.0225 -0.0282 -0.0451 -0.3157 -0.8511 -0.0169 -0.5469 -0.0395 -0.0676 -1.0762 -0.0225 -0.0620 -0.4395 -0.0282 -0.0451 -0.0225 -0.0338 -0.0282', 'S-413\t157 GEBRAUCHSINFORMATION - INFORMATION FÜR DEN ANWENDER', 'T-413\t135 PACKAGE LEAFLET <<unk>> INFORMATION FOR THE USER', 'H-413\t-1.1123046875\t146 PACKAGE LEAFLET : INFORMATION FOR THE USER', 'D-413\t-1.1123046875\t146 PACKAGE LEAFLET: INFORMATION FOR THE USER', 'P-413\t-0.4902 -1.7939 -0.3198 -0.3213 -0.0395 -0.0056 -0.1635 -0.3213 -0.3213 -0.3213 -0.2959 -1.8848 -0.8228 -0.0338 -0.0113 -0.0338 -0.0225 -0.0113 -0.0676 -0.0225 -0.0507 -0.0789 -0.0169 -0.0395', 'S-1854\t9 Es gibt Patienten, die Pioglitazon in einer höheren als der empfohlenen Höchstdosis von 45 mg täglich eingenommen haben.', 'T-1854\tPatients have taken pioglitazone at higher than the recommended highest dose of 45 mg daily.', 'H-1854\t-1.380859375\tThere are patients who take pioglitazone at greater than the maximum recommended dose of 45 mg daily .', 'D-1854\t-1.380859375\tThere are patients who take pioglitazone at greater than the maximum recommended dose of 45 mg daily.', 'P-1854\t-2.1250 -0.7070 -0.0493 -0.0718 -0.3157 -0.0592 -0.0282 -0.0169 -0.0169 -0.0225 -1.9639 -1.5273 -0.1917 -0.0395 -1.0820 -0.0225 -0.0845 -0.0338 -0.0789 -0.0395 -0.5186 -0.0338 -0.0338', 'S-1750\tEs ist wichtig, mit dem Einatmen so langsam wie möglich zu beginnen, unmittelbar bevor das Dosier-Aerosol angewendet wird.', 'T-1750\tIt is important that patients start to breathe in as slowly as possible just before operating their inhaler.', 'H-1750\t-0.97412109375\tIt is important to start to breathe in as slowly as possible immediately before using the inhaler .', 'D-1750\t-0.97412109375\tIt is important to start to breathe in as slowly as possible immediately before using the inhaler.', 'P-1750\t-0.1992 -0.0313 -0.0509 -0.0444 -0.8564 -0.3169 -0.7173 -0.0296 -0.2423 -0.1268 -0.0352 -0.0282 -0.0296 -0.2507 -0.7046 -0.4453 -0.2057 -1.1973 -0.2423 -0.2649 -0.0338', 'S-1517\tSuchen Sie sich eine passende, gut beleuchtete, saubere Fläche und legen Sie die gesamte Ausstattung, die Sie brauchen, in Reichweite hin.', 'T-1517\tFind a comfortable, well-lit, clean surface and put all the equipment you need within reach.', 'H-1517\t-0.75439453125\tFind a comfortable , well @-@ lit , clean surface and put everything you need where you can reach it .', 'D-1517\t-0.75439453125\tFind a comfortable, well-lit, clean surface and put everything you need where you can reach it.', 'P-1517\t-0.2603 -0.1212 -1.1562 -0.0535 -0.0634 -0.1395 -0.0423 -0.0775 -0.0366 -0.3254 -0.0986 -0.2803 -0.4946 -0.1353 -0.0451 -0.3916 -0.0845 -0.3071 -0.3157 -0.2761 -0.0507 -0.0648', 'S-323\t14 / 20 GEBRAUCHSINFORMATION Fevaxyn Pentofel, Injektionslösung für Katzen', 'T-323\tFevaxyn Pentofel, solution for injection, for cats', 'H-323\t-1.23828125\t14 / 20 PACKAGE LEAFLET Fevaxyn Pentofel , solution for injection for cats', 'D-323\t-1.23828125\t14 / 20 PACKAGE LEAFLET Fevaxyn Pentofel, solution for injection for cats', 'P-323\t-0.9639 -0.0282 -0.0268 -0.3213 -0.3213 -0.0718 -0.0606 -0.1353 -0.3213 -0.3213 -0.3198 -0.2847 -3.1699 -0.0395 -0.0169 -0.0113 -0.0338 -0.0282 -0.0056 -0.9526 -0.5806 -0.0901 -0.1691 -0.0845 -0.2761 -0.2817 -0.0338', 'S-910\tWAS MÜSSEN SIE VOR DER EINNAHME VON EFFICIB BEACHTEN?', 'T-910\tBEFORE YOU TAKE EFFICIB', 'H-910\t-0.352783203125\tBEFORE YOU TAKE EFFICIB', 'D-910\t-0.352783203125\tBEFORE YOU TAKE EFFICIB', 'P-910\t-0.3213 -0.0178 -0.0063 -0.5039 -0.0169 -0.0148 -0.3101 -0.0085 -0.0099 -0.1909 -0.0085 -0.0113 -0.0240 -0.0240 -0.3228', 'S-868\tWAS MÜSSEN SIE VOR DER EINNAHME VON AVAGLIM BEACHTEN?', 'T-868\tBEFORE YOU TAKE AVAGLIM', 'H-868\t-0.317138671875\tBEFORE YOU TAKE AVAGLIM', 'D-868\t-0.317138671875\tBEFORE YOU TAKE AVAGLIM', 'P-868\t-0.3213 -0.0178 -0.0056 -0.3169 -0.0155 -0.0155 -0.3005 -0.0085 -0.0099 -0.1965 -0.0148 -0.0211 -0.0247 -0.0190 -0.3228', 'S-1591\tEur.), Polysorbat 80, Wasser für Injektionszwecke, Salzsäure und Natriumhydroxid.', 'T-1591\tThe solvent ingredients are croscarmellose sodium, mannitol, polysorbate 80, water for injections, hydrochloric acid and sodium hydroxide.', 'H-1591\t-0.77001953125\tstearate , polysorbate 80 , water for injections , hydrochloric acid and sodium hydroxide .', 'D-1591\t-0.77001953125\tstearate, polysorbate 80, water for injections, hydrochloric acid and sodium hydroxide.', 'P-1591\t-2.4785 -0.2959 -0.0437 -0.3269 -0.8564 -0.0338 -0.0366 -0.0282 -0.0338 -0.0451 -0.1353 -0.0592 -0.0423 -0.5605 -0.0395 -0.0451 -0.0197 -0.0113 -0.0113 -0.0225 -0.0282 -0.2283 -0.0338 -0.0113 -0.0141 -0.2507 -0.0254 -0.0592 -0.0282', 'S-1708\tDie Zahl der Abonnenten von EMEA- Dokumenten ging 2000 zurück, da der Direktzugriff über die Webseite zunehmend genutzt wird.', 'T-1708\tHowever work continued in 2000 to set definitive MRLs for those substances currently in Annex III of Council Regulation (EEC) No 2377 / 90 and allocated provisional status pending provision of additional data, mainly relating to validation of analytical methods for surveillance purposes.', 'H-1708\t-1.6162109375\tThe number of subscribers to EMEA documents decreased in 2000 , as direct access to EMEA documents is increasingly utilised .', 'D-1708\t-1.6162109375\tThe number of subscribers to EMEA documents decreased in 2000, as direct access to EMEA documents is increasingly utilised.', 'P-1708\t-0.2842 -0.1383 -0.0271 -0.1655 -0.0870 -0.0870 -0.6733 -0.0662 -0.0268 -0.1028 -1.1035 -0.0254 -0.0423 -0.0352 -0.8071 -0.5269 -1.2764 -0.0732 -0.3860 -1.4199 -0.0282 -0.0282 -0.1409 -1.9102 -1.5156 -0.7666 -0.2930 -0.1127 -0.0338', 'S-331\t• Kit mit 90 x 1 perforierte PVC / Aluminium Einzeldosis-Blisterpackung zu 3 mg (3 m', 'T-331\t• A kit containing 90 x 1 of 1 mg PVC / Aluminium perforated unit dose blisters (3 pouches), 1 insulin inhaler, 1 spare chamber and 6 spare Insulin Release Units (IRU)', 'H-331\t-1.0126953125\tand 2 spare Insulin Release Units ( IRU ) M', 'D-331\t-1.0126953125\tand 2 spare Insulin Release Units (IRU) M', 'P-331\t-0.3472 -0.3179 -0.3240 -0.3228 -0.2917 -0.3142 -0.3228 -0.2212 -0.3228 -0.0352 -0.5903 -0.3213 -0.3127 -0.0620 -0.7354 -0.5015', 'S-1865\tDie Wirkungen von Parecoxib in der Spätphase der Trächtigkeit oder in der prä- und postnatalen Phase wurden nicht untersucht.', 'T-1865\tThe effects of parecoxib have not been evaluated in late pregnancy or in the pre- and postnatal period.', 'H-1865\t-1.1494140625\tThe effects of parecoxib in late @-@ pregnancy and through pre- and post @-@ natal period have not been studied .', 'D-1865\t-1.1494140625\tThe effects of parecoxib in late-pregnancy and through pre- and post-natal period have not been studied.', 'P-1865\t-0.0909 -0.0400 -0.0284 -0.1736 -0.0255 -0.0051 -0.0204 -0.1296 -0.7856 -1.0088 -0.3198 -0.9282 -1.2002 -0.8057 -0.0648 -0.0338 -0.6509 -0.0282 -0.0451 -0.0282 -0.6650 -0.5410 -0.0282 -0.0282 -0.5693 -0.0338 -0.0282', 'S-1199\tDer Arzt muss den Patienten auf die Wichtigkeit der fortlaufenden Anwendung aufmerksam machen, vor allem in den ersten Behandlungsmonaten (siehe Überempfindlichkeit).', 'T-1199\t4 Physicians should counsel patients on the importance of uninterrupted dosing, particularly in the early months of treatment (see hypersensitivity).', 'H-1199\t-1.4697265625\tThe physician should inform the patient of the importance of continued administration , especially during the first few months of treatment ( see hypersensitivity ) .', 'D-1199\t-1.4697265625\tThe physician should inform the patient of the importance of continued administration, especially during the first few months of treatment (see hypersensitivity).', 'P-1199\t-0.7988 -0.7539 -0.0155 -1.2275 -1.3975 -0.0282 -0.6426 -0.0254 -0.7466 -0.0282 -0.0479 -0.0338 -1.2256 -1.0146 -0.0732 -0.0958 -0.1635 -0.0338 -0.0395 -0.9639 -0.0282 -0.0564 -0.4790 -0.0395 -0.0338 -1.4033 -0.0169 -0.0169 -0.0451 -0.0338 -0.0282', 'S-202\t13 dieser Patienten (9 ALL, 4 AML) wurden nach dem Clofarabin- Dosierungsschema 52 mg / m2 / Tag behandelt.', 'T-202\tThirteen of these patients (9 ALL, 4 AML) were treated with the 52 mg / m2 / day clofarabine regimen.', 'H-202\t-1.189453125\tThirteen of these patients ( 9 ALL , 4 AML ) were treated with the clofarabine regimen of 52 mg / m2 / day .', 'D-202\t-1.189453125\tThirteen of these patients (9 ALL, 4 AML) were treated with the clofarabine regimen of 52 mg / m2 / day.', 'P-202\t-2.0137 -0.0141 -0.0718 -0.2141 -0.0254 -0.0366 -0.0395 -0.0211 -0.9736 -0.0282 -0.0225 -0.0197 -0.0338 -0.1014 -0.0592 -0.8931 -1.1182 -0.8906 -0.1747 -0.2986 -0.1240 -1.5615 -0.0169 -0.5352 -0.0282 -0.0113 -0.0282 -0.0169 -0.0395 -0.0395 -0.0338 -0.0282', 'S-1690\tSchwangerschaft Wenn Sie schwanger sind, dürfen Sie Revlimid nicht einnehmen, da zu erwarten ist, dass es dem ungeborenen Kind schadet.', 'T-1690\tPregnancy You must not take Revlimid if you are pregnant, as it is expected to be harmful for an unborn baby.', 'H-1690\t-1.4052734375\tPregnancy', 'D-1690\t-1.4052734375\tPregnancy', 'P-1690\t-0.5737 -0.0099 -0.0176 -2.6270', 'S-670\t90 (3x30) Filmtabletten in opaken weißen Blisterpackungen (PVC / PVDC / Aluminium).', 'T-670\t90 (3x30) tablets in opaque white (PVC / PVDC / Aluminium) blister packs.', 'H-670\t-0.88330078125\t90 ( 3x30 ) tablets in opaque white ( PVC / PVDC / aluminum ) blister packs .', 'D-670\t-0.88330078125\t90 (3x30) tablets in opaque white (PVC / PVDC / aluminum) blister packs.', 'P-670\t-0.7764 -0.0698 -0.0282 -0.0225 -0.0275 -0.0282 -1.7207 -0.0310 -0.1409 -0.1790 -0.0141 -0.0141 -0.0395 -1.2930 -0.0423 -0.0169 -0.0366 -0.0282 -0.0282 -0.0141 -0.0366 -0.6367 -0.7437 -0.0225 -0.0338 -0.0451 -0.4846 -0.2817 -0.0225 -0.0451 -0.0282', 'S-1023\tDas entwickelte Clearance-Modell zeigte, dass Körpergewicht, Geschlecht, Alter und Serumkreatinin die wichtigsten Kovariablen waren.', 'T-1023\tThe clearance model developed showed that body weight, gender, age, and serum creatinine were the main covariates.', 'H-1023\t-0.8310546875\tThe clearance model showed that body weight , gender , age and serum creatinine were the most important covariates .', 'D-1023\t-0.8310546875\tThe clearance model showed that body weight, gender, age and serum creatinine were the most important covariates.', 'P-1023\t-0.1498 -1.2520 -0.0268 -0.0211 -1.5430 -0.0423 -0.1945 -0.0169 -0.0282 -0.5352 -0.0310 -0.0254 -0.3467 -0.1747 -0.0310 -0.0310 -0.0225 -0.0282 -0.0310 -0.0395 -0.0423 -0.4480 -0.0423 -0.0817 -0.0169 -0.8735 -0.0338 -0.0282', 'S-992\t• einen Gehirntumor, Gefäßmissbildungen oder Ausbuchtungen der Gefäßwände (Aneurysmen) im Gehirn haben', 'T-992\t• have a brain tumour or a malformed blood vessel or a vessel wall dilatation (aneurysm) in the brain', 'H-992\t-1.333984375\t• have a brain tumour , vascular malformations , or a sac in the vascular wall ( aneurysm ) of the brain', 'D-992\t-1.333984375\t• have a brain tumour, vascular malformations, or a sac in the vascular wall (aneurysm) of the brain', 'P-992\t-0.1112 -0.2032 -0.4392 -0.0606 -0.0169 -0.1578 -0.2910 -0.5669 -0.0085 -0.0197 -0.5845 -0.4509 -0.0282 -1.0342 -0.2367 -0.3691 -0.3213 -0.1803 -0.2959 -0.5186 -1.3135 -0.0169 -0.0169 -1.5840 -0.1803 -0.0395 -0.0225 -0.2255 -0.0169 -0.0282 -0.5581 -0.6255 -0.0225 -0.5186', 'S-1838\tDie Patienten sollten darüber informiert werden, OSSEOR unverzüglich und dauerhaft abzusetzen und einen Arzt aufzusuchen, sobald ein Ausschlag auftritt.', 'T-1838\tPatients should be informed to stop OSSEOR immediately and permanently when a rash occurs and to seek medical advice.', 'H-1838\t-0.99951171875\tPatients should be informed to stop taking OSSEOR immediately and permanently when a rash occurs and to seek medical advice .', 'D-1838\t-0.99951171875\tPatients should be informed to stop taking OSSEOR immediately and permanently when a rash occurs and to seek medical advice.', 'P-1838\t-0.2942 -0.0199 -0.0313 -0.0342 -0.5303 -0.4509 -0.6440 -0.6211 -0.1099 -0.0155 -0.0282 -0.0197 -0.1198 -0.0789 -0.0366 -0.0197 -1.7754 -0.1437 -0.0873 -0.0113 -0.2227 -0.0197 -0.2761 -0.2986 -0.5298 -0.0845 -0.7495 -0.2593 -0.0282', 'S-1537\tDiese Verhaltensauffälligkeiten können sich beispielsweise durch destruktives Verhalten oder unangemessenen Kot- und Harnabsatz im Haus äußern.', 'T-1537\tThese behavioural problems might be expressed for example by destructive behaviour or inappropriate defecation or urination in the house.', 'H-1537\t-1.10546875\tThese behavioural problems may , for example , be expressed by destruction and inappropriate defecation or urination in the house .', 'D-1537\t-1.10546875\tThese behavioural problems may, for example, be expressed by destruction and inappropriate defecation or urination in the house.', 'P-1537\t-0.2935 -0.0977 -0.0736 -0.0292 -0.5151 -1.0605 -0.8184 -0.2734 -0.2649 -0.0282 -0.6650 -0.3325 -0.5103 -0.3381 -0.4368 -0.1521 -0.4565 0.0000 -0.0225 -1.1611 -0.0451 -0.0451 -0.1183 -0.0451 -0.1409 -0.0338 -0.0282', 'S-968\ter Wenn Ihr Blutzucker zu hoch ansteigt Ihr Blutzucker kann zu hoch ansteigen (dies wird Hyperglykämie genannt).', 'T-968\tIf your blood sugar gets too high Your blood sugar may get too high (this is called hyperglycaemia). i', 'H-968\t-1.078125\t- If your blood sugar gets too high , your blood sugar may get too high ( this is called hyperglycaemia ) .', 'D-968\t-1.078125\t- If your blood sugar gets too high, your blood sugar may get too high (this is called hyperglycaemia).', 'P-968\t-2.5488 -0.5142 -0.0507 -0.0451 -0.0564 -0.4368 -0.0366 -0.0395 -0.6733 -0.4199 -0.0338 -0.0479 -0.2255 -1.1211 -0.0338 -0.0338 -0.0395 -0.7554 -0.0282 -0.5127 -0.0225 -0.0225 -0.0169 -0.2593 -0.0282 -0.0225 -0.0338 -0.0451 -0.0282', 'S-650\tBei Diabetikern ist unter Umständen eine Dosisanpassung von Insulin oder oralen Blutzucker senkenden Substanzen erforderlich.', 'T-650\tIn diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required.', 'H-650\t-1.052734375\tDosage adjustment of insulin or hypoglycaemic agents may be necessary in diabetic patients .', 'D-650\t-1.052734375\tDosage adjustment of insulin or hypoglycaemic agents may be necessary in diabetic patients.', 'P-650\t-0.6792 -0.8511 -0.0296 -0.0395 -0.0155 -0.1071 -0.0606 -0.0113 -0.2197 -0.0465 -0.9102 -0.0423 -0.0056 -0.4028 -0.0732 -0.0028 -0.7017 -0.2676 -0.2339 -1.1270 -0.4114 -0.9692 -0.0056 -0.2705 -0.0564 -0.0338 -0.0282', 'S-207\tImletzteren Fall wird Ihr Arzt regelmäßig Blutuntersuchungen durchführen, vor allem zur Bestimmung der Kaliumspiegel bei schlechter Nierenfunktion,', 'T-207\tlatter case your doctor may perform regular blood tests, especially for measuring blood potassium levels in case of poor kidney function,', 'H-207\t-1.65234375\tIn the latter case , your doctor will carry out regular blood tests , especially for determining potassium levels in the presence of renal impairment ,', 'D-207\t-1.65234375\tIn the latter case, your doctor will carry out regular blood tests, especially for determining potassium levels in the presence of renal impairment,', 'P-207\t-0.6567 -1.1240 -0.1169 -0.2917 -0.9409 -0.0366 -0.0366 -0.0338 -1.4600 -0.0254 -0.3071 -0.0282 -0.0366 -0.2705 -0.7437 -0.6084 -0.8623 -0.0282 -0.2367 -0.0056 -0.0282 -0.3042 -0.0507 -1.7471 -0.3213 -0.0282 -1.2793 -0.0225 -0.6426 -0.0451 -0.0113 -0.0338 -0.3833 -0.9580', 'S-1843\t⋅ Voranbringen der Neufassung von Leitlinien für Rückstände an der Injektionsstelle und Hinwirken auf einen Konsens innerhalb des CVMP', 'T-1843\t⋅ to progress the re-evaluation of guidelines on injection site residues and to reach consensus within CVMP', 'H-1843\t-1.8623046875\t⋅ to progress the revision of existing guideline on injection site residues and encourage a common position in the CVMP', 'D-1843\t-1.8623046875\t⋅ to progress the revision of existing guideline on injection site residues and encourage a common position in the CVMP', 'P-1843\t-0.0385 -0.8877 -1.0273 -1.4131 -0.5186 -0.0507 -0.0310 -1.5889 -0.5239 -0.1747 -0.0338 -0.4565 -0.2874 -0.1521 -0.0732 -0.0564 -0.0282 -0.0338 -0.4453 -1.5381 -0.9019 -1.3359 -0.7212 -0.8452 -0.5972 -0.1691 -0.0225 -0.0113 -0.0789', 'S-767\tBitte sprechen Sie mit Ihrem Arzt oder Apotheker, wenn Sie den Eindruck haben, dass die Wirkung von Procoralan zu stark oder zu schwach ist.', 'T-767\tIf you think that the effect of Procoralan is too strong or too weak, talk to your doctor or pharmacist.', 'H-767\t-0.382568359375\tIf you have the impression that the effect of Procoralan is too strong or too weak , talk to your doctor or pharmacist .', 'D-767\t-0.382568359375\tIf you have the impression that the effect of Procoralan is too strong or too weak, talk to your doctor or pharmacist.', 'P-767\t-0.3125 -0.0678 -0.6479 -0.1071 -0.0718 -0.0500 -0.0698 -0.1282 -0.0324 -0.1268 -0.0211 -0.0240 -0.0225 -0.1986 -0.0507 -0.0817 -0.0338 -0.0535 -0.0549 -0.0662 -0.3142 -0.0662 -0.0409 -0.0634 -0.0395 -0.0380 -0.0169 -0.0521 -0.0324', 'S-1677\tKontrollieren Sie das Pen-Etikett, um sicher zu sein, dass der Pen das Insulin enthält, das Ihnen verschrieben wurde.', 'T-1677\tCheck the label on the pen to be sure the pen contains the type of insulin that has been prescribed for you.', 'H-1677\t-1.1201171875\tCheck the pen label to make sure it contains the insulin you have been prescribed .', 'D-1677\t-1.1201171875\tCheck the pen label to make sure it contains the insulin you have been prescribed.', 'P-1677\t-0.8628 -0.6841 -0.6060 -0.2479 -0.0507 -1.0283 -0.0282 -0.9355 -0.0564 -0.0366 -0.2255 -0.0113 -1.1670 -0.2141 -0.0282 -0.2537 -0.0169 -0.0564 -0.0451', 'S-1193\t• Rapinyl löst sich rasch unter der Zunge auf, und der Wirkstoff wird dort schnell aufgenommen, um den Schmerz lindern zu können.', 'T-1193\t• Rapinyl will dissolve rapidly under the tongue and be absorbed in order to provide pain relief.', 'H-1193\t-1.275390625\tRapinyl dissolves rapidly under the tongue , where it is rapidly absorbed to alleviate pain .', 'D-1193\t-1.275390625\tRapinyl dissolves rapidly under the tongue, where it is rapidly absorbed to alleviate pain.', 'P-1193\t-0.8130 -0.0261 -0.0204 -1.2529 -0.0225 -0.0211 -0.4636 -0.5283 -0.2395 -0.0113 -0.0141 -2.0195 -0.5015 -0.2930 -0.0676 -0.6201 -0.3889 -0.0169 -0.1409 -1.0088 -0.0113 -0.0282 -0.1973 -0.0507 -0.0395', 'S-1626\tWAS IST LIPROLOG MIX50 PEN UND WOFÜR WIRD ES ANGEWENDET?', 'T-1626\tWHAT LIPROLOG MIX50 PEN IS AND WHAT IT IS USED FOR', 'H-1626\t-0.36279296875\tWHAT LIPROLOG MIX50 PEN IS AND WHAT IT IS USED FOR', 'D-1626\t-0.36279296875\tWHAT LIPROLOG MIX50 PEN IS AND WHAT IT IS USED FOR', 'P-1626\t-0.0292 -0.0177 -0.3215 -0.0141 -0.0285 -0.0183 -0.0634 -0.0299 -0.0349 -0.0257 -0.0694 -0.0162 -0.1145 -0.2712 -0.0465 -0.1761 -0.3149 -0.0634 -0.2029 -0.0310 -0.1620 -0.0127 -0.3169', 'S-856\tWAS IST LIPROLOG BASAL PEN UND WOFÜR WIRD ES ANGEWENDET?', 'T-856\tWHAT LIPROLOG Basal PEN IS AND WHAT IT IS USED FOR', 'H-856\t-0.5263671875\tWHAT LIPROLOG BASAL PEN IS AND WHAT IT IS USED FOR', 'D-856\t-0.5263671875\tWHAT LIPROLOG BASAL PEN IS AND WHAT IT IS USED FOR', 'P-856\t-0.0256 -0.0163 -0.3206 -0.0155 -0.0271 -0.0183 -0.0546 -1.0059 -0.0113 -0.1437 -0.0746 -0.0225 -0.1254 -0.2649 -0.0465 -0.1592 -0.3142 -0.0803 -0.1930 -0.0338 -0.1691 -0.0141 -0.3184', 'S-412\tDie Schachtel beinhaltet einen Beipackzettel mit einer vollständigen Anleitung zur Benutzung und Handhabung des vorgefüllten Injektors.', 'T-412\t169 The carton contains a package leaflet with the full instructions for use and handling.', 'H-412\t-0.9892578125\tThe carton contains a package leaflet with the full instructions for use and handling of the pre @-@ filled pen .', 'D-412\t-0.9892578125\tThe carton contains a package leaflet with the full instructions for use and handling of the pre-filled pen.', 'P-412\t-0.5845 -0.3525 -0.0458 -0.4121 -0.0859 -0.2578 -0.1790 -0.0099 -0.0169 -0.0775 -0.3748 -0.2944 -0.0817 -0.6201 -0.4509 -0.3860 -0.0592 -1.1777 -0.0423 -0.8198 -0.0282 -0.0169 -0.3213 -0.1014 -0.0282', 'S-24\tWAS MÜSSEN SIE VOR DER ANWENDUNG VON TRUDEXA BEACHTEN?', 'T-24\tBEFORE YOU USE TRUDEXA', 'H-24\t-0.383544921875\tBEFORE YOU USE TRUDEXA', 'D-24\t-0.383544921875\tBEFORE YOU USE TRUDEXA', 'P-24\t-0.3213 -0.0178 -0.0056 -0.3181 -0.0155 -0.0169 -0.6318 -0.0049 -0.1106 -0.0254 -0.0197 -0.0324 -0.0254 -0.3228', 'S-249\tDer Grad der Unterschiede zwischen einzelnen Patienten und zwischen den Laborbestimmungen der CD34 + -Zellmengen erschwert einen direkten Vergleich zwischen unterschiedlichen Studien.', 'T-249\tIt is therefore difficult to recommend an optimum method.', 'H-249\t-0.62744140625\tThe degree of variation between individual patients and between laboratory assays of CD34 + cells mean that direct comparison between different studies is difficult .', 'D-249\t-0.62744140625\tThe degree of variation between individual patients and between laboratory assays of CD34 + cells mean that direct comparison between different studies is difficult.', 'P-249\t-0.0531 -0.1227 -0.0349 -0.3120 -0.6411 -0.1895 -0.1360 -0.0324 -0.2874 -0.1353 -0.0620 -0.0197 -0.3213 -0.1381 -0.1085 -0.0775 -0.0169 -0.0240 -0.3340 -0.3296 -0.1381 -0.1719 -0.3494 -0.2001 -0.1240 -0.0676 -0.0535 -0.0817 -0.2367 -0.0282', 'S-1662\tDas relative Risiko (HR) lag bei 0,21 [95% CI 0,12-0,37] p < 0,0001.', 'T-1662\t(0.2%) for lumiracoxib versus 64 / 6968 patients (0.92%) for NSAIDs, with a hazard ratio (HR) of 0.21 [95% CI 0.12-0.37] p < 0.0001.', 'H-1662\t-0.399169921875\tThe relative risk ( HR ) was 0.21 &#91; 95 % CI , 0.12 @-@ 0.37 &#93; p &lt; 0.0001 .', 'D-1662\t-0.399169921875\tThe relative risk (HR) was 0.21 [95% CI, 0.12-0.37] p < 0.0001.', 'P-1662\t-0.3354 -1.1777 -0.0578 -0.0507 -0.1761 -0.0141 -0.0282 -0.0564 -0.0606 -0.0282 -0.0197 -0.0141 -0.0268 -0.0620 -0.0352 -0.3213 -0.0352 -0.0352 -0.0437 -0.0183 -0.0169 -0.0352 -0.2986 -0.0085 -0.0169 -0.0197 -0.0169 -0.0113 -0.0535 -0.0310 -0.0282', 'S-865\tDies entspricht einem Unterschied von 9,4 Monaten, ermittelt mit einem stratifizierten log-rank-Test, p-Wert = 0,0001.', 'T-865\tIn the ITT analysis of 358 patients (179 azacitidine and 179 CCR), Vidaza treatment was associated with a median survival of 24.46 months versus 15.02 months for those receiving CCR treatment, a difference of 9.4 months, with a stratified log-rank p-value of 0.0001.', 'H-865\t-0.87548828125\tThis corresponds to a difference of 9.4 months , determined by a stratified log @-@ rank test , p @-@ value = 0.0001 .', 'D-865\t-0.87548828125\tThis corresponds to a difference of 9.4 months, determined by a stratified log-rank test, p-value = 0.0001.', 'P-865\t-0.0531 -1.1826 -0.0225 -0.0345 -0.0458 -0.0930 -0.0324 -0.0507 -0.0254 -0.0324 -0.8296 -1.0811 -1.0820 -0.1155 -0.0225 -0.0169 -0.0282 -0.0113 -0.8145 -0.0085 -0.0930 -0.0451 -0.7046 -0.2255 -0.0338 -0.0225 -0.0338 -0.0169 -0.0564 -0.0338 -0.0282', 'S-293\tLatvija Magnum Veterinaaria AS Vae 16 EE-76401 Laagri Tel: + 372 650 1920', 'T-293\tLatvija Magnum Veterinaaria AS Vae 16 EE-76401 Laagri Tel: + 372 650 1920 Lietuva Magnum Veterinaaria AS Vae 16 EE-76401 Laagri Tel: + 372 650 1920', 'H-293\t-0.125244140625\tLatvija Magnum Veterinaaria AS Vae 16 EE @-@ 76401 Laagri Tel : + 372 650 1920', 'D-293\t-0.125244140625\tLatvija Magnum Veterinaaria AS Vae 16 EE-76401 Laagri Tel: + 372 650 1920', 'P-293\t-0.2527 -0.0306 -0.0127 -0.0113 -0.0255 -0.0099 -0.0271 -0.0243 -0.0127 -0.0106 -0.0292 -0.0155 -0.0292 -0.0271 -0.0218 -0.0349 -0.0085 -0.0257 -0.0211 -0.0313 -0.0211 -0.0113 -0.0729 -0.0655 -0.0211 -0.0240 -0.0099 -0.0092 -0.0183 -0.0254 -0.0430', 'S-825\tDie durchschnittliche Zeit für die Bearbeitung von Erstattungsansprüchen wurde reduziert, die Zahlungsberechnungen für alle Sitzungen wurden innerhalb einer Woche abgeschlossen.', 'T-825\tOverview Administration Unit Head of Unit Andreas POTT', 'H-825\t-1.7890625\tThe average response time to the reimbursement process has been reduced with payments for all meetings completed within one week .', 'D-825\t-1.7890625\tThe average response time to the reimbursement process has been reduced with payments for all meetings completed within one week.', 'P-825\t-0.5317 -0.2976 -0.8896 -0.1803 -1.0479 -0.4819 -0.3860 -0.0197 -0.0056 -0.0225 -0.3411 -1.2402 -0.0395 -0.2874 -1.6514 -1.2061 -1.2734 -0.0620 -0.2479 -1.3975 -0.0676 -0.5747 -0.0225 -0.0338 -0.0338', 'S-489\tNur bei Dosen, die deutlich über der Humandosis lagen, kam es bei Ratten und Kaninchen zu Foetotoxizität.', 'T-489\tIn prenatal / postnatal toxicity studies,', 'H-489\t-1.2880859375\tIn rats and rabbits , foetotoxicity occurred only at doses that were considerably higher than the human dose .', 'D-489\t-1.2880859375\tIn rats and rabbits, foetotoxicity occurred only at doses that were considerably higher than the human dose.', 'P-489\t-1.1592 -0.0817 -0.0310 -0.0106 -0.0077 -0.0232 -0.9688 -0.4861 -0.0211 -0.2620 -0.0225 -0.0282 -0.0254 -1.2344 -0.5073 -0.1578 -0.0564 -0.0169 -1.2002 -0.1014 -0.7046 -0.0225 -0.7158 -0.0282 -1.3408 -0.1747 -0.2479 -0.0451 -0.0282', 'S-166\tInformieren Sie den Arzt, der bei Ihnen diese Blutuntersuchungen durchführen lässt, dass Sie eine Impfung mit Pandemrix erhalten haben.', 'T-166\tTell the doctor requesting these tests that you have recently received Pandemrix.', 'H-166\t-1.025390625\tTell the doctor requesting these tests that you have recently received Prepandrix .', 'D-166\t-1.025390625\tTell the doctor requesting these tests that you have recently received Prepandrix.', 'P-166\t-0.5908 -0.0176 -0.0641 -0.1060 -0.3276 -0.0240 -0.2163 -0.5303 -0.1000 -0.0352 -0.1155 -0.3564 -0.2986 -0.6270 -1.6230 -0.4001 -0.0395 -0.0423 -0.3296 -0.3438', 'S-208\t• HBeAg-positiver und HBeAg-negativer chronischer Hepatitis B mit kompensierter Lebererkrankung', 'T-208\t• HBeAg positive and HBeAg negative chronic hepatitis B with compensated liver disease.', 'H-208\t-0.8291015625\t• HBeAg positive and HBeAg negative chronic hepatitis B with compensated liver disease', 'D-208\t-0.8291015625\t• HBeAg positive and HBeAg negative chronic hepatitis B with compensated liver disease', 'P-208\t-0.3699 -2.6230 -0.0254 -0.0254 -0.0282 -0.7749 -0.4255 -0.0282 -0.0225 -0.0254 -0.0282 -0.0225 -0.0197 -0.2339 -0.0085 -0.0141 -0.0225 -0.3127 -0.0169 -0.0310 -0.0395 -0.2986 -0.0451', 'S-1313\tNach meiner Auffassung sollten wir dieses Prinzip beibehalten, da es positive Auswirkungen auf die Leistungsqualität der EMEA und der nationalen Zulassungsbehörden hat.', 'T-1313\tIn my opinion we should maintain this principle as it has a positive influence on the quality of performance of the EMEA and the national regulatory authorities.', 'H-1313\t-1.8232421875\tI start with firm foundations built by the Sector for scientific advice and orphan drugs .', 'D-1313\t-1.8232421875\tI start with firm foundations built by the Sector for scientific advice and orphan drugs.', 'P-1313\t-0.2527 -0.8340 -0.2986 -1.6230 -0.3213 -0.0254 -0.8877 -0.6001 -0.8145 -1.1719 -0.1521 -0.3213 -0.8003 -0.3269 -0.7046 -0.8115 -0.3101 -0.2649 -0.3213 -0.3606 -0.1240', 'S-1594\tWas sind Doxazosin Retard Arrow [und andere Bezeichnungen] 4 mg Retardtabletten und wofür werden sie angewendet?', 'T-1594\tWhat Doxazosin Retard Arrow 4 mg prolonged release tablets and associated names is and what it is used for 2.', 'H-1594\t-0.66796875\tWhat Doxazosin Retard Arrow 4 mg prolonged release tablets and associated names is and what it is used for 2 .', 'D-1594\t-0.66796875\tWhat Doxazosin Retard Arrow 4 mg prolonged release tablets and associated names is and what it is used for 2.', 'P-1594\t-0.0285 -0.6162 -0.0183 -0.0155 -0.0141 -0.0490 -0.0211 -0.0268 -0.0155 -0.0113 -0.3120 -0.0127 -0.3228 -0.3184 -0.0366 -0.3142 -0.0676 -0.0380 -0.2974 -0.3228 -0.3228 -0.3213 -0.3071 -0.1381 -0.3213 -0.1324 -0.1099 -0.0310 -0.3213 -0.3184 -0.0592', 'S-469\tNovartis Animal Health UK Ltd Frimley Business Park Frimley / Camberley, Surrey, GU16 7SR United Kingdom', 'T-469\tNovartis Animal Health UK Ltd Frimley Business Park Frimley / Camberley, Surrey, GU16 7SR United Kingdom', 'H-469\t-0.0826416015625\tNovartis Animal Health UK Ltd Frimley Business Park Frimley / Camberley , Surrey , GU16 7SR United Kingdom', 'D-469\t-0.0826416015625\tNovartis Animal Health UK Ltd Frimley Business Park Frimley / Camberley, Surrey, GU16 7SR United Kingdom', 'P-469\t-0.0099 -0.0071 -0.0249 -0.0070 -0.0142 -0.0127 -0.0156 -0.0077 -0.0177 -0.0241 -0.0142 -0.0269 -0.0171 -0.0171 -0.0241 -0.0141 -0.0393 -0.0127 -0.0185 -0.0127 -0.0298 -0.0056 -0.0327 -0.0257 -0.0229 -0.0264 -0.0229 -0.0363 -0.0211 -0.0560 -0.0141 -0.0299', 'S-953\tEinschränkung der Leberfunktion Es liegen keine Daten zu Patienten mit schwerer Einschränkung der Leberfunktion (Child-Pugh- Klasse C) vor.', 'T-953\tHepatic impairment No data are available in patients with severe hepatic impairment (Child-Pugh class C).', 'H-953\t-0.7177734375\tHepatic impairment There are no data on patients with severe hepatic impairment ( Child @-@ Pugh Class C ) .', 'D-953\t-0.7177734375\tHepatic impairment There are no data on patients with severe hepatic impairment (Child-Pugh Class C).', 'P-953\t-0.7686 -0.0120 -0.2339 -0.2551 -0.0225 -0.0113 -0.0268 -0.2676 -0.1212 -0.0352 -0.0718 -1.1670 -0.0423 -0.0535 -0.0310 -0.5186 -0.0338 -0.0197 -0.0197 -0.0056 -0.0085 -0.0282 -0.0395 -0.2817 -0.2113 -0.0141 -0.1635 -0.9355 -0.0225 -0.0310 -0.2593 -0.0310', 'S-1026\tBioMarin Pharmaceutical Inc, Galli Drive Facility, 46 Galli Drive, Novato, CA 94949, USA', 'T-1026\tBioMarin Pharmaceutical Inc, Galli Drive Facility, 46 Galli Drive, Novato, CA 94949, USA', 'H-1026\t-0.306640625\tBioMarin Pharmaceutical Inc , Galli Drive , 46 Galli Drive , Novato , CA 94949 , USA', 'D-1026\t-0.306640625\tBioMarin Pharmaceutical Inc, Galli Drive, 46 Galli Drive, Novato, CA 94949, USA', 'P-1026\t-0.0085 -0.0242 -0.0270 -0.0270 -0.0085 -0.0234 -0.0128 -0.0213 -0.0142 -0.0856 -0.0070 -0.0262 -0.0185 -1.2129 -0.0127 -0.0085 -0.0268 -0.0113 -0.0296 -0.0113 -0.0127 -0.0296 -0.0127 -0.0282 -0.0113 -0.0183 -0.2085 -0.0366 -0.3367', 'S-619\tZur optimalen Behandlung von Flohbefall in einem Haushalt mit mehreren Tieren sollten sämtliche Haustiere mit einem geeigneten Insektizid behandelt werden.', 'T-619\tFor optimum control of flea problems in a multi-pet household, all pets in the household should be treated with a suitable insecticide.', 'H-619\t-1.1533203125\tTo benefit from optimal control of flea infestations in a household with several animals , all pets should be treated with a suitable insecticide .', 'D-619\t-1.1533203125\tTo benefit from optimal control of flea infestations in a household with several animals, all pets should be treated with a suitable insecticide.', 'P-619\t-0.7905 -1.6709 -0.0746 -0.2817 -0.3325 -0.0564 -0.2057 -0.0254 -0.1353 -0.0085 -0.7554 -0.0676 -0.1888 -0.2029 -0.8398 -1.1670 -0.0620 -0.0676 -0.9863 -0.7666 -0.0225 -0.0451 -0.0451 -0.0338 -0.0338 -0.3889 -0.0225 -0.0282 -0.0056 -0.0169 -0.0113 -0.0338 -0.0282', 'S-1289\tSmithKline Beecham Crawley Manufacturing Site Manor Royal West Sussex RH10 2QJ Vereinigtes Königreich 88', 'T-1289\tManufacturer or SmithKline Beecham Crawley Manufacturing Site Manor Royal West Sussex RH10 2QJ United Kingdom', 'H-1289\t-0.1427001953125\tSmithKline Beecham Crawley Manufacturing Site Manor Royal West Sussex RH10 2QJ United Kingdom 88', 'D-1289\t-0.1427001953125\tSmithKline Beecham Crawley Manufacturing Site Manor Royal West Sussex RH10 2QJ United Kingdom 88', 'P-1289\t-0.0049 -0.0227 -0.0263 -0.0184 -0.0184 -0.0121 -0.0234 -0.0028 -0.0156 -0.0113 -0.0199 -0.0255 -0.0206 -0.0113 -0.0185 -0.0241 -0.0213 -0.3599 -0.0085 -0.0141 -0.0271 -0.0243 -0.0261 -0.0197 -0.0197 -0.0120 -0.2410 -0.0120 -0.0085 -0.0275', 'S-1945\tSie dürfen Cetrotide 0,25 mg nicht verwenden, wenn Sie bereits schwanger sind oder vermuten, schwanger zu sein oder wenn Sie stillen.', 'T-1945\tYou should not use Cetrotide 0.25 mg if you are already pregnant, or suspect that you might be pregnant, or if you are breast-feeding.', 'H-1945\t-0.8701171875\tYou should not use Cetrotide 0.25 mg if you are already pregnant , or suspect that you might be pregnant , or if you are breast @-@ feeding .', 'D-1945\t-0.8701171875\tYou should not use Cetrotide 0.25 mg if you are already pregnant, or suspect that you might be pregnant, or if you are breast-feeding.', 'P-1945\t-0.3992 -0.2585 -0.0409 -0.3667 -0.2050 -0.0247 -0.0254 -0.1050 -0.2402 -0.0704 -0.0296 -0.0606 -0.0268 -0.0437 -0.0775 -0.0225 -0.7427 -0.3718 -0.5522 -0.3748 -0.0338 -0.9326 -0.0338 -0.2085 -0.6538 -0.0225 -0.2085 -0.0338 -0.0507 -0.5806 -0.3381 -0.0225 -0.0338 -0.0282', 'S-516\tWird der Inhalt von mehr als einer Durchstechflasche benötigt, so verfahren Sie entsprechend den Punkten c und d, bis die erforderliche Menge gelöst ist.', 'T-516\tIf you need to dissolve more than one freeze-dried cake, then repeat the actions described under points c. and d. until the required number of freeze-dried cakes is dissolved.', 'H-516\t-1.1220703125\tIf you need to dissolve more than one vial , then repeat the actions described under points c and d until the required number of solvents is dissolved .', 'D-516\t-1.1220703125\tIf you need to dissolve more than one vial, then repeat the actions described under points c and d until the required number of solvents is dissolved.', 'P-516\t-0.0774 -0.2959 -0.3650 -0.3318 -0.3232 -0.0169 -0.1268 -0.0296 -0.0352 -0.1859 -0.0141 -0.1268 -0.6904 -0.6777 -0.2001 -0.3240 -0.3157 -0.3662 -0.2761 -0.0395 -0.0338 -0.0169 -0.2705 -0.1155 -0.2986 -1.3613 -0.4338 -0.9355 -0.6143 -0.0225 -0.3833 -0.2311 -0.0169 -0.0225 -0.0338 -0.0282', 'S-333\t1 g alle 8 Stunden über 7 bis 10 Tage kommt es zu keiner Akkumulation von Doripenem bei Patienten mit normaler Nierenfunktion.', 'T-333\tThere is no accumulation of doripenem following multiple intravenous infusions of either 500 mg or 1 g administered every 8 hours for 7 to 10 days in patients with normal renal function.', 'H-333\t-0.75244140625\t1 g every 8 hours for 7 to 10 days , there is no accumulation of doripenem in patients with normal renal function .', 'D-333\t-0.75244140625\t1 g every 8 hours for 7 to 10 days, there is no accumulation of doripenem in patients with normal renal function.', 'P-333\t-0.4485 -0.0342 -0.0715 -0.0423 -0.0271 -0.3169 -0.5361 -0.0704 -0.0282 -0.0268 -1.0664 -1.9531 -0.0535 -0.0338 -0.0310 -0.0225 -0.0310 -0.1747 -0.0113 -0.0479 -0.0254 -0.0366 -0.3240 -0.0338 -0.0395 -0.1917 -0.0197 -0.0254 -0.0338 -0.0310', 'S-664\tEs können also Interaktionen auftreten, wenn Effentora zusammen mit Substanzen angewendet wird, die die CYP3A4-Aktivität beeinflussen.', 'T-664\tFentanyl is metabolised mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4), therefore potential interactions may occur when Effentora is given concurrently with agents that affect CYP3A4 activity.', 'H-664\t-1.0673828125\tTherefore , interactions may occur when Effentora is used in combination with substances influencing CYP3A4 activity .', 'D-664\t-1.0673828125\tTherefore, interactions may occur when Effentora is used in combination with substances influencing CYP3A4 activity.', 'P-664\t-0.4463 -0.0176 -0.2886 -1.0381 -0.0324 -0.1803 -0.0409 -0.8159 -0.1127 -0.0169 -0.0169 -0.3972 -0.6567 -0.8564 -0.6479 -0.0282 -0.3296 -0.0169 -1.5215 -0.0225 -0.0901 -0.0225 -0.0282 -0.0225 -0.0113 -0.1578 -0.0338 -0.0282', 'S-1415\tInsgesamt 118 Patienten wurden randomisiert einer Behandlung mit Xeloda in Kombination mit Oxaliplatin und Bevacizumab zugeteilt:', 'T-1415\tXeloda (800 mg / m2 twice daily for two weeks followed by a 7-day rest period), irinotecan (200 mg / m2 as a 30 minute infusion on day 1 every 3 weeks), and bevacizumab (7.5 mg / kg as a 30 to 90 minute infusion on day 1 every 3 weeks); a total of 118 patients were randomised to treatment with Xeloda combined with oxaliplatin plus bevacizumab:', 'H-1415\t-0.35498046875\tA total of 118 patients were randomised to treatment with Xeloda in combination with oxaliplatin and bevacizumab :', 'D-1415\t-0.35498046875\tA total of 118 patients were randomised to treatment with Xeloda in combination with oxaliplatin and bevacizumab:', 'P-1415\t-0.1266 -0.0213 -0.0270 -0.0255 -0.0227 -0.6187 -0.0528 -0.0042 -0.2360 -0.0070 -0.0268 -0.0571 -0.3269 -0.0366 -0.0225 -0.0056 -0.0183 -0.4438 -0.0197 -0.0296 -0.0127 -0.0113 -0.0197 -0.5000 -0.0310 -0.0225 -0.0183 -0.0070 -0.0056 -0.0169 -0.0211 -0.0704 -0.0282', 'S-492\tTritace 1.25 Evropská 2590 / 33c Tritace 2.5 16000 Praha 6 Tritace 5 Tschechien Tritace 10', 'T-492\tTritace 1.25 Evropská 2590 / 33c Tritace 2.5 16000 Praha 6 Tritace 5 Czech Republic Tritace 10', 'H-492\t-0.481201171875\tTritace 1.25 Evropská 2590 / 33c Tritace 2.5', 'D-492\t-0.481201171875\tTritace 1.25 Evropská 2590 / 33c Tritace 2.5', 'P-492\t-0.0270 -0.0092 -0.0113 -0.0220 -0.0228 -0.0976 -0.0113 -0.0472 -0.0099 -0.0227 -0.0178 -0.0278 -0.0162 -0.0229 -0.0285 -0.0085 -0.0099 -0.0099 -2.3926', 'S-1046\tDie Ergebnisse zeigten keinen bedeutenden Effekt einer Leberfunktionsstörung auf die AUC oder Cmax von Methylnaltrexonium.', 'T-1046\tResults showed no meaningful effect of hepatic impairment on the AUC or Cmax of methylnaltrexone.', 'H-1046\t-0.6494140625\tThe results showed no significant effect of hepatic impairment on AUC or Cmax of methylnaltrexone .', 'D-1046\t-0.6494140625\tThe results showed no significant effect of hepatic impairment on AUC or Cmax of methylnaltrexone.', 'P-1046\t-0.5654 -0.0518 -0.8960 -0.0338 -0.0352 -0.0437 -0.0395 -0.4805 -0.0690 -0.0197 -0.5718 -0.1240 -0.0141 -0.0310 -0.0507 -0.8198 -0.0225 -0.3240 -0.0338 -0.0141 -0.0564 -0.0113 -0.0310 -0.0225 -0.1635 -0.0732 -0.0169 -0.3213 -0.0338 -0.0282', 'S-1807\tDieses Syndrom ist eine granulomatöse entzündliche Erkrankung, die die Augen, das Gehörsystem, die Meningen und die Haut betrifft.', 'T-1807\tThis syndrome is a granulomatous inflammatory disorder affecting the eyes, auditory system, meninges, and skin.', 'H-1807\t-0.9345703125\tThis syndrome is a granulomatous inflammatory disorder that affects the eyes , the ear system , the meninges and skin .', 'D-1807\t-0.9345703125\tThis syndrome is a granulomatous inflammatory disorder that affects the eyes, the ear system, the meninges and skin.', 'P-1807\t-0.7817 -0.2410 -0.0169 -0.0359 -0.0451 -0.3445 -0.0268 -0.0380 -0.0268 -0.0141 -0.2720 -0.0197 -0.0141 -0.0155 -0.3550 -1.2188 -0.2705 -0.0451 -0.0423 -0.0310 -1.0938 -0.3269 -0.1014 -0.0310 -0.7637 -0.3381 -0.0056 -0.0282 -0.6030 -0.2705 -0.0338 -0.0282', 'S-1911\tZweitens müssen die zuständigen europäischen Einrichtungen davon überzeugt werden, daß es notwendig ist, der Agentur zu gestatten, eine begrenzte mehrjährige Rücklage zu schaffen.', 'T-1911\tSecondly, the relevant European institutions will need to be persuaded of the need to allow the Agency to create a limited pluri-annual reserve.', 'H-1911\t-1.7958984375\tSecondly , the national competent authorities must be convinced of the need to allow the Agency to provide a limited multi @-@ State reserve .', 'D-1911\t-1.7958984375\tSecondly, the national competent authorities must be convinced of the need to allow the Agency to provide a limited multi-State reserve.', 'P-1911\t-1.9287 -0.0183 -0.3438 -0.5088 -0.9595 -0.2395 -0.0225 -1.0059 -0.8623 -0.0338 -0.3662 -0.1353 -0.0282 -0.2423 -0.0507 -0.5747 -0.0395 -0.7778 -0.0395 -0.4001 -0.8677 -0.0338 -1.7021 -0.0282 -0.7383 -1.2402 -0.0451 -0.0338', 'S-683\tJuli 1999 erteilte die Europäische Kommission dem Unternehmen Norton Healthcare Limited eine Genehmigung für das Inverkehrbringen von Paxene in der gesamten Europäischen Union.', 'T-683\tThe European Commission granted a marketing authorisation valid throughout the European Union, for Paxene to Norton Healthcare Limited on 19 July 1999.', 'H-683\t-1.416015625\tIn July 1999 , the European Commission granted a marketing authorisation valid throughout the European Union for Paxene to Norton Healthcare Limited .', 'D-683\t-1.416015625\tIn July 1999, the European Commission granted a marketing authorisation valid throughout the European Union for Paxene to Norton Healthcare Limited.', 'P-683\t-3.0469 -0.0282 -0.0169 -0.9326 -0.0338 -0.0535 -0.0225 -0.2507 -0.2874 -0.1014 -0.0535 -0.0141 -0.3213 -0.0423 -0.2169 -0.0338 -0.4114 -0.0282 -0.8398 -1.2002 -0.0225 -0.0169 -0.0732 -2.9141 -0.0056 -0.0113 -0.0225 -0.0225 -0.0113 -0.0507 -0.0282', 'S-863\tJuli 1997 erteilte die Europäische Kommission dem Unternehmen Intervet International B.V. eine Genehmigung für das Inverkehrbringen von Quadrisol in der gesamten Europäischen Union.', 'T-863\tThe European Commission granted a marketing authorisation valid throughout the European Union, for Quadrisol to Intervet International B. V. on 16 July 1997.', 'H-863\t-0.7880859375\tThe European Commission granted a marketing authorisation valid throughout the European Union for Quadrisol to Intervet International B. V. on 14 July 1997 .', 'D-863\t-0.7880859375\tThe European Commission granted a marketing authorisation valid throughout the European Union for Quadrisol to Intervet International B. V. on 14 July 1997.', 'P-863\t-0.3074 -0.0752 -0.0236 -0.2800 -0.2993 -0.1085 -0.0592 -0.0183 -0.3220 -0.0423 -0.2283 -0.0352 -0.4226 -0.0324 -0.5620 -0.3960 -0.0225 -0.0648 -0.0225 -0.1296 -0.1155 -0.0113 -0.0225 -0.3213 -0.0760 -0.2507 -1.7754 -0.0732 -0.0282 -0.0338 -0.0282', 'S-999\tDieser Anteil ist ca. um das 3fache höher als die nicht an Protein gebundene (freie) Efavirenz-Fraktion in Plasma.', 'T-999\tThis proportion is approximately 3-fold higher than the non-protein-bound (free) fraction of efavirenz in plasma.', 'H-999\t-1.4384765625\tThis proportion is approximately 3 @-@ fold higher than the proteinbound ( free ) efavirenz fraction in plasma .', 'D-999\t-1.4384765625\tThis proportion is approximately 3-fold higher than the proteinbound (free) efavirenz fraction in plasma.', 'P-999\t-0.9902 -0.3677 -0.4988 -0.8594 -0.5972 -0.5239 -0.4226 -0.3352 -0.0366 -0.5186 -1.9326 -0.8623 -1.0312 -0.1973 -0.1296 -0.0282 -0.4058 -0.0113 -0.0845 -0.0620 -0.2761 -0.0225 -0.0225 -0.1635 -0.3777 -0.0113 -0.0169 -0.0338 -0.0282', 'S-1432\tDie nachfolgend aufgeführten Nebenwirkungen wurden aus allen klinischen Studien mit insgesamt 5.788 hypertensiven mit Telmisartan behandelten Patienten gesammelt.', 'T-1432\tThe following adverse drug reactions listed below have been accumulated from all clinical trials including 5788 hypertensive patients treated with telmisartan.', 'H-1432\t-1.1181640625\tThe adverse reactions listed below have been collected from all clinical studies including 5,788 hypertensive patients treated with telmisartan .', 'D-1432\t-1.1181640625\tThe adverse reactions listed below have been collected from all clinical studies including 5,788 hypertensive patients treated with telmisartan.', 'P-1432\t-0.1282 -1.4902 -0.0056 -1.0693 -0.0042 -0.4072 -0.0254 -0.3748 -0.0310 -0.7690 -0.2874 -0.0535 -0.0366 -0.9072 -0.8340 -1.4033 -0.0225 -0.0113 -0.0169 -0.0169 -0.0169 -0.0676 -0.4395 -0.0282 -0.0225 -0.0225 -0.0113 -0.0282 -0.0451 -0.0282', 'S-1466\tKinder Fentanyl-ratiopharm sollte bei Kindern unter 12 Jahren nicht angewendet werden, da nur begrenzte Erfahrungen mit der Anwendung bei Kindern vorliegen.', 'T-1466\tChildren Fentanyl-ratiopharm should not be administered to children under 12 years of age because there is limited experience of use in children.', 'H-1466\t-1.505859375\tChildren Lansoprazol should not be used in children under 12 years of age because of limited experience with use in children .', 'D-1466\t-1.505859375\tChildren Lansoprazol should not be used in children under 12 years of age because of limited experience with use in children.', 'P-1466\t-1.1865 -1.6768 -0.8340 -1.4453 -0.3213 -0.0310 -0.4846 -0.0338 -0.0338 -0.0676 -0.4678 -0.0282 -0.5635 -0.1183 -0.1296 -0.2930 -0.0225 -1.6172 -0.6763 -0.1071 -0.0845 -0.1409 -0.3606 -0.0620 -0.0338 -0.0338 -0.0282', 'S-192\tAugenleiden Trockene Augen, Hornhauttrübungen, Nachtblindheit und Keratitis klingen nach Absetzen der Behandlung gewöhnlich ab.', 'T-192\tHowever, discontinuation isotretinoin may be insufficient to alleviate symptoms and therefore further psychiatric psychological evaluation may be necessary.', 'H-192\t-1.0712890625\tBenign intracranial hypertension Cases of benign intracranial hypertension have been reported .', 'D-192\t-1.0712890625\tBenign intracranial hypertension Cases of benign intracranial hypertension have been reported.', 'P-192\t-0.3293 -0.2089 -0.0486 -0.3240 -0.1683 -0.3303 -0.0085 -0.0183 -0.3206 -0.2212 -0.3325 -0.1691 -0.2734 -0.3269 -0.0056 -0.0197 -0.3325 -0.1521 -0.2029 -0.0028 -0.0141 -0.3101 -0.1268 -0.3381 -0.2620 -0.2057 -2.8086 -0.0507', 'S-1932\t55 --------------------------------------------------------------------------------------------------------------------------- Die folgenden Informationen sind nur für Ärzte bzw. medizinisches Fachpersonal bestimmt:', 'T-1932\t52 ----------------------------------------------------------------------------------------------------------------------------- This information is intended for medical or healthcare professionals only.', 'H-1932\t-0.73046875\t52 --------------------------------------------------------------------------------------------------------------------------- The following information is intended for medical or healthcare professionals only :', 'D-1932\t-0.73046875\t52 --------------------------------------------------------------------------------------------------------------------------- The following information is intended for medical or healthcare professionals only:', 'P-1932\t-1.6543 -0.1198 -0.0183 -0.0211 -0.0240 -0.0268 -0.0268 -0.0254 -0.0254 -0.0240 -0.0225 -0.0211 -0.0211 -0.0225 -0.0352 -0.4001 -1.0703 -0.3101 -0.0282 -0.0479 -0.0564 -0.1635 -0.1550 -0.2057 -0.3184 -0.2959 -0.0310 -0.0732 -0.3523 -0.0282', 'S-563\tSchwindel, Kopfschmerzen, Somnolenz plötzliches Einschlafen, Synkope Amnesie, Dyskinesie, Hyperkinesie', 'T-563\tdizziness, headache, somnolence sudden onset of sleep, syncope amnesia, dyskinesia, hyperkinesia', 'H-563\t-0.3994140625\tdizziness , headache , somnolence sudden onset of sleep , syncope amnesia , dyskinesia , hyperkinesia', 'D-563\t-0.3994140625\tdizziness, headache, somnolence sudden onset of sleep, syncope amnesia, dyskinesia, hyperkinesia', 'P-563\t-1.0430 -0.0099 -0.0211 -0.0296 -0.0190 -0.0113 -0.1388 -0.0303 -0.0099 -0.0331 -0.0099 -0.0514 -0.1790 -0.5298 -0.0225 -0.0704 -0.1508 -0.0310 -0.0324 -0.0197 -0.4170 -0.0028 -0.0056 -0.0282 -0.0282 -0.0113 -0.0141 -0.0141 -0.0338 -0.0197 -0.0197 -0.0141 -0.2283 -0.0338', 'S-669\tEine geringe bis mäßige Nierenfunktionsstörung beeinflusst die pharmakokinetischen Parameter von Palonosetron nicht signifikant.', 'T-669\tRenal impairment: mild to moderate renal impairment does not significantly affect palonosetron pharmacokinetic parameters.', 'H-669\t-0.560546875\tMild to moderate renal impairment does not significantly affect the pharmacokinetic parameters of palonosetron .', 'D-669\t-0.560546875\tMild to moderate renal impairment does not significantly affect the pharmacokinetic parameters of palonosetron.', 'P-669\t-0.9531 -0.0162 -0.0465 -0.0169 -0.1169 -0.0169 -0.6567 -0.0718 -0.0099 -0.0268 -0.2944 -0.0268 -0.0845 -0.8579 -0.2283 -0.0479 -0.0113 -0.0085 -0.2620 -0.1635 -0.0141 -0.0197 -0.0310 -0.1747 -0.0225 -0.0141 -0.0197 -0.0395 -0.0338 -0.0282', 'S-964\tFrance Laboratoire GlaxoSmithKline Tél: + 33 (0) 1 39 17 84 44 diam @ gsk.com', 'T-964\tFrance Laboratoire GlaxoSmithKline Tél: + 33 (0) 1 39 17 84 44 diam @ gsk. com', 'H-964\t-0.2037353515625\tFrance Laboratoire GlaxoSmithKline Tél : + 33 ( 0 ) 1 39 17 84 44 diam @ gsk.com', 'D-964\t-0.2037353515625\tFrance Laboratoire GlaxoSmithKline Tél: + 33 (0) 1 39 17 84 44 diam @ gsk.com', 'P-964\t-0.0414 -0.0321 -0.4143 -0.0257 -0.0211 -0.0127 -0.0134 -0.0225 -0.0236 -0.0070 -0.0243 -0.0278 -0.0197 -0.1032 -0.0282 -0.0197 -0.0366 -0.0282 -0.0218 -0.0275 -0.0254 -0.0282 -0.0268 -0.0162 -0.0211 -0.0127 -0.0204 -0.4648 -0.0211 -0.0197 -0.0014 -0.0211 -0.0310', 'S-1056\tÍsland Actelion Pharmaceuticals Sverige AB Simi: + 46- (0) 8 544 982 50', 'T-1056\tÍsland Actelion Pharmaceuticals Sverige AB Sími: + 46- (0) 8 544 982 50', 'H-1056\t-0.53564453125\tActelion Pharmaceuticals Sverige AB Simi : + 46- ( 0 ) 8 544 982 50', 'D-1056\t-0.53564453125\tActelion Pharmaceuticals Sverige AB Simi: + 46- (0) 8 544 982 50', 'P-1056\t-3.3242 -0.0169 -0.0254 -0.0282 -0.0395 -0.0113 -0.0225 -0.0113 -0.0169 -0.0254 -0.0564 -0.0197 -0.0056 -0.0056 -0.1014 -0.0254 -0.0507 -0.0338 -0.0282 -0.0282 -0.0254 -0.0254 -0.0282 -0.0310 -0.0254 -0.0141 -0.0225 -0.0113 -0.0254 -0.0366', 'S-138\tWachstumshormonmangel bei Erwachsenen Spritzen Sie 0,15 - 0,30 Milligramm (mg) einmal täglich unter die Haut (subkutan).', 'T-138\tGrowth hormone deficiency in adults Inject 0.15 - 0.30 milligrams (mg) once daily under the skin (subcutaneously).', 'H-138\t-0.452880859375\tGrowth hormone deficiency in adults Inject 0.15 - 0.30 milligrams ( mg ) once daily under the skin ( subcutaneously ) .', 'D-138\t-0.452880859375\tGrowth hormone deficiency in adults Inject 0.15 - 0.30 milligrams (mg) once daily under the skin (subcutaneously).', 'P-138\t-0.0931 -0.0170 -0.1044 -0.0171 -0.0227 -0.0070 -0.0248 -0.0458 -0.0276 -0.2688 -0.0472 -0.0740 -0.0254 -0.0979 -0.0247 -0.0303 -0.0437 -0.0655 -0.0296 -0.0127 -0.0296 -0.5552 -0.8721 -0.2324 -0.2494 -0.0169 -0.0310 -0.0395 -0.0085 -0.0113 -0.0310 -0.5747 -0.0282 -0.0366 -0.0282', 'S-1627\tB. die Epilepsie selbst, dazu beitragen können, weisen die verfügbaren Erkenntnisse darauf hin, dass dieser Anstieg weitgehend auf die Behandlung zurückzuführen ist.', 'T-1627\tAlthough other factors, e. g. the epilepsy, can contribute, available evidence suggests that this increase, to a large extent, is caused by the treatment.', 'H-1627\t-2.755859375\tA higher risk of lipodystrophy has been reported .', 'D-1627\t-2.755859375\tA higher risk of lipodystrophy has been reported.', 'P-1627\t-2.4434 -2.2168 -1.1387 -0.1127 -1.1553 -0.4170 -0.3213 -0.2479 -0.0056 -0.8057 -0.6201 -0.5635 -2.9141 -0.4622', 'S-1641\tApril 2004 verfügbaren zusätzlichen Daten kam der CHMP zu der Schlussfolgerung, dass seine früheren Schlussfolgerungen und Empfehlungen nicht aufgrund dieser Daten verändert werden.', 'T-1641\tThe CHMP, having considered the additional data that became available after the opinion of 22 April 2004, concluded that such data do not change its previous conclusions and recommendations.', 'H-1641\t-1.82421875\tThe CHMP came to the conclusion that the additional data available on 19 April 2004 do not change its previous conclusions and recommendations based on these data .', 'D-1641\t-1.82421875\tThe CHMP came to the conclusion that the additional data available on 19 April 2004 do not change its previous conclusions and recommendations based on these data.', 'P-1641\t-0.7148 -0.4590 -0.0092 -1.8066 -0.0225 -0.0423 -0.0197 -0.1437 -1.1074 -1.3271 -0.0535 -0.3804 -0.6821 -1.7080 -0.0901 -0.0338 -2.3105 -0.5186 -0.4395 -0.1578 -0.2141 -0.0338 -0.0225 -0.0676 -0.1803 -1.1943 -0.0451 -0.4282 -0.0451 -0.0338 -0.0338', 'S-403\tDie genaue Dauer des Impfschutzes gegenüber einer Hepatitis-A- oder Hepatitis-B-Virusinfektion ist nicht bekannt.', 'T-403\tIt is not known exactly how long protection against infection with hepatits A and B viruses will last, although protection against hepatitis A virus probably lasts about 10 years.', 'H-403\t-0.83349609375\tThe exact duration of protection against hepatitis A or B virus infection is unknown .', 'D-403\t-0.83349609375\tThe exact duration of protection against hepatitis A or B virus infection is unknown.', 'P-403\t-0.3081 -0.4075 -0.0500 -0.0254 -0.0317 -1.6387 -0.3284 -0.1409 -0.0085 -0.0169 -0.0366 -0.0479 -0.7944 -0.1240 -0.0986 -0.0366 -0.7188 -0.0338 -0.0310', 'S-764\tDies steht im Einklang mit der Empfehlung der Arbeitsgruppe Pharmakovigilanz des CHMP zur Anwendung von ACE-Hemmern in der Schwangerschaft.', 'T-764\tThis is in line with the recommendation of the CHMP <<unk>> s Pharmacovigilance Working Party on the use of ACE inhibitors in pregnancy.', 'H-764\t-1.310546875\tThis is in line with the recommendations of the CHMP Pharmacovigilance Working Party on use of AEC @-@ I in pregnancy .', 'D-764\t-1.310546875\tThis is in line with the recommendations of the CHMP Pharmacovigilance Working Party on use of AEC-I in pregnancy.', 'P-764\t-1.1924 -0.1965 -0.2529 -0.2944 -0.0282 -0.0409 -1.4756 -0.6821 -0.2847 -0.1803 -0.0141 -0.7720 -0.0085 -0.0141 -0.0141 -0.0056 -0.0197 -0.0197 -0.2705 -0.0225 -0.4846 -1.0986 -0.3381 -0.0282 -0.5635 -0.3213 -0.3606 -0.9805 -0.3833 -0.0789 -0.0338 -0.0282', 'S-832\tDaTSCAN sollte nur bei Patienten angewendet werden, die von Ärzten mit Erfahrung in der Behandlung von Bewegungsstörungen und / oder Demenz überwiesen werden.', 'T-832\tDaTSCAN should only be used in patients referred by physicians experienced in the management of movement disorders and / or dementia.', 'H-832\t-0.6103515625\tDaTSCAN should only be used in patients who have been referred by physicians experienced in the management of movement disorders and / or dementia .', 'D-832\t-0.6103515625\tDaTSCAN should only be used in patients who have been referred by physicians experienced in the management of movement disorders and / or dementia.', 'P-832\t-0.0538 -0.0256 -0.0128 -0.0142 -0.0342 -0.1028 -0.0299 -0.2367 -0.1373 -0.4360 -0.2974 -0.3860 -0.0606 -0.0423 -0.0803 -0.5366 -0.0183 -0.6680 -0.0395 -0.2676 -0.7383 -0.0310 -0.2620 -0.0958 -0.0169 -0.0338 -0.0282 -0.0225 -0.0197 -0.0338 -0.0282', 'S-10\tBei beiden Studien zeigte die überwiegende Zahl der Patienten eine teilweise Reaktion auf die Behandlung mit Atriance, wobei die Blutwerte auf normale Werte zurückgingen.', 'T-10\tIn both studies, more patients had a partial response to Atriance treatment, with blood counts returning towards normal levels.', 'H-10\t-1.5107421875\tIn both studies , the majority of patients showed a partial reaction to Atriance treatment , with blood tests returning to normal levels .', 'D-10\t-1.5107421875\tIn both studies, the majority of patients showed a partial reaction to Atriance treatment, with blood tests returning to normal levels.', 'P-10\t-0.9219 -0.0310 -0.4207 -0.3381 -0.1733 -0.5059 -0.0352 -0.5044 -1.0479 -1.2285 -0.0141 -0.6226 -0.0338 -0.4395 -0.0056 -0.0225 -1.2451 -0.7100 -0.1578 -0.2311 -1.4375 -0.1691 -0.2537 -0.0732 -0.2255 -0.0338 -0.0282', 'S-842\tEconor enthält den arzneilich wirksamen Bestandteil Valnemulin in den Konzentrationen 0,5%, 1%, 10% oder 50%.', 'T-842\tEconor contains the active substance valnemulin at 0.5%, 1%, 10%, and 50%.', 'H-842\t-0.79931640625\tEconor contains the active ingredient valnemulin at concentrations of 0.5 % , 1 % , 10 % or 50 % .', 'D-842\t-0.79931640625\tEconor contains the active ingredient valnemulin at concentrations of 0.5%, 1%, 10% or 50%.', 'P-842\t-0.0444 -0.0249 -0.5869 -0.6514 -0.2184 -1.3652 -0.0169 -0.0085 -0.5918 -0.0338 -0.0310 -0.0395 -1.4482 -0.5015 -0.0113 -0.0197 -0.0648 -0.0817 -0.0479 -0.0282 -0.0282 -0.0282 -0.0282 -0.0282 -0.0282 -0.0789 -0.0225 -0.0282 -0.0338 -0.0338', 'S-885\tDarüber hinaus muss im Falle eines Absetzens der Glucocorticoide die schrittweise Dosisreduktion über einen längeren Zeitraum durchgeführt werden.', 'T-885\tMoreover, in case of withdrawal of glucocorticoids progressive dose reduction may be required over a longer period.', 'H-885\t-1.4521484375\tFurthermore , in case of withdrawal of glucocorticoids progressive dose reduction may have to be performed over a longer period of time .', 'D-885\t-1.4521484375\tFurthermore, in case of withdrawal of glucocorticoids progressive dose reduction may have to be performed over a longer period of time.', 'P-885\t-2.1504 -0.0183 -0.0282 -0.0704 -2.5664 -1.1436 -0.0676 -0.3101 -0.0507 -0.2537 -0.0395 -0.0169 -0.0282 -0.0225 -0.0225 -0.3833 -0.3325 -0.1353 -0.3606 -0.3269 -0.0225 -0.0395 -0.3833 -0.0507 -0.5635 -0.6538 -0.0507 -1.2285 -0.0225 -0.0338 -0.0282', 'S-398\tDiese Dosis entsprach dem 25.000fachen der empfohlenen humantherapeutischen Tagesdosis für Erwachsene (bei einem Körpergewicht von 50 kg).', 'T-398\tThis dose is equivalent to 25,000 times the recommended daily adult human dose (based on an adult patient weight of 50 kg).', 'H-398\t-1.517578125\tThis dose was equivalent to 25,000 times the recommended daily human therapeutic dose for adults ( for body weight of 50 kg ) .', 'D-398\t-1.517578125\tThis dose was equivalent to 25,000 times the recommended daily human therapeutic dose for adults (for body weight of 50 kg).', 'P-398\t-0.7124 -0.3953 -0.3057 -2.9355 -0.0310 -0.1437 -0.2367 -0.3240 -0.3748 -0.3945 -0.7158 -1.2852 -0.0282 -0.0789 -0.2930 -0.0282 -0.0338 -1.1494 -0.6367 -0.0338 -0.3718 -0.0676 -0.0395 -0.0395 -0.0282 -0.0282', 'S-1129\tBei Patienten mit Hypertonie und Typ-2-Diabetes wird Irbesartan Krka zusätzlich zu anderen Mitteln gegen Hypertonie verabreicht.', 'T-1129\tIn patients with hypertension and type 2 diabetes, Irbesartan Krka is added to other treatments for hypertension.', 'H-1129\t-0.302734375\tIn patients with hypertension and type 2 diabetes , Irbesartan Krka is added to other treatments for hypertension .', 'D-1129\t-0.302734375\tIn patients with hypertension and type 2 diabetes, Irbesartan Krka is added to other treatments for hypertension.', 'P-1129\t-0.1926 -0.0546 -0.0437 -0.0269 -0.0056 -0.0342 -0.0255 -0.0299 -0.0141 -0.0574 -0.6665 -0.0113 -0.0092 -0.0218 -0.0268 -0.0127 -0.0373 -0.3164 -0.0366 -0.0352 -0.3113 -0.0732 -0.0282 -0.0056 -0.0338 -0.0282', 'S-56\tReaktionen an der Injektionsstelle können vermieden werden, indem bei jeder Injektion eine andere Stelle verwendet wird (Wechsel der Injektionsstellen).', 'T-56\tInjection site reactions can be avoided by changing the injection site at each injection (injection site rotation).', 'H-56\t-1.232421875\tReactions at the injection site can be avoided if a different site is used for each injection ( rotate the injection site ) .', 'D-56\t-1.232421875\tReactions at the injection site can be avoided if a different site is used for each injection (rotate the injection site).', 'P-56\t-2.1406 -0.0183 -0.0479 -0.5239 -0.6201 -0.0113 -0.0451 -1.0000 -0.0282 -0.0564 -1.6846 -0.1127 -0.0901 -0.2817 -0.0338 -0.2479 -0.5581 -0.2705 -0.0395 -0.0056 -0.0338 -0.3157 -0.5972 -0.2649 -0.0338 -0.0113 -0.3213 -0.0338 -0.0338 -0.0282', 'S-601\tDie Dosierung sollte individuell entsprechend des Ausgangs-LDL-Cholesterinwertes, dem Ziel der Therapie sowie dem Ansprechen des Patienten erfolgen.', 'T-601\tDosage should be individualized according to baseline LDL-C levels, the goal of therapy, and patient response.', 'H-601\t-1.6650390625\tThe dose should be adjusted individually according to the baseline LDL cholesterol , the goal of therapy , and the patient &quot; s response .', 'D-601\t-1.6650390625\tThe dose should be adjusted individually according to the baseline LDL cholesterol, the goal of therapy, and the patient "s response.', 'P-601\t-0.9463 -0.8320 -0.0366 -0.0437 -0.6719 -1.0762 -0.0254 -0.6592 -0.0310 -0.5127 -1.3525 -0.0113 -0.1747 -0.0113 -0.9355 -0.0113 -0.0113 -0.6538 -0.7495 -0.5352 -0.0338 -1.1045 -0.6934 -0.0732 -0.5469 -0.3945 -0.7891 -0.0225 -0.0451 -0.0564 -0.0338', 'S-1583\tIn den drei weiteren Studien wurde festgestellt, dass auch die Kombination von MabThera mit anderen Chemotherapien das Behandlungsergebnis für den Patienten verbessert.', 'T-1583\tThe three additional studies also showed that adding MabThera to other types of chemotherapy also improved the patients <<unk>> outcome.', 'H-1583\t-1.162109375\tA further three studies showed that adding MabThera to other types of chemotherapy improved the patients &quot; outcome .', 'D-1583\t-1.162109375\tA further three studies showed that adding MabThera to other types of chemotherapy improved the patients "outcome.', 'P-1583\t-1.3154 -0.0240 -0.0310 -0.0676 -0.2847 -0.0578 -1.3867 -0.0366 -0.0197 -0.0197 -0.0282 -0.0845 -0.0564 -1.4453 -0.0282 -0.0197 -0.0085 -0.0451 -0.8677 -0.5186 -1.0820 -0.1747 -0.3213 -0.0620 -0.0282', 'S-717\tEntfernen Sie diese, indem Sie sanft gegen die Spritze klopfen und den Kolben bis zur entsprechenden Markierung auf der Spritze drücken.', 'T-717\tRemove them by gently tapping the syringe and pushing the plunger to the respective marking on the syringe.', 'H-717\t-0.83056640625\tRemove it by gently tapping the syringe and pushing the plunger to the appropriate mark on the syringe .', 'D-717\t-0.83056640625\tRemove it by gently tapping the syringe and pushing the plunger to the appropriate mark on the syringe.', 'P-717\t-0.0619 -0.0213 -0.0191 -1.5527 -0.0493 -0.4409 -0.1719 -0.0085 -0.5425 -0.1859 -0.0056 -0.0056 -0.1268 -0.3127 -0.0620 -0.2141 -0.0254 -1.0225 -0.0704 -0.6958 -0.2705 -0.1409 -0.0338 -0.0113 -0.0056 -0.0056 -0.0338 -0.0338', 'S-1624\tDie empfohlene Dosis beträgt 40 mg einmal täglich, bei einigen Patienten kann aber auch bei einer Dosis von 20 mg eine ausreichende Wirkung erzielt werden.', 'T-1624\tThe recommended dose is 40 mg once a day, but some patients may benefit from using a 20-mg dose.', 'H-1624\t-0.8046875\tThe recommended dose is 40 mg once a day , but some patients may benefit from using a 20 mg dose .', 'D-1624\t-0.8046875\tThe recommended dose is 40 mg once a day, but some patients may benefit from using a 20 mg dose.', 'P-1624\t-0.0590 -0.0299 -0.0774 -0.4148 -0.3022 -0.0282 -0.0479 -0.7832 -0.0268 -0.0845 -0.2690 -0.2847 -0.0268 -0.1973 -0.3916 -0.3606 -0.3352 -0.2169 -0.2283 -0.9160 -0.0395 -0.1268 -0.0338', 'S-1495\tDieser Botenstoff ist an der Entstehung von Entzündungen beteiligt und findet sich in großen Mengen bei Patienten mit aktivem Morbus Crohn.', 'T-1495\tThis messenger is involved in causing inflammation and is found at high levels in patients with active Crohn <<unk>> s disease.', 'H-1495\t-0.6240234375\tThis messenger is involved in causing inflammation and is found at high levels in patients with active Crohn &quot; s disease .', 'D-1495\t-0.6240234375\tThis messenger is involved in causing inflammation and is found at high levels in patients with active Crohn "s disease.', 'P-1495\t-0.7124 -0.0965 -0.0070 -0.0183 -0.1768 -0.0535 -0.0317 -0.3621 -0.0155 -0.0113 -0.0338 -0.0521 -0.1155 -0.1465 -0.5381 -0.1733 -0.1973 -0.0324 -0.0254 -0.0338 -1.0664 -0.0197 -0.0028 -0.5835 -0.0197 -0.0225 -0.0310 -0.0282', 'S-1499\tNur solche Patientinnen sollten sich Ovitrelle selbst verabreichen, die entsprechend geschult wurden und die die Möglichkeit haben, ärztlichen Rat einzuholen.', 'T-1499\tSelf-administration of Ovitrelle should only be performed by patients who are adequately trained and have access to expert advice.', 'H-1499\t-0.79443359375\tSelf @-@ administration of Ovitrelle should only be performed by patients who have been trained and with access to expert advice .', 'D-1499\t-0.79443359375\tSelf-administration of Ovitrelle should only be performed by patients who have been trained and with access to expert advice.', 'P-1499\t-0.4036 -0.0243 -0.0760 -0.2976 -0.1993 -0.1451 -0.0120 -0.0345 -0.0113 -0.2473 -0.2423 -0.0831 -0.3101 -0.1071 -0.1846 -0.2690 -0.5283 -0.3071 -0.2197 -0.7437 -0.3213 -0.3157 -0.0310 -0.3240 -0.2113 -0.0620 -0.0282', 'S-1926\tBei der Verringerung der Symptome der rheumatoiden Arthritis war Trudexa wirksamer als das Placebo.', 'T-1926\tge In rheumatoid arthritis, Trudexa was more effective than placebo in reducing symptoms.', 'H-1926\t-0.443115234375\tTrudexa was more effective than placebo in reducing the symptoms of rheumatoid arthritis .', 'D-1926\t-0.443115234375\tTrudexa was more effective than placebo in reducing the symptoms of rheumatoid arthritis.', 'P-1926\t-0.2544 -0.0269 -0.0199 -0.0313 -0.0518 -0.0486 -0.0327 -0.1592 -0.1648 -0.0204 -0.0169 -0.0240 -0.9624 -0.3677 -0.2522 -0.5396 -0.0310 -0.0338 -0.0113 -0.0197 -0.0169 -0.0056 -0.0197 -0.0141 -0.0141 -0.0338 -0.0282', 'S-257\tWird das Präparat bei Patienten mit schwerem kongenitalen Protein C Mangel verwendet, können sich Antikörper gegen das Protein C bilden.', 'T-257\tIf the preparation is used in patients with severe congenital protein C deficiency, antibodies inhibiting protein C may develop.', 'H-257\t-0.74755859375\tIf the product is used in patients with severe congenital protein C deficiency , antibodies to protein C may develop .', 'D-257\t-0.74755859375\tIf the product is used in patients with severe congenital protein C deficiency, antibodies to protein C may develop.', 'P-257\t-0.4932 -0.6030 -0.5972 -0.0268 -0.0507 -0.0760 -0.0254 -0.4155 -0.0324 -0.0549 -0.0113 -0.0099 -0.0211 -0.0310 -0.0155 -0.0099 -0.0310 -0.1169 -0.0310 -0.0127 -1.0654 -0.3071 -0.0282 -0.2930 -0.9775 -0.0338 -0.0282', 'S-708\t7-9) beträgt die empfohlene Dosis 450 mg Fosamprenavir zweimal täglich zusammen mit 100 mg Ritonavir einmal täglich.', 'T-708\t7-9) the recommended dose is 450 mg fosamprenavir twice daily with 100 mg ritonavir once daily.', 'H-708\t-0.35302734375\t9 ) the recommended dose is 450 mg fosamprenavir twice daily with 100 mg ritonavir once daily .', 'D-708\t-0.35302734375\t9) the recommended dose is 450 mg fosamprenavir twice daily with 100 mg ritonavir once daily.', 'P-708\t-0.3865 -0.3547 -0.1670 -0.0345 -0.0641 -0.0859 -0.2656 -0.0366 -0.1761 -0.0183 -0.0141 -0.0085 -0.0437 -0.0183 -0.0578 -0.0831 -0.3296 -0.0268 -0.0183 -0.0521 -0.0282 -0.0169 -0.0197 -0.1000 -0.0817 -0.0338 -0.0296', 'S-1248\tEine Durchstechflasche mit Keppra Konzentrat enthält 500 mg Levetiracetam in 5 ml (entsprechend 100 mg / ml).', 'T-1248\tA Keppra concentrate vial contains 500 mg levetiracetam in 5 ml (corresponding to 100 mg / ml).', 'H-1248\t-0.57568359375\tOne vial of Keppra concentrate contains 500 mg levetiracetam in 5 ml ( equivalent to 100 mg / ml ) .', 'D-1248\t-0.57568359375\tOne vial of Keppra concentrate contains 500 mg levetiracetam in 5 ml (equivalent to 100 mg / ml).', 'P-1248\t-1.5186 -0.0648 -0.0183 -0.1254 -0.0409 -0.0113 -0.0169 -0.1423 -0.0324 -0.1198 -0.0268 -0.6650 -0.0127 -0.0211 -0.0085 -0.0183 -0.0380 -0.0916 -0.0310 -0.0225 -0.0423 -1.1523 -0.0366 -0.0197 -0.0113 -0.0310 -0.0169 -0.0310 -0.0338 -0.0310', 'S-1340\tDie Tabletten sind runde, leicht bikonvexe, hellgelbe Tabletten mit einzelnen gelben Flecken und einer Prägung <unk> 7,5 <unk>.', 'T-1340\tTablets are round, slightly biconvex, slightly yellow tablets with possible individual yellow spots and an inscription <<unk>> 7.5 <<unk>>.', 'H-1340\t-1.16796875\tTablets are round , slightly biconvex , slightly yellow tablets with possible individual yellow spots and an inscription &quot; Pfizer &quot; on one side .', 'D-1340\t-1.16796875\tTablets are round, slightly biconvex, slightly yellow tablets with possible individual yellow spots and an inscription "Pfizer" on one side.', 'P-1340\t-0.8926 -0.0289 -0.0388 -0.0528 -0.0493 -0.0310 -0.1261 -0.0113 -0.0183 -0.0310 -0.0726 -0.3213 -0.1592 -0.2466 -0.0169 -0.0873 -0.3228 -0.3157 -0.0240 -0.3381 -0.1635 -0.2227 -0.3213 -0.2057 -0.0197 -0.3101 -2.7070 -0.0507 -0.3042 -0.1691 -1.5215 -0.1465 -0.3325 -0.0282', 'S-1646\tDas Vergleichsmedikament war Selamectin bei Katzen sowie Milbemycin Oxim und Praziquantel bei Hunden.', 'T-1646\tThe comparator was selamectin in cats, and milbemycin oxime and praziquantel in dogs.', 'H-1646\t-0.77197265625\tThe comparator medicine was selamectin in cats and mite mycin oxim and praziquantel in dogs .', 'D-1646\t-0.77197265625\tThe comparator medicine was selamectin in cats and mite mycin oxim and praziquantel in dogs.', 'P-1646\t-0.2842 -0.3826 -0.6973 -0.5127 -0.0423 -0.0592 -0.0240 -0.0225 -0.0169 -0.3438 -0.0155 -1.2227 -1.2168 -0.0986 -0.0310 -0.0197 -0.0282 -0.4368 -0.0310 -0.0338 -0.0254 -0.0169 -0.0225 -0.1183 -0.0141 -0.0338 -0.0141 -0.0282 -0.0282', 'S-1822\tPegaptanib-Natrium wurde bei Patienten mit einer Kreatinin-Clearance unter 20 ml / min nicht ausreichend untersucht.', 'T-1822\tPegaptanib sodium has not been adequately studied in patients with creatinine clearance below 20 ml / min.', 'H-1822\t-0.771484375\tPegaptanib sodium has not been adequately studied in patients with a creatinine clearance below 20 ml / min .', 'D-1822\t-0.771484375\tPegaptanib sodium has not been adequately studied in patients with a creatinine clearance below 20 ml / min.', 'P-1822\t-1.5127 -0.0197 -0.0141 -0.0254 -0.0099 -0.0254 -0.0803 -0.0127 -0.2057 -0.0437 -0.0366 -0.7100 -0.0183 -0.2776 -0.0535 -0.1803 -0.0535 -0.9751 -0.0310 -0.0197 -0.0282 -0.0366 -0.0197 -0.0225 -0.7158 -0.0648 -0.0451 -0.0282 -0.4988 -0.2593 -0.0282', 'S-531\tDaher sollte Enbrel mit Vorsicht angewendet werden bei Patienten mit Blutdyskrasie (fehlerhafter Blutzusammensetzung) in der Anamnese.', 'T-531\tCaution should be exercised in patients being treated with Enbrel who have a previous history of blood dyscrasias.', 'H-531\t-0.77783203125\tTherefore , Enbrel should be used with caution in patients with a history of blood dyscrasias ( abnormal blood composition ) .', 'D-531\t-0.77783203125\tTherefore, Enbrel should be used with caution in patients with a history of blood dyscrasias (abnormal blood composition).', 'P-531\t-0.9609 -0.0183 -0.4902 -0.3240 -0.0169 -0.0197 -0.0338 -0.0352 -0.3662 -0.1353 -0.0986 -0.0746 -0.0451 -0.0465 -0.2676 -0.1127 -0.0310 -0.1353 -0.0254 -0.3269 -0.4988 -0.1973 -0.0958 -1.4121 -0.0085 -0.1691 -0.0507 -0.0169 -0.0282 -0.0338 -0.0282', 'S-1008\tWechselwirkungen mit Arzneimitteln des Allgemeingebrauches, einschließlich Präparaten, die bei empfindlichen Patienten eine Histaminfreisetzung bewirken können, sind möglich.', 'T-1008\tHowever, interactions with commonly used medicinal products, including products that may induce histamine release in susceptible individuals, may occur.', 'H-1008\t-1.376953125\tInteractions with commonly used medicinal products , including preparations that may cause histamine release in susceptible patients , are possible .', 'D-1008\t-1.376953125\tInteractions with commonly used medicinal products, including preparations that may cause histamine release in susceptible patients, are possible.', 'P-1008\t-1.1514 -0.3535 -0.0366 -0.4875 -0.0676 -0.0620 -0.9893 -0.0310 -0.2593 -0.0282 -0.6821 -0.0225 -0.9019 -1.4932 -1.2793 -0.5918 -0.0169 -0.4678 -0.0395 -0.3042 -0.0395 -0.0113 -0.0225 -0.0169 -0.1747 -0.5859 -0.3718 -0.0564 -0.0282 -0.0282', 'S-92\tDie venösen thromboembolischen Ereignisse umfassten tiefe Beinvenenthrombosen, Lungenembolien und Thrombophlebitis.', 'T-92\tVenous thromboembolic events include deep venous thrombosis, pulmonary embolism and thrombophlebitis.', 'H-92\t-0.572265625\tVenous thromboembolic events included deep vein thrombosis , pulmonary embolism and thrombophlebitis .', 'D-92\t-0.572265625\tVenous thromboembolic events included deep vein thrombosis, pulmonary embolism and thrombophlebitis.', 'P-92\t-0.8691 -0.0085 -0.0028 -0.0092 -0.0141 -0.0218 -0.0225 -0.0197 -0.8423 -0.0310 -1.1963 -0.0113 -0.0028 -0.2339 -0.0141 -0.0789 -0.0056 -0.0056 -0.0197 -0.0197 -0.3662 -0.0845 -0.0113 -0.5156 -0.0085 -0.0338 -0.0141 -0.0169 -0.0282 -0.0113 -0.0310 -0.0282', 'S-1832\tRosafarben, rund, bikonvex, mit Prägung <unk> 75 <unk> auf der einen Seite und <unk> 1171 <unk> auf der anderen Seite.', 'T-1832\tPink, round, biconvex, engraved with <<unk>> 75 <<unk>> on one side and <<unk>> 1171 <<unk>> on the other side.', 'H-1832\t-0.75244140625\tPink , round , biconvex , embossed &apos; 75 &quot; on one side and &apos; 1171 &quot; on the other side .', 'D-1832\t-0.75244140625\tPink, round, biconvex, embossed \'75 "on one side and\' 1171" on the other side.', 'P-1832\t-0.3145 -0.1097 -0.0736 -0.8638 -0.1310 -0.0155 -0.0296 -0.0197 -0.2817 -1.5205 -0.0028 -0.0254 -0.3213 -0.1183 -0.3157 -0.0620 -0.0338 -0.0310 -0.0704 -0.1465 -0.6592 -0.0648 -0.0338 -0.0479 -0.0479 -0.0282 -0.0254 -0.3157 -0.0507 -0.0282', 'S-1804\tErwärmen Sie Biograstim nicht auf andere Weise (erwärmen Sie es zum Beispiel nicht in der Mikrowelle oder in heißem Wasser).', 'T-1804\tDo not warm Biograstim in any other way (for example, do not warm it in a microwave or in hot water).', 'H-1804\t-0.342041015625\tDo not warm Biograstim in any other way ( for example , do not warm it in a microwave or in hot water ) .', 'D-1804\t-0.342041015625\tDo not warm Biograstim in any other way (for example, do not warm it in a microwave or in hot water).', 'P-1804\t-0.0560 -0.0284 -0.2729 -0.1127 -0.0250 -0.0243 -0.0113 -0.1296 -0.1483 -0.0296 -0.0395 -0.0388 -0.2078 -0.0542 -0.0754 -0.0796 -0.0268 -0.3079 -0.1859 -0.1409 -0.1859 -0.0127 -0.0197 -0.0648 -0.1747 -0.0549 -0.0254 -0.0338 -0.0352 -0.0296', 'S-1332\tBis heute gibt es nur wenige Berichte über Extravasate von Pemetrexed, welche von den Prüfern nicht als schwerwiegende eingestuft wurden.', 'T-1332\tThere have been few reported cases of pemetrexed extravasation, which were not assessed as serious by the investigator.', 'H-1332\t-1.7529296875\tTo date , there are very few reports of extravasation of pemetrexed , which have not been classified as serious by the investigators .', 'D-1332\t-1.7529296875\tTo date, there are very few reports of extravasation of pemetrexed, which have not been classified as serious by the investigators.', 'P-1332\t-1.4932 -0.0493 -0.8706 -1.1709 -0.7354 -1.2627 -0.3127 -0.0338 -0.0620 -0.1409 -0.3101 -0.2479 -0.3213 -0.1803 -0.2649 -0.0225 -0.0225 -0.0282 -0.0338 -1.0986 -1.6113 -0.7607 -0.0338 -0.0282 -2.1133 -0.0901 -0.1578 -0.0338 -0.1127 -0.3494 -0.0338 -0.0338', 'S-512\tDer Inhaber der Genehmigung für das Inverkehrbringen muss vor der Vermarktung, wie mit den zuständigen Behörden der Mitgliedstaaten vereinbart, national Nachfolgendes implementieren:', 'T-512\tThe Marketing Authorisation Holder must implement nationally, prior to marketing, and as agreed with the competent authorities in the Member States:', 'H-512\t-0.90087890625\tThe Marketing Authorisation Holder must implement nationally , prior to marketing , the following :', 'D-512\t-0.90087890625\tThe Marketing Authorisation Holder must implement nationally, prior to marketing, the following:', 'P-512\t-0.3347 -1.0283 -0.0162 -0.0704 -0.0282 -0.2184 -0.0197 -0.9043 -0.1564 -0.4775 -0.0254 -0.1831 -0.3438 -0.0282 -0.5747 -0.1606 -0.4480 -0.0507 -0.3381 -0.0310', 'S-508\tWenn Sie sich übergeben haben Wenn Sie sich in weniger als einer Stunde nach der Einnahme von Emtriva übergeben haben, müssen Sie eine weitere Kapsel einnehmen.', 'T-508\tIf you are sick (vomit) If it <<unk>> s less than an hour since you took Emtriva, take another capsule.', 'H-508\t-0.9248046875\tIf you throw up If you throw up less than 1 hour after taking Emtriva , take another capsule .', 'D-508\t-0.9248046875\tIf you throw up If you throw up less than 1 hour after taking Emtriva, take another capsule.', 'P-508\t-0.0671 -0.0313 -1.6367 -0.0366 -0.2522 -0.0282 -1.6611 -0.0282 -0.5298 -0.0310 -0.3071 -0.0282 -0.0592 -0.0760 -0.0225 -0.0225 -0.0113 -0.2761 -0.7832 -0.2367 -0.0507 -0.0169 -0.0225 -0.0789 -0.0845', 'S-1284\tNukleosidische wie auch nukleotidische Reverse-Transkriptase-Hemmer werden üblicherweise als NRTIs bezeichnet.', 'T-1284\tBoth nucleoside and nucleotide reverse transcriptase inhibitors are commonly known as NRTIs.', 'H-1284\t-0.52392578125\tNucleoside and nucleotide reverse transcriptase inhibitors are commonly called NRTIs .', 'D-1284\t-0.52392578125\tNucleoside and nucleotide reverse transcriptase inhibitors are commonly called NRTIs.', 'P-1284\t-0.6304 -0.0313 -0.0243 -0.1993 -0.2169 -0.2494 -0.0155 -0.0240 -0.0881 -0.0254 -0.0352 -0.0183 -0.0197 -0.0183 -0.0085 -0.0197 -0.0155 -0.0113 -0.0268 -0.0465 -0.9355 -1.0000 -0.0141 -0.0225 -0.0169 -0.0366 -0.0338', 'S-1094\tWird die Anwendung gestoppt, so werden die Ausgangswerte der erythropoetischen Parameter innerhalb einer Erholungsphase von 1-3 Monaten erreicht.', 'T-1094\tSubcutaneous administration results in a similar pattern of erythropoietic stimulation as after intravenous administration.', 'H-1094\t-1.5029296875\tIf therapy is discontinued , the baseline values of erythropoietic parameters are reached within 1 @-@ 3 months of recovery .', 'D-1094\t-1.5029296875\tIf therapy is discontinued, the baseline values of erythropoietic parameters are reached within 1-3 months of recovery.', 'P-1094\t-0.5674 -1.3027 -0.2197 -0.8848 -0.0085 -0.3606 -0.2451 -0.8564 -0.0620 -2.2422 -0.0958 -1.2910 -0.0225 -0.0113 -0.0225 -0.2197 -0.6030 -0.0338 -0.0169 -0.0169 -0.1071 -0.4282 -0.4338 -0.8906 -0.0732 -0.0282 -0.0395 -0.1353 -0.2423 -0.3042 -0.0338', 'S-175\tReproduktionsstudien bei Tieren ergaben keinen Hinweis auf eine eventuelle Teratogenität oder Auswirkungen auf die männliche oder weibliche Fertilität.', 'T-175\tReproductive studies in animals have not shown evidence of teratogenicity, and showed no effect on male or female fertility.', 'H-175\t-1.21484375\tReproduction studies in animals have not produced any evidence of teratogenicity or effects on male or female fertility .', 'D-175\t-1.21484375\tReproduction studies in animals have not produced any evidence of teratogenicity or effects on male or female fertility.', 'P-175\t-0.5430 -0.6055 -0.0345 -0.7461 -0.0296 -0.8145 -0.3438 -1.5215 -0.1353 -0.1888 -0.7749 -0.5015 -0.0225 -0.0282 -0.0225 -0.3325 -0.0225 -1.0879 -0.3213 -0.0338 -0.3213 -0.0451 -0.0169 -0.0282 -0.1973 -0.0338 -0.0282', 'S-1221\tDie Häufigkeiten von unerwünschten Arzneimittelwirkungen, die in klinischen Studien beobachtet und mit Actrapid in Zusammenhang gebracht wurden, sind unten dargestellt.', 'T-1221\tFrequencies of adverse drug reactions from clinical trials that are considered related to Actrapid, are listed below.', 'H-1221\t-0.56005859375\tFrequencies of adverse drug reactions from clinical trials that are considered related to Actrapid are listed below .', 'D-1221\t-0.56005859375\tFrequencies of adverse drug reactions from clinical trials that are considered related to Actrapid are listed below.', 'P-1221\t-0.3284 -0.0213 -0.1060 -0.0127 -0.0409 -0.0567 -0.0106 -0.0729 -0.2537 -0.0085 -0.4917 -0.1353 -0.1550 -0.5073 -0.3101 -0.3269 -0.3157 -0.0423 -0.1831 -0.0169 -0.0141 -0.0225 -0.0873 -0.4395 -0.0225 -0.0338 -0.0310', 'S-182\tFondaparinux ist ein synthetisch hergestellter, selektiver Inhibitor des aktivierten Faktors X (Xa).', 'T-182\tFondaparinux is a synthetic and selective inhibitor of activated Factor X (Xa).', 'H-182\t-0.77490234375\tFondaparinux is a synthetic , selective inhibitor of activated factor X ( Xa ) .', 'D-182\t-0.77490234375\tFondaparinux is a synthetic, selective inhibitor of activated factor X (Xa).', 'P-182\t-0.2874 -0.0255 -0.0056 -0.0241 -0.0148 -0.0356 -0.0370 -0.0190 -0.6426 -1.2188 -0.0366 -0.0141 -0.7495 -0.0113 -0.0113 -0.0282 -0.0338 -0.8960 -0.0282 -0.9805 -0.0282 -0.3157 -0.0310 -0.0282 -0.0282 -0.0338 -0.0310', 'S-37\tEin bestimmtes Arzneimittel, ein sogenannter Alpha-Blocker, wird manchmal zur Behandlung von Bluthochdruck oder einer vergrößerten Prostata eingesetzt.', 'T-37\tA type of medicine called an alpha blocker is sometimes used to treat high blood pressure and enlarged prostate.', 'H-37\t-0.85791015625\tSome medicines called alpha @-@ blockers are used to treat high blood pressure or prostate enlargement .', 'D-37\t-0.85791015625\tSome medicines called alpha-blockers are used to treat high blood pressure or prostate enlargement.', 'P-37\t-0.5234 -0.3535 -0.0606 -1.0381 -0.0338 -0.0070 -0.0296 -0.5552 -0.4114 -0.0254 -0.0564 -0.7017 -0.1212 -0.0310 -0.3494 -0.0113 -0.0141 -0.2734 -1.1016 -0.0225 -0.0676 -0.0169 -0.0395 -0.0451 -0.0282', 'S-1737\tAufgrund von in-vitro- Studien ist keine signifikante Verdrängung zu erwarten, wenn diese Arzneimittel in therapeutischen Dosen angewendet werden.', 'T-1737\tAccording to in vitro studies, significant displacement is not anticipated at therapeutic concentrations of the medicinal products.', 'H-1737\t-1.26953125\tBased on in vitro studies , no significant displacement is expected when these medicinal products are administered at therapeutic doses .', 'D-1737\t-1.26953125\tBased on in vitro studies, no significant displacement is expected when these medicinal products are administered at therapeutic doses.', 'P-1737\t-1.4180 -0.0317 -0.0395 -0.0859 -0.0155 -0.0578 -0.6694 -0.2578 -0.0592 -0.7578 -0.0169 -0.3411 -0.9272 -0.5918 -0.2169 -0.4648 -0.6367 -0.0338 -0.0338 -1.8086 -0.0169 -0.5581 -0.1917 -0.0225 -0.0338 -0.0282 -0.0282 -0.0282', 'S-97\tCardoreg [und andere Bezeichnungen] 4 mg Retardtabletten dürfen während der Schwangerschaft nur bei strikter Indikationsstellung verabreicht werden.', 'T-97\tCardoreg 4 mg prolonged release tablets and associated names should not be used during pregnancy unless clearly needed.', 'H-97\t-1.017578125\tCardoreg 4 mg prolonged release tablets and associated names should not be used during pregnancy unless clearly needed .', 'D-97\t-1.017578125\tCardoreg 4 mg prolonged release tablets and associated names should not be used during pregnancy unless clearly needed.', 'P-97\t-0.7715 -0.0578 -0.0063 -0.3206 -0.0127 -0.3220 -0.3086 -0.0380 -0.3184 -0.0958 -0.0352 -0.4170 -0.3228 -0.3042 -0.4312 -1.1240 -0.0310 -0.2085 -0.1409 -0.0310 -0.2395 -0.3523 -0.9863 -0.1127 -0.0338', 'S-678\tIn vier Fällen handelte es sich um umgewandelte Anträge, die nach dem konzertierten Verfahren eingereicht worden waren, in 26 Fällen um neue zentralisierte Anträge.', 'T-678\tFour procedures concerned converted <<unk>> ex-concertation procedures <<unk>> and 26 concerned new centralised applications.', 'H-678\t-1.078125\tFour procedures concerned converted &apos; ex @-@ concertation procedures &quot; and 26 new centralised applications .', 'D-678\t-1.078125\tFour procedures concerned converted \'ex-concertation procedures "and 26 new centralised applications.', 'P-678\t-1.1592 -0.3706 -0.3508 -0.1859 -0.9790 -0.3213 -0.1606 -0.3213 -0.0592 -0.3157 -0.3296 -0.4395 -0.1719 -0.8311 -0.2311 -0.1127 -0.0056 -0.0507 -0.2367 -0.0395 -0.0282', 'S-1070\tWenn Sie mit einer Kombination aus Anti-HIV-Arzneimitteln behandelt werden, kann es zu einer Zunahme, Abnahme oder Umverteilung von Körperfett kommen.', 'T-1070\tbody fat may occur if you take a combination of anti-HIV medicines.', 'H-1070\t-1.4091796875\tIf you are treated with a combination of anti @-@ HIV medicines , the level of body fat may increase , fall or redistribution .', 'D-1070\t-1.4091796875\tIf you are treated with a combination of anti-HIV medicines, the level of body fat may increase, fall or redistribution.', 'P-1070\t-0.6592 -0.0588 -0.0592 -1.0322 -0.0338 -0.2100 -0.2043 -0.0296 -0.6299 -0.0338 -0.0225 -0.1691 -0.1099 -0.8369 -2.1211 -1.1162 -0.0338 -0.0451 -0.0282 -0.2649 -0.8564 -0.0451 -0.3157 -0.7437 -0.4058 -0.2649 -0.0451 -0.0282', 'S-972\tTabletten Tabletten Tabletten Tabletten Tabletten Tabletten Tabletten Tabletten Tabletten Tabletten Tabletten', 'T-972\tTablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet', 'H-972\t-0.970703125\tTablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet', 'D-972\t-0.970703125\tTablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet', 'P-972\t-0.3162 -0.3149 -0.2795 -0.1578 -0.1064 -0.0810 -0.0704 -0.0606 -0.0514 -0.3157 -2.3379', 'S-919\tBei Kindern zwischen 12 und 24 Monaten kann der Impfstoff im Bereich der Deltoid-Region verabreicht werden (siehe Abschnitte 4.4 und 4.5).', 'T-919\t(see also sections 4.4 and 4.5)', 'H-919\t-1.212890625\tThe vaccine can be administered to children aged between 12 and 24 months in the area of the deltoid region ( see sections 4.4 and 4.5 ) .', 'D-919\t-1.212890625\tThe vaccine can be administered to children aged between 12 and 24 months in the area of the deltoid region (see sections 4.4 and 4.5).', 'P-919\t-1.3184 -0.3071 -0.5605 -0.0324 -0.5933 -0.0183 -0.9453 -0.2874 -0.9355 -0.7832 -0.0282 -0.7383 -0.0225 -0.0282 -0.9355 -0.0507 -0.7666 -0.2986 -0.0676 -0.1465 -0.0169 -0.0225 -0.0282 -0.0338 -0.0338 -0.8174 -0.0225 -0.0282 -0.0395 -0.0225 -0.0282 -0.0451 -0.0338 -0.0282', 'S-928\tDezember 1997 von der Firma Prodes S.A., einem Inhaber der Genehmigung für das Inverkehrbringen für Terfenadin 60 mg Tabletten, mitgeteilt.', 'T-928\tAn intent of appeal against the opinion was submitted on 12 December 1997 by Prodes S. A., Marketing Authorisation Holder for a terfenadine 60 mg tablet formulation.', 'H-928\t-2.318359375\tHexal comes in a pre @-@ filled syringe ready to use .', 'D-928\t-2.318359375\tHexal comes in a pre-filled syringe ready to use.', 'P-928\t-1.2705 -0.4207 -2.2930 -0.9580 -0.2959 -0.3240 -0.0338 -1.1162 -0.4114 -0.2649 -0.0056 -0.5239 -0.2311 -0.3269 -3.1445 -0.6084', 'S-1505\tSpironolacton, Triamteren oder Amilorid), von Kaliumzusatzstoffen oder von kaliumhaltigen Salzen.', 'T-1505\tRisk factors for the development of hyperkalaemia include renal insufficiency, diabetes mellitus, and concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene or amiloride), potassium supplements or potassium-containing salt substitutes.', 'H-1505\t-0.99658203125\tspironolactone , triamterene or amiloride ) , potassium supplements or potassium @-@ containing salts .', 'D-1505\t-0.99658203125\tspironolactone, triamterene or amiloride), potassium supplements or potassium-containing salts.', 'P-1505\t-2.4648 -0.5283 -0.0085 -0.0028 -0.0338 -0.0338 -0.0141 -0.0225 -0.1071 -0.0169 -0.2986 -0.1014 -0.0113 -0.0056 -0.0254 -0.0338 -0.0479 -0.0310 -0.0113 -0.0225 -1.7832 -0.0366 -0.6704 -0.4846 -0.0056 -0.0282 -0.1353 -0.1071 -0.8057 -0.0282 -0.0395 -0.0282', 'S-765\tWarfarin) Ciprofloxacin kann wie die anderen Chinolone die Wirkung von Cumarinderivaten einschließlich Warfarin erhöhen.', 'T-765\tOral anticoagulants (e. g. warfarin) Ciprofloxacin, like other quinolones, may enhance the effect of coumarin derivates including warfarin.', 'H-765\t-1.298828125\twarfarin ) Ciprofloxacin , like other quinolones , may increase the effect of coumarin derivatives including warfarin .', 'D-765\t-1.298828125\twarfarin) Ciprofloxacin, like other quinolones, may increase the effect of coumarin derivatives including warfarin.', 'P-765\t-3.5371 -0.0169 -0.0310 -0.0535 -0.1381 -0.0056 -0.0197 -0.0225 -0.0197 -0.0254 -0.5806 -0.5469 -0.8145 -0.0395 -0.0169 -0.0225 -0.0338 -0.0451 -0.9468 -0.7383 -0.0395 -1.1104 -0.0282 -0.0676 0.0000 -0.5127 -0.3438 -0.0169 -0.0282 -1.0371 -0.0225 -0.0169 -0.0282 -0.0338 -0.0282', 'S-1420\tKörpergewicht 63 kg 67,25 kg 71,75 kg 76,25 kg 81 kg 85,75 kg 90,75 kg 95,75 kg 101 kg', 'T-1420\t9st 8lbs 10st 3lbs 10st 13lbs 11st 9lbs 12st 5lbs 13st 2lbs 13st 13lbs 14st 10lbs 15st 8lbs', 'H-1420\t-0.275146484375\tBodyweight 63 kg 67.25 kg 71.75 kg 76.25 kg 81 kg 85.75 kg 90.75 kg 95.75 kg 101 kg', 'D-1420\t-0.275146484375\tBodyweight 63 kg 67.25 kg 71.75 kg 76.25 kg 81 kg 85.75 kg 90.75 kg 95.75 kg 101 kg', 'P-1420\t-1.3867 -0.0134 -0.0232 -0.0190 -0.0268 -0.1465 -0.0240 -0.0183 -0.0240 -0.0648 -0.0155 -0.0183 -0.0254 -0.0282 -0.0211 -0.0155 -0.0113 -0.0183 -0.0183 -0.0282 -0.0155 -0.0183 -0.0211 -0.0803 -0.0141 -0.0141 -0.0197 -0.0268 -0.0155 -0.0155 -0.0085 -0.0169 -0.0282', 'S-1467\tBrechen Sie die Einnahme von Lamictal nicht ohne ärztlichen Rat ab Nehmen Sie Lamictal so lange ein, wie es Ihr Arzt Ihnen empfiehlt.', 'T-1467\tDon <<unk>> t stop taking Lamictal without advice Take Lamictal for as long as your doctor recommends.', 'H-1467\t-1.138671875\tDo not stop taking Lamictal without advice If you take Lamictal , take it for as long as your doctor recommends .', 'D-1467\t-1.138671875\tDo not stop taking Lamictal without advice If you take Lamictal, take it for as long as your doctor recommends.', 'P-1467\t-0.7642 -0.4805 -0.1198 -0.0225 -0.0247 -0.0162 -0.0176 -0.0254 -0.0690 -0.3494 -0.5762 -0.5352 -1.4258 -0.3972 -0.0169 -0.0141 -0.0254 -1.8486 -0.6084 -0.3833 -0.2197 -0.0282 -0.0225 -0.0282 -0.0507 -0.0282 -0.4565 -0.0169 -0.1578 -0.0338', 'S-1438\tDer Dosierbecher oder die Dosierspritze müssen unmittelbar nach Gebrauch mit warmem Wasser und Geschirrspülmittel ausgespült werden.', 'T-1438\tThe dosage cup or oral syringe should be cleaned immediately with hot water and dish soap after use.', 'H-1438\t-0.64892578125\tThe dosing cup or syringe must be rinsed immediately after use with warm water and soap .', 'D-1438\t-0.64892578125\tThe dosing cup or syringe must be rinsed immediately after use with warm water and soap.', 'P-1438\t-0.9102 -0.1909 -0.0486 -0.2479 -0.0451 -0.0704 -0.0056 -0.0070 -1.0273 -0.0380 -0.6211 -0.0282 -0.2001 -0.0535 -0.0338 -0.0564 -0.0732 -0.0225 -0.0310 -0.3381 -0.0648 -0.0310', 'S-456\tDrei dieser Patienten hatten vor ihrer Aufnahme in die Studie zwei Therapiezyklen mit MabThera erhalten, sodass sie während der Studie einen dritten Behandlungszyklus bekamen.', 'T-456\tThree of the patients had received two courses of MabThera before enrollment and thus were given a third course', 'H-456\t-1.3779296875\tThree of these patients had received two cycles of MabThera before enrolment and they received a third course of MabThera during the study .', 'D-456\t-1.3779296875\tThree of these patients had received two cycles of MabThera before enrolment and they received a third course of MabThera during the study.', 'P-456\t-0.0320 -0.0480 -0.1014 -0.0386 -0.1182 -0.3247 -0.7007 -0.8115 -0.0085 -0.0296 -0.0338 -0.0183 -0.0169 -0.0282 -0.8652 -1.0566 -0.2227 -0.0141 -0.0225 -0.2930 -2.9023 -0.1353 -0.0395 -0.0282 -0.9468 -0.1127 -0.5073 -0.0225 -0.0225 -0.0282 -1.4990 -0.0338 -0.5015 -0.0338 -0.0338', 'S-134\tBei Mäusen kommt es bei intakter Blut-Hirn-Schranke nicht zu einem Übertritt wesentlicher Mengen an Tasonermin in das Gehirn.', 'T-134\tTasonermin does not cross the intact blood-brain barrier to a significant extent in mice.', 'H-134\t-2.11328125\tIn mice , with their blood @-@ brain barrier still in place , there is no excretion of large amounts of tasonermin into the brain .', 'D-134\t-2.11328125\tIn mice, with their blood-brain barrier still in place, there is no excretion of large amounts of tasonermin into the brain.', 'P-134\t-2.0312 -0.3777 -0.0183 -0.4465 -2.9707 -0.5015 -0.4114 -0.5972 -0.0225 -0.0395 -0.3718 -0.5186 -0.0958 -0.1859 -2.1191 -0.0732 -0.4114 -1.9951 -0.1691 -0.0789 -0.0451 -1.7129 -0.3494 -0.0338 -0.2141 -0.0225 -0.2255 -0.0113 -0.2817 -1.0479 -0.0564 -0.0338 -0.0338 -0.0338', 'S-1365\tAuch EudraSafe, der Dienst für den sicheren Dokumentenaustausch, wurde neu organisiert, um eine bessere Verwaltung der Nutzerkonten und noch mehr Sicherheit zu bieten.', 'T-1365\tThe EudraTrack system that supports the mutual recognition process is not included in the transfer.', 'H-1365\t-0.90869140625\tCooperation tools ( e. g .', 'D-1365\t-0.90869140625\tCooperation tools (e. g.', 'P-1365\t-0.9487 -0.3176 -0.4775 -0.3381 -0.3269 -0.3284 -0.3057 -0.0310 -0.3213', 'S-1039\t10 Glasfläschchen mit Bioset ® -Aufsatz und 10 Fertigspritzen + 20 Nadeln / Kanülen 10 x 1 Dosis (0,5 ml)', 'T-1039\t10 vials with bioset ® and 10 pre-filled syringes + 20 needles 10 x 1 dose (0.5 ml)', 'H-1039\t-0.399169921875\t10 vials with bioset ® and 10 pre @-@ filled syringes + 20 needles 10 x 1 dose ( 0.5 ml )', 'D-1039\t-0.399169921875\t10 vials with bioset ® and 10 pre-filled syringes + 20 needles 10 x 1 dose (0.5 ml)', 'P-1039\t-0.0393 -0.3118 -0.0291 -0.2595 -0.3770 -0.0183 -0.0268 -0.0768 -0.3423 -0.0338 -0.2690 -0.0282 -0.1676 -0.0169 -0.0085 -0.0268 -0.0564 -0.0282 -0.0085 -0.0225 -0.5835 -0.0268 -0.0310 -0.0409 -0.0324 -0.0634 -0.0141 -0.0310 -0.0395', 'S-1004\tDie beobachteten Anstiege im Mittel des Verhältnisses von Herzgewicht zu terminalem Körpergewicht sind hauptsächlich auf die Unterschiede bei den terminalen Körpergewichten zurückzuführen.', 'T-1004\tObserved increases in mean heart-to-final body weight differences were attributed principally to the difference in the terminal body weights.', 'H-1004\t-1.24609375\tThe observed increases in the mean ratio of heart weight to terminal body weight are mainly due to differences in terminal body weights .', 'D-1004\t-1.24609375\tThe observed increases in the mean ratio of heart weight to terminal body weight are mainly due to differences in terminal body weights.', 'P-1004\t-0.1870 -0.1328 -0.2866 -0.5234 -1.0117 -0.7300 -0.2734 -0.0732 -0.1775 -0.0282 -0.6396 -0.4592 -0.2141 -0.0197 -0.4988 -0.7017 -0.8677 -0.0282 -0.6875 -0.1917 -0.2817 -0.0225 -0.6875 -0.0225 -0.0282 -0.0282', 'S-1363\tNach jeder vorliegenden oder vermuteten Überdosierung mit Aripiprazol ist eine engmaschige medizinische Überwachung solange angezeigt, bis sich der Patient erholt hat.', 'T-1363\tFollowing any confirmed or suspected overdose with aripiprazole, close medical supervision and monitoring should continue until the patient recovers.', 'H-1363\t-1.486328125\tAfter each presence or suspected overdose with aripiprazole , close medical supervision is recommended until the patient has recovered .', 'D-1363\t-1.486328125\tAfter each presence or suspected overdose with aripiprazole, close medical supervision is recommended until the patient has recovered.', 'P-1363\t-1.1260 -0.1958 -2.8379 -0.0451 -0.0310 -0.0789 -0.0169 -0.1888 -0.1353 -0.0169 -0.0338 -0.0169 -0.0028 -0.1945 -1.1553 -0.0282 -1.0596 -0.0113 -0.3157 -1.3242 -0.0338 -0.2479 -0.0169 -1.4766 -0.0901 -0.0338 -0.0282', 'S-1837\tIhr Arzt wird mit Ihnen besprechen, welche Art von Pumpe für Sie am geeignetsten ist und wann Sie die Pumpe neu befüllen lassen müssen.', 'T-1837\tYour doctor will discuss with you the kind of pump that will be most suitable for you and when you need to have your pump refilled.', 'H-1837\t-1.1474609375\tYour doctor will discuss with you which type of pump is best for you and when you need to refill the pump .', 'D-1837\t-1.1474609375\tYour doctor will discuss with you which type of pump is best for you and when you need to refill the pump.', 'P-1837\t-0.2822 -0.0421 -0.0342 -0.1099 -0.0722 -0.0271 -0.4177 -1.8291 -0.0282 -0.0155 -0.3396 -0.4453 -0.0535 -0.0282 -0.2874 -0.0310 -0.5269 -1.2793 -0.0676 -1.6904 -0.0225 -0.1071 -0.1071 -0.0395 -0.0338', 'S-29\tJede Infusion dauert 2 Stunden. <unk> Busilvex wird in sechsstündlichen Intervallen während 4 aufeinanderfolgenden Tagen vor der Transplantation verabreicht.', 'T-29\tEach infusion will last 2 hours. − Busilvex will be administered every 6 hours during 4 consecutive days prior to transplant.', 'H-29\t-1.498046875\tEach infusion lasts for two hours and it is given at 6 @-@ hour intervals for 4 consecutive days prior to the transplant .', 'D-29\t-1.498046875\tEach infusion lasts for two hours and it is given at 6-hour intervals for 4 consecutive days prior to the transplant.', 'P-29\t-0.0444 -0.0249 -0.0099 -0.5264 -0.0134 -0.4829 -0.5254 -0.0211 -0.9624 -0.3479 -0.0760 -0.2563 -1.8545 -0.6592 -0.0732 -0.2761 -0.0169 -0.0169 -1.3408 -0.5859 -0.6367 -0.0225 -0.6084 -0.0282 -0.8174 -0.0225 -0.0395 -0.9805 -0.0282', 'S-584\twenn Sie überempfindlich (allergisch) gegen Insulin oder einen der sonstigen Bestandteile von Insulin Human Winthrop Comb 25 sind.', 'T-584\tIf you are allergic (hypersensitive) to insulin or any of the other ingredients of Insulin Human Winthrop Comb 25.', 'H-584\t-0.295166015625\tIf you are allergic ( hypersensitive ) to insulin or any of the other ingredients of Insulin Human Winthrop Comb 25 .', 'D-584\t-0.295166015625\tIf you are allergic (hypersensitive) to insulin or any of the other ingredients of Insulin Human Winthrop Comb 25.', 'P-584\t-0.2703 -0.0285 -0.0372 -0.3118 -0.0197 -0.2703 -0.1296 -0.0162 -0.0373 -0.0345 -0.0169 -0.0099 -0.0423 -0.0901 -0.0824 -0.0373 -0.2930 -0.1620 -0.1057 -0.0606 -0.0211 -0.0085 -0.0296 -0.0099 -0.0042 -0.0211 -0.0268 -0.0254 -0.0268 -0.0564 -0.0310', 'S-1136\tWenn Sie dennoch befürchten, dass Sie eine zu hohe Dosis CANCIDAS erhalten haben, wenden Sie sich umgehend an Ihren Arzt oder eine medizinische Fachkraft.', 'T-1136\tHowever, if you are concerned that you may have been given too much CANCIDAS, contact your doctor or another healthcare professional immediately.', 'H-1136\t-0.81201171875\tHowever , if you are concerned that you may have been given too large a dose of CANCIDAS , contact your doctor or another healthcare professional immediately .', 'D-1136\t-0.81201171875\tHowever, if you are concerned that you may have been given too large a dose of CANCIDAS, contact your doctor or another healthcare professional immediately.', 'P-1136\t-0.5610 -0.0430 -0.0416 -0.0320 -0.1705 -0.1099 -0.0648 -0.0366 -0.4932 -0.0310 -0.3833 -0.7085 -0.1803 -0.8750 -0.0564 -0.0338 -0.4875 -0.0366 -0.0141 -0.0282 -0.0282 -0.0310 -0.0113 -0.2029 -0.5693 -0.0310 -0.0451 -0.0338 -0.5044 -0.3662 -0.0113 -0.4565 -0.0338 -0.0282', 'S-1464\tBei Patienten mit Thrombozytopenie oder hämorrhagischer Diathese darf der Impfstoff ausnahmsweise subkutan appliziert werden.', 'T-1464\tExceptionally, the vaccine may be administered subcutaneously in patients with thrombocytopenia or bleeding disorders.', 'H-1464\t-0.65625\tExceptionally , the vaccine may be administered subcutaneously in patients with thrombocytopenia or haemorrhagic diathesis .', 'D-1464\t-0.65625\tExceptionally, the vaccine may be administered subcutaneously in patients with thrombocytopenia or haemorrhagic diathesis.', 'P-1464\t-0.8135 -0.0261 -0.0803 -0.4438 -0.1465 -0.0338 -0.0887 -0.0296 -0.5454 -0.0197 -0.1000 -0.0127 -0.0085 -0.0268 -0.0352 -0.3987 -0.0324 -0.0606 -0.0479 -0.0225 -0.0113 -0.0113 -0.6172 -0.0085 -0.0366 -1.7021 -0.0085 -0.0085 -0.0282 -0.0282 -0.0366 -0.0254 -0.0620 -0.0169 -0.0310 -0.0282', 'S-111\tPalivizumab wird einmal im Monat intramuskulär verabreicht, vorzugsweise in die anterolaterale Seite des Oberschenkels.', 'T-111\tPalivizumab is administered once a month intramuscularly, preferably in the anterolateral aspect of the thigh.', 'H-111\t-0.521484375\tPalivizumab is administered intramuscularly once a month , preferably in the anterolateral aspect of the thigh .', 'D-111\t-0.521484375\tPalivizumab is administered intramuscularly once a month, preferably in the anterolateral aspect of the thigh.', 'P-111\t-0.6426 -0.0099 -0.0197 -0.0070 -0.0155 -0.0211 -0.0373 -0.8149 -0.0169 -0.8423 -0.0225 -0.0141 -0.0845 -0.0395 -0.0535 -0.0437 -0.0254 -0.3916 -0.0338 -0.0225 -0.2395 -0.0310 -0.0310 -0.0197 -0.0169 -0.0141 -0.3269 -0.0282 -0.0282 -0.2141 -0.0338 -0.0282', 'S-1266\tAufgrund dieser Daten ist eine Dosisanpassung bei Patienten mit Leberfunktionsstörung nicht notwendig, außer bei gleichzeitiger Nierenfunktionsstörung.', 'T-1266\tBased on these data, no dose adjustment is necessary in patients with hepatic impairment unless accompanied by renal impairment.', 'H-1266\t-0.927734375\tBased on these data , no dose adjustment is necessary in patients with hepatic impairment unless accompanied by renal impairment .', 'D-1266\t-0.927734375\tBased on these data, no dose adjustment is necessary in patients with hepatic impairment unless accompanied by renal impairment.', 'P-1266\t-0.3135 -0.0356 -0.3293 -0.0342 -0.2878 -0.7383 -0.8398 -0.0437 -0.0155 -0.0338 -0.0676 -0.3157 -0.5552 -0.0282 -0.0366 -0.5493 -0.0423 -0.0254 -0.6060 -0.0704 -0.0141 -0.0310 -1.0400 -0.2874 -0.2029 -0.2367 -0.4395 -0.2367 -0.0169 -0.0056 -0.0225 -0.0338 -0.0282', 'S-226\tANLEITUNG ZUR INJEKTION VON ARANESP MIT EINER FERTIGSPRITZE', 'T-226\tINSTRUCTIONS FOR INJECTING WITH THE ARANESP PRE-FILLED SYRINGE', 'H-226\t-0.88037109375\tINSTRUCTIONS FOR INJECTION OF ARANESP WITH A PRE @-@ FILLED SYRINGE', 'D-226\t-0.88037109375\tINSTRUCTIONS FOR INJECTION OF ARANESP WITH A PRE-FILLED SYRINGE', 'P-226\t-0.2120 -0.2089 -0.0750 -0.0271 -0.0042 -0.4829 -0.0901 -0.1853 -0.0211 -0.3120 -0.0225 -0.0465 -1.1182 -0.0141 -0.0423 -0.0183 -0.1508 -0.0225 -0.0169 -0.0254 -0.0732 -0.0056 -0.0141 -1.7979 -0.3213 -0.3157 -0.2141 -0.3157 -0.3101 -0.3101 -0.1859 -0.0338 -0.0338 -0.0395 -0.0338 -0.4565', 'S-270\tMIRCERA ist in Fertigspritzen mit laminiertem Kolbenstopfen und einer Schutzkappe mit einer Nadel 27G1 / 2 erhältlich.', 'T-270\tMIRCERA comes in pre-filled syringes with laminated plunger stopper and tip cap with one needle 27G1 / 2.', 'H-270\t-0.88330078125\tMIRCERA is available in pre @-@ filled syringes with laminated plunger stopper and a protective cap with a needle 27G1 / 2 .', 'D-270\t-0.88330078125\tMIRCERA is available in pre-filled syringes with laminated plunger stopper and a protective cap with a needle 27G1 / 2.', 'P-270\t-0.0797 -0.0141 -0.0313 -0.0170 -0.0270 -0.0422 -0.0400 -0.0773 -1.4775 -0.0282 -0.2494 -0.0197 -0.0056 -0.0268 -0.3550 -0.1099 -0.2085 -0.4509 -0.0113 -0.7944 -0.0169 -0.0366 -0.4846 -1.3809 -0.6030 -0.3101 -0.1747 -0.2537 -0.0225 -0.0676 -0.0225 -0.0282 -0.0282 -0.0282 -0.0338 -0.0282', 'S-1644\tSuomi / Finland Galena Oy PL / PB 1450 FI-70501 Kuopio + 358-17 288 1250', 'T-1644\tSuomi / Finland Galena Oy PL / PB 1450 FI-70501 Kuopio + 358-17 288 1250', 'H-1644\t-0.1251220703125\tSuomi / Finland Galena Oy PL / PB 1450 FI @-@ 70501 Kuopio + 358 @-@ 17 288 1250', 'D-1644\t-0.1251220703125\tSuomi / Finland Galena Oy PL / PB 1450 FI-70501 Kuopio + 358-17 288 1250', 'P-1644\t-0.0700 -0.0042 -0.0298 -0.0177 -0.0198 -0.0149 -0.0085 -0.0284 -0.0255 -0.0241 -0.0213 -0.0285 -0.0292 -0.0199 -0.0229 -0.0243 -0.0320 -0.0292 -0.0278 -0.0197 -0.0271 -0.0271 -0.0370 -0.0176 -0.0070 -0.0236 -0.0264 -0.0141 -0.0285 -0.2318 -0.0155 -0.0240 -0.0254 -0.0240 -0.0289', 'S-180\t60% der Pimecrolimus-Blutspiegel waren niedriger als 0,5 ng / ml, und 97% aller Proben lagen unter 2 ng / ml.', 'T-180\tAround 60% of pimecrolimus blood concentrations were below 0.5 ng / ml and 97% of all samples were below 2 ng / ml.', 'H-180\t-0.88818359375\tSixty percent of pimecrolimus blood concentrations were below 0.5 ng / ml and 97 % of the samples were below 2 ng / ml .', 'D-180\t-0.88818359375\tSixty percent of pimecrolimus blood concentrations were below 0.5 ng / ml and 97% of the samples were below 2 ng / ml.', 'P-180\t-1.2275 -0.0176 -0.1733 -0.2135 -0.3818 -0.0268 -0.0254 -0.0254 -0.0254 -0.0127 -1.0605 -0.5469 -0.0085 -0.0197 -0.1381 -0.9355 -0.0282 -0.0197 -0.0254 -0.0282 -0.0310 -0.4763 -0.0169 -0.1719 -0.0338 -0.5298 -0.4678 -0.0507 -0.5298 -0.2255 -0.0225 -0.0225 -0.0282 -0.0169 -0.0338 -0.0282', 'S-532\tGleichzeitiger Genuss von Alkohol oder heißen Getränken kann Nebenwirkungen wie Flush verstärken und sollte daher zeitgleich mit der Einnahme von Trevaclyn vermieden werden.', 'T-532\tSimultaneous use of alcohol or hot drinks can enhance the effects of flushing and should therefore be avoided around the time of ingestion of Trevaclyn.', 'H-532\t-0.5986328125\tSimultaneous use of alcohol or hot drinks can enhance the effects of flushing and should therefore be avoided around the time of ingestion of Trevaclyn .', 'D-532\t-0.5986328125\tSimultaneous use of alcohol or hot drinks can enhance the effects of flushing and should therefore be avoided around the time of ingestion of Trevaclyn.', 'P-532\t-0.2900 -0.0141 -0.0157 -0.0539 -0.3125 -0.0285 -0.0278 -0.0373 -0.0218 -0.0901 -0.3572 -0.4163 -0.0155 -0.3960 -0.3184 -0.1818 -0.1790 -0.2791 -0.1268 -0.0704 -0.3381 -0.0282 -0.0282 -0.3777 -0.0676 -0.0507 -0.2593 -0.3325 -0.1917 -0.0225 -0.0423 -0.0704 -0.0254 -0.0056 -0.0338 -0.0310', 'S-617\tEine derartige Situation verlangt eine schnelle Bekanntgabe sicherheitsrelevanter Informationen, welche die größten Auswirkungen auf das Nutzen-Risiko-Verhältnis während einer Pandemie haben können.', 'T-617\tPrompt analysis of 21 cumulative safety information, in light of extent of exposure, will be crucial for regulatory decisions and protection of the population to be vaccinated.', 'H-617\t-1.0400390625\tPrompt analysis of cumulative safety information , in light of extent of exposure , will be crucial for regulatory decisions and protection of the population to be vaccinated .', 'D-617\t-1.0400390625\tPrompt analysis of cumulative safety information, in light of extent of exposure, will be crucial for regulatory decisions and protection of the population to be vaccinated.', 'P-617\t-0.3384 -0.0481 -0.0662 -0.3223 -0.0993 -0.3232 -0.0092 -0.0254 -0.3191 -0.2197 -0.2747 -0.3240 -0.3254 -0.0296 -0.3269 -0.2255 -0.3296 -0.2423 -0.3042 -0.2255 -0.3127 -0.4001 -0.3213 -0.2903 -0.2930 -0.3213 -0.1859 -0.2367 -0.3213 -0.3213 -0.1578 -0.9805 -0.0225 -0.2029 -0.0338', 'S-583\tFentanyl wird in der Leber und Darmschleimhaut durch CYP3A4 Isoform zu Norfentanyl metabolisiert.', 'T-583\tFentanyl is metabolised in the liver and in the intestinal mucosa to norfentanyl by CYP3A4 isoform.', 'H-583\t-0.57958984375\tFentanyl is metabolised in the liver and intestinal mucosa by CYP3A4 isoform to norfentanyl .', 'D-583\t-0.57958984375\tFentanyl is metabolised in the liver and intestinal mucosa by CYP3A4 isoform to norfentanyl.', 'P-583\t-0.1366 -0.0128 -0.0163 -0.0212 -0.1815 -0.0257 -0.0204 -0.6138 -1.3438 -0.0564 -0.0211 -0.0338 -0.7651 -0.0366 -0.0254 -0.1635 -0.0141 -0.0338 -0.3718 -0.0451 -0.0254 -0.0254 -0.0225 -0.0141 -0.4058 -0.0451 -0.0141 -0.2141 -0.0507 -0.0254 -0.0169 -0.0197 -0.0169 -0.0310 -0.0282', 'S-1839\tVIRAMUNE wurde ursprünglich unter <unk> außergewöhnlichen Umständen <unk> genehmigt, da aus wissenschaftlichen Gründen zum Zeitpunkt der Genehmigung nur eingeschränkte Informationen über das Arzneimittel vorlagen.', 'T-1839\tVIRAMUNE was originally authorised under <<unk>> Exceptional Circumstances <<unk>>, because, for scientific reasons, limited information was available at the time of the approval.', 'H-1839\t-0.7607421875\tVIRAMUNE was originally authorised under exceptional circumstances as , for scientific reasons , limited information was available at the time of approval .', 'D-1839\t-0.7607421875\tVIRAMUNE was originally authorised under exceptional circumstances as, for scientific reasons, limited information was available at the time of approval.', 'P-1839\t-0.1958 -0.0127 -0.0120 -0.0327 -0.0227 -0.0357 -0.1173 -0.2754 -0.0268 -0.1515 -1.5332 -0.0099 -1.1592 -0.3184 -0.1240 -0.0366 -0.0395 -0.0507 -0.2874 -0.0282 -0.1719 -0.0254 -0.3184 -0.0310 -0.0282 -0.1127 -0.2620 -0.2903 -0.0282', 'S-468\tDas Interferon alfa-2b in PegIntron wurde pegyliert, d. h. mit Polyethylenglykol beschichtet.', 'T-468\tIn PegIntron, the interferon alfa-2b has been <<unk>> pegylated <<unk>> (coated with a chemical called polyethylene glycol).', 'H-468\t-0.65283203125\tIn PegIntron , the interferon alfa @-@ 2b has been &apos; pegylated &quot; ( coated with polyethylene glycol ) .', 'D-468\t-0.65283203125\tIn PegIntron, the interferon alfa-2b has been \'pegylated "(coated with polyethylene glycol).', 'P-468\t-0.9209 -0.5698 -0.0395 -0.0395 -0.0127 -0.0282 -0.1155 -0.1790 -0.0901 -0.0113 -0.0282 -0.0338 -0.0155 -0.0282 -0.0225 -0.0225 -0.2747 -0.0268 -0.6074 -0.1578 -0.0141 -0.0056 -0.5327 -0.3015 -0.2423 -0.0254 -0.0535 -1.2344 -0.0113 -0.0225 -0.0113 -0.0169 -0.0225 -0.0141 -0.0310 -0.0197 -0.0338 -0.0395 -0.0282', 'S-994\tVelmetia sollte zweimal täglich zu den Mahlzeiten eingenommen werden, um die mit Metformin assoziierten gastrointestinalen Nebenwirkungen zu reduzieren.', 'T-994\tVelmetia should be given twice daily with meals to reduce the gastrointestinal undesirable effects associated with metformin.', 'H-994\t-0.69775390625\tVelmetia should be taken twice a day with meals to reduce the gastrointestinal undesirable effects associated with metformin .', 'D-994\t-0.69775390625\tVelmetia should be taken twice a day with meals to reduce the gastrointestinal undesirable effects associated with metformin.', 'P-994\t-0.0270 -0.0249 -0.0085 -0.0328 -0.0306 -0.6777 -0.8452 -1.0449 -0.0254 -0.1198 -0.2507 -0.4932 -0.0479 -0.3240 -0.0395 -0.0366 -0.0056 -0.0113 -0.0197 -0.4424 -0.2734 -0.1888 -0.1917 -0.0507 -0.0310 -0.0282 -0.0056 -0.0282 -0.0338 -0.0310', 'S-78\tLIPIDSENKENDE WIRKSTOFFE HMG-CoA Reduktasehemmer Simvastatin Lovastatin', 'T-78\tSimvastatin Lovastatin', 'H-78\t-0.93408203125\tLIPID CONDITIONS HMG @-@ CoA Reductase Inhibitors Simvastatin Lovastatin', 'D-78\t-0.93408203125\tLIPID CONDITIONS HMG-CoA Reductase Inhibitors Simvastatin Lovastatin', 'P-78\t-2.7539 -0.0197 -0.2197 -0.7666 -0.8340 -0.0958 -0.0760 -0.0085 -0.1042 -0.0254 -0.0254 -0.0169 -0.0282 -0.0225 -0.0254 -1.0654 -0.0113 -0.0113 -0.0056 -0.0507 -0.0056 -0.0113 -0.1240 -0.0395 -0.0169 -0.0113 -0.0169 -0.4338 -0.0225 -0.2930 -0.0113 -0.3213', 'S-1027\t8 1164 София Тел.: + 359 2 962 12 00 E-mail: uk _ medinfo @ allergan.com', 'T-1027\t8 1164 София', 'H-1027\t-0.5869140625\tTel : + 359 2 962 12 00 E @-@ mail : uk _ medinfo @ allergan. com', 'D-1027\t-0.5869140625\tTel: + 359 2 962 12 00 E-mail: uk _ medinfo @ allergan. com', 'P-1027\t-1.5723 -0.6396 -0.0282 -0.4958 -0.0183 -0.0521 -0.0282 -0.0169 -0.0423 -0.0197 -0.1493 -0.0282 -0.0169 -0.0282 -0.0085 -0.0282 -0.0141 -0.0169 -0.0225 -0.0085 -0.0141 -0.3213 -0.3101 -0.0732', 'S-1538\tIhr Arzt wird daher Laboruntersuchungen durchführen um zu überprüfen, ob Ihre Leber richtig arbeitet, zu Beginn der Behandlung und danach in regelmäßigen Abständen.', 'T-1538\tYour doctor will therefore run laboratory tests to check that your liver is working', 'H-1538\t-1.33203125\tYour doctor will therefore run laboratory tests to check that your liver is working properly at the initiation of treatment and then periodically thereafter .', 'D-1538\t-1.33203125\tYour doctor will therefore run laboratory tests to check that your liver is working properly at the initiation of treatment and then periodically thereafter.', 'P-1538\t-0.4011 -0.4744 -0.0373 -1.6348 -1.3643 -0.8789 -0.0282 -0.1324 -0.0423 -0.3015 -0.2057 -0.0310 -0.0141 -0.1268 -0.1155 -0.1353 -0.3213 -0.0395 -1.7412 -0.0225 -0.0507 -0.2367 -0.1409 -1.0312 -0.4622 -0.0169 -0.0225 -0.5469 -0.0225 -0.0225 -0.0282 -0.0282', 'S-521\t3 Tuben mit je 0,25 ml (30 mg Selamectin) 6 Tuben mit je 0,25 ml (30 mg Selamectin)', 'T-521\tSix tubes each containing 0.25 ml (30 mg selamectin).', 'H-521\t-0.43017578125\tSix tubes each containing 0.25 ml ( 30 mg selamectin ) .', 'D-521\t-0.43017578125\tSix tubes each containing 0.25 ml (30 mg selamectin).', 'P-521\t-0.6470 -0.1166 -0.0162 -0.0282 -0.2993 -0.1733 -0.1205 -0.0599 -0.0521 -0.0338 -0.0366 -0.0141 -0.1620 -0.0296 -0.0197 -0.0409 -0.0296 -0.3184 -0.3184', 'S-414\tDie Packung enthält außerdem einen 30-ml-Messbecher aus Polypropylen mit einer Mess-Skala in 1,0-ml-Schritten.', 'T-414\tThe pack also contains a 30 ml polypropylene measuring cup with 1.0 ml graduations.', 'H-414\t-1.4521484375\tThe pack also contains a 30 ml polypropylene measuring cup with a kg scale in steps of 1.0 ml .', 'D-414\t-1.4521484375\tThe pack also contains a 30 ml polypropylene measuring cup with a kg scale in steps of 1.0 ml.', 'P-414\t-0.8325 -1.0254 -0.8594 -0.0986 -0.5986 -1.1328 -0.0535 -0.2367 -0.0113 -0.0141 -0.0169 -0.5806 -0.0423 -0.3015 -0.0789 -0.0676 -2.2598 -0.1296 -0.5239 -0.9468 -0.0338 -0.2537 -0.0282 -0.0564 -0.0395 -0.0338', 'S-970\tEs wurde gezeigt, dass CRIXIVAN hilft, das Risiko zu verringern, eine Krankheit zu entwickeln, die mit der HIV-Erkrankung assoziiert ist.', 'T-970\tCRIXIVAN has been shown to help reduce the risk of developing illnesses associated with HIV disease.', 'H-970\t-1.0986328125\tCRIXIVAN has been shown to help lower the risk of getting an illness associated with HIV disease .', 'D-970\t-1.0986328125\tCRIXIVAN has been shown to help lower the risk of getting an illness associated with HIV disease.', 'P-970\t-0.2318 -0.0127 -0.0241 -0.0178 -0.0120 -0.6470 -0.0289 -0.1564 -0.0282 -0.7544 -0.6509 -0.0380 -0.6187 -0.0366 -1.5381 -0.5747 -0.1465 -0.0704 -0.0282 -0.0254 -1.4932 -0.0395 -0.0338', 'S-1609\tEU / 1 / 01 / 185 / 052 (1-er Packung) EU / 1 / 01 / 185 / 064 (4-er Packung)', 'T-1609\tEU / 1 / 01 / 185 / 052 1 pack EU / 1 / 01 / 185 / 064 4 pack', 'H-1609\t-0.23876953125\tEU / 1 / 01 / 185 / 052 1 pack EU / 1 / 01 / 185 / 064 4 pack', 'D-1609\t-0.23876953125\tEU / 1 / 01 / 185 / 052 1 pack EU / 1 / 01 / 185 / 064 4 pack', 'P-1609\t-0.0270 -0.0299 -0.0291 -0.0291 -0.0291 -0.0291 -0.0077 -0.0285 -0.0276 -0.2771 -0.3215 -0.3057 -0.1064 -0.0289 -0.0296 -0.0275 -0.0268 -0.0268 -0.0056 -0.0268 -0.0211 -0.0169 -0.0564 -0.0451 -0.0873', 'S-571\tDie Zusammensetzung des Verwal- tungsrates änderte sich im Laufe des Jahres mehrmals; die Mitglieder am Ende des Jahres 1996 sind in Anhang 1 dieses Berichtes aufgeführt.', 'T-571\ta number of times during the year and membership as at the end of 1996 is shown in annex 1 to this Report.', 'H-571\t-0.99951171875\tThe composition of the Management Board changed a number of times during the year ; members at the end of 1996 can be found in Annex 1 to this report .', 'D-571\t-0.99951171875\tThe composition of the Management Board changed a number of times during the year; members at the end of 1996 can be found in Annex 1 to this report.', 'P-571\t-0.1250 -0.1007 -0.0171 -0.0285 -0.0357 -0.4473 -0.0507 -0.2008 -0.3071 -0.1198 -0.0296 -0.0268 -0.1536 -0.0578 -0.0760 -0.7959 -1.7383 -0.2620 -0.0310 -0.0282 -0.0282 -0.0225 -2.0625 -0.0225 -0.0789 -0.0338 -0.0564 -0.0282 -0.0507 -0.7554 -0.3889 -0.0789 -0.0282 -0.0282', 'S-745\tN Histologische Besserungb Besserung gemäß Ishak-Fibrose-Score Verschlechterung gemäß Ishak-Fibrose- Score', 'T-745\tHistological improvementb Ishak fibrosis score improvement Ishak fibrosis score worsening n', 'H-745\t-1.001953125\tN Histological Responseb Worsening according to Ishak Fibrosis Score Worsening according to Ishak Fibrosis Score', 'D-745\t-1.001953125\tN Histological Responseb Worsening according to Ishak Fibrosis Score Worsening according to Ishak Fibrosis Score', 'P-745\t-0.1735 -0.0991 -0.0423 -0.7354 -0.2874 -0.3953 -0.4888 -0.0042 -0.0282 -0.7974 -0.0338 -0.4536 -0.0141 -0.0395 -0.6650 -0.0225 -0.0366 -1.3242 -0.0169 -0.0789 -0.0028 -0.0225 -0.5947 -0.0282 -0.0113 -0.0169 -0.0338 -0.5635 -0.0338 -0.5859 -0.4958 -0.0113 -0.0338', 'S-1423\tDie Analyse der Ergebnisse hinsichtlich des ER-Status zeigte, dass die Verwendung von Fulvestrant auf Patientinnen mit ER-positivem Brustkrebs beschränkt werden sollte.', 'T-1423\tAnalysis of results by ER status showed that the use of fulvestrant should be restricted to patients with ER positive breast cancer.', 'H-1423\t-1.1513671875\tAnalysis of the results for ER status showed that the use of fulvestrant should be restricted to patients with ER @-@ positive breast cancer .', 'D-1423\t-1.1513671875\tAnalysis of the results for ER status showed that the use of fulvestrant should be restricted to patients with ER-positive breast cancer.', 'P-1423\t-1.1631 -0.0521 -0.0317 -0.3845 -0.2690 -2.6973 -0.0732 -0.0310 -0.5835 -0.0338 -0.2479 -0.1803 -0.0282 -0.0451 -0.0113 -0.0620 -0.0507 -0.0338 -0.9131 -0.2255 -0.1578 -0.0451 -0.0225 -1.0430 -0.0113 -0.0169 -0.2085 -0.0338 -0.0282', 'S-432\tIhr Arzt wird Sie über geeignete Empfängnisverhütungsmaßnahmen während der Behandlung mit ORENCIA und für bis zu 14 Wochen nach der letzten Dosis beraten.', 'T-432\tYour doctor will advise you on adequate contraceptive methods while using ORENCIA and up to 14 weeks after the last dose.', 'H-432\t-0.82275390625\tYour doctor will advise you about suitable contraception during treatment with ORENCIA and for up to 14 weeks after the last dose .', 'D-432\t-0.82275390625\tYour doctor will advise you about suitable contraception during treatment with ORENCIA and for up to 14 weeks after the last dose.', 'P-432\t-0.2335 -0.0407 -0.0357 -0.0532 -0.0211 -0.3223 -0.7866 -0.6074 -0.5708 -1.0000 -0.0254 -0.7241 -0.6904 -0.0338 -0.0254 -0.0197 -0.0141 -0.0507 -0.3718 -0.0254 -0.0282 -0.0254 -0.0225 -0.0704 -0.0451 -0.2479 -0.0451 -0.0338 -0.0338', 'S-457\tDer Anteil der Cefovecin-resistenten Isolate beträgt bei den Koagulase-negativen Staphylococci spp.', 'T-457\tThe percentage of cefovecin resistant isolates in coagulase negative Staphylococci spp.', 'H-457\t-1.310546875\tThe fraction of cefovecin @-@ resistant isolates in coagulase @-@ negative staphylococci spp .', 'D-457\t-1.310546875\tThe fraction of cefovecin-resistant isolates in coagulase-negative staphylococci spp.', 'P-457\t-0.7715 -1.8037 -0.0225 -0.0296 -0.6665 -0.0169 -0.0310 -0.0197 -0.0282 -0.5522 -0.0197 -0.0169 -0.0310 -0.0254 -0.5156 -2.2617 -0.0169 -0.0282 -0.0282 -0.5972 -0.3550 -1.2227 -0.0225 -0.0282 -0.0282 -0.3438 -0.0395 -0.4958 -0.0395 -0.0282', 'S-603\t92 Die Behandlung wird so lange fortgesetzt, wie Sie Immunsuppressiva benötigen, um Sie vor einer Abstoßung Ihres transplantierten Organes zu schützen.', 'T-603\tTreatment will continue for as long as you need immunosuppression to prevent you rejecting your transplanted organ.', 'H-603\t-1.21484375\tTreatment is continued as long as you need immunosuppression to prevent you from rejecting your transplanted organ .', 'D-603\t-1.21484375\tTreatment is continued as long as you need immunosuppression to prevent you from rejecting your transplanted organ.', 'P-603\t-1.5684 -0.0169 -0.0225 -1.4980 -0.0676 -1.0029 -0.0197 -0.0282 -0.0535 -0.2085 -0.0395 -0.0085 -0.0169 -0.0085 -0.0225 -1.4375 -0.3042 -0.6084 -1.1494 -0.6763 -0.0901 -0.0395 -0.0225 -0.0507 -0.0338 -0.0620 -0.0395 -0.0338 -0.0338', 'S-1101\tDie Kombination von Levodopa, Carbidopa und Entacapon kann Benommenheit und orthostatische Symptome hervorrufen.', 'T-1101\tLevodopa, carbidopa and entacapone together may cause dizziness and symptomatic orthostatism.', 'H-1101\t-0.865234375\tThe combination of levodopa , carbidopa and entacapone may cause dizziness and symptomatic orthostatism .', 'D-1101\t-0.865234375\tThe combination of levodopa, carbidopa and entacapone may cause dizziness and symptomatic orthostatism.', 'P-1101\t-0.8486 -0.9038 -0.0324 -0.0718 -0.0169 -0.0310 -0.0183 -0.0310 -0.6045 -0.0296 -0.0254 -0.0324 -0.0169 -0.0296 -0.3000 -0.0451 -0.0282 -0.0169 -0.2734 -0.2705 -0.1409 -0.9131 -0.0479 -0.0169 -0.0423 -0.3916 -0.2593 -0.0169 -0.0817 -0.0141 -1.2793 -0.2817 -0.0338 -0.0282', 'S-878\tMIRAPEXIN wird nicht empfohlen für die Anwendung bei Kindern und Jugendlichen unter 18 Jahren aufgrund des Fehlens von Daten zur Unbedenklichkeit und Wirksamkeit.', 'T-878\tDosing in children and adolescents MIRAPEXIN is not recommended for use in children and adolescents below 18 years due to a lack of data on safety and efficacy.', 'H-878\t-0.62548828125\tMIRAPEXIN is not recommended for use in children and adolescents below 18 years due to a lack of data on safety and efficacy .', 'D-878\t-0.62548828125\tMIRAPEXIN is not recommended for use in children and adolescents below 18 years due to a lack of data on safety and efficacy.', 'P-878\t-1.2148 -0.0106 -0.0254 -0.0134 -0.0296 -0.0430 -0.0345 -0.0303 -0.0451 -0.0592 -0.1550 -0.0254 -0.5312 -0.1212 -0.0169 -0.0169 -0.3184 -0.1973 -0.0873 -0.8452 -0.0282 -0.4988 -0.0338 -0.0282 -0.2029 -0.1521 -0.1042 -0.0395 -0.0958 -0.0085 -0.0141 -0.0395 -0.0310', 'S-1186\tGONAL-f ist entweder als Injektionslösung in einem Fertigpen oder als Pulver und Lösungsmittel zur Herstellung einer Injektionslösung erhältlich.', 'T-1186\tGONAL-f is available either as a solution for injection in a pre-filled pen or as a powder and solvent to be made up into a solution for injection.', 'H-1186\t-0.7431640625\tGONAL @-@ f is available as a solution for injection in a pre @-@ filled pen or as a powder and solvent for solution for injection .', 'D-1186\t-0.7431640625\tGONAL-f is available as a solution for injection in a pre-filled pen or as a powder and solvent for solution for injection.', 'P-1186\t-0.0451 -0.0170 -0.0184 -0.0278 -0.0263 -0.0466 -0.0634 -0.7241 -0.2881 -0.8325 -0.2197 -0.0676 -0.0324 -0.1226 -0.0732 -0.3113 -0.0310 -0.2761 -0.0789 -0.0873 -0.8818 -0.0592 -0.0282 -0.0676 -0.0479 -0.0225 -0.4763 -0.6084 -0.3184 -0.0507 -0.0169 -0.0620 -0.0282', 'S-118\tSuchen Sie unv erzüglich Ihren Arzt auf oder nehmen Sie ärztliche Nothilfe in Anspruch, wenn das Kind irgendwelche ungewöhnlichen Verhaltensmuster zeigt,', 'T-118\tImmediately contact the doctor or seek emergency care if they display any unusual behavioural symptoms, feel depressed, or feel they want to harm themselves or others. lp', 'H-118\t-1.5341796875\tContact your doctor immediately or seek emergency treatment if they display any unusual behavioural symptoms ,', 'D-118\t-1.5341796875\tContact your doctor immediately or seek emergency treatment if they display any unusual behavioural symptoms,', 'P-118\t-1.6553 -0.0352 -0.0521 -0.9229 -0.0690 -0.0817 -0.1028 -1.2031 -0.0366 -0.6367 -0.3157 -0.0535 -0.0338 -0.2169 -0.9019 -0.0225 -0.3157 -0.4395 -1.8818', 'S-1301\tPatienten mit Nierenerkrankung − Blutdruckanstieg, der möglicherweise mit Arzneimitteln behandelt werden muss oder die Anpassung einer bereits bestehenden Hochdrucktherapie erfordert.', 'T-1301\tKidney patients <<unk>> raised blood pressure which may require treatment with medicinal products or adjustment of the dosage of medicinal products you already take for high blood pressure.', 'H-1301\t-1.611328125\tPatients with kidney disease - raised blood pressure which may require therapy with medicines or adjustment of existing hypertension therapy .', 'D-1301\t-1.611328125\tPatients with kidney disease - raised blood pressure which may require therapy with medicines or adjustment of existing hypertension therapy.', 'P-1301\t-0.4668 -0.0211 -0.0518 -0.9102 -0.0127 -0.0254 -0.1719 -0.8789 -0.0225 -0.0211 -0.6128 -0.1465 -0.6338 -0.4087 -0.2255 -0.8906 -0.6592 -0.9805 -1.5049 -0.0564 -0.5298 -0.3101 -0.8789 -1.2344 -0.0789 -0.0901 -0.0451 -0.0338', 'S-687\tNach wiederholter Gabe gehen die Plasmakonzentrationen allmählich auf 50 bis 65% der Konzentrationen nach einmaliger Gabe zurück.', 'T-687\t16 Upon multiple dosing, plasma concentrations of bosentan decrease gradually to 50% <<unk>> 65% of those seen after single dose administration.', 'H-687\t-1.7373046875\tAfter repeated dosing , plasma concentrations decline gradually to 50 to 65 % of that in a single dose .', 'D-687\t-1.7373046875\tAfter repeated dosing, plasma concentrations decline gradually to 50 to 65% of that in a single dose.', 'P-687\t-1.3184 -0.3960 -1.4355 -0.3777 -0.8989 -0.3748 -0.0113 -0.0141 -0.6084 -0.0085 -0.0197 -0.9214 -0.2197 -0.0507 -0.0789 -0.4453 -0.0169 -0.0395 -0.2593 -2.2422 -0.7495 -0.8398 -0.1183 -0.7607 -0.0338 -0.0338', 'S-720\tEU / 1 / 01 / 195 / 001 EU / 1 / 01 / 195 / 008 EU / 1 / 01 / 195 / 009', 'T-720\tEU / 1 / 01 / 195 / 001 EU / 1 / 01 / 195 / 008 EU / 1 / 01 / 195 / 009', 'H-720\t-0.136962890625\tEU / 1 / 01 / 195 / 001 EU / 1 / 01 / 195 / 008 EU / 1 / 01 / 195 / 009', 'D-720\t-0.136962890625\tEU / 1 / 01 / 195 / 001 EU / 1 / 01 / 195 / 008 EU / 1 / 01 / 195 / 009', 'P-720\t-0.2627 -0.0313 -0.0285 -0.0299 -0.0278 -0.0285 -0.0148 -0.0250 -0.0292 -0.0257 -0.0313 -0.0264 -0.0313 -0.0285 -0.0299 -0.0257 -0.0285 -0.0141 -0.0250 -0.0282 -0.0240 -0.0268 -0.0254 -0.0303 -0.0282 -0.0289 -0.0240 -0.0282 -0.0148 -0.0261 -0.0289 -0.0240 -0.0247 -0.0296', 'S-145\tJanuar 2008 erteilte die Europäische Kommission Merck Sharp & Dohme Ltd eine Genehmigung für das Inverkehrbringen von IVEMEND in der gesamten Europäischen Union.', 'T-145\tThe European Commission granted a marketing authorisation valid throughout the European Union for IVEMEND to Merck Sharp & Dohme Ltd on 11 January 2008.', 'H-145\t-0.73974609375\tThe European Commission granted a marketing authorisation valid throughout the European Union for IVEMEND to Merck Sharp &amp; Dohme Ltd. on 10 January 2008 .', 'D-145\t-0.73974609375\tThe European Commission granted a marketing authorisation valid throughout the European Union for IVEMEND to Merck Sharp & Dohme Ltd. on 10 January 2008.', 'P-145\t-0.3013 -0.0590 -0.0250 -0.2688 -0.3069 -0.0430 -0.0507 -0.0169 -0.3220 -0.0444 -0.2515 -0.0338 -0.6694 -0.0310 -0.2438 -0.2382 -0.0197 -0.0169 -0.0225 -0.0930 -0.0395 -0.0197 -0.0113 -0.0225 -0.0169 -0.0085 -0.0225 -0.8989 -0.0648 -0.0282 -0.1831 -1.8145 -0.0789 -0.0225 -0.0338 -0.0282', 'S-892\tZYPREXA Pulver zur Herstellung einer Injektionslösung darf nicht in einer Spritze mit anderen im Handel erhältlichen Arzneimitteln gemischt werden.', 'T-892\tZYPREXA Powder for Solution for Injection must not be combined in the syringe with any commercially available medicinal products.', 'H-892\t-1.1298828125\tZYPREXA powder for solution for injection must not be mixed in a syringe with other medicinal products are commercially available .', 'D-892\t-1.1298828125\tZYPREXA powder for solution for injection must not be mixed in a syringe with other medicinal products are commercially available.', 'P-892\t-0.5083 -0.0278 -0.0099 -0.0169 -0.0271 -0.3892 -0.1528 -0.3220 -0.3142 -0.0620 -0.0324 -0.9243 -0.0338 -0.0310 -0.3579 -0.1635 -0.4790 -0.0085 -0.0141 -0.0028 -0.0395 -0.3635 -1.7158 -0.9917 -0.0338 -0.7271 -0.9976 -0.0169 -0.0395 -0.0395 -0.0282', 'S-1612\t• ActiTrak, SI2, SIAMED, EudraWatch • EudraNet, Intranet, Internet, sichere Dokumentenübermittlung', 'T-1612\t• ActiTrak, SI2, SIAMED, EudraWatch • EudraNet, intranet, internet, secure document transmission', 'H-1612\t-0.755859375\t• ActiTrak , SI2 , SIAMED , EudraWatch , EudraNet , Intranet , the Internet , secure document transfer', 'D-1612\t-0.755859375\t• ActiTrak, SI2, SIAMED, EudraWatch, EudraNet, Intranet, the Internet, secure document transfer', 'P-1612\t-0.4668 -0.0437 -0.0077 -0.0141 -0.0211 -0.0278 -0.0141 -0.0257 -0.0278 -0.0176 -0.0141 -0.0113 -0.0292 -0.0243 -0.0169 -0.0141 -0.8296 -0.6016 -0.0183 -0.2930 -0.0352 -0.5366 -0.0197 -0.0197 -0.0366 -1.2627 -0.0704 -0.0648 -1.1270 -0.0845 -0.2141 -0.0564', 'S-1470\tDas frühzeitige Erkennen atypischer klinischer Manifestationen schwerer Infektionen ist entscheidend, um Verzögerungen der Diagnosestellung und Behandlung zu vermeiden.', 'T-1470\tEarly recognition of atypical clinical presentations of serious infections is critical in order to minimize delays in diagnosis and treatment.', 'H-1470\t-0.82568359375\tEarly detection of atypical clinical manifestations of severe infections is important to avoid a delay in diagnosis and treatment .', 'D-1470\t-0.82568359375\tEarly detection of atypical clinical manifestations of severe infections is important to avoid a delay in diagnosis and treatment.', 'P-1470\t-1.1045 -0.2374 -0.0247 -0.0303 -0.0402 -0.0085 -0.0225 -0.0197 -0.0662 -0.0296 -0.0310 -0.5708 -0.0366 -0.0127 -0.2676 -1.3330 -0.7524 -0.4734 -0.3240 -0.0395 -0.0423 -0.0704 -0.0310 -0.2029 -0.0338 -0.0282', 'S-370\tFalls die Diacomit-Therapie während des Stillens fortgesetzt wird, muss der gestillte Säugling sorgfältig auf potentielle Nebenwirkungen überwacht werden.', 'T-370\tIn case Diacomit therapy is continued during breast-feeding, the breast-fed infant should be carefully observed for potential adverse effects.', 'H-370\t-1.603515625\tIf Diacomit therapy is continued during breastfeeding , the breast @-@ fed infant should be carefully monitored for adverse effects .', 'D-370\t-1.603515625\tIf Diacomit therapy is continued during breastfeeding, the breast-fed infant should be carefully monitored for adverse effects.', 'P-370\t-0.5303 -1.6172 -0.0268 -0.3184 -0.1282 -0.3042 -0.5806 -0.1691 -0.3972 -1.0879 -0.0169 -0.0141 -0.2283 -0.2903 -0.9751 -0.0564 -0.7495 -0.7100 -0.0225 -0.6313 -0.0338 -0.8564 -0.0451 -0.0225 -0.0338 -1.7412 -0.0113 -0.6650 -0.0451 -0.0338', 'S-1456\tDaher sind die Endprodukte von Stickstoffmonoxid, die in den systemischen Kreislauf eintreten, vorwiegend Methämoglobin und Nitrat.', 'T-1456\tThus, the end products of nitric oxide that enter the systemic circulation are predominantly methaemoglobin and nitrate.', 'H-1456\t-0.75732421875\tTherefore the end products of nitric oxide that enter the systemic circulation are predominantly methaemoglobin and nitrate .', 'D-1456\t-0.75732421875\tTherefore the end products of nitric oxide that enter the systemic circulation are predominantly methaemoglobin and nitrate.', 'P-1456\t-1.5283 -0.0197 -1.7178 -0.1324 -0.0479 -0.0338 -0.0507 -0.0197 -0.0169 -0.2959 -0.0789 -0.1353 -0.2001 -0.0141 -0.0197 -0.3184 -0.0310 -0.0817 -0.1803 -0.0225 -0.0338 -0.2451 -0.3157 -0.2367 -0.0113 -0.0282 -0.0338 -0.0169 -0.0225 -0.0282 -0.0282', 'S-1158\tDie klinische Erfahrung hat gezeigt, dass die Therapie mit Paroxetin nicht mit einer Beeinträchtigung der kognitiven oder psychomotorischen Leistungen verbunden ist.', 'T-1158\tClinical experience has shown that therapy with paroxetine is not associated with impairment of cognitive or psychomotor function.', 'H-1158\t-0.990234375\tClinical experience has shown that treatment with paroxetine is not associated with impairment of cognitive or psychomotor performance .', 'D-1158\t-0.990234375\tClinical experience has shown that treatment with paroxetine is not associated with impairment of cognitive or psychomotor performance.', 'P-1158\t-1.3965 -0.0254 -0.0338 -0.5732 -0.3818 -0.0366 -1.8525 -0.0338 -0.0254 -0.0085 -0.0225 -0.0310 -0.5215 -0.0338 -0.0817 -0.0282 -0.5469 -0.7749 -0.0169 -0.0395 -0.2311 -0.0620 -0.0113 -0.0282 -0.3269 -0.0732 -0.3269 -0.0169 -0.0564 -0.2705 -0.0282 -0.0282', 'S-1564\tFrauen im gebärfähigen Alter und auch Männer müssen während der Behandlung mit Zevalin und bis zu 12 Monate danach eine wirksame Verhütungsmethode anwenden.', 'T-1564\tFemales of childbearing potential as well as males should use effective contraceptive methods during treatment with Zevalin and for 12 months afterwards.', 'H-1564\t-1.04296875\tWomen of childbearing potential and men should use an effective method of contraception during treatment with Zevalin and up to 12 months after treatment .', 'D-1564\t-1.04296875\tWomen of childbearing potential and men should use an effective method of contraception during treatment with Zevalin and up to 12 months after treatment.', 'P-1564\t-0.7627 -0.0430 -0.4446 -0.0085 -0.3220 -0.2085 -0.1888 -0.9385 -0.3411 -1.2676 -0.0169 -0.1973 -0.0451 -0.0535 -0.0197 -0.0056 -0.2649 -0.4001 -0.0423 -0.0507 -0.0085 -0.0225 -0.0282 -0.0760 -1.3271 -0.0282 -0.0282 -0.0282 -0.5972 -0.5073 -0.0395 -0.0282', 'S-135\tStellen Sie sicher, dass die Lösung in der Fertigspritze klar, farblos oder blassgelb und so gut wie frei von sichtbaren Partikeln ist.', 'T-135\tMake sure the solution in the pre-filled syringe is clear, colourless or pale yellow, and practically free from visible particles.', 'H-135\t-0.958984375\tMake sure the liquid in the syringe is clear , colourless or pale yellow and practically free from visible particles .', 'D-135\t-0.958984375\tMake sure the liquid in the syringe is clear, colourless or pale yellow and practically free from visible particles.', 'P-135\t-1.2979 -0.0254 -0.4368 -0.7241 -0.2029 -0.6128 -1.3330 -0.0085 -0.0056 -0.0366 -0.0564 -0.0395 -0.0817 -0.0197 -0.0225 -0.0592 -0.0535 -0.0085 -0.2986 -0.4875 -0.3101 -0.0169 -0.0225 -0.7158 -0.2367 -0.0225 -0.0282 -0.0338 -0.0338', 'S-1706\tDas große scheinbare Verteilungsvolumen im Steady state (von ungefähr 3 bis 5 l / kg), zeigt, dass überwiegend eine extravasale Verteilung vorliegt.', 'T-1706\tThe large apparent volume of distribution at steady state (Vdss) of approximately 3 to 5 l / kg suggests that distribution is largely extravascular.', 'H-1706\t-1.2138671875\tThe large apparent volume of distribution at steady state ( approximately 3 to 5 l / kg ) indicates that distribution is predominantly extravascular .', 'D-1706\t-1.2138671875\tThe large apparent volume of distribution at steady state (approximately 3 to 5 l / kg) indicates that distribution is predominantly extravascular.', 'P-1706\t-0.0502 -0.7866 -0.0704 -1.2031 -0.0760 -0.0873 -1.0537 -0.0789 -0.3860 -0.0564 -0.2817 -0.0507 -0.5073 -0.0338 -0.2986 -0.0282 -0.0197 -0.0310 -2.1250 -0.0282 -0.2874 -0.7383 -0.2085 -0.8511 -0.0225 -0.0395 -0.1183 -0.0338 -0.0225 -0.0676 -0.0395 -0.0282', 'S-917\tEs gab außerdem keinen Unterschied der 28-Tages-Gesamtmortalität (17,1% in der Xigris- versus 17,3% in der Placebogruppe).', 'T-917\tThere was also no difference in 28-day mortality (17.1% versus 17.3% in the Xigris and placebo groups, respectively).', 'H-917\t-0.85302734375\tIn addition , there was no difference in 28 @-@ day mortality rate ( 17.1 % in the Xigris versus 17.3 % in the placebo group ) .', 'D-917\t-0.85302734375\tIn addition, there was no difference in 28-day mortality rate (17.1% in the Xigris versus 17.3% in the placebo group).', 'P-917\t-0.9834 -0.3325 -0.1902 -0.1437 -0.0324 -0.0310 -0.1620 -0.2255 -0.3184 -0.0746 -0.0338 -0.3494 -0.0169 -1.1211 -0.0395 -0.0282 -0.0282 -0.0366 -0.5522 -0.0704 -0.2029 -0.0169 -0.2395 -1.8486 -0.0225 -0.0282 -0.0282 -0.0338 -0.0395 -0.0169 -0.0225 -0.0056 -0.0282 -0.0564 -0.0282 -0.0282 -0.0282', 'S-1554\t16 Es wurde kein direkter Vergleich von GONAL-f / LH mit humanem Menopausengonadotropin (hMG) durchgeführt.', 'T-1554\tNo direct comparison of GONAL-f / LH versus human menopausal gonadotrophin (hMG) has been performed.', 'H-1554\t-0.53271484375\tNo direct comparison of GONAL @-@ f / LH versus human menopausal gonadotrophin ( hMG ) has been performed .', 'D-1554\t-0.53271484375\tNo direct comparison of GONAL-f / LH versus human menopausal gonadotrophin (hMG) has been performed.', 'P-1554\t-1.0312 -0.0416 -0.0634 -0.2507 -0.0437 -0.0176 -0.0169 -0.0324 -0.0296 -0.0338 -0.2197 -0.0225 -0.6567 -0.0493 -0.0366 -0.0197 -0.0409 -0.0197 -0.0183 -0.0197 -0.0113 -0.0183 -0.3127 -0.0676 -0.0535 -0.0366 -0.0338 -0.0282 -0.0197 -0.0282 -0.6143 -0.0282 -0.5156 -0.0338 -0.0310', 'S-1693\tDie Behandlung mit Kuvan darf nur von einem Arzt eingeleitet und beaufsichtigt werden, der Erfahrung in der Behandlung der Krankheiten PKU und BH4-Mangel hat.', 'T-1693\tTreatment with Kuvan must be started and supervised by a doctor who has experience in the treatment of PKU and BH4 deficiency.', 'H-1693\t-1.115234375\tTreatment with Kuvan should only be initiated and supervised by a doctor who has experience in the treatment of PKU and BH4 deficiency .', 'D-1693\t-1.115234375\tTreatment with Kuvan should only be initiated and supervised by a doctor who has experience in the treatment of PKU and BH4 deficiency.', 'P-1693\t-2.0605 -0.0169 -0.0240 -0.0465 -0.0423 -0.0056 -0.2634 -1.4854 -0.0310 -0.6201 -0.0282 -0.0395 -1.4795 -0.0169 -0.0169 -0.0282 -0.2593 -0.1071 -0.4001 -0.0901 -0.0564 -0.0676 -0.3718 -0.6650 -0.0282 -0.6030 -0.0338 -0.0282 -0.0395 -0.0395 -0.0282 -0.0282 -0.0169 -0.0113 -0.0901 -0.5352 -0.0282', 'S-855\tDer Wirkstoff in Pylobactell, 13C-Harnstoff, ist mit Kohlenstoff-13 (13C) markierter natürlicher Harnstoff.', 'T-855\tThe active substance in Pylobactell, 13C-urea, is the natural chemical urea that has been labelled with carbon-13 (13C).', 'H-855\t-0.7841796875\tThe active substance in Pylobactell , 13C @-@ urea , is broken down by H Pylobactell into carbon dioxide that also contains 13C .', 'D-855\t-0.7841796875\tThe active substance in Pylobactell, 13C-urea, is broken down by H Pylobactell into carbon dioxide that also contains 13C.', 'P-855\t-0.1942 -0.2771 -0.2227 -0.0514 -0.5469 -0.0141 -0.0662 -0.0514 -0.0528 -0.4424 -0.0254 -0.2888 -0.0366 -0.0225 -0.0465 -0.0310 -0.3228 -0.0493 -0.3579 -0.3606 -0.3240 -0.0395 -0.0732 -0.0760 -0.2791 -0.2311 -0.4368 -0.0113 -0.3240 -0.3972 -0.2479 -0.4001 -0.0282 -0.2593 -0.0338', 'S-1025\tBei Verabreichung des Tierarzneimittels in den Gehörgang ist die Aufnahme von Miconazol und Gentamicin über die Haut vernachlässigbar.', 'T-1025\tAfter application of the veterinary medicinal product into the ear canal, absorption of miconazole and gentamicin through the skin is negligible.', 'H-1025\t-1.302734375\tWhen administering the product to the ear canal , the absorption of miconazole and gentamicin through the skin is negligible .', 'D-1025\t-1.302734375\tWhen administering the product to the ear canal, the absorption of miconazole and gentamicin through the skin is negligible.', 'P-1025\t-1.2773 -1.0449 -0.5635 -0.2057 -1.2227 -0.7637 -0.0366 -0.2113 -0.0169 -0.0282 -0.4453 -0.7437 -1.2910 -0.0113 -0.0338 -0.2085 -0.0282 -0.0113 -0.0113 -0.0338 -0.0056 -0.4790 -0.0169 -0.0395 -1.1553 -0.0338 -0.0225 -0.4790 -0.2930 -0.0056 -0.0113 -0.0169 -0.0282 -0.0282', 'S-1571\tAbseamed sollte intravenös gegeben werden, damit die Hämoglobinkonzentration nicht über 12 g / dl (7,5 mmol / l) steigt.', 'T-1571\tAbseamed should be administered intravenously in order to increase haemoglobin to not greater than 12 g / dl (7.5 mmol / l).', 'H-1571\t-0.62353515625\tAbseamed should be administered intravenously in order to increase haemoglobin to not greater than 12 g / dl ( 7.5 mmol / l ) .', 'D-1571\t-0.62353515625\tAbseamed should be administered intravenously in order to increase haemoglobin to not greater than 12 g / dl (7.5 mmol / l).', 'P-1571\t-0.2764 -0.0285 -0.0070 -0.0372 -0.0327 -0.8916 -0.0190 -0.5415 -0.0155 -0.0113 -0.0282 -0.5933 -0.0437 -0.4663 -0.3606 -0.2903 -0.0056 -0.0169 -0.0282 -0.3860 -0.2734 -0.3240 -0.0282 -0.0676 -0.0338 -0.0310 -0.3042 -0.0338 -0.0338 -0.0254 -0.0197 -0.0197 -0.0310 -0.0451 -0.0282 -0.0338 -0.0282', 'S-1688\tBei klinisch relevanter Erniedrigung der Hämoglobinkonzentration sollten in weiteren Bewertungen und Untersuchungen die Ursache und Notwendigkeit einer spezifischen Behandlung geklärt werden.', 'T-1688\tIf a clinically relevant decrease in haemoglobin concentration occurs, further evaluation and investigation should be undertaken to determine the cause and need for specific treatment.', 'H-1688\t-1.537109375\tIf a clinically relevant decrease in haemoglobin concentration is observed , carry out further evaluation and evaluation to determine the cause and need for specific treatment .', 'D-1688\t-1.537109375\tIf a clinically relevant decrease in haemoglobin concentration is observed, carry out further evaluation and evaluation to determine the cause and need for specific treatment.', 'P-1688\t-1.0254 -0.4009 -0.0690 -0.0225 -0.8804 -0.3381 -0.0155 -0.3057 -0.2339 -0.0085 -0.0141 -0.0282 -1.2627 -0.6821 -0.7271 -0.0564 -0.9976 -0.0282 -0.0676 -1.4600 -0.0169 -0.0169 -0.0451 -0.9639 -0.0225 -0.0225 -0.1635 -0.7437 -0.1183 -0.2930 -0.2423 -0.3833 -0.9917 -0.5298 -0.1691 -0.0338 -0.0338', 'S-1707\tDie SAG wurde insbesondere ersucht, die Definition eines Stimmungsstabilisators und die Notwendigkeit der Wirkung eines Arzneimittels auf beide Pole der Störungen zu klären.', 'T-1707\tSpecifically, the SAG was asked to clarify the definition of a mood stabiliser and the need for a medicinal product to act on both poles of the disorders.', 'H-1707\t-1.6416015625\tIn particular , the SAG was requested to clarify the definition of mood stabiliser and the need for the effect of a medicinal product on both sides of the disorder .', 'D-1707\t-1.6416015625\tIn particular, the SAG was requested to clarify the definition of mood stabiliser and the need for the effect of a medicinal product on both sides of the disorder.', 'P-1707\t-1.2559 -0.0254 -0.4375 -0.9409 -0.2227 -0.1578 -0.0873 -0.9043 -0.0310 -2.3945 -0.0169 -0.0395 -0.0507 -0.0282 -0.6030 -0.0282 -0.1691 -0.0451 -0.5352 -0.1240 -0.0789 -0.7666 -0.8228 -0.5522 -0.4338 -1.2734 -0.0789 -0.0451 -0.0451 -0.0338 -1.4648 -0.0338 -0.0789 -0.2141 -0.0338 -0.0338', 'S-496\tDehydrierung, Hypokaliämie, Hyperkaliämie, Hypomagnesiämie Hyponatriämie Hypokalzämie', 'T-496\tDehydration, hypokalaemia, hyperkalaemia, hypomagnesaemia, hyponatraemia, hypocalcaemia', 'H-496\t-0.7861328125\tdehydration , hypokalaemia , hyperkalaemia , hypomagnesaemia , hyponatraemia , hypocalcaemia', 'D-496\t-0.7861328125\tdehydration, hypokalaemia, hyperkalaemia, hypomagnesaemia, hyponatraemia, hypocalcaemia', 'P-496\t-1.5986 -0.0310 -0.0085 -0.0225 -0.0310 -0.0183 -0.0859 -0.3157 -0.0380 -0.0254 -0.0296 -0.0380 -0.0183 -0.0564 -0.0225 -0.0240 -0.0296 -0.0592 -0.0211 -0.0197 -0.0127 -0.3228 -0.2507 -0.0056 -0.0225 -1.2451 -0.3804 -0.0056 -0.0169 -0.0395 -0.9019 -0.0113 -0.0225 -1.0879 -0.0169 -0.0451 -0.2311 -0.0113 -0.0225 -0.0451', 'S-1721\tUnmittelbar danach die Durchstechflasche mit der Lösung aufrecht in die bleiabgeschirmte Halterung im kochenden Wasserbad stellen und 10 Minuten inkubieren.', 'T-1721\tIncubate for 10 minutes in this condition.', 'H-1721\t-2.4296875\tJust after that , set the vial and solution upright in the lead vial shielded , turn the vial into a boiling water bath and incubate for 10 minutes .', 'D-1721\t-2.4296875\tJust after that, set the vial and solution upright in the lead vial shielded, turn the vial into a boiling water bath and incubate for 10 minutes.', 'P-1721\t-1.4014 -1.0303 -1.1807 -0.3325 -1.2090 -0.1859 -0.4536 -0.0282 -1.5156 -0.9072 -0.1465 -0.0113 -0.0225 -0.4958 -0.0507 -0.0732 -0.3269 -0.0845 -0.8564 -0.9751 -0.0732 -0.8003 -2.4004 -0.7437 -0.2029 -0.0338 -2.5586 -0.3157 -0.0564 -0.0225 -0.1127 -0.0225 -0.2593 -2.4902 -0.0113 -0.0225 -1.0146 -0.0451 -0.0225 -0.0338 -0.0338', 'S-732\t24 Verkehrstüchtigkeit und das Bedienen von Maschinen Die Einnahme von Xyrem wird sich bei Ihnen spürbar auswirken, wenn Sie Fahrzeuge führen, Geräte oder Maschinen bedienen.', 'T-732\tDriving and using machines Xyrem will affect you if you drive or operate tools or machines.', 'H-732\t-2.078125\tIf you drive vehicles , use tools , or machines , Xyrem may have practical consequences for you .', 'D-732\t-2.078125\tIf you drive vehicles, use tools, or machines, Xyrem may have practical consequences for you.', 'P-732\t-2.3066 -0.0620 -0.5000 -0.7383 -0.0760 -0.6172 -0.4705 -0.8228 -0.0479 -0.8564 -0.0732 -1.1943 -0.0338 -0.0056 -1.3691 -1.3916 -1.6064 -0.5859 -0.0901 -0.0451 -0.1014 -0.2817', 'S-1920\tEtwaige weitere Zweifel hinsichtlich der wesentlichen Ähnlichkeit der Präparate werden durch die Verpflichtung des Antragstellers zur Anwendungsbeobachtung nach dem Inverkehrbringen ausgeräumt.', 'T-1920\tAny additional doubts regarding essential similarity are overcome by a commitment for post-marketing surveillance of the applicant.', 'H-1920\t-2.376953125\tAny additional concerns related to the similarity of the products are resolved by the Applicant &quot; s obligation to monitor the use after launch .', 'D-1920\t-2.376953125\tAny additional concerns related to the similarity of the products are resolved by the Applicant "s obligation to monitor the use after launch.', 'P-1920\t-0.3135 -2.7422 -0.8594 -1.5020 -0.0282 -1.1328 -1.5723 -0.0113 -0.0225 -0.0676 -0.5972 -0.2255 -1.1270 -0.5073 -0.9580 -0.1014 -0.7437 -0.0225 -0.0113 -0.5522 -0.1240 -0.7324 -0.0338 -0.6084 -0.2705 -1.0703 -0.5747 -0.8340 -1.2168 -0.0564 -0.0338', 'S-1390\tPatienten, die einen Hautausschlag bekommen, müssen engmaschig überwacht und VFEND muss abgesetzt werden, wenn es zu einer Zunahme der Hautschäden kommt.', 'T-1390\tIf patients develop a rash they should be monitored closely and VFEND discontinued if lesions progress.', 'H-1390\t-1.673828125\tPatients who develop a skin rash should be monitored closely and Lamictal withdrawn if there is an increase in skin damage .', 'D-1390\t-1.673828125\tPatients who develop a skin rash should be monitored closely and Lamictal withdrawn if there is an increase in skin damage.', 'P-1390\t-0.3972 -0.0197 -0.2959 -0.7891 -0.5747 -1.0596 -0.0338 -0.0113 -0.2930 -0.0507 -1.2656 -0.0197 -0.0254 -0.0789 -1.2285 -0.3213 -0.3213 -0.3157 -1.1943 -0.2593 -0.1071 -2.4395 -0.0395 -0.1409 -0.0451 -0.0395 -0.1071 -1.3408 -0.0338 -0.0338', 'S-600\tAus diesem Grund müssen die empfohlenen Standardmaßnahmen zur Immunisierung von Säuglingen angewandt werden, um eine Ansteckung des Neugeborenen mit HBV zu verhindern.', 'T-600\tTherefore, the standard recommended procedures for immunisation of infants should be followed to prevent neonatal acquisition of HBV.', 'H-600\t-1.705078125\tTherefore the standard immunisation measures as recommended should be used to prevent neonatal acquisition of HBV .', 'D-600\t-1.705078125\tTherefore the standard immunisation measures as recommended should be used to prevent neonatal acquisition of HBV.', 'P-600\t-1.3799 -0.0183 -1.3740 -0.3325 -1.0029 -0.1719 -0.4988 -2.0684 -0.0789 -1.0596 -0.0338 -1.5049 -0.1578 -0.0564 -0.3269 -0.0113 -0.7100 -0.0282 -0.3213 -0.0845 -0.0282 -0.0282 -0.1691 -0.0338', 'S-1338\tThromboembolische Komplikationen (Blutgerinnsel) können auftreten, wenn TachoSil versehentlich in ein Blutgefäß eingebracht wird.', 'T-1338\tThromboembolic complications (blood clots) may occur if TachoSil is unintentionally applied inside a blood vessel.', 'H-1338\t-0.38134765625\tThromboembolic complications ( blood clots ) may occur if TachoSil is accidentally inserted into a blood vessel .', 'D-1338\t-0.38134765625\tThromboembolic complications (blood clots) may occur if TachoSil is accidentally inserted into a blood vessel.', 'P-1338\t-0.2228 -0.0092 -0.0042 -0.0113 -0.0185 -0.0213 -0.3037 -0.0285 -0.0465 -0.2455 -0.0359 -0.0099 -0.0282 -0.2275 -0.0740 -0.7798 -0.0282 -0.0141 -0.0268 -0.0268 -0.0127 -0.0409 -0.2720 -0.0197 -0.2649 -0.0578 -0.0254 -0.1000 -0.0395 -0.0338 -0.0197 -0.0310 -0.0282', 'S-1964\tDaher sollte sofort ein Monitoring der kardiovaskulären Funktionen eingeleitet werden inklusive kontinuierlicher elektrokardiographischer Überwachung zur Identifizierung möglicher Arrhythmien.', 'T-1964\tTherefore cardiovascular monitoring should be started immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias.', 'H-1964\t-1.0908203125\tCardiovascular monitoring should be administered immediately and should include continuous electrocardiographic monitoring to identify possible arrhythmias .', 'D-1964\t-1.0908203125\tCardiovascular monitoring should be administered immediately and should include continuous electrocardiographic monitoring to identify possible arrhythmias.', 'P-1964\t-0.8403 -0.0148 -0.0197 -0.0162 -0.3486 -0.2014 -1.3203 -1.4395 -0.0141 -0.5776 -0.7920 -0.4226 -0.1973 -0.1071 -0.0282 -0.0395 -0.0225 -0.0169 -0.0338 -0.0620 -0.0507 -0.1183 -0.8960 -0.1521 -0.0113 -0.0169 -0.2367 -0.0338 -0.3325 -0.0282', 'S-15\tDie pharmakokinetischen Eigenschaften von Doxazosin in Form von Retardtabletten führen zu einer geringfügigen Änderung der Plasmaspiegel.', 'T-15\tThe pharmacokinetic properties of doxazosin in prolonged-release tablets lead to a minor variation in plasma levels.', 'H-15\t-0.86083984375\tThe pharmacokinetic properties of doxazosin in the form of prolonged @-@ release tablets lead to small changes in plasma levels .', 'D-15\t-0.86083984375\tThe pharmacokinetic properties of doxazosin in the form of prolonged-release tablets lead to small changes in plasma levels.', 'P-15\t-0.1490 -0.0234 -0.0106 -0.0092 -0.6621 -0.0620 -0.0289 -0.0197 -0.0169 -0.0296 -0.0141 -0.1028 -0.1768 -0.0486 -0.0211 -0.0282 -0.8735 -0.2986 -0.3157 -0.3127 -0.0141 -0.0535 -0.0197 -1.1328 -0.0282 -2.3672 -0.0676 -0.0451 -0.0789 -0.0113 -0.0113 -0.0451 -0.0338 -0.0282', 'S-224\tÖsterreich Bayer Austria GmbH Geschäftsbereich Tiergesundheit Lerchenfelder Gürtel 9-11 A-1164 Wien Tel: + 43 1 71146 2850', 'T-224\tÖsterreich Bayer Austria GmbH Geschäftsbereich Tiergesundheit Herbststraβ e 6-10 A-1160 Wien Tel: + 43 1 71146 2850', 'H-224\t-0.407958984375\tBayer Austria GmbH Geschäftsbereich Tiergesundheit Lerchenfelder Gelt9 @-@ 11 A @-@ 1164 Wien Tel : + 43 1 71146 2850', 'D-224\t-0.407958984375\tBayer Austria GmbH Geschäftsbereich Tiergesundheit Lerchenfelder Gelt9-11 A-1164 Wien Tel: + 43 1 71146 2850', 'P-224\t-0.4216 -0.0243 -0.0313 -0.3223 -0.0395 -0.1521 -0.2620 -0.2064 -0.0578 -0.0211 -0.0169 -0.0099 -0.0352 -0.5015 -0.4565 -0.0310 -0.0225 -0.0352 -0.0296 -0.0240 -0.0225 -0.0268 -0.2311 -0.1353 -0.0535 -0.0282 -0.0225 -0.0310 -0.0282 -0.0254 -0.0197 -0.0254 -0.0225 -0.0225 -0.0479', 'S-637\tEs ist in Form von Tabletten erhältlich (10 mg: weiß, rund; 20 mg: gelb, dreieckig; 100 mg: weiß, rund).', 'T-637\tIt is available as tablets (10 mg: white, round; 20 mg: yellow, triangular; 100 mg: white, round).', 'H-637\t-0.2120361328125\tIt is available as tablets ( 10 mg : white , round ; 20 mg : yellow , triangular ; 100 mg : white , round ) .', 'D-637\t-0.2120361328125\tIt is available as tablets (10 mg: white, round; 20 mg: yellow, triangular; 100 mg: white, round).', 'P-637\t-0.0774 -0.0509 -0.0494 -0.2302 -0.0870 -0.0444 -0.0384 -0.0796 -0.0155 -0.0437 -0.0282 -0.0486 -0.0211 -0.0345 -0.0289 -0.0113 -0.0296 -0.0190 -0.4705 -0.0169 -0.0275 -0.0127 -0.0197 -0.0268 -0.0211 -0.0113 -0.0296 -0.0169 -0.0282 -0.0141 -0.0310 -0.0338 -0.0296', 'S-841\tEptacog alfa (aktiviert) 5 mg / Durchstechflasche (250 kIE / Durchstechflasche), 1 mg / ml nach Rekonstitution', 'T-841\teptacog alfa (activated) 5 mg / vial (250 KIU / vial), 1 mg / ml after reconstitution', 'H-841\t-0.462890625\teptacog alfa ( activated ) 5 mg / vial ( 250 KIU / vial ) , 1 mg / ml after reconstitution', 'D-841\t-0.462890625\teptacog alfa (activated) 5 mg / vial (250 KIU / vial), 1 mg / ml after reconstitution', 'P-841\t-0.3418 -0.0042 -0.0269 -0.0229 -0.0327 -0.0113 -0.0472 -0.0155 -0.0271 -0.0299 -1.2598 -0.4155 -0.0366 -0.0437 -0.0183 -0.0380 -0.0225 -0.3213 -0.3169 -0.1888 -0.0366 -0.0085 -0.0141 -0.0338 -0.0676 -0.0507 -0.0113 -0.0310 -0.0169 -0.1183 -0.1183 -0.0056 -0.0366', 'S-1520\tBevor ein radioaktives Arzneimittel einer stillenden Mutter gegeben wird, ist zu prüfen, ob die Anwendung auf einen Zeitpunkt nach Beendigung der Stillzeit verschoben werden kann.', 'T-1520\tBefore administering a radioactive medicinal product to a mother who is breast feeding, consideration should be given to whether the investigation could be reasonably delayed until the mother has ceased breastfeeding.', 'H-1520\t-0.9296875\tBefore administering a radioactive medicinal product to a mother who is breast @-@ feeding , consideration should be given to whether the administration could be reasonably delayed until the mother has ceased breastfeeding .', 'D-1520\t-0.9296875\tBefore administering a radioactive medicinal product to a mother who is breast-feeding, consideration should be given to whether the administration could be reasonably delayed until the mother has ceased breastfeeding.', 'P-1520\t-0.1569 -0.3005 -0.0169 -0.5967 -0.2219 -0.0169 -0.5176 -0.0465 -0.0211 -0.0310 -0.1099 -1.0078 -0.2141 -0.0366 -0.4282 -0.1296 -0.0141 -0.0564 -0.3352 -0.2255 -0.0282 -0.0113 -0.4028 -0.2169 -0.2367 -0.3381 -0.3352 -0.0282 -0.6934 -0.1127 -0.2423 -0.1240 -0.2874 -0.3269 -0.1296 -0.3213 -0.0225 -0.2479 -0.0169 -0.0901 -0.0338 -0.0282', 'S-1935\t1992 wurde er Professor für klinische Pharmakologie und Therapeutik sowie Direktor des Master- / Diplom- Studiengangs für Europäische Arzneimittelzulassung (UAB).', 'T-1935\tIn 1992, he became Professor of Clinical Pharmacology and Therapeutics and Director of the Masters / Diploma course on European Registration of Medicinal Products (UAB).', 'H-1935\t-0.59619140625\tIn 1992 he became Professor of Clinical Pharmacology and Therapeutics and Director of the Masters / Diploma course on European Registration of Medicinal Products ( UAB ) .', 'D-1935\t-0.59619140625\tIn 1992 he became Professor of Clinical Pharmacology and Therapeutics and Director of the Masters / Diploma course on European Registration of Medicinal Products (UAB).', 'P-1935\t-0.2979 -0.0141 -1.0186 -0.2656 -0.1606 -0.1169 -0.0775 -0.0155 -0.0240 -0.0099 -0.0310 -0.0211 -0.0324 -0.0070 -0.0113 -0.0254 -0.2352 -0.1042 -0.0324 -0.0437 -0.3057 -0.1648 -0.0535 -0.0451 -0.2986 -0.4001 -0.0760 -0.3184 -0.0225 -0.2903 -0.0845 -0.5127 -0.0113 -0.0225 -0.1747 -0.0254 -0.0085 -0.0310 -0.0310 -0.0282', 'S-89\tWas die Änderungsanträge betraf, so wurden insgesamt 12 Typ I-Änderungen abgeschlossen (wovon 4 noch Anträge nach dem früheren konzertierten Verfahren betrafen).', 'T-89\tWith regard to variations, a total of 12 type I variations have been finalised (of which 4 related to ex- <<unk>> concertation <<unk>> procedures) and 1 type II has been finalised with a further type II in progress.', 'H-89\t-1.833984375\tConcerning variations , there were a total of 12 type I variations completed ( of which 4 were full applications under the ex- &apos; concertation procedure &quot; ) .', 'D-89\t-1.833984375\tConcerning variations, there were a total of 12 type I variations completed (of which 4 were full applications under the ex- \'concertation procedure ").', 'P-89\t-1.7598 -0.0070 -0.0268 -0.9790 -0.5381 -0.4170 -1.8457 -0.1663 -0.8145 -0.0282 -0.0282 -0.0338 -0.4114 -0.0732 -0.7271 -0.0676 -0.2593 -0.0564 -1.0479 -0.0282 -0.2255 -0.7324 -1.6064 -0.4509 -0.4958 -0.0564 -0.9805 -0.3042 -0.3269 -0.1578 -0.0113 -0.3269 -0.2367 -0.6875 -0.0338 -0.0338 -0.0338', 'S-706\tECU gegenüber 1997, vor allem aufgrund der für 1998 erwarteten Zunahme der Anzahl an Sitzungen sowie an Beurteilungen der Berichterstatter und Mitberichterstatter.', 'T-706\tOperational expenditure for 1998 amounts to ECU 14. 19 million, an increase of ECU 3.18 million over 1997, mainly because of the rise in number of meetings expected in 1998 and increase in the evaluation services provided by rapporteurs and co-rapporteurs.', 'H-706\t-2.087890625\tThe number of meetings relating to the establishment of maximum residue limits for essential old veterinary substances was reduced due to a contingency plan and planned recruitment was delayed .', 'D-706\t-2.087890625\tThe number of meetings relating to the establishment of maximum residue limits for essential old veterinary substances was reduced due to a contingency plan and planned recruitment was delayed.', 'P-706\t-0.4272 -2.4336 -0.0296 -0.0873 -1.7500 -0.0310 -0.5581 -0.8257 -0.0395 -0.3945 -0.3213 -0.3213 -0.3213 -0.6704 -0.7832 -0.3213 -0.3269 -0.0338 -0.3269 -0.0338 -1.4824 -0.7554 -0.8115 -0.0564 -0.6313 -0.8115 -0.3157 -0.2593 -0.3269 -0.6426 -0.3494 -0.3269 -0.4395 -0.3381 -0.0451', 'S-1922\t1 090 ng / ml bei Patienten mit normaler Leberfunktion einschließlich Patienten mit einem primären Leberzellkarzinom oder Lebermetastasen.', 'T-1922\tIn patients with solid tumours and with moderately impaired hepatic function (Child-Pugh score 7-9), geometric mean erlotinib AUC0-t and Cmax was 27000 ng • h / mL and 805 ng / mL, respectively, as compared to 29300 ng • h / mL and 1090 ng / mL in patients with adequate hepatic function including patients with primary liver cancer or hepatic metastases.', 'H-1922\t-0.82568359375\t1,090 ng / ml in patients with normal hepatic function , including patients with primary liver cell carcinoma or liver metastases .', 'D-1922\t-0.82568359375\t1,090 ng / ml in patients with normal hepatic function, including patients with primary liver cell carcinoma or liver metastases.', 'P-1922\t-0.8516 -0.0232 -0.0451 -0.0211 -0.0197 -0.0289 -0.0296 -0.4600 -0.7241 -0.0366 -0.1635 -0.9185 -0.0620 -0.0197 -0.0338 -0.2817 -0.0310 -0.1296 -0.2451 -0.0169 -0.6313 -0.0338 -0.3635 -0.0085 -0.0141 -0.0395 -0.9326 -0.0113 -0.3325 -0.0282 -0.0395 -0.0282', 'S-721\tDies bedeutet, dass sich einige ihrer Gene so umgelagert haben, dass ein spezielles Chromosom entstanden ist, das als Philadelphia-Chromosom bezeichnet wird.', 'T-721\tThis means that some of their genes have re-arranged themselves to form a special chromosome called the Philadelphia chromosome.', 'H-721\t-0.67822265625\tThis means that some of the patient &quot; s genes have re @-@ arranged themselves to form a special chromosome called the Philadelphia chromosome .', 'D-721\t-0.67822265625\tThis means that some of the patient "s genes have re-arranged themselves to form a special chromosome called the Philadelphia chromosome.', 'P-721\t-0.3899 -0.0430 -0.3096 -0.0528 -0.0359 -1.0254 -0.3423 -0.3523 -0.0310 -0.1212 -0.0845 -0.3198 -0.0282 -0.2507 -0.2791 -0.4170 -0.2903 -0.0366 -0.2423 -0.0310 -0.0254 -0.0169 -0.0141 -0.4312 -0.0760 -0.0197 -0.0395 -0.0282 -0.0169 -0.0141 -0.0338 -0.0282', 'S-1811\tHaltbarkeit der gebrauchsfertigen Lösung Chemische und physikalische Stabilität wurde für 24 Stunden bei 2 ° C - 8 ° C und für 8 Stunden bei 30 ° C nachgewiesen.', 'T-1811\tReconstituted solution Chemical and physical in-use stability has been demonstrated for 24 hours at 2-8 ° C and 8 hours at 30 ° C.', 'H-1811\t-0.927734375\tShelf @-@ life of the reconstituted solution Chemical and physical in use stability has been demonstrated for 24 hours at 2 ° C - 8 ° C and 8 hours at 30 ° C .', 'D-1811\t-0.927734375\tShelf-life of the reconstituted solution Chemical and physical in use stability has been demonstrated for 24 hours at 2 ° C - 8 ° C and 8 hours at 30 ° C.', 'P-1811\t-0.8735 -0.0183 -0.8184 -0.0183 -0.0437 -0.1550 -0.7778 -0.0859 -0.0465 -0.2761 -0.0817 -0.0254 -0.0395 -0.0197 -0.3213 -1.2959 -0.0901 -0.2339 -0.0282 -0.2395 -0.0873 -0.0423 -0.0564 -0.0423 -0.0423 -0.6875 -0.0338 -0.7495 -0.0225 -0.0225 -0.0225 -0.6313 -0.3269 -0.0282 -0.0282 -0.0282 -0.0225 -0.0395 -0.0564 -0.0282', 'S-348\tEs ist ein aktualisiertes TSE-Zertifikat für die <unk> Rousselot Acid hide gelatin <unk> (Europäischern Ursprungs) vorzulegen.', 'T-348\tAn up-to-date certificate of suitability should be provided for Rousselot Acid hide gelatin (European origin) II. E.', 'H-348\t-2.15625\tReproduction is authorised provided the source is acknowledged .', 'D-348\t-2.15625\tReproduction is authorised provided the source is acknowledged.', 'P-348\t-1.3555 -1.9785 -0.3352 -0.9243 -0.0197 -0.3213 -0.3184 -0.3213 -0.3042 -2.9707 -0.3718 -0.3606', 'S-338\tIn klinischen Studien bewirkte bereits eine Dosis von 5 mg Montelukast eine Hemmung der durch LTD4 hervorgerufenen Bronchokonstriktion.', 'T-338\tIn clinical studies, montelukast inhibits bronchoconstriction due to inhaled LTD4 at doses as low as 5 mg.', 'H-338\t-1.0595703125\tIn clinical studies , a 5 mg dose of montelukast inhibited exercise @-@ induced bronchoconstriction induced by LTD4 .', 'D-338\t-1.0595703125\tIn clinical studies, a 5 mg dose of montelukast inhibited exercise-induced bronchoconstriction induced by LTD4.', 'P-338\t-0.5454 -0.0197 -0.1106 -0.6372 -1.4199 -0.8286 -0.0197 -0.1127 -0.0423 -0.0789 -0.0141 -0.0592 -0.0113 -0.8174 -0.0479 -0.2113 -0.3213 -0.4453 -0.0789 -0.0113 -0.0225 -0.0338 -0.5015 -0.0169 -0.0225 -2.1309 -0.0113 -0.0282 -0.0395 -0.0282 -0.0282 -0.0282 -0.0395 -0.0282', 'S-1876\tPrometax 4,6 mg / 24 Stunden transdermales Pflaster Prometax 9,5 mg / 24 Stunden transdermales Pflaster Rivastigmin', 'T-1876\tPrometax 4.6 mg / 24 h transdermal patch Prometax 9.5 mg / 24 h transdermal patch rivastigmine', 'H-1876\t-0.334228515625\tPrometax 4.6 mg / 24 h transdermal patch Prometax 9.5 mg / 24 h transdermal patch rivastigmine', 'D-1876\t-0.334228515625\tPrometax 4.6 mg / 24 h transdermal patch Prometax 9.5 mg / 24 h transdermal patch rivastigmine', 'P-1876\t-0.0270 -0.0213 -0.0113 -0.1143 -0.0459 -0.0099 -0.0299 -0.0327 -0.9531 -0.0402 -0.0127 -0.0141 -0.0134 -0.0211 -0.0190 -0.0190 -0.0092 -0.0232 -0.0282 -0.0113 -0.0282 -0.0268 -0.0662 -0.0113 -0.0099 -0.0211 -0.0085 -0.0225 -0.5103 -0.0099 -0.0254 -0.0211 -0.5059', 'S-1863\tEin Vergleich mit historischen Daten zeigt, dass die unter Luveris / FSH erreichte Ovulationsrate vergleichbar der unter hMG erreichten Ovulationsrate ist.', 'T-1863\tComparison with historical data suggests that the ovulation rate obtained with Luveris / FSH is similar to what can be obtained with hMG.', 'H-1863\t-0.79248046875\tComparison with historical data suggests that the ovulation rate obtained with Luveris / FSH is comparable to what can be obtained with hMG .', 'D-1863\t-0.79248046875\tComparison with historical data suggests that the ovulation rate obtained with Luveris / FSH is comparable to what can be obtained with hMG.', 'P-1863\t-0.5518 -0.1515 -0.0947 -0.6870 -0.1437 -0.0803 -1.0820 -0.0479 -0.0578 -0.0732 -0.0169 -0.0366 -0.3494 -0.4902 -0.0366 -0.0197 -0.0282 -0.0451 -0.0113 -0.0197 -0.0507 -0.6567 -0.0282 -0.6001 -0.3325 -0.3213 -0.0338 -0.3042 -0.0676 -0.0507 -0.0282 -0.0169 -0.0338 -0.0282', 'S-1844\tBei schwangeren Frauen mit Erkrankungen, die das Risiko der Komplikationen einer Grippeerkrankung erhöhen, wird die Anwendung des Impfstoffs unabhängig vom Schwangerschaftsstadium empfohlen.', 'T-1844\tFor pregnant women with medical conditions that increase their risk of complications from the flu, administration of the vaccine is recommended, irrespective of their stage of pregnancy.', 'H-1844\t-0.83349609375\tFor pregnant women with medical conditions that increase their risk of complications of influenza , administration of the vaccine is recommended , irrespective of their stage of pregnancy .', 'D-1844\t-0.83349609375\tFor pregnant women with medical conditions that increase their risk of complications of influenza, administration of the vaccine is recommended, irrespective of their stage of pregnancy.', 'P-1844\t-0.2318 -0.0255 -0.0255 -0.2427 -0.5269 -0.0134 -0.1711 -0.0859 -0.5171 -0.0324 -0.3240 -0.9707 -0.0338 -0.2791 -0.9526 -0.0085 -0.0282 -0.0958 -0.3550 -0.0366 -0.4226 -0.0197 -0.0423 -0.0479 -0.3213 -0.4226 -0.0113 -0.0282 -0.3042 -0.1635 -0.0620 -0.0564 -0.0282 -0.0282', 'S-1231\tExelon 4,6 mg / 24 Stunden transdermales Pflaster Exelon 9,5 mg / 24 Stunden transdermales Pflaster Rivastigmin', 'T-1231\tExelon 4.6 mg / 24 h transdermal patch Exelon 9.5 mg / 24 h transdermal patch rivastigmine', 'H-1231\t-0.2406005859375\tExelon 4.6 mg / 24 h transdermal patch Exelon 9.5 mg / 24 h transdermal patch rivastigmine', 'D-1231\t-0.2406005859375\tExelon 4.6 mg / 24 h transdermal patch Exelon 9.5 mg / 24 h transdermal patch rivastigmine', 'P-1231\t-0.0313 -0.0198 -0.0284 -0.0692 -0.0502 -0.0099 -0.0299 -0.0349 -0.6899 -0.0345 -0.0148 -0.0127 -0.0197 -0.0225 -0.0648 -0.0176 -0.0261 -0.0232 -0.0275 -0.0113 -0.0282 -0.0268 -0.0578 -0.0113 -0.0099 -0.0183 -0.0113 -0.0225 -0.2832 -0.0099 -0.0254 -0.0183 -0.1986', 'S-1740\tEasotic wird zur Behandlung von Hunden eingesetzt, die an akuten oder wiederkehrenden Episoden von Ohrinfektionen (Otitis externa) leiden.', 'T-1740\tEasotic is used to treat dogs that suffer from acute or recurrent episodes of ear infections (otitis externa).', 'H-1740\t-0.405029296875\tEasotic is used to treat dogs that suffer from acute or recurrent episodes of ear infections ( otitis externa ) .', 'D-1740\t-0.405029296875\tEasotic is used to treat dogs that suffer from acute or recurrent episodes of ear infections (otitis externa).', 'P-1740\t-0.0371 -0.0234 -0.0134 -0.0364 -0.0429 -0.1624 -0.0127 -0.0581 -0.8086 -0.7100 -0.0775 -0.1240 -0.0127 -0.0338 -0.0268 -0.3889 -0.0127 -0.0690 -0.0296 -0.1071 -0.1663 -0.0085 -0.0282 -0.0620 -0.0225 -0.0169 -0.0254 -0.0141 -0.0254 -0.0282 -0.0282 -0.0282', 'S-1850\tWeißes, opakes Kapselunterteil und rotes, opakes Kapseloberteil bedruckt mit einem Logo und <unk> ZONEGRAN 100 <unk> in schwarz.', 'T-1850\tA white opaque body and a red opaque cap printed with a logo and <<unk>> ZONEGRAN 100 <<unk>> in black.', 'H-1850\t-0.556640625\tA white opaque body and red opaque cap printed with a logo and &quot; ZONEGRAN 100 &quot; in black .', 'D-1850\t-0.556640625\tA white opaque body and red opaque cap printed with a logo and "ZONEGRAN 100" in black.', 'P-1850\t-0.4646 -0.0947 -0.1705 -0.0254 -0.0155 -0.3228 -0.2874 -1.0303 -0.0352 -0.0211 -0.0169 -0.3198 -0.3042 -0.0395 -0.1465 -0.0282 -0.0760 -0.3494 -0.1183 -0.0254 -0.0254 -0.0338 -0.0113 -0.0169 -0.0282 -0.0789 -0.0704 -0.0254 -0.0760 -0.0282', 'S-925\t4 / 26 Die Möglichkeit, dass Sevofluran bei empfindlichen Hunden Episoden von maligner Hyperthermie auslöst, lässt sich nicht ausschließen.', 'T-925\tThe possibility of sevoflurane triggering episodes of malignant hyperthermia in susceptible dogs cannot be ruled out.', 'H-925\t-1.064453125\t4 / 26 The possibility that sevoflurane will cause major episodes of malignant hyperthermia in sensitive dogs cannot be excluded .', 'D-925\t-1.064453125\t4 / 26 The possibility that sevoflurane will cause major episodes of malignant hyperthermia in sensitive dogs cannot be excluded.', 'P-925\t-1.8242 -0.0282 -0.6792 -0.5962 -0.2705 -0.2479 -0.0704 -0.0225 -0.0310 -0.0197 -0.0704 -1.5215 -0.4958 -0.7891 -0.2255 -0.0282 -0.1578 -0.0169 -0.0282 -0.0282 -0.0225 -0.2986 -0.0620 -0.1917 -0.0169 -0.2649 -0.0225 -0.2311 -0.0225 -0.0395 -0.0282', 'S-335\tEine Durchstechflasche enthält 20 Mikrogramm Protein (die spezifische In-vivo-Bioaktivität entspricht etwa 10 000 IE FSH / mg Protein).', 'T-335\tOne vial contains 20 microgram of protein (specific in vivo bioactivity equal to approximately 10 000 IU FSH / mg protein).', 'H-335\t-0.35205078125\tOne vial contains 20 microgram of protein ( specific in vivo bioactivity equal to approximately 10 000 IU FSH / mg protein ) .', 'D-335\t-0.35205078125\tOne vial contains 20 microgram of protein (specific in vivo bioactivity equal to approximately 10 000 IU FSH / mg protein).', 'P-335\t-0.1680 -0.0284 -0.0157 -0.0655 -0.1733 -0.0320 -0.3081 -0.2212 -0.0176 -0.0359 -0.2466 -0.0542 -0.0641 -0.0113 -0.0895 -0.0169 -0.3169 -0.0845 -0.2423 -0.1747 -0.0197 -0.0535 -0.0028 -0.1113 -0.0197 -0.0324 -0.0169 -0.0409 -0.0324 -0.0366 -0.0296', 'S-1\tWenn eine alternative Injektionsstelle verwendet wird, ist es besonders wichtig, genügend Oberflächenspannung an der Injektionsstelle zu erzeugen, um eine erfolgreiche Injektion zu ermöglichen.', 'T-1\tWhen using alternate injection sites, it is particularly important to create enough surface tension on the site to be able to successfully complete the injection.', 'H-1\t-0.94970703125\tis When using alternate injection sites , it is particularly important to create enough surface tension on the', 'D-1\t-0.94970703125\tis When using alternate injection sites, it is particularly important to create enough surface tension on the', 'P-1\t-0.4668 -0.3350 -0.1846 -0.3486 -0.0331 -0.0578 -0.0141 -0.1042 -0.1917 -0.0479 -0.0296 -0.8496 -0.0296 -0.4663 -1.0117 -0.2339 -0.0310 -0.0113 -0.6172 -0.0366 -0.8003', 'S-1574\t74 Phenylalanin Wasser für Injektionszwecke Natriumhydroxid (zur pH-Einstellung) Salzsäure (zur pH-Einstellung)', 'T-1574\t64 Water for injections Sodium hydroxide (pH adjuster) Hydrochloric acid (pH adjuster)', 'H-1574\t-0.60498046875\t64 Phenylalanine Water for injections Sodium hydroxide ( pH adjuster ) Hydrochloric acid ( pH adjuster )', 'D-1574\t-0.60498046875\t64 Phenylalanine Water for injections Sodium hydroxide (pH adjuster) Hydrochloric acid (pH adjuster)', 'P-1574\t-0.6758 -2.5059 -0.0338 -0.0141 -0.0225 -0.0197 -0.0310 -0.1240 -0.0620 -0.0789 -0.3101 -0.0395 -0.0085 -0.0225 -0.0085 -0.0225 -0.0423 -0.3015 -0.0197 -0.1803 -0.3184 -0.0310 -0.0197 -0.0169 -0.0141 -0.0085 -0.0056 -0.0254 -0.0169 -0.0282 -0.0366 -0.0225 -0.0141 -0.0366 -0.0310 -0.0479', 'S-440\tDiese wird in zwei geteilten Dosen verabreicht, entweder als zwei 1 mg / 500 mg-Tabletten oder als eine 2 mg / 1 000 mg-Tablette.', 'T-440\tIt is given in two divided doses, either as two 1 mg / 500 mg tablets or one 2 mg / 1,000 mg tablet.', 'H-440\t-0.82568359375\tThis can be administered in two divided doses , either as two 1 mg / 500 mg tablets or as one 2 mg / 1,000 mg tablet .', 'D-440\t-0.82568359375\tThis can be administered in two divided doses, either as two 1 mg / 500 mg tablets or as one 2 mg / 1,000 mg tablet.', 'P-440\t-1.0029 -1.4756 -0.0409 -0.9917 -0.0169 -0.4199 -0.0564 -0.2113 -0.0225 -0.0197 -0.0676 -0.2507 -0.1606 -0.0732 -0.0732 -0.0225 -0.0366 -0.0760 -0.0225 -0.0451 -0.0197 -0.3550 -0.1127 -0.2423 -0.0338 -0.0169 -0.0282 -0.6763 -0.0169 -0.0225 -0.0564 -0.0338 -0.0282', 'S-1138\tVerkehrstüchtigkeit und das Bedienen von Maschinen Es ist zu berücksichtigen, dass manche Personen sich nach der Einnahme von EMEND schwindelig oder schläfrig fühlen.', 'T-1138\t74 Driving and using machines It should be taken into account that some people feel dizzy and sleepy after taking EMEND.', 'H-1138\t-1.12109375\tDriving and using machines It should be taken into account that some people have dizziness or sleepiness after taking EMEND .', 'D-1138\t-1.12109375\tDriving and using machines It should be taken into account that some people have dizziness or sleepiness after taking EMEND.', 'P-1138\t-0.4170 -0.1814 -0.0990 -0.2959 -0.1655 -0.1205 -0.7778 -0.0352 -0.5859 -0.0395 -0.0958 -0.0409 -0.0620 -0.3352 -0.7524 -0.4705 -0.1775 -0.0169 -0.6113 -1.6064 -0.0056 -0.0338 -1.2061 -0.1296 -0.0507 -0.0338 -0.0169 -0.0395 -0.0507', 'S-585\tFalls Sie sich unsicher sind, ob einer der oben erwähnten Punkte auf Sie zutrifft, fragen Sie Ihren Arzt oder Apotheker bevor Sie Velmetia einnehmen.', 'T-585\tIf you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking Velmetia.', 'H-585\t-0.59033203125\tIf you are not sure if any of the above applies to you , talk to your doctor or pharmacist before taking Velmetia .', 'D-585\t-0.59033203125\tIf you are not sure if any of the above applies to you, talk to your doctor or pharmacist before taking Velmetia.', 'P-585\t-0.8516 -0.0289 -0.0430 -0.3352 -0.0359 -0.2197 -0.2410 -0.0310 -0.0437 -0.0507 -0.8423 -0.0521 -0.0282 -0.0451 -0.5298 -0.0451 -0.0423 -0.0789 -0.0395 -0.0366 -0.0169 -0.0507 -0.5156 -0.0423 -0.0225 -0.0085 -0.0423 -0.0395', 'S-90\tDie Differenz in den VTE-Raten, die nicht signifikant war, beruhte hauptsächlich auf einer Reduktion der asymptoma- tischen distalen TVT.', 'T-90\tThe difference in total VTE rates between the treatment groups, which was not statistically significant, was mainly due', 'H-90\t-1.068359375\tThe difference in the rate of VTE , which was not significant , was mainly due to a reduction in asymptomatic distal DVT .', 'D-90\t-1.068359375\tThe difference in the rate of VTE, which was not significant, was mainly due to a reduction in asymptomatic distal DVT.', 'P-90\t-0.2252 -0.2996 -0.0384 -0.4370 -1.5684 -0.0310 -0.0606 -0.0085 -0.9160 -1.0879 -0.1381 -0.0507 -0.0254 -0.2197 -0.1240 -0.7158 -0.4509 -0.0282 -0.6538 -0.4114 -0.2705 -0.1859 -0.0225 -0.0169 -0.0169 -0.0451 -0.0169 -0.2141 -0.0395 -0.0395 -0.0282', 'S-309\tVerwenden Sie dieses Arzneimittel nicht mehr nach dem auf dem Blister aufgedruckten Verfalldatum [Verwendbar bis...], das aus 6 Ziffern besteht.', 'T-309\t• Do not use this medicine after the date shown by the six numbers following EXP on the blister.', 'H-309\t-1.4443359375\tDo not use this medicine after the expiry date ( EXP ) as indicated on the blister after EXP .', 'D-309\t-1.4443359375\tDo not use this medicine after the expiry date (EXP) as indicated on the blister after EXP.', 'P-309\t-0.9917 -0.0296 -0.0359 -0.4980 -0.1353 -0.1508 -0.0578 -0.5708 -0.1324 -0.0268 -1.0762 -0.3213 -0.3213 -0.7578 -1.7080 -0.3213 -0.0395 -0.0564 -0.3718 -0.0113 -0.7212 -0.8115 -0.2197 -0.3157 -0.2817', 'S-671\tALT- und / oder AST-Werte Behandlung und Kontrollempfehlungen > 3 und ≤ 5 × ONW Durch einen weiteren Leberenzymtest verifizieren.', 'T-671\t4 ALT / AST levels > 3 and ≤ 5 × ULN', 'H-671\t-1.642578125\tALT and / or AST levels Treatment and control recommendations &gt; 3 and ≤ 5 x ULN Verification with a further liver enzyme assay .', 'D-671\t-1.642578125\tALT and / or AST levels Treatment and control recommendations > 3 and ≤ 5 x ULN Verification with a further liver enzyme assay.', 'P-671\t-1.8926 -0.0704 -0.0479 -0.0395 -0.0254 -0.0197 -0.0225 -3.2578 -0.0760 -0.0197 -0.0254 -0.0310 -0.9243 -0.0338 -0.1578 -0.0338 -0.0395 -0.0056 -0.0338 -0.7212 -0.3213 -0.3157 -1.1670 -0.0169 -1.3867 -0.2311 -0.8286 -0.8003 -0.3833 -0.0113 -0.0113 -0.0225 -0.9917 -0.0338 -0.0676 -0.0338', 'S-1265\tDaher ist CellCept bei Patienten, die gegen Mycophenolatmofetil oder Mycophenolsäure überempfindlich sind, kontraindiziert.', 'T-1265\tTherefore, CellCept is contraindicated in patients with a hypersensitivity to mycophenolate mofetil or mycophenolic acid.', 'H-1265\t-0.490966796875\tTherefore , CellCept is contraindicated in patients who may be hypersensitive to mycophenolate mofetil or mycophenolic acid .', 'D-1265\t-0.490966796875\tTherefore, CellCept is contraindicated in patients who may be hypersensitive to mycophenolate mofetil or mycophenolic acid.', 'P-1265\t-0.9116 -0.0176 -0.4023 -0.2324 -0.0141 -0.0310 -0.0014 -0.0423 -0.0268 -0.0056 -0.1014 -0.0366 -0.1508 -1.2021 -0.0451 -0.0507 -0.0169 -0.0338 -0.0395 -0.0169 -0.0197 -0.0958 -0.0254 -0.0282 -0.0254 -0.0310 -0.2649 -0.0113 -0.0169 -0.0225 -0.1212 -0.0254 -0.0169 -0.0338 -0.0282', 'S-903\tFür die Wirbelsäule bei 37% eine Abnahme und bei 63% ein Anstieg, für die Hüfte bei 29% eine Abnahme sowie bei 71% ein Anstieg.', 'T-903\tIn the prevention trials, the percentage of subjects experiencing an increase or decrease in BMD during raloxifene therapy was: for the spine 37% decreased and 63% increased; and for the total hip 29% decreased and 71% increased.', 'H-903\t-1.6171875\tA decrease in the spine at 37 % and an increase at 63 % , a decrease for the hip at 29 % and an increase at 71 % .', 'D-903\t-1.6171875\tA decrease in the spine at 37% and an increase at 63%, a decrease for the hip at 29% and an increase at 71%.', 'P-903\t-2.4453 -0.7031 -0.2367 -0.2423 -1.2119 -0.3606 -0.0479 -2.0117 -0.0225 -0.0338 -0.6704 -0.7720 -0.0282 -1.0430 -0.0169 -0.0282 -0.0620 -0.0564 -0.0845 -0.0169 -1.1895 -0.4846 -0.1014 -0.0225 -0.0113 -0.0225 -0.0676 -0.9243 -0.0225 -0.0451 -0.0225 -0.0338 -0.3494 -0.0338', 'S-966\tDie möglichen Konsequenzen einer Kombination von Voriconazol mit anderen HIV-Protease-Hemmern beim Menschen können allerdings nicht alleine aus In-vitro-Studien abgeleitet werden.', 'T-966\tPatients should be carefully monitored for any occurrence of drug toxicity and / or loss of efficacy during the co-administration of voriconazole and HIV protease inhibitors.', 'H-966\t-1.0078125\tHowever , the potential consequences of a combination of voriconazole with other HIV protease inhibitors in humans cannot be predicted by in vitro studies alone .', 'D-966\t-1.0078125\tHowever, the potential consequences of a combination of voriconazole with other HIV protease inhibitors in humans cannot be predicted by in vitro studies alone.', 'P-966\t-0.3992 -0.0402 -0.7168 -0.3472 -0.7100 -0.5806 -1.1992 -0.0225 -0.0310 -0.0085 -0.0056 -0.0085 -0.0113 -0.0648 -0.2311 -0.0817 -0.6763 -0.0141 -0.0282 -0.0169 -0.0141 -0.0254 -0.0817 -0.3860 -0.2001 -0.0620 -1.2852 -0.2930 -0.0845 -0.0564 -0.0169 -0.0507 -0.6987 -0.0282 -0.0282', 'S-1411\tIm Rahmen der ambulanten Anwendung kann der Patient Binocrit einmalig für einen Zeitraum von maximal 3 Tagen außerhalb des Kühlschrankes und nicht über 25 ° C lagern.', 'T-1411\t14 For the purpose of ambulatory use, the patient may remove Binocrit from the refrigerator and store it not above 25 ° C for one single period of up to 3 days.', 'H-1411\t-0.90869140625\tFor the purpose of ambulatory use , the patient may remove Binocrit from the refrigerator and store it not above 25 ° C for one single period of up to 3 days .', 'D-1411\t-0.90869140625\tFor the purpose of ambulatory use, the patient may remove Binocrit from the refrigerator and store it not above 25 ° C for one single period of up to 3 days.', 'P-1411\t-1.1709 -0.2620 -0.3042 -0.0282 -0.2944 -0.0451 -0.1691 -0.1296 -0.1451 -0.0183 -0.2268 -0.4353 -0.0338 -0.0254 -0.0225 -0.0282 -0.1973 -0.0507 -0.1155 -0.0141 -0.0141 -0.0310 -0.3240 -0.2227 -0.0479 -0.4170 -0.2734 -0.3860 -0.0254 -0.0395 -0.1663 -0.9526 -0.3157 -0.2255 -0.3157 -0.7666 -0.0282 -0.0789 -0.0282 -0.0338 -0.0282', 'S-458\tKinder, die eine zweite Dosis ProQuad erhielten Die Nebenwirkungsrate war nach einer zweiten Dosis ProQuad generell gleich oder niedriger als nach der ersten Dosis.', 'T-458\tChildren who received a second dose of ProQuad The rates of adverse reactions after a second dose of ProQuad were generally similar to, or lower than, those seen with the first dose.', 'H-458\t-1.1806640625\tChildren who received a second dose of ProQuad The rate of adverse reactions after a second dose of ProQuad was generally the same or lower than the first dose .', 'D-458\t-1.1806640625\tChildren who received a second dose of ProQuad The rate of adverse reactions after a second dose of ProQuad was generally the same or lower than the first dose.', 'P-458\t-0.3716 -0.1719 -0.0687 -0.0803 -0.0331 -0.0141 -0.0514 -0.0380 -0.0211 -0.0155 -1.1543 -0.8115 -0.0310 -0.1747 -0.0169 -1.0732 -0.0056 -0.8257 -1.1895 -0.0282 -0.0169 -0.0732 -0.0282 -0.0225 -0.0169 -0.4622 -0.8228 -0.7666 -0.0169 -0.0395 -0.1183 -0.0507 -1.2910 -0.0564 -0.2874 -0.0338 -0.0282', 'S-774\tAls Dosierung werden zwei Dosen 0,9 mg Thyrotropin alfa in 24-stündigem Abstand bei ausschließlich intramuskulärer Verabreichung empfohlen.', 'T-774\tThe recommended dose regimen is two doses of 0.9 mg thyrotropin alfa administered at a 24-hour interval by intramuscular injection only.', 'H-774\t-1.060546875\tThe recommended dose is two doses of 0.9 mg thyrotropin alfa given at 24 h intervals with intramuscular administration only .', 'D-774\t-1.060546875\tThe recommended dose is two doses of 0.9 mg thyrotropin alfa given at 24 h intervals with intramuscular administration only.', 'P-774\t-1.3721 -0.0359 -0.7881 -0.1113 -0.1409 -0.0972 -0.0268 -0.1747 -0.3635 -0.0592 -0.0169 -0.6030 -0.0225 -0.3127 -0.0169 -0.0423 -0.0310 -0.0113 -0.9497 -0.2874 -0.6621 -0.5859 -0.0113 -0.0169 -1.3750 -0.2705 -0.0338 -0.0113 -0.0113 -0.0338 -0.1071 -0.0282 -0.0282', 'S-1782\tDanmark GlaxoSmithKline Pharma A / S Tlf: + 45 36 35 91 00 info @ glaxosmithkline.dk', 'T-1782\tDanmark GlaxoSmithKline Pharma A / S Tlf: + 45 36 35 91 00 info @ glaxosmithkline.dk', 'H-1782\t-0.451904296875\tDanmark GlaxoSmithKline Pharma A / S Tlf : + 45 36 35 91 00', 'D-1782\t-0.451904296875\tDanmark GlaxoSmithKline Pharma A / S Tlf: + 45 36 35 91 00', 'P-1782\t-0.8164 -0.0141 -0.0162 -0.0225 -0.0247 -0.0085 -0.0240 -0.0282 -0.0183 -0.0240 -0.0169 -0.0268 -0.0275 -0.0211 -0.0373 -0.0254 -0.0183 -0.0296 -0.0240 -0.0197 -0.0254 -0.0254 -0.0148 -0.0254 -1.7822', 'S-1436\tAndere NSAID oder Glukokortikoide dürfen nicht gleichzeitig oder innerhalb eines Monats nach der letztmaligen Gabe von Trocoxil angewendet werden.', 'T-1436\t30 / 32 Do not administer other NSAIDs or glucocorticoids concurrently or within at least 1 month of the last administration of Trocoxil.', 'H-1436\t-0.861328125\tDo not administer other NSAIDs or glucocorticoids concomitantly or within one month of the last administration of Trocoxil .', 'D-1436\t-0.861328125\tDo not administer other NSAIDs or glucocorticoids concomitantly or within one month of the last administration of Trocoxil.', 'P-1436\t-0.4216 -0.0278 -0.7700 -0.0056 -0.1381 -0.0049 -0.0070 -0.0423 -0.0409 -0.0113 -0.0296 -0.0183 -0.0240 -0.0211 -0.4719 -1.3496 -0.5718 -0.0028 -0.0423 -0.0366 -0.0507 -1.2959 -0.0282 -0.9893 -0.0901 -0.1240 -0.2874 -0.0395 -0.0732 -0.0282 -0.0225 -0.0169 -0.0338 -0.0282', 'S-1152\tETIKETTIERUNG ge rz ug el as se n ANGABEN AUF DER ÄUSSEREN UMHÜLLUNG', 'T-1152\tLABELLING lo ng er au th or is ed PARTICULARS TO APPEAR ON THE OUTER PACKAGING', 'H-1152\t-0.97021484375\tLABELLING lo ng er au th or is ed PARTICULARS TO APPEAR ON THE OUTER PACKAGING', 'D-1152\t-0.97021484375\tLABELLING lo ng er au th or is ed PARTICULARS TO APPEAR ON THE OUTER PACKAGING', 'P-1152\t-0.4170 -0.0377 -0.1624 -0.1846 -0.0056 -0.3228 -0.3325 -0.3071 -0.3621 -0.3564 -0.3228 -0.3254 -0.3240 -0.3269 -0.3269 -0.2255 -0.1099 -0.2930 -0.2791 -0.2734 -0.3157 -0.3240 -0.2874 -0.1747 -0.2986 -0.2874 -0.1071 -0.1014 -0.0845 -0.0282 -0.2479 -0.3213 -0.3213 -0.0620 -0.0169 -0.1521 -0.0395', 'S-760\tAnwendung bei Kindern und Jugendlichen PROTELOS wird nicht empfohlen für die Anwendung bei Kindern und Jugendlichen, aufgrund des Fehlens von Daten zur Unbedenklichkeit und Wirksamkeit.', 'T-760\tUse in children and adolescents PROTELOS is not recommended for use in children and adolescents due to a lack of data on safety and efficacy.', 'H-760\t-0.52734375\tUse in children and adolescents PROTELOS is not recommended for use in children and adolescents due to a lack of data on safety and efficacy .', 'D-760\t-0.52734375\tUse in children and adolescents PROTELOS is not recommended for use in children and adolescents due to a lack of data on safety and efficacy.', 'P-760\t-1.8867 -0.1268 -0.0535 -0.0366 -0.0578 -0.0197 -0.0155 -0.4861 -0.0113 -0.0225 -0.0155 -0.0437 -0.0409 -0.0310 -0.0366 -0.0324 -0.1014 -0.0423 -0.1917 -0.0338 -0.0564 -0.0225 -0.0169 -0.2395 -0.0282 -0.3127 -0.0282 -0.0282 -0.1353 -0.1240 -0.0732 -0.0338 -0.1268 -0.0085 -0.0141 -0.0366 -0.0310', 'S-883\tWenn einer der oben genannten Umstände für Sie zutrifft, wird der Arzt oder das Pflegepersonal Ihre Blutgerinnungswerte überwachen und gegebenenfalls die Dosierung anpassen.', 'T-883\t22 If any of the above apply to you, the doctor or nurse will monitor your blood for clotting activity and may change your dose or dosing schedule accordingly.', 'H-883\t-1.3525390625\tIf any of the above applies to you , the doctor or nurse will monitor your blood clotting times and adjust the dose if necessary .', 'D-883\t-1.3525390625\tIf any of the above applies to you, the doctor or nurse will monitor your blood clotting times and adjust the dose if necessary.', 'P-883\t-0.4358 -0.5386 -0.0331 -0.0451 -0.1945 -1.5723 -0.0535 -0.0268 -0.2930 -0.1212 -0.0789 -0.0310 -0.1973 -0.0423 -0.1578 -0.4058 -0.0676 -1.0283 -0.1465 -0.0254 -0.3945 -0.0564 -1.7812 -0.0169 -1.0703 -0.8286 -0.5859 -0.1240 -0.0282 -0.0282', "S-1573\tAbacavir wird intrazellulär zum aktiven Molekül Carbovir-5 '-Triphosphat (TP) metabolisiert.", 'T-1573\tAbacavir is metabolised intracellularly to the active moiety, carbovir 5 <<unk>> - triphosphate (TP).', 'H-1573\t-0.426513671875\tAbacavir is metabolised intracellularly to the active molecule carbovir @-@ 5 &apos; -triphosphate ( TP ) .', "D-1573\t-0.426513671875\tAbacavir is metabolised intracellularly to the active molecule carbovir-5 '-triphosphate (TP).", 'P-1573\t-0.0227 -0.0177 -0.0184 -0.0184 -0.0539 -0.2996 -0.0134 -0.7651 -0.1388 -0.0211 -0.0092 -0.0704 -0.1099 -0.0690 -0.0380 -0.0268 -0.0197 -0.0099 -0.1282 -0.0183 -0.0155 -0.0183 -0.6338 -0.1212 -0.6284 -0.1268 -0.0282 -0.0282 -0.0085 -0.0225 -0.0310 -0.0254 -0.0197 -0.0282 -0.0310 -0.0282', 'S-283\tWenn Sie Avandamet zusammen mit anderen Arzneimitteln zur Behandlung Ihres Diabetes anwenden, besteht eine höhere Wahrscheinlichkeit, dass Ihr Blutzucker möglicherweise unter den Normalwert abfallen kann.', 'T-283\tIf you are taking Avandamet with other medicines for diabetes, it is more likely that your blood sugar could fall below the normal level.', 'H-283\t-0.7666015625\tIf you are taking Avandamet with other medicines for diabetes , it is more likely that your blood sugar may fall below the normal level .', 'D-283\t-0.7666015625\tIf you are taking Avandamet with other medicines for diabetes, it is more likely that your blood sugar may fall below the normal level.', 'P-283\t-0.1097 -0.0386 -0.4177 -0.2061 -0.0190 -0.0176 -0.0240 -0.0232 -0.3359 -0.5044 -0.0493 -0.0718 -0.5591 -0.5171 -0.1099 -0.6509 -0.0789 -0.1099 -0.0451 -0.0958 -0.0564 -0.0254 -0.0592 -0.4536 -0.5918 -0.1691 -0.3550 -0.1493 -0.1014 -0.0338 -0.0338', 'S-394\tDer Test darf nicht bei Patienten mit einer dokumentierten oder vermuteten Mageninfektion verwendet werden, die sich störend auf den Harnstoff-Atemtest auswirken könnte.', 'T-394\tThe test must not be used in patients with documented or suspected gastric infection that might interfere with the urea breath test.', 'H-394\t-0.93896484375\tThe test must not be used in people with a documented or suspected gastric infection , which might interfere with the urea breath test .', 'D-394\t-0.93896484375\tThe test must not be used in people with a documented or suspected gastric infection, which might interfere with the urea breath test.', 'P-394\t-0.3320 -0.0428 -1.0283 -0.0310 -0.0296 -0.0296 -0.1000 -1.1357 -0.4326 -0.9526 -0.0564 -0.0338 -0.0085 -0.4958 -0.0310 -0.0197 -0.0282 -1.1973 -0.0564 -0.5972 -0.1859 -0.0113 -0.0338 -0.0901 -0.0169 -0.0225 -0.1353 -0.0282 -0.0338 -0.0282', 'S-624\tSchrauben Sie die Injektionsnadel immer nach jeder Injektion ab und bewahren Sie Ihren NovoLet Fertigpen ohne aufgeschraubte Injektionsnadel auf.', 'T-624\tRemove the needle after each injection and store NovoLet without a needle attached.', 'H-624\t-0.70654296875\tRemove the needle after each injection and store your NovoLet pre @-@ filled pen without the needle attached .', 'D-624\t-0.70654296875\tRemove the needle after each injection and store your NovoLet pre-filled pen without the needle attached.', 'P-624\t-0.3589 -0.0127 -0.0211 -0.0444 -0.4131 -0.0232 -0.1367 -0.1007 -0.0507 -0.0113 -0.0901 -0.2036 -0.5508 -0.0606 -0.0169 -0.0479 -1.4805 -0.0282 -0.2705 -0.1324 -0.0592 -0.2734 -0.2537 -0.0282 -0.3071 -0.0958 -0.0338', 'S-429\tInverkehrbringen als Teil der systematischen Identifizierung der Arzneimittelrisiken (signal detection) zu prüfen und nur dann im Bericht aufzunehmen, wenn ein Hinweis auf ein Sicherheitsrisiko vorliegt.', 'T-429\tand will only form part of the report if an issue of concern arises.', 'H-429\t-1.763671875\tprocedures and additional pharmacovigilance activities .', 'D-429\t-1.763671875\tprocedures and additional pharmacovigilance activities.', 'P-429\t-1.1543 -0.7363 -1.9023 -0.3213 -0.3213 -0.1691 -0.0310 -0.0310 -0.3213 -2.0957 -0.3494', 'S-330\tWährend seiner Sitzung im März 2008 war der CHMP angesichts der insgesamt vorgelegten Daten und der wissenschaftlichen Erörterung im Ausschuss der Ansicht, dass das Nutzen-Risiko-Verhältnis für Alvesco', 'T-330\tA positive opinion was adopted by consensus on 19 March 2008.', 'H-330\t-1.2744140625\tExisting Marketing Authorisations should be varied and pending Marketing Authorisation Applications should be granted to include these amendments .', 'D-330\t-1.2744140625\tExisting Marketing Authorisations should be varied and pending Marketing Authorisation Applications should be granted to include these amendments.', 'P-330\t-2.6680 -0.0268 -0.3228 -0.3213 -0.1775 -0.5859 -0.0197 -0.3269 -0.2227 -0.3916 -0.0704 -0.3579 -0.3240 -0.3269 -0.2537 -0.0395 -0.1747 -0.3213 -0.0169 -0.2311 -0.2479 -0.0732 -0.5469 -0.3777 -0.3213 -0.3325 -0.3213 -0.0225 -0.2874 -0.0958', 'S-1892\tEs wurde beschlossen, das Ergebnis der Revision des EU-Arzneimittelrechts der Gemeinschaft abzuwarten, bevor der Europäischen Kommission Empfehlungen zu strukturellen Veränderungen des Gebührensystems vorgelegt werden.', 'T-1892\tUseful web site:', 'H-1892\t-1.861328125\tIt was decided to wait for the outcome of the revision of EU pharmaceutical legislation before making recommendations to the European Commission on the necessary structural changes in the structure of the fee system .', 'D-1892\t-1.861328125\tIt was decided to wait for the outcome of the revision of EU pharmaceutical legislation before making recommendations to the European Commission on the necessary structural changes in the structure of the fee system.', 'P-1892\t-2.2227 -0.4185 -0.4734 -0.0564 -1.6035 -1.3408 -0.0338 -0.4001 -0.0282 -0.0620 -0.7944 -0.0169 -0.0338 -0.9751 -0.2761 -0.0169 -0.1183 -0.0676 -0.5073 -0.3945 -0.2141 -0.0564 -0.0282 -0.0395 -0.0282 -0.8735 -0.7891 -1.3975 -0.2255 -0.0225 -0.1127 -0.9917 -0.1240 -0.9917 -0.0338 -0.5073 -0.5747 -0.1014 -0.0338 -0.0338', 'S-845\tIn den beiden Studien zu ösophagealer Candidose wurden etwa 90% der Patienten mit Mycamine, Fluconazol oder Caspofungin erfolgreich behandelt.', 'T-845\tIn the two studies of oesophageal candidiasis, around 90% of the patients were successfully treated with Mycamine, fluconazole or caspofungin.', 'H-845\t-1.0224609375\tIn the two studies of oesophageal candidiasis , around 90 % of patients have been successfully treated with mycamine , fluconazole or caspofungin .', 'D-845\t-1.0224609375\tIn the two studies of oesophageal candidiasis, around 90% of patients have been successfully treated with mycamine, fluconazole or caspofungin.', 'P-845\t-0.2603 -0.6709 -0.0542 -0.1310 -0.9800 -0.5425 -0.0113 -0.0324 -0.0211 -0.0197 -0.0310 -0.0310 -0.0648 -0.3987 -0.4932 -0.0254 -0.6226 -0.8115 -0.0197 -0.0338 -0.0338 -0.8423 -1.2061 -0.0789 -0.2029 -0.0169 -0.3438 -1.1211 -0.0113 -0.2029 -0.0338 -0.0113 -0.0282 -0.0113 -0.0056 -0.1014 -0.0113 -0.0113 -0.0113 -0.0113 -0.1465 -0.0338 -0.0282', 'S-1780\ts innerhalb von 60 Tagen nach Erreichen eines wichtigen (die Pharmakovigilanz oder Risikoverminderung betreffenden) Meilensteins einer Studie bzw. wenn Studienergebnisse verfügbar', 'T-1780\ted medicinal products for human use, should be submitted at the same time as the PSURs, within 60 days of an important (Pharmacovigilance or Risk minimisation) milestone being reached or when the results of a study becoming available or at the request of the Competent authority.', 'H-1780\t-1.708984375\tstudies should be performed within 60 days of an important ( pharmacovigilance or risk minimisation ) milestone being reached or when the results of the studies becoming available', 'D-1780\t-1.708984375\tstudies should be performed within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached or when the results of the studies becoming available', 'P-1780\t-2.6641 -1.1846 -0.0760 -1.1777 -0.9497 -0.0225 -0.0282 -0.1183 -0.2986 -0.0338 -0.2593 -0.2197 -0.0169 -0.0056 -0.0169 -0.0395 -0.0564 -0.0225 -0.5635 -0.4734 -0.0282 -0.0451 -0.0845 -0.0169 -0.3550 -0.1465 -0.4001 -0.2593 -1.4600 -0.3945 -0.5522 -0.1578 -1.2061 -0.6650 -0.0225 -0.6538', 'S-931\tMai 2007 beschrieben, die in Modul 1.8.1 des Zulassungsantrages dargestellt ist, vorhanden und funktionsfähig ist, bevor sowie während das Produkt im Markt ist.', 'T-931\tPharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in the version dated 10 May 2007 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.', 'H-931\t-1.1689453125\tPharmacovigilance system The MAH must ensure that the system of pharmacovigilance , as described in version 1.8.1. of the Marketing Authorisation Application , is in place and functioning before and whilst the product is on the market .', 'D-931\t-1.1689453125\tPharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.', 'P-931\t-1.5088 -0.2522 -0.0268 -0.3198 -0.0521 -0.0620 -0.0887 -0.3213 -0.3213 -0.3213 -0.3213 -0.3213 -0.3213 -0.1240 -0.2197 -0.3213 -0.3127 -0.3184 -0.2649 -0.0620 -0.0056 -0.0225 -0.2986 -0.3101 -0.0845 -0.0395 -0.3213 -2.9980 -0.2986 -0.3213 -0.0732 -0.0564 -0.3101 -0.0169 -0.1917 -0.0338 -0.1071 -0.0113 -0.0282 -0.0901 -0.0732 -0.2367 -0.0338 -0.0451 -0.2141 -0.2817 -0.0789 -0.1014 -0.3157 -0.0451 -0.0451 -0.0451 -0.1014 -0.0338 -0.0225 -0.0338 -0.0338', 'S-835\tPatienten mit CLL, für die möglicherweise ein höheres Risiko eines besonders schweren Zytokin-Freisetzungs-Syndroms besteht, sollen nur unter besonderer Vorsicht behandelt werden.', 'T-835\tPatients with a high tumour burden or with a high number (≥ 25 x 109 / l) of circulating malignant cells such as patients with CLL, who may be at higher risk of especially severe cytokine release syndrome, should only be treated with extreme caution.', 'H-835\t-1.1591796875\tPatients with CLL who might be at increased risk of very severe cytokine release syndrome should be treated with particular caution .', 'D-835\t-1.1591796875\tPatients with CLL who might be at increased risk of very severe cytokine release syndrome should be treated with particular caution.', 'P-835\t-0.0841 -0.0199 -1.0078 -0.0951 -0.0190 -0.3479 -0.5791 -0.5156 -0.0211 -1.1934 -0.0141 -0.3889 -1.9072 -0.4001 -0.0789 -0.0225 -0.0056 -0.0395 -0.1747 -0.0169 -0.0169 -0.0845 -0.1240 -0.0169 -0.1071 -0.6821 -0.6875 -0.0676 -0.0282', 'S-768\t36 Bei der Umstellung von einer Ciclosporin- auf eine Tacrolimus-basierte Therapie ist Vorsicht geboten (siehe Abschnitte 4.4 und 4.5).', 'T-768\tConversion from ciclosporin to Advagraf Care should be taken when converting patients from ciclosporin-based to tacrolimus-based therapy (see sections 4.4 and 4.5).', 'H-768\t-1.2822265625\t36 Caution should be exercised when switching from ciclosporin to tacrolimus therapy ( see sections 4.4 and 4.5 ) .', 'D-768\t-1.2822265625\t36 Caution should be exercised when switching from ciclosporin to tacrolimus therapy (see sections 4.4 and 4.5).', 'P-768\t-2.4277 -1.1064 -0.0225 -0.5186 -0.0310 -0.4705 -0.0225 -0.4170 -0.9243 -0.0451 -0.6479 -0.0113 -0.0113 -0.0113 -0.4001 -0.5522 -0.0395 -0.0225 -0.0225 -0.0056 -2.0898 -0.0338 -0.0451 -0.1465 -0.0225 -0.0282 -0.0338 -0.0225 -0.0282 -0.0338 -0.0338 -0.0282', 'S-1244\tNieren- und Leberfunktionsstörungen und Leberfibrose Es liegen keine Daten über die Anwendung von Deferipron bei Patienten mit Nieren- oder Leberschäden vor.', 'T-1244\tRenal or hepatic impairment and liver fibrosis There are no data available on the use of deferiprone in patients with renal or hepatic impairment.', 'H-1244\t-0.92626953125\tRenal or hepatic impairment and hepatic fibrosis There are no data on the use of deferiprone in patients with renal and hepatic impairment .', 'D-1244\t-0.92626953125\tRenal or hepatic impairment and hepatic fibrosis There are no data on the use of deferiprone in patients with renal and hepatic impairment.', 'P-1244\t-0.2534 -0.0269 -0.8828 -0.2739 -0.0380 -0.0268 -0.5410 -0.0859 -0.0085 -0.1169 -0.0507 -0.8818 -0.0395 -0.0254 -0.0310 -0.0225 -0.0225 -0.7324 -0.4819 -0.0310 -0.0423 -1.1357 -0.0704 -0.0732 -0.0282 -0.2141 -0.0113 -0.0169 -0.3213 -0.0507 -0.4790 -0.0395 -0.2761 -0.0225 -0.5972 -0.5127 -0.0282 -0.0225 -0.2817 -0.0056 -0.0056 -0.0958 -0.0395 -0.0282', 'S-1881\tDie am häufigsten berichteten Nebenwirkungen waren Reaktionen im Zusammenhang mit der Infusion, die bei 13,7% der in klinischen Studien mit Replagal behandelten Patienten auftraten.', 'T-1881\tThe most commonly reported undesirable effects were infusion associated reactions, which occurred in 13.7% of patients treated with Replagal in clinical trials.', 'H-1881\t-1.1064453125\tThe most commonly reported adverse reactions were infusion @-@ related reactions , occurring in 13.7 % of patients treated with Replagal in clinical trials .', 'D-1881\t-1.1064453125\tThe most commonly reported adverse reactions were infusion-related reactions, occurring in 13.7% of patients treated with Replagal in clinical trials.', 'P-1881\t-0.4963 -0.0243 -0.6382 -0.0169 -0.5347 -0.0028 -0.7974 -0.0056 -0.6313 -0.2311 -0.4170 -0.1888 -0.0760 -0.0986 -0.0141 -0.7466 -2.0684 -0.0225 -0.0282 -0.0113 -0.0225 -0.0338 -0.2423 -0.2141 -0.4846 -0.0958 -0.1296 -0.0169 -0.0169 -0.0169 -0.1409 -0.0507 -0.7607 -0.0338 -0.0282', 'S-281\tMonotard kann beim Typ-1-Diabetes, bei dem die Bauchspeicheldrüse kein Insulin produzieren kann, sowie beim Typ-2-Diabetes, bei dem ich', 'T-281\tMonotard can be used in type 1 diabetes, when the pancreas cannot produce insulin, and in type 2 diabetes, when the body is not able to use insulin effectively.', 'H-281\t-0.97216796875\tMonotard can be treated in type 1 diabetes , when the pancreas cannot produce insulin , and in type 2 diabetes , when the body is not able to use insulin effectively .', 'D-281\t-0.97216796875\tMonotard can be treated in type 1 diabetes, when the pancreas cannot produce insulin, and in type 2 diabetes, when the body is not able to use insulin effectively.', 'P-281\t-1.1172 -0.0261 -0.0824 -0.5186 -0.2001 -1.3438 -0.2734 -0.1465 -0.0366 -0.0141 -0.4368 -0.3833 -0.0395 -0.0197 -0.0085 -0.0225 -0.1353 -0.0395 -0.0141 -0.0141 -0.0423 -0.2507 -0.2930 -0.0282 -0.0282 -0.0197 -0.2649 -0.3101 -0.3833 -0.2874 -0.2817 -0.2874 -0.1859 -0.0564 -0.3269 -0.1973 -0.1240 -0.3718 -0.2423 -0.0395', 'S-1765\tIm Verlauf der Therapie mit Erythropoetin ist aufgrund des erhöhten Hämatokrits häufig eine Steigerung der Heparindosis während der Hämodialyse notwendig.', 'T-1765\tAn increase in heparin dose during haemodialysis is frequently required during the course of therapy with erythropoietin as a result of the increased packed cell volume.', 'H-1765\t-1.2197265625\tAn increase in heparin dose during haemodialysis is frequently required during erythropoietin therapy due to the increased packed cell volume .', 'D-1765\t-1.2197265625\tAn increase in heparin dose during haemodialysis is frequently required during erythropoietin therapy due to the increased packed cell volume.', 'P-1765\t-0.7402 -0.0993 -0.1345 -0.6758 -0.0183 -0.0296 -0.3960 -0.0423 -0.9976 -0.0225 -0.0197 -0.0141 -0.0197 -0.0479 -0.5835 -0.9160 -0.4282 -0.8960 -0.0225 -0.0056 -0.0282 0.0000 -0.2705 -0.3438 -1.0879 -0.0282 -0.5469 -0.3606 -0.4282 -0.3213 -0.3157 -0.0732 -0.0282', 'S-1147\tDie Beurteilung der Nebenwirkungen basiert auf den Daten aus drei Studien mit Erwachsenen (n = 1.479) und drei pädiatrischen Studien (n = 169).', 'T-1147\tAssessment of adverse reactions is based on data from three studies in adults (n = 1,479) and three paediatric studies (n = 169).', 'H-1147\t-0.97412109375\tAssessment of adverse reactions is based on data from three studies involving adults ( n = 1,479 ) and three paediatric studies ( n = 169 ) .', 'D-1147\t-0.97412109375\tAssessment of adverse reactions is based on data from three studies involving adults (n = 1,479) and three paediatric studies (n = 169).', 'P-1147\t-1.0859 -0.0141 -0.0388 -0.0359 -0.4036 -0.0070 -0.4861 -0.0085 -0.1085 -0.0296 -0.0324 -0.5762 -0.7017 -0.8677 -0.8906 -1.6846 -0.0225 -0.0282 -0.0338 -0.0225 -0.3662 -0.0225 -0.0113 -0.0282 -0.0338 -0.5918 -0.2649 -0.0169 -0.0113 -0.0282 -0.1183 -0.0282 -0.0225 -0.0225 -0.0225 -0.0225 -0.0282 -0.0282 -0.0282', 'S-847\tDie am häufigsten (> 1 / 10) in klinischen Studien berichteten Nebenwirkungen waren Übelkeit, Mund- trockenheit und Schwitzen (einschließlich Nachtschweiß).', 'T-847\tThe most commonly (> 1 / 10) reported adverse reactions in clinical studies were nausea, dry mouth, headache and sweating (including night sweats).', 'H-847\t-0.8525390625\tThe most commonly ( &gt; 1 / 10 ) reported adverse reactions in clinical trials were nausea , dry mouth and sweating ( including night sweats ) .', 'D-847\t-0.8525390625\tThe most commonly (> 1 / 10) reported adverse reactions in clinical trials were nausea, dry mouth and sweating (including night sweats).', 'P-847\t-0.6206 -0.0349 -0.6885 -0.2664 -0.0254 -0.0296 -0.0324 -0.0296 -0.0282 -0.1691 -0.0817 -0.0042 -0.8564 -0.0070 -1.4570 -0.0169 -0.6479 -0.3411 -0.0113 -0.0056 -0.5073 -0.0676 -0.0169 -0.5806 -0.0676 -0.2141 -0.0395 -0.0338 -0.0225 -0.0564 -0.0225 -0.0282 -0.0338 -0.0282', 'S-520\tDa keine Kompatibilitätsstudien durchgeführt wurden, darf dieses Arzneimittel nicht mit anderen Arzneimitteln vermischt oder gleichzeitig über den gleichen intravenösen Zugang infundiert werden.', 'T-520\tIn the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products or infused simultaneously through the same intravenous line.', 'H-520\t-0.8798828125\tIn the absence of compatibility studies , this medicinal product must not be mixed or co @-@ infused in the same intravenous line with other medicinal products .', 'D-520\t-0.8798828125\tIn the absence of compatibility studies, this medicinal product must not be mixed or co-infused in the same intravenous line with other medicinal products.', 'P-520\t-0.6152 -0.0430 -0.0120 -0.0271 -0.5664 -0.0169 -0.0169 -0.0225 -0.2747 -0.4368 -0.2776 -0.0310 -0.0197 -0.5620 -0.0366 -0.0310 -0.0592 -0.8511 -1.7695 -0.0282 -0.0704 -0.0085 -0.3213 -0.0676 -0.0225 -0.1803 -0.0282 -0.0113 -0.0282 -0.3381 -0.3550 -0.0732 -0.0338 -0.0282 -0.3550 -0.0338 -0.0282', 'S-1568\tEs konnte gezeigt werden, dass die beiden Druckluft-Verneblersysteme HaloLite und ProDose zur Vernebelung von Ventavis geeignet sind.', 'T-1568\tTwo compressed air nebuliser systems, HaloLite and Prodose, have been shown to be suitable nebulisers for the administration of Ventavis.', 'H-1568\t-1.275390625\tIt has been shown that the HaloLite and Prodose nebulising systems are suitable for spraying Ventavis .', 'D-1568\t-1.275390625\tIt has been shown that the HaloLite and Prodose nebulising systems are suitable for spraying Ventavis.', 'P-1568\t-0.9341 -1.5049 -0.0380 -0.1592 -0.0507 -0.0916 -1.1777 -0.0282 -0.0197 -0.0197 -0.0338 -0.4424 -0.6792 -1.1162 -0.0056 -0.0113 -0.9131 -0.0395 -0.1071 -0.2817 -0.0395 -1.0654 -0.1465 -0.0620 -0.0169 -0.0282 -0.3777 -0.0338', 'S-1532\tDie pharmakokinetische Analyse einer gepoolten Population zeigte keine deutlichen Unterschiede in der Pharmakokinetik von Rosiglitazon zwischen Männern und Frauen.', 'T-1532\tIn the pooled population pharmacokinetic analysis, there were no marked differences in the pharmacokinetics of rosiglitazone between males and females.', 'H-1532\t-0.54296875\tIn the pooled population pharmacokinetic analysis , there were no marked differences in the pharmacokinetics of rosiglitazone between men and women .', 'D-1532\t-0.54296875\tIn the pooled population pharmacokinetic analysis, there were no marked differences in the pharmacokinetics of rosiglitazone between men and women.', 'P-1532\t-0.4863 -0.2505 -0.3184 -0.0141 -0.0261 -0.0451 -0.2866 -0.0099 -0.0113 -0.0831 -0.0296 -0.4988 -0.2423 -0.1212 -0.0338 -0.3467 -0.1183 -0.0845 -0.1635 -0.0395 -0.0169 -0.0169 -0.0423 -0.0338 -0.0732 -0.0056 -0.0197 -0.0169 -0.0254 -0.3269 -0.6792 -0.0282 -0.0310 -0.0310 -0.0282', 'S-1703\tEntsprechend dieser Carbidopa-Tagesdosis wird für Stalevo 200 mg / 50 mg / 200 mg eine maximale Tagesdosis von 7 Tabletten empfohlen.', 'T-1703\tAccording to this daily carbidopa dose, the maximum recommended daily Stalevo 200 mg / 50 mg / 200 mg dose is 7 tablets per day.', 'H-1703\t-0.876953125\tBased on this daily dose of carbidopa , Stalevo 200 mg / 50 mg / 200 mg is recommended using a maximum daily dose of 7 tablets .', 'D-1703\t-0.876953125\tBased on this daily dose of carbidopa, Stalevo 200 mg / 50 mg / 200 mg is recommended using a maximum daily dose of 7 tablets.', 'P-1703\t-1.6963 -0.0352 -0.3650 -0.2563 -0.1282 -0.0648 -0.4888 -0.0310 -0.0423 -0.0197 -0.0282 -0.3860 -0.8115 -0.0141 -0.0254 -0.2029 -0.0113 -0.0310 -0.0254 -0.0085 -0.0282 -0.0197 -0.0141 -0.4143 -0.1917 -0.5327 -0.0564 -0.0395 -1.2734 -0.0732 -0.0282 -0.0564 -0.0451 -0.0225 -0.0338 -0.0282', 'S-1468\tDas pharmakokinetische Profil von kurz nach einer Docetaxel -Infusion gegebenem Cisplatin ist ähnlich dem von Cisplatin allein.', 'T-1468\tThe pharmacokinetic profile of cisplatin administered shortly after docetaxel infusion is similar to that observed with cisplatin alone.', 'H-1468\t-0.60498046875\tThe pharmacokinetic profile of cisplatin given shortly after the docetaxel infusion is similar to that of cisplatin alone .', 'D-1468\t-0.60498046875\tThe pharmacokinetic profile of cisplatin given shortly after the docetaxel infusion is similar to that of cisplatin alone.', 'P-1468\t-0.2720 -0.0414 -0.0085 -0.0070 -0.2603 -0.0169 -0.0370 -0.0285 -0.0211 -0.0299 -0.0275 -0.7866 -0.8032 -0.0338 -0.5425 -0.4678 -0.0225 -0.0141 -0.0113 -0.0310 -0.0282 -0.0141 -0.3184 -0.0310 -0.0338 -0.0873 -0.3662 -0.0085 -0.0197 -0.0254 -0.0282 -0.5352 -0.0310 -0.0282', 'S-1114\tIn regelmäßigen Abständen wurden Blut- und Milchproben gesammelt und mithilfe eines Festphasen-ELISA (Enzyme-linked Immunoassay) ausgewertet.', 'T-1114\tBlood and milk samples were collected at regular intervals and analysed using a solid phase enzyme-linked immunoassay (ELISA) test.', 'H-1114\t-1.23828125\tBlood and milk samples in regular intervals were collected and evaluated by an ELISA ( enzyme @-@ linked immunoassay ) .', 'D-1114\t-1.23828125\tBlood and milk samples in regular intervals were collected and evaluated by an ELISA (enzyme-linked immunoassay).', 'P-1114\t-1.3330 -0.0190 -0.1993 -0.0183 -0.0211 -1.2695 -0.3127 -0.0732 -0.0141 -0.2339 -0.1803 -0.0338 -1.2451 -0.0254 -0.6680 -0.8286 -1.5498 -0.0169 -0.0113 -0.1747 -0.1240 -0.0338 -0.0282 -0.0282 -0.0732 -0.0225 -0.4958 -0.0113 -0.0113 -0.0282 -0.7944 -0.0282', 'S-944\tDer Blutdruck muss gemessen werden und eine körperliche Untersuchung muss unter Beachtung der Gegenanzeigen (siehe Abschnitt 4.3) und Warnhinweise (siehe Abschnitt 4.4) durchgeführt werden.', 'T-944\tBlood pressure should be measured and a physical examination should be performed guided by the contraindications (see section 4.3) and warnings (see section 4.4).', 'H-944\t-1.0908203125\tBlood pressure should be measured and physical examination should be performed taking into account contraindications ( see section 4.3 ) and warnings ( see section 4.4 ) .', 'D-944\t-1.0908203125\tBlood pressure should be measured and physical examination should be performed taking into account contraindications (see section 4.3) and warnings (see section 4.4).', 'P-944\t-0.0472 -0.0177 -0.0127 -1.3115 -0.0296 -0.2930 -0.0831 -0.5298 -0.8652 -1.3135 -0.0395 -0.8594 -1.3438 -0.4678 -0.0620 -0.5469 -0.3662 -0.0282 -0.0338 -0.0507 -0.1353 -0.0225 -0.0282 -0.0338 -0.0338 -0.2817 -0.0282 -0.0225 -0.0225 -0.0225 -0.0282 -0.0282 -0.0338 -0.0282', 'S-1645\tUnter Berücksichtigung der Recovery im Urin beträgt die Resorption mindestens 56% und wird durch die Gegenwart von Nahrungsmitteln im Magen-Darm-Trakt nicht wesentlich beeinflusst.', 'T-1645\tBased on urinary recovery, the extent of absorption is at least 56% and is not significantly influenced by the presence of food in the gastrointestinal tract.', 'H-1645\t-1.689453125\tTaking into account the patient &quot; s urine output , the extent of absorption is at least 56 % and is not significantly affected by the presence of food in the gastrointestinal tract .', 'D-1645\t-1.689453125\tTaking into account the patient "s urine output, the extent of absorption is at least 56% and is not significantly affected by the presence of food in the gastrointestinal tract.', 'P-1645\t-2.5762 -0.3594 -0.0732 -0.6367 -0.9692 -0.3579 -0.0732 -0.9609 -1.2227 -0.6538 -0.1803 -1.3525 -1.0312 -0.0451 -0.1635 -0.0225 -0.0958 -0.3042 -0.0225 -0.0225 -0.0395 -0.8057 -0.6201 -0.3945 -0.6987 -0.7437 -0.0338 -0.1353 -0.0113 -0.0338 -0.1353 -0.0564 -0.3833 -0.1917 -0.3494 0.0000 -0.0113 -0.0113 -0.0338 -0.0225 -0.0338 -0.0338', 'S-693\t24 Patienten, die bekanntermaßen ein CYP 2C9-Enzymsystem mit verminderter Aktivität haben, sollen mit Vorsicht behandelt werden (siehe Abschnitt 5.2).', 'T-693\tPatients known to be CYP2C9 poor metabolisers should be treated with caution (see 5.2.).', 'H-693\t-1.083984375\t24 Patients known to be CYP2C9 poor metabolisers should be treated with caution ( see section 5.2 ) .', 'D-693\t-1.083984375\t24 Patients known to be CYP2C9 poor metabolisers should be treated with caution (see section 5.2).', 'P-693\t-2.0312 -1.3330 -0.0225 -0.4565 -0.0338 -0.3325 -0.3071 -0.0282 -0.9551 -0.0254 -0.0282 -0.0282 -0.3240 -0.3213 -0.0113 -1.1895 -0.0789 -0.0395 -0.0451 -0.0451 -0.1014 -0.0395 -0.0395 -0.1973 -0.0225 -0.0282 -0.0395 -0.0451 -0.0282', 'S-424\t1.3 Transparenz und zulassungsrechtlicher Dialog Der Direktor wurde vom Verwaltungsrat auf dessen Sitzung im Februar 2001 mit der stufenweisen Umsetzung der Empfehlungen beauftragt, die der Workshop zur Transparenz am 23.', 'T-424\tThe report was forwarded to the European Commission as part of the planned report to the European Parliament and Council on the implementation of the fee system.', 'H-424\t-1.6826171875\tand in particular the costs of services provided by national authorities for inspections and rapporteurships .', 'D-424\t-1.6826171875\tand in particular the costs of services provided by national authorities for inspections and rapporteurships.', 'P-424\t-2.0137 -0.3381 -0.5396 -0.2113 -0.3550 -0.1465 -0.3381 -0.3352 -0.2141 -0.3381 -0.2930 -0.3916 -0.3467 -0.5239 -0.4678 -0.3381 -0.0958 -0.2649 -0.4958 -0.2479 -2.0410 -0.4114', 'S-1553\tFaltschachtel mit 1 Blisterpackung mit 3 x 0,80 ml-Pipetten Faltschachtel mit 2 Blisterpackungen mit 3 x 0,80 ml-Pipetten', 'T-1553\tBox of 1 blister card of 3 x 0.80 ml pipettes Box of 2 blister cards of 3 x 0.80 ml pipettes', 'H-1553\t-0.42626953125\tBox of 1 blister card of 3 x 0.80 ml pipettes Box of 2 blister cards of 3 x 0.80 ml pipettes', 'D-1553\t-0.42626953125\tBox of 1 blister card of 3 x 0.80 ml pipettes Box of 2 blister cards of 3 x 0.80 ml pipettes', 'P-1553\t-0.3213 -0.3030 -0.0655 -0.0176 -0.0334 -0.3228 -0.3213 -0.0373 -0.0275 -0.1395 -0.3945 -0.0282 -0.2029 -0.0451 -0.0141 -0.3240 -0.0465 -0.0352 -0.0127 -0.0296 -0.0352 -0.0831 -0.0282 -0.0254 -0.0225 -0.2451 -0.0225 -0.0845 -0.0169 -0.0113 -0.0479', 'S-1579\tViraferonPeg 100 Mikrogramm Pulver und Lösungsmittel zur Herstellung einer Injektionslösung, vorgefüllter Injektor Peginterferon alfa-2b', 'T-1579\tViraferonPeg 100 micrograms powder and solvent for solution for injection pre-filled pen peginterferon alfa-2b', 'H-1579\t-0.34521484375\tViraferonPeg 100 micrograms powder and solvent for solution for injection pre @-@ filled pen peginterferon alfa @-@ 2b', 'D-1579\t-0.34521484375\tViraferonPeg 100 micrograms powder and solvent for solution for injection pre-filled pen peginterferon alfa-2b', 'P-1579\t-0.0357 -0.0227 -0.0184 -0.0227 -0.0199 -0.0227 -0.0299 -0.1136 -0.2384 -0.1233 -0.0327 -0.0243 -0.0282 -0.1240 -0.3213 -0.3213 -0.1085 -0.0211 -0.3213 -0.0451 -0.0282 -0.3228 -0.2001 -0.0352 -0.0141 -0.0113 -0.0282 -0.0310 -0.0085 -0.0282 -0.0240 -0.0240 -0.0634', 'S-773\tBei Hunden, die über 12 Monate mit bis zu 20 mg / kg / 2 Wochen RISPERDAL CONSTA behandelt wurden, wurde keine Osteodystrophie beobachtet.', 'T-773\tNo osteodystrophy was observed in dogs treated for 12 months with RISPERDAL CONSTA up to 20 mg / kg / 2 weeks.', 'H-773\t-0.70458984375\tIn dogs treated with RISPERDAL CONSTA up to 20 mg / kg / 2 weeks for 12 months , no osteodystrophy was observed .', 'D-773\t-0.70458984375\tIn dogs treated with RISPERDAL CONSTA up to 20 mg / kg / 2 weeks for 12 months, no osteodystrophy was observed.', 'P-773\t-0.4058 -0.2057 -0.6602 -0.9067 -0.2113 -0.0141 -0.0169 -0.0155 -0.0211 -0.0183 -0.0169 -0.0240 -0.7383 -0.0282 -0.0648 -0.0113 -0.0310 -0.0141 -0.2423 -0.0366 -0.0282 -0.5835 -0.4819 -0.0338 -0.2029 -0.1296 -0.0873 -0.0197 -0.0310 -0.0141 -0.0197 -0.0113 -0.1493 -0.5103 -0.0338 -0.0282', 'S-954\tAm Ende des MRP-Verfahrens bestand eine Unstimmigkeit zwischen CMS, die den Wortlaut der Indikation betraf, die die EUROPA-Daten angemessen wiedergibt.', 'T-954\tAt the end of the MRP procedure there was a discrepancy between CMS regarding the wording of the indication that adequately reflects the EUROPA data.', 'H-954\t-1.61328125\tAt the end of the MRP procedure , there was a discrepancy between the CMS regarding the wording of the indication that mirrors sufficiently the EUROPA data .', 'D-954\t-1.61328125\tAt the end of the MRP procedure, there was a discrepancy between the CMS regarding the wording of the indication that mirrors sufficiently the EUROPA data.', 'P-954\t-0.8003 -0.0296 -0.0331 -0.0282 -0.0409 -0.1176 -0.0197 -0.1226 -1.3271 -0.7578 -0.0395 -0.4001 -1.3750 -0.0141 -0.0113 -0.2649 -0.8003 -0.1973 -0.5127 -1.2910 -0.0338 -0.0282 -0.0225 -0.0338 -0.0395 -0.0507 -1.3242 -2.5918 -0.0113 -0.0225 -1.1719 -0.0113 -0.0225 -0.4622 -0.1014 -0.0225 -0.5186 -0.0338 -0.0338 -0.0338', 'S-304\tDie Differenz ist auf die Patientengruppe mit einem > 5% igen Gewichtsverlust nach 12 Wochen Orlistat-Behandlung zurückzuführen, die 19% der Anfangspopulation verkörpert.', 'T-304\tThe difference was driven by the outcome in the group of patients with ≥ 5% weight loss after 12 weeks of treatment with orlistat representing 19% of the initial population.', 'H-304\t-1.6298828125\tThe difference is due to the incidence of weight loss &gt; 5 % after 12 weeks of treatment with orlistat , representing 19 % of the starting population .', 'D-304\t-1.6298828125\tThe difference is due to the incidence of weight loss > 5% after 12 weeks of treatment with orlistat, representing 19% of the starting population.', 'P-304\t-0.5972 -0.2793 -0.6367 -0.8174 -0.0310 -0.2352 -1.3682 -0.0423 -0.1747 -0.9326 -0.3494 -1.1689 -0.0282 -0.0507 -2.4004 -0.0225 -0.0225 -0.0451 -0.4338 -0.0901 -0.0789 -0.0113 -0.0395 -1.2852 -0.5352 -0.2029 -0.0338 -0.0338 -0.0338 -1.2168 -0.0225 -0.0338 -0.0338', 'S-712\tSiehe Abschnitte 4.4 und 5.1 für wichtige Informationen zur klinischen Wirksamkeit von Retapamulin gegenüber verschiedenen Staphylococcus-aureus-Typen.', 'T-712\tSee sections 4.4 and 5.1 for important information regarding the clinical activity of retapamulin against different types of Staphylococcus aureus.', 'H-712\t-1.0048828125\tSee sections 4.4 and 5.1 for important information on the clinical efficacy of retapamulin against various Staphylococcus aureus types .', 'D-712\t-1.0048828125\tSee sections 4.4 and 5.1 for important information on the clinical efficacy of retapamulin against various Staphylococcus aureus types.', 'P-712\t-0.3689 -0.4541 -0.0240 -0.0282 -0.0338 -0.0211 -0.0282 -0.2444 -0.6968 -0.3748 -1.2822 -0.8286 -0.0197 -0.0958 -0.0113 -0.0197 -0.0282 -0.3101 -0.0282 -0.0282 -0.0282 -0.0310 -0.5469 -1.1582 -0.9692 -0.0225 -0.0225 -0.4958 -0.0225 -0.0113 -0.0225 -0.0282 -0.0338 -0.0225 -0.3718 -0.0338 -0.0282', 'S-1533\tPatienten mit schwerer Leberfunktionsstörung sollten Lansoprazol-ratiopharm 15 mg nicht einnehmen und auch keine Kombinationstherapie mit Clarithromycin erhalten.', 'T-1533\tPatients with severely impaired liver function should not take Lansoprazol-ratiopharm, nor should they be given combination therapy with clarithromycin.', 'H-1533\t-0.740234375\tPatients with severely impaired liver function should not take Lansoprazol @-@ ratiopharm , nor should they be given combination therapy with clarithromycin .', 'D-1533\t-0.740234375\tPatients with severely impaired liver function should not take Lansoprazol-ratiopharm, nor should they be given combination therapy with clarithromycin.', 'P-1533\t-0.0722 -0.0184 -0.0473 -1.0938 -0.2360 -0.0028 -0.6338 -0.0183 -0.0254 -0.0578 -0.0380 -0.2466 -0.0042 -0.3198 -0.1550 -0.0197 -0.0479 -0.0085 -0.0225 -0.0085 -1.6543 -0.3184 -0.1493 -0.0366 -0.3550 -0.1859 -0.2197 -0.0789 -0.0338 -0.1183 -0.0056 -0.0113 -0.0225 -0.0282 -0.0338 -0.0282', 'S-939\tCerepro sollte in Kombination mit Ganciclovir-Natrium eingesetzt werden, um hochgradige Gliome bei Patienten, bei denen eine Operation möglich ist, zu behandeln.', 'T-939\tCerepro was to be used in combination with ganciclovir sodium to treat high-grade glioma in patients who are eligible for surgery.', 'H-939\t-0.72998046875\tCerepro should be used in combination with ganciclovir sodium to treat high @-@ grade gliomas in patients undergoing surgery .', 'D-939\t-0.72998046875\tCerepro should be used in combination with ganciclovir sodium to treat high-grade gliomas in patients undergoing surgery.', 'P-939\t-0.2163 -0.0185 -0.0185 -0.6436 -0.0317 -0.0493 -0.0444 -0.7842 -0.0282 -0.0958 -0.0676 -0.0042 -0.0211 -0.0296 -0.0197 -0.0437 -0.0155 -0.6606 -0.0296 -0.1648 -0.4226 -0.0085 -0.0085 -0.5103 -0.0254 -0.0366 -0.5889 -1.0400 -0.0113 -0.1268 -0.0451 -0.0282', 'S-1778\tDas Sicherheitsprofil der mit 40 mg Simvastatin behandelten Patienten war über die mittlere Studiendauer von 5 Jahren mit dem der Plazebo-Gruppe vergleichbar.', 'T-1778\tDiscontinuation rates due to side effects were comparable (4.8% in patients treated with < Zocord > 40 mg compared with 5.1% in patients treated with placebo).', 'H-1778\t-1.42578125\tThe safety profile of patients treated with &lt; Zocord &gt; 40 mg simvastatin was comparable to that of the placebo group for a mean duration of 5 years .', 'D-1778\t-1.42578125\tThe safety profile of patients treated with < Zocord > 40 mg simvastatin was comparable to that of the placebo group for a mean duration of 5 years.', 'P-1778\t-0.1288 -0.0114 -0.0213 -0.0560 -0.1136 -0.0241 -0.4424 -0.7905 -0.0070 -0.0155 -0.3284 -0.3228 -0.3228 -0.3213 -0.1353 -0.0169 -2.0098 -0.0254 -0.0113 -0.0085 -0.0056 -0.4143 -0.3467 -0.0282 -0.6143 -0.7944 -0.8623 -0.8452 -0.3889 -0.0225 -0.0169 -0.0225 -0.4565 -2.4453 -0.2255 -0.4734 -0.3042 -0.0225 -0.0338 -0.0901 -0.0225 -0.0338 -0.0338', 'S-1668\tDie benannten Berichterstatter und Mitberichterstatter waren jeweils Sif Ormarsdottir / Tomas Salmonson und Gottfried Kreutz / Julia Dunne.', 'T-1668\tThe Rapporteur and Co-Rapporteur appointed were Sif Ormarsdottir / Tomas Salmonson, Gottfried Kreutz / Julia Dunne respectively.', 'H-1668\t-1.0654296875\tThe Rapporteurs and Co @-@ Rapporteurs appointed were , in particular , Sif Ormarsdottir / Tomas Salmonson and Gottfried Kreutz / Julia Dunne .', 'D-1668\t-1.0654296875\tThe Rapporteurs and Co-Rapporteurs appointed were, in particular, Sif Ormarsdottir / Tomas Salmonson and Gottfried Kreutz / Julia Dunne.', 'P-1668\t-0.3240 -0.3142 -0.0049 -0.0218 -0.4846 -0.0127 -0.3367 -1.0098 -0.0338 -0.0817 -0.0099 -0.0240 -0.1099 -0.0141 -0.2944 -0.0873 -1.8965 -1.3867 -1.1387 -0.0338 -0.0620 -0.0225 -0.0169 -0.0169 -0.0225 -0.0282 -0.0169 -0.0282 -0.0225 -0.0395 -2.3945 -0.0282 -0.0113 -0.0225 -0.0225 -0.0338 -0.0113 -0.0056 -0.0056 0.0000 -0.0282 -0.0507 -0.0113 -0.0169 -0.0338 -0.0282', 'S-951\tDie begrenzten Erfahrungen mit dem Verfahren zur gegenseitigen Anerkennung erlauben keine zuverlässigen Schätzungen der Anzahl an Schiedsgerichtsverfahren, die angestrengt werden, wenn dieses Verfahren 1998 zur Regel wird.', 'T-951\tThe limited experience of the mutual recognition procedure does not make it possible to give valid estimates for the number of arbitrations which will arise once the procedure becomes systematic in 1998.', 'H-951\t-0.79248046875\tThe limited experience of the mutual recognition procedure does not make it possible to given valid estimates for the number of arbitrations which will be initiated once the procedure becomes systematic in 1998 .', 'D-951\t-0.79248046875\tThe limited experience of the mutual recognition procedure does not make it possible to given valid estimates for the number of arbitrations which will be initiated once the procedure becomes systematic in 1998.', 'P-951\t-0.2064 -0.0262 -0.0220 -0.3088 -0.2029 -0.1127 -0.0148 -0.0887 -0.1487 -0.0282 -0.3916 -0.0859 -0.0409 -0.0324 -0.3296 -0.3254 -0.0183 -0.0268 -0.9258 -0.0395 -0.0817 -0.0282 -0.0676 -0.0085 -0.2255 -0.5835 -0.1014 -0.3184 -0.2339 -0.0282 -1.1973 -0.2649 -0.1803 -0.0732 -0.3213 -0.0225 -0.0620 -0.0169 -0.0282 -0.0282', 'S-904\t• Die Docetaxel Winthrop 80 mg Durchstechflasche enthält eine Lösung von Docetaxel in Polysorbat 80 in einer Konzentration von 40 mg / ml.', 'T-904\t• The Docetaxel Winthrop 80 mg vial contains a solution of docetaxel in polysorbate 80 at a concentration of 40 mg / ml.', 'H-904\t-0.1900634765625\t• The Docetaxel Winthrop 80 mg vial contains a solution of docetaxel in polysorbate 80 at a concentration of 40 mg / ml .', 'D-904\t-0.1900634765625\t• The Docetaxel Winthrop 80 mg vial contains a solution of docetaxel in polysorbate 80 at a concentration of 40 mg / ml.', 'P-904\t-0.0693 -0.1175 -0.0879 -0.0248 -0.0155 -0.0099 -0.0220 -0.0213 -0.0035 -0.0211 -0.0796 -0.0148 -0.0264 -0.0243 -0.0356 -0.0669 -0.0395 -0.0299 -0.1082 -0.0232 -0.0155 -0.0106 -0.0218 -0.0395 -0.1401 -0.0155 -0.0402 -0.0197 -0.0254 -0.1790 -0.1169 -0.0352 -0.0296 -0.0493 -0.0099 -0.0310 -0.0197 -0.0409 -0.0310', 'S-1280\tEs wird zusammen mit Methotrexat (einem entzündungshemmenden Arzneimittel) bei Patienten angewendet, die auf Methotrexat allein nicht ausreichend angesprochen haben.', 'T-1280\tIt is used in combination with methotrexate (a medicine used to reduce inflammation) in patients who have not responded adequately to methotrexate alone.', 'H-1280\t-0.64404296875\tIt is used together with methotrexate ( an anti @-@ inflammatory medicine ) in patients who have had an inadequate response to methotrexate alone .', 'D-1280\t-0.64404296875\tIt is used together with methotrexate (an anti-inflammatory medicine) in patients who have had an inadequate response to methotrexate alone.', 'P-1280\t-0.5161 -0.0356 -0.2864 -0.9565 -0.0282 -0.0225 -0.0240 -0.0296 -0.0240 -0.0225 -0.0634 -0.0380 -0.0479 -0.0282 -0.0085 -0.0197 -0.0113 -0.0211 -0.2776 -0.0282 -0.4888 -0.0451 -0.0564 -0.5186 -1.0566 -0.1691 -0.0620 -0.1353 -0.0254 -0.0310 -0.0113 -0.0225 -0.0310 -0.0282 -0.0225 -0.4565 -0.0310 -0.0282', 'S-67\t0,302 ± 0,089 1,191 ± 0,451 1,68 ± 0,763 0,239 ± 0,128 0,217 ± 0,081 1,94 ± 1,09', 'T-67\t0.302 ± 0.089 1.191 ± 0.451 1.68 ± 0.763 0.239 ± 0.128 0.217 ± 0.081 1.94 ± 1.09', 'H-67\t-0.2467041015625\t0.302 ± 0.089 1.191 ± 0.451 1.68 ± 0.763 0.239 ± 0.128 0.217 ± 0.081 1.94 ± 1.09', 'D-67\t-0.2467041015625\t0.302 ± 0.089 1.191 ± 0.451 1.68 ± 0.763 0.239 ± 0.128 0.217 ± 0.081 1.94 ± 1.09', 'P-67\t-0.2712 -0.0227 -0.0299 -0.0148 -0.1164 -0.0148 -0.3022 -0.0176 -0.0282 -0.0141 -0.0873 -0.0197 -0.0148 -0.1733 -0.2395 -0.0113 -0.0430 -0.0247 -0.0183 -0.0986 -0.0240 -0.0169 -0.0155 -0.0578 -0.0240 -0.0254 -0.0916 -0.0240 -0.0254 -0.0113 -0.0423 -0.0085 -0.1310 -0.0141 -0.0155 -0.0549 -0.0155 -0.0282', 'S-191\tZenapax erhöht dieses Risiko nicht weiter, wenn es zusammen mit anderen immunsuppressiven Arzneimitteln, einschließlich Ciclosporin und Corticosteroiden, angewendet wird.', 'T-191\tZenapax does not increase this risk when it is used together with other immunosuppressive drugs, including cyclosporine and corticosteroids.', 'H-191\t-1.1591796875\tZenapax has not been proven to increase this risk when used with other immunosuppressive medicines , including ciclosporin and corticosteroids .', 'D-191\t-1.1591796875\tZenapax has not been proven to increase this risk when used with other immunosuppressive medicines, including ciclosporin and corticosteroids.', 'P-191\t-0.8003 -0.0183 -0.0247 -1.0986 -0.2423 -0.2563 -0.6201 -0.0338 -0.0901 -1.7529 -0.3296 -0.3606 -1.2480 -0.7046 -0.0338 -0.2761 -0.0169 -0.0169 -0.0169 -0.0169 -0.0845 -0.1353 -0.3438 -0.9692 -0.0282 -0.3889 -0.0113 -0.0113 -0.0113 -0.2986 -0.0338 -0.0225 -0.0225 -0.0225 -0.0113 -0.0169 -0.0113 -0.0282 -0.0282', 'S-1368\tNach oraler Gabe von MicardisPlus werden maximale Hydrochlorothiazid- Konzentrationen etwa 1,0-3,0 Stunden nach der Einnahme erreicht.', 'T-1368\tFollowing oral administration of MicardisPlus peak concentrations of hydrochlorothiazide are reached in approximately 1.0 <<unk>> 3.0 hours after dosing.', 'H-1368\t-0.73681640625\tFollowing oral administration of MicardisPlus peak concentrations of hydrochlorothiazide are reached in approximately 1.0 @-@ 3.0 hours after dosing .', 'D-1368\t-0.73681640625\tFollowing oral administration of MicardisPlus peak concentrations of hydrochlorothiazide are reached in approximately 1.0-3.0 hours after dosing.', 'P-1368\t-0.8052 -0.0345 -0.0824 -0.0402 -0.0155 -0.0225 -0.0183 -0.0127 -0.6353 -0.3467 -0.0085 -0.0155 -0.0324 -0.0225 -0.0254 -0.0099 -0.0240 -0.0155 -0.0099 -0.0085 -0.0423 -0.0944 -0.2859 -0.7681 -0.2283 -0.0958 -0.0282 -0.5918 -0.0282 -0.0254 -0.2649 -0.6030 -0.9243 -0.0958 -0.0395 -0.0282', 'S-566\t< Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur (EMEA) http: / / www.emea.europa.eu verfügbar >.', 'T-566\tDetailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / / www.emea.europa.eu', 'H-566\t-0.7060546875\tDetailed information on this medicinal product is available on the website of the European Medicines Agency ( EMEA ) http : / / www.emea.europa.eu &gt; .', 'D-566\t-0.7060546875\tDetailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / / www.emea.europa.eu >.', 'P-566\t-0.3196 -0.0134 -0.0248 -0.1152 -0.0796 -1.4346 -0.0338 -0.0155 -0.0549 -0.0296 -0.0549 -0.0310 -1.2764 -0.0310 -0.0310 -0.0225 -0.0254 -0.0282 -0.2141 -0.0423 -0.0225 -0.0141 -0.0282 -0.0282 -0.2283 -0.0282 -0.0282 -0.0310 -1.1670 -0.0085 -0.0085 -0.0056 -0.5889 -0.0225 -0.0169 -0.0338 -0.0282', 'S-1696\tDie Pharmakokinetik von Aliskiren und Hydrochlorothiazid war bei Patienten mit leichter bis mäßiger Leberinsuffizienz nicht signifikant beeinflusst.', 'T-1696\tThe pharmacokinetics of aliskiren and hydrochlorothiazide are not significantly affected in patients with mild to moderate liver disease.', 'H-1696\t-0.489501953125\tThe pharmacokinetics of aliskiren and hydrochlorothiazide were not significantly affected in patients with mild to moderate hepatic impairment .', 'D-1696\t-0.489501953125\tThe pharmacokinetics of aliskiren and hydrochlorothiazide were not significantly affected in patients with mild to moderate hepatic impairment.', 'P-1696\t-0.1910 -0.0241 -0.0092 -0.0185 -0.0357 -0.0342 -0.3198 -0.3105 -0.1219 -0.0542 -0.0310 -0.0134 -0.0240 -0.0106 -0.0268 -0.0127 -0.0373 -0.0042 -0.0197 -0.3113 -0.0338 -0.0310 -0.6045 -0.0592 -0.3960 -0.0380 -0.2001 -0.5776 -0.0169 -0.2791 -0.0225 -0.0225 -0.3213 -0.0169 -0.0169 -0.0310 -0.0366 -0.0282', 'S-844\tDie Behandlung mit Pravastatin hatte im Vergleich mit der Placebo-Gruppe keine Auswirkung auf die stationären Aufnahmen für eine der nicht-kardiovaskulären Kategorien.', 'T-844\tPravastatin treatment had no effect on hospital admissions for any non-cardiovascular category, relative to the placebo group.', 'H-844\t-0.908203125\tTreatment with pravastatin had no effect on hospitalisations in either of the non @-@ cardiovascular categories compared to the placebo group .', 'D-844\t-0.908203125\tTreatment with pravastatin had no effect on hospitalisations in either of the non-cardiovascular categories compared to the placebo group.', 'P-844\t-0.2568 -0.0141 -0.0248 -0.0334 -0.0171 -0.0190 -0.0085 -0.0077 -0.1145 -0.0356 -0.3391 -0.0380 -0.3303 -0.2515 -1.1807 -0.0225 -0.1859 -0.9131 -0.3296 -0.2903 -0.2986 -0.2791 -0.1155 -0.0113 -0.0169 -0.0113 -0.3523 -0.4143 -0.6143 -0.7324 -0.4678 -0.0225 -0.0169 -0.0225 -0.0732 -0.0338 -0.0282', 'S-477\tALIMTA 500 mg Pulver zur Herstellung eines Konzentrates zur Herstellung einer Infusionslösung Pemetrexed Nach Auflösen und Verdünnung zur intravenösen Anwendung.', 'T-477\tALIMTA 500 mg powder for concentrate for solution for infusion pemetrexed For intravenous use after reconstitution and dilution.', 'H-477\t-0.53759765625\tALIMTA 500 mg powder for concentrate for solution for infusion pemetrexed For intravenous use after reconstitution and dilution .', 'D-477\t-0.53759765625\tALIMTA 500 mg powder for concentrate for solution for infusion pemetrexed For intravenous use after reconstitution and dilution.', 'P-477\t-0.0458 -0.0149 -0.0085 -0.0342 -0.0128 -0.0811 -0.1328 -0.3215 -0.3149 -0.3206 -0.3206 -0.0859 -0.0254 -0.3169 -0.0240 -0.0211 -0.0268 -0.0380 -0.3198 -0.1127 -0.0296 -0.0127 -0.0211 -0.3452 -0.1747 -0.3213 -0.3213 -0.0676 -0.0930 -0.0085 -0.2959 -0.0338', 'S-245\tProtein C spielt eine wichtige Rolle bei der Vorbeugung überschießender Gerinnung und verhindert so der Bildung von Blutgerinnseln in den Gefäßen bzw. behandelt bereits bestehende.', 'T-245\tProtein C plays a major role in prevention of excessive clot formation thus, prevent and / or treat intravascular thrombosis.', 'H-245\t-1.64453125\tProtein C plays an important role in the prevention of an excess of coagulation and prevents blood clots from forming in the blood vessels or treats existing blood clots .', 'D-245\t-1.64453125\tProtein C plays an important role in the prevention of an excess of coagulation and prevents blood clots from forming in the blood vessels or treats existing blood clots.', 'P-245\t-0.0516 -0.0184 -0.0299 -0.5908 -0.8706 -0.3494 -0.0282 -0.0338 -1.1133 -0.0338 -0.0225 -0.0282 -0.5552 -0.3157 -0.2874 -1.7354 -0.0113 -0.0169 -1.4092 -1.7578 -0.0225 -0.4114 -0.0225 -0.2367 -0.6763 -0.0338 -0.0564 -0.4622 -1.4873 -0.0113 -0.0113 -0.1465 -0.1803 -0.0113 -0.8115 -0.6875 -0.0338 -0.0225 -0.4170 -0.0338', 'S-1606\tZur Behandlung der primären Hyperhidrosis axillaris wird ein Injektionsvolumen von 0,1 <unk> 0,2 ml pro intradermaler Injektion empfohlen.', 'T-1606\tThe recommended injection volume per intradermal injection in primary axillary hyperhidrosis is 0.1-0.2 ml.', 'H-1606\t-0.7109375\tAn injection volume of 0.1 to 0.2 ml is recommended for the treatment of primary axilar hyperhidrosis .', 'D-1606\t-0.7109375\tAn injection volume of 0.1 to 0.2 ml is recommended for the treatment of primary axilar hyperhidrosis.', 'P-1606\t-1.3486 -0.0240 -0.0155 -0.1219 -0.0380 -0.0521 -0.0648 -0.3733 -0.0197 -0.0549 -0.0634 -0.2676 -0.0352 -0.5918 -0.3777 -0.0254 -0.0282 -0.0395 -0.6538 -0.3157 -0.4536 -0.0282 -0.0254 -0.0085 -0.0169 -0.0620 -0.0282', 'S-947\tAußerdem hat Stickstoffmonoxid eine Affinität zu Metalloproteinen und kann ebenso mit Sulfhydryl-Gruppen in Protein reagieren und Nitrosylverbindungen bilden.', 'T-947\tThe clinical significance of the', 'H-947\t-1.2451171875\tNitric oxide also has affinity to metalloproteins and may react with sulphydryl groups in proteins and form nitrosyl compounds .', 'D-947\t-1.2451171875\tNitric oxide also has affinity to metalloproteins and may react with sulphydryl groups in proteins and form nitrosyl compounds.', 'P-947\t-1.2041 -0.0141 -0.1007 -0.0204 -0.3669 -0.0831 -0.3423 -0.0282 -0.0268 -0.6426 -0.0704 -0.0338 -0.0169 -0.0085 -0.4312 -0.5806 -0.6846 -0.0564 -0.0197 -0.3945 -0.2085 -0.0930 -0.0366 -0.6396 -0.6030 -0.8228 -0.4902 -1.1436 -0.4846 -0.0225 -0.0169 -0.6987 -0.2367 -0.0113 -0.0338 -0.0282', 'S-1410\tThromboembolische Komplikationen (Bildung von Blutgerinnseln) sind möglich, wenn Evicel versehentlich in ein Blutgefäß injiziert wird.', 'T-1410\tThromboembolic complications (blood clots) may occur if Evicel is unintentionally injected into a blood vessel.', 'H-1410\t-0.51513671875\tThromboembolic complications ( formation of blood clots ) may occur if Evicel is accidentally injected into a blood vessel .', 'D-1410\t-0.51513671875\tThromboembolic complications (formation of blood clots) may occur if Evicel is accidentally injected into a blood vessel.', 'P-1410\t-0.2185 -0.0099 -0.0049 -0.0099 -0.0199 -0.0234 -0.1664 -0.0306 -0.0437 -0.7861 -0.0282 -0.1085 -0.0282 -0.0085 -0.0296 -1.0186 -0.4128 -0.2227 -0.0310 -0.0141 -0.0056 -0.0366 -0.3101 -0.0197 -0.1240 -0.0225 -0.0564 -0.2085 -0.0423 -0.0169 -0.0338 -0.0282', 'S-519\tDer CHMP ist der Ansicht, dass eine neue epidemiologische Studie zu Mammakarzinom bei Implanon- Anwenderinnen zum jetzigen Zeitpunkt nicht gerechtfertigt ist.', 'T-519\tThe CHMP is of the opinion that a new epidemiological study of breast cancer in Implanon users is not justified at the present time.', 'H-519\t-1.2509765625\tThe CHMP considers that a new epidemiological study of breast cancer in users of implants is not justified at this time .', 'D-519\t-1.2509765625\tThe CHMP considers that a new epidemiological study of breast cancer in users of implants is not justified at this time.', 'P-519\t-0.8101 -0.0218 -0.0099 -1.3252 -0.0395 -0.8481 -0.0930 -0.0141 -0.0225 -0.0338 -0.0338 -0.9893 -0.0282 -0.0451 -0.0873 -0.4958 -0.0338 -0.9751 -0.6704 -0.3213 -0.1859 -0.3889 -0.0395 -0.3606 -1.1045 -0.0338 -0.0282', 'S-502\tBei der Gabe von AVANDAMET an gesunde Freiwillige hatte die Einnahme einer Mahlzeit keinen Einfluss auf die AUC von Rosiglitazon oder Metformin.', 'T-502\tFood had no effect on the AUC of rosiglitazone or metformin when AVANDAMET was administered to healthy volunteers.', 'H-502\t-0.9931640625\tWhen AVANDAMET was administered to healthy volunteers , a meal had no effect on the AUC of rosiglitazone or metformin .', 'D-502\t-0.9931640625\tWhen AVANDAMET was administered to healthy volunteers, a meal had no effect on the AUC of rosiglitazone or metformin.', 'P-502\t-1.1406 -1.0234 -0.0254 -0.0085 -0.0225 -0.0155 -0.0366 -1.0605 -0.0169 -0.2311 -0.0366 -0.4763 -0.0592 -1.6797 -0.0564 -0.5693 -0.0338 -0.6538 -0.0338 -0.1635 -0.0451 -0.0282 -0.0620 -0.0789 -0.0113 -0.0225 -0.0169 -0.0338 -0.4678 -0.0225 -0.0113 -0.0282 -0.0395 -0.0282', 'S-590\tWenn Topotecan mit anderen Chemotherapeutika kombiniert wird, kann eine Dosisreduktion jedes einzelnen Arzneimittels erforderlich sein, um die Verträglichkeit zu verbessern.', 'T-590\tIn combining topotecan with other chemotherapy agents, reduction of the doses of each medicinal product may be required to improve tolerability.', 'H-590\t-1.2451171875\tIf topotecan is combined with other chemotherapeutic agents , dose reduction of each agent may be required to improve tolerability .', 'D-590\t-1.2451171875\tIf topotecan is combined with other chemotherapeutic agents, dose reduction of each agent may be required to improve tolerability.', 'P-590\t-1.3564 -0.3042 -0.0282 -0.0282 -0.0225 -0.0310 -0.0648 -0.0282 -0.0352 -0.0240 -0.0085 -0.4001 -0.2043 -0.0817 -0.0479 -0.7666 -0.6621 -0.1747 -0.3467 -1.7246 -0.0395 -0.0282 -1.1494 -0.0789 -0.9863 -0.0451 -0.6538 -0.0395 -0.0282', 'S-1958\tIst der Blutdruck durch eine medikamentöse Therapie oder diätetische Maßnahmen nur schwer zu kontrollieren, muss die Dosis reduziert oder Anwendung unterbrochen werden (siehe Abschnitt 4.2).', 'T-1958\tIf high blood pressure is difficult to control by medical treatment or dietary measures, the dose must be reduced or administration discontinued (see section 4.2).', 'H-1958\t-1.4375\tIf blood pressure cannot be controlled using drug therapy or dietary measures , the dose should be reduced or the injection discontinued ( see section 4.2 ) .', 'D-1958\t-1.4375\tIf blood pressure cannot be controlled using drug therapy or dietary measures, the dose should be reduced or the injection discontinued (see section 4.2).', 'P-1958\t-0.3706 -0.8179 -0.0155 -1.0557 -0.0352 -0.0493 -0.7920 -0.4509 -0.1437 -0.0310 -1.3076 -0.0282 -0.8257 -0.3101 -0.1127 -0.0901 -0.3042 -0.0338 -0.2761 -0.0338 -0.8228 -1.3916 -0.9580 -1.0596 -0.0169 -0.0395 -0.0451 -0.1240 -0.0225 -0.0338 -0.0451 -0.0338 -0.0338', 'S-1713\tDie empfohlene Dosierung für APTIVUS ist 500 mg, in Kombination mit 200 mg Ritonavir (niedrig dosiertes Ritonavir), zweimal täglich.', 'T-1713\tThe recommended dose of APTIVUS is 500 mg, co-administered with 200 mg ritonavir (low dose ritonavir), twice daily.', 'H-1713\t-0.833984375\tThe recommended dose of APTIVUS is 500 mg in combination with 200 mg ritonavir ( low dose ritonavir ) twice daily .', 'D-1713\t-0.833984375\tThe recommended dose of APTIVUS is 500 mg in combination with 200 mg ritonavir (low dose ritonavir) twice daily.', 'P-1713\t-0.6133 -0.0292 -1.3076 -0.6284 -0.0310 -0.0254 -0.0155 -0.0169 -0.0366 -0.1338 -0.0240 -0.6411 -0.0225 -0.0310 -0.1437 -0.0169 -0.5806 -0.0282 -0.0169 -0.0197 -0.0423 -0.0507 -0.1324 -0.4028 -0.0254 -0.0197 -0.0169 -0.0310 -0.8115 -0.7158 -0.0338 -0.0282', 'S-1734\tBei Auftreten von allergischen oder anaphylaktischen Reaktionen ist die Verabreichung von ReFacto AF sofort zu unterbrechen und eine entsprechende medizinische Behandlung einzuleiten.', 'T-1734\tIf allergic or anaphylactic reactions occur, administration of ReFacto AF is to be discontinued immediately, and an appropriate treatment must be initiated.', 'H-1734\t-1.0380859375\tIf allergic or anaphylactic reactions occur , the administration of ReFacto AF should be discontinued immediately and appropriate medical treatment initiated .', 'D-1734\t-1.0380859375\tIf allergic or anaphylactic reactions occur, the administration of ReFacto AF should be discontinued immediately and appropriate medical treatment initiated.', 'P-1734\t-0.5928 -0.1982 -0.0155 -0.0345 -0.0254 -0.0268 -0.0085 -0.0169 -0.0134 -0.8740 -0.0169 -0.1169 -0.2847 -0.5806 -0.0521 -0.0282 -0.0254 -0.4705 -0.0310 -0.0113 -0.9834 -0.0366 -1.3555 -0.0169 -0.1917 -0.0451 -0.2817 -0.3042 -0.9526 -0.7778 -0.0282 -0.0282 -0.0282', 'S-596\tBei den Aktivitäten mit anderen zuständigen nationalen Behörden liegt der Schwerpunkt in erster Linie auf den Beziehungen zur Food and Drug Administration (FDA) der USA und zum japanischen Ministerium für Gesundheit und Wohlfahrt.', 'T-596\tActivities with other national competent authorities are primarily focused on relations with the US Food and Drug Administration (FDA) and the Japanese Ministry of Health and Welfare.', 'H-596\t-1.64453125\tScientific advice is a priority area for the EMEA and is provided on any aspect of research and', 'D-596\t-1.64453125\tScientific advice is a priority area for the EMEA and is provided on any aspect of research and', 'P-596\t-1.7432 -0.0197 -0.8467 -0.6001 -0.9468 -0.3411 -0.6313 -0.4255 -0.2791 -0.4509 -0.3213 -0.0225 -0.3494 -0.3157 -0.8623 -0.4058 -0.4058 -0.3213 -0.0789 -0.5298 -0.2537 -0.3550', 'S-1276\tEs gibt nicht viele Belege für die Wirksamkeit von Chlormezanon, und sie zeigen eine dem einfachen Analgetikum Paracetamol vergleichbare Wirksamkeit.', 'T-1276\tThe evidence of efficacy for chlormezanone is limited and demonstrates similar efficacy to the simple analgesic, paracetamol.', 'H-1276\t-1.4482421875\tEvidence of efficacy with chlormezanone is limited and of comparable effectiveness to the natural analgesic paracetamol .', 'D-1276\t-1.4482421875\tEvidence of efficacy with chlormezanone is limited and of comparable effectiveness to the natural analgesic paracetamol.', 'P-1276\t-1.7451 -0.0056 -0.0211 -0.2620 -0.3564 -0.0070 -0.0211 -0.3875 -0.0578 -0.0113 -0.0296 -0.0113 -0.0817 -0.0113 -0.0535 -0.4509 -0.3523 -2.5195 -0.4622 -0.0507 -0.8623 -0.0225 -0.3945 -1.8486 -1.3691 -0.3042 -0.0338 -0.0225 -0.0225 -0.5073 -0.0225 -0.0113 -0.0225 -0.0113 -0.0451 -0.0338', 'S-1352\tStillzeit Es ist nicht bekannt, ob Fesoterodin beim Menschen in die Muttermilch übergeht; daher wird nicht empfohlen, während der Behandlung mit TOVIAZ zu stillen.', 'T-1352\tLactation It is not known whether fesoterodine is excreted into human milk; therefore, breast-feeding is not recommended during treatment with TOVIAZ.', 'H-1352\t-0.87255859375\tLactation It is not known whether fesoterodine is excreted in human milk ; therefore , breast @-@ feeding is not recommended during treatment with TOVIAZ .', 'D-1352\t-0.87255859375\tLactation It is not known whether fesoterodine is excreted in human milk; therefore, breast-feeding is not recommended during treatment with TOVIAZ.', 'P-1352\t-1.2979 -0.0042 -0.0331 -0.0634 -0.0303 -0.0648 -0.0380 -0.1465 -0.1564 -0.0282 -0.3113 -0.2803 -0.0268 -0.2438 -0.5410 -0.1268 -0.0197 -0.2705 -0.1381 -0.6621 -0.8032 -0.1465 -0.2479 -0.2817 -0.1409 -0.0169 -0.8003 -0.0282 -0.2705 -0.0901 -0.1578 -0.0395 -0.0225 -0.0225 -0.0056 -0.0338 -0.0282', 'S-573\tDunajska cesta 119 SI 1000 Любляна, Словения Teл: + 386 1 560 3 800', 'T-573\tDunajska cesta 119 SI 1000 Любляна, Словения Teл: + 386 1 560 3 800', 'H-573\t-0.94970703125\tTel : + 386 1 560 3 800', 'D-573\t-0.94970703125\tTel: + 386 1 560 3 800', 'P-573\t-2.4961 -0.0338 -0.0704 -0.2014 -0.0296 -0.0366 -0.0296 -0.0225 -0.4902 -0.0197 -0.5747', 'S-1437\tZum Abschluss war der CHMP nicht für die Einschränkung der Anwendung von lang wirkendem Risperidon für Patienten, denen 6 mg Risperidon pro Tag verabreicht wurde.', 'T-1437\tIn conclusion, the CHMP was not in favour of restricting the use of long-acting risperidone for patients who were administered with 6 mg risperidone per day.', 'H-1437\t-0.72607421875\tIn conclusion , the CHMP was not in favour of restricting the use of long @-@ acting risperidone in patients receiving 6 mg / day risperidone .', 'D-1437\t-0.72607421875\tIn conclusion, the CHMP was not in favour of restricting the use of long-acting risperidone in patients receiving 6 mg / day risperidone.', 'P-1437\t-0.2368 -0.1052 -0.0409 -0.1022 -0.0190 -0.0113 -0.6768 -0.0352 -0.1282 -0.2043 -0.0296 -0.9341 -0.0240 -0.2141 -0.3718 -0.0282 -0.3325 -0.1803 -0.0085 -0.0254 -0.0169 -0.0113 -0.0028 -0.2311 -0.0507 -1.0342 -0.0958 -0.0169 -0.4536 -0.0507 -0.4368 -0.0225 -0.0113 -0.0056 -0.0564 -0.0282', 'S-1996\tDie Fertigspritzen enthalten, in Abhängigkeit vom Gehalt an Epoetin zeta, zwischen 0,3 ml und 1,0 ml Lösung (siehe "Was Retacrit enthält").', 'T-1996\tThe pre-filled syringes contain between 0.3 and 1.0 ml solution, depending on the content of epoetin zeta (see <<unk>> What Retacrit contains <<unk>>).', 'H-1996\t-0.51611328125\tThe pre @-@ filled syringes contain between 0.3 and 1.0 ml solution , depending on the content of epoetin zeta ( see &quot; What Retacrit contains &quot; ) .', 'D-1996\t-0.51611328125\tThe pre-filled syringes contain between 0.3 and 1.0 ml solution, depending on the content of epoetin zeta (see "What Retacrit contains").', 'P-1996\t-0.2163 -0.3813 -0.0278 -0.1831 -0.1324 -0.0099 -0.0254 -0.0493 -0.2367 -0.0458 -0.0402 -0.8916 -0.0437 -0.0254 -0.0197 -0.4128 -0.4001 -0.2339 -0.0310 -0.0592 -0.0732 -0.0310 -0.0817 -0.0225 -0.0197 -0.0310 -0.0197 -0.0113 -0.0395 -0.0479 -0.0789 -0.0620 -0.2227 -0.0310 -0.1917 -0.1606 -0.0366 -0.0338 -0.0310 -0.0282', 'S-599\tKeppra ist zur Monotherapie partieller Anfälle mit oder ohne sekundärer Generalisierung bei Patienten ab 16 Jahren mit neu diagnostizierter Epilepsie indiziert.', 'T-599\tKeppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.', 'H-599\t-0.68212890625\tKeppra is indicated for monotherapy in the treatment of partial seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy .', 'D-599\t-0.68212890625\tKeppra is indicated for monotherapy in the treatment of partial seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.', 'P-599\t-0.0206 -0.0163 -0.0170 -0.0436 -0.0142 -0.8018 -0.1973 -0.0296 -0.0197 -0.9312 -0.4170 -0.1790 -0.0296 -0.0366 -0.7607 -0.0085 -0.0197 -0.2395 -0.2507 -0.0254 -0.0197 -0.0254 -0.7241 -0.0423 -0.0986 -0.4028 -0.2001 -0.0395 -0.0845 -0.0310 -0.1409 -0.0113 -0.1465 -0.0113 -0.0056 -0.0225 -0.0169 -0.0338 -0.0282', 'S-1100\tAnwendung bei Patienten mit eingeschränkter Leberfunktion Lenalidomid wurde bei Patienten mit eingeschränkter Leberfunktion nicht explizit untersucht, und es gibt keine spezifischen Dosierungsempfehlungen.', 'T-1100\tUse in patients with impaired hepatic function Lenalidomide has not formally been studied in patients with impaired hepatic function and there are no specific dose recommendations.', 'H-1100\t-1.138671875\tUse in patients with hepatic impairment Lenalidomide has not been formally studied in patients with hepatic impairment and no specific dose recommendations are available .', 'D-1100\t-1.138671875\tUse in patients with hepatic impairment Lenalidomide has not been formally studied in patients with hepatic impairment and no specific dose recommendations are available.', 'P-1100\t-1.0957 -0.7222 -0.3169 -0.0310 -0.7651 -0.0254 -0.0197 -0.1353 -0.1099 -0.0113 -0.0254 -0.1324 -0.0169 -0.0169 -0.0056 -0.0254 -0.0676 -0.0282 -0.0366 -0.6426 -0.2930 -0.2903 -0.3606 -0.0310 -0.4536 -0.0197 -0.0141 -0.0113 -0.0028 -0.0085 -0.0225 -0.5918 -0.6201 -0.0845 -1.6289 -0.4678 -0.8340 -0.1578 -0.2649 -0.0282', 'S-1840\tZubrin 50 mg Lyophilisate zum Eingeben für Hunde Zubrin 100 mg Lyophilisate zum Eingeben für Hunde Zubrin 200 mg Lyophilisate zum Eingeben für Hunde', 'T-1840\tZubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates for dogs', 'H-1840\t-0.234375\tZubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates for dogs', 'D-1840\t-0.234375\tZubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates for dogs', 'P-1840\t-0.2979 -0.0400 -0.0085 -0.0377 -0.0127 -0.3445 -0.1853 -0.0416 -0.0373 -0.1148 -0.0458 -0.0416 -0.1888 -0.0176 -0.0042 -0.0275 -0.0113 -0.0155 -0.0535 -0.0225 -0.0169 -0.0282 -0.0282 -0.0282 -0.1381 -0.0141 -0.0042 -0.0183 -0.0113 -0.0085 -0.0521 -0.0183 -0.0141 -0.0310 -0.0282 -0.0282 -0.0296', 'S-1084\tWenn Sie mit NovoMix 30 Penfill und einer anderen Insulin Penfill Patrone behandelt werden, müssen Sie je ein Insulininjektionssystem für jeden Insulintyp benutzen.', 'T-1084\tIf you are treated with NovoMix 30 Penfill and another insulin Penfill cartridge, you must use one insulin delivery system for each type of insulin.', 'H-1084\t-0.319580078125\tIf you are treated with NovoMix 30 Penfill and another insulin Penfill cartridge , you must use one insulin delivery system for each type of insulin .', 'D-1084\t-0.319580078125\tIf you are treated with NovoMix 30 Penfill and another insulin Penfill cartridge, you must use one insulin delivery system for each type of insulin.', 'P-1084\t-0.1389 -0.0364 -0.0656 -0.1233 -0.0395 -0.0384 -0.0162 -0.0085 -0.0271 -0.0402 -0.0211 -0.0430 -0.1459 -0.0704 -0.0113 -0.2910 -0.0183 -0.0789 -0.0070 -0.0190 -0.0909 -0.0662 -0.2810 -0.0986 -0.0958 -0.0113 -0.0169 -0.3213 -0.0409 -0.0972 -0.0282 -0.2634 -0.0352 -0.0070 -0.0254 -0.0409 -0.0296', 'S-778\tLiprolog ist, verglichen mit Normalinsulin, bei subkutaner Anwendung ein Präparat mit rascherem Wirkungseintritt und kürzerer Wirkdauer (2 bis 5 Stunden).', 'T-778\tLiprolog takes effect rapidly and has a shorter duration of activity (2 to 5 hours) given subcutaneously as compared with regular insulin.', 'H-778\t-0.60986328125\tLiprolog takes effect rapidly and has a shorter duration of activity ( 2 to 5 hours ) given subcutaneously as compared with regular insulin .', 'D-778\t-0.60986328125\tLiprolog takes effect rapidly and has a shorter duration of activity (2 to 5 hours) given subcutaneously as compared with regular insulin.', 'P-778\t-0.2302 -0.0327 -0.0553 -0.3220 -0.2600 -0.3228 -0.1036 -0.2881 -0.0986 -0.0268 -0.0225 -0.1057 -0.0268 -0.0535 -0.5493 -0.0676 -0.1465 -0.0634 -0.0268 -0.0282 -0.0338 -0.3228 -0.0760 -0.0085 -0.0056 -0.0254 -0.2986 -0.3071 -0.0930 -0.6226 -0.4395 -0.0113 -0.0113 -0.0338 -0.0310', 'S-43\tDer Prozess der Knochenbildung verläuft von der Außenseite des Implantats zur Mitte, bis das gesamte InductOs Implantat von trabekulärem Knochen ersetzt ist.', 'T-43\tThe bone formation process develops from the outside of the implant towards the center until the entire InductOs implant is replaced by trabecular bone.', 'H-43\t-1.5595703125\tBone formation continues from the outside of the implant to the centre until the entire implant is replaced with trabecular bone .', 'D-43\t-1.5595703125\tBone formation continues from the outside of the implant to the centre until the entire implant is replaced with trabecular bone.', 'P-43\t-1.6738 -0.0183 -0.3411 -2.2676 -0.2029 -0.1409 -0.5103 -0.0366 -0.0366 -0.0592 -0.0141 -0.0592 -0.0423 -0.6396 -0.5469 -0.3606 -0.2986 -1.4033 -0.4678 -1.2168 -0.0620 -0.9355 -0.0564 -0.0056 -0.0169 -0.0282 -0.0395 -0.0395', 'S-976\tWenn Sie während Ihrer der Schwangerschaft STOCRIN eingenommen haben, kann Ihr Arzt regelmäßige Blutuntersuchungen und andere diagnostische Tests anordnen, um die Entwicklung Ihres Kindes zu überwachen.', 'T-976\tIf you have taken STOCRIN during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child.', 'H-976\t-0.35302734375\tIf you have taken STOCRIN during your pregnancy , your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child .', 'D-976\t-0.35302734375\tIf you have taken STOCRIN during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child.', 'P-976\t-0.0364 -0.0299 -0.1014 -0.2081 -0.0602 -0.0257 -0.0243 -0.0465 -0.0923 -0.1127 -0.0282 -0.0472 -0.0359 -0.0359 -0.1120 -0.9502 -0.1226 -0.0240 -0.0690 -0.0338 -0.0380 -0.0127 -0.0296 -0.0352 -0.0578 -0.0493 -0.2156 -0.0451 -0.0282 -0.0268 -0.0803 -0.0310 -0.0310', 'S-1767\tEinige weitere Nebenwirkungen, die nicht in klinischen Studien gesehen wurden, wurden bei Männern, die CIALIS eingenommen hatten, berichtet, die Häufigkeit dieser Nebenwirkung ist nicht ermittelbar.', 'T-1767\tSome additional side effects have been reported in men taking CIALIS that were not seen in clinical trials and their incidence is unknown.', 'H-1767\t-0.78173828125\tSome additional side effects have been reported in men taking CIALIS that were not seen in clinical trials and their incidence is unknown .', 'D-1767\t-0.78173828125\tSome additional side effects have been reported in men taking CIALIS that were not seen in clinical trials and their incidence is unknown.', 'P-1767\t-0.1389 -0.3789 -0.3269 -0.0345 -0.5845 -0.1240 -0.0240 -0.1183 -0.0803 -0.4128 -0.0409 -0.0282 -0.0225 -0.0197 -0.2563 -0.5366 -0.0282 -0.1719 -0.0338 -0.0310 -0.1296 -0.7437 -0.3467 -0.6538 -0.0169 -0.2339 -0.3101 -0.0338 -0.0338', 'S-1955\tDie erste Impfung kann in einem Lebensalter von 6-12 Wochen verabreicht werden, die zweite Impfung hat mit einem Abstand von mindestens 6 Wochen in einem Lebensalter von 14-18 Wochen zu erfolgen.', 'T-1955\tThe second injection has to be administered at least 6 weeks later at an age of 14 - 18 weeks.', 'H-1955\t-1.720703125\tThe first dose may be administered at 10 @-@ 17 weeks of age and the second dose should be given at least 6 weeks later at an age of 14 @-@ 18 weeks .', 'D-1955\t-1.720703125\tThe first dose may be administered at 10-17 weeks of age and the second dose should be given at least 6 weeks later at an age of 14-18 weeks.', 'P-1955\t-0.2603 -0.5151 -0.8940 -0.2761 -0.0409 -1.3330 -0.0197 -0.6455 -0.9131 -1.0654 -1.0537 -0.0338 -0.3550 -0.0282 -0.5806 -0.0451 -0.0338 -0.6084 -1.3691 -0.0564 -0.4565 -0.8623 -0.3550 -0.5972 -0.0338 -1.0938 -0.3494 -0.3718 -0.0789 -0.0451 -0.2255 -0.0338 -0.0338 -0.0225 -0.0451 -0.0338', 'S-792\tErbB2-überexprimierende Tumore sind definiert durch IHC3 +, oder IHC2 + und Genamplifikation oder Genamplifikation allein.', 'T-792\tErbB2 overexpressing tumours are defined by IHC3 +, or IHC2 + and gene amplification or gene amplification alone.', 'H-792\t-0.9130859375\tOverexpressing ErbB2 tumours are defined by IHC3 + or IHC2 + and gene amplification or gene amplification alone .', 'D-792\t-0.9130859375\tOverexpressing ErbB2 tumours are defined by IHC3 + or IHC2 + and gene amplification or gene amplification alone.', 'P-792\t-2.9648 -0.1409 -0.0338 -0.3550 -0.0282 -0.0282 -0.1183 -0.2395 -0.0366 -0.3325 -1.0879 -0.0282 -0.0225 -0.0282 -0.0310 -0.0282 -0.5552 -0.0338 -0.0225 -0.0282 -0.0282 -0.0225 -0.3269 -0.2085 -0.0169 -0.0282 -0.1127 -0.0338 -0.0113 -0.0169 -0.0282 -0.1127 -0.5581 -0.0338 -0.0282', 'S-425\tMIRCERA 200 µg / 0,3 ml Injektionslösung Methoxy-Polyethylenglycol-Epoetin beta s.c. / i.v.', 'T-425\tMIRCERA 200 µg / 0.3 ml injection methoxy polyethylene glycol-epoetin beta SC / IV', 'H-425\t-0.25\tMIRCERA 200 µg / 0.3 ml injection methoxy polyethylene glycol @-@ epoetin beta SC / IV', 'D-425\t-0.25\tMIRCERA 200 µg / 0.3 ml injection methoxy polyethylene glycol-epoetin beta SC / IV', 'P-425\t-0.0393 -0.0127 -0.0285 -0.0170 -0.0284 -0.0227 -0.0113 -0.0227 -0.0285 -0.1111 -0.0356 -0.0169 -0.1831 -0.0271 -0.3223 -0.0070 -0.2100 -0.0134 -0.0211 -0.0155 -0.0134 -0.0268 -0.0141 -0.0218 -0.0162 -0.1310 -0.0275 -0.0232 -0.0127 -0.0296 -0.0113 -0.0296 -0.3228 -0.0648 -0.1353 -0.0930', 'S-649\tDie empfohlene Dosis beträgt 1,5 mg / m2 Körperoberfläche, gegeben als intravenöse Infusion über 24 Stunden mit einem dreiwöchigen Intervall zwischen den Therapiezyklen.', 'T-649\tThe recommended dose is 1.5 mg / m2 body surface area, administered as an intravenous infusion over 24 hours with a three-week interval between cycles.', 'H-649\t-1.0732421875\tThe recommended dose is 1.5 mg / m2 of body surface area administered as an', 'D-649\t-1.0732421875\tThe recommended dose is 1.5 mg / m2 of body surface area administered as an', 'P-649\t-0.3418 -0.0357 -0.0993 -0.0458 -0.0782 -0.0113 -0.0327 -0.0155 -0.4202 -0.0514 -0.1360 -0.2184 -0.4719 -0.0183 -1.2979 -0.0930 -2.5059', 'S-1127\t• Arzneimittel für Kinder unzugänglich aufbewahren. • Sie dürfen EXJADE nach dem auf der Blisterpackung und dem Umkarton angegebenen Verfallsdatum nicht mehr anwenden.', 'T-1127\t• Keep out of the reach and sight of children. • Do not use EXJADE after the expiry date which is stated on the blister and the carton.', 'H-1127\t-0.6943359375\t• Keep out of the reach and sight of children . • Do not use EXJADE after the expiry date which is stated on the blister and the carton .', 'D-1127\t-0.6943359375\t• Keep out of the reach and sight of children. • Do not use EXJADE after the expiry date which is stated on the blister and the carton.', 'P-1127\t-0.0590 -0.1326 -0.3188 -0.0327 -0.2360 -0.0169 -0.3228 -0.3228 -0.0282 -0.0564 -0.1085 -0.0535 -0.2324 -0.0324 -0.0592 -0.1719 -0.0211 -0.0183 -0.0197 -0.0887 -0.0690 -0.0676 -0.1282 -0.0324 -0.5947 -0.1550 -0.2734 -0.0423 -0.0535 -0.1071 -0.0141 -0.6367 -0.9043 -0.2817 -0.0310 -0.2959 -0.0395', 'S-1628\tViraferon Injektionslösung kann nach Entnahme der geeigneten Dosis aus der Durchstechflasche mittels einer sterilen Injektionsspritze direkt injiziert werden. eim', 'T-1628\tViraferon solution for injection, may be injected directly after withdrawal of the appropriate doses from the lon vial with a sterile injection syringe.', 'H-1628\t-0.80859375\tra Viraferon solution for injection , may be injected directly after withdrawal of the appropriate doses from the vial with a sterile injection syringe .', 'D-1628\t-0.80859375\tra Viraferon solution for injection, may be injected directly after withdrawal of the appropriate doses from the vial with a sterile injection syringe.', 'P-1628\t-0.4656 -0.3374 -0.0254 -0.0225 -0.0564 -0.4749 -0.3352 -0.0944 -0.0704 -0.3396 -0.3169 -0.0479 -0.1958 -0.0197 -0.1169 -0.4087 -0.3325 -0.0479 -0.1014 -0.1409 -0.7554 -0.5186 -0.2255 -0.0845 -0.0451 -0.0282 -0.3042 -0.0789 -0.1014 -0.0169 -0.2197 -0.0282 -0.0169 -0.0338 -0.0113 -0.5972 -0.0451', 'S-1842\tZur Anwendung bei kongestiver Herzinsuffizienz durch valvuläre Regurgitation bei Hunden in Kombination mit einer Standardtherapie (und gegebenenfalls mit einer diuretischen Zusatzbehandlung).', 'T-1842\tFor use in combination with standard therapy (including diuretic support, where necessary) for the treatment of congestive heart failure caused by valvular regurgitation in dogs.', 'H-1842\t-1.0\tFor use in congestive heart failure due to valvular regurgitation in dogs in combination with standard therapy ( and - where appropriate - additional diuretic treatment ) .', 'D-1842\t-1.0\tFor use in congestive heart failure due to valvular regurgitation in dogs in combination with standard therapy (and - where appropriate - additional diuretic treatment).', 'P-1842\t-0.3030 -0.1815 -0.0620 -0.1451 -0.0092 -0.0120 -0.0486 -0.0113 -0.7529 -0.0282 -0.5254 -0.0662 -0.0028 -0.0070 -0.0197 -0.0113 -0.0254 -0.0352 -0.0169 -0.3564 -0.3071 -0.0282 -0.0760 -0.3157 -0.3606 -0.1493 -1.2510 -0.3972 -0.5693 -0.0282 -1.5273 -0.0225 -0.0338 -0.0282 -1.0596 -0.0282 -0.0395 -0.0282', 'S-150\tPNH-Patienten sollten auf Anzeichen und Symptome einer intravaskulären Hämolyse einschließlich der Laktatdehydrogenase (LDH) -Spiegel im Serum überwacht werden.', 'T-150\tPNH patients should be monitored for signs and symptoms of intravascular haemolysis, including serum lactate dehydrogenase (LDH) levels.', 'H-150\t-0.650390625\tPNH patients should be monitored for signs and symptoms of intravascular haemolysis including lactate dehydrogenase ( LDH ) levels in serum .', 'D-150\t-0.650390625\tPNH patients should be monitored for signs and symptoms of intravascular haemolysis including lactate dehydrogenase (LDH) levels in serum.', 'P-150\t-1.6094 -0.0183 -0.0254 -0.0324 -0.0310 -0.0535 -0.0225 -0.0310 -0.0366 -0.0296 -0.0225 -0.0324 -0.2227 -0.0183 -0.0183 -0.0099 -0.2057 -0.0197 -0.0155 -0.0268 -0.0240 -0.9131 -0.6509 -0.1409 -0.0338 -0.0197 -0.0056 -0.0197 -0.0169 -0.4846 -0.0282 -0.0254 -0.0169 -0.0282 -0.4338 -0.4028 -0.1240 -0.0282 -0.0395 -0.0282', 'S-1658\tIn Studien mit Mehrfachanwendung stiegen die Konzentrationen und AUC für Norelgestromin und Ethinylestradiol gegenüber Woche 1 in Zyklus 1 nur leicht an.', 'T-1658\tIn multiple-dose studies, serum concentrations and AUC for norelgestromin and EE were found to increase only slightly over time when compared to week 1 cycle 1.', 'H-1658\t-1.3388671875\tIn repeat @-@ dose studies , the concentrations and AUC of norelgestromin and ethinyl estradiol increased only slightly compared to week 1 in Cycle 1 .', 'D-1658\t-1.3388671875\tIn repeat-dose studies, the concentrations and AUC of norelgestromin and ethinyl estradiol increased only slightly compared to week 1 in Cycle 1.', 'P-1658\t-0.2418 -1.3096 -0.7666 -0.3169 -0.2847 -0.1099 -0.4143 -1.1270 -0.0085 -0.0197 -0.0366 -0.0141 -0.0676 -0.9751 -0.4509 -0.0507 -0.0056 -0.0451 -0.2930 -0.0282 -0.3269 -0.0338 -0.0676 -0.0564 -0.0113 -0.0282 -0.6875 -0.6763 -0.0901 -1.0371 -0.5693 -0.7212 -0.0451 -0.1071 -0.9243 -0.0113 -0.0338 -0.0338 -0.0338', 'S-1161\tDie Clearance von Cinacalcet ist bei Rauchern höher als bei Nichtrauchern, möglicherweise aufgrund der Induktion eines CYP1A2-vermittelten Metabolismus.', 'T-1161\tClearance of cinacalcet is higher in smokers than in non-smokers, likely due to induction of CYP1A2- mediated metabolism.', 'H-1161\t-0.71435546875\tClearance of cinacalcet is higher in smokers than non @-@ smokers , possibly due to induction of CYP1A2 @-@ mediated metabolism .', 'D-1161\t-0.71435546875\tClearance of cinacalcet is higher in smokers than non-smokers, possibly due to induction of CYP1A2-mediated metabolism.', 'P-1161\t-0.4351 -0.0042 -0.0278 -0.3101 -0.3105 -0.0261 -0.0254 -0.0296 -0.0183 -0.0881 -0.5254 -0.0690 -0.0606 -0.0197 -0.2296 -0.8296 -0.0366 -0.0169 -0.0141 -0.0535 -0.9326 -0.0789 -0.0282 -0.2057 -0.0197 -0.0310 -0.3015 -0.0254 -0.0282 -0.0254 -0.0282 -0.0254 -1.4902 -0.0338 -0.0282 -0.0282 -0.0056 -0.0225 -0.0338 -0.0282', 'S-1080\tOrgantransplantatempfänger Da es bei Organtransplantatempfängern keine Erfahrungen gibt, wird die Anwendung von Febuxostat in dieser Patientengruppe nicht empfohlen (siehe Abschnitt 5.1).', 'T-1080\tOrgan transplant recipients As there has been no experience in organ transplant recipients, the use of febuxostat in such patients is not recommended (see section 5.1).', 'H-1080\t-1.072265625\tAs there is no experience in organ transplant recipients , the use of febuxostat is not recommended in this group of patients ( see section 5.1 ) .', 'D-1080\t-1.072265625\tAs there is no experience in organ transplant recipients, the use of febuxostat is not recommended in this group of patients (see section 5.1).', 'P-1080\t-1.4375 -0.3232 -0.7749 -0.0352 -0.0986 -1.0020 -0.0366 -0.2507 -0.0732 -0.8564 -0.0338 -0.0620 -0.1409 -0.0620 -0.0282 -0.2649 -0.2169 -0.0225 -0.0169 -0.0085 -0.0310 -1.0762 -0.0282 -0.0395 -0.2537 -0.0395 -1.3408 -0.3550 -0.0338 -0.0395 -0.0395 -0.1917 -0.0225 -0.0282 -0.0338 -0.0282 -0.0282', 'S-1460\tZinkchlorid, m-Cresol, Glycerol, Salzsäure, Polysorbat 20, Natriumhydroxid, Wasser für Injektionszwecke.', 'T-1460\tZinc chloride, m-cresol, glycerol, hydrochloric acid, Polysorbate 20, sodium hydroxide, water for injections', 'H-1460\t-0.383544921875\tZinc chloride , m @-@ cresol , glycerol , hydrochloric acid , polysorbate 20 , sodium hydroxide , water for injections .', 'D-1460\t-0.383544921875\tZinc chloride, m-cresol, glycerol, hydrochloric acid, polysorbate 20, sodium hydroxide, water for injections.', 'P-1460\t-1.0684 -0.0225 -0.3733 -0.0169 -0.0268 -0.0211 -0.0324 -0.0479 -0.0296 -0.0324 -0.0155 -0.0183 -0.0310 -0.0268 -0.0099 -0.4509 -0.0155 -0.0296 -0.0310 -0.0197 -0.0099 -0.0056 -0.0211 -0.0169 -0.2578 -0.0240 -0.0169 -0.0225 -0.0225 -0.0268 -0.0296 -0.0310 -0.0099 -0.0141 -0.0127 -0.0225 -0.0338 -0.0958 -0.0507 -0.0338 -0.3127 -0.2451 -0.0282', 'S-1439\tAußerdem wurde die Beziehung zwischen der Pharmakokinetik und der Pharmakodynamik von oral verabreichtem Norfloxacin bei der Behandlung der komplizierten Pyelonephritis festgestellt.', 'T-1439\tAdditionally, the relationship between the Pharmacokinetic and the Pharmacodynamic of orally administered norfloxacin in the treatment of complicated pyelonephritis was been established.', 'H-1439\t-1.0478515625\tThe relationship between pharmacokinetics and the pharmacodynamics of orally administered norfloxacin in the treatment of complicated pyelonephritis has been demonstrated .', 'D-1439\t-1.0478515625\tThe relationship between pharmacokinetics and the pharmacodynamics of orally administered norfloxacin in the treatment of complicated pyelonephritis has been demonstrated.', 'P-1439\t-1.8896 -0.2227 -0.5820 -0.5552 -0.4705 -0.0141 -0.0225 -0.0310 -0.7271 -0.0564 -0.0366 -0.0366 -0.0113 -0.0225 -0.0310 -0.9775 -0.0113 -0.0366 -0.0197 -0.0732 -0.0113 -0.0225 -0.0225 -0.0282 -0.5859 -0.0845 -0.0507 -0.0282 -0.1917 -0.0282 -0.0225 -0.0225 -0.0113 -0.0338 -0.0169 -0.5581 -0.9976 -0.9468 -0.0676 -0.0282', 'S-266\tHandhabung und Entsorgung Bei der Zubereitung, Anwendung und Entsorgung von VISTIDE müssen angemessene Vorsichtsmaßnahmen getroffen und geeignete Sicherheitsausrüstungen eingesetzt werden.', 'T-266\tHandling and disposal Adequate precautions including the use of appropriate safety equipment are recommended for the preparation, administration and disposal of VISTIDE.', 'H-266\t-1.0146484375\tHandling and disposal The preparation , use and disposal of VISTIDE requires appropriate precautions and the use of appropriate safety equipment .', 'D-266\t-1.0146484375\tHandling and disposal The preparation, use and disposal of VISTIDE requires appropriate precautions and the use of appropriate safety equipment.', 'P-266\t-0.2195 -0.0262 -0.0327 -0.4092 -0.0271 -1.1553 -0.0916 -0.0310 -0.7593 -0.0395 -0.0211 -0.0268 -0.0282 -0.0380 -0.0169 -0.0197 -0.0225 -1.7861 -1.5723 -0.0507 -0.0056 -0.0676 -0.0732 -0.6255 -0.1973 -0.0282 -0.3945 -0.0789 -0.0620 -0.0338 -0.0282', 'S-397\tJuli 1998 erteilte die Europäische Kommission dem Unternehmen Sanofi Pharma Bristol- Myers Squibb SNC eine Genehmigung für das Inverkehrbringen von Iscover in der gesamten Europäischen Union.', 'T-397\tThe Marketing Authorisation was renewed on 15 July 2003.', 'H-397\t-0.93603515625\tThe European Commission granted a marketing authorisation valid throughout the European Union for Iscover to Sanofi Pharma Bristol @-@ Myers Squibb SNC on 16 July 1998 .', 'D-397\t-0.93603515625\tThe European Commission granted a marketing authorisation valid throughout the European Union for Iscover to Sanofi Pharma Bristol-Myers Squibb SNC on 16 July 1998.', 'P-397\t-0.3049 -0.0458 -0.0227 -0.2866 -0.2944 -0.1155 -0.0465 -0.0183 -0.3220 -0.0380 -0.2240 -0.0324 -0.6763 -0.0296 -0.5835 -2.7031 -0.0141 -0.1663 -0.0225 -0.0225 -0.0056 -0.0225 -0.0113 -0.0056 -0.0845 -0.0225 -0.0113 -0.0282 -0.0113 -0.0225 -0.0225 -0.0225 -0.0225 -0.2817 -1.7080 -0.0901 -0.0282 -0.0338 -0.0282', 'S-672\t(45) 44 88 93 34 Fax (45) 44 88 91 09 E-post: jyl @ dkma.dk Internet: http: / / www.dkma.dk', 'T-672\tRequests may be made either in writing to the EMEA or sent to the following e-mail addresses:', 'H-672\t-0.3134765625\t( 45 ) 44 88 93 34 Fax ( 45 ) 44 88 91 09 E @-@ post : jyl @ dkma.dk Internet : http : / / www.dkma.dk', 'D-672\t-0.3134765625\t(45) 44 88 93 34 Fax (45) 44 88 91 09 E-post: jyl @ dkma.dk Internet: http: / / www.dkma.dk', 'P-672\t-0.1967 -0.0269 -0.0299 -0.0206 -0.0157 -0.0171 -0.2334 -0.0250 -0.0313 -0.0243 -0.0285 -0.0148 -0.0113 -0.0092 -0.0197 -0.0958 -0.0282 -0.3042 -0.0338 -0.0373 -0.0099 -0.0218 -0.0240 -0.0268 -0.0225 -0.0240 -0.2001 -0.0254 -0.7524 -0.0380 -0.0141 -0.0282 -0.0282 -0.0296 -0.1564 -0.0240 -0.0254 -0.0197 -0.0254 -0.1973 -0.0254 -0.0310', 'S-1209\tDie individuelle Schwankungsbreite ist mit einem Variationskoeffizienten (coefficient of variation (CV%)) von etwa 50% bei CL und 60% bei Vss hoch.', 'T-1209\tInter-subject variability is high with a CV% of about 50% for CL and 60% for Vss', 'H-1209\t-1.263671875\tThe individual variation between the two doses is high with a coefficient of variation ( CV % ) of about 50 % in CL and 60 % in Vss .', 'D-1209\t-1.263671875\tThe individual variation between the two doses is high with a coefficient of variation (CV%) of about 50% in CL and 60% in Vss.', 'P-1209\t-0.2451 -1.1621 -0.2374 -0.7593 -0.9834 -0.3889 -0.5410 -0.4255 -0.4536 -0.0704 -0.5947 -1.0820 -0.2705 -1.3301 -0.0113 -0.0282 -0.0113 -0.0225 -0.0395 -0.0282 -0.0225 -0.0282 -0.0282 -0.0395 -0.7720 -0.0282 -0.0282 -0.2537 -0.2874 -0.3269 -0.2085 -0.0338 -0.0282 -0.0451 -0.0395 -0.2874 -0.0395 -0.0282', 'S-1589\tWenn Sie die Anwendung von Fuzeon vergessen haben Wenden Sie die vergessene Dosis an, sobald Sie sich daran erinnern; danach sollen Sie die nächste Dosis zur regulären Zeit anwenden.', 'T-1589\tIf you forget to take Fuzeon Take the dose as soon as you remember and then take your next dose at its regular time.', 'H-1589\t-1.22265625\tIf you forget to use Fuzeon Take the missed dose as soon as you remember and then go back to your regular schedule .', 'D-1589\t-1.22265625\tIf you forget to use Fuzeon Take the missed dose as soon as you remember and then go back to your regular schedule.', 'P-1589\t-0.1498 -0.0256 -0.1036 -0.0255 -0.1576 -3.0684 -0.0085 -0.0366 -0.2986 -0.2339 -0.1803 -0.0310 -0.0732 -0.0197 -0.0254 -0.0254 -0.0141 -1.1582 -0.4453 -0.9639 -0.3101 -0.0620 -0.1521 -0.1578 -0.7778 -0.0676 -0.2649', 'S-1821\tUnabhängig von der Ursache kommt es aufgrund von Änderungen in Muskeln und Blutgefäßen dazu, dass nicht genügend Blut im Penis ist, um einen ausreichend harten Penis zu bekommen oder beizubehalten.', 'T-1821\tWhatever the cause is, due to muscle and blood vessel changes not enough blood stays in the penis to make it hard and keep it hard.', 'H-1821\t-2.146484375\tRegardless of cause , these changes in muscles and blood vessels may mean that there is not enough blood in the penis to achieve or maintain a hard penis .', 'D-1821\t-2.146484375\tRegardless of cause, these changes in muscles and blood vessels may mean that there is not enough blood in the penis to achieve or maintain a hard penis.', 'P-1821\t-3.1172 -0.0141 -0.0141 -0.0282 -0.4592 -0.4678 -2.0762 -0.8057 -1.1670 -1.3018 -0.0395 -0.3213 -0.0169 -0.0169 -0.9243 -1.7637 -0.4734 -0.2255 -0.0564 -0.2141 -0.0338 -0.0225 -0.0789 -0.3606 -0.0225 -0.0225 -0.4058 -1.6797 -0.2255 -0.0676 -0.9580 -0.3494 -0.2479 -0.0338 -0.3945 -0.0338', 'S-989\tMyocet / CPA Dox 60 / CPA Myocet / CPA Epi / CPA (60 / 600 (60 / 600 (75 / 600 (75 / 600', 'T-989\tMyocet / CPA Dox 60 / CPA Myocet / CPA (60 / 600 (60 / 600 (75 / 600', 'H-989\t-0.349853515625\tMyocet / CPA Dox 60 / CPA Myocet / CPA Epi / CPA ( 60 / 600 ( 60 / 600 ( 75 / 600 ( 75 / 600 )', 'D-989\t-0.349853515625\tMyocet / CPA Dox 60 / CPA Myocet / CPA Epi / CPA (60 / 600 (60 / 600 (75 / 600 (75 / 600)', 'P-989\t-0.2219 -0.0171 -0.0255 -0.0199 -0.0255 -0.0278 -0.0113 -0.0370 -0.0285 -0.0271 -0.0278 -0.0285 -0.0099 -0.0292 -0.0134 -0.0243 -0.0204 -0.0285 -0.0257 -0.0127 -0.0134 -0.0285 -0.0278 -0.0240 -0.0113 -0.0268 -0.0247 -0.0296 -0.0155 -0.0275 -0.0486 -0.0289 -0.0162 -0.0282 -0.0204 -0.0296 -0.0155 -0.0296 -0.0197 -0.0296 -0.0155 -2.1191 -0.0507', 'S-445\tWenn Sie eine Insulinmischung spritzen müssen, ziehen Sie zuerst das andere Insulin in die Injektionsspritze auf und dann erst Insulin Human Winthrop Comb 50.', 'T-445\tIf you need to inject a mixture, draw the other insulin into the injection syringe before Insulin Human Winthrop Comb 50.', 'H-445\t-0.408203125\tIf you need to inject a mixture , draw the other insulin into the injection syringe before Insulin Human Winthrop Comb 50 .', 'D-445\t-0.408203125\tIf you need to inject a mixture, draw the other insulin into the injection syringe before Insulin Human Winthrop Comb 50.', 'P-445\t-0.1506 -0.0379 -0.1289 -0.0539 -0.1068 -0.0120 -0.2856 -0.0690 -0.0211 -0.3049 -0.3169 -0.1028 -0.0634 -0.0395 -0.0127 -0.1691 -0.0493 -0.1226 -0.0240 -0.2156 -0.0169 -0.0056 -0.3101 -0.4692 -0.0395 -0.0113 -0.0564 -0.0113 -0.0028 -0.0225 -0.0395 -0.0225 -0.0366 -0.0817 -0.0338', 'S-1619\tIst dies nicht der Fall, drehen Sie die Verschlusskappe, bis der Druckknopf vollständig hineingedrückt ist. • Halten Sie Ihren NovoRapid NovoLet waagerecht.', 'T-1619\tIf it isn <<unk>> t, turn the cap until the push-button is fully depressed • Hold your NovoRapid NovoLet horizontally.', 'H-1619\t-0.56689453125\tIf not , turn the cap until the push @-@ button is fully depressed • Hold your NovoRapid NovoLet horizontally .', 'D-1619\t-0.56689453125\tIf not, turn the cap until the push-button is fully depressed • Hold your NovoRapid NovoLet horizontally.', 'P-1619\t-0.1259 -1.1797 -0.0345 -0.0796 -0.0352 -0.1536 -0.1127 -0.0535 -0.1493 -0.2141 -0.0296 -0.0831 -0.1747 -0.3213 -0.0310 -0.3213 -0.2791 -0.0479 -0.1127 -0.0197 -0.0169 -0.0113 -0.0338 -0.4932 -0.0676 -0.1155 -0.0141 -0.0169 -0.0760 -0.0197 -0.0592 -0.0507', 'S-99\tBei Patienten, die auf eine vorangegangene Therapie nicht angesprochen oder einen Rückfall erlitten haben, sollte die Behandlung über ein Jahr durchgeführt werden (abhängig vom Ansprechen nach den ersten 12 Wochen der Behandlung).', 'T-99\t270 In patients who have not responded previously or relapsed, the treatment should continue for one year (contingent upon the response after the first 12 weeks of therapy).', 'H-99\t-1.6416015625\tIn patients who failed to respond to previous therapy or who had relapsed , treatment should be continued for one year ( depending on the response after the first 12 weeks of treatment ) .', 'D-99\t-1.6416015625\tIn patients who failed to respond to previous therapy or who had relapsed, treatment should be continued for one year (depending on the response after the first 12 weeks of treatment).', 'P-99\t-0.8799 -0.0676 -0.3452 -0.3164 -1.7217 -0.0254 -0.0535 -1.1641 -0.2367 -0.0648 -1.4932 -0.4170 -0.2085 -0.0056 -0.1071 -0.0564 -0.2197 -0.0451 -0.5859 -1.2627 -0.9131 -0.2197 -0.0282 -0.4734 -1.1836 -0.0338 -1.1836 -0.3606 -0.3718 -0.0451 -0.0338 -0.0225 -0.0225 -0.2593 -0.0338 -0.0338 -0.0338 -0.0338', 'S-1130\tVerteilung Robenacoxib hat ein relativ niedriges Verteilungsvolumen (Vss 240 ml / kg) und ist stark gebunden an Plasmaproteine (> 99%).', 'T-1130\tDistribution Robenacoxib has a relatively small volume of distribution (Vss 240 ml / kg) and is highly bound to plasma proteins (> 99%).', 'H-1130\t-0.38427734375\tDistribution Robenacoxib has a relatively small volume of distribution ( Vss 240 ml / kg ) and is highly bound to plasma proteins ( &gt; 99 % ) .', 'D-1130\t-0.38427734375\tDistribution Robenacoxib has a relatively small volume of distribution (Vss 240 ml / kg) and is highly bound to plasma proteins (> 99%).', 'P-1130\t-0.2805 -0.0171 -0.0206 -0.0248 -0.0243 -0.0056 -0.0204 -0.0486 -0.0402 -0.0553 -0.5474 -0.3472 -0.1444 -0.0916 -0.0338 -0.0986 -0.0324 -0.0296 -0.0197 -0.0296 -0.0169 -0.0296 -0.0380 -0.0521 -0.3748 -0.4902 -0.0366 -0.0423 -0.0113 -0.0197 -0.2563 -0.0085 -0.0282 -0.0197 -0.0141 -0.0254 -0.0282 -0.0310 -0.0282', 'S-1506\tWenn Irbesartan Winthrop Patienten mit eingeschränkter Nierenfunktion verabreicht wird, wird eine regelmäßige Kontrolle des Serumkalium- und -kreatininspiegels empfohlen.', 'T-1506\tRenal impairment and kidney transplantation: when Irbesartan Winthrop is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended.', 'H-1506\t-0.7001953125\tWhen Irbesartan Winthrop is used in patients with impaired renal function , periodic monitoring of potassium and creatinine serum levels is recommended .', 'D-1506\t-0.7001953125\tWhen Irbesartan Winthrop is used in patients with impaired renal function, periodic monitoring of potassium and creatinine serum levels is recommended.', 'P-1506\t-1.1689 -0.2466 -0.0049 -0.0092 -0.0225 -0.0606 -0.0042 -0.0211 -0.0310 -0.3198 -0.2438 -0.0366 -0.0352 -0.6777 -0.0056 -0.2479 -0.0254 -0.0254 -0.0648 -1.4033 -0.0310 -0.1888 -0.0366 -0.3213 -0.0056 -0.0254 -0.0507 -0.0648 -0.0169 -0.3127 -0.0564 -0.2311 -0.0338 -0.0507 -0.0338 -0.0395 -0.0282 -0.0282', 'S-254\tZu Beginn der Behandlung verursacht IntronA gewöhnlich grippeähnliche Krankheitszeichen mit Fieber, Ermüdung, Kopfschmerzen, Muskelschmerzen, Gelenkschmerzen und Schüttelfrost.', 'T-254\t<<unk>> 348 At the beginning of treatment with IntronA, you may experience a flu-like reaction, with fever, fatigue, headache, muscle ache, joint pain and chills / rigors.', 'H-254\t-0.919921875\tAt the beginning of treatment with IntronA , you may experience a flu @-@ like reaction , with fever , fatigue , headache , muscle ache , joint pain and chills / rigors .', 'D-254\t-0.919921875\tAt the beginning of treatment with IntronA, you may experience a flu-like reaction, with fever, fatigue, headache, muscle ache, joint pain and chills / rigors.', 'P-254\t-1.8467 -0.0775 -0.4016 -0.0338 -0.1296 -0.4749 -0.0676 -0.0113 -0.0254 -0.1071 -0.3157 -0.3071 -0.1127 -0.3606 -0.0845 -0.0901 -0.0310 -0.3213 -0.3325 -0.2113 -0.0535 -0.0197 -0.0282 -0.1917 -0.0141 -0.0113 -0.0282 -0.0141 -0.0113 -0.1635 -0.0282 -0.1465 -0.7944 -0.0338 -0.1691 -0.0507 -0.4678 -0.2593 -0.0056 -0.4565 -0.3213 -0.2141 -0.0564 -0.0282', 'S-555\tZu Patienten mit schwerem unbehandeltem Asthma, anaphylaktischen Reaktionen oder schwerer Urtikaria oder Angioödem in der Vorgeschichte liegen keine Daten vor.', 'T-555\tHypersensitivity Degarelix has not been studied in patients with a history of severe untreated asthma, anaphylactic reactions or severe urticaria or angioedema.', 'H-555\t-1.626953125\tThere are no data in patients with severe uncorrected asthma , anaphylactic reactions , or severe urticaria or angioedema with a history of peripheral neuropathy .', 'D-555\t-1.626953125\tThere are no data in patients with severe uncorrected asthma, anaphylactic reactions, or severe urticaria or angioedema with a history of peripheral neuropathy.', 'P-555\t-0.9849 -0.1881 -0.0345 -0.1205 -1.6035 -0.2311 -0.0423 -0.4592 -0.2734 -1.5410 -0.0254 -0.0197 -0.0197 -0.0197 -0.3213 -0.0395 -0.0225 -0.0113 -0.0225 -0.2311 -0.9580 -0.0225 -0.9692 -0.3381 -0.3438 -1.1777 -0.0113 -0.0113 -0.0395 -0.0282 -0.4958 -0.0056 -0.0056 -0.0056 -1.2451 -0.1578 -0.5859 -0.0338 -1.7578 -0.0564 -0.0225 -1.0029 -0.6201 -0.0113 -0.0338 -0.0338', 'S-1664\tInsbesondere bei großen chirurgischen Eingriffen ist eine genaue Überwachung der Substitutionstherapie mit Hilfe einer Koagulationsanalyse (Faktor VIII-Aktivität im Plasma) unbedingt erforderlich.', 'T-1664\tIn the case of major surgical interventions in particular, precise monitoring of the substitution therapy by means of coagulation analysis (plasma factor VIII activity) is indispensable.', 'H-1664\t-0.81787109375\tIn the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of coagulation analysis ( plasma factor VIII activity ) is essential .', 'D-1664\t-0.81787109375\tIn the case of major surgical interventions in particular, precise monitoring of the substitution therapy by means of coagulation analysis (plasma factor VIII activity) is essential.', 'P-1664\t-0.9805 -0.3113 -0.0796 -0.0303 -0.1099 -0.4775 -0.2043 -0.0197 -0.3240 -0.0197 -0.2720 -0.0225 -0.1071 -0.2874 -0.0732 -0.1212 -0.8481 -0.1099 -0.0338 -0.0366 -0.3523 -0.0901 -0.0282 -0.7578 -0.0169 -0.0197 -0.0366 -0.0338 -0.3889 -0.0113 -0.0282 -0.0789 -0.0338 -0.0169 -0.0958 -0.0282 -0.1859 -0.7495 -0.0282 -0.0282', 'S-1005\t<unk> Kinder Gadograf wird nicht für die Anwendung bei Patienten unter 18 Jahren empfohlen, da nicht genügend Daten über die Sicherheit und Wirksamkeit vorliegen. <unk> Das Gutachten des CHMP wurde am 13.', 'T-1005\tSection 4.2 (Posology): <<unk>> Paediatric patients Gadograf is not recommended for use in population below age 18 due to a lack of data on efficacy and safety.', 'H-1005\t-2.087890625\tChildren / adolescents Due to a lack of information on safety and effectiveness , the CHMP Opinion was adopted on 30 June 2005 .', 'D-1005\t-2.087890625\tChildren / adolescents Due to a lack of information on safety and effectiveness, the CHMP Opinion was adopted on 30 June 2005.', 'P-1005\t-1.5879 -0.8945 -0.2776 -0.0127 -0.0183 -1.4219 -1.5752 -0.0282 -0.6934 -0.0225 -0.0282 -0.7495 -0.1973 -0.3550 -0.0395 -0.7554 -0.0169 -0.1803 -1.1895 -0.4338 -0.0169 -0.3213 -0.0225 -0.0282 -0.1071 -0.3662 -0.0958 -2.4180 -1.1162 -1.5215 -0.1803 -0.0338', 'S-1689\tEU / 1 / 99 / 125 / 001 EU / 1 / 99 / 125 / 005 EU / 1 / 99 / 125 / 009 EU / 1 / 99 / 125 / 013', 'T-1689\tEU / 1 / 99 / 125 / 001 EU / 1 / 99 / 125 / 005 EU / 1 / 99 / 125 / 009 EU / 1 / 99 / 125 / 013', 'H-1689\t-0.11273193359375\tEU / 1 / 99 / 125 / 001 EU / 1 / 99 / 125 / 005 EU / 1 / 99 / 125 / 009 EU / 1 / 99 / 125 / 013', 'D-1689\t-0.11273193359375\tEU / 1 / 99 / 125 / 001 EU / 1 / 99 / 125 / 005 EU / 1 / 99 / 125 / 009 EU / 1 / 99 / 125 / 013', 'P-1689\t-0.0328 -0.0313 -0.0270 -0.0298 -0.0142 -0.0284 -0.0099 -0.0299 -0.0269 -0.0313 -0.0255 -0.0313 -0.0276 -0.0299 -0.0113 -0.0285 -0.0085 -0.0299 -0.0225 -0.0306 -0.0257 -0.0313 -0.0278 -0.0299 -0.0127 -0.0285 -0.0092 -0.0292 -0.0250 -0.0254 -0.0282 -0.0303 -0.0275 -0.0303 -0.0127 -0.0289 -0.0092 -0.0296 -0.0444 -0.0240 -0.0289', 'S-1191\tDer Cmax -Wert von Sulfamethoxazol bei Hühnern beträgt ungefähr 9,0 µg / ml, und der von Trimethoprim 0,12 µg / ml.', 'T-1191\tThe Cmax of sulfamethoxazole in chickens is approximately 9.0 µg / g, whereas that of trimethoprim is 0.12 µg / g.', 'H-1191\t-0.62939453125\tThe Cmax of sulfamethoxazole in chickens is approximately 9.0 µg / ml and for trimethoprim is 0.12 µg / ml .', 'D-1191\t-0.62939453125\tThe Cmax of sulfamethoxazole in chickens is approximately 9.0 µg / ml and for trimethoprim is 0.12 µg / ml.', 'P-1191\t-0.1592 -0.0812 -0.0157 -0.2188 -0.1342 -0.0451 -0.0402 -0.0070 -0.0243 -0.0141 -0.0211 -0.2739 -0.9180 -0.0070 -0.0225 -0.0507 -0.5425 -0.0521 -0.0296 -0.0507 -0.0211 -0.0282 -0.0240 -0.5044 -1.4453 -0.0451 -0.0113 -0.0225 -0.0225 -0.0254 -0.5747 -0.0676 -0.0310 -0.0113 -0.0225 -0.0310 -0.0141 -0.0310 -0.0282', 'S-1123\t281 127 (45,2%) 170 (60,5%) 193 (68,7%) 149 (53,0%) 189 (67,3%)', 'T-1123\t281 127 (45.2%) 170 (60.5%) 193 (68.7%) 149 (53.0%) 189 (67.3%)', 'H-1123\t-0.34228515625\t281 127 ( 45.2 % ) 170 ( 60.5 % ) 193 ( 68.7 % ) 149 ( 53.0 % ) 189 ( 67.3 % )', 'D-1123\t-0.34228515625\t281 127 (45.2%) 170 (60.5%) 193 (68.7%) 149 (53.0%) 189 (67.3%)', 'P-1123\t-0.3188 -0.1356 -0.0264 -0.0236 -0.0271 -0.0243 -0.0662 -0.0292 -0.0271 -0.0285 -0.4773 -0.0254 -0.3008 -0.0183 -0.0254 -0.0282 -0.0183 -0.0254 -0.0254 -0.3396 -0.0155 -0.0240 -0.0254 -0.0282 -0.0211 -0.0254 -0.0254 -0.0211 -0.0197 -0.0282 -0.0254 -0.0282 -0.0169 -0.0254 -0.0254 -0.4099 -0.0197 -0.0268 -0.0268 -0.0282 -0.3184', 'S-1078\t59 France Laboratoires Merck Sharp & Dohme <unk> Chibret Tél: + 33 (0) 1 47 54 87 00 contact @ msd-france.com', 'T-1078\tFrance Laboratoires Merck Sharp & Dohme <<unk>> Chibret Tél: + 33 (0) 1 47 54 87 00 contact @ msd-france. com', 'H-1078\t-1.4248046875\t59 France Laboratoires Merck Sharp &amp; Dohme Luxembourg Sverige : + 33 ( 0 ) 1 47 54 87 00 contact @ msd @-@ france.com', 'D-1078\t-1.4248046875\t59 France Laboratoires Merck Sharp & Dohme Luxembourg Sverige: + 33 (0) 1 47 54 87 00 contact @ msd-france.com', 'P-1078\t-2.4570 -0.0240 -0.0155 -0.0197 -0.0197 -0.0282 -0.0141 -0.0169 -0.0225 -0.0211 -0.0225 -0.0254 -0.0254 -0.0338 -3.0156 -0.0113 -1.1836 -2.4570 -0.2874 -1.9102 -0.0451 -0.0225 -0.0451 -0.0225 -0.0338 -0.0338 -0.0225 -0.0225 -0.0113 -0.0225 -0.1803 -0.0225 -0.0113 -0.0225 -0.0225 -0.0113 -0.0113 -0.6313 -0.0338', 'S-1462\tFerner beteiligt sich diese Arbeitsgruppe an der Weiterentwicklung und Einführung des Krisenmanagements, d.h. der Beurteilung von Meldungen unerwünschter Arzneimittelwirkungen (UAW) (EudraWatch).', 'T-1462\tIt will also be involved in the further development and introduction of the Crisis Management, evaluation of adverse drug reaction (ADR) reports (EudraWatch).', 'H-1462\t-1.7255859375\tIt is also involved in the development and implementation of crisis management , i. e. the evaluation of adverse drug reaction case reports ( ADRs ) ( EudraWatch ) .', 'D-1462\t-1.7255859375\tIt is also involved in the development and implementation of crisis management, i. e. the evaluation of adverse drug reaction case reports (ADRs) (EudraWatch).', 'P-1462\t-1.8545 -1.0273 -0.1226 -0.1353 -0.0338 -0.4143 -0.9272 -0.0366 -0.2197 -0.0282 -1.7500 -0.2141 -2.0449 -0.5972 -0.3157 -0.3777 -0.0282 -0.7944 -1.0938 -0.0225 -0.0113 -0.0338 -0.8228 -0.0113 -0.2255 -0.6538 -0.9805 -0.0901 -0.0338 -0.3157 -0.3157 -0.0225 -0.0338 -0.0338 -0.0225 -0.0225 -0.0113 -0.0338 -0.0338 -0.0338', 'S-332\tWenn Sie allerdings gleichzeitig Arzneimittel einnehmen, die Ciclosporin oder Tacrolimus enthalten, müssen Sie dies gegenüber Ihrem Arzt erwähnen, da die Dosierung dieser Arzneimittel wieder angepasst werden muss.', 'T-332\tHowever if you were taking medicines containing ciclosporin or tacrolimus you must mention this to your doctor, as the dose will need to be adjusted.', 'H-332\t-1.47265625\tHowever , if you take concomitant medicines containing ciclosporin or tacrolimus , you should tell your doctor , as the dose of these medicines must be adjusted .', 'D-332\t-1.47265625\tHowever, if you take concomitant medicines containing ciclosporin or tacrolimus, you should tell your doctor, as the dose of these medicines must be adjusted.', 'P-332\t-0.5918 -0.0444 -0.0493 -0.0472 -1.3213 -1.3018 -0.2395 -0.0056 -0.5635 -0.0592 -0.1014 -0.1381 -0.6030 -0.0113 -0.0113 -0.0141 -0.2874 -0.0338 -0.0282 -0.0254 -0.0254 -0.0085 -0.1155 -1.1924 -0.5581 -0.9131 -0.0282 -0.0395 -1.6113 -0.6592 -1.1045 -0.5298 -0.0564 -0.2141 -0.2029 -0.0676 -0.2029 -0.0451 -0.3833 -0.1917 -0.0338', 'S-1306\t108 Bei Patienten mit chronischer Nierenerkrankung kann eine Erhöhung des Blutdrucks erfolgen bzw. die Verstärkung einer bereits bestehenden Hypertension auftreten, insbesondere in Fällen eines schnellen Hämatokrit-Anstiegs.', 'T-1306\tIn chronic renal failure patients an increase in blood pressure or aggravation of existing hypertension, especially in cases of rapid PCV increase can occur.', 'H-1306\t-1.5537109375\t108 In patients with chronic kidney disease , an increase in blood pressure may occur or aggravation of existing hypertension , especially in cases of rapid PCV increase .', 'D-1306\t-1.5537109375\t108 In patients with chronic kidney disease, an increase in blood pressure may occur or aggravation of existing hypertension, especially in cases of rapid PCV increase.', 'P-1306\t-2.3945 -0.2620 -0.7876 -0.0423 -0.1917 -0.0507 -0.0141 -0.0197 -0.4678 -2.8594 -0.1183 -0.1127 -0.0282 -0.0225 -1.3643 -0.2761 -0.3325 -0.4453 -0.1917 -0.0113 -0.0338 -0.4058 -0.0395 -0.0169 -0.8115 -0.1465 -0.1521 -0.0451 -0.0564 -0.1127 -0.3269 -0.3269 -0.3042 -0.3157 -0.0338', 'S-945\tBei gleichzeitiger Verabreichung des Arzneimittels mit einer standardisierten Mahlzeit wurde kein signifikanter klinischer Effekt auf das Plasmakonzentrationsprofil von Losartan beobachtet.', 'T-945\tThere was no clinically significant effect on the plasma concentration profile of losartan when the drug was administered with a standardized meal.', 'H-945\t-1.2978515625\tNo significant clinical effect on losartan plasma concentration profile was observed when administered with a standard meal .', 'D-945\t-1.2978515625\tNo significant clinical effect on losartan plasma concentration profile was observed when administered with a standard meal.', 'P-945\t-0.9902 -0.0402 -0.0225 -0.3867 -0.8296 -0.5127 -0.0099 -0.0268 -0.3254 -0.0141 -0.0113 -0.3691 -0.4648 -0.0479 -0.3467 -0.6426 -1.0117 -0.0338 -0.5015 -0.9526 -0.4902 -0.0451 -0.5635 -0.0958', 'S-606\tZu Begi nn der Behandlung verursacht Viraferon gewöhnlich grippeähnliche Krankheitszeichen mit Fieber, Ermüdung, Kopfschmerzen, Muskelschmerzen, Gelenkschmerzen und Schüttelfrost.', 'T-606\ted headache, muscle ache, joint pain and chills / rigors.', 'H-606\t-1.1884765625\tAt the beginning of treatment , Viraferon usually causes flu @-@ like symptoms such as fever , fatigue , headache , muscle ache , joint pain and chills .', 'D-606\t-1.1884765625\tAt the beginning of treatment, Viraferon usually causes flu-like symptoms such as fever, fatigue, headache, muscle ache, joint pain and chills.', 'P-606\t-2.5820 -0.0549 -0.5298 -0.0282 -0.1973 -0.2029 -0.0648 -0.0197 -0.0225 -0.1719 -0.7129 -0.1465 -0.6733 -0.0395 -0.0310 -0.1663 -1.4395 -0.0282 -0.3438 -0.0169 -0.0282 -0.2761 -0.0169 -0.0113 -0.0282 -0.0113 -0.0113 -0.1578 -0.2479 -0.2311 -1.1211 -0.0282 -0.2537 -0.0451 -0.4790 -0.2255 -0.0056 -0.0282 -0.0282', 'S-1379\tFür Kinder wird als Anfangsdosis die Einnahme von 50 - 55 mg / kg Körpergewicht zweimal täglich oder bei dreimal täglicher Einnahme eine Dosis von jeweils 25 - 30 mg / kg Körpergewicht empfohlen.', 'T-1379\tFor children able to take tablets,', 'H-1379\t-1.3642578125\tThe starting dose recommended for children is 50 - 55 mg / kg body weight twice daily or 25 - 30 mg / kg body weight three times daily .', 'D-1379\t-1.3642578125\tThe starting dose recommended for children is 50 - 55 mg / kg body weight twice daily or 25 - 30 mg / kg body weight three times daily.', 'P-1379\t-2.3945 -0.3423 -0.1169 -1.3750 -0.1437 -0.2451 -0.0507 -0.0564 -0.8481 -0.0310 -0.0113 -0.0366 -0.0225 -0.4902 -0.0169 -0.0901 -0.7778 -0.4453 -0.3213 -0.0395 -0.0225 -0.0113 -0.0282 -0.0113 -0.6479 -0.0225 -1.2852 -0.0113 -0.7271 -0.0507 -0.0338', 'S-1775\tEine Packung enthält einen bzw. vier vorgefüllte (n) Injektor (en) mit 80 μ g Aranesp Injektionslösung in 0,4 ml (200 µg / ml).', 'T-1775\tPackage containing one or four pre-filled pens of a 80 µg Aranesp solution for injection in 0.4 ml (200 µg / ml).', 'H-1775\t-0.521484375\tPackage containing one or four pre @-@ filled pens of a 80 µg Aranesp solution for injection in 0.4 ml ( 200 µg / ml ) .', 'D-1775\t-0.521484375\tPackage containing one or four pre-filled pens of a 80 µg Aranesp solution for injection in 0.4 ml (200 µg / ml).', 'P-1775\t-0.3196 -0.0886 -0.3188 -0.0564 -0.0514 -0.0402 -0.1711 -0.0282 -0.0092 -0.3228 -0.3213 -0.3015 -0.3479 -0.4875 -0.2974 -0.0254 -0.1071 -0.0113 -0.0225 -0.0225 -0.1945 -0.3213 -0.1493 -0.0423 -0.1240 -0.0423 -0.0451 -0.0197 -0.0310 -0.0254 -0.0169 -0.0254 -0.0310 -0.0141 -0.0310 -0.0592 -0.0310', 'S-1963\tBei 30 von 44 untersuchten Patienten kehrte die Viruspopulation über eine Nachbeobachtungsphase von 203 Tagen wieder zu einem reinen CCR5-Tropismus zurück und bei 14 Patienten war weiterhin', 'T-1963\tOut of 44 patients studied, the virus population in 30 reverted back to exclusively CCR5-tropism during a median follow-up of 203 days; 14 patients continued to have detectable CXCR4 -using virus.', 'H-1963\t-3.27734375\tIn 30 of the 44 patients studied , viral populations reverted to CCR5 tropism after a follow @-@ up period of 203 days and in 14 patients , the incidence of inflammation was significantly ( P &lt; 0.05 ) less in patients treated with INTELENCE compared to', 'D-1963\t-3.27734375\tIn 30 of the 44 patients studied, viral populations reverted to CCR5 tropism after a follow-up period of 203 days and in 14 patients, the incidence of inflammation was significantly (P < 0.05) less in patients treated with INTELENCE compared to', 'P-1963\t-2.8652 -0.0789 -0.5918 -0.3494 -0.0282 -0.2874 -0.9663 -0.0986 -0.9834 -0.8057 -0.0169 -1.7412 -0.0676 -0.6143 -0.3718 -0.0282 -0.0282 -0.1240 -0.0225 -0.0169 -1.6230 -0.1240 -0.3381 -0.0451 -0.0225 -0.9468 -0.0338 -0.0225 -0.0225 -0.0225 -0.5410 -1.7471 -0.0338 -0.0789 -0.8677 -1.0146 -1.9834 -0.0113 -0.1014 -2.2324 -0.6538 -0.0225 -0.5972 -1.1719 -0.4282 -0.3381 -0.3381 0.0000 -0.0225 -0.5635 -1.5332 -0.1803 -0.3606 -0.4509 -1.0820 -0.7891 -0.3157 -1.6006 -0.9019 -0.3157 -0.3157 -0.3157 -0.7212 -0.6084 -4.5742', 'S-1899\tDie Veränderung der Aliskiren-Plasmaspiegel bei Anwesenheit von Ketoconazol liegt schätzungsweise in dem Bereich, der bei Verdoppelung der Aliskiren-Dosis erreicht würde.', 'T-1899\tPreclinical studies indicate that aliskiren and ketoconazole co-administration enhances aliskiren gastrointestinal absorption and decreases biliary excretion.', 'H-1899\t-1.3603515625\tThe change in plasma levels of aliskiren in the presence of ketoconazole is estimated to be within the range achieved with doubling of plasma dose .', 'D-1899\t-1.3603515625\tThe change in plasma levels of aliskiren in the presence of ketoconazole is estimated to be within the range achieved with doubling of plasma dose.', 'P-1899\t-0.6733 -0.1254 -0.5645 -0.3359 -0.0113 -0.0141 -0.0493 -0.9692 -0.3228 -0.2986 -0.2141 -0.0282 -0.0789 -0.0648 -0.0113 -0.0282 -0.0085 -0.0282 -0.0310 -0.0113 -0.0056 -0.2847 -0.0479 -0.0620 -0.0564 -1.1582 -0.0423 -0.0451 -0.7300 -1.5498 -0.7720 -0.0225 -0.5469 -0.7324 -0.0113 -0.0169 -0.9409 -1.3242 -0.0338', 'S-1670\tLangfristig sanken die Punktwerte für Juckreiz von durchschnittlich rund 3,9 am ersten Tag nach sechswöchiger Behandlung mit Emadine auf 0,8 und mit Levocabastin auf 2,0.', 'T-1670\tIn the long term, the itching scores fell from an average of around 3.9 on the first day, falling to 0.8 for Emadine and 2.0 for levocabastine after six weeks.', 'H-1670\t-1.4423828125\tIn a long term perspective , itching scores fell from an average of about 3.9 on the first day after six weeks of treatment with Emadine to 0.8 and by 2.0 with levocabastine .', 'D-1670\t-1.4423828125\tIn a long term perspective, itching scores fell from an average of about 3.9 on the first day after six weeks of treatment with Emadine to 0.8 and by 2.0 with levocabastine.', 'P-1670\t-0.2467 -0.6045 -0.1705 -0.6030 -0.5649 -0.2676 -0.3042 -0.1437 -0.0704 -0.7495 -0.0901 -1.5273 -0.0225 -0.0451 -1.0879 -0.0225 -0.4958 -0.3777 -0.8677 -0.0338 -0.0395 -1.1104 -0.5918 -0.0338 -0.5352 -0.2593 -0.0507 -0.1859 -0.0169 -0.0169 -0.3438 -0.0282 -0.0225 -0.5186 -1.2402 -0.1465 -0.1014 -0.1127 -0.0338 -0.0225 -0.0113 -0.1917 -0.0338 -0.0338', 'S-509\tEine Vollremission (VR) wurde definiert als das Fehlen sichtbarer Leukämiezellen im Knochenmark und die periphere Regeneration von Thrombozyten und Leukozyten.', 'T-509\tComplete remission (CR) was defined as the absence of visible leukaemic cells in the bone marrow and peripheral recovery of platelets and white blood cells.', 'H-509\t-1.33203125\tComplete remission ( CR ) was defined as absence of overt leukaemia cells in bone marrow and peripheral platelet and white blood cell recovery .', 'D-509\t-1.33203125\tComplete remission (CR) was defined as absence of overt leukaemia cells in bone marrow and peripheral platelet and white blood cell recovery.', 'P-509\t-1.0908 -0.0218 -1.2510 -0.0070 -0.2184 -0.3523 -0.2283 -0.0282 -0.1240 -0.1831 -0.0366 -1.0312 -0.0282 -1.3555 -0.1071 -0.0507 -0.2029 -0.4678 -0.0282 -0.0395 -0.2874 -1.3184 -0.3833 -0.0113 -0.0564 -0.0507 -0.0169 -0.0338 -1.1104 -0.0169 -0.0338 -0.0451 -0.6704 -0.1859 -0.2593 -0.4001 -0.0451 -0.0338', 'S-582\tDiese Nebenwirkungen treten generell in der ersten Behandlungswoche auf, sind meist vorübergehend und 25 / 32 klingen nach Abbruch der Behandlung ab, können aber in sehr seltenen Fällen auch schwerwiegend oder lebensbedrohlich sein.', 'T-582\tThese side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.', 'H-582\t-1.7333984375\tThese side effects usually occur during the first week of treatment and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal .', 'D-582\t-1.7333984375\tThese side effects usually occur during the first week of treatment and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.', 'P-582\t-0.6357 -1.2930 -0.0592 -1.5283 -1.1211 -0.8848 -0.0310 -0.0282 -0.3691 -0.3042 -0.2874 -0.6934 -0.1183 -0.8174 -0.0789 -0.0169 -0.3101 -0.0113 -0.4734 -0.0789 -0.7158 -0.0451 -1.2168 -0.5015 -0.0338 -0.0676 -1.4424 -0.1578 -0.5298 -0.2593 -0.0789 -0.0564 -0.0338 -0.2930 -0.2367 -0.2029 -0.0338 -0.7324 -0.0338 -0.0338', 'S-501\tDie Analyse dieser begrenzten Daten deuten darauf hin, dass keine Dosisanpassungen bezüglich Alter (12-76 Jahre), ethnischer Herkunft oder Geschlecht benötigt werden (siehe Abschnitt 4.2).', 'T-501\tAnalyses of these limited data suggest that no dose adjustments are necessary for age (12-76 years), race, ethnicity or gender (see section 4.2).', 'H-501\t-1.009765625\tAnalyses of these limited data suggest that no dose adjustments are necessary for age ( 12 @-@ 76 years ) , race , ethnicity or gender ( see section 4.2 ) .', 'D-501\t-1.009765625\tAnalyses of these limited data suggest that no dose adjustments are necessary for age (12-76 years), race, ethnicity or gender (see section 4.2).', 'P-501\t-0.3064 -1.4629 -0.0380 -0.1536 -0.0395 -0.0395 -0.5156 -0.0887 -0.1691 -0.2324 -0.1550 -0.0141 -0.0732 -0.1945 -1.0059 -0.3777 -0.0507 -0.0338 -0.5835 -0.0507 -0.1324 -0.0760 -0.0564 -0.0282 -0.4453 -0.3438 -0.5747 -0.0113 -0.0225 -0.9805 -0.1465 -0.0338 -0.0507 -0.4622 -0.0282 -0.0282 -0.0338 -0.0282 -0.0282', 'S-359\tDermonekrotisches Toxin produzierende Pasteurella multocida sind verantwortlich für die Nasenmuschelatrophie bei progressiver atrophischer Rhinitis.', 'T-359\tDermonecrotic toxin producing Pasteurella multocida is the pathogen responsible for turbinate atrophy in progressive atrophic rhinitis.', 'H-359\t-0.496337890625\tDermonecrotic toxin producing Pasteurella multocida is responsible for nasal turbinate atrophy associated with progressive atrophic rhinitis .', 'D-359\t-0.496337890625\tDermonecrotic toxin producing Pasteurella multocida is responsible for nasal turbinate atrophy associated with progressive atrophic rhinitis.', 'P-359\t-0.4121 -0.0285 -0.0472 -0.0581 -0.0141 -0.0155 -0.0243 -0.6196 -0.0296 -0.0134 -0.0268 -0.0070 -0.0190 -0.0204 -0.0254 -0.0183 -0.6733 -0.1747 -0.0296 -0.2169 -0.0282 -0.0211 -0.3523 -0.3198 -0.3213 -0.0338 -0.0113 -0.6226 -0.0310 -0.0225 -0.0479 -0.0141 -0.0254 -0.0310 -0.0141 -0.0225 -0.0141 -0.0366 -0.0282', 'S-1867\tSie werden Ihre erste Dosis Filgrastim ratiopharm in der Regel mindestens 24 Stunden nach Ihrer Chemotherapie, aber in einem Abstand von weniger als 24 Stunden zu Ihrer Knochenmarktransfusion erhalten.', 'T-1867\tYou will normally receive your first dose of Filgrastim ratiopharm at least 24 hours after your chemotherapy but within 24 hours of receiving your bone marrow transfusion.', 'H-1867\t-0.3017578125\tYou will normally receive your first dose of Filgrastim ratiopharm at least 24 hours after your chemotherapy but within 24 hours of receiving your bone marrow transfusion .', 'D-1867\t-0.3017578125\tYou will normally receive your first dose of Filgrastim ratiopharm at least 24 hours after your chemotherapy but within 24 hours of receiving your bone marrow transfusion.', 'P-1867\t-0.1181 -0.0349 -0.3020 -0.1373 -0.0285 -0.0313 -0.0070 -0.0327 -0.1398 -0.0141 -0.0211 -0.0141 -0.0113 -0.0218 -0.0042 -0.0359 -0.0254 -0.0261 -0.0225 -0.0373 -0.0472 -0.0282 -0.0155 -0.0148 -0.2537 -0.3206 -0.3157 -0.0211 -0.0901 -0.3228 -0.0268 -0.0409 -0.0183 -0.0042 -0.0183 -0.0141 -0.0296 -0.0296', 'S-1156\tDie in den Histaminstoffwechsel involvierten Hauptenzyme sind HNMT (Histamin-N-Methyltransferase) und DAO (Diaminoxidase).', 'T-1156\tThe main enzymes involved in the metabolism of histamine are HNMT (histamine-N-methyltransferase) and DAO (diamine', 'H-1156\t-0.74267578125\tThe major enzymes involved in histamine metabolism are HNMT ( histamine N- methyltransferase ) and DAO ( diaminoxidase ) .', 'D-1156\t-0.74267578125\tThe major enzymes involved in histamine metabolism are HNMT (histamine N- methyltransferase) and DAO (diaminoxidase).', 'P-1156\t-0.2754 -0.9917 -0.0141 -0.0120 -0.0240 -0.2085 -0.0324 -0.9775 -0.0155 -0.0296 -0.0141 -0.0155 -0.4861 -0.0479 -0.0254 -0.0225 -0.0197 -0.0282 -0.2255 -0.0338 -1.7021 -0.1042 -0.0085 -0.4902 -0.0451 -0.0113 -0.0113 -0.0282 -0.0395 -0.0113 -0.0282 -0.0282 -0.3945 -0.1071 -0.2141 -0.0338 -0.0282 -0.0169 -0.0282 -0.0338 -0.0282', 'S-1225\tAlpträume2 Manie Agitiertheit2 Halluzinatio -nen Psychomoto -rische Unruhe (einschließli ch Akathisie und Hyperkinesi e)', 'T-1225\tNightmares2 Mania Agitation2 Hallucinations Psychomotor restlessness (incl. akathisia, hyperkinesia)', 'H-1225\t-1.4052734375\tIt is recommended to discontinue treatment with mirtazapine gradually to avoid withdrawal symptoms ( see section 4.4 ) .', 'D-1225\t-1.4052734375\tIt is recommended to discontinue treatment with mirtazapine gradually to avoid withdrawal symptoms (see section 4.4).', 'P-1225\t-0.3945 -0.2255 -0.3276 -0.2783 -0.3438 -0.3000 -0.3142 -0.3691 -0.3296 -0.3213 -0.2113 -0.3157 -0.3127 -0.3269 -0.3157 -0.3269 -0.3240 -0.1550 -0.4875 -0.3325 -0.4453 -0.7495 -1.4648 -0.4790 -0.2085 -0.2649', 'S-813\tSchließt sich der Ductus arteriosus 48 Stunden nach der letzten Injektion nicht, oder öffnet er sich erneut, kann ein zweiter Behandlungszyklus mit drei Infusionen durchgeführt werden.', 'T-813\tIf the ductus arteriosus does not close 48 hours after the last injection or if it reopens, a second course of three doses may be given.', 'H-813\t-0.71484375\tIf the ductus arteriosus does not close 48 hours after the last injection or if it re @-@ opens , a second course of 3 infusions may be used .', 'D-813\t-0.71484375\tIf the ductus arteriosus does not close 48 hours after the last injection or if it re-opens, a second course of 3 infusions may be used.', 'P-813\t-0.1235 -0.0729 -0.0372 -0.0458 -0.0299 -0.0085 -0.0171 -0.0255 -0.1014 -0.0257 -0.0099 -0.3352 -0.0268 -0.0331 -0.0380 -0.3979 -0.0261 -0.0092 -0.5591 -0.1620 -0.3228 -0.3015 -0.0282 -0.0535 -0.0535 -0.1423 -0.0282 -0.5493 -0.0592 -0.4875 -0.0592 -0.0197 -0.0197 -0.5493 -0.0310 -1.4824 -0.0395 -0.0282', 'S-51\tBesondere Hinweise zur Handhabung (für die Infrarot-Spektroskopie) Der Test ist nach Anleitung durch eine medizinische Fachkraft und unter angemessener ärztlicher Aufsicht durchzuführen.', 'T-51\tSpecial Instructions for use (for infrared spectroscopy) The test is to be performed after instruction by a healthcare professional and under appropriate medical supervision.', 'H-51\t-0.73681640625\tSpecial instructions for use ( for Infrared Spectroscopy ) The test is to be performed after instruction by a healthcare professional and under appropriate medical supervision .', 'D-51\t-0.73681640625\tSpecial instructions for use (for Infrared Spectroscopy) The test is to be performed after instruction by a healthcare professional and under appropriate medical supervision.', 'P-51\t-0.2014 -0.5190 -0.1536 -0.2395 -0.1085 -0.1606 -0.3586 -0.0085 -0.0141 -0.4382 -0.0155 -0.0197 -0.0099 -0.0338 -0.1198 -0.1169 -0.6328 -0.0873 -0.0282 -0.3042 -0.4226 -0.2986 -0.0169 -0.3606 -0.0423 -0.5972 -0.0310 -0.1240 -0.0535 -0.1803 -0.0423 -0.0169 -0.0141 -0.4170 -0.0338', 'S-1548\tFibrinogen ist ein Konzentrat eines gerinnungsfähigen Proteins, und Thrombin ist ein Enzym, das dazu führt, dass sich gerinnungsfähiges Protein bindet.', 'T-1548\tFibrinogen is a concentrate of clottable protein and Thrombin is an enzyme that causes clottable protein to coalesce.', 'H-1548\t-0.91796875\tFibrinogen is a concentrate of a blood coagulant protein , and thrombin is an enzyme that binds to a blood coagulant protein .', 'D-1548\t-0.91796875\tFibrinogen is a concentrate of a blood coagulant protein, and thrombin is an enzyme that binds to a blood coagulant protein.', 'P-1548\t-0.1530 -0.0085 -0.0128 -0.0327 -0.3049 -0.0451 -0.0342 -0.1973 -0.3262 -0.2563 -0.0056 -0.6299 -0.1381 -0.0240 -0.9736 -0.0676 -0.0056 -0.0197 -0.0282 -0.0282 -0.1888 -0.0113 -0.0169 -0.0225 -0.2169 -1.5020 -0.0254 -0.6201 -0.6987 -0.4058 -0.2029 -0.0113 -0.5972 -0.0732 -0.0676 -0.0338 -0.0282', 'S-48\tBitte nehmen Sie INTELENCE daher erst nach Rücksprache mit Ihrem Arzt ein, wenn Ihnen bekannt ist, dass Sie unter einer Unverträglichkeit gegenüber bestimmten Zuckern (Lactose) leiden.', 'T-48\tIf you have been told by your doctor that you have an intolerance to some sugars (lactose), contact your doctor before taking this medicine.', 'H-48\t-0.64892578125\tIf you are intolerant to some sugars ( lactose ) , consult your doctor before taking INTELENCE .', 'D-48\t-0.64892578125\tIf you are intolerant to some sugars (lactose), consult your doctor before taking INTELENCE.', 'P-48\t-0.3206 -0.0768 -0.8359 -0.3206 -0.0127 -0.0268 -0.0831 -0.3169 -0.0634 -0.0169 -0.0437 -0.2014 -0.0155 -0.0169 -0.0310 -0.1874 -1.4824 -0.0169 -0.0620 -0.0704 -0.2395 -0.1465 -0.0451 -0.0254 -0.0169 -0.0169 -0.0085 -0.0620 -0.1296', 'S-679\tWenn Sie sowohl mit HIV als auch mit Hepatitis B infiziert sind, ist es besonders wichtig, dass Sie Ihre Behandlung mit Atripla nicht ohne vorherige Rücksprache mit Ihrem Arzt absetzen.', 'T-679\tIf you have both HIV infection and hepatitis B, it is especially important not to stop your Atripla treatment without talking to your doctor first.', 'H-679\t-0.9482421875\tIf you have both HIV infection and hepatitis B , it is especially important not to stop your treatment with Atripla without talking to your doctor first .', 'D-679\t-0.9482421875\tIf you have both HIV infection and hepatitis B, it is especially important not to stop your treatment with Atripla without talking to your doctor first.', 'P-679\t-0.2418 -0.0299 -0.6973 -0.9243 -0.0662 -0.5845 -0.0324 -0.0535 -0.0085 -0.0113 -0.0211 -0.0916 -0.0352 -0.0310 -0.6479 -0.0225 -0.2479 -0.0282 -0.2113 -1.1299 -0.8115 -0.3606 -0.0451 -0.0169 -0.0169 -0.0282 -0.0564 -0.3213 -0.0789 -0.0395 -0.0732 -0.8340 -0.0338 -0.0338', 'S-185\tSie werden möglicherweise mit der Einnahme von antiretroviralen Arzneimitteln (Anti-HIV- Arzneimittel) und Arzneimitteln zur Verhütung von opportunistischen Infektionen bei AIDS fortfahren.', 'T-185\tYou may continue taking antiretrovirals (anti-HIV medications) and medication to prevent AIDS- related opportunistic infections.', 'H-185\t-1.2626953125\tYou may continue to take antiretroviral medicinal products ( anti- HIV medicinal products ) and medicinal products to prevent opportunistic infections in AIDS .', 'D-185\t-1.2626953125\tYou may continue to take antiretroviral medicinal products (anti- HIV medicinal products) and medicinal products to prevent opportunistic infections in AIDS.', 'P-185\t-0.5684 -0.2854 -2.0215 -0.1057 -0.0958 -0.1465 -0.0225 -0.0141 -0.2761 -0.4678 -0.9214 -0.1437 -0.4592 -0.3042 -0.3889 -0.0113 -0.4170 -0.1183 -0.0338 -0.0282 -0.0564 -1.5439 -0.0845 -0.0845 -0.1917 -0.2029 -0.0169 -0.0282 -0.0395 -0.0225 -0.1859 -0.0113 -0.6143 -1.0312 -0.0113 -0.0338 -0.0282', 'S-1246\tWenn Sie eine größere Menge von Comtess eingenommen haben, als Sie sollten Falls Sie eine zu hohe Dosis eingenommen haben, wenden Sie sich sofort an Ihren Arzt oder an das nächstgelegene Krankenhaus.', 'T-1246\tIf you take more Comtess than you should In the event of an overdose, consult your doctor or the nearest hospital immediately.', 'H-1246\t-0.64013671875\tIf you forget to take Comtess', 'D-1246\t-0.64013671875\tIf you forget to take Comtess', 'P-1246\t-0.1389 -0.0277 -1.2783 -0.0465 -0.0437 -0.3184 -0.0197 -0.0155 -0.5029', 'S-1937\t<unk> Der Wirkstoff ist: rekombinantes Interferon alfa-2b, 5 Millionen I.E. in einer Einzeldosis- Durchstechflasche. <unk> Die sonstigen Bestandteile sind:', 'T-1937\t- The active substance is recombinant interferon alfa-2b, 5 million IU in a single dose vial', 'H-1937\t-0.68212890625\t- The active substance is recombinant interferon alfa @-@ 2b , 5 million IU in a single dose vial', 'D-1937\t-0.68212890625\t- The active substance is recombinant interferon alfa-2b, 5 million IU in a single dose vial', 'P-1937\t-1.0693 -0.1127 -0.3015 -0.3086 -0.0662 -0.2085 -0.0268 -0.0169 -0.0296 -0.0366 -0.0099 -0.0296 -0.0324 -0.0141 -0.0282 -0.0254 -0.0211 -0.0564 -1.4102 -0.0507 -0.0451 -0.1859 -0.1014 -0.1945 -0.0225 -0.1635 -0.0958 -0.0113 -0.4705', 'S-298\t483 Wenn Sie nicht schlucken können oder bewusstlos sind, müssen Sie Glukoselösung oder Glukagon (ein Mittel zur Erhöhung des Blutzuckers) gespritzt bekommen.', 'T-298\tIf you are not able to swallow or if you are unconscious, you will require an injection of glucose or glucagon (a medicine which increases blood sugar).', 'H-298\t-1.2080078125\tIf you are not able to swallow or if you are unconscious , you must be injected with glucose solution or glucagon ( a medicine to increase blood sugar ) .', 'D-298\t-1.2080078125\tIf you are not able to swallow or if you are unconscious, you must be injected with glucose solution or glucagon (a medicine to increase blood sugar).', 'P-298\t-0.3789 -0.0299 -0.5024 -0.3113 -0.0634 -0.0268 -0.0120 -0.0183 -0.5742 -0.3113 -0.0352 -0.1691 -0.0395 -0.0127 -0.2240 -0.1930 -0.6875 -1.1553 -0.6284 -0.0141 -0.0338 -0.3381 -0.0169 -0.0225 -0.6367 -0.0564 -0.2423 -0.0225 -0.0113 -0.0507 -0.0564 -1.2002 -1.1162 -0.6479 -0.4622 -0.4734 -0.0395 -0.0395 -0.0282', 'S-1643\t{HANDELSNAME} 100 mg Filmtabletten {HANDELSNAME} 200 mg Filmtabletten {HANDELSNAME} 400 mg Filmtabletten', 'T-1643\t{INVENTED NAME} 100 mg film-coated tablets {INVENTED NAME} 200 mg film-coated tablets {INVENTED NAME} 400 mg film-coated tablets', 'H-1643\t-0.4208984375\t{ PRODUCT } 100 mg film @-@ coated tablets { PRODUCT } 200 mg film @-@ coated tablets { PRODUCT } 400 mg film @-@ coated tablets', 'D-1643\t-0.4208984375\t{PRODUCT} 100 mg film-coated tablets {PRODUCT} 200 mg film-coated tablets {PRODUCT} 400 mg film-coated tablets', 'P-1643\t-0.0991 -0.3213 -0.0789 -0.2367 -0.0035 -0.2395 -0.0169 -0.0810 -0.0176 -0.2627 -0.3191 -0.3228 -0.1183 -0.0620 -0.2255 -0.0113 -0.0268 -0.0042 -0.0225 -0.0014 -0.0423 -0.0113 -0.1042 -0.0169 -0.2043 -0.1000 -0.0338 -0.0225 -0.0451 -0.2255 -0.0310 -0.0225 -0.0028 -0.0197 0.0000 -0.0366 -0.0113 -0.1859 -0.0141 -0.1803 -0.0564 -0.0197 -0.0197 -0.0451 -0.2283 -0.0366', 'S-1384\tCervarix Injektionssuspension in einer Fertigspritze Humaner Papillomvirus -Impfstoff [Typen 16, 18] (rekombinant, adjuvantiert, adsorbiert)', 'T-1384\tCervarix suspension for injection in pre-filled syringe Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed)', 'H-1384\t-0.455078125\tCervarix suspension for injection in pre @-@ filled syringe Human Papillomavirus vaccine &#91; Types 16 , 18 &#93; ( Recombinant , adjuvanted , adsorbed )', 'D-1384\t-0.455078125\tCervarix suspension for injection in pre-filled syringe Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed)', 'P-1384\t-0.0472 -0.0299 -0.0270 -0.5454 -0.3152 -0.0775 -0.0409 -0.1099 -0.8779 -0.0268 -0.2903 -0.0662 -0.0155 -0.0028 -0.1606 -0.0901 -0.0113 -0.1536 -0.0282 -0.0028 -0.1324 -0.0366 -0.1635 -0.0254 -0.0310 -0.0338 -0.0254 -0.0282 -0.0282 -0.3662 -0.0169 -0.0113 -0.0282 -0.0310 -0.2141 -0.0901 -0.0141 -0.0310 -0.0225 -0.0085 -0.0254 -0.0310 -0.0338', 'S-1878\tDer derzeitige Direktor für Zulassungsangelegenheiten beim Veterinary Medicines Directorate des Vereinigten Königreichs fungierte früher auch als Vorsitzender der Arbeitsgruppe zur Erleichterung der gegenseitigen Anerkennung.', 'T-1878\tHe is currently Director of Licensing at the Veterinary Medicines Directorate in the UK and is a past Chairman of the Veterinary Mutual Recognition Facilitation Group.', 'H-1878\t-1.4580078125\tHe is now director of regulatory affairs at', 'D-1878\t-1.4580078125\tHe is now director of regulatory affairs at', 'P-1878\t-0.3118 -0.0662 -1.3369 -0.3945 -0.2268 -1.0000 -0.2395 -0.9043 -0.9692', 'S-243\tEinige Stoffe (Allergene) wie Pollen, Hausstaub oder Tierhaare können an der Oberfläche Ihres Auges allergische Reaktionen wie Jucken, Rötung und Schwellung auslösen.', 'T-243\tSome materials (allergens) like pollens, house dust or animal fur may cause allergic reactions resulting in itching, redness as well as swelling of the surface of your eye.', 'H-243\t-0.83740234375\tSome substances ( allergens ) such as pollen , house dust or animal hair may cause allergic reactions at the top of your eye such as itching , redness and swelling .', 'D-243\t-0.83740234375\tSome substances (allergens) such as pollen, house dust or animal hair may cause allergic reactions at the top of your eye such as itching, redness and swelling.', 'P-243\t-0.2418 -0.2211 -0.0155 -0.0370 -0.0106 -0.0148 -0.0285 -0.7817 -0.0282 -0.0275 -0.0056 -0.0317 -0.2339 -0.0183 -0.4043 -0.1071 -0.3340 -0.2100 -0.1986 -0.1831 -0.0113 -0.3916 -0.0141 -1.0908 -0.0310 -0.7974 -0.0423 -0.0564 -0.0648 -0.6509 -0.0282 -0.3101 -0.0282 -0.0282 -0.4226 -0.0169 -0.5522 -0.0225 -0.0225 -0.0338 -0.0282', 'S-372\tDer Wirkstoff in Beromun, Tasonermin, ist eine Kopie des humanen Proteins Tumor-Nekrose-Faktor alfa-1a (TNFα).', 'T-372\tThe active substance in Beromun, tasonermin, is a copy of the human protein tumour necrosis factor alfa-1a (TNF α).', 'H-372\t-0.384521484375\tThe active substance in Beromun , tasonermin , is a copy of the human protein tumour necrosis factor alfa @-@ 1a ( TNFα ) .', 'D-372\t-0.384521484375\tThe active substance in Beromun, tasonermin, is a copy of the human protein tumour necrosis factor alfa-1a (TNFα).', 'P-372\t-0.0472 -0.0767 -0.2113 -0.0539 -0.0285 -0.0155 -0.0169 -0.0356 -0.1205 -0.0155 -0.0760 -0.0176 -0.3047 -0.0373 -0.0296 -0.0310 -0.0303 -0.0282 -0.1465 -0.0303 -0.0373 -0.9536 -0.4565 -0.0380 -0.0070 -0.0141 -0.0197 -0.0254 -0.3296 -0.0282 -0.0254 -0.0254 -0.0310 -0.0310 -0.0282 -0.0282 -0.0028 -0.0282 -0.0282 -0.0282', 'S-467\tNatriumchlorid Eisessig (zur Einstellung des pH-Werts) Natriumhydroxid (zur Einstellung des pH-Werts) Wasser für Injektionszwecke', 'T-467\tSodium chloride Acetic acid, glacial (for pH adjustment) Sodium hydroxide (for pH adjustment) Water for injections', 'H-467\t-0.4326171875\tSodium chloride Glacial acetic acid ( for pH adjustment ) Sodium hydroxide ( for pH adjustment ) Water for injections', 'D-467\t-0.4326171875\tSodium chloride Glacial acetic acid (for pH adjustment) Sodium hydroxide (for pH adjustment) Water for injections', 'P-467\t-0.1879 -0.0099 -0.0991 -0.0141 -0.0234 -0.0241 -0.3247 -0.1219 -0.2169 -0.0606 -0.0345 -0.4453 -0.1648 -0.2817 -0.0169 -0.8325 -0.0127 -0.0338 -0.0310 -0.0254 -0.0113 -0.0141 -0.0056 -0.0197 -0.0282 -0.0395 -0.0479 -0.0197 -0.0282 -0.0225 -0.0310 -0.0282 -0.0676 -0.0676 -0.0282 -0.3157 -0.0395', 'S-449\tDie Anwendung bei Hunden mit geschädigtem Herzen, geschädigter Nierenfunktion oder bei Hunden, die dehydriert, hypovolämisch oder hypotensiv sind, kann zusätzliche Risiken beinhalten.', 'T-449\tUse in dogs with impaired cardiac or renal function or dogs that are dehydrated, hypovolaemic or hypotensive may involve additional risks.', 'H-449\t-0.79736328125\tUse in dogs with impaired function of the heart , kidneys or liver or in dogs that are dehydrated , hypovolaemic or hypotensive may involve additional risks .', 'D-449\t-0.79736328125\tUse in dogs with impaired function of the heart, kidneys or liver or in dogs that are dehydrated, hypovolaemic or hypotensive may involve additional risks.', 'P-449\t-0.2910 -0.0546 -0.1829 -0.1180 -0.3145 -0.0063 -1.0752 -0.1493 -0.0887 -0.0352 -0.2311 -0.1874 -0.6553 -0.0113 -0.3071 -0.8452 -0.1888 -0.7300 -0.0479 -0.1268 -0.0451 -0.0282 -0.0141 -0.0254 -0.0338 -0.0169 -0.0282 -0.2930 -0.1747 -0.0056 -0.0395 -0.0338 -0.0113 -0.0169 -0.2367 -0.1353 -0.1465 -0.0338 -0.3718 -0.0338 -0.0282', 'S-615\tEntzündung an der Injektionsstelle, Veränderung an der Injektionsstelle, Erschöpfung, Schüttelfrost, Fieber, grippeartige Symptome, Asthenie, Reizbarkeit', 'T-615\tInjection site inflammation, injection site reaction, fatigue, rigors, fever, flu-like symptoms, asthenia, irritability', 'H-615\t-0.63818359375\tInjection site inflammation , injection site reaction , fatigue , chills , fever , flu @-@ like symptoms , asthenia , irritability', 'D-615\t-0.63818359375\tInjection site inflammation, injection site reaction, fatigue, chills, fever, flu-like symptoms, asthenia, irritability', 'P-615\t-0.6187 -0.6045 -0.0183 -0.0451 -0.0127 -0.0282 -0.0338 -0.2649 -0.0197 -0.0127 -0.3240 -0.0352 -0.2268 -0.0127 -0.0169 -0.0310 -0.9775 -0.0028 -0.0310 -0.0197 -0.0169 -0.0310 -0.7861 -0.3972 -0.0338 -0.5352 -0.0310 -0.0197 -0.0169 -0.0225 -0.0169 -0.0366 -0.0282 -0.0225 -0.0564', 'S-550\tThelin wird zur Behandlung von erwachsenen Patienten mit Pulmonalarterienhypertonie (PAH) der Funktionsklasse III der Weltgesundheitsorganisation (WHO) zur Verbesserung der körperlichen Belastbarkeit angewendet.', 'T-550\tThelin is used for the treatment of adult patients with class III pulmonary arterial hypertension, to improve exercise capacity.', 'H-550\t-0.73486328125\tThelin is used to treat adult patients with pulmonary arterial hypertension ( PAH ) classified as WHO functional class III , to improve exercise capacity .', 'D-550\t-0.73486328125\tThelin is used to treat adult patients with pulmonary arterial hypertension (PAH) classified as WHO functional class III, to improve exercise capacity.', 'P-550\t-0.1421 -0.0042 -0.0401 -0.0509 -0.5757 -0.1521 -0.3845 -0.0380 -0.0564 -0.1099 -0.0028 -0.0183 -0.0141 -0.2438 -0.0042 -0.0085 -0.0042 -0.4353 -0.0352 -0.0268 -0.0155 -0.0296 -0.3184 -0.1676 -0.3228 -0.3213 -0.0254 -0.1099 -0.0169 -0.3494 -0.2311 -0.0986 -0.3213 -0.1635 -1.4395 -0.0282', 'S-633\tCopalia darf außerdem nicht angewendet werden bei Patienten mit schweren Leber-, Nieren- oder Gallenproblemen oder bei Patienten, die sich einer Dialyse (einem Verfahren zur Blutreinigung) unterziehen müssen.', 'T-633\tCopalia should also not be used in patients who have severe liver, kidney or bile problems, or in patients undergoing dialysis (a blood clearance technique).', 'H-633\t-0.58251953125\tIt should also not be used in patients who have severe liver , kidney or bile problems , or in patients undergoing dialysis ( a blood clearance technique ) .', 'D-633\t-0.58251953125\tIt should also not be used in patients who have severe liver, kidney or bile problems, or in patients undergoing dialysis (a blood clearance technique).', 'P-633\t-0.5581 -0.2479 -0.6299 -0.0564 -0.0296 -0.0479 -0.1183 -0.0352 -0.3030 -0.0803 -0.1338 -0.0916 -0.0338 -0.0324 -0.0127 -0.0817 -0.1859 -0.0070 -0.0493 -0.6807 -0.0423 -0.2169 -0.0648 -0.2817 -0.0169 -0.0310 -0.0113 -0.0169 -0.0620 -0.0507 -0.1296 -0.3213 -0.0310 -0.3042 -0.0282 -0.0338 -0.0282', 'S-1211\tBei Patienten mit Hypertonie und normaler Nierenfunktion bewirken therapeutische Dosen von Amlodipin eine Verringerung des renalen Gefäßwiderstandes sowie eine Erhöhung der glomerulären', 'T-1211\tIn hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal vascular resistance and an increase in glomerular filtration rate and effective renal plasma flow, without change in filtration fraction or proteinuria.', 'H-1211\t-1.2763671875\tIn patients with hypertension and normal renal function , therapeutic doses of amlodipine lead to a reduction in renal vascular resistance and an increase in active tubular neurotransmission .', 'D-1211\t-1.2763671875\tIn patients with hypertension and normal renal function, therapeutic doses of amlodipine lead to a reduction in renal vascular resistance and an increase in active tubular neurotransmission.', 'P-1211\t-1.0293 -0.0338 -0.0416 -0.0254 -0.0063 -0.0310 -0.0613 -0.1451 -0.0211 -0.0268 -0.3396 -0.3494 -0.0240 -0.1338 -0.0169 -0.0282 -0.0240 -0.0225 -0.0197 -0.0240 -0.0197 -1.2598 -0.0282 -0.9272 -0.5581 -0.1747 -0.0592 -0.0282 -0.1663 -0.0141 -0.0395 -0.0310 -0.1127 -0.6143 -0.0338 -0.0676 -1.0430 -0.9805 -0.4114 -0.2029 -1.5781 -0.6704 -0.0056 -0.0113 -0.5186 -0.8677 -0.0338', 'S-1257\tBevacizumab hatte keine klinisch signifikanten Wirkungen auf die pharmakokinetischen Parameter von Capecitabin oder dessen Metaboliten in Gegenwart von Oxaliplatin.', 'T-1257\tBevacizumab: there was no clinically significant effect of bevacizumab on the pharmacokinetic parameters of capecitabine or its metabolites in the presence of oxaliplatin.', 'H-1257\t-0.5556640625\tBevacizumab had no clinically significant effect on the pharmacokinetic parameters of capecitabine or its metabolites in the presence of oxaliplatin .', 'D-1257\t-0.5556640625\tBevacizumab had no clinically significant effect on the pharmacokinetic parameters of capecitabine or its metabolites in the presence of oxaliplatin.', 'P-1257\t-0.7666 -0.0183 -0.0070 -0.0056 -0.0176 -0.0211 -0.8657 -0.0437 -0.0296 -0.0197 -0.0254 -0.5469 -0.0310 -0.9834 -0.0225 -0.0113 -0.0085 -0.0282 -0.2085 -0.0169 -0.0197 -0.0310 -0.0282 -0.0254 -0.0197 -0.0225 -0.0254 -0.0366 -0.4705 -0.0225 -0.0113 -0.4509 -0.1691 -0.0366 -0.0197 -0.0282 -0.0113 -0.0085 -0.0197 -0.0366 -0.0310 -0.0282', 'S-1729\tHypokaliämie, Hyponatriämie, Hypokalzämie, Hypophosphatämie, Dehydratation, Appetitverlust, gesteigerter Appetit.', 'T-1729\tUncommon: hypokalaemia, hyponatraemia, hypocalcaemia, hypophosphataemia, dehydration, decreased appetite, increased appetite.', 'H-1729\t-0.6708984375\tHyponatraemia , hyponatraemia , hypocalcaemia , hypophosphataemia , dehydration , loss of appetite , increased appetite .', 'D-1729\t-0.6708984375\tHyponatraemia, hyponatraemia, hypocalcaemia, hypophosphataemia, dehydration, loss of appetite, increased appetite.', 'P-1729\t-1.1514 -1.0303 -0.0352 -0.3184 -0.0155 -0.0254 -0.0338 -0.4282 -0.0085 -0.0310 -0.0310 -0.4114 -0.0141 -0.0254 -0.0310 -0.0310 -0.0338 -0.8003 -0.0113 -0.0225 -0.0310 -0.0564 -0.0113 -0.1831 -0.0789 -0.0141 -0.5947 -0.0197 -0.0254 -0.0310 -0.0254 -0.0225 -0.0085 -0.0225 -0.0310 -0.0507 -0.0282 -0.0169 -0.0197 -0.0395 -0.5073 -0.0169 -0.0225 -0.2141 -0.0282', 'S-1254\tDass die Behandlung mit Tracleer mit einem Abfall des Hämoglobinwertes einhergehen kann. o Notwendigkeit von Blutwertkontrollen Vor Behandlungsbeginn Monatlich während der ersten 4 Monate Danach vierteljährlich.', 'T-1254\tThat treatment with Tracleer is associated with a decrease in haemoglobin. o Need for blood monitoring Prior to initiation of treatment Monthly during the first 4 months Quarterly thereafter.', 'H-1254\t-1.4921875\tThat treatment with Tracleer may be associated with a decrease in haemoglobin levels. o Need for blood tests before starting treatment Monthly during the first 4 months thereafter quarterly .', 'D-1254\t-1.4921875\tThat treatment with Tracleer may be associated with a decrease in haemoglobin levels. o Need for blood tests before starting treatment Monthly during the first 4 months thereafter quarterly.', 'P-1254\t-0.2610 -0.6167 -0.0444 -0.0500 -0.0183 -0.0254 -0.2057 -0.2100 -0.8286 -0.0310 -0.1973 -0.4087 -0.0197 -0.0901 -0.4114 -0.0056 -0.0169 -0.0310 -1.0537 -0.3240 -0.0254 -0.2817 -0.0197 -0.5552 -0.4453 -0.4395 -0.8228 -1.6963 -0.2930 -0.3777 -0.0169 -0.6426 -0.0395 -0.0338 -0.6479 -0.0395 -1.4648 -0.0113 -0.0338 -1.4199 -0.0338 -0.0338 -0.0338', 'S-1563\tDie Anwendung von Rebetol und Interferon alfa-2b bei Kindern und Jugendlichen mit bestehenden oder in der Vorgeschichte bekannten schweren psychiatrischen Störungen ist kontraindiziert (siehe Abschnitt 4.3).', 'T-1563\tThe use of Rebetol and interferon alfa-2b in children and adolescents with existence of or history of severe psychiatric conditions is contraindicated (see section 4.3).', 'H-1563\t-0.60107421875\tThe use of Rebetol and interferon alfa @-@ 2b in children and adolescents with existence of or history of severe psychiatric conditions is contraindicated ( see section 4.3 ) .', 'D-1563\t-0.60107421875\tThe use of Rebetol and interferon alfa-2b in children and adolescents with existence of or history of severe psychiatric conditions is contraindicated (see section 4.3).', 'P-1563\t-1.5654 -0.0916 -0.0282 -0.2100 -0.0183 -0.0197 -0.0183 -0.0338 -0.1606 -0.0141 -0.0268 -0.0310 -0.1874 -0.0282 -0.0254 -0.0211 -0.0859 -0.0395 -0.0366 -0.0493 -0.0211 -0.0169 -0.0409 -0.3213 -0.7861 -0.2479 -0.1831 -0.0310 -0.0958 -0.0169 -0.0225 -0.7383 -0.0423 -0.0395 -0.0056 -0.0338 -0.0423 -0.2141 -0.0225 -0.0282 -0.0395 -0.0310 -0.0282', 'S-1376\t* für Dosierungen < 0,5 mg Baraclude wird die Lösung zum Einnehmen empfohlen. * * an Hämodialyse-Tagen erfolgt die Entecavirgabe nach der Hämodialyse.', 'T-1376\t* for doses < 0.5 mg Baraclude oral solution is recommended. * * on haemodialysis days, administer entecavir after haemodialysis.', 'H-1376\t-0.93603515625\t* the oral solution &lt; 0.5 mg of Baraclude is recommended . * * on haemodialysis days , administer entecavir after haemodialysis .', 'D-1376\t-0.93603515625\t* the oral solution < 0.5 mg of Baraclude is recommended. * * on haemodialysis days, administer entecavir after haemodialysis.', 'P-1376\t-0.1735 -1.8320 -0.4692 -0.1930 -0.9902 -0.0169 -0.0225 -0.0789 -0.0169 -1.3047 -0.1381 -0.0282 -0.0085 -0.0282 -0.3213 -0.0423 -0.1635 -0.0338 -0.0338 -0.2197 -0.3438 -0.0169 -0.0225 -0.0113 -0.0282 -0.0507 -0.1691 -0.3213 -0.2141 -0.2874 -0.0451 -0.3101 -0.0395 -0.1465 -0.4001 -0.0282 -0.0169 -0.0169 -0.0225 -0.0451 -0.0395', 'S-1954\tPatienten mit leichter oder mäßiger Nierenisuffizienz (Kreatininclearance = 20-59 ml / min) sollte die empfohlene Mindestdosis von 400 mg als Anfangsdosis gegeben werden.', 'T-1954\tPatients with mild or moderate renal dysfunction (creatinine clearance = 20 <<unk>> 59 ml / min) should be given the minimum recommended dose of 400 mg daily as starting dose.', 'H-1954\t-0.69580078125\tPatients with mild or moderate renal impairment ( creatinine clearance = 20 @-@ 59 ml / min ) should be given the recommended starting dose of 400 mg .', 'D-1954\t-0.69580078125\tPatients with mild or moderate renal impairment (creatinine clearance = 20-59 ml / min) should be given the recommended starting dose of 400 mg.', 'P-1954\t-0.8340 -0.0176 -0.3411 -0.0824 -0.0430 -0.0232 -0.1183 -0.0197 -0.9243 -0.0465 -0.0296 -0.0268 -0.0310 -0.0395 -0.0211 -0.2903 -0.1071 -0.0564 -0.0254 -0.0423 -0.0254 -0.0423 -0.7578 -0.0648 -0.0282 -0.0225 -0.0338 -0.0366 -0.5859 -0.1240 -0.4199 -0.4199 -0.2930 -0.0282 -0.0395 -0.1071 -0.0282 -0.0620 -0.0282', 'S-862\t≥ 1 / 10 ≥ 1 / 100, < 1 / 10 ≥ 1 / 1.000, < 1 / 100 ≥ 1 / 10.000, < 1 / 1.000 < 1 / 10.000', 'T-862\t≥ 1 / 10 ≥ 1 / 100 to < 1 / 10 ≥ 1 / 1,000 to < 1 / 100 ≥ 1 / 10,000 to < 1 / 1,000', 'H-862\t-0.254150390625\t≥ 1 / 10 ≥ 1 / 100 , &lt; 1 / 10 ≥ 1 / 1,000 , &lt; 1 / 100 ≥ 1 / 10,000 , &lt; 1 / 1,000 &lt; 1 / 10,000', 'D-862\t-0.254150390625\t≥ 1 / 10 ≥ 1 / 100, < 1 / 10 ≥ 1 / 1,000, < 1 / 100 ≥ 1 / 10,000, < 1 / 1,000 < 1 / 10,000', 'P-862\t-0.1266 -0.0291 -0.5024 -0.0334 -0.0021 -0.0285 -0.0296 -0.0254 -0.6050 -0.0176 -0.0345 -0.0225 -0.0296 -0.0296 -0.0296 -0.0056 -0.0282 -0.0282 -0.0521 -0.0254 -0.0141 -0.0310 -0.0225 -0.0268 -0.0296 -0.0240 -0.0042 -0.0282 -0.0296 -0.0155 -0.0254 -0.0127 -0.0282 -0.0211 -0.0268 -0.0310 -0.2423 -0.0155 -0.0225 -0.0225 -0.0324 -0.0296 -0.0141 -0.0268', 'S-406\tEs wurden Daten über die pharmazeutische Qualität, die Sicherheit des Arzneimittels bei Hunden und die Sicherheit beim Menschen (Anwender, die mit dem Arzneimittel in Kontakt kommen) und für die Umwelt vorgelegt.', 'T-406\tData were provided on pharmaceutical quality, the safety of the medicine in dogs and its safety in humans (people who come into contact with the medicine) and in the environment.', 'H-406\t-0.80712890625\tData were provided on the pharmaceutical quality , the safety of the medicine in dogs and the safety in humans ( people in contact with the medicine ) and the environment .', 'D-406\t-0.80712890625\tData were provided on the pharmaceutical quality, the safety of the medicine in dogs and the safety in humans (people in contact with the medicine) and the environment.', 'P-406\t-0.5591 -0.3132 -0.2839 -0.1148 -0.3254 -0.0423 -0.0183 -0.0225 -0.0310 -0.1676 -0.5591 -0.0437 -0.0324 -0.0521 -1.2246 -0.0592 -0.0169 -0.5215 -0.2339 -0.0338 -0.1691 -0.0648 -0.0310 -0.3184 -0.2649 -0.0338 -0.0282 -0.1071 -0.7578 -0.0282 -0.0732 -0.2085 -0.0113 -0.0338 -0.0282', 'S-1692\tAbacavir-, Lamivudin- und Zidovudin-Triphosphate zeigen eine signifikant geringere Affinität zu der DNA-Polymerase der Wirtszellen.', 'T-1692\tAbacavir, lamivudine and zidovudine triphosphates show significantly less affinity for host cell DNA polymerases.', 'H-1692\t-0.5224609375\tAbacavir , lamivudine and zidovudine triphosphates show significantly less affinity for host cell DNA polymerase .', 'D-1692\t-0.5224609375\tAbacavir, lamivudine and zidovudine triphosphates show significantly less affinity for host cell DNA polymerase.', 'P-1692\t-0.0444 -0.0206 -0.2434 -0.0678 -0.0356 -0.0930 -0.0197 -0.0141 -0.0444 -0.0169 -0.3103 -0.0564 -0.0176 -0.0190 -0.0211 -0.0183 -0.0388 -0.0141 -0.1106 -0.0049 -0.0275 -0.2184 -0.3718 -0.4875 -0.0155 -0.0324 -0.0254 -0.9580 -0.3269 -0.1042 -0.0338 -0.0225 -0.0169 -0.5664 -0.0366 -0.0310', 'S-777\tDas Tierarzneimittel kann unbedenklich an Tiere verabreicht werden, die mit adulten Herzwürmern infiziert sind, es hat jedoch keine therapeutische Wirksamkeit gegenüber adulten Dirofilaria immitis.', 'T-777\tAlthough the product may be safely administered to dogs infected with adult heartworms, it has no therapeutic effect against adult Dirofilaria immitis.', 'H-777\t-0.51513671875\tAlthough the product may be safely administered to dogs infected with adult heartworms , it has no therapeutic efficacy against adult Dirofilaria immitis .', 'D-777\t-0.51513671875\tAlthough the product may be safely administered to dogs infected with adult heartworms, it has no therapeutic efficacy against adult Dirofilaria immitis.', 'P-777\t-0.3889 -0.1483 -0.3801 -0.3142 -0.1388 -0.1853 -0.1423 -0.0197 -0.0676 -0.4072 -0.1028 -0.0380 -0.0268 -0.1113 -0.0169 -0.3169 -0.1169 -0.0451 -0.1859 -0.0366 -0.0423 -0.0282 -0.2676 -0.0085 -0.0141 -0.2761 -0.0254 -0.3494 -0.0282 -0.0113 -0.0169 -0.0113 -0.0169 -0.0338 -0.0310', 'S-1900\tDie gleichzeitige Gabe von Rasilez hatte keinen signifikanten Einfluss auf die Pharmakokinetik von Atorvastatin, Valsartan, Metformin oder Amlodipin.', 'T-1900\tCo- administration of Rasilez had no significant impact on atorvastatin, valsartan, metformin or', 'H-1900\t-0.492431640625\tCo- administration of Rasilez had no significant impact on atorvastatin , valsartan , metformin or amlodipine pharmacokinetics .', 'D-1900\t-0.492431640625\tCo- administration of Rasilez had no significant impact on atorvastatin, valsartan, metformin or amlodipine pharmacokinetics.', 'P-1900\t-1.2734 -0.3228 -0.2747 -0.0352 -0.0352 -0.0197 -0.0197 -0.0211 -0.3396 -0.0395 -0.0366 -0.8423 -0.0310 -0.3635 -0.0225 -0.0113 -0.0141 -0.0310 -0.0141 -0.0225 -0.0141 -0.0282 -0.0310 -0.0197 -0.0113 -0.0310 -0.1437 -0.0225 -0.0225 -0.0197 -0.0451 -0.0197 -0.0564 -0.0113 -0.0197 -0.0338 -0.0366 -0.0310', 'S-1925\tIn den beiden anderen Studien mit insgesamt 1 159 Patienten in einem späteren Stadium der Krankheit wurde AZILECT als Zusatzmedikament zu der bereits bestehenden Behandlung mit Levodopa, verabreicht.', 'T-1925\tThe other two studies involved a total of 1,159 patients with later stage disease, where AZILECT was added to the patients <<unk>> existing treatment including levodopa.', 'H-1925\t-0.96435546875\tIn the other two studies , comprising a total of 1,159 patients at a late stage of the disease , AZILECT was added to existing levodopa treatment .', 'D-1925\t-0.96435546875\tIn the other two studies, comprising a total of 1,159 patients at a late stage of the disease, AZILECT was added to existing levodopa treatment.', 'P-1925\t-1.5488 -0.2423 -0.1409 -0.0409 -0.0704 -0.4790 -0.6875 -0.0395 -0.1945 -0.0282 -0.0282 -0.1127 -0.0197 -0.0225 -0.0704 -0.7212 -0.1324 -0.3833 -0.0986 -0.0901 -0.3972 -0.0225 -0.1719 -0.0451 -0.0282 -0.0282 -0.0169 -0.0282 -0.0225 -0.0451 -0.5693 -0.0395 -0.6367 -0.2761 -0.0282 -0.0282 -0.0225 -0.0282 -1.2959 -0.0395 -0.0282', 'S-1413\tErbrechen, Durchfall, Verdauungsstörungen, Bauchschmerzen, anormaler Stuhl, Übelkeit, Kopfschmerzen, erhöhte Triglyceridwerte (Fette) in Ihrem Blut.', 'T-1413\t24 Common (affects 1 to 10 users in 100): vomiting, diarrhoea, indigestion, abdominal pain, abnormal stools, feeling sick, headache, raised levels of triglycerides (fats) in your blood.', 'H-1413\t-0.6513671875\tVomiting , diarrhoea , indigestion , abdominal pain , abnormal stools , nausea , headache , increased triglyceride levels ( fats ) in your blood .', 'D-1413\t-0.6513671875\tVomiting, diarrhoea, indigestion, abdominal pain, abnormal stools, nausea, headache, increased triglyceride levels (fats) in your blood.', 'P-1413\t-1.0977 -0.0085 -0.0296 -0.0296 -0.0254 -0.0099 -0.5552 -0.0141 -0.0310 -0.2339 -0.0099 -0.0268 -0.0310 -0.0732 -0.0282 -0.0183 -0.0479 -0.0296 -0.0324 -0.0085 -0.6157 -0.0085 -0.0282 -0.0169 -0.0056 -0.0310 -0.0085 -0.0085 -0.4565 -0.0338 -0.5605 -0.4875 -0.0141 -0.0310 -0.0085 -0.1071 -0.9551 -0.0423 -0.3042 -0.0113 -0.0282 -0.2649 -0.0282 -0.0225 -0.0338 -0.0282', 'S-551\tPatienten mit Niereninsuffizienz Patienten mit leichter Niereninsuffizienz (Kreatinin-Clearance [CrCl] Dosierungsanpassung von TESAVEL.', 'T-551\t2 Patients with renal insufficiency For patients with mild renal insufficiency (creatinine clearance [CrCl] ≥ 50 ml / min), no dosage adjustment for TESAVEL is required.', 'H-551\t-0.5244140625\tPatients with renal insufficiency For patients with mild renal insufficiency ( creatinine clearance &#91; CrCl &#93; dose adjustment of TESAVEL .', 'D-551\t-0.5244140625\tPatients with renal insufficiency For patients with mild renal insufficiency (creatinine clearance [CrCl] dose adjustment of TESAVEL.', 'P-551\t-0.5132 -0.0218 -0.0349 -0.0634 -0.0243 -0.2603 -0.0099 -0.0141 -0.0225 -1.0527 -0.0648 -0.0324 -0.0775 -0.0113 -0.0254 -0.0958 -0.0042 -0.0183 -0.0240 -0.0493 -0.1113 -0.0211 -0.0254 -0.0324 -0.0282 -0.0211 -0.0493 -0.2410 -0.0282 -0.4932 -0.0310 -0.8228 -0.0620 -0.0141 -0.0282 -0.3833 -0.0310 -0.0169 -0.0282 -0.0225 -0.0141 -0.0535 -0.0310', 'S-168\tBei Patienten mit einer chronischen Nierenerkrankung unter Hämodialyse und mit dem Risiko einer Shunt-Thrombose können sich Blutgerinnsel (Thrombosen) im Verbindungsstück zum', 'T-168\tIf you are a kidney patient under haemodialysis and at risk of shunt thrombosis, blood clots (thromboses) may form in your shunt (vessel used for connection to the dialysis system).', 'H-168\t-1.8359375\tIn patients with chronic kidney disease requiring haemodialysis and at risk of shunt thrombosis , blood clots ( thromboses ) may form in the blood vessels for', 'D-168\t-1.8359375\tIn patients with chronic kidney disease requiring haemodialysis and at risk of shunt thrombosis, blood clots (thromboses) may form in the blood vessels for', 'P-168\t-1.1748 -0.3169 -0.0409 -0.3269 -0.0282 -0.0141 -0.0240 -1.6748 -0.2874 -0.0507 -0.0197 -0.0113 -0.0225 -0.2734 -0.4114 -0.0366 -1.0283 -0.0845 -0.0056 -0.0225 -0.0169 -0.0169 -0.0451 -1.1104 -0.0507 -0.0113 -0.3325 -0.0056 -0.6821 -0.0282 -0.0282 -1.2002 -0.5918 -0.2141 -0.6367 -2.4746 -0.7212 -0.0225 -0.9805 -1.7695', 'S-1805\tEs wird vermutet, dass abhängig von ihrer Aktivität die bakterielle Darmflora zur Einleitung des Abbauvorgangs beitragen könnte, was zu einem unterschiedlichen Ausmaß der Metabolisierung des Moleküls führt.', 'T-1805\tIt is suggested that depending on its activity, the intestinal bacterial flora may contribute to the initiation of the degradation process, thus leading to a variable extent of metabolism of the molecule.', 'H-1805\t-1.81640625\tIt is thought that , depending on its activity , the bacterial intestinal flora may contribute to the initiation of the breakdown process , leading to a variable degree of metabolism of the molecule .', 'D-1805\t-1.81640625\tIt is thought that, depending on its activity, the bacterial intestinal flora may contribute to the initiation of the breakdown process, leading to a variable degree of metabolism of the molecule.', 'P-1805\t-1.0723 -0.3184 -0.5537 -0.2240 -0.4790 -0.6465 -0.0366 -1.7920 -0.1803 -0.0310 -0.5776 -1.1943 -0.0169 -0.0113 -0.4453 -0.0282 -0.0169 -0.0620 -0.0056 -0.6255 -0.4395 -0.0395 -0.2197 -1.3916 -0.0225 -0.0282 -0.3606 -0.6201 -0.8228 -0.4622 -1.4990 -0.0338 -1.0596 -0.7891 -0.1803 -0.7666 -0.0338 -0.5410 -0.0225 -0.2141 -0.0564 -0.0338 -0.2255 -0.0225 -0.0225 -0.0338 -0.0338', 'S-1905\tBei leichter bis moderater Einschränkung der Nierenfunktion ist gemäß pharmakokinetischer Daten keine Dosisanpassung nötig (Kreatinin-Clearance 30-80 ml / min).', 'T-1905\tHepatic impairment: the use of < Nimesulide containing medicinal products > is contraindicated in patients with hepatic impairment (see section 5.2).', 'H-1905\t-1.2548828125\tNo dose adjustment is necessary in patients with mild to moderate renal impairment according to pharmacokinetic data ( creatinine clearance 30 @-@ 80 ml / min ) .', 'D-1905\t-1.2548828125\tNo dose adjustment is necessary in patients with mild to moderate renal impairment according to pharmacokinetic data (creatinine clearance 30-80 ml / min).', 'P-1905\t-1.7881 -0.8892 -0.0578 -0.0155 -0.0366 -0.0690 -0.9170 -1.0059 -0.9243 -0.0676 -0.1465 -0.4453 -0.0169 -0.5186 -0.0225 -0.7212 -0.0169 -0.0113 -0.0282 -1.4482 -0.0282 -0.0225 -0.0169 -0.0113 -0.0676 -0.0225 -0.0338 -0.0564 -0.0169 -0.0395 -0.0395 -0.0338 -0.0225 -0.8174 -1.2451 -0.0225 -0.0225 -0.0338 -0.0225 -0.0338 -0.0338 -0.0338', 'S-950\tEs muss auch erwähnt werden, das bei einer täglichen Dosis von 60 mg der Cmax in Affen (1800 ng / ml) zweimal so hoch ist wie der beim Menschen beobachtete Mittelwert für Cmax.', 'T-950\tIt is also to be noted that the Cmax observed in the monkeys (1800 ng / ml) is two-fold compared to the mean Cmax observed in humans at a daily dose of 60 mg.', 'H-950\t-1.7578125\tIt should also be stated that a 60 mg daily dose of Cmax in monkeys ( 1800 ng / ml ) is twice as high as the mean Cmax value observed in humans .', 'D-950\t-1.7578125\tIt should also be stated that a 60 mg daily dose of Cmax in monkeys (1800 ng / ml) is twice as high as the mean Cmax value observed in humans.', 'P-950\t-1.3154 -1.4238 -0.5352 -0.0254 -1.1611 -0.0507 -1.6875 -1.3359 -0.0338 -0.0451 -0.0338 -0.0564 -0.2141 -0.0169 -0.0789 -0.0451 -0.0113 -0.0451 -0.0845 -0.0225 -0.0225 -0.0282 -0.0395 -0.0282 -0.3718 -0.9131 -1.4141 -0.0732 -0.0395 -0.4790 -1.1611 -0.6426 -0.0113 -1.3076 -0.4170 -0.0451 -0.5522 -0.0338 -0.0338', 'S-1190\tSolche Berichte sollten den Arzt dazu veranlassen, die Zahl der Leukozyten zu überprüfen und im Fall einer Neutropenie die Therapie mit Riluzol abzubrechen (siehe Abschnitt 4.8).', 'T-1190\tThe report of a febrile illness should prompt physicians to check white blood cell counts and to discontinue riluzole in case of neutropenia (see section 4.8).', 'H-1190\t-1.6767578125\tSuch reports should lead the physician to re @-@ evaluate the white blood cell count and , if neutropenia occurs , to discontinue therapy with riluzole ( see section 4.8 ) .', 'D-1190\t-1.6767578125\tSuch reports should lead the physician to re-evaluate the white blood cell count and, if neutropenia occurs, to discontinue therapy with riluzole (see section 4.8).', 'P-1190\t-1.4551 -0.0338 -0.0409 -0.4932 -0.3479 -0.8608 -0.0141 -0.0310 -1.7607 -0.0310 -0.2817 -0.0282 -0.5776 -1.2734 -0.1240 -0.0901 -0.6313 -0.0620 -1.8037 -1.1045 -0.0451 -0.5747 -0.0225 -0.0113 -0.6313 -0.0225 -0.0338 -0.6201 -1.3750 -0.0113 -0.9805 -0.0338 -0.0113 -0.0451 -0.0676 -0.0113 -0.0338 -0.0564 -0.4395 -0.0225 -0.0338 -0.0451 -0.0338 -0.0338', 'S-1966\tExogenes Calcitonin wird aus dem Blutkreislauf rasch eliminiert; die mittlere apparente Halbwertszeit beträgt 1,1 h nach intramuskulärer und 1,1-1,4 h nach subkutaner Anwendung.', 'T-1966\tExogenous calcitonin is rapidly eliminated from the circulation, mean apparent half-lives being 1.1 hours after i. m. and 1.1 - 1.4 hours after subcutaneous. administration.', 'H-1966\t-1.1796875\tExogenous calcitonin is rapidly eliminated from the systemic circulation with a mean half @-@ life of 1.1 h after intramuscular administration and 1.1 @-@ 1.4 h after subcutaneous administration .', 'D-1966\t-1.1796875\tExogenous calcitonin is rapidly eliminated from the systemic circulation with a mean half-life of 1.1 h after intramuscular administration and 1.1-1.4 h after subcutaneous administration.', 'P-1966\t-0.1467 -0.0255 -0.0227 -0.0334 -0.0164 -0.0199 -0.0299 -0.3916 -0.4016 -1.5693 -0.0141 -0.0352 -0.2296 -1.5947 -0.0789 -0.0225 -0.1945 -0.0225 -2.1660 -0.3269 -0.0507 -0.3718 -0.0901 -0.0451 -0.2255 -0.0564 -0.3213 -0.3777 -0.4338 -0.0225 -0.0169 -0.0113 -0.7046 -0.0451 -0.0169 -0.9751 -0.0169 -0.0169 -0.1803 -0.0282 -0.0225 -0.0113 -0.0225 -0.0225 -0.3833 -0.0338 -0.0338', 'S-280\tCCR bestand aus BSC alleine (n = 105), niedrig dosiertem Cytarabin plus BSC (n = 49) oder einer Standard-Induktions-Chemotherapie plus BSC (n = 25).', 'T-280\tCCR consisted of BSC alone (n = 105), low-dose cytarabine plus BSC (n = 49) or standard induction chemotherapy plus BSC (n = 25).', 'H-280\t-0.53759765625\tCCR consisted of BSC alone ( n = 105 ) , low dose cytarabine plus BSC ( n = 49 ) or standard induction chemotherapy plus BSC ( n = 25 ) .', 'D-280\t-0.53759765625\tCCR consisted of BSC alone (n = 105), low dose cytarabine plus BSC (n = 49) or standard induction chemotherapy plus BSC (n = 25).', 'P-280\t-1.3418 -0.0225 -0.0993 -0.0282 -0.0338 -0.0056 -0.2747 -0.0282 -0.0310 -0.0197 -0.0099 -0.0296 -0.4819 -0.0324 -0.7539 -0.0676 -0.0141 -0.0225 -0.0169 -0.2311 -0.0028 -0.0282 -0.0225 -0.0225 -0.3635 -0.0282 -0.3494 -0.1240 -0.0282 -0.0113 -0.0395 -0.0113 -0.0169 -0.2874 -0.0028 -0.0254 -0.0225 -0.0254 -0.0225 -0.0282 -0.0310 -0.0282', 'S-181\tDie PNEC für Wachstumseffekte auf terrestrische Pflanzen beträgt 45 µg / kg, abgeleitet aus einer NOEC von 0,45 mg / kg für P. trivialis und einem Bewertungsfaktor von 10.', 'T-181\tThe PNEC for growth effects on terrestrial plants is 45 µg / kg determined from the NOEC of 0.45 mg / kg for P. trivialis and an assessment factor of 10.', 'H-181\t-0.8466796875\tThe PNEC for growth effects on terrestrial plants is 45 µg / kg , derived from a NOEC of 0.45 mg / kg for P. trivialis and a score of 10 .', 'D-181\t-0.8466796875\tThe PNEC for growth effects on terrestrial plants is 45 µg / kg, derived from a NOEC of 0.45 mg / kg for P. trivialis and a score of 10.', 'P-181\t-1.1396 -0.1113 -0.0162 -0.0268 -0.3064 -0.4424 -0.3086 -0.0549 -0.0395 -0.0070 -0.0240 -0.0944 -0.2423 -0.0521 -0.3494 -0.0197 -0.0310 -0.0197 -0.2339 -2.7539 -0.0282 -0.0282 -0.0507 -0.0451 -0.0169 -0.0451 -0.0451 -0.0282 -0.0113 -0.0282 -0.0169 -0.0338 -0.0225 -0.0169 -0.0225 -0.0338 -0.0282 -0.0507 -0.5469 -0.4453 -0.0338 -0.0338 -0.2874 -0.0282', 'S-1196\tWährend der 24-wöchigen Doppelblindphase erhielten die Patienten entweder 5 mg / kg Infliximab oder Placebo in den Wochen 0, 2, 6, 14 und 22 (100 Patienten je Gruppe).', 'T-1196\tDuring the 24-week double-blind phase, patients received either 5 mg / kg infliximab or placebo at weeks 0, 2, 6, 14, and 22 (100 patients', 'H-1196\t-0.81103515625\tDuring the 24 @-@ week double @-@ blind phase , patients received either 5 mg / kg infliximab or placebo at weeks 0 , 2 , 6 , 14 and 22 ( 100 patients in each group ) .', 'D-1196\t-0.81103515625\tDuring the 24-week double-blind phase, patients received either 5 mg / kg infliximab or placebo at weeks 0, 2, 6, 14 and 22 (100 patients in each group).', 'P-1196\t-0.1926 -0.4417 -0.1969 -0.5454 -0.0155 -0.1705 -0.2014 -0.0479 -0.9258 -0.2128 -0.0479 -0.0845 -0.9663 -0.7324 -0.0085 -0.0310 -0.0169 -0.1212 -0.4790 -0.0225 -0.0225 -0.0366 -0.0395 -0.0197 -0.0169 -0.0225 -0.1296 -0.7720 -0.0338 -0.0282 -0.0282 -0.0282 -0.0282 -0.0282 -0.0169 -0.7271 -0.0225 -0.0338 -0.0282 -0.0395 -0.3381 -0.0282 -0.0451 -0.0282 -0.0338 -0.0282', 'S-1823\tDa eine derartige Dosisreduktion mit Trizivir nicht möglich ist, sind Abacavir-, Lamivudin- und Zidovudin-haltige Monopräparate anzuwenden.', 'T-1823\tAs dosage adjustment of Trizivir is not possible separate preparations of zidovudine, abacavir and lamivudine should be used.', 'H-1823\t-0.693359375\tAs dosage adjustment of Trizivir is not possible , separate preparations of abacavir , lamivudine and zidovudine should be used .', 'D-1823\t-0.693359375\tAs dosage adjustment of Trizivir is not possible, separate preparations of abacavir, lamivudine and zidovudine should be used.', 'P-1823\t-0.3682 -0.3320 -0.0754 -0.0345 -0.9424 -0.0070 -0.1423 -0.3086 -0.3169 -0.1395 -0.0282 -0.0169 -0.1057 -0.1099 -0.1437 -0.8003 -0.3240 -0.2057 -0.0254 -0.3184 -0.0901 -0.0225 -0.2311 -0.0169 -0.0338 -0.0338 -0.0197 -0.0113 -0.0507 -0.0254 -0.3945 -0.0507 -0.0197 -0.0197 -0.0225 -0.0395 -0.2593 -0.0338 -0.2479 -0.0395 -0.0282', 'S-1814\tEine Distribution von Ambrisentan in die roten Blutzellen findet nur in geringem Umfang statt; der mittlere Blut / Plasma-Quotient beträgt 0,57 bei Männern und 0,61 bei Frauen.', 'T-1814\tThe distribution of ambrisentan into red blood cells is low, with a mean blood: plasma ratio of 0.57 and 0.61 in males and females, respectively.', 'H-1814\t-1.0869140625\tAmbrisentan is moderately distributed into red blood cells ; the mean blood @-@ to @-@ plasma ratio is 0.57 for males and 0.61 for females .', 'D-1814\t-1.0869140625\tAmbrisentan is moderately distributed into red blood cells; the mean blood-to-plasma ratio is 0.57 for males and 0.61 for females.', 'P-1814\t-1.7988 -0.0155 -0.0042 -0.1324 -0.0859 -0.4016 -0.0183 -0.0479 -0.0155 -1.2100 -0.1409 -0.0254 -0.0197 -1.6006 -0.0535 -0.0873 -0.4678 -1.0762 -0.2537 -0.0282 -0.0282 -0.0113 -0.0113 -0.0282 -0.1691 -0.0338 -0.0169 -0.8906 -0.7495 -0.0225 -0.0338 -0.0169 -0.0169 -0.0338 -0.0225 -0.0056 -0.0338 -0.0338', 'S-464\tHierdurch wird die Bildung von Schaum (Blasenbildung) unterdrückt. • Sobald sich das Lösungsmittel in der Enbrel-Durchstechflasche befindet, kann sich der Kolben selbständig nach oben bewegen.', 'T-464\tThis will help to reduce foaming (lots of bubbles). <<unk>> Once the solvent is added to the Enbrel, the plunger may move up by itself.', 'H-464\t-1.283203125\tThis suppresses foaming . • Once the solvent is added to the Enbrel , the plunger may move up by itself .', 'D-464\t-1.283203125\tThis suppresses foaming. • Once the solvent is added to the Enbrel, the plunger may move up by itself.', 'P-464\t-0.5630 -1.4775 -0.0211 -0.2507 -0.3113 -1.2529 -0.5327 -0.9834 -0.0507 -0.0451 -0.0197 -0.0732 -0.5664 -0.0451 -0.0395 -0.0507 -0.0169 -0.0225 -1.3584 -0.0451 -0.2874 -0.0113 -0.3494 -0.1296 -0.1917 -0.3550 -0.0225 -0.2874 -0.3157', 'S-299\tFalls Patienten Symptome im Zusammenhang mit der Behandlung zeigen, die ihr Sehvermögen und / oder ihre Konzentrations- und Reaktionsfähigkeit beeinflussen, wird empfohlen, dass sie kein Kraftfahrzeug führen oder Maschinen bedienen, bis diese Symptome nachlassen.', 'T-299\tIf patients experience treatment-related symptoms affecting their vision and / or ability to concentrate and react, it is recommended that they do not drive or use machines until the effect subsides.', 'H-299\t-1.5615234375\tIf patients show treatment @-@ related symptoms affecting their vision and / or concentration and ability to react , it is recommended that they avoid driving or operating machinery until these symptoms abate .', 'D-299\t-1.5615234375\tIf patients show treatment-related symptoms affecting their vision and / or concentration and ability to react, it is recommended that they avoid driving or operating machinery until these symptoms abate.', 'P-299\t-0.7183 -0.0694 -1.9424 -0.7241 -0.0564 -0.1155 -0.0254 -0.8789 -0.3606 -0.9243 -0.3606 -0.0282 -0.0282 -0.4395 -0.0958 -0.8677 -0.0282 -0.3889 -0.0676 -0.1465 -0.0338 -0.0789 -0.0564 -0.0338 -1.3525 -0.0282 -0.3945 -0.0845 -0.2649 -0.0225 -0.0169 -0.0507 -1.4092 -0.2593 -1.4092 -0.0113 -0.0338 -0.0338', 'S-1547\tBei Frauen mit Eileitererkrankungen in der Anamnese besteht das Risiko einer ektopen Schwangerschaft, unabhängig davon, ob die Schwangerschaft durch spontane Konzeption oder durch Fertilitätsbehandlungen eingetreten ist.', 'T-1547\tWomen with a history of tubal disease are at risk of ectopic pregnancy, whether the pregnancy is obtained by spontaneous conception or with fertility treatments.', 'H-1547\t-0.92138671875\tWomen with a history of tubal disease are at risk of ectopic pregnancy , whether the pregnancy is obtained by spontaneous conception or with fertility treatments .', 'D-1547\t-0.92138671875\tWomen with a history of tubal disease are at risk of ectopic pregnancy, whether the pregnancy is obtained by spontaneous conception or with fertility treatments.', 'P-1547\t-0.4148 -0.0743 -0.2371 -0.3333 -0.0282 -1.2090 -0.0183 -0.0127 -0.1663 -0.2382 -0.1099 -0.0465 -0.3662 -0.2874 -0.0113 -0.0366 -1.4707 -0.3015 -0.1747 -0.0254 -0.3101 -0.3213 -0.1973 -0.0338 -0.0113 -0.0225 -0.0056 -0.5806 -0.0338 -0.3213 -0.0282 -0.0225 -0.2649 -0.0338 -0.0282', 'S-790\tEs wurden vier Studien mit ZIMULTI an übergewichtigen Patienten und Patienten mit Adipositas durchgeführt, an denen etwa 7 000 Patienten teilnahmen, deren Gewicht zu Beginn der Studien durchschnittlich bei 94 bis 104 kg lag.', 'T-790\tOne study looked more dic', 'H-790\t-1.7919921875\tFour studies of ZIMULTI in overweight and obese patients were carried out in a total of about 7,000 patients with a mean baseline weight of 94 to 104 kg .', 'D-790\t-1.7919921875\tFour studies of ZIMULTI in overweight and obese patients were carried out in a total of about 7,000 patients with a mean baseline weight of 94 to 104 kg.', 'P-790\t-0.2014 -0.2145 -1.5732 -0.1846 -0.0085 -0.0113 -0.0338 -0.0409 -0.7383 -0.2227 -0.0113 -0.8174 -0.1268 -0.0197 -0.3718 -0.5410 -0.7778 -0.0282 -1.0986 -0.6255 -1.0938 -0.0620 -1.7471 -0.1973 -0.0676 -1.2002 -0.9805 -0.2255 -0.6313 -0.0113 -0.1578 -0.5410 -0.2255 -0.8564 -0.0225 -0.0564 -0.1353 -0.0338', 'S-1551\tJede Tablette Irbesartan Hydrochlorothiazide Winthrop 150 mg / 12,5 mg enthält 150 mg Irbesartan und 12,5 mg Hydrochlorothiazid.', 'T-1551\tEach tablet of Irbesartan Hydrochlorothiazide Winthrop 150 mg / 12.5 mg contains 150 mg irbesartan and 12.5 mg hydrochlorothiazide.', 'H-1551\t-0.17431640625\tEach tablet of Irbesartan Hydrochlorothiazide Winthrop 150 mg / 12.5 mg contains 150 mg irbesartan and 12.5 mg hydrochlorothiazide .', 'D-1551\t-0.17431640625\tEach tablet of Irbesartan Hydrochlorothiazide Winthrop 150 mg / 12.5 mg contains 150 mg irbesartan and 12.5 mg hydrochlorothiazide.', 'P-1551\t-0.0715 -0.0641 -0.0234 -0.0481 -0.2593 -0.0092 -0.0085 -0.0225 -0.0796 -0.0085 -0.0225 -0.0092 -0.0257 -0.0120 -0.0190 -0.0070 -0.0271 -0.0141 -0.0049 -0.0240 -0.0465 -0.0127 -0.0310 -0.0782 -0.0359 -0.0155 -0.0366 -0.0254 -0.0099 -0.3101 -0.0113 -0.0085 -0.0296 -0.0345 -0.0141 -0.0240 -0.0141 -0.0690 -0.0240 -0.0099 -0.0240 -0.0099 -0.0268 -0.0056 -0.0254 -0.0338 -0.0296', 'S-1043\tEs liegen Berichte über vermehrte Blutungen einschließlich spontaner kutaner Hämatome und Hämarthrosen bei Patienten mit Hämophilie A und B vor, die mit Proteasehemmern behandelt wurden.', 'T-1043\t3 There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in type A and B haemophiliac patients treated with protease inhibitors.', 'H-1043\t-0.6611328125\tThere have been reports of increased bleeding , including spontaneous skin haematomas and haemarthroses , in patients with haemophilia A and B treated with protease inhibitors .', 'D-1043\t-0.6611328125\tThere have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in patients with haemophilia A and B treated with protease inhibitors.', 'P-1043\t-0.9033 -0.2382 -0.0296 -0.0613 -0.0331 -0.0627 -0.1120 -0.0225 -0.2197 -0.0310 -0.0296 -0.0085 -0.0268 -0.3438 -0.2734 -0.0662 -0.0141 -0.4749 -0.0225 -0.0395 -0.2113 -0.1071 -0.1353 -0.9917 -0.0113 -0.0366 -0.7158 -0.0535 -0.1324 -0.1945 -0.1437 -0.0254 -0.0056 -0.0169 -0.3269 -0.0338 -0.0169 -0.2593 -0.0338 -0.0395 -0.0113 -0.0282 -0.0169 -0.0169 -0.0282 -0.0282 -0.0282', 'S-197\tGenerell weisen Daten von intramuskulär verabreichten Influenza-Impfungen bei schwangeren Frauen auf keine negativen Folgen für den Fetus oder die Mutter hin, die auf den Impfstoff zurückzuführen wären.', 'T-197\tIn general data from intramuscular influenza vaccinations in pregnant women do not indicate adverse fetal and maternal outcomes attributable to the vaccine.', 'H-197\t-1.5029296875\tIn general , data from intramuscular influenza vaccinations in pregnant women do not indicate that adverse foetal and maternal outcomes were attributable to the vaccine .', 'D-197\t-1.5029296875\tIn general, data from intramuscular influenza vaccinations in pregnant women do not indicate that adverse foetal and maternal outcomes were attributable to the vaccine.', 'P-197\t-0.2754 -0.0292 -0.3689 -0.1853 -0.4910 -1.7949 -0.0338 -0.0169 -0.4226 -0.1381 -0.0085 -0.0282 -0.1888 -0.6592 -0.5103 -0.0169 -0.0254 -0.9326 -0.0282 -0.4453 -0.8286 -0.7778 -0.0056 -0.9976 -0.3438 -0.0620 -0.8115 -0.0395 -0.0056 -0.0282 -0.5859 -0.0169 -1.4766 -0.3718 -0.6084 -0.0225 -0.0338 -0.2479 -0.0225 -0.0338 -0.0338', 'S-641\t0,5 ml Suspension in einer Fertigspritze (Glas Typ I) mit einem Gummistopfen (Chlorobutyl) mit Kanüle - Packungen mit 1, 10, 25 und 50 Dosen.', 'T-641\t0.5 ml of suspension in pre-filled syringe (type I glass) with a plunger stopper (chlorobromobutyl) with attached needle - pack of 1, 10, 25 and 50.', 'H-641\t-0.79296875\t0.5 ml of suspension in pre @-@ filled syringe ( type I glass ) with a plunger stopper ( chlorobutyl ) with needle - pack of 1 , 10 , 25 and 50 .', 'D-641\t-0.79296875\t0.5 ml of suspension in pre-filled syringe (type I glass) with a plunger stopper (chlorobutyl) with needle - pack of 1, 10, 25 and 50.', 'P-641\t-0.1120 -0.0199 -0.6016 -0.1276 -0.0627 -0.5684 -0.0282 -0.1409 -0.0197 -0.0099 -0.0042 -0.0564 -0.8550 -0.0437 -0.0380 -0.0324 -0.0901 -0.1930 -0.4678 -0.1635 -0.3352 -0.0254 -0.0620 -0.0338 -0.0085 -0.0310 -0.6592 -0.0169 -0.0310 -0.1437 -1.1328 -0.0225 -0.1296 -0.3269 -0.1973 -0.0282 -0.0282 -0.0282 -0.0282 -0.0282 -0.2479 -0.0282 -0.4453 -0.0282', 'S-247\tDie häufigsten Nebenwirkungen bei Erwachsenen sind Myalgie (Muskelschmerzen), Arthralgie (Gelenkschmerzen) und Ödeme (Schwellungen), diese wurde bei mehr als 1 von 10 Patienten beobachtet.', 'T-247\tThe most common side effects in adults are myalgia (muscle pain), arthralgia (joint pain) and oedema (swelling), and these are seen in more than 1 in 10 patients.', 'H-247\t-0.55908203125\tThe most common side effects in adults are myalgia ( muscle pain ) , arthralgia ( joint pain ) and oedema ( swelling ) , seen in more than 1 in 10 patients .', 'D-247\t-0.55908203125\tThe most common side effects in adults are myalgia (muscle pain), arthralgia (joint pain) and oedema (swelling), seen in more than 1 in 10 patients.', 'P-247\t-0.2996 -0.0357 -0.0620 -0.2761 -0.0356 -0.1138 -0.0296 -0.0684 -0.0218 -0.0211 -0.0127 -0.0338 -0.2676 -0.2522 -0.0296 -0.0296 -0.0268 -0.0789 -0.0465 -0.0240 -0.0183 -0.0282 -0.0240 -0.0324 -0.0296 -0.2690 -0.1676 -0.0310 -0.0028 -0.0296 -0.0099 -0.0282 -0.0310 -0.3367 -1.0732 -0.0282 -0.2367 -0.0282 -0.0535 -1.0449 -0.0310 -0.0479 -0.0338 -0.0310', 'S-1192\tDie Kombination von Remicade und Anakinra wird nicht empfohlen (siehe Abschnitt 4.4 <unk> <unk> Gleichzeitige Anwendung eines TNF-alpha-Inhibitors und Anakinra <unk>).', 'T-1192\tThe combination of Remicade and anakinra is not recommended (see section 4.4 - "Concurrent administration of TNF-alpha inhibitor and anakinra <<unk>>).', 'H-1192\t-0.9912109375\tThe combination of Remicade and anakinra is not recommended ( see section 4.4 ) .', 'D-1192\t-0.9912109375\tThe combination of Remicade and anakinra is not recommended (see section 4.4).', 'P-1192\t-1.1123 -0.3303 -0.0296 -0.0423 -0.0113 -0.0085 -0.0310 -0.1818 -0.0282 -0.0254 -0.0648 -0.0395 -0.0310 -0.0395 -0.0395 -0.0451 -0.1663 -0.0211 -0.5044 -0.8804 -2.2520 -0.4509', 'S-561\t431 Ελλάδα Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ: + 30-210 98 97 300', 'T-561\tΕλλάδα Αγίου Δημητρίου 63 GR-174 55 Άλιμος Tηλ: + 30-210 98 97 300', 'H-561\t-0.60498046875\tGR @-@ 174 55 Άλιμος Tηλ : + 30 @-@ 210 98 97 300', 'D-561\t-0.60498046875\tGR-174 55 Άλιμος Tηλ: + 30-210 98 97 300', 'P-561\t-2.1309 -0.1198 -0.1057 -0.1423 -0.0366 -0.1367 -0.3269 -0.1691 -0.1296 -0.0056 -0.0535 -0.0958 -0.1183 -0.0423 -0.0169 -0.0310 -0.0395 -0.0282 -0.0310 -0.0113 -0.0197 -0.0169 -0.0282 -0.2367', 'S-1314\t71,4% der Patienten hatten zuvor eine Therapie mit PUVA, Methotrexat, Ciclosporin oder Acitretin erhalten, wobei diese nicht notwendigerweise therapieresistent waren.', 'T-1314\tPrior therapy with PUVA, methotrexate, cyclosporin, or acitretin had been received by 71.4% of patients, although they were not necessarily therapy resistant.', 'H-1314\t-1.5595703125\t71.4 % of the patients had previously received treatment with PUVA , methotrexate , ciclosporin or acitretin , although they were not necessarily refractory .', 'D-1314\t-1.5595703125\t71.4% of the patients had previously received treatment with PUVA, methotrexate, ciclosporin or acitretin, although they were not necessarily refractory.', 'P-1314\t-0.4243 -0.0264 -0.0285 -0.4963 -1.1572 -0.2479 -0.0775 -1.3057 -0.2593 -2.5137 -0.5186 -0.0395 -0.0282 -0.0113 -0.0338 -0.2029 -0.0225 -0.0282 -0.0225 -0.0225 -0.0282 -0.8677 -0.0113 -0.0113 -0.0113 -0.3042 -0.4734 -0.1521 -0.0225 -0.0282 -0.0282 -0.8228 -1.6289 -1.2510 -0.3042 -0.0338 -0.4395 -0.5073 -0.0338 0.0000 -0.3833 -0.0564 -0.0338', 'S-225\tWenn Sie sich einer Operation unterziehen müssen, informieren Sie bitte Ihren Arzt über Ihre Behandlung mit NeuroBloc, da es zu Wechselwirkungen mit den Arzneimitteln, die vor einer Vollnarkose verabreicht werden, kommen kann.', 'T-225\tIf you are going to have an operation, please tell your doctor if you have been given NeuroBloc as it can interfere with medicines you may be given before a general anaesthetic.', 'H-225\t-1.451171875\tIf you have to undergo surgery , tell your doctor about your treatment with NeuroBloc , as there may be interactions with medicines taken prior to general anaesthesia .', 'D-225\t-1.451171875\tIf you have to undergo surgery, tell your doctor about your treatment with NeuroBloc, as there may be interactions with medicines taken prior to general anaesthesia.', 'P-225\t-0.0826 -0.0328 -0.4395 -0.1655 -0.1782 -0.0225 -0.3176 -0.0620 -1.4736 -0.0352 -0.0380 -0.2339 -0.1747 -0.0620 -0.0423 -0.0225 -0.0197 -0.0282 -1.3975 -0.8286 -1.5947 -0.9297 -0.0338 -0.2255 -0.2593 -0.0395 -1.2568 -0.1521 -1.2344 -0.8564 -0.0338 -0.2367 -0.0225 -0.1465 -0.1014 -0.0225 -0.0338 -0.0338', 'S-1279\tReversible Azo- und Oligospermie wurde in seltenen Fällen beim Menschen beobachtet, wobei diese Störungen auch mit der zugrunde liegenden Krankheit assoziiert sind (siehe 4.8, 5.3).', 'T-1279\tReversible azo- and oligo-spermia have been rarely observed in man, although these disorders are also associated with the underlying disease (see 4.8, 5.3).', 'H-1279\t-1.0888671875\tReversible azo- and oligospermia have been observed rarely in humans , but these disorders are also associated with the underlying disease ( see sections 4.8 and 5.3 ) .', 'D-1279\t-1.0888671875\tReversible azo- and oligospermia have been observed rarely in humans, but these disorders are also associated with the underlying disease (see sections 4.8 and 5.3).', 'P-1279\t-0.0693 -0.0156 -0.0170 -0.0042 -0.5200 -0.0299 -0.0327 -0.0204 -0.0056 -0.0240 -0.0268 -0.0070 -1.5615 -0.3452 -0.9199 -0.8677 -0.0310 -0.2339 -0.9385 -0.5239 -0.8340 -0.1240 -0.0169 -0.4734 -0.2761 -0.0507 -0.0282 -0.0901 -0.0282 -0.1859 -0.3269 -0.0564 -0.3213 -0.0169 -0.0282 -0.9131 -0.0225 -0.0282 -0.0395 -0.0282 -0.0282', 'S-635\tMecasermin ist ein aus Escherichia coli-Zellen mittels rekombinanter DNA-Technologie gewonnener humaner Insulin-like Growth Factor-1 (IGF-1).', 'T-635\tMecasermin is a recombinant DNA-derived human insulin-like growth factor-1 (IGF-1) produced in Escherichia coli.', 'H-635\t-0.4375\tMecasermin is a human insulin @-@ like growth factor @-@ 1 ( IGF @-@ 1 ) derived from Escherichia coli cells by recombinant DNA technology .', 'D-635\t-0.4375\tMecasermin is a human insulin-like growth factor-1 (IGF-1) derived from Escherichia coli cells by recombinant DNA technology.', 'P-635\t-0.4990 -0.0141 -0.0197 -0.0204 -0.2524 -0.0366 -0.0578 -0.0240 -0.0373 -0.0099 -0.0373 -0.0268 -0.0324 -0.0134 -0.0712 -0.0310 -0.0296 -0.0070 -0.0190 -0.0275 -0.0310 -0.0289 -1.6650 -0.0197 -0.0338 -0.0592 -0.0056 -0.0085 -0.0169 -0.0225 -0.0254 -0.0225 -0.3042 -0.1859 -0.0225 -0.0141 -0.0366 -0.0169 -0.2113 -0.0310 -0.0310', 'S-1461\tBei Patienten, die Tasigna nehmen, sind daher für die gleichzeitige Gabe andere Therapeutika mit geringerem Potenzial zur CYP3A4-Induktion zu wählen (siehe Abschnitt 4.5).', 'T-1461\tTherefore, in patients receiving Tasigna, coadministration of alternative therapeutic agents with less potential for CYP3A4 induction should be selected (see section 4.5).', 'H-1461\t-1.2119140625\tIn patients who are taking Tasigna , alternative agents with less potential for CYP3A4 induction should be selected for coadministration ( see section 4.5 ) .', 'D-1461\t-1.2119140625\tIn patients who are taking Tasigna, alternative agents with less potential for CYP3A4 induction should be selected for coadministration (see section 4.5).', 'P-1461\t-0.4590 -0.0518 -0.7954 -0.6099 -0.0775 -0.5537 -0.0099 -0.0056 -0.1324 -0.3706 -0.8198 -0.0789 -0.4790 -0.0564 -0.8540 -0.4958 -0.0282 -0.5015 -0.0225 -0.0113 -0.4678 -0.0169 -0.2817 -0.7554 -0.5469 -0.0901 -1.1328 -0.2817 -0.0507 -0.0395 -0.1859 -0.0225 -0.0282 -0.0338 -0.0282 -0.0282', 'S-572\tSie sollten daher zusammen mit Ihrem Arzt die Vorteile von Retacrit abwägen, insbesondere dann, wenn Sie übergewichtig sind oder wenn bei Ihnen schon einmal Blutgerinnsel oder Blutgerinnungsstörungen aufgetreten sind.', 'T-572\tTherefore, you should discuss the benefits of Retacrit with your doctor, particularly if you are obese or have a history of blood clots / blood clotting disorders.', 'H-572\t-0.8388671875\tTherefore , you should discuss the benefits of Retacrit with your doctor , particularly if you are obese or have a history of blood clots / blood clotting disorders .', 'D-572\t-0.8388671875\tTherefore, you should discuss the benefits of Retacrit with your doctor, particularly if you are obese or have a history of blood clots / blood clotting disorders.', 'P-572\t-0.2910 -0.0178 -0.1326 -0.1007 -0.1451 -0.3257 -0.6904 -0.1747 -0.0338 -0.4819 -0.0310 -0.1550 -0.0437 -0.0296 -0.0916 -0.0521 -0.2551 -0.0676 -0.0282 -0.0451 -0.7129 -0.0197 -0.3777 -0.1606 -0.2705 -0.0338 -0.0282 -0.1775 -0.0254 -0.0254 -1.3047 -0.3269 -0.0732 -0.5298 -0.0282 -0.1803 -0.0169 -0.0395 -0.0338', 'S-3\tMetabolismus und Ausscheidung von Dabigatran wurden nach einmaliger intravenöser Gabe von radioaktiv markiertem Dabigatran bei gesunden männlichen Probanden untersucht.', 'T-3\tMetabolism and excretion of dabigatran were studied following a single intravenous dose of radiolabeled dabigatran in healthy male subjects.', 'H-3\t-1.14453125\tThe disposition of dabigatran was studied in healthy male volunteers following a single intravenous dose of radiolabelled dabigatran .', 'D-3\t-1.14453125\tThe disposition of dabigatran was studied in healthy male volunteers following a single intravenous dose of radiolabelled dabigatran.', 'P-3\t-1.0254 -0.6235 -0.3269 -0.7817 -0.1254 -0.0197 -0.0141 -0.0169 -0.0085 -0.2874 -0.5103 -0.1859 -0.1831 -0.2507 -0.2227 -1.3359 -1.0596 -0.0845 -0.1071 -0.0169 -0.0113 -0.0225 -0.9185 -0.0338 -0.6763 -0.2367 -0.1635 -0.2649 -0.0338 -0.0169 -0.0113 -0.0169 -0.0056 -0.0395 -0.0282', 'S-1299\tBei älteren Patienten soll mit einer Initialdosis von 2 mg begonnen werden, die schrittweise nach einem Monat auf 4 mg und dann wenn nötig in Abhängigkeit von der Nierenfunktion auf 8 mg erhöht werden kann (siehe Tabelle).', 'T-1299\tblister strip in', 'H-1299\t-2.166015625\tIn elderly patients , a starting dose of 2 mg should be administered and then increased gradually to 4 mg after one month then to 8 mg depending on renal function ( see Table ) .', 'D-1299\t-2.166015625\tIn elderly patients, a starting dose of 2 mg should be administered and then increased gradually to 4 mg after one month then to 8 mg depending on renal function (see Table).', 'P-1299\t-1.5938 -1.1270 -0.2578 -0.2986 -2.1211 -0.8511 -0.0338 -0.0395 -0.0958 -0.0169 -0.1409 -0.2705 -0.8003 -0.0169 -2.0176 -0.7720 -0.5073 -0.7832 -0.1240 -0.0338 -0.0113 -0.3718 -1.1270 -0.0338 -1.9277 -1.5107 -0.0225 -0.0113 -0.9468 -0.0338 -0.2930 -0.0225 -0.0113 -0.1127 -0.0338 -1.0146 -0.0564 -0.0338 -0.0338', 'S-1285\t12 ANGABEN AUF DER ÄUSSEREN UMHÜLLUNG FALTSCHACHTEL FÜR EINE EINZELNE 5 ML-FLASCHE', 'T-1285\t12 PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON FOR SINGLE BOTTLE 5 ml', 'H-1285\t-0.990234375\t12 PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON FOR SINGLE BOTTLE 5 ML', 'D-1285\t-0.990234375\t12 PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON FOR SINGLE BOTTLE 5 ML', 'P-1285\t-0.4001 -0.3228 -0.2910 -0.0444 -0.3022 -0.1683 -0.1423 -0.3157 -0.3228 -0.2649 -0.1986 -0.2930 -0.2930 -0.1240 -0.0704 -0.0592 -0.0366 -0.1747 -0.3184 -0.3157 -0.0958 -0.0254 -0.3071 -0.3213 -0.2930 -0.3042 -0.3213 -0.1014 -0.0169 -0.3606 -0.0169 -0.0113 -0.0056 -0.7212 -0.0225 -0.0338 -0.0564 -0.7891 -0.5127 -0.0169 -0.4001', 'S-399\tDer vorgefüllte PegIntron-Injektor enthält ein Pulver mit Peginterferon alfa-2b in einer Stärke von 80 Mikrogramm zur Einmalanwendung und ein Lösungsmittel zur Auflösung.', 'T-399\tPegIntron pre-filled pen contains a powder of peginterferon alfa-2b and a solvent for solution at a strength of 80 micrograms for single use.', 'H-399\t-0.58984375\tPegIntron pre @-@ filled pen contains a powder of peginterferon alfa @-@ 2b and a solvent for solution at a strength of 80 micrograms for single use .', 'D-399\t-0.58984375\tPegIntron pre-filled pen contains a powder of peginterferon alfa-2b and a solvent for solution at a strength of 80 micrograms for single use.', 'P-399\t-0.5757 -0.0299 -0.0271 -0.0141 -0.0257 -0.2937 -0.0282 -0.0444 -0.3220 -0.1310 -0.0817 -0.2014 -0.2479 -0.2410 -0.0282 -0.0127 -0.0141 -0.0282 -0.0380 -0.0127 -0.0282 -0.0254 -0.0254 -0.5693 -0.1578 -0.1831 -0.0169 -0.2113 -0.3184 -0.2507 -0.1973 -0.2761 -0.0310 -0.0423 -0.0535 -0.0901 -0.1888 -0.2197 -0.1014 -0.0535 -0.0338', 'S-275\t16 Die Wirksamkeit und die Sicherheit von Biograstim wurden in randomisierten, kontrollierten Phase- III-Studien an Patienten mit Brustkrebs, Lungenkrebs und Non-Hodgkin-Lymphom untersucht.', 'T-275\tThe efficacy and safety of Biograstim has been assessed in randomised, controlled phase III studies in breast cancer, lung cancer and Non-Hodgkin-Lymphoma.', 'H-275\t-0.73779296875\tThe efficacy and safety of Biograstim has been assessed in randomised , controlled phase III studies in breast cancer , lung cancer and Non @-@ Hodgkin @-@ Lymphoma .', 'D-275\t-0.73779296875\tThe efficacy and safety of Biograstim has been assessed in randomised, controlled phase III studies in breast cancer, lung cancer and Non-Hodgkin-Lymphoma.', 'P-275\t-0.4177 -0.2761 -0.0106 -0.0183 -0.0275 -0.0183 -0.0310 -0.2346 -0.0211 -0.0486 -0.0134 -0.8975 -0.0310 -0.2888 -0.0141 -0.0395 -0.0930 -0.2072 -0.0085 -0.0240 -0.3423 -0.1550 -0.1719 -0.0225 -0.4282 -0.1071 -0.3579 -0.2367 -0.0282 -0.0254 -0.0169 -0.4368 -0.4368 -0.0366 -0.0056 -0.0141 -1.0732 -0.1127 -0.0169 -0.0113 -0.1521 -0.0338', 'S-1513\tIhre Tätigkeit umfaßte außerdem die allgemeine Beratung in Fragen der Herstellung und Kontrolle von biotechnologischen und biologischen Arzneimitteln, darunter von aus Blut und Blutplasma gewonnenen Präparaten und immunologischen Präparaten.', 'T-1513\tGeneral advice has also been given on the manufacture and control of biotechnological and biological medicinal products, including products derived from blood and plasma, and of immunological products.', 'H-1513\t-2.162109375\tFrench', 'D-1513\t-2.162109375\tFrench', 'P-1513\t-2.9531 -0.3240', 'S-198\tEine Wirksamkeit von Ceftriaxon kann bei der Mehrzahl der Bakterien, die Penicillin-bindende Proteine mit reduzierter Affinität für Beta- Laktame aufweisen, nicht erwartet werden.', 'T-198\tCeftriaxone cannot be expected to be active against the majority of bacteria with penicillin-binding proteins that have reduced affinity for beta-lactam medicinal products.', 'H-198\t-1.1572265625\tThe efficacy of ceftriaxone cannot be expected in the majority of bacteria possessing penicillin @-@ binding proteins with reduced affinity for Beta @-@ lactams .', 'D-198\t-1.1572265625\tThe efficacy of ceftriaxone cannot be expected in the majority of bacteria possessing penicillin-binding proteins with reduced affinity for Beta-lactams.', 'P-198\t-0.7817 -0.7622 -0.0099 -0.0169 -0.0282 -0.0704 -0.0099 -0.0155 -0.0127 -0.0183 -1.1768 -0.0282 -0.0366 -0.5469 -0.0958 -0.0366 -0.0282 -0.0395 -2.3730 -0.0282 -0.1014 -0.0225 -0.0169 -0.0282 -0.5581 -0.0169 -0.0225 -0.0225 -0.0113 -0.4790 -1.0371 -0.0225 -0.0282 -0.0282 -0.8398 -0.4958 -0.0395 -0.1635 -0.6426 -0.0113 -0.2874 -0.0338 -0.0338', 'S-898\tBetarezeptorenblocker, Angiotensin-Converting-Enzyme (ACE) -Hemmer, Salicylate, Alkohol, anabole Steroide oder Sulfonamide. ni', 'T-898\tis blocking agents, angiotensin converting enzyme (ACE) inhibitors, salicylates, alcohol, anabolic steroids or sulphonamides.', 'H-898\t-0.748046875\tge receptor blockers , angiotensin converting enzyme ( ACE ) inhibitors , salicylates , alcohol , anabolic steroids or sulphonamides .', 'D-898\t-0.748046875\tge receptor blockers, angiotensin converting enzyme (ACE) inhibitors, salicylates, alcohol, anabolic steroids or sulphonamides.', 'P-898\t-0.5093 -3.0117 -0.0085 -0.0282 -0.1183 -0.0282 -0.0310 -0.0310 -0.0169 -0.0197 -0.0141 -0.0282 -0.1014 -0.0254 -0.0085 -0.3157 -0.0704 -0.0423 -0.0197 -0.0254 -0.0282 -0.3101 -0.0113 -0.0113 -0.0282 -0.0310 -0.0113 -0.0169 -0.0225 -0.0310 -0.0310 -0.0197 -0.0310 -0.0282 -0.0056 -0.0225 -0.0141 -0.0169 -0.0197 -0.6987 -0.0225 -0.2930 -0.0395 -0.0113 -0.7720 -0.3494 -0.2085', 'S-1617\tNifedipine Pharmamatch 60 mg Tabletten sind als Retardtabletten in einer Kalenderpackung mit 28 Tabletten (2 Blisterstreifen mit je 14 Tabletten) erhältlich.', 'T-1617\tNifedipine Pharmamatch 60 mg tablets are available as prolonged-release tablets in a calendar packaging of 28 tablets (2 blisters of 14 tablets).', 'H-1617\t-0.7021484375\tNifedipine Pharmamatch 60 mg tablets are available as prolonged @-@ release tablets in a calendar packaging of 28 tablets ( 2 blisters of 14 tablets each ) .', 'D-1617\t-0.7021484375\tNifedipine Pharmamatch 60 mg tablets are available as prolonged-release tablets in a calendar packaging of 28 tablets (2 blisters of 14 tablets each).', 'P-1617\t-0.0184 -0.0241 -0.0220 -0.0285 -0.0213 -0.0342 -0.0070 -0.0313 -0.0262 -0.0213 -1.2852 -0.0127 -0.1071 -0.0352 -0.0409 -0.1099 -0.0690 -0.3340 -0.3042 -0.3325 -0.3213 -0.0451 -0.0451 -0.0254 -0.1409 -0.0507 -0.0395 -0.8906 -0.2479 -0.2451 -0.0254 -0.0169 -0.0225 -0.0338 -0.0648 -0.0169 -0.7300 -0.1747 -0.0282 -0.0169 -0.0225 -0.7271 -0.0338 -0.0338 -0.0282', 'S-1655\tPatienten mit einer Kreatinin-Clearance < 50 ml / min dürfen nicht mit PegIntron in Kombination mit Ribavirin behandelt werden (beachten Sie die Fachinformation zu Ribavirin).', 'T-1655\tPatients with creatinine clearance < 50 ml / minute must not be treated with PegIntron in combination with ribavirin (see ribavirin SPC).', 'H-1655\t-0.383544921875\tPatients with creatinine clearance &lt; 50 ml / minute must not be treated with PegIntron in combination with ribavirin ( see ribavirin SPC ) .', 'D-1655\t-0.383544921875\tPatients with creatinine clearance < 50 ml / minute must not be treated with PegIntron in combination with ribavirin (see ribavirin SPC).', 'P-1655\t-0.0722 -0.0199 -0.0916 -0.3552 -0.0169 -0.0285 -0.0342 -0.0169 -0.0250 -0.0211 -0.0113 -0.0229 -0.0760 -0.0676 -0.0289 -0.3206 -0.3000 -0.0338 -0.0690 -0.0211 -0.0352 -0.0803 -0.0225 -0.0282 -0.0127 -0.0310 -0.0507 -0.1803 -0.0296 -0.0324 -0.0169 -0.0127 -0.0380 -0.0535 -0.2832 -0.3142 -0.0141 -0.0141 -0.0423 -0.3296 -0.2507 -0.1409 -0.0366 -0.0310', 'S-741\tBei Kaninchen traten signifikant häufiger fetale äußere Weichteil- und Skelettanomalien bei einer Dosis von 1,0 mg / kg / Tag auf, die auch für das Muttertier toxisch waren.', 'T-741\tA significantly increased foetal incidence of external, soft tissue and skeletal anomalies occurred in rabbits at 1.0 mg / kg / day, which was also maternally toxic.', 'H-741\t-1.291015625\tThere was a significantly higher incidence of foetal soft tissue and skeletal anomalies in rabbits at a dose of 1.0 mg / kg / day , which caused maternal toxicity .', 'D-741\t-1.291015625\tThere was a significantly higher incidence of foetal soft tissue and skeletal anomalies in rabbits at a dose of 1.0 mg / kg / day, which caused maternal toxicity.', 'P-741\t-1.0273 -0.1071 -0.0782 -0.3840 -0.2847 -0.8916 -0.0197 -0.0479 -0.8511 -0.0056 -0.0282 -0.7271 -0.3748 -0.0423 -0.1381 -0.0141 -0.0169 -0.0282 -1.0762 -0.0169 -0.0169 -0.0282 -0.0901 -0.0225 -0.0056 -0.0225 -0.0845 -1.8545 -0.0338 -0.0338 -0.0789 -0.0282 -0.0113 -0.0282 -0.0169 -0.0451 -0.0395 -0.5073 -0.3438 -2.3496 -0.6538 -0.0113 -0.0338 -0.0564 -0.2029 -0.0225 -0.3606 -0.0338', 'S-93\tBei Sauen und Jungsauen, die noch nicht mit diesem Impfstoff geimpft wurden, sollte eine Impfung 6-8 Wochen vor dem erwarteten Abferkeltermin erfolgen, gefolgt von einer zweiten Impfung 4 Wochen später.', 'T-93\tSows / gilts which have not yet been vaccinated with the product shall be given an injection preferably 6 to 8 weeks before the expected date of farrowing followed by a second injection 4 weeks later.', 'H-93\t-0.97412109375\tSows and gilts which have not been vaccinated with the product should be vaccinated 6 @-@ 8 weeks before the expected date of farrowing .', 'D-93\t-0.97412109375\tSows and gilts which have not been vaccinated with the product should be vaccinated 6-8 weeks before the expected date of farrowing.', 'P-93\t-1.7607 -0.0310 -0.2888 -0.1226 -0.0042 -0.0141 -0.3508 -0.1183 -0.0324 -0.1733 -0.0873 -0.0197 -0.1240 -1.0449 -0.3662 -0.1381 -0.4678 -0.5776 -0.0169 -0.1550 -0.0789 -0.0282 -0.0225 -0.1071 -0.0958 -0.0845 -0.1803 -0.2367 -0.2479 -0.1071 -0.0056 -0.5410 -0.3101', 'S-1952\tWie ABILIFY aussieht und Inhalt der Packung ABILIFY 10 mg Tabletten sind rechteckig und rosafarben, mit Prägung von A-008 und 10 auf einer Seite.', 'T-1952\tWhat ABILIFY looks like and contents of the pack ABILIFY 10 mg tablets are rectangular and pink, marked with A-008 and 10 on one side.', 'H-1952\t-0.2486572265625\tWhat ABILIFY looks like and contents of the pack ABILIFY 10 mg tablets are rectangular and pink , marked with A @-@ 008 and 10 on one side .', 'D-1952\t-0.2486572265625\tWhat ABILIFY looks like and contents of the pack ABILIFY 10 mg tablets are rectangular and pink, marked with A-008 and 10 on one side.', 'P-1952\t-0.2434 -0.0365 -0.0157 -0.0327 -0.0285 -0.0211 -0.0363 -0.0299 -0.0430 -0.1567 -0.0183 -0.0384 -0.1285 -0.0930 -0.0528 -0.0141 -0.0296 -0.0289 -0.0204 -0.1155 -0.0113 -0.0578 -0.0310 -0.0352 -0.0634 -0.0092 -0.0113 -0.0176 -0.0338 -0.0338 -0.0859 -0.3213 -0.1268 -0.0746 -0.0296 -0.0211 -0.0254 -0.0324 -0.0352 -0.0380 -0.0366 -0.0296 -0.0310 -0.0324', 'S-1973\tWichtige Informationen über bestimmte sonstige Bestandteile von RoActemra Dieses Arzneimittel enthält 26,55 mg Natrium pro maximaler Dosis von 1.200 mg (8,85 mg pro 400 mg Durchstechflasche).', 'T-1973\t33 Important information about some of the ingredients of RoActemra This medicinal product contains 26.55 mg sodium per maximum dose of 1200 mg (8.85 mg sodium per 400 mg vial).', 'H-1973\t-0.52001953125\tImportant information about some of the ingredients of RoActemra This medicinal product contains 26.55 mg of sodium per maximum dose of 1200 mg ( 8.85 mg per 400 mg vial ) .', 'D-1973\t-0.52001953125\tImportant information about some of the ingredients of RoActemra This medicinal product contains 26.55 mg of sodium per maximum dose of 1200 mg (8.85 mg per 400 mg vial).', 'P-1973\t-0.0313 -0.0127 -0.0256 -0.1181 -0.1616 -0.3101 -0.3057 -0.0444 -0.2803 -0.0571 -0.0338 -0.0211 -0.0056 -0.0169 -0.1635 -0.2847 -0.0310 -0.0141 -0.0352 -0.0211 -0.0479 -0.0338 -0.6440 -0.0197 -0.0099 -0.0324 -0.0535 -0.0606 -0.0324 -0.7158 -0.0225 -0.0310 -0.0225 -0.0197 -0.0169 -0.4875 -0.0310 -0.5859 -0.0197 -0.0113 -0.0310 -0.0310 -0.0310', 'S-1503\tEine Durchstechflasche enthält 200 mg Voriconazol, was nach Auflösung durch Ihren Krankenhausapotheker oder das medizinische Fachpersonal gemäß Anweisung 10 mg / ml ergibt (siehe Informationen am Ende der Gebrauchsinformation).', 'T-1503\tEach vial contains 200 mg voriconazole, equivalent to a 10 mg / ml solution when reconstituted as directed by your hospital pharmacist or nurse (see the information at the end of this leaflet).', 'H-1503\t-1.54296875\tOne vial contains 200 mg of voriconazole , resulting in 10 mg / ml following dissolution by your hospital pharmacist or nurse , on the advice of your healthcare professional ( see the end of the leaflet . )', 'D-1503\t-1.54296875\tOne vial contains 200 mg of voriconazole, resulting in 10 mg / ml following dissolution by your hospital pharmacist or nurse, on the advice of your healthcare professional (see the end of the leaflet.)', 'P-1503\t-0.8594 -0.0634 -0.0148 -0.0592 -0.0578 -0.0134 -0.7666 -0.0240 -0.0070 -0.0085 -0.0141 -0.8086 -0.9497 -0.0564 -0.1042 -0.0085 -0.0423 -0.0225 -1.9189 -0.8340 -0.0282 -0.0451 -0.0507 -0.0958 -0.0395 -0.0113 -0.0338 -0.6479 -0.9355 -0.8623 -0.2479 -0.3494 -0.4226 -0.9580 -0.9019 -0.0901 -0.0451 -0.0451 -0.4622 -0.4395 -0.1127 -0.1803 -0.7778 -0.0113 -0.0113 -0.5635 -0.0901 -0.6426', 'S-1808\tDie sorgfältige Reinigung aller Glasgeräte, Kanülen, usw. für die Zubereitung des radioaktiv zu markierenden Arzneimittels ist von größter Bedeutung, um solche Verunreinigungen durch Metallspuren zu vermeiden.', 'T-1808\t1t is important that all glassware, syringe needles etc, used for the preparation of the radiolabelled medicinal product are thoroughly cleaned to ensure freedom from such trace metal impurities.', 'H-1808\t-2.0234375\tCareful cleaning of all glassware , needles , etc for the preparation of the medicinal product to be radiolabelled is essential to prevent such contamination from the presence of traces of trace metal .', 'D-1808\t-2.0234375\tCareful cleaning of all glassware, needles, etc for the preparation of the medicinal product to be radiolabelled is essential to prevent such contamination from the presence of traces of trace metal.', 'P-1808\t-0.4417 -0.0271 -0.3125 -0.0380 -0.6401 -0.7495 -0.0099 -0.1183 -0.0113 -0.0493 -0.3157 -0.0282 -1.0400 -0.2507 -0.2847 -0.5972 -0.0113 -0.0282 -0.2761 -1.7979 -0.0901 -0.0620 -0.8174 -0.0282 -0.2930 -0.2874 -0.2255 -0.2874 -0.0507 -1.3643 -0.4226 -0.5581 -0.3777 -1.5332 -0.3381 -0.8228 -1.2168 -0.4509 -0.0338 -0.2930 -0.5635 -0.0338 -1.6348 -1.3867 -0.1240 -0.0338 -0.0338', 'S-39\tDie Dosierung von Efficib sollte Sitagliptin in einer Dosierung von zweimal täglich 50 mg (100 mg Gesamttagesdosis) und eine Metformindosis, die etwa der bisherigen Dosis entspricht, enthalten.', 'T-39\tFor patients inadequately controlled on dual combination therapy with the maximal tolerated dose of metformin and a sulphonylurea The dose of Efficib should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and a dose of metformin similar to the dose already being taken.', 'H-39\t-0.7744140625\tThe dose of Efficib should provide sitagliptin dosed as 50 mg twice daily ( 100 mg total daily dose ) and a dose of metformin similar to the dose already being taken .', 'D-39\t-0.7744140625\tThe dose of Efficib should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and a dose of metformin similar to the dose already being taken.', 'P-39\t-0.6206 -1.0986 -0.0395 -0.0732 -0.0056 -0.0225 -0.0310 -0.4719 -0.2563 -0.0662 -0.0183 -0.0366 -0.3875 -0.3101 -0.3213 -0.1945 -0.0282 -0.1042 -0.0986 -0.0507 -0.0535 -0.0225 -0.1381 -0.0197 -0.1099 -0.0282 -0.1014 -0.1606 -0.2113 -0.3157 -0.0282 -0.0254 -0.0282 -0.3325 -0.0338 -0.1183 -0.3157 -0.3157 -0.3213 -0.3101 -0.0395 -0.0282', 'S-1715\tBei Patienten mit Leberproblemen (einschließlich einer Hepatitis-B- oder Hepatitis-C-Infektion) kann während der Einnahme von Kaletra ein erhöhtes Risiko für eine Leberschädigung bestehen.', 'T-1715\tPatients who have problems with their liver (including hepatitis B or C infection) may be at an elevated risk of liver damage when taking Kaletra.', 'H-1715\t-0.428955078125\tPatients who have problems with their liver ( including hepatitis B or C infection ) may be at an elevated risk of liver damage when taking Kaletra .', 'D-1715\t-0.428955078125\tPatients who have problems with their liver (including hepatitis B or C infection) may be at an elevated risk of liver damage when taking Kaletra.', 'P-1715\t-0.2129 -0.0199 -0.3101 -0.1053 -0.3169 -0.0486 -0.2092 -0.0451 -0.0437 -0.0225 -0.0810 -0.0070 -0.0134 -0.0282 -0.0535 -0.3228 -0.1508 -0.0296 -0.0592 -0.1240 -0.1395 -0.2339 -0.3113 -0.0197 -0.0141 -0.0676 -0.0507 -0.0507 -0.2930 -0.0986 -0.0310 -0.0282 -0.0113 -0.0338 -0.0338', 'S-1998\tDEXDOMITOR enthält den Wirkstoff Dexmedetomidin, der zu einer Gruppe von Arzneimitteln mit psycholeptischer (sedativer, d. h. beruhigender bzw. dämpfender) Wirkung gehört.', 'T-1998\tDEXDOMITOR contains the active substance dexmedetomidine, which belongs to a class of medicines having a psycholeptic (sedative) action.', 'H-1998\t-1.1103515625\tDEXDOMITOR contains the active substance dexmedetomidine , which belongs to a group of medicines having a psycholeptic effect ( i. e. sedative or depressant effect ) .', 'D-1998\t-1.1103515625\tDEXDOMITOR contains the active substance dexmedetomidine, which belongs to a group of medicines having a psycholeptic effect (i. e. sedative or depressant effect).', 'P-1998\t-0.3101 -0.0213 -0.0227 -0.0243 -0.0127 -0.0271 -0.0162 -0.0402 -0.0901 -0.0257 -0.3403 -0.0909 -0.0423 -0.0472 -0.0218 -0.0232 -0.0514 -0.0268 -0.2255 -0.0578 -0.0620 -0.0183 -0.0296 -0.2832 -0.2479 -0.0296 -0.2128 -0.1493 -1.3584 -1.1104 -0.0197 -0.0395 -0.0254 -0.0254 -0.7324 -0.0507 -0.8906 -0.3157 -0.4565 -0.0338 -0.3945 -0.0395 -0.0056 -1.9053 -0.3381 -0.6821 -0.1071 -0.5635 -0.0338 -0.0338 -0.0338', 'S-218\tDie empfohlene Dosis für Pegasys beträgt 180 Mikrogramm einmal wöchentlich durch subkutane Injektion im Bereich von Abdomen oder Oberschenkel in Kombination mit oralem Ribavirin oder als Monotherapie.', 'T-218\tThe recommended dose for Pegasys is 180 micrograms once weekly by subcutaneous administration in the abdomen or thigh given in combination with oral ribavirin or as monotherapy.', 'H-218\t-1.158203125\tThe recommended dosage of Pegasys is 180 micrograms once weekly by subcutaneous administration in the abdomen or thigh area in combination with oral ribavirin or as monotherapy .', 'D-218\t-1.158203125\tThe recommended dosage of Pegasys is 180 micrograms once weekly by subcutaneous administration in the abdomen or thigh area in combination with oral ribavirin or as monotherapy.', 'P-218\t-0.0553 -0.0342 -2.0703 -0.0324 -0.0225 -0.5845 -0.0254 -0.0127 -0.0183 -0.0366 -0.1381 -0.3606 -0.0310 -0.3269 -0.9976 -0.2169 -0.0958 -0.0169 -0.0085 -0.0254 -0.0282 -0.7778 -0.2537 -0.0620 -0.1578 -0.0056 -0.2085 -0.0451 -0.2141 -2.3555 -0.3889 -0.0169 -0.0282 -0.0169 -0.0225 -0.0113 -0.0169 -0.0395 -0.2874 -0.2593 -0.6821 -0.0282 -0.0113 -0.3101 -0.0282', 'S-461\tAuf den Packungsgrößen zu 14, 28, 56, 84 und 98 Tabletten können Sie den letzten Einnahmetag von Efient anhand der aufgedruckten Wochentage auf der Blisterpackung erkennen.', 'T-461\tFor the 14, 28, 56 84 and 98 tablet pack sizes, you can check the day on which you last took a tablet of Efient by referring to the calendar printed on the blister.', 'H-461\t-1.3662109375\tFor the 7 tablets pack sizes of 14 , 28 , 56 , 84 and 98 tablets , you can see when you last took Efient by referring to the packaged days of the week which is stated on the blister .', 'D-461\t-1.3662109375\tFor the 7 tablets pack sizes of 14, 28, 56, 84 and 98 tablets, you can see when you last took Efient by referring to the packaged days of the week which is stated on the blister.', 'P-461\t-0.3865 -0.2025 -0.5088 -1.3770 -0.6367 -0.7437 -0.0451 -0.0169 -0.2479 -0.0479 -0.0310 -0.0225 -0.0310 -0.0169 -0.0310 -0.0141 -0.0676 -0.0169 -0.1917 -0.0282 -0.3860 -0.3550 -0.0479 -0.3748 -1.7637 -0.6763 -0.4170 -0.1240 -0.0507 -0.0282 -0.0225 -0.2930 -0.4338 -0.0338 -0.2311 -0.9072 -0.7100 -0.6426 -0.2817 -0.0338 -0.0225 -0.5859 -0.3157 -0.3269 -0.0564 -0.0564 -0.1578 -0.0225 -0.2255 -0.0338', 'S-1324\tDie Faktor IX-Aktivität im Plasma wird entweder als Prozentsatz (bezogen auf normales menschliches Plasma) oder in Internationalen Einheiten (bezogen auf einen internationalen Standard für Faktor IX im Plasma) ausgedrückt.', 'T-1324\tFactor IX activity in plasma is expressed either as a percentage (relative to normal human plasma) or in International Units (relative to an international standard for factor IX in plasma).', 'H-1324\t-0.370849609375\tFactor IX activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in International Units ( relative to an International Standard for factor IX in plasma ) .', 'D-1324\t-0.370849609375\tFactor IX activity in plasma is expressed either as a percentage (relative to normal human plasma) or in International Units (relative to an International Standard for factor IX in plasma).', 'P-1324\t-0.1616 -0.0226 -0.0227 -0.1749 -0.0518 -0.1782 -0.0113 -0.0197 -0.0486 -0.0342 -0.2156 -0.1240 -0.1268 -0.0268 -0.0444 -0.1825 -0.0282 -0.0564 -0.0324 -0.0296 -0.0099 -0.0169 -0.0296 -0.0366 -0.1409 -0.3718 -0.0423 -0.0254 -0.0282 -0.0972 -0.0282 -0.1113 -0.4143 -0.0338 -0.0620 -0.2959 -0.0225 -0.0197 -0.0366 -0.1071 -0.0113 -0.0197 -0.0282 -0.0310 -0.0282', 'S-824\tSymptome einer Anämie und Anämie-Folgeerscheinungen können abhängig von Alter, Geschlecht und Gesamtbelastung an Erkrankungen unterschiedlich sein; daher ist die Beurteilung des individuellen klinischen Verlaufs und Krankheitszustands durch den Arzt erforderlich.', 'T-824\tAnemia symptoms and sequaelea may vary with age, gender and overall burden of disesase; a physician <<unk>> s evaluation of the individual patient <<unk>> s clinical course and condition is necessary.', 'H-824\t-0.8994140625\tAnaemia symptoms and sequelae may vary with age , gender and overall burden of disease ; a physician &apos;s evaluation of the individual patient &apos;s clinical course and condition is necessary .', "D-824\t-0.8994140625\tAnaemia symptoms and sequelae may vary with age, gender and overall burden of disease; a physician's evaluation of the individual patient's clinical course and condition is necessary.", 'P-824\t-0.9609 -0.0993 -0.0183 -0.0282 -0.1036 -0.0409 -0.3381 -0.0817 -0.0014 -0.4001 -0.0760 -0.0141 -0.6099 -0.0380 -0.0296 -0.3296 -0.9214 -0.1719 -0.2620 -0.1578 -0.3606 -0.3550 -0.3325 -0.1917 -0.0113 -0.1747 -0.2761 -0.0225 -0.0169 -0.0338 -0.2986 -0.0507 -0.3381 -0.0676 -0.0789 -0.2705 -0.1973 -0.2367 -0.0507 -0.3494 -0.0451 -0.0282', 'S-1941\tPatienten mit den seltenen erblichen Störungen Fruktose-Intoleranz, Glukose-Galaktose-Malabsorption oder Saccharase-Isomaltase-Mangel sollten dieses Arzneimittel nicht einnehmen.', 'T-1941\tPatients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.', 'H-1941\t-0.50146484375\tPatients with rare hereditary problems of fructose intolerance , glucose @-@ galactose malabsorption or sucrase @-@ isomaltase insufficiency should not take this medicine .', 'D-1941\t-0.50146484375\tPatients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.', 'P-1941\t-0.5327 -0.0169 -0.0532 -0.2722 -0.1663 -0.0113 -0.0282 -0.3516 -0.2922 -0.0225 -0.0155 -0.0070 -0.0070 -0.0113 -0.0197 -0.0296 -0.0113 -0.0211 -0.0127 -0.1465 -0.0141 -0.0197 -0.0127 -0.0127 -0.0169 -0.0169 -0.1818 -0.0380 -0.9805 -0.3213 -0.2620 -0.0085 -0.0169 -0.0113 -0.0141 -0.3213 -0.0366 -0.0113 -0.0282 -0.0338 -0.0592 -0.1240 -0.0338 -0.3240 -0.0310 -0.0310', 'S-971\tBei intravenöser Infusion von vier Dosen Imiglucerase über eine Stunde (7,5, 15, 30, 60 E / kg) wurde die Steady-state-Enzymaktivität nach 30 min. erreicht.', 'T-971\tDuring 1 hour intravenous infusions of 4 doses (7.5, 15, 30, 60 U / kg) of imiglucerase, steady-state enzymatic activity was achieved by 30 minutes.', 'H-971\t-1.09375\tIntravenous infusion of four doses of imiglucerase over one hour ( 7.5 , 15 , 30 , 60 U / kg ) resulted in steady @-@ state enzyme activity at 30 minutes .', 'D-971\t-1.09375\tIntravenous infusion of four doses of imiglucerase over one hour (7.5, 15, 30, 60 U / kg) resulted in steady-state enzyme activity at 30 minutes.', 'P-971\t-2.2285 -0.0465 -0.0141 -0.0409 -0.1733 -0.3381 -0.0831 -0.4199 -0.0310 -0.0141 -0.3467 -0.2620 -0.0197 -0.0169 -0.0113 -0.0169 -0.7808 -0.4509 -0.0254 -0.0310 -0.1071 -0.0282 -0.0197 -0.0282 -0.0225 -0.0338 -0.0366 -0.2339 -0.0282 -0.0169 -0.0282 -0.5635 -0.0338 -1.0430 -0.9863 -0.0169 -0.0169 -0.0169 -0.3550 -0.0338 -1.4141 -0.0901 -0.1521 -0.0564 -0.0282', 'S-1087\tDa Oxybutynin durch das Cytochrom-P 450 Isoenzym CYP 3A4 metabolisiert wird, können Wechselwirkungen mit Arzneimitteln, die dieses Isoenzym hemmen, nicht ausgeschlossen werden.', 'T-1087\tAs oxybutynin is metabolised by cytochrome P 450 isoenzyme CYP 3A4, interactions with drugs that inhibit this isoenzyme cannot be ruled out.', 'H-1087\t-1.0703125\tSince oxybutynin is metabolised by the cytochrome P450 isoenzyme CYP3A4 , interactions with drugs that inhibit this isoenzyme cannot be excluded .', 'D-1087\t-1.0703125\tSince oxybutynin is metabolised by the cytochrome P450 isoenzyme CYP3A4, interactions with drugs that inhibit this isoenzyme cannot be excluded.', 'P-1087\t-1.9805 -0.5605 -0.0099 -0.0395 -0.0352 -0.0338 -0.0211 -0.0155 -0.2113 -0.0423 -0.5972 -0.1296 -0.0225 -0.0197 -0.0338 -0.9019 -0.0113 -0.2874 -0.1493 -1.0791 -0.0169 -0.0225 -0.1691 -0.0282 -0.5635 -0.0282 -0.0169 -0.0507 -0.4902 -0.0507 -0.0338 -1.3643 -0.7778 -0.1465 -0.0113 -0.0113 -0.0507 -0.0056 -0.0564 -0.4790 -0.0225 -0.0169 -0.0564 -0.0225 -0.1691 -0.0225 -0.0282 -0.0282', 'S-384\t22 Als Konsequenz sollte jeder HIV-infizierte Patient, unabhängig von der ethnischen Zugehörigkeit, vor Beginn der Behandlung mit Abacavir auf das Vorhandensein des HLA-B * 5701-Allels getestet werden.', 'T-384\tAs a consequence, before initiating treatment with abacavir, screening for carriage of the HLA-B * 5701 allele should be performed in any HIV-infected patient, irrespective of racial origin.', 'H-384\t-0.98681640625\tIn consequence , before initiating treatment with abacavir , screening for carriage of the HLA @-@ B * 5701 allele should be performed in any HIV @-@ infected patient , irrespective of racial origin .', 'D-384\t-0.98681640625\tIn consequence, before initiating treatment with abacavir, screening for carriage of the HLA-B * 5701 allele should be performed in any HIV-infected patient, irrespective of racial origin.', 'P-384\t-2.1543 -0.4465 -0.0197 -0.0887 -0.6777 -0.2847 -0.5918 -0.1353 -0.0366 -0.1973 -0.0225 -0.0197 -0.0197 -0.0760 -0.6313 -0.1635 -0.3523 -0.3213 -0.0845 -0.1578 -0.0395 -0.3606 -0.0507 -0.0225 -0.0395 -0.0113 -0.0169 -0.0169 -0.0113 -0.1465 -0.0564 -0.3157 -0.2986 -0.2930 -0.0395 -0.2085 -0.1409 -0.0564 -0.1747 -0.4170 -0.0113 -0.0282 -0.3269 -0.2817 -0.0338 -0.0338 -0.0338', 'S-912\tIn allen Studien betrug die Soliris-Dosis 600 mg Studienmedikament alle 7 ± 2 Tage über 4 Wochen, gefolgt von 900 mg 7 ± 2 Tage später und anschließend 900 mg alle 14 ± 2 Tage für die Dauer der Studie.', 'T-912\tIn all studies, the dose of Soliris was 600 mg study drug every 7 ± 2 days for 4 weeks, followed by 900 mg 7 ± 2 days later, then 900 mg every 14 ± 2 days for the study duration.', 'H-912\t-0.91455078125\tIn all studies , Soliris dosing was 600 mg every 7 ± 2 days for 4 weeks , followed by 900 mg 7 ± 2 days later and then 900 mg every 14 ± 2 days for the duration of the study .', 'D-912\t-0.91455078125\tIn all studies, Soliris dosing was 600 mg every 7 ± 2 days for 4 weeks, followed by 900 mg 7 ± 2 days later and then 900 mg every 14 ± 2 days for the duration of the study.', 'P-912\t-0.7686 -0.0296 -0.2937 -0.8413 -0.8057 -0.0113 -1.1611 -0.3157 -0.0479 -0.0338 -0.0197 -0.3325 -0.0225 -0.0113 -0.0310 -0.0310 -0.1663 -0.4480 -0.0225 -0.3071 -0.3579 -0.0282 -0.0169 -0.0113 -0.8057 -0.0113 -0.0282 -0.0282 -0.0395 -0.1240 -0.9019 -0.0113 -0.0113 -0.0338 -0.0225 -0.0113 -0.0282 -0.0338 -0.0338 -0.1859 -0.6030 -0.0282 -0.0282 -0.0338 -0.0395 -0.0282 -0.0282', 'S-1631\tDie Ergebnisse von P901 ergaben, dass das Nutzen-Risiko-Verhältnis einer Behandlung von leichtem persistierendem Asthma mit Montelukast wie auch mit inhalierbarem Fluticason günstig ist.', 'T-1631\tThe results of P910 suggest that with montelukast, as good benefit-risk ratio can be achieved in the treatment of paediatric mild, persistent asthma as with inhaled fluticasone.', 'H-1631\t-1.1123046875\tThe results of P901 showed that the benefit / risk ratio for the treatment of mild persistent asthma with montelukast and inhaled fluticasone is favourable .', 'D-1631\t-1.1123046875\tThe results of P901 showed that the benefit / risk ratio for the treatment of mild persistent asthma with montelukast and inhaled fluticasone is favourable.', 'P-1631\t-1.1631 -0.0676 -0.3782 -0.0986 -0.0225 -0.0169 -0.7129 -0.0620 -0.0493 -0.5059 -0.2311 -0.0282 -0.6904 -1.6367 -0.2649 -0.0338 -0.0282 -0.0282 -0.1635 -0.0169 -0.0169 -0.0225 -0.0169 -0.6030 -0.1521 -0.0113 -0.0395 -0.0113 -1.3867 -0.5972 -0.3213 -0.0225 -0.0225 -0.0338 -0.0169 -0.5469 -0.2029 -0.0169 -0.0225 -0.0338 -0.0282', 'S-908\tSteve Dean war in der veterinärmedizinischen Praxis, als Dozent für Anatomie und Radiologie am Royal Veterinary College in London sowie in fachlichen und verwaltungstechnischen Positionen in der Tierarzneimittel-Industrie tätig.', 'T-908\tMr Dean has spent periods of time in general veterinary practice, as a lecturer in anatomy and radiology at the Royal Veterinary College, London and in technical and business positions in the veterinary pharmaceutical industry.', 'H-908\t-1.6484375\tHe has held posts in veterinary practice , as a lecturer in anatomy and radiology at the Royal Veterinary College , London and in technical and administrative posts in the veterinary pharmaceutical industry .', 'D-908\t-1.6484375\tHe has held posts in veterinary practice, as a lecturer in anatomy and radiology at the Royal Veterinary College, London and in technical and administrative posts in the veterinary pharmaceutical industry.', 'P-908\t-1.7402 -0.5820 -0.4395 -0.8735 -0.1071 -0.3296 -0.0113 -0.4368 -0.0620 -1.8086 -0.4902 -0.1296 -0.0113 -0.0282 -0.8115 -0.2649 -0.0225 -0.0113 -0.5073 -0.4226 -0.0225 -0.1803 -0.0676 -0.0113 -0.0169 -0.0056 -0.0620 -0.7832 -0.0338 -1.0654 -1.0596 -1.1494 -0.0338 -0.2029 -0.7778 -0.9243 -0.0338 -0.1578 -0.0225 -0.3157 -0.0113 -0.0564 -0.0338 -0.0338 -0.0338', 'S-818\tSchwellung des Gesichts, der Zunge oder des Halses, Atem- oder Schluckbeschwerden, Hautausschlag), müssen Sie die Einnahme von OSSEOR unverzüglich beenden und ärztlichen Rat einholen.', 'T-818\t25 During treatment, if you experience an allergic reaction (such as swelling of the face, tongue or throat, difficulty in breathing or swallowing, skin rash), you must immediately stop taking OSSEOR and seek medical advice.', 'H-818\t-0.8916015625\tswelling of the face , tongue or throat , difficulty in breathing or swallowing , skin rash ) , you must immediately stop taking OSSEOR and seek medical advice .', 'D-818\t-0.8916015625\tswelling of the face, tongue or throat, difficulty in breathing or swallowing, skin rash), you must immediately stop taking OSSEOR and seek medical advice.', 'P-818\t-2.5664 -0.0225 -0.0409 -0.1057 -0.0338 -0.0338 -0.0085 -0.0155 -0.1508 -0.0986 -0.0479 -0.3071 -0.6338 -0.0141 -0.3972 -0.0085 -0.0113 -0.1578 -0.7212 -0.0310 -0.0197 -0.0479 -0.6338 -0.2423 -0.7607 -0.3101 -0.0564 -0.0507 -0.0564 -0.0169 -0.0282 -0.0225 -0.0451 -0.0620 -0.0395 -0.0395 -0.0338 -0.0338', 'S-1407\tMehrere Mechanismen wie Veränderung der Angriffstelle am Ribosom, die Nutzung aktiver Effluxmechanismen und die Bildung inaktivierender Enzyme werden für die Resistenzentwicklung gegenüber Makroliden verantwortlich gemacht.', 'T-1407\t4 It is considered that there are multiple mechanisms responsible for resistance development to macrolide compounds: namely alteration of the ribosomal target site, utilisation of active efflux mechanism and production of inactivating enzymes.', 'H-1407\t-1.4443359375\tSeveral mechanisms such as the alteration of the target site at the ribosome , the utilisation of active efflux mechanisms and the formation of inactivating enzymes are responsible for resistance to macrolides .', 'D-1407\t-1.4443359375\tSeveral mechanisms such as the alteration of the target site at the ribosome, the utilisation of active efflux mechanisms and the formation of inactivating enzymes are responsible for resistance to macrolides.', 'P-1407\t-2.5957 -0.0493 -0.0240 -1.5117 -0.0282 -0.5889 -0.2874 -0.0366 -0.0338 -0.1465 -1.6064 -0.1240 -0.4395 -0.0338 -0.2311 -0.0113 -0.1240 -0.0338 -0.0507 -0.4790 -0.6538 -0.0282 -0.0732 -0.1747 -0.2593 -0.0169 -0.0338 -0.3777 -0.8677 -0.0676 -0.2649 -0.0282 -0.0282 -0.0338 -0.0282 -0.0113 -0.0113 -0.0282 -0.4790 -0.8906 -0.0225 -0.3269 -1.2285 -0.0225 -0.0225 -0.0225 -0.4058 -0.0338 -0.0338', 'S-766\tFlecainid, Propafenon, Metoprolol in der Indikation Herzinsuffizienz, Desipramin, Nortriptylin, Clopramin) (siehe Abschnitt 4.4).', 'T-766\tDose adjustments of concomitant medicinal products may be required when Mimpara is administered with individually titrated, narrow therapeutic index substances that are predominantly metabolised by CYP2D6 (e. g., flecainide, propafenone, metoprolol given in heart failure, desipramine, nortriptyline, clomipramine) (see section 4.4).', 'H-766\t-0.66845703125\tFlecainide , propafenone , metoprolol in the indication heart failure , desipramine , nortriptyline , clopramine ) ( see section 4.4 ) .', 'D-766\t-0.66845703125\tFlecainide, propafenone, metoprolol in the indication heart failure, desipramine, nortriptyline, clopramine) (see section 4.4).', 'P-766\t-2.6816 -0.2072 -0.0282 -0.0254 -0.0338 -0.5015 -0.0423 -0.0254 -0.0338 -0.0366 -0.0310 -0.0254 -0.0225 -0.0169 -0.0282 -0.4143 -0.5806 -0.3127 -0.2085 -0.0113 -0.0395 -0.2986 -0.0113 -0.0056 -0.0310 -0.1521 -0.0225 -0.0282 -0.0113 -0.0113 -0.0395 -0.0113 -0.0113 -0.0056 -0.0676 -0.0338 -0.0395 -0.1521 -0.0225 -0.0282 -0.0338 -0.0338 -0.0282', 'S-1923\tAndere Arzneimittel oder Phytopharmaka, die als Induktoren fungieren, wie zum Beispiel Rifampicin und Johanniskraut (Hypericum perforatum) könnten ähnliche Effekte auf Paliperidon haben.', 'T-1923\tOther medicinal products or herbals which are inducers, e. g. rifampicin and St John <<unk>> s wort (Hypericum perforatum) may have similar effects on paliperidone.', 'H-1923\t-1.029296875\tOther medicines or herbal remedies that act as inducers , such as rifampicin and St John &quot; s wort ( Hypericum perforatum ) may be expected to have similar effects on paliperidone .', 'D-1923\t-1.029296875\tOther medicines or herbal remedies that act as inducers, such as rifampicin and St John "s wort (Hypericum perforatum) may be expected to have similar effects on paliperidone.', 'P-1923\t-0.1862 -0.3994 -0.7031 -0.0557 -0.1169 -0.0225 -0.8467 -0.1155 -0.0254 -0.2761 -0.7466 -0.0310 -0.1917 -0.0141 -0.1606 -0.5327 -0.2817 -0.0282 -0.0507 -0.0197 -0.0225 -0.4705 -0.0423 -0.0535 -0.2847 -0.6226 -0.7554 -0.0338 -0.4170 -0.0338 -0.2593 -0.0225 -0.0225 -0.0225 -0.0225 -0.0169 -0.0225 -0.0225 -0.0282 -1.4199 -0.9580 -0.3269 -0.0282 -0.1071 -0.0676 -0.0338 -0.0451 -0.0845 -0.0113 -0.0113 -0.0056 -0.0338 -0.0282', 'S-428\tKeines der Isoenzyme CYP1A, CYP2C9, CYP2C19, CYP2D6 und CYP3A4 wurde durch Dexrazoxan gehemmt.', 'T-428\tCYP1A, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, none of these were inhibited by dexrazoxane.', 'H-428\t-0.424072265625\tNone of CYP1A , CYP2C9 , CYP2C19 , CYP2D6 and CYP3A4 isoenzymes have been inhibited by dexrazoxane .', 'D-428\t-0.424072265625\tNone of CYP1A, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 isoenzymes have been inhibited by dexrazoxane.', 'P-428\t-0.2375 -0.0285 -1.0918 -0.0254 -0.0282 -0.0282 -0.0268 -0.0310 -0.0240 -0.0254 -0.0268 -0.0240 -0.0282 -0.0268 -0.0296 -0.0240 -0.0254 -0.0268 -0.0225 -0.0282 -0.0240 -0.0296 -0.0240 -0.0254 -0.0254 -0.0225 -0.0225 -0.0254 -0.4888 -0.0240 -0.0240 -0.0268 -0.0254 -0.0127 -0.0352 -0.0760 -0.3198 -0.0169 -0.0282 -0.5581 -0.0282 -0.5835 -0.0225 -0.0197 -0.0395 -0.0423 -0.0395 -0.0254 -0.0169 -0.0282 -0.0395 -0.0338 -0.0310', 'S-165\tPatrone aus Glas (Glasart I), die einen Kolben (Brombutylgummi) enthält und mit einer Scheibe (Brombutyl- / Polyisoprengummi) verschlossen ist, sie enthält 3 ml Lösung.', 'T-165\tA glass (Type 1) cartridge which contains a piston (bromobutyl rubber) and is closed with a disc (bromobutyl / polyisoprene rubber) containing 3 ml of solution.', 'H-165\t-0.8212890625\tA glass ( Type 1 ) cartridge which contains a piston ( bromobutyl rubber ) and is closed with a disc ( bromobutyl / polyisoprene rubber ) , containing 3 ml of solution .', 'D-165\t-0.8212890625\tA glass (Type 1) cartridge which contains a piston (bromobutyl rubber) and is closed with a disc (bromobutyl / polyisoprene rubber), containing 3 ml of solution.', 'P-165\t-0.3337 -0.1421 -0.4089 -0.3071 -0.3113 -0.0676 -0.0775 -0.0085 -0.0169 -0.4875 -0.0873 -0.1550 -0.7383 -0.0254 -0.0423 -0.3860 -0.1859 -0.1663 -0.0395 -0.6060 -0.0310 -0.2734 -0.1465 -0.1550 -0.1183 -0.0366 -0.2479 -0.1381 -0.0310 -0.0225 -0.0282 -0.0282 -0.0282 -0.1747 -0.0338 -0.0113 -0.0338 -0.0338 -0.0395 -0.0282 -0.6763 -0.3777 -0.1071 -0.0169 -0.6592 -0.0451 -0.2367 -0.0282', 'S-718\tDie für Kinder vorgeschlagene Dosierung wurde in klinischen Studien erprobt, ist jedoch auch das Ergebnis von Dosisanpassungen nach Körpergewicht und Ausscheidung (Clearance), die je nach Entwicklungsstand des Nierensystems variiert.', 'T-718\tThe posology proposed for children has been tested in clinical trials, but also results from dosing adaptations based on body weight and clearance that varies according to the maturation of the renal system.', 'H-718\t-2.2109375\tThe proposed dosage for children was studied in clinical studies but is also the result of dose adjustments based on body weight and excretion ( clearance ) , based on their renal system development .', 'D-718\t-2.2109375\tThe proposed dosage for children was studied in clinical studies but is also the result of dose adjustments based on body weight and excretion (clearance), based on their renal system development.', 'P-718\t-1.0811 -0.7021 -1.6768 -0.0225 -0.0282 -0.7808 -0.5469 -0.6904 -0.5859 -0.6763 -0.0451 -0.7212 -1.1211 -0.5806 -1.2061 -0.8228 -0.0451 -0.0282 -0.6875 -0.0789 -0.0113 -0.0451 -0.4509 -0.4958 -0.7324 -0.0113 -0.0338 -0.7437 0.0000 -0.0564 -0.7324 -0.0225 -0.0225 -0.0338 -1.5107 -1.9502 -0.0338 -1.0254 -0.3833 -0.0225 -0.4734 -0.3381 -0.1127 -0.0338', 'S-433\tBei Einnahme von ADROVANCE mit anderen Arzneimitteln Calciumergänzungsmittel, Antazida und einige andere Arzneimittel zum Einnehmen können die Wirksamkeit von ADROVANCE bei gleichzeitiger Einnahme behindern.', 'T-433\tTaking other medicines It is likely that calcium supplements, antacids, and some oral medicines will interfere with the absorption of ADROVANCE if taken at the same time.', 'H-433\t-0.85888671875\tTaking ADROVANCE with other medicines It is likely that calcium supplements , antacids , and some oral medicines will interfere with the absorption of ADROVANCE if taken at the same time .', 'D-433\t-0.85888671875\tTaking ADROVANCE with other medicines It is likely that calcium supplements, antacids, and some oral medicines will interfere with the absorption of ADROVANCE if taken at the same time.', 'P-433\t-0.3853 -0.1068 -0.0250 -0.0264 -0.0197 -0.0099 -0.0895 -0.4998 -0.0289 -0.5742 -0.3340 -0.2607 -0.3804 -0.0479 -0.2156 -0.0197 -0.0254 -0.0225 -0.0225 -0.0366 -0.0817 -0.0366 -0.0395 -1.0312 -0.1071 -0.1606 -0.6987 -0.0789 -0.1127 -0.3269 -0.9526 -0.0113 -0.0338 -0.0676 -0.6030 -0.0282 -0.1014 -0.0338 -0.0282 -0.0282 -0.0225 -0.0113 -0.3550 -0.2367 -0.4846 -0.0507 -0.0282 -0.0282 -0.0395 -0.0282', 'S-1473\tEs sind sowohl von den männlichen als auch den weiblichen Patienten wirksame Empfängnisverhütungsmaßnahmen zu treffen, wenn sie Temodal erhalten (siehe auch oben <unk> Besondere Vorsicht bei der Einnahme von Temodal ist erforderlich <unk>).', 'T-1473\tEffective contraceptive precautions must be taken by both male and female patients who are taking Temodal (see also <<unk>> Take special care with Temodal <<unk>> above).', 'H-1473\t-1.1396484375\tBoth male and female patients receiving Temodal must use effective contraception ( see above ) .', 'D-1473\t-1.1396484375\tBoth male and female patients receiving Temodal must use effective contraception (see above).', 'P-1473\t-1.1270 -1.0596 -0.0296 -0.0240 -0.0507 -1.6318 -0.0479 -0.0197 -0.0282 -0.4453 -0.3972 -0.5327 -0.0310 -0.2085 -0.0141 -0.5186 -0.0958 -0.1353 -0.1521 -0.4565 -0.0789', 'S-1953\tDie Ad-hoc-Arbeitsgruppe der GMP-Inspektoren wird 2002 fünfmal zusammentreten und sich mit der Erarbeitung von Anleitungen zu GMP-Fragen sowie mit der Harmonisierung der Inspektionsverfahren befassen.', 'T-1953\tStates.', 'H-1953\t-1.1328125\tSampling and testing', 'D-1953\t-1.1328125\tSampling and testing', 'P-1953\t-1.7031 -0.3367 -0.1212 -0.3142 -0.4805 -0.3635', 'S-422\tNederland Č eská republika Alcon Nederland BV Alcon Pharmaceuticals (Czech Republic) s.r.o. + 31 (0) 183 654321 + + 420 225 377 300', 'T-422\tNederland Česká republika Alcon Nederland BV Alcon Pharmaceuticals (Czech Republic) s.r.o. + 31 (0) 183 654321 + + 420 225 377 300', 'H-422\t-0.339599609375\tNederland Česká republika Alcon Nederland BV Alcon Pharmaceuticals ( Czech Republic ) s.r.o. + 31 ( 0 ) 183 654321 + + 420 225 377 300', 'D-422\t-0.339599609375\tNederland Česká republika Alcon Nederland BV Alcon Pharmaceuticals (Czech Republic) s.r.o. + 31 (0) 183 654321 + + 420 225 377 300', 'P-422\t-0.7251 -0.0134 -0.0240 -0.2881 -0.0134 -0.0746 -0.0042 -0.1642 -0.0275 -0.0690 -0.0134 -0.1444 -0.0155 -0.0183 -0.0254 -0.0211 -0.1648 -0.0141 -0.0254 -0.0070 -0.0211 -0.0113 -0.0141 -0.0240 -0.0296 -0.0113 -0.0155 -0.0268 -0.4917 -0.0211 -0.0211 -0.0268 -0.0366 -0.5044 -0.0282 -0.0254 -0.0282 -0.0197 -0.0254 -0.0113 -0.0085 -0.0197 -0.0282 -0.0338 -0.1493 -0.0254 -0.0254 -0.0225 -0.0225 -0.0085 -0.0169 -0.0310', 'S-938\t126 Česká republika Merck spol.s.r.o Zděbradská 72 CZ-251 01 Říčany- Jažlovice Tel. + 420 323619211', 'T-938\tČeská republika Merck spol.s.r.o Zděbradská 72 CZ-251 01 Říčany- Jažlovice Tel. + 420 323619211', 'H-938\t-1.5146484375\tČ eská republika Merck spol. s. r. o Zd . Pot k 72 CZ @-@ 251 01 Útibú Tel . + 420 323619211', 'D-938\t-1.5146484375\tČ eská republika Merck spol. s. r. o Zd. Pot k 72 CZ-251 01 Útibú Tel. + 420 323619211', 'P-938\t-1.5840 -0.3860 -0.0676 -0.0225 -0.0197 -0.0395 -0.0732 -0.0240 -0.0366 -0.0225 -0.3198 -0.9497 -0.3213 -0.0338 -0.1071 -0.3240 -0.8877 -1.3018 -0.3213 -0.7944 -1.0312 -0.0395 -0.0225 -0.0338 -0.0225 -0.0282 -0.0225 -0.7437 -0.3269 -0.3606 -0.3213 -2.5645 -0.3494 -0.0676 -0.0338 -0.0225 -0.6084 -0.0451 -0.0338 -0.0225 -0.0338 -0.0225 -0.0676', 'S-801\tDie empfohlene Mindestdosis beträgt 10 mg / kg Körpergewicht Imidacloprid und 1 mg / kg Körpergewicht Moxidectin, äquivalent zu 0,1 ml / kg Körpergewicht Advocate für Katzen.', 'T-801\tThe recommended minimum doses are 10 mg / kg bodyweight imidacloprid and 1.0 mg / kg bodyweight moxidectin, equivalent to 0.1ml / kg bodyweight Advocate for cats.', 'H-801\t-0.458984375\tThe recommended minimum doses are 10 mg / kg bodyweight imidacloprid and 1 mg / kg bodyweight moxidectin , equivalent to 0.1 mL / kg bodyweight Advocate for cats .', 'D-801\t-0.458984375\tThe recommended minimum doses are 10 mg / kg bodyweight imidacloprid and 1 mg / kg bodyweight moxidectin, equivalent to 0.1 mL / kg bodyweight Advocate for cats.', 'P-801\t-0.0364 -0.0678 -0.0349 -0.6055 -0.2627 -0.1550 -0.0930 -0.0127 -0.4805 -0.0183 -0.5103 -0.0197 -0.0690 -0.0211 -0.0197 -0.0225 -0.0183 -0.0549 -0.0310 -0.0352 -0.0127 -0.0296 -0.0141 -0.1635 -0.0141 -0.0380 -0.0225 -0.0127 -0.0155 -0.0338 -0.0958 -0.0282 -0.0310 -0.0254 -0.4536 -0.3157 -0.0958 -0.0282 -0.0169 -0.0986 -0.0197 -0.1945 -0.0085 -0.0225 -0.0338 -0.0169 -0.2451 -0.0282', 'S-543\tHANDELSNAME sollte in der niedrigsten wirksamen Dosis über einen möglichst kurzen Zeitraum verabreicht werden, da das kardiovaskuläre Risiko einer Celecoxib-Therapie mit Dosis und Behandlungsdauer ansteigen kann.', 'T-543\t4.2 Posology and method of administration As the cardiovascular risks of celecoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used.', 'H-543\t-1.3701171875\t{ INVENTED NAME } should be administered at the lowest effective dose for the shortest possible duration because the cardiovascular risks of celecoxib therapy may increase with dose and duration of treatment .', 'D-543\t-1.3701171875\t{INVENTED NAME} should be administered at the lowest effective dose for the shortest possible duration because the cardiovascular risks of celecoxib therapy may increase with dose and duration of treatment.', 'P-543\t-0.3284 -1.6289 -0.3452 -0.3101 -0.1395 -0.2268 -0.3269 -0.0986 -0.0423 -0.5186 -0.0958 -0.0310 -0.7944 -0.0225 -0.8789 -0.0564 -0.2197 -0.2255 -0.0620 -0.2649 -0.6313 -0.0113 -0.0169 -0.2367 -0.5410 -0.0282 -1.5273 -0.8057 -0.2029 -0.0113 -0.0169 -0.0169 -0.3157 -0.1747 -0.5918 -0.0225 -0.0113 -0.0225 -0.9468 -0.1691 -0.2141 -0.3269 -0.1240 -0.0338 -0.2141 -0.0225 -0.0564 -0.3494 -0.0338 -0.0338', 'S-1317\tDie Patienten sollen informiert werden, dass Impfungen während der Behandlung mit Mycophenolatmofetil Teva weniger wirksam sein können, und die Anwendung von attenuierten Lebend-Impfstoffen soll vermieden werden (siehe Abschnitt 4.5).', 'T-1317\tPatients should be advised that during treatment with Mycophenolate mofetil Teva vaccinations may be less effective and the use of live attenuated vaccines should be avoided (see section 4.5).', 'H-1317\t-0.4716796875\tPatients should be informed that during treatment with Mycophenolate mofetil Teva , vaccinations may be less effective and the use of live attenuated vaccines should be avoided ( see section 4.5 ) .', 'D-1317\t-0.4716796875\tPatients should be informed that during treatment with Mycophenolate mofetil Teva, vaccinations may be less effective and the use of live attenuated vaccines should be avoided (see section 4.5).', 'P-1317\t-0.1421 -0.0213 -0.1288 -0.0334 -0.7798 -0.0352 -0.4009 -0.2522 -0.0380 -0.4790 -0.0169 -0.0127 -0.0549 -0.0366 -0.0395 -0.0197 -0.0183 -0.0282 -0.0197 -0.2664 -0.1071 -0.3550 -0.0986 -0.0535 -0.0310 -0.0282 -0.2507 -0.1296 -0.0760 -0.0282 -0.0930 -0.0451 -0.0535 -0.0338 -0.0197 -0.0282 -0.0592 -0.0282 -0.0254 -0.0338 -0.0423 -0.1550 -0.0225 -0.0310 -0.0366 -0.0338 -0.0282', 'S-124\tDie empfohlene Dosis von ALIMTA 500 mg / m ² Körperober- fläche (KOF) verabreicht als intravenöse Infusion über einen Zeitraum von 10 Minuten am ersten Tag jedes 21-tägigen Behandlungszyklus.', 'T-124\tThe recommended dose of ALIMTA is 500 mg / m2 of body surface area (BSA) administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.', 'H-124\t-1.03515625\tThe recommended dose of ALIMTA is 500 mg / m2 of body surface ( BSA ) administered as an intravenous infusion over 10 minutes on the first day of each 21 @-@ day cycle .', 'D-124\t-1.03515625\tThe recommended dose of ALIMTA is 500 mg / m2 of body surface (BSA) administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.', 'P-124\t-0.5469 -0.0334 -0.1335 -0.0388 -0.0324 -0.0134 -0.0070 -1.4736 -0.0564 -0.0099 -0.0324 -0.2423 -1.1670 -0.0760 -0.0704 -0.9805 -0.6763 -0.3269 -0.0338 -0.1973 -0.0225 -0.9580 -0.0732 -0.2930 -0.0282 -0.0113 -0.0282 -0.0507 -0.0113 -0.3777 -0.4734 -0.0338 -0.0789 -0.1747 -0.0338 -0.0338 -0.0338 -0.0958 -0.0282 -0.3042 -0.0338 -0.4453 -0.2197 -0.0282', 'S-1543\tIn gesunden Probanden, denen 100 mg 14C-markiertes Dasatinib gegeben wurde, bestand die zirkulierende Radioaktivität im Plasma zu 29% aus unverändertem Dasatinib.', 'T-1543\tIn healthy subjects administered 100 mg of [14C] -labelled dasatinib, unchanged dasatinib represented 29% of circulating radioactivity in plasma.', 'H-1543\t-1.2646484375\tIn healthy subjects given 100 mg 14C @-@ labeled dasatinib , 29 % of the circulating radioactivity in plasma consisted of unchanged dasatinib .', 'D-1543\t-1.2646484375\tIn healthy subjects given 100 mg 14C-labeled dasatinib, 29% of the circulating radioactivity in plasma consisted of unchanged dasatinib.', 'P-1543\t-1.0410 -0.0282 -0.7905 -1.8770 -0.3860 -0.0169 -0.3635 -0.0254 -0.0620 -0.4255 -0.7524 -0.3635 -0.0225 -0.0169 -0.0225 -0.2874 -0.7554 -0.0338 -0.0732 -0.9243 -0.1014 -0.0113 -0.0338 -0.4790 -0.0282 -0.1353 -0.4902 -0.0113 -0.0169 -0.9917 -0.2479 -0.0338 -0.0564 -0.2537 -0.2817 -0.0225 -0.0169 -0.0225 -0.0338 -0.0282', 'S-1393\tNovoNorm ist ein orales Antidiabetikum, das Repaglinid enthält und das Ihrer Bauchspeicheldrüse hilft, mehr Insulin zu produzieren und damit Ihren Blutzucker (Glucose) zu senken.', 'T-1393\tNovoNorm is an oral antidiabetic agent containing repaglinide which helps your pancreas produce more insulin and thereby lower your blood sugar (glucose).', 'H-1393\t-0.54150390625\tNovoNorm is an oral antidiabetic agent containing repaglinide which helps your pancreas produce more insulin and thereby lower your blood sugar ( glucose ) .', 'D-1393\t-0.54150390625\tNovoNorm is an oral antidiabetic agent containing repaglinide which helps your pancreas produce more insulin and thereby lower your blood sugar (glucose).', 'P-1393\t-0.2163 -0.0199 -0.0262 -0.0306 -0.0349 -0.0292 -0.0127 -0.5645 -0.2303 -0.0099 -0.0176 -0.4072 -0.5015 -0.0521 -0.0155 -0.0240 -0.1620 -0.4719 -0.1071 -0.0845 -0.2593 -0.0113 -0.0254 -0.2311 -0.0423 -0.0113 -0.0141 -0.2817 -0.3296 -0.0197 -0.2817 -0.0817 -0.0254 -0.0732 -0.0845 -0.0901 -0.0197 -0.0141 -0.0282 -0.0564 -0.0310', 'S-866\tBEGRÜNDUNG FÜR DIE AUFRECHTERHALTUNG DER GENEHMIGUNG FÜR DAS INVERKEHRBRINGEN VON HEXAVAC', 'T-866\tGROUNDS FOR MAINTAINING THE MARKETING AUTHORISATION OF HEXAVAC', 'H-866\t-1.3779296875\tGROUNDS FOR THE LIDDING OF THE MARKETING AUTHORISATION for HEXAVAC', 'D-866\t-1.3779296875\tGROUNDS FOR THE LIDDING OF THE MARKETING AUTHORISATION for HEXAVAC', 'P-866\t-1.0381 -0.2683 -0.1635 -0.3184 -0.1113 -0.0183 -0.4946 -1.6006 -0.9751 -0.3184 -0.1635 -0.2563 -0.2986 -0.9751 -0.3213 -0.1521 -0.1691 -0.2649 -0.3213 -0.0901 -0.0451 -0.3042 -0.1240 -0.0169 -0.3213 -1.3018 -0.0225 -0.0282 -0.0282 -0.0169 -0.2874', 'S-1194\tLUMIGAN wurde bei Patienten mit entzündlichen Augenerkrankungen, mit neovaskulärem und mit entzündlich bedingtem Glaukom, mit kongenitalem Glaukom sowie mit Engwinkelglaukom nicht untersucht.', 'T-1194\tLUMIGAN has not been studied in patients with inflammatory ocular conditions, neovascular, inflammatory, angle-closure glaucoma, congenital glaucoma or narrow-angle glaucoma.', 'H-1194\t-0.51611328125\tLUMIGAN has not been studied in patients with inflammatory ocular conditions , neovascular , inflammatory glaucoma , congenital glaucoma and narrow @-@ angle glaucoma .', 'D-1194\t-0.51611328125\tLUMIGAN has not been studied in patients with inflammatory ocular conditions, neovascular, inflammatory glaucoma, congenital glaucoma and narrow-angle glaucoma.', 'P-1194\t-0.0414 -0.0099 -0.0085 -0.0191 -0.1204 -0.0400 -0.0241 -0.2324 -0.0423 -0.0500 -0.0416 -0.0546 -0.0243 -0.0162 -0.0155 -0.3169 -0.0077 -0.4028 -0.0479 -0.0620 -0.0211 -0.0183 -0.0183 -0.3367 -0.4805 -0.0409 -0.0155 -0.0183 -0.1536 -0.0113 -0.0296 -0.0395 -0.0521 -0.0155 -0.0099 -0.1367 -0.0113 -0.0254 -1.7559 -0.1521 -0.1240 -0.0310 -0.0225 -0.0113 -0.0254 -0.0338 -0.0310', 'S-702\tInsgesamt erhielten ungefähr 400 Patienten in pädiatrischen Behandlungsstudien (Studie 524, 566, PACTG 377 / 725 und PENTA-7) Nelfinavir über einen Zeitraum von bis zu 96 Wochen.', 'T-702\tA total of approximately 400 patients received nelfinavir in paediatric treatment trials (Studies 524, 556, PACTG 377 / 725, and PENTA-7) for up to 96 weeks.', 'H-702\t-0.9736328125\tA total of approximately 400 patients received nelfinavir for up to 96 weeks in paediatric treatment studies ( Studies 524 , 566 , PACTG 377 / 725 and PENTA @-@ 7 ) .', 'D-702\t-0.9736328125\tA total of approximately 400 patients received nelfinavir for up to 96 weeks in paediatric treatment studies (Studies 524, 566, PACTG 377 / 725 and PENTA-7).', 'P-702\t-1.6348 -0.0268 -0.0282 -0.7847 -0.0169 -0.0451 -0.8623 -0.0254 -0.0338 -0.0169 -0.0254 -0.0141 -0.8511 -0.1437 -0.0282 -0.0310 -0.0282 -0.1888 -0.5327 -0.0141 -0.0113 -0.0254 -0.7974 -1.3301 -0.0395 -1.4375 -0.0225 -0.0282 -0.0338 -0.0225 -0.0113 -0.0282 -0.0282 -0.0225 -0.0056 -0.0225 -0.0113 -0.0282 -0.0225 -0.0282 -0.5581 -0.0282 -0.0169 -0.0113 -0.0282 -0.0282 -0.0282 -0.0395 -0.0282', 'S-1700\tStudien zur chronischen Toxizität, Genotoxizität und Reproduktionstoxizität an Tieren sind aufgrund der Induktion und Wechselwirkung durch entstehende Antikörper gegen heterologe Proteine nicht durchführbar.', 'T-1700\tStudies of repeated dose toxicity, genotoxicity, and toxicity to reproduction in animals are impracticable due to induction of and interference by developing antibodies to heterologous proteins.', 'H-1700\t-1.4853515625\tReproduction toxicity studies in animals are impracticable due to induction and interaction by antibodies against heterologous proteins .', 'D-1700\t-1.4853515625\tReproduction toxicity studies in animals are impracticable due to induction and interaction by antibodies against heterologous proteins.', 'P-1700\t-0.4490 -1.4521 -0.1226 -0.0240 -0.2141 -1.0088 -1.3496 -0.0282 -0.6284 -0.4170 -0.0085 -0.5186 -0.0225 -0.8286 -0.0282 -0.1691 -0.0282 -0.0451 -0.1635 -0.0395 -0.6030 -1.1777 -0.0225 -0.4958 -0.5469 -0.0225 -0.0225 -0.0225 -0.0282 -0.0113 -1.2568 -0.1240', 'S-1463\tDie Inzidenzrate für Synkopen ist <unk> gelegentlich <unk> und unterscheidet sich nicht zwischen mit Lacosamid (0,1%) und Placebo (0,3%) behandelten Epilepsiepatienten.', 'T-1463\tThe incidence rate for syncope is uncommon and did not differ between lacosamide treated epilepsy patients (0.1%) and placebo treated epilepsy patients (0.3%).', 'H-1463\t-1.2080078125\tThe incidence rate of syncope is uncommon and is not different between patients receiving lacosamide ( 0.1 % ) and placebo ( 0.3 % ) .', 'D-1463\t-1.2080078125\tThe incidence rate of syncope is uncommon and is not different between patients receiving lacosamide (0.1%) and placebo (0.3%).', 'P-1463\t-0.4551 -0.0225 -0.0127 -0.1296 -1.0986 -0.2395 -0.2438 -0.4072 -0.4705 -1.4062 -0.0901 -0.7749 -0.4424 -0.1296 -0.2874 -1.5889 -0.9526 -0.0958 -0.1973 -0.0225 -0.0169 -0.0395 -0.0225 -0.0282 -0.0564 -0.0282 -0.0395 -0.6201 -0.0225 -0.0169 -0.0282 -0.5239 -0.0169 -0.0282 -0.0225 -0.0282 -0.0789 -0.0282', 'S-79\tWie NovoMix 30 aussieht und Inhalt der Packung Die Injektionssuspension wird als weiße Suspension in Packungen mit 5 oder 10 Patronen zu 3 ml geliefert (es werden möglicherweise nicht alle Packungen in den Verkehr gebracht).', 'T-79\tWhat NovoMix 30 looks like and contents of the pack The suspension for injection comes as a white suspension in packs of 5 or 10 cartridges of 3 ml (not all packs may be marketed).', 'H-79\t-0.5478515625\tWhat NovoMix 30 looks like and contents of the pack The suspension for injection comes as a white suspension in packs of 5 or 10 cartridges of 3 ml ( not all packs may be marketed ) .', 'D-79\t-0.5478515625\tWhat NovoMix 30 looks like and contents of the pack The suspension for injection comes as a white suspension in packs of 5 or 10 cartridges of 3 ml (not all packs may be marketed).', 'P-79\t-0.5215 -0.0613 -0.0169 -0.0113 -0.0313 -0.0363 -0.0299 -0.0426 -0.2410 -0.0211 -0.0564 -0.0740 -0.2537 -0.0979 -0.3494 -0.3086 -0.1169 -0.1381 -0.2974 -0.1733 -0.1000 -0.0423 -0.1042 -0.2705 -0.2197 -0.0141 -0.0535 -0.0423 -0.3523 -0.0254 -0.1071 -0.0113 -0.0225 -0.1465 -0.0592 -0.0197 -0.0732 -0.2537 -0.0395 -0.1606 -0.0225 -0.1268 -0.0507 -0.2734 -0.0141 -0.0423 -0.0338 -0.0310', 'S-282\tAllen an dieser Studie teilnehmenden Patienten war mindestens acht Wochen lang Eprex / Erypo in eine Vene injiziert worden, bevor sie entweder auf Abseamed umgestellt wurden oder weiterhin Eprex / Erypo erhielten.', 'T-282\tAll of the patients had been taking Eprex / Erypo injected into a vein for at least eight weeks before they were either switched to Abseamed or remained on Eprex / Erypo.', 'H-282\t-0.5322265625\tAll of the patients had been taking Eprex / Erypo injected into a vein for at least eight weeks before they were either switched to Abseamed or remained on Eprex / Erypo .', 'D-282\t-0.5322265625\tAll of the patients had been taking Eprex / Erypo injected into a vein for at least eight weeks before they were either switched to Abseamed or remained on Eprex / Erypo.', 'P-282\t-0.0597 -0.6636 -0.0373 -0.0782 -0.7363 -0.0901 -0.3269 -0.1324 -0.0155 -0.0268 -0.0395 -0.0296 -0.0113 -0.0282 -0.2212 -0.2227 -0.0549 -0.0831 -0.0282 -0.0085 -0.0564 -0.0986 -0.0225 -0.2649 -0.0225 -0.0986 -0.2197 -0.1859 -0.0873 -0.3184 -0.0676 -0.0873 -0.0282 -0.0085 -0.1606 -0.3240 -0.0620 -0.0564 -0.0169 -0.0282 -0.0338 -0.0310 -0.0113 -0.0282 -0.0479 -0.0310', 'S-927\tUnterschiedliche Gewichtskategorien Extreme Körpergewichte (< 50 kg oder > 120 kg) hatten nur einen geringen Einfluss auf die Plasmakonzentration von Rivaroxaban (weniger als 25%).', 'T-927\tDifferent weight categories Extremes in body weight (< 50 kg or > 120 kg) had only a small influence on rivaroxaban plasma concentrations (less than 25%).', 'H-927\t-0.90673828125\tDifferent weight categories ( &lt; 50 kg or &gt; 120 kg ) had little effect on rivaroxaban plasma concentrations ( less than 25 % ) .', 'D-927\t-0.90673828125\tDifferent weight categories (< 50 kg or > 120 kg) had little effect on rivaroxaban plasma concentrations (less than 25%).', 'P-927\t-1.4609 -0.0225 -0.1521 -0.2283 -1.1172 -0.0310 -0.0085 -0.0225 -0.0845 -0.0930 -0.0760 -0.0113 -0.0225 -0.0197 -0.0310 -0.4453 -1.5635 -0.7749 -0.0507 -0.2479 -0.0056 -0.0282 -0.0169 -0.0282 -0.4338 -0.0113 -0.0113 -0.7554 -0.0113 -0.0225 -0.0395 -0.0451 -0.0282 -0.0225 -0.0282 -0.0282 -0.0338 -0.0282', 'S-1234\tDie empfohlene Dosis beträgt 14 ml Telzir Suspension zum Einnehmen (700 mg Fosamprenavir) zweimal täglich mit 100 mg Ritonavir (als Kapsel oder Lösung zum Einnehmen) zweimal täglich.', 'T-1234\tThe recommended dose is 14 ml Telzir oral suspension (700 mg fosamprenavir) twice daily with 100 mg ritonavir (as capsule or oral solution) twice daily.', 'H-1234\t-0.457275390625\tThe recommended dose is 14 ml Telzir oral suspension ( 700 mg fosamprenavir ) twice daily with 100 mg ritonavir ( capsules or oral solution ) twice daily .', 'D-1234\t-0.457275390625\tThe recommended dose is 14 ml Telzir oral suspension (700 mg fosamprenavir) twice daily with 100 mg ritonavir (capsules or oral solution) twice daily.', 'P-1234\t-0.0693 -0.0313 -0.0842 -0.0539 -0.0842 -0.0780 -0.2825 -0.0127 -0.0197 -0.3228 -0.0472 -0.0486 -0.0395 -0.0395 -0.1818 -0.0183 -0.0120 -0.0070 -0.0331 -0.0211 -0.0366 -0.1099 -0.0845 -0.1945 -0.0254 -0.0225 -0.1451 -0.0282 -0.0197 -0.0197 -0.2859 -0.4353 -0.0141 -0.5327 -0.0423 -0.3213 -0.1465 -0.0310 -0.0451 -0.0395 -0.2085 -0.0310', 'S-140\tEinhaltung der vorgegebenen Fristen bei Anträgen auf Erstellung eines Gutachtens zur Ausweisung als Arzneimittel für seltene Leiden durch den COMP Veröffentlichung von Zusammenfassungen von Gutachten zum Zeitpunkt der Entscheidung über die Ausweisung durch die Europäische Kommission', 'T-140\tAdhere to regulatory timelines for applications for opinions from the COMP on orphan drug designation Publication of summaries of opinion at the time of decision on designation by the European Commission', 'H-140\t-1.291015625\tAdhere to regulatory timelines for applications for orphan medicine designation Opinion time by the COMP Publication of summaries of opinion at the time of the European Commission decision granting marketing authorisation', 'D-140\t-1.291015625\tAdhere to regulatory timelines for applications for orphan medicine designation Opinion time by the COMP Publication of summaries of opinion at the time of the European Commission decision granting marketing authorisation', 'P-140\t-0.5190 -0.4106 -0.0331 -0.4058 -0.5996 -0.2255 -0.0141 -0.1648 -0.3311 -0.0845 -0.6157 -0.0028 -0.0169 -0.9438 -0.2227 -0.0254 -3.2012 -0.0113 -0.0845 -0.7832 -0.2029 -0.4001 -0.0225 -0.0113 -0.0395 -0.1409 -0.0338 -0.0845 -0.0395 -0.0282 -0.0395 -0.4170 -0.2255 -0.0564 -0.0732 -0.1183 -0.2141 -0.5410 -0.0282 -0.3101 -0.4058 -0.0225 -0.4282 -0.1691 -0.0113 -0.0789', 'S-830\tKombinationstherapie Wenn es sich bei Ihnen um ein bisher nicht behandeltes multiples Myelom handelt, erhalten Sie VELCADE zusammen mit zwei weiteren Arzneimitteln, die Melphalan und Prednison enthalten.', 'T-830\tCombination therapy If you have not been treated before for multiple myeloma, you will receive VELCADE together with two other medicines containing melphalan and prednisone.', 'H-830\t-1.3408203125\tIf you have previously untreated multiple myeloma you will be receiving VELCADE with two other medicines containing melphalan and prednisone .', 'D-830\t-1.3408203125\tIf you have previously untreated multiple myeloma you will be receiving VELCADE with two other medicines containing melphalan and prednisone.', 'P-830\t-0.3770 -0.3938 -0.5918 -2.7676 -0.0564 -0.0310 -0.0141 -0.0085 -0.0197 -0.0085 -0.9497 -0.1296 -0.3972 -1.5020 -0.0282 -0.0225 -0.0282 -0.0113 -0.0225 -1.1553 -0.0564 -0.1296 -0.3269 -0.5806 -1.5215 -0.0282 -0.0282 -0.0113 -0.1353 -0.0338 -0.0113 -0.0169 -0.0056 -0.0225 -0.0451 -0.0395', 'S-1181\tEine herabgesetzte oder fehlende N-Acetylgalaktosamin-4-Sulfatsulfatase-Aktivität resultiert in der Akkumulation von Dermatansulfat in vielen Zelltypen und Geweben.', 'T-1181\tReduced or absent N-acetyl galactosamine 4-sulfatase activity results in the accumulation of dermatan sulfate in many cell types and tissues.', 'H-1181\t-0.94873046875\tReduced or absent N @-@ acetylgalactosamine 4 @-@ sulfatase activity results in the accumulation of dermatan sulphate in many cell types and tissue .', 'D-1181\t-0.94873046875\tReduced or absent N-acetylgalactosamine 4-sulfatase activity results in the accumulation of dermatan sulphate in many cell types and tissue.', 'P-1181\t-1.3232 -0.3269 -0.0310 -0.4819 -0.0127 -0.0930 -0.0282 -0.0282 -0.0169 -0.0521 -0.0268 -0.0437 -0.1324 -0.0564 -0.5312 -0.2057 -0.0113 -0.3015 -0.0085 -0.0535 -0.2676 -0.0366 -2.0508 -0.0282 -0.0225 -0.0282 -0.1353 -0.0282 -0.0732 -0.0056 -0.4902 -0.0225 -0.0395 -0.4001 -0.3213 -0.0282 -0.0282 -0.7891 -0.0901 -0.0282', 'S-1793\tDas lyophilisierte BeneFIX Pulver zur Herstellung einer Injektionslösung mit Hilfe der doppelseitigen Übertragungskanüle in dem mitgelieferten Lösungsmittel (Wasser für Injektionszwecke) auflösen.', 'T-1793\tReconstitute lyophilised BeneFIX powder for solution for injection with the supplied solvent (water for injection) using the sterile double-ended transfer needle.', 'H-1793\t-1.2607421875\tThe lyophilised BeneFIX powder for solution for injection will be dissolved in the supplied solvent ( water for injections ) using the double @-@ ended needle .', 'D-1793\t-1.2607421875\tThe lyophilised BeneFIX powder for solution for injection will be dissolved in the supplied solvent (water for injections) using the double-ended needle.', 'P-1793\t-0.3835 -0.1205 -0.0257 -0.0257 -0.6533 -0.0359 -0.0127 -0.0218 -0.0345 -0.1459 -0.3228 -0.3198 -0.0564 -0.0282 -0.7412 -0.1691 -0.7861 -0.0141 -0.0254 -0.8564 -0.4790 -1.1943 -0.0225 -0.0564 -0.0169 -0.0507 -0.0676 -0.0507 -0.0451 -0.3213 -0.0338 -1.1045 -0.3157 -0.6479 -0.5073 -0.3269 -1.3691 -0.0282 -0.0845 -0.0282', 'S-655\tIm Jahre 2002 empfing die Agentur Delegationen des deutschen Gesundheitsministeriums, des Sozialausschusses des italienischen Parlaments, der norwegischen Arzneimittelagentur, des schwedischen Sozialministeriums und des Direktorats für Tierarzneimittel des Vereinigten Königreichs.', 'T-655\t• Reduced EMEA 2002 draft budget from', 'H-655\t-2.0234375\tIn 2002 , the Agency received delegations from the German Ministry of Health , the Committee for Social Affairs of the European Parliament , the CVMP , the Swedish Ministry of Social Affairs and United Kingdom Veterinary Medicinal Products Directorate .', 'D-655\t-2.0234375\tIn 2002, the Agency received delegations from the German Ministry of Health, the Committee for Social Affairs of the European Parliament, the CVMP, the Swedish Ministry of Social Affairs and United Kingdom Veterinary Medicinal Products Directorate.', 'P-655\t-1.8301 -0.0211 -0.6733 -0.1268 -0.5352 -0.6338 -0.0479 -0.0225 -0.1353 -0.0423 -2.0410 -0.1127 -0.0338 -0.1747 -0.0338 -0.4622 -2.0352 -0.2986 -1.6113 -0.0732 -0.0564 -0.0282 -0.9976 -0.0225 -0.3042 -0.0338 -1.1836 -0.3157 -0.3157 -1.0146 -0.0451 -0.8789 -0.0676 -0.0789 -0.1917 -0.1240 -0.3833 -1.8262 -0.0225 -0.4058 -0.0225 -0.9355 -0.6987 -0.0225 -0.0225 -0.0901 -0.0113 -0.0451 -0.0338 -0.0338', 'S-858\tGesunde Spender vor allogener PBPC-Transplantation Die Mobilisierung von PBPC bietet keinen direkten klinischen Nutzen für gesunde Spender und sollte nur zum Zweck allogener Stammzelltransplantation in Erwägung gezogen werden.', 'T-858\tNormal donors prior to allogeneic PBPC transplantation Mobilisation of PBPC does not provide a direct clinical benefit to normal donors and should only be considered for the purposes of allogeneic stem cell transplantation.', 'H-858\t-0.75\tNormal donors prior to allogeneic PBPC transplantation The mobilisation of PBPC does not provide a direct clinical benefit to normal donors and should only be considered for the purposes of allogeneic stem cell transplantation .', 'D-858\t-0.75\tNormal donors prior to allogeneic PBPC transplantation The mobilisation of PBPC does not provide a direct clinical benefit to normal donors and should only be considered for the purposes of allogeneic stem cell transplantation.', 'P-858\t-0.3276 -0.0409 -0.2825 -0.2169 -0.0275 -0.0416 -0.0218 -0.0472 -0.0331 -0.1036 -0.0275 -0.6162 -0.0409 -0.3142 -1.0566 -0.0254 -0.1437 -0.0282 -0.1071 -0.0282 -0.4226 -0.1945 -0.0254 -0.2339 -0.3184 -0.0254 -0.0225 -0.0986 -0.1465 -0.6621 -0.0225 -0.2705 -0.0338 -0.1465 -0.0282 -0.0620 -0.1071 -0.3269 -0.2874 -0.0282 -0.0056 -0.0113 0.0000 -0.0169 -0.6479 -0.0282 -0.0113 -0.0620 -0.0395 -0.0282', 'S-1173\tZum Ende meiner ersten dreijährigen Amtszeit möchte ich den Mitgliedern des CVMP meinen herzlichsten Dank für ihre ausgezeichnete Mitarbeit und ihren Anteil daran aussprechen, daß die Sitzungen in einer angenehmen, konstruktiven und professionellen Atmosphäre verlaufen.', 'T-1173\tAt the end of my first 3 year period in office I wish to express my deepest thanks to the members of the CVMP for their excellent co-operation and their efforts to hold the meetings in a convivial, positive and professional atmosphere.', 'H-1173\t-2.158203125\tAt the end of my first three years in office , I should like to thank both the members of the CVMP for their excellent contribution and of the great support of the ad hoc group to the sector .', 'D-1173\t-2.158203125\tAt the end of my first three years in office, I should like to thank both the members of the CVMP for their excellent contribution and of the great support of the ad hoc group to the sector.', 'P-1173\t-0.1918 -0.0299 -0.0567 -0.0285 -1.3018 -0.2817 -0.1465 -0.8174 -0.3916 -0.2930 -0.2395 -0.0423 -0.5693 -0.0310 -0.0310 -0.2649 -0.4734 -0.4199 -1.0400 -0.0338 -0.3213 -0.0451 -0.0282 -0.0113 -0.6084 -0.2705 -0.1014 -0.6084 -0.3606 -1.7695 -0.7554 -1.3301 -0.3269 -0.3269 -0.3042 -1.2402 -0.0113 -0.0113 -0.5298 -1.3975 -0.6201 -1.6230 -1.5781 -0.0451', 'S-1012\tSlovenská republika Bayer s.r.o., Animal Health Litvínovská 609 / 3 CZ-190 21 Praha 9 Č eská republika Tel: + 420 2 66 10 14 71', 'T-1012\tSlovenská republika Bayer s. r. o., Animal Health Litvínovská 609 / 3 CZ-190 21 Praha 9 Č eská republika Tel: + 420 2 66 10 14 71', 'H-1012\t-0.28369140625\tSlovenská republika Bayer s. r. o . , Animal Health Litvínovská 609 / 3 CZ @-@ 190 21 Praha 9 Č eská republika Tel : + 420 2 66 10 14 71', 'D-1012\t-0.28369140625\tSlovenská republika Bayer s. r. o., Animal Health Litvínovská 609 / 3 CZ-190 21 Praha 9 Č eská republika Tel: + 420 2 66 10 14 71', 'P-1012\t-0.0523 -0.0120 -0.0737 -0.0184 -0.0170 -0.0185 -0.0056 -0.9536 -0.2917 -0.1536 -0.0268 -0.0338 -0.0141 -0.0225 -0.0268 -0.0099 -0.0690 -0.0070 -0.0197 -0.0282 -0.0127 -0.0225 -0.0183 -0.0282 -0.0268 -0.0254 -0.0197 -0.0282 -0.0056 -0.0197 -0.0183 -0.0338 -0.0268 -0.2930 -0.0366 -0.0352 -0.0127 -0.0056 -0.0254 -0.1564 -0.0493 -0.0211 -0.0296 -0.0254 -0.0296 -0.0127 -0.0240 -0.0225 -0.0113 -0.0366', 'S-960\tArzneimittel mit dem Wirkstoff Rifampicin (ein Antibiotikum) oder Johanniskraut können die Wirksamkeit von APTIVUS beeinträchtigen und dürfen nicht zusammen mit APTIVUS eingenommen werden (siehe oben, Abschnitt 2.', 'T-960\tJohn <<unk>> s wort are likely to prevent APTIVUS from working properly and should not be taken together with APTIVUS (see 2.', 'H-960\t-1.0234375\tJohn &quot; s Wort ) may interfere with the efficacy of APTIVUS and must not be taken with APTIVUS ( see section 2 above ) .', 'D-960\t-1.0234375\tJohn "s Wort) may interfere with the efficacy of APTIVUS and must not be taken with APTIVUS (see section 2 above).', 'P-960\t-1.0098 -0.5063 -0.0507 -0.7930 -0.3015 -0.4917 -1.0000 -0.0169 -0.0310 -0.2339 -0.9468 -0.0113 -0.0197 -0.0310 -0.0169 -0.0225 -0.0169 -0.0169 -0.3438 -1.4648 -0.0338 -0.0282 -0.0845 -0.4902 -0.0225 -0.0225 -0.0169 -0.0169 -0.0507 -0.0451 -0.4395 -0.0338 -0.0338 -0.0789 -0.0338 -0.0282', 'S-1691\tVon den Patientinnen, denen mehr als 6 Behandlungszyklen verabreicht wurden, beendeten 91% die Studie wie geplant oder wurden bis zur Progression der Erkrankung behandelt, während nur 3% die Studie wegen unerwünschter Ereignisse abbrachen.', 'T-1691\tFor patients administered more than 6 cycles of therapy, 91% completed the study as planned or were treated until disease progression with only 3% withdrawn for adverse events.', 'H-1691\t-1.7158203125\tOf patients who received more than 6 treatment cycles , 91 % completed the study as planned or were treated until disease progression , while only 3 % were withdrawn due to adverse events .', 'D-1691\t-1.7158203125\tOf patients who received more than 6 treatment cycles, 91% completed the study as planned or were treated until disease progression, while only 3% were withdrawn due to adverse events.', 'P-1691\t-1.4170 -1.2324 -0.8540 -0.9385 -0.4790 -0.0282 -0.0873 -0.9834 -0.0282 -0.0113 -0.1747 -0.0113 -0.0282 -0.4565 -0.1803 -0.5806 -0.9297 -1.4707 -0.0395 -0.4226 -0.0338 -0.1635 -0.5806 -0.0169 -0.0225 -1.0371 -0.5522 -0.5747 -0.0338 -0.0225 -1.4873 -0.3269 -0.0113 -0.2593 -0.0338 -0.1014 -0.0113 -0.0113 -0.0338 -0.0338', 'S-691\tKomplette hämatologische Remission oder MCyR wurden bei Patienten mit einer Vielzahl von BCR-ABL-Mutationen, die mit Imatinib-Resistenz assoziiert sind, erzielt, mit Ausnahme von T315I.', 'T-691\tComplete haematologic response or MCyR was achieved in patients harboring a variety of BCR-ABL mutations associated with imatinib resistance except T315I.', 'H-691\t-0.91064453125\tComplete haematological response or MCyR was achieved in patients with a wide variety of BCR @-@ ABL mutations associated with imatinib resistance , except T315I .', 'D-691\t-0.91064453125\tComplete haematological response or MCyR was achieved in patients with a wide variety of BCR-ABL mutations associated with imatinib resistance, except T315I.', 'P-691\t-0.8389 -0.0155 -0.2148 -0.0169 -0.0197 -0.3479 -0.5708 -0.5283 -0.0268 -0.0423 -0.0183 -0.7720 -0.0760 -0.0366 -0.3352 -0.4875 -0.1831 -1.2402 -0.1803 -0.0282 -0.0338 -0.0282 -0.0225 -0.1183 -0.0169 -0.0225 -0.1578 -0.0282 -0.0395 -0.0282 -0.1014 -0.0338 -0.0113 -0.0282 -0.3157 -0.4338 -0.9580 -0.1973 -0.0225 -0.0282 -0.0282 -0.0338 -0.0338', 'S-762\tEntnehmen Sie die Spritze aus der Faltschachtel und überprüfen Sie, dass: • das Verfalldatum nicht abgelaufen ist • die Lösung klar und farblos ist und keine Partikel enthält • die Spritze nicht geöffnet oder beschädigt ist.', 'T-762\tRemove the syringe from the carton and check that: • the expiry date has not passed • the solution is clear and colourless to slightly yellow and doesn <<unk>> t contain particles', 'H-762\t-0.75\tRemove the syringe from the carton and check that : • the expiry date has not passed • the solution is clear and colourless and doesn &apos;t contain particles • the syringe has not been opened or damaged .', "D-762\t-0.75\tRemove the syringe from the carton and check that: • the expiry date has not passed • the solution is clear and colourless and doesn't contain particles • the syringe has not been opened or damaged.", 'P-762\t-0.3472 -0.0171 -0.0169 -0.2303 -0.0395 -0.0141 -0.0049 -0.0458 -0.0479 -0.7495 -0.0268 -0.0648 -0.2507 -0.0873 -0.0718 -0.0564 -0.1775 -0.0211 -0.1324 -0.0268 -0.1536 -0.0282 -0.2859 -0.0535 -0.0592 -0.3494 -0.0282 -0.0620 -0.7046 -0.0395 -0.0197 -0.0254 -0.2197 -0.5747 -0.9639 -0.0282 -0.1409 -0.3157 -0.2761 -0.0395 -0.0225 -0.0056 -0.0056 -0.3662 -0.0507 -0.0620 -0.0395 -0.0338 -0.0282 -0.4958 -0.0338', 'S-289\tGelegentlich kann es zu Herzversagen (welches Atembeschwerden verursachen kann), Kardiomyopathie (Beeinträchtigung des Herzmuskels, welche Atembeschwerden oder Brustschmerzen verursachen kann) oder Herzinfarkt kommen.', 'T-289\tUncommonly, heart failure (which may cause difficulty breathing), cardiomyopathy (impairment of heart muscle, which may cause difficulty breathing or chest pain) or heart attack can occur.', 'H-289\t-1.740234375\tOccasionally the result can be heart failure ( which may cause difficulty breathing ) , cardiomyopathy ( harm to the heart muscle which may cause breathing difficulties or chest pain ) or heart attack .', 'D-289\t-1.740234375\tOccasionally the result can be heart failure (which may cause difficulty breathing), cardiomyopathy (harm to the heart muscle which may cause breathing difficulties or chest pain) or heart attack.', 'P-289\t-2.1465 -0.0127 -0.0085 -0.0197 -1.9834 -0.9917 -0.5493 -0.1268 -0.6934 -0.0225 -0.0338 -0.0451 -0.8340 -0.1973 -1.2959 -0.5073 -0.0338 -0.0338 -0.0169 -0.0225 -0.0282 -0.0225 -0.0113 -0.0225 -0.0282 -0.5073 -0.0676 -0.2649 -0.0507 -0.2197 -0.8789 -0.6538 -0.0451 -1.6348 -0.8003 -0.0451 -0.3606 -0.4282 -0.0338 -0.3157 -0.7554 -0.0338 -0.0338 -0.0338', 'S-141\tZur Minimierung des Risikos von Opioid-bedingten Nebenwirkungen und zur Ermittlung der individuell wirksamen Dosis ist es unabdingbar, die Patienten während des Titrationsprozesses unter engmaschige ärztliche Kontrolle zu stellen.', 'T-141\tIn order to minimise the risks of opioid-related undesirable effects and to identify the effective dose, it is imperative that patients be monitored closely by health professionals during the titration process.', 'H-141\t-1.8798828125\tIn order to minimize the risk of opioid @-@ related adverse reactions and to determine the appropriate individual dose , it is important to monitor patients closely during the titration process .', 'D-141\t-1.8798828125\tIn order to minimize the risk of opioid-related adverse reactions and to determine the appropriate individual dose, it is important to monitor patients closely during the titration process.', 'P-141\t-2.0879 -0.0240 -0.0282 -0.0380 -1.1299 -0.0197 -0.0366 -0.0310 -0.0338 -0.0310 -0.0225 -0.0141 -0.3071 -0.5972 -0.4028 -0.0169 -0.2479 -0.0282 -0.3748 -0.1747 -1.6680 -0.0732 -0.6030 -1.0596 -0.2649 -0.2423 -0.2705 -0.0282 -1.2852 -0.5918 -2.2207 -0.4170 -0.0225 -0.8789 -0.3269 -0.2817 -0.0338 -0.0225 -1.4424 -0.0338 -0.0338', 'S-1312\tDie Studien zeigten einen Unterschied von 15% zwischen den Behandlungsgruppen (61% bei mit Visudyne behandelten Patienten im Vergleich zu 46% bei mit Plazebo behandelten Patienten, p < 0,001, ITT-Analyse).', 'T-1312\tThe studies showed a difference of 15% between treatment groups (61% for Visudyne-treated patients compared to 46% placebo-treated patients, p < 0.001, ITT analysis).', 'H-1312\t-0.9150390625\tThe studies have shown a difference of 15 % between treatment groups ( 61 % for Visudyne @-@ treated patients compared with 46 % for placebo @-@ treated patients , p &lt; 0.001 , ITT estimates ) .', 'D-1312\t-0.9150390625\tThe studies have shown a difference of 15% between treatment groups (61% for Visudyne-treated patients compared with 46% for placebo-treated patients, p < 0.001, ITT estimates).', 'P-1312\t-0.1296 -0.8350 -1.6826 -0.3184 -0.0423 -0.5776 -0.0310 -0.0310 -0.0338 -0.2255 -0.4958 -0.2085 -0.0310 -0.0169 -0.0254 -0.6030 -0.1803 -0.0197 -0.0141 -0.0141 -0.9946 -0.0169 -0.0507 -0.6143 -0.9297 -0.0113 -0.0225 -0.0451 -0.0113 -0.0225 -0.0169 -0.0225 -0.2537 -0.0113 -0.0282 -0.0338 -0.0225 -0.0113 -0.0169 -0.0225 -0.0395 -0.0056 -0.0338 -0.0113 -0.0225 -0.5806 -0.0282 -0.0338 -0.0282', 'S-160\tBei mit VIRAMUNE behandelten Patienten traten schwerwiegende und lebensbedrohliche Auswirkungen auf die Haut auf, darunter Stevens-Johnson-Syndrom (SJS) und toxische epidermale Nekrolyse (TEN).', 'T-160\tSevere and life-threatening skin reactions have occurred in patients treated with VIRAMUNE, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).', 'H-160\t-0.77490234375\tSevere and life @-@ threatening skin reactions experienced by patients treated with VIRAMUNE include Stevens @-@ Johnson syndrome ( SJS ) and toxic epidermal necrolysis ( TEN ) .', 'D-160\t-0.77490234375\tSevere and life-threatening skin reactions experienced by patients treated with VIRAMUNE include Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).', 'P-160\t-0.3835 -0.0197 -0.1373 -0.0264 -0.3965 -0.0204 -0.3896 -0.2874 -0.1902 -1.5840 -0.1183 -0.1212 -0.3296 -0.0423 -0.0282 -0.0141 -0.0141 -0.0197 -0.0254 -1.8594 -0.3157 -0.2537 -0.0113 -0.1578 -0.0169 -0.0338 -0.0282 -0.0282 -0.4170 -0.0282 -0.0395 -0.0169 -0.0169 -0.0282 -0.0113 -0.0225 -0.0451 -0.0113 -0.0225 -0.0225 -0.0282 -0.0282 -0.0225 -0.0282 -0.0338 -0.0282', 'S-802\tBei Hühnern wurde Aivlosin angewendet, um entweder bereits erkrankte Hühner zu behandeln oder um einem Ausbruch der Krankheit bei sehr jungen Küken vorzubeugen, die in Eiern ausgebrütet wurden, die aus infizierten Beständen stammen.', 'T-802\tIn chicken, Aivlosin was used either to treat already diseased chicken or to help preventing an outbreak of the disease in very young chicks that hatched from eggs, which came from flocks where the disease is present.', 'H-802\t-1.521484375\tIn chickens , Aivlosin was used either to treat chickens already affected by the disease or to prevent the outbreak of the disease in very young chicks , which have hatched in eggs obtained from infected flocks .', 'D-802\t-1.521484375\tIn chickens, Aivlosin was used either to treat chickens already affected by the disease or to prevent the outbreak of the disease in very young chicks, which have hatched in eggs obtained from infected flocks.', 'P-802\t-0.7510 -0.5664 -0.0127 -0.0197 -0.2578 -0.1508 -0.0197 -0.0113 -0.0296 -0.1958 -0.1240 -0.4763 -0.0437 -0.0240 -1.7471 -0.0085 -0.0197 -0.9297 -0.3157 -0.5918 -0.1691 -0.0451 -0.5469 -0.0451 -0.2423 -0.7554 -0.2930 -0.1691 -0.1240 -0.0225 -0.1917 -0.1973 -0.0113 -0.0282 -0.9019 -1.2402 -0.2761 -0.4058 -0.3269 -0.0113 -0.2367 -0.1014 -1.3301 -0.0338 -0.2817 -1.1836 -0.1803 -0.0338 -0.0338', 'S-1983\tGONAL-f 450 I.E. / 0,75 ml (33 Mikrogramm / 0,75 ml) darf nicht mit dem Inhalt weiterer GONAL-f- Behältnisse in derselben Durchstechflasche oder Spritze gemischt werden.', 'T-1983\tGONAL-f 450 IU / 0.75 ml (33 micrograms / 0.75 ml) preparation is not to be mixed with other GONAL-f containers within the same vial or syringe.', 'H-1983\t-0.40234375\tGONAL @-@ f 450 IU / 0.75 ml ( 33 micrograms / 0.75 ml ) preparation is not to be mixed with other GONAL @-@ f containers within the same vial or syringe .', 'D-1983\t-0.40234375\tGONAL-f 450 IU / 0.75 ml (33 micrograms / 0.75 ml) preparation is not to be mixed with other GONAL-f containers within the same vial or syringe.', 'P-1983\t-0.1553 -0.0184 -0.0177 -0.0313 -0.0285 -0.0157 -0.0495 -0.3057 -0.0342 -0.1145 -0.0331 -0.0169 -0.0437 -0.0254 -0.0486 -0.0930 -0.0331 -0.0225 -0.0169 -0.0204 -0.0296 -0.3228 -0.4749 -0.1282 -0.3071 -0.0338 -0.0437 -0.3352 -0.2438 -0.1465 -0.0197 -0.0169 -0.0451 -0.0282 -0.1014 -0.0113 -0.0282 -0.3269 -0.0592 -0.0254 -0.0592 -0.0423 -0.0395 -0.0282 -0.0085 -0.0028 -0.0423 -0.0310', 'S-1226\tSevofluran verursacht eine dosisabhängige Atemdepression, weshalb die Atmung während einer Sevofluran-Narkose engmaschig überwacht und die eingeatmete Sevoflurankonzentration entsprechend angepasst werden muss.', 'T-1226\tSevoflurane causes dose-dependant respiratory depression, therefore respiration should be closely monitored during sevoflurane anaesthesia and the inspired concentration of sevoflurane adjusted accordingly.', 'H-1226\t-0.89892578125\tSevoflurane causes dose @-@ related respiratory depression , therefore respiration should be closely monitored during sevoflurane anaesthesia and the inspired concentration of sevoflurane adjusted accordingly .', 'D-1226\t-0.89892578125\tSevoflurane causes dose-related respiratory depression, therefore respiration should be closely monitored during sevoflurane anaesthesia and the inspired concentration of sevoflurane adjusted accordingly.', 'P-1226\t-0.1608 -0.0269 -0.0220 -0.0192 -0.0349 -0.3196 -0.2529 -0.0592 -1.1660 -0.0592 -0.0127 -0.0141 -0.0197 -0.4734 -1.2422 -0.6987 -0.2479 -0.0141 -0.3213 -0.0338 -0.3860 -0.0254 -0.0197 -0.2593 -0.1014 -0.0225 -0.0282 -0.0225 -0.0845 -0.0620 -0.1183 -0.2537 -0.0169 -0.2255 -0.0507 -0.3213 -0.3213 -0.1691 -0.1127 -0.0282 -0.0282 -0.0225 -0.0338 -0.3550 -0.8286 -0.0225 -0.0282 -0.0282', 'S-1585\tInsulin Human Winthrop führte zu einer Abnahme des HbA1c-Spiegels, die darauf hindeutete, dass die Blutzuckerspiegel auf ein ähnliches Niveau wie mit halbsynthetischem Humaninsulin eingestellt worden waren.', 'T-1585\tInsulin Human Winthrop led to a decrease in the level of HbA1c, indicating that blood glucose levels had been controlled to a similar level to that seen with semi-synthetic human insulin.', 'H-1585\t-0.52978515625\tInsulin Human Winthrop led to a decrease in the level of HbA1c , indicating that blood sugar levels had been controlled to a similar level to that seen with semi @-@ synthetic human insulin .', 'D-1585\t-0.52978515625\tInsulin Human Winthrop led to a decrease in the level of HbA1c, indicating that blood sugar levels had been controlled to a similar level to that seen with semi-synthetic human insulin.', 'P-1585\t-0.0872 -0.0057 -0.0106 -0.1750 -0.0127 -0.0028 -0.0213 -0.5796 -0.0310 -0.0592 -0.1642 -0.0148 -0.0718 -0.3845 -0.1831 -0.0282 -0.0296 -0.0197 -0.0324 -0.0240 -0.0254 -0.1113 -0.2227 -0.0268 -0.0507 -0.1381 -0.6719 -0.0423 -0.1381 -0.0366 -0.3240 -0.1324 -0.1831 -0.2395 -0.0592 -0.1803 -0.2649 -0.2986 -0.0789 -0.0817 -0.0282 -0.0141 -0.0141 -0.0225 -0.0113 -0.0113 -0.0310 -0.0282', 'S-1270\tOpadry 85F32004 (Polyvinylalkohol part. hydrolysiert,, Titandioxid (E 171), Macrogol 3350, Talkum, Eisenoxidhydrat (E 172)).', 'T-1270\tOpadry 85F32004 (Polyvinyl alcohol-part. hydrolyzed, Titanium dioxide (E171), Macrogol 3350, Talc, Iron oxide yellow (E172)).', 'H-1270\t-0.58056640625\tOpadry 85F32004 ( Polyvinyl alcohol @-@ part. hydrolyzed , , Titanium dioxide ( E171 ) , Macrogol 3350 , Talc , Iron oxide yellow ( E172 ) ) .', 'D-1270\t-0.58056640625\tOpadry 85F32004 (Polyvinyl alcohol-part. hydrolyzed,, Titanium dioxide (E171), Macrogol 3350, Talc, Iron oxide yellow (E172)).', 'P-1270\t-0.0619 -0.0227 -0.0198 -0.0255 -0.0220 -0.0241 -0.0255 -0.0248 -0.0299 -0.2261 -0.0099 -0.0218 -0.0299 -0.3223 -0.3093 -0.0331 -0.0077 -0.0127 -0.2430 -0.0338 -0.4128 -0.2859 -0.0099 -0.0240 -0.0648 -0.0070 -0.0310 -0.2352 -0.0155 -0.0282 -0.0296 -0.0296 -0.0732 -0.0225 -0.0225 -0.0197 -0.0127 -0.0240 -0.0282 -0.1606 -0.0676 -0.0366 -0.7271 -0.1775 -1.6006 -0.2817 -0.1409 -0.0169 -0.0282 -0.0282 -0.0338 -0.0732 -0.0282', 'S-1458\tMetaflumizon und Amitraz bieten als Kombinationspräparat aufgrund einer nichtsystemischen Exposition der Parasiten auf der Haut und den Haaren ein breites Wirkungsspektrum sowohl gegen Flöhe als auch Zecken.', 'T-1458\tMetaflumizone and amitraz are combined in the final formulation to provide a broad spectrum of activity against both fleas and ticks, respectively, due to non-systemic exposure of the parasites on the skin and hair.', 'H-1458\t-0.99267578125\tMetaflumizone and amitraz are used in combination therapy to protect against fleas and ticks due to non @-@ systemic exposure of the parasites on the skin and hair .', 'D-1458\t-0.99267578125\tMetaflumizone and amitraz are used in combination therapy to protect against fleas and ticks due to non-systemic exposure of the parasites on the skin and hair.', 'P-1458\t-0.1655 -0.0299 -0.0162 -0.0185 -0.1320 -0.0377 -0.1895 -0.0204 -0.0327 -0.2888 -0.7451 -0.2479 -0.0268 -0.3198 -1.6904 -1.4316 -0.1775 -0.1465 -0.0254 -0.4902 -0.0451 -0.0169 -1.3867 -0.0282 -0.3101 -0.0282 -0.0958 -0.0113 -0.0282 -0.0564 -0.0564 -0.2141 -0.0282 -0.0113 -0.0395 -0.4453 -0.0958 -0.0225 -0.0338 -0.0958 -0.0338 -0.0338', 'S-1749\tBei Patienten mit erhöhter Aktivität des Renin-Angiotensin-Aldosteron-Systems besteht das Risiko eines plötzlichen ausgeprägten Blutdruckabfalls und einer Verschlechterung der Nierenfunktion aufgrund der ACE-Hemmung.', 'T-1749\tPatients with strongly activated renin-angiotensin-aldosterone system are at risk of an acute pronounced fall in blood pressure and deterioration of renal function due to ACE inhibition, especially when an ACE inhibitor or a concomitant diuretic is given for the first time or at first dose increase.', 'H-1749\t-1.1796875\tPatients with a strongly activated renin @-@ angiotensin @-@ aldosterone system are at risk of a sudden fall in blood pressure and worsening of renal function due to ACE inhibition .', 'D-1749\t-1.1796875\tPatients with a strongly activated renin-angiotensin-aldosterone system are at risk of a sudden fall in blood pressure and worsening of renal function due to ACE inhibition.', 'P-1749\t-0.2235 -0.0192 -0.0782 -0.8550 -0.3804 -0.3184 -0.0296 -0.0465 -0.0423 -0.1648 -0.0240 -0.0155 -0.0169 -0.0155 -0.0268 -0.0648 -0.0225 -0.0211 -0.0169 -0.0254 -0.0423 -0.6890 -0.1691 -0.0592 -0.5381 -0.3296 -0.1324 -2.6035 -0.3606 -0.0395 -0.0169 -0.0451 -1.8877 -0.0056 -0.3381 -0.1465 -0.5693 -0.0225 -0.0282 -1.0146 -0.0282 -0.2255 -0.0225 -0.0676 -0.0225 -0.0338 -0.0338', 'S-20\tIn der ersten Studie mit Erwachsenen mit Typ-1-Diabetes wurde nach sechs Monaten eine Senkung von 0,14% (von 7,60% auf 7,46%) im Vergleich zu einer Senkung von 0,14% bei Insulinlispro festgestellt.', 'T-20\tIn the first study of adults with type 1 diabetes, there was a decrease of 0.14% (from 7.60% to 7.46%) after six months, compared with a decrease of 0.14% for insulin lispro.', 'H-20\t-1.1416015625\tIn the first study in adults with type 1 diabetes , there was a 0.14 % reduction ( from 7.60 % to 7.46 % ) at six months , compared with 0.14 % in insulin lispro .', 'D-20\t-1.1416015625\tIn the first study in adults with type 1 diabetes, there was a 0.14% reduction (from 7.60% to 7.46%) at six months, compared with 0.14% in insulin lispro.', 'P-20\t-0.4351 -0.0356 -0.0402 -0.5303 -1.0693 -0.0197 -0.0324 -0.0366 -0.0324 -0.0113 -0.4001 -0.9072 -0.0282 -0.0901 -1.2285 -0.0225 -0.0395 -0.2001 -0.2029 -0.0535 -0.0225 -0.0366 -0.5269 -0.0282 -0.0169 -0.0169 -0.0225 -0.0282 -0.8789 -0.9409 -0.0282 -0.1917 -0.0564 -0.7495 -0.9019 -0.0225 -0.0282 -0.3325 -0.2085 -0.0113 -0.3269 -0.3213 -0.0282 -0.0395 -0.0282', 'S-985\tRegelmäßiges Überwachen des Serum-Kaliums und des EKGs wird bei Gabe von Losartan / Hydrochlorothiazid mit Arzneimitteln, die durch Schwankungen des Serum-Kaliums beeinflusst werden (z.', 'T-985\tmonitoring', 'H-985\t-1.3193359375\tPeriodic monitoring of serum potassium and ECG is recommended if losartan / hydrochlorothiazide is administered with medicines influenced by serum potassium disturbances ( e. g .', 'D-985\t-1.3193359375\tPeriodic monitoring of serum potassium and ECG is recommended if losartan / hydrochlorothiazide is administered with medicines influenced by serum potassium disturbances (e. g.', 'P-985\t-1.5762 -0.0127 -0.0930 -0.0240 -0.0338 -0.0916 -0.0338 -0.2705 -0.0085 -0.0268 -0.0366 -0.8804 -0.0254 -0.3381 -1.2285 -1.4062 -0.0338 -0.0113 -0.0282 -0.3381 -0.0113 -0.0282 -0.0113 -0.0282 -0.0113 -0.0282 -0.0056 -0.0169 -0.3662 -0.7271 -0.0225 -0.1183 -0.7607 -0.6592 -1.0820 -0.0225 -0.0282 -0.2649 -0.0282 -0.0056 -0.0056 -0.0282 -0.3381 -0.1578 -0.0225 -0.0451 -1.4033 -0.0451 -0.8452 -0.0338 -0.3157', 'S-1610\tIn der Studie R076477- SCH-305 wurde auch eine Dosierung von 15 mg eingesetzt, jedoch werden die Ergebnisse für diese Dosierung hier nicht dargestellt, da diese über der empfohlenen Tageshöchstdosis von 12 mg liegt.', 'T-1610\tA 15 mg dose was also included in Study R076477-SCH-305, but results are not presented since this is above the maximum recommended daily dose of 12 mg.', 'H-1610\t-1.5615234375\tThe R076477 @-@ SCH @-@ 305 study also used a dose of 15 mg , but the results for this dose are not presented since this dosage is above the maximum recommended daily dose of 12 mg .', 'D-1610\t-1.5615234375\tThe R076477-SCH-305 study also used a dose of 15 mg, but the results for this dose are not presented since this dosage is above the maximum recommended daily dose of 12 mg.', 'P-1610\t-1.2002 -0.3086 -0.0169 -0.0338 -0.0324 -0.2522 -0.1042 -0.0127 -0.0183 -0.0282 -0.0197 -0.0254 -0.4648 -0.4521 -0.3042 -0.7437 -0.4705 -0.2734 -0.0986 -0.0141 -1.0479 -0.1071 -2.2207 -0.0451 -0.6313 -0.2479 -0.5239 -0.4958 -0.0338 -0.9185 -0.3213 -0.5469 -1.5107 -0.0338 -0.0225 -0.7778 -0.6084 -0.1578 -0.2930 -0.1240 -0.0225 -0.0338 -0.0338 -0.0225 -0.0113 -0.0338 -0.0338', 'S-1112\tEs hat sich gezeigt, dass kombinierte hormonelle Kontrazeptiva bei gemeinsamer Verabreichung mit Lamotrigin dessen Plasmakonzentrationen durch Induktion der Lamotrigin-Glucuronidierung signifikant vermindern.', 'T-1112\tCombined hormonal contraceptives have been shown to significantly decrease plasma concentrations of lamotrigine when co-administered due to induction of lamotrigine glucuronidation.', 'H-1112\t-1.265625\tCombined hormonal contraceptives have been shown to significantly reduce the plasma concentrations of lamotrigine in case of co @-@ administration of lamotrigine by induction of lamotrigine glucuronidation .', 'D-1112\t-1.265625\tCombined hormonal contraceptives have been shown to significantly reduce the plasma concentrations of lamotrigine in case of co-administration of lamotrigine by induction of lamotrigine glucuronidation.', 'P-1112\t-2.0312 -0.7510 -0.0197 -0.0197 -0.0296 -0.0211 -0.0324 -0.0141 -0.0225 -0.6538 -0.0395 -0.0592 -0.0479 -0.5693 -0.6030 -0.5835 -0.0760 -0.0113 -0.0169 -0.4509 -0.0113 -0.0169 -0.3042 -0.0732 -0.0225 -0.0113 -0.0282 -1.5498 -0.4565 -0.0789 -0.8623 -0.0282 -0.0225 -0.8228 -0.1014 -0.0225 -0.0113 -0.0225 -1.4482 -0.0451 -0.4509 -0.0338 -0.0451 -0.0225 -0.0113 -0.0225 -0.7437 -0.0225 -0.1127 -0.0225 -0.0338 -0.0338', 'S-329\t1 mg Estradiol / 0,1 mg NETA auf eine ausreichende schützende Wirkung hin, obwohl die obere Grenze des Konfidenzintervalls für die Hyperplasierate über der in der Leitlinie empfohlenen Grenze liegt;', 'T-329\t- on the level of endometrial hyperplasia, the trial on the 1 mg estradiol / 0.1 mg NETA product', 'H-329\t-1.7822265625\t1 mg estradiol / 0.1 mg NETA results in an adequate protective effect , although the upper limit of the confidence interval for hyperplasia rate is above the threshold recommended in the guidance ;', 'D-329\t-1.7822265625\t1 mg estradiol / 0.1 mg NETA results in an adequate protective effect, although the upper limit of the confidence interval for hyperplasia rate is above the threshold recommended in the guidance;', 'P-329\t-0.5376 -0.0148 -0.0518 -0.0028 -0.0211 -0.0384 -0.0430 -0.0416 -0.0155 -0.0760 -0.0155 -2.4277 -0.0366 -1.8682 -0.0901 -0.0789 -0.4846 -0.6821 -0.8340 -0.0338 -0.2255 -0.1973 -0.2141 -0.7100 -0.1578 -0.0338 -0.0113 -0.2537 -0.3438 -0.0056 -0.1296 -0.7324 -0.7832 -0.7100 -0.6538 -1.1270 -0.9805 -0.2479 -0.0338 -1.1494 -0.6538 -0.0338', 'S-920\tNach oraler Verabreichung von radioaktiv markiertem Mycophenolatmofetil wurde die verabreichte Dosis vollständig ausgeschieden, wobei 93% der verabreichten Dosis mit dem Urin und 6% mit den Fäzes eliminiert wurden.', 'T-920\tOrally administered radiolabelled mycophenolate mofetil results in complete recovery of the administered dose; with 93%', 'H-920\t-1.0244140625\tOrally administered radiolabelled mycophenolate mofetil results in complete recovery of the administered dose ; with 93 % of the administered dose excreted in the urine and 6 % in the faeces .', 'D-920\t-1.0244140625\tOrally administered radiolabelled mycophenolate mofetil results in complete recovery of the administered dose; with 93% of the administered dose excreted in the urine and 6% in the faeces.', 'P-920\t-0.4783 -0.0176 -0.1265 -0.0243 -0.3213 -0.2120 -0.3191 -0.2776 -0.0366 -0.0141 -0.0155 -0.1141 -0.0338 -0.0211 -0.0282 -0.0409 -0.3213 -0.1254 -0.1986 -0.3228 -0.1606 -0.1917 -0.3127 -0.0282 -0.0338 -1.0479 -0.4790 -0.1183 -0.0310 -0.2169 -0.1859 -0.1465 -0.0225 -0.0113 -0.8906 -0.0056 -0.0282 -0.5239 -0.5469 -0.0169 -0.0225 -0.2197 -0.0395 -0.0282 -1.8711 -0.2197 -0.2761 -0.0056 -0.0395 -0.0395 -0.0282', 'S-144\tDer Inhalt der 500-mg-Durchstechflaschen von CellCept 500 mg Pulver zur Herstellung eines Infusionslösungskonzentrats muss mit je 14 ml 5% iger Glucose-Infusionslösung rekonstituiert werden.', 'T-144\tThe content of CellCept 500 mg powder for concentrate for solution for infusion vials must be reconstituted with 14 ml of glucose intravenous infusion 5% each.', 'H-144\t-1.3125\tThe content of each 500 mg vial by CellCept 500 mg powder for concentrate for solution for infusion must be reconstituted with glucose intravenous infusion 5 % solution , each containing 14 ml .', 'D-144\t-1.3125\tThe content of each 500 mg vial by CellCept 500 mg powder for concentrate for solution for infusion must be reconstituted with glucose intravenous infusion 5% solution, each containing 14 ml.', 'P-144\t-2.2422 -0.5605 -0.0310 -1.2881 -0.3240 -0.0395 -0.0760 -0.0310 -0.4734 -0.0310 -0.0113 -0.0310 0.0000 -0.0338 -0.0113 -0.1155 -0.1635 -0.6338 -0.3213 -0.3213 -0.3213 -0.1465 -0.0225 -0.5352 -0.0282 -0.0676 -0.0169 -0.0169 -0.1014 -1.3135 -0.0169 -0.0225 -0.4114 -0.3213 -0.1803 -0.0338 -0.3213 -0.0338 -0.3213 -0.0282 -0.9580 -0.6426 -0.1917 -0.4170 -0.0338 -0.0676 -0.0451 -0.0338', 'S-1002\tPharmakokinetische Wechselwirkungen mit anderen Substanzen Nichtsteroidale Antirheumatika reduzieren die Lithium Clearance und führen zu erhöhten Plasma- Lithium-Werten und Lithium-Toxizität.', 'T-1002\tNon-steroidal anti-inflammatory drugs have been reported to reduce the clearance of lithium, resulting in elevated plasma levels and lithium toxicity.', 'H-1002\t-1.1572265625\tPharmacokinetic interactions with other substances Non @-@ steroidal anti @-@ inflammatory drugs reduce plasma clearance and may lead to increased plasma lithium levels and lithium toxicity .', 'D-1002\t-1.1572265625\tPharmacokinetic interactions with other substances Non-steroidal anti-inflammatory drugs reduce plasma clearance and may lead to increased plasma lithium levels and lithium toxicity.', 'P-1002\t-0.5542 -0.0141 -0.0391 -0.4727 -0.0085 -0.0423 -0.0472 -0.0373 -0.2839 -0.0395 -0.4326 -0.0169 -0.9766 -0.0620 -0.0085 -0.0451 -0.0254 -0.0141 -0.7891 -0.0338 -0.2283 -0.0225 -0.0113 -0.0845 -0.6338 -1.0850 -0.9297 -0.0113 -0.0225 -0.3889 -0.0225 -0.0958 -0.8115 -1.4766 -0.0282 -0.4395 -0.0507 -0.0113 -0.0113 -0.1296 -0.0225 -0.0225 -1.3975 -0.0338 -0.0225 -0.0225 -0.0225 -0.0225 -0.2930 -0.0225 -0.0338 -0.0338', 'S-1309\tIn der Patienten-Untergruppe, die sich einer PCI unterzogen, wurden starke Blutungen häufig und zwar bei 9,7% der mit Eptifibatid behandelten Patienten im Gegensatz zu 4,6% der mit Placebo behandelten Patienten beobachtet.', 'T-1309\tIn the subgroup of patients undergoing PCI, major bleeding was observed commonly, in 9.7% of eptifibatide-treated patients vs 4.6% of placebo-treated patients.', 'H-1309\t-1.5859375\tIn the subgroup of patients undergoing PCI , serious haemorrhage was observed commonly in 9.7 % of patients treated with eptifibatide compared to 4.6 % of placebo @-@ treated patients .', 'D-1309\t-1.5859375\tIn the subgroup of patients undergoing PCI, serious haemorrhage was observed commonly in 9.7% of patients treated with eptifibatide compared to 4.6% of placebo-treated patients.', 'P-1309\t-1.0762 -0.0479 -0.5947 -0.3325 -1.3809 -0.2085 -0.8623 -0.0169 -0.0282 -0.0901 -0.0845 -1.1045 -1.3242 -0.0169 -0.0056 -0.4226 -0.3213 -1.4141 -1.4424 -0.0620 -0.0169 -0.0282 -0.0338 -0.0282 -0.3550 -0.3438 -0.0338 -0.0225 -0.0338 -0.0338 -0.0225 -0.0225 -0.0564 -1.1494 -0.5859 -0.0225 -0.0338 -0.0225 -0.3042 -1.3301 -0.0225 -0.0113 -0.0225 -0.7100 -0.0113 -0.0225 -0.0338 -0.0338', 'S-1852\tPräklinische Daten zur okulären Toxizität Eine mit Vigabatrin verbundene Retinotoxizität ist nur bei Albino-Ratten beobachtet worden, nicht aber bei pigmentierten Ratten, Hunden oder Affen.', 'T-1852\tPreclinical data related to ocular toxicity Vigabatrin associated retinotoxicity has only been observed in albino rats, but not in pigmented rats, dogs or monkeys.', 'H-1852\t-0.8916015625\tPreclinical data on ocular toxicity A retinotoxicity associated with vigabatrin has only been observed in albino rats , but not in pigmented rats , dogs or monkeys .', 'D-1852\t-0.8916015625\tPreclinical data on ocular toxicity A retinotoxicity associated with vigabatrin has only been observed in albino rats, but not in pigmented rats, dogs or monkeys.', 'P-1852\t-0.7593 -0.3381 -0.0056 -0.0141 -0.8804 -0.2944 -0.0225 -0.0070 -0.0141 -0.0127 -0.0197 -1.7852 -0.3184 -0.0085 -0.0141 -0.0225 -0.0197 -0.0197 -0.5605 -0.0310 -0.3184 -0.2283 -0.0169 -0.0704 -0.4958 -0.7158 -0.0282 -0.6875 -0.0338 -0.0338 -0.0169 -0.0338 -0.0395 -0.3438 -0.1409 -0.0451 -0.0564 -0.0676 -0.0113 -0.1240 -0.0282 -0.0169 -0.1691 -0.0507 -0.0113 -0.0282 -0.0282', 'S-391\t• Bei Patienten mit einer besonderen Art von Lungenerkrankung, der chronischen obstruktiven Lungenerkrankung (COPD), sind unter Behandlung mit einem anderen TNF-Blocker von Krebsarten, die keine Lymphome waren, aufgetreten.', 'T-391\t• There have been cases of cancers, other than lymphoma in patients with a specific type of lung disease called Chronic Obstructive Pulmonary Disease (COPD) treated with another TNF blocker.', 'H-391\t-0.671875\t• There have been reports of cancers other than lymphoma in patients with a specific type of lung disease called Chronic Obstructive Pulmonary Disease ( COPD ) treated with another TNF blocker .', 'D-391\t-0.671875\t• There have been reports of cancers other than lymphoma in patients with a specific type of lung disease called Chronic Obstructive Pulmonary Disease (COPD) treated with another TNF blocker.', 'P-391\t-0.0969 -0.3533 -0.4148 -0.0373 -1.0859 -0.0789 -0.3254 -0.0268 -0.3042 -0.0324 -0.0254 -0.3606 -0.0845 -0.0704 -0.0535 -0.0592 -0.3240 -0.0451 -0.0282 -0.0676 -0.0564 -0.3157 -0.4226 -0.0169 -0.1831 -0.0085 -0.0141 -0.0169 -0.0028 -0.0197 -0.0282 -0.0085 -0.0197 -0.0338 -0.0225 -0.0056 -0.0282 -0.3240 -0.0338 -0.1663 -0.0423 -0.0282 -0.0282 -0.9834 -0.0113 -0.0451 -0.0282', 'S-262\tbetrifft mehr als 1 Patienten von 10 betrifft 1 bis weniger als 10 von 100 Patienten betrifft 1 bis weniger als 10 von 1.000 Patienten betrifft 1 bis weniger als 10 von 10.000 Patienten betrifft weniger als 1 Patienten von 10.000 Häufigkeit kann anhand der vorliegenden Daten nicht geschätzt werden', 'T-262\taffects more than 1 user in 10 affects 1 to less than 10 users in 100 affects 1 to less than 10 users in 1,000 affects 1 to less than 10 users in 10,000 affects less than 1 user in 10,000 frequency cannot be estimated from the available data', 'H-262\t-0.7177734375\taffects more than 1 patient in 10 affects 1 to less than 10 in 100 patients affects 1 to less than 10 in 1,000 patients affects 1 to less than 10 in 10,000 patients affects less than 1 patient in 10,000 frequency cannot be estimated from the available data', 'D-262\t-0.7177734375\taffects more than 1 patient in 10 affects 1 to less than 10 in 100 patients affects 1 to less than 10 in 1,000 patients affects 1 to less than 10 in 10,000 patients affects less than 1 patient in 10,000 frequency cannot be estimated from the available data', 'P-262\t-0.1074 -0.0327 -0.0299 -0.2874 -1.9697 -0.2634 -0.0479 -0.0479 -0.0324 -0.0718 -0.2311 -0.0282 -0.0338 -1.5303 -0.0310 -0.0760 -0.0366 -0.0282 -0.0282 -0.0620 -0.0254 -0.0282 -0.0366 -0.0395 -0.0395 -0.0338 -0.0282 -0.0310 -0.0676 -0.0225 -0.0310 -0.0310 -0.0254 -0.0310 -0.0338 -0.0479 -0.0225 -0.0282 -0.0225 -0.0338 -0.0197 -0.3635 -0.0169 -0.0845 -0.0225 -0.0338 -0.2930 -0.1409 -0.1917 -0.0282 -0.7666', 'S-1886\tIst ein Monat nach Einsetzen der Nitisinonbehandlung noch immer Succinylaceton im Urin nachweisbar, sollte die Nitisinondosis auf 1,5 mg / kg Körpergewicht / Tag in 2 verteilten Dosen erhöht werden.', 'T-1886\tIf urine succinylacetone is still detectable one month after the start of nitisinone treatment, the nitisinone dose should be increased to 1.5 mg / kg body weight / day divided in 2 doses.', 'H-1886\t-1.623046875\tIf in urine , one month after the start of nitisinone treatment , succinylacetone is still detectable , the dose of nitisinone should be increased to 1.5 mg / kg body weight / day at two divided doses .', 'D-1886\t-1.623046875\tIf in urine, one month after the start of nitisinone treatment, succinylacetone is still detectable, the dose of nitisinone should be increased to 1.5 mg / kg body weight / day at two divided doses.', 'P-1886\t-0.5039 -1.0479 -0.5298 -0.0211 -2.3457 -0.4424 -0.0282 -0.0366 -0.2507 -1.1494 -0.0282 -1.3643 -0.0845 -0.0507 -0.0169 -0.9805 -0.0732 -0.1635 -0.0620 -0.1240 -0.1296 -0.0338 -0.0169 -0.0225 -1.2959 -0.6030 -0.9580 -0.0564 -0.0225 -0.4509 -0.3833 -0.9692 -0.1127 -0.0225 -0.0564 -0.0564 -0.0225 -0.0338 -0.2705 -0.0564 -0.3269 -0.0789 -0.0113 -0.0338 -0.0225 -0.6763 -0.0113 -0.2817 -0.0338 -0.9468 -0.2593 -0.4958 -0.0225 -0.0225 -0.0338 -0.0338', 'S-1035\tWeiterhin kam es unter Sitagliptin zu ähnlichen Reduktionen von HbA1c und FPG wie in den anderen plazebo-kontrollierten Monotherapie- Studien bei Patienten mit normaler Nierenfunktion (siehe Abschnitt 5.2).', 'T-1035\tIn addition, the reductions in HbA1c and FPG with sitagliptin compared to placebo were generally similar to those observed in other monotherapy studies in patients with normal renal function (see section 5.2).', 'H-1035\t-0.84619140625\tSitagliptin also gave similar reductions in HbA1c and FPG compared to the other placebo @-@ controlled monotherapy studies in patients with normal renal function ( see section 5.2 ) .', 'D-1035\t-0.84619140625\tSitagliptin also gave similar reductions in HbA1c and FPG compared to the other placebo-controlled monotherapy studies in patients with normal renal function (see section 5.2).', 'P-1035\t-0.2343 -0.0285 -0.0070 -0.0400 -1.4648 -1.5078 -0.2959 -0.2339 -0.0197 -0.0958 -0.0535 -0.0225 -0.0310 -0.0254 -0.0225 -0.0310 -0.0282 -0.0169 -0.8960 -0.4819 -0.3635 -0.2029 -0.0282 -0.0225 -0.0169 -0.0282 -0.0451 -0.0225 -0.0507 -0.0338 -0.0169 -0.5298 -0.2255 -0.6143 -0.0338 -0.0451 -0.2311 -0.0225 -0.0225 -0.0338 -0.0338 -0.2255 -0.0225 -0.0282 -0.0338 -0.0282 -0.0282', 'S-569\tEesti INFAI, Institut für biomedizinische Analytik und NMR-Imaging GmbH Universitätsstraße 142 D-44799 Bochum Deutschland / Germany Tel: + 49 234 971130 Ελλάδα:', 'T-569\tDeutschland INFAI, Institut für biomedizinische Analytik und NMR-Imaging GmbH Universitätsstraße 142 D-44799 Bochum Tel: + 49 234 971130 Eesti INFAI, Institut für biomedizinische Analytik und NMR-Imaging GmbH Universitätsstraße 142 D-44799 Bochum Tel: + 49 234 971130 Ελλάδα:', 'H-569\t-0.3115234375\tEesti INFAI , Institut für biomedizinische Analytik und NMR @-@ Imaging GmbH Universitätsstraße 142 D @-@ 44799 Bochum Tel : + 49 234 971130 Ελάδα :', 'D-569\t-0.3115234375\tEesti INFAI, Institut für biomedizinische Analytik und NMR-Imaging GmbH Universitätsstraße 142 D-44799 Bochum Tel: + 49 234 971130 Ελάδα:', 'P-569\t-0.4377 -0.0183 -0.0278 -0.1687 -0.0148 -0.0264 -0.0345 -0.3169 -0.2367 -0.1859 -0.0099 -0.0211 -0.0944 -0.0127 -0.0268 -0.0240 -0.0183 -0.0240 -0.0254 -0.0211 -0.0366 -0.0113 -0.0211 -0.0240 -0.0099 -0.0718 -0.0282 -0.0254 -0.0240 -0.0296 -0.0268 -0.0141 -0.0141 -0.0042 -0.4763 -0.0493 -0.0282 -0.0169 -0.0254 -0.0141 -0.0211 -0.0240 -0.0169 -0.0254 -0.0056 -0.0014 -0.3931 -0.0056 -0.0028 -0.0676 -0.0366', 'S-798\tDas Ergebnis des NeoSpect-Scans wurde mit der tatsächlichen Diagnose verglichen, die anhand der histologischen Untersuchung des Rundherdes (Untersuchung des Rundherdgewebes unter dem Mikroskop, nachdem es in einer Operation entfernt wurde) gestellt wurde.', 'T-798\t(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail @ emea. europa. eu http: / / www. emea. europa. eu © EMEA 2007 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged nodule (when the tissue of the nodule is analysed under the microscope after it has been removed in an operation).', 'H-798\t-1.916015625\tThe result of the NeoSpect scan was compared with the true diagnosis made using a histological examination of the pulmonary nodule ( examination of surrounding tissue under a microscope after complete removal in surgery ) .', 'D-798\t-1.916015625\tThe result of the NeoSpect scan was compared with the true diagnosis made using a histological examination of the pulmonary nodule (examination of surrounding tissue under a microscope after complete removal in surgery).', 'P-798\t-0.2252 -0.1925 -0.0395 -0.0796 -0.0416 -0.0264 -0.0218 -0.0183 -0.0863 -0.0162 -0.0514 -0.0500 -0.7910 -0.0592 -1.4316 -0.0254 -0.5469 -0.7158 -0.7666 -0.0423 -0.5269 -2.0352 -0.0338 -0.0338 -0.6704 -0.0507 -0.0225 -0.3213 -0.1803 -0.0395 -2.8398 -0.0451 -0.7554 -0.7437 -0.2141 -0.1465 -0.0225 -0.0113 -0.0113 -0.6538 -1.6006 -0.7891 -1.0596 -1.1719 -0.0338 -0.0338 -0.0338', 'S-1779\tCaspofungin (33,9%) war so wirksam wie liposomales Amphotericin B (33,7%) [0,2% Differenz (95,2% KI -5,6; 6,0)].', 'T-1779\tThere were 1095 patients included in the primary Modified Intention-To-Treat (MITT) efficacy analysis of overall favourable response; caspofungin (33.9%) was as effective as liposomal amphotericin B (33.7%) [% difference 0.2 (95.2% CI <<unk>> 5.6, 6.0)].', 'H-1779\t-0.2335205078125\tCaspofungin ( 33.9 % ) was as effective as liposomal amphotericin B ( 33.7 % ) &#91; 0.2 % difference ( 95.2 % CI -5.6 , 6.0 ) &#93; .', 'D-1779\t-0.2335205078125\tCaspofungin (33.9%) was as effective as liposomal amphotericin B (33.7%) [0.2% difference (95.2% CI -5.6, 6.0)].', 'P-1779\t-0.1259 -0.0177 -0.0070 -0.0099 -0.1006 -0.0313 -0.1226 -0.0458 -0.0236 -0.0257 -0.0292 -0.0504 -0.0384 -0.0553 -0.0306 -0.0299 -0.0092 -0.0169 -0.0183 -0.0197 -0.0120 -0.0169 -0.0148 -0.0331 -0.0254 -0.0268 -0.0218 -0.0176 -0.0240 -0.0240 -0.0296 -0.0225 -0.0810 -0.0310 -0.0268 -0.0211 -0.0289 -0.0225 -0.0225 -0.0268 -0.0240 -0.0416 -0.0282 -0.0402 -0.0225 -0.0268 -0.3169 -0.0324 -0.0282 -0.0324 -0.5366 -0.0324 -0.0296', 'S-441\tanzuwendenden Arzneimittels wie Oracea für die vorliegende Indikation gegenüber dem Risikopotenzial für schädliche Wirkungen im Zusammenhang mit einer Resistenzentwicklung überwiegen, und beurteilt das Nutzen-Risiko-Verhältnis von Oracea als positiv <unk>', 'T-441\tindication outweigh the risk for potential harmful effects related to resistance development and therefore considers the benefit-risk ratio to be positive,', 'H-441\t-2.20703125\tThe Committee for Medicinal products to be used in the present indication outweighs the risk for potential harmful effects related to resistance development and consider the benefit / risk balance to be positive .', 'D-441\t-2.20703125\tThe Committee for Medicinal products to be used in the present indication outweighs the risk for potential harmful effects related to resistance development and consider the benefit / risk balance to be positive.', 'P-441\t-1.1602 -1.6650 -2.0156 -0.3127 -0.1212 -0.7778 -1.1836 -0.0225 -1.0029 -0.1973 -0.4170 -1.5615 -0.1578 -0.9243 -0.0789 -0.0225 -0.1465 -0.3042 -0.3157 -0.5410 -0.6084 -0.0225 -0.0338 -0.6426 -0.0338 -0.3833 -0.1014 -0.6538 -1.4873 -0.1803 -0.1127 -0.8115 -0.0338 -1.0371 -0.4282 -0.0338 -0.0676 -0.2367 -0.0338', 'S-285\tBei Anwendung von Voriconazol bei bereits bestehender Tacrolimus-Therapie wird empfohlen, die Tacrolimus-Dosis auf ein Drittel der Ausgangsdosis zu reduzieren und die Tacrolimus-Spiegel sorgfältig zu überwachen.', 'T-285\tWhen initiating voriconazole in patients already receiving tacrolimus, it is recommended that the tacrolimus dose be reduced to a third of the original dose and tacrolimus level carefully monitored.', 'H-285\t-1.451171875\tWhen initiating voriconazole treatment in patients already receiving tacrolimus , it is recommended that the dose of tacrolimus be reduced to about one third of the original dose and that tacrolimus levels be carefully monitored .', 'D-285\t-1.451171875\tWhen initiating voriconazole treatment in patients already receiving tacrolimus, it is recommended that the dose of tacrolimus be reduced to about one third of the original dose and that tacrolimus levels be carefully monitored.', 'P-285\t-1.6289 -0.6846 -0.0676 -0.2903 -0.0056 -0.0085 -0.0169 -0.5352 -0.3325 -0.3184 -0.3579 -0.2255 -0.1973 -0.0254 -0.0254 -0.0169 -0.7412 -0.1578 -0.0310 -0.0395 -0.2847 -1.2627 -0.6367 -0.5015 -0.0958 -0.0225 -0.0225 -0.0169 -0.8452 -0.2874 -0.0338 -0.6201 -0.1014 -0.5859 -0.4282 -0.1917 -0.6875 -0.0676 -0.2479 -0.7437 -0.2930 -0.0225 -0.0225 -0.0225 -0.4170 -0.3606 -0.7100 -0.0225 -0.0225 -0.0338 -0.0338', 'S-874\tThiazide können die Ausscheidung von Kalzium über den Urin vermindern und zu einer intermittierenden und leichten Erhöhung des Kalziumspieges im Serum führen, auch ohne dass bekannte Störungen des Kalziumstoffwechsels vorliegen.', 'T-874\tThiazides may reduce urinary calcium excretion and cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism.', 'H-874\t-1.267578125\tThiazides may decrease urinary calcium excretion and cause an intermittent and slight increase in serum calcium levels without known disorders of calcium metabolism .', 'D-874\t-1.267578125\tThiazides may decrease urinary calcium excretion and cause an intermittent and slight increase in serum calcium levels without known disorders of calcium metabolism.', 'P-874\t-0.4358 -0.0472 -0.0285 -0.0356 -0.2703 -1.2402 -0.0197 -0.3269 -0.1014 -0.2776 -0.0183 -0.0211 -0.3423 -0.0169 -0.0310 -0.0817 -0.3916 -1.5918 -0.1917 -0.0085 -0.0282 -0.2761 -0.7720 -1.4600 -0.0901 -0.1071 -0.0395 -0.1183 -0.0113 -0.0225 -0.9805 -1.0146 -0.4001 -0.5352 -0.0169 -0.6201 -0.1353 -0.0113 -0.0225 -0.0225 -0.0113 -0.0225 -0.0338 -0.0451', 'S-1661\tBei Patienten, die aufgrund einer klinisch bedeutsamen Überempfindlichkeit gegenüber dem Wirkstoff, dem Arzneimittel oder gegenüber anderen Arzneimitteln auf Sulfonamidbasis kein Probenecid einnehmen können, ist die Anwendung von Cidofovir kontraindiziert.', 'T-1661\tCidofovir administration is contraindicated in patients unable to receive probenecid because of a clinically significant hypersensitivity to the active substance or medicinal product or to other sulfa- containing medicines.', 'H-1661\t-1.404296875\tCidofovir administration is contraindicated in patients who are unable to take probenecid due to clinically significant hypersensitivity to the active substance , medicinal product or other sulphonamide based medicinal products .', 'D-1661\t-1.404296875\tCidofovir administration is contraindicated in patients who are unable to take probenecid due to clinically significant hypersensitivity to the active substance, medicinal product or other sulphonamide based medicinal products.', 'P-1661\t-0.5415 -0.0225 -0.0176 -0.0169 -0.0197 -0.9370 -0.0507 -0.0493 -0.0042 -0.1169 -0.0324 -0.2847 -1.2168 -0.7861 -0.0282 -0.1663 -0.0845 -0.0225 -0.0282 -0.0451 -0.7070 -0.0282 -0.3157 -0.0197 -0.3071 -0.0338 -0.0113 -0.0113 -0.0395 -0.4114 -0.0958 -0.1917 -0.0451 -1.8652 -0.1409 -0.0732 -0.3101 -0.3606 -0.7046 -1.6348 -0.0564 -0.0113 -0.0113 -1.5107 -0.9805 -0.0564 -0.0338 -0.0338 -0.0338', 'S-1076\tBei diesen Patienten ist anzuraten, die Behandlung mit einer separaten Gabe von Entacapon-Tabletten zu beginnen und die Levodopa-Dosis, falls erforderlich, anzupassen, bevor auf die Behandlung mit Stalevo umgestellt wird.', 'T-1076\tIn such patients it is advisable to introduce entacapone treatment as a separate treatment (entacapone tablets) and adjust the levodopa dose if necessary, before switching to Stalevo.', 'H-1076\t-1.6904296875\tIn these patients , it is recommended to start treatment with a separate dose of entacapone tablets and adjust levodopa dose if necessary before switching to Stalevo treatment .', 'D-1076\t-1.6904296875\tIn these patients, it is recommended to start treatment with a separate dose of entacapone tablets and adjust levodopa dose if necessary before switching to Stalevo treatment.', 'P-1076\t-1.6357 -0.3411 -0.0254 -0.5806 -0.2169 -0.0338 -0.9819 -0.5215 -1.3213 -1.0537 -0.0845 -0.4565 -0.4453 -0.4282 -0.0282 -0.4114 -0.0282 -0.0169 -0.2930 -0.0451 -0.0282 -0.2537 -0.8115 -0.0169 -0.6313 -0.0225 -0.0338 -0.0225 -0.0282 -1.1045 -0.5410 -0.3833 -0.6201 -0.4509 -0.0789 -0.2029 -0.0113 -0.0225 -1.4092 -0.0338 -0.0338', 'S-105\t4 ml Lösung in einer 5 ml-Durchstechflasche (Glastyp I), die mit einem latexfreien Stopfen (Bromobutyl / Isoprenpolymer) und einer Kappe (lackierter Kunststoff) verschlossen ist.', 'T-105\t4 ml of solution in a 5 ml vial (type I glass) closed with a latex-free stopper (bromobutyl / isoprene polymer) and a seal (lacquered plastic).', 'H-105\t-1.568359375\t3 ml solution in a 5 ml vial ( Type I glass ) closed with a non @-@ latex stopper ( silica ) and a seal ( lacquered plastic ) .', 'D-105\t-1.568359375\t3 ml solution in a 5 ml vial (Type I glass) closed with a non-latex stopper (silica) and a seal (lacquered plastic).', 'P-105\t-1.3213 -1.1777 -0.0789 -0.0493 -0.3086 -0.2311 -0.0197 -0.1099 -0.0310 -0.0451 -1.6768 -0.3157 -0.1212 -0.0366 -1.1553 -0.1071 -0.0395 -0.7324 -0.0451 -0.1183 -0.0113 -0.1353 -0.0282 -0.0338 -0.7495 -0.2593 -1.7529 -0.0564 -0.0564 -0.5186 -0.6592 -0.8228 -0.0113 -0.0225 -0.0225 -0.5073 -0.0338 -0.2141 -0.5073', 'S-13\tEs hat sich gezeigt, dass die Monotherapie mit Nelfinavir oder die Behandlung in Kombination mit anderen antiretroviralen Arzneimitteln die Viruslast reduziert und die CD4-Zellzahlen bei HIV-1-seropositiven Patienten erhöht.', 'T-13\tClinical pharmacodynamic data: treatment with nelfinavir alone or in combination with other antiretroviral agents has been documented to reduce viral load and increase CD4 cell counts in HIV-1 seropositive patients.', 'H-13\t-0.80712890625\tNelfinavir monotherapy or nelfinavir in combination with other antiretroviral agents has been shown to reduce viral loads and increase CD4 cell counts in HIV @-@ 1 seropositive patients .', 'D-13\t-0.80712890625\tNelfinavir monotherapy or nelfinavir in combination with other antiretroviral agents has been shown to reduce viral loads and increase CD4 cell counts in HIV-1 seropositive patients.', 'P-13\t-0.8037 -0.0183 -0.0113 -0.0225 -0.0197 -0.1451 -0.0296 -0.0183 -0.1176 -1.3389 -0.0521 -0.0211 -0.0225 -0.0211 -0.6807 -0.0141 -0.0282 -0.0366 -0.0817 -0.0197 -0.0141 -0.0169 -1.0371 -0.1803 -0.0310 -0.0338 -0.0282 -0.5298 -0.2874 -0.6680 -0.0338 -0.3325 -0.1803 -0.0282 -0.2593 -0.1014 -0.0338 -0.2649 -0.4001 -0.0282 -0.0395 -0.0282 -0.0282 -0.0282 -0.0169 -0.0451 -0.0282 -0.0282', 'S-682\tBei einer Dosis von 0,1 mmol Gadobutrol pro kg Körpergewicht betrug die Konzentration von Gadobutrol im Plasma 2 Minuten nach Injektion durchschnittlich 0,59 mmol / l und nach 60 Minuten 0,3 mmol / l.', 'T-682\tAt a dose of 0.1 mmol gadobutrol / kg BW, an average of 0.59 mmol gadobutrol / l plasma was measured 2 minutes after the injection and 0.3 mmol gadobutrol / l plasma 60 minutes post injection.', 'H-682\t-1.232421875\tAt a dose of 0.1 mmol gadobutrol / kg body weight , the concentration of gadobutrol in plasma at 2 minutes after injection averaged 0.59 mmol / l and 0.3 mmol / l at 60 minutes .', 'D-682\t-1.232421875\tAt a dose of 0.1 mmol gadobutrol / kg body weight, the concentration of gadobutrol in plasma at 2 minutes after injection averaged 0.59 mmol / l and 0.3 mmol / l at 60 minutes.', 'P-682\t-0.9272 -0.7070 -0.1663 -0.0324 -0.0352 -0.0352 -0.0310 -0.0197 -0.0211 -0.1099 -0.0225 -0.0183 -0.0183 -0.0437 -0.8638 -0.0197 -0.3467 -0.0225 -0.8481 -0.7324 -0.8228 -0.0338 -0.0113 -0.0169 -0.0225 -0.0169 -0.0338 -0.4170 -0.6084 -0.0113 -0.0169 -2.0684 -0.4058 -0.0395 -0.6367 -0.2367 -0.0113 -1.0088 -0.0169 -0.3325 -0.1578 -0.5298 -0.0225 -0.0225 -0.0338 -0.0338 -0.0676 -0.1465 -0.0225 -0.0225 -0.0225 -0.0225 -0.0338 -0.0338 -1.1387 -0.0338 -0.0338 -0.0338 -0.0338', 'S-1408\tJedoch wird gemäß guter tierärztlicher Praxis empfohlen, dass alle über 6 Monate alten Tiere, die in Ländern leben, in denen der Überträger anzutreffen ist, vor der Behandlung mit STRONGHOLD auf eine vorhandene Infektion mit Herzwürmern untersucht werden.', 'T-1408\tSTRONGHOLD may be safely administered to animals infected with adult heartworms, however, it is recommended, in accordance with good veterinary practice, that all animals 6 months of age or more living in countries where a vector exists should be tested for existing adult heartworm infections before beginning medication with STRONGHOLD.', 'H-1408\t-1.33984375\tThrough a reduction in the flea population , monthly treatment of pregnant and lactating animals will also aid in the prevention of flea infestations .', 'D-1408\t-1.33984375\tThrough a reduction in the flea population, monthly treatment of pregnant and lactating animals will also aid in the prevention of flea infestations.', 'P-1408\t-0.3972 -0.3057 -0.3269 -0.2981 -0.2444 -0.3396 -0.2761 -0.2578 -0.2043 -0.3284 -0.3213 -0.3269 -0.3213 -0.3804 -0.3213 -0.0141 -0.1381 -0.1155 -0.3550 -0.7974 -0.5186 -0.1635 -0.2537 -0.3101 -0.0056 -0.0901 -0.3606 -0.2029 -0.3438 -0.0056 -0.2255 -2.0449 -0.3213', 'S-1831\tDie Halbwertszeit von Lamotrigin ist generell bei Kindern kürzer als bei Erwachsenen und beträgt im Mittel etwa 7 Stunden, wenn Lamotrigin gleichzeitig mit enzyminduzierenden Arzneimitteln wie Carbamazepin und Phenytoin verabreicht', 'T-1831\tThe half-life of lamotrigine is generally shorter in children than in adults with a mean value of approximately 7 hours when given with enzyme-inducing medicinal products such as carbamazepine and phenytoin and increasing to mean values of 45 to 50 hours when co-administered with valproate alone (see section 4.2).', 'H-1831\t-1.208984375\tThe half @-@ life of lamotrigine is generally shorter in children than in adults and averages about 7 hours when lamotrigine is co @-@ administered with enzyme @-@ inducing medicines such as carbamazepine and phenytoin .', 'D-1831\t-1.208984375\tThe half-life of lamotrigine is generally shorter in children than in adults and averages about 7 hours when lamotrigine is co-administered with enzyme-inducing medicines such as carbamazepine and phenytoin.', 'P-1831\t-0.4302 -0.1814 -0.0810 -0.0388 -0.0373 -0.0402 -0.0247 -0.0127 -0.0211 -1.1621 -0.2791 -0.1479 -0.0197 -0.0732 -0.7988 -0.0366 -0.0958 -0.0197 -0.9805 -0.2734 -0.1747 -0.9497 -0.0451 -0.2141 -0.3945 -0.2874 -0.0225 -0.0113 -0.0225 -0.0282 -1.9219 -0.0282 -0.0225 -0.0169 -0.0395 -0.2255 -0.0225 -0.3606 -1.4824 -0.1296 -0.2367 -0.4678 -0.0901 -0.7324 -0.0225 -0.0338 -0.0225 -0.0113 -0.0113 -0.0225 -0.0338 -0.0113 -0.0225 -0.0225 -0.1127 -0.6313 -0.0338', 'S-1331\tCiprofloxacin Bayer und zugehörige Namen (siehe Anhang I) 500 mg Suspension zum Einnehmen in Einzeldosisbeuteln [siehe Anhang I - ist national auszufüllen] Ciprofloxacin Zum Einnehmen.', 'T-1331\tCiprofloxacin Bayer and associated names (see Annex I) 500 mg oral suspension in single-dose sachets [See Annex I - To be completed nationally] Ciprofloxacin Oral use', 'H-1331\t-0.427978515625\tCiprofloxacin Bayer and associated names ( see Annex I ) 500 mg oral suspension in single @-@ dose sachets &#91; See Annex I - To be completed nationally &#93; Ciprofloxacin Oral use', 'D-1331\t-0.427978515625\tCiprofloxacin Bayer and associated names (see Annex I) 500 mg oral suspension in single-dose sachets [See Annex I - To be completed nationally] Ciprofloxacin Oral use', 'P-1331\t-0.0516 -0.0070 -0.0170 -0.0242 -0.0206 -0.0248 -0.0106 -0.0407 -0.2169 -0.0271 -0.0342 -0.0486 -0.2473 -0.0247 -0.0282 -0.0310 -0.0676 -0.0092 -0.3228 -0.0500 -0.2148 -0.0606 -0.1846 -0.0296 -0.1141 -0.0395 -0.0437 -0.3071 -0.0535 -0.0225 -0.0296 -0.0535 -0.3169 -0.0211 -0.2507 -0.0310 -0.0254 -0.0395 -0.1663 -0.0056 -0.0169 -0.0254 -0.0197 -0.0254 -0.3213 -0.0254 -0.3213 -0.2986', 'S-1586\tWie viel STELARA wird angewendet? • Ihr Arzt wird entscheiden, wie viel und für wie lange Sie STELARA benötigen. • Dies kann von Ihrem Gewicht abhängen • Die übliche Anfangsdosis beträgt 45 mg Ustekinumab.', 'T-1586\tHow much STELARA is given • Your doctor will decide how much STELARA you need and for how long • This may depend on your weight • The usual starting dose is 45 mg ustekinumab.', 'H-1586\t-0.73974609375\tHow much STELARA is given • Your doctor will decide how much and for how long you need STELARA • This may depend on your weight . • The usual starting dose is 45 mg ustekinumab .', 'D-1586\t-0.73974609375\tHow much STELARA is given • Your doctor will decide how much and for how long you need STELARA • This may depend on your weight. • The usual starting dose is 45 mg ustekinumab.', 'P-1586\t-0.2910 -0.0386 -0.0474 -0.0197 -0.0204 -0.0271 -0.2201 -0.8135 -0.7397 -0.4846 -0.0183 -0.2438 -0.3042 -0.0507 -0.0366 -1.0283 -0.0451 -0.0225 -0.0310 -0.0535 -0.3101 -0.0338 -0.0169 -0.0197 -0.0282 -0.6846 -0.1155 -0.0704 -0.0676 -0.0338 -0.0282 -0.0225 -0.8906 -0.0395 -0.0676 -0.0507 -0.0845 -0.0620 -0.0395 -0.0676 -0.0282 -0.1747 -0.0169 -0.0113 -0.0225 -0.0169 -0.0225 -0.0451 -0.0338', 'S-1549\tBesondere Vorsicht ist geboten, wenn Kaletra Patienten verschrieben wird, die Digoxin einnehmen, da der akute inhibitorische Effekt von Ritonavir auf Pgp einen signifikanten Anstieg der Digoxin-Spiegel erwarten lässt.', 'T-1549\tParticular caution should be used when prescribing Kaletra in patients taking digoxin as the acute inhibitory effect of ritonavir on Pgp is expected to significantly increase digoxin levels.', 'H-1549\t-0.8173828125\tParticular caution should be used when Kaletra is prescribed to patients taking digoxin since the acute inhibitory effect of ritonavir on Pgp is expected to significantly increase digoxin levels .', 'D-1549\t-0.8173828125\tParticular caution should be used when Kaletra is prescribed to patients taking digoxin since the acute inhibitory effect of ritonavir on Pgp is expected to significantly increase digoxin levels.', 'P-1549\t-0.9546 -0.0070 -0.0211 -0.1134 -0.2352 -0.0331 -0.6528 -0.0704 -0.3960 -0.0225 -0.0127 -0.0310 -0.0676 -0.0183 -0.0549 -0.0395 -0.3748 -0.0451 -0.0338 -0.0113 -0.0338 -1.5273 -0.0592 -0.0535 -0.0113 -0.0338 -0.0197 -0.0169 -0.0423 -0.4734 -0.0338 -0.0479 -0.0310 -0.0282 -0.0197 -0.0423 -0.0592 -0.2451 -0.0225 -0.5693 -0.0620 -0.0338 -1.3867 -0.1296 -0.1803 -0.0056 -0.0225 -0.0282 -0.1691 -0.0338 -0.0282', 'S-676\tHautblutungen (punktförmige Kapillarblutungen und entzündliche, meist, symmetrische Hautblutungen), Haarausfall, übermäßiges Schwitzen, Gefäßentzündung mit Hautveränderungen (Erythema multiforme).', 'T-676\t29 Rare: skin bleeding (punctiform capillary bleeding and inflamed, mainly symmetrical skin bleeding), hair loss, excessive sweating, blood vessel inflammation with skin changes (erythema multiforme).', 'H-676\t-1.71484375\tSkin bleeding ( pin @-@ point bleeding and inflammatory , usually symmetrical skin bleeding ) , alopecia , excessive sweating , blood vessel inflammation with skin disorders ( erythema multiforme ) .', 'D-676\t-1.71484375\tSkin bleeding (pin-point bleeding and inflammatory, usually symmetrical skin bleeding), alopecia, excessive sweating, blood vessel inflammation with skin disorders (erythema multiforme).', 'P-676\t-1.0059 -0.0225 -0.5947 -0.3904 -0.0338 -0.5962 -0.0901 -0.2959 -1.5693 -0.2255 -1.5889 -0.0169 -0.2593 -0.0169 -0.0169 -1.5439 -0.9580 -0.1803 -0.0113 -0.0169 -0.7212 -0.0225 -0.4565 -0.6650 -0.0225 -0.0282 -0.0338 -1.3525 -0.0113 0.0000 -0.0113 -0.0338 -1.1387 -0.0676 -0.0225 -0.0338 -1.2510 -0.3606 -0.0451 -0.0113 -0.0225 -0.2255 -0.4395 -1.5664 -0.0225 -0.0338 -0.2141 -0.0225 0.0000 -0.0113 -0.0451 -0.0225 -0.0338 -0.5635 -0.0338', 'S-1783\tElimination Nach Verabreichung einer radioaktiv-markierten 14C-Etravirin-Dosis konnten 93,7% der verabreichten Dosis von 14C-Etravirin in den Fäzes und 1,2% im Urin nachgewiesen werden.', 'T-1783\tElimination After administration of a radiolabeled 14C-etravirine dose, 93.7% and 1.2% of the administered dose of 14 C-etravirine could be retrieved in faeces and urine, respectively.', 'H-1783\t-1.240234375\tElimination After administration of a radiolabelled dose of 14C @-@ etravirine , 93.7 % of the administered dose of 14C @-@ etravirine was recovered in faeces and 1.2 % in urine .', 'D-1783\t-1.240234375\tElimination After administration of a radiolabelled dose of 14C-etravirine, 93.7% of the administered dose of 14C-etravirine was recovered in faeces and 1.2% in urine.', 'P-1783\t-0.5073 -0.0113 -0.0306 -1.0098 -0.7061 -0.0352 -0.6523 -1.4854 -0.2847 -0.1409 -0.5186 -0.5073 -0.0338 -0.5298 -0.0338 -0.1296 -0.2255 -0.0451 -0.0225 -0.2874 -0.2197 -0.0282 -0.0676 -0.0225 -0.0338 -0.1691 -0.0789 -0.5581 -0.0282 -0.0282 -0.0338 -0.0225 -0.0282 -0.0282 -0.0845 -0.0395 -0.0169 -0.2930 -1.1328 -0.8057 -0.3494 -0.6367 0.0000 -0.0338 -0.3945 -0.1465 -0.0225 -0.0789 -0.6084 -0.0225 -0.0338 -0.0338', 'S-54\tKomplette hä- matologische Remission, keine Leukämie mehr nachweisbar (Verschwinden der Blasten aus Knochen- mark und Blut, jedoch keine komplette hämatologische Rekonstitution) oder Wiedereintritt in die chronische Phase der CML.', 'T-54\tThe primary efficacy variable was the rate of haematological response, reported as either complete haematological response, no evidence of leukaemia (i. e. clearance of blasts from the marrow and the blood, but without a full peripheral blood recovery as for complete responses), or return to chronic phase CML.', 'H-54\t-1.19921875\tComplete haematological response , no evidence of leukaemia ( clearance of bone marrow or blood blasts , but no complete haematological reconstitution ) or return to chronic phase CML .', 'D-54\t-1.19921875\tComplete haematological response, no evidence of leukaemia (clearance of bone marrow or blood blasts, but no complete haematological reconstitution) or return to chronic phase CML.', 'P-54\t-0.7158 -0.0183 -0.3254 -0.0155 -0.0169 -0.7749 -0.9595 -0.0564 -0.0930 -0.3184 -0.0535 -0.0113 -0.2057 -0.0113 -0.0282 -0.0732 -0.4565 -0.0310 -0.0845 -0.8398 -0.0310 -0.0113 -0.9214 -0.3606 -0.1296 -0.0113 -0.4678 -0.4453 -0.0564 -0.7046 -0.0901 -0.0225 -0.0225 -0.2537 -0.1803 -0.0113 -0.0338 -0.5581 -0.6143 -0.0395 -0.2705 -0.8789 -0.7437 -0.0338 -0.0225 -0.0451 -0.0338', 'S-1434\t7 (0,7) 5 (0,5) 14 (1,4) 10 (1,0) 21 (2,1) 28 (2,9) 40 (4,1) 26 (2,7) 18 (1,8) 22 (2,3) 3 (0,3) 9 (0,9)', 'T-1434\t7 (0.7) 14 (1.4) 21 (2.1) 40 (4.1) 18 (1.8) 3 (0.3)', 'H-1434\t-0.27392578125\t7 ( 0.7 ) 5 ( 0.5 ) 14 ( 1.4 ) 10 ( 1.0 ) 21 ( 2.1 ) 28 ( 2.9 ) 40 ( 4.1 ) 26 ( 2.7 ) 18 ( 1.8 ) 22 ( 2.3 ) 3 ( 0.3 ) 9 ( 0.9 )', 'D-1434\t-0.27392578125\t7 (0.7) 5 (0.5) 14 (1.4) 10 (1.0) 21 (2.1) 28 (2.9) 40 (4.1) 26 (2.7) 18 (1.8) 22 (2.3) 3 (0.3) 9 (0.9)', 'P-1434\t-1.1562 -0.0268 -0.2268 -0.0225 -0.0289 -0.0282 -0.0268 -0.0338 -0.0282 -0.0183 -0.0254 -0.0859 -0.0282 -0.0254 -0.0268 -0.0352 -0.0225 -0.0282 -0.0225 -0.0254 -0.0409 -0.0268 -0.0282 -0.0183 -0.0268 -0.0409 -0.0254 -0.0282 -0.0225 -0.0254 -0.0465 -0.0296 -0.0282 -0.0197 -0.0268 -0.0282 -0.0225 -0.0282 -0.0254 -0.0254 -0.1888 -0.0113 -0.0282 -0.0240 -0.0254 -0.0352 -0.0282 -0.0282 -0.0254 -0.0254 -0.0395 -0.0254 -0.0282 -0.0225 -0.0254 -0.0395 -0.0225 -0.0282 -0.0282', 'S-673\t9 alle 2 Wochen haben innerhalb eines Behandlungszeitraums von 6 Monaten zu einer Besserung der hämatologischen und der viszeralen Parameter geführt, und die Dauertherapie mit dieser Dosierung hat entweder die Knochenerkrankung gebessert oder deren Progression aufgehalten.', 'T-673\t9 improvement in haematological and visceral parameters within 6 months of therapy and continued use has either stopped progression of or improved bone disease.', 'H-673\t-0.97900390625\t9 improvement in haematological and visceral parameters within 6 months of therapy and continued use has either stopped progression of or improved bone disease .', 'D-673\t-0.97900390625\t9 improvement in haematological and visceral parameters within 6 months of therapy and continued use has either stopped progression of or improved bone disease.', 'P-673\t-2.1777 -0.3228 -0.2255 -0.2466 -0.0197 -0.0225 -0.2761 -0.0507 -0.0676 -0.0113 -0.0056 -0.0451 -0.0169 -0.0197 -0.3042 -0.3296 -0.0535 -0.1775 -0.3606 -0.3184 -0.3071 -0.3157 -0.4395 -0.0620 -0.3381 -0.3042 -0.0225 -0.3945 -0.3213 -0.0732 -0.1521 -0.0395 -0.1691 -0.1353', 'S-1901\tDer Tablettenüberzug enthält Methacrylsäure-Ethylacrylat-Copolymer (1: 1), Hochdisperses Siliciumdioxid, Macrogol und Titandioxid (E171).', 'T-1901\tThe tablet coating contains methacrylic acid copolymer, colloidal anhydrous silica, macrogol and titanium dioxide (E171).', 'H-1901\t-0.76806640625\tThe tablet film coating contains methacrylic acid - ethyl acrylate copolymer ( 1 : 1 ) , colloidal anhydrous silica , macrogol and titanium dioxide ( E171 ) .', 'D-1901\t-0.76806640625\tThe tablet film coating contains methacrylic acid - ethyl acrylate copolymer (1: 1), colloidal anhydrous silica, macrogol and titanium dioxide (E171).', 'P-1901\t-0.7041 -0.0835 -0.0296 -0.6455 -0.5718 -0.0225 -0.0564 -0.3777 -0.0296 -0.0197 -0.0183 -0.8369 -0.8086 -0.0113 -0.1042 -0.0141 -0.0141 -0.0310 -0.2649 -0.0254 -0.0225 -0.0169 -0.0310 -0.0310 -0.0310 -0.0282 -0.0282 -0.0310 -0.8145 -0.2537 -0.1917 -0.0056 -0.7778 -0.2593 -0.0451 -0.2817 -0.0282 -0.0564 -0.0901 -0.0225 -0.0451 -0.0225 -0.4001 -0.0282 -0.0113 -0.0225 -0.0282 -0.0113 -0.0338 -0.0451 -0.0225 -0.0282 -0.0282 -0.0338 -0.0282', 'S-1988\t0. <unk> Veranschlagt sind Mittel zur Deckung der Kosten für Übersetzungsarbeiten; sie umfassen Zahlungen an das Übersetzungszentrum in Luxemburg im Zusammenhang mit sämtlichen Texten, die nicht direkt mit der Durchführung des Arbeitsprogramms der Agentur zusammenhängen.', "T-1988\t0. <<unk>> This appropriation is intended to cover the cost of translations, including payments made to the Translation Centre in Luxembourg for all texts not directly connected with the implementation of the Agency's work programme.", 'H-1988\t-1.4892578125\t0 - This appropriation is intended to cover the costs of translation which consists of payments by the Translation Centre in Luxembourg for all texts not directly connected with the implementation of the Agency &apos;s work programme .', "D-1988\t-1.4892578125\t0 - This appropriation is intended to cover the costs of translation which consists of payments by the Translation Centre in Luxembourg for all texts not directly connected with the implementation of the Agency's work programme.", 'P-1988\t-0.6938 -0.8447 -0.3198 -0.5073 -0.1282 -0.6875 -0.1550 -0.0366 -0.0704 -0.1465 -0.7046 -0.0535 -0.3748 -1.1494 -1.4873 -1.0479 -0.6479 -0.0507 -0.6255 -1.1670 -0.2874 -0.5693 -0.0225 -0.0338 -0.0564 -0.0113 -0.0113 -0.5522 -0.1917 -0.0564 -0.2255 -0.0451 -0.3157 -0.1240 -0.0564 -0.0901 -0.0338 -0.0789 -0.3833 -0.2029 -0.0901 -0.0225 -0.0338 -0.0338', 'S-642\tAußerdem wurden veröffentlichte Daten aus nicht vom Sponsor veranlassten Studien eingereicht, in denen UMAN BIG bei etwa 1 000 Neugeborenen von Müttern, die HBsAg-Trägerinnen waren, zur Prophylaxe gegen Hepatitis B eingesetzt wurde.', 'T-642\tFurthermore, published data from non-sponsor driven studies using UMAN BIG in the prophylaxis of hepatitis B in approximately 1000 newborns of HBsAg carrier mothers was submitted.', 'H-642\t-1.6240234375\tThe company also presented published data from non @-@ sponsor studies of the use of UMAN BIG in the prophylaxis of hepatitis B in about 1,000 newborns with HBsAg carrier mothers .', 'D-642\t-1.6240234375\tThe company also presented published data from non-sponsor studies of the use of UMAN BIG in the prophylaxis of hepatitis B in about 1,000 newborns with HBsAg carrier mothers.', 'P-642\t-0.4377 -0.8213 -0.0768 -0.5742 -0.9580 -0.4790 -0.0507 -1.3838 -0.0310 -0.9639 -0.2705 -2.2266 -0.3550 -0.1296 -0.0338 -0.1183 -0.0169 -0.0282 -0.0056 -0.6084 -0.2479 -0.2649 -0.0113 -0.0282 -0.0169 -0.0507 -0.1014 -0.3381 -0.0113 -0.0169 -0.0169 -0.1353 -0.9805 -0.4170 -1.2852 -0.2705 -0.0113 -1.1836 -0.6987 -0.0225 -0.0225 -0.0225 -0.3157 -0.0451 -0.0338 -0.0338', 'S-11\tThalidomide Celgene ist während der Schwangerschaft und bei gebärfähigen Frauen kontraindiziert, es sei denn, alle Anforderungen des Thalidomide Celgene-Schwangerschafts-Präventions-Programms werden erfüllt (siehe Abschnitt 4.3).', 'T-11\tThalidomide Celgene is contraindicated during pregnancy and in women of childbearing potential unless all the conditions of the Thalidomide Celgene Pregnancy Prevention Programme are met (see section 4.3)', 'H-11\t-0.55517578125\tThalidomide Celgene is contraindicated during pregnancy and in women of childbearing potential unless all the conditions of the Thalidomide Celgene Pregnancy Prevention Programme are met ( see section 4.3 ) .', 'D-11\t-0.55517578125\tThalidomide Celgene is contraindicated during pregnancy and in women of childbearing potential unless all the conditions of the Thalidomide Celgene Pregnancy Prevention Programme are met (see section 4.3).', 'P-11\t-0.2627 -0.0120 -0.0171 -0.0262 -0.0269 -0.0178 -0.0106 -0.0430 -0.0155 -0.0035 -0.5693 -0.0303 -0.0430 -0.0958 -0.1698 -0.4036 -0.5327 -0.0070 -0.3198 -0.5889 -0.0732 -0.2367 -0.4958 -0.1831 -0.0564 -0.1099 -0.0141 -0.0169 -0.0169 -0.0310 -0.0141 -0.0113 -0.0760 -0.1973 -0.0169 -0.0423 -0.0141 -0.2479 -0.0620 -0.1437 -0.0366 -0.0479 -0.1663 -0.0254 -0.0282 -0.0451 -0.0310 -0.0282', 'S-692\tAchtfach erhöhte Werte wurden bei 3,7% der mit zweimal täglich 125 mg behandelten Patienten mit pulmonal arterieller Hypertonie und bei 7,1% der mit zweimal täglich 250 mg behandelten Patienten mit pulmonal arterieller Hypertonie beobachtet.', 'T-692\tEight-fold increases were seen in 3.7% of pulmonary arterial hypertension patients on 125 mg twice daily and 7.1% of pulmonary arterial hypertension patients on 250 mg twice daily.', 'H-692\t-1.1650390625\tAn 8 @-@ fold increase was observed in 3.7 % of patients with pulmonary arterial hypertension treated with 125 mg twice daily and 7 % of patients with pulmonary arterial hypertension treated with 250 mg twice daily .', 'D-692\t-1.1650390625\tAn 8-fold increase was observed in 3.7% of patients with pulmonary arterial hypertension treated with 125 mg twice daily and 7% of patients with pulmonary arterial hypertension treated with 250 mg twice daily.', 'P-692\t-3.3184 -0.2930 -0.0620 -0.0085 -0.1973 -0.8765 -0.0676 -0.0395 -0.0282 -0.0225 -0.0338 -0.3662 -0.1353 -0.2761 -0.1014 -0.0338 -0.0225 -0.0338 -0.0169 -0.0113 -0.0169 -0.0056 -0.7046 -0.2311 -0.6143 -0.0169 -0.6538 -0.0564 -0.2479 -1.8145 -0.0282 -0.0338 -0.4790 -0.0789 -0.1127 -0.0225 -0.0225 -0.8286 -0.0113 -0.0113 -0.0225 0.0000 -0.0338 -0.0564 -0.0225 -0.0113 -0.0113 -0.0225 -0.0338 -0.0338', 'S-1913\tÜberlaufblase, Anurie oder progrediente Niereninsuffizienz Obstruktion von Ösophagus / Gastrointestinaltrakt oder Lumeneinengung des Gastrointestinaltrakts in der Anamnese', 'T-1913\t• Hypersensitivity to the active substance, other quinazolines (e. g. prazosin, terazosin), or to any of the excipients • Benign hyperplasia and concomitant congestion of the upper urinary tract, chronic urinary tract infections or bladder stones • Overflow bladder, anuria or progressive renal insufficiency • History of oesophageal or gastrointestinal obstruction or decreased lumen diameter of the gastrointestinal tract • Lactation.', 'H-1913\t-1.1162109375\tOverflow bladder , anuria or progressive renal insufficiency Obstruction of oesophageal tract or gastrointestinal narrowing of the gastrointestinal tract in patients &quot; histories', 'D-1913\t-1.1162109375\tOverflow bladder, anuria or progressive renal insufficiency Obstruction of oesophageal tract or gastrointestinal narrowing of the gastrointestinal tract in patients "histories', 'P-1913\t-0.1227 -0.0213 -0.0916 -0.0049 -0.0327 -0.0134 -0.0085 -0.0241 -0.1052 -0.0430 -0.0486 -0.0229 -0.7451 -0.0127 -0.0120 -0.0268 -2.4688 -0.0056 -0.3467 -0.3101 -0.0141 -0.8848 -0.0113 -0.0338 -0.0366 -0.3213 -0.0141 -0.1747 -0.0507 -0.0225 -0.0056 -0.0169 -0.0225 -1.9609 -0.0395 -0.0958 -0.1973 -0.2311 -0.2197 -0.0056 -0.0169 -0.0225 -0.0113 -0.0169 -0.5410 -0.3325 -1.3867 -0.3889 -0.0901 -0.0338', 'S-981\tWenn Sie mehr Prialt erhalten, als Ihr Arzt vorgesehen hat, können Sie sich unwohl fühlen mit Zeichen wie Verwirrung, Sprechschwierigkeiten, Wortfindungsschwierigkeiten, übermäßigem Schütteln, Benommenheit, übermäßiger Schläfrigkeit, Krankheitsgefühl oder Krankheit.', 'T-981\tIf you receive more Prialt than your doctor intended, you may feel unwell with signs such as confusion, problems with speech, word finding difficulties, excessive shaking, light-headedness, excessive sleepiness, feeling or being sick.', 'H-981\t-1.8681640625\tIf you are given more Prialt than your doctor recommended , you may become unwell with signs such as confusion , difficulty in speaking , difficulty thinking words , excessive shaking , drowsiness , somnolence , feeling sick or being sick .', 'D-981\t-1.8681640625\tIf you are given more Prialt than your doctor recommended, you may become unwell with signs such as confusion, difficulty in speaking, difficulty thinking words, excessive shaking, drowsiness, somnolence, feeling sick or being sick.', 'P-981\t-0.0707 -0.0321 -0.8066 -0.2937 -0.0535 -0.9849 -0.0338 -0.0380 -0.5747 -0.0282 -1.4424 -0.1493 -0.0366 -0.6396 -1.1553 -0.2649 -0.0789 -1.1611 -1.1943 -0.5469 -0.0282 -0.0169 -0.2593 -0.6367 -1.4316 -0.1014 -0.0338 -0.7437 -0.4622 -0.4958 -0.0338 -0.2817 -0.1803 -0.0225 -0.0338 -1.7920 -0.0113 -0.0225 -0.0113 -0.0338 -1.8145 -0.0564 0.0000 -0.0113 -0.0338 -0.5972 -0.6084 -0.1465 -0.3157 -0.1240 -0.0338 -0.0338', 'S-1847\tDies bedeutet, dass ORENCIA, bevor es bei Ihnen angewendet wird, erst in Wasser für Injektionszwecke aufgelöst und dann mit 0,9% -iger (9 mg / ml) Natriumchloridlösung für Injektionszwecke weiter verdünnt wird.', 'T-1847\tThis means that before ORENCIA is given to you, it is first dissolved in water for injections, then further diluted with sodium chloride 9 mg / ml (0.9%) solution for injection.', 'H-1847\t-1.1005859375\tThis means that ORENCIA is first dissolved in water for injections before it is given to you and then further diluted with sodium chloride 9 mg / ml ( 0.9 % ) solution for injections .', 'D-1847\t-1.1005859375\tThis means that ORENCIA is first dissolved in water for injections before it is given to you and then further diluted with sodium chloride 9 mg / ml (0.9%) solution for injections.', 'P-1847\t-0.2815 -0.0342 -0.0676 -0.1606 -0.0197 -0.0148 -0.5840 -2.0137 -0.2339 -0.0113 -0.0225 -0.1635 -0.0901 -0.0451 -0.0282 -0.3157 -0.6592 -1.2119 -0.0901 -0.5186 -0.0451 -0.0507 -0.6934 -0.6367 -0.4509 -0.0451 -0.0169 -0.0451 -0.8848 -0.0113 -0.0338 -0.0113 -0.0169 -0.0282 -0.5522 -0.1521 -0.0395 -0.0338 -0.2817 -0.0451 -0.0282 -0.0338 -0.1071 -0.1353 -0.0451 -0.1859 -0.1296 -0.0395 -0.0282', 'S-1507\tBegrenzte Daten deuten zwar auf eine erhöhte Rate von Feigwarzenreduktionen bei HIV-positiven Patienten hin, Imiquimod-Creme hat in dieser Patientengruppe in bezug auf die Beseitigung der Feigwarzen jedoch eine geringere Wirksamkeit gezeigt.', 'T-1507\tWhile limited data have shown an increased rate of wart reduction in HIV positive patients, imiquimod cream has not been shown to be as effective in terms of wart clearance in this patient group.', 'H-1507\t-1.8203125\tLimited data indicate an increased rate of genital warts reduction in HIV @-@ positive patients , but imiquimod cream was less effective than placebo at eliminating their genital warts in this group .', 'D-1507\t-1.8203125\tLimited data indicate an increased rate of genital warts reduction in HIV-positive patients, but imiquimod cream was less effective than placebo at eliminating their genital warts in this group.', 'P-1507\t-0.5571 -0.0356 -1.2188 -0.3550 -0.0451 -0.0662 -0.0310 -1.3564 -0.0085 -0.0225 -0.0056 -0.1606 -0.0592 -0.2029 -0.4114 -0.2451 -0.0310 -0.9072 -0.1183 -1.3184 -0.0282 -0.0282 -0.0169 -0.0113 -0.0564 -1.3750 -1.0596 -0.2705 -1.0703 -0.4565 -0.1917 0.0000 -0.0225 -0.7666 -1.9160 -0.0225 -0.0225 -0.6426 -1.1943 -0.0225 -0.0225 -0.0113 -0.0901 -0.0789 -0.9580 -0.8115 -0.0338', 'S-366\tNormale Nierenfunktion (≥ 90ml / min) Leichte Niereninsuffizienz (60-89 ml / min) Mittelschwere Niereninsuffizienz (30-59 ml / min) Schwere Niereninsuffizienz (10-29 ml / min)', 'T-366\t(ml / min / kg) Normal renal function (≥ 90ml / min) Mild renal impairment (60-89 ml / min) Moderate renal impairment (30-59 ml / min) Severe renal impairment (10-29 ml / min)', 'H-366\t-0.42578125\tNormal renal function ( ≥ 90ml / min ) Mild renal impairment ( 60 @-@ 89 ml / min ) Moderate renal impairment ( 30 @-@ 59 ml / min ) Severe renal impairment ( 10 @-@ 29 ml / min )', 'D-366\t-0.42578125\tNormal renal function (≥ 90ml / min) Mild renal impairment (60-89 ml / min) Moderate renal impairment (30-59 ml / min) Severe renal impairment (10-29 ml / min)', 'P-366\t-0.2996 -0.0070 -0.4768 -0.0218 -0.0232 -0.0268 -0.0049 -1.0137 -0.0380 -0.0282 -0.0183 -0.0296 -0.4255 -0.0155 -0.0338 -0.0240 -0.7817 -0.0479 -0.0254 -0.0254 -0.0282 -0.0254 -0.0310 -0.0197 -0.0169 -0.0282 -0.0197 -0.0310 -0.1663 -0.0254 -0.0169 -0.0254 -0.0901 -0.0113 -0.0085 -0.0225 -0.0282 -0.0254 -0.0282 -0.2113 -0.0197 -0.0282 -0.0169 -0.0282 -0.2930 -0.0338 -0.0169 -0.0254 -0.0620 -0.0113 -0.0056 -0.0225 -0.0282 -0.0254 -0.0282 -0.0225 -0.0169 -0.0282 -0.0197 -0.0282 -0.0282', 'S-1249\tFälle von Hypophosphatämie CTCAE Grad 4 (< 1 mg / dl) wurden in Studie 1 weder bei Nexavar- noch bei Placebo-Patienten und in Studie 3 in einem Fall in der Placebo-Gruppe berichtet.', 'T-1249\tThere were no cases of CTCAE Grade 4 hypophosphataemia (< 1 mg / dl) reported in either Nexavar or placebo patients in study 1, and 1 case in the placebo group in study 3.', 'H-1249\t-0.99267578125\tCases of grade 4 hypophosphataemia ( &lt; 1 mg / dl ) have not been reported in study 1 in Nexavar and placebo patients and in study 3 in the placebo group .', 'D-1249\t-0.99267578125\tCases of grade 4 hypophosphataemia (< 1 mg / dl) have not been reported in study 1 in Nexavar and placebo patients and in study 3 in the placebo group.', 'P-1249\t-0.1545 -0.0249 -0.0299 -0.8643 -0.0402 -0.1635 -0.0056 -0.0873 -0.0853 -0.0240 -0.9624 -0.0113 -0.0254 -0.2212 -0.1521 -0.0099 -0.0240 -0.0817 -0.0085 -0.0310 -0.1071 -0.0282 -0.6396 -0.0845 -0.0282 -0.6084 -0.0535 -0.7212 -0.0310 -0.4734 -0.3777 -0.0225 -0.0113 -0.0169 -1.2119 -0.2479 -0.0225 -0.0169 -0.0225 -0.6875 -0.5918 -0.5073 -0.0395 -0.0282 -0.0338 -0.5859 -0.0113 -0.0225 -0.0169 -0.0225 -0.4058 -0.0338 -0.0282', 'S-997\tDie gleichzeitige Anwendung von Calciumfolinat mit 5-Fluorouracil hat gezeigt, dass dadurch die Wirksamkeit und Toxizität von 5-Fluorouracil verstärkt wird [(siehe die Abschnitte 4.2, 4.4 und 4.8)].', 'T-997\tConcomitant administration of calcium folinate with 5-fluorouracil has been shown to enhance the efficacy and toxicity of 5-fluorouracil [(see sections 4.2, 4.4 and 4.8)].', 'H-997\t-0.818359375\tConcomitant use of calcium folinate with 5 @-@ fluorouracil has been shown to increase the efficacy and toxicity of 5 @-@ fluorouracil ( see sections 4.2 , 4.4 and 4.8 ) .', 'D-997\t-0.818359375\tConcomitant use of calcium folinate with 5-fluorouracil has been shown to increase the efficacy and toxicity of 5-fluorouracil (see sections 4.2, 4.4 and 4.8).', 'P-997\t-2.1465 -0.5088 -0.0169 -0.0296 -0.1127 -0.0296 -0.0775 -0.0141 -0.0282 -0.0085 -0.0141 -0.2423 -0.0310 -0.0282 -0.0732 -0.0225 -0.0225 -0.0225 -0.0141 -0.6821 -0.7808 -0.0395 -0.0310 -0.9526 -0.0620 -0.7720 -0.0056 -0.0225 -0.0282 -0.0113 -0.0113 -0.0225 -0.0282 -0.0282 -0.0282 -0.0282 -0.0225 -0.0225 -0.0169 -0.0113 -0.7720 -0.0395 -0.3777 -0.0225 -0.0282 -0.0338 -0.0225 -0.0282 -0.2986 -0.0225 -0.0282 -0.0338 -0.1691 -0.0338', 'S-9\t10 Aus präklinischen Studien ergaben sich Hinweise darauf, dass Palonosetron nur in sehr hohen Konzentrationen Ionenkanäle blockieren kann, die an der ventrikulären De- und Repolarisation beteiligt sind und die Aktionspotentialdauer verlängern kann.', 'T-9\tNonclinical studies indicate that palonosetron, only at very high concentrations, may block ion channels involved in ventricular de- and re-polarisation and prolong action potential duration.', 'H-9\t-1.42578125\t9 It appeared from preclinical studies that palonosetron is able to block ion channels involved in ventricular de- and re @-@ polarisation and to prolong action potential time only at very high concentrations .', 'D-9\t-1.42578125\t9 It appeared from preclinical studies that palonosetron is able to block ion channels involved in ventricular de- and re-polarisation and to prolong action potential time only at very high concentrations.', 'P-9\t-1.1689 -0.7817 -1.3457 -0.0873 -0.1719 -0.0085 -0.0197 -0.0366 -0.0479 -0.2029 -0.0254 -0.0197 -0.0197 -0.0451 -2.5566 -0.6704 -0.0395 -0.3777 -0.1635 -0.0338 -0.0395 -0.5581 -0.0282 -0.0282 -0.0225 -0.0113 -0.0282 -0.1917 -0.0338 -0.4453 -0.0282 -0.0056 -0.3101 -0.0395 -1.4990 -0.4734 -0.2029 -0.0113 -0.3042 -0.0901 -1.2959 -0.1353 -0.2479 -0.1014 -0.0225 -0.8452 -0.0113 -0.0113 -0.0338 -0.0338', 'S-1897\tObwohl die Ergänzung einer bereits bestehenden Insulintherapie durch Galvus zu einer stärkeren Senkung der HbA1c-Werte führte als durch das Placebo, war die Größenordnung dieser Wirkung zu gering, um für Patienten als bedeutsam erachtet zu werden.', 'T-1897\tAlthough adding Galvus to existing insulin therapy caused a greater reduction in HbA1c levels than placebo, the size of this effect was too small to be considered meaningful for patients.', 'H-1897\t-1.5693359375\tAlthough the addition of Galvus to existing insulin therapy resulted in greater decreases in HbA1c levels than placebo , the magnitude of this effect was too low to be considered relevant for patients .', 'D-1897\t-1.5693359375\tAlthough the addition of Galvus to existing insulin therapy resulted in greater decreases in HbA1c levels than placebo, the magnitude of this effect was too low to be considered relevant for patients.', 'P-1897\t-0.9326 -1.6963 -0.0690 -0.0366 -0.2382 -0.0169 -0.0282 -0.0366 -1.1270 -0.0113 -0.3042 -0.1973 -1.1670 -0.0282 -0.7554 -1.6621 -0.1353 -0.0395 -0.2930 -0.0225 -0.0338 -0.0225 -0.0225 -1.2061 -0.0395 -1.2402 -0.0225 -0.0169 -0.0282 -0.2705 -0.0564 -0.2817 -0.0113 -0.0113 -0.0338 -0.6763 -0.2705 -0.4282 -0.1917 -1.0596 -0.0789 -0.1014 -0.0789 -0.8003 -0.1353 -0.0338 -0.0338 -0.0338', 'S-1159\tBei Patienten mit stabiler Angina pectoris erhöht die einmal tägliche Anwendung von Amlodipin die Belastbarkeit, die Zeit bis zum Angina pectoris-Anfall und die Zeit, die zu einer Absenkung des ST- Segments um 1 mm führt.', 'T-1159\tIn patients with stable angina pectoris, amlodipine once daily increases total exercise tolerance, time to angina and time to a 1 mm ST segment depression.', 'H-1159\t-1.66796875\tIn patients with stable angina pectoris , once @-@ a @-@ day administration of amlodipine increases exercise capacity , the time to angina pectoris seizure and the time to reduce the ST segment by 1 mm .', 'D-1159\t-1.66796875\tIn patients with stable angina pectoris, once-a-day administration of amlodipine increases exercise capacity, the time to angina pectoris seizure and the time to reduce the ST segment by 1 mm.', 'P-1159\t-1.1943 -0.0331 -0.3684 -0.0972 -0.0338 -0.0183 -1.2158 -0.0197 -0.0085 -0.0254 -0.2593 -0.9692 -0.4902 -1.2568 -0.0282 -0.0338 -0.8340 -0.0282 -0.0338 -0.0225 -0.0225 -0.0282 -0.0169 -0.2986 -0.3213 -0.1183 -0.0395 -0.6875 -0.4846 -0.8848 -0.3157 -0.0169 -0.0282 -0.0169 -0.0056 -0.0225 -1.1328 -0.8623 -0.0225 -0.6763 -0.0564 -0.3157 -1.9727 -1.0146 -0.6201 -0.1803 -0.1691 -0.3945 -0.0789 -0.0225 -0.0338 -0.0338', 'S-1802\tJede Person, die die Absicht hat, Nobilis Influenza H5N2 einzuführen, zu verkaufen, abzugeben und / oder anzuwenden, muss sich vor der Einfuhr, dem Verkauf, der Abgabe und / oder der Anwendung über die geltenden nationalen Vorschriften informieren.', 'T-1802\tAny person intending to import, sell, supply and / or use Nobilis Influenza H5N2 must consult the relevant Member State <<unk>> s competent authority on the current vaccination policies prior to the import, sale, supply and / or use.', 'H-1802\t-0.66357421875\tAny person intending to import , sell , supply and / or use Nobilis Influenza H5N2 must consult the relevant Member State &quot; s competent authority on the current vaccination policies prior to the import , sale , supply and / or use .', 'D-1802\t-0.66357421875\tAny person intending to import, sell, supply and / or use Nobilis Influenza H5N2 must consult the relevant Member State "s competent authority on the current vaccination policies prior to the import, sale, supply and / or use.', 'P-1802\t-0.3643 -0.0560 -0.0803 -0.0229 -0.0285 -0.1145 -0.0190 -0.0299 -0.0292 -0.0303 -0.3169 -0.0479 -0.0289 -0.0225 -0.1705 -0.0486 -0.0070 -0.0268 -0.0887 -0.0056 -0.0099 -0.0268 -0.0282 -0.0268 -0.0225 -0.0268 -0.1381 -0.2959 -0.0113 -0.1606 -0.2479 -0.3213 -0.2227 -0.5103 -0.1212 -0.3213 -0.0760 -0.3213 -0.3157 -0.1831 -0.3157 -0.3213 -0.0958 -0.3213 -0.1803 -0.0282 -0.2874 -0.1521 -0.0169 -0.0338 -0.0451 -0.0338 -0.3042 -0.0451 -0.0282 -0.0225 -0.2423 -0.2367 -0.0282', 'S-264\tIn einer Studie zur Beurteilung von Absetzsymptomen mittels der Discontinuation Emergent Signs and Symptoms (DESS) -Checkliste bei Patienten in der Remission induzierte Thymanax nach abruptem Behandlungsabbruch kein Absetzsyndrom.', 'T-264\tIn a study designed to assess discontinuation symptoms by the Discontinuation Emergent Signs and Symptoms (DESS) check-list in patients with remitted depression, Thymanax did not induce discontinuation syndrome after abrupt treatment cessation.', 'H-264\t-0.70263671875\tIn a study designed to assess discontinuation symptoms by the Discontinuation Emergent Signs and Symptoms ( DESS ) check @-@ list in patients with remitted depression , Thymanax did not induce discontinuation syndrome after abrupt treatment cessation .', 'D-264\t-0.70263671875\tIn a study designed to assess discontinuation symptoms by the Discontinuation Emergent Signs and Symptoms (DESS) check-list in patients with remitted depression, Thymanax did not induce discontinuation syndrome after abrupt treatment cessation.', 'P-264\t-0.3542 -0.0507 -0.1282 -1.0986 -0.0338 -0.5283 -0.2747 -0.0127 -0.0324 -0.0704 -0.2959 -0.2705 -0.0366 -0.0366 -0.0254 -0.0085 -0.0620 -0.0169 -0.0169 -0.0282 -0.0366 -0.0225 -0.0395 -0.0225 -0.0113 -0.0254 -0.0282 -0.3157 -0.2874 -0.0197 -0.1071 -0.1155 -0.3635 -0.0338 -0.3916 -0.3240 -0.0930 -0.0901 -0.0282 -0.0282 -0.0113 -0.1296 -0.0338 -0.1803 -0.0225 -0.1635 -0.0113 -0.0338 -0.1691 -0.0113 -0.2874 -0.1240 -0.0395 -0.6704 -0.3606 -0.0169 -0.0225 -0.0338 -0.0282', 'S-942\tWeitere Infusionen Weitere Infusionen von MabThera können mit einer Infusionsgeschwindigkeit von 100 mg / h begonnen werden, die im weiteren Verlauf in Abständen von 30 Minuten um 100 mg / h bis auf einen Höchstwert von 400 mg / h gesteigert werden kann.', 'T-942\t4 Subsequent infusions Subsequent doses of MabThera can be infused at an initial rate of 100 mg / hr, and increased by 100 mg / hr increments at 30 minutes intervals, to a maximum of 400 mg / hr.', 'H-942\t-0.87060546875\tAdditional doses Subsequent doses of MabThera can be infused at a rate of 100 mg / hr , and increased by 100 mg / hr increments at 30 minutes intervals , to a maximum of 400 mg / hr .', 'D-942\t-0.87060546875\tAdditional doses Subsequent doses of MabThera can be infused at a rate of 100 mg / hr, and increased by 100 mg / hr increments at 30 minutes intervals, to a maximum of 400 mg / hr.', 'P-942\t-1.4707 -0.6367 -0.0760 -0.4509 -0.0409 -0.1240 -0.0606 -0.0451 -0.0395 -0.0197 -0.0169 -0.0282 -0.1973 -0.1493 -0.4480 -0.0254 -0.1945 -0.7974 -0.1663 -0.0366 -0.1268 -0.0113 -0.0310 -0.2537 -0.2874 -0.3127 -0.2986 -0.2479 -0.0282 -0.0056 -0.0282 -0.0282 -0.3662 -0.0845 -0.2986 -0.1465 -0.3381 -0.0225 -0.0056 -0.4790 -0.2423 -0.0732 -0.0676 -0.0958 -0.0225 -0.0056 -0.0282 -0.0395 -0.0507 -0.0507', 'S-85\tEXJADE 125 mg Tabletten zur Herstellung einer Suspension zum Einnehmen EXJADE 250 mg Tabletten zur Herstellung einer Suspension zum Einnehmen EXJADE 500 mg Tabletten zur Herstellung einer Suspension zum Einnehmen Deferasirox', 'T-85\tEXJADE 125 mg dispersible tablets EXJADE 250 mg dispersible tablets EXJADE 500 mg dispersible tablets Deferasirox', 'H-85\t-0.623046875\tEXJADE 125 mg dispersible tablets', 'D-85\t-0.623046875\tEXJADE 125 mg dispersible tablets', 'P-85\t-0.0170 -0.0227 -0.0163 -0.0199 -0.0184 -0.0156 -0.3223 -0.3188 -0.3206 -0.0951 -0.0718 -1.5283', 'S-1198\tPatientinnen, die eine Schwangerschaft planen, sollten auf alternative blutdrucksenkende Therapien mit einem bewährten Sicherheitsprofil zur Anwendung in der Schwangerschaft umgestellt werden, es sei denn, dass die Fortführung einer Losartan-Therapie als unbedingt erforderlich erachtet wird.', 'T-1198\tUnless continued losartan therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy.', 'H-1198\t-0.67138671875\tUnless continued Losartan therapy is considered essential , patients planning pregnancy should be changed to alternative anti @-@ hypertensive treatments which have an established safety profile for use in pregnancy .', 'D-1198\t-0.67138671875\tUnless continued Losartan therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy.', 'P-1198\t-0.4668 -0.0243 -0.3079 -0.3157 -0.0099 -0.0247 -0.1635 -0.0345 -0.2029 -0.2466 -0.0521 -0.2100 -0.1747 -0.2352 -0.0395 -0.2184 -0.3198 -0.0479 -0.0592 -0.7749 -0.0338 -0.0197 -0.1155 -0.0113 -0.3325 -0.3213 -0.1268 -0.3184 -0.0592 -0.1042 -0.0197 -0.0845 -0.0564 -0.2311 -0.0254 -0.0338 -0.0395', 'S-427\tWiederanstieg auf ≥ 0,5 x 109 / l bei Neutropenie als einzige beobachtete Toxizität Wiederanstieg auf ≥ 0,5 x 109 / l bei Beobachtung anderer dosisabhängiger hämatologischer Toxizitäten außer Neutropenie', 'T-427\tWhen neutrophils First fall to < 0.5 x 109 / l Return to ≥ 0.5 x 109 / l when neutropenia is the only observed toxicity Return to ≥ 0.5 x 109 / l when dose-dependent haematological toxicities other than neutropenia are observed', 'H-427\t-1.5400390625\tFor neutropenia , return to ≥ 0.5 x 109 / l as the only NCI , increase to ≥ 0.5 x 109 / l for dose @-@ related haematological toxicities except neutropenia', 'D-427\t-1.5400390625\tFor neutropenia, return to ≥ 0.5 x 109 / l as the only NCI, increase to ≥ 0.5 x 109 / l for dose-related haematological toxicities except neutropenia', 'P-427\t-0.3240 -0.0370 -0.1941 -0.0190 -0.0197 -0.5586 -0.8286 -0.0549 -0.2296 -0.0873 -0.0310 -0.0183 -0.0211 -0.0324 -0.3157 -1.9854 -0.4199 -0.2930 -0.4819 -0.4453 -1.0537 -1.1670 -0.2930 -0.0113 -0.0225 -0.0282 -0.0169 -0.0225 -0.0282 -0.0732 -0.7100 -0.6201 -0.0676 -1.0762 -0.3945 -0.0113 -0.0338 -0.0789 -0.0225 -0.2367 -0.0225 -1.8486 -0.0564 -0.0225 -0.0225 -0.0225 -1.1494', 'S-347\tWirkungen auf die Nieren Mit Teststreifen diagnostizierte Proteinurie meist tubulärer Genese wurde bei Patienten, die mit höheren Dosen Crestor, insbesondere 40 mg behandelt wurden, beobachtet, wobei diese in den meisten Fällen vorübergehend oder intermittierend war.', 'T-347\tRenal Effects Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with higher doses of Crestor, in particular 40 mg, where it was transient or intermittent in most cases.', 'H-347\t-1.6005859375\tRenal Effects Proteinuria , detected by dipstick testing and mostly tubular in origin , was observed in patients treated with higher doses of Crestor , particularly 40 mg , with most cases transient or intermittent .', 'D-347\t-1.6005859375\tRenal Effects Proteinuria, detected by dipstick testing and mostly tubular in origin, was observed in patients treated with higher doses of Crestor, particularly 40 mg, with most cases transient or intermittent.', 'P-347\t-1.8291 -0.0225 -0.5142 -0.0211 -2.2969 -0.0113 -0.0056 -0.0225 -0.2649 -0.3184 -0.0225 -0.2930 -0.3240 -0.3213 -0.2423 -0.2986 -0.2986 -0.2255 -0.2593 -0.0113 -0.0225 -0.3213 -0.4509 -0.0507 -0.1521 -0.9917 -0.5186 -0.0395 -0.0507 -0.0958 -0.0338 -0.1635 -0.1859 -0.0169 -0.0338 -0.1071 -0.0056 -0.0225 -0.6084 -0.9131 -0.1014 -0.0113 -0.7437 -1.4541 -0.4846 -1.1387 -1.1387 -0.0113 -0.0676 -0.0338 -0.0225 -0.0113 -0.0225 -0.0564 -0.0338', 'S-782\tDie Wirkung von Cerezyme auf die neurologischen Symptome von Patienten mit chronisch- neuronopathischer Gaucher-Krankheit wurde noch nicht nachgewiesen, so dass für diese Manifestationen kein spezielles Dosierschema empfohlen werden kann (siehe Abschnitt 5.1).', 'T-782\tThe efficacy of Cerezyme on neurological symptoms of chronic neuronopathic Gaucher patients has not been established and no special dosage regimen can be recommended for these manifestations (see section 5.1).', 'H-782\t-1.2705078125\tThe effect of Cerezyme on the neurological symptoms of patients with chronic neuronopathic Gaucher disease has not yet been demonstrated and therefore no special dosage regimen can be recommended for these manifestations ( see section 5.1 ) .', 'D-782\t-1.2705078125\tThe effect of Cerezyme on the neurological symptoms of patients with chronic neuronopathic Gaucher disease has not yet been demonstrated and therefore no special dosage regimen can be recommended for these manifestations (see section 5.1).', 'P-782\t-0.2460 -0.5049 -0.0310 -0.1528 -0.0169 -0.0162 -0.0141 -0.1648 -0.2593 -0.0127 -0.0352 -0.6465 -0.0493 -0.2057 -0.0578 -0.0760 -0.1859 -0.0465 -0.0254 -0.0113 -0.0620 -0.0099 -0.0169 -0.0916 -0.6792 -0.0479 -1.2197 -0.0254 -0.9946 -1.3867 -1.1553 -0.7944 -0.4622 -0.4170 -0.1859 -0.0338 -0.5352 -0.0395 -0.3101 -0.0282 -0.0225 -1.0986 -0.6426 -0.3269 -0.0225 -0.0451 -0.0451 -0.1465 -0.0225 -0.0225 -0.0338 -0.0338 -0.0338', 'S-1797\tDie effektive Halbwertszeit von Enalaprilat nach Mehrfachdosen ist bei Niereninsuffizienz in diesem Stadium verlängert, das Erreichen des Steady- State ist verzögert (siehe 4.2 Dosierung, Art und Dauer der Anwendung).', 'T-1797\tThe effective half-life of enalaprilat following multiple doses of enalapril maleate is prolonged at this level of renal insufficiency and time to steady state is delayed.', 'H-1797\t-1.4130859375\tAfter multiple doses , the effective half @-@ life of enalaprilat is prolonged in renal impairment at this stage and reaching steady state is delayed ( see 4.2 Posology and method of administration ) .', 'D-1797\t-1.4130859375\tAfter multiple doses, the effective half-life of enalaprilat is prolonged in renal impairment at this stage and reaching steady state is delayed (see 4.2 Posology and method of administration).', 'P-1797\t-0.9282 -0.1360 -0.0282 -0.0225 -0.4177 -0.0718 -0.0465 -0.1550 -0.0817 -0.0395 -0.0395 -0.0380 -0.0183 -0.0282 -0.0268 -0.5845 -0.3042 -0.1014 -0.3523 -0.0141 -0.0197 -0.1183 -0.7832 -0.0254 -0.8228 -0.0338 -0.0225 -0.0254 -2.5645 -0.1691 -0.2423 -1.1162 -0.9131 -0.8623 -0.2649 -0.2029 -0.4846 -0.0338 -0.0338 -0.4395 -0.0338 -0.3945 -0.3269 -0.3157 -0.6201 -0.0676 -0.2817 -0.0564 -0.0338 -0.0338', 'S-44\t18 Überempfindlichkeitsreaktionen gegenüber Hydrochlorothiazid können bei Patienten mit und ohne anamnestisch bekannter Allergie oder Bronchialasthma auftreten, sind aber bei Patienten, bei denen dies in der Anamnese bekannt ist, eher wahrscheinlich.', 'T-44\tHypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history.', 'H-44\t-1.4677734375\t18 Hypersensitivity reactions against hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma , but are more likely in patients with a history of these symptoms .', 'D-44\t-1.4677734375\t18 Hypersensitivity reactions against hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with a history of these symptoms.', 'P-44\t-2.4473 -0.3494 -0.0240 -0.0268 -0.0141 -0.3340 -0.0169 -0.6821 -0.0225 -0.0254 -0.0113 -0.0254 -0.0113 -0.0395 -0.0028 -0.0197 -0.3550 -0.0676 -0.0395 -0.0366 -0.0395 -0.8086 -0.0282 -0.4622 -0.3662 -0.0282 -0.3381 -0.0113 -0.0282 -0.5239 -0.0113 -0.0225 -0.0282 -0.0225 -0.0169 -0.0113 -0.7778 -0.9131 -1.4482 -0.2367 -0.0395 -0.7944 -0.0676 -0.9019 -0.2479 -0.1691 -0.0338 -0.8452 -1.6904 -0.0338 -0.0338', 'S-887\tEs wurde die Hypothese aufgestellt, dass ein Zusammenhang zwischen viszeraler Lipomatose und Proteaseinhibitoren einerseits und Lipoatrophie und nukleosidischen Reverse-Transkriptase- Inhibitoren andererseits besteht.', 'T-887\tA connection between visceral lipomatosis and protease inhibitors, and lipoatrophy and nucleoside reverse transcriptase inhibitors has been hypothesised.', 'H-887\t-0.6201171875\tA connection between visceral lipomatosis and protease inhibitors and lipoatrophy and nucleoside reverse transcriptase inhibitors has been hypothesised .', 'D-887\t-0.6201171875\tA connection between visceral lipomatosis and protease inhibitors and lipoatrophy and nucleoside reverse transcriptase inhibitors has been hypothesised.', 'P-887\t-1.5186 -0.6807 -0.1479 -0.0479 -0.0113 -0.0085 -0.0254 -0.0113 -0.0240 -0.0338 -0.0183 -0.0310 -0.8145 -0.0085 -0.0254 -0.0113 -0.0113 -0.0254 -0.2085 -0.0225 -0.0197 -0.0141 -0.0085 -0.0732 -0.4114 -0.0141 -0.0282 -0.1888 -0.2507 -0.0535 -0.0197 -0.0254 -0.0197 -0.0085 -0.0225 -0.0113 -0.0141 -0.0254 -0.4028 -0.0310 -0.4170 -0.0085 -0.2986 -0.0395 -0.0451 -0.0282', 'S-400\tDer CHMP befasste sich mit den vorgelegten Daten zur Stützung der Indikation <unk> Blasenkarzinom <unk> und stellte fest, dass alle vorgelegten Studien an Patienten mit lokal fortgeschrittenem oder metastasiertem Blasenkarzinom durchgeführt worden waren.', 'T-400\tThe CHMP considered the data submitted in support of the bladder cancer indication and noted that all the submitted studies were conducted in patients with locally advanced or metastatic bladder cancer.', 'H-400\t-1.47265625\tThe CHMP reviewed the data provided to support the indication in bladder cancer and noted that all of the studies submitted were carried out in patients with locally advanced or metastatic bladder cancer .', 'D-400\t-1.47265625\tThe CHMP reviewed the data provided to support the indication in bladder cancer and noted that all of the studies submitted were carried out in patients with locally advanced or metastatic bladder cancer.', 'P-400\t-0.0931 -0.0163 -0.0099 -1.0312 -0.1584 -0.4128 -1.4004 -0.5918 -0.1606 -0.0535 -1.6113 -0.8511 -0.2479 -0.0056 -0.2311 -0.6704 -0.3662 -0.0395 -0.0338 -1.4766 -0.5693 -0.1353 -1.2510 -0.9580 -0.4846 -0.0225 -0.1917 -0.0338 -0.0338 -0.0338 -0.0225 -0.2029 -0.0338 -0.0225 -0.0225 -0.0338 -0.0113 -0.0113 -0.0564 -0.0338 -0.0338', 'S-804\tDie eingegangenen Dossiers wurden vom Sekretariat durchschnittlich innerhalb von 10 der formell dafür vorgesehenen 30 Tagen auf Vollständigkeit geprüft. w Der im Arbeitsprogramm 1997 angestrebte Zeitraum von 15 Tagen für 80% der Anträge wurde mit einer Ausnahme (18 Tage) eingehalten.', 'T-804\tThe dossiers received were, on average validated by the Secretariat within 10 days of the 30 days formally allowed.', 'H-804\t-2.455078125\tThe Secretariat reviewed incoming dossiers in a maximum of 10 of the 30 days provided for formally .', 'D-804\t-2.455078125\tThe Secretariat reviewed incoming dossiers in a maximum of 10 of the 30 days provided for formally.', 'P-804\t-0.7285 -0.5693 -0.0099 -0.0338 -0.9019 -1.1895 -0.0648 -0.5972 -0.0085 -0.0310 -1.6934 -1.9443 -0.3550 -0.2874 -0.0732 -0.8003 -0.3777 -0.0901 -0.1409 -1.6396 -0.8848 -0.9243 -1.9727 -1.2168', 'S-1137\tWie auch bei anderen Gadolinium enthaltenden Kontrastmitteln kann es in seltenen Fällen zu allergieartigen Reaktionen (Überempfindlichkeit und Anaphylaxie) einschließlich schweren Reaktionen (Schock) kommen, die eine sofortige medizinische Intervention erforderndern.', 'T-1137\tAs with other gadolinium containing contrast media, in rare cases allergy-like reactions (hypersensitivity and anaphylaxis) may occur, including severe reactions (shock) that may need immediate medical intervention.', 'H-1137\t-1.5244140625\tAs with other contrast media containing gadolinium , very rare cases of allergic reactions ( hypersensitivity and anaphylaxis ) , including severe reactions ( shock ) , may occur , which require immediate medical intervention .', 'D-1137\t-1.5244140625\tAs with other contrast media containing gadolinium, very rare cases of allergic reactions (hypersensitivity and anaphylaxis), including severe reactions (shock), may occur, which require immediate medical intervention.', 'P-1137\t-0.6938 -0.1064 -0.2671 -1.4707 -0.7070 -0.0395 -0.0113 0.0000 -0.0141 -0.0225 -0.6113 -0.9805 -0.7241 -1.0225 -0.3438 -0.1353 -0.0507 -0.0564 -0.0113 -0.4226 -0.1465 -0.0169 -0.0169 -0.0451 -0.0225 -0.0225 -0.0113 -0.0169 -0.0225 -0.0282 -1.3018 -0.0676 -0.0507 -0.2479 -0.0169 -0.5073 -0.2705 -0.0338 -1.3408 -0.1353 -0.0564 -1.0596 -0.7891 -0.6763 -0.5747 -0.1240 -0.3833 -0.0338 -0.0338', 'S-242\tMit der 20 mg Dosierung traten bei älteren Patienten (≥ 65 Jahre) häufiger Kopfschmerzen (16,2% im Vergleich zu 11,8%) und Schwindel (3,7% im Vergleich zu 0,7%) auf als bei jüngeren Patienten (< 65 Jahre).', 'T-242\tAt the 20mg dose, elderly (≥ 65 years old) patients had higher frequencies of headaches (16.2% versus 11.8%) and dizziness (3.7% versus 0.7%) than younger patients (< 65 years old).', 'H-242\t-1.404296875\tHigher incidences of headache ( 16.2 % versus 11.8 % ) and dizziness ( 3.7 % versus 0.7 % ) were reported in elderly patients ( ≥ 65 years ) at the 20 mg dose than in younger patients ( &lt; 65 years ) .', 'D-242\t-1.404296875\tHigher incidences of headache (16.2% versus 11.8%) and dizziness (3.7% versus 0.7%) were reported in elderly patients (≥ 65 years) at the 20 mg dose than in younger patients (< 65 years).', 'P-242\t-3.3750 -0.0197 -0.5718 -0.2791 -0.0225 -0.0338 -0.0169 -0.0141 -0.0873 -0.3127 -0.0254 -0.0282 -0.0338 -0.6592 -0.0141 -0.0282 -0.0254 -0.5156 -0.0338 -0.0676 -0.0056 -0.0113 -0.0338 -0.0225 -0.0225 -0.0282 -0.1409 -0.0169 -0.0225 -0.0225 -0.0338 -0.4114 -0.5186 -0.1240 -1.2168 -0.5239 -0.4226 -0.1183 -0.0169 -0.0338 -0.5469 -1.1494 -0.6084 -0.1578 -0.3157 -0.1240 -1.8594 -0.4282 -0.1917 -0.2141 -0.0338 -0.0338 -0.0113 -0.0225 -0.0113 -0.0225 -0.5073 -0.0338 -0.0338', 'S-1157\tDie Therapiedauer betrug 48 Wochen mit einer Nachbeobachtungszeit von 6 Monaten, außer für Patienten, die mit Genotyp 2 oder 3 infiziert waren und eine Viruslast von < 800.000 I.E. / ml (Amplicor) hatten, die über 24 Wochen mit einer 6- eim', 'T-1157\tThe duration of therapy was 48 weeks with a follow-up period of 6 months except for patients infected with genotypes 2 or 3 and viral load na', 'H-1157\t-0.943359375\tThe duration of therapy was 48 weeks with a follow @-@ up period of 6 months except for patients infected with genotypes 2 or 3 and viral load &lt; 800,000 IU / ml ( Amplicor ) who were treated for 24 weeks with a 6 to 15 fold follow @-@ up period .', 'D-1157\t-0.943359375\tThe duration of therapy was 48 weeks with a follow-up period of 6 months except for patients infected with genotypes 2 or 3 and viral load < 800,000 IU / ml (Amplicor) who were treated for 24 weeks with a 6 to 15 fold follow-up period.', 'P-1157\t-0.8755 -0.3105 -0.0296 -0.0423 -0.2339 -0.0310 -0.6890 -0.0296 -0.0690 -0.0606 -0.2522 -0.0662 -0.0240 -0.2791 -0.0282 -0.0930 -0.0310 -0.5044 -0.1155 -0.1042 -0.0845 -0.0338 -0.0423 -0.3071 -0.1888 -0.0395 -0.0479 -0.0310 -0.1775 -0.3213 -0.2479 -0.1635 -0.0056 -0.0225 -0.0254 -0.0085 -0.0169 -0.2507 -0.0282 -0.0395 -0.0395 -0.2761 -0.0169 -0.0282 -0.0282 -0.1917 -0.2141 -0.1859 -0.4170 -0.0620 -0.0225 -0.0789 -0.0958 -0.1465 -0.2930 -1.3018 -0.6201 -0.6030 -0.1917 -0.0282 -0.2986 -0.2141 -0.0282', 'S-1791\tQuixidar (in Stärken von 1,5 und 2,5 mg) wird zur Vorbeugung venöser thromboembolischer Ereignisse (VTE, durch Blutgerinnsel verursachte Probleme) bei Patienten eingesetzt, die sich größeren Eingriffen an den unteren Extremitäten unterziehen müssen, wie beispielsweise ich', 'T-1791\tQuixidar (1.5 and 2.5 mg strengths) is used to prevent venous thromboembolic events (VTEs, no', 'H-1791\t-0.82373046875\tQuixidar ( 1.5 and 2.5 mg strengths ) is used to prevent venous thromboembolic events du', 'D-1791\t-0.82373046875\tQuixidar (1.5 and 2.5 mg strengths) is used to prevent venous thromboembolic events du', 'P-1791\t-1.5430 -0.0268 -0.0127 -0.0127 -0.1254 -0.2197 -0.1085 -0.0578 -0.0169 -0.3071 -0.0268 -0.0324 -0.0423 -0.0465 -0.0944 -0.0380 -0.3718 -0.0113 -0.0028 -0.0056 -0.0113 -0.0197 -0.0338 -0.0254 -2.2969 -0.3269', 'S-1647\tFür Ihren Arzt ist es besonders wichtig zu wissen, wenn Sie Arzneimittel anwenden, die Phenytoin oder Carbamazepin (bei Epilepsie), Rifampicin (ein Antibiotikum), Phenobarbital oder Johanniskraut Ar', 'T-1647\tIt is particularly important for your doctor to know if you are taking medicines containing phenytoin, and carbamazepine (for epilepsy), rifampicin (antibiotic), phenobarbital or St John <<unk>> s wort, medicines no', 'H-1647\t-1.1875\tIt is especially important for your doctor to know if you are taking medicines containing phenytoin or carbamazepine ( for epilepsy ) , rifampicin ( an antibiotic ) , phenobarbital or St John &quot; s Wort , ranitidine ,', 'D-1647\t-1.1875\tIt is especially important for your doctor to know if you are taking medicines containing phenytoin or carbamazepine (for epilepsy), rifampicin (an antibiotic), phenobarbital or St John "s Wort, ranitidine,', 'P-1647\t-0.5254 -0.0342 -0.5254 -0.0289 -0.1148 -0.0268 -0.0416 -0.0268 -0.0310 -0.0796 -0.0282 -0.2451 -0.7651 -0.5649 -0.0760 -0.2029 -0.0141 -0.0225 -0.0282 -0.0451 -0.0338 -0.0282 -0.0254 -0.0141 -0.0085 -0.0282 -0.0282 -0.3042 -0.0225 -0.0056 -0.0225 -0.0141 -0.0310 -0.0282 -0.0169 -0.0169 -0.0225 -0.0197 -0.0901 -0.0282 -0.0338 -0.0169 -0.0141 -0.0169 -0.0282 -0.0282 -0.0141 -0.0169 -0.0169 -0.0282 -0.0056 -0.0789 -0.6538 -0.3325 -0.3213 -0.0564 -1.2061 -1.0762 -1.4824 -0.3718 -0.3213 -0.2986 -0.5918 -3.1777', 'S-18\tIvabradin, der arzneilich wirksame Bestandteil in Corlentor, wirkt durch Hemmung der lf- Kanäle: dies sind spezialisierte Zellen im Sinusknoten, dem <unk> Schrittmacher <unk> des Herzens, der die Herzschläge kontrolliert und die Herzfrequenz reguliert.', 'T-18\tIvabradine, the active substance in Corlentor, works by inhibiting the lf channels: these are specialised cells in the sinus node, the <<unk>> pacemaker <<unk>> for the heart that controls the heart contractions and regulates heart rate.', 'H-18\t-0.89599609375\tIvabradine , the active substance in Corlentor , works by blocking the l08 channels : these are specialised cells in the sinus node , the &apos; pacemaker &quot; for the heart that controls the heart contractions and regulates heart rate .', 'D-18\t-0.89599609375\tIvabradine, the active substance in Corlentor, works by blocking the l08 channels: these are specialised cells in the sinus node, the \'pacemaker "for the heart that controls the heart contractions and regulates heart rate.', 'P-18\t-0.2318 -0.0227 -0.0234 -0.3206 -0.1560 -0.0359 -0.0493 -0.2825 -0.3191 -0.4058 -0.9424 -0.0380 -0.0169 -0.0366 -0.0380 -0.2141 -0.0282 -1.0254 -0.1042 -0.1353 -0.6733 -0.2001 -1.4121 -0.1014 -0.0225 -0.0620 -0.1691 -0.0225 -0.0564 -0.0338 -0.0056 -0.0901 -0.0451 -0.0225 -0.0395 -0.0395 -0.3269 -0.0451 -0.0225 -0.0113 -0.3213 -0.3213 -0.0282 -0.0169 -0.1917 -0.0676 -0.2367 -0.2874 -0.3269 -0.0901 -0.0395 -0.0338 -0.0282 -0.2141 -0.0451 -0.0282 -0.0282', 'S-1601\tWie Avaglim aussieht und Inhalt der Packung Avaglim 4 mg / 4 mg Filmtabletten sind rosa, abgerundete, dreieckige Filmtabletten und auf einer Seite mit <unk> gsk <unk>, auf der anderen mit <unk> 4 / 4 <unk> gekennzeichnet.', 'T-1601\tWhat Avaglim looks like and contents of the pack Avaglim 4 mg / 4 mg tablets are pink, rounded triangular-shaped, and marked "gsk" on one side and "4 / 4" on the other.', 'H-1601\t-1.1865234375\tWhat Avaglim looks like and contents of the pack Avaglim 4 mg / 4 mg film coated tablets are pink , rounded triangular film @-@ coated tablets , marked &quot; Є pr &quot; on one side and &quot; ß &quot; on the other .', 'D-1601\t-1.1865234375\tWhat Avaglim looks like and contents of the pack Avaglim 4 mg / 4 mg film coated tablets are pink, rounded triangular film-coated tablets, marked "Є pr" on one side and "ß" on the other.', 'P-1601\t-0.3384 -0.0241 -0.0204 -0.0243 -0.0285 -0.0539 -0.0409 -0.0507 -0.2106 -0.0176 -0.0486 -0.1071 -0.2227 -0.3662 -0.0183 -0.0240 -0.0296 -0.5522 -0.0099 -0.0296 -0.1831 -0.0127 -0.1550 -0.3228 -0.2959 -0.0479 -0.0282 -0.0535 -0.1183 -0.0507 -0.5156 -0.0113 -0.3438 -0.0282 -0.0141 -0.0254 -0.8540 -1.8740 -0.0564 -0.0113 -0.0225 -0.0225 -0.8286 -0.1747 -0.8735 -1.5439 -0.3718 -0.6875 -0.1353 -0.0451 -0.0338 -0.0338 -0.1014 -0.0676 -1.0596 -0.0789 -0.0451 -0.0338 -0.0225 -0.5522 -0.0338', 'S-871\tBei der empfohlenen therapeutischen Dosierung waren die durchschnittlichen Wirkstoffkonzentrationen im Plasma für einen Zeitraum von mindestens 158 Stunden höher als die MHK90 Werte (< 0.2µg / ml) der Krankheitserreger, die in den klinischen Studien isoliert wurden.', 'T-871\tAt the recommended therapeutic dose, concentrations in plasma were higher than the MIC (< 0.2 µg / ml) for the target bacteria isolated in clinical studies for at least 158 hours.', 'H-871\t-1.5849609375\tAt the recommended therapeutic dose , mean drug concentrations in plasma were higher than the MIC90 values ( &lt; 0.2 µg / ml ) of pathogens isolated in the clinical studies for at least 158 hours .', 'D-871\t-1.5849609375\tAt the recommended therapeutic dose, mean drug concentrations in plasma were higher than the MIC90 values (< 0.2 µg / ml) of pathogens isolated in the clinical studies for at least 158 hours.', 'P-871\t-1.5215 -0.0944 -0.0324 -0.6538 -0.0225 -0.4846 -0.3042 -1.5693 -0.8594 -0.1521 -0.0085 -0.0141 -0.2903 -0.5859 -0.0113 -0.0225 -1.2344 -0.1071 -0.0732 -0.5186 -0.3438 -0.3718 -0.1747 -0.9863 -0.1578 -0.0169 -0.0169 -0.0225 -0.0225 -0.7158 -0.4338 -0.0225 -0.0338 -0.0338 -0.0338 -0.0676 -1.2959 -0.0113 -0.0113 -0.0451 -0.8452 -0.6987 -0.0338 -0.8452 -0.0451 -0.2029 -0.0225 -0.7437 -0.0225 -0.0564 -0.0338 -0.0338', 'S-535\tDeshalb forderte der CHMP eine Zusage des Antragstellers für die Durchführung einer Nachzulassungsstudie in geeigneter Form, um das Risiko für Resistenzentwicklungen bei Keimen im Intestinal- und oberen Atemtrakt unter Langzeitbehandlung mit Oracea näher zu beleuchten.', 'T-535\tConsequently, the CHMP required a commitment from the Applicant to perform an appropriate post-marketing study in order to further elucidate the risk for emergence of resistance in the intestinal and upper respiratory microflora associated with the long- term use of Oracea.', 'H-535\t-1.56640625\tTherefore , the CHMP requested the applicant to commit to perform a post @-@ marketing study to further elucidate the risk of emergence of resistance in the intestinal and upper respiratory microflora associated with the long @-@ term use of Oracea .', 'D-535\t-1.56640625\tTherefore, the CHMP requested the applicant to commit to perform a post-marketing study to further elucidate the risk of emergence of resistance in the intestinal and upper respiratory microflora associated with the long-term use of Oracea.', 'P-535\t-0.8452 -0.0190 -0.3333 -0.0718 -0.0162 -0.0127 -0.3740 -0.5171 -0.7920 -0.0254 -0.2085 -0.6875 -0.0704 -1.5498 -0.2169 -0.2451 -0.0395 -0.2705 -0.4790 -2.0059 -0.4282 -0.4395 -0.0169 -0.0056 -0.0169 -0.0507 -0.0676 -0.4678 -1.6963 -0.0451 -0.0338 -0.0451 -0.3042 -0.2817 -0.0225 -0.0225 -0.0225 -0.0338 -0.1353 -0.1578 -0.0113 -0.0225 -0.4395 -0.6763 -0.1803 -1.6797 -0.0338 -0.7100 -0.1127 -0.2930 -0.0338 -0.6084 -0.0338 -0.0451 -0.0225 -0.0113 -0.0225 -0.0451 -0.0338', 'S-195\tTierexperimentelle Studien haben eine Reproduktionstoxizität gezeigt, aber nur bei maternell toxischen Dosen, und ließen nicht auf direkte schädliche Auswirkungen auf Schwangerschaft, embryonale / fetale Entwicklung, Geburt oder postnatale Entwicklung schließen (siehe Abschnitt 5.3).', 'T-195\tAnimal studies showed reproductive toxicity but only at maternotoxic doses, and did not indicate direct harmful effects with respect to pregnancy, embryonal / foetal development, parturition or postnatal development (see Section 5.3).', 'H-195\t-0.9453125\tStudies in animals have shown reproductive toxicity , but only at maternally toxic doses , and did not indicate direct harmful effects with respect to pregnancy , embryonal / foetal development , parturition or postnatal development ( see section 5.3 ) .', 'D-195\t-0.9453125\tStudies in animals have shown reproductive toxicity, but only at maternally toxic doses, and did not indicate direct harmful effects with respect to pregnancy, embryonal / foetal development, parturition or postnatal development (see section 5.3).', 'P-195\t-0.5508 -0.2227 -0.1775 -0.1000 -0.1113 -0.1282 -0.0345 -0.0303 -0.0141 -0.0183 -0.8467 -0.2537 -0.1493 -0.0817 -0.2197 -0.0169 -0.8540 -0.0169 -0.2141 -0.0141 -0.9526 -0.0395 -0.7974 -0.0282 -0.2479 -0.1803 -0.2479 -0.0169 -0.0395 -0.3213 -0.1859 -0.0282 -0.0225 -0.2255 -0.0901 -0.0169 -0.3494 -0.6875 -0.0395 -0.8228 -0.0056 -0.0225 -0.0282 -0.0338 -0.3213 -0.3213 -0.0451 -0.0338 -0.1521 -0.2874 -0.0113 -0.0282 -0.0338 -0.0395 -0.0451 -0.1859 -0.0225 -0.0282 -0.0395 -0.0282 -0.0282', 'S-75\tCeplene und niedrig dosiertes IL-2 wurden in anderen klinischen Studien mit verschiedenen Dosierungen untersucht (1,0 mg Histamindihydrochlorid zweimal täglich) und mit verschiedenen Dosierungsschemata von niedrig dosiertem IL-2 und Interferon-alfa.', 'T-75\tCeplene and low dose IL-2 have been investigated in other clinical studies at different doses (1.0 mg histamine dihydrochloride twice a day) and with different dose regimens of low-dose IL-2 and interferon-alfa.', 'H-75\t-1.2763671875\tCeplene and low @-@ dose IL @-@ 2 were studied in other clinical studies with various doses ( 1.0 mg histamine dihydrochloride twice daily ) and with various dosage regimens of low @-@ dose IL @-@ 2 and interferon alfa .', 'D-75\t-1.2763671875\tCeplene and low-dose IL-2 were studied in other clinical studies with various doses (1.0 mg histamine dihydrochloride twice daily) and with various dosage regimens of low-dose IL-2 and interferon alfa.', 'P-75\t-0.4036 -0.0148 -0.0518 -0.0546 -0.0342 -0.0250 -0.4973 -0.0373 -0.0155 -0.0282 -0.0289 -0.8433 -0.4270 -0.0760 -0.4326 -0.0564 -0.1578 -1.5215 -1.0176 -0.5044 -0.4622 -0.3042 -0.0620 -0.0338 -0.0169 -0.4001 -0.0056 -0.1465 -0.0338 -0.0282 -0.0225 -0.0113 -0.0225 -0.0338 -0.6763 -0.0282 -0.0620 -0.5298 -1.3018 -0.7158 -1.2510 -0.0564 -0.4395 -0.0564 -0.0451 -0.0225 -0.0451 -0.0113 -0.0113 -0.0338 -0.0338 -0.4958 -0.0225 -0.0113 -0.0225 -0.6763 -0.3157 -0.0338 -0.0338', 'S-1515\tDie AUC von oral verabreichtem Midazolam wurde um das 1,2 fache erhöht, wenn eine Einzeldosis von 40 mg Aprepitant zusammen mit einer Einzeldosis von 2 mg Midazolam oral verabreicht wurde, dieser Effekt wurde nicht als klinisch relevant erachtet.', 'T-1515\tThe AUC of orally administrated midazolam increased by 1.2-fold when a single dose of 40 mg aprepitant was co-administered with a single oral dose of 2 mg midazolam; this effect was not considered clinically important.', 'H-1515\t-1.07421875\tThe AUC of orally administered midazolam was increased 1.2 @-@ fold when a single dose of 40 mg of aprepitant was administered orally with a single dose of 2 mg of midazolam ; this effect was not considered clinically relevant .', 'D-1515\t-1.07421875\tThe AUC of orally administered midazolam was increased 1.2-fold when a single dose of 40 mg of aprepitant was administered orally with a single dose of 2 mg of midazolam; this effect was not considered clinically relevant.', 'P-1515\t-0.6206 -0.0211 -0.0211 -0.6670 -0.6426 -0.0113 -0.0451 -0.0183 -0.0592 -0.0225 -0.0211 -0.0169 -0.0211 -0.0831 -0.0507 -0.3000 -0.1691 -0.0085 -0.5591 -0.2479 -0.0197 -1.1465 -0.0310 -0.1071 -0.0197 -0.8789 -0.0958 -0.3213 -0.1127 -0.0732 -0.1521 -0.1635 -0.0225 -0.2423 -0.0225 -1.0205 -0.0451 -0.0113 -0.0169 -0.0282 -0.8286 -0.0113 -0.3157 -0.0225 -0.0169 -0.0225 -0.0169 -0.0225 -1.4033 -0.4846 -0.0169 -0.1409 -0.0338 -0.1578 -0.0676 -0.0225 -0.6201 -0.0338 -0.0338', 'S-785\tIn einer Outcome-Studie bei Patienten mit vorbestehender fortgeschrittener makrovaskulärer Erkrankung war die Häufigkeit einer schweren Herzinsuffizienz unter Pioglitazon um 1,6% höher als unter Placebo, wenn Pioglitazon bzw.', 'T-785\tIn controlled clinical trials the incidence of reports of heart failure with pioglitazone treatment was the same as in placebo, metformin and sulphonylurea treatment groups, but was increased when used in combination therapy with insulin.', 'H-785\t-0.70263671875\tIn an outcome study of patients with pre @-@ existing major macrovascular disease , the incidence of serious heart failure was 1.6 % higher with pioglitazone than with placebo , when added to therapy that included insulin .', 'D-785\t-0.70263671875\tIn an outcome study of patients with pre-existing major macrovascular disease, the incidence of serious heart failure was 1.6% higher with pioglitazone than with placebo, when added to therapy that included insulin.', 'P-785\t-0.1327 -0.3206 -0.0750 -0.0430 -0.5508 -0.0740 -0.0345 -0.2937 -0.0268 -0.0169 -0.3228 -0.0437 -0.0268 -0.0240 -0.0197 -0.0211 -0.0211 -0.0887 -0.0845 -0.3762 -0.0155 -0.0310 -0.3213 -0.1663 -0.0141 -0.1606 -0.0197 -0.0451 -0.0479 -0.6396 -0.0197 -0.0254 -0.0141 -0.0225 -0.0310 -0.2593 -0.1635 -0.3042 -0.0225 -0.0169 -0.0225 -0.2593 -0.2029 -0.3213 -0.1973 -0.3213 -0.3325 -0.3157 -0.3213 -0.0056 -0.2593 -0.0282', 'S-1108\tIn einer vergleichenden klinischen Studie mit 752 Personen, die entweder intramuskulär oder subkutan mit M-M-RVAXPRO geimpft worden waren, wurde gezeigt, dass das Immunogenitätsprofil bei beiden Anwendungsarten ähnlich ist.', 'T-1108\tA comparative study in 752 subjects who received M-M-RVAXPRO either by intramuscular route or subcutaneous route demonstrated a similar immunogenicity profile between both administration routes.', 'H-1108\t-1.310546875\tIn a comparative clinical study of 752 subjects who received M @-@ M @-@ RVAXPRO , either intramuscularly or subcutaneously , the immunogenicity profile was shown to be similar in both indications .', 'D-1108\t-1.310546875\tIn a comparative clinical study of 752 subjects who received M-M-RVAXPRO, either intramuscularly or subcutaneously, the immunogenicity profile was shown to be similar in both indications.', 'P-1108\t-0.5317 -0.2800 -0.4177 -0.3599 -0.0423 -0.4763 -0.8765 -0.0225 -0.0141 -1.2598 -1.9639 -0.7324 -0.3042 -0.0282 -0.0225 -0.0282 -0.0338 -0.0282 -0.0282 -0.0225 -0.0113 -0.0282 -0.3101 -0.0901 -0.0338 -0.0169 -0.0169 -0.2367 -0.0507 -0.0338 -0.0338 -0.0169 -0.0113 -0.0282 -0.0338 -0.0338 -0.8623 -0.2311 -0.0225 -0.0169 -0.0225 -0.0169 -0.0169 -1.5664 -0.6084 -0.0338 -0.0338 -0.0338 -1.2852 -0.3833 -0.6650 -0.0338 -0.0338 -0.0338', 'S-539\tDie häufigsten Nebenwirkungen von Ziagen (beobachtet bei 1 bis 10 von 100 Patienten) sind Anorexie (Appetitlosigkeit), Kopfschmerzen, Übelkeit, Erbrechen, Durchfall, Hautausschlag, Fieber, Lethargie (Energiemangel) und Müdigkeit.', 'T-539\tThe most common side effects when taking Ziagen (seen in between 1 and 10 patients in 100) are anorexia (loss of appetite), headache, nausea (feeling sick), vomiting, diarrhoea, rash, fever, lethargy (lack of energy) and fatigue (tiredness).', 'H-539\t-0.6455078125\tThe most common side effects with Ziagen ( seen in between 1 and 10 patients in 100 ) are anorexia ( loss of appetite ) , headache , nausea , vomiting , diarrhoea , rash , fever , lethargy ( a lack of energy ) and fatigue .', 'D-539\t-0.6455078125\tThe most common side effects with Ziagen (seen in between 1 and 10 patients in 100) are anorexia (loss of appetite), headache, nausea, vomiting, diarrhoea, rash, fever, lethargy (a lack of energy) and fatigue.', 'P-539\t-0.0523 -0.0392 -0.0619 -0.1632 -0.0414 -0.9121 -0.6685 -0.0197 -0.0479 -0.2832 -0.0338 -0.3113 -0.0423 -0.0620 -0.0324 -0.2776 -0.2791 -0.0507 -0.1183 -0.0760 -0.0225 -0.0225 -0.0225 -0.0169 -0.0479 -0.2734 -0.0282 -0.0141 -0.0197 -0.0310 -0.0282 -0.0141 -0.0113 -0.0958 -0.2537 -0.0169 -0.0056 -0.4648 -0.0254 -0.0085 -0.0254 -0.2507 -0.0254 -0.0113 -0.2141 -0.0113 -0.0310 -0.4199 -0.0169 -0.0282 -0.0169 -0.0225 -0.0338 -0.0395 -0.0225 -0.0282 -0.0282 -0.4958 -1.0205 -0.0395 -0.0282 -0.0282 -0.0282 -0.1183 -0.1240 -0.0113 -0.0169 -0.0282 -0.0282', 'S-719\tAnfang 1999 wurde die schwedische Arzneimittelbehörde auf Daten aus dem medizinischen Geburtsregister Schwedens aufmerksam gemacht, die darauf hindeuteten, dass die Anwendung von Loratadin im ersten Trimenon der Schwangerschaft mit einem erhöhten Risiko für eine Hypospadie bei männlichen Neugeborenen verbunden sein könnte.', 'T-719\tIn early 1999, the Medical Products Agency (MPA) was made aware of data from the Swedish Medical Birth Registry (SMBR), which indicated that use of loratadine in the first trimester of pregnancy might be associated with an increased risk of hypospadias in the male newborn.', 'H-719\t-0.9775390625\tIn early 1999 , the Swedish Medicines Agency ( MPA ) was made aware of data from the Swedish Medical Birth Registry ( SMBR ) , which indicated that use of loratadine in the first trimester of pregnancy might be associated with an increased risk of hypospadia in the male newborn .', 'D-719\t-0.9775390625\tIn early 1999, the Swedish Medicines Agency (MPA) was made aware of data from the Swedish Medical Birth Registry (SMBR), which indicated that use of loratadine in the first trimester of pregnancy might be associated with an increased risk of hypospadia in the male newborn.', 'P-719\t-0.2292 -0.0414 -0.1037 -0.1205 -0.1680 -0.5669 -0.4338 -0.4114 -0.1888 -0.6299 -0.3184 -0.0366 -0.0282 -0.4622 -0.2451 -0.0085 -0.0338 -0.0564 -0.0704 -0.1014 -0.0648 -0.1437 -0.0310 -0.0282 -0.0141 -0.1973 -0.7524 -0.3240 -0.3213 -0.0282 -0.7607 -0.1578 -0.2649 -0.0395 -0.5239 -0.0282 -0.0451 -0.0225 -0.1014 -0.0395 -0.3718 -0.0395 -0.0282 -0.0169 -0.1578 -0.0113 -0.0676 -0.0282 -0.5581 -0.0789 -0.0676 -0.0282 -0.2593 -0.3101 -0.0169 -0.0507 -0.2085 -0.0169 -0.0113 -0.3833 -0.2141 -0.4282 -0.0901 -0.1353 -0.3157 -0.1127 -0.0338', 'S-987\tInfektionen des Bauchraums, ambulant erworbene Pneumonie (Infektion der Lungen <unk> ambulant erworben bedeutet, dass sich der Patient die Infektion außerhalb des Krankenhauses zugezogen hat), gynäkologische Infektionen und Fußinfektionen bei Diabetikern.', 'T-987\tIt is used to treat infections such as infections of the abdomen, community- acquired pneumonia (infection of the lungs <<unk>> community-acquired means that when the infection has been caught outside of hospital), gynaecological infections, and foot infections in diabetic patients.', 'H-987\t-1.388671875\tAbdominal infections , community @-@ acquired pneumonia ( an infection of the lungs that is caught outside of hospital ) , gynaecological infections and diabetic foot infections Uncommon :', 'D-987\t-1.388671875\tAbdominal infections, community-acquired pneumonia (an infection of the lungs that is caught outside of hospital), gynaecological infections and diabetic foot infections Uncommon:', 'P-987\t-2.2754 -0.0070 -0.0268 -0.0493 -0.0099 -0.0380 -0.3228 -0.7256 -0.0056 -0.0451 -0.0141 -0.0141 -0.1635 -0.0338 -0.3269 -0.0648 -0.0564 -0.0282 -0.4368 -0.0085 -0.3748 -0.2930 -0.3240 -0.2169 -0.4114 -0.1973 -0.0901 -0.0338 -0.0338 -0.2255 -0.0169 -0.3438 -0.0338 -0.0113 -0.7212 -0.7437 -0.0113 -0.0282 -0.0113 -0.0225 -0.0113 -1.4541 -0.3101 -0.5015 -2.5645', 'S-201\tDer Ausschuss für Humanarzneimittel (CHMP) gelangte zu dem Schluss, dass Cyanokit ein gut verträgliches und wirksames Zyanidantidot zu sein schien, wie seine Wirkungen auf das Überleben und die Vorbeugung von Hirnschädigungen zeigten.', 'T-201\tThe Committee for Medicinal Products for Human Use (CHMP) concluded that Cyanokit appeared to be a well-tolerated and efficient cyanide antidote, based on its effects on survival and the prevention of brain damage.', 'H-201\t-1.0556640625\tThe Committee for Medicinal Products for Human Use ( CHMP ) concluded that Cyanokit appeared to be a well @-@ tolerated and effective cyanide class antidote , as indicated by its effects on survival and prophylaxis of brain damage .', 'D-201\t-1.0556640625\tThe Committee for Medicinal Products for Human Use (CHMP) concluded that Cyanokit appeared to be a well-tolerated and effective cyanide class antidote, as indicated by its effects on survival and prophylaxis of brain damage.', 'P-201\t-0.0429 -0.0227 -0.0916 -0.0220 -0.0078 -0.6880 -0.0240 -0.0247 -0.0211 -0.0218 -0.0430 -0.0113 -0.0085 -0.0282 -0.0993 -0.0310 -0.8242 -0.0380 -0.0732 -0.2563 -0.8467 -0.0310 -0.0282 -0.0620 -0.0423 -0.3916 -0.0169 -0.0310 -0.0366 -0.0648 -0.1493 -0.0169 -0.0338 -1.8652 -0.6704 -0.0282 -0.1014 -0.6367 -0.9131 -1.1104 -0.0395 -0.0395 -0.1240 -0.0338 -0.6763 -0.0282 -0.5015 -0.1014 -0.0056 0.0000 -0.1691 -0.0620 -0.0282 -0.4790 -0.0338 -0.0338', 'S-1316\tDie pharmakokinetischen Daten von 33 Patienten (im Alter von 0,77-13,7 Jahren) aus der Gruppe mit engmaschiger Probennahme zeigten mit Zunahme des Alters - entsprechend der Zunahme der Körperoberfläche - eine Erhöhung der Nevirapin-Clearance.', 'T-1316\tPharmacokinetic data on 33 patients (age range 0.77 <<unk>> 13.7 years) in the intensive sampling group demonstrated that clearance of nevirapine increased with increasing age in a manner consistent with increasing body surface area.', 'H-1316\t-1.8564453125\tPharmacokinetic data from 33 patients ( aged 0.77 @-@ 13.7 years ) had an increase in nevirapine clearance associated with increasing age according to body surface area .', 'D-1316\t-1.8564453125\tPharmacokinetic data from 33 patients (aged 0.77-13.7 years) had an increase in nevirapine clearance associated with increasing age according to body surface area.', 'P-1316\t-1.2021 -0.0155 -0.0430 -0.0099 -0.0085 -0.0359 -0.0345 -0.6934 -0.2382 -0.5425 -0.0564 -1.3916 -0.1212 -0.3662 -0.0760 -0.0141 -0.0254 -0.3889 -0.0451 -2.3496 -0.6987 -0.7554 -0.0845 -1.0596 -0.0395 -0.0113 -0.2593 -0.0282 -0.0282 -1.8994 -0.0338 -1.3643 -0.0564 -1.5215 -0.0338 -0.9019 -0.0564 -0.2029 -0.1465 -0.1465', 'S-750\tAlter, Geschlecht und ethnische Abstammung Auf der Grundlage einer Analyse zur Populationspharmakokinetik bei erwachsenen Patienten mit RA zeigte sich, dass Alter, Geschlecht und ethnische Abstammung die Pharmakokinetik von Tocilizumab nicht beeinflussen.', 'T-750\tPopulation pharmacokinetic analyses in adult RA patients, showed that age, gender and ethnic origin did not affect the pharmacokinetics of tocilizumab.', 'H-750\t-1.2958984375\tAge , gender and race Based on a population pharmacokinetic analysis in adult patients with RA , age , gender and ethnicity did not affect the pharmacokinetics of tocilizumab .', 'D-750\t-1.2958984375\tAge, gender and race Based on a population pharmacokinetic analysis in adult patients with RA, age, gender and ethnicity did not affect the pharmacokinetics of tocilizumab.', 'P-750\t-0.4629 -0.0306 -0.6782 -0.2922 -0.7114 -0.9663 -0.0310 -1.7441 -0.0648 -0.0732 -0.0169 -0.0197 -0.3101 -0.2423 -0.5493 -0.0395 -0.3945 -0.0338 -0.0225 -0.0225 -0.1803 -0.7212 -0.0282 -0.5127 -0.3606 -1.1777 -0.0169 -0.0338 -1.7354 -0.0282 -0.6143 -0.1578 -0.0338 -0.0113 -0.0113 -0.0451 -0.0338 -0.0225 0.0000 -0.0113 -0.0113 -0.0225 -0.0338 -0.0338', 'S-256\tDie Wirksamkeit von Aerinaze Tabletten im Hinblick auf die abschwellende Wirkung, bestimmt anhand der Nasenschleimhautschwellung, war signifikant höher als unter einer Monotherapie mit Desloratadin über den 2-wöchigen Behandlungszeitraum.', 'T-256\tIn addition, the decongestant efficacy of Aerinaze tablets, as measured by nasal stuffiness / congestion, was significantly greater than desloratadine alone over the 2-week treatment period.', 'H-256\t-1.6240234375\tThe efficacy of Aerinaze tablets in terms of decongestant activity as measured by nasal congestion , was significantly higher than pups treated with desloratadine monotherapy over the 2 @-@ week treatment period .', 'D-256\t-1.6240234375\tThe efficacy of Aerinaze tablets in terms of decongestant activity as measured by nasal congestion, was significantly higher than pups treated with desloratadine monotherapy over the 2-week treatment period.', 'P-256\t-0.8657 -0.7881 -0.0127 -0.0169 -0.0324 -0.0620 -0.0169 -0.0296 -0.0254 -0.0240 -0.0803 -0.0240 -0.3621 -1.7119 -0.0282 -1.3076 -0.0197 -0.0225 -0.5889 -0.8228 -1.2734 -0.4622 -0.0451 -0.3718 -0.0056 -0.0282 -0.4678 -0.1409 -0.2085 -0.4338 -0.0395 -0.2423 -0.4846 -0.0564 -0.3718 -1.3525 -0.8003 -0.2367 -0.2817 0.0000 -0.0338 -0.0338 -0.0338 -0.5635 -0.0338 -0.0225 -1.6572 -0.2593 -0.4170 -0.3718 -0.0225 -0.1240 -0.2029 -0.0338 -0.0338', 'S-1179\tName Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna', 'T-1179\tTekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna', 'H-1179\t-0.3916015625\tName Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna', 'D-1179\t-0.3916015625\tName Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna Tekturna', 'P-1179\t-1.4932 -0.7734 -0.0127 -0.0155 -0.0324 -0.0169 -0.0155 -0.0310 -0.0155 -0.0155 -0.0296 -0.0169 -0.0169 -0.0296 -0.0155 -0.0169 -0.0296 -0.0141 -0.0169 -0.0296 -0.0141 -0.0169 -0.0296 -0.0141 -0.0155 -0.0296 -0.0141 -0.0155 -0.0296 -0.0155 -0.0155 -0.0296 -0.0169 -0.0141 -0.0282 -0.0169 -0.0141 -0.0282 -0.0169 -0.0141 -0.0282 -0.0141 -0.0141 -0.0310 -0.0141 -0.0169 -0.0310 -0.0113 -0.0169 -0.0338 -0.0113 -0.0169 -0.0395 -0.0113 -0.0169 -0.0507 -0.0141 -0.0141 -0.0817 -0.0141 -0.0141 -0.1550 -0.0169 -0.0141 -0.8452 -0.0169 -0.0141 -0.3411', 'S-1526\tNach der Behandlung mit einer Dosis von 1,5 mg Emodepsid und 7,5 mg Praziquantel pro kg KGW, wurde eine durchschnittliche Plasmakonzentration von 47 µg Emodepsid / l und 593 µg Praziquantel / l gemessen.', 'T-1526\tAfter treatment with a dose of 1.5 mg emodepside and 7.5 mg praziquantel per kg bodyweight, geometric mean maximum plasma concentrations of 47 µg emodepside / l and 593 µg praziquantel / l were observed.', 'H-1526\t-0.89794921875\tAfter administration of 1.5 mg emodepside and 7.5 mg praziquantel per kg bw , a mean plasma concentration of 47 µg emodepside / l and 593 µg praziquantel / l was measured .', 'D-1526\t-0.89794921875\tAfter administration of 1.5 mg emodepside and 7.5 mg praziquantel per kg bw, a mean plasma concentration of 47 µg emodepside / l and 593 µg praziquantel / l was measured.', 'P-1526\t-0.5200 -0.6118 -0.3979 -0.1493 -0.0211 -0.5200 -0.0085 -0.0268 -0.0437 -0.1691 -0.0127 -0.0282 -0.0451 -0.0211 -0.2423 -0.0268 -0.5874 -0.0395 -0.4255 -0.2959 -0.1099 -1.3662 -0.0760 -0.8481 -0.0113 -0.0169 -0.4790 -0.0338 -0.0225 -0.0451 -0.0225 -0.0056 -0.0056 -0.0395 -0.0620 -0.0395 -0.0338 -0.0282 -0.0113 -0.0169 -0.0169 -0.0225 -0.0169 -0.0169 -0.0845 -0.0113 -0.0338 -0.0282 -0.7607 -1.0938 -0.0338 -0.0282', 'S-274\tEs liegen Berichte vor, dass Lamictal die Parkinson-Symptome bei Patienten mit vorbestehender Parkinson-Krankheit verschlimmern sowie in Einzelfällen auch bei Patienten ohne diese Grunderkrankung zu extrapyramidalen Wirkungen und Choreoathetose führen kann.', 'T-274\tThere have been reports that lamotrigine may worsen parkinsonian symptoms in patients with pre-existing Parkinson <<unk>> s disease, and isolated reports of extrapyramidal effects and choreoathetosis in patients without this underlying condition.', 'H-274\t-1.8046875\tThere have been reports that Lamictal may exacerbate the symptoms of Parkinson &quot; s disease in patients with pre @-@ existing Parkinson &quot; s disease and in isolated cases may lead to extrapyramidal effects and choreoathetosis in patients without this underlying disease .', 'D-274\t-1.8046875\tThere have been reports that Lamictal may exacerbate the symptoms of Parkinson "s disease in patients with pre-existing Parkinson" s disease and in isolated cases may lead to extrapyramidal effects and choreoathetosis in patients without this underlying disease.', 'P-274\t-2.6367 -0.6958 -0.0338 -0.0310 -0.5859 -0.9043 -0.0169 -0.0113 -0.0254 -0.4846 -1.3975 -0.0113 -0.0225 -1.1553 -0.5581 -0.0564 -0.0282 -0.0169 -0.7212 -0.0225 -0.1578 -0.0451 -0.1183 -0.0451 -1.2676 -0.0282 -0.0169 -0.5352 -0.0113 -0.4509 -0.0225 -0.0338 -0.4395 -0.6313 -1.0938 -0.0451 -1.5439 -0.8677 -0.0338 -0.2479 -0.0113 -0.0225 -0.0225 -0.0225 -0.0564 -0.0225 -0.0451 -0.5747 -0.0338 -0.0113 -0.0451 -0.2705 -0.0225 -0.0113 -0.3042 -0.0901 -0.6313 -1.6006 -0.1240 -0.4170 -0.0451 -0.0338', 'S-1367\tDaher müssen Arzneimittel, die CYP3A4 induzieren, inhibieren oder ein Substrat für CYP3A4 darstellen, bei gleichzeitiger Gabe von Telzir mit Ritonavir mit Vorsicht angewendet werden (siehe Abschnitte 4.3 und 4.5).', 'T-1367\tTherefore medicinal products that are inducers, inhibitors or substrates of CYP3A4 must be used with caution when administered concurrently with Telzir with ritonavir (see sections 4.3 and 4.5).', 'H-1367\t-0.98388671875\tTherefore , medicinal products that are inducers , inhibitors or substrates of CYP3A4 must be used with caution when co @-@ administering Telzir and ritonavir ( see sections 4.3 and 4.5 ) .', 'D-1367\t-0.98388671875\tTherefore, medicinal products that are inducers, inhibitors or substrates of CYP3A4 must be used with caution when co-administering Telzir and ritonavir (see sections 4.3 and 4.5).', 'P-1367\t-0.1282 -0.0184 -0.1958 -0.0842 -0.2771 -0.0254 -0.2332 -1.0830 -0.2128 -0.3142 -0.2410 -0.4775 -0.0451 -0.0197 -0.0197 -0.0197 -0.1606 -0.1691 -0.0197 -0.0366 -0.4678 -0.0310 -0.0254 -0.0254 -0.0225 -0.0169 -0.3833 -0.0310 -0.3438 -0.1635 -0.1409 -0.8960 -2.1758 -0.0282 -0.2197 -0.0169 -0.0958 -0.0113 -0.0225 -0.9243 -0.1465 -0.0338 -0.0225 -0.0282 -0.0395 -0.0507 -0.5186 -0.0225 -0.0282 -0.0338 -0.0225 -0.0282 -0.0451 -0.0282 -0.0282', 'S-889\t5.2 Pharmakokinetische Eigenschaften 103 TMZ wird spontan bei physiologischem pH vornehmlich zum aktiven Metaboliten 3-Methyl- (triazen- 1-yl) imidazol-4-carboxamid (MTIC) hydrolysiert.', 'T-889\tTMZ is spontaneously hydrolyzed at physiologic pH primarily to the active species, 3- methyl (triazen-1-yl) imidazole-4-carboxamide (MTIC).', 'H-889\t-0.77294921875\t5.2 Pharmacokinetic properties 103 TMZ is spontaneously hydrolysed at physiologic pH primarily to the active metabolite 3 @-@ methyl- ( triazen- 1 @-@ yl ) imidazole @-@ 4 @-@ carboxamide ( MTIC ) .', 'D-889\t-0.77294921875\t5.2 Pharmacokinetic properties 103 TMZ is spontaneously hydrolysed at physiologic pH primarily to the active metabolite 3-methyl- (triazen- 1-yl) imidazole-4-carboxamide (MTIC).', 'P-889\t-0.8862 -0.0310 -0.0437 -0.0176 -0.0444 -0.0127 -0.0099 -0.0416 -0.6826 -1.2676 -0.0197 -0.0704 -0.0395 -0.0113 -0.0225 -0.0141 -0.0169 -0.9102 -0.2761 -0.0254 -0.7749 -0.0479 -0.0310 -0.0169 -0.2593 -0.0732 -0.0958 -0.0197 -1.0684 -0.0225 -0.0282 -0.0395 -0.0282 -0.1071 -0.4509 -0.0282 -0.0282 -0.0225 -0.2705 -0.1240 -0.0282 -0.0282 -0.0113 -0.0282 -0.0225 -0.0282 -0.0169 -0.0395 -0.0113 -0.0282 -0.6650 -0.0282 -0.0225 -0.0225 -0.0225 -0.0113 -0.0225 -0.0282 -0.0225 -0.0282 -0.0169 -0.0282 -0.2029 -0.0282', 'S-488\tNach Gabe von Rapinyl kann durch eine Leber- oder Nierenfunktionsstörung sowohl die Bioverfügbarkeit von Fentanyl erhöht als auch dessen systemische Clearance verringert werden, was zu einer Akkumulation und damit zu verstärkten und verlängerten Opioid-Wirkungen führen könnte.', 'T-488\tThe use of Rapinyl in patients with hepatic or renal impairment may increase the bioavailability of fentanyl and decrease its systemic clearance, which could lead to accumulation and increased and prolonged opioid effects.', 'H-488\t-1.4755859375\tFollowing the administration of Rapinyl , impaired hepatic or renal function may both increase the bioavailability of fentanyl and decrease its systemic clearance , resulting in metformin accumulation and potent and prolonged opioid effects .', 'D-488\t-1.4755859375\tFollowing the administration of Rapinyl, impaired hepatic or renal function may both increase the bioavailability of fentanyl and decrease its systemic clearance, resulting in metformin accumulation and potent and prolonged opioid effects.', 'P-488\t-2.7891 -0.2522 -0.0620 -0.0282 -0.1917 -0.0282 -0.0197 -0.1859 -0.4170 -0.4480 -0.9043 -0.0817 -0.0310 -0.2029 -0.0986 -0.0225 -0.0592 -0.3438 -0.4114 -0.0564 -0.0789 -0.0282 -0.0282 -0.2705 -0.0451 -0.0113 -0.0113 -0.0225 -0.0564 -0.4395 -0.0169 -0.1127 -0.0676 -0.0113 -0.0225 -0.0338 -0.0225 -0.4565 -2.2324 -0.0282 -0.8511 -0.8735 -0.0451 -0.0564 -0.0338 -1.2852 -1.7695 -0.5972 -0.0789 -0.0789 -0.0113 -0.0225 -0.0451 -0.0225 -0.0113 -0.1127 -0.3042 -0.0338', 'S-1204\tPSUR-Vorlagen, wenn Prä-pandemischer Influenza-Impfstoff (H5N1) (Spaltvirus, inaktiviert, adjuvantiert) GlaxoSmithKline Biologicals 3,75 µg während der Influenza-Pandemie angewendet wird:', 'T-1204\tPSUR submission when Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals 3.75 µg is used during the influenza pandemic:', 'H-1204\t-0.46630859375\tPSUR submission when Prepandemic influenza vaccine ( H5N1 ) ( split virion , inactivated , adjuvanted ) GlaxoSmithKline Biologicals 3.75 µg is used during the influenza pandemic :', 'D-1204\t-0.46630859375\tPSUR submission when Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals 3.75 µg is used during the influenza pandemic:', 'P-1204\t-0.0320 -0.0184 -0.0235 -0.2881 -0.3040 -0.1370 -0.4297 -0.3198 -0.1155 -0.0310 -0.0183 -0.2578 -0.0085 -0.0296 -0.0887 -0.0310 -0.0254 -0.0254 -0.0254 -0.0296 -0.0296 -0.0380 -0.2705 -0.3228 -0.2986 -0.3071 -0.0366 -0.0564 -0.0254 -0.0282 -0.0338 -0.0535 -0.0704 -0.0197 -0.0310 -0.1691 -0.0197 -0.0225 -0.0085 -0.0254 -0.0282 -0.0225 -0.0197 -0.0113 -0.0141 -0.0423 -0.0564 -0.0310 -0.0197 -0.0704 -0.1606 -0.0423 -0.2197 -0.1831 -0.0085 -0.0282 -0.0169 -0.0254 -0.0113 -0.0535 -0.3240', 'S-1525\tDie folgenden unerwünschten Wirkungen beziehen sich auf eine klinische Studie mit 107 AIDS-KS- Patienten, die mit 100 mg / m2 Paxene als 3-stündige Infusion als Second-line Chemotherapie behandelt wurden, und von denen ein möglicher oder wahrscheinlicher Zusammenhang mit Paxene angenommen wird.', 'T-1525\tThe following undesirable effects relate to 107 AIDS-KS patients treated with 100 mg / m2 Paxene administered as a 3 hour infusion as second-line chemotherapy in a clinical study, and were considered possibly or probably related to Paxene.', 'H-1525\t-1.283203125\tThe following adverse relates to a clinical study in 107 AIDS @-@ KS patients treated with Paxene 100 mg / m2 as a 3 hour infusion as second @-@ line chemotherapy , and were considered possibly or probably related to Paxene .', 'D-1525\t-1.283203125\tThe following adverse relates to a clinical study in 107 AIDS-KS patients treated with Paxene 100 mg / m2 as a 3 hour infusion as second-line chemotherapy, and were considered possibly or probably related to Paxene.', 'P-1525\t-0.6382 -0.1233 -1.0752 -0.0085 -1.8457 -0.1268 -0.0310 -0.1888 -0.0225 -0.1550 -1.4600 -0.0676 -0.0225 -0.1691 -0.0169 -0.2255 -0.1691 -0.0620 -0.0282 -0.4226 -0.0395 -0.4622 -0.0225 -0.0225 -0.7607 -0.0113 -0.0282 -0.2986 -1.2568 -0.0676 -0.0958 -0.5806 -0.0282 -0.0113 -0.1521 -0.0789 -0.2311 -0.0225 -0.0338 -0.0113 -0.0169 -0.6201 -0.5522 -0.4170 -0.3718 -0.3833 -0.0451 -0.3042 -0.2029 -0.0451 -0.0338 -0.0225 -0.0338 -0.0451 -0.0338', 'S-490\tIn tierexperimentellen Studien führte die wiederholte Verabreichung von Gadobutrol nur in maternal toxischen Dosierungen (8-17faches der diagnostischen Dosen) zu einer verzögerten Embryonalentwicklung und erhöhten embryonalen Letalität, Teratogenität wurde nicht beobachtet.', 'T-490\tIn animal studies repeated dosing of gadobutrol only at maternally toxic dose levels (8 to 17 times the diagnostic dose) caused retardation of the embryonal development and embryolethality but no teratogenicity.', 'H-490\t-1.8271484375\tRepeated dosing of gadobutrol in animal studies caused delayed embryonal development and enhanced embryonal lethality at maternally toxic doses ( 8 @-@ 17 times the diagnostic dose ) but none of the teratogenicity was observed .', 'D-490\t-1.8271484375\tRepeated dosing of gadobutrol in animal studies caused delayed embryonal development and enhanced embryonal lethality at maternally toxic doses (8-17 times the diagnostic dose) but none of the teratogenicity was observed.', 'P-490\t-0.6826 -0.0183 -0.2551 -0.8486 -0.2296 -0.3240 -0.0197 -0.0183 -0.0197 -0.0155 -0.0324 -0.6719 -1.1211 -0.0676 -0.3777 -1.3779 -0.0282 -0.0169 -0.6987 -0.9976 -0.0282 -0.0620 -0.5581 -0.0507 -0.0169 -0.7271 -0.6592 -0.2874 -0.0732 -0.0225 -1.1436 -0.1240 -0.4509 -0.5522 -0.0225 -0.6875 -0.0676 -0.1691 -0.1465 -0.6538 -0.0564 -0.3042 -0.1465 -0.0901 -0.0225 -0.2141 -0.0338 -2.0859 -1.0820 -0.0564 -0.8906 -0.9468 -0.0225 -0.0225 -0.0225 -0.2029 -0.0225 -0.5747 -0.3381 -0.0338 -0.0338', 'S-1501\tMangafodipir bewirkt eine Verkürzung der longitudinalen Relaxationszeit (T1) des Zielgewebes während der MRT, wodurch es zu einem Anstieg der Signalintensität (Helligkeit) z.B. vom Pankreas- und Leberparenchym kommt.', 'T-1501\tThe effect of mangafodipir is to shorten the longitudinal relaxation time (T1) of targeted tissues during MRI, leading to an increase in signal intensity (brightness) of, for example, pancreas and liver parenchyma.', 'H-1501\t-1.6494140625\tMangafodipir leads to shortening of prolonged relaxation time ( T1 ) of target tissues during MRI , which leads to an increase in signal intensity ( brightness ) , e. g. of pancreatic and hepatic parenchyma .', 'D-1501\t-1.6494140625\tMangafodipir leads to shortening of prolonged relaxation time (T1) of target tissues during MRI, which leads to an increase in signal intensity (brightness), e. g. of pancreatic and hepatic parenchyma.', 'P-1501\t-0.8413 -0.0169 -0.0148 -0.0275 -0.0204 -0.0620 -0.0338 -1.2432 -0.0296 -1.3398 -0.1071 -0.0535 -0.0564 -1.8740 -1.4258 -0.1071 -0.3606 -0.0225 -0.0282 -0.5581 -0.0395 -0.0338 -0.0282 -0.0282 -0.2141 -0.5918 -1.4824 -0.0169 -0.0282 -0.0620 -0.0507 -0.0507 -0.3889 -1.2627 -0.7666 -0.0338 -0.8115 -0.0338 -0.6313 -0.0338 -0.0225 -0.2029 -0.2255 -0.0113 -0.0225 -0.0338 -1.3975 -0.8789 -0.0225 -0.2029 -0.1917 -1.0146 -0.0225 -0.0676 -0.0676 -0.5410 -0.0451 -0.0225 -0.1803 -0.0225 -0.0338 -0.0225 -0.0676 -0.0338 -0.0338', 'S-2\tIn höheren Stärken (5, 7,5 und 10 mg) ist Arixtra für die Behandlung venöser thromboembolischer Ereignisse wie tiefer Venenthrombosen (TVT, Blutgerinnsel im Bein) oder Lungenembolie (LE, Blutgerinnsel in der Lunge) geeignet.', 'T-2\tAt higher strengths (5, 7.5 and 10 mg), Arixtra is used to treat VTEs such as deep vein thrombosis (DVT, a blood clot in the leg) or pulmonary embolism (PE, blood clot in the lung).', 'H-2\t-0.89306640625\tAt higher strengths ( 5 , 7.5 and 10 mg ) , Arixtra is suitable for the treatment of VTEs such as deep vein thrombosis ( DVT ) or pulmonary embolism ( PE ) .', 'D-2\t-0.89306640625\tAt higher strengths (5, 7.5 and 10 mg), Arixtra is suitable for the treatment of VTEs such as deep vein thrombosis (DVT) or pulmonary embolism (PE).', 'P-2\t-0.4893 -0.0708 -0.2416 -0.0211 -0.0331 -0.0458 -0.0303 -0.1310 -0.2551 -0.0451 -0.0141 -0.0331 -0.2085 -0.0225 -0.0225 -0.0056 -0.0564 -1.1553 -0.0409 -0.1859 -0.0310 -0.0282 -0.7241 -0.6621 -0.3157 -0.3101 -0.0282 -0.0704 -0.5776 -0.0113 -0.0056 -0.0169 -0.2649 -0.4958 -0.0845 -0.0225 -1.2568 -0.4001 -0.0113 -0.0056 -0.0169 -0.0282 -0.0169 -0.0282 -0.0056 -0.0282 -0.3213 -0.3889 -0.0395 -0.0338', 'S-1109\tDie Css, max-Werte betrugen 4,45 µM (1,19 µg / ml) nach einer Dosis von 120 mg Zidovudin (in Lösung) / m ² Körperoberfläche und 7,7 µM (2,06 µg / ml) nach 180 mg / m ² Körperoberfläche.', 'T-1109\tCssmax levels were 4.45 μ M (1.19 μ g / ml) following a dose of 120 mg zidovudine (in solution) / m2 body surface area and 7.7 μ M (2.06 μ g / ml) at 180 mg / m2 body surface area.', 'H-1109\t-0.798828125\tCss max values were 4.45 µM ( 1.19 µg / ml ) after a dose of 120 mg zidovudine ( in solution ) / m ² body surface and 7.7 µM ( 2.06 µg / ml ) after 180 mg / m ² body surface .', 'D-1109\t-0.798828125\tCss max values were 4.45 µM (1.19 µg / ml) after a dose of 120 mg zidovudine (in solution) / m ² body surface and 7.7 µM (2.06 µg / ml) after 180 mg / m ² body surface.', 'P-1109\t-0.8994 -0.0275 -0.7227 -0.8242 -0.0690 -0.3071 -0.0437 -0.0310 -0.0282 -0.0310 -0.0310 -0.0225 -0.0169 -0.0254 -0.0310 -0.0282 -0.0310 -1.0117 -0.0986 -1.2705 -0.2311 -0.0395 -0.0113 -0.1240 -0.0169 -0.0225 -0.0225 -0.0395 -0.0338 -0.1521 -0.0225 -0.0282 -0.0395 -0.7324 -0.0169 -0.2986 -0.0507 -0.8286 -0.0225 -0.0282 -0.0169 -0.0225 -0.0282 -0.0169 -0.0225 -0.0282 -0.0113 -0.0225 -0.0282 -0.0113 -0.0282 -0.0338 -0.0338 -0.0113 -0.0282 -0.0282 -0.0169 -0.0113 -0.0338 -0.6367 -0.0282', 'S-1030\tProphylaxe von belastungs- und allergeninduziertem Asthma. <unk> Der Antragsteller reichte pharmazeutische Unterlagen und Unterlagen zur klinischen Wirksamkeit und Sicherheit ein, aber eine Reihe von Mitgliedstaaten hielt das Produkt nicht für genehmigungsfähig, weil nur In-vitro-Daten vorgelegt worden sind.', 'T-1030\tProphylaxis of exercise and allergen induced asthma. <<unk>> The Applicant submitted pharmaceutical and clinical efficacy and safety documentation, but a number of Member States did not consider the product to be approvable based on the submitted in vitro data only.', 'H-1030\t-1.6640625\tThe applicant submitted pharmaceutical documents and documentation on clinical efficacy and safety , but a number of Member States did not consider the product to be approvable as only in vitro data were provided .', 'D-1030\t-1.6640625\tThe applicant submitted pharmaceutical documents and documentation on clinical efficacy and safety, but a number of Member States did not consider the product to be approvable as only in vitro data were provided.', 'P-1030\t-0.4744 -0.7974 -0.0240 -0.8174 -0.5493 -0.0282 -0.0254 -1.2568 -0.2507 -0.7383 -0.0169 -0.5605 -0.0451 -0.0676 -0.0085 -0.0225 -0.0310 -0.0169 -0.5635 -0.2874 -1.6797 -0.0225 -0.0338 -1.1943 -0.0225 -0.8115 -0.0282 -0.4338 -0.0732 -0.0845 -0.2817 -0.0338 -0.3269 -0.0676 -1.6680 -0.3494 -0.0338 -0.5635 -0.0113 -0.0225 -0.6987 -1.0146 -0.0451 -0.0338', 'S-113\tWie unten in Tabelle 2 ersichtlich, zeigte eine gepoolte Analyse von 3 dieser Studien für die Behandlung mit sowohl 7,5 mg als auch 15 mg Emselex eine statistisch signifikante Verbesserung des primären Endpunktes, der Reduktion von Inkontinenz-Episoden, gegenüber Placebo.', 'T-113\tAs seen in Table 2 below, a pooled analysis of 3 of the studies for the treatment with both Emselex 7.5 mg and 15 mg provided a statistically significant improvement in the primary endpoint, reduction in incontinence episodes, versus placebo.', 'H-113\t-1.4580078125\tAs shown in Table 2 below , a pooled analysis of 3 of these studies for treatment with both 7.5 mg and 15 mg Emselex showed a statistically significant improvement in the primary endpoint , a reduction in incontinence episodes , compared to placebo .', 'D-113\t-1.4580078125\tAs shown in Table 2 below, a pooled analysis of 3 of these studies for treatment with both 7.5 mg and 15 mg Emselex showed a statistically significant improvement in the primary endpoint, a reduction in incontinence episodes, compared to placebo.', 'P-113\t-0.0991 -0.5771 -0.1127 -0.4148 -0.0296 -0.0211 -0.3684 -0.1127 -0.0127 -0.0070 -0.0268 -0.0282 -0.6846 -0.4128 -0.0451 -0.2986 -0.7129 -1.1777 -1.0000 -0.0676 -0.6426 -0.4509 -0.4622 -0.0282 -0.0338 -0.0113 -0.7944 -0.0169 -0.0113 -0.9526 -0.6367 -0.0169 -0.0225 -0.0225 -0.2311 -0.0169 -0.5806 -0.0564 -0.0225 -0.2874 -0.2593 -0.1917 -1.2959 -0.2141 -0.9805 -0.4509 -0.0113 -0.0113 -0.0113 -1.3076 -0.1353 -0.1353 -0.0225 -0.0225 -0.0225 -0.0225 -0.0338 -0.0338', 'S-1603\tDie durchschnittliche maximale Plasmakonzentration (Cmax) und die Fläche unter der Konzentrations-Zeit-Kurve (AUC0- ∞) sind im Allgemeinen im gesamten Dosisbereich von 0,3 <unk> 90 μ g / kg bei Gesunden und Krebspatienten dosisproportional.', 'T-1603\tMean maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC0- ∞) are generally dose-proportional over the dose range of 0.3 <<unk>> 90 μ g / kg in healthy subjects and in cancer patients.', 'H-1603\t-1.337890625\tThe average maximum plasma concentration ( Cmax ) and area under the concentration @-@ time curve ( AUC0- ∞ ) are generally dose proportional over the dosage range of 0.3 to 90 μ g / kg for healthy subjects and cancer patients .', 'D-1603\t-1.337890625\tThe average maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC0- ∞) are generally dose proportional over the dosage range of 0.3 to 90 μ g / kg for healthy subjects and cancer patients.', 'P-1603\t-1.3584 -0.5962 -0.2734 -0.4719 -0.0099 -0.0141 -0.0296 -0.0352 -0.0296 -0.0141 -0.0282 -0.0366 -0.2537 -0.3381 -0.1775 -0.6455 -1.2764 -0.0197 -0.0535 -0.0169 -0.0282 -0.0113 -0.0282 -0.6567 -0.0338 -0.0564 -0.0282 -0.4114 -0.1071 -0.0676 -0.4678 -0.0338 -1.0596 -0.1240 -0.5469 -0.6030 -0.0282 -0.0507 -0.3945 -0.0282 -0.0395 -0.7778 -0.0732 -1.1211 -0.0789 -0.0338 -0.0113 -1.5107 -0.1127 -0.4170 -0.0451 -0.0564 -0.0225 -0.0338 -0.0338', 'S-1951\tEs wird empfohlen, nach Abklingen der Neutropenie das Blutbild, die Leukozytenzahl, die Neutrophilen- und die Thrombozytenzahl drei Wochen lang jede Woche zu kontrollieren, um sicher sein zu können, dass sich der Patient von der Neutropenie vollständig erholt.', 'T-1951\tIt is recommended that following recovery from neutropenia, weekly CBC, WBC, neutrophil and platelet counts continue to be obtained for three consecutive weeks, to ensure that the patient recovers fully.', 'H-1951\t-2.033203125\tAfter both neutropenia and neutropenia have resolved it is recommended that blood counts , white blood cells , neutropenia and platelets be monitored every week for three weeks to ensure complete recovery of the patient .', 'D-1951\t-2.033203125\tAfter both neutropenia and neutropenia have resolved it is recommended that blood counts, white blood cells, neutropenia and platelets be monitored every week for three weeks to ensure complete recovery of the patient.', 'P-1951\t-0.8403 -0.3972 -0.1838 -0.1859 -0.0254 -0.0254 -0.3296 -1.9678 -0.4143 -0.0282 -0.0085 -0.7524 -1.7783 -0.2761 -0.0338 -0.3381 -0.2593 -0.4790 -0.3777 -0.0564 -0.4958 -0.0338 -1.1836 -0.5352 -0.0564 -0.6255 -0.0338 -0.0338 -1.0371 -0.3157 -0.0113 -0.1691 -0.3157 -0.5747 -0.0225 -1.0479 -0.4734 -0.3945 -0.4170 -0.0225 -0.5410 -0.8789 -1.6455 -0.3381 -0.7891 -0.0564 -0.0451 -0.1127 -0.0338', 'S-1178\tFALTSCHACHTEL FÜR EINE EINZELNE FLASCHE 2,5 ml + FALTSCHACHTEL FÜR 3 x 2,5 ml FLASCHEN + FALTSCHACHTEL FÜR 6 x 2,5 ml FLASCHEN', 'T-1178\t14 PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON FOR SINGLE BOTTLE 2.5 ml + CARTON FOR 3 x 2.5 ml BOTTLES + CARTON FOR 6 x 2.5 ml BOTTLES', 'H-1178\t-0.5126953125\tCARTON FOR SINGLE BOTTLE 2.5 ml + CARTON FOR 3 x 2.5 ml BOTTLES + CARTON FOR 6 x 2.5 ml BOTTLES', 'D-1178\t-0.5126953125\tCARTON FOR SINGLE BOTTLE 2.5 ml + CARTON FOR 3 x 2.5 ml BOTTLES + CARTON FOR 6 x 2.5 ml BOTTLES', 'P-1178\t-0.8877 -0.3049 -0.3105 -0.3127 -0.2479 -0.0113 -0.3127 -0.0113 -0.0099 -0.0042 -0.0662 -0.0324 -0.0113 -0.0986 -0.0789 -0.5396 -0.0254 -0.0986 -0.0169 -0.0338 -0.2227 -0.0282 -0.0141 -0.2903 -0.0395 -0.0282 -0.4028 -0.0310 -0.0169 -0.0085 -0.0507 -0.0310 -0.0254 -0.1071 -0.0141 -0.0338 -0.2563 -0.0169 -0.0113 -0.0282 -0.0282 -0.0197 -0.0225 -0.0169 -0.0225 -0.0085 -0.0395 -0.0310 -0.0338', 'S-154\tEU / 1 / 00 / 131 / 001 EU / 1 / 00 / 131 / 002 EU / 1 / 00 / 131 / 003 EU / 1 / 00 / 131 / 004 EU / 1 / 00 / 131 / 005 EU / 1 / 00 / 131 / 026', 'T-154\tEU / 1 / 00 / 131 / 001 EU / 1 / 00 / 131 / 002 EU / 1 / 00 / 131 / 003 EU / 1 / 00 / 131 / 004 EU / 1 / 00 / 131 / 005 EU / 1 / 00 / 131 / 026', 'H-154\t-0.1480712890625\tEU / 1 / 00 / 131 / 001 EU / 1 / 00 / 131 / 002 EU / 1 / 00 / 131 / 003 EU / 1 / 00 / 131 / 004 EU / 1 / 00 / 131 / 005 EU / 1 / 00 / 131 / 026', 'D-154\t-0.1480712890625\tEU / 1 / 00 / 131 / 001 EU / 1 / 00 / 131 / 002 EU / 1 / 00 / 131 / 003 EU / 1 / 00 / 131 / 004 EU / 1 / 00 / 131 / 005 EU / 1 / 00 / 131 / 026', 'P-154\t-0.0349 -0.0313 -0.0263 -0.0298 -0.0284 -0.0284 -0.0199 -0.0285 -0.0285 -0.0241 -0.0342 -0.0269 -0.0312 -0.0271 -0.0299 -0.0271 -0.0285 -0.0183 -0.0285 -0.0285 -0.0204 -0.0306 -0.0257 -0.0313 -0.0271 -0.0296 -0.0261 -0.0282 -0.0183 -0.0282 -0.0282 -0.0225 -0.0331 -0.0268 -0.0310 -0.0261 -0.0296 -0.0268 -0.0282 -0.0183 -0.0282 -0.0282 -0.0225 -0.0275 -0.0268 -0.0310 -0.0268 -0.0296 -0.0254 -0.0282 -0.0183 -0.0282 -0.0282 -0.0225 -0.0254 -0.0296 -0.0310 -0.0268 -0.0296 -0.0282 -0.0282 -0.0183 -0.0296 -0.0282 -0.0535 -0.0197 -0.0296', 'S-922\tDie Sicherheit und Wirksamkeit von Avastin zusätzlich zu einer Platin-haltigen Chemotherapie in der First-Line-Behandlung von Patienten mit nicht-kleinzelligem Bronchialkarzinom ohne Plattenepithel- Histologie wurde in den Studien E4599 und BO17704 untersucht.', 'T-922\tThe safety and efficacy of Avastin, in addition to platinum-based chemotherapy, in the first-line treatment of patients with non-squamous non-small cell lung cancer (NSCLC), was investigated in studies E4599 and BO17704.', 'H-922\t-1.0380859375\tThe safety and efficacy of Avastin in addition to platinum @-@ based chemotherapy were studied in first @-@ line treatment of patients with NSCLC without squamous cell histology in studies E4599 and BO17704 .', 'D-922\t-1.0380859375\tThe safety and efficacy of Avastin in addition to platinum-based chemotherapy were studied in first-line treatment of patients with NSCLC without squamous cell histology in studies E4599 and BO17704.', 'P-922\t-0.1158 -0.0170 -0.0277 -0.0305 -0.0127 -0.0141 -0.0292 -0.2534 -0.0113 -0.0257 -0.0694 -0.5928 -0.0282 -0.1360 -0.0254 -0.4861 -0.1155 -0.3340 -0.0197 -0.0099 -0.0169 -1.4609 -1.1045 -0.0395 -0.5103 -0.7241 -0.0282 -0.6987 -0.0958 -0.6426 -0.0564 -0.4678 -0.0732 -0.0113 -1.2344 -0.0958 -0.0056 -0.4338 -0.0225 -0.0225 -0.2537 -0.5073 -0.0338 -0.0113 -0.0113 -0.0338 -0.0225 -0.0225 -0.0225 -0.0225 -0.0395 -0.0282', 'S-602\tBei diesen Studien wurde Foetotoxizität, jedoch keine Teratogenizität in Ratten und Kaninchen nur bei intravenösen Dosen (größer als das Äquivalent von 4 mg / kg) und bei größerer (täglicher) Häufigkeit als bei den klinischen Anwendungen gefunden.', 'T-602\tIn these studies foetotoxicity, but not teratogenicity, occurred in rats and rabbits only at evaluated intravenous doses (greater than of equal to 4 mg / kg) and at greater frequency (daily) compared in the clinical use.', 'H-602\t-1.5302734375\tFoetotoxicity , but not teratogenicity , was found in rats and rabbits and was limited to intravenous doses ( greater than the equivalent of 4 mg / kg ) and higher frequency ( daily ) than the clinical exposure .', 'D-602\t-1.5302734375\tFoetotoxicity, but not teratogenicity, was found in rats and rabbits and was limited to intravenous doses (greater than the equivalent of 4 mg / kg) and higher frequency (daily) than the clinical exposure.', 'P-602\t-1.4355 -0.0141 -0.3198 -0.0268 -0.0155 -0.0211 -1.2295 -0.0760 -1.0537 -0.0254 -0.0225 -0.0254 -0.0338 -0.0085 -0.0225 -0.2141 -0.4226 -1.2598 -0.2593 -0.0732 -0.0338 -0.3325 -0.0113 -0.0225 -1.2227 -0.3494 -0.5747 -0.0451 -0.0958 -0.0338 -0.0113 -0.0225 -0.0451 -0.0225 -0.0620 -2.0684 -0.0282 -0.4058 -0.3269 -0.0338 -0.0789 -0.0113 -0.0338 -0.0113 -0.0338 -0.0901 -1.9502 -0.4509 -0.0789 -0.4958 -0.2817 -0.0338 -0.4058 -0.3945 -0.0338 -0.5972 -0.1691 -0.0338', 'S-342\t• wenn Sie überempfindlich (allergisch) gegen Clopidogrel oder einen der sonstigen Bestandteile von Iscover sind; • wenn Sie eine akute Blutung haben, beispielsweise verursacht durch ein Magengeschwür oder eine Hirnblutung; • wenn Sie an einer schweren Lebererkrankung leiden.', 'T-342\t• If you are allergic (hypersensitive) to clopidogrel or any of the other ingredients of Iscover; • If you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain; • If you suffer from severe liver disease.', 'H-342\t-0.798828125\t• If you are allergic ( hypersensitive ) to clopidogrel or any of the other ingredients of Iscover ; • If you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain ; • If you suffer from severe liver disease .', 'D-342\t-0.798828125\t• If you are allergic (hypersensitive) to clopidogrel or any of the other ingredients of Iscover; • If you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain; • If you suffer from severe liver disease.', 'P-342\t-0.3311 -1.2920 -0.0282 -0.0395 -0.3042 -0.0183 -0.2551 -0.1846 -0.0141 -0.0366 -0.0338 -0.0409 -0.0225 -0.0183 -0.0099 -0.0183 -0.0380 -0.1268 -0.0901 -0.0592 -0.3127 -0.1014 -0.1014 -0.0310 -0.0141 -0.0479 -0.0338 -0.2847 -0.0395 -0.2507 -0.3438 -0.3213 -0.1747 -0.3101 -0.2169 -0.3269 -0.3213 -0.3213 -0.0169 -0.2874 -0.0282 -0.1578 -0.1691 -0.0282 -0.0113 -0.1635 -0.3157 -0.0845 -0.3325 -0.0338 -0.0282 -0.0507 -0.0789 -0.1296 -0.0338 -0.5352 -0.0338 -0.1917 -0.0282 -0.0338 -0.1917 -0.0282', 'S-1530\tWenn nach etwa 6-monatiger Therapie persistierende Antikörper vermutet werden, entweder aufgrund einer verminderten Wirksamkeit oder aufgrund des Auftretens infusionsbedingter Ereignisse, lassen sich die Antikörper möglicherweise in einem Wiederholungstest 6 Wochen nach der ersten positiven Testung nachweislich belegen.', 'T-1530\tIf, after approximately 6 months of therapy, persistent antibodies are suspected, either due to reduced efficacy or due to occurrence of infusion-related events, they may be detected and confirmed with a subsequent test 6 weeks after the first positive test.', 'H-1530\t-1.8037109375\tIf , after approximately 6 months of therapy , persistent antibodies are suspected , either due to decreased efficacy or due to the occurrence of infusion related events , the antibodies may be demonstrated in a repeat test 6 weeks after the first positive test .', 'D-1530\t-1.8037109375\tIf, after approximately 6 months of therapy, persistent antibodies are suspected, either due to decreased efficacy or due to the occurrence of infusion related events, the antibodies may be demonstrated in a repeat test 6 weeks after the first positive test.', 'P-1530\t-0.4639 -0.9648 -0.1212 -0.8115 -0.0972 -0.0366 -0.0620 -0.6553 -0.0338 -0.6958 -0.0338 -0.0225 -0.0169 -0.0479 -0.0564 -1.2168 -0.0282 -0.3269 -0.0282 -0.9468 -0.0338 -0.1240 -0.0113 -0.0225 -0.0395 -1.4766 -0.0282 -0.3494 -1.1943 -0.0169 -0.0169 -0.0225 -0.0282 -0.8115 -0.2649 -1.2119 -0.3718 -0.2367 -0.6987 -0.4509 -0.0225 -0.5073 -0.2705 -1.0820 -0.0789 -0.9468 -0.7778 -0.5410 -0.5859 -0.0225 -0.0451 -0.8115 -0.1465 -0.0113 -0.4058 -0.0338 -0.0338', 'S-707\t24 * In klinischen Studien mit Sitagliptin als Monotherapie und Sitagliptin als Teil der Kombinationstherapie mit Metformin, waren die Häufigkeiten der unter Sitagliptin berichteten Hypoglykämien mit Sitagliptin mit der in der Plazebogruppe vergleichbar.', 'T-707\tIn clinical trials of sitagliptin as monotherapy and sitagliptin as part of combination therapy with metformin, rates of hypoglycaemia reported with sitagliptin were similar to rates in patients taking placebo.', 'H-707\t-0.9658203125\t21 * In clinical trials with sitagliptin as monotherapy and sitagliptin as part of combination therapy with metformin , rates of hypoglycaemia reported with sitagliptin were comparable with rates in the placebo group .', 'D-707\t-0.9658203125\t21 * In clinical trials with sitagliptin as monotherapy and sitagliptin as part of combination therapy with metformin, rates of hypoglycaemia reported with sitagliptin were comparable with rates in the placebo group.', 'P-707\t-2.0664 -0.0338 -0.1240 -0.0465 -0.6284 -0.9385 -0.1747 -0.0564 -0.0197 -0.0564 -0.7383 -0.3381 -0.0310 -0.0113 -0.0423 -0.0592 -0.0197 -0.0197 -0.0423 -0.1099 -0.0873 -0.0282 -0.2734 -0.0564 -0.0282 -0.0225 -0.0113 -0.0282 -0.0732 -0.3157 -0.0338 -0.0564 -0.0169 -0.0113 -0.2817 -0.0564 -0.0732 -0.0676 -0.2930 -0.0507 -0.0169 -0.0225 -0.0338 -0.5806 -0.7891 -0.0225 -0.7832 -0.5239 -0.2423 -0.2930 -0.0113 -0.0169 -0.0225 -0.0282 -0.0507 -0.0338 -0.0282', 'S-644\tZu den Arzneimitteln, die über CYP 2D6 metabolisiert werden, zählen Antidepressiva (trizyklische Antidepressiva und selektive Serotonin-Wiederaufnahmehemmer (SSRI)), Neuroleptika, Antiarrhythmika etc.', 'T-644\tExamples of medicines which are metabolised by CYP2D6 are antidepressants (tricyclics and SSRIs), neuroleptics, anti-arrhythmics, etc.', 'H-644\t-0.87646484375\tMedicinal products metabolised by CYP2D6 include antidepressants ( tricyclic antidepressants and selective serotonin reuptake inhibitors ( SSRIs ) ) , neuroleptics , antiarrhythmics , etc .', 'D-644\t-0.87646484375\tMedicinal products metabolised by CYP2D6 include antidepressants (tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs)), neuroleptics, antiarrhythmics, etc.', 'P-644\t-0.4590 -0.8257 -0.0437 -0.3000 -0.0211 -0.7144 -0.5718 -0.0507 -0.0282 -0.7495 -0.0197 -0.0225 -0.0282 -0.0507 -0.3071 -0.0085 -0.0197 -0.1945 -0.5522 -0.0423 -0.0169 -0.0310 -0.0648 -0.0085 -0.0225 -0.0254 -0.0423 -0.9834 -0.0113 -0.0225 -0.0225 -0.0169 -0.0282 -0.0732 -0.0056 -0.0113 -0.0225 -0.0056 -0.0113 -0.0282 -0.0395 -0.0169 -0.0225 -0.0451 -0.0282 -0.0338 -0.0282 -0.3213 -0.0225 -0.0282 -0.0282 -0.0338 -0.2986 -0.0056 -0.0113 -1.3525 -1.3584 -0.0282 -0.0282 -0.0282', 'S-1489\tWährend einer mittleren Behandlungsdauer von 53 Wochen wurde bei keinem der aufgenommenen Patienten unter Volibris ein bestätigter Anstieg der ALT-Serumkonzentration auf mehr als das Dreifache der oberen Normgrenze (> 3 x ULN) verzeichnet, der die dauernde Beendigung der Behandlung erforderlich gemacht hätte.', 'T-1489\tDuring a mean of 53 weeks of treatment with Volibris, none of the patients enrolled had a confirmed serum ALT > 3xULN that required permanent discontinuation of treatment.', 'H-1489\t-2.15625\tDuring a median duration of treatment of 53 weeks , no patients enrolled with Volibris experienced a confirmed increase in serum ALT concentrations more than three times the upper limit of normal ) ( &gt; 3 x ULN ) requiring permanent discontinuation of treatment .', 'D-1489\t-2.15625\tDuring a median duration of treatment of 53 weeks, no patients enrolled with Volibris experienced a confirmed increase in serum ALT concentrations more than three times the upper limit of normal) (> 3 x ULN) requiring permanent discontinuation of treatment.', 'P-1489\t-1.5205 -0.3000 -0.7690 -0.0254 -1.1162 -0.0282 -0.0282 -0.7070 -0.3945 -0.0141 -0.0254 -0.2085 -0.3240 -1.4541 -0.5859 -0.0113 -1.7637 -0.0507 -0.0225 0.0000 -1.4316 -0.7554 -0.0507 -0.0676 -0.0789 -0.3606 -0.0338 -0.2255 -0.0338 -1.5889 -0.0113 -0.0113 -0.6201 -0.0338 -1.0254 -0.3945 -0.4509 -0.5635 -0.3157 -0.1240 -0.3718 -1.9951 -0.0901 -0.1240 -1.0479 -0.0225 -0.1803 -0.0225 -0.0338 -1.3975 -0.4282 -0.7437 -0.0225 -0.0451 -0.4958 -0.0451 -0.0225 -0.0225', 'S-1979\tEs ist zu erwarten, dass die Symptome einer Fentanylüberdosierung mit denen von intravenös angewendetem Fentanyl und anderen Opioiden vergleichbar sind und eine Erweiterung der pharmakologischen Wirkungen darstellen, wobei die Atemdepression die schwerwiegendste Auswirkung darstellt.', 'T-1979\tThe symptoms of fentanyl overdose are expected to be similar in nature to those of intravenous fentanyl and other opioids, and are an extension of its pharmacological actions, with the most serious significant effect being respiratory depression.', 'H-1979\t-1.224609375\tSymptoms of fentanyl overdose are expected to be similar to those of intravenous fentanyl and other opioids and to increase pharmacological effects , the most serious effect being respiratory depression .', 'D-1979\t-1.224609375\tSymptoms of fentanyl overdose are expected to be similar to those of intravenous fentanyl and other opioids and to increase pharmacological effects, the most serious effect being respiratory depression.', 'P-1979\t-2.4238 -0.0042 -0.3086 -0.1395 -0.0127 -0.0085 -0.0254 -0.0169 -0.5581 -0.8086 -0.0620 -0.0282 -0.0282 -0.2141 -0.0338 -0.2649 -0.0535 -0.1240 -0.0310 -0.0085 -0.0817 -0.0423 -0.0113 -0.0113 -0.0225 -0.3325 -0.0282 -0.1493 -0.0225 -0.0169 -0.0113 -0.7554 -1.5381 -1.0205 -0.5469 -0.3438 -0.9185 -0.4509 -0.3101 -0.0338 -0.2141 -0.3042 -0.1578 -0.0451 -0.0113 -0.0225 -0.0338 -0.0338 -0.0338', 'S-1704\tPioglitazon ist auch angezeigt für die Kombination mit Insulin bei Patienten mit Typ 2 Diabetes mellitus, deren Blutzucker mit Insulin unzureichend eingestellt und bei denen Metformin aufgrund von Kontraindikationen oder Unverträglichkeit ungeeignet ist (siehe Abschnitt 4.4).', 'T-1704\tPioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4.4).', 'H-1704\t-1.013671875\tPioglitazone is also indicated for which the combination with insulin is indicated in patients with type 2 diabetes mellitus whose blood sugar levels are not adequately controlled by insulin and for whom metformin is inappropriate due to contraindications or intolerance ( see section 4.4 ) .', 'D-1704\t-1.013671875\tPioglitazone is also indicated for which the combination with insulin is indicated in patients with type 2 diabetes mellitus whose blood sugar levels are not adequately controlled by insulin and for whom metformin is inappropriate due to contraindications or intolerance (see section 4.4).', 'P-1704\t-0.0560 -0.0256 -0.0127 -0.0142 -0.0291 -0.0501 -0.0356 -0.0539 -0.3853 -0.7749 -0.3718 -0.3284 -0.0592 -0.0127 -0.0141 -0.3086 -0.9849 -0.1099 -0.8706 -0.0423 -0.2761 -0.0310 -0.0197 -0.2197 -0.0225 -0.0056 -0.5493 -0.1917 -0.1578 -0.5073 -0.1071 -0.2593 -0.2367 -0.0225 -0.2479 -1.1611 -0.0225 -0.2930 -0.2255 -1.0205 -0.0395 -0.0169 -0.0113 -0.0282 -0.0395 -0.7212 -0.4058 -0.0282 -0.0395 -0.0958 -0.0338 -0.0338 -0.0338 -0.0113 -0.1353 -0.0338 -0.0451 -0.1578 -0.0225 -0.0225 -0.0338 -0.0338 -0.0338', 'S-1578\tENGERIX B sollte intramuskulär verabreicht werden, bei Erwachsenen und älteren Kindern bevorzugt in die Region des M.deltoideus (Deltamuskel), bei Neugeborenen, Säuglingen und Kleinkindern in den ventro-lateralen Oberschenkelbereich.', 'T-1578\tENGERIX B should be injected intramuscularly in the deltoid region in adults and children or in the anterolateral thigh in neonates, infants and young children.', 'H-1578\t-1.6328125\tENGERIX B should be administered intramuscularly , preferably in adults and older children in the deltoid region , and in neonates , infants and toddlers in the deltoid region .', 'D-1578\t-1.6328125\tENGERIX B should be administered intramuscularly, preferably in adults and older children in the deltoid region, and in neonates, infants and toddlers in the deltoid region.', 'P-1578\t-0.0285 -0.0299 -0.0177 -0.0255 -0.0177 -0.0342 -0.0532 -0.0313 -0.6060 -0.0183 -0.6904 -0.0254 -0.0127 -0.0634 -0.0451 -0.3113 -0.1676 -0.2563 -0.1381 -0.8423 -0.0338 -0.2817 -0.3071 -2.1387 -0.0338 -0.2423 -0.0564 -0.0169 -0.9580 -0.1578 -0.8286 -1.2451 -1.0312 -0.0282 -0.0507 -0.0282 -0.3945 -0.0169 -0.7944 -1.5332 -0.0225 -0.1917 -0.0338 -0.8115 -0.0564 -0.0113 -0.7100 -1.3975 -0.0338', 'S-625\t(9 mg / ml) Natriumchloridlösung für Injektionszwecke, die dem Volumen der rekonstituierten Durchstechflaschen entspricht (für 2 Durchstechflaschen 20 ml, für 3 Durchstechflaschen 30 ml, für 4 Durchstechflaschen 40 ml entnehmen).', 'T-625\tsolution for injection equal to the volume of the reconstituted vials (for 2 vials remove 20 ml, for 3 vials remove 30 ml, for 4 vials remove 40 ml).', 'H-625\t-0.8818359375\twith sodium chloride injection equal to the volume of the reconstituted vials ( for 2 vials remove 20 ml , for 3 vials remove 30 ml , for 4 vials remove 40 ml ) .', 'D-625\t-0.8818359375\twith sodium chloride injection equal to the volume of the reconstituted vials (for 2 vials remove 20 ml, for 3 vials remove 30 ml, for 4 vials remove 40 ml).', 'P-625\t-2.0801 -1.9375 -0.0085 -0.0366 -0.0141 -0.0141 -0.0254 -1.6143 -0.0282 -0.5410 -0.0338 -0.1127 -0.1014 -0.0395 -0.2141 -0.2255 -0.0113 -0.0282 -0.0282 -0.0338 -0.0564 -0.1917 -0.0789 -0.0113 -0.0225 -0.3213 -0.0564 -0.0225 -0.0620 -0.0338 -0.0282 -0.0113 -0.0169 -0.3157 -0.0225 -0.0169 -0.0451 -0.0282 -0.0282 -0.0056 -0.0169 -0.1917 -0.0225 -0.0169 -0.0338 -0.0620 -0.0395', 'S-1291\tDie diagnostische Szintigraphie sollte 48 bis 72 Stunden nach der Radiojod-Verabreichung durchgeführt werden (72 bis 96 Stunden nach der letzten Injektion von Thyrogen), während die post-therapeutische Szintigraphie nach der Behandlung um weitere Tage hinausgezögert werden kann, damit die Hintergrundaktivität abnehmen kann.', 'T-1291\tDiagnostic scintigraphy should be performed 48 to 72 hours after the radioiodine administration (72 to 96 hours after the final injection of Thyrogen), whereas post-therapy scintigraphy may be delayed additional days to allow background activity to decline.', 'H-1291\t-1.54296875\tDiagnostic scintigraphy should be performed 48 to 72 hours following radioiodine administration ( 72 to 96 hours after the final Thyrogen injection ) , while post @-@ therapeutic scintigraphy may be delayed for several days after treatment to reduce background activity .', 'D-1291\t-1.54296875\tDiagnostic scintigraphy should be performed 48 to 72 hours following radioiodine administration (72 to 96 hours after the final Thyrogen injection), while post-therapeutic scintigraphy may be delayed for several days after treatment to reduce background activity.', 'P-1291\t-0.0487 -0.0213 -0.0249 -0.6162 -0.1705 -0.0190 -0.1655 -0.4001 -0.2255 -0.1874 -0.3030 -0.0141 -0.0211 -1.7441 -0.1521 -0.0366 -0.0338 -0.0197 -0.3945 -0.0310 -0.0254 -0.0338 -0.0197 -0.0169 -0.0789 -0.0732 -0.8423 -0.6934 -0.0225 -0.0169 -0.0564 -0.0451 -0.0113 -0.0338 -0.5635 -1.4482 -0.2311 -0.6538 -1.0479 -0.0225 -0.5469 -0.0958 -0.0225 -0.4226 -0.0338 -0.4846 -0.7100 -1.3975 -0.0564 -0.5859 -0.1465 -1.3408 -0.2367 -0.6875 -0.0451 -0.0338 -0.0338', 'S-564\tÄltere Patienten und Patienten mit eingeschränkter Nieren- oder Leberfunktion Bei älteren Menschen sowie bei Patienten mit schweren Nierenfunktionsstörungen oder mit Leberfunktionsstörungen treten erhöhte Paroxetin-Plasmaspiegel auf, aber der Schwankungsbereich dieser Plasmakonzentrationen überlappt sich mit demjenigen bei gesunden Erwachsenen.', 'T-564\tElderly and Renal / Hepatic Impairment Increased plasma concentrations of paroxetine occur in elderly subjects and in those subjects with severe renal impairment or in those with hepatic impairment, but the range of plasma concentrations overlaps that of healthy adult subjects.', 'H-564\t-1.3349609375\tElderly and Patients with Renal or Hepatic Impairment Increased plasma concentrations of paroxetine occur in the elderly and in patients with severe renal or hepatic impairment , but the range of concentrations overlaps with that in healthy adults .', 'D-564\t-1.3349609375\tElderly and Patients with Renal or Hepatic Impairment Increased plasma concentrations of paroxetine occur in the elderly and in patients with severe renal or hepatic impairment, but the range of concentrations overlaps with that in healthy adults.', 'P-564\t-0.6401 -0.0134 -0.4805 -0.6943 -0.0296 -0.0507 -0.5425 -0.0310 -0.7920 -0.6509 -0.0056 -0.2507 -0.4143 -0.1888 -0.0225 -0.2791 -0.0197 -0.0225 -0.3213 -0.0113 -0.0113 -0.5693 -0.0113 -0.0169 -0.2537 -0.0507 -0.0056 -0.0225 -0.0395 -0.1803 -0.0564 -1.0430 -0.0282 -0.7271 -0.7495 -0.1071 -0.0338 -0.0620 -1.4482 -0.0225 -0.4453 -0.2423 -0.0676 -0.0225 -0.2705 -0.1353 -0.0113 -0.0789 -0.6201 -0.0564 -0.1353 -0.1014 -0.0451 -0.3269 -0.0113 -0.0225 -0.2817 -0.0451 -0.0338 -0.2479 -0.6875 -1.2061 -0.0225 -0.4058 -0.0338 -0.0338', 'S-152\tAorten- und Mitralklappenstenose, obstruktive hypertrophe Kardiomyopathie Wie mit anderen Vasodilatatoren ist bei Patienten mit Aorten- oder Mitralklappenstenose oder obstruktiver hypertropher Kardiomyopathie besondere Vorsicht geboten.', 'T-152\tAortic and mitral valve stenosis, obstructive hypertrophic cardiomyophathy As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.', 'H-152\t-0.6025390625\tAortic and mitral valve stenosis , obstructive hypertrophic cardiomyopathy As with other vasodilators , special care should be taken in patients suffering from aortic or mitral stenosis or obstructive hypertrophic cardiomyopathy .', 'D-152\t-0.6025390625\tAortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy As with other vasodilators, special care should be taken in patients suffering from aortic or mitral stenosis or obstructive hypertrophic cardiomyopathy.', 'P-152\t-0.1158 -0.0184 -0.0199 -0.0502 -0.0285 -0.0070 -0.0141 -0.0715 -0.0255 -0.0178 -0.0271 -0.0169 -0.0613 -0.0648 -0.0197 -0.0197 -0.0560 -0.0155 -0.0169 -0.0070 -0.0099 -0.0169 -0.0292 -0.0197 -0.0120 -0.0296 -0.1162 -0.3367 -0.2734 -0.0648 -0.0183 -0.0268 -0.0155 -0.0085 -0.0380 -0.0592 -0.5806 -1.8584 -0.6875 -0.0282 -0.0395 -0.1155 -0.0282 -0.2903 -0.0338 -0.0423 -0.0169 -0.0169 -0.1691 -0.0225 -0.0028 -0.0141 -0.6172 -0.0225 -0.0169 -0.8174 -0.0395 -0.0169 -0.0169 -0.0169 -0.0113 -0.0282 -0.0056 -0.0056 -0.0169 -0.0282 -0.0225 -0.0113 -0.0282 -0.3325 -0.0282', 'S-851\tMetformin behandelten Gruppe (29,8 Ereignisse / 1000 Patientenjahre) gegenüber Diät allein (43,3 Ereignisse / 1000 Patientenjahre), p = 0,0023, sowie gegenüber den mit Sulfonylharnstoffen und mit Insulin allein behandelten Gruppen (40,1 Ereignisse / 1000 Patientenjahre), p = 0,0034;', 'T-851\tgroup (29.8 events / 1000 patient -ye ars) versus diet alone (43.3 events / 1000 patient-years), p = 0.0023, and versus the combined sulfonylurea and insulin monotherapy groups (40.1 events / 1000 patient-years), p = 0.0034.', 'H-851\t-0.5673828125\tgroup treated with metformin ( 29.8 events / 1000 patient @-@ years ) versus diet alone ( 43.3 events / 1000 patient @-@ years ) , p = 0.0023 , and versus the combined sulphonylurea and insulin monotherapy groups ( 40.1 events / 1000 patient @-@ years ) , p = 0.0034 ;', 'D-851\t-0.5673828125\tgroup treated with metformin (29.8 events / 1000 patient-years) versus diet alone (43.3 events / 1000 patient-years), p = 0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events / 1000 patient-years), p = 0.0034;', 'P-851\t-0.3223 -0.5005 -0.0542 -0.0578 -0.0042 -0.0310 -0.0472 -0.0388 -0.0268 -0.0310 -0.0585 -0.8286 -0.1409 -0.7778 -0.0395 -0.0282 -0.2255 -0.0507 -0.0592 -0.0282 -0.0254 -0.0282 -0.0282 -0.0282 -0.0310 -0.1493 -0.0254 -0.0310 -0.0282 -0.0282 -0.0366 -0.0282 -0.0225 -0.0254 -0.0197 -0.0254 -0.0958 -0.1550 -0.2141 -0.1888 -0.3550 -0.2113 -0.6396 -0.0507 -0.0451 -0.0676 -0.0282 -0.0395 -0.0732 -0.0113 -0.0113 -0.3269 -0.2255 -0.1353 -0.0901 -0.0451 -0.0282 -0.0225 -0.0282 -0.0282 -0.0282 -0.1353 -0.0169 -0.0282 -0.0282 -0.0282 -0.0338 -0.0225 -0.0282 -0.0169 -0.0169 -0.0169 -0.0507 -0.0282', 'S-1409\tPharmakovigilanzsystem Der Inhaber der Genehmigung für das Inverkehrbringen muss sicherstellen, dass ein Pharmakovigilanzsystem so, wie es in der Version 3.3 des Zulassungsantrages im Modul 1.8.1 beschrieben ist, zur Verfügung steht und funktionstüchtig ist, bevor und während das Arzneimittel in den Verkehr gebracht wird.', 'T-1409\tPharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 3.3 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.', 'H-1409\t-0.791015625\tPharmacovigilance system The MAH must ensure that the system of pharmacovigilance , as described in version 3.3 presented in Module 1.8.1 of the Marketing Authorisation Application , is in place and functioning before and whilst the product is on the market .', 'D-1409\t-0.791015625\tPharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 3.3 presented in Module 1.8.1 of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.', 'P-1409\t-0.3101 -0.0085 -0.0213 -0.0134 -0.0070 -0.0164 -0.0243 -0.3289 -0.0620 -0.6016 -0.3228 -0.3030 -0.0845 -0.0395 -0.2649 -0.2959 -0.2184 -0.0930 -0.0197 -0.0085 -0.0141 -0.0197 -0.2791 -0.0676 -0.1071 -0.0366 -0.1437 -0.0225 -0.0282 -1.0400 -0.0592 -0.3662 -0.0169 -0.0338 -0.0254 -1.0537 -0.1127 -0.0395 -0.3157 -0.0113 -0.0901 -0.0225 -0.1747 -0.0113 -0.0282 -0.0620 -0.0451 -0.3101 -0.0620 -0.0451 -0.2537 -0.2537 -0.0901 -0.0507 -0.3157 -0.0845 -0.2761 -0.0451 -0.3101 -0.0395 -0.0282 -0.0395 -0.0282', 'S-1813\tRegister für Schwangerschaften unter antiretroviraler Therapie (Antiretroviral Pregnancy Registry) Ein Register für Schwangerschaften unter antiretroviraler Therapie wurde zur Überwachung der maternalen bzw. fetalen Daten von Patientinnen, denen versehentlich während ihrer Schwangerschaft ISENTRESS verabreicht wurde, eingerichtet.', 'T-1813\tAnti-retroviral Pregnancy Registry To monitor maternal-foetal outcomes in patients inadvertently administered ISENTRESS while pregnant, an Anti-retroviral Pregnancy Registry has been established.', 'H-1813\t-1.5380859375\tAntiretroviral Pregnancy Registry A registry for exposed pregnancies with antiretroviral therapy was set up to monitor maternal and foetal data from patients inadvertently given ISENTRESS during pregnancy .', 'D-1813\t-1.5380859375\tAntiretroviral Pregnancy Registry A registry for exposed pregnancies with antiretroviral therapy was set up to monitor maternal and foetal data from patients inadvertently given ISENTRESS during pregnancy.', 'P-1813\t-1.5488 -0.0282 -0.0183 -0.0169 -0.3972 -0.0028 -0.0085 -0.0155 -0.0183 -1.4736 -0.1917 -0.0169 -0.8174 -0.7158 -0.1071 -0.0197 -0.0169 -1.5811 -0.8511 -0.0225 -0.0225 -0.0169 -0.6875 -0.5073 -0.9976 -0.0282 -0.4846 -0.1691 -0.5806 -0.0113 -0.2255 -0.1465 -0.5410 -0.0113 -0.0225 -0.1240 -0.6084 -0.4395 -0.9468 -0.0676 -0.0113 -0.0225 -1.0938 -0.0676 -0.0225 -0.0225 -0.0225 -0.0113 -0.3833 -0.1917 -0.0451 -0.0676', 'S-1381\tsich als Mitglied der Delegation der Europäischen Kommission an der Arbeit der Europäischen Arzneibuchkommission beteiligt und Vertreter des Sekretariats der Europäischen Arzneibuchkommission zu Sitzungen der Gemeinsamen CPMP / CVMP-Arbeitsgruppe Qualität und zu Sitzungen der Ad-hoc-Arbeitsgruppe der Inspektoren für Gute Herstellungspraxis einlädt.', 'T-1381\t10000 Useful web sites:', 'H-1381\t-1.318359375\tParticipates in the work of the European Pharmacopoeia Commission as part of the European Commission delegation and holds meetings of the Joint CPMP / CVMP Quality Working Party and the ad hoc EMEA Inspectors &quot; Working Party .', 'D-1381\t-1.318359375\tParticipates in the work of the European Pharmacopoeia Commission as part of the European Commission delegation and holds meetings of the Joint CPMP / CVMP Quality Working Party and the ad hoc EMEA Inspectors "Working Party.', 'P-1381\t-0.9009 -0.0183 -0.0873 -0.8276 -0.0310 -0.1973 -0.0310 -0.0296 -0.0535 -0.0380 -0.0070 -0.0070 -0.0268 -0.2156 0.0000 -0.0268 -0.3762 -0.2197 -0.3296 -0.0282 -0.0564 -0.7891 -0.0282 -0.1381 -0.0282 -0.2423 -2.5137 -0.2761 -0.0789 -0.0395 -0.3718 -0.0564 -0.0338 -0.0113 -0.0789 -0.0282 -0.0225 -0.0113 -0.5186 -0.0225 -0.1071 -0.0225 -0.6143 -0.3550 -0.9409 -0.6255 -0.0338 -0.0282 -1.0762 -0.3157 -0.0451 -0.7778 -0.0225 -0.2930 -0.4282 -0.1465 -0.0225 -0.6084 -0.0901 -0.0338', 'S-291\tDas kli nische Ansprechen wurde als Prozentsatz der Patienten, die eine Ansprechrate von ACR 20, 50 oder 70 erreichten, und als Prozentsatz der Patienten mit einer Besserung der Psoriasis-Arthritis- Ansprechkriterien (Psoriatic Arthritis Response Criteria, PsARC) ausgedrückt.', 'T-291\tClinical responses were expressed as percentages of patients achieving the ACR 20, 50, and 70 response and percentages with improvement in Psoriatic Arthritis Response Criteria (PsARC).', 'H-291\t-1.5947265625\tClinical response was expressed as the percentage of patients achieving ACR 20 , 50 or 70 responses , and the percent of patients with improvement in the Psoriatic Arthritis treatment Response Criteria ( PsARC ) .', 'D-291\t-1.5947265625\tClinical response was expressed as the percentage of patients achieving ACR 20, 50 or 70 responses, and the percent of patients with improvement in the Psoriatic Arthritis treatment Response Criteria (PsARC).', 'P-291\t-1.6572 -0.0296 -0.6074 -0.3296 -0.2874 -0.0732 -1.1865 -1.3584 -0.0338 -0.2029 -1.1719 -0.6030 -0.0395 -0.0338 -0.0282 -0.0225 -0.4565 -0.0169 -0.3606 -0.7437 -0.0564 -0.2255 -1.0254 -0.0451 -0.2255 -1.2627 -0.8452 -0.4058 -0.5859 -0.3042 -0.0338 -0.1917 -0.0338 -0.0225 -0.0113 -0.0113 -0.5747 -1.0596 -0.0113 -0.0338 -0.0225 -0.0338 -0.0338 -0.0338 -0.0225 -0.0225 -0.0338 -0.0338 -0.0338', 'S-660\tDoxazosin Winthrop [und andere Bezeichnungen] 4 mg Retardtabletten sind während der Stillzeit kontraindiziert, da sich der Wirkstoff in der Milch laktierender Ratten anreichert (siehe Abschnitt 5.3) und keine Informationen über einen Übergang des Arzneimittels in die Muttermilch beim Menschen vorliegen.', 'T-660\tDoxazosin Winthrop 4 mg prolonged release tablets and associated names [See Annex I] is contraindicated during lactation as the medicinal product accumulates in the milk of lactating rats (see section 5.3) and there is no information about the excretion of the medicinal product into human breast milk.', 'H-660\t-0.865234375\tDoxazosin Winthrop 4 mg prolonged release tablets and associated names is contraindicated during lactation as the medicinal product accumulates in the milk of lactating rats ( see section 5.3 ) and there is no information about the excretion of the medicinal product into human breast milk .', 'D-660\t-0.865234375\tDoxazosin Winthrop 4 mg prolonged release tablets and associated names is contraindicated during lactation as the medicinal product accumulates in the milk of lactating rats (see section 5.3) and there is no information about the excretion of the medicinal product into human breast milk.', 'P-660\t-0.2551 -0.0185 -0.0155 -0.0171 -0.0576 -0.0218 -0.0035 -0.0243 -0.3057 -0.0113 -0.3220 -0.3176 -0.0486 -0.3157 -0.1071 -0.0310 -0.4580 -0.3213 -0.3101 -0.4170 -0.0395 -0.0056 -0.0789 -0.5215 -0.0113 -0.0254 -0.2649 -0.1014 -0.8481 -0.0986 -0.2791 -0.2085 -0.0169 -0.0225 -0.0395 -0.2649 -0.1071 -0.0282 -0.0395 -0.0169 -0.0282 -0.0225 -0.0620 -0.0338 -0.2255 -0.0282 -0.0282 -0.0620 -0.0789 -0.2029 -0.3157 -0.0338 -0.0676 -1.2451 -0.1973 -0.3213 -0.2930 -0.0395 -0.0507 -0.0901 -0.2817 -0.0451 -0.0395 -0.1296 -0.1973 -0.3606 -0.0338 -0.0395 -0.0282', 'S-121\tEMEA / H / C / 910 / 07 EMEA / H / C / 910 / 08 EMEA / H / C / 910 / 09 EMEA / H / C / 910 / 10 EMEA / H / C / 910 / 11 EMEA / H / C / 910 / 12', 'T-121\tEMEA / H / C / 910 / 07 EMEA / H / C / 910 / 08 EMEA / H / C / 910 / 09 EMEA / H / C / 910 / 10 EMEA / H / C / 910 / 11 EMEA / H / C / 910 / 12', 'H-121\t-0.1929931640625\tEMEA / H / C / 910 / 07 EMEA / H / C / 910 / 08 EMEA / H / C / 910 / 09 EMEA / H / C / 910 / 10 EMEA / H / C / 910 / 11 EMEA / H / C / 910 / 12', 'D-121\t-0.1929931640625\tEMEA / H / C / 910 / 07 EMEA / H / C / 910 / 08 EMEA / H / C / 910 / 09 EMEA / H / C / 910 / 10 EMEA / H / C / 910 / 11 EMEA / H / C / 910 / 12', 'P-121\t-0.3643 -0.0141 -0.0243 -0.0356 -0.0356 -0.0299 -0.0236 -0.0306 -0.0211 -0.0264 -0.0327 -0.0264 -0.3223 -0.0141 -0.0225 -0.0331 -0.0373 -0.0289 -0.0254 -0.0296 -0.0197 -0.0254 -0.0310 -0.0218 -0.0254 -0.0148 -0.0225 -0.0310 -0.0352 -0.0282 -0.0225 -0.0296 -0.0183 -0.0240 -0.0310 -0.0197 -0.0254 -0.0155 -0.0225 -0.0310 -0.0352 -0.0296 -0.0211 -0.0296 -0.0169 -0.0240 -0.0324 -0.0324 -0.0254 -0.0155 -0.0225 -0.0310 -0.0254 -0.0296 -0.0211 -0.0296 -0.0183 -0.0240 -0.0310 -0.0268 -0.0254 -0.0141 -0.0225 -0.0310 -0.0310 -0.0282 -0.0225 -0.0296 -0.0183 -0.0240 -0.0324 -0.0282 -0.0310', 'S-1502\tDarüber hinaus blieben die anti-HPV-Antikörperkonzentrationen (GMTs) bei den Probanden, die den Impfstoff erhalten hatten, in der Langzeit-Nachbeobachtung der Phase III-Studien auf Höhe oder über der Nachweisgrenze (cut-off) (siehe nachstehend unter Persistenz).', 'T-1502\tFurthermore, anti-HPV levels (GMTs) in vaccinated subjects remained at or above serostatus cut-off during the long-term follow-up of the phase III studies (see below under Persistence).', 'H-1502\t-2.46484375\tFurthermore , anti @-@ HPV antibody concentrations ( GMTs ) in subjects who received the vaccine remained similar to or greater than the limit of detection ( see &quot; persistence &quot; below ) in the long @-@ term follow @-@ up of phase III studies .', 'D-1502\t-2.46484375\tFurthermore, anti-HPV antibody concentrations (GMTs) in subjects who received the vaccine remained similar to or greater than the limit of detection (see "persistence" below) in the long-term follow-up of phase III studies.', 'P-1502\t-1.6973 -0.0169 -0.0268 -0.0437 -2.4355 -0.0338 -0.0310 -0.0254 -0.0225 -1.1719 -0.0225 -1.3916 -0.0056 -0.0169 -0.3325 -0.6934 -0.0507 -0.0282 -0.0282 -0.5469 -0.4453 -0.3777 -0.3833 -0.1465 -0.0225 -0.7046 -1.5273 -0.8228 -0.2479 -1.1387 -0.0338 -0.5972 -1.9951 -0.2141 -0.6538 -0.0338 -1.0146 -0.0338 -1.8594 -1.4648 -0.0564 -0.0225 -0.0338 -0.1353 -0.0338 -0.7100 -1.1270 -0.3833 -0.2930 -0.0225 -0.0225 -0.0451 -0.0225 -0.6538 -1.7354 -0.0225 -0.7437 -0.0225 -0.0225', 'S-494\tAuch wurde die einigermaßen niedrige intra-individuelle Schwankung der Plasmakonzentrationen von Fentynal zur Kenntnis genommen, einschließlich der Schwankung in Zusammenhang mit der Flüssigkeitsaufnahme, Wunden im Mund, Xerostomie (Mundtrockenheit) und Mukositis (Schleimhautentzündung).', 'T-494\tThe reasonably low intra-individual variation in fentanyl plasma concentrations was also noted, including variation related to fluid intake, mouth wounds, xerostomia (dry mouth) and mucositis.', 'H-494\t-1.4453125\tThe relatively low intra @-@ individual variability in the plasma concentrations of fentynal has also been recognised , including variability associated with fluid intake , mouth wounds , xerostomia ( dry mouth ) and mucositis ( mucosal inflammation ) .', 'D-494\t-1.4453125\tThe relatively low intra-individual variability in the plasma concentrations of fentynal has also been recognised, including variability associated with fluid intake, mouth wounds, xerostomia (dry mouth) and mucositis (mucosal inflammation).', 'P-494\t-2.0137 -0.2466 -0.3269 -0.2072 -0.3564 -0.0338 -0.7437 -0.2283 -0.8481 -0.1635 -1.1104 -0.0901 -0.0282 -0.0113 -0.3833 -0.0113 -0.0169 -0.0395 -0.1973 -0.0113 -0.0169 -0.0282 -1.1611 -0.0732 -0.0282 -1.4199 -0.0507 -0.0338 -0.6143 -1.0029 -0.2817 -0.0338 -0.1014 -0.0225 -0.3494 -0.0225 -0.0338 -0.9355 -0.5522 -0.0338 -0.0225 -0.0113 -0.2255 -0.0564 -0.0676 -0.5410 -0.0113 -0.0338 -0.2817 -0.2705 -0.1014 -0.0451 -0.0113 -0.5972 -0.7437 -0.1014 -0.1803 -0.0564 -0.0113 -0.0338 -0.0338 -0.0338 -0.0338', 'S-609\tDer Ausschuss für Humanarzneimittel (CHMP) gelangte zu dem Schluss, dass die Vorteile von Glivec bei der Behandlung der oben aufgeführten Krankheiten, einschließlich derjenigen, für die nur begrenzte Daten vorlagen, gegenüber den Risiken überwiegen, und empfahl, die Genehmigung für das Inverkehrbringen von Glivec zu erteilen.', 'T-609\tThey recommended that Glivec be given marketing authorisation.', 'H-609\t-0.6201171875\tThe Committee recommended that Glivec be given marketing authorisation .', 'D-609\t-0.6201171875\tThe Committee recommended that Glivec be given marketing authorisation.', 'P-609\t-0.3933 -0.0120 -0.3223 -0.0690 -0.6328 -0.0148 -0.0240 -0.2240 -0.2917 -0.2930 -0.1000 -0.0155 -0.3071 -0.3213', 'S-983\t15 von 120 (13%) Patienten im Behandlungsarm mit REYATAZ + Ritonavir und 17 von 123 (14%) Patienten im Behandlungsarm mit Lopinavir + Ritonavir zeigten vier oder mehr der PI Mutationen Substitutionen L10, M46, I54, V82, I84 und L90.', 'T-983\tFifteen of 120 (13%) patients in the REYATAZ + ritonavir treatment arm and 17 of 123 (14%) patients in the lopinavir + ritonavir arm had four or more of the PI substitutions L10, M46, I54, V82, I84, and L90.', 'H-983\t-1.455078125\tOf 120 ( 13 % ) patients in the REYATAZ + ritonavir arm and 17 of 123 ( 14 % ) patients in the lopinavir + ritonavir arm , four or more of these PI mutations harbour substitutions L10 , M46 , I54 , V82 , I84 and L90 .', 'D-983\t-1.455078125\tOf 120 (13%) patients in the REYATAZ + ritonavir arm and 17 of 123 (14%) patients in the lopinavir + ritonavir arm, four or more of these PI mutations harbour substitutions L10, M46, I54, V82, I84 and L90.', 'P-983\t-2.9902 -0.7212 -0.0676 -0.3833 -0.0282 -0.0282 -0.2197 -0.4678 -0.3127 -0.3296 -0.0254 -0.0169 -0.0113 -0.0141 -0.1071 -0.0254 -0.0169 -0.0225 -0.5015 -0.4902 -0.0395 -0.7666 -0.0113 -0.0282 -0.0282 -0.0225 -0.0282 -0.1071 -0.2817 -0.0451 -0.1465 -0.3157 -0.0056 -0.0225 -0.0225 -0.0169 -0.0225 -0.0169 -0.0225 -0.0113 -1.2510 -0.7324 -0.0225 -0.0282 -0.3606 -0.8228 -0.1353 -0.5747 -0.0338 -1.5107 -2.3887 -0.2255 -0.0451 -0.0338 -1.0938 -0.0338 -0.0338 -0.0225 -0.0113 -0.0338 -0.0338 -0.0113 -0.0338 -0.0225 -0.0113 -0.0338 -0.0338 -0.0113 -0.6538 -0.0338 -0.0225 -0.0338 -0.0338', 'S-518\tMit Ausnahme von Untersuchungen mit Lamivudin, Adefovir-Dipivoxil und Tenofovir-Disoproxilfumarat wurden die Auswirkungen der gleichzeitigen Anwendung von Entecavir mit Arzneimitteln, die über die Niere ausgeschieden werden oder die Nierenfunktion beeinflussen,', 'T-518\tApart from lamivudine, adefovir dipivoxil and tenofovir disoproxil fumarate, the effects of coadministration of entecavir with medicinal products that are excreted renally or affect renal function have not been evaluated.', 'H-518\t-1.41796875\tWith the exception of studies with lamivudine , adefovir dipivoxil and tenofovir disoproxil fumarate , the effect of co @-@ administration of entecavir with medicinal products that are eliminated via the kidney or modulate renal function has not been studied .', 'D-518\t-1.41796875\tWith the exception of studies with lamivudine, adefovir dipivoxil and tenofovir disoproxil fumarate, the effect of co-administration of entecavir with medicinal products that are eliminated via the kidney or modulate renal function has not been studied.', 'P-518\t-1.4512 -0.0324 -0.0211 -0.0282 -1.9697 -1.0088 -0.0423 -0.0197 -0.0197 -0.0197 -0.0169 -0.0310 -0.2649 -0.0197 -0.0169 -0.0197 -0.3157 -0.0197 -0.0113 -0.0254 -0.0225 -0.0732 -0.0113 -0.0282 -0.0169 -0.0141 -0.0225 -0.1747 -0.0169 -0.0423 -0.0564 -0.2255 -0.0225 -0.0113 -0.0282 -0.0225 -0.4846 -0.0958 -1.0986 -0.0338 -1.2344 -0.0282 -0.2029 -0.0789 -0.2874 -0.1465 -0.3042 -0.0169 -0.5806 -0.1409 -0.6479 -0.0282 -0.3042 -0.0564 -0.5298 -0.0113 -0.8228 -0.4958 -0.0225 -0.5410 -0.2705 -1.5439 -0.0225 -0.1691 -0.0225 -0.0225 -0.5073 -0.5410 -0.0338 -0.3606 -0.5859 -0.0338', 'S-1175\tAufgrund der relativ niedrigen Anzahl an Patienten, die über längere Zeiträume behandelt wurden, wurde der Antragsteller aufgefordert, die Endergebnisse der Studien EN3267-005 und EN3267-007 sowie die vollständigen Daten der Sicherheitsanalyse von SUE als Voraussetzung für die Genehmigungen für das Inverkehrbringen vorzulegen.', 'T-1175\tHowever, due to the quite low number of patients exposed for a long time, the Applicant was asked to provide the final results of the studies EN3267-005 and EN3267-007 and the full safety analysis data on SAEs as conditions to the Marketing Authorisations.', 'H-1175\t-1.439453125\tDue to the relatively low number of patients exposed for a long time , the applicant was requested to submit the final results of the studies EN3267 @-@ 005 and EN3267 @-@ 007 and the full safety analysis data from SUE as conditions to the Marketing Authorisations .', 'D-1175\t-1.439453125\tDue to the relatively low number of patients exposed for a long time, the applicant was requested to submit the final results of the studies EN3267-005 and EN3267-007 and the full safety analysis data from SUE as conditions to the Marketing Authorisations.', 'P-1175\t-0.8052 -0.0155 -0.0275 -0.0444 -0.1050 -0.6201 -0.3833 -0.0282 -0.0197 -0.4622 -0.4932 -0.8765 -0.6846 -0.3240 -0.1973 -0.0592 -0.6313 -0.0282 -0.1859 -0.7944 -0.0282 -1.4766 -0.0113 -0.1071 -0.1071 -0.0958 -0.4058 -0.9409 -0.1691 -0.0395 -0.0225 -0.0225 -0.0282 -0.0282 -0.0169 -0.0282 -0.0338 -0.0225 -0.0225 -0.0225 -0.0225 -0.0282 -0.0225 -0.0225 -1.2793 -0.9019 -0.2141 -0.2367 -0.2817 -0.0451 -0.6313 -0.0225 -0.0225 -0.4846 -0.4734 -0.7100 -0.3157 -0.6084 -0.0564 -0.0338 -0.5298 -0.0225 -0.0451 -0.0338', 'S-453\tIn zwei Placebo-kontrollierten Monotherapie-Studien mit flexibler Dosierung über 3 Wochen mit Patienten mit einer manischen oder gemischten Episode der Bipolar-I-Störung zeigte Aripiprazol eine gegenüber Placebo überlegene Wirksamkeit bei der Verringerung manischer Symptome über 3 Wochen.', 'T-453\tIn two 3-week, flexible-dose, placebo-controlled monotherapy trials involving patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole demonstrated superior efficacy to placebo in reduction of manic symptoms over 3 weeks.', 'H-453\t-1.23046875\tIn two 3 @-@ week , placebo @-@ controlled , flexible @-@ dose monotherapy trials involving patients with a manic or mixed episode of Bipolar I Disorder , aripiprazole demonstrated superior efficacy in reduction of manic symptoms over 3 weeks compared to placebo .', 'D-453\t-1.23046875\tIn two 3-week, placebo-controlled, flexible-dose monotherapy trials involving patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole demonstrated superior efficacy in reduction of manic symptoms over 3 weeks compared to placebo.', 'P-453\t-0.1934 -0.0414 -1.1191 -0.2776 -0.0620 -0.2690 -0.8677 -0.0211 -0.0211 -0.0268 -0.0535 -0.0338 -0.4114 -0.5239 -0.1212 -0.0845 -0.0789 -0.0310 -0.0169 -0.9976 -1.5889 -0.0507 -0.0564 -0.1409 -0.0507 -0.0169 -0.0338 -0.0507 -0.0113 -0.0282 -0.6650 -0.0225 -0.0169 -0.0451 -0.2705 -0.0395 -0.0901 -0.0732 -0.0169 -0.0282 -0.0113 0.0000 -1.0088 -0.0395 -0.0789 -0.0113 -0.0169 -0.8960 -1.2676 -0.0338 -0.3042 -0.0338 -0.0225 -0.5522 -0.7212 -0.0225 -0.9131 -0.0901 -0.2141 -0.0225 -0.0225 -0.0225 -0.0338 -0.0338', 'S-783\tDie Gabe von Cyclosporin A (ein ABCB1-, ABCC1 [MRP-1] - und CYP3A4-Inhibitor) mit oralem Topotecan führte zu einem ungefähr 2- bis -2.5-fachen Anstieg der Topotecan-AUC im Vergleich zur Kontrolle.', 'T-783\tCyclosporin A (an inhibitor of ABCB1, ABCC1 [MRP-1], and CYP3A4) administered with oral topotecan increased topotecan AUC to approximately 2-2.5-fold of control.', 'H-783\t-0.79248046875\tCyclosporin A ( an inhibitor of ABCB1 , ABCC1 &#91; MRP @-@ 1 &#93; , and CYP3A4 ) administered with oral topotecan increased topotecan AUC to approximately 2 - 2.5 @-@ fold of control .', 'D-783\t-0.79248046875\tCyclosporin A (an inhibitor of ABCB1, ABCC1 [MRP-1], and CYP3A4) administered with oral topotecan increased topotecan AUC to approximately 2 - 2.5-fold of control.', 'P-783\t-0.4216 -0.0204 -0.0162 -1.0088 -0.0338 -0.0873 -0.0549 -0.3325 -0.0070 -0.0113 -0.0282 -0.1057 -0.0338 -0.0268 -0.0225 -0.0479 -0.0310 -0.0141 -0.0099 -0.0282 -0.2690 -0.0099 -0.1747 -0.0282 -0.0310 -0.0268 -0.9678 -0.1775 -0.0310 -0.0254 -0.0282 -0.0225 -0.0141 -0.0423 -0.3042 -0.0197 -0.1550 -0.0958 -0.0451 -0.0310 -0.0282 -0.0395 -0.5439 -0.2339 -0.0282 -0.0282 -0.0282 -0.0732 -0.0676 -0.3325 -0.1747 -0.1803 -0.8452 -0.0451 -0.6030 -0.0338 -0.6592 -0.2705 -0.1521 -0.0338', 'S-1523\tDie Zugabe von TMZ als Begleittherapie zur RT, gefolgt von TMZ-Monotherapie bei der Behandlung von Patienten mit erstmalig diagnostiziertem Glioblastoma multiforme zeigte ein statistisch signifikante Verbesserung des Gesamtüberlebens (Overall Survival, OS) verglichen mit alleiniger RT (Abb.', 'T-1523\tThe addition of concomitant TMZ to RT, followed by TMZ monotherapy in the treatment of patients with newly-diagnosed glioblastoma multiforme demonstrated a statistically significant improvement in overall survival (OS) compared with RT alone (Figure 1).', 'H-1523\t-0.986328125\tThe addition of TMZ as adjunctive therapy to RT followed by TMZ monotherapy in the treatment of patients with newly @-@ diagnosed glioblastoma multiforme showed a statistically significant improvement in overall survival ( OS ) compared to RT alone ( Fig .', 'D-1523\t-0.986328125\tThe addition of TMZ as adjunctive therapy to RT followed by TMZ monotherapy in the treatment of patients with newly-diagnosed glioblastoma multiforme showed a statistically significant improvement in overall survival (OS) compared to RT alone (Fig.', 'P-1523\t-0.5757 -0.0229 -0.0313 -0.0356 -0.5757 -0.9946 -0.0127 -0.1635 -0.1859 -0.0986 -0.0254 -0.4932 -0.0310 -0.1240 -0.8623 -0.0282 -0.0141 -0.4678 -0.1606 -0.0451 -0.0282 -0.1127 -0.0479 -0.2676 -0.6763 -0.0113 -0.0282 -0.0113 -0.0169 0.0000 -0.0338 -0.0169 -0.0507 -0.0282 -1.4316 -0.3777 -0.0225 -0.0169 -0.0282 -0.0169 -0.0620 -0.6538 -0.0338 -0.0113 -0.2367 -0.0901 -0.0282 -0.0789 -0.6143 -0.0676 -0.3550 -0.0282 -0.5015 -0.0113 -0.0282 -0.0676', 'S-884\tIn reproduktionstoxikologischen Studien führte die wiederholte Verabreichung nur bei maternal toxischen Dosen (das 8-17fache der diagnostischen Dosis) zu einer Verzögerung der Embryonalentwicklung bei Ratten und zu einem Anstieg der Embryonalletalität bei Affen und Kaninchen.', 'T-884\tRepeated dosing in reproduction toxicological studies caused a retardation of embryonal development in rats and an increase in embryolethality in monkeys and in rabbits at maternally toxic dose levels (8 to 17 times', 'H-884\t-1.44140625\tRepeated dosing in reproductive toxicity studies caused a retardation of embryonic development in rats and an increase in embryonic albicity in monkeys and rabbits at maternally toxic dose levels ( 8 to 17 times the diagnostic dose ) only .', 'D-884\t-1.44140625\tRepeated dosing in reproductive toxicity studies caused a retardation of embryonic development in rats and an increase in embryonic albicity in monkeys and rabbits at maternally toxic dose levels (8 to 17 times the diagnostic dose) only.', 'P-884\t-0.2979 -0.1805 -0.2537 -0.3071 -0.7109 -0.2296 -0.0859 -0.5537 -0.3960 -0.0169 -1.2510 -0.0507 -0.3269 -0.2029 -0.3015 -0.0451 -0.3184 -0.8677 -0.1014 -0.0113 -0.5581 -0.8340 -0.0282 -0.0507 -0.3042 -0.2537 -0.1465 -0.0338 -0.2705 -0.0225 -0.0113 -0.4678 -0.9917 -0.7495 -0.6934 -0.0564 -0.1803 -0.0338 -0.0113 -0.0338 -0.3606 -0.0113 -0.0225 -0.3833 -0.1465 -0.3606 -0.4958 -0.0225 -0.8789 -0.2817 -0.1578 -0.0564 -1.0146 -0.0338 -0.0564 -0.1240 -0.0676 -0.0225 -0.0451 -0.0338 -0.4282 -0.0338 -0.0338', 'S-1967\t* rekombinanter murin- / human-chimärer monoklonaler Antikörper, gerichtet gegen die Interleukin-2- Rezeptor-α -Kette (CD25-Antigen), hergestellt in einer Maus-Myelom-Zelllinie mittels rekombinanter DNS-Technologie', 'T-1967\t* recombinant murine / human chimeric monoclonal antibody directed against the interleukin-2 receptor α -chain (CD25 antigen) produced in a mouse myeloma cell line by recombinant DNA technology.', 'H-1967\t-0.64306640625\t* recombinant murine / human chimeric monoclonal antibody directed against the interleukin @-@ 2 receptor α -chain ( CD25 antigen ) produced in a mouse myeloma cell line by recombinant DNA technology', 'D-1967\t-0.64306640625\t* recombinant murine / human chimeric monoclonal antibody directed against the interleukin-2 receptor α -chain (CD25 antigen) produced in a mouse myeloma cell line by recombinant DNA technology', 'P-1967\t-0.2129 -0.1305 -0.0278 -0.0120 -0.0342 -0.0955 -0.0257 -0.0402 -0.0134 -0.0760 -0.0183 -0.0342 -0.0204 -0.0247 -0.0092 -0.0120 -0.0204 -0.0345 -1.9219 -0.1521 -0.3213 -0.0310 -0.0085 -0.0282 -0.2986 -0.0395 -0.3550 -0.0113 -0.0310 -0.1578 -0.5073 -0.0338 -0.0310 -0.0085 -0.0282 -0.1747 -0.0028 -0.0282 -0.3071 -0.2423 -0.0732 -0.2479 -0.0113 -0.0113 -0.0225 -0.0056 -0.0113 -0.0338 -0.2930 -0.0732 -0.0225 -0.0113 -0.0395 -0.0169 -0.0507 -0.7100', 'S-1125\tIm Rahmen der Überwachung der Arzneimittelsicherheit nach der Zulassung wurde von vereinzelten, idiosynkratischen Fällen von Hypotonie und / oder Verschlechterung der Herzinsuffizienz bei Patienten mit einer beeinträchtigten kardialen Funktion berichtet, was möglicherweise durch die Verminderung der Serumcalciumspiegel vermittelt wurde.', 'T-1125\tIn post-marketing safety surveillance, isolated, idiosyncratic cases of hypotension and / or worsening heart failure have been reported in patients with impaired cardiac function, in which a causal relationship to cinacalcet could not be completely excluded and may be mediated by reductions in serum calcium levels.', 'H-1125\t-1.0498046875\tThere have been reports of isolated , idiosyncratic cases of hypotension and / or worsening heart failure in cinacalcet @-@ treated patients with impaired cardiac function in post @-@ marketing safety surveillance .', 'D-1125\t-1.0498046875\tThere have been reports of isolated, idiosyncratic cases of hypotension and / or worsening heart failure in cinacalcet-treated patients with impaired cardiac function in post-marketing safety surveillance.', 'P-1125\t-0.3223 -0.0923 -0.0313 -0.3923 -0.1268 -0.0430 -0.1902 -0.0120 -0.0197 -0.0141 -0.0106 -0.0500 -0.0310 -0.0232 -0.0077 -0.0225 -0.0423 -0.0324 -0.0296 -0.0240 -0.0507 -0.0042 -0.1888 -0.3960 -0.0169 -0.2494 -0.3269 -0.3213 -0.3213 -0.3213 -0.3213 -0.2705 -0.3213 -0.0225 -0.2593 -0.1183 -0.0085 -0.0141 -0.0113 -0.0310 -1.9072 -0.0958 -0.8174 -0.2423 -0.2761 -0.3438 -1.6396 -0.2930', 'S-1435\tTel: + 31- (0) 76 523 60 45 Norge CSL Behring AB Tlf: + 46- (0) 8-54496670 Österreich CSL Behring GmbH Tel: + 43- (0) 1-80101-0 Polska Imed Poland sp. z.o.o.', 'T-1435\tTel: + 31- (0) 76 523 60 45 Norge CSL Behring AB Tlf: + 46- (0) 8-54496670 Österreich CSL Behring GmbH Tel: + 43- (0) 1-80101-0 Polska Imed Poland sp. z. o. o.', 'H-1435\t-0.3271484375\tTel : + 31- ( 0 ) 76 523 60 45 Norge CSL Behring AB Tlf : + 46- ( 0 ) 8 @-@ 54496670 Österreich CSL Behring GmbH Tel : + 43- ( 0 ) 1 @-@ 80101 @-@ 0 Polska Imed Poland sp. z.o.o .', 'D-1435\t-0.3271484375\tTel: + 31- (0) 76 523 60 45 Norge CSL Behring AB Tlf: + 46- (0) 8-54496670 Österreich CSL Behring GmbH Tel: + 43- (0) 1-80101-0 Polska Imed Poland sp. z.o.o.', 'P-1435\t-0.1181 -0.0342 -0.0306 -0.0893 -0.0269 -0.0285 -0.0269 -0.0285 -0.0285 -0.0183 -0.0271 -0.0197 -0.0162 -0.0183 -0.0327 -0.0162 -0.0106 -0.0229 -0.0014 -0.0278 -0.0056 -0.0278 -0.0243 -0.0190 -0.0327 -0.0225 -0.0162 -0.0275 -0.0282 -0.0282 -0.0282 -0.0289 -0.0345 -0.0127 -0.0106 -0.0099 -0.0155 -0.5161 -0.0099 -0.0254 -0.0014 -0.0296 -0.0211 -0.0620 -0.0310 -0.0240 -0.0225 -0.0268 -0.0282 -0.0282 -0.0282 -0.0268 -0.0310 -0.0127 -0.0070 -0.0282 -0.0254 -0.2100 -0.0141 -0.0127 -0.0338 -0.0155 -0.0380 -0.0282 -1.3643 -0.3718 -0.0254 -0.0254 -0.0395 -0.0282', 'S-819\tVidaza wird bei Patienten angewendet, die ein mittleres bis hohes Risiko, dass die Krankheit zu AML oder Tod führt, aufweisen; <unk> chronische myelomonozytäre Leukämie (CMML, eine Art von Krebs der als Monozyten bezeichneten weißen Blutkörperchen).', 'T-819\tVidaza is used in patients with an intermediate to high risk of progressing to AML or death; <<unk>> chronic myelomonocytic leukaemia (CMML, a type of cancer affecting white blood cells called monocytes).', 'H-819\t-1.015625\tVidaza is used in patients with medium to high risk of AIDS resulting in AML or death ; chronic myelomonocytic leukaemia ( CMML , a type of cancer affecting white blood cells called monocytes ) .', 'D-819\t-1.015625\tVidaza is used in patients with medium to high risk of AIDS resulting in AML or death; chronic myelomonocytic leukaemia (CMML, a type of cancer affecting white blood cells called monocytes).', 'P-819\t-0.4434 -0.0271 -0.0099 -0.0384 -0.0782 -0.0518 -0.0458 -0.7876 -0.8691 -0.0789 -0.0395 -0.0916 -0.2776 -1.7373 -0.0254 -0.5918 -0.0338 -0.0254 -0.0197 -0.2563 -0.0254 -0.8145 -0.5469 -0.1521 -0.0225 -0.0225 -0.0225 -0.0338 -0.0113 -0.0169 -0.0113 -0.4846 -0.0169 -0.0282 -0.0338 -0.0282 -0.0282 -0.0282 -0.0225 -0.1127 -0.0338 -0.1014 -0.0282 -0.0169 -0.9805 -0.6592 -0.0113 -0.0225 -0.3381 -0.0338 -1.0088 -0.0282 -0.0169 -0.0282 -0.0395 -0.0282', 'S-1391\tNach dem Absetzen von Sebivo wird Ihr Arzt Ihren Gesundheitszustand überwachen und regelmäßige Blutuntersuchungen durchführen, um Ihre Leber zu kontrollieren.Wenn Sie nach Beendigung der Behandlung neu auftretende oder ungewöhnliche Beschwerden bemerken, informieren Sie umgehend Ihren Arzt (siehe <unk> Wie ist Sebivo einzunehmen? <unk> im Abschnitt 3 dieser Gebrauchsinformation).', 'T-1391\tTell your doctor immediately about any new or unusual symptoms that you notice after stopping treatment (see <<unk>> If you stop taking Sebivo <<unk>> in section 3 of this leaflet).', 'H-1391\t-1.5234375\tYour doctor will monitor your health and do regular blood tests to check your liver after you stop taking Sebivo . If you notice any new or unusual symptoms after stopping treatment , notify your doctor immediately ( see How to take Sebivo ) .', 'D-1391\t-1.5234375\tYour doctor will monitor your health and do regular blood tests to check your liver after you stop taking Sebivo. If you notice any new or unusual symptoms after stopping treatment, notify your doctor immediately (see How to take Sebivo).', 'P-1391\t-0.8291 -0.0599 -0.1909 -0.1451 -0.1508 -1.0645 -0.2268 -0.4719 -0.1042 -0.0254 -0.0760 -0.1014 -0.9355 -0.1353 -0.0732 -0.1635 -0.6001 -0.5859 -1.1777 -0.0507 -0.0169 -0.0225 -0.4902 -0.3777 -0.0564 -1.0654 -0.6704 -0.1635 -0.1014 -0.0676 -0.3101 -0.9355 -0.5693 -0.2705 -0.4622 -1.4316 -0.0225 -0.0338 -0.0451 -0.3269 -0.0451 -0.0564 -0.3157 -0.0564 -0.1465 -0.0225 -0.0225 -0.0113 -0.7666 -0.0338 -0.0338', 'S-1064\t(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail @ emea.europa.eu http: / / www.emea.europa.eu © EMEA 2006 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Wie wurde die Wirksamkeit von Econor untersucht?', 'T-1064\t(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail @ emea. europa. eu http: / / www. emea. europa. eu © EMEA 2006 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged How has Econor been studied?', 'H-1064\t-0.58056640625\t( 44 @-@ 20 ) 74 18 84 00 Fax ( 44 @-@ 20 ) 74 18 84 16 E @-@ mail : mail @ emea. europa. eu http : / / www. emea. europa. eu © EMEA 2006 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged How has the effectiveness of Econor been studied ?', 'D-1064\t-0.58056640625\t(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail @ emea. europa. eu http: / / www. emea. europa. eu © EMEA 2006 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged How has the effectiveness of Econor been studied?', 'P-1064\t-0.0678 -0.0199 -0.0277 -0.0255 -0.0291 -0.0142 -0.0269 -0.0113 -0.0227 -0.0199 -0.0285 -0.0127 -0.0269 -0.0227 -0.0276 -0.0085 -0.0271 -0.0099 -0.0197 -0.0574 -0.0285 -0.0127 -0.0278 -0.0155 -0.0183 -0.0056 -0.3223 -0.0085 -0.3228 -0.3228 -0.2507 -0.0169 -0.0282 -0.0296 -0.0310 -0.3228 -0.2690 -0.0648 -0.0155 -0.3228 -0.0085 -0.3213 -0.2507 -0.3213 -0.0169 -0.0338 -0.0141 -0.0338 -0.0254 -0.0451 -0.0197 -0.0282 -0.0282 -0.0254 -0.0197 -0.0282 -0.0282 -0.0169 -0.0282 -0.1155 -0.0225 -0.0282 -0.0366 -0.3101 -0.0338 -0.0254 -0.0225 -0.0310 -0.0225 -0.0169 -0.0338 -0.0310 -0.1578 -1.8203 -0.1521 -0.7046 -0.0676 -0.0169 -0.0282 -0.0225 -0.0282 -0.0282 -0.2874 -0.0338 -0.0338', 'S-1369\tBei Lungenentzündung und chronischer Bronchitis war Ketek genauso wirksam wie Amoxicillin, Clarithromycin, Trovafloxacin, Amoxicillin / Clavulansäure und Cefuroxim-Axetil, wobei 82% bis 95% der Patienten am Ende der Behandlung symptomfrei waren.', 'T-1369\tFor pneumonia and chronic bronchitis, Ketek was as effective as amoxicillin, clarithromycin, trovafloxacin, amoxicillin / clavulanic acid and cefuroxime axetil, with between 82 and 95% of the patients having no symptoms at the end of treatment.', 'H-1369\t-0.77001953125\tFor pneumonia and chronic bronchitis , Ketek was as effective as amoxicillin , clarithromycin , trovafloxacin , amoxicillin / clavulanic acid and cefuroxime acetil , with 82 % to 95 % of patients asymptomatic at the end of treatment .', 'D-1369\t-0.77001953125\tFor pneumonia and chronic bronchitis, Ketek was as effective as amoxicillin, clarithromycin, trovafloxacin, amoxicillin / clavulanic acid and cefuroxime acetil, with 82% to 95% of patients asymptomatic at the end of treatment.', 'P-1369\t-1.6836 -0.1846 -0.0099 -0.0113 -0.2451 -0.4819 -0.0282 -0.0085 -0.0085 -0.0113 -0.4719 -0.0704 -0.0225 -0.0282 -0.0732 -0.1409 -0.0423 -0.0282 -0.0197 -0.0197 -0.0197 -0.0169 -0.0254 -0.0282 -0.0423 -0.0056 -0.0113 -0.0254 -0.0282 -0.0310 -0.0338 -0.0225 -0.0141 -0.0225 -0.0225 -0.0225 -0.0254 -0.0310 -0.0141 -0.0225 -0.0254 -0.0169 -0.0254 -0.0366 -0.0225 -0.0141 -0.1127 -0.0197 -0.6763 -0.0056 -0.0282 -0.0225 -0.1183 -0.0423 -1.0283 -0.1240 -0.0169 -0.6201 -0.1296 -0.0620 -0.4058 -0.3101 -0.0113 -0.0225 -0.0451 -0.6143 -0.5918 -0.0845 -0.0113 -0.0282 -0.7666 -0.0732 -0.0395 -0.0338 -0.1353 -0.0282 -0.0282', 'S-1760\tLapatinib war weder klastogen noch mutagen in einer Testbatterie, die einen Chromosomenaberrationstest an Zellen des chinesischen Hamsters, einen Ames-Test, einen Chromosomenaberrationstest an humanen Lymphozyten und einen Chromosomenaberrationstest am Knochenmark von Ratten in vivo einschloss.', 'T-1760\tLapatinib was not clastogenic or mutagenic in a battery of assays including the Chinese hamster chromosome aberration assay, the Ames assay, human lymphocyte chromosome aberration assay and an in vivo rat bone marrow chromosome aberration assay.', 'H-1760\t-1.158203125\tLapatinib was not clastogenic or mutagenic in a test battery , including a chromosomal aberration test in Chinese hamster cells , an Ames test , a chromosomal aberration test in human lymphocytes , and a in vivo chromosome aberration test in rat bone marrow .', 'D-1760\t-1.158203125\tLapatinib was not clastogenic or mutagenic in a test battery, including a chromosomal aberration test in Chinese hamster cells, an Ames test, a chromosomal aberration test in human lymphocytes, and a in vivo chromosome aberration test in rat bone marrow.', 'P-1760\t-0.1443 -0.0227 -0.0121 -0.0285 -0.0437 -0.6792 -0.1606 -0.0141 -0.0578 -0.0254 -0.0944 -0.0070 -0.0211 -0.0155 -0.3164 -0.0423 -1.1309 -0.0775 -0.5352 -0.8818 -0.7070 -0.4368 -0.0225 -0.0113 -0.2339 -0.0225 -0.0085 -0.0113 -0.3381 -0.6255 -0.1353 -0.5581 -0.0169 -0.0395 -0.0282 -0.2930 -0.0225 -0.0282 -0.8003 -0.0282 -0.0507 -0.2761 -0.0225 -0.0113 -0.7554 -0.0225 -0.0056 -0.2141 -0.1859 -0.1691 -0.0225 -0.0169 -0.0169 -0.0169 -0.0225 -0.8115 -0.0282 -0.1465 -0.5635 -0.0225 -0.0113 -1.1045 -0.0225 -0.0113 -0.6875 -0.0113 -0.2255 -0.3718 -0.0789 -0.6987 -0.0676 -0.0113 -0.0113 -0.0338 -0.0338', 'S-701\tDie Ergebnisse der Hauptindikatoren für die Wirksamkeit (die Anzahl der Patienten, bei denen die Behandlung anschlug, sowie die durchschnittliche Zeitdauer bis zum Fehlschlagen der Behandlung) standen zum Zeitpunkt der Beurteilung nicht zur Verfügung, so dass das Unternehmen Daten über die Veränderung der HIV-Menge im Blut der Patienten (Viruslast) nach einer Behandlungsdauer von 24 Wochen vorlegte.', 'T-701\tThe results of the main measures of effectiveness (the number of patients in whom treatment had been successful and the average time to the failure of treatment) were not available at the time of the assessment, so the company presented information on the change in the levels of HIV in the patients <<unk>> blood (viral load) after 24 weeks of treatment.', 'H-701\t-1.759765625\tThe results of the main measures of effectiveness ( the number of patients whose treatment responded and the average time taken for treatment to not function ) were not available at the time of assessment , so the company presented information on the change in the level of HIV in the patients &quot; blood ( viral load ) after 24 weeks of treatment .', 'D-701\t-1.759765625\tThe results of the main measures of effectiveness (the number of patients whose treatment responded and the average time taken for treatment to not function) were not available at the time of assessment, so the company presented information on the change in the level of HIV in the patients "blood (viral load) after 24 weeks of treatment.', 'P-701\t-1.1611 -0.5112 -0.2986 -0.6763 -0.1169 -0.3213 -0.0366 -0.2227 -0.0197 -0.0366 -0.1917 -0.0338 -0.0282 -0.0564 -1.0957 -0.3718 -1.2959 -0.6255 -0.0564 -0.4565 -0.1353 -0.6084 -0.3889 -0.2874 -0.0789 -0.9692 -0.8286 -0.0338 -0.1521 -0.1578 -0.0282 -0.0451 -0.0676 -0.0338 -0.0395 -1.5723 -1.1719 -0.6201 -0.0451 -0.1014 -0.5410 -0.8906 -0.5186 -0.1691 -0.0789 -0.0451 -0.2029 -0.9468 -0.0338 -0.0225 -0.0564 -0.1691 -1.4541 -0.1353 -0.0225 -0.0338 -0.0338 -0.2817 -0.0338 -0.3269 -0.2141 -0.0225 -0.4282 -0.0338 -0.0338 -0.0338', 'S-787\tDie physiologische Wirkung von PTH beinhaltet die Stimulation der Knochenbildung durch direkte Wirkung auf die knochenbildenden Zellen (Osteoblasten); indirekt bewirkt es eine Steigerung der intestinalen Calciumabsorption, eine Steigerung der tubulären Calcium-Reabsorption und der renalen Phosphat-Ausscheidung.', 'T-787\tPhysiological actions of PTH include stimulation of bone formation by direct effects on bone forming cells (osteoblasts) indirectly increasing the intestinal absorption of calcium and increasing the tubular re-absorption of calcium and excretion of phosphate by the kidney.', 'H-787\t-1.6455078125\tThe physiological effect of PTH involves stimulating bone formation by a direct action on bone forming cells ( osteoblasts ) ; it indirectly increases the intestinal absorption of calcium , increasing the tubular absorption of calcium and urinary excretion of phosphate .', 'D-787\t-1.6455078125\tThe physiological effect of PTH involves stimulating bone formation by a direct action on bone forming cells (osteoblasts); it indirectly increases the intestinal absorption of calcium, increasing the tubular absorption of calcium and urinary excretion of phosphate.', 'P-787\t-0.9819 -0.0760 -0.4775 -1.7949 -0.0310 -0.0338 -0.0310 -0.0197 -0.8706 -1.1133 -0.0282 -0.4255 -0.4622 -0.1521 -0.5186 -0.0169 -0.8228 -0.0395 -0.6650 -0.1859 -0.0282 -0.0338 -0.0451 -0.0113 -0.0169 -0.0225 -0.0169 -0.0282 -0.8398 -0.5806 -1.3525 -0.0113 -2.0410 -0.5522 -0.0338 -0.0225 -0.0338 -0.1917 -0.0225 -0.0338 -0.1578 -0.0113 -0.0225 -0.0451 -1.1943 -0.7100 -0.0676 -0.0113 -0.4395 -0.3157 -0.0113 -0.0338 -0.1353 -0.0113 -0.0225 -0.1127 -1.1045 -0.0564 -1.0703 -0.0113 -0.0338 -0.1014 -0.0225 -0.0338 -0.0451 -0.0338 -0.0338', 'S-1584\tLeflunomid ist ein antirheumatisches Basistherapeutikum (<unk> disease modifying antirheumatic drug <unk> (DMARD)) zur Behandlung von Erwachsenen mit: • aktiver rheumatoider Arthritis, • aktiver Psoriasis-Arthritis (Arthritis psoriatica),', 'T-1584\tLeflunomide is indicated for the treatment of adult patients with: • active rheumatoid arthritis as a "disease-modifying antirheumatic drug" (DMARD), • active psoriatic arthritis,.', 'H-1584\t-0.85009765625\tLeflunomide is indicated for the treatment of adult patients with : • active rheumatoid arthritis as a &quot; disease @-@ modifying antirheumatic drug &quot; ( DMARD ) , • active psoriatic arthritis .', 'D-1584\t-0.85009765625\tLeflunomide is indicated for the treatment of adult patients with: • active rheumatoid arthritis as a "disease-modifying antirheumatic drug" (DMARD), • active psoriatic arthritis.', 'P-1584\t-0.0313 -0.0135 -0.0263 -0.0099 -0.0213 -0.0386 -0.6919 -0.4648 -0.1092 -0.0289 -0.0310 -0.3875 -0.0873 -0.0423 -0.0634 -0.0507 -0.0535 -0.0254 -0.0183 -0.0183 -0.0211 -0.0113 -0.0169 -0.0169 -0.0155 -0.9648 -0.2874 -0.3213 -1.7666 -0.2930 -0.0113 -0.0282 -0.4958 -0.0395 -0.0282 -0.0169 -0.0338 -0.3662 -0.0732 -0.0395 -0.0225 -0.2930 -0.0225 -0.0282 -0.4902 -0.1465 -0.0169 -0.0056 -0.0225 -0.0845 -0.0169 -0.0169 -0.0169 -0.6479 -0.5239', 'S-1044\tEinschränkung der Leber- und Nierenfunktion Obwohl die Unbedenklichkeit und Wirksamkeit von Hydroxocobalamin bei Patienten mit eingeschränkter Leber- und Nierenfunktion nicht untersucht wurde, ist eine Dosisanpassung bei diesen Patienten nicht erforderlich, da Cyanokit nur als Notfallbehandlung in einer akuten lebensbedrohlichen Situation angewendet wird.', 'T-1044\tRenal and hepatic impairments Although the safety and efficacy of hydroxocobalamin have not been studied in renal and hepatic impairments, Cyanokit is administered as emergency therapy in an acute, life-threatening situation only and no dosage adjustment is required in these patients.', 'H-1044\t-1.697265625\tHepatic and renal impairment Although the safety and efficacy of hydroxocobalamin in patients with hepatic or renal impairment has not been evaluated , no dose adjustment is necessary in these patients since Cyanokit is only used as an emergency treatment in an acute life @-@ threatening situation .', 'D-1044\t-1.697265625\tHepatic and renal impairment Although the safety and efficacy of hydroxocobalamin in patients with hepatic or renal impairment has not been evaluated, no dose adjustment is necessary in these patients since Cyanokit is only used as an emergency treatment in an acute life-threatening situation.', 'P-1044\t-0.8594 -0.0225 -0.2944 -0.2593 -0.0564 -0.0211 -0.2847 -0.0169 -0.0099 -0.0282 -0.7451 -1.1436 -0.0338 -0.0338 -0.0760 -0.0085 -0.0169 -0.0310 -0.0395 -0.0225 -0.0310 -0.0310 -0.0141 -0.0901 -1.4316 -0.2986 -0.0338 -0.8564 -0.0338 -0.0225 -1.0938 -0.0676 -0.0225 -0.0338 -0.0056 -0.0113 -0.0338 -1.0146 -0.0282 -0.0338 -0.8511 -0.0282 -0.0395 -2.1309 -0.5186 -0.0564 -0.0113 -0.2593 -0.0676 -0.7778 -0.3833 -0.2593 -0.0225 -0.8564 -0.9468 -0.0338 -0.1014 -0.1803 -0.0451 -0.8115 -0.6426 -0.0564 -0.2255 -0.0113 -0.1014 -1.4199 -1.6904 -0.1691 -0.0113 -0.3606 -0.2479 -0.0225 -0.0338 -0.0338 -0.0338', 'S-84\tDie folgende Tabelle zeigt die Häufigkeit und Schwere unerwünschter Wirkungen, die in > 5% von 168 Patienten mit Mesotheliom berichtet wurden und die randomisiert Cisplatin und Pemetrexed er- hielten sowie 163 Patienten mit Mesotheliom, die randomisiert Cisplatin als Monotherapie erhielten.', 'T-84\tThe table below provides the frequency and severity of undesirable effects that have been reported in > 5% of 168 patients with mesothelioma who were randomised to receive cisplatin and pemetrexed and 163 patients with mesothelioma randomised to receive single agent cisplatin.', 'H-84\t-0.8564453125\tThe table below shows the frequency and severity of undesirable effects that have been reported in &gt; 5 % of 168 patients with mesothelioma who were randomised to receive cisplatin and pemetrexed and 163 patients with mesothelioma who were randomised to receive cisplatin monotherapy .', 'D-84\t-0.8564453125\tThe table below shows the frequency and severity of undesirable effects that have been reported in > 5% of 168 patients with mesothelioma who were randomised to receive cisplatin and pemetrexed and 163 patients with mesothelioma who were randomised to receive cisplatin monotherapy.', 'P-84\t-0.1655 -0.8018 -0.0437 -0.9814 -0.1014 -0.2339 -0.2100 -0.0324 -0.0296 -0.0268 -0.0282 -0.3691 -0.1803 -0.0732 -0.1465 -0.4395 -0.3042 -0.0254 -0.0310 -0.0564 -0.0732 -0.0254 -0.0282 -0.4536 -0.0338 -0.0225 -0.2930 -0.0507 -0.0564 -0.0225 -0.0254 -0.0225 -0.0085 -0.5835 -0.3101 -0.0113 -1.5947 -0.0113 -0.0282 -0.0338 -0.0282 -0.0338 -0.0225 -0.0282 -0.0282 -0.0395 -0.0901 -0.0338 -0.0225 -0.0338 -0.0282 -0.5693 -0.7944 -0.0282 -0.0732 -0.0395 -0.0564 -0.0225 -0.0225 -0.0225 -0.0113 -0.0958 -0.2537 -0.0113 -0.0338 -0.0056 -0.0282 -0.0338 -0.0056 -0.0056 -0.0225 -0.0338 -0.0282 -1.0205 -0.0338 -0.0225 -0.0338 -0.0338', 'S-933\tFevaxyn Pentofel hat sich gegen die feline Leukämie, gegen Atemwegserkrankungen, die durch das feline Rhinotracheitisvirus, das feline Calicivirus und feline Chlamydia psittaci verursacht werden, sowie gegen Krankheiten verursacht durch das feline Panleukopenievirus als wirksam erwiesen.', 'T-933\tFevaxyn Pentofel has been shown to be effective against Feline Leukaemia, against respiratory diseases caused by Feline Rhinotracheitis virus, Feline Calicivirus and Feline Chlamydia psittaci, as well as against disease caused by Feline Panleukopenia virus.', 'H-933\t-1.181640625\tFevaxyn Pentofel has shown its effectiveness in treating feline leukaemia , respiratory disease caused by feline viral rhinotracheitis , feline calicivirus and feline calicivirus , and against diseases caused by feline panleucopenia virus .', 'D-933\t-1.181640625\tFevaxyn Pentofel has shown its effectiveness in treating feline leukaemia, respiratory disease caused by feline viral rhinotracheitis, feline calicivirus and feline calicivirus, and against diseases caused by feline panleucopenia virus.', 'P-933\t-1.1084 -0.0127 -0.0127 -0.0085 -0.0070 -0.0296 -0.0035 -1.1562 -1.0879 -1.2031 -0.1888 -0.0141 -0.6143 -0.7188 -0.0338 -0.0282 -0.0169 -0.2479 -0.0113 -0.0282 -0.0676 -0.6030 -0.0056 -0.0169 -0.2930 -0.3833 -0.0282 -0.1353 -0.0282 -0.3213 -0.0676 -0.0169 -0.0789 -0.0225 -0.0225 -0.0338 -0.0225 -0.0451 -0.0113 -0.0282 -0.1071 -0.0338 -0.0169 -0.8735 -0.0056 -0.0282 -0.6592 -0.2367 -0.0225 -0.3889 -0.1859 -0.9863 -1.0371 -0.2817 -0.0225 -0.2141 -0.0338 -0.0113 -0.0113 -0.3042 -0.0338 -0.0338 -0.1014 -0.0338 -0.0338', 'S-1060\tBEDINGUNGEN ODER EINSCHRÄNKUNGEN FÜR DIE ABGABE UND DEN ge GEBRAUCH, DIE DEM INHABER DER GENEHMIGUNG FÜR DAS INVERKEHRBRINGEN AUFERLEGT WERDEN än', 'T-1060\tTHE MARKETING AUTHORISATION HOLDER', 'H-1060\t-0.88623046875\tCONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER', 'D-1060\t-0.88623046875\tCONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER', 'P-1060\t-0.3762 -0.0306 -0.0070 -0.0141 -0.0070 -0.0183 -0.0546 -0.0211 -0.0916 -0.2458 -0.0225 -0.0740 -0.0232 -0.0613 -0.0240 -0.6758 -0.2705 -0.2803 -0.0409 -0.0169 -0.3184 -0.2817 -0.1831 -0.0873 -0.2197 -0.0789 -0.0225 -0.3213 -0.0704 -0.3213 -0.1042 -0.3184 -0.4338 -0.4199 -0.0789 -0.2001 -0.3042 -0.3269 -0.0676 -0.0338 -0.2817 -0.2986 -0.1183 -0.3213 -0.2930 -0.1578 -0.9072', 'S-1247\tApril 2002 beantragte Schweden ein Verfahren gemäß Artikel 31 der Richtlinie 2001 / 83 / EG, einschließlich Änderungen, bei der EMEA auf der Grundlage der Daten aus dem schwedischen medizinischen Geburtsregister, aufgrund derer nicht ausgeschlossen werden konnte, dass die Anwendung von Loratadin während des ersten Trimenons der Schwangerschaft mit einem erhöhten Risiko für eine Hypospadie verbunden sein könnte.', 'T-1247\tOn 25 April 2002, Sweden triggered a referral to the EMEA under Article 31 of Directive 2001 / 83 / EC, as amended, based on the data from the Swedish Medical Birth Registry, which could not exclude that the use of loratadine during the first trimester of pregnancy may be associated with increased risk of hypospadia.', 'H-1247\t-1.1015625\tOn 25 April 2002 , Sweden presented to the EMEA a referral under Article 31 of Directive 2001 / 83 / EC , as amended , reflecting the data from the Swedish Medical Birth Registry , which could not exclude that the use of loratadine during the first trimester of pregnancy may be associated with an increased risk of hypospadia .', 'D-1247\t-1.1015625\tOn 25 April 2002, Sweden presented to the EMEA a referral under Article 31 of Directive 2001 / 83 / EC, as amended, reflecting the data from the Swedish Medical Birth Registry, which could not exclude that the use of loratadine during the first trimester of pregnancy may be associated with an increased risk of hypospadia.', 'P-1247\t-0.3909 -1.0986 -0.0578 -0.0225 -0.1324 -0.0240 -0.9819 -0.4932 -0.0620 -0.0676 -0.0113 -0.0254 -0.3101 -0.3213 -0.0028 -0.1775 -0.0254 -0.0197 -0.0338 -0.0395 -0.0197 -0.0141 -0.0310 -0.0141 -0.0535 -0.0197 -0.2029 -0.3213 -0.1465 -0.0169 -0.2113 -1.8994 -0.0225 -0.3945 -0.1127 -0.1635 -0.0451 -0.0225 -0.1296 -0.0225 -0.0282 -0.0113 -0.2141 -0.4678 -0.4846 -0.3157 -0.0282 -0.3494 -0.0225 -0.2367 -0.8398 -0.0958 -0.0282 -0.0564 -0.0225 -0.1014 -0.0395 -0.3777 -0.0338 -0.0338 -0.0225 -0.0338 -0.0113 -0.0338 -0.0338 -1.1494 -0.1691 -0.0789 -0.0338 -0.7212 -0.0338 -0.0225 -0.0451 -0.3157 -0.0225 -0.0225 -0.3945 -0.0338 -0.0338', 'S-1747\tVerglichen mit der schnell freisetzenden Darreichungsform entsprach die relative Bioverfügbarkeit von Doxazosin aus Doxazosin Winthrop [und andere Bezeichnungen] 4 mg Retardtabletten im Fließgleichgewicht 54% bei der 4-mg-Dosis und 59% bei der 8-mg-Dosis.', 'T-1747\tAt steady-state, the relative bioavailability of doxazosin from Doxazosin Winthrop 4 mg prolonged release tablets and associated names [See Annex I] prolonged release tablets compared to immediate release form was 54% at the 4 mg dose and 59% at the 8 mg dose.', 'H-1747\t-0.818359375\tThe relative bioavailability of doxazosin from Doxazosin Winthrop 4 mg prolonged @-@ release compared to immediate release form was 54 % at the 4 mg dose and 59 % at the 8 mg dose .', 'D-1747\t-0.818359375\tThe relative bioavailability of doxazosin from Doxazosin Winthrop 4 mg prolonged-release compared to immediate release form was 54% at the 4 mg dose and 59% at the 8 mg dose.', 'P-1747\t-2.4492 -0.0211 -0.0155 -0.0296 -0.0338 -0.4734 -0.0141 -0.0338 -0.0169 -0.1493 -0.1719 -0.2563 -0.0197 -0.0169 -0.0169 -0.0564 -0.0197 -0.0028 -0.0254 -0.3184 -0.0113 -0.3213 -0.3157 -0.0254 -0.5269 -0.0254 -0.6509 -0.4734 -0.3494 -0.1127 -0.2537 -0.1521 -0.0789 -0.0282 -0.1521 -0.1296 -0.0620 -0.0113 -0.0338 -0.0620 -0.0169 -0.0225 -0.0338 -0.0901 -0.0282 -0.0056 -0.0113 -0.2761 -0.0507', 'S-1011\tNach einmal täglicher Gabe von je einem Tropfen 0,03% Bimatoprost in beide Augen über einen Zeitraum von zwei Wochen wurden innerhalb von 10 Minuten nach der Verabreichung die Plasmaspitzenspiegel erreicht, innerhalb von 1,5 Stunden nach der Anwendung sank die Konzentration im Blut unter die Nachweisgrenze (0,025 ng / ml).', 'T-1011\tAfter once daily ocular administration of one drop of 0.03% bimatoprost to both eyes for two weeks, blood concentrations peaked within 10 minutes after dosing and declined to below the lower limit of detection (0.025 ng / ml) within 1.5 hours after dosing.', 'H-1011\t-2.37890625\tFollowing once @-@ daily administration of 0.03 % bimatoprost to both eyes for a period of two weeks , peak plasma levels were achieved within 10 minutes of administration , with blood levels returning below the detection limit ( 0.025 ng / ml ) within 1.5 hours of application .', 'D-1011\t-2.37890625\tFollowing once-daily administration of 0.03% bimatoprost to both eyes for a period of two weeks, peak plasma levels were achieved within 10 minutes of administration, with blood levels returning below the detection limit (0.025 ng / ml) within 1.5 hours of application.', 'P-1011\t-1.2207 -0.4050 -1.0938 -0.4988 -0.5073 -0.0395 -0.2001 -0.0254 -0.0225 -0.7466 -0.0169 -0.0225 -0.0169 -0.0338 -0.0028 -1.2168 -0.0620 -0.0225 -0.4282 -1.2510 -1.5664 -0.0282 -0.3042 -0.0169 -0.1071 -0.7212 -0.4958 -0.0113 -0.0113 -0.6255 -0.3157 -1.3867 -0.2930 -0.0789 -0.0225 -1.1045 -0.9131 -2.3438 -1.3867 -1.0820 -0.8789 -1.1162 -0.5073 -0.2479 -1.1270 -0.0225 -0.5859 -0.0676 -0.0225 -0.0451 -0.0225 -0.0225 -0.0225 -0.0225 -0.0225 -0.4734 -0.1578 -0.0225 -0.8115 -1.4199 -0.0225 -0.0225', 'S-1273\tBei HIV-infizierten erwachsenen Patienten (n = 33, kombinierte Studien) betrug die mittlere Eliminationshalbwertszeit innerhalb eines Dosierungsintervalls von Atazanavir 12 Stunden im Steady State nach Einnahme von 300 mg täglich zusammen mit 100 mg Ritonavir einmal täglich zu einer leichten Mahlzeit.', 'T-1273\tIn HIV-infected adult patients (n = 33, combined studies) the mean half-life within a dosing interval for atazanavir was 12 hours at steady state following a dose of 300 mg daily with ritonavir 100 mg once daily with a light meal.', 'H-1273\t-1.4091796875\tIn HIV @-@ infected adult patients ( n = 33 , combined studies ) the mean elimination half @-@ life in a dosing interval of atazanavir was 12 hours at steady state when administered 300 mg daily with 100 mg ritonavir once daily with a light meal .', 'D-1273\t-1.4091796875\tIn HIV-infected adult patients (n = 33, combined studies) the mean elimination half-life in a dosing interval of atazanavir was 12 hours at steady state when administered 300 mg daily with 100 mg ritonavir once daily with a light meal.', 'P-1273\t-0.4941 -0.1902 -0.8481 -0.0437 -0.5605 -0.0380 -0.0352 -0.0254 -0.0240 -0.0197 -0.0493 -0.0718 -0.4128 -0.0296 -0.8765 -0.5747 -0.3042 -0.0254 -0.3269 -0.5972 -0.0423 -0.9355 -1.2285 -0.4734 -0.0620 -0.0395 -0.0169 -0.0564 -0.0282 -0.0225 -0.0169 -0.0169 -0.0225 -0.5581 -0.5298 -0.0451 -1.4141 -0.2311 -0.1747 -0.7666 -1.7354 -0.0338 -0.1240 -0.0338 -0.0564 -0.2705 -0.8677 -0.0225 -0.2255 -0.0225 -0.0113 -0.0225 -0.1014 -0.1465 -0.3157 -0.0676 -0.0338 -0.0451 -0.0338 -0.0338', 'S-593\tArixtra darf nicht angewendet werden: • wenn Sie überempfindlich (allergisch) gegen Fondaparinux-Natrium oder einen der sonstigen Bestandteile von Arixtra sind • wenn Sie eine schwere Blutung haben • wenn Sie eine bakterielle Infektion des Herzens haben • wenn Sie eine sehr schwere Nierenerkrankung haben.', 'T-593\tDo not use Arixtra: • if you are allergic (hypersensitive) to fondaparinux sodium or to any of the other ingredients of Arixtra • if you are bleeding excessively • if you have a bacterial heart infection • if you have very severe kidney disease. → Tell your doctor if you think any of these applies to you.', 'H-593\t-0.736328125\tDo not use Arixtra : • if you are allergic ( hypersensitive ) to fondaparinux sodium or to any of the other ingredients of Arixtra • if you are bleeding excessively • if you have a bacterial heart infection • if you have severe kidney disease .', 'D-593\t-0.736328125\tDo not use Arixtra: • if you are allergic (hypersensitive) to fondaparinux sodium or to any of the other ingredients of Arixtra • if you are bleeding excessively • if you have a bacterial heart infection • if you have severe kidney disease.', 'P-593\t-0.4177 -0.0320 -0.2759 -0.0634 -0.0225 -0.0070 -0.3882 -0.0359 -0.3157 -0.0268 -0.0395 -0.3071 -0.0169 -0.2734 -0.2141 -0.0113 -0.0423 -0.0338 -0.2986 -0.0718 -0.0085 -0.0254 -0.0197 -0.0423 -0.0085 -0.0395 -0.6821 -0.0423 -0.3411 -0.0620 -0.3718 -0.1775 -0.0507 -0.0141 -0.0225 -0.0085 -0.0507 -0.0225 -0.0310 -0.5581 -0.1945 -0.0141 -0.3213 -0.0225 -0.0113 -0.2141 -0.0225 -0.0338 -0.0338 -0.0676 -0.0169 -0.0169 -0.0169 -0.3494 -0.0282 -0.0169 -0.0282 -0.0282 -0.1409 -0.6934 -0.0282 -0.0169 -0.2649 -0.1973 -0.7554', 'S-421\tAuf der Grundlage zusätzlicher MHK-Daten aus verschiedenen Veröffentlichungen (einschließlich zweier Arbeiten aus dem Jahr 2004 über die Empfindlichkeit verschiedener Isolate aus Atemwegsproben von Schweinen aus Dänemark) und der Resistenzüberwachung durch das BVL in Deutschland im Jahr 2006 kann der CVMP die vorgeschlagene Änderung der Indikation billigen:', 'T-421\tOn the basis of further additional MIC data from various publications (including two 2004 published papers showing susceptibility of various isolates from pig respiratory samples from Denmark) and from resistance monitoring by the BVL in Germany in 2006, the CVMP can accept the proposed revision of the indication:', 'H-421\t-2.205078125\tOn the basis of any supplementary ( Denmark ) MIC data from several publications ( including two publications from 2004 on the sensitivity of various isolates from swine respiratory infections ) and the residue monitoring by the BVL in Germany in 2006 , the CVMP can accept the proposed revision of the indication :', 'D-421\t-2.205078125\tOn the basis of any supplementary (Denmark) MIC data from several publications (including two publications from 2004 on the sensitivity of various isolates from swine respiratory infections) and the residue monitoring by the BVL in Germany in 2006, the CVMP can accept the proposed revision of the indication:', 'P-421\t-1.7529 -0.0282 -0.0254 -0.0310 -1.4707 -1.1943 -0.0676 -0.0197 -1.0342 -0.9917 -0.6821 -0.3042 -0.3213 -0.0338 -1.1162 -0.5747 -0.0451 -0.0225 -0.0676 -0.3494 -0.0507 -0.8115 -0.0225 -1.5840 -0.0225 -0.1917 -1.2285 -0.3269 -0.0225 -0.0338 -1.3301 -0.0789 -0.0225 -1.4316 -0.7324 -0.0113 -0.1691 -0.0113 -0.0113 -1.0254 -0.0113 -0.5972 -0.2593 -0.2029 -1.5664 -1.1045 -0.7666 -1.6006 -0.0676 -0.2479 -0.0225 -0.0225 -0.0451 -0.0225 -0.7212 -0.0225 -0.0451 -0.5859 -0.0451 -0.0225 0.0000 -0.1578 -0.3157 -0.0451 -0.0451 -0.3157 -0.0225 -0.0676 -0.0451 -0.2029 -0.2255 -0.0225', "S-1795\tBei CYP2D6 'schlechten' (= '' poor '') Metabolisierern kann die gemeinsame Anwendung mit hochwirksamen Inhibitoren von CYP3A4 in höheren Plasmakonzentrationen von Aripiprazol resultieren im Vergleich zu CYP2D6 extensiven Metabolisierern.", 'T-1795\tIn CYP2D6 poor metabolisers, concomitant use of potent inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolizers.', 'H-1795\t-1.1416015625\tFor CYP2D6 metabolisers , co @-@ administration with potent inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to extensive metabolisers of CYP2D6 .', 'D-1795\t-1.1416015625\tFor CYP2D6 metabolisers, co-administration with potent inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to extensive metabolisers of CYP2D6.', 'P-1795\t-2.6270 -0.2085 -0.0240 -0.0282 -0.0254 -0.0225 -0.0282 -0.6763 -0.0113 -0.5859 -1.5244 -0.5664 -0.0282 -0.3042 -0.0395 -1.9443 -0.0395 -0.1071 -0.0113 -0.0113 -0.0282 -0.0507 -0.0282 -0.0225 -0.0282 -0.0282 -0.0113 -0.4058 -0.2197 -0.0282 -0.1578 -0.3101 -0.0113 -0.0169 -0.2761 -0.0113 -0.0169 -0.0282 -0.0451 -0.0225 -0.0225 -0.0225 -0.0056 -0.4395 -0.0732 -1.1494 -0.2255 -0.0113 -0.2141 -0.1127 -0.0338 -0.0225 -0.0225 -0.0225 -0.0225 -0.0225 -0.0338 -0.0338', 'S-630\tMicafungin zeigte während der Behandlung eine geringere Reduktion des durchschnittlichen Maximalwertes der geschätzten glomerulären Filtra- tionsrate (p < 0,001) und eine geringere Häufigkeit von infusionsbedingten Reaktionen (p = 0,001) als liposomales Amphotericin B.', 'T-630\tMicafungin demonstrated a smaller mean peak decrease in estimated glomerular filtration rate during treatment (p < 0.001) and a lower incidence of infusion-related reactions (p = 0.001) than liposomal amphotericin B.', 'H-630\t-1.4873046875\tMicafungin was associated with a lower reduction in mean peak glomerular filtration rate ( p &lt; 0.001 ) and a lower incidence of infusion @-@ related reactions ( p = 0.001 ) than liposomal amphotericin B during treatment .', 'D-630\t-1.4873046875\tMicafungin was associated with a lower reduction in mean peak glomerular filtration rate (p < 0.001) and a lower incidence of infusion-related reactions (p = 0.001) than liposomal amphotericin B during treatment.', 'P-630\t-0.2169 -0.0313 -0.0085 -0.0393 -2.8320 -0.3718 -0.0366 -0.6455 -0.4958 -0.3777 -0.1099 -0.5947 -1.0938 -1.7471 -0.0169 -0.0225 -0.0225 -0.0225 -0.0225 -0.0225 -0.2593 -0.5522 -0.0225 -0.0113 -0.0169 -0.0338 -0.0282 -0.0056 -0.0282 -0.2255 -1.0479 -0.8735 -1.0938 -0.0338 -0.0338 -0.4958 -0.0113 -0.8677 -0.8115 -0.0676 -0.0113 -0.0451 -0.0225 -0.0225 -0.0113 -0.0113 -0.0338 -1.0254 -0.0225 -0.0113 -0.0225 -0.0113 -0.0113 -0.0225 -0.0225 -0.0113 -0.0338 -0.0338 -0.6084 -0.3833 -0.0338 -0.0338', 'S-450\tIn einer kleinen Studie, in der die Kombination von Actos und Insulin bei 289 Patienten untersucht wurde, wiesen die Patienten, die Actos zusätzlich zu Insulin nahmen, eine Senkung der HbA1c-Werte von 0,69% nach 6 Monaten auf, verglichen mit 0,14% bei den Patienten, die zusätzlich Placebo nahmen.', 'T-450\tIn a small study examining the combination of Actos and insulin in 289 patients, patients adding Actos to insulin had a 0.69% reduction in HbA1c levels after 6 months, compared to 0.14% in those adding placebo.', 'H-450\t-1.087890625\tIn a small study examining the combination of Actos and insulin in 289 patients , patients taking Actos in addition to insulin had a 0.69 % reduction in HbA1c levels after six months , compared with 0.14 % in those taking placebo supplements .', 'D-450\t-1.087890625\tIn a small study examining the combination of Actos and insulin in 289 patients, patients taking Actos in addition to insulin had a 0.69% reduction in HbA1c levels after six months, compared with 0.14% in those taking placebo supplements.', 'P-450\t-0.6313 -0.0504 -0.0211 -0.1106 -0.7163 -0.0211 -0.1028 -0.0423 -0.0310 -0.4480 -0.0070 -0.0395 -0.0085 -0.0141 -0.0479 -0.0197 -0.0240 -0.0366 -0.0395 -0.8228 -0.2283 -0.0310 -0.0056 -0.0845 -0.0282 -0.0282 -0.0141 -0.3157 -0.3213 -0.0986 -0.6821 -0.0141 -0.0451 -0.1268 -0.0507 -0.1521 -0.0197 -0.0310 -0.0225 -0.0225 -1.3975 -0.3494 -0.8789 -0.0282 -0.1635 -0.0282 -0.5581 -0.0282 -0.0225 -0.0282 -0.1747 -0.6763 -0.6084 -0.2649 -0.0225 -0.0113 -0.0282 -1.1104 -0.8228 -0.0338 -0.0338', 'S-205\tAUC0- ∞ (I.E. <unk> h / dl) t 1 / 2 (h) Recovery (I.E. / dL / I.E. / kg) Cmax (I.E. / dl) Clearance (dl / kg <unk> h) MRT (h) VSS (dl / kg) * Geometrisches Mittel', 'T-205\t(IU / dl / IU / kg) Cmax (IU / dl) Clearance (dl / kg <<unk>> h) MRT (h) VSS (dl / kg) * Geometric Mean', 'H-205\t-0.65771484375\tAUC0- ∞ ( IU <unk> h / dl ) t 1 / 2 ( h ) Recovery ( IU / dL / IU / kg ) Cmax ( IU / dl )', 'D-205\t-0.65771484375\tAUC0- ∞ (IU <unk> h / dl) t 1 / 2 (h) Recovery (IU / dL / IU / kg) Cmax (IU / dl)', 'P-205\t-0.0249 -0.0502 -0.2859 -0.0285 -0.3359 -0.0282 -0.0359 -0.9531 -1.1338 -0.0507 -0.0310 -0.1803 -0.0282 -0.3777 -0.4565 -0.0338 -0.0282 -0.0282 -0.0141 -0.0254 -0.3184 -0.0141 -0.0113 -0.0282 -0.0225 -0.2169 -0.0451 -0.0310 -0.0225 -0.0310 -0.0254 -0.0535 -0.0366 -0.0141 -0.0282 -0.0338 -0.0225 -0.0282 -0.0225 -0.0169 -0.0366 -0.0141 -0.0282 -1.1357', 'S-88\tBitte folgen Sie unbedingt den Hinweisen 2), 3), 4) und 5), um den Transport der FOSAVANCE Tablette in den Magen zu erleichtern und um mögliche Reizungen der Speiseröhre (Ösophagus <unk> die Röhre, die Ihren Mund mit dem Magen verbindet) zu vermindern.', 'T-88\tIt is very important to follow instructions 2), 3), 4) and 5) to help the FOSAVANCE tablet reach your stomach quickly and help reduce the chance of irritating your gullet (oesophagus - the tube that connects your mouth with your stomach).', 'H-88\t-1.1357421875\tIt is very important to follow instructions 2 ) , 3 ) , 4 ) and 5 ) to help the ADROVANCE tablet reach your stomach quickly and help reduce the chance of irritating your gullet ( oesophagus - the tube that connects your mouth with your stomach ) .', 'D-88\t-1.1357421875\tIt is very important to follow instructions 2), 3), 4) and 5) to help the ADROVANCE tablet reach your stomach quickly and help reduce the chance of irritating your gullet (oesophagus - the tube that connects your mouth with your stomach).', 'P-88\t-0.5601 -0.0532 -1.1455 -0.0366 -0.3833 -0.0845 -0.2874 -0.0831 -0.0338 -0.0310 -0.0268 -0.0282 -0.0296 -0.0268 -0.0268 -0.2043 -0.0282 -0.0282 -0.1437 -0.4028 -0.2874 -0.3240 -1.5156 -0.3101 -0.1521 -0.0056 -0.1296 -0.0395 -0.3101 -0.2649 -0.0169 -0.4338 -0.2817 -0.3213 -0.3325 -0.2537 -0.3101 -0.0338 -0.1803 -1.4932 -0.4001 -0.9526 -0.0113 -0.0113 -0.0451 -0.2817 -0.0113 -0.0338 -0.0225 -0.0225 -0.3381 -0.0338 -0.0338 -0.1803 -0.0451 -0.0225 -0.0451 -0.0113 -0.3606 -0.1465 -0.0113 -0.0338 -0.0451 -0.0338', 'S-1492\tIm Vergleich mit einem Diuretikum (Hydrochlorothiazid - HCTZ) senkte 300 mg Riprazo nach einer 12-wöchigen Behandlung den systolischen / diastolischen Blutdruck um 17,0 / 12,3 mmHg gegenüber 14,4 / 10,5 mmHg unter 25 mg HCTZ.', 'T-1492\tCompared to a diuretic (hydrochlorothiazide - HCTZ), Riprazo 300 mg lowered systolic / diastolic blood pressure by 17.0 / 12.3 mmHg, compared to 14.4 / 10.5 mmHg for HCTZ 25 mg after 12 weeks of treatment.', 'H-1492\t-0.55322265625\tCompared to a diuretic ( hydrochlorothiazide - HCTZ ) , Ratio 300 mg lowered systolic / diastolic blood pressure by 17.0 / 12.3 mmHg , compared to 14.4 / 10.5 mmHg for HCTZ 25 mg after 12 weeks of treatment .', 'D-1492\t-0.55322265625\tCompared to a diuretic (hydrochlorothiazide - HCTZ), Ratio 300 mg lowered systolic / diastolic blood pressure by 17.0 / 12.3 mmHg, compared to 14.4 / 10.5 mmHg for HCTZ 25 mg after 12 weeks of treatment.', 'P-1492\t-0.2032 -0.0213 -0.3518 -0.0909 -0.0430 -0.0085 -0.0183 -0.0528 -0.0388 -0.0225 -0.0106 -0.0254 -0.0113 -0.0331 -0.0021 -0.0197 -0.0944 -0.0296 -0.0296 -0.0444 -0.0155 -0.0282 -0.1282 -0.5342 -1.7500 -0.2255 -0.0366 -0.0197 -0.2255 -0.0254 -0.0366 -0.0169 -0.0085 -0.0423 -0.0225 -0.0113 -0.0113 -0.0225 -0.0451 -0.0197 -0.0845 -0.0620 -0.0338 -0.0338 -0.0169 -0.0338 -0.1550 -0.0254 -0.0225 -0.3101 -0.1268 -0.1042 -0.0338 -0.0254 -0.0282 -0.0141 -0.0282 -0.0169 -0.0282 -0.0254 -0.3213 -0.2874 -0.0282 -0.0507 -0.0113 -0.3213 -0.0225 -0.1859 -0.0620 -0.0395 -0.2874 -0.0564 -0.0338 -0.0282', 'S-1052\tDiacomit wird als Zusatztherapie zu Clobazam und Valproat (andere Antiepileptika) zur Behandlung von generalisierten tonisch-klonischen Anfällen (schwere so genannte Grand-mal-Anfälle mit Bewusstlosigkeit) angewendet, wenn diese mit Clobazam und Valproat nicht angemessen kontrolliert werden können.', 'T-1052\tDiacomit is used as an add-on to clobazam and valproate (other anti-epileptic medicines) to treat generalised tonic-clonic seizures (major fits, including loss of consciousness) when these are not adequately controlled with clobazam and valproate.', 'H-1052\t-1.1640625\tDiacomit is used as an add @-@ on to clobazam and valproate ( other anti @-@ epileptic drugs ) to treat generalised tonic @-@ clonic seizures ( severe grand mal seizures , where the seizures are not adequately controlled with clobazam and valproate ) .', 'D-1052\t-1.1640625\tDiacomit is used as an add-on to clobazam and valproate (other anti-epileptic drugs) to treat generalised tonic-clonic seizures (severe grand mal seizures, where the seizures are not adequately controlled with clobazam and valproate).', 'P-1052\t-0.1068 -0.0227 -0.3213 -0.1420 -0.0465 -0.4941 -0.1036 -0.2607 -0.5479 -0.0352 -0.0338 -0.1761 -0.0859 -0.0155 -0.0113 -0.0817 -0.0380 -0.0197 -0.0225 -0.0296 -0.0352 -0.0521 -1.5527 -0.0310 -0.0085 -0.0085 -0.0225 -0.3042 -1.4092 -0.0282 -0.4001 -0.0395 -0.1859 -0.4338 -0.0282 -0.0338 -0.4001 -0.0113 -0.0958 -0.0564 -0.0113 -0.0169 -0.0338 -1.0479 -0.2255 -0.0451 -0.9072 -0.0056 -0.0169 -0.5410 -0.3101 -0.2986 -1.8936 -0.0225 -0.0225 -0.5186 -0.2367 -0.1691 -0.0225 -0.0451 -0.6875 -0.0338 -0.0113 -0.0113 -0.0451 -0.0451 -0.0113 -0.0225 -0.0338 -0.0564 -0.0338 -0.0338', 'S-592\tHinsichtlich der Überlebensrate der Patienten nach drei Jahren gab es in der Studie mit einer Zweierkombination von Immunsuppressiva einen signifikanten Unterschied zwischen Placebo und Daclizumab (88% gegenüber 96%; p = 0,017), nicht aber in der Studie mit einer Dreierkombination von Immunsuppressiva (94% gegenüber 92%).', 'T-592\tThe three year patient survival rate was significantly different between placebo and daclizumab in the', 'H-592\t-1.6162109375\tThere was a significant difference between placebo and daclizumab ( 88 % versus 96 % ; p = 0.017 ) on the double immunosuppressive trial in terms of survival at three years , but not in the triple immunosuppressive study ( 94 % versus 92 % ) .', 'D-592\t-1.6162109375\tThere was a significant difference between placebo and daclizumab (88% versus 96%; p = 0.017) on the double immunosuppressive trial in terms of survival at three years, but not in the triple immunosuppressive study (94% versus 92%).', 'P-592\t-2.8340 -0.0310 -0.0352 -0.0310 -0.0282 -0.2141 -0.2141 -0.0225 -0.0197 -0.0254 -0.0282 -0.0310 -0.0282 -0.0225 -0.0085 -0.0197 -0.0225 -1.8740 -0.0085 -0.0338 -0.2197 -0.0113 -0.0197 -0.4282 -0.0225 -0.0225 -0.0282 -0.0225 -0.0338 -1.5723 -0.1859 -0.9468 -0.3269 -0.0169 -0.0169 -0.0056 -0.0225 -0.8228 -0.4282 -1.5781 -1.7812 -0.0338 -0.8003 -0.4509 -0.6875 -0.0338 -0.8115 -0.0789 -0.1465 -0.3945 -0.0451 -0.3718 -1.0820 -0.0225 -0.0225 -0.0113 -0.0225 -0.0451 -0.8906 -0.0338 -0.0113 -0.0225 -0.1240 -0.0113 -0.0225 -0.0338 -0.0338 -0.0338', 'S-1639\tElektrokardiographische Veränderungen Ein erhöhter Blutspiegel an Gadofosveset (z.B. nach kurzfristiger wiederholter Anwendung [innerhalb von 6-8 Stunden] oder durch versehentliche Überdosierung > 0,05 mmol / kg) kann mit geringfügigen Verlängerungen des QT-Intervalls verbunden sein (8,5 ms mittels Korrektur nach Fridericia).', 'T-1639\t3 Electrocardiographic Changes Elevated levels of gadofosveset (e. g. repeated use in the short term [within 6-8 hours], or an inadvertent overdose > 0.05 mmol / kg) may be associated with mild QT prolongation (8.5 msec by Fridericia correction).', 'H-1639\t-1.9443359375\tElectrocardiographic changes Elevated levels of gadofosveset in your blood ( e. g. after repeated use for a short period of time ( within 6 @-@ 8 hours ) or by accidental overdose &gt; 0.05 mmol / kg ) may be associated with a slight prolongation of the QT interval ( 8.5 msec by Frederica &quot; s Correction ) .', 'D-1639\t-1.9443359375\tElectrocardiographic changes Elevated levels of gadofosveset in your blood (e. g. after repeated use for a short period of time (within 6-8 hours) or by accidental overdose > 0.05 mmol / kg) may be associated with a slight prolongation of the QT interval (8.5 msec by Frederica "s Correction).', 'P-1639\t-0.7544 -0.0197 -0.0113 -0.0310 -0.0606 -1.9102 -0.8311 -0.0395 -0.0282 -0.3411 -0.0366 -0.7637 -0.0113 -0.0873 -0.0113 -0.0225 -0.0254 -0.8818 -1.4033 -0.0225 -0.0338 -0.8398 -0.0338 -0.2423 -0.4453 -0.5522 -1.3135 -0.5918 -0.9976 -0.0338 -1.0596 -0.1803 -0.0338 -0.9692 -0.2255 -0.0451 -0.0564 -0.0225 -0.0338 -0.0451 -0.2705 -0.6875 -0.2255 -0.0113 -0.0451 -0.5522 -0.1240 -0.0225 -0.0338 -0.0338 -0.0225 -0.0225 -0.0338 -0.0225 -0.0338 -0.4958 -0.0901 -0.0676 -0.0338 -1.0596 -1.0938 -0.8452 -0.0564 -0.0225 -0.5522 -0.6763 -0.0225 -0.0225 -0.5635 -0.0113 -0.0338 -0.0338 -0.0451 -0.3042 -0.0901 -0.1353 -1.8262 -1.2627 -0.5859 -0.3381 -0.3157 -0.3606 0.0000 -0.1127 -0.0451 -0.0225 -0.0225', 'S-1033\tTel: + 421 220 663 111 Suomi / Finland Oy Eli Lilly Finland Ab Puh / Tel: + 358- (0) 9 85 45 2 50 Sverige Eli Lilly Sweden AB Tel: + 46 (0) 8 7378800 United Kingdom Daiichi Sankyo UK Ltd Tel: + 44 (0) 1753 893 600', 'T-1033\tTel: + 421 220 663 111 Suomi / Finland Oy Eli Lilly Finland Ab Puh / Tel: + 358- (0) 9 85 45 250 Sverige Eli Lilly Sweden AB Tel: + 46 (0) 8 7378800 United Kingdom Daiichi Sankyo UK Ltd Tel: + 44 (0) 1753 893 600', 'H-1033\t-0.182861328125\tTel : + 421 220 663 111 Suomi / Finland Oy Eli Lilly Finland Ab Puh / Tel : + 358- ( 0 ) 9 85 45 2 50 Sverige Eli Lilly Sweden AB Tel : + 46 ( 0 ) 8 7378800 United Kingdom Daiichi Sankyo UK Ltd Tel : + 44 ( 0 ) 1753 893 600', 'D-1033\t-0.182861328125\tTel: + 421 220 663 111 Suomi / Finland Oy Eli Lilly Finland Ab Puh / Tel: + 358- (0) 9 85 45 2 50 Sverige Eli Lilly Sweden AB Tel: + 46 (0) 8 7378800 United Kingdom Daiichi Sankyo UK Ltd Tel: + 44 (0) 1753 893 600', 'P-1033\t-0.0560 -0.0313 -0.0277 -0.0256 -0.0213 -0.0128 -0.0242 -0.0148 -0.0099 -0.0349 -0.0028 -0.0299 -0.0185 -0.0185 -0.0285 -0.0271 -0.0197 -0.0278 -0.0056 -0.0218 -0.0197 -0.0211 -0.3181 -0.0359 -0.0197 -0.0275 -0.0169 -0.0289 -0.0232 -0.0859 -0.0254 -0.0268 -0.0268 -0.0254 -0.0282 -0.0232 -0.0190 -0.0176 -0.2944 -0.0240 -0.0268 -0.0155 -0.0014 -0.0141 -0.0296 -0.0056 -0.0240 -0.0183 -0.0056 -0.0268 -0.0282 -0.0225 -0.0155 -0.0268 -0.0268 -0.0282 -0.0268 -0.0310 -0.0211 -0.0211 -0.0141 -0.1790 -0.0169 -0.0127 -0.0254 -0.0113 -0.0268 -0.0085 -0.0225 -0.0099 -0.0155 -0.0113 -0.0366 -0.0282 -0.0211 -0.0113 -0.0268 -0.0254 -0.0268 -0.0211 -0.0127 -0.0211 -0.0127 -0.0155 -0.0324', 'S-1323\tAluminiumhydroxid, Dinatriumphosphat als Pufferlösung, Monokaliumphosphat, Natriumkarbonat, Natriumbikarbonat, Trometamol, Saccharose, Medium 199 (enthält unter anderem Aminosäuren, Mineralsalze, Vitamine und andere Inhaltsstoffe) sowie Wasser für Injektionszwecke.', 'T-1323\tThe other ingredients are: aluminium hydroxide and a buffer solution of disodium phosphate, monopotassium phosphate, sodium carbonate, sodium bicarbonate, trometamol, sucrose, medium 199 (complex blend of amino acids, mineral salts, vitamins and other ingredients) and water for injections.', 'H-1323\t-0.85400390625\tAluminium hydroxide , disodium phosphate as buffer solution , mono potassium phosphate , sodium carbonate , sodium bicarbonate , trometamol , sucrose , medium 199 ( containing amino acids , mineral salts , vitamins and other ingredients ) and water for injections .', 'D-1323\t-0.85400390625\tAluminium hydroxide, disodium phosphate as buffer solution, mono potassium phosphate, sodium carbonate, sodium bicarbonate, trometamol, sucrose, medium 199 (containing amino acids, mineral salts, vitamins and other ingredients) and water for injections.', 'P-1323\t-1.0117 -0.0895 -0.0416 -0.0268 -0.0261 -0.0388 -0.7690 -0.0380 -0.0127 -0.0155 -0.0155 -0.0211 -0.5088 -0.9663 -0.0085 -0.4395 -0.2197 -0.0225 -1.0000 -0.1268 -0.0169 -0.0254 -0.0141 -0.0141 -0.0225 -0.0310 -0.4114 -0.0113 -0.0451 -0.0169 -0.0282 -0.2593 -0.0395 -0.0113 -0.0113 -0.0282 -0.0113 -0.0225 -0.0282 -0.9355 -0.0282 -0.0169 -0.0282 -0.0282 -0.0225 -0.0056 -0.0169 -0.0338 -0.1296 -0.0338 -0.0225 -0.0338 -0.8057 -0.1691 -0.0113 -0.1465 -0.0169 -0.0282 -0.0169 -0.0169 -0.0113 -0.0282 -0.0282 -0.0169 -0.0169 -0.0225 -0.5469 -0.0282 -0.4958 -0.1973 -0.4509 -0.0620 -0.0395 -0.0282 -0.3101 -0.2537 -0.0338', 'S-586\tNach der Zubereitung muss das fertige Präparat in 0,9% iger Natriumchloridlösung oder 5% iger Glukoselösung auf ein Endvolumen von 40 ml bis 120 ml pro 50 mg rekonstituiertes Myocet weiter verdünnt werden, damit eine Endkonzentration von 0,4 bis 1,2 mg / ml Doxorubicin erhalten wird.', 'T-586\tAfter reconstitution the finished product must be further diluted in 0.9% (w / v) sodium chloride for injection, or 5% (w / v) glucose for injection to a final volume of 40 ml to 120 ml per 50 mg reconstituted Myocet so that a final concentration of 0.4 to 1.2 mg / ml doxorubicin is obtained.', 'H-586\t-1.142578125\tAfter reconstitution the finished product must be further diluted in 0.9 % ( w / v ) sodium chloride for injection , or 5 % ( w / v ) glucose for injection to a final volume of 40 to 120 ml per 50 mg reconstituted Myocet so that a final concentration of 0.4 to 1.2 mg / ml doxorubicin is obtained .', 'D-586\t-1.142578125\tAfter reconstitution the finished product must be further diluted in 0.9% (w / v) sodium chloride for injection, or 5% (w / v) glucose for injection to a final volume of 40 to 120 ml per 50 mg reconstituted Myocet so that a final concentration of 0.4 to 1.2 mg / ml doxorubicin is obtained.', 'P-586\t-0.4883 -0.3220 -0.3213 -0.5537 -0.1930 -0.2607 -0.3142 -0.0409 -0.8311 -0.0620 -0.0169 -0.0760 -0.6060 -0.0282 -0.0310 -1.1689 -0.3411 -0.2001 -0.3213 -0.1014 -0.1409 -0.0056 -0.0338 -0.0113 -0.0169 -0.0282 -0.8906 -0.3213 -0.3381 -0.3325 -0.0620 -0.1240 -0.0282 -0.1127 -0.2705 -0.0564 -0.2874 -0.0507 -0.0395 -0.0169 -0.0169 -0.2593 -0.3157 -0.1071 -0.2423 -0.1578 -0.0395 -0.0564 -0.1635 -0.1521 -1.2627 -0.0225 -0.0338 -0.3042 -0.0225 -0.2930 -0.2930 -0.0113 -0.0225 -0.3269 -0.0113 -0.0451 -0.0225 -0.6201 -0.2479 -0.2029 -0.0225 -0.0225 -0.0451 -0.3269 -0.0338 -0.0338 -0.0113 -0.0113 -0.1240 -0.0225 -0.1691 -0.0225 -0.0225 -0.0113 -0.0113 -0.0338 -0.0901 -0.2479 -0.5522 -0.0338', 'S-739\tIst eine einzelne PK-Studie, die mit einer anderen als der für die Genehmigung für das Inverkehrbringen beabsichtigten Population und mit einer anderen Behandlungsdosis durchgeführt wird, ohne spezifische klinische Studie zur Wirksamkeit angemessen und ausreichend, um die Wirksamkeit bei allen in der europäischen zentralen Zusammenfassung der Merkmale des Arzneimittels für Immunglobuline vorgesehenen Indikationen zu belegen?', 'T-739\tIs a single PK study conducted in a population and dose regimen different from the one intended for the Marketing Authorisation adequate and sufficient to support efficacy in all indications foreseen in the European core SPC for immunoglobulins, with no specific efficacy clinical trial?', 'H-739\t-2.4140625\tWhether a single PK study conducted on a different population to the population intended for marketing authorisation and with a different treatment dose , without special clinical trials of efficacy , is adequate and sufficient to prove the efficacy in all indications detailed in the core SPC .', 'D-739\t-2.4140625\tWhether a single PK study conducted on a different population to the population intended for marketing authorisation and with a different treatment dose, without special clinical trials of efficacy, is adequate and sufficient to prove the efficacy in all indications detailed in the core SPC.', 'P-739\t-2.0156 -0.3296 -0.0423 -0.2029 -0.0423 -0.1226 -1.0381 -0.9468 -0.1803 -0.2734 -0.0338 -1.3105 -0.1747 -0.3889 -0.2255 -0.0676 -0.8906 -0.0732 -0.4902 -0.5015 -1.2402 -0.2930 -0.0395 -0.6426 -0.3269 -0.1803 -0.6313 -1.4424 -0.0225 -1.3975 -0.9692 -0.1240 -0.0113 -0.0113 -0.2141 -0.2029 -1.0254 -0.0564 -0.2141 -0.0338 -1.7578 -1.1943 -0.3157 -0.0113 -0.0225 -0.7891 -0.5073 -0.7100 -0.0225 -0.9468 -0.0451 -0.0451 -0.4058 -0.3157 -0.2255 -1.5332 -0.0225', 'S-1383\tNebenwirkungen, die wahrscheinlich oder möglicherweise mit CellCept in Zusammenhang stehen und in kontrollierten klinischen Studien bei ≥ 1 / 10 und bei ≥ 1 / 100 bis < 1 / 10 der mit CellCept behandelten Nieren- (2-g-Daten), Herz- und Lebertransplantationspatienten gemeldet wurden, sind in der nachfolgenden Tabelle aufgelistet.', 'T-1383\tAdverse reactions, probably or possibly related to CellCept, reported in ≥ 1 / 10 and in ≥ 1 / 100 to < 1 / 10 of patients treated with CellCept in the controlled clinical trials of renal (2 g data), cardiac and hepatic transplant patients are listed in the following table.', 'H-1383\t-0.74365234375\tAdverse reactions , probably or possibly related to CellCept , reported in ≥ 1 / 10 and in ≥ 1 / 100 to &lt; 1 / 10 of patients treated with CellCept in the controlled clinical trials of renal ( 2 g data ) , cardiac and hepatic transplant patients are listed in the following table .', 'D-1383\t-0.74365234375\tAdverse reactions, probably or possibly related to CellCept, reported in ≥ 1 / 10 and in ≥ 1 / 100 to < 1 / 10 of patients treated with CellCept in the controlled clinical trials of renal (2 g data), cardiac and hepatic transplant patients are listed in the following table.', 'P-1383\t-0.2351 -0.0056 -0.3186 -0.0070 -0.2944 -0.3113 -0.0564 -0.0930 -0.1705 -0.0338 -0.0324 -0.0155 -0.0296 -0.0042 -0.0986 -0.1042 -0.0324 -1.0371 -0.0282 -0.0310 -0.0310 -0.0648 -0.3804 -0.0366 -0.0310 -0.0310 -0.0169 -0.0535 -0.0141 -0.0169 -0.0225 -0.0254 -0.0310 -0.0423 -0.0451 -0.3127 -0.1409 -0.0395 -0.0366 -0.0141 -0.0282 -0.0056 -0.2620 -0.2593 -0.3213 -0.0535 -0.1493 -0.2113 -0.2791 -0.0282 -0.0451 -0.1353 -0.2423 -0.1240 -0.0282 -0.0451 -0.2930 -0.0676 -0.0958 -0.3157 -0.0395 -0.0282 -0.0225 -0.0789 -0.1353 -0.1859 -0.7437 -0.0789 -0.0395 -0.8789 -0.1240 -0.0620 -0.0282', 'S-1165\tEnge Beziehungen werden mit den Diensten der Europäischen Kommission gepflegt, die für die Aufsicht über die Finanzoperationen der Agentur verantwortlich sind (Generaldirektionen für Personal und Verwaltung, DG IX, sowie für Haushalt, DG XIX), sowie mit den Ausschüssen für Haushalt und Haushaltskontrolle des Europäischen Parlaments, mit dem Haushaltsausschuß des Rates und dem Europäischen Rechnungshof.', 'T-1165\tClose relations will be maintained with the Commission services responsible for overseeing the financial activities of the Agency (Directorates-General for Personnel and Administration DG IX and for Budget DG XIX), with the Committees on Budgets and Budgetary Control of the European Parliament, with the Council <<unk>> s Budgetary Committee and the European Court of Auditors.', 'H-1165\t-0.86083984375\tClose relations will be maintained with the Commission services responsible for overseeing the financial operations of the Agency ( Directorates @-@ General for Personnel and Administration , DG IX ; and for Budgets , DG XIX ) , with the Committees on Budgets and Budgetary Control of the European Parliament , with the Council &quot; s Budgetary Committee and also the European Court of Auditors .', 'D-1165\t-0.86083984375\tClose relations will be maintained with the Commission services responsible for overseeing the financial operations of the Agency (Directorates-General for Personnel and Administration, DG IX; and for Budgets, DG XIX), with the Committees on Budgets and Budgetary Control of the European Parliament, with the Council "s Budgetary Committee and also the European Court of Auditors.', 'P-1165\t-0.1592 -0.0227 -0.2605 -0.2593 -0.0690 -0.1304 -0.0373 -0.0430 -0.4458 -0.1902 -0.1479 -0.0282 -0.2847 -0.0310 -0.0986 -0.4719 -0.2507 -0.0310 -0.0310 -0.8848 -0.0338 -0.0760 -0.0113 -0.0648 -0.1353 -0.0254 -0.0338 -0.0817 -0.0085 -0.0338 -0.0310 -0.0592 -0.0225 -0.0141 -0.0254 -0.0225 -0.9751 -0.2197 -0.2395 -0.3157 -0.1409 -0.0282 -0.0282 -0.0169 -0.0225 -0.0282 -0.0225 -0.0282 -0.2986 -0.3381 -0.0507 -0.4282 -0.0169 -0.3213 -0.1071 -0.1183 -0.0338 -0.0507 -0.0282 -0.0169 -0.0564 -0.0395 -0.0338 -0.0282 -0.0225 -0.0395 -0.2367 -0.0338 -0.3494 -0.3889 -0.0338 -0.4282 -0.5635 -0.0169 -0.0282 -0.1917 -0.6030 -0.4565 -0.2367 -0.0225 -0.0338 -0.0225 -0.0113 -0.0338 -0.0338', 'S-1001\tEs gibt keinen Beleg, dass Lamotrigin eine klinisch signifikante Induktion oder Hemmung der oxidativen, arzneimittelmetabolisierenden Enzyme in der Leber verursacht, und es ist unwahrscheinlich, dass Wechselwirkungen zwischen Lamotrigin und Arzneimitteln, die durch Cytochrom-P450-Enzyme metabolisiert werden, auftreten.', 'T-1001\tThere is no evidence that lamotrigine causes clinically significant induction or inhibition of hepatic oxidative drug-metabolising enzymes, and interactions between lamotrigine and medicinal products metabolised by cytochrome P450 enzymes are unlikely to occur.', 'H-1001\t-1.0341796875\tThere is no evidence that lamotrigine causes clinically significant induction or inhibition of the oxidative metabolising enzymes in the liver and interactions between lamotrigine and medicinal products metabolised by cytochrome P450 enzymes are unlikely to occur .', 'D-1001\t-1.0341796875\tThere is no evidence that lamotrigine causes clinically significant induction or inhibition of the oxidative metabolising enzymes in the liver and interactions between lamotrigine and medicinal products metabolised by cytochrome P450 enzymes are unlikely to occur.', 'P-1001\t-0.0575 -0.3293 -0.0278 -0.0680 -0.0775 -0.0225 -0.0243 -0.0113 -0.0243 -1.0508 -0.9565 -0.0169 -0.0197 -0.3789 -0.1691 -0.5298 -0.0254 -0.0169 -0.0451 -0.9497 -0.0225 -0.0310 -0.0169 -0.8511 -0.0056 -0.5439 -0.1803 -0.0169 -0.0282 -1.0762 -0.0395 -0.0113 -1.2910 -0.2874 -0.0451 -0.1973 -0.0395 -0.0225 -0.0113 -0.0225 -0.0282 -0.3662 -0.7495 -0.0451 -0.2649 -0.0225 -0.3945 -0.0451 -0.4565 -0.0225 -0.0225 -0.0564 -0.1014 -0.0113 -0.0338 -0.0225 -0.0225 -0.0451 -0.0338 -0.0451 -0.0225 -0.0338 -0.0338', 'S-1684\tDocetaxel verlängerte die mediane Zeit bis zur Progression (24,6 Wochen gegenüber 15,6 Wochen; p < 0,01) und die mediane Überlebenszeit (15,3 Monate gegenüber 12,7 Monaten; p = 0,03), ohne den primären Endpunkt, die Gesamtansprechrate (32% gegenüber 25%, p = 0,10) zu beeinflussen.', 'T-1684\tWithout affecting the primary endpoint, overall response rate (32% vs 25%, p = 0.10), docetaxel prolonged median time to progression (24.6 weeks vs 15.6 weeks; p < 0.01) and median survival (15.3 months vs 12.7 months; p = 0.03).', 'H-1684\t-1.078125\tDocetaxel prolonged the median time to progression ( 24.6 weeks versus 15.6 weeks ; p &lt; 0.01 ) and the median survival time ( 15.3 months versus 12.7 months ; p = 0.03 ) without affecting the primary endpoint , the overall response rate ( 32 % versus 25 % , p = 0.10 ) .', 'D-1684\t-1.078125\tDocetaxel prolonged the median time to progression (24.6 weeks versus 15.6 weeks; p < 0.01) and the median survival time (15.3 months versus 12.7 months; p = 0.03) without affecting the primary endpoint, the overall response rate (32% versus 25%, p = 0.10).', 'P-1684\t-1.4092 -0.0218 -0.0169 -0.0085 -0.0197 -0.9468 -0.0099 -0.0197 -1.2021 -0.0169 -0.0254 -1.8320 -0.0451 -0.0197 -0.0282 -0.0338 -0.0141 -0.0254 -0.0423 -1.2676 -0.0113 -0.0282 -0.0338 -0.3438 -0.0282 -0.0113 -0.0169 -0.0225 -0.0225 -0.0282 -0.0282 -0.0395 -0.7271 -0.0169 -0.0225 -0.0789 -0.3889 -0.0282 -0.0169 -0.0282 -0.0282 -0.1240 -0.0113 -0.0282 -0.0225 -0.6650 -0.0225 -0.0225 -0.0225 -0.0225 -0.0282 -0.8564 -0.6821 -0.1917 -0.0113 -0.0113 -0.0225 -0.6987 -1.1943 -0.2479 -0.0225 -0.1014 -0.0338 -0.0225 -0.0338 -0.1465 -0.0225 -0.0225 -0.0564 -0.0225 -0.0225 -0.0225 -0.0225 -0.0338 -0.0338 -0.0338', 'S-103\tDie Häufigkeiten sind wie folgt definiert: sehr häufig (≥ 1 / 10), häufig (≥ 1 / 100 bis < 1 / 10), gelegentlich (≥ 1 / 1.000 bis < 1 / 100), selten (≥ 1 / 10.000 bis < 1 / 1.000) und sehr selten (< 1 / 10.000 einschließlich gemeldeter Einzelfälle).', 'T-103\tFrequencies are defined as: very common (≥ 1 / 10), common (≥ 1 / 100 to < 1 / 10), uncommon (≥ 1 / 1,000 to < 1 / 100), rare (≥ 1 / 10,000 to < 1 / 1000) and very rare (< 1 / 10,000 including isolated reports).', 'H-103\t-0.53515625\tFrequencies are defined as : very common ( ≥ 1 / 10 ) , common ( ≥ 1 / 100 to &lt; 1 / 10 ) , uncommon ( ≥ 1 / 1,000 to &lt; 1 / 100 ) , rare ( ≥ 1 / 10,000 to &lt; 1 / 1,000 ) and very rare ( &lt; 1 / 10,000 including isolated reports ) .', 'D-103\t-0.53515625\tFrequencies are defined as: very common (≥ 1 / 10), common (≥ 1 / 100 to < 1 / 10), uncommon (≥ 1 / 1,000 to < 1 / 100), rare (≥ 1 / 10,000 to < 1 / 1,000) and very rare (< 1 / 10,000 including isolated reports).', 'P-103\t-0.8086 -0.0141 -0.0796 -0.0106 -0.0500 -0.0634 -0.0345 -0.2113 -0.0564 -0.1493 -0.0282 -0.0056 -0.0310 -0.0310 -0.0296 -0.0296 -0.2184 -0.1986 -0.0268 -0.0070 -0.0310 -0.0296 -0.0183 -0.0465 -0.0113 -0.0296 -0.0240 -0.0282 -0.0296 -0.0296 -0.0282 -0.3340 -0.3228 -0.0225 -0.0282 -0.0113 -0.0310 -0.0282 -0.3945 -0.0310 -0.2959 -0.0225 -0.0254 -0.0282 -0.0310 -0.0225 -0.0282 -0.0310 -0.0704 -0.0254 -0.0085 -0.0282 -0.0282 -0.0366 -0.0310 -0.0085 -0.0169 -0.0254 -0.0254 -0.0310 -0.0535 -0.0282 -0.7046 -0.0676 -0.0423 -0.0282 -0.0113 -0.0197 -0.0338 -0.0254 -0.0310 -0.0225 -1.1016 -0.3101 -0.3157 -0.0338 -0.0338 -0.0282', 'S-435\tTel.: + 421 2 555 711 82 Suomi / Finland CSL Behring AB Puh / Tel: + 46- (0) 8-54496670 Sverige CSL Behring AB Tel: + 46- (0) 8-54496670 United Kingdom CSL Behring UK Limited Tel: + 44- (0) 1444 447400', 'T-435\tTel.: + 421 2 555 711 82 Suomi / Finland CSL Behring AB Puh / Tel: + 46- (0) 8-54496670 Sverige CSL Behring AB Tel: + 46- (0) 8-54496670 United Kingdom CSL Behring UK Limited Tel: + 44- (0) 1444 447400', 'H-435\t-0.25146484375\tTel . : + 421 2 555 711 82 Suomi / Finland CSL Behring AB Puh / Tel : + 46- ( 0 ) 8 @-@ 54496670 Sverige CSL Behring AB Tel : + 46- ( 0 ) 8 @-@ 54496670 United Kingdom CSL Behring UK Limited Tel : + 44- ( 0 ) 1444 447400', 'D-435\t-0.25146484375\tTel.: + 421 2 555 711 82 Suomi / Finland CSL Behring AB Puh / Tel: + 46- (0) 8-54496670 Sverige CSL Behring AB Tel: + 46- (0) 8-54496670 United Kingdom CSL Behring UK Limited Tel: + 44- (0) 1444 447400', 'P-435\t-0.1273 -0.7368 -0.0444 -0.0261 -0.5107 -0.0211 -0.0338 -0.0282 -0.0183 -0.0282 -0.0211 -0.0113 -0.0338 -0.0028 -0.0465 -0.0141 -0.0169 -0.0141 -0.0240 -0.0014 -0.0268 -0.0056 -0.0789 -0.0197 -0.0409 -0.0549 -0.0704 -0.0211 -0.0409 -0.0282 -0.0254 -0.0282 -0.0282 -0.0282 -0.0409 -0.0127 -0.0127 -0.0099 -0.0155 -0.0240 -0.0169 -0.0028 -0.0085 -0.0225 -0.0014 -0.0282 -0.0070 -0.0395 -0.0352 -0.0225 -0.0296 -0.0268 -0.0268 -0.0296 -0.0282 -0.0240 -0.0296 -0.0113 -0.0099 -0.0099 -0.0169 -0.3042 -0.0197 -0.0085 -0.0225 -0.0028 -0.0282 -0.0141 -0.0085 -0.0451 -0.0366 -0.0197 -0.0113 -0.0282 -0.0282 -0.0254 -0.0282 -0.0197 -0.0169 -0.0254 -0.0169 -0.0197 -0.0338', 'S-1997\tBei transplantierten, mit Immunsuppressiva (wie z.B. systemischem Tacrolimus) behandelten Patienten ist das Risiko der Entstehung eines Lymphoms erhöht; daher sind mit Protopic behandelte Patienten, die eine Lymphadenopathie entwickeln, zu überwachen, um sicherzustellen, dass die Lymphadenopathie abklingt.', 'T-1997\tTransplant patients receiving immunosuppressive regimens (e. g. systemic tacrolimus) are at increased risk for developing lymphoma; therefore patients who receive Protopic and who develop lymphadenopathy should be monitored to ensure that the lymphadenopathy resolves.', 'H-1997\t-0.9404296875\tTransplanted patients receiving immunosuppressive regimens ( e. g. systemic tacrolimus ) are at increased risk of developing lymphoma ; therefore patients who receive Protopic and who develop lymphadenopathy should be monitored to ensure that the lymphadenopathy resolves .', 'D-1997\t-0.9404296875\tTransplanted patients receiving immunosuppressive regimens (e. g. systemic tacrolimus) are at increased risk of developing lymphoma; therefore patients who receive Protopic and who develop lymphadenopathy should be monitored to ensure that the lymphadenopathy resolves.', 'P-1997\t-0.2137 -0.0085 -0.7256 -0.0331 -0.8755 -0.0127 -0.0085 -0.0183 -0.0127 -0.0211 -0.6636 -0.4775 -0.0592 -0.0704 -0.6479 -0.0310 -0.2676 -0.0451 -0.0141 -0.0282 -0.0395 -0.0282 -0.0254 -0.0225 -0.0282 -0.2255 -0.0958 -0.6934 -0.0197 -0.8931 -0.3101 -0.0282 -0.1071 -0.3101 -0.1747 -0.2930 -0.4958 -0.3381 -0.3550 -0.0225 -0.0225 -0.3101 -0.2930 -0.0507 -0.0451 -0.0225 -0.0169 -0.0225 -0.0113 -0.0338 -0.2479 -0.0395 -0.0282 -0.0169 -0.3494 -0.5298 -0.1353 -0.2479 -0.1071 -0.0225 -0.0113 -0.0225 -0.0169 -0.0395 -0.3494 -0.0225 -0.0338 -0.0338', 'S-553\tIm ersten Therapiezyklus gab es bei den Frauen im Vergleich zu den Männern eine höhere Rate an Grad 4-Neutropenien (ANC < 0,5 x 109 / l), 12% im Vergleich zu 5%, und Thrombozytopenien (< 20 x 109 / l), 9% im Vergleich zu 3%.', 'T-553\tThere were higher rates of Grade 4 neutropenia (ANC < 0.5 x 109 / l), 12% vs 5%, and thrombocytopenia (< 20 x 109 / l), 9% vs 3%, in women vs men in the first cycle of therapy.', 'H-553\t-1.1337890625\tIn the first cycle , women had a higher rate of Grade 4 neutropenia ( ANC &lt; 0.5 x 109 / l ) compared to men , 12 % compared to 5 % , and thrombocytopenia ( &lt; 20 x 109 / l ) , 9 % compared to 3 % .', 'D-553\t-1.1337890625\tIn the first cycle, women had a higher rate of Grade 4 neutropenia (ANC < 0.5 x 109 / l) compared to men, 12% compared to 5%, and thrombocytopenia (< 20 x 109 / l), 9% compared to 3%.', 'P-553\t-0.8066 -0.0388 -0.0345 -0.7432 -0.1859 -2.5078 -1.0625 -0.6792 -0.2197 -0.0958 -0.0338 -0.7607 -0.0225 -0.0338 -0.0676 -0.0169 -0.0225 -0.0225 -0.2085 -0.0225 -0.0225 -0.0113 -0.0282 -0.0338 -0.0395 -0.0338 -0.0225 -0.0225 -0.0338 -0.3662 -0.0338 -0.1973 -0.9297 -0.0451 -0.6426 -0.5693 -0.0338 -0.1071 -0.8960 -0.0338 -0.0225 -0.6987 -0.0225 -0.8452 -0.0225 -0.0113 -0.0113 -0.0338 -0.0113 -0.0225 -0.0113 -0.0113 -0.0338 -0.0225 -0.0338 -0.0225 -0.0225 -0.0338 -0.0338 -0.0338 -0.0338 -0.0338 -0.0225 -0.1127 -0.4058 -0.0338 -0.0225 -0.0338 -0.0338', 'S-631\thochdisperses Siliciumdioxid, Magnesiumstearat (E 470b) und Lactose-Monohydrat im Tablettenkern sowie Talkum (E 553b), Hypromellose (E 464), Titandioxid (E 171) und Macrogol 8000 im Filmüberzug.', 'T-631\tcolloidal anhydrous, magnesium stearate (E470b), and lactose monohydrate in the tablet core as well as talc (E553b), hypromellose (E464), titanium dioxide (E171), and macrogol 8000 in the film- coating.', 'H-631\t-0.6201171875\tcolloidal anhydrous , magnesium stearate ( E 470b ) , and lactose monohydrate in the tablet core as well as talc ( E 553b ) , hypromellose ( E 464 ) , titanium dioxide ( E 171 ) and macrogol 8000 in the film @-@ coating .', 'D-631\t-0.6201171875\tcolloidal anhydrous, magnesium stearate (E 470b), and lactose monohydrate in the tablet core as well as talc (E 553b), hypromellose (E 464), titanium dioxide (E 171) and macrogol 8000 in the film-coating.', 'P-631\t-0.5801 -0.2610 -0.1986 -0.0070 -0.3472 -0.2896 -0.0817 -0.5000 -0.3000 -0.0197 -0.0240 -0.0338 -0.0268 -0.0240 -0.1254 -0.9170 -0.0366 -0.0197 -0.0310 -0.0310 -0.4226 -0.3494 -0.0338 -0.0113 -0.0113 -0.0254 -0.0141 -0.0282 -0.0169 -0.0282 -0.1042 -0.0676 -0.1635 -0.0282 -0.0423 -0.5410 -0.0338 -0.0282 -0.0113 -0.1521 -0.0282 -0.0282 -0.0113 -0.0225 -0.0282 -0.0282 -0.0282 -0.1747 -0.0225 -0.0169 -0.0732 -0.0113 -0.0282 -0.0282 -0.0113 -0.0282 -0.0282 -0.0282 -0.0225 -0.0113 -0.0225 -0.0225 -0.0056 -0.0282 -0.0282 -0.0169 -0.0282 -0.0282 -0.8115 -0.2593 -0.0225 -0.0282 -0.0225 -0.0113 -0.0845 -0.0676 -0.1353 -0.3157 -0.0395 -0.0225 -0.0676 -0.0282', 'S-1229\tNatriumchlorid-Lösung 0,9%, Natriumchlorid- (0,45%) und Glucose- (2,5%) Lösung, Glucose-Lösung 5% oder 10%, Dextran 6% in Glucose-Lösung 5%, Hydroxyethylenstärke-Lösung 6 <unk> 10%.', 'T-1229\tThe content of the infusion bottle is dissolved in 40 ml of one of the following calcium-free infusion solutions by swirling, resulting in a concentration of 0.05 g / ml: sodium chloride solution 0.9%, sodium chloride (0.45%) and glucose (2.5%) solution, glucose solution 5% or 10%, dextran 6% in glucose solution 5%, hydroxyethylen starch solution 6 <<unk>> 10%.', 'H-1229\t-0.50390625\tSodium chloride solution 0.9 % , sodium chloride solution ( 0.45 % ) and glucose solution ( 2.5 % ) , glucose solution 5 % or 10 % , dextran 6 % in glucose solution 5 % , hydroxyethylene starch solution 6 % or 10 % .', 'D-1229\t-0.50390625\tSodium chloride solution 0.9%, sodium chloride solution (0.45%) and glucose solution (2.5%), glucose solution 5% or 10%, dextran 6% in glucose solution 5%, hydroxyethylene starch solution 6% or 10%.', 'P-1229\t-1.4873 -0.0099 -0.0887 -0.0127 -0.0155 -0.0254 -0.0324 -0.6060 -0.0268 -0.0380 -0.0549 -0.0380 -0.0085 -0.0240 -0.0141 -0.0113 -0.0296 -0.2057 -0.5508 -0.0197 -0.0197 -0.0225 -0.0310 -0.3494 -0.0197 -0.0225 -0.0254 -0.0704 -0.0282 -0.0141 -0.0225 -0.0282 -0.0423 -0.1212 -0.0197 -0.0141 -0.0225 -0.0310 -0.0254 -0.0479 -0.0254 -0.0225 -0.0310 -0.0254 -0.0197 -0.0225 -0.0282 -0.0310 -0.0225 -0.1409 -0.3579 -0.0197 -0.0141 -0.0169 -0.0282 -0.0225 -0.0310 -0.0169 -0.0310 -0.0282 -0.0225 -0.0225 -0.0197 -0.0197 -0.0169 -0.4199 -0.0254 -0.0732 -0.2761 -0.0282 -0.0225 -0.4226 -0.0282', 'S-1395\tDidanosin AUC ↔ 0,99 (0,79-1,25) Didanosin Cmin nicht durchgeführt Didanosin Cmax ↔ 0,91 (0,58-1,42) Etravirin AUC ↔ 1,11 (0,99-1,25) Etravirin Cmin ↔ 1,05 (0,93-1,18) Etravirin Cmax ↔ 1,16 (1,02-1,32)', 'T-1395\tdidanosine AUC ↔ 0.99 (0.79-1.25) didanosine Cmin ND didanosine Cmax ↔ 0.91 (0.58-1.42) etravirine AUC ↔ 1.11 (0.99-1.25) etravirine Cmin ↔ 1.05 (0.93-1.18) etravirine Cmax ↔ 1.16 (1.02-1.32)', 'H-1395\t-0.58837890625\tDidanosine AUC ↔ 0.99 ( 0.79 @-@ 1.25 ) Didanosine Cmin ND atorvastatin Didanosine Cmax ↔ 0.91 ( 0.58 @-@ 1.42 ) Etravirine AUC ↔ 1.11 ( 0.99 @-@ 1.25 ) Etravirine Cmin ↔ 1.05 ( 0.93 @-@ 1.18 ) Etravirine Cmax ↔ 1.16 ( 1.02 @-@ 1.32 )', 'D-1395\t-0.58837890625\tDidanosine AUC ↔ 0.99 (0.79-1.25) Didanosine Cmin ND atorvastatin Didanosine Cmax ↔ 0.91 (0.58-1.42) Etravirine AUC ↔ 1.11 (0.99-1.25) Etravirine Cmin ↔ 1.05 (0.93-1.18) Etravirine Cmax ↔ 1.16 (1.02-1.32)', 'P-1395\t-0.0715 -0.0142 -0.0184 -0.0379 -0.3445 -0.0190 -0.0014 -0.0356 -0.0148 -0.0264 -0.0243 -0.0155 -0.0285 -0.0264 -0.0211 -0.0268 -0.3923 -0.0113 -0.0148 -0.0225 -0.0282 -0.0141 -0.3220 -1.2666 -0.1042 -0.2339 -0.0113 -2.6348 -0.0169 -0.0169 -0.2986 -0.7554 -0.0225 -0.0056 -0.0338 -0.0113 -0.0282 -0.0169 -0.0113 -0.0282 -0.0225 -0.0113 -0.0282 -0.0338 -0.0225 -0.0338 -0.2141 -0.0113 -0.0225 -0.0056 -0.0338 -0.0225 -0.0282 -0.0169 -0.0169 -0.0282 -0.0225 -0.0225 -0.0282 -0.0282 -0.0225 -0.0169 -0.2479 -0.0282 -0.0113 -0.0056 -0.0282 -0.0169 -0.0225 -0.0225 -0.0113 -0.0282 -0.0225 -0.0225 -0.0282 -0.0282 -0.0225 -0.0169 -0.2761 -0.0282 -0.0169 -0.0056 -0.0282 -0.0225 -0.0282 -0.0338 -0.0169 -0.0282 -0.0225 -0.0225 -0.0282 -0.0282', 'S-758\tDennoch erfordert der erfolgreiche Suizidversuch Beachtung, und da Depression und Stimmungsschwankungen als unerwünschte Ereignisse in der Zusammenfassung der Merkmale des Arzneimittels über Actiq aufgeführt sind, war der CHMP der Ansicht, dass diese Art von Ereignissen eingehend zu überwachen ist, und verlangte eine Nachuntersuchung dieser Problematik bei der Anwendungsbeobachtung im Rahmen der Pharmakovigilanz.', 'T-758\tHowever, the successful suicidal attempt requires attention, and because depression and mood liability are adverse events listed in the SPC of Actiq, the CHMP considered that these kinds of events should be closely monitored and requested the issue to be followed up in post-marketing Pharmacovigilance.', 'H-758\t-2.21875\tNevertheless , the success of suicide attempts requires special attention and , as depression and mood liability are included as an adverse event in the SPC .', 'D-758\t-2.21875\tNevertheless, the success of suicide attempts requires special attention and, as depression and mood liability are included as an adverse event in the SPC.', 'P-758\t-1.3838 -0.0176 -0.2205 -1.2354 -1.7305 -0.0366 -0.9214 -0.2593 -1.1670 -1.4873 -0.4790 -0.2141 -0.1127 -1.2119 -0.0113 -0.0338 -0.0225 -0.7158 -0.3157 -0.1127 -1.3643 -0.0901 -0.9580 -0.1014 -0.0225 -0.0225 -0.0451 -0.0676 -0.7666 -0.2705 -2.0293 -0.3269', 'S-1986\tNach 52 Wochen erreichten 42,9% der Patienten, die die Trudexa / Methotrexat-Kombinationstherapie erhielten, eine klinische Remission (DAS28 < 2,6), verglichen mit 20,6% der Patienten, die Methotrexat als Monotherapie und 23,4% der Patienten, die Trudexa als Monotherapie erhielten.', 'T-1986\tau At week 52, 42.9% of patients who received Trudexa / methotrexate combination therapy achieved clinical remission (DAS28 < 2.6) compared to 20.6% of patients receiving methotrexate monotherapy and 23.4% of patients receiving Trudexa monotherapy.', 'H-1986\t-0.58837890625\tAt Week 52 , 42.9 % of patients receiving Trudexa / methotrexate combination therapy achieved clinical remission ( DAS28 &lt; 2.6 ) compared to 20.6 % of patients receiving methotrexate monotherapy and 23.4 % of patients receiving Trudexa monotherapy .', 'D-1986\t-0.58837890625\tAt Week 52, 42.9% of patients receiving Trudexa / methotrexate combination therapy achieved clinical remission (DAS28 < 2.6) compared to 20.6% of patients receiving methotrexate monotherapy and 23.4% of patients receiving Trudexa monotherapy.', 'P-1986\t-0.2169 -0.3452 -0.0155 -0.0606 -0.0327 -0.0204 -0.0257 -0.0261 -0.0303 -0.1282 -1.3242 -1.0820 -0.0254 -0.0225 -0.0310 -0.0479 -0.0507 -0.0197 -0.0310 -0.0282 -0.0225 -0.0507 -0.0395 -0.1493 -0.2085 -0.0310 -0.0085 -0.3213 -0.0254 -0.0282 -0.0225 -0.0113 -0.0141 -0.0254 -0.0366 -0.0282 -0.0282 -0.8286 -0.0986 -0.0113 -0.0282 -0.0225 -0.0451 -0.2395 -0.0338 -0.0845 -0.0225 -0.0338 -0.0282 -0.0225 -0.5186 -0.0395 -0.0282 -0.1747 -0.0113 -0.0282 -0.0225 -0.1240 -0.1071 -0.0338 -0.0225 -0.0282 -0.0225 -0.0338 -0.0620 -0.0225 -0.0169 -0.0282 -0.0282', 'S-1261\tEine Kombinationsanalyse zweier klinischer Studien, die 805 unbehandelte Patienten mit metastasiertem Prostatakarzinom einschlossen und die eine Sterblichkeit von 43% erwarten ließ, zeigte, daß die Behandlung mit Bicalutamid weniger effektiv für die Überlebenszeit ist als die Kastration (HR = 1,30 Zufallsintervall 1,04-1,65).', 'T-1261\tCombined analysis of 2 clinical studies comprising 805 patients with metastatic prostatic carcinoma, who had not been treated before with expected mortality 43%, showed that the treatment with bicalutamide 150 mg is less effective than castration as for the survival time (HR = 1.30 [confidence interval 1.04 <<unk>> 1.65]).', 'H-1261\t-1.591796875\tA combined analysis of two clinical trials involving 805 treatment @-@ naïve patients with metastatic prostate cancer , which produced a mortality of 43 % , showed that treatment with bicalutamide was less effective than castration ( HR = 1.30 randomised interval 1.04 @-@ 1.65 ) .', 'D-1261\t-1.591796875\tA combined analysis of two clinical trials involving 805 treatment-naïve patients with metastatic prostate cancer, which produced a mortality of 43%, showed that treatment with bicalutamide was less effective than castration (HR = 1.30 randomised interval 1.04-1.65).', 'P-1261\t-0.3660 -0.8550 -0.0444 -0.3120 -0.0395 -0.0310 -0.6567 -0.5171 -0.0225 -0.0225 -1.7432 -0.4932 -0.3213 -0.0310 -0.0254 -0.0732 -0.3127 -0.0338 -0.0113 -0.0169 -0.0225 -0.0225 -0.0845 -2.4961 -0.8677 -1.7920 -0.3833 -0.3606 -0.0225 -0.3833 -0.0225 -0.0338 -0.0451 -0.6650 -0.0451 -1.0371 -0.0338 -0.0338 -0.0225 -0.0225 -0.0113 -0.0225 -0.8789 -0.0338 -0.0225 -0.4395 -0.1803 -0.0113 -0.6763 -0.1127 -0.0113 -0.1578 -0.0451 -0.0225 -0.7212 -0.6313 0.0000 -0.4846 -0.0338 -0.2479 -0.0789 -0.0113 -0.6538 -0.0225 -0.0225 -0.0338 -0.0901 -0.0338', 'S-1575\t17.804 Arthrosepatienten und 5.700 Patienten mit rheumatoider Arthritis wurden mit Etoricoxib 60 mg (Arthrose) oder 90 mg (Arthrose und rheumatoide Arthritis) pro Tag oder mit Diclofenac 150 mg pro Tag im Mittel 20,3 Monate (maximal 42,3 Monate, median 21,3 Monate) behandelt.', 'T-1575\tThe MEDAL Study, was an endpoint driven CV Outcomes study in 17,804 OA and 5,700 RA patients treated with etoricoxib 60 (OA) or 90 mg (OA and RA) or diclofenac 150 mg daily for a mean period of 20.3 months (maximum of 42.3 months, median 21.3 months).', 'H-1575\t-1.275390625\t17,804 OA patients and 5,700 patients with rheumatoid arthritis were treated with etoricoxib 60 mg daily ( OA ) or 90 mg daily ( OA and RA ) or diclofenac 150 mg daily for a mean period of 20.3 months ( maximum 34.3 months , median 21.3 months ) .', 'D-1575\t-1.275390625\t17,804 OA patients and 5,700 patients with rheumatoid arthritis were treated with etoricoxib 60 mg daily (OA) or 90 mg daily (OA and RA) or diclofenac 150 mg daily for a mean period of 20.3 months (maximum 34.3 months, median 21.3 months).', 'P-1575\t-2.4395 -0.0225 -0.0183 -0.4465 -0.3213 -0.7524 -0.0366 -0.0310 -0.0113 -1.0342 -0.0395 -0.3916 -0.0113 -0.0169 -0.0197 -0.0085 -0.0197 -0.0169 -0.0141 -0.0873 -0.0310 -0.0451 -0.6367 -0.0282 -0.0113 -0.0113 -0.0225 -0.3269 -0.1521 -1.9053 -0.0507 -0.6650 -0.2874 -0.0451 -0.4058 -0.0225 -0.0113 -0.3833 -0.0338 -0.2311 -0.0564 -0.1296 -0.0451 -0.0225 -0.0282 -0.3945 -0.2930 0.0000 -0.0113 -0.0113 -0.0225 -0.0113 -0.1127 -0.3381 -0.9243 -0.0789 -0.3833 -0.0338 -0.0225 -0.0225 -0.0338 -0.0338 -0.1578 -0.4846 -1.1270 -0.2141 -0.0338 -0.1465 -0.0338 -0.0225 -0.7100 -0.0225 -0.0338 -0.0338 -0.0338 -0.0338', 'S-297\tBei Ratten zeigte die Behandlung mit Sunitinib während der Organogenese Auswirkungen auf die Entwicklung in Form einer erhöhten Zahl von fetalen Skelettmissbildungen, die sich hauptsächlich als verzögerte Ossifikation der thorakalen / lumbalen Wirbelkörper manifestierten, und zeigten sich bei Plasmakonzentrationen, die um das 6fache über den beim Menschen beobachteten lagen.', 'T-297\tSunitinib treatment in rats during organogenesis resulted in developmental effects at ≥ 5 mg / kg / day consisting of increased incidence of foetal skeletal malformations, predominantly characterized as retarded ossification of thoracic / lumbar vertebrae and occurred at plasma exposure levels 6-fold higher than is observed in clinic.', 'H-297\t-2.529296875\tIn rats , treatment with sunitinib resulted in increased foetal skeletal malformations as decreased ossification of the thoracic / lumbar vertebral body was seen during organogenesis , and profiles were seen at plasma concentrations that were 6 @-@ fold higher than is observed in humans .', 'D-297\t-2.529296875\tIn rats, treatment with sunitinib resulted in increased foetal skeletal malformations as decreased ossification of the thoracic / lumbar vertebral body was seen during organogenesis, and profiles were seen at plasma concentrations that were 6-fold higher than is observed in humans.', 'P-297\t-0.8452 -0.4016 -0.1459 -1.3984 -0.0366 -0.0535 -0.0155 -0.0085 -0.0282 -1.9697 -0.0535 -1.8340 -0.7778 -0.0056 -0.0282 -0.0901 -0.0113 -0.0169 -0.0282 -1.2676 -0.0789 -0.0282 -1.3359 -0.7437 -0.0620 -0.4902 -0.0225 -0.0451 -0.4170 -1.9609 -0.0225 -0.0225 -0.0564 -0.0225 -0.0113 -0.0113 -0.0451 0.0000 -0.0225 -0.6538 -1.0703 -0.9917 -1.2627 -1.5889 -0.5522 -0.0225 -0.0113 -0.0225 -1.1611 -0.5073 -2.3555 -0.7212 -0.9917 -1.2627 -0.3157 -0.1127 0.0000 -0.0225 -0.8564 0.0000 -0.0225 -0.5635 -0.3381 -0.7212 -0.9468 -0.0676 -0.4958 -0.0451 -0.3833 -0.1353 -0.0451 -0.7212 -0.0225 -0.0451', 'S-81\tDer Ausschuss für Humanarzneimittel (CHMP) gelangte zu dem Schluss, dass die Vorteile von PROTELOS bei der Behandlung von Osteoporose bei Frauen nach den Wechseljahren, um das Risiko von Wirbel- und Hüftfrakturen zu senken, gegenüber den Risiken überwiegen, und empfahl, die Genehmigung für das Inverkehrbringen von PROTELOS zu erteilen.', 'T-81\tThe Committee recommended that PROTELOS be given marketing authorisation.', 'H-81\t-0.68701171875\tThe Committee recommended that PROTELOS be given marketing authorisation .', 'D-81\t-0.68701171875\tThe Committee recommended that PROTELOS be given marketing authorisation.', 'P-81\t-0.3525 -0.0211 -0.6055 -0.0838 -0.9487 -0.0127 -0.0211 -0.0183 -0.0211 -0.1917 -0.3042 -0.2959 -0.1071 -0.0169 -0.3042 -0.3213', 'S-310\tSie an schweren Durchblutungsstörungen des Herzens (koronare Herzkrankheit), der Arterien der Beine oder Arme (periphere arterielle Verschlusskrankheit), der Halsgefäße (vaskuläre Erkrankung der Karotiden) oder des Gehirns (zerebrovaskuläre Erkrankung) leiden Sie vor kurzem einen Herzinfarkt oder Schlaganfall hatten.', 'T-310\tyou have severe disorders of blood circulation of the heart (coronary heart disease), arteries of the legs or arms (peripheral arterial occlusive disease), neck vessels (vascular disease of the carotids) or the brain (cerebrovascular disease) you had a recent heart attack or stroke', 'H-310\t-1.4775390625\tyou have recently had a heart attack or stroke for severe reductions in blood supply to the heart ( coronary heart disease ) , arteries of the legs or arms ( peripheral arterial disease ) , the neck vessels ( vascular disease of the carotids ) or the brain ( cerebrovascular disease ) .', 'D-310\t-1.4775390625\tyou have recently had a heart attack or stroke for severe reductions in blood supply to the heart (coronary heart disease), arteries of the legs or arms (peripheral arterial disease), the neck vessels (vascular disease of the carotids) or the brain (cerebrovascular disease).', 'P-310\t-2.1504 -0.3127 -0.7524 -0.4424 -0.0282 -0.2874 -0.0197 -0.0282 -0.0310 -2.4746 -0.2423 -1.4707 -0.3269 -0.0901 -0.2311 -1.6455 -0.4622 -0.0451 -0.0225 -0.0282 -0.2085 -0.0169 -0.0225 -0.1127 -0.0169 -0.0282 -0.0338 -0.6650 -0.0225 -0.3269 -0.1127 -0.0225 -0.0338 -0.3945 -0.0338 -0.0113 -0.0113 -0.0338 -0.0338 -0.6313 -0.0113 -0.4622 -0.0338 -0.0338 -1.3184 -0.5522 -0.3945 -0.0225 -0.0225 -0.1240 -0.0225 -0.0113 -0.0451 -0.0338 -0.5186 -0.2593 -0.0338 -0.0338 -0.3833 -0.0338 -0.0901 -0.6201 -0.0113 -0.0225 -0.0225 -0.0113 -0.0338 -0.0225 -0.0225 -0.0113 -0.0338 -0.0225 -0.3833 -0.0338', 'S-772\tDer Ausschuss für Humanarzneimittel (CHMP) gelangte zu dem Schluss, dass die Vorteile von Circadin bei der kurzfristigen Behandlung der durch einen schlechten Schlaf gekennzeichneten primären Insomnie bei Patienten ab 55 Jahren trotz der nur geringen nachgewiesenen Effektgröße bei einem relativ kleinen Teil der Patienten gegenüber den Risiken überwiegen, und empfahl, die Genehmigung für das Inverkehrbringen von Circadin zu erteilen.', 'T-772\tThe Committee recommended that Circadin be given marketing authorisation.', 'H-772\t-1.12109375\tThe Committee recommended that Tamiflu be given marketing authorisation .', 'D-772\t-1.12109375\tThe Committee recommended that Tamiflu be given marketing authorisation.', 'P-772\t-0.3599 -0.0227 -0.6123 -0.1176 -2.2168 -0.5352 -0.0056 -0.2367 -0.3042 -0.2930 -0.1409 -0.0197 -0.2761 -0.3213', 'S-937\tHäufige Nebenwirkungen Fieber verbunden mit einer niedrigen Anzahl weißer Blutzellen (febrile Neutropenie) Anorexie (verminderter Appetit) Kopfschmerzen Schlaflosigkeit Schläfrigkeit Husten Laufende Nase Verstopfung Durchfall Schmerzen, Rötung, Schwellung oder Wundsein im Mund Juckreiz Schwitzen Muskelschmerzen Rückenschmerzen Fieber Schwäche Schüttelfrost', 'T-937\t41 Chills', 'H-937\t-1.1279296875\tCommon side effects Fever associated with low white blood cell count ( febrile neutropenia ) Anorexia ( decreased appetite ) Headache Insomnia Somnolence Cough Runny nose Constipation Diarrhoea Pain , redness , swelling or soreness of the mouth Itching sweating Muscle pain Back pain Fever Weakness Chills', 'D-937\t-1.1279296875\tCommon side effects Fever associated with low white blood cell count (febrile neutropenia) Anorexia (decreased appetite) Headache Insomnia Somnolence Cough Runny nose Constipation Diarrhoea Pain, redness, swelling or soreness of the mouth Itching sweating Muscle pain Back pain Fever Weakness Chills', 'P-937\t-0.2153 -0.0227 -0.0796 -0.0313 -0.9131 -0.0056 -0.9624 -0.0282 -0.6919 -0.3606 -0.0225 -0.4988 -0.6958 -0.0310 -0.0395 -0.0225 -0.0169 -0.0169 -0.0113 -0.0113 -0.0197 -0.0141 -0.0282 -0.0620 -0.0197 -0.0197 -0.0141 -0.0310 -0.2930 -0.0254 -0.0141 -0.0197 -0.0282 -0.7017 -0.0113 -0.0056 -0.0676 -0.2367 -0.0056 -0.0056 -1.2734 -0.2705 -0.1409 -0.0789 -0.2705 -0.0113 -0.3494 -0.3494 -0.1183 -0.6143 -0.0169 -0.0113 -0.0225 -0.0564 -0.0225 -0.2423 -0.0169 -0.9976 -0.0056 -0.0282 -0.0395 -0.0169 -0.0338 -0.0113 -0.0225 -0.0845 -0.1071 -0.6479 -0.8228 -0.2479 -0.0113 -0.7554 -0.0225 -0.0225 -0.0676 -0.0564 -0.9805 -0.0789 -0.0564 -0.0451 -0.0338 -0.4509 -0.0113 -0.3494 -0.0113 -0.0338 -0.0789 -0.1353 -0.2367', 'S-1930\tIm Rahmen der Untersuchung zur Sicherheit von Bosentan wurde der mögliche Einfluss von Bosentan auf die antiretrovirale Therapie (z.B. erniedrigte Plasmakonzentration der gleichzeitig angewendeten antiretroviralen Medikation, die zu einer verminderten Wirksamkeit der antiretroviralen Therapie führen könnte) anhand der CD4- Zellzahl und des HIV-1-RNA-Titers beurteilt.', 'T-1930\tAs part of the safety assessment, the effect of bosentan on the antiretroviral therapy (i.e. reduced systemic concentrations of the co- administered antiretroviral agents with a potential negative impact on the efficacy of the antiretroviral therapy) was assessed through CD4 cell counts and HIV-1 RNA titers.', 'H-1930\t-1.9541015625\tThe effect of bosentan on antiretroviral therapy ( e. g. decreased plasma concentrations of co @-@ administered antiretroviral medications , which could result in reduced efficacy of antiretroviral therapy ) was assessed by the CD4 cell count and HIV @-@ 1 RNA titre .', 'D-1930\t-1.9541015625\tThe effect of bosentan on antiretroviral therapy (e. g. decreased plasma concentrations of co-administered antiretroviral medications, which could result in reduced efficacy of antiretroviral therapy) was assessed by the CD4 cell count and HIV-1 RNA titre.', 'P-1930\t-0.6250 -2.7441 -0.0423 -0.0113 -0.0141 -0.0507 -0.0479 -0.2903 -0.0225 -0.0141 -0.0197 -0.4734 -0.2141 -0.3213 -0.0282 -0.3606 -0.5972 -0.0338 -0.0395 -0.0113 -0.0113 -1.2959 -0.0113 -0.0169 -0.0845 -1.2168 -0.0282 -0.3157 -0.0225 -0.0395 -0.0225 -0.0225 -0.2479 -0.3042 -0.5469 -1.5615 -0.4282 -1.0596 -1.4092 -0.0338 -1.8818 -0.1917 -0.0113 -0.0225 -0.0564 -0.3381 -0.0225 -0.0225 -0.0225 -0.2593 -0.0338 -0.5859 -0.3157 -0.0113 -1.0254 -1.2852 -1.7129 -0.0225 -0.5972 -0.3606 -0.0451 -0.3157 -0.0676 -0.0225 -0.0451 -0.0225 -0.2930 -0.2930 -0.4282 -0.0451', 'S-1806\tIn der 5 mg / kg Infliximab-Behandlungsgruppe (28 / 242; 11,6% [n.s.]) und in der 10 mg / kg Infliximab- Behandlungsgruppe (18 / 242; 7,4% [p = 0,011]) wurde bei weniger Patienten eine Kolektomie durchgeführt als in der Placebo-Behandlungsgruppe (36 / 244; 14,8%).', 'T-1806\tFewer subjects underwent colectomy in the 5 mg / kg infliximab group (28 / 242 or 11.6% [N. S.]) and the 10 mg / kg infliximab group (18 / 242 or 7.4% [p = 0.011]) than in the placebo group (36 / 244; 14.8%).', 'H-1806\t-0.77197265625\tFewer patients underwent colectomy in the infliximab 5 mg / kg group ( 28 / 242 , 11.6 % ) and infliximab 10 mg / kg group ( 18 / 242 , 7.4 % &#91; p = 0.011 &#93; ) than in the placebo group ( 36 / 244 , 14.8 % ) .', 'D-1806\t-0.77197265625\tFewer patients underwent colectomy in the infliximab 5 mg / kg group (28 / 242, 11.6%) and infliximab 10 mg / kg group (18 / 242, 7.4% [p = 0.011]) than in the placebo group (36 / 244, 14.8%).', 'P-1806\t-0.1886 -0.0227 -0.0560 -1.8799 -0.0225 -0.0916 -0.0296 -0.1578 -0.0324 -0.6328 -0.0395 -0.6172 -0.0113 -0.0225 -0.0197 -0.2451 -0.0169 -0.0282 -0.0169 -0.9131 -0.0310 -0.0254 -0.0338 -0.0225 -0.0254 -0.3101 -0.0282 -0.0282 -0.0254 -1.0088 -0.0507 -0.8115 -0.0395 -0.0169 -0.0225 -0.0395 -0.0113 -0.0282 -0.0113 -0.1691 -0.0282 -0.0225 -0.0282 -0.0169 -0.0282 -0.0282 -0.2085 -0.0282 -0.0225 -0.0282 -0.0225 -0.0338 -0.0282 -0.0282 -0.0338 -0.0282 -0.5298 -0.2593 -0.0395 -0.0056 -0.0225 -0.0169 -0.0225 -0.7832 -0.0282 -0.0169 -0.0282 -0.0169 -0.0282 -0.0282 -0.0169 -0.0225 -0.0225 -0.0282 -0.0338 -0.0338', 'S-459\tDer Ausschuss gelangte unter Berücksichtigung des Befassungsverfahrens für Casodex (Bicalutamid 150 mg) gemäß Artikel 31 der Richtlinie 2001 / 83 / EG für Arzneimittel, die Bicalutamid enthalten, zu dem Schluss, dass Bicalutamid 150 mg in der Behandlung des lokal fortgeschrittenen Prostatakarzinoms wirksam ist, das Anwendungsgebiet jedoch beschränkt werden sollte auf:', 'T-459\tThe Committee, considering the Casodex Referral (bicalutamide 150 mg) made under article 31 of Directive 2001 / 83 / EC for medicinal products containing bicalutamide, reached the conclusion that bicalutamide 150mg is effective in the treatment of locally advanced prostate cancer; however the CHMP considered that the therapeutic indication should be restricted to: <<unk>> Bicalutamide 150mg is indicated either alone or as adjuvant to radical prostatectomy or radiotherapy in patients with locally advanced prostate cancer at high risk for disease progression <<unk>>.', 'H-459\t-1.01953125\tConsidering the referral for Casodex ( bicalutamide 150 mg ) under Article 31 of Directive 2001 / 83 / EC for medicinal products containing bicalutamide , the Committee concluded that bicalutamide 150 mg is effective in the treatment of locally advanced prostate cancer , but that the indication should be limited to :', 'D-459\t-1.01953125\tConsidering the referral for Casodex (bicalutamide 150 mg) under Article 31 of Directive 2001 / 83 / EC for medicinal products containing bicalutamide, the Committee concluded that bicalutamide 150 mg is effective in the treatment of locally advanced prostate cancer, but that the indication should be limited to:', 'P-459\t-1.4521 -0.0099 -0.0169 -0.0451 -0.1493 -0.0070 -0.3157 -0.5239 -0.0296 -0.0070 -0.0324 -0.4395 -0.0197 -0.0254 -0.0169 -0.0225 -0.0535 -0.0141 -0.5269 -1.1689 -0.0366 -0.0169 -0.0338 -0.0620 -0.0197 -0.0141 -0.0282 -0.0113 -0.0395 -0.0197 -0.6226 -0.0451 -0.0282 -0.0169 -0.0225 -0.0338 -0.0169 -0.0282 -0.0113 -0.0225 -0.0395 -0.0338 -0.0732 -0.5635 -0.0282 -0.1409 -0.0169 -0.0225 -0.0056 -0.0282 -0.0169 -0.0113 -0.2593 -0.1691 -0.2255 -0.1353 -0.0225 -0.0282 -0.1296 -0.0169 -0.0395 -0.0282 -0.0225 -0.0901 -1.2168 -0.2817 -0.4058 -1.3584 -0.6084 -0.2255 -0.0338 -1.2061 -0.0338 -0.0338 -0.0338', 'S-171\tStarlix ist kontraindiziert bei Patienten: • mit Überempfindlichkeit gegen den Wirkstoff oder einen der sonstigen Bestandteile • mit Typ-1-Diabetes (insulinabhängiger Diabetes mellitus, C-Peptid negativ) • mit diabetischer Ketoazidose, mit oder ohne Koma • während der Schwangerschaft und Stillzeit (siehe Abschnitt 4.6) • mit schwerer Lebererkrankung', 'T-171\tStarlix is contraindicated in patients with: • Hypersensitivity to the active substance or to any of the excipients • Type 1 diabetes (insulin-dependent diabetes mellitus, C-peptide negative) • Diabetic ketoacidosis, with or without coma • Pregnancy and breast-feeding (see section 4.6) • Severe hepatic impairment', 'H-171\t-0.6875\tStarlix is contraindicated in patients with : • Hypersensitivity to the active substance or to any of the excipients • Type 1 diabetes ( insulin @-@ dependent diabetes mellitus , C @-@ peptide negative ) • Diabetic ketoacidosis , with or without coma • Pregnancy and breast @-@ feeding ( see section 4.6 ) • Severe hepatic impairment', 'D-171\t-0.6875\tStarlix is contraindicated in patients with: • Hypersensitivity to the active substance or to any of the excipients • Type 1 diabetes (insulin-dependent diabetes mellitus, C-peptide negative) • Diabetic ketoacidosis, with or without coma • Pregnancy and breast-feeding (see section 4.6) • Severe hepatic impairment', 'P-171\t-0.4143 -0.0197 -0.0257 -0.0423 -0.4822 -0.0042 -0.0528 -0.0535 -0.4636 -0.0704 -0.0451 -0.3213 -0.0127 -0.0324 -0.0113 -0.0338 -0.1000 -0.1028 -0.5298 -0.0352 -0.2664 -0.0760 -0.0592 -0.1831 -0.5493 -0.0873 -0.0197 -0.0817 -0.2874 -0.0423 -0.0338 -0.0310 -0.0310 -0.4114 -0.0141 -0.2169 -0.0338 -0.0225 -0.3972 -0.0225 -0.0028 -0.0479 -0.0507 -0.0845 -0.0225 -0.0169 -0.0056 -0.0507 -0.0338 -0.2085 -0.1859 -0.0113 -0.0225 -0.0282 -0.0338 -0.0056 -0.0056 -0.0169 -0.1127 -0.0451 -0.0282 -0.0225 -0.0845 -0.0451 -0.1973 -0.2479 -0.0169 -0.0676 -0.0451 -0.7891 -0.1127 -0.0113 -0.0395 -0.0395 -0.1578 -0.0225 -0.0282 -0.0338 -0.0451 -0.0282 -0.0169 -0.6592 -0.0113 -0.0282 -0.5410 -0.0282 -0.0169 -0.0282 -0.0564', 'S-1552\tEU / 1 / 98 / 090 / 005 EU / 1 / 98 / 090 / 006 EU / 1 / 98 / 090 / 007 EU / 1 / 98 / 090 / 008 EU / 1 / 98 / 090 / 014 EU / 1 / 98 / 090 / 016 EU / 1 / 98 / 090 / 018 EU / 1 / 98 / 090 / 020', 'T-1552\tEU / 1 / 98 / 090 / 005 EU / 1 / 98 / 090 / 006 EU / 1 / 98 / 090 / 007 EU / 1 / 98 / 090 / 008 EU / 1 / 98 / 090 / 014 EU / 1 / 98 / 090 / 016 EU / 1 / 98 / 090 / 018 EU / 1 / 98 / 090 / 020', 'H-1552\t-0.161376953125\tEU / 1 / 98 / 090 / 005 EU / 1 / 98 / 090 / 006 EU / 1 / 98 / 090 / 007 EU / 1 / 98 / 090 / 008 EU / 1 / 98 / 090 / 014 EU / 1 / 98 / 090 / 016 EU / 1 / 98 / 090 / 018 EU / 1 / 98 / 090 / 020', 'D-1552\t-0.161376953125\tEU / 1 / 98 / 090 / 005 EU / 1 / 98 / 090 / 006 EU / 1 / 98 / 090 / 007 EU / 1 / 98 / 090 / 008 EU / 1 / 98 / 090 / 014 EU / 1 / 98 / 090 / 016 EU / 1 / 98 / 090 / 018 EU / 1 / 98 / 090 / 020', 'P-1552\t-0.0357 -0.0313 -0.0270 -0.0299 -0.0163 -0.0291 -0.0292 -0.0255 -0.0292 -0.0276 -0.0334 -0.0248 -0.0312 -0.0278 -0.0299 -0.0134 -0.0292 -0.0271 -0.0243 -0.0285 -0.0271 -0.0271 -0.0250 -0.0313 -0.0271 -0.0299 -0.0141 -0.0282 -0.0268 -0.0225 -0.0282 -0.0310 -0.0289 -0.0254 -0.0310 -0.0268 -0.0289 -0.0141 -0.0282 -0.0268 -0.0247 -0.0282 -0.0317 -0.0254 -0.0261 -0.0310 -0.0275 -0.0296 -0.0127 -0.0282 -0.0254 -0.0225 -0.0282 -0.0423 -0.0197 -0.0282 -0.0310 -0.0268 -0.0296 -0.0127 -0.0282 -0.0254 -0.0211 -0.0282 -0.0296 -0.0268 -0.0282 -0.0310 -0.0268 -0.0296 -0.0127 -0.0296 -0.0254 -0.0225 -0.0282 -0.0296 -0.0254 -0.0296 -0.0310 -0.0282 -0.0296 -0.0141 -0.0296 -0.0268 -0.0268 -0.0296 -0.0296 -0.0225 -0.0296', 'S-1337\t• Entzündungen der Nase und des Rachens • Entzündungen der Nasennebenhöhlen • Pilzinfektionen • Angstzustände • Sinuskopfschmerzen • Hoher oder erhöhter Blutdruck • Durchfall • Schmerzen im Oberbauch • Mundtrockenheit • Rückenschmerzen • Schmerzen • Veränderungen bei manchen Bluttests (zur Bestimmung des Blutzuckerspiegels oder der Leberfunktion).', 'T-1337\t• Inflammation of the nose and throat • Inflammation of the sinuses • Fungal infection • Anxiety • Sinus headache • High or increased blood pressure • Diarrhoea • Pain in the upper part of the abdomen • Dry mouth • Back pain • Pain • Changes in some blood tests (amount of glucose in blood or tests of liver function).', 'H-1337\t-1.408203125\t• inflammation of the nose and throat • infection of the sinuses • fungal infections • anxiety • sinus headache • high or high blood pressure • diarrhoea • abdominal pain • dry mouth • back pain • pain • changes in some blood tests ( used to measure the level of blood sugar or liver function ) .', 'D-1337\t-1.408203125\t• inflammation of the nose and throat • infection of the sinuses • fungal infections • anxiety • sinus headache • high or high blood pressure • diarrhoea • abdominal pain • dry mouth • back pain • pain • changes in some blood tests (used to measure the level of blood sugar or liver function).', 'P-1337\t-0.6045 -1.5918 -0.0127 -0.0690 -0.0310 -0.2747 -0.0240 -0.5708 -0.0535 -0.0338 -1.3945 -0.0310 -0.0395 -0.0395 -0.0113 -0.0423 -0.0592 -0.0056 -0.0592 -0.2903 -0.0141 -0.0310 -0.4932 -0.0732 -0.0451 -0.0564 -0.3438 -0.0056 -0.4678 -0.0395 -0.0395 -0.0395 -1.0479 -0.0225 -0.0169 -0.0282 -0.0225 -0.0056 -0.2029 -0.0113 -0.0395 -0.8735 -0.0113 -0.0282 -0.0338 -0.0451 -0.1917 -0.0113 -0.0395 -0.3833 -0.0338 -0.0282 -0.0507 -0.2817 -1.0029 -0.6704 -0.0789 -0.0451 -0.0338 -0.1917 -0.6426 -0.5410 -0.6875 -1.1270 -0.5859 -0.0338 -0.5635 -0.5635 -0.0564 -1.0479 -0.0225 -0.0338 -0.3718 -0.0338', 'S-1921\tBesondere Vorsicht bei der Anwendung von Rotarix ist erforderlich Informieren Sie Ihren Arzt, wenn Ihr Kind • engen Kontakt, wie z.B. zu einem Haushaltsmitglied mit geschwächtem Immunsystem (z.B. eine Person, die Krebs hat oder die Arzenimittel einnimmt, die das Immunsystem schwächen) hat; • eine Erkrankung des Magen-Darmtraktes hat; • nicht wie erwartet wächst und an Gewicht zulegt; • frühgeboren ist, da der Grad der Schutzwirkung durch den Impfstoff in diesem Fall nicht be kannt ist.', 'T-1921\t63 Take special care with Rotarix Inform your doctor / health care professional if your child: • has a close contact such as a household member who has a weakened immune system, e.g., a person with cancer or who is taking medicines that may weaken the immune system. • has any disorder of the gastrointestinal system. • has not been gaining weight and growing as expected. • was born prematurely, because the level of protection afforded by the vaccine is unknown in this case.', 'H-1921\t-1.1494140625\t50 Take special care with Rotarix Inform your doctor if your child : • has a close contact such as a household member who has a weakened immune system , e.g. , a person with cancer or who is taking medicines that may weaken the immune system . • has any disorder of the gastrointestinal system . • has not been gaining weight and growing as expected . • was born prematurely , because the level of protection afforded by the vaccine is unknown in this case .', 'D-1921\t-1.1494140625\t50 Take special care with Rotarix Inform your doctor if your child: • has a close contact such as a household member who has a weakened immune system, e.g., a person with cancer or who is taking medicines that may weaken the immune system. • has any disorder of the gastrointestinal system. • has not been gaining weight and growing as expected. • was born prematurely, because the level of protection afforded by the vaccine is unknown in this case.', 'P-1921\t-0.6846 -0.3516 -0.2600 -0.0388 -0.3120 -0.2395 -0.0141 -0.0240 -0.3157 -0.0113 -0.0352 -0.0521 -0.6226 -0.3184 -0.0423 -0.3296 -0.0535 -0.0676 -0.3127 -0.0507 -0.0958 -0.2563 -0.0310 -0.1945 -0.2113 -0.0451 -0.3240 -0.0592 -0.6030 -0.1578 -0.0169 -0.1465 -0.0282 -0.6313 -0.2761 -0.0225 -0.2817 -0.1635 -0.0451 -0.2423 -0.0282 -0.1803 -0.1691 -0.2367 -0.1183 -0.2593 -0.4958 -0.0958 -0.3718 -0.1409 -0.0169 -0.3325 -0.0225 -0.0225 -0.7554 -0.0338 -0.0958 -0.3438 -0.3157 -0.1578 -0.0338 -0.4395 -0.2029 0.0000 -0.0113 -0.0113 -0.7554 -0.3269 -0.0338 -0.3157 -0.0676 -0.3042 -0.3157 -0.0901 -0.2593 -0.1803 -0.0451 -0.0564 -0.0901 -0.1353 -0.2479 -0.0451 -0.0225 -0.1917 -0.0225 -0.0113 -0.1917 -0.2817 -0.0789 -0.2141 -0.0225 -0.0901 -0.3157 -0.0225 -0.0338 -0.0789 -0.0338 -0.1465 -0.3042 -0.1691 -0.1014 -0.1240 -0.0338 -0.0338', 'S-1659\tIn einer anderen Studie wurde an den Tagen 1 bis 21 je eine Einzeldosis eines aus Ethinylestradiol und Norethindron bestehenden oralen Kontrazeptivums zusammen mit EMEND, in einem Therapieschema mit 125 mg an Tag 8 und 80 mg / Tag an den Tagen 9 und 10, sowie Ondansetron 32 mg i.v. an Tag 8 und Dexamethason oral 12 mg an Tag 8 und 8 mg / Tag an den Tagen 9, 10 und 11, verabreicht.', 'T-1659\tIn another study, single doses of an oral contraceptive containing ethinyl estradiol and norethindrone were administered on Days 1 through 21 with EMEND, given as a regimen of 125 mg on Day 8 and 80 mg / day on Days 9 and 10 with ondansetron 32 mg intravenouslyon Day 8 and oral dexamethasone given as 12 mg on Day 8 and 8 mg / day on Days 9, 10, and 11.', 'H-1659\t-0.97705078125\tIn another study , single doses of an oral contraceptive containing ethinyl estradiol and norethindrone were administered on Days 1 to 21 withEMEND , given as a regimen of 125 mg on Day 8 and 80 mg / day on Days 9 and 10 with ondansetron 32 mg intravenously on Day 8 and oral dexamethasone given as 12 mg on Day 8 and 8 mg / day on Days 9 , 10 and 11 .', 'D-1659\t-0.97705078125\tIn another study, single doses of an oral contraceptive containing ethinyl estradiol and norethindrone were administered on Days 1 to 21 withEMEND, given as a regimen of 125 mg on Day 8 and 80 mg / day on Days 9 and 10 with ondansetron 32 mg intravenously on Day 8 and oral dexamethasone given as 12 mg on Day 8 and 8 mg / day on Days 9, 10 and 11.', 'P-1659\t-0.0575 -0.0604 -0.2184 -0.0856 -0.2859 -0.1064 -0.0275 -0.0507 -0.1345 -0.0155 -0.0627 -0.0127 -0.0218 -0.2627 -0.0211 -0.0303 -0.3691 -0.5142 -0.0042 -0.0310 -0.0409 -0.0183 -0.0183 -0.0254 -0.2311 -0.1028 -0.4282 -0.0225 -0.3889 -0.7974 -0.0282 -0.8706 -0.0169 -0.4480 -0.0282 -0.0338 -0.0225 -0.2593 -0.3213 -0.2930 -0.1521 -0.2874 -0.0282 -0.1973 -0.0395 -0.0169 -0.1296 -0.5747 -0.0338 -0.0564 -0.0282 -0.0113 -0.0338 -0.0338 -0.0338 -0.0338 -0.0225 -0.0282 -0.0282 -0.7778 -0.1917 -0.0113 -0.0225 -0.0113 -0.0507 -0.0451 -0.0113 -0.6426 -0.0395 -0.0901 -0.1803 -0.9297 -0.0676 -0.0338 -0.0676 -0.2930 -0.1465 -0.0113 -0.0225 -0.0113 -0.0113 -0.0113 -0.3269 -0.1353 -0.2367 -0.0113 -0.4622 -0.9355 -0.0225 -0.0338 -0.0451 -0.0113 -0.0338 -0.0225 -0.0338 -0.0225 -0.0225 -0.0338 -0.0225 -1.0029 -0.0225 -0.0676 -0.0338', 'S-7\tIn Tabelle 1 sind die unerwünschten Arzneimittelreaktionen aufgeführt (Ereignisse, bei denen ein kausaler Zusammenhang mit dem Arzneimittel angenommen wird), die bei 291 Alzheimer-Patienten auftraten, die im Rahmen einer spezifischen 24-wöchigen doppelblinden, placebo- und wirkstoffkontrollierten klinischen Studie zu Prometax transdermalen Pflastern die Dosis 9,5 mg / 24 Stunden erhielten (anfangs 4,6 mg / 24 Stunden, gesteigert auf 9,5 mg / 24 Stunden).', 'T-7\tTable 1 displays the adverse reactions (events reasonably believed to be causally related to the medicinal product) reported in 291 patients with Alzheimer <<unk>> s dementia treated in a specific 24-week double-blind, placebo and active-controlled clinical study with Prometax transdermal patches at target dose of 9.5 mg / 24 h (4.6 mg / 24 h titrated to 9.5 mg / 24 h).', 'H-7\t-0.92822265625\tTable 1 lists the adverse reactions ( events reasonably believed to be causally related to the medicinal product ) reported in 291 patients with Alzheimer &quot; s dementia treated in a specific 24 @-@ week double @-@ blind , placebo and active @-@ controlled clinical study with Prometax transdermal patches at target dose of 9.5 mg / 24 h ( 4.6 mg / 24 h titrated to 9.5 mg / 24 h ) .', 'D-7\t-0.92822265625\tTable 1 lists the adverse reactions (events reasonably believed to be causally related to the medicinal product) reported in 291 patients with Alzheimer "s dementia treated in a specific 24-week double-blind, placebo and active-controlled clinical study with Prometax transdermal patches at target dose of 9.5 mg / 24 h (4.6 mg / 24 h titrated to 9.5 mg / 24 h).', 'P-7\t-0.1553 -0.0327 -1.3701 -0.2776 -0.0423 -0.0070 -0.6172 -0.0085 -0.0972 -0.0310 -0.3254 -0.0789 -0.2986 -0.0395 -0.0564 -0.0310 -0.2817 -0.1775 -0.0845 -0.1859 -0.3352 -0.1240 -0.0310 -0.0282 -0.4790 -0.0676 -0.1409 -0.0282 -0.3438 -0.1409 -0.0282 -0.3213 -0.0282 -0.3269 -0.3269 -0.4453 -0.0676 -0.1409 -0.0789 -0.1409 -0.0169 -0.1071 -0.0507 -0.0225 -0.1859 -0.0113 -0.0225 -0.0113 -0.0225 -0.3662 -0.3042 -0.2649 -0.3213 -0.1071 -0.8677 -0.4001 -0.1071 -0.0169 -0.0113 -0.0338 -0.0169 -0.0113 -0.0113 -0.0225 -0.1803 -0.3269 -0.0789 -0.1465 -0.0338 -0.0564 -0.0113 -0.0338 -0.0338 -0.3718 -0.0338 -0.3157 -0.0338 -0.0113 -0.0338 -0.0338 -0.0338 -0.3269 -0.3269 -0.2029 -0.0789 -0.0225 -0.0338 -0.0113 -0.0338 -0.0338 -0.0225 -0.1127 -0.0338 -0.0338', 'S-929\tNebenwirkungen können mit bestimmten Häufigkeiten auftreten, die wie folgt definiert werden: • Sehr häufig: betrifft mehr als 1 von 10 Anwendern • Häufig: betrifft 1 bis 10 von 100 Anwendern • Gelegentlich: betrifft 1 bis 10 von 1.000 Anwendern • Selten: betrifft 1 bis 10 von 10.000 Anwendern • Sehr selten: betrifft weniger als 1 von 10.000 Anwendern • Unbekannt: die Häufigkeit kann auf der Grundlage der vorliegenden Daten nicht abgeschätzt werden', 'T-929\tSide effects may occur with certain frequencies, which are defined as follows: • very common: affects more than 1 user in 10 • common: affects 1 to 10 users in 100 • uncommon: affects 1 to 10 users in 1,000 • rare: affects 1 to 10 users in 10,000', 'H-929\t-0.7021484375\tSide effects may occur with certain frequencies , which are defined as follows : • very common : affects more than 1 user in 10 • common : affects 1 to 10 users in 100', 'D-929\t-0.7021484375\tSide effects may occur with certain frequencies, which are defined as follows: • very common: affects more than 1 user in 10 • common: affects 1 to 10 users in 100', 'P-929\t-0.6108 -0.0887 -0.2078 -0.0373 -0.1487 -0.1282 -0.0254 -0.0423 -0.0155 -0.3606 -0.3804 -0.1888 -0.2113 -0.0310 -0.2930 -0.0423 -0.0352 -0.4775 -0.1493 -0.4255 -0.0479 -0.0451 -0.0282 -0.0310 -0.3184 -0.2001 -0.0479 -0.3579 -0.2649 -0.0254 -0.0310 -0.0423 -0.0592 -0.0310 -0.1775 -0.0451 -0.0282 -0.5469', 'S-799\tDie Daten zur Pharmakokinetik von Nevirapin stammen aus zwei größeren Quellen: einer in Südafrika durchgeführte Studie über 48 Wochen (BI 1100.1368) an insgesamt 123 HIV- positiven, antiretroviral unbehandelten Kindern im Alter von 3 Monaten bis 16 Jahren; und einer konsolidierten Analyse von fünf Studien der Paediatric AIDS Clinical Trial Group (PACTG), in die 495 Patienten im Alter von 14 Tagen bis 19 Jahren eingeschlossen wurden.', 'T-799\tData concerning the pharmacokinetics of nevirapine has been derived from two major sources: a 48 week paediatric trial in South Africa (BI 1100.1368) involving 123 HIV-1 positive, antiretroviral naïve patients aged 3 months to 16 years; and a consolidated analysis of five Paediatric AIDS Clinical Trials Group (PACTG) protocols comprising 495 patients aged 14 days to 19 years.', 'H-799\t-1.9189453125\tPharmacokinetic data for nevirapine are obtained from two large data for 48 weeks ( BID 1100.1368 ) in a total of 123 HIV @-@ positive , antiretroviral @-@ naïve children aged 3 months to 16 years , and also in a pooled analysis of five studies carried out by the Paediatric AIDS Clinical Trial Group ( PACTG ) enrolling 495 patients aged 14 days to 19 years .', 'D-799\t-1.9189453125\tPharmacokinetic data for nevirapine are obtained from two large data for 48 weeks (BID 1100.1368) in a total of 123 HIV-positive, antiretroviral-naïve children aged 3 months to 16 years, and also in a pooled analysis of five studies carried out by the Paediatric AIDS Clinical Trial Group (PACTG) enrolling 495 patients aged 14 days to 19 years.', 'P-799\t-1.4375 -0.0169 -0.0437 -0.0085 -0.0141 -0.2888 -0.0240 -0.5762 -0.1014 -0.0310 -0.0099 -0.2803 -1.1416 -1.7246 -0.0366 -0.0338 -0.2959 -0.3213 -0.7666 -0.9355 -0.0395 -0.0901 -0.9805 -1.2227 -0.0676 -0.0225 -0.1465 -0.0225 -0.0169 -0.0338 -0.8057 -0.6592 -0.0451 -0.0338 -0.0113 -0.0225 -0.7891 -0.0113 -1.0371 -0.3494 -0.0225 -0.0113 -0.0338 -1.2959 -0.3269 -0.0225 -0.0225 -0.0564 -1.0938 -1.2734 -0.0338 -0.5747 -0.0338 -0.0338 -1.0254 -0.0451 -1.1270 -0.7778 -0.0789 -0.8340 0.0000 -0.0225 -0.0225 -0.0451 -0.0451 -0.2029 -1.6680 -0.0225 -0.3381 -0.0451 -0.1353 0.0000 0.0000 -0.0225 -0.0225 -0.0225 -0.0225 -0.0225 -0.0225 -0.5859 -0.0225 -0.0225 -0.0225 -0.0225 0.0000 -0.0225 -2.0059 -0.1578 -0.0225 -0.0225 -0.0451 -0.2479 -0.9019 -0.0451 -0.0451 -0.0225 -0.0225 -0.0676 -0.0225', 'S-1164\tBei der Intent- To-Treat Analyse (Patienten mit fehlenden Werten werden als Therapieversager betrachtet) lag nach 24 Wochen der Anteil an Patienten mit < 400 (< 50) Kopien / ml HIV-RNA bei 75% (58%) und die durchschnittliche Erhöhung bei der CD4-Zellzahl gegenüber dem Ausgangswert bei den 36 Patienten, die Kaletra in einer Dosierung von 400 / 100 mg erhielten, 174 Zellen / mm3.', 'T-1164\tBy intent-to-treat analysis where patients with missing values are considered virologic failures, the proportion of patients with HIV RNA < 400 (< 50) copies / ml at 24 weeks was 75% (58%) and the mean increase from baseline in CD4 cell count was 174 cells / mm3 for the 36 patients receiving the 400 / 100 mg dose of Kaletra.', 'H-1164\t-0.9501953125\tBy intent to treat analysis where patients with missing values are considered virologic failures , the proportion of patients with HIV RNA &lt; 400 ( &lt; 50 ) copies / ml at 24 weeks was 75 % ( 58 % ) and the mean increase from baseline in CD4 cell count was 174 cells / mm3 for the 36 patients receiving the 400 / 100 mg dose of Kaletra .', 'D-1164\t-0.9501953125\tBy intent to treat analysis where patients with missing values are considered virologic failures, the proportion of patients with HIV RNA < 400 (< 50) copies / ml at 24 weeks was 75% (58%) and the mean increase from baseline in CD4 cell count was 174 cells / mm3 for the 36 patients receiving the 400 / 100 mg dose of Kaletra.', 'P-1164\t-1.4180 -0.3220 -0.4973 -0.0592 -0.2676 -0.4226 -0.0901 -0.1493 -0.1493 -0.1606 -0.1127 -0.1071 -0.3240 -0.3184 -0.2959 -0.2367 -0.1465 -0.0197 -0.0817 -0.1945 -0.1691 -0.0310 -0.0310 -0.4988 -0.3438 -0.1014 -0.0169 -0.3101 -0.0169 -0.0338 -0.0338 -0.2761 -0.0113 -0.0113 -0.0338 -0.0225 -0.0282 -0.0113 -0.0732 -0.0845 -0.2874 -0.3381 -0.0282 -0.0676 -0.0845 -0.0338 -0.0395 -0.0113 -0.0225 -0.0282 -0.6426 -0.0732 -0.1353 -0.0451 -0.6255 0.0000 -0.0113 -0.8286 -0.1071 -0.0282 -0.1635 -0.1691 -0.2085 -0.0225 -0.0225 -0.0169 -0.0338 -0.0338 -0.0338 -0.6426 -0.1127 -0.0225 -0.0338 -0.3606 -0.3042 -0.0451 -0.0338 -0.0451 -0.0113 -0.0564 -0.2029 -0.1353 -0.0225 -0.0113 -0.0338 -0.0338', 'S-1875\tKeppra ist indiziert zur Zusatzbehandlung • partieller Anfälle mit oder ohne sekundärer Generalisierung bei Erwachsenen und Kindern ab 4 Jahren mit Epilepsie. • myoklonischer Anfälle bei Erwachsenen und Jugendlichen ab 12 Jahren mit Juveniler Myoklonischer Epilepsie. • primär generalisierter tonisch-klonischer Anfälle bei Erwachsenen und Jugendlichen ab 12 Jahren mit Idiopathischer Generalisierter Epilepsie.', 'T-1875\tKeppra is indicated as adjunctive therapy • in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. • in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. • in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.', 'H-1875\t-0.89306640625\tKeppra is indicated for the adjunctive treatment • partial seizures with or without secondary generalization in adults and children from 4 years of age with epilepsy . • myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy . • primary generalized tonic @-@ clonic seizures in adults and adolescents from 12 years of age with idiopathic generalized epilepsy .', 'D-1875\t-0.89306640625\tKeppra is indicated for the adjunctive treatment • partial seizures with or without secondary generalization in adults and children from 4 years of age with epilepsy. • myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. • primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalized epilepsy.', 'P-1875\t-0.0313 -0.0149 -0.0156 -0.0502 -0.0128 -0.4646 -0.3701 -0.2734 -0.0282 -0.0655 -0.2683 -0.8892 -1.0273 -0.5156 -0.0141 -0.0225 -0.1465 -0.2817 -0.0254 -0.0169 -0.0423 -0.8257 -0.0338 -0.0225 -0.0310 -0.0338 -1.3408 -0.4565 -0.0395 -0.1465 -0.0225 -0.0395 -0.0225 -0.0225 -0.0225 -0.0225 -0.9019 -0.0282 -0.1071 -0.0113 -0.0225 -0.0338 -0.0113 -0.0113 -0.0225 -0.0338 -0.0225 -0.0282 -0.1183 -0.0169 -0.0225 -1.3018 -0.4453 -0.0338 -0.0732 -0.0225 -0.0395 -0.3042 -0.0113 -0.0169 -0.0225 -0.0113 -0.0169 -0.0282 -0.0564 -0.0507 -0.0169 -0.0282 -0.0338 -0.0338 -0.0225 -0.0901 -0.0225 -0.4282 -0.0225 -0.0338 -0.1353 -0.0113 -0.1127 -0.0676 -0.0113 -0.0225 -0.0338 -0.1803 -0.0225 -0.0451 -0.0225 -0.0338 -0.1353 -0.0225 -0.0338 -0.0451 -0.0225 -0.0338 -0.4282 -0.0225 -0.0113 -0.0225 -0.1803 -0.6201 -0.0338 -0.0225 -0.0225 -0.0225 -0.0338 -0.0338', 'S-204\tBeim Vergleichsimpfstoff, der intramuskulär verabreicht wird, lagen - alle 3 Influenzastämme zusammen betrachtet - die Seroprotektionsraten zwischen 74,8% und 95,4%, die Raten der Serokonversion oder des signifikanten Anstiegs zwischen 56,4% und 69,3% und die GMTRs zwischen dem 6,63- und 11,2-Fachen über dem Basiswert der HI-Titer.', 'T-204\t5 Across all three influenza strains, for the comparator intramuscular vaccine seroprotection rates ranged between 74.8% and 95.4%, seroconversion or significant increase rates ranged between 56.4% and 69.3% and GMTRs ranged between 6.63 and 11.2-fold over baseline HI titres.', 'H-204\t-1.1513671875\tAcross all three influenza strains , for the comparator intramuscular vaccine GMTRs ranged between 74.8 % and 95.4 % , seroconversion or significant increase rates ranged between 56.4 % and 69.3 % and GMTRs ranged between 6.63 and 11.2 @-@ fold over baseline HI titres .', 'D-204\t-1.1513671875\tAcross all three influenza strains, for the comparator intramuscular vaccine GMTRs ranged between 74.8% and 95.4%, seroconversion or significant increase rates ranged between 56.4% and 69.3% and GMTRs ranged between 6.63 and 11.2-fold over baseline HI titres.', 'P-204\t-0.3635 -0.0701 -0.1367 -0.1444 -0.3499 -0.0063 -0.0268 -0.0704 -0.0113 -0.3931 -2.1465 -0.1324 -0.2507 -0.2986 -0.3467 -0.0338 -0.0113 -0.3296 -0.0507 -0.3269 -0.1859 -0.0366 -1.0508 -0.0169 -1.0820 -0.0225 -0.0282 -0.0282 -0.0901 -0.4734 -0.0225 -0.0225 -0.0282 -0.0282 -0.1071 -0.0564 -0.5239 -0.4902 -0.0113 -0.2986 -0.0845 -0.2141 -0.1859 -0.2367 -0.0113 -0.5239 -0.0282 -0.0169 -0.0282 -0.0282 -0.0338 -0.0225 -0.0169 -0.0282 -0.0225 -0.4058 -0.1240 -0.0564 -0.0338 -0.1014 -0.0113 -0.4846 -0.0338 -0.0338 -0.7778 -0.0113 -0.0225 -0.3269 -0.0338 -0.4282 -0.2705 0.0000 -0.2479 -0.3833 -0.0564 -0.3157 -0.0338 -0.0338 -0.0338', 'S-1474\tRotaTeq kann zeitgleich mit anderen Impfstoffen verabreicht werden, die üblicherweise zur Impfung von Kindern empfohlen werden, wie Diphtherie-, Tetanus-, Pertussis- (Keuchhusten), Haemophilus influenzae Typ b-Impfstoffen, inaktiviertem oder oralem Polio-Impfstoff, Hepatitis B-Impfstoff und Pneumokokken-Konjugatimpfstoff.', 'T-1474\tRotaTeq may be given at the same time as your child receives other normally recommended vaccinations, such as diphtheria, tetanus, pertussis (whooping cough), Haemophilus influenzae type b, inactivated or oral poliomyelitis, hepatitis B and pneumococcal conjugate vaccines.', 'H-1474\t-0.8212890625\tRotaTeq can be given at the same time as other routine paediatric vaccines such as diphtheria , tetanus , pertussis , Haemophilus influenzae type b vaccines , inactivated or oral polio vaccine , hepatitis B vaccine and pneumococcal conjugate vaccine .', 'D-1474\t-0.8212890625\tRotaTeq can be given at the same time as other routine paediatric vaccines such as diphtheria, tetanus, pertussis, Haemophilus influenzae type b vaccines, inactivated or oral polio vaccine, hepatitis B vaccine and pneumococcal conjugate vaccine.', 'P-1474\t-0.2874 -0.0269 -0.0148 -0.0141 -0.4700 -0.0289 -0.7896 -0.6636 -0.0592 -0.0240 -0.5044 -0.4312 -0.0535 -1.9385 -0.7690 -0.0113 -0.0113 -0.0225 -0.0225 -0.0507 -0.5581 -0.0282 -0.0901 -0.0169 -0.0056 -0.0056 -0.0507 -0.0169 -0.0113 -0.0282 -0.0282 -0.0282 0.0000 -0.0169 -0.0282 -0.2423 -0.2593 -0.0225 -0.0225 -0.0113 -0.0225 -0.0225 -0.0113 -0.0732 -0.3777 -0.1409 -0.3213 -0.0282 -0.0282 -0.1747 -0.0564 -0.0282 -0.0620 -0.0113 -0.0169 -0.0225 -0.8340 -0.0282 -0.0338 -0.0056 -0.0113 -0.0169 -0.0507 -0.5298 -0.0395 -0.0113 -0.0113 -0.0338 -0.0169 -0.0451 -0.0056 -0.0282 -0.0113 -0.0564 -0.2311 -0.0338 -0.0338', 'S-1263\t(44-20) 74 18 84 00 Fax (44-20) 74 18 84 68 E-mail: mail @ emea.europa.eu http: / / www.emea.europa.eu © EMEA 2007 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged über 6 Monate) wurde die Wirksamkeit von TRAVATAN als Ergänzungstherapie für Patienten untersucht, denen gleichzeitig auch Timolol verabreicht wurde.', 'T-1263\t(44-20) 74 18 84 00 Fax (44-20) 74 18 84 68 E-mail: mail @ emea. europa. eu http: / / www. emea. europa. eu © EMEA 2007 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged What benefit has TRAVATAN shown during the studies?', 'H-1263\t-0.81103515625\t( 44 @-@ 20 ) 74 18 84 00 Fax ( 44 @-@ 20 ) 74 18 84 68 E @-@ mail : mail @ emea. europa. eu http : / / www. emea. europa. eu © EMEA 2007 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged for more than 6 months ) 74 18 84 00', 'D-1263\t-0.81103515625\t(44-20) 74 18 84 00 Fax (44-20) 74 18 84 68 E-mail: mail @ emea. europa. eu http: / / www. emea. europa. eu © EMEA 2007 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged for more than 6 months) 74 18 84 00', 'P-1263\t-0.4822 -0.0183 -0.0278 -0.0257 -0.0285 -0.0141 -0.0299 -0.0120 -0.0211 -0.0176 -0.0278 -0.0127 -0.0275 -0.0225 -0.0268 -0.0085 -0.0268 -0.0127 -0.0085 -0.0648 -0.0282 -0.0120 -0.0282 -0.0148 -0.0169 -0.0070 -0.3228 -0.0070 -0.3228 -0.3213 -0.0944 -0.0141 -0.0282 -0.0296 -0.0310 -0.3228 -0.2634 -0.0564 -0.0183 -0.3213 -0.0085 -0.3213 -0.2563 -0.3184 -0.0141 -0.0310 -0.0141 -0.0338 -0.0282 -0.0564 -0.0254 -0.0282 -0.0310 -0.0254 -0.0197 -0.0282 -0.0282 -0.0169 -0.0282 -0.1353 -0.0225 -0.0282 -0.0395 -0.3071 -0.0366 -0.0225 -0.0197 -0.0310 -0.0225 -0.0169 -0.0338 -0.0338 -0.1550 -0.2227 -1.7783 -0.0282 -0.0395 -0.0282 -0.0395 -1.2227 -0.0507 -0.0845 -0.0564 -2.6309', 'S-340\tIn einer zwölfwöchigen placebokontrollierten Studie an Kindern von 2-5 Jahren konnte unter der einmal täglichen Gabe von 4 mg Montelukast eine Verbesserung der asthmaspezifischen Zielparameter im Vergleich zu Placebo, unabhängig von einer Begleittherapie mit anderen Arzneimitteln (Controller) zur Dauertherapie (Kortikosteroide oder Cromoglicinsäure inhalativ / mittels Inhalationsgerät), erreicht werden.', 'T-340\tIn a 12-week, placebo-controlled study in paediatric patients 2 to 5 years of age, montelukast 4 mg once daily improved parameters of asthma control compared with placebo irrespective of concomitant controller therapy (inhaled / nebulized corticosteroids or inhaled / nebulized sodium cromoglycate).', 'H-340\t-2.150390625\tIn a 12 @-@ week , placebo @-@ controlled trial in children aged 2 @-@ 5 years , with once daily administration of 4 mg montelukast , improvement in the variables of asthma control was achieved compared to placebo , regardless of concomitant treatment with other medicinal products .', 'D-340\t-2.150390625\tIn a 12-week, placebo-controlled trial in children aged 2-5 years, with once daily administration of 4 mg montelukast, improvement in the variables of asthma control was achieved compared to placebo, regardless of concomitant treatment with other medicinal products.', 'P-340\t-0.4377 -0.2120 -0.1237 -0.4819 -0.0268 -0.3157 -0.1818 -0.0225 -0.0155 -0.0268 -0.0676 -0.0352 -1.4512 -1.1074 -0.0338 -0.6172 -0.0564 -0.6592 -0.0282 -0.1859 -0.5693 -0.7720 -0.6650 -0.7832 -0.4846 -0.2986 -0.0901 -0.0169 -0.1465 -0.0113 -0.0282 -0.0113 -0.3662 -0.6821 -0.5747 -0.7437 -0.6875 -0.9580 -0.4282 -0.7324 -0.0113 -0.0113 -1.0371 -0.8452 -1.0938 -0.9917 -0.1014 -0.0225 -0.0225 -0.0225 -0.0225 -0.4846 -1.2510 -0.0338 -0.4622 -0.2705 0.0000 -0.0338 -1.3643 -0.0676 -0.2930 -0.4058 -0.3157 -0.0676 -2.0742 -0.1353', 'S-127\tDer Ausschuss gelangte zu dem Schluss, dass die Vorteile von Ranexa als zusätzliche Behandlung der Symptome bei Patienten mit stabiler Angina pectoris, bei denen eine nicht ausreichende Kontrolle erzielt werden kann oder die die Mittel der ersten Wahl gegen Angina pectoris (wie Beta-Blocker und Calciumantagonisten) nicht vertragen, gegenüber den Risiken überwiegen, und empfahl, die Genehmigung für das Inverkehrbringen von Ranexa zu erteilen.', 'T-127\tThe Committee recommended that Ranexa be given marketing authorisation.', 'H-127\t-1.302734375\tThe Committee recommended that RANEXA be given marketing authorisation .', 'D-127\t-1.302734375\tThe Committee recommended that RANEXA be given marketing authorisation.', 'P-127\t-0.6338 -0.1243 -0.3228 -0.0718 -3.4902 -0.2141 -0.1042 -0.0225 -0.2791 -0.2537 -0.3213 -0.1296 -0.0169 -0.3101 -0.3213', 'S-588\tIntronA, 18 Millionen I.E. / Pen, Injektionslösung: <unk> Packung mit 1 Pen, 12 Injektionsnadeln und 12 Reinigungstupfern <unk> Packung mit 2 Pens, 24 Injektionsnadeln und 24 Reinigungstupfern <unk> Packung mit 8 Pens, 96 Injektionsnadeln und 96 Reinigungstupfern Es werden möglicherweise nicht alle Packungsgrößen in den Verkehr gebracht.', 'T-588\t- Pack of 8 pens, 96 injection needles and 96 cleansing swabs', 'H-588\t-1.017578125\tIntronA , 18 million IU / pen , solution for injection : Pack of 1 pen , 12 injection needles and 12 cleansing swabs Box of 2 pens , 24 injection needles and 24 cleansing swabs Package of 8 pens , 96 injection needles and 96 cleansing swabs Not all packs may be marketed .', 'D-588\t-1.017578125\tIntronA, 18 million IU / pen, solution for injection: Pack of 1 pen, 12 injection needles and 12 cleansing swabs Box of 2 pens, 24 injection needles and 24 cleansing swabs Package of 8 pens, 96 injection needles and 96 cleansing swabs Not all packs may be marketed.', 'P-588\t-0.0285 -0.0199 -0.0256 -0.0371 -0.2705 -0.1036 -0.1212 -0.2371 -0.0430 -0.1797 -0.2388 -0.3213 -0.2085 -0.0704 -0.0620 -1.3555 -0.6567 -0.0704 -0.4846 -0.1917 -0.0535 -0.0310 -0.0254 -0.2903 -0.0507 -0.0395 -0.0254 -0.0676 -0.0254 -0.2874 -0.0986 -0.3213 -0.0113 -1.9951 -0.0338 -0.0282 -0.0451 -0.0282 -0.2255 -0.0225 -0.1578 -0.0169 -0.0338 -0.0225 -0.0395 -0.0282 -0.2085 -0.0564 -0.0620 -0.0056 -0.7666 -0.0338 -0.5693 -0.0395 -0.0395 -0.0225 -0.0282 -0.0169 -0.1521 -0.0225 -0.0169 -0.0282 -0.0338 -0.0169 -0.1296 -0.0732 -0.0169 -0.0113 -0.5747 -0.0451 -1.4648 -0.1127 -0.2141 -0.0564 -0.2141 -0.0113 -0.0789 -0.0338', 'S-1777\tIn einer Placebo-kontrollierten Studie über 26 Wochen gefolgt von einer Langzeit-Erweiterungsphase über 74 Wochen bei manischen Patienten, die mit Aripiprazol während einer Stabilisierungsphase vor Randomisierung eine Remission erreicht hatten, zeigte sich Aripiprazol gegenüber Placebo überlegen im Hinblick auf die Prävention eines bipolaren Rückfalls, vorwiegend bei der Prävention eines Rückfalls in die Manie.', 'T-1777\tIn a 26-week, placebo-controlled trial, followed by a 74-week extension, in manic patients who achieved remission on aripiprazole during a stabilization phase prior to randomization, aripiprazole demonstrated superiority over placebo in preventing bipolar recurrence, primarily in preventing recurrence into mania but failed to demonstrate superiority over placebo in preventing recurrence into depression.', 'H-1777\t-0.78173828125\t102 In a 26 @-@ week , placebo @-@ controlled trial , followed by a 74 @-@ week extension , in manic patients who achieved remission on aripiprazole during a stabilization phase prior to randomization , aripiprazole demonstrated superiority over placebo in preventing bipolar recurrence , primarily in preventing recurrence into mania but failed to demonstrate superiority over placebo in preventing recurrence into depression .', 'D-1777\t-0.78173828125\t102 In a 26-week, placebo-controlled trial, followed by a 74-week extension, in manic patients who achieved remission on aripiprazole during a stabilization phase prior to randomization, aripiprazole demonstrated superiority over placebo in preventing bipolar recurrence, primarily in preventing recurrence into mania but failed to demonstrate superiority over placebo in preventing recurrence into depression.', 'P-1777\t-0.6338 -0.3223 -0.0838 -0.3542 -0.1726 -0.0352 -0.3198 -0.0085 -0.0197 -0.0225 -0.0254 -0.0662 -0.0310 -0.2156 -0.2903 -0.0127 -0.0296 -0.0817 -0.0746 -0.1761 -0.0395 -0.3157 -0.3071 -0.1747 -0.1691 -0.0113 -0.0366 -0.0789 -0.3157 -0.0366 -0.0085 -0.3127 -0.1127 -0.0141 -0.0310 -0.0141 -0.0028 -0.0564 -0.0676 -0.0676 -0.1973 -0.1155 -0.1353 -0.0282 -0.0310 -0.3972 -0.0338 -0.0338 -0.1578 -0.0113 -0.0225 -0.0113 0.0000 -0.3042 -0.3157 -0.0225 -0.0056 -0.1353 -0.0169 -0.0225 -0.0225 -0.0225 -0.1353 -0.2311 -0.0451 -0.0169 -0.0225 -0.3042 -0.0338 -0.0113 -0.0169 -0.0564 -0.1747 -0.0958 -0.0845 -0.2761 -0.0225 -0.0113 -0.0225 -0.3157 -0.0507 -0.0056 -0.3213 -0.3269 -0.0732 -0.3101 -0.3213 -0.0282 -0.0056 -0.2705 -0.0338 -0.0225 -0.0225 -0.0282 -0.3042 -0.3101 -0.3213 -0.0225 -0.0225 -0.0225 -0.3606 -0.3494 -0.0564 -0.0338', 'S-984\tBei klinischen Studien mit ADVATE an 145 Kindern und Erwachsenen 10 mit diagnostizierter schwerer bis mittelschwerer Hämophilie A (FVIII ≤ 2%) und vorheriger Exposition gegenüber Faktor VIII- Konzentraten (≥ 150 Tage) zeigte nur ein Patient nach 26 Expositionstagen mit ADVATE einen niedrigen Inhibitortiter (2,4 B.E. im modifizierten Bethesda-Ansatz).', 'T-984\tDuring clinical trials with ADVATE in 145 paediatric and adult patients 10 diagnosed with severe to moderately severe haemophilia A (FVIII ≤ 2%), with previous exposure to factor VIII concentrates ≥ 150 days, one patient developed a low-titre inhibitor (2.4 BU in the modified Bethesda assay) after 26 exposure days to ADVATE.', 'H-984\t-0.80224609375\tDuring clinical trials with ADVATE in 145 paediatric and adult patients 12 diagnosed with severe to moderately severe haemophilia A ( FVIII ≤ 2 % ) , with previous exposure to factor VIII concentrates ≥ 150 days , one patient developed a low @-@ titre inhibitor ( 2.4 BU in the modified Bethesda assay ) after 26 exposure days to ADVATE .', 'D-984\t-0.80224609375\tDuring clinical trials with ADVATE in 145 paediatric and adult patients 12 diagnosed with severe to moderately severe haemophilia A (FVIII ≤ 2%), with previous exposure to factor VIII concentrates ≥ 150 days, one patient developed a low-titre inhibitor (2.4 BU in the modified Bethesda assay) after 26 exposure days to ADVATE.', 'P-984\t-0.3364 -0.0662 -0.1553 -0.2205 -0.0211 -0.0268 -0.0155 -0.0240 -0.2001 -0.0148 -0.0261 -0.3220 -0.0113 -0.0521 -0.1353 -0.0972 -0.0732 -0.0732 -2.3613 -0.2423 -0.0507 -0.0254 -0.1381 -0.3157 -0.0451 -0.0225 -0.2113 -0.0225 -0.0028 -0.0254 -0.0366 -0.0310 -0.0225 -0.0282 -0.0169 -0.0085 -0.0310 -0.0225 -0.0282 -0.3523 -0.2479 -0.2537 -0.0225 -0.0338 -0.1635 -0.2705 -0.0507 -0.0676 -0.0225 -0.3213 -0.0169 -0.0282 -0.0732 -0.3213 -0.0395 -0.3213 -0.1803 -0.0451 -0.3213 -0.3213 -0.2479 -0.0338 -0.0056 -0.0113 -0.0282 -0.2255 -0.0507 -0.0338 -0.2593 -0.2930 -0.0901 -0.1465 -0.1127 -0.0225 -0.0282 -0.0225 -0.0225 -0.3213 -0.0282 -0.0451 -0.1071 -0.0338 -0.3157 -0.0338 -0.3042 -0.0225 -0.0225 -0.0113 -0.0225 -0.0451 -0.0338', 'S-1699\tDie systemische Verfügbarkeit und die Halbwertszeit von Nateglinid unterscheidet sich bei Diabetikern mit leichter bis mittelschwerer (Kreatinin-Clearance 31 <unk> 50 ml / min) und schwerer (Kreatinin-Clearance 15 <unk> 30 ml / min) Nierenfunktionsstörung (ohne Dialysepflicht) in einem nicht klinisch signifikanten Ausmaß von denen bei Gesunden.', 'T-1699\tThe systemic availability and half-life of nateglinide in diabetic patients with mild, moderate (creatinine clearance 31 <<unk>> 50 ml / min) and severe (creatinine clearance 15 <<unk>> 30 ml / min) renal impairment (not undergoing dialysis) did not differ to a clinically significant degree from those in healthy subjects.', 'H-1699\t-1.4375\tThe systemic availability and half @-@ life of nateglinide differs to a similar level in non @-@ clinically significant patients with mild to moderate ( creatinine clearance 15 to 30 ml / min ) and severe ( creatinine clearance 15 to 30 ml / min ) renal impairment ( without dialysis ) .', 'D-1699\t-1.4375\tThe systemic availability and half-life of nateglinide differs to a similar level in non-clinically significant patients with mild to moderate (creatinine clearance 15 to 30 ml / min) and severe (creatinine clearance 15 to 30 ml / min) renal impairment (without dialysis).', 'P-1699\t-1.1621 -0.1564 -0.0134 -0.0232 -0.1917 -0.0296 -0.0578 -0.0606 -0.0380 -0.0972 -0.2072 -0.0099 -0.0578 -0.0690 -1.4775 -0.0451 -0.9609 -0.2874 -0.8989 -0.7100 -0.4790 -1.9785 -0.0282 -0.1973 -0.0169 -0.0225 -0.9019 -0.1465 -0.0451 -0.7158 -0.3213 -0.1803 -0.2479 -0.0225 -0.0225 -0.0225 -0.0564 -0.0225 -1.2510 -0.5410 -0.1014 -0.0338 -0.0338 -0.0225 -0.0338 -0.4958 -0.0451 -0.0338 -0.0225 -0.0225 -0.0225 -0.0225 -0.0113 -0.0225 -0.1917 -0.2817 -0.6650 -0.0113 -0.0338 -0.0225 -0.0338 -0.2817 -0.0225 -0.8452 -0.0338 -0.0113 -0.0789 -0.0564 -0.4170 -0.4622 -0.0113 -0.0225 -0.1465 -0.8115 -0.0338', 'S-634\tEU / 1 / 06 / 368 / 076 (3 Patronen zu je 3 ml) EU / 1 / 06 / 368 / 077 (4 Patronen zu je 3 ml) EU / 1 / 06 / 368 / 078 (5 Patronen zu je 3 ml) EU / 1 / 06 / 368 / 079 (6 Patronen zu je 3 ml) EU / 1 / 06 / 368 / 080 (9 Patronen zu je 3 ml) EU / 1 / 06 / 368 / 081 (10 Patronen zu je 3 ml)', 'T-634\tEU / 1 / 06 / 368 / 076 (3 cartridges of 3 ml) EU / 1 / 06 / 368 / 077 (4 cartridges of 3 ml) EU / 1 / 06 / 368 / 078 (5 cartridges of 3 ml) EU / 1 / 06 / 368 / 079 (6 cartridges of 3 ml) EU / 1 / 06 / 368 / 080 (9 cartridges of 3 ml) EU / 1 / 06 / 368 / 081 (10 cartridges of 3 ml)', 'H-634\t-0.2276611328125\tEU / 1 / 06 / 368 / 076 ( 3 cartridges of 3 ml ) EU / 1 / 06 / 368 / 077 ( 4 cartridges of 3 ml ) EU / 1 / 06 / 368 / 078 ( 5 cartridges of 3 ml ) EU / 1 / 06 / 368 / 079 ( 6 cartridges of 3 ml ) EU / 1 / 06 / 368 / 080 ( 9 cartridges of 3 ml ) EU / 1 / 06 / 368 / 081 ( 10 cartridges of 3 ml )', 'D-634\t-0.2276611328125\tEU / 1 / 06 / 368 / 076 (3 cartridges of 3 ml) EU / 1 / 06 / 368 / 077 (4 cartridges of 3 ml) EU / 1 / 06 / 368 / 078 (5 cartridges of 3 ml) EU / 1 / 06 / 368 / 079 (6 cartridges of 3 ml) EU / 1 / 06 / 368 / 080 (9 cartridges of 3 ml) EU / 1 / 06 / 368 / 081 (10 cartridges of 3 ml)', 'P-634\t-0.0371 -0.0285 -0.0278 -0.0284 -0.0241 -0.0291 -0.0269 -0.0113 -0.0299 -0.0299 -0.0171 -0.0400 -0.0467 -0.1694 -0.0127 -0.0229 -0.1726 -0.1120 -0.0324 -0.1310 -0.0296 -0.0289 -0.0289 -0.0282 -0.0204 -0.0282 -0.0282 -0.0113 -0.0282 -0.0254 -0.0162 -0.0282 -0.0310 -0.1042 -0.0155 -0.0240 -0.0395 -0.0395 -0.0099 -0.1198 -0.0254 -0.0282 -0.0296 -0.0282 -0.0211 -0.0282 -0.0268 -0.0099 -0.0282 -0.0254 -0.0127 -0.0282 -0.0296 -0.0662 -0.0141 -0.0240 -0.0352 -0.0324 -0.0085 -0.0859 -0.0240 -0.0282 -0.0282 -0.0282 -0.0197 -0.0296 -0.0268 -0.0113 -0.0296 -0.0225 -0.0113 -0.0268 -0.0310 -0.0493 -0.0169 -0.0254 -0.0338 -0.0324 -0.0085 -0.0859 -0.0254 -0.0282 -0.0282 -0.0282 -0.0225 -0.0282 -0.0282 -0.0113 -0.0310 -0.0254 -0.0169 -0.0282 -0.0282 -0.0423 -0.0113 -0.0225 -0.0366 -0.0338 -0.0085 -0.0873 -0.0282 -0.0282 -0.0310 -0.0282 -0.0197 -0.0310 -0.0282 -0.0113 -0.0310 -0.0254 -0.0113 -0.0282 -0.0254 -0.0423 -0.0113 -0.0254 -0.0338 -0.0310 -0.0085 -0.0930 -0.0310', 'S-1593\tEU / 1 / 97 / 030 / 116 (3 Patronen zu je 3 ml) EU / 1 / 97 / 030 / 117 (4 Patronen zu je 3 ml) EU / 1 / 97 / 030 / 118 (5 Patronen zu je 3 ml) EU / 1 / 97 / 030 / 119 (6 Patronen zu je 3 ml) EU / 1 / 97 / 030 / 120 (9 Patronen zu je 3 ml) EU / 1 / 97 / 030 / 121 (10 Patronen zu je 3 ml)', 'T-1593\tEU / 1 / 97 / 030 / 116 (3 cartridges of 3 ml) EU / 1 / 97 / 030 / 117 (4 cartridges of 3 ml) EU / 1 / 97 / 030 / 118 (5 cartridges of 3 ml) EU / 1 / 97 / 030 / 119 (6 cartridges of 3 ml) EU / 1 / 97 / 030 / 120 (9 cartridges of 3 ml) EU / 1 / 97 / 030 / 121 (10 cartridges of 3 ml)', 'H-1593\t-0.2216796875\tEU / 1 / 97 / 030 / 116 ( 3 cartridges of 3 ml ) EU / 1 / 97 / 030 / 117 ( 4 cartridges of 3 ml ) EU / 1 / 97 / 030 / 118 ( 5 cartridges of 3 ml ) EU / 1 / 97 / 030 / 119 ( 6 cartridges of 3 ml ) EU / 1 / 97 / 030 / 120 ( 9 cartridges of 3 ml ) EU / 1 / 97 / 030 / 121 ( 10 cartridges of 3 ml )', 'D-1593\t-0.2216796875\tEU / 1 / 97 / 030 / 116 (3 cartridges of 3 ml) EU / 1 / 97 / 030 / 117 (4 cartridges of 3 ml) EU / 1 / 97 / 030 / 118 (5 cartridges of 3 ml) EU / 1 / 97 / 030 / 119 (6 cartridges of 3 ml) EU / 1 / 97 / 030 / 120 (9 cartridges of 3 ml) EU / 1 / 97 / 030 / 121 (10 cartridges of 3 ml)', 'P-1593\t-0.0393 -0.0299 -0.0270 -0.0284 -0.0128 -0.0284 -0.0270 -0.0241 -0.0292 -0.0269 -0.0234 -0.0342 -0.0430 -0.1726 -0.0127 -0.0229 -0.1642 -0.1141 -0.0296 -0.1183 -0.0303 -0.0289 -0.0282 -0.0282 -0.0113 -0.0282 -0.0247 -0.0240 -0.0282 -0.0240 -0.0218 -0.0282 -0.0310 -0.1007 -0.0169 -0.0240 -0.0366 -0.0380 -0.0099 -0.1042 -0.0254 -0.0296 -0.0282 -0.0282 -0.0099 -0.0282 -0.0240 -0.0240 -0.0282 -0.0254 -0.0254 -0.0282 -0.0296 -0.0704 -0.0141 -0.0254 -0.0338 -0.0324 -0.0085 -0.0620 -0.0254 -0.0282 -0.0282 -0.0282 -0.0113 -0.0282 -0.0240 -0.0240 -0.0282 -0.0268 -0.0211 -0.0282 -0.0310 -0.0521 -0.0183 -0.0254 -0.0324 -0.0310 -0.0085 -0.0620 -0.0282 -0.0282 -0.0282 -0.0282 -0.0113 -0.0282 -0.0254 -0.0254 -0.0282 -0.0113 -0.0282 -0.0282 -0.0451 -0.0141 -0.0225 -0.0338 -0.0310 -0.0085 -0.0535 -0.0310 -0.0282 -0.0310 -0.0282 -0.0113 -0.0282 -0.0254 -0.0254 -0.0310 -0.0254 -0.0282 -0.0282 -0.0254 -0.0451 -0.0113 -0.0254 -0.0310 -0.0310 -0.0085 -0.0648 -0.0310', 'S-1050\tWirkstoffe, die den Metabolismus über CYP3A induzieren Die gemeinsame Anwendung von TORISEL mit Rifampicin, einem starken CYP3A4 / 5-Induktor, hatte keinen signifikanten Effekt auf die Cmax (maximale Konzentration) von Temsirolimus und AUC (Fläche unter der Konzentrationskurve gegen die Zeit) nach intervenöser Anwendung, erniedrigte aber die Sirolimus-Cmax um 65% und die -AUC um 56%, verglichen mit der alleinigen Behandlung mit TORISEL.', 'T-1050\tAgents inducing CYP3A metabolism Co-administration of TORISEL with rifampicin, a potent CYP3A4 / 5 inducer, had no significant effect on temsirolimus Cmax (maximum concentration) and AUC (area under the concentration vs. time curve) after intravenous administration, but decreased sirolimus Cmax by 65% and AUC by 56%, compared to TORISEL treatment alone.', 'H-1050\t-1.421875\tAgents that induce CYP3A metabolism Co @-@ administration of TORISEL with rifampicin , a potent CYP3A4 / 5 inducer , had no significant effect on Cmax ( maximum concentration ) of temsirolimus and AUC ( area under the curve versus time ) after invasive administration , but decreased sirolimus Cmax by 65 % and AUC by 56 % compared to Treatment with TORISEL alone .', 'D-1050\t-1.421875\tAgents that induce CYP3A metabolism Co-administration of TORISEL with rifampicin, a potent CYP3A4 / 5 inducer, had no significant effect on Cmax (maximum concentration) of temsirolimus and AUC (area under the curve versus time) after invasive administration, but decreased sirolimus Cmax by 65% and AUC by 56% compared to Treatment with TORISEL alone.', 'P-1050\t-0.3213 -0.0349 -0.9863 -0.4438 -0.0225 -0.6113 -0.0225 -0.0254 -0.0240 -0.0296 -0.0564 -0.0056 -0.0169 -0.3184 -0.0507 -0.2676 -0.0366 -0.0310 -0.0197 -0.0141 -0.0197 -0.0395 -0.0592 -0.0169 -0.0197 -0.0169 -0.0310 -0.0395 -0.0366 -1.0342 -0.0338 -0.0338 -0.0254 -0.0254 -0.0225 -0.0141 -0.0338 -0.0282 -0.0338 -0.0197 -0.2791 -0.1917 -0.6426 -0.0338 -0.0395 -0.4282 -0.0395 -1.3867 -0.0169 -0.3269 -0.1353 -0.1409 -0.0338 -0.2593 -0.2197 -0.0338 -0.0282 -0.4902 -0.0113 -0.0395 -0.0113 -0.5410 -0.0338 -0.0845 -0.2537 -0.1353 -0.6479 -0.0169 -2.0801 -0.0676 -0.0564 -0.7554 -1.9502 -0.0225 -0.0225 -0.3042 -0.8906 -0.0564 -0.8003 -0.0225 -0.6875 -0.0338 -0.0338 -0.0225 -0.4058 -0.0113 -0.0338 -0.0225 -0.0338 -0.2479 -0.2479 -0.2141 -0.0676 -0.0225 -0.0225 -0.5747 -0.5859 -1.5215 -0.0225 -0.0225 -0.1353 -0.0225 -0.0225 -0.0225 -0.0225 -0.0225 -0.0225 -0.0451', 'S-909\tZur Behandlung von subklinischer Mastitis bei laktierenden Kühen hervorgerufen durch Pirlimycin- empfindliche, grampositive Kokken einschließlich Staphylokokken wie Staphylococcus aureus, sowohl Penicillinase-positive als auch Penicillinase-negative und Koagulase-negative Staphylokokken; Streptokokken, einschließlich Streptococcus agalactiae, Streptococcus dysgalactiae und Streptococcus uberis', 'T-909\tFor the treatment of subclinical mastitis in lactating cows due to Gram-positive cocci susceptible to pirlimycin including staphylococcal organisms such as Staphylococcus aureus, both penicillinase-positive and penicillinase-negative, and coagulase-negative staphylococci; streptococcal organisms including Streptococcus agalactiae, Streptococcus dysgalactiae and Streptococcus uberis.', 'H-909\t-1.1904296875\tTreatment of subclinical mastitis in lactating cows caused by pirlimycin @-@ susceptible Gram @-@ positive staphylococci , including Staphylococcus aureus , penicillinase @-@ positive , penicillinase @-@ negative and coagulase @-@ negative staphylococci ; Streptococci , including Streptococcus agalactiae , Streptococcus dysgalactiae and Streptococcus uberis', 'D-909\t-1.1904296875\tTreatment of subclinical mastitis in lactating cows caused by pirlimycin-susceptible Gram-positive staphylococci, including Staphylococcus aureus, penicillinase-positive, penicillinase-negative and coagulase-negative staphylococci; Streptococci, including Streptococcus agalactiae, Streptococcus dysgalactiae and Streptococcus uberis', 'P-909\t-1.3564 -0.0606 -0.0359 -0.0479 -0.6890 -0.0183 -0.0225 -0.0113 -0.0099 -1.1074 -0.1465 -0.0197 -0.0310 -0.8564 -0.0141 -0.9775 -0.0282 -0.5972 -0.0225 -0.0282 -0.0507 -0.0225 -0.6821 -0.4678 -0.0282 -0.0225 -0.0169 -0.0169 -0.9185 -0.0169 -0.7720 -0.0395 -1.5557 -0.1353 -0.0169 -0.0169 -0.0507 -1.4648 -0.0225 -0.8789 -0.0225 -0.0225 -0.0225 -0.0225 -0.0113 -0.0225 -0.0113 -0.0225 -0.0225 -0.3606 -0.4058 -0.0225 -0.0338 -0.0225 -0.0113 -1.0254 -0.0676 -1.0703 -0.1127 -0.0225 -0.3494 -0.0113 -0.0225 -0.0338 -0.0113 -0.8228 -0.0338 -0.0113 -0.0338 -0.0225 -0.0338 -0.0225 -0.5298 -0.0564 -0.0225 -0.0225 -0.0225 -0.3269 -0.0901 -0.0225 -0.0113 -0.0113 -0.0676 -0.5972 -0.0113 -0.0225 -0.0225 -0.0225 -0.0225 -0.0113 -0.0338 -0.0225 -0.0225 -0.0338 -0.0113 -0.0113 -0.0338 -0.0113 -0.0225 -0.0225 -0.0225 -0.0113 -0.0225 -0.0113 -0.0113 -0.0225 -0.0225 -0.0113 -0.4170 -0.0225 -0.0225 -0.0225 -0.0225 -0.0113 -0.0225 -0.0338 -0.0113 -0.0225 -0.0564', 'S-610\tKopfschmerzen, Heißhunger, Übelkeit, Erbrechen, Müdigkeit, Schläfrigkeit, Schlafstörungen, Unruhe, Aggressivität, Konzentrationsstörungen, eingeschränktes Reaktionsvermögen, Niedergeschlagenheit, Verwirrtheit, Sprachstörungen (möglicherweise können Sie überhaupt nicht sprechen), Sehstörungen, Zittern, Lähmungen, Gefühlsstörungen (Parästhesien), Taubheit und Kribbeln im Bereich des Mundes, Schwindel, Verlust der Selbstkontrolle, Hilflosigkeit, Krampfanfälle, Bewusstlosigkeit.', 'T-610\tExamples of symptoms that indicate a low sugar level in the brain: headaches, intense hunger, nausea, vomiting, tiredness, sleepiness, sleep disturbances, restlessness, aggressive behaviour, lapses in concentration, impaired reactions, depression, confusion, speech disturbances (sometimes total loss of speech), visual disorders, trembling, paralysis, tingling sensations (paraesthesia), numbness and tingling sensations in the area of the mouth, dizziness, loss of self-control, inability to look after yourself, convulsions, loss of consciousness.', 'H-610\t-1.537109375\tHeadache , intense hunger , nausea , vomiting , tiredness , drowsiness , sleep disturbances , restlessness , aggressiveness , lapses in concentration , impaired reactions , depression , confusion , speech disturbances ( sometimes total loss of speech ) , visual disorders , tremor , paralysis , tingling sensation ( paraesthesia ) , numbness and tingling sensation in the area of the mouth , dizziness , loss of self @-@ control , inability to look after yourself , convulsions , loss of consciousness .', 'D-610\t-1.537109375\tHeadache, intense hunger, nausea, vomiting, tiredness, drowsiness, sleep disturbances, restlessness, aggressiveness, lapses in concentration, impaired reactions, depression, confusion, speech disturbances (sometimes total loss of speech), visual disorders, tremor, paralysis, tingling sensation (paraesthesia), numbness and tingling sensation in the area of the mouth, dizziness, loss of self-control, inability to look after yourself, convulsions, loss of consciousness.', 'P-610\t-2.0449 -0.0113 -0.0127 -0.1620 -0.0324 -0.3228 -0.3198 -0.0310 -0.5186 -0.0085 -0.3296 -0.0197 -0.0056 -0.0282 -0.2339 -0.8906 -0.0141 -0.0254 -0.0310 -1.6094 -0.0113 -0.0169 -0.0225 -0.0282 -0.8511 -0.5859 -0.4282 -0.0225 -0.0282 -0.4846 -0.0056 -0.0225 -0.0282 -0.6255 -0.1127 -0.0113 -0.0282 -1.4873 -0.0845 -0.2197 -0.5186 -0.0338 -0.3042 -0.0113 -0.3494 -0.5186 -0.0338 -0.4958 -0.0338 -0.0338 -0.0338 -0.6538 -0.3945 -0.3381 -0.0225 -0.0338 -0.3381 -0.3269 -0.3157 -0.0338 -0.1240 -0.0451 -0.0338 -0.3494 -1.1494 -0.0225 -0.0338 -0.2255 -0.3606 -0.2141 -0.0338 -0.1691 -0.0225 -0.0338 -0.0338 -0.3606 -0.0225 -0.0225 -0.3042 -0.6426 -1.1162 -0.3606 -0.0338 -0.0451 -0.0338 -0.0338 -0.0451 -0.0564 -0.0113 -0.0225 -0.2705 -0.0338 0.0000 -0.0225 -0.3718 -0.3157 -0.2255 -0.0451 -0.3157 -0.0451 -0.2255 -0.0225 -0.0451 -0.0676 0.0000 -0.0225 -0.0225 -0.0225 -0.0225 -0.0451 -0.0676 -0.0225 -0.0225 -0.3381 -0.1127 -0.3157 -0.3157 -0.2479 -0.0451 -0.3833 0.0000 -0.3833 -0.9019 -0.2479 -0.0225 -0.0225 -0.0225 -0.2029 -0.0225', 'S-1908\tDie häufigsten Nebenwirkungen von Efient (beobachtet bei 1 bis 10 von 100 Patienten) sind Anämie (niedrige Zahl roter Blutzellen), Hämatom (Ansammlung von Blut unter der Haut oder in einem Muskel), Nasenbluten, gastrointestinale Blutungen (Magen- oder Darmblutungen), Ausschlag, Hämaturie (Blut im Urin), Blutungen an der Nadeleinstichstelle und Hämatom (Bluterguss) an der Nadeleinstichstelle.', 'T-1908\tThe most common side effects with Efient (seen in between 1 and 10 patients in 100) are anaemia (low red blood cell counts), haematoma (a collection of blood under the skin or in a muscle), epistaxis (nosebleeds), gastrointestinal haemorrhage (bleeding in the stomach or gut), rash, haematuria (blood in the urine), bleeding from needle puncture sites, haematoma at puncture sites and bruising.', 'H-1908\t-1.1474609375\tThe most common side effects with Efient ( seen in between 1 and 10 patients in 100 ) are anaemia ( low red blood cell counts ) , haematoma ( build @-@ up of blood under the skin or into a muscle ) , nosebleeds , gastrointestinal bleeding ( bleeding in the stomach or gut ) , rash , haematuria ( blood in the urine ) , bleeding at the needle puncture site and haematoma ( bruising ) at the needle puncture site .', 'D-1908\t-1.1474609375\tThe most common side effects with Efient (seen in between 1 and 10 patients in 100) are anaemia (low red blood cell counts), haematoma (build-up of blood under the skin or into a muscle), nosebleeds, gastrointestinal bleeding (bleeding in the stomach or gut), rash, haematuria (blood in the urine), bleeding at the needle puncture site and haematoma (bruising) at the needle puncture site.', 'P-1908\t-0.0737 -0.0371 -0.0575 -0.2551 -0.0416 -0.3176 -0.1162 -0.0169 -0.0183 -0.0437 -0.2866 -0.0331 -0.3113 -0.0395 -0.0662 -0.0324 -0.2776 -0.2817 -0.0578 -0.1099 -0.0916 -0.0254 -0.2634 -0.0056 -0.0254 -0.0282 -0.0760 -0.4819 -0.0395 -0.4902 -0.2847 -0.0282 -0.0310 -0.4282 -0.0395 -0.0169 -0.0141 -0.0282 -1.8740 -0.0845 -0.0282 -0.0282 -0.0225 -0.1803 -0.0676 -0.0169 -0.0282 -0.3777 -0.2874 -0.0169 -0.0282 -0.0282 -1.6621 -0.0169 -0.0113 -0.0056 -0.2423 -0.4622 -0.2029 -0.0395 -0.0056 -0.0113 -0.0113 -0.9751 -0.0338 -0.0225 -0.3157 -0.0113 -0.6987 -0.1578 -0.0225 -0.0338 -1.2510 -0.0338 -0.0338 -0.0338 -0.0451 -0.0338 -0.1014 -0.0338 -0.0225 -0.0225 -0.0225 -0.0338 -0.0901 -0.0338 -0.8452 -0.0113 -0.0225 -0.0338 -0.0338 -0.9692 -0.0113 -0.5186 -0.0338 -0.0564 -0.0338 -0.8564 -0.0225 -0.0451 -0.2705 -0.0676 -0.0225 -0.0113 -0.0113 -0.0338 -0.1578 -0.0564 -0.0338 -0.0338 -0.0338 -0.0113 -0.0225 -1.0371 -0.0113 -0.0338 -0.0338 -0.0338', 'S-811\tIn seiner Sitzung im Juni 2006 war der CHMP angesichts der insgesamt vorgelegten Daten und der wissenschaftlichen Erörterung innerhalb des Ausschusses der Ansicht, dass das Nutzen-Risiko- Verhältnis für Doxagamma 4 mg Retardtabletten und zugehörige Namen günstig ist, dass die vorgebrachten Einwände kein Hindernis für die Erteilung einer Genehmigung für das Inverkehrbringen darstellen und dass die Zusammenfassung der Merkmale des Arzneimittels, die Etikettierung und die Packungsbeilage des Referenzmitgliedstaats geändert werden sollten.', 'T-811\tDuring the June 2006 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit / risk ratio is favourable for Doxagamma 4 mg prolonged release tablets and associated names, that the objections raised should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.', 'H-811\t-0.78759765625\tDuring the June 2006 meeting , the CHMP , in the light of the overall data submitted and the scientific discussion within the Committee , was of the opinion that the benefit / risk ratio is favourable for Doxagamma 4 mg prolonged release tablets and associated names , that the objections raised should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics , labelling and package leaflet of the Reference Member State should be amended .', 'D-811\t-0.78759765625\tDuring the June 2006 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit / risk ratio is favourable for Doxagamma 4 mg prolonged release tablets and associated names, that the objections raised should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.', 'P-811\t-0.3188 -1.0146 -0.1022 -0.0289 -0.1113 -0.1381 -0.1831 -0.0197 -0.0113 -0.2720 -0.1888 -0.1564 -0.0254 -0.0282 -0.1254 -0.1127 -0.0690 -0.2903 -0.0564 -0.1353 -0.0479 -0.1212 -0.0732 -0.0423 -0.0760 -0.0338 -0.3101 -0.0282 -0.0310 -0.0732 -0.0282 -0.0423 -0.0169 -0.1268 -0.0197 -0.0423 -0.2874 -0.0535 -0.0141 -0.0225 -0.0451 -0.2283 -0.0225 -0.4958 -0.0141 -0.0282 -0.7070 -0.0113 -0.3213 -0.3101 -0.0338 -0.2423 -0.0451 -0.0282 -0.0507 -0.1578 -0.0395 -0.0451 -0.0395 -0.0507 -0.0451 -0.0225 -0.0958 -0.8174 -0.0338 -0.2986 -0.2085 -0.1071 -0.0225 -0.0282 -0.1917 -0.3213 -0.0507 -0.1183 -0.0282 -0.1183 -0.0338 -0.0451 -0.3101 -0.0113 -0.0451 -0.3157 -0.1578 -0.0113 -0.0056 -0.0169 -0.0225 -0.0507 -0.3494 -0.0225 -0.0338 -0.2367 -0.1803 -0.0225 -0.0451 -0.0789 -0.0338 -0.2930 -0.0338 -0.0113 -0.0225 -0.0225 -0.0225 -0.1691 -0.0225 -0.0338 -0.0338', 'S-1327\tPhantasiebezeichnung Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge', 'T-1327\tExforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge', 'H-1327\t-0.451904296875\tInvented name Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge', 'D-1327\t-0.451904296875\tInvented name Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge Exforge', 'P-1327\t-0.8750 -0.2507 -0.3198 -0.0930 -0.0296 -0.0211 -0.0254 -0.0282 -0.0225 -0.0225 -0.0282 -0.0211 -0.0211 -0.0282 -0.0211 -0.0211 -0.0282 -0.0211 -0.0197 -0.0296 -0.0211 -0.0197 -0.0310 -0.0225 -0.0197 -0.0310 -0.0225 -0.0197 -0.0310 -0.0225 -0.0197 -0.0310 -0.0225 -0.0197 -0.0310 -0.0225 -0.0197 -0.0310 -0.0225 -0.0197 -0.0310 -0.0225 -0.0197 -0.0310 -0.0225 -0.0197 -0.0310 -0.0240 -0.0183 -0.0324 -0.0240 -0.0197 -0.0324 -0.0225 -0.0197 -0.0338 -0.0240 -0.0197 -0.0352 -0.0254 -0.0197 -0.0366 -0.0254 -0.0225 -0.0366 -0.0254 -0.0225 -0.0366 -0.0254 -0.0254 -0.0366 -0.0254 -0.0282 -0.0338 -0.0254 -0.0282 -0.0338 -0.0254 -0.0310 -0.0338 -0.0254 -0.0310 -0.0338 -0.0254 -0.0310 -0.0338 -0.0254 -0.0338 -0.0338 -0.0254 -0.0338 -0.0338 -0.0254 -0.0732 -0.0338 -0.0254 -0.0817 -0.0338 -0.0254 -0.0845 -0.0366 -0.0254 -0.0930 -0.0366 -0.0254 -0.1071 -0.0338 -0.0254 -0.1240 -0.0338 -0.0254 -0.1521 -0.0338 -0.0254 -0.2001 -0.0338 -0.0254 -2.6309', 'S-117\tChlamydophila felis (Stamm 905) <unk>. <unk> <unk> <unk> <unk> <unk> <unk> <unk>.. <unk> <unk> <unk> <unk>.. <unk> <unk> <unk> <unk> <unk> <unk> <unk>. ≥ 103,0 EID50 FPV (Stamm PLI IV) <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk>... ≥ 103,5 GKID50 FeLV-Rekombinante des Kanarienpockenvirus (Stamm vCP97) <unk> <unk> <unk>.. <unk> <unk> <unk> <unk>. ≥ 107,2 GKID50 Gentamicin, max. <unk> <unk> <unk> <unk>. <unk> <unk> <unk> <unk> <unk> <unk> <unk>. <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk>. <unk> <unk> <unk> <unk> <unk> 34 µg', 'T-117\tChlamydophila felis (905 strain)......................................................................................... ≥ 103.0 EID50 FPV (PLI IV).................................................................................................................... ≥ 103.5 CCID50 FeLV recombinant canarypox virus (vCP97).................................................................. ≥ 107.2 CCID50 Gentamicin, at most........................................................................................................................ .34 µg', 'H-117\t-4.484375\tΠλλάδα ΛΙΑΝΕΞ &amp; Σικολευκου &amp; Σικολευκολευκωσίολάου Χρ / / Λτευκωσωσία . &quot; &amp; &lt; / &lt; .ΕΞ .Ε. ) • − − − − − − − − − − − − − − − − − − − − − − − − − − −', 'D-117\t-4.484375\tΠλλάδα ΛΙΑΝΕΞ & Σικολευκου & Σικολευκολευκωσίολάου Χρ / / Λτευκωσωσία. "& < / < .ΕΞ .Ε.) • − − − − − − − − − − − − − − − − − − − − − − − − − − −', 'P-117\t-1.7949 -0.8892 -1.0527 -0.2903 -0.3127 -0.3157 -0.5298 -1.5664 -0.3269 -0.6201 -0.4958 -0.3213 -1.0088 -0.3269 -0.3833 -0.3718 -0.3606 -0.9580 -0.9917 -0.4395 -0.4282 -0.4170 -1.1719 -0.9243 -0.3269 -0.6201 -0.5522 -0.8115 -1.7578 -1.3750 -0.4282 -0.9805 -1.0146 -1.1494 -1.6904 -0.5186 -0.7212 -0.8789 -0.8789 -1.0820 -0.9917 -1.2852 -0.9019 -0.4282 -0.8564 -0.9917 -0.6538 -0.8340 -0.3606 -0.8115 -1.7129 -0.9917 -0.4509 -0.6538 -0.8789 -0.5635 -1.1045 -0.6084 -1.2627 -0.7212 -0.9917 -0.9917 -1.4424 -0.3157 0.0000 -0.0451 -1.2627 -0.3157 0.0000 -0.0451 -0.9917 -0.3606 -0.4958 -0.8564 -0.4509 -0.8564 -1.1270 -0.4058 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -5.9961', 'S-932\tInfluenza A / equi-2 / Ohio / 03 [H3N8] -Rekombinante des Kanarienpockenvirus (Stamm vCP2242)....................................................................... ≥ 5,3 log10 FAID50 * Influenza A / equi-2 / Newmarket / 2 / 93 [H3N8] -Rekombinante des Kanarienpockenvirus (Stamm vCP1533)....................................................................... ≥ 5,3 log10 FAID50 * * Im Fluoreszenz-Assay ermittelte zellkulturinfektiöse Dosis 50%.', 'T-932\tInfluenza A / equi-2 / Ohio / 03 [H3N8] recombinant Canarypox virus (vCP2242) ≥ 5.3 log10 FAID * 50 Influenza A / equi-2 / Newmarket / 2 / 93 [H3N8] recombinant Canarypox virus (vCP1533) ≥ 5.3 log10 FAID * 50 * Fluorescent assay infectious dose 50% Clostridium tetani toxoid', 'H-932\t-2.0\tInfluenza A / equi @-@ 2 / Ohio / 03 &#91; H3N8 &#93; recombinant Canarypox virus ( vCP2242 ) ............................................... ≥ 5.3 log10 FAID50 * Influenza A / equi @-@ 2 / Newmarket / 2 / 93 &#91; H3N8 &#93; recombinant Canarypox virus ( vCP1533 ) .......................................................................................................................................................................................................................................................................................................................................... ≥ 5.3 log10 FAID50 *', 'D-932\t-2.0\tInfluenza A / equi-2 / Ohio / 03 [H3N8] recombinant Canarypox virus (vCP2242)............................................... ≥ 5.3 log10 FAID50 * Influenza A / equi-2 / Newmarket / 2 / 93 [H3N8] recombinant Canarypox virus (vCP1533).......................................................................................................................................................................................................................................................................................................................................... ≥ 5.3 log10 FAID50 *', 'P-932\t-0.0560 -0.0056 -0.0085 -0.0285 -0.0299 -0.0299 -0.0386 -0.0313 -0.0285 -0.0292 -0.0299 -0.0113 -0.0306 -0.0164 -0.0285 -0.0271 -0.0278 -0.0225 -0.0236 -0.0250 -0.4368 -0.0240 -0.0176 -0.0282 -0.3176 -0.3220 -0.3113 -0.0901 -0.0169 -0.0465 -0.0366 -0.3198 -0.0282 -0.0268 -0.0225 -0.0197 -0.0268 -0.3157 -0.0141 -0.0225 -0.0254 -0.0254 -0.0282 -0.0282 -0.0282 -0.0254 -0.0254 -0.0254 -0.3240 -2.4590 -0.0056 -0.2255 -0.3042 -0.0225 -0.0282 -0.0338 -0.0169 -0.0282 -0.0225 -0.0338 -0.0564 -0.0169 -0.0056 -0.0282 -0.0225 -0.0282 -0.0169 -0.0338 -0.0282 -0.0282 -0.0282 -0.0113 -0.0169 -0.0282 -0.0282 -0.0282 -0.0113 -0.0225 -0.0282 -0.0282 -0.0225 -0.0225 -0.0282 -0.0676 -0.0282 -0.0113 -0.0282 -0.3101 -0.2197 -0.0225 -0.0225 -0.0225 -0.0169 -0.0282 -0.0901 -0.0282 -0.0282 -0.0225 -0.0169 -0.6821 -0.0169 -0.0282 -0.0282 -0.0282 -0.0282 -0.0282 -0.0282 -0.0282 -0.0282 -0.0282 -0.0282 -0.0282 -0.0282 -0.0282 -0.0282 -0.0338 -0.0338 -0.3101 -0.2986 -0.0451 -0.0564 -0.0676 -0.0732 -0.2817 -0.3042 -0.4114 -0.4902 -0.4846 -0.4622 -0.4509 -0.4282 -0.4058 -0.3718 -0.1465 -0.3494 -0.3718 -0.3833 -0.3945 -0.3718 -0.5972 -0.7100 -0.7324 -0.7100 -0.6538 -0.6084 -0.5859 -0.3718 -0.3833 -0.3833 -0.3833 -0.4170 -0.4509 -0.6084 -0.8564 -0.9019 -0.6763 -0.6763 -0.8789 -0.8564 -0.6313 -0.4509 -0.4509 -0.4509 -0.4509 -0.4734 -0.4734 -0.5186 -0.4958 -0.4958 -0.5186 -0.5410 -0.5635 -0.6084 -0.6084 -0.5635 -0.5635 -0.5635 -0.5859 -0.6538 -0.7437 -0.8115 -1.6680 -0.9692 -0.0676 -0.0225 -0.0225 -0.0225 -0.0225 -0.0451 -0.0225 -0.0225 -0.0225 -0.3381 -2.9531', 'S-33\tDer Zulassungsantrag für Compagel Gel für Pferde stützte sich auf Artikel 13 der Richtlinie 2001 / 82 / EG, einschließlich Änderungen, worin festgestellt wird, dass <unk> Abweichend von Artikel 12 Absatz 3 Unterabsatz 1 Buchstabe j) und unbeschadet des Rechts über den Schutz des gewerblichen und kommerziellen Eigentums der Antragsteller nicht verpflichtet ist, die Ergebnisse der Unbedenklichkeits- und Rückstandsversuche oder der vorklinischen und klinischen Versuche vorzulegen, wenn er nachweisen kann, dass es sich bei dem Arzneimittel um ein Generikum eines Referenzarzneimittels handelt, das gemäß Artikel 5 seit mindestens acht Jahren in einem Mitgliedstaat oder in der Gemeinschaft genehmigt ist oder wurde. <unk>', 'T-33\t13 of Directive 2001 / 82 / EC as amended, in which it is stated that <<unk>> By way of derogation from point (j) of the first subparagraph of Article 12 (3), and without prejudice to the law relating to the protection of industrial and commercial property, the applicant shall not be required to provide the results of the safety and residue tests or of the preclinical and clinical trials if he can demonstrate that the medicinal product is a generic of a reference medicinal product which is or has been authorized under Article 5 for not less than eight years in a Member State or the Community. <<unk>>', 'H-33\t-2.599609375\tThe Marketing Authorisation Application for Compagel Gel for Horses was based on Article 13 of Directive 2001 / 82 / EC , as amended , stating that , in accordance with Article 12 ( 3 ) ( 1 ) ( j ) of Directive 2001 / 82 / EC and without prejudice to the legislation on the protection of the Applicants &quot; industrial and commercial health and safety and residue studies it is not required to provide the results of preclinical and clinical trials if it is established that the product is a generic with a reference medicine , registered in a Member State or the Community for at least eight years in accordance with Article 5 .', 'D-33\t-2.599609375\tThe Marketing Authorisation Application for Compagel Gel for Horses was based on Article 13 of Directive 2001 / 82 / EC, as amended, stating that, in accordance with Article 12 (3) (1) (j) of Directive 2001 / 82 / EC and without prejudice to the legislation on the protection of the Applicants "industrial and commercial health and safety and residue studies it is not required to provide the results of preclinical and clinical trials if it is established that the product is a generic with a reference medicine, registered in a Member State or the Community for at least eight years in accordance with Article 5.', 'P-33\t-0.5161 -2.8711 -0.0282 -0.1155 -0.0225 -0.1859 -0.0085 -0.0282 -0.0507 -0.0564 -0.0141 -0.0113 -0.8594 -0.0169 -0.0592 -0.6904 -0.0197 -0.2676 -0.0620 -0.0395 -0.0282 -0.0225 -0.0338 -0.0338 -0.0169 -0.0113 -0.0282 -0.0113 -0.0507 -0.0282 -0.4790 -0.3213 -0.0338 -0.0169 -0.1747 -0.7720 -0.0451 -1.8369 -1.0938 -0.3157 -0.0225 -0.0282 -0.0676 -1.0146 -0.0338 -0.0225 -0.0338 -0.1578 -0.0338 -0.0225 -0.0564 -0.0338 -0.0338 -0.3042 -0.8677 -0.0225 -1.7695 -0.0338 -0.0564 -0.0564 -0.0338 -0.3494 -1.6230 -0.3718 -0.0113 -0.2479 -0.0225 -1.0479 -0.8452 -0.8228 -1.1611 -0.1803 -0.0338 -0.8340 -1.2852 -0.7212 0.0000 -0.0225 -0.6538 -1.2852 -0.0451 -0.0451 -0.3157 -1.1494 -0.9019 -1.1270 -0.0225 -0.1353 -0.6538 -1.5332 -0.0901 -0.0676 -0.5186 -0.0451 -0.9917 -0.0901 -0.0225 -0.2479 -1.0146 0.0000 -0.0225 -0.0676 -0.0225 -0.2479 -0.8564 -0.1803 -0.3157 -0.3157 -0.0451 -0.0451 -0.2705 -0.0676 -0.2029 -0.0451 0.0000 -0.7666 -1.1719 -0.0451 -1.2402 -0.7891 -0.8789 -1.1719 -1.3301 -0.2255 0.0000 -0.0451 -0.4958 -0.0901 -0.6763 -0.2255 -0.0451 -0.0451 -0.0451 -1.6230 -0.2255 -0.0451 -0.0451 -0.0451 -0.0451 -0.0451 -0.0451', 'S-1888\tEine größere Zahl von Patienten, die mit {(Name (Phantasiebezeichnung)} behandelt wurden, war über 6 Monate [Kinder (61% mit {(Name (Phantasiebezeichnung)} gegenüber 34% in der Kontrollgruppe), Kleinkinder (70% mit {(Name (Phantasiebezeichnung)} gegenüber 33% in der Kontrollgruppe)] bzw. über 12 Monate [Kinder (51% mit {(Name (Phantasiebezeichnung)} gegenüber 28% in der Kontrollgruppe), Kleinkinder (57% mit {(Name (Phantasiebezeichnung)} gegenüber 28% in der Kontrollgruppe)] frei von akuten Ekzemschüben.', 'T-1888\tMore patients treated with < Invented Name > completed 6 months [children (61% < Invented Name > vs 34% control), infants (70% < Invented Name > vs 33% control)] and 12 months with no flare [children (51% < Invented Name > vs 28% control), infants (57% < Invented Name > vs 28% control)].', 'H-1888\t-1.845703125\t&lt; Invented Name &gt; had a sparing effect on the use of topical corticosteroids : more patients treated with &lt; Invented Name &gt; did not develop acute dermatitis over 6 months &#91; children ( 61 % &lt; Invented Name &gt; vs 34 % control ) , infants ( 70 % &lt; Invented Name &gt; vs 33 % control ) &#93; or more than 12 months &#91; children ( 51 % &lt; Invented Name &gt; vs 28 % control ) , infants ( 57 % &lt; Invented Name &gt; vs 28 % control ) &#93; .', 'D-1888\t-1.845703125\t< Invented Name > had a sparing effect on the use of topical corticosteroids: more patients treated with < Invented Name > did not develop acute dermatitis over 6 months [children (61% < Invented Name > vs 34% control), infants (70% < Invented Name > vs 33% control)] or more than 12 months [children (51% < Invented Name > vs 28% control), infants (57% < Invented Name > vs 28% control)].', 'P-1888\t-0.4805 -0.0042 -0.0169 -0.3501 -0.2881 -0.3423 -0.3086 -0.3213 -0.1803 -0.3579 -0.3198 -0.1945 -0.0986 -0.3015 -1.3389 -0.2593 -1.0762 -0.6650 -0.3718 -0.6650 -0.1917 0.0000 -0.6030 -0.0056 -2.0508 -0.2930 -0.1240 -0.3889 -0.0564 -0.3269 -0.0113 -0.0225 -0.3269 -0.0789 -0.0789 -0.2817 -0.5747 -0.0564 -2.3438 -1.1943 -0.0225 -1.4648 -0.0225 -0.0113 -1.6680 -1.0146 -0.0338 -0.1803 -0.1127 -0.1127 -0.0225 -0.0338 -0.3269 -0.0113 -0.0225 -0.3157 -0.0113 -0.0338 -0.2705 -0.3157 -0.1240 -0.0225 -0.2705 -0.3606 -0.1578 -0.3381 -0.0451 -0.0451 -0.0225 -0.0225 -0.3157 -0.0225 -0.0225 -0.0225 0.0000 -0.0225 -0.1127 -0.2479 -0.0225 -0.0225 -0.0451 -0.1578 -0.4958 -1.0371 -0.8340 -0.0676 -0.0225 -0.0225 -0.1803 -0.7437 -0.1578 -0.0225 -0.0225 -0.3157 0.0000 -0.0225 -0.0676 0.0000 -0.0225 -0.1127 -0.2479 -0.5859 -0.0225 -0.0451 -0.0676 -0.2479 -0.2705 -0.0225 -0.0451 -0.0225 -0.0225 -0.3157 0.0000 -0.0225 0.0000 0.0000 -0.0451 -0.0451 -0.2479 -0.4958 -0.0225 -0.0451 -0.1353 -0.1127 -0.9468 -0.0451', 'S-1293\t(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail @ emea.europa.eu http: / / www.emea.europa.eu © EMEA 2007 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged eingeschleust wurde, das die Zelle zur Bildung eines Pasteurella-multocida-Toxoids befähigt, d.h. einer genetisch veränderten Form des Toxins, die eine angemessene immunogene (zur Immunität führende) Aktivität entfaltet und keine toxischen Eigenschaften aufweist.', 'T-1293\t(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail @ emea. europa. eu http: / / www. emea. europa. eu © EMEA 2007 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged How has the effectiveness of Porcilis AR-T DF been studied?', 'H-1293\t-0.6376953125\t( 44 @-@ 20 ) 74 18 84 00 Fax ( 44 @-@ 20 ) 74 18 84 16 E @-@ mail : mail @ emea. europa. eu http : / / www. emea. europa. eu © EMEA 2007 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged How has Elaprase been studied ?', 'D-1293\t-0.6376953125\t(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail @ emea. europa. eu http: / / www. emea. europa. eu © EMEA 2007 Reproduction and / or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged How has Elaprase been studied?', 'P-1293\t-0.2842 -0.0213 -0.0285 -0.0255 -0.0291 -0.0127 -0.0285 -0.0113 -0.0218 -0.0162 -0.0278 -0.0127 -0.0271 -0.0225 -0.0278 -0.0077 -0.0271 -0.0099 -0.0197 -0.0726 -0.0282 -0.0127 -0.0282 -0.0169 -0.0162 -0.0070 -0.3220 -0.0085 -0.3228 -0.3228 -0.1465 -0.0183 -0.0282 -0.0296 -0.0310 -0.3228 -0.2761 -0.0549 -0.0183 -0.3213 -0.0085 -0.3213 -0.2847 -0.3184 -0.0113 -0.0254 -0.0141 -0.0366 -0.0310 -0.0423 -0.0254 -0.0282 -0.0310 -0.0254 -0.0225 -0.0282 -0.0282 -0.0141 -0.0310 -0.1071 -0.0225 -0.0282 -0.0366 -0.3157 -0.0338 -0.0225 -0.0169 -0.0310 -0.0225 -0.0197 -0.0338 -0.0310 -0.1635 -0.3662 -0.3240 -0.8906 -0.3213 -0.3213 -0.3213 -0.2761 -0.3213 -0.2930 -0.3213', 'S-1171\tJede Faltschachtel enthält eine 180-ml Flasche Xyrem; einen Flaschenadapter zum Eindrücken, der aus einer LDPE-Gehäusevertiefung, einem Silastic biomedizinischen ETR Elastomer-Ventil, einer Acrylnitril-Butadien-Styrol-Terpolymer-Ventilhalterung und einem LDPE-Rohr besteht; eine 10-ml Dosierhilfe mit Messeinteilung (Polypropylen-Spritze); zwei Polypropylen-Dosierbecher und zwei kindergesicherte HDPE-Schraubverschlüsse.', 'T-1171\tEach carton contains one bottle of 180ml Xyrem, a press-in bottle adaptor consisting of an LDPE bottle-well housing, a Silastic Biomedical ETR Elastomer valve, an acrylonitrile butadiene styrene terpolymer valve retainer and LDPE tubing, a graduated 10ml measuring device (polypropylene syringe), two polypropylene dosing cups and two HDPE child resistant screw closures.', 'H-1171\t-2.19921875\tEach carton contains one 180 ml bottle of Xyrem ; a press @-@ in @-@ bottle @-@ adapter consisting of an LDPE bottom cavity , a Silastinal Biomedical ETR elastomer valve , an acrylonitrile butadiene styrene valve , and one LDPE tube ; a 10 ml graduated dosage spike device ( polypropylene syringe ) ; two polypropylene dosing cups , and two child resistant HDPE screw caps .', 'D-1171\t-2.19921875\tEach carton contains one 180 ml bottle of Xyrem; a press-in-bottle-adapter consisting of an LDPE bottom cavity, a Silastinal Biomedical ETR elastomer valve, an acrylonitrile butadiene styrene valve, and one LDPE tube; a 10 ml graduated dosage spike device (polypropylene syringe); two polypropylene dosing cups, and two child resistant HDPE screw caps.', 'P-1171\t-0.2335 -0.2986 -0.0085 -0.0722 -0.6885 -0.1614 -0.0535 -0.5396 -0.3635 -0.2563 -0.0268 -0.0141 -0.6060 -0.1747 -0.2197 -0.0648 -0.1042 -0.4480 -0.0535 -1.0117 -0.0845 -0.6143 -1.1270 -0.0169 -0.0282 -1.8145 -0.4001 -0.0225 -0.0113 -2.3047 -1.1387 -0.0225 -0.0113 -0.0451 -0.2930 -0.1240 -0.8115 -1.6230 -0.5410 -0.0113 -0.0225 -0.0113 -0.0225 -0.0225 -0.2255 -0.0113 -0.0113 -0.4170 -0.4282 -0.0225 -0.0338 -0.6650 -0.7666 -0.0113 -0.0113 -0.0113 -0.0225 -0.0113 -0.9580 -0.0113 -0.0113 -0.2479 -0.0113 -0.9355 -0.0225 -0.9917 -0.0451 -1.4648 -0.2479 -0.0225 -0.0225 -0.8340 -0.0225 -0.6084 -0.7437 -0.0225 -1.0596 -0.0451 -1.3750 -0.3157 -0.0225 -0.5859 -0.2705 -1.6455 -0.0451 -0.0676 -0.0225 -0.0225 -0.0225 -0.3157 0.0000 0.0000 -0.0225 -0.0225 -0.5186 -0.0225 -0.0225 -0.0225 -0.0225 -0.2029 -0.0901 -0.0676 -1.0820 -0.0225 -0.0451 -0.5635 -0.9019 -0.0225 -0.1127 0.0000 -0.0451 -0.0225 -1.5107 -0.3157 -0.0225', 'S-1119\tEine schwere Hämolyse ist erkennbar an höheren LDH-Spiegeln im Serum als vor der Behandlung in Verbindung mit Folgendem: absolute Abnahme der Größe des PNH-Klons um mehr als 25% (nicht eingerechnet Verdünnungseffekte aufgrund von Transfusion) in einer Woche oder weniger; ein Hämoglobin- Spiegel von < 5 g / dl oder eine Abnahme von > 4 g / dl in einer Woche oder weniger; Angina pectoris; Veränderung des Geisteszustandes; Anstieg des Kreatinin-Spiegels im Serum um 50% oder Thrombose.', 'T-1119\tSerious haemolysis is identified by serum LDH levels greater than the pre-treatment level, along with any of the following: greater than 25% absolute decrease in PNH clone size (in the absence of dilution due to transfusion) in one week or less; a haemoglobin level of < 5 gm / dL or a decrease of > 4 gm / dL in one week or less; angina; change in mental status; a 50% increase in serum creatinine level; or thrombosis.', 'H-1119\t-2.162109375\tSevere haemolysis is as evidenced by higher serum LDH levels than before treatment in association with the following : absolute decrease in size of PNH clone of more than 25 % ( not including dilution effects due to transfusion ) in one week or less ; a hemoglobin level &lt; 5 g / dl or &gt; 4 g / dl decrease in one week or less ; angina pectoris ; mental status changes ; serum creatinine levels increased by 50 % or thrombosis .', 'D-1119\t-2.162109375\tSevere haemolysis is as evidenced by higher serum LDH levels than before treatment in association with the following: absolute decrease in size of PNH clone of more than 25% (not including dilution effects due to transfusion) in one week or less; a hemoglobin level < 5 g / dl or > 4 g / dl decrease in one week or less; angina pectoris; mental status changes; serum creatinine levels increased by 50% or thrombosis.', 'P-1119\t-0.2805 -0.0269 -0.2419 -0.0292 -0.0113 -0.0264 -0.0218 -0.8311 -0.9863 -0.2607 -1.1689 -0.0282 -0.2451 -0.5522 -0.4734 -0.0395 -0.1521 -0.0254 -0.0169 -0.6396 -0.0845 -0.3213 -0.1071 -1.5498 -0.6313 -0.0282 -0.7607 -0.0395 -0.1803 -0.4001 -0.5635 -0.0225 -0.0789 -1.5381 -0.2029 -0.5972 -0.0225 -0.0113 -0.0564 -1.2061 -0.5522 -0.0338 -0.0225 -0.0338 -0.0564 -2.0176 -0.1465 -0.6875 -0.0789 -0.5635 -0.6875 -0.0338 -0.0225 -0.0225 -0.0338 -1.1494 -0.5747 -0.0225 -0.0225 -0.0225 -0.0338 -0.4622 -0.5859 0.0000 -0.0113 -0.0338 -0.1578 -0.4509 -0.0225 -0.0225 -0.0564 -0.0451 -0.0225 -0.3157 -0.6313 -1.0596 -0.0451 -0.0225 -0.0225 -0.0225 -0.4734 -0.0225 -0.6987 -0.2930 -0.0225 -0.0225 -0.0225 -0.0225 -0.2479 -0.0225 -1.2168 -0.0225 0.0000 -0.0225 -0.0225 -0.7212 -1.1270 -0.4734 -0.0225 -2.3672 -0.0451 -0.0676 -0.0225 -0.0225 -0.0451 -1.4648 -1.7354 -0.0676 -0.0225 -0.0225 -0.7212 -0.0225 0.0000 -0.0225 -0.0225 -0.0225', 'S-151\tDer Ausschuss für Humanarzneimittel (CHMP) gelangte zu dem Schluss, dass die Vorteile von Betaferon bei der Behandlung von Patienten mit schubförmig-remittierender Multipler Sklerose, sekundär progredienter Multipler Sklerose und bei Patienten mit erstmaligem demyelinisierenden Ereignis, das so schwer ist, dass eine Behandlung mit injizierbaren Corticosteroiden gerechtfertigt ist, gegenüber den Risiken überwiegen, und empfahl, die Genehmigung für das Inverkehrbringen von Betaferon zu erteilen.', 'T-151\tThe Committee for Medicinal products for Human Use (CHMP) decided that Betaferon <<unk>> s benefits are greater than its risks for the treatment of patients with relapsing remitting multiple sclerosis, secondary progressive multiple sclerosis, and in patients with a single episode of demyelination, severe enough to justify treatment with injected corticosteroids.', 'H-151\t-1.302734375\tThe Committee for Medicinal Products for Human Use ( CHMP ) concluded that the benefits of Betaferon exceed the risks for the treatment of patients with relapsing @-@ remitting multiple sclerosis , secondary progressive multiple sclerosis and patients with a single demyelinating event , if it is severe enough to justify treatment with injectable corticosteroids , and recommended that EFPIA be given a marketing authorisation .', 'D-151\t-1.302734375\tThe Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Betaferon exceed the risks for the treatment of patients with relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis and patients with a single demyelinating event, if it is severe enough to justify treatment with injectable corticosteroids, and recommended that EFPIA be given a marketing authorisation.', 'P-151\t-0.0451 -0.0241 -0.8877 -0.0261 -0.0077 -0.5845 -0.0254 -0.0254 -0.0183 -0.0211 -0.0409 -0.0127 -0.0085 -0.0282 -0.1338 -0.0296 -0.9946 -0.0676 -0.0451 -0.2874 -0.0169 -0.0141 -0.1973 -0.3213 -0.7920 -0.1099 -0.0197 -0.2847 -0.1973 -0.0423 -0.0282 -1.2568 -0.0732 -0.0282 -0.0056 -0.0338 -0.4282 -0.0113 -0.0225 -0.3042 -0.0225 -0.0113 -0.0282 -0.0169 -0.0676 -0.1014 -0.0676 -0.0225 -0.0225 -0.0113 -0.0225 -0.0169 -0.5352 -1.1943 -0.0676 -0.1803 -0.3213 -0.2367 -0.0225 -0.0282 -0.1353 -0.0732 -0.0338 -0.2930 -0.3381 -0.2141 -0.0789 -0.2705 -0.0338 -0.0676 -0.8677 -0.1240 -0.0451 -0.0225 -0.8452 -0.0225 -0.0225 -0.0225 -0.0225 -0.0113 -0.0113 -0.0225 -0.7891 -0.0338 -0.0451 -0.1465 -2.2207 -1.2510 -0.3269 -0.1465 -0.5859 -0.2930 -0.1014 -0.0789 -0.0113 -0.1240 -0.0338', 'S-1987\t• Überempfindlichkeit gegen den Wirkstoff oder gegen einen der sonstigen Bestandteile (siehe Abschnitt 6.1). • Bekannte Überempfindlichkeit gegen Sulfonamide. • Aktive peptische Ulzera oder gastrointestinale (GI) Blutungen. • Patienten, die nach Einnahme von Acetylsalicylsäure oder nicht steroidalen Antirheumatika (NSAR) einschließlich selektiven COX-2 (Cyclooxigenase-2) -Hemmern mit Asthma, akuter Rhinitis, Nasenschleimhautpolypen, angioneurotischen Ödemen, Urtikaria oder sonstigen allergischen Erkrankungen reagiert haben. • In der Schwangerschaft und bei Frauen, die schwanger werden können, es sei denn, dass sie eine sichere Methode zur Schwangerschaftsverhütung anwenden (siehe Abschnitte 4.5, 4.6 und 5.3). • In der Stillzeit (siehe Abschnitte 4.6 und 5.3). • Schwere Leberfunktionsstörung (Serumalbumin < 25 g / l oder Child-Pugh-Score ≥ 10) (Klasse C). • Geschätzten Kreatinin-Clearance < 30 ml / min. • Entzündliche Darmerkrankungen. • Herzinsuffizienz (NYHA II-IV). • Klinisch gesicherte koronare Herzkrankheit, periphere arterielle Verschlusskrankheit und / oder zerebrovaskuläre Erkrankungen.', 'T-1987\t2 • Hypersensitivity to the active substance or to any of the excipients (see section 6.1). • Known hypersensitivity to sulphonamides. • Active peptic ulceration or gastrointestinal (GI) bleeding. • Patients who have experienced asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic-type reactions after taking acetylsalicylic acid or non steroidal anti-inflammatory drugs (NSAIDs) including COX-2 (cyclooxigenase-2) selective inhibitors. • In pregnancy and in women who can become pregnant unless using an effective method of contraception (see sections 4.5, 4.6 and 5.3) • Breast feeding (see sections 4.6 and 5.3) • Severe hepatic dysfunction (serum albumin < 25 g / l or Child-Pugh score > 10) (Class C). • Patients with renal insufficiency with estimated creatinine clearance < 30 ml / min. • Inflammatory bowel disease. • Congestive heart failure (NYHA II-IV). • Established ischaemic heart disease, peripheral arterial disease and / or cerebrovascular disease', 'H-1987\t-1.798828125\t14 • Hypersensitivity to the active substance or to any of the excipients ( see section 6.1 ) . • Known hypersensitivity to sulphonamides . • Active peptic ulceration or gastrointestinal ( GI ) bleeding . • Patients who have experienced asthma , acute rhinitis , nasal polyps , angioneurotic oedema , urticaria or other allergic @-@ type reactions after taking acetylsalicylic acid or non steroidal anti @-@ inflammatory drugs ( NSAIDs ) including COX @-@ 2 ( cyclooxigenase @-@ 2 ) selective inhibitors . • In pregnancy and in women who can become pregnant unless using an effective method of contraception ( see sections 4.5 , 4.6 and 5.3 ) . • Breast feeding ( see sections 4.6 and 5.3 ) • Severe hepatic dysfunction ( serum albumin &lt; 25 g / l or Child @-@ Pugh score &gt; 10 ) ( Class C ) . • Patients with renal insufficiency with estimated creatinine clearance &lt; 30 ml / min . • Inflammatory bowel disease . • Inflammatory bowel disease . • Congestive heart failure ( NYHA II @-@ IV ) . • Established ischaemic heart disease', 'D-1987\t-1.798828125\t14 • Hypersensitivity to the active substance or to any of the excipients (see section 6.1). • Known hypersensitivity to sulphonamides. • Active peptic ulceration or gastrointestinal (GI) bleeding. • Patients who have experienced asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic-type reactions after taking acetylsalicylic acid or non steroidal anti-inflammatory drugs (NSAIDs) including COX-2 (cyclooxigenase-2) selective inhibitors. • In pregnancy and in women who can become pregnant unless using an effective method of contraception (see sections 4.5, 4.6 and 5.3). • Breast feeding (see sections 4.6 and 5.3) • Severe hepatic dysfunction (serum albumin < 25 g / l or Child-Pugh score > 10) (Class C). • Patients with renal insufficiency with estimated creatinine clearance < 30 ml / min. • Inflammatory bowel disease. • Inflammatory bowel disease. • Congestive heart failure (NYHA II-IV). • Established ischaemic heart disease', 'P-1987\t-0.8413 -0.4001 -0.2593 -0.0099 -0.0155 -0.0127 -0.0352 -0.2072 -0.0732 -0.2423 -0.0395 -0.1790 -0.0507 -0.0493 -0.1310 -0.3228 -0.0901 -0.0197 -0.1071 -0.0676 -0.0423 -0.2197 -0.0282 -0.0282 -0.0479 -0.1521 -0.0197 -0.0704 -0.0056 -0.0338 -0.0085 -0.0197 -0.0310 -0.0169 -0.2847 -0.0225 -0.0085 -0.0535 -0.0282 -0.0225 -0.0535 -0.0169 -0.0338 -0.0254 -0.0169 -0.0254 -0.9272 -0.1888 -0.1296 -0.0085 -0.0254 -0.0028 -0.0113 -0.0197 -0.0845 -0.0282 -0.0282 -0.0282 -0.0901 -0.0225 -0.0338 -0.1635 -0.0732 -0.0169 -0.0676 -0.0620 -0.3269 -0.3213 -0.0169 -0.0282 -0.0395 -0.0225 -0.0113 -0.0169 -0.0113 -0.0113 -0.0113 -0.0282 -0.0732 -0.0056 -0.0282 -0.2479 -0.0113 -0.0338 -0.0395 -0.0282 -0.0169 -0.4395 -0.0507 -0.0113 -0.1240 -0.0169 -0.0169 -0.0282 -0.0169 -0.0056 -0.0169 -0.3606 -0.0958 -0.0169 -0.0169 -0.3213 -0.3101 -0.3213 -0.0056 -0.1973 -0.0958 -0.3213 -0.0225 -0.1296 -0.0113 -0.0169 -0.0169 -0.0169 -0.0113 -0.0451 -0.3718 -0.6592 -0.0676 -0.0225 0.0000 -0.1691 -0.0338 -0.0451 -0.0113 -0.0113 -0.0225 -0.0789 -0.1465 0.0000 -0.0564 -0.0113 -0.0225 -0.3269 -0.6084 -0.0225 -0.0338 -0.0338 -0.1240 -0.0901 -0.1917 -0.0113 -0.3718 -0.0113 -0.0113 -0.0564 -0.0338 -0.0338 -0.1917 -0.0113 -0.0338 -0.0113 -0.0113 -0.0338 -0.0338 -0.0338 -0.2479 -0.0338 -0.0451 -0.1578 -0.0676 -0.0789 -0.3945 -0.0676 -0.0113 -0.1917 -0.3042 -0.4846 -0.2141 -0.0564 -0.2141 -0.2479 -0.0564 0.0000 -0.0451 -0.0451 -0.1465 -0.0225 -0.0338 -0.0338 -0.0225 -0.0338 -0.2255 -0.0225 -0.0338 -0.0338 -0.9019 -0.0225 -0.3157 -0.4395 -0.1578 -0.1578 -0.0338 -0.0676 -0.0225 -0.0338 -0.0338 -0.0225 -0.0338 -0.0338 -0.5522 -0.0113 -0.0113 -0.2593 -0.0225 -0.0113 -0.2255 -0.0225 -0.0451 -0.0225 -0.0225 0.0000 -0.1127 -0.0225 0.0000 0.0000 -0.1127 -0.0113 -0.3157 -0.0901 -0.3157 -0.3269 -0.3157 -0.2705 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -0.3157 -1.2627 -0.3606 -0.2930 -0.2705 -0.2479 -0.0676 -0.7212 -0.0225 -0.3606 -0.7437 -0.0225 -0.3157 -0.0451 -0.0451 -0.0225 -0.4734 -0.3606 -0.3157 -0.2479 -0.2930 -0.3157 -0.3157 -0.1578 -0.3381 0.0000 -0.2479 -0.3157 -0.3157 -0.4058 -0.3157 -0.1127 -0.0901 -0.6763 -0.2705 -0.3157 -0.1127 -0.0451 -0.3381 0.0000 -0.0901 -1.4648 -0.1578 -1.2627 -0.1578 -0.2479 -0.0676 -0.0901 -0.5859 0.0000 -0.0901 -2.0293 -0.1803 -1.2627 -0.3157 -0.2479 -0.3381 -0.3381 -0.7437 -0.3157 -0.3157 -0.3157 -0.6313 -0.5410 -0.1353 -1.4424 -0.1353 -0.2255 -1.0820 -0.0901 -0.0901 -0.3157 -0.3157 -0.6313 -0.0451 -0.6313 -0.3606 -1.6680', 'S-42\tOlanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva', 'T-42\tOlanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva', 'H-42\t-0.59033203125\tOlanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva', 'D-42\t-0.59033203125\tOlanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva Olanzapine Teva', 'P-42\t-0.1158 -0.0142 -0.0227 -0.0170 -0.0198 -0.0269 -0.0171 -0.0379 -0.0092 -0.0213 -0.0171 -0.0199 -0.0199 -0.0171 -0.0327 -0.0085 -0.0225 -0.0169 -0.0204 -0.0197 -0.0183 -0.0334 -0.0077 -0.0229 -0.0169 -0.0197 -0.0197 -0.0176 -0.0370 -0.0085 -0.0211 -0.0180 -0.0197 -0.0197 -0.0183 -0.0345 -0.0085 -0.0211 -0.0169 -0.0197 -0.0197 -0.0176 -0.0458 -0.0085 -0.0211 -0.0169 -0.0190 -0.0197 -0.0176 -0.1014 -0.0070 -0.0211 -0.0162 -0.0190 -0.0204 -0.0169 -0.1198 -0.0070 -0.0225 -0.0162 -0.0197 -0.0211 -0.0183 -0.1169 -0.0070 -0.0225 -0.0169 -0.0197 -0.0211 -0.0169 -0.1423 -0.0056 -0.0240 -0.0169 -0.0197 -0.0225 -0.0169 -0.1493 -0.0070 -0.0225 -0.0169 -0.0197 -0.0225 -0.0169 -0.1917 -0.0070 -0.0225 -0.0155 -0.0197 -0.0225 -0.0169 -0.2128 -0.0070 -0.0225 -0.0169 -0.0197 -0.0225 -0.0183 -0.2395 -0.0056 -0.0225 -0.0169 -0.0197 -0.0225 -0.0169 -0.2847 -0.0056 -0.0225 -0.0169 -0.0197 -0.0225 -0.0197 -0.2227 -0.0056 -0.0225 -0.0169 -0.0197 -0.0254 -0.0197 -0.2339 -0.0056 -0.0225 -0.0169 -0.0197 -0.0254 -0.0169 -0.2227 -0.0056 -0.0225 -0.0169 -0.0197 -0.0254 -0.0169 -0.2620 -0.0085 -0.0225 -0.0169 -0.0197 -0.0254 -0.0197 -0.2367 -0.0056 -0.0225 -0.0169 -0.0197 -0.0254 -0.0197 -0.2479 -0.0056 -0.0225 -0.0169 -0.0197 -0.0254 -0.0197 -0.2620 -0.0056 -0.0225 -0.0169 -0.0169 -0.0225 -0.0225 -0.2761 -0.0056 -0.0225 -0.0169 -0.0225 -0.0282 -0.0225 -0.2649 -0.0056 -0.0225 -0.0169 -0.0225 -0.0282 -0.0225 -0.2479 -0.0056 -0.0225 -0.0169 -0.0225 -0.0282 -0.0225 -0.2593 -0.0056 -0.0225 -0.0169 -0.0225 -0.0282 -0.0282 -0.2593 -0.0056 -0.0225 -0.0169 -0.0225 -0.0282 -0.0282 -0.2423 -0.0056 -0.0225 -0.0169 -0.0225 -0.0282 -0.0282 -0.2479 -0.0056 -0.0225 -0.0169 -0.0225 -0.0282 -0.0282 -0.2423 -0.0056 -0.0282 -0.0169 -0.0225 -0.0282 -0.0282 -0.2423 -0.0056 -0.0282 -0.0169 -0.0225 -0.0338 -0.0282 -0.2423 -0.0056 -0.0282 -0.0169 -0.0225 -0.0338 -0.0282 -0.2537 -0.0056 -0.0282 -0.0225 -0.0225 -0.0395 -0.0282 -0.3042 -0.0056 -0.0282 -0.0225 -0.0225 -0.0395 -0.0282 -0.3269 -0.0056 -0.0282 -0.0225 -0.0282 -0.0451 -0.0338 -0.2705 -0.0056 -0.0282 -0.0225 -0.0225 -0.0732 -0.0338 -0.4170 -0.0113 -0.0225 -0.0225 -0.0225 -0.0789 -0.0338 -0.4282 -0.0113 -0.0225 -0.0225 -0.0225 -0.0789 -0.0338 -0.2817 -0.0113 -0.0225 -0.0225 -0.0225 -0.0789 -0.0338 -0.2930 -0.0113 -0.0225 -0.0225 -0.0225 -0.0901 -0.0338 -0.2930 -0.0113 -0.0225 -0.0225 -0.0225 -0.0901 -0.0338 -0.3042 -0.0113 -0.0225 -0.0225 -0.0225 -0.1014 -0.0451 -0.3042 -0.0113 -0.0225 -0.0225 -0.0225 -0.1014 -0.0451 -0.3042 -0.0113 -0.0225 -0.0225 -0.0225 -0.0676 -0.0451 -0.3042 -0.0113 -0.0225 -0.0225 -0.0225 -0.0676 -0.0451 -2.5469', 'S-434\tRifampicin, ein Antibiotikum zur Behandlung von Tuberkulose; Astemizol oder Terfenadin (im Allgemeinen zur Behandlung von allergischen Erkrankungen verwendet; diese Arzneimittel können auch rezeptfrei erhältlich sein); Cisaprid (zur Behandlung der Reflux-Krankheit des Magens, auch Sodbrennen genannt); Pimozid (zur Behandlung von Schizophrenie); Chinidin oder Bepridil (zur Behandlung von Herzrhythmusstörungen); Ergotamin, Dihydroergotamin, Ergometrin, Methylergometrin (zur Behandlung von Migräne); Arzneimittel, die Johanniskraut (Hypericum perforatum, ein pflanzliches Präparat), enthalten; Triazolam und oral angewendetes (durch den Mund eingenommenes) Midazolam (ein Schlaf- und Beruhigungsmittel) (siehe Abschnitt 2 unter "REYATAZ darf nicht eingenommen werden").', 'T-434\tJohn <<unk>> s wort (Hypericum perforatum, a herbal preparation), triazolam and oral (taken by mouth) midazolam (used to help you sleep) (see section 2, under Do not take REYATAZ).', 'H-434\t-1.4873046875\tRifampicin , an antibiotic used to treat tuberculosis ; astemizole or terfenadine ( commonly used to treat allergy conditions - these medicines may also be available without prescription ) ; cisapride ( used to treat gastric reflux disease , also known as heartburn ) ; pimozide ( used to treat schizophrenia ) ; quinidine or bepridil ( used to correct irregular heartbeat ) ; ergotamine , dihydroergotamine , ergonovine , methylergonovine ( used to treat migraine ) ; medicinal products containing St John &quot; s wort ( Hypericum perforatum , a herbal preparation ) ; triazolam and oral ( taken by mouth ) midazolam ( used to help you sleep and / to relieve anxiety ) ( see section 2 , Do not take REYATAZ ) .', 'D-434\t-1.4873046875\tRifampicin, an antibiotic used to treat tuberculosis; astemizole or terfenadine (commonly used to treat allergy conditions - these medicines may also be available without prescription); cisapride (used to treat gastric reflux disease, also known as heartburn); pimozide (used to treat schizophrenia); quinidine or bepridil (used to correct irregular heartbeat); ergotamine, dihydroergotamine, ergonovine, methylergonovine (used to treat migraine); medicinal products containing St John "s wort (Hypericum perforatum, a herbal preparation); triazolam and oral (taken by mouth) midazolam (used to help you sleep and / to relieve anxiety) (see section 2, Do not take REYATAZ).', 'P-434\t-0.9502 -0.0190 -0.0148 -0.0197 -0.0557 -0.5254 -0.6465 -0.2043 -0.0099 -0.0155 -0.4636 -0.3777 -0.0310 -0.0282 -0.0113 -0.0197 -0.0085 -0.0225 -0.0310 -0.1014 -0.1409 -0.0845 -0.0113 -0.0395 -0.0141 -0.0085 -0.1014 -0.0620 -0.0310 -1.2227 -0.0197 -0.1381 -0.0141 -0.7666 -0.0169 -0.0282 -1.4375 -0.6821 -0.2029 -0.0958 -0.5635 -0.5239 -0.8677 -0.0225 -0.0507 -0.3042 -0.1353 -0.0338 -0.0225 -0.0507 -0.0169 -0.0225 -0.0113 -0.0282 -0.5410 -0.0789 -0.0225 -1.3184 -0.0338 -0.0225 -0.0225 -0.0113 -0.0225 -0.1691 -0.5298 -0.5635 -0.5186 -0.0225 -0.1578 -0.0113 -0.0338 -0.0225 -0.0338 -0.0113 -0.0338 -0.2930 -0.0338 -0.0338 -0.2705 -0.0676 -0.0225 -0.1465 -0.0113 -0.0225 0.0000 -0.0113 -0.0338 -0.0225 -0.0113 -0.0113 -0.0225 -0.0338 -0.0451 -0.0338 -0.0225 -0.0451 -0.0338 -0.0676 -0.0676 -0.8789 -0.6313 -0.0113 -0.9355 -0.2255 -0.0451 -0.0225 -0.0451 -0.0113 -0.0338 -0.0338 -0.0225 -0.0225 -0.0225 -0.0113 -0.0225 -0.0338 -0.0225 -0.3269 -0.3269 -0.1240 -0.0338 -0.0225 -0.1240 -0.0338 -0.0225 -0.7778 -0.3157 -0.2255 -0.0338 -0.3606 -0.0676 -0.0338 -0.0225 -0.0113 -0.1353 -0.2930 -0.0225 -0.0225 -0.9917 -0.0451 -0.0225 -0.2930 -0.4282 -0.3157 -0.2930 -0.2930 -0.0451 -0.0901 -0.0225 -0.0225 -0.0225 -0.0225 -0.0225 -0.0225 -0.0225 -0.0451 -0.2930 -0.0451 -0.0225 -0.2705 -0.0225 -0.0225 -0.2930 0.0000 -0.0225 -0.0225 -0.0676 -0.8564 -0.1127 -0.1127 -0.1353 -0.0225 -0.0225 -0.4509 -0.0225 -0.0225 -0.0225 -0.0225 -0.0225 -0.3381 -0.3157 -0.3833 -0.3157 -0.0451 -0.0676 -0.7437 -0.7212 -0.3381 -0.0225 -0.3157 -0.0451 -0.0451 -0.0451 -1.0596 -0.0451 -0.6987 -1.3076 -0.0676 -0.0451 -0.0676 -0.0225 -0.0225 -0.0225 -0.0451 -0.0451 -0.0225', 'S-415\tEU / 1 / 98 / 090 / 001 EU / 1 / 98 / 090 / 002 EU / 1 / 98 / 090 / 003 EU / 1 / 98 / 090 / 004 EU / 1 / 98 / 090 / 005 EU / 1 / 98 / 090 / 006 EU / 1 / 98 / 090 / 007 EU / 1 / 98 / 090 / 008 EU / 1 / 98 / 090 / 009 EU / 1 / 98 / 090 / 010 EU / 1 / 98 / 090 / 011 EU / 1 / 98 / 090 / 012 EU / 1 / 98 / 090 / 013 EU / 1 / 98 / 090 / 014 EU / 1 / 98 / 090 / 015 EU / 1 / 98 / 090 / 016 EU / 1 / 98 / 090 / 017 EU / 1 / 98 / 090 / 018 EU / 1 / 98 / 090 / 019 EU / 1 / 98 / 090 / 020', 'T-415\tEU / 1 / 98 / 090 / 001 EU / 1 / 98 / 090 / 002 EU / 1 / 98 / 090 / 003 EU / 1 / 98 / 090 / 004 EU / 1 / 98 / 090 / 005 EU / 1 / 98 / 090 / 006 EU / 1 / 98 / 090 / 007 EU / 1 / 98 / 090 / 008 EU / 1 / 98 / 090 / 009 EU / 1 / 98 / 090 / 010 EU / 1 / 98 / 090 / 011 EU / 1 / 98 / 090 / 012 EU / 1 / 98 / 090 / 013 EU / 1 / 98 / 090 / 014 EU / 1 / 98 / 090 / 015 EU / 1 / 98 / 090 / 016 EU / 1 / 98 / 090 / 017 EU / 1 / 98 / 090 / 018 EU / 1 / 98 / 090 / 019 EU / 1 / 98 / 090 / 020', 'H-415\t-0.404052734375\tEU / 1 / 98 / 090 / 001 EU / 1 / 98 / 090 / 002 EU / 1 / 98 / 090 / 003 EU / 1 / 98 / 090 / 004 EU / 1 / 98 / 090 / 005 EU / 1 / 98 / 090 / 006 EU / 1 / 98 / 090 / 007 EU / 1 / 98 / 090 / 008 EU / 1 / 98 / 090 / 009 EU / 1 / 98 / 090 / 010 EU / 1 / 98 / 090 / 011 EU / 1 / 98 / 090 / 012 EU / 1 / 98 / 090 / 013 EU / 1 / 98 / 090 / 015 EU / 1 / 98 / 090 / 016 EU / 1 / 98 / 090 / 017 EU / 1 / 98 / 090 / 018 EU / 1 / 98 / 090 / 019 EU / 1 / 98 / 090 / 020', 'D-415\t-0.404052734375\tEU / 1 / 98 / 090 / 001 EU / 1 / 98 / 090 / 002 EU / 1 / 98 / 090 / 003 EU / 1 / 98 / 090 / 004 EU / 1 / 98 / 090 / 005 EU / 1 / 98 / 090 / 006 EU / 1 / 98 / 090 / 007 EU / 1 / 98 / 090 / 008 EU / 1 / 98 / 090 / 009 EU / 1 / 98 / 090 / 010 EU / 1 / 98 / 090 / 011 EU / 1 / 98 / 090 / 012 EU / 1 / 98 / 090 / 013 EU / 1 / 98 / 090 / 015 EU / 1 / 98 / 090 / 016 EU / 1 / 98 / 090 / 017 EU / 1 / 98 / 090 / 018 EU / 1 / 98 / 090 / 019 EU / 1 / 98 / 090 / 020', 'P-415\t-0.0357 -0.5093 -0.0271 -0.0292 -0.0155 -0.0299 -0.0271 -0.0229 -0.0289 -0.0352 -0.0521 -0.0296 -0.0331 -0.0275 -0.0296 -0.0141 -0.0296 -0.0261 -0.0225 -0.0282 -0.0268 -0.0458 -0.0261 -0.0317 -0.0268 -0.0296 -0.0134 -0.0289 -0.0254 -0.0211 -0.0282 -0.0303 -0.0951 -0.0268 -0.0324 -0.0268 -0.0296 -0.0141 -0.0296 -0.0254 -0.0240 -0.0282 -0.0282 -0.0916 -0.0268 -0.0324 -0.0282 -0.0310 -0.0127 -0.0296 -0.0254 -0.0268 -0.0282 -0.0282 -0.0380 -0.0268 -0.0310 -0.0268 -0.0296 -0.0127 -0.0296 -0.0268 -0.0240 -0.0282 -0.0338 -0.0352 -0.0296 -0.0310 -0.0268 -0.0296 -0.0113 -0.0296 -0.0240 -0.0225 -0.0282 -0.0395 -0.0310 -0.0268 -0.0310 -0.0254 -0.0296 -0.0127 -0.0296 -0.0282 -0.0225 -0.0282 -0.0338 -0.0395 -0.0282 -0.0310 -0.0282 -0.0310 -0.0141 -0.0310 -0.0282 -0.0254 -0.0282 -0.0338 -0.0282 -0.0282 -0.0310 -0.0282 -0.0310 -0.0113 -0.0282 -0.0254 -0.0282 -0.0282 -0.0451 -0.0479 -0.0310 -0.0310 -0.0282 -0.0310 -0.0113 -0.0282 -0.0254 -0.0254 -0.0282 -0.0310 -0.0225 -0.0282 -0.0310 -0.0282 -0.0282 -0.0113 -0.0310 -0.0225 -0.0197 -0.0282 -0.0282 -0.0423 -0.0310 -0.0310 -0.0254 -0.0310 -0.0141 -0.0282 -0.0225 -0.0310 -0.0282 -0.0254 -0.0507 -0.0338 -0.0310 -0.0282 -0.0310 -0.0141 -0.0310 -0.0254 -0.0986 -0.0282 -0.0282 -3.4160 -0.0338 -0.0338 -0.0282 -0.0282 -0.0169 -0.0282 -0.0282 -0.0225 -0.0282 -0.0282 -0.0225 -0.0338 -0.0282 -0.0282 -0.0282 -0.0113 -0.0282 -0.0225 -0.0338 -0.0282 -0.0282 -0.0225 -0.0338 -0.0338 -0.0282 -0.0282 -0.0169 -0.0282 -0.0282 -0.0225 -0.0282 -0.0282 -0.0338 -0.0395 -0.0338 -0.0282 -0.0282 -0.0169 -0.0282 -0.0282 -0.0845 -0.0282 -0.0282 -0.0282 -0.0338 -0.0338 -0.0282 -0.0282 -0.0225 -0.0282 -0.0225 -0.0282 -0.0282 -0.0282 -0.0338 -0.0282', 'S-505\t• wenn Sie überempfindlich (allergisch) gegen Telmisartan oder einen der sonstigen Bestandteile von Kinzalkomb Tabletten sind (eine Auflistung der sonstigen Bestandteile finden Sie unter <unk> Weitere Informationen <unk>); • wenn Sie überempfindlich (allergisch) gegen Hydrochlorothiazid oder anderen Sulfonamid- Abkömmlingen sind; • während den letzten 6 Monaten einer Schwangerschaft (siehe Abschnitt Schwangerschaft und Stillzeit); • wenn Sie stillen; • wenn Sie an schweren Leberfunktionsstörungen wie einer Cholestase oder einer Gallengangsobstruktion (Abflussstörung der Gallenflüssigkeit aus der Gallenblase) oder einer sonstigen schweren Lebererkrankung leiden; • wenn Sie an einer schweren Nierenerkrankung leiden; • wenn Ihr Arzt feststellt, dass Ihr Blut einen zu niedrigen Kalium- oder zu hohen Calciumspiegel aufweist, der sich unter Behandlung nicht bessert.', 'T-505\t• if you are allergic (hypersensitive) to telmisartan or any other ingredients included in Kinzalkomb tablets (see "Further Information" for a list of other ingredients). • if you are allergic (hypersensitive) to hydrochlorothiazide or to any other sulfonamide-derived medicines. • during the last six months of pregnancy (see section Pregnancy and breast-feeding). • if you are breast-feeding. • if you have severe liver problems such as cholestasis or biliary obstruction (problems with drainage of the bile from the gall bladder) or any other severe liver disease.', 'H-505\t-0.94091796875\t• if you are allergic ( hypersensitive ) to telmisartan or any other ingredients included in Kinzalkomb tablets ( see &quot; Further information &quot; for a list of other ingredients ) . • if you are allergic ( hypersensitive ) to hydrochlorothiazide or to any other sulfonamide @-@ derived medicines . • during the last six months of pregnancy ( see section Pregnancy and breast @-@ feeding ) . • if you are breast @-@ feeding . • if you have severe liver problems such as cholestasis or biliary obstruction ( problems with drainage of the bile from the gall bladder ) or any other severe liver disease .', 'D-505\t-0.94091796875\t• if you are allergic (hypersensitive) to telmisartan or any other ingredients included in Kinzalkomb tablets (see "Further information" for a list of other ingredients). • if you are allergic (hypersensitive) to hydrochlorothiazide or to any other sulfonamide-derived medicines. • during the last six months of pregnancy (see section Pregnancy and breast-feeding). • if you are breast-feeding. • if you have severe liver problems such as cholestasis or biliary obstruction (problems with drainage of the bile from the gall bladder) or any other severe liver disease.', 'P-505\t-0.2534 -0.0678 -0.0269 -0.0372 -0.3142 -0.0162 -0.2551 -0.3169 -0.0183 -0.0345 -0.0317 -0.0465 -0.0282 -0.0127 -0.0282 -0.0423 -0.1324 -0.5649 -0.3030 -0.4058 -0.0395 -0.0254 -0.0169 -0.0141 -0.2537 -0.0254 -0.0676 -0.0225 -0.0366 -0.2057 -1.1865 -0.3213 -0.7100 -0.0676 -0.1183 -0.0507 -0.1296 -0.0732 -0.2817 -0.0507 -0.0338 -0.3213 -0.0282 -0.0451 -0.0282 -0.0338 -0.3101 -0.0113 -0.0507 -0.3213 -0.0113 -0.0282 -0.0338 -0.0113 -0.0282 -0.0113 -0.0225 -0.0113 -0.0282 -0.0056 -0.0169 -0.0395 -0.3042 -0.3213 -0.0732 -0.0507 -0.0958 -0.0056 -0.0225 -0.3213 -0.0169 -0.0958 -0.3213 -0.1353 -0.0958 -0.0338 -0.1183 -0.0395 -0.0676 -0.1917 -0.0282 -0.0338 -0.0564 -0.0507 -0.0395 -0.2705 -0.1353 -0.0169 -0.0169 -0.0338 -0.5410 -0.1465 -0.0113 -0.0789 -0.4846 -0.0225 -0.0338 -0.0338 -0.0564 -0.2817 -0.0564 -0.0338 -0.0564 -0.0225 -0.0338 -0.1127 -0.2029 -0.1014 -0.0789 -0.3157 -0.1240 -0.0225 -0.0564 -0.0225 -0.0338 -0.0225 -0.1353 -0.2817 -0.0338 -0.3042 -0.0113 -0.0901 -0.3157 -0.1465 -0.3269 -0.1465 -0.0338 -0.0451 -0.3157 -0.1578 -0.0113 -0.0789 -0.0338 -0.3606 -0.0225 -0.0113 -0.0113 -0.0338 -0.5073 -0.2479 -0.0338 -0.2255 -0.0338 -0.0564 -0.0451 -0.6201', 'S-1674\tReizung oder Rötung an der Injektionsstelle, Kopfschmerzen, Müdigkeitsgefühl, Schüttelfrost, Fieber, grippeähnliche Symptome, Schwindel, Übelkeit, Appetitverlust, Diarrhö, Magenschmerzen, Erbrechen, Muskelschmerzen, Schmerzen in Gelenken und Muskeln, Gefühl der Niedergeschlagenheit oder Reizbarkeit, Schwierigkeiten beim Ein- oder Durchschlafen, Stimmungsschw ankungen, Virusinfektion, Haarverlust, Ausschlag, Pharyngitis (Rachenentzündung), Abnahme der Anzahl der roten Blutkörperchen oder bestimmter weißer Blutzellen, sogenannter Neutrophile, die Infektionen bekämpfen, verringerte Schilddrüsenaktivität (was Sie müde oder, weniger häufig, überaktiv machen kann), Unwohlsein, Abnahme der Wachstumsrate (Körpergröße und <unk> gewicht).', 'T-1674\tVery commonly reported side effects (at least 1 in every 10 patients): irritation or redness at the site of injection, headache, tired feeling, shaking chills, fever, flu-like symptoms, dizziness, nausea, loss of appetite, diarrhoea, stomach pain, vomiting, muscle aches, pain in joints and muscles, feeling depressed or irritable, trouble falling asleep or staying asleep, mood swings, virus infection, hair loss, rash, pharyngitis (sore throat), decrease in the number of red blood cells or decrease in certain white blood cells called neutrophils that fight infection, change in thyroid gland activity (which may make you feel tired or, less commonly, energetic), feeling unwell, and decrease in their rate of growth (height and weight).', 'H-1674\t-1.13671875\tIrritation or redness at the injection site , headache , tired feeling , shaking chills , fever , flu @-@ like symptoms , dizziness , nausea , loss of appetite , diarrhoea , stomach pain , vomiting , muscle aches , pain in joints and muscles , feeling depressed or irritable , trouble falling asleep or staying asleep , mood swings , virus infection , hair loss , rash , pharyngitis ( sore throat ) , decrease in the number of red blood cells or certain white blood cells called neutrophils that fight infection , decreased activity of the thyroid gland ( which may make you feel tired or , less commonly , energetic ) , feeling unwell , and decrease in their rate of growth ( height and weight ) .', 'D-1674\t-1.13671875\tIrritation or redness at the injection site, headache, tired feeling, shaking chills, fever, flu-like symptoms, dizziness, nausea, loss of appetite, diarrhoea, stomach pain, vomiting, muscle aches, pain in joints and muscles, feeling depressed or irritable, trouble falling asleep or staying asleep, mood swings, virus infection, hair loss, rash, pharyngitis (sore throat), decrease in the number of red blood cells or certain white blood cells called neutrophils that fight infection, decreased activity of the thyroid gland (which may make you feel tired or, less commonly, energetic), feeling unwell, and decrease in their rate of growth (height and weight).', 'P-1674\t-1.6240 -0.0169 -0.0282 -0.0366 -0.0718 -0.0183 -0.0507 -0.4861 -0.8174 -0.0141 -0.0282 -0.0958 -0.0141 -0.0141 -0.1183 -0.0310 -0.3748 -0.1240 -0.0310 -0.6987 -0.1859 -0.3101 -0.0056 -0.2141 -0.1296 -0.0169 -0.0338 -0.1550 -0.0423 -0.0338 -0.1521 -0.0338 -0.0620 -0.0056 -0.0169 -0.0282 -0.0282 -0.0056 -0.0282 -0.0676 -0.0282 -0.0169 -0.0169 -0.0282 -0.0282 -0.0056 -0.1409 -0.0113 -0.0282 -0.0225 -0.7495 -0.0282 -0.0113 -0.0056 -0.0225 -0.0282 -0.1747 -0.6592 -0.0507 -0.1973 -0.0338 -0.2423 -0.0056 -0.4001 -0.0113 -0.0282 -0.0564 -0.5522 -0.0225 -0.2705 -0.0225 -0.0282 -0.0338 -0.3157 -0.0958 -0.2367 -0.0113 -0.1353 -0.3101 -0.0564 -0.0113 -0.0338 -0.0620 -0.0338 -0.0225 -0.2537 -0.6763 -0.0225 -0.3157 -0.0225 -0.0225 -0.0338 -0.0338 -0.0225 -0.0338 -0.0113 -0.0113 -0.0225 -0.0225 -0.0225 -0.4509 -0.3269 -0.0113 -0.0113 -0.0451 -0.0338 -0.1353 -0.7778 -0.2255 -0.5859 -0.1240 -0.0225 -0.0225 -0.0225 -0.0338 -0.2029 -0.0901 -0.0225 -0.0225 -0.0113 -0.3269 -0.0451 -0.0338 -0.0338 0.0000 -0.2029 -0.0676 -0.2593 -0.0338 -0.7212 -0.0225 -0.9019 -0.0789 -0.0676 -0.0338 -0.0113 -0.0113 -0.0225 -0.3494 -0.0225 -0.0338 -0.0676 -0.3833 -0.0451 -0.0225 -0.3042 -0.1014 -0.0451 -0.1917 -0.1803 -0.3157 -0.1014 -0.3269 -0.0225 -0.0338 -0.0338 -0.5298 -0.2479 -0.0113 -0.0451 -0.3718 -0.2930 -0.7891 -0.1578 -0.3381 -0.3157 -0.0225 -0.0225 -0.0451 -0.1803 -0.0225 -0.0225 -0.0225 -0.0451 -0.0225', 'S-784\tGelegentlich (tritt bei mehr als 1 von 1.000, aber weniger als 1 von 100 Behandelten auf): • Anämie, rote oder bräunliche Punkte auf der Haut (manchmal besonders an den Füßen, Beinen, Armen und am Gesäß, mit Gelenkschmerzen, Schwellungen der Hände und Füße und Magenschmerzen), verringerte Anzahl von weissen Blutzellen, Gerinnungsprobleme und Blutergüsse • Appetitverlust, erhöhte Harnsäurespiegel oder Gicht, erhöhte Blutzuckerwerte, abnormale Blutelektrolytspiegel • Angst, Nervosität, Panikstörung (wiederholte Panikattacken), Verwirrung, Depression, verändertes Träumen, Schlafstörungen, Schläfrigkeit, Gedächtnisstörungen • Kribbeln / Nadelstiche oder ähnliche Missempfindungen, Schmerzen in den Gliedmaßen, Zittern, Migräne, Ohnmachtsanfall • Verschwommensehen, Brennen oder Stechen in den Augen, Bindehautentzündung, Verschlechterung der Sehkraft, Gelbsehen • Klingeln, Dröhnen, Tosen oder Klicken in den Ohren • Niedriger Blutdruck möglicherweise im Zusammenhang einem Lagewechsel (Schwindel- oder Schwächegefühl beim Aufstehen), Angina pectoris (Schmerzen im Brustkorb), unregelmäßiger Herzrhythmus, Schlaganfall (TIA, "Minischlag"), Herzinfarkt, Herzklopfen • Entzündung der Blutgefäße, oft zusammen mit Hautausschlag oder Blutergüssen • Kratzen im Hals, Atemnot, Bronchitis, Lungenentzündung, Wasser in der Lunge (das Atembeschwerden verursacht), Nasenbluten, laufende oder verstopfte Nase • Verstopfung, Blähungen, Magenverstimmung, Magenkrämpfe, Erbrechen, Mundtrockenheit, Entzündungen der Speicheldrüsen, Zahnschmerzen • Gelbsucht (Gelbfärbung von Augen und Haut), Entzündung der Bauchspeicheldrüse', 'T-784\tUncommon (affecting less than one person in 100 but more than one person in 1,000): • Anaemia, red or brownish spots on the skin (sometimes especially on the feet, legs, arms and buttocks, with joint pain, swelling of the hands and feet and stomach pain), bruising, reduction in white blood cells, clotting problems and bruising, • Loss of appetite, increased uric acid levels or frank gout, increased blood sugar levels, abnormal blood electrolyte levels, • Anxiety, nervousness, panic disorder (recurring panic attacks), confusion, depression, abnormal dreams, sleep disorders, sleepiness, memory impairment, • Pins and needles or similar sensations, pain in the extremities, trembling, migraine, fainting, • Blurred vision, burning or stinging in the eyes, conjunctivitis, worsening eyesight, seeing things in yellow, • Ringing, buzzing, roaring or clicking in the ears, • Low blood pressure, which may be associated with changes in posture (feeling light-headed or weak when you stand up, angina (chest pain), abnormal heartbeat, cerebrovascular accident (TIA, <<unk>> mini-stroke <<unk>>), heart attack, palpitations, • Inflammation of blood vessels, which is often associated with a skin rash or bruising, • Sore throat, breathlessness, bronchitis, pneumonia, water on the lungs (which causes difficulty breathing), nosebleed, runny nose, congestion, • Constipation, wind, stomach upsets, stomach spasms, vomiting, dry mouth, inflammation of a salivary gland, toothache, • Jaundice (yellowing of the eyes and skin), inflammation of the pancreas, • Hives, itching, inflammation of the skin, rash, redness of the skin, sensitivity to light, dry skin, flushing, sweating, hair loss, • Pain in the arms, shoulders, hips, knees or other joints, joint swelling, stiffness, muscle weakness, • Frequent urination including at night, abnormal kidney function including inflammation of the kidneys, urinary infection, sugar in the urine, • Decreased sexual appetite, impotence, • Swelling of the face, fever.', 'H-784\t-3.490234375\tUncommon ( occurring in more than 1 in 1,000 but less than 1 in 100 patients treated ) : • anaemia , red or brownish spots on the skin ( sometimes especially in the feet , legs , arms and buttocks , joint pain , swelling of the hands and feet and stomach pain ) , decreased number of white blood cells , clotting problems and bruising • loss of appetite , increased levels of uric acid or gout , increased blood sugar levels , abnormal blood electrolyte levels • anxiety , nervousness , panic disorder ( repeated panic attack ) , confusion , depression , abnormal dreaming , sleep disorders , sleepiness , memory impairment • tingling / pins or similar abnormal sensations , pain in the extremities , tremor , migraine , fainting ) • blurred vision , burning or stening in the eyes , conjunctivitis , visual disturbance , visual disturbance , visual disturbance or flu @-@ like symptoms ; • stomach inflammation ; • stomach inflammation ; • stomach inflammation ; redness ; redness ; redness ; redness ; redness of the skin due to repeated panic attack .', 'D-784\t-3.490234375\tUncommon (occurring in more than 1 in 1,000 but less than 1 in 100 patients treated): • anaemia, red or brownish spots on the skin (sometimes especially in the feet, legs, arms and buttocks, joint pain, swelling of the hands and feet and stomach pain), decreased number of white blood cells, clotting problems and bruising • loss of appetite, increased levels of uric acid or gout, increased blood sugar levels, abnormal blood electrolyte levels • anxiety, nervousness, panic disorder (repeated panic attack), confusion, depression, abnormal dreaming, sleep disorders, sleepiness, memory impairment • tingling / pins or similar abnormal sensations, pain in the extremities, tremor, migraine, fainting) • blurred vision, burning or stening in the eyes, conjunctivitis, visual disturbance, visual disturbance, visual disturbance or flu-like symptoms; • stomach inflammation; • stomach inflammation; • stomach inflammation; redness; redness; redness; redness; redness of the skin due to repeated panic attack.', 'P-784\t-0.3853 -0.2544 -0.0754 -2.7617 -0.5918 -0.0817 -0.2986 -0.0282 -0.0479 -0.6001 -1.0732 -0.5806 -0.0732 -0.0282 -0.0338 -0.0395 -0.0282 -0.5352 -0.4282 -0.0451 -0.0395 -0.1296 -0.4282 -0.2479 -0.0056 -0.0282 -0.0564 -0.0507 -0.0395 -0.1014 -0.0056 -0.3157 -1.0596 -0.0676 -0.0225 -0.0282 -0.0620 -0.5298 -1.2910 -0.2930 -0.0451 -0.0338 -0.0225 -0.0338 -0.0225 -0.0676 -0.3042 -0.0113 -0.6426 -0.0451 -1.0703 -0.6084 -0.0338 -0.0113 -0.0225 -0.0338 -0.6084 -0.1803 -0.0338 -0.0113 -0.4622 -0.0225 -0.5859 -0.0338 -0.0901 -1.7812 -0.3042 -0.6987 -0.0225 -0.0225 -0.2255 -0.0113 -0.0338 -1.8594 -0.1578 -0.0225 -0.1353 -0.0451 -0.1578 -0.9019 -0.0451 -0.0451 -0.0225 0.0000 -0.0225 -0.0225 -0.7666 -1.1943 -0.0225 -0.2705 -0.0225 -0.0225 -0.3381 -0.0225 0.0000 -0.0451 -1.1943 -0.7212 -0.0901 -0.5186 -0.0225 -0.1127 0.0000 -0.0676 -0.3157 -0.0225 0.0000 -0.7212 -0.1127 -0.0225 -0.1127 -0.2479 -0.1353 -0.0225 -0.0225 0.0000 -0.3381 -0.0225 -0.3157 0.0000 -0.3381 -0.0225 -0.0451 -0.3606 -0.0225 -0.0225 -0.0225 -0.4958 -0.0225 -0.6987 -0.0225 -0.0225 -1.2168 -1.6680 -0.0225 -0.0225 -0.8115 0.0000 -0.0225 -0.0225 -0.9019 -0.5859 -0.0451 0.0000 -0.0901 -0.0225 -0.4509 0.0000 -0.0225 -0.0676 -0.6987 -0.1803 -0.0451 -0.5859 -0.6538 -0.4282 -0.0901 -0.0451 -0.0451 -0.9468 -0.0451 -0.6313 -0.8564 -0.2029 -0.0225 -0.0676 -0.3833 -0.2255 -0.5859 0.0000 0.0000 -0.2255 -0.2255 -0.0901 -0.0451 -0.0451 -0.5859 0.0000 -0.1353 -0.1803 0.0000 -0.0451 -0.3606 -0.0451 -0.3606 -0.0451 -0.6763 -0.0451 -0.4058 -0.0451 -0.2255 0.0000 -0.2705 0.0000 0.0000 -0.3157 -0.8564 -0.3606 -0.4509 0.0000 -0.2705 -0.7666 -0.3157 -0.5859 0.0000 -0.9917 -1.2168 -0.3157 -0.6313 0.0000 -1.1719 -0.9019 -0.3606 -0.1353 -0.0901 -1.8486 -0.4958 -0.9468 -0.8115 0.0000 -0.0451 -1.8486 -0.1803 -0.7666 -0.5859 0.0000 -0.0451 -1.1719 -1.6230 -1.5781 -0.6763 0.0000 -0.0451 -1.0820 -1.7129 0.0000 -0.9917 -1.7578 0.0000 -1.0371 -1.7578 0.0000 -1.1270 -1.8037 0.0000 -1.3076 -1.8037 0.0000 -1.4873 -0.6763 -1.4873 -1.1719 -0.2705 -0.9019 -0.1803 -0.4509 -1.8936 -1.3525', 'S-1485\t• Dass Volibris zu schweren Missbildungen bei ungeborenen Kindern führen kann, die vor, während oder innerhalb eines Monats nach dem Ende der Behandlung empfangen werden. • Dass eine Therapie mit Volibris bei Schwangeren nicht begonnen werden darf. • Dass bei Frauen im gebärfähigen Alter unmittelbar vor der ersten Verordnung sowie in monatlichen Abständen im Verlauf der Einnahme von Volibris ein Schwangerschaftstest durchgeführt werden muss. • Dass es erforderlich ist sicherzustellen, dass Frauen im gebärfähigen Alter eine zuverlässige Methode zur Empfängnisverhütung anwenden und dass die Patientinnen vor einer erneuten Verschreibung ihren Arzt über jeden Anhaltspunkt für eine mögliche Schwangerschaft informieren müssen. • Dass Frauen im gebärfähigen Alter, die ihre Verhütungsmethode wechseln oder absetzen möchten, den Arzt, der ihnen das Kontrazeptivum verschreibt, über die Einnahme von Volibris informieren. • Dass Frauen im gebärfähigen Alter, die ihre Verhütungsmethode wechseln oder absetzen möchten, den Arzt, der ihnen Volibris verschreibt, informieren. • Dass Patientinnen ihren behandelnden Arzt unverzüglich darüber informieren müssen, wenn sie glauben, schwanger zu sein. • Dass Patientinnen mit ihrem Arzt darüber sprechen müssen, wenn sie schwanger werden möchten. • Dass Volibris Leberschäden verursachen kann. • Dass bei den Patienten aufgrund des möglichen Auftretens eines Leberschadens oder einer Anämie regelmäßige Blutuntersuchungen durchgeführt werden müssen, und dass sie ihren Arzt über etwaige Symptome einer Leberschädigung informieren müssen. • Dass die Patienten Volibris nicht an Dritte weitergeben dürfen. • Dass die Patienten ihren behandelnden Arzt über jede Nebenwirkung informieren müssen.', 'T-1485\t• That Volibris may cause serious birth defects in unborn babies conceived before, during, or within a month after stopping treatment. • That Volibris cannot be initiated if patient is pregnant. • Women with child-bearing potential must have a pregnancy test immediately prior to the first prescription and at monthly intervals whilst taking Volibris. • The need to ensure that women of child-bearing potential are using reliable contraception and that patients should inform their doctors of any possibility of pregnancy before a new prescription is issued. • That if a women of child-bearing potential needs to change or stop her method of contraception she should inform the physician prescribing her contraception that she is taking Volibris. • That if a women of child-bearing potential needs to change or stop her method of contraception she should inform the physician prescribing Volibris. • The need for female patients to contact their treating doctor immediately if they suspect that they might be pregnant. • The need for the patient to discuss with her doctor if she is planning to become pregnant. • That Volibris may cause liver injury. • That because of the potential for liver injury and anaemia, patients should have regular blood tests and also tell their doctor if experiencing any symptoms of liver injury. • That the patient should not give Volibris to any other person. • That the patient should tell their doctor about any adverse event.', 'H-1485\t-2.83984375\t• That Volibris may cause serious birth defects in unborn babies conceived before , during , or within a month after stopping treatment . • That Volibris therapy must not be initiated in pregnant women . • That Volibris treatment must be performed in women of child @-@ bearing potential prior to the first prescription and at monthly intervals whilst taking Volibris . • The need to ensure that women of child @-@ bearing potential are using reliable contraception and that patients should inform their doctors of any possibility of pregnancy before a new prescription is issued . • That if a woman of child @-@ bearing potential needs to change or stop her method of contraception . • That if a women of child @-@ bearing potential needs to change or stop her method of contraception she should inform the physician prescribing her contraceptive pill that she has changed or stopped her method of contraception . • That the patient should inform the physician prescribing Volibris . • That the need for female patients who become pregnant to contact their treating doctor immediately if they suspect that they might be pregnant to any patient .', 'D-1485\t-2.83984375\t• That Volibris may cause serious birth defects in unborn babies conceived before, during, or within a month after stopping treatment. • That Volibris therapy must not be initiated in pregnant women. • That Volibris treatment must be performed in women of child-bearing potential prior to the first prescription and at monthly intervals whilst taking Volibris. • The need to ensure that women of child-bearing potential are using reliable contraception and that patients should inform their doctors of any possibility of pregnancy before a new prescription is issued. • That if a woman of child-bearing potential needs to change or stop her method of contraception. • That if a women of child-bearing potential needs to change or stop her method of contraception she should inform the physician prescribing her contraceptive pill that she has changed or stopped her method of contraception. • That the patient should inform the physician prescribing Volibris. • That the need for female patients who become pregnant to contact their treating doctor immediately if they suspect that they might be pregnant to any patient.', 'P-1485\t-0.1296 -0.1735 -0.1862 -0.0218 -0.0014 -0.1926 -0.5161 -0.4353 -0.3284 -0.0056 -0.1324 -0.1212 -0.0620 -0.0183 -0.3228 -0.2283 -0.0155 -0.0845 -0.0310 -0.0254 -1.2148 -0.0338 -0.0310 -0.5664 -0.0310 -0.4622 -0.5298 -0.0845 -0.1747 -0.0338 -0.3213 -0.2593 -0.0169 0.0000 -0.8115 -1.0879 -0.0395 -0.0507 -0.5469 -0.0282 -0.0676 -0.3438 -0.0338 -0.0789 -0.0282 -0.8452 -0.3269 -0.0169 0.0000 -1.8203 -0.3381 -0.3042 -0.6201 -1.9609 -0.3157 -0.0338 -0.8789 -0.2141 -0.0789 -0.5747 -1.3643 -0.0338 -0.1465 -0.0676 -0.0451 -0.2817 -0.3269 -0.0451 -0.0113 -0.0113 -0.5073 -0.1014 -0.0338 -0.0113 0.0000 -0.0789 -0.0225 -1.2734 -0.1240 -0.0338 -0.1465 -0.0338 -0.0789 -0.0338 -0.7100 -0.0225 0.0000 -0.3157 -0.3157 -0.1127 -1.3750 -0.2705 -0.2705 -0.0225 -0.2930 -0.0451 -0.1803 -0.3157 -0.1353 -0.0225 -0.0225 -0.5859 -0.2930 -0.1353 -0.3157 -0.0451 -0.1803 -0.1353 -0.3157 -0.1578 -0.0225 -0.2479 -0.2705 -0.0225 -0.0225 -0.9468 -0.3606 -0.3606 -1.5557 -0.0451 -0.6763 -0.0225 0.0000 -0.3157 -0.3157 -0.0676 -0.0676 -0.0901 -0.2255 -0.2930 -0.2029 -0.0451 -0.1353 -0.0225 0.0000 -0.6538 -0.0225 -0.5186 -0.4058 -0.2930 -0.4282 -0.0451 -0.6084 -0.0451 -0.0225 -0.3157 -0.3833 -0.0451 -0.0676 -0.0451 -0.1803 -0.2255 -0.0451 -0.0225 -0.0901 -0.0225 0.0000 -0.2930 -0.1578 -0.3606 -0.0225 -0.0901 -0.5859 -0.0225 -0.1803 -0.0225 -0.7212 -0.0901 -0.6084 -0.0451 -1.6230 -0.1578 -0.8115 -0.2255 -0.9917 -0.3606 -0.3606 -0.4058 -0.1803 -0.0901 -0.0451 -0.1353 -0.0451 0.0000 -0.0451 -0.1353 -0.5859 -0.4058 -0.4058 -0.3157 -1.3975 0.0000 -1.1719 -0.4058 0.0000 -0.5410 -0.0451 -0.4509 0.0000 0.0000 -1.3525 -0.1803 -0.7666 -0.4509 -0.7212 -1.5332 -0.3157 -0.0901 -1.5781 -1.0371 -0.0451 -0.4058 -0.4958 -0.3606 -0.4509 -0.2705 -0.1803 -0.1353 -0.1353 -0.4509 -0.2255 -0.3157 -0.4058 -1.3525 -0.1803 -1.0820 -0.5410 -2.0293 -0.7212 -1.3975', 'Generate test with beam=4: BLEU = 55.20 77.6/64.5/56.6/50.9 (BP = 0.896 ratio = 0.901 hyp_len = 35174 ref_len = 39049)', 'KNN overhead time is not recoreded', '']